Doc Code: TRACK1.REQ
Document Description: TrackOne Request

PTO/AIA/424 (04-14)

CERTIFICATION AND REQUEST FOR PRIORITIZED EXAMINATION UNDER 37 CFR 1.102(e) (Page 1 of 1)

First Named Inventor:	Peter C. Simpson	Nonprovisional Application Number (if known):	
Title of Invention:	ANALYTE SENSOR		

APPLICANT HEREBY CERTIFIES THE FOLLOWING AND REQUESTS PRIORITIZED EXAMINATION FOR THE ABOVE-IDENTIFIED APPLICATION.

1. The processing fee set forth in 37 CFR 1.17(i)(1) and the prioritized examination fee set forth in 37 CFR 1.17(c) have been filed with the request. The publication fee requirement is met because that fee, set forth in 37 CFR 1.18(d), is currently $0. The basic filing fee, search fee, and examination fee are filed with the request or have been already been paid. I understand that any required excess claims fees or application size fee must be paid for the application.

2. I understand that the application may not contain, or be amended to contain, more than four independent claims, more than thirty total claims, or any multiple dependent claims, and that any request for an extension of time will cause an outstanding Track I request to be dismissed.

3. The applicable box is checked below:

I. ☑ Original Application (Track One) - Prioritized Examination under § 1.102(e)(1)

i. (a) The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a). This certification and request is being filed with the utility application via EFS-Web.

---OR---

(b) The application is an original nonprovisional plant application filed under 35 U.S.C. 111(a). This certification and request is being filed with the plant application in paper.

ii. An executed inventor's oath or declaration under 37 CFR 1.63 or 37 CFR 1.64 for each inventor, **or** the application data sheet meeting the conditions specified in 37 CFR 1.53(f)(3)(i) is filed with the application.

II. ☐ Request for Continued Examination - Prioritized Examination under § 1.102(e)(2)

i. A request for continued examination has been filed with, or prior to, this form.
ii. If the application is a utility application, this certification and request is being filed via EFS-Web.
iii. The application is an original nonprovisional utility application filed under 35 U.S.C. 111(a), or is a national stage entry under 35 U.S.C. 371.
iv. This certification and request is being filed prior to the mailing of a first Office action responsive to the request for continued examination.
v. No prior request for continued examination has been granted prioritized examination status under 37 CFR 1.102(e)(2).

Signature /Rose M. Thiessen/	Date 2020-12-23
Name (Print/Typed) Rose M. Thiessen	Practitioner Registration Number 40202

Note: *This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. Submit multiple forms if more than one signature is required.**

☑ *Total of 1 forms are submitted.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.



20a
10
20
20b
26
26
28
18
18c
12b
12
18a
18b
14a
14
30
20c
14
20i
30
24

FIG. 1A



20a
12b
18
18a
20h
20
20b
26
28
18b
12
14a
18c
14
14b
20c
14
20i
30
24

FIG. 1B




FIG. 1C$_1$




FIG. $1C_2$



20a
24
18a
18c
20d
14
20
30
28
20h
18
26
20i
20g
20c
20e

FIG. 1D



18a
18
12
12b
12a
14
26
18b

FIG. 1E




FIG. 1F




FIG. 1G



20n
20s
20k
20a
20f
20
20b
28
12
18
14
26
20i
1J

FIG. 1H



20n
20k
20f
20
20a
14
20s
20c

FIG. 1J




FIG. 1K




FIG. 1L




FIG. 1M



218e
218d
218a
210
214
218d
218c
218
218a
214a
232
212c
212
240
212b

FIG. 2A



218a
218b
218e
218c
218a
218d
218
212
232
214
240
214a

FIG. 2B




FIG. 2C




FIG. 2D




FIG. 2E




FIG. 2F




FIG. 2G




FIG. 2H




FIG. 2I




FIG. 2J




FIG. 2K




FIG. 2L




FIG. 2M




FIG. 2N





FIG. 2O






FIG. 2P




FIG. 2Q



273
272
254
254
240
240
270
272
273
273
272
254
240
240
260
254
272
273

FIG. 2R



282
260
240
Flow
Flow
254
280
282

FIG. 2S




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 3F

Abbott Ex. 1003 - 24/1058




FIG. 3G




FIG. 3H




FIG. 3I




FIG. 3J




FIG. 3K




FIG. 4

Abbott Ex. 1003 - 28/1058




FIG. 5

Abbott Ex. 1003 - 29/1058




FIG. 6




FIG. 7




FIG. 8A

Abbott Ex. 1003 - 32/1058




FIG. 8B

Abbott Ex. 1003 - 33/1058




FIG. 8C




FIG. 9



602
606c
606a
606b
606e
606d
12
602
606a
802
805
803
807
809
12
803
806
604

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D

Abbott Ex. 1003 - 39/1058




FIG. 10E



Step Response
Signal (counts)
t (time)
0
0
1002
1004
1006
1008
1010
1012
1014
1016

FIG. 11




FIG. 12



Level vs Rate
Level (counts)
Rate (counts/mg/dL)
1080
1082
1084
1086
1088

FIG. 13



SENSOR SENSITIVITY EVALUATION
1400
RECEIVE SENSOR DATA
1402
INTERMITTENTLY CALCULATE A SENSOR SENSITIVITY
1404
EVALUATE A PLURALITY OF TIME-SPACED SENSITIVITY CALCULATIONS OVER A PREDETERMINED TIME PERIOD
1406

FIG. 14



SENSOR STABILITY EVALUATION
1500
RECEIVE FIRST SENSOR DATA AND SECOND SENSOR DATA
1502
DETERMINE SENSOR STABILITY BASED AT LEAST IN PART ON THE SECOND SENSOR DATA
1504

FIG. 15



SYSTEM DIAGNOSITICS
1600
INTERMITTENTLY EXPOSING THE SENSOR TO A BIOLOGICAL SAMPLE AND TO AN INFUSION SOLUTION
1602
RECEIVE A FIRST SIGNAL AND A SECOND SIGNAL
1604
EVALUATE THE SYSTEM BASED AT LEAST IN PART ON THE SECOND SIGNAL
1606

FIG. 16



Counts
1100
900
700
500
300
100
10:40
11:09
11:38
12:07
12:36
13:04
13:33
14:02
14:31
15:00
time
Test
Control
700
600
500
400
300
200
100
0
Glucose (mg/dl)

FIG. 17



Glucose (mg/dL)
450
400
350
300
250
200
150
100
50
0
8:30
9:00
9:30
10:00
10:30
11:00
11:30
12:00
12:30
13:00
13:30
14:00
14:30
15:00
15:30
16:00
time
Test
YSI

FIG. 18




FIG. 19A

Abbott Ex. 1003 - 49/1058



9000
8000
7000
6000
5000
4000
3000
2000
1000
0
Raw Counts
E1, No GOx
E2, No GOx
Acetaminophen
4:00 PM
6:24 PM
8:48 PM
11:12 PM
1:36 AM
4:00 AM
6:24 AM
8:48 AM
11:12 AM

FIG. 19B



14000
12000
10000
8000
6000
4000
2000
0
Raw Counts
E1, Plus GOx
E2, No GOx
Acetaminophen
1:55 PM
5:31 PM
9:07 PM
12:43 AM
4:19 AM
7:55 AM
11:31 AM
3:07 PM

FIG. 20A



14000
12000
10000
8000
6000
4000
2000
0
Raw Counts
E2, No GOx
E1, Plus GOx
Acetaminophen
6:00 PM
10:48 PM
3:36 AM
8:24 AM
1:12 PM
6:00 PM
10:48 PM

FIG. 20B




FIG. 21A

Abbott Ex. 1003 - 53/1058



y = 0.9769x - 1.8291
R2 = 0.9799
Glucose (mg/dL)
YSI Values (mg/dL)
0
100
200
300
400
500
600
A
B
C
D
E

FIG. 21B



300
250
200
150
100
50
Counts
2202
2204
2206
0
20
40
60
80
100
120
Sample Points(2 sec)

FIG. 22



260
240
220
200
180
160
140
120
100
80
60
Counts
0
20
40
60
80
100
120
Sample Points
2302
2304
2306

FIG. 23




FIG. 24

Abbott Ex. 1003 - 57/1058



hour 0
hour 1
hour 2
Sensitivity (pA/mg/dL)
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
5:00 PM
5:30 PM
6:00 PM
6:30 PM
7:00 PM
7:30 PM
8:00 PM
8:30 PM
9:00 PM
9:30 PM
2504b
2504b
2504
2502
2502a
2502b
2506a
2506

FIG. 25

ANALYTE SENSOR

INCORPORATION BY REFERENCE TO RELATED APPLICATIONS

[0001] Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation-in part of U.S. Application No. 17/078,609, filed October 23, 2020, and is a continuation-in-part of U.S. Application No. 17/082,627, filed October 28, 2020. The disclosures of each of the abovementioned applications is hereby expressly incorporated by reference in its entirety and is hereby expressly made a portion of this application.

FIELD OF THE INVENTION

[0002] The preferred embodiments relate generally to systems and methods for measuring an analyte in a host.

BACKGROUND OF THE INVENTION

[0003] In today's medical practice, analyte levels in patient biological samples (e.g., fluids, tissues and the like collected from patients) are routinely measured during the process of diagnosing, monitoring and/or prognosticating a patient's medical status. For example, a basic metabolic panel (e.g., BMP or chem.-7) measures sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine and glucose. Bodily sample analyte tests are routinely conducted in a variety of medical settings (e.g., doctor's office, clinic, hospital, by medical personnel) and in the home by the host and/or a caretaker. For example, some medical conditions require frequent testing of blood analyte levels. For example, diabetes mellitus, a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent), is one exemplary medical condition, wherein bodily fluid samples (e.g., blood, interstitial fluid) are routinely tested, in order to ascertain the patient's (e.g., host's) glucose status, often by the host or a caretaker. In the diabetic state, the victim suffers from high blood sugar, which can cause an array of physiological derangements associated with the deterioration of small blood vessels, for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye. A hypoglycemic reaction (low blood sugar) can be induced by an

Abbott Ex. 1003 - 59/1058

inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake.

[0004] Conventionally, a person admitted to a hospital for certain conditions (with or without diabetes) is tested for blood sugar level by a single point blood glucose meter, which typically requires uncomfortable finger pricking methods or blood draws and can produce a burden on the hospital staff during a patient's hospital stay. Due to the lack of convenience, blood sugar glucose levels are generally measured as little as once per day or up to once per hour. Unfortunately, such time intervals are so far spread apart that hyperglycemic or hypoglycemic conditions unknowingly occur, incurring dangerous side effects. It is not only unlikely that a single point value will not catch some hyperglycemic or hypoglycemic conditions, it is also likely that the trend (direction) of the blood glucose value is unknown based on conventional methods. This inhibits the ability to make educated insulin therapy decisions.

[0005] A variety of sensors are known that use an electrochemical cell to provide output signals by which the presence or absence of an analyte, such as glucose, in a sample can be determined. For example, in an electrochemical cell, an analyte (or a species derived from it) that is electro-active generates a detectable signal at an electrode, and this signal can be used to detect or measure the presence and/or amount within a biological sample. In some conventional sensors, an enzyme is provided that reacts with the analyte to be measured, and the byproduct of the reaction is qualified or quantified at the electrode. An enzyme has the advantage that it can be very specific to an analyte and also, when the analyte itself is not sufficiently electro-active, can be used to interact with the analyte to generate another species which is electro-active and to which the sensor can produce a desired output. In one conventional amperometric glucose oxidase-based glucose sensor, immobilized glucose oxidase catalyses the oxidation of glucose to form hydrogen peroxide, which is then quantified by amperometric measurement (for example, change in electrical current) through a polarized electrode.

SUMMARY OF THE INVENTION

[0006] In a first aspect, an integrated sensor system is provided for measuring an analyte in a sample of a host and for fluid infusion into the host, comprising: an analyte sensor configured and arranged for measuring an analyte concentration in a biological sample of a

Abbott Ex. 1003 - 60/1058

circulatory system of a host; a vascular access device; tubing assembly comprising tubing; and a flow control device configured to regulate exposure of the analyte sensor to a biological sample and to a reference solution according to a flow profile, wherein the flow control device comprises a valve, and wherein the valve is configured and arranged with a gravity flow position and a controlled flow position.

[0007] In an embodiment of the first aspect, the system is configured such that the analyte sensor is flushed by the reference solution when the valve is in the gravity flow position.

[0008] In an embodiment of the first aspect, the gravity flow position comprises a first flow rate of the solution, wherein the controlled flow position comprises a second flow rate of the solution, and wherein a ratio of the first flow rate to the second flow rate is at least about 10:1.

[0009] In an embodiment of the first aspect, the gravity flow position has a flow rate of at least about 600 ml/hr.

[0010] In an embodiment of the first aspect, the controlled flow position has a flow rate of from about 0.5ml/hr to about 4.0 ml/hour.

[0011] In an embodiment of the first aspect, the valve is configured and arranged to receive the tubing in a substantially linear configuration.

[0012] In an embodiment of the first aspect, the valve and the tubing assembly are configured and arranged such that the tubing is in a stretched state after installation of the tubing in the valve.

[0013] In an embodiment of the first aspect, valve is configured and arranged such that the tubing is substantially linear in the gravity flow position and the tubing is substantially non-linear in the controlled flow position.

[0014] In an embodiment of the first aspect, the valve is configured and arranged to preclude tubing installation when the valve is in the controlled flow position.

[0015] In an embodiment of the first aspect, the valve is configured and arranged to receive the tubing assembly in only one orientation.

[0016] In an embodiment of the first aspect, the valve and tubing assembly are configured and arranged to releasably interlock such that a portion of the valve mechanically interlocks with a portion of the tubing assembly.

Abbott Ex. 1003 - 61/1058

[0017] In an embodiment of the first aspect, the vascular access device and the tubing assembly are configured and arranged to substantially preclude rotational movement between the vascular access device and the tubing assembly when engaged.

[0018] In an embodiment of the first aspect, the system further comprises a free-flow mitigation device.

[0019] In an embodiment of the first aspect, the free-flow mitigation device comprises a spring clip occluder located on the tubing assembly.

[0020] In an embodiment of the first aspect, the system is configured for electronic control of the free-flow mitigation device.

[0021] In an embodiment of the first aspect, the system further comprises an electronic solenoid associated with the flow control device, wherein the electronic solenoid provides electronic control of the free-flow mitigation device.

[0022] In an embodiment of the first aspect, the system is configured and arranged such that the free-flow mitigation device precludes flow responsive to at least one of power removal, loss to the system, and loss to the flow control device.

[0023] In an embodiment of the first aspect, the system is configured and arranged such that the free-flow mitigation device is controlled at least in part by the flow profile.

[0024] In an embodiment of the first aspect, the system further comprises an intravenous bag containing a reference solution, wherein the reference solution has a known analyte concentration.

[0025] In an embodiment of the first aspect, the analyte sensor is configured to measure at least one analyte selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0026] In a second aspect, a system configured to measure at least one analyte in a host is provided, the system comprising: a vascular access device comprising a first portion configured for insertion into a host and a second portion configured to remain outside the host after insertion of the first portion; at least one analyte sensor located within the second portion of the vascular access device, such that the at least one analyte sensor is exposed to a biological

Abbott Ex. 1003 - 62/1058

sample when the biological sample is drawn back by a distance of about 40 mm or less into the vascular access device, when the vascular access device is in fluid communication with a circulatory system of the host; and a flow control device configured to regulate exposure of the at least one analyte sensor to a biological sample and to a reference solution according to a flow profile.

[0027] In an embodiment of the second aspect, the at least one analyte sensor is exposed to the biological sample when a volume of about 300 μl or less of the biological sample is drawn back.

[0028] In an embodiment of the second aspect, the at least one analyte sensor is exposed to the biological sample when a volume of about 200 μl or less of the biological sample is drawn back.

[0029] In an embodiment of the second aspect, the vascular access device comprises a catheter.

[0030] In an embodiment of the second aspect, the second portion comprises a connecting end of the catheter, wherein the connecting end is configured for connection to tubing.

[0031] In an embodiment of the second aspect, the vascular access device is a catheter, and wherein the catheter is 22 gauge or smaller.

[0032] In an embodiment of the second aspect, the second portion comprises a fluid coupler, wherein the fluid coupler is configured to releasably mate with the catheter.

[0033] In an embodiment of the second aspect, the at least one sensor is incorporated into the second portion.

[0034] In an embodiment of the second aspect, the at least one sensor is located on an inner surface of the second portion.

[0035] In an embodiment of the second aspect, the at least one sensor is disposed within a lumen of the second portion.

[0036] In an embodiment of the second aspect, at least a portion of the at least one sensor is disposed in an orientation substantially parallel to a longitudinal axis of the second portion.

Abbott Ex. 1003 - 63/1058

[0037] In an embodiment of the second aspect, at least a portion of the at least one sensor is disposed in an orientation substantially perpendicular to a longitudinal axis of the second portion.

[0038] In an embodiment of the second aspect, the at least one sensor comprises an exposed electroactive surface area with a dimension substantially equal to a width of a lumen of the second portion.

[0039] In an embodiment of the second aspect, the exposed electroactive surface area intersects the lumen of the second portion.

[0040] In an embodiment of the second aspect, the second portion is configured to provide identification information associated with the flow profile.

[0041] In an embodiment of the second aspect, the system is configured to program the flow profile of the flow control device in response to an automatic receipt of the identification information.

[0042] In an embodiment of the second aspect, the identification information is provided by a mechanical structure of the second portion.

[0043] In an embodiment of the second aspect, the identification information is provided by electronics of the second portion.

[0044] In an embodiment of the second aspect, the vascular access device comprises at least two lumens, and wherein the system is configured and arranged to infuse a fluid into a first lumen of the vascular access device, and wherein the system is configured and arranged to draw back a biological sample into a second lumen of the vascular access device.

[0045] In an embodiment of the second aspect, the at least one analyte sensor is configured to measure an analyte selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0046] In an embodiment of the second aspect, the system comprises at least three analyte sensors located within the second portion of the vascular access device, wherein the three sensors in combination are configured to measure at least three analytes selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate

Abbott Ex. 1003 - 64/1058

aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0047] In an embodiment of the second aspect, the system comprises at least eight analyte sensors located within the second portion of the vascular access device, wherein the three sensors in combination are configured to measure at least eight analytes selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0048] In an embodiment of the second aspect, a lumen of the second portion is wider than a lumen of the first portion.

[0049] In a third aspect, a system configured to measure at least one analyte in a host is provided, the system comprising: a catheter comprising a first portion configured for insertion into a host and a second portion configured to remain outside the host after insertion of the first portion; and at least one analyte sensor located within the second portion of the catheter, such that the at least one analyte sensor is exposed to a biological sample when the biological sample is drawn back into the catheter to a distance of about 40 mm or less, when the catheter is in fluid communication with a circulatory system of the host.

[0050] In an embodiment of the third aspect, the at least one analyte sensor is exposed to the biological sample when a volume of about 300 µl or less of the biological sample is drawn back.

[0051] In an embodiment of the third aspect, the at least one analyte sensor is exposed to the biological sample when a volume of about 200 µl or less of the biological sample is drawn back.

[0052] In an embodiment of the third aspect, the catheter is 22 gauge or smaller.

[0053] In an embodiment of the third aspect, the second portion comprises a fluid coupler, wherein the fluid coupler is configured to releasably mate with the catheter.

Abbott Ex. 1003 - 65/1058

[0054] In an embodiment of the third aspect, the at least one sensor is incorporated into the second portion.

[0055] In an embodiment of the third aspect, the at least one sensor is located on an inner surface of the second portion.

[0056] In an embodiment of the third aspect, the at least one sensor is disposed within a lumen of the second portion.

[0057] In an embodiment of the third aspect, at least a portion of the at least one sensor is disposed in an orientation substantially parallel to a longitudinal axis of the second portion.

[0058] In an embodiment of the third aspect, at least a portion of the at least one sensor is disposed in an orientation substantially perpendicular to a longitudinal axis of the second portion.

[0059] In an embodiment of the third aspect, the at least one sensor comprises an exposed electroactive surface area with a dimension substantially equal to a width of a lumen of the second portion.

[0060] In an embodiment of the third aspect, the exposed electroactive surface area intersects the lumen of the second portion.

[0061] In an embodiment of the third aspect, the second portion is configured to provide identification information associated with a flow profile.

[0062] In an embodiment of the third aspect, the system is configured to program the flow profile of the flow control device in response to an automatic receipt of the identification information.

[0063] In an embodiment of the third aspect, the identification information is provided by a mechanical structure of the catheter.

[0064] In an embodiment of the third aspect, the identification information is provided by electronics associated with the catheter.

[0065] In an embodiment of the third aspect, the catheter comprises at least two lumens, and wherein the system is configured and arranged to infuse a fluid into a first lumen of the catheter, and wherein the system is configured and arranged draw back a biological sample into a second lumen of the catheter.

Abbott Ex. 1003 - 66/1058

[0066] In an embodiment of the third aspect, the at least one analyte sensor is configured to measure an analyte selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0067] In an embodiment of the third aspect, the system comprises at least three analyte sensors located within the second portion of the catheter, wherein the three sensors in combination are configured to measure at least three analytes selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0068] In an embodiment of the third aspect, the system comprises at least eight analyte sensors located within the second portion of the catheter, wherein the eight sensors in combination are configured to measure at least eight analytes selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0069] In an embodiment of the third aspect, the system further comprises a flow control device configured to regulate exposure of the at least one sensor to a biological sample and to a solution according to a flow profile.

[0070] In an embodiment of the third aspect, a lumen of the second portion is wider than a lumen of the first portion.

[0071] In a fourth aspect, a system configured to measure at least one analyte in a biological sample of the host is provided, the system comprising: a fluid coupler comprising a first end and a second end, wherein the first end is configured to releasably mate with a connecting end of a catheter, and wherein the second end is configured to releasably mate with a tubing assembly; and at least one analyte sensor located within the fluid coupler such that when the fluid coupler is mated to a catheter inserted into a circulatory system of a host, the at

Abbott Ex. 1003 - 67/1058

least one analyte sensor is exposed to a biological sample when the biological sample is drawn back into the catheter to a distance of about 40 mm or less.

[0072] In an embodiment of the fourth aspect, the at least one analyte sensor is exposed to the biological sample when a volume of about 300 µl or less of the biological sample is drawn back.

[0073] In an embodiment of the fourth aspect, the at least one analyte sensor is exposed to the biological sample when a volume of about 200 µl or less of the biological sample is drawn back.

[0074] In an embodiment of the fourth aspect, the at least one analyte sensor is incorporated into the fluid coupler.

[0075] In an embodiment of the fourth aspect, the at least one analyte sensor is located on an inner surface of the fluid coupler.

[0076] In an embodiment of the fourth aspect, the at least one analyte sensor is disposed within a lumen of the fluid coupler.

[0077] In an embodiment of the fourth aspect, at least a portion of the at least one sensor is disposed in an orientation substantially parallel to a longitudinal axis of the fluid coupler.

[0078] In an embodiment of the fourth aspect, at least a portion of the at least one sensor is disposed in an orientation substantially perpendicular to a longitudinal axis of the fluid coupler.

[0079] In an embodiment of the fourth aspect, the at least one sensor comprises an exposed electroactive surface area with a dimension substantially equal to a width of a lumen of the fluid coupler.

[0080] In an embodiment of the fourth aspect, the exposed electroactive surface area intersects the lumen of the fluid coupler.

[0081] In an embodiment of the fourth aspect, the fluid coupler is configured to provide identification information associated with a flow profile.

[0082] In an embodiment of the fourth aspect, the system is configured to program the flow profile of the flow control device in response to an automatic receipt of the identification information.

Abbott Ex. 1003 - 68/1058

[0083] In an embodiment of the fourth aspect, the identification information is provided by a mechanical structure of the fluid coupler.

[0084] In an embodiment of the fourth aspect, the identification information is provided by electronics associated with the fluid coupler.

[0085] In an embodiment of the fourth aspect, the fluid coupler comprises at least two lumens, and wherein the system is configured and arranged to infuse a fluid into a first lumen of the fluid coupler, and wherein the system is configured and arranged draw back a biological sample into a second lumen of the fluid coupler.

[0086] In an embodiment of the fourth aspect, the at least one analyte sensor is configured to measure an analyte selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0087] In an embodiment of the fourth aspect, the system comprises at least three analyte sensors located within the fluid coupler, wherein the three sensors in combination are configured to measure at least three analytes selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0088] In an embodiment of the fourth aspect, the system comprises at least eight analyte sensors located within the fluid coupler, wherein the three sensors in combination are configured to measure at least eight analytes selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, carbon dioxide, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug.

[0089] In an embodiment of the fourth aspect, the system further comprises a catheter.

Abbott Ex. 1003 - 69/1058

[0090] In an embodiment of the fourth aspect, the system further comprises a flow control device configured to regulate exposure of the at least one sensor to a biological sample and to a solution according to a flow profile.

[0091] In a fifth aspect, a method for evaluating a change in a sensitivity of an analyte sensor over a predetermined time period is provided, the method comprising: receiving sensor data from an analyte sensor, wherein the sensor data comprises one or more sensor analyte values measured in a biological sample of a host; intermittently calculating a sensitivity of the analyte sensor based at least in part on reference analyte data; and evaluating a change in sensitivity by evaluating a plurality of time-spaced sensitivity calculations over a predetermined time period.

[0092] In an embodiment of the fifth aspect, the predetermined time period is less than or equal to about 30 minutes.

[0093] In an embodiment of the fifth aspect, the predetermined time period is less than or equal to about 20 minutes.

[0094] In an embodiment of the fifth aspect, the predetermined time period is less than or equal to about 10 minutes.

[0095] In an embodiment of the fifth aspect, the step of evaluating a change in sensitivity comprises evaluating at least two sensitivity measurements during the predetermined time period.

[0096] In an embodiment of the fifth aspect, the method further comprises averaging and/or filtering the at least two sensitivity measurements prior to the step of evaluating the at least two sensitivity measurements.

[0097] In an embodiment of the fifth aspect, the step of evaluating a change in sensitivity comprises comparing the change in sensitivity with one or more criteria.

[0098] In an embodiment of the fifth aspect, the method further comprises using a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity meets one or more criteria.

[0099] In an embodiment of the fifth aspect, the method further comprises not using a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity does not meet one or more criteria.

Abbott Ex. 1003 - 70/1058

[0100] In an embodiment of the fifth aspect, the step of intermittently calculating a sensitivity of the analyte sensor comprises intermittently receiving a reference analyte value.

[0101] In an embodiment of the fifth aspect, the step of intermittently receiving a reference analyte value comprises periodically receiving a measured analyte concentration from a reference analyte solution.

[0102] In an embodiment of the fifth aspect, the step of intermittently receiving a reference analyte value comprises receiving a reference analyte value obtained from an *in vitro* analyte monitor.

[0103] In an embodiment of the fifth aspect, the step of evaluating a sensitivity is iteratively performed on the plurality of time-spaced sensitivity calculations over the predetermined time period.

[0104] In an embodiment of the fifth aspect, the predetermined time period is at least about 30 minutes.

[0105] In an embodiment of the fifth aspect, the predetermined time period is at least about 60 minutes.

[0106] In an embodiment of the fifth aspect, the predetermined time period is at least about 120 minutes.

[0107] In an embodiment of the fifth aspect, the step of evaluating a sensitivity is iteratively performed on the plurality of time-spaced sensitivity calculations over the predetermined time period.

[0108] In an embodiment of the fifth aspect, the step of evaluating a sensitivity comprises evaluating all sensitivity calculations over a sensor session.

[0109] In an embodiment of the fifth aspect, the step of evaluating a sensitivity is based at least in part on *a priori* sensitivity information.

[0110] In an embodiment of the fifth aspect, the *a priori* sensitivity information is an expected profile.

[0111] In an embodiment of the fifth aspect, the *a priori* sensitivity information defines a range of acceptable change in sensitivity.

[0112] In an embodiment of the fifth aspect, the analyte sensor comprises a first working electrode and a second working electrode, wherein the first working electrode is configured to provide a first signal comprising an analyte component and a baseline component

Abbott Ex. 1003 - 71/1058

and wherein the second working electrode is configured to provide a second signal comprising a baseline component without an analyte component.

[0113] In an embodiment of the fifth aspect, the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on the first signal.

[0114] In an embodiment of the fifth aspect, the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on the second signal.

[0115] In an embodiment of the fifth aspect, the method further comprises subtracting the second signal from the first signal to obtain a subtracted signal, wherein the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on the subtracted signal.

[0116] In an embodiment of the fifth aspect, the analyte sensor is intermittently exposed to a biological sample and to a reference solution.

[0117] In an embodiment of the fifth aspect, the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on a signal obtained when the analyte sensor is exposed to a biological sample.

[0118] In an embodiment of the fifth aspect, the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on a signal obtained when the analyte sensor is exposed to a reference solution.

[0119] In an embodiment of the fifth aspect, the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on a signal obtained when the analyte sensor is exposed to a biological sample and a signal obtained when the analyte sensor is exposed to a reference solution.

[0120] In a sixth aspect, a system for evaluating a change in a sensitivity of an analyte sensor over a predetermined time period is provided, the system comprising: an analyte sensor; and a computer system, wherein the computer system comprises: an input module configured to receive sensor analyte data and reference analyte data, wherein the sensor data comprises one or more sensor analyte values measured in a biological sample of a host and wherein the reference data comprises one or more reference analyte values; and a processor module configured to intermittently calculate a sensitivity of the analyte sensor based at least in part on the reference analyte data and to evaluate a change in sensitivity by evaluating a plurality of time-spaced sensitivity calculations over a predetermined time period.

Abbott Ex. 1003 - 72/1058

[0121] In an embodiment of the sixth aspect, the predetermined time period is less than or equal to about 30 minutes.

[0122] In an embodiment of the sixth aspect, the predetermined time period is less than or equal to about 20 minutes.

[0123] In an embodiment of the sixth aspect, the predetermined time period is less than or equal to about 10 minutes.

[0124] In an embodiment of the sixth aspect, the processor module is configured to evaluate the change in sensitivity at least in part by evaluating at least two sensitivity measurements during the predetermined time period.

[0125] In an embodiment of the sixth aspect, the processor module is further configured to average and/or filter the at least two sensitivity measurements prior to evaluating the at least two sensitivity measurements.

[0126] In an embodiment of the sixth aspect, the processor module is further configured to compare the change in sensitivity with one or more criteria.

[0127] In an embodiment of the sixth aspect, the processor module is further configured to use a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity meets one or more criteria.

[0128] In an embodiment of the sixth aspect, the processor module is further configured to not use a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity does not meet one or more criteria.

[0129] In an embodiment of the sixth aspect, the predetermined time period is at least about 30 minutes.

[0130] In an embodiment of the sixth aspect, the predetermined time period is at least about 60 minutes.

[0131] In an embodiment of the sixth aspect, the predetermined time period is at least about 120 minutes.

[0132] In an embodiment of the sixth aspect, the processor module is configured to iteratively evaluate a sensitivity of the plurality of time-spaced sensitivity calculations over the predetermined time period.

[0133] In an embodiment of the sixth aspect, the processor module is configured to evaluate all sensitivity calculations over a sensor session.

Abbott Ex. 1003 - 73/1058

[0134] In an embodiment of the sixth aspect, the processor module is configured to evaluate a sensitivity based at least in part on *a priori* sensitivity information.

[0135] In an embodiment of the sixth aspect, the *a priori* sensitivity information is an expected profile.

[0136] In an embodiment of the sixth aspect, the a priori sensitivity information defines a range of acceptable change in sensitivity.

[0137] In an embodiment of the sixth aspect, the analyte sensor data comprises a first signal comprising an analyte component and a baseline component and a second signal comprising a baseline component without an analyte component.

[0138] In an embodiment of the sixth aspect, the processor module is configured to calculate a sensitivity of the analyte sensor based at least in part on the first signal.

[0139] In an embodiment of the sixth aspect, the processor module is configured to calculate a sensitivity of the analyte sensor based at least in part on the second signal.

[0140] In an embodiment of the sixth aspect, the processor module is further configured to calculate a sensitivity of the analyte sensor based at least in part on a subtracted signal, wherein the subtracted signal comprises the second signal subtracted from the first signal.

[0141] In an embodiment of the sixth aspect, the system further comprises a flow control device configured to intermittently expose the sensor to the biological sample and to a reference solution.

[0142] In an embodiment of the sixth aspect, the processor module is configured to intermittently calculate a sensitivity of the analyte sensor based at least in part on a signal obtained when the analyte sensor is exposed to the biological sample.

[0143] In an embodiment of the sixth aspect, the processor module is configured to intermittently calculate a sensitivity of the analyte sensor based at least in part on a signal obtained when the analyte sensor is exposed to the reference solution.

[0144] In an embodiment of the sixth aspect, the processor module is configured to intermittently calculate a sensitivity of the analyte sensor based on a signal obtained when the analyte sensor is exposed to the biological sample and a signal obtained when the analyte sensor is exposed to the reference solution.

Abbott Ex. 1003 - 74/1058

[0145] In a seventh aspect, a method for performing a diagnostic of an analyte sensor system is provided, comprising: providing a sensor system comprising an analyte sensor and a flow control device configured to intermittently expose the analyte sensor to a biological sample and an infusion solution, wherein the analyte sensor comprises: a first working electrode configured to provide a first signal comprising an analyte component and a baseline component; and a second working electrode configured to provide a second signal comprising a baseline component substantially without an analyte component; and evaluating the sensor system based at least in part on the second signal.

[0146] In an embodiment of the seventh aspect, the second signal comprises a signal waveform, and wherein the step of evaluating the sensor system comprises evaluating the signal waveform for at least one of an expected shape and a pattern when the analyte sensor is exposed to at least one of the biological sample and the infusion solution.

[0147] In an embodiment of the seventh aspect, the step of evaluating the signal waveform comprises evaluating at least one of a similarity and a correlation between the signal waveform and a waveform template.

[0148] In an embodiment of the seventh aspect, the waveform template is based at least in part on *a priori* information.

[0149] In an embodiment of the seventh aspect, the waveform template is based at least in part on a signal waveform measured by the sensor system.

[0150] In an embodiment of the seventh aspect, the step of evaluating at least one of a similarity and a correlation of the signal waveform to a waveform template comprises performing a correlation waveform analysis.

[0151] In an embodiment of the seventh aspect, the method further comprises updating the waveform template when at least one of the similarity and the correlation between the signal waveform and the waveform template meets one or more criteria.

[0152] In an embodiment of the seventh aspect, the method further comprises detecting a level of interferent in the biological sample, wherein the waveform template is updated when the level of interferent meets one or more criteria.

[0153] In an embodiment of the seventh aspect, the step of evaluating the signal waveform comprises evaluating a monotonicity of the signal waveform.

Abbott Ex. 1003 - 75/1058

[0154] In an embodiment of the seventh aspect, the step of evaluating a monotonicity of the signal waveform comprises performing a correlation waveform analysis of the signal waveform with the waveform template.

[0155] In an embodiment of the seventh aspect, the step of evaluating a monotonicity of the signal waveform comprises performing a time-series analysis.

[0156] In an embodiment of the seventh aspect, the step of evaluating the sensor system comprises detecting an interferent by evaluating at least one of an amplitude, a change in amplitude, a signal waveform, and a change in a signal waveform of the second signal when the sensor is exposed to the biological sample.

[0157] In an embodiment of the seventh aspect, the step of detecting an interferent is further based at least in part on a calibrated analyte value.

[0158] In an embodiment of the seventh aspect, the method further comprises controlling a display of the sensor system based at least in part on a level of interferent detected on the second signal.

[0159] In an embodiment of the seventh aspect, the method further comprises processing the first signal and the second signal to obtain a subtracted signal, wherein the step of processing is based at least in part a level of interferent of the sensor system.

[0160] In an embodiment of the seventh aspect, the method further comprises determining a level of reliability of the sensor system by comparing at least one of an amplitude, a change in amplitude, a signal waveform, and a change in a signal waveform of the second signal to one or more criteria.

[0161] In an embodiment of the seventh aspect, the method further comprises controlling a display of the sensor system based at least in part on the level of reliability of the sensor system.

[0162] In an embodiment of the seventh aspect, the step of evaluating comprises determining a success of a biological sample draw-back from a host's circulatory system to the analyte sensor.

[0163] In an embodiment of the seventh aspect, the method further comprises displaying an analyte value measured during the biological sample draw-back in response to a determination of a successful biological sample draw-back.

Abbott Ex. 1003 - 76/1058

[0164] In an embodiment of the seventh aspect, the step of evaluating comprises determining a success of infusing the infusion solution such that the biological sample is washed from the sensor.

[0165] In an embodiment of the seventh aspect, the step of determining a success of infusing comprises displaying an analyte value measured in the biological sample after infusing the infusion solution in response to a determination of a successful infusion.

[0166] In an eighth aspect, a system for performing a diagnostic of an analyte sensor system is provided, comprising: an analyte sensor system comprising a sensor, wherein the analyte sensor comprises a first working electrode configured to provide a first signal comprising an analyte component and a baseline component and a second working electrode configured to provide a second signal comprising a baseline component substantially without an analyte component; a flow control device configured to intermittently expose the analyte sensor to a biological sample and an infusion solution; and a processor module configured to evaluate the analyte sensor system based at least in part on the second signal.

[0167] In an embodiment of the eighth aspect, the second signal comprises a signal waveform, and wherein the processor module is configured to evaluate the signal waveform for at least one of an expected shape and a pattern when the analyte sensor is exposed to at least one of the biological sample and the infusion solution.

[0168] In an embodiment of the eighth aspect, the processor module is configured to evaluate the signal waveform by evaluating at least one of a similarity and a correlation between the signal waveform and a waveform template.

[0169] In an embodiment of the eighth aspect, the waveform template is based at least in part on *a priori* information.

[0170] In an embodiment of the eighth aspect, the waveform template is based at least in part on a signal waveform measured by the analyte sensor system.

[0171] In an embodiment of the eighth aspect, the processor module is configured to evaluate at least one of a similarity and a correlation between the signal waveform and the waveform template by performing a correlation waveform analysis.

[0172] In an embodiment of the eighth aspect, the processor module is further configured to update the waveform template when at least one of a similarity and a correlation between the signal waveform and the waveform template meets one or more criteria.

Abbott Ex. 1003 - 77/1058

[0173] In an embodiment of the eighth aspect, the processor module is configured to detect a level of an interferent in the biological sample, and wherein the processor module is further configured to update the waveform template when the level of the interferent meets one or more criteria.

[0174] In an embodiment of the eighth aspect, the processor module is configured to evaluate the signal waveform by evaluating a monotonicity of the signal waveform.

[0175] In an embodiment of the eighth aspect, the processor module is configured to evaluate a monotonicity at least in part by performing a correlation waveform analysis of the signal waveform with a waveform template.

[0176] In an embodiment of the eighth aspect, the processor module is configured evaluate a monotonicity at least in part by performing a time-series analysis.

[0177] In an embodiment of the eighth aspect, the processor module is configured to detect an interferent at least in part by evaluating at least one of an amplitude, a change in amplitude, a signal waveform, and a change in a signal waveform of the second signal when the sensor is exposed to a biological sample.

[0178] In an embodiment of the eighth aspect, the processor module is configured to detect an interferent at least in part by evaluating a calibrated analyte value with one or more criteria.

[0179] In an embodiment of the eighth aspect, the one or more criteria are based on physiological feasibility.

[0180] In an embodiment of the eighth aspect, the processor module is configured to control a display of the analyte sensor system based at least in part on a level of an interferent detected on the second signal.

[0181] In an embodiment of the eighth aspect, the processor module is further configured to process the first signal and the second signal to obtain a subtracted signal based at least in part on a level of an interferent of the sensor system.

[0182] In an embodiment of the eighth aspect, the processor module is configured evaluate a level of reliability of the sensor system at least in part by comparing at least one of an amplitude, a change in amplitude, a signal waveform, and a change in a signal waveform of the second signal to one or more criteria.

Abbott Ex. 1003 - 78/1058

[0183] In an embodiment of the eighth aspect, the processor module is configured to control a display of the sensor system based at least in part on a level of reliability of the sensor system.

[0184] In an embodiment of the eighth aspect, processor module is further configured determine a success of drawing-back of a biological sample from a host's circulatory system to the analyte sensor, based at least in part on the evaluation of the analyte sensor system.

[0185] In an embodiment of the eighth aspect, the processor module is configured to display an analyte value measured during the biological sample draw-back, in response to a determination of a successful draw-back of the biological sample.

[0186] In an embodiment of the eighth aspect, the processor module is further configured to determine a success of infusing the infusion solution such that the biological sample is washed from the sensor.

[0187] In an embodiment of the eighth aspect, the processor module is configured to display an analyte value measured in the biological sample after infusing the infusion solution, in response to a determination of a successful infusion.

[0188] In a ninth aspect, a method for determining a stability of an analyte sensor is provided, the method comprising: exposing an analyte sensor to a biological sample, wherein the analyte sensor comprises a first working electrode that measures an analyte component and a baseline component and a second working electrode that measures a baseline component substantially without an analyte component; receiving sensor data from the analyte sensor, wherein the sensor data comprises first sensor data associated with the first working electrode and second sensor data associated with the second working electrode; and determining a stability of the analyte sensor based at least in part on the second sensor data.

[0189] In an embodiment of the ninth aspect, the second sensor data comprises a plurality of time spaced data points, and wherein the step of determining a stability of the analyte sensor comprises evaluating a change in amplitude of two or more of the plurality of time spaced data points.

[0190] In an embodiment of the ninth aspect, the step of exposing the analyte sensor to a biological sample comprises intermittently exposing the analyte sensor to a biological sample and to an infusion solution.

Abbott Ex. 1003 - 79/1058

[0191] In an embodiment of the ninth aspect, the step of evaluating comprises comparing a plurality of time spaced points measured when the analyte sensor is exposed to the biological sample.

[0192] In an embodiment of the ninth aspect, the step of evaluating comprises comparing a first point measured when the analyte sensor is exposed to the biological sample to a second point measured when the analyte sensor is exposed to the infusion solution.

[0193] In an embodiment of the ninth aspect, the step of evaluating comprises evaluating transient information of the second sensor data during a step change from exposure of the sensor to the infusion solution to exposure of the sensor to the biological sample.

[0194] In an embodiment of the ninth aspect, the method further comprises determining a predetermined level of stability when a change in an amplitude of the second sensor data meets one or more criteria.

[0195] In an embodiment of the ninth aspect, the method further comprises controlling a display associated with the analyte sensor system in response to the determination of the predetermined level of stability.

[0196] In an embodiment of the ninth aspect, the step of controlling a display comprises providing at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of a plurality of estimated analyte values.

[0197] In an embodiment of the ninth aspect, the step of controlling a display comprises requesting reference analyte data.

[0198] In an embodiment of the ninth aspect, the step of determining a stability of the analyte sensor is performed during a predetermined time period.

[0199] In an embodiment of the ninth aspect, the step of determining a stability of the analyte sensor is performed after a predetermined time period.

[0200] In an embodiment of the ninth aspect, the method further comprises repeating the step of determining a stability, wherein the step is conducted after a system re-start.

[0201] In an embodiment of the ninth aspect, the analyte sensor is a glucose sensor.

[0202] In a tenth aspect, a system for determining a stability of an analyte sensor is provided, the system comprising: an analyte sensor; and a computer system, the computer system comprising: an input module operatively connected to the analyte sensor and

Abbott Ex. 1003 - 80/1058

configured to receive sensor data from an analyte sensor, wherein the analyte sensor comprises a first working electrode configured to provide first sensor data comprising an analyte component and a baseline component and a second working electrode configured to provide second sensor data comprising a baseline component substantially without an analyte component; and a processor module configured to determine a stability of the analyte sensor based at least in part on the second sensor data.

[0203] In an embodiment of the tenth aspect, the processor module is configured to determine a stability of the analyte sensor at least in part by evaluating a change in amplitude of a plurality of time spaced points from the second sensor data.

[0204] In an embodiment of the tenth aspect, the system further comprises a flow control device configured and arranged to intermittently expose the analyte sensor to a biological sample and to an infusion solution.

[0205] In an embodiment of the tenth aspect, the processor module is configured to evaluate the change in amplitude at least in part by comparing a plurality of time spaced points from the second sensor data measured when the analyte sensor is exposed to the biological sample.

[0206] In an embodiment of the tenth aspect, the processor module is configured to evaluate the change in amplitude at least in part by comparing a first point measured when the analyte sensor is exposed to the biological sample to a second point measured when the analyte sensor is exposed to the infusion solution.

[0207] In an embodiment of the tenth aspect, the processor module is configured to evaluate the change in amplitude at least in part by evaluating transient information of the second sensor data during a step change from exposure of the sensor to the infusion solution to exposure of the sensor to the biological sample.

[0208] In an embodiment of the tenth aspect, the processor module is configured to determine a level of stability when a change in amplitude of a plurality of time spaced points from the second sensor data meets one or more criteria.

[0209] In an embodiment of the tenth aspect, the processor module is configured to control a display of calibrated sensor based at least in part on the level of stability.

Abbott Ex. 1003 - 81/1058

[0210] In an embodiment of the tenth aspect, the calibrated sensor data comprises at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of a plurality of estimated analyte values.

[0211] In an embodiment of the tenth aspect, the processor module is configured to request reference analyte data based at least in part on the level of stability.

[0212] In an embodiment of the tenth aspect, the processor module is further configured to determine a stability of the analyte sensor during a predetermined time period.

[0213] In an embodiment of the tenth aspect, processor module is further configured to determine a stability of the analyte sensor after a predetermined time period.

[0214] In an embodiment of the tenth aspect, the analyte sensor is a glucose sensor.

BRIEF DESCRIPTION OF THE DRAWINGS

[0215] Fig. 1A is a perspective view of one embodiment of an analyte sensor system, including a vascular access device (e.g., a catheter), a sensor, a fluid connector, and a protective sheath.

[0216] Fig. 1B is a side view of the analyte sensor system of Fig. 1A, showing the protective sheath removed.

[0217] Fig. $1C_1$ is a close-up cut away view of a portion of the analyte sensor system of Fig. 1A.

[0218] Fig. $1C_2$ is a close-up cut away view of a portion of the analyte sensor system of Fig. 1A.

[0219] Fig. 1D is a close-up cut away view of a portion of the analyte sensor system of Fig. 1A.

[0220] Fig. 1E is a close-up cut away view of a portion of the analyte sensor system of Fig. 1A.

[0221] Fig. 1F is a schematic an analyte sensor system in another embodiment, including a vascular access device, a sensor, a fluid connector, and a protective sheath.

[0222] Fig. 1G is an exploded view of the analyte sensor system of Fig. 1F.

[0223] Fig. 1H is a cut-away view of the analyte sensor system of Fig. 1F.

[0224] Fig. 1J is a magnified view of the encircled portion of the analyte sensor system of Fig. 1H.

Abbott Ex. 1003 - 82/1058

[0225] Fig. 1K is a cut-away view of an analyte sensor system in another embodiment.

[0226] Fig. 1L is a cut-away view of an analyte sensor system in another embodiment.

[0227] Fig. 1M is a cut-away view of an analyte sensor system in another embodiment.

[0228] Fig. 2A is a perspective view of another embodiment of the analyte sensor system, including a catheter with a sensor integrally formed thereon.

[0229] Fig. 2B is a perspective view of the analyte sensor system of Fig. 2A.

[0230] Fig. 2C is a close-up view of a portion of the analyte sensor system of Fig. 2A in an alternative configuration of an embodiment having three electrodes disposed on the catheter.

[0231] Fig. 2D is a close-up view of a portion of the analyte sensor system of Fig. 2A in an alternative configuration of an embodiment having three electrodes disposed on the catheter.

[0232] Fig. 2E is a close-up view of a portion of the analyte sensor system of Fig. 2A in an alternative embodiment having two electrodes disposed on the catheter.

[0233] Fig. 2F is a close-up view of a portion of the analyte sensor system of Fig. 2A in an alternative embodiment having one electrode disposed on the catheter.

[0234] Fig. 2G is a cross-section of analyte sensor system in one embodiment, including a plurality of analyte sensors disposed within the connector of a catheter.

[0235] Fig. 2H is a cross-section of analyte sensor system in one embodiment, including a plurality of analyte sensors disposed within a fluid coupler, such as but not limited to a connector, a valve, and a Leur lock.

[0236] Fig. 2I is a cross-section of analyte sensor system of Fig. 2H, taken along line 2I – 2I.

[0237] Fig. 2J is a cross-section of analyte sensor system of Fig. 2H, taken along line 2I – 2I.

[0238] Fig. 2K is a cross-section of analyte sensor system of Fig. 2H, taken along line 2I – 2I.

Abbott Ex. 1003 - 83/1058

[0239] Fig. 2L is a cross-section of analyte sensor system of Fig. 2H, taken along line 2I – 2I.

[0240] Fig. 2M is a side view schematic of an analyte sensor system in another embodiment, including a plurality of electrodes disposed in a fluid coupler.

[0241] Fig. 2N is a schematic of an analyte sensor system in yet another embodiment, including a fluid coupler having a plurality of lumens, each of which includes an analyte sensor.

[0242] Fig. 2O is a schematic illustrating a method of manufacturing the analyte sensor system of Fig. 2M, in one embodiment.

[0243] Fig. 2P is a schematic illustrating a method of manufacturing the analyte sensor system of Fig. 2M, in another embodiment.

[0244] Fig. 2Q is a side view schematic of an analyte sensor system, including a fluid coupler including a plurality of sensor electrodes disposed therein, in one embodiment.

[0245] Fig. 2R is a cross-sectional schematic of an analyte sensor system, including a fluid coupler including a plurality of sensor electrodes disposed therein, in another embodiment.

[0246] Fig. 2S is a side view schematic of an analyte sensor system, including a fluid coupler including a plurality of sensor electrodes disposed therein, in still another embodiment.

[0247] Fig. 3A is a perspective view of a first portion of one embodiment of an analyte sensor.

[0248] Fig. 3B is a perspective view of a second portion of the analyte sensor of Fig. 3A.

[0249] Fig. 3C is a cross section of the analyte sensor of Fig. 3B, taken on line C – C.

[0250] Fig. 3D is a cross-sectional schematic view of a sensing region of a dual-electrode continuous analyte sensor in one embodiment wherein an active enzyme of an enzyme domain is positioned over the first working electrode but not over the second working electrode.

[0251] Fig. 3E is a perspective view of a dual-electrode continuous analyte sensor in one embodiment.

Abbott Ex. 1003 - 84/1058

[0252] Fig. 3F is a schematic illustrating metabolism of glucose by Glucose Oxidase (GOx) and one embodiment of a diffusion barrier ***D*** that substantially prevents the diffusion of H_2O_2 produced on a first side of the sensor (e.g., from a first working electrode that has active GOx) to a second side of the sensor (e.g., to the second working electrode that lacks active GOx).

[0253] Fig. 3G is a two-dimensional schematic of a dual-electrode sensor in one embodiment, illustrating the sensor's first and second electroactive surfaces (of the first and second working electrodes, respectively) beneath a sensor membrane, wherein noise-causing species produced by a plurality of point sources can impinge upon an electroactive surface.

[0254] Fig. 3H is a two-dimensional schematic of a dual-electrode sensor in one embodiment, illustrating the sensor's first and second electroactive surfaces (of the first and second working electrodes, respectively) beneath a sensor membrane, wherein noise from a single point source (e.g., a cell) can impinge upon both electroactive surfaces.

[0255] Fig. 3I is a cross-sectional schematic illustrating a dual-electrode sensor, in one embodiment, including a physical diffusion barrier.

[0256] Fig. 3J is a graph illustrating signal response of the electrodes of a dual-electrode sensor, in one embodiment.

[0257] Fig. 3K is a graph illustrating signal response of the electrodes of a dual-electrode sensor, in one embodiment.

[0258] Fig. 4 is a graph illustrating *in vivo* function of an analyte sensor system of the embodiment shown in Fig. 1A.

[0259] Fig. 5 is a graph illustrating *in vivo* function of an analyte sensor system of the embodiment shown in Fig. 1A.

[0260] Fig. 6 is a schematic of an integrated sensor system.

[0261] Fig. 7 is a block diagram of an integrated sensor system

[0262] Figs. 8A through 8C are schematic illustrations of a flow control device in one exemplary embodiment, including is relative movement/positions and the consequential effect on the flow of fluids through the sensor/catheter inserted in a host.

[0263] Fig. 9 is a cut-away illustration of one exemplary embodiment of a catheter implanted in a host's vessel.

Abbott Ex. 1003 - 85/1058

[0264] Fig. 10A is a schematic illustrating one exemplary embodiment of a flow control device and tubing assembly.

[0265] Fig. 10B is a schematic illustrating another exemplary embodiment of a flow control device and tubing assembly.

[0266] Fig. 10C is a schematic illustrating another exemplary embodiment of a flow control device with installed tubing assembly, wherein the valve is in a gravity flow position.

[0267] Fig. 10D is a schematic illustrating another exemplary embodiment of a flow control device with installed tubing assembly, wherein the valve is in a controlled-flow position.

[0268] Fig. 10E is a graph illustrating an exemplary flow profile, in one embodiment.

[0269] Fig. 11 is a graph that schematically illustrates a signal produced during exposure of the sensor to a step change in analyte concentration, in one exemplary embodiment.

[0270] Fig. 12 is a graph that schematically illustrates a derivative of the step response shown in Fig. 9.

[0271] Fig. 13 is a graph that illustrates level vs. rate for a plurality of time-spaced signals associated with exposure of the sensor to biological samples of unknown or uncalibrated analyte concentration.

[0272] Fig. 14 is a flow chart illustrating sensor sensitivity evaluation, in one embodiment.

[0273] Fig. 15 is a flow chart illustrating sensor stability evaluation, in one embodiment.

[0274] Fig. 16 is a flow chart illustrating system diagnostics, in one embodiment.

[0275] Fig. 17 is a graphical representation showing exemplary glucose sensor data and corresponding blood glucose values over time in a pig.

[0276] Fig. 18 is a graphical representation showing exemplary calibrated glucose sensor data (test) and corresponding blood glucose values (YSI control) over time in a human.

[0277] Fig. 19A is a graph that illustrates an *in vivo* signal (counts) detected from a dual-electrode sensor, in one embodiment, implanted in a non-diabetic human host.

Abbott Ex. 1003 - 86/1058

[0278] Fig. 19B is a graph that illustrates an *in vivo* signal (counts) detected from a dual-electrode, in another embodiment, implanted in a non-diabetic human host.

[0279] Fig. 20A is a graph that illustrates an *in vivo* signal (counts) detected from a dual-electrode, in one embodiment, implanted in a non-diabetic human host.

[0280] Fig. 20B is a graph that illustrates an *in vivo* signal (counts) detected from a dual-electrode, in another embodiment, implanted in a non-diabetic human host.

[0281] Fig. 21A is a graph that illustrates an *in vivo* glucose values detected from a dual-electrode, in another embodiment, implanted in a non-diabetic porcine host.

[0282] Fig. 21B is a Clark Error Grid graph of the data of Fig. 21A.

[0283] Fig. 22 is a graph of a signal waveform generated during a successful infusion of the reference solution into the host *versus* the adaptive calibration waveform template.

[0284] Fig. 23 is a graph of a signal waveform generated during an unsuccessful infusion of the reference solution into the host *versus* the adaptive calibration waveform template.

[0285] Fig. 24 is a graph of the signals generated from the plus-enzyme working electrode and from the no-enzyme working electrode illustrating sensor stabilization.

[0286] Fig. 25 is a graph illustrating sensor sensitivity over time.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0287] The following description and examples illustrate some exemplary embodiments of the disclosed invention in detail. Those of skill in the art will recognize that there are numerous variations and modifications of this invention that are encompassed by its scope. Accordingly, the description of a certain exemplary embodiment should not be deemed to limit the scope of the preferred embodiments.

Definitions

[0288] In order to facilitate an understanding of the preferred embodiments, a number of terms are defined below.

[0289] The term "analyte" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological sample (e.g., bodily fluids, including, blood, serum, plasma,

Abbott Ex. 1003 - 87/1058

interstitial fluid, cerebral spinal fluid, lymph fluid, ocular fluid, saliva, oral fluid, urine, excretions or exudates). Analytes can include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensing regions, devices, and methods is albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO_2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, metabolic markers, and drugs. However, other analytes are contemplated as well, including but not limited to acetaminophen, dopamine, ephedrine, terbutaline, ascorbate, uric acid, oxygen, d-amino acid oxidase, plasma amine oxidase, xanthine oxidase, NADPH oxidase, alcohol oxidase, alcohol dehydrogenase, pyruvate dehydrogenase, diols, Ros, NO, bilirubin, cholesterol, triglycerides, gentisic acid, ibuprophen, L-Dopa, methyl dopa, salicylates, tetracycline, tolazamide, tolbutamide, acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-ß hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, hemoglobin S, hemoglobin C, hemoglobin D, hemoglobin E, hemoglobin F, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free ß-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; glucose-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated

Abbott Ex. 1003 - 88/1058

hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17-alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, ß); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids can also constitute analytes in certain embodiments. The analyte can be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte can be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl,

Abbott Ex. 1003 - 89/1058

meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body can also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), histamine, Advanced Glycation End Products (AGEs) and 5-hydroxyindoleacetic acid (FHIAA).

[0290] The term "antegrade" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to orientation (e.g., of a catheter) with the direction of blood flow.

[0291] The term "baseline," "noise" and "background signal" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a component of an analyte sensor signal that is not related to the analyte concentration. In one example of a glucose sensor, the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation/reduction potential that overlaps with hydrogen peroxide). In some embodiments wherein a calibration is defined by solving for the equation $y=mx+b$, the value of b represents the baseline, or background, of the signal.

[0292] The terms "baseline and/or sensitivity shift," "baseline and/or sensitivity drift," "shift," and "drift" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a change in the baseline and/or sensitivity of the sensor signal over time. While the term "shift" generally refers to a substantially distinct change over a relatively short time period, and the term "drift" generally refers to a substantially gradual change over a relatively longer time period, the terms can be used interchangeably and can also be generally referred to as "change" in baseline and/or sensitivity.

Abbott Ex. 1003 - 90/1058

[0293] The term "biological sample" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to a sample of a host body, for example, blood, serum, plasma, interstitial fluid, cerebral spinal fluid, lymph fluid, ocular fluid, saliva, oral fluid, urine, sweat, excretions, exudates, and the like.

[0294] The term "blood chemistry analysis device" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a device that measures a variety of blood components, characteristics or analytes therein. In one embodiment, a blood chemistry analysis device periodically withdraws an aliquot of blood from the host, measures glucose, O_2, CO_2, PCO_2, PO_2, potassium, sodium, pH, lactate, urea, bilirubin, creatinine, hematocrit, various minerals, and/or various metabolites, and the like, and returns the blood to the host's circulatory system. A variety of devices exist for testing various blood properties/analytes at the bedside, such as but not limited to the blood gas and chemistry devices manufactured by Via Medical (Austin, Texas, USA).

[0295] The term "blood pressure monitor" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to an instrument for monitoring the blood pressure of a human or other animal. For example, a blood pressure monitor can be an invasive blood pressure monitor, which periodically monitors the host's blood pressure *via* a peripheral artery, using a blood pressure transducer, such as but not limited to a disposable blood pressure transducer. Utah Medical Products Inc. (Midvale, Utah, USA) produces a variety of DELTRAN® Brand disposable blood pressure transducers that are suitable for use with various embodiments disclosed herein.

[0296] The term "calibration" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the relationship and/or process of determining the relationship between the sensor data and the corresponding reference data, which can be used to convert sensor data into values substantially equivalent to the reference data. In some embodiments, namely, in continuous analyte sensors, calibration can be updated or recalibrated over time if changes in the relationship between the sensor data

Abbott Ex. 1003 - 91/1058

and reference data occur, for example, due to changes in sensitivity, baseline, transport, metabolism, and the like.

[0297] The term "casting" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a process where a fluid material is applied to a surface or surfaces and allowed to cure or dry. The term is broad enough to encompass a variety of coating techniques, for example, using a draw-down machine (*i.e.*, drawing-down), dip coating, spray coating, spin coating, and the like.

[0298] The term "catheter" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a tube that can be inserted into a host's body (e.g., cavity, duct or vessel). In some circumstances, catheters allow drainage or injection of fluids or access by medical instruments or devices. In some embodiments, a catheter is a thin, flexible tube (e.g., a "soft" catheter). In alternative embodiments, the catheter can be a larger, solid tube (e.g., a "hard" catheter). The term "cannula" is interchangeable with the term "catheter" herein.

[0299] The term "coaxial" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to having a common axis, having coincident axes or mounted on concentric shafts.

[0300] The term "constant analyte" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to an analyte that remains relatively constant over a time period, for example over an hour to a day as compared to other variable analytes. For example, in a person with diabetes, oxygen and urea may be relatively constant analytes in particular tissue compartments relative to glucose, which is known to oscillate between about 40 and 400 mg/dL during a 24-hour cycle. Although analytes such as oxygen and urea are known to oscillate to a lesser degree, for example due to physiological processes in a host, they are substantially constant, relative to glucose, and can be digitally filtered, for example low pass filtered, to minimize or eliminate any relatively low amplitude oscillations. Constant analytes other than oxygen and urea are also contemplated.

Abbott Ex. 1003 - 92/1058

[0301] The terms "constant noise" and "constant background" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refer without limitation to the component of the background signal that remains relatively constant over time. For example, certain electroactive compounds found in the human body are relatively constant factors (e.g., baseline of the host's physiology) and do not significantly adversely affect accuracy of the calibration of the glucose concentration (e.g., they can be relatively constantly eliminated using the equation $y=mx+b$). In some circumstances, constant background noise can slowly drift over time (*e.g.*, increases or decreases), however this drift need not adversely affect the accuracy of a sensor, for example, because a sensor can be calibrated and re-calibrated and/or the drift measured and compensated for.

[0302] The terms "continuous" and "continuously" as used herein are broad terms, and are to be given their ordinary and customary meanings to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to the condition of being marked by substantially uninterrupted extension in space, time or sequence. In one embodiment, an analyte concentration is measured continuously or continually, for example at time intervals ranging from fractions of a second up to, for example, about 1, 2, 5, 10, 15, 20, 30, 40, 50 or 60 minutes, or longer. It should be understood that continuous glucose sensors generally continually measure glucose concentration without required user initiation and/or interaction for each measurement, such as described with reference to U.S. Pat. No. 6,001,067, for example. These terms include situations wherein data gaps can exist (e.g., when a continuous glucose sensor is temporarily not providing data).

[0303] The term "continuous (or continual) analyte sensing" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the period in which monitoring of analyte concentration is continuously, continually, and or intermittently (regularly or irregularly) performed, for example, about every 5 to 10 minutes.

[0304] The term "count" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a unit of measurement of

Abbott Ex. 1003 - 93/1058

a digital signal. For example, a raw data stream or raw data signal measured in counts is directly related to a voltage (for example, converted by an A/D converter), which is directly related to current from the working electrode. In some embodiments, the terms can refer to data that has been integrated or averaged over a time period (e.g., 5 minutes).

[0305] The terms "coupling" and "operatively coupling" as used herein are broad terms, and are to be given their ordinary and customary meanings to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a joining or linking together of two or more things, such as two parts of a device or two devices, such that the things can function together. In one example, two containers can be operatively coupled by tubing, such that fluid can flow from one container to another. Coupling does not imply a physical connection. For example, a transmitter and a receiver can be operatively coupled by radio frequency (RF) transmission/communication.

[0306] The term "diffusion barrier" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning) and refers without limitation to something that obstructs the random movement of compounds, species, atoms, molecules, or ions from one site in a medium to another. In some embodiments, a diffusion barrier is structural, such as a wall that separates two working electrodes and substantially prevents diffusion of a species from one electrode to the other. In some embodiments, a diffusion barrier is spatial, such as separating working electrodes by a distance sufficiently large enough to substantially prevent a species at a first electrode from affecting a second electrode. In other embodiments, a diffusion barrier can be temporal, such as by turning the first and second working electrodes on and off, such that a reaction at a first electrode will not substantially affect the function of the second electrode.

[0307] The term "dip coating" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to coating, which involves dipping an object or material into a liquid coating substance.

[0308] The term "distal to" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship

Abbott Ex. 1003 - 94/1058

between various elements in comparison to a particular point of reference. In general, the term indicates an element is located relatively far from the reference point than another element.

[0309] The term "domain" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a region of the membrane system that can be a layer, a uniform or non-uniform gradient (for example, an anisotropic region of a membrane), or a portion of a membrane.

[0310] The term "electrochemical break-in" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the time, after *in vitro* and/or *in vivo* settling of the current output from the sensor following the application of the potential to the sensor.

[0311] The term "electrochemically reactive surface" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a surface where an electrochemical reaction takes place. For example, a working electrode measures hydrogen peroxide produced by the enzyme-catalyzed reaction of the analyte detected, which reacts to create an electric current. Glucose analyte can be detected utilizing glucose oxidase, which produces H_2O_2 as a byproduct. H_2O_2 reacts with the surface of the working electrode, producing two protons ($2H^+$), two electrons ($2e^-$) and one molecule of oxygen (O_2), which produces the electronic current being detected.

[0312] The terms "electronic connection," "electrical connection," "electrical contact" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refer without limitation to any connection between two electrical conductors known to those in the art. In one embodiment, electrodes are in electrical connection with the electronic circuitry of a device.

[0313] The terms "electronics" and "sensor electronics" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to electronics operatively coupled to the sensor and configured to measure, process,

Abbott Ex. 1003 - 95/1058

receive, and/or transmit data associated with a sensor. In some embodiments, the electronics include at least a potentiostat that provides a bias to the electrodes and measures a current to provide the raw data signal. The electronics are configured to calculate at least one analyte sensor data point. For example, the electronics can include a potentiostat, A/D converter, RAM, ROM, and/or transmitter. In some embodiments, the potentiostat converts the raw data (e.g., raw counts) collected from the sensor and converts it to a value familiar to the host and/or medical personnel. For example, the raw counts from a glucose sensor can be converted to milligrams of glucose per deciliter of blood (e.g., mg/dl). In some embodiments, the sensor electronics include a transmitter that transmits the signals from the potentiostat to a receiver (e.g., a remote analyzer, such as but not limited to a remote analyzer unit), where additional data analysis and glucose concentration determination can occur.

[0314] The term "*ex vivo* portion" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a portion of a device (for example, a sensor) adapted to remain and/or exist outside of a living body of a host.

[0315] The term "fluid communication" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to two or more components (e.g., things such as parts of a body or parts of a device) functionally linked such that fluid can move from one component to another. These terms do not imply directionality.

[0316] The term "GOx" as used herein is a broad term, and is to be given their ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to the enzyme Glucose Oxidase (e.g., GOx is an abbreviation).

[0317] The term "helix" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to a spiral or coil, or something in the form of a spiral or coil (e.g. a corkscrew or a coiled spring). In one example, a helix is a mathematical curve that lies on a cylinder or cone and makes a constant angle with the straight lines lying in the cylinder or cone. A "double helix" is a pair of parallel helices intertwined about a common axis, such as but not limited to that in the structure of DNA.

Abbott Ex. 1003 - 96/1058

[0318] The term "host" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to animals or plants, for example humans.

[0319] The term "hyperglycemia" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a condition in which an excessive or high amount of glucose exists in a host. Hyperglycemia is one of the classic symptoms of diabetes mellitus. Non-diabetic hyperglycemia is associated with obesity and certain eating disorders, such as bulimia nervosa. Hyperglycemia is also associated with other diseases (or medications) affecting pancreatic function, such as pancreatic cancer. Hyperglycemia is also associated with poor medical outcomes in a variety of clinical settings, such as intensive or critical care settings.

[0320] The term "hypoglycemia" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a condition in which a limited or low amount of glucose exists in a host. Hypoglycemia can produce a variety of symptoms and effects but the principal problems arise from an inadequate supply of glucose as fuel to the brain, resulting in impairment of function (neuroglycopenia). Derangements of function can range from vaguely "feeling bad" to coma, and (rarely) permanent brain damage or death.

[0321] The terms "inactive enzyme" or "inactivated enzyme" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refer without limitation to an enzyme (e.g., glucose oxidase, GOx) that has been rendered inactive (e.g., "killed" or "dead") and has no enzymatic activity. Enzymes can be inactivated using a variety of techniques known in the art, such as but not limited to heating, freeze-thaw, denaturing in organic solvent, acids or bases, cross-linking, genetically changing enzymatically critical amino acids, and the like. In some embodiments, a solution containing active enzyme can be applied to the sensor, and the applied enzyme subsequently inactivated by heating or treatment with an inactivating solvent.

Abbott Ex. 1003 - 97/1058

[0322] The term "indwell" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to reside within a host's body. Some medical devices can indwell within a host's body for various lengths of time, depending upon the purpose of the medical device, such as but not limited to a few hours, days, or weeks, to months, years, or even the host's entire lifetime. In one exemplary embodiment, an arterial catheter may indwell within the host's artery for a few hours, days, a week, or longer, such as but not limited to the host's perioperative period (e.g., from the time the host is admitted to the hospital to the time he is discharged).

[0323] The terms "insulative properties," "electrical insulator" and "insulator" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning) and refers without limitation to the tendency of materials that lack mobile charges to prevent movement of electrical charges between two points. In one exemplary embodiment, an electrically insulative material may be placed between two electrically conductive materials, to prevent movement of electricity between the two electrically conductive materials. In some embodiments, the terms refer to a sufficient amount of insulative property (e.g., of a material) to provide a necessary function (electrical insulation). The terms "insulator" and "non-conductive material" can be used interchangeably herein.

[0324] The terms "integral," "integrally," "integrally formed," integrally incorporated," "unitary" and "composite" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and they are not to be limited to a special or customized meaning), and refer without limitation to the condition of being composed of essential parts or elements that together make a whole. The parts are essential for completeness of the whole. In one exemplary embodiment, at least a portion (e.g., the *in vivo* portion) of the sensor is formed from at least one platinum wire at least partially covered with an insulative coating, which is at least partially helically wound with at least one additional wire, the exposed electroactive portions of which are covered by a membrane system (see description of Fig. 1B or 9B); in this exemplary embodiment, each element of the sensor is formed as an integral part of the sensor (e.g., both functionally and structurally).

Abbott Ex. 1003 - 98/1058

[0325] The terms "interferants" and "interfering species" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and they are not to be limited to a special or customized meaning), and refer without limitation to effects and/or species that interfere with the measurement of an analyte of interest in a sensor to produce a signal that does not accurately represent the analyte measurement. In one example of an electrochemical sensor, interfering species are compounds with an oxidation/reduction potential that overlaps with the analyte to be measured, producing a false positive signal. In another example of an electrochemical sensor, interfering species are substantially non-constant compounds (e.g., the concentration of an interfering species fluctuates over time). Interfering species include but are not limited to compounds with electroactive acidic, amine or sulfhydryl groups, urea, lactic acid, phosphates, citrates, peroxides, amino acids, amino acid precursors or break-down products, nitric oxide (NO), NO-donors, NO-precursors, acetaminophen, ascorbic acid, bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen, L-dopa, methyl dopa, salicylate, tetracycline, tolazamide, tolbutamide, triglycerides, and uric acid electroactive species produced during cell metabolism and/or wound healing, electroactive species that arise during body pH changes and the like.

[0326] The term "*in vivo* portion" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a portion of a device (for example, a sensor) adapted for insertion into and/or existence within a living body of a host.

[0327] The term "medical device" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to an instrument, apparatus, implement, machine, contrivance, implant, *in vitro* reagent, or other similar or related article, including a component part, or accessory which is intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals. Medical devices that can be used in conjunction with various embodiments of the analyte sensor system include any monitoring device requiring placement in a human vessel, duct or body cavity, a dialysis machine, a heart-lung bypass machine, blood

Abbott Ex. 1003 - 99/1058

collection equipment, a blood pressure monitor, an automated blood chemistry analysis device and the like.

[0328] The terms "membrane" and "membrane system" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a permeable or semi-permeable membrane that can be comprised of one or more domains and is typically constructed of materials of one or more microns in thickness, which is permeable to oxygen and to an analyte, *e.g.*, glucose or another analyte. In one example, the membrane system includes an immobilized glucose oxidase enzyme, which enables a reaction to occur between glucose and oxygen whereby a concentration of glucose can be measured.

[0329] The term "membrane break-in" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to equilibration of the membrane to its surrounding environment (*e.g.*, physiological environment *in vivo).*

[0330] The term "needle" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a slender hollow instrument for introducing material into or removing material from the body.

[0331] The term "non-constant noise" or non-constant background" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refer without limitation to a component of the background signal that is relatively non-constant, for example, transient and/or intermittent. For example, certain electroactive compounds, are relatively non-constant (e.g., intermittent interferents due to the host's ingestion, metabolism, wound healing, and other mechanical, chemical and/or biochemical factors), which create intermittent (e.g., non-constant) "noise" on the sensor signal that can be difficult to "calibrate out" using a standard calibration equations (e.g., because the background of the signal does not remain constant).

[0332] The term "non-enzymatic" as used herein is a broad term, and is to be given their ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to a lack of enzyme

Abbott Ex. 1003 - 100/1058

activity. In some embodiments, a "non-enzymatic" membrane portion contains no enzyme; while in other embodiments, the "non-enzymatic" membrane portion contains inactive enzyme. In some embodiments, an enzyme solution containing inactive enzyme or no enzyme is applied.

[0333] The terms "operatively connected," "operatively linked," "operably connected," and "operably linked" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to one or more components linked to one or more other components. The terms can refer to a mechanical connection, an electrical connection, or any connection that allows transmission of signals between the components. For example, one or more electrodes can be used to detect the amount of analyte in a sample and to convert that information into a signal; the signal can then be transmitted to a circuit. In such an example, the electrode is "operably linked" to the electronic circuitry. The terms include wired and wireless connections.

[0334] The term "potentiostat" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to an electronic instrument that controls the electrical potential between the working and reference electrodes at one or more preset values. Typically, a potentiostat works to keep the potential constant by noticing changes in the resistance of the system and compensating inversely with a change in the current. As a result, a change to a higher resistance would cause the current to decrease to keep the voltage constant in the system. In some embodiments, a potentiostat forces whatever current is necessary to flow between the working and counter electrodes to keep the desired potential, as long as the needed cell voltage and current do not exceed the compliance limits of the potentiostat.

[0335] The term "pressure transducer" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a component of an intra-arterial blood pressure monitor that measures the host's blood pressure.

[0336] The terms "processor module" and "microprocessor" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary

Abbott Ex. 1003 - 101/1058

skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a computer system, state machine, processor, and the like designed to perform arithmetic or logic operations using logic circuitry that responds to and processes the basic instructions that drive a computer.

[0337] The term "proximal to" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the spatial relationship between various elements in comparison to a particular point of reference. In general, the term indicates an element is located relatively near to the reference point than another element.

[0338] The term "pump" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a device used to move liquids, or slurries. In general, a pump moves liquids from lower pressure to higher pressure, and overcomes this difference in pressure by adding energy to the system (such as a water system).

[0339] The term "sensor break-in" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the time (after implantation) during which the sensor's signal is becoming substantially representative of the analyte (*e.g.*, glucose) concentration (*e.g.*, where the current output from the sensor is stable relative to the glucose level). The signal may not be 'flat' when the sensor has broken-in, but in general, variation in the signal level at that point is due to a change in the analyte (*e.g.*, glucose) concentration. In some embodiments, sensor break-in occurs prior to obtaining a meaningful calibration of the sensor output. In some embodiments, sensor break-in generally includes both electrochemical break-in and membrane break-in.

[0340] The terms "small diameter sensor," "small structured sensor," and "micro-sensor" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to sensing mechanisms that are less than about 2 mm in at least one dimension, and more preferably less than about 1 mm in at least one dimension. In some embodiments, the sensing mechanism (sensor) is less than about 0.95,

Abbott Ex. 1003 - 102/1058

0.9, 0.85, 0.8, 0.75, 0.7, 0.65, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 mm. In some embodiments, the sensing mechanism is a needle-type sensor, wherein the diameter is less than about 1 mm (see, for example, U.S. Patent No. 6,613,379 and U.S. Patent Publication No. US-2006-0020187-A1, each of which is incorporated herein by reference in its entirety). In some alternative embodiments, the sensing mechanism includes electrodes deposited on a planar substrate, wherein the thickness of the implantable portion is less than about 1 mm, see, for example U.S. Patent No. 6,175,752 and U.S. Patent No. 5,779,665, both of which are incorporated herein by reference in their entirety.

[0341] The terms "raw data," "raw data stream", "raw data signal", "data signal", and "data stream" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an analog or digital signal from the analyte sensor directly related to the measured analyte. For example, the raw data stream is digital data in "counts" converted by an A/D converter from an analog signal (for example, voltage or amps) representative of an analyte concentration. The terms can include a plurality of time spaced data points from a substantially continuous analyte sensor, each of which includes individual measurements taken at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer. In some embodiments, the terms can refer to data that has been integrated or averaged over a time period (e.g., 5 minutes).

[0342] The term "regulator" or "flow control device," as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a device that regulates the flow of a fluid or gas, for example, a valve or a pump.

[0343] The term "retrograde" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to orientation (e.g., of a catheter) against the direction of blood flow.

[0344] The term "sensing region" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the region of a monitoring device responsible for the detection of a particular analyte.

Abbott Ex. 1003 - 103/1058

[0345] The terms "sensitivity" and "slope" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to an amount of electrical current produced by a predetermined amount (unit) of the measured analyte. For example, in one preferred embodiment, a glucose sensor has a sensitivity (or slope) of from about 1 to about 25 picoAmps of current for every 1 mg/dL of glucose.

[0346] The terms "sensor" and "sensor system" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a device, component, or region of a device by which an analyte can be quantified.

[0347] The term "sheath" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a covering or supporting structure that fits closely around something, for example, in the way that a sheath covers a blade. In one exemplary embodiment, a sheath is a slender, flexible, polymer tube that covers and supports a wire-type sensor prior to and during insertion of the sensor into a catheter.

[0348] The term "single point glucose monitor" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a device that can be used to measure a glucose concentration within a host at a single point in time, for example, some embodiments utilize a small volume *in vitro* glucose monitor that includes an enzyme membrane such as described with reference to U.S. Patent No. 4,994,167 and U.S. Patent No. 4,757,022. It should be understood that single point glucose monitors can measure multiple samples (for example, blood, or interstitial fluid); however only one sample is measured at a time and typically requires some user initiation and/or interaction.

[0349] The term "slot" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a relatively narrow opening.

[0350] The terms "solvent" and "solvent system" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the

Abbott Ex. 1003 - 104/1058

art (and are not to be limited to a special or customized meaning), and refer without limitation to substances (e.g., liquids) capable of dissolving or dispersing one or more other substances. Solvents and solvent systems can include compounds and/or solutions that include components in addition to the solvent itself.

[0351] The term "specific gravity" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the ratio of density of a material (e.g., a liquid or a solid) to the density of distilled water.

[0352] The term "spin coating" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a coating process in which a thin film is created by dropping a raw material solution onto a substrate while it is rotating.

[0353] The term "spray coating" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to coating, which involves spraying a liquid coating substance onto an object or material.

[0354] The terms "substantial" and "substantially" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to a sufficient amount that provides a desired function. For example, an amount greater than 50 percent, an amount greater than 60 percent, an amount greater than 70 percent, an amount greater than 80 percent, or an amount greater than 90 percent.

[0355] The term "twisted" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to united by having one part or end turned in the opposite direction to the other, such as, but not limited to the twisted strands of fiber in a string, yarn, or cable.

[0356] The term "valve" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a device that

Abbott Ex. 1003 - 105/1058

regulates the flow of substances (either gases, fluidized solids, slurries, or liquids), for example, by opening, closing, or partially obstructing a passageway through which the substance flows. In general, a valve allows no flow, free flow and/or gravity flow and/or metered flow through movement of the valve between one or more discreet positions.

[0357] The term "vascular access device" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to any device that is in communication with the vascular system of a host. Vascular access devices include but are not limited to catheters, shunts, blood withdrawal devices, connectors, valves, tubing and the like.

Overview

[0358] Intensive care medicine or critical care medicine is concerned with providing greater than ordinary medical care and/or observation to people in a critical or unstable condition. In recent years, an increasingly urgent need has arisen, for more intensive care medicine. People requiring intensive care include those recovering after major surgery, with severe head trauma, life-threatening acute illness, respiratory insufficiency, coma, hemodynamic insufficiency, severe fluid imbalance or with the failure of one or more of the major organ systems (life-critical systems or others). More than five million people are admitted annually to intensive care units (ICUs) and critical care units (CCUs) in the United States.

[0359] Intensive care is generally the most expensive, high technology and resource intensive area of medical care. In the United States estimates of the year 2000 expenditure for critical care medicine ranged from $15-55 billion accounting for about 0.5% of GDP and about 13% of national health care expenditure. As the U.S. population ages, these costs will increase substantially. Accordingly, there is an urgent need to reduce costs while at the same time reducing ICU/CCU mortality rates by improving care.

[0360] Intensive medical care requires frequent testing and/or monitoring of a variety of analytes, such as but not limited to albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO_2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric

Abbott Ex. 1003 - 106/1058

acid, a metabolic marker and a drug. Some embodiments disclosed herein are suitable for use in an intensive care or critical care unit of a medical care facility for substantially continuously measuring the concentration of one or more analytes in the host.

[0361] For example, diabetes is one medical condition requiring frequent testing of the host's analyte levels (e.g., blood glucose levels), in hospital settings. Hosts having diabetes, for example, are at risk of developing hyperglycemia, a medical condition in which an excessive amount of glucose circulates in a host. Perioperative hyperglycemia is associated with increased rates and severity of myocardial infarction (MI) and stroke, while tight glucose control with intravenous (IV) insulin therapy is linked to a 30% reduction in mortality one year after admission for acute MI. Furthermore, strict in-hospital glucose control is associated with 40% reductions of morbidity, mortality, sepsis, dialysis, blood transfusions, as well as reduced length of stay, reduced costs and the like. On the other hand, diabetic hosts are also susceptible to hypoglycemia (e.g., excessively low circulating blood glucose), which can cause shock and death (immediate problems), which the clinical staff rigorously avoids, often by maintaining the host at elevated blood glucose concentrations (which can degrade the clinical outcome in the long run) and causes the problems of hyperglycemia discussed above. Unfortunately, using generally available technology, tight glucose control requires frequent monitoring of the host by the clinical staff, IV insulin or injections, and on-time feeding. Frequent monitoring typically requires a nurse or other staff member to measure the host's glucose concentration using a lancet (to obtain a blood sample) and a hand held glucose monitor. The nurse can perform this task many times a day (e.g., every hour or more frequently). This task becomes an undue burden that takes the nurse away from his/her other duties, or requires extra staff. In spite of clinically demonstrated improvements associated with tight glucose control, institutions are slow to adopt the therapy due to the increased workload on the staff as well as a pervasive fear of hypoglycemia, which is potentially life ending.

[0362] Therefore, there is an urgent need for devices and methods that offer continuous, robust analyte monitoring, to improve patient care and lower medical costs. Some embodiments disclose systems and methods to reduce and/or minimize the interaction required to regularly (e.g., continuously) measure the host's glucose concentration. Additional and/or alternative analytes can also be continuously monitored using the devices and methods of the preferred embodiments. The preferred embodiments describe systems and methods for

Abbott Ex. 1003 - 107/1058

providing continuous analyte monitoring while providing alarms or alerts that aid in avoiding adverse events.

[0363] The *in vivo* continuous analyte monitoring system of the preferred embodiments can be used in clinical settings, such as in the hospital, the doctor's office, long-term nursing facilities, or even in the home. The present device can be used in any setting in which frequent or continuous analyte monitoring is desirable. For example, in the ICU, hosts are often recovering from serious illness, disease, or surgery, and control of host glucose levels is important for host recovery. For example, use of a continuous glucose sensor as described in the some embodiments allows tight control of host glucose concentration and improved host care, while reducing hypoglycemic episodes and reducing the ICU staff work load. For example, the system can be used for the entire hospital stay or for only a part of the hospital stay.

[0364] In another example, the continuous glucose monitor of the preferred embodiments can be used in medical settings wherein the host is unable to communicate with the medical staff, such as an ER setting. For example, in the ER, a host may be unconscious and therefore unable to communicate with the staff. In another example, a very young, non-verbal host may also be unable to communicate with the staff regarding his or her condition. In still another example, a host undergoing surgery is unable to communicate with the anesthesiologist, due to certain drugs being delivered. Routine use of a continuous analyte monitors (e.g., glucose, calcium, sodium, potassium, CO_2, chloride, blood urea nitrogen, creatinine, pH, oxygen, albumin, total protein, alkaline phosphatase, alanine amino transferase, aspartate amino transferase, bilirubin, phosphate, electrolytes, hematocrit and/or drugs) can enable medical staff to monitor and respond to analyte concentration changes indicative of the host's condition without host input.

[0365] In yet another example, a continuous analyte monitor can be used in the general hospital population to monitor host analyte concentrations, for various lengths of time, such as during the entire hospital stay or for a portion of the hospital stay (e.g., only during surgery). For example, a diabetic host's glucose concentration can be monitored during his or her entire stay. In another example, a cardiac host's glucose can be monitored during surgery and while in the ICU, but not after being moved to the general host population. In another

Abbott Ex. 1003 - 108/1058

example, a jaundiced newborn infant can have his or her bilirubin concentration continuously monitored by an in-dwelling continuous analyte monitor until the condition has receded.

[0366] In addition to use in the circulatory system, the analyte sensor of the preferred embodiments can be used in other body locations. In some embodiments, the sensor is used subcutaneously. In another embodiment, the sensor can be used intracranially. In another embodiment, the sensor can be used within the spinal compartment, such as but not limited to the epidural space. In some embodiments, the sensor of the preferred embodiments can be used with or without a catheter.

Applications/Uses

[0367] One aspect of the preferred embodiments provides a system for *in vivo* continuous analyte monitoring (e.g., albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO_2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, a drug, various minerals, various metabolites, and the like) that can be operatively coupled to a catheter to measure analyte concentration within the host's blood stream. In some embodiments, the system includes an analyte sensor that extends a short distance into the blood stream (e.g., out of the catheter) without substantially occluding the catheter or the host's blood stream. The catheter can be fluidly coupled to additional IV and diagnostic devices, such as a saline bag, an automated blood pressure monitor, or a blood chemistry monitor device. In some embodiments, blood samples can be removed from the host *via* the sensor system, as described elsewhere herein. In one embodiment, the sensor is a glucose sensor, and the medical staff monitors the host's glucose level. In other embodiments, described elsewhere herein, the analyte sensor is disposed within or on the catheter itself, such as the *in vivo* portion of the catheter. In still other embodiments, the analyte sensor is disposed entirely within and/or on the fluid coupler, which is in turn fluidly coupled to a catheter or other vascular access device, as described elsewhere herein.

[0368] **Figs. 1A** to **1J** illustrate two embodiments of an exemplary analyte sensor system **10** for measuring an analyte, as described elsewhere herein, that includes a catheter **12** configured to be inserted or pre-inserted into a host's blood stream. In clinical settings, catheters are often inserted into hosts to allow direct access to the circulatory system without

Abbott Ex. 1003 - 109/1058

frequent needle insertion (e.g., venipuncture). Suitable catheters can be sized as is known and appreciated by one skilled in the art, such as but not limited to from about 1 French (0.33mm) or less to about 30 French (10mm) or more; and can be, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 French (3 French is equivalent to about 1 mm) and/or from about 33 gauge or less to about 16 gauge or more, for example, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, or 16 gauge. Additionally, the catheter can be shorter or longer, for example 0.75, 1.0, 1.25, 1.5, 1.75, 2.0 inches in length or longer. In some embodiments, the catheter is a venous catheter. In other embodiments, the catheter is configured for insertion into a peripheral or a central artery. In some embodiments, the catheter is configured to extend from a peripheral artery to a central portion of the host's circulatory system, such as but not limited to the heart. In still other embodiments, the catheter is configured for insertion into neonatal or other pediatric hosts (e.g., 22-24 gauge or smaller). The catheter can be manufactured of any medical grade material known in the art, such as but not limited to polymers and glass as described herein. A catheter can include a single lumen or multiple lumens. A catheter can include one or more perforations, to allow the passage of host fluid through the lumen of the catheter.

[0369] The terms "inserted" or "pre-inserted" as used herein are broad terms, and are to be given their ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refer without limitation to insertion of one thing into another thing. For example, a catheter can be inserted into a host's blood stream. In some embodiments, a catheter is "pre-inserted," meaning inserted before another action is taken (e.g., insertion of a catheter into a host's blood stream prior to insertion of a sensor into the catheter). In some exemplary embodiments, a sensor is coupled to a pre-inserted catheter, namely, one that has been previously inserted (or pre-inserted) into the host's circulatory system. Alternatively, the sensor and the catheter can be configured to be inserted together and/or the sensor can be integrally formed with the catheter.

[0370] Referring now to **Figs. 1A** to **1J**, in some embodiments, the catheter **12** is a thin, flexible tube having a lumen **12a**, such as is known in the art. In some embodiments, the catheter can be rigid; in other embodiments, the catheter can be custom manufactured to desired specifications (e.g., rigidity, dimensions, etc). The catheter can be a single-lumen catheter or a multi-lumen catheter. In some embodiments, the catheter is a peripheral catheter

Abbott Ex. 1003 - 110/1058

configured and arranged for insertion into a peripheral vessel (e.g., vein and/or artery) in a host's arm and/or leg. In some embodiments, the catheter is a central catheter, configured and arranged for insertion into a host's central vessel (e.g., internal jugular vein, subclavian vein, femoral vein and/or pulmonary artery). At the catheter's proximal end is a small orifice **12b** for fluid connection of the catheter to the blood stream. At the catheter's distal end is a connector **18,** such as a Leur connector or other fluid connector known in the art.

[0371] The illustrations of **Figs. 1A** to **1J** show two exemplary embodiments of the connector **18** including a flange **18a** and a duct **18b.** In the exemplary embodiment, the flange **18a** is configured to enable connection of the catheter to other medical equipment (e.g., saline bag, pressure transducer, blood chemistry device, and the like) or capping (e.g., with a bung and the like). Although one exemplary connector is shown, one skilled in the art appreciates a variety of standard or custom made connectors suitable for use with the preferred embodiments. The duct **18b** is in fluid communication with the catheter lumen and terminates in a connector orifice **18c**.

[0372] In some embodiments, the catheter is inserted into the host's blood stream, such as into a vein or artery by any useful method known in the art. Generally, prior to and during insertion, the catheter is supported by a hollow needle or trochar (not shown). For example, the supported catheter can be inserted into a peripheral vein or artery, such as in the host's arm, leg, hand, or foot. Typically, the supporting needle is removed (e.g., pulled out of the connector) and the catheter is connected (e.g., *via* the connector **18**) to IV tubing and a saline drip, for example. However, in one embodiment, the catheter is configured to operatively couple to medical equipment, such as but not limited to a sensor system of the preferred embodiments. Additionally and/or alternatively, the catheter can be configured to operatively couple to another medical device, such as a pressure transducer, for measurement of the host's blood pressure.

[0373] In some embodiments, the catheter and the analyte sensor are configured to indwell within the host's blood stream *in vivo*. An indwelling medical device, such as a catheter or implant, is disposed within a portion of the body for a period of time, from a few minutes or hours to a few days, months, or even years. An indwelling catheter is typically inserted within a host's vein or artery for a period of time, often 2 or more days, a month, or even a few months. In some embodiments, the catheter can indwell in a host's artery or vein

Abbott Ex. 1003 - 111/1058

for the length of a perioperative period (e.g., the entire hospital stay) or for shorter or longer periods. In some embodiments, the use of an indwelling catheter permits continuous access of an analyte sensor to a blood stream while simultaneously allowing continuous access to the host's blood stream for other purposes, for example, the administration of therapeutics (e.g., fluids, drugs, etc.), measurement of physiologic properties (e.g., blood pressure), fluid removal, and the like.

[0374] Referring again to **Figs. 1A** to **1J**, the system **10** also includes an analyte sensor **14** configured to extend through the catheter lumen **12a** (see **Fig. 1E**), out of the catheter orifice **12b** and into the host's blood stream by about 0.010 inches to about 1 inch, or shorter or longer lengths. In some embodiments, however, the sensor may not extend out of the catheter, for example, can reside just inside the catheter tip. The sensor can extend through the catheter in any functional manner. In some embodiments, the sensor is configured to be held (e.g., located, disposed) on an inner surface (e.g., the lumenal surface) or outer surface of the catheter. In some embodiments, the sensor is deposited (e.g., formed) on a surface of the catheter. In some embodiments, a sensor is attached to a surface of the catheter, such as by an adhesive and/or welding. In some other embodiments, the sensor is configured to "free float" within the lumen of the catheter. In some embodiments, the sensor resides within the fluid coupler.

[0375] In some embodiments, the sensor **14** is configured to measure the concentration of an analyte (e.g., albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO_2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, various drugs, various minerals, various metabolites, and the like) within the host's blood stream. In some preferred embodiments, the sensor includes at least one electrode (see, e.g., **Fig. 3B**), for example a working electrode; however any combination of working electrode(s), reference electrode(s), and/or counter electrode(s) can be implemented as is appreciated by one skilled in the art. For example, in some preferred embodiments, the sensor includes at least two working electrodes, as is described with reference to **Figs. 3D** through **3I**. In still other embodiments, two or more analyte sensors are in fluid communication with the vascular access device (e.g., disposed within the vascular access device), such that two or more

Abbott Ex. 1003 - 112/1058

analytes can be monitored simultaneously, and/or sequentially, continuously and/or intermittently, and the like. Preferably, the sensor **14** includes at least one exposed electroactive area (e.g., working electrode), a membrane system (e.g., including an enzyme), a reference electrode (proximal to or remote from the working electrode), and an insulator material. Various systems and methods for design and manufacture of continuous analyte sensors are described in more detail elsewhere herein. In some embodiments, the sensor is a needle-type continuous analyte sensor, configured as disclosed in U.S. Patent Publication No. US-2006-0020192-A1 and U.S. Patent Publication No. US-2006-0036143-A1, both of which are incorporated herein by reference in their entirety. In some embodiments, the sensor is disposed on a planar substrate, configured as disclosed in U.S. Patent No. 6,175,752, U.S. Patent No. 6,512,939 and U.S. Patent No. 7,402,153, each of which are incorporated herein by reference in their entirety. In some embodiments, the sensor is configured to measure glucose concentration. Exemplary sensor configurations are discussed in more detail, elsewhere herein.

[0376] Referring to an embodiment illustrated in **Figs 1A** to **1E**, the sensor has a proximal end **14a** and a distal end **14b**. At its distal end **14b**, the sensor **14** is associated with (e.g., connected to, held by, extends through, and the like) a fluid coupler **20** having first and second sides (**20a** and **20b**, respectively). The fluid coupler is configured to mate (*via* its first side **20a**) to the catheter connector **18**. In one embodiment, a skirt **20c** is located at the fluid coupler's first side and includes an interior surface **20d** with threads **20e** (see **Figs. 1D** and **1E**). In this embodiment, the fluid coupler is configured to mate with the connector flange **18a**, which is screwed into the fluid coupler *via* the screw threads. However, in other embodiments, the fluid coupler is configured to mate with the connector using any known mating configuration, for example, a snap-fit, a press-fit, an interference-fit, and the like, and can include a locking mechanism to prevent separation of the connector and fluid coupler. The fluid coupler **20** includes a lumen **20f** extending from a first orifice **20h** on its first side **20a** to a second orifice **20i** located on the fluid coupler's second side **20b** (**Figs. 1C1** to **1E**). When the catheter connector is mated with the fluid coupler, the catheter's lumen **12a** is in fluid communication with the fluid coupler's lumen **20f** *via* orifices **18c** and **20h**.

[0377] **Figs. 1A** to **1D** show one embodiment of a fluid coupler **20**, namely, a Y-coupler; however, any known coupler configuration can be used, including but not limited to

Abbott Ex. 1003 - 113/1058

a straight coupler, a T-coupler, a cross-coupler, a custom configured coupler, and the like. In some embodiments, the fluid coupler includes at least one valve (e.g., a septum, a 3-way valve, a stop-cock valve), which can be used for a variety of purposes (e.g., injection of drugs). As another example, **Figs. 1F-1J** illustrate a fluid coupler configured for connection of the sensor to sensor electronics *via* a female socket **20n** configured to releasably mate with a male plug on an electronic cable. The fluid coupler can be made of any convenient material, such as but not limited to plastic, glass, metal or combinations thereof and can be configured to withstand known sterilization techniques.

[0378] In the exemplary embodiment, the second side **20b** of the fluid coupler **20** is configured to be operably connected to IV equipment, another medical device or to be capped, and can use any known mating configuration, for example, a snap-fit, a press-fit, an interference-fit, and the like. In one exemplary embodiment, the second side **20b** is configured to mate with a saline drip, for delivery of saline to the host. For example, the saline flows from an elevated bag of sterile saline *via* tubing, through the fluid coupler, through the catheter and into the host's blood system (e.g., vein or artery). In another embodiment, a syringe can be mated to the fluid coupler, for example, to withdraw blood from the host, *via* the catheter. Additional connection devices (e.g., a three-way valve) can be operably connected to the fluid coupler, to support additional functionality and connection of various devices, such as but not limited to a blood pressure transducer.

[0379] Referring to the exemplary embodiment of **Figs. 1A** and **1E**, at least a portion of the sensor **14** passes through the fluid coupler **20** (e.g., the fluid coupler lumen **20f**) and is operatively connected to sensor electronics (not shown) *via* a hardwire **24**. In alternative embodiments however, the sensor electronics can be disposed in part or in whole with the fluid coupler (e.g., integrally with or proximal to) or can be disposed in part or in whole remotely from the fluid coupler (*e.g.,* on a stand or at the bed side). Connections between the sensor and sensor electronics (in part or in whole) can be accomplished using known wired or wireless technology. In one exemplary embodiment, the sensor is hardwired to the electronics located substantially wholly remote from the fluid coupler (e.g., disposed on a stand or near the bedside); one advantage of remote electronics includes enabling a smaller sized fluid coupler design. In another exemplary embodiment, a portion of the sensor electronics, such as a potentiostat, is disposed on the fluid coupler and the remaining electronics (e.g., electronics

Abbott Ex. 1003 - 114/1058

for receiving, data processing, printing, connection to a nurses' station, etc.) are disposed remotely from the fluid coupler (e.g., on a stand or near the bedside). One advantage of this design can include more reliable electrical connection with the sensor in some circumstances. In this embodiment, the potentiostat can be hardwired directly to the remaining electronics or a transmitter can be disposed on or proximal to the fluid coupler, for remotely connecting the potentiostat to the remaining electronics (e.g., by radio frequency (RF)). In another exemplary embodiment, all of the sensor electronics can be disposed on the fluid coupler. In still another embodiment, the sensor electronics disposed on the fluid coupler include a potentiostat.

[0380] Referring again to **Figs. 1A** to **1E**, a protective sheath **26** is configured to cover at least a portion of the sensor **14** during insertion, and includes hub **28** and slot **30**. In general, the protective sheath protects and supports the sensor prior to and during insertion into the catheter **12** *via* the connector **18**. The protective sheath can be made of biocompatible polymers known in the art, such as but not limited to polyethylene (PE), polyurethane (PE), polyvinyl chloride (PVC), polycarbonate (PC), nylon, polyamides, polyimide, polytetrafluoroethylene (PTFE), Teflon, nylon and the like. The protective sheath includes a hub **28**, for grasping the sheath (e.g., while maintaining sterilization of the sheath). In this embodiment, the hub additionally provides for mating with the second side **20b** of the fluid coupler **20**, prior to and during sensor insertion into the catheter. In this exemplary embodiment, the slot of the protective sheath is configured to facilitate release of the sensor therefrom. In this embodiment, after the sensor has been inserted into the catheter, the hub is grasped and pulled from the second side of the fluid coupler. This action peels the protective sheath from the sensor (e.g., the sensor slides through the slot as the sheath is removed), leaving the sensor within the catheter. The second side of the fluid coupler can be connected to other medical devices (e.g., a blood pressure monitor) or an IV drip (e.g., a saline drip), or capped. In alternative embodiments, the sheath can fold (e.g., fold back or concertinas) or retract (e.g., telescope) during insertion, to expose the sensor. In other embodiments, the sheath can be configured to tear away from the sensor before, during, or after insertion of the sensor. In still other embodiments, the sheath can include an outlet hole **30a**, to allow protrusion of the sensor from the back end of the sheath (e.g., near the hub **28**). One skilled in the art will recognize that additional configurations can be used, to separate the sensor **14** from the sheath **26**.

Abbott Ex. 1003 - 115/1058

[0381] In some embodiments, the sensor includes at least two working electrodes **14**, which can be twisted and/or bundled, such as in a helical and/or coaxial configuration. In some embodiments, the two working electrodes are twisted into a "twisted pair," which can be configured to be inserted into and to extend within a vascular access device, such as a catheter **12** or cannula implanted in a host's vein or artery, as is described in more detail in the section entitled "Integrated Sensor System." In some embodiments, the twisted pair is configured to reside within the lumen **12a** of the catheter **12**; while in other embodiments, the twisted pair is configured to protrude from the catheter's proximal orifice **12b**. In still other embodiments, the twisted pair is configured to intermittently protrude from the catheter's proximal orifice **12b**.

[0382] In some embodiments, the sheath **26** can be optional, depending upon the sensor design. For example, the sensor can be inserted into a catheter or other vascular access device with or without the use of a protective sheath). In some embodiments, the sensor can be disposed on the outer surface of a catheter (as described elsewhere herein) or on the inner surface of a catheter; and no sheath is provided. In other embodiments, a multi-lumen catheter can be provided with a sensor already disposed within one of the lumens; wherein the catheter is inserted into the host's vein or artery with the sensor already disposed in one of the lumens. In one exemplary embodiment, the system includes a catheter having multiple lumens, and is configured and arranged to infuse a fluid in a first lumen of the catheter and to draw back a biological sample into a second lumen of the catheter. In a further embodiment, an analyte sensor is located in the second lumen of the catheter. In some embodiments, the system is configured to infuse a fluid into the second lumen, such as to reinfuse a drawn back sample into the host and/or to wash the sensor. In some embodiments, a flow control device is configured and arranged for infusion of at least two solutions, such as via a multi-lumen catheter, and includes at least two valves, such as described with reference to **Figs 8A** through **10D**.

[0383] In some alternative embodiments, an analyte sensor is integrally formed on a catheter. In various embodiments, the catheter can be placed into a host's vein or artery in the usual way a catheter is inserted, as is known by one skilled in the art, and the host's analyte concentration measured substantially continuously. In some embodiments, the sensor system can be coupled to one or more additional devices, such as a saline bag, an automated blood

Abbott Ex. 1003 - 116/1058

pressure monitor, a blood chemistry monitor device, and the like. In one exemplary embodiment, the integrally formed analyte sensor is a glucose sensor.

[0384] **Figs. 1F** through **1J** illustrate another embodiment of the sensor system, wherein the fluid coupler **20** includes a housing **20j** configured and arranged for electrical connection of the analyte sensor **14** to at least some system electronics, such as an electronic cable (not shown). The housing **20j** includes a housing cover **20k** and an electrical connector **20n**. While a female socket **20n** (e.g., configured to releasably mate with a male plug) is shown, any electrical connection known in the art can be used, as is appreciate by one skilled in the art.

[0385] **Figs. 1G-1H** are exploded and cut-away views, respectively, of the embodiment shown in **Fig. 1F**. The encircled portion of **Fig. 1H** is shown in **Fig. 1J** and illustrates the configuration of the distal portion of the analyte sensor **14** within the housing **20j**, in this embodiment. The analyte sensor can be configured and arranged to detect one or more analytes, as described elsewhere herein. The proximal portion (*ex vivo* portion) of the analyte sensor **14** is configured and arranged for electrical connection with the sensor electronics *via* one or more elastomeric contacts and/or connectors **20s** and a printed circuit board (PCB) **20t** disposed within the housing. In this embodiment, the connection is a solderless connection. However, in some embodiments, electrical connection of the electrodes to the electronics can be made by other means, for example, wires, contact pads, pogo pins, domed metallic contacts, cantilevered fingers, metallic springs, soldering and/or conductive adhesive. In the embodiment shown in **Figs. 1G-1J**, an elastomeric contact and/or connector **20s**, which can be manufactured of an conductive elastomeric material such as a carbon black elastomer, makes an electrical connection between each of the sensor's electrodes (e.g., working (plus or minus enzyme), counter and/or reference electrodes) and the PCB. For example, as shown in **Fig. 1J**, the electrodes make contact with the elastomeric contacts, and the elastomeric contacts make contact with the PCB. The PCB is configured and arranged to make an electrical connection with at least some of the system electronics, such as but not limited to by socket **20n**. Conductive elastomers are advantageously employed because their resilient properties create a natural compression against mutually engaging contacts, forming a secure press fit therewith. In some embodiments, conductive elastomers can be molded in such a way that pressing the elastomer against an adjacent contact performs a wiping action on

Abbott Ex. 1003 - 117/1058

the surface of the contact, thereby creating a cleaning action during initial connection. Additionally, in some embodiments, the sensor **14** extends through the contacts **20s** wherein the sensor is electrically and mechanically secured by the relaxation of elastomer around the sensor.

[0386] In an alternative embodiment, a conductive, stiff plastic forms the contacts, which are shaped to comply upon application of pressure (for example, a leaf-spring shape). Contacts of such a configuration can be used instead of a metallic spring, for example, and advantageously avoid the need for crimping or soldering through compliant materials; additionally, a wiping action can be incorporated into the design to remove contaminants from the surfaces during connection. Non-metallic contacts can be advantageous because of their seamless manufacturability, robustness to thermal compression, non-corrosive surfaces, and native resistance to electrostatic discharge (ESD) damage due to their higher-than-metal resistance.

[0387] While in this embodiment (e.g., shown in **Figs. 1H** and **1J**), the proximal portion (e.g., part of the *ex vivo* portion, also referred to herein as the first portion) of each electrode physically contacts the bottom of (e.g., beneath) an elastomeric connector, the electrodes can make an electrical connection with elastomeric contacts by a variety of other ways. For example, in some embodiments, one or more of the electrodes can contact the top and/or side of the elastomeric contacts (e.g., above and/or beside). In still other embodiments, an electrode can intersect an elastomeric contact (e.g., pass through at least a portion of the elastomeric contact). In yet another embodiment, the proximal portion of an electrode can be wrapped around an elastomeric contact. Additional configurations are considered in the preferred embodiments. For example, the different configurations can be combined, such as for example, with one electrode touching the bottom of a first elastomeric contact, a second electrode touching the top of a second elastomeric contact, and a third electrode passing through yet another elastomer contact.

[0388] In some embodiments, the interior of the housing is configured to guide placement of the electrodes for contact with the elastomeric contacts, which can simplify manufacturing and ensure formation of a good electrical contact between each electrode and its corresponding elastomeric contact. For example, in the embodiment shown in **Figs. 1H** and **1J**, pathways (e.g., recessed) are provided, to guide the placement of the electrode wires within

Abbott Ex. 1003 - 118/1058

the housing, and wells or cups are provided to receive the elastomeric contacts. For example, in **Fig. 1G**, the proximal portion of each of the sensor's electrodes are received into one of the three pathways provided, an elastomeric contact **20s** is placed in each of the three wells, and then the PCB **20t** is placed on top of the elastomeric contacts. Then, the housing cover **20k**, which, in some embodiments, includes a connector **20n**, is applied to close the housing.

[0389] **Fig. 1K** illustrates another embodiment of the analyte sensor **14** is incorporated into a fluid coupler **20**. In this embodiment, the sensor is configured such that it extends at least a portion of the length of the lumen **20f** of the fluid coupler, but does not extend out of the fluid coupler itself (e.g., past the fluid coupler's first orifice **20h**). When the fluid coupler of this embodiment is fluidly coupled to an implanted catheter, the first side **20a** of the fluid coupler releasably mates with the catheter hub **18**, such that a portion of the fluid coupler's first orifice **20h** is located within a portion of the catheter hub's duct or lumen (e.g., **18b**, see **Figs. 1D-1E**). Accordingly, in this embodiment, the sensor tip **14a** can be located within the catheter hub's duct or lumen. Advantageously, this embodiment simplifies device installation as no insertion of the sensor into a catheter is required. Additionally, sensor performance is maintained because the sensor is protected by the fluid coupler's hard structure during connection of the fluid coupler to the catheter (e.g., the sensor cannot be accidentally touched, bent or flexed during installation).

[0390] As described elsewhere herein, function of an enzymatic analyte sensor is dependent upon the kinetics of the enzyme comprised in the sensor. For example, the function of a glucose sensor is dependent upon the kinetics of the glucose oxidase contained in the sensor's membrane. As is understood by one skilled in the art, enzyme kinetics are influenced by the availability of the reactants. When all required reactants are freely available, the enzyme will react at its maximum rate, given the prevailing temperature and pH conditions. If, on the other hand, the concentration of one of the reactants is low (e.g., limiting), the enzyme reaction will proceed at a slower rate, which is associated with the concentration of the limited reactant. Accordingly, to measure the concentration of a particular reactant (e.g., the analyte), that reactant should be present in limiting amounts. In other words, the other reactants (e.g., a co-reactant) should be present in excess (e.g., non-limiting amounts). For example, glucose and oxygen are the reactants of some GOX-containing glucose sensors. Since the analyte is glucose, oxygen (e.g., the co-reactant) should be present in excess (e.g., non-limiting), so that

Abbott Ex. 1003 - 119/1058

the reaction rate is dependent upon the glucose concentration. In some circumstances, however, the co-reactant is limiting. For example, if ischemia occurs around and/or near the sensor, the amount of available oxygen can be reduced and thus become the limiting reactant. In another example, the analyte can exist in excess (e.g., in the body) relative to the concentration of a reactant, such as oxygen. In some embodiments, the sensor is configured to compensate for a limiting reactant, such as but not limited to oxygen. For example, the membrane can be configured and arranged to restrict the amount of excess reactant that diffuses therethrough (e.g., see the section entitled "Resistance Domain.") In other embodiments, the sensor can be configured to increase the level of limiting reactant (e.g., co-reactant). For example, in some embodiments, the membrane can include a domain configured to increase the concentration of oxygen. In other embodiments, the vascular access device, such as the *ex vivo* portion of a catheter or a fluid coupler can be configured to increase the amount of oxygen (e.g., co-reactant) available to the enzyme. For example, the fluid coupler **20** of **Fig. 1K** includes an enrichment body **20p** configured and arranged to increase the oxygen concentration at the sensor **14**. An enrichment body **20p** can be provided in many forms. For example, in the embodiment shown in **Fig. 1K**, the enrichment body includes an "oxygen port" including a membrane, plug or filter located in a side of the fluid coupler. In this embodiment, the oxygen port intersects the fluid coupler wall, such that oxygen can diffuse from the exterior of the fluid coupler to the lumen **20f**. In some embodiments, the oxygen port includes a plug and/or membrane formed of silicone, ePTFE or other polymer known to increase oxygen diffusion. In other embodiments, the enrichment body **20p** includes an "oxygen capacitor" configured to absorb oxygen when the oxygen concentration (e.g., around the sensor) is high, and to release the absorbed (e.g., stored) oxygen when the oxygen concentration is low. For example, in some embodiments, the infusion solution is oxygenated, such that as the infusion solution flows through the fluid coupler and/or catheter and contacts the oxygen capacitor, the capacitor absorbs at least some of the oxygen present in the solution. Then, when blood is drawn back and contacts the capacitor, at least some of the oxygen stored in the capacitor diffuses into the blood. For example, in some embodiments, the oxygen capacitor is an oxygen-absorbing and oxygen-releasing polymer applied to the lumenal surface of the fluid coupler and/or catheter. In other embodiments, the oxygen capacitor is a membrane or plug

Abbott Ex. 1003 - 120/1058

attached to the lumenal surface of the catheter and/or fluid coupler. In yet another embodiment, the enrichment body is inserted into the lumen of the fluid coupler and/or catheter hub.

[0391] **Fig. 1L** illustrated an embodiment similar to that of **Fig. 1K**, except that at least a portion of the sensor **14** extends toward the fluid coupler's **20** second side **20b**. In some embodiments, the sensor tip extends to the fluid coupler's second orifice **20i**, but not there past. In other embodiments, the sensor is configured to extend into connected tubing. Accordingly, in this embodiment, the sensor's electroactive surface(s) can be located at any point along the length of the fluid coupler's lumen **20f**.

[0392] **Fig. 1M** illustrates yet another embodiment of an analyte sensor incorporated into a fluid coupler **20**. In this embodiment, at least one analyte sensor **14** is located on a support **20q** that is located on the lumenal surface of the fluid coupler. In some embodiments, the support, including the at least one analyte sensor located thereon, is inserted into the fluid coupler via an orifice (e.g., **20i**). In other embodiments, the fluid coupler includes a port (e.g., an orifice, hole or opening, not shown) configured and arranged to receive the support (e.g., the port and the support are configured to mate with each other), such as *via* insertion through the wall of the fluid coupler. In some embodiments, the at least one analyte sensor comprises two or more analyte sensors, wherein the analyte sensors are configured to detect one or more analytes. In some embodiments, the at least one analyte sensor comprises 3, 4, 5, 6, 7, 8, 9, 10 or more analytes sensors. In some embodiments, the at least one analyte sensor comprises a plurality of micro-fabricated sensors, such as but not limited to a sensor array. The sensor(s) can be applied to and/or deposited on the support using any method known in the art, such as but not limited to thin and/or thin film techniques, printing, plating, and the like. In some embodiments, an analyte sensor is configured to intersect the support, such as described with reference to **Figs. 2M-2Q**. In some embodiments, the sensor (e.g., working electrode) is substantially flush with the support, similar to the manner of some glucose test strips that have electrodes printed on a planar support using thin and/or thick film techniques. In some embodiments, the sensor (e.g., working electrode) is at least partially embedded in the support. For example, the working electrode material can be deposited in a groove or well located on the support. In preferred embodiments, the support is manufactured from a polymer. Preferably, the polymer is configured for malleability during manufacture but also provides sufficient strength to function as a side of the fluid coupler. In other embodiments, the support

Abbott Ex. 1003 - 121/1058

is formed from a metal, a ceramic or glass. The support can have any shape, such as a planar or non-planar shape. In some embodiments, the support has a planar lumenal surface (e.g., the surface of the support that faces the lumen of the fluid coupler). However, in other embodiments, the support's lumenal surface is curved. In some embodiments, the support (e.g., with sensor(s) applied thereto) is received into a port. In some embodiments, the support makes a friction fit into the port. In other embodiments, the support and port are configured for a snap fit of the support into the port. In some embodiments, the support can be secured into the port with an adhesive, hooks, pins, and/or *via* welding. In other embodiments, the support (including one or more analyte sensors) is inserted into the lumen of the fluid coupler. For example, in one embodiment, the fluid coupler does not include a port; rather the support (e.g., including sensors) is inserted through one of the fluid coupler's orifices, such that the support is located adjacent to and/or on the fluid coupler's lumenal surface. In a further embodiment, the support is configured to conform to the lumenal surface of the fluid coupler. In some embodiments, the support is attached to the lumenal surface of the fluid coupler, such as with adhesive or welding. In some embodiments, a catheter hub includes a port configured for receipt of the support. Advantageously, manufacturing the sensor(s) on a support and then integrating them with the fluid coupler simplify manufacturing and reduce costs by enabling high through put, automated manufacturing methods. Additionally, a wider array of sensors and custom-order sensors can be easily manufactured (e.g., as "panels" of sensors that test a panel of analytes) and subsequently integrated into the fluid couplers and/or catheter hubs. For example, in one embodiment cassettes of sensors are manufactured in an automated reel-to-reel process wherein sensor panels (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 13, 14, 15, 16, 17, 18, 19 or 20 or more sensors) are applied to a continuous roll of polymer material (e.g., the support), wherein the individual sensor cassettes are subsequently cut out of the roll, such as using a die. In a second automated process, the completed sensor cassettes are installed into the ports of separately manufactured fluid couplers. Sensor electronics, such as a PCB and electronic connectors are applied in yet another automated process. In some embodiments, 2, 3, 4, 5, or more different types of sensor cassettes (e.g., each type of sensor cassette includes a different panel of analyte sensors) can be manufactured (e.g., simultaneously on separate manufacturing lines or on a single line at different times) and then subsequently integrated into separately manufactured fluid couplers. In other embodiments, for fluid couplers and/or catheters hubs

Abbott Ex. 1003 - 122/1058

having different configurations, each configuration includes a port configured to receive a single size and/or shape of sensor cassette, wherein the size and/or shape of the cassette is associated with a fluid coupler or catheter configuration. In some embodiments, each type of sensor cassette (e.g., analyte panel) includes a unique shape, such that it must be received by a port configured to mate with it, similar to an interlocking lock and key, such that certain cassettes are used with certain fluid couplers and/or catheters. In some embodiments, certain interlocking cassette and port configurations are associated with a particular panel of analytes and/or a client. In yet another embodiment, the sensor cassettes are configured to be replaceable prior-to and/or during use. For example, in one embodiment, the fluid coupler is provided with two or more types of cassettes (e.g., different panels), such that the user inserts a selected cassette into the fluid coupler's port prior to use. In an alternative embodiment, the fluid coupler can be provided with two or more cassettes of the same type, such that the cassette can be changed out during use. For example, if a sensor on a first cassette fails, the cassette can be replaced with a second cassette of the same type. Analyte sensors and manufacturing methods suitable for use with these embodiments can be found in U.S. Patent No. 5,108,819, U.S. Patent No. 5,178,957, U.S. Patent No. 5,879,828, U.S. Patent No. 6,175,752, U.S. Patent No. 6,284,478, U.S. Patent No. 6,329,161, U.S. Patent No. 6,565,509, U.S. Patent No. 6,990,366, U.S. Patent No. 6,134,461, U.S. Patent No. 7,003,336, U.S. Patent No. 6,784,274, U.S. Patent No. 6,103,033, and U.S. Patent No. 5,899,855, each of which is incorporated herein by reference in its entirety.

[0393] **Figs. 2A** to **2B** illustrate one exemplary embodiment of an analyte sensor integrally formed on a catheter. The system **210** is configured to measure an analyte and generally includes a catheter **212** configured for insertion into a host's blood stream (e.g., *via* a vein or artery) and a sensor at least partially integrally formed on the catheter's exterior surface **232**. Preferably, the sensor **214** includes at least one exposed electroactive area **240** (e.g., a working electrode), a membrane system (e.g., including an enzyme), a reference electrode (proximal to or remote from the working electrode), and an insulator.

[0394] In this embodiment, the catheter includes a lumen **212a** and an orifice **212b** at its proximal end, for providing fluid connection from the catheter's lumen to the host's blood stream (see **Fig. 2A**).

Abbott Ex. 1003 - 123/1058

[0395] In some embodiments, the catheter is inserted into a vein, as described elsewhere herein. In other embodiments, the catheter is inserted into an artery, as described elsewhere herein. The catheter can be any type of venous or arterial catheter commonly used in the art (e.g., peripheral catheter, central catheter, Swan-Gantz catheter, etc.). The catheter can be made of any useful medical grade material (e.g., polymers and/or glass) and can be of any size, such as but not limited to from about 1 French (0.33mm) or less to about 30 French (10mm) or more; for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 French (3 French is equivalent to about 1 mm). In some embodiments, the catheter is configured and arranged for insertion into neonatal or other pediatric hosts (e.g., 22-24 gauge or smaller). In certain embodiments, the catheter can be a single lumen catheter or a multi-lumen catheter. In some embodiments, the catheter can include one or more perforations, to allow the passage of host fluid through the lumen of the catheter. In one embodiment, the catheter is a dual-lumen catheter wherein a first lumen is configured to receive an analyte sensor and a second lumen is configured for fluid infusion. In preferred embodiments, the catheter is configured such that the orifice of the first lumen is sufficiently proximal to connector (of the catheter) relative to the orifice of the second lumen, that samples drawn back into the first lumen (e.g., to be tested by the analyte sensor) are substantially undiluted by the infused fluid.

[0396] At its distal end **212c**, the catheter **212** includes (e.g., in fluid communication) a connector **218**. The connector can be of any known type, such as a Leur lock, a T-connector, a Y-connector, a cross-connector or a custom configuration, for example. In some embodiments, the connector includes at least one valve. At a second side **218e** (e.g., back end), the connector **218** can be operatively connected to a saline system (e.g., saline bag and tubing), other medical devices (e.g., automatic blood chemistry machine, dialysis machine, a blood bag for collecting donated blood, etc.), or capped.

[0397] In some embodiments, the system **210** includes sensor electronics (not shown) operatively connected to the analyte sensor, wherein the sensor electronics are generally configured to measure and/or process the sensor data as described in more detail elsewhere herein. In some embodiments, the sensor electronics can be partially or wholly disposed with (e.g., integral with, disposed on, or proximal to) the connector **218** at the distal end of the catheter or partially or wholly remote from the catheter (e.g., on a stand or on the

Abbott Ex. 1003 - 124/1058

bedside). In one embodiment, the sensor electronics disposed with the connector include a potentiostat. In some embodiments, the sensor electronics are configured to measure the host's analyte concentration substantially continuously. For example, the sensor can measure the analyte concentration continuously or at time intervals ranging from fractions of a second up to, for example, 1, 2, or 5 minutes or longer.

[0398] **Figs. 2C** to **2F** illustrate additional embodiments of the sensor shown in **Figs. 2A** to **2B**. The catheter **212** is shown with an integral sensor **214** having at least one electrode **240** formed on its exterior surface **232** (e.g., **Fig. 2F**). In general, the sensor can be designed with 1, 2, 3, 4 or more electrodes and can be connected by traces (or the like) to electrical contacts **218d** (or the like) at the second end of the connector **218** (e.g., **Figs. 2A** to **2F**). In some embodiments, the sensor is hard-wired to the sensor electronics; alternatively, any operable connection can be used. Preferably, the sensor includes at least one working electrode and at least one reference or counter electrode. In some embodiments, the reference electrode is located proximal to the at least one working electrode (e.g., adjacent to or near to the working electrode). In some alternative embodiments, the reference electrode is located remotely from the working electrode (e.g., away from the working electrode, such as but not limited to within the lumen of the catheter **212** (or connector **218**), on the exterior of the sensor system, in contact with the patient (e.g., on the skin), or the like). In some embodiments, the reference electrode is located proximal to or within the fluid connector, such as but not limited to, coiled about the catheter adjacent to the fluid connector or coiled within the fluid connector and in contact with fluid flowing through the fluid coupler, such as saline or blood. In some embodiments, the sensor can also include one or more additional working electrodes (e.g., for measuring baseline, for measuring a second analyte, or for measuring a substantially non-analyte related signal, and the like, such as described in more detail in U.S. Patent Publication No. US-2005-0143635-A1 and U.S. Patent Publication No. US-2007-0027385-A1, which are incorporated herein by reference in their entirety. In some embodiments one or more counter electrodes can be provided on a surface of the catheter or within or on the fluid connector.

[0399] In some of the preferred embodiments, the catheter is designed to indwell within a host's blood flow (e.g., a peripheral vein or artery) and remain in the blood flow for a period of time (e.g., the catheter is not immediately removed). In some embodiments, the indwelling catheter can be inserted into the blood flow for example, for a few minutes or more,

Abbott Ex. 1003 - 125/1058

or from about 1 to 24 hours, or from about 1 to 10 days, or even longer. For example, the catheter can indwell in the host's blood stream during an entire perioperative period (e.g., from host admittance, through an operation, and to release from the hospital).

[0400] In some embodiments, the catheter is configured as an intravenous catheter (e.g., configured to be inserted into a vein). The catheter can be inserted into any commonly used vein, such as in a peripheral vein (e.g., one of the metacarpal veins of the arm); in some embodiments (e.g., such as described with reference to **Figs. 1A** to **1E**) the analyte sensor inserted into a catheter. In alternative embodiments, the sensor is integrally formed on a catheter such as described in more detail with reference to **Figs. 2A** to **2F**, for example. Other veins, such as leg or foot veins, hand veins, or even scalp or umbilical veins, can also be used.

[0401] In addition to sensing analyte levels *via* a sensor system as described herein, the intravenous catheter can be used for delivery of fluids and/or drugs to the host's circulatory system. The catheter can be configured to be coupled to other medical devices or functions, for example, saline, blood products, total parenteral feeding or medications can be given to the host *via* the indwelling intravenous catheter. In some embodiments, the catheter can be operatively connected to a pump, such as an infusion pump, to facilitate flow of the fluids into the host and a desired rate. For example, an infusion pump can pump saline into the host at a rate of 1cc per minute, or at higher or lower rates. The rate of infusion can be changed (increased or decreased). For example, an infusion can be temporarily stopped, to permit injection of pain medication into the IV system, followed by increasing the infusion rate (e.g., for 5 minutes) to rapidly deliver the pain medication to the host's circulatory system.

[0402] In some embodiments, the catheter is configured as an arterial catheter (e.g., configured to be inserted into an arterial line or as part of an arterial line). Typically, an arterial catheter is inserted in the wrist (radial artery), armpit (axillary artery), groin (femoral artery), or foot (pedal artery). Generally, arterial catheters provide access to the host's blood stream (arterial side) for removal of blood samples and/or application of test devices, such as but not limited to a pressure transducer (for measuring blood pressure automatically), however, arterial catheters can also be used for delivery of fluids or medications. In one embodiment, a catheter is inserted into an arterial line and the sensor inserted into the catheter (e.g., functionally coupled) as described elsewhere herein. Saline filled non-compressible tubing is then coupled to the sensor, followed by a pressure transducer. An automatic flushing system (e.g., saline)

Abbott Ex. 1003 - 126/1058

is coupled to the tubing as well as a pressure bag to provide the necessary pressure. Electronics are generally operatively coupled to the pressure transducer for calculating and displaying a variety of parameters including blood pressure. Other medical devices can also be connected to the arterial catheter, to measure various blood components, such as but not limited to O_2, CO_2, PCO_2, PO_2, potassium, sodium, pH, lactate, urea, bilirubin, creatinine, hematocrit, various minerals, various metabolites, and the like.

[0403] In another embodiment, a blood pressure measurement system is inserted into the host and can be used as is known in the art. The analyte sensor (e.g., glucose sensor), such as the embodiment shown in **Figs. 1A-1E**, is inserted into the pre-inserted (e.g., already in-dwelling) catheter using the following general methodology. First, the pressure transducer is temporarily disabled by disconnecting from the pre-inserted catheter. A cap (optionally) covers the protective slotted sheath and can be removed so as to enable the sensor to be grasped at the fluid coupler. The sheath, which is generally more rigid than the sensor but less flexible than a needle, is then threaded through the pre-inserted catheter so as to extend beyond the catheter into the blood stream (e.g., by about 0.001 inches to about 1 inches). The sheath is then removed by sliding the sensor through a small outlet hole and/or slot in the sheath. Thus, the sensor remains within the pre-inserted catheter and the fluid coupler, which supports the distal portion of the sensor, is coupled to the catheter itself. Saline filled non-compressible tubing is then coupled to the second side (e.g., back end) of the fluid coupler. The sensor electronics (whether adjacent to the fluid coupler or otherwise wired to the fluid coupler) are then operatively connected (e.g., wired or wirelessly) to the sensor to initiate sensor function.

[0404] In some embodiments, a portion of the sensor system (e.g., sensor, catheter, or other component) can be configured to allow removal of blood samples from the host's blood stream (e.g., artery or vein). Sample removal can be done using any systems and methods known in the art, for example, as is practiced for removing a blood sample from an arterial catheter (e.g., and arterial line). In one such exemplary embodiment, any tubing or equipment coupled to the second side of the fluid coupler is disconnected. A syringe is then be coupled to the second side and blood removed *via* the catheter by pulling back on the syringe plunger. In a further embodiment, saline can be flushed through the fluid coupler and catheter. In another embodiment, the fluid coupler can be configured with a side valve, to allow coupling of a syringe, for removal of blood samples or delivery of fluids, such as medications, without

Abbott Ex. 1003 - 127/1058

disconnecting attached tubing of equipment, and the like. In still another embodiment, a valve or diaphragm, for access to the system by a syringe, can be coupled into the tubing at a short distance from the fluid coupler. In yet another embodiment, the sensor is integrally formed on the arterial catheter, such as the embodiment shown in **Figs. 2A-2B**, and tubing can be disconnected from the connector, a syringe operably associated with the connector, and blood removed with the syringe. After blood collection, the syringe is removed and the tubing reconnected to the connector.

[0405] In still another embodiment, the analyte sensor can be functionally coupled to an extracorporeal blood flow device. A variety of devices exist for testing various blood properties and/or analytes at the bedside, such as but not limited to the blood gas and chemistry devices manufactured by Via Medical, Austin, Texas, USA. These devices generally withdraw a blood sample from the host, test the blood sample, and then return it to the host. Such a device can be connected in series to the arterial catheter, with the sensor in-between, and using systems and methods known in the art. In one embodiment, a sensor, such as the embodiment shown in **Figs. 1A-1E**, is functionally connected to an in-dwelling arterial catheter, as described herein, and the extracorporeal blood flow device is connected to the second side of the fluid coupler. In an alternative embodiment, the sensor is integrally formed on the arterial catheter, such as the embodiment shown in **Figs. 2A-2F**, and the extracorporeal blood flow device is functionally connected to the connector **218**. Other devices, such as but not limited to dialysis machines, heart-lung bypass machines or blood collection bags, or other vascular access devices, can be functionally coupled to the analyte sensor.

[0406] The analyte sensor system of the preferred embodiments can be designed with a variety of alternative configurations. In some embodiments, the sensor is connected to a fluid connection device. The fluid connection device in these embodiments can be any standard fluid connection device known in the art, such as a fluid coupler, or a fluid coupler custom manufactured to preferred specifications. On its first side, the fluid coupler is configured to couple to an existing catheter or cannula (as described with reference to **Figs. 1A-1E**). The catheter (or cannula) is typically inserted into a vascular access device and/or into a hospital host during a hospital stay. For example, the catheter can be inserted into an arterial line (e.g., for removing blood samples or for measuring blood pressure using a pressure transducer) or a venous line (e.g., for intravenous delivery of drugs and other fluids). In general

Abbott Ex. 1003 - 128/1058

practice, the catheter is inserted into the host's blood vessel, for example, and maintained there for a period of time during the host's hospital stay, such as part of the stay or during the entire stay (e.g., perioperatively). In one alternative embodiment, another vascular access device (e.g., other than a catheter) can be used to receive the sensor. In yet another alternative embodiment, the sensor system of the preferred embodiments can be inserted into a vascular access device (e.g., rather than the vascular system directly). Some examples of vascular access devices include but are not limited to, catheters, shunts, automated blood withdrawal devices and the like.

[0407] In some embodiments, such as the embodiment illustrated in **Figs. 1A** to **1E**, the system **10** is configured such that the sensor is inserted into a vascular access device, such as but not limited to a catheter **12** (e.g., a catheter that has been inserted into the host's blood stream prior to sensor insertion). In general, catheters are small, flexible tubes (e.g., soft catheter) but they can also be larger, rigid tubes. Catheters are inserted into a host's body cavity, vessel, or duct to provide access for fluid removal or insertion, or for access to medical equipment. Catheters can also be inserted into extracorporeal devices, such as but not limed to an arterio-venous shunt for the transfer of blood from an artery to a vein. Some catheters are used to direct access to the circulatory system (e.g., venous or arterial catheters, Swan Gantz catheters) to allow removal of blood samples, the infusion of fluids (e.g., saline, medications, blood or total parenteral feeding) or access by medical devices (e.g., stents, extracorporeal blood chemistry analysis devices, invasive blood pressure monitors, etc.).

[0408] Preferably, the sensor is designed to include a protective cap, as illustrated in **Figs. 1A-1E**. Namely, **Fig. 1A** and **1B** illustrates the catheter (the catheter cap having been removed prior to insertion), well known to those skilled in the art, which can be inserted into the host's blood vessel using standard methods. The sensor **14** is configured for measurement of an analyte (e.g., glucose) in the host's body, and is in fluid connection within the catheter lumen, which is in fluid connection with the fluid coupler **20** of the sensor. The first side **20a** of the fluid coupler **20** of the sensor is designed to couple to the catheter, e.g., by screwing or snapping thereon, and can also couple (on its second side **20b**) with other medical devices. One advantage of the fluid coupler is that it provides for a small amount of bleed back, to prevent air bubbles in the host's blood stream.

Abbott Ex. 1003 - 129/1058

[0409] The exemplary sensor system **10** of **Fig. 1A** and **1B** further includes a slotted protective sheath **26** that supports and protects the sensor during sensor insertion, for example, the sheath increases the sensor visibility (e.g., the sensor is so thin that it can be difficult for some people to see without the protective sheath) and provides for ease of sliding the sensor into the catheter. The slotted protective sheath is configured to fit within the fluid coupler and houses the sensor during insertion of the sensor into the catheter (e.g., an indwelling catheter within the host's blood flow). Preferably, the protective sheath is substantially more rigid than the sensor and at the same time substantially more flexible that a standard syringe needle, however other designs are possible. To facilitate removal of the protective sheath, a slot **30** is provided with an optional outlet hole **30a**, which is described in more detail with reference to **Fig. 1C**, and a hub **28**. By grasping and pulling the hub, the user (e.g., health care professional) can withdraw the protective sheath after coupling the fluid coupler to the catheter. Prior to insertion of the sensor, a cap is provided, to cover the protective sheath, for example, to keep the sheath and sensor sterile, and to prevent damage to the components during shipping and/or handling.

[0410] In general, the sensor system is configured with a potentiostat and/or sensor electronics that are operatively coupled to the sensor. In some embodiments, a portion of the sensor electronics, such as the potentiostat, can be disposed directly on the fluid coupler. However, some or all of the sensor electronics (including the potentiostat) can be disposed remotely from the fluid coupler (e.g., on the bedside or on a stand) and can be functionally coupled (e.g., wired or wireless), as is generally known to those skilled in the art.

[0411] **Figs. 1C1** and **1C2** are cross-sectional views (not to scale) of the fluid coupler, including a protective sheath **26**, a sensor **14**, and a cap **32** (cap to be removed prior to insertion) in one embodiment. The protective sheath **26** extends through the fluid coupler and houses the sensor, for sensor insertion into a catheter. The protective sheath includes an optional outlet hole **30a**, through which the sensor extends and a slot **30** along a length of the protective sheath that communicates with the outlet hole and enables the protective sheath to be removed after the sensor has been inserted into the host's body. The protective sheath includes a hub **28** for ease of handling.

[0412] In some embodiments, the glucose sensor is utilized in combination with another medical device (e.g., a medical device or access port that is already coupled to, applied

Abbott Ex. 1003 - 130/1058

to, or connected to the host) in a hospital or similar clinical setting. For example, a catheter can be inserted into the host's vein or artery, wherein the catheter can is connected to additional medical equipment. In an alternative example, the catheter is placed in the host to provide quick access to the host's circulatory system (in the event of a need arising) and is simply capped. In another example, a dialysis machine can be connected to the host's circulatory system. In another example, a central line can be connected to the host, for insertion of medical equipment at the heart (e.g., the medical equipment reaches the heart through the vascular system, from a peripheral location such as a leg or arm pit).

[0413] In practice of coupling to a catheter, before insertion of the sensor, the access port is opened. In one exemplary embodiment of a pre-inserted catheter that is capped, the cap is removed and the sensor inserted into the catheter. The back end of the sensor system can be capped or attached to additional medical equipment (e.g., saline drip, blood pressure transducer, dialysis machine, blood chemistry analysis device, etc.). In another exemplary embodiment, medical equipment (e.g., saline drip, blood pressure transducer, dialysis machine, blood chemistry analysis device, etc.) is already connected to the catheter. The medical equipment is disconnected from the catheter, the sensor inserted into (and coupled to) the catheter and then the medical equipment reconnected (e.g., coupled to the back end of the sensor system).

[0414] In some embodiments, the sensor is inserted directly into the host's circulatory system without a catheter or other medical device. In one such exemplary embodiment, the sheath covering the sensor is relatively rigid and supports the sensor during insertion. After the sensor has been inserted into the host's vein or artery, the supportive sheath is removed, leaving the exposed sensor in the host's vein or artery. In an alternative example, the sensor is inserted into a vascular access device (e.g., with or without a catheter) and the sheath removed, to leave the sensor in the host's vein or artery (e.g., through the vascular access device).

[0415] In various embodiments, in practice, prior to insertion, the cap **32** over the protective sheath is removed as the health care professional holds the glucose sensor by the fluid coupler **20**. The protective sheath **26**, which is generally more rigid than the sensor but more flexible than a needle, is then threaded through the catheter so as to extend beyond the catheter into the blood flow (e.g., by about 0.010 inches to about 1 inches). The protective

Abbott Ex. 1003 - 131/1058

sheath is then removed by sliding the sensor through the (optional) outlet hole **30a** and slotted portion **30** of the sheath (e.g., by withdrawing the protective sheath by pulling the hub **28**). Thus the sensor remains within the catheter; and the fluid coupler **20**, which holds the sensor **14**, is coupled to the catheter itself (*via* its connector **18**). Other medical devices can be coupled to the second side of the fluid coupler as desired. The sensor electronics (e.g., adjacent to the fluid coupler or otherwise coupled to the fluid coupler) are then operatively connected (e.g., wired or wirelessly) to the sensor for proper sensor function as is known in the art.

[0416] In another embodiment, the catheter **12** includes a plurality of perforations (e.g., holes) that allow the host's fluid (e.g., blood) to flow through the lumen **12a** of the catheter. The fluid flowing through the catheter can make contact with a sensor **14** inserted therein. In a further embodiment, the sensor does not protrude out of the catheter's tip **12b** and the host's blood flowing through the perforated catheter's lumen contacts the sensor's electroactive surfaces.

[0417] In still another embodiment, the catheter **12** includes at least a first lumen and a second lumen. The sensor **14** is configured for insertion into the catheter's first lumen. The second lumen can be used for infusions into the host's circulatory system or sample removal without disturbing the sensor within the first lumen.

[0418] **Figs. 2A-2F** are schematic views of a sensor integrally formed (integrally incorporated) onto a surface of a catheter, in some exemplary embodiments. In some embodiments, the sensor can be integrally formed on an exterior surface **232** of the catheter. In other embodiments, the sensor can be integrally formed on an interior surface of the catheter (e.g., on a lumenal surface). In still other embodiments, the sensor can be integrally formed on the sensor's tip (e.g., as indicated by **214a**). In yet other embodiments, the sensor can be integrally incorporated with the catheter, for example by bonding a sensor of the type described in **Figs. 3A** to **3C** into an inner or outer surface of the catheter.

[0419] In some embodiments, one or more of the electrodes is deposited on the *in vivo* portion of the catheter **212**, such as *via* screen-printing and/or electrospinning. In some embodiments, at least one of the electrodes **240**, such as but not limited to a counter and/or a reference electrode is deposited within the *ex vivo* portion of the catheter (e.g., within the connector/hub). In one embodiment, two working electrodes **240** are disposed on the exterior surface **232** of the catheter's *in vivo* portion. The first working electrode is configured to

Abbott Ex. 1003 - 132/1058

generate a signal associated with the analyte and with non-analyte-related species that have an oxidation/reduction potential that overlaps with that of the analyte. The second working electrode is configured to generate a signal associated with non-analyte-related species that have an oxidation/reduction potential that overlaps with that of the analyte. As described elsewhere herein, the signals of the first and second working electrodes can be processed to provide a substantially analyte-only signal. Continuous analyte sensors including two working electrodes are described in greater detail elsewhere herein, in U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, U.S. Patent Publication No. US-2007-0027284-A1, U.S. Patent Publication No. US-2007-0032717-A1, U.S. Patent Publication No. US-2007-0093704-A1, and U.S. Patent Publication No. US-2008-0083617-A1, each of which is incorporated herein by reference in its entirety.

[0420] In some alternative embodiments, one or more analyte sensors are disposed (e.g., deposited, formed) on the exterior surface of the *in vivo* portion of the catheter. Each sensor can include one, two or more working electrodes. The electrodes can be configured as described elsewhere therein. In some embodiments, the catheter **12** is configured with two or more analyte sensors, wherein each of the sensors is configured to detect a different analyte and/or a property of the sample, as described elsewhere herein. For example, in some embodiments, the sensors are configured to detect at least two analytes such as but not limited to albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO_2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker, various drugs, various minerals, various metabolites, and the like. In some embodiments, at least one of the sensors is configured to detect a property of the host's blood, such as but not limited to pH, oxygen tension, PCO_2, PO_2, temperature, hematocrit, and the like. In some circumstances, one or more of the plurality of analyte sensor can be configured as a back-up or redundant sensor to a first sensor, such as to confirm the correct functioning of the first sensor. For example, two glucose sensors could be disposed within the connector, such that the second glucose sensor provides a confirmation of the first glucose sensor's measurements.

[0421] Generally, the sensor system is provided with a cap **32** that covers the catheter and the *in vivo* portion of the integral sensor (e.g., see **Fig. 1C2**). A needle or trochar

Abbott Ex. 1003 - 133/1058

that runs the length of the catheter supports the device during insertion into the host's blood stream. Prior to use, medical caregiver holds the device by the fluid connector **218** and removes the cap to expose the *in vivo* portion of the device (e.g., the catheter). The caregiver inserts the *in vivo* portion of the device into one of the host's veins or arteries (depending upon whether the catheter is an intravenous catheter or an arterial catheter). After insertion, the needle is withdrawn from the device. The device is then capped or connected to other medical equipment (e.g., saline bag, pressure transducer, blood collection bag, total parenteral feeding, dialysis equipment, automated blood chemistry equipment, etc.). In some alternative embodiments, the sensor-integrated catheter can be in communication (e.g., fluid communication) with the host's vascular system through a vascular access device.

[0422] In some embodiments, an analyte sensor system includes a sensing mechanism substantially similar to that described in U.S. Patent Publication No. US-2006-0020187-A1, which is incorporated herein by reference in its entirety; for example, with platinum working electrode and silver reference electrode coiled there around. Alternatively, the reference electrode can be located remote from the working electrode so as not to be inserted into the host, and can be located, for example, within the fluid coupler **20**, thereby allowing a smaller footprint in the portion of the sensor adapted for insertion into the body (e.g., blood stream); for example, without a coiled or otherwise configured reference electrode proximal to the working electrode. Although a platinum working electrode is discussed, a variety of known working electrode materials can be utilized (e.g., Platinum-Iridium or Iridium). When located remotely, the reference electrode can be located away from the working electrode (e.g., the electroactive portion) at any location and with any configuration so as to maintain bodily and/or in fluid communication therewith as is appreciated by one skilled in the art.

[0423] In an alternative embodiment, the sensor tip **14a** includes an enlarged, atraumatic area, for example a dull or bulbous portion about two times the diameter of the sensor or larger. In one exemplary embodiment, the enlarged portion is created by heating, welding, crushing or bonding a substantially rounded structure onto the tip of the sensor (e.g., polymer or metal). In another exemplary embodiment, the tip of the sensor is heated (e.g., arc welded or flash-butt resistance welded) to cause the tip to enlarge (e.g., by melting). The enlarged portion can be of any atraumatic shape, such as but not limited to oval, round, cone-

Abbott Ex. 1003 - 134/1058

shaped, cylindrical, teardrop, etc. While not wishing to be bound by theory, it is believed that an atraumatic or enlarged area enables enhanced stability of a small diameter sensor in the blood flow and ensures that the sensor remains within the blood flow (e.g., to avoid piercing a vessel wall and/or becoming inserted subluminally.)

[0424] In some embodiments, one or more additional working electrodes can be provided on the sensor for measuring baseline, and thereby subtracting the baseline from the first working electrode to obtain a glucose-only signal and/or to measure additional analytes, as disclosed in copending U.S. Patent Publication No. US-2005-0143635-A1, U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, and U.S. Patent Publication No. US-2008-0083617-A1, all of which are herein incorporated by reference in their entirety.

[0425] Referring now to **Figs. 2A-2E** in more detail, some embodiments of the analyte sensor system include a catheter **212** adapted for inserting into a host in a hospital or clinical setting, wherein the analyte sensor **214** is built integrally with the catheter **212**. For example, a glucose sensor can be integrally formed on the catheter itself. **Figs 2A-2B** illustrate one embodiment, wherein the catheter **212** is configured both for insertion into a host, and can be configured to couple to other medical devices on its *ex vivo* end. However, coupling to other medical devices is not necessary. In some embodiments, the catheter includes a connector **218** configured for connection to tubing or other medical devices, as described herein. The embodiment shown in **Figs. 2A-2B** includes two or three electrodes **240** on the outer surface of the *in vivo* portion of the catheter **212**. In some embodiments, the catheter is perforated (as described elsewhere herein) and at least one electrode is disposed within the lumen (not shown) of the perforated catheter. In some embodiments, the catheter includes a single lumen. In other embodiment, the catheter includes two or more lumens.

[0426] With reference to **Figs. 2C-2E**, in some embodiments, at least one working electrode **240** is disposed on the exterior surface of the *in vivo* portion of the catheter. Alternatively, the at least one working electrode can be disposed on an interior surface of the catheter, on the tip of the catheter, extend from the catheter, and the like. In general, the preferred embodiments can be designed with any number of electrodes, including one or more counter electrodes, one or more reference electrodes, and/or one or more auxiliary working electrodes. In further embodiments, the electrodes can be of relatively larger or smaller surface

Abbott Ex. 1003 - 135/1058

area, depending upon their uses. In one example, a sensor includes a working electrode and a reference electrode that has a larger surface area (relative to the surface area of the working electrode) on the surface of the catheter. In another example, a sensor includes a working electrode, a counter electrode, and a reference electrode sized to have an increased surface area as compared to the working and/or counter electrode. In some embodiments, the reference electrode is disposed at a location remote from the working electrode, such as within the connector (e.g., coiled within the connector). In some embodiments, the reference electrode is located on the host's body (e.g., in body contact).

[0427] The electrodes **240** can be deposited on the catheter using any suitable techniques known in the art, for example, thick or thin film deposition techniques. The electrodes can be formed of any advantageous electrode materials known in the art (e.g., platinum, platinum-iridium, palladium, graphite, gold, carbon, silver, silver-silver chloride, conductive polymer, alloys, combinations thereof, and the like). In other embodiments, one or more of the electrodes is formed from an electrically conductive material (e.g., wire or foil comprising platinum, platinum-iridium, palladium, graphite, gold, carbon, silver, silver-silver chloride, conductive polymer, alloys, combinations thereof, and the like) applied to the exterior surface of the catheter, such as but not limited twisting, coiling, rolling or adhering.

[0428] In some embodiments, the catheter is (wired or wirelessly) connected to sensor electronics (not shown, disposed on the catheter's connector and/or remote from the catheter) so as to electrically connect the electrodes on the catheter with the sensor electronics. The inserted catheter (including the sensor integrally formed thereon) can be utilized by other medical devices for a variety of functions (e.g., blood pressure monitor, drug delivery, etc).

[0429] Referring now to **Figs. 2G** through **2S**, in some preferred embodiments a plurality of analyte sensors **240** are disposed within a widened portion of the catheter, such as but not limited to a flared portion and/or a connector portion **212,** or within the interior of a connector **250**, such as but not limited to a Leur lock, a Y-connector, a T-connector, an X-connector, and a valve, wherein a first side/end of the connector is configured to be coupled and/or connected to another vascular access device, such as a catheter or cannula, and a second side (e.g., end) of the connector is configured to be coupled/connected to other IV equipment, such as another connector, a valve, IV tubing, and the like.

Abbott Ex. 1003 - 136/1058

[0430] **Fig. 2G** is a cross section of a vascular access device including a plurality of analyte sensors **240** in one embodiment. The vascular access device, such as a catheter includes an *in vivo* portion configured for insertion into a circulatory system of the host, including a lumen **212a**, and a connector **218** having a wall **260** defining a duct **218b**. In some embodiments, an inner diameter of the connector is greater than an inner diameter of the *in vivo* portion. For example, in some embodiments, the vascular access device is a 20-guage or smaller catheter. In some embodiments, the *in vivo* portion of the catheter is configured and arranged for insertion into a circulatory system of a pediatric host, such as but not limited to a neonatal host. The vascular access device is configured and arranged for receipt of a sample of a bodily fluid of a host (e.g., blood after catheter insertion). At the proximal end, also referred to herein as the *in vivo* portion, the vascular access device includes a catheter **212** having a lumen **212a** and a small orifice **212b**. At the distal end, also referred to here as the *ex vivo* portion, the vascular access device includes a connector **218**, also referred to herein as the "hub." The hub includes an orifice **218c**, which is configured for connection (e.g., fluid communication) with other IV equipment, such as *via* one or more flanges **218a**. The connector **218** also includes a duct **218b**, also referred to a widened portion (as compared to lumen **212a**, which may be referred to as the connector's lumen. A plurality of analyte sensors **240** is disposed within the duct **218b**. In some embodiments, the device includes an analyte sensor **240**, wherein at least a portion of the analyte sensor is located in the lumen or duct, such that the analyte sensor is located within about 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1-mm or less from a source of the biological sample. For example, in some embodiments, the electroactive surfaces are within about 40-mm or less of the blood prior to drawing the blood back into the hub of an implanted catheter or into a fluid coupler connected to an implanted catheter. In some embodiments, the analyte sensor is located within about 30-mm or less from a source of the sample. Configuring the system such that the analyte sensor(s) (e.g., the electroactive surfaces of the electrodes) are located within only 60-mm or less from the sample (e.g., prior to drawing back the sample into the catheter) translates into a requirement for only very small sample volumes. For example, in some embodiments, the device is configured such that the analyte sensor is bathed in the sample when (no more than) about 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, 25, 15, 10, or 5-μl or less of the bodily fluid (e.g., blood) is drawn back. In some embodiments, one or more of the analyte

Abbott Ex. 1003 - 137/1058

sensors **240** is deposited and/or formed on a surface of the duct **218b**, such as by screen printing or other useful deposition techniques. In some embodiments, one or more of the analyte sensors **240** is applied to the duct's surface, such as by adhering or micro welding a previously formed sensor to the duct's surface. In some embodiments, at least a portion of one or more of the analyte sensors **240** is unattached to the duct's surface. The analyte sensors can be configured to detect one or more analytes using any means known in the art, such as but not limited to electrochemical detection, enzymatic detection, chemical detection, physical detection, immunochemical detection, optical detection, radiometric detection, and combinations thereof. For example, in one embodiment of a device including three sensors **240** within the hub **218**, a first sensor **240** is configured to detect glucose electrochemically, a second sensor **240** is configured to detect oxygen optically, and the third sensor **240** is configured to detect bilirubin immunochemically.

[0431] In one exemplary embodiment, a system configured to measure one or more analytes in a host is provided, wherein the system includes a vascular access device including a first portion configured for insertion into a host and a second portion configured to remain outside the host after insertion of the first portion; at least one analyte sensor **240** located within the second portion of the vascular access device, such that the at least one analyte sensor is exposed to a biological sample when the biological sample is drawn back about 40-mm or less, when the vascular access device is in fluid communication with a circulatory system of the host; and a flow control device configured to regulate exposure of the at least one sensor to a biological sample and to a reference solution according to a flow profile. In some embodiments, the system is configured such that the at least one analyte sensor is exposed to the biological sample when about 300-μl or less of the biological sample is drawn back. In another embodiment, the system is configured such that the at least one analyte sensor is exposed to the biological sample when about 200-μl or less of the biological sample is drawn back. In some embodiments, the vascular access device includes a catheter. For example, in some embodiments, the catheter is 22-gauge or smaller. In some embodiments, a lumen of the second portion is wider than a lumen of the first portion. For example, the lumen (e.g., duct) of a catheter hub is wider than the lumen of the *in vivo* portion of the catheter, in exemplary embodiments. In some embodiments, the second portion includes a connecting end on the catheter. For example, the second end of the catheter (e.g., the hub) is configured and arranged

Abbott Ex. 1003 - 138/1058

for connection to tubing (e.g., IV tubing, the tubing assembly). In other embodiments, the second portion includes a fluid coupler, wherein the fluid coupler is configured to releasably mate with a catheter. In some embodiments, the at least one sensor is incorporated into the second portion (e.g., the *ex vivo* portion of the catheter), such as on an inner surface of the second portion. In some embodiments, at least a portion of the at least one sensor is disposed in an orientation substantially parallel to a longitudinal axis of the second portion. In some embodiments, at least a portion of the at least one sensor is disposed in an orientation substantially perpendicular to a longitudinal axis of the second portion. In some embodiments, the at least one sensor includes an exposed electroactive surface area with a dimension substantially equal to a width of a lumen of the second portion. In some embodiments, the exposed electroactive surface area intersects the lumen of the second portion. In some embodiments, the at least one analyte sensor includes at least three analyte sensors located within the second portion of the catheter. In a further embodiment, the at least one analyte sensor includes at least eight analyte sensors located within the second portion of the catheter. In some embodiments, the second portion is configured to provide identification information associated with a flow profile, such as described elsewhere herein. In some embodiments, the system is configured to program the flow profile (of a flow control device) in response to automatic receipt of the identification information. In some embodiments, the identification information is provided by a mechanical structure of the second portion (e.g., the catheter). In some embodiments, the identification information is provided by electronics of the second portion (e.g., the catheter).

[0432] In another exemplary embodiment, a system configured to measure one or more analytes in a host is provided, wherein the system includes a fluid coupler including a first end and a second end, wherein the first end is configured to releasably mate with a connecting end of a catheter, and wherein the second end is configured to releasably mate with a tubing assembly; and at least one analyte sensor located within the fluid coupler such that when the fluid coupler is mated to a catheter inserted into a circulatory system of a host, the at least one analyte sensor is exposed to a biological sample when the biological sample is drawn back about 40-mm or less. In one embodiment, the at least one sensor is located on an inner surface of the fluid coupler. In some embodiments, the at least one sensor is incorporated into the fluid coupler. In a further embodiment, the at least one sensor is disposed within a lumen

Abbott Ex. 1003 - 139/1058

of the fluid coupler (e.g., the second portion). In some embodiments, the system is configured such that the at least one analyte sensor is exposed to the biological sample when about 300-µl or less of the biological sample is drawn back. In another embodiment, the system is configured such that the at least one analyte sensor is exposed to the biological sample when about 200-µl or less of the biological sample is drawn back. In some embodiments, the at least one sensor is incorporated into the fluid coupler. In some embodiments, the at least one sensor is located on an inner surface of the fluid coupler. In some embodiments, the at least one sensor is disposed within a lumen of the fluid coupler. The at least one analyte sensor can be disposed in an orientation substantially parallel to a longitudinal axis of the fluid coupler, or in an orientation substantially perpendicular to the longitudinal axis of the fluid coupler. In some embodiments, the at least one sensor includes an exposed electroactive surface area with a dimension substantially equal to a width of a lumen of the fluid coupler, such as described with reference to **Figs. 2M-2P**. In some further embodiments, the exposed electroactive surface area intersects the lumen of the fluid coupler. In preferred embodiments, the fluid coupler is configured to provide identification information associated with a flow profile, such as described with reference to **Fig. 10E**, herein. For example, in one embodiment, the system is configured to program the flow profile of the flow control device in response to automatic receipt of the identification information. In some embodiments, the identification information is provided by a mechanical structure of the fluid coupler. For example, in some embodiments, a portion of the fluid coupler is configured to form a mechanical interlock with a portion of the flow control device and/or the tubing assembly, wherein formation of the mechanical interlock automatically selects a flow profile associated with the fluid coupler (or with a catheter size, with a type of host (e.g., infant host *versus* child host *versus* adult host) and the like). In some other embodiments, the fluid coupler includes electronics that provide identification information. In still other embodiments, the fluid coupler includes both a mechanical structure and electronics configured to provide the identification information associated with the flow profile. In some embodiments, the fluid coupler includes multiple lumens, wherein the system is configured and arranged to infuse a fluid a fluid in a first lumen of the fluid coupler, and to draw back a biological sample into a second lumen of the fluid coupler. For examples, in embodiments wherein the at least one analyte sensor is located in the second lumen, a hydration, nutrition and/or medicament solution can be infused *via* the first lumen without

Abbott Ex. 1003 - 140/1058

substantially affecting the at least one sensor. In some embodiments, the system is configured to infuse another solution, such as a calibration, wash or hydration solution through the second lumen of the fluid coupler, such as for washing the sensor and/or for making reference measurements. While some embodiments include a single analyte sensor located in the fluid coupler, in other embodiments, the at least one analyte sensor includes at least 2, 3, 4, 5, 6, 7, 8, or 9 or more analyte sensors. In some embodiments, two or more of the analyte sensors are configured to detect the same analyte, such as for a back-up (e.g., in case a first sensor fails the other sensor can be used) and/or as a quality check (e.g., to make sure the sensors are working substantially the same). In other embodiments, the analyte sensors are each configured to measure a different analyte. In still other embodiments, some of the analyte sensors are configured to detect the same analyte, while the remaining analyte sensors are configured to detect different analytes. One skilled in the art appreciates the variety of possible analyte sensor configuration combinations.

[0433] In some embodiments, the system is configured and arranged such that the at least one analyte sensor is located within about 35, 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1-mm or less from a source of the biological sample. In some embodiments, the at least one analyte sensor is located (e.g., within the vascular access device), such that the analyte sensor is bathed in the sample when about 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, 25, 15, 10, or 5-μl or less of the bodily fluid (e.g., blood) is drawn back. In some embodiments, a lumen of the second portion is wider than a lumen of the first portion. For example, the lumen of the fluid coupler is wider than the lumen of the catheter. In some embodiments, the second portion is a fluid coupler, wherein the fluid coupler is configured to releasably mate with the catheter. In some embodiments, the at least one sensor is incorporated into the second portion. For example, in one embodiment, the at least one sensor is located on an inner surface (e.g., the lumenal surface) of the fluid coupler (e.g., the second portion). In a further embodiment, the at least one sensor is disposed within a lumen of the fluid coupler (e.g., the second portion). In some embodiments, at least a portion of the at least one sensor is disposed in an orientation substantially parallel to a longitudinal axis of the fluid coupler (e.g., the second portion). In some embodiments, at least a portion of the at least one sensor is disposed in an orientation substantially perpendicular to a longitudinal axis of the fluid coupler (e.g., the second portion). In some embodiments, the at least one sensor includes an exposed electroactive surface area

Abbott Ex. 1003 - 141/1058

with a dimension substantially equal to a width of a lumen of the fluid coupler (e.g., the second portion). In some embodiments, the exposed electroactive surface area intersects the lumen of the fluid coupler (e.g., the second portion). In some embodiments, the fluid coupler (e.g., the second portion) is configured to provide identification information associated with the flow profile. In some embodiments, the system is configured to program the flow profile of the flow control device in response to automatic receipt of the identification information (e.g., via a wired or wireless connection and/or triggered by a physical and/or operable connection of the vascular access device (e.g., fluid coupler and/or catheter) with the flow control device and/or system electronics). In some embodiments, the identification information is provided by a mechanical structure of the fluid coupler (e.g., the second portion). In some embodiments, the identification information is provided by electronics of the fluid coupler (e.g., the second portion).

[0434] In some embodiments, the at least one analyte sensor is configured to measure an analyte selected from the group consisting of albumin, alkaline phosphatase, alanine transaminase, aspartate aminotransferase, bilirubin, blood urea nitrogen, calcium, CO_2, chloride, creatinine, glucose, gamma-glutamyl transpeptidase, hematocrit, lactate, lactate dehydrogenase, magnesium, oxygen, pH, phosphorus, potassium, sodium, total protein, uric acid, a metabolic marker and a drug. In some embodiments, the at least one analyte sensor includes at least three analyte sensors located within the second portion of the vascular access device and configured to measure at least three analytes. For example, in one embodiment the second portion of the vascular access device is the second portion of a catheter (e.g., the *ex vivo* portion, the hub), and the at least three analyte sensors are located therein. In some embodiments, the at least one analyte sensor includes at least eight analyte sensors located within the second portion of the vascular access device (e.g., the fluid coupler or the second portion (e.g., hub or *ex vivo* portion) of a catheter) and configured to measure at least eight analytes.

[0435] In one exemplary embodiment, the catheter is a peripheral catheter (e.g., for insertion into a vein located in an arm and/or leg) having the analyte sensor located within the catheter hub. In some embodiments, the volume that the catheter hub can hold has been restricted (e.g., reduced), such as by fabricating the catheter hub with a reduced internal diameter. In this embodiment, the sample is drawn back only about 50, 45, 40 or 35-mm (e.g.,

Abbott Ex. 1003 - 142/1058

into the catheter hub, depending upon the length of the catheter), such that the analyte sensor is bathed in the sample.

[0436] In yet another exemplary embodiment, the analyte sensor is located within the lumen of a fluid coupler (e.g., configured for fluid connection with a catheter). In this embodiment, when the fluid coupler is coupled to an implanted peripheral catheter, the sensor's electrodes are bathed in a sample when the sample is drawn back a distance of about 50, 45, 40, 35 or 30-mm, depending upon the length of the catheter, which correlates with a sample volume of about 500, 450, 400, 350, 300 or 250-μl or less.

[0437] Alternatively, when the catheter is coupled to a central catheter (e.g., a catheter for insertion into vessels in the body, such as to access the heart), the distance the sample is drawn back (e.g., to sufficiently contact/bathe the electrodes such that analyte measurements can be taken) is much farther (e.g., relative to the distance of draw-back into a peripheral catheter), since central catheters range from about 12 to about 24-inches in length. Thus, in this exemplary embodiment, the distance the sample is drawn back includes the entire length of the central catheter (including the catheter's hub) and a portion of the connector, such as but not limited to about 12, 13, 14 or 15 inches, to about 18, 19, 20, 21, 22, 23, 24 or 25-inches or more, depending upon the length of the catheter, which can correspond with a sample volume of about 1.5-ml, 1.25-ml, 1-ml, 900-μl, 800-μl, 700-μl, 600-μl or 500-μl or less, depending upon the catheter's size and/or configuration, the fluid coupler's configuration, and the like. If the sensor extends from the fluid coupler into the central catheter, the distance the sample is drawn back is reduced to a portion of the central catheter's length, with a corresponding reduction in sample volume.

[0438] **Fig. 2H** is a cross section of a vascular access device including a plurality of analyte sensor **240** in another embodiment. In this embodiment, the vascular access device is a connector **250** (e.g., fluid coupler) and/or valve, such as but not limited to a Leur lock, a Y-connector, a T-connector, and an X-connector. In general, the connector **250** (e.g., fluid coupler) is configured to be coupled/connected to vascular access devices, such that a fluid can pass between two vascular access devices coupled to the connector's two ends. For example, a first end of the connector can be coupled to a catheter or cannula implanted (e.g., pre-implanted) in a host's vein or artery, and a second end of the connector can be coupled to another connector, a valve, IV tubing, and IV bag, a test device, etc. In some embodiments,

Abbott Ex. 1003 - 143/1058

the connector **240** is a fluid coupler, such as described with reference for **Figs. 1A-1M** and **2M-2S**. The connector includes a duct **254** (e.g., lumen) and a proximal orifice **258**. A plurality of analyte sensors **240** is disposed within the duct **254**. As described with reference to the device shown in **Fig. 2G**, the plurality of analyte sensors can be disposed within the duct **254** using any means known in the art. In some embodiments, one or more of the analyte sensors are deposited (e.g., formed) on a surface of the duct **254** (e.g., on an interior surface). In some embodiments, one or more of the analyte sensors are applied to the surface of the duct **254**. In some embodiments, one or more of the analyte sensors is configured to pass through (e.g., intersect) the wall **252** of the connector such that a first portion of the sensor **240** is disposed within the duct **254** and a second portion of the sensor **240** is disposed at the exterior of the connector **250** (described in more detail herein).

[0439] **Fig. 2I** is a cross-section of a vascular access device of either **Fig. 2G** or **Fig. 2H** taken along line **2I – 2I**, looking towards the proximal end of the vascular access device. The device includes a duct/lumen **212b/254** defined by a wall **260**. The *in vivo* orifice (also referred to as the proximal orifice with relation to the host) of the device is represented by circle **212b/258**. As shown in this embodiment, a plurality of sensors can be disposed within the duct, such as but not limited at the in the interior surface of the wall. In some embodiments, the device includes two analyte sensors. In some embodiments, the device includes 3, 4, 5, 6, 7 or more analyte sensors. In some embodiments, one or more of the analyte sensors are configured to be disposed entirely within the duct (e.g., to not protrude out of the duct). In some embodiments, one or more analyte sensors can be configured such that a portion thereof protrudes out the duct, such as but not limited to into the lumen of a catheter **212** or through the proximal orifice **212b/258** of the device. In some embodiments, a portion or one or more of the sensors can be configured to protrude through the *ex vivo* orifice (also referred to as the distal orifice with ration to the host) of the device. The analyte sensors 240 disposed within the device can be of any configuration and can use any detection method, including but not limited to electrochemical, enzymatic, optical, radiometric, chemical, physical, immunochemical and the like, including a combination thereof.

[0440] **Fig. 2J** is a cross-section of a vascular access device of either **Fig. 2G** or **Fig. 2H** taken along line **2I – 2I**, looking towards the proximal end of the vascular access device, prior to installation of any analyte sensors **240**. **Fig. 2K** depicts the **Fig. 2J** device after

Abbott Ex. 1003 - 144/1058

sensor installation. In this embodiment, a plurality of sensor sites **262** is located at the surface of the wall **260**. While **Figs. 2J** and **2K** depict the sensor sites **262** as being depressions in the wall **260**, the sensor sites **262** can be of any configuration, such as but not limited to a portion of the wall's inner surface that is flush with the remaining portion of the inner surface, a textured portion of the inner surface, a channel, a hole, and the like. In some embodiments, the sensor sites can have a plurality of configurations. For example, in a device including four sensor sited **262**, a first site can have a first configuration, the second and third sites a second configuration, and the fourth site yet another configuration.

[0441] **Fig. 2L** is a cross-section of a vascular access device of either **Fig. 2G** or **Fig. 2H** taken along line **2I – 2I**, looking towards the proximal end of the vascular access device, in an alternative embodiment. In this embodiment, the sensor sites **262** can be formed to include a plug **264** and/or a breakaway portion of the wall **260**, which can be removed to enable sensor installation. For example, a plug/breakaway portion can be pushed and/or punched out of the sensor site and then the sensor installed in the sensor site. In some embodiments, removal of a plug/breakaway portion creates a channel through the wall, such that a sensor (at least a portion thereof) can be inserted through the channel and into the duct **254**. In some embodiments, the portion of an installed sensor remaining on the external side of the wall is configured to functionally connect to sensor electronics, as is appreciated by one skilled in the art. While not wishing to be bound by theory, it is believed that this configuration enables increased accuracy and speed in device assembly because the sensors can be manufactured separately from the device and then installed into the device in a "plug-and-play" fashion.

[0442] **Fig. 2M** illustrates another embodiment of the analyte sensor system configured to measure one or more analytes in a bodily fluid of a host, namely a fluid coupler (e.g., connector) **250** having a wall **260**, a lumen **254**, a first end **258** configured and arranged for fluid communication with a vascular access device, and a second end **256** configured and arranged for fluid communication with an infusion device, such as *via* IV tubing and/or a tubing assembly, such as described elsewhere herein. The analyte sensor **240** (e.g., **240a**, **240b** and/or **240c**) is configured and arranged to generate a signal associated with an analyte in a sample of a circulatory system of a host (e.g., a bodily fluid such as but not limited to blood), wherein at least a portion of the analyte sensor is disposed within the lumen **254** of the fluid coupler **250**.

Abbott Ex. 1003 - 145/1058

In preferred embodiments, the device is configured such that, when it is fluidly connected to an implanted catheter, at least a portion of the analyte sensor **240** is located within about 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, 4, 3, 2, or 1-mm or less from the source of the sample, such as from the tip of the inserted catheter. In some embodiments, the analyte sensor is located within about 30-mm or less from a source of the sample. Advantageously, locating the sensor close to the source of sample (e.g., bodily fluid, blood) and configuring the system for use of very small samples, including return of the sample to the host, limits the loss of blood from the host, thereby enabling the use of the device in circumstances, such as neonatal and critical care settings, wherein loss of blood is a critical issue for host health and/or survival. For example, in one embodiment, the device is configured such that analyte sensor is bathed in the sample when about 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, 25, 15, 10, or 5-μl of the bodily fluid is drawn back.

[0443] In some embodiments, the vascular access device (e.g., a catheter or a fluid coupler) includes a longitudinal axis. For example, if the device is a catheter, the longitudinal axis can extend from the tip **212b** of the *in vivo* portion to the hub orifice **218c**. In another example, if the device is a fluid coupler, the longitudinal axis can extend from the proximal orifice **258** to the distal orifice **256**. The analyte sensor (e.g., the electrodes, electroactive surfaces) can be disposed in the catheter hub or fluid coupler lumen in various orientations with relation to the longitudinal axis. For example, in some embodiments, the analyte sensor is disposed in an orientation parallel to the longitudinal axis. For example, in one embodiment, the analyte sensor intersects the wall **260**, such that the electroactive surface(s) are located along an interior (e.g., luminal) surface of the wall. For example, the electrode can intersect the wall at two points that are separated by a longitudinal distance on the wall, such that the electroactive surface(s) are oriented parallel to the longitudinal axis of the device. For example, with reference to the device of **Fig. 2M**, in an alternative embodiment, one or more of the electrodes (e.g., **240a**, **240b** and/or **240c**) can intersect the wall at two points along one side of the device (e.g., **260a** or **260b**) such that the length of the electrode runs parallel to the longitudinal axis of the device. For example, if the device includes three electrodes, the electrodes can be spaced about the inner circumference of the lumen, such as but not limited to equidistant from each other, wherein each electrode runs parallel along the luminal wall in an orientation parallel to the longitudinal axis of the device. In another embodiment, one or

Abbott Ex. 1003 - 146/1058

more sensors (e.g., twisted and/or bundled working and/or reference electrodes, instead of individual electrodes) can be placed in the device such that a length of the electroactive surfaces of the sensor(s) is parallel to the longitudinal axis of the device. For example, the device could include 2, 3, 4, 5 or more analyte sensors. In some embodiments, the reference electrode is disposed remotely from the working and/or counter electrode(s). In some embodiments, one reference electrode is configured to function as the reference electrode for two or more analyte sensors.

[0444] In some embodiments, the electrode(s) are disposed within the catheter hub or fluid coupler such that they are oriented perpendicularly to a longitudinal axis of the device. Returning again to the exemplary embodiment illustrated in **Fig. 2M**, the device can be configured such that the individual electrodes (e.g., **240a**, **240b** and **240c**) intersect wall **260** on opposite sides (e.g., **260a** and **260b**) of the device, such that each electrode is perpendicular to the longitudinal axis of the fluid coupler. For example, in some embodiments, the first and second points can be connected by a line that is perpendicular to the longitudinal axis of the device. One skilled in the art appreciates that while **Fig. 2M** illustrates individual electrodes **240a**, **240b** and **240c**, in other embodiments, one complete sensor (e.g., having bundled and/or twisted working, counter and/or reference electrodes) can be used. In some further embodiments, the device is configured such that the electroactive surface of each electrode has a surface area having a first dimension (e.g., length or width) substantially equal to a diameter of the lumen of the connector or hub. For example, in the embodiment shown in **Fig. 2M**, the length of the electroactive surfaces (e.g. window **343** of **Fig. 3B**) can be substantially equal to the inner diameter of the fluid coupler. In a further example, each electrode can be formed, including the membrane, as described herein, inserted through the wall(s) of fluid coupler (e.g., through holes or using a needle to pierce the wall(s) formed of elastomeric material as described herein), such that the electroactive surface is disposed within the lumen, excess electrode material removed from one side (e.g., **260b**) and then electrical connection with system electronics (e.g., *via* soldering electrical wires) on the opposite side (e.g., **260a**).

[0445] While the electrodes of the embodiment illustrated in **Fig. 2M** are disposed individually, additional configurations are contemplated in the preferred embodiments. For example, in some embodiments, the electrodes are bundled and/or twisted, such that the electrodes intersect the wall together. In other embodiments, the analyte sensor includes an

Abbott Ex. 1003 - 147/1058

electrode located within the lumen of the *in vivo* portion of the catheter, such as at the tip **212b** of the catheter. In another embodiment, the electrode is located at and/or on the luminal surface of the *in vivo* portion of the catheter. For example, in some embodiments, the electrodes are deposited on a flexible support, which is inserted into the lumen. In another example, in some embodiments, the electrodes are deposited on the flexible support when the flexible support having a planar configuration, which is then cut to size, rolled into a cylindrical configuration (such that the electrodes are within the interior of the cylinder), and then inserted into the catheter lumen. In a further exemplary embodiment, the flexible support is formed of an appropriate material to form the *in vivo* portion of a catheter, electrodes are applied to a surface of the material (e.g., when in a planar configuration) using methods known in the art, the material is cut to size, rolled and the cut edges sealed (e.g., by welding or an adhesive), and a catheter hub applied thereto, such that the rolled and sealed flexible support forms the wall of the *in vivo* portion of the catheter, wherein the electrodes are located on the luminal surface of the electrode wall. Forming the catheter and electrodes in this manner enables easy manufacturing techniques and a variety of electrode configurations, such as but not limited to linear electrodes, circular electrodes, electrodes that spiral along/around the interior of the catheter, and the like. In additional embodiments, a plurality of analyte sensors (e.g., including two or more electrodes) can be disposed in the catheter lumen, such that two or more analytes can be measured, or such that redundant sensors (e.g., two or more glucose sensors) can measure a single analyte.

[0446] **Fig. 2N** illustrates an embodiment of a fluid coupler configured to include two or more analyte sensors, namely the fluid coupler is divided into two or more channels, each of which includes an analyte sensor. In one illustrated embodiment, the fluid coupler is divided into two flow channels **254** (e.g., two lumens), each with an analyte sensor disposed therein (e.g., electrode **240a**, **240b** and **240c**). For example, the analyte sensor in one flow channel can be configured to detect glucose and the analyte sensor in the other flow channel can be configured to detect a cardiac marker, in one embodiment. In another illustrated embodiment, the fluid coupler is divided into three flow channels (e.g., three lumens), each with an analyte sensor disposed therein. Inclusion of additional lumens enables incorporation of additional analyte sensors such that each analyte sensor receives a sample uncontaminated by reagents and/or products and/or for infusion of a medicament. For example, a glucose

Abbott Ex. 1003 - 148/1058

sensor using GOX to detect glucose generates H_2O_2, which can affect the other sensors of the device. If the sensors are located in separate lumens, the H_2O_2 generated by the glucose sensor cannot affect the sensors located in the other lumens. As a further example, sample that is drawn back flows into each of the lumens, such that each of the sensors is bathed in sample uncontaminated by reagents and reaction products from another of the sensors. When the device is flushed (e.g., with saline or calibrant solution), each of the sensors are washed and does not contaminate another sensor with its reagents/reaction products. Accordingly, in some embodiments, the fluid coupler is divided into additional channels, such as a network of 4, 5, 6, 7, 8, 9, 10 or more channels, such that panels of analytes can be continuously measured at the same time. In some embodiments, the fluid coupler is miniaturized, thereby providing a micro-scale, multi-sensor device, such that about 5, 10, 15, 20, 25, 30, 40, 50, 100 or more analytes can be continuously monitored simultaneously. This configuration provides certain advantages, such as but not limited to, this device is amenable to high-throughput, modular manufacturing on an assembly line; the device can be connected to a wide variety of catheters currently in use; a plurality of sensors can be used simultaneously; and the device is amenable to custom-made analyte panels (e.g., Hospital #1 wants glucose and oxygen sensors, while Hospital #2 wants glucose, creatinine and temperature sensors).

[0447] A variety of techniques can be used to manufacture an integrated fluid coupler and analyte sensor device. For example, in some embodiments, the wall **260** is formed of a self-sealing material (not shown), such that the analyte sensor can be inserted through the wall using a needle. For example, a needle containing the sensor in its barrel can be inserted through the wall, followed by withdrawal of the needle over the sensor, such that the sensor remains inserted through the wall. For example, polymer tubing, such as but not limited to silicone tubing, can be used to form the central body of a fluid coupler, and connector ends (e.g., configured for connecting the fluid coupler to a catheter and/or tubing) attached thereto. Additional methods of manufacturing the preferred embodiments are detailed in the section entitled "Multi-Sensor Apparatus."

[0448] **Figs. 2O** and **2P** illustrate another method of manufacturing an integrated fluid coupler and analyte sensor device, such as that shown in **Fig. 2M**. In one embodiment, the fluid coupler is formed of two or more mateable portions (e.g., **260-1**, **260-2**), wherein the first and second mateable portions are configured and arranged to form a seal **260e** when mated

Abbott Ex. 1003 - 149/1058

together, such that the lumen is formed **254**. For example, the two mateable portions can be formed by injection molding a suitable medical-grade plastic. In the embodiment shown in **Fig. 2O**, the two mateable portions **260-1**, **260-2** are configured to mate together, such as but not limited to in a clam shell configuration. One or both of the two mateable portions **260-1**, **260-2** includes an indentation **260c** on the sealing edge(s) (e.g., mating edges) configured to receive an analyte sensor (and/or an electrode). In the illustrated embodiment, the two mateable portions each include three indentations, wherein the indentations are configured to receive the electrodes **240**. In some embodiments, the sensor electrodes are inserted separately (e.g., as opposed to in a bundled or twisted configuration). In a further embodiment, the electrodes can be spaced along the length of the lumen to optimize fluid flow and analyte detection. For example, in some embodiments, the electrodes are spaced equally within the lumen (e.g., the distance between electrodes **240a** and **240b** is substantially equal to the distance between electrodes **240b** and **240c**). In some embodiments, the device is configured such that the diameter of the lumen is substantially the same as the length of the electroactive surfaces (e.g., which span the lumen). Additional configurations are contemplated, such as non-linear spacing and non-equal spacing of the electrodes.

[0449] Referring again to **Figs. 2O** and **2P**, in some embodiments, a grommet **260d** can be included at the point at which the electrode intersects the mated wall. In other embodiments, the wall surrounding the electrode (e.g., at **260d**) can be welded, to form a seal between the electrode and the wall. In some embodiments, the seal is fluid-tight. In some embodiments, a portion of the wall material is melted by the welding, such that a portion of the melted wall material can soak into the membrane of the electrode. **Fig. 2P** illustrates an alternative method of forming the integrated fluid coupler and analyte sensor device, wherein the two mateable portions **260-1**, **260-2** comprise cylinders configured to mate together such that the analyte sensor **240** spans the lumen **254**.

[0450] A connection between the analyte sensor (and/or individual electrodes) and sensor electronics can be made on the exterior surface of the fluid connector. For example, in some embodiments, the analyte sensor electrodes are soldered to wires, which in turn make electrical connection with the sensor electronics. In other embodiments, the electrodes are clipped off substantially flush with the exterior surface of the wall and a PCB **20t** (e.g., configured to make suitable electrical connection with each of the electrodes) is attached to the

Abbott Ex. 1003 - 150/1058

clipped-off ends of the electrodes (e.g., *via* adhesive or welding), such that the electrical connections are made; the PCB is then used to connect the sensor to sensor electronics. In still other embodiments, elastomeric contacts can be used to make a connection between the electrodes and sensor electronics, in a manner similar to that illustrated in **Figs. 1H** and **1J**. Additional methods of connecting analyte sensors to sensor electronics are appreciated by those skilled in the art.

[0451] **Fig. 2Q** illustrates an alternative embodiment of an integrated fluid coupler and analyte sensor device, in which the electrodes are formed of conductive elastomeric material (e.g., contacts **240**). A portion of the fluid coupler can be configured with one or more holes **260c** to receive the elastomeric contacts. For example, the fluid coupler can be injection molded of plastic, including the holes **260c** configured to receive the elastomeric contacts **240**. The electrode/elastomeric contacts can be formed of any conductive elastomeric materials, such as but not limited to carbon black elastomer. Each elastomeric contact is configured with an interior side **240e** and an exterior side **240d**. The interior side is configured and arranged as an electrode, such as one or more working electrodes (plus and/or minus enzyme), a counter electrode or a reference electrode, as described elsewhere herein. The exterior side is configured and arranged for electrical connection with the sensor electronics. The electrode/elastomeric contact can have any useful shape, such that the interior side can be inserted through a hole of the fluid coupler, such that the electroactive surface can be bathed by a sample drawn back into the fluid coupler, and such that the exterior side is sufficiently exposed for making the electrical connection with the sensor electronics. The conductive material can be formed into any shape. For example, the electrode/elastomeric contact can be a ball, or wedge or cylinder. In the embodiment shown in **Fig. 2Q**, the electrode/elastomeric contact includes a cylindrical body with a flat electroactive surface at the interior side **240e**, and sloped or flared sides. The interior side **240e** is configured and arranged to be substantially flush with the lumenal surface of the fluid conduit wall, such that fluid turbulence, biofouling and/or clotting is/are substantially reduced when the device is in use. The exterior side **240d** includes a flat butt end, which is somewhat larger in diameter than cylindrical body, and a shoulder. In some embodiments, the elastomeric material is sufficiently pliable that the elastomeric contact can conform to the structure of the hole, when it is inserted into the hole; such that it makes a substantially water-tight seal with the wall of the fluid coupler. For

Abbott Ex. 1003 - 151/1058

example, in the illustrated embodiments, the flared sides are configured to conform to the hole (e.g., an interference fit), such that the conformed side and the shoulder make a water-tight seal with the wall of the fluid conduit.

[0452] Electrical connection between the electrode/elastomeric contacts **240** and sensor electronics can be made with their exterior surfaces by any method known in the art. For example, in some embodiments, a PCB **20t** configured and arranged for electrical contact with the elastomeric contacts is adhered over the elastomeric contacts. A cover, such as one configured with a female connector **20n** (e.g., see cover **20k** in **Figs. 1H-1J**) is adhered over the PCB, or the PCB is hard-wired to an electrical cable. In another embodiment, the electrode/elastomeric contacts are simply soldered to the wires of an electrical cable. In still other embodiments, conductive traces (e.g., vias) is applied to the exterior surface of the fluid conduit (e.g., prior to insertion of the electrode/elastomeric contacts) such that when the elastomeric contacts are inserted into the holes, the shoulder of each electrode/elastomeric contact makes an electrical connection with one of the conductive traces. The electrical traces, in turn, make electrical connections with sensor electronics, as is known to one skilled in the art.

[0453] Use of electrode/elastomeric contacts **240** enables unique manufacturing methods which are amenable to high through-put, modular manufacturing. In one embodiment, the individual electrode/elastomeric contacts are formed and then processed in batches, such as to deposit the electroactive surfaces and membranes on the interior surfaces. For example, to prepare a batch of working electrode/elastomeric contacts, a batch of unprepared elastomeric contacts (e.g., 100, 1000, etc.) can be placed, head-up, in a holder. Platinum or other conductive electrode material can then be deposited on the heads, sides and/or entire electrode/elastomeric contacts using suitable means such as electroplating, electrospinning, spraying, and the like, to form the electroactive surfaces. A membrane is applied as one or more layers, using known thin-film or thick-film techniques. To form reference electrode/elastomeric contacts, Ag/AgCl particles or other conductive electrode material can be mixed or otherwise formed in or on the material used to form the electrode/elastomeric contacts, or Ag/AgCl can be applied to the interior surfaces of the reference electrode/elastomeric contacts, for example.

Abbott Ex. 1003 - 152/1058

[0454] In a another embodiment, the electrode/elastomeric contacts are formed by preparing a sheet of the elastomeric conductive material, preparing a surface of the sheet, such as forming an electroactive surface thereon, and then punching the individual electrode/elastomeric contacts from the sheet.

[0455] **Fig. 2R** is a cross-section of another embodiment of a fluid coupler including a continuous analyte sensor **240** disposed within the lumen **254**. Namely, a central body **270** is inserted within the lumen. The central body includes conductive bodies **272** disposed within a non-conductive material. Each conductive body **272** includes a conductive member **273**, for making electrical contact with sensor electronics. The sensor electrodes **240** are deposited on the conductive bodies **272**, such that when the central body **270** is inserted into the lumen of the fluid coupler, the electrodes are bathed in sample when the sample is drawn back. In some embodiments, the conductive members provide stabilization to the central body. In other embodiments, the central body and conductive members are configured and arranged such that the lumen is divided into a plurality of chambers (e.g., smaller lumens), such that a plurality of analyte sensors are deposited on the conductive bodies and such that each analyte sensor contacts a separate sample (e.g., uncontaminated by reagents or reaction products from an analyte sensor in another chamber). In one embodiment, the central body is configured as an elongated core, such as but not limited to a cylindrical core. In some embodiments, the central body **270** is configured as a plurality of conductive bodies **272**, which run the length of the central body, bundled in a dielectric material, wherein the conductive members **273** extend out an end of the central body (e.g., rather than out the sides as shown in **Fig. 2R**). In this embodiment, a plurality of analyte sensors can be deposited on the conductive bodies, wherein the central body is inserted into the lumen of the fluid coupler.

[0456] **Fig. 2S** illustrates yet another embodiment of an analyte sensor disposed in a fluid coupler, including an electrode support **280** having one or more analyte sensors **240** deposited thereon. The electrode support **280** is configured and arranged to optimize fluid flow there around and to substantially reduce biofouling and/or clotting thereon. For example, in some embodiments, the electrode support **280** is cigar or football shaped. The electrodes can be working, counter and/or reference electrodes. In some embodiments, the electrode support **280** is stabilized by stabilizers **282**. While the stabilizers **282** shown in **Fig. 2S** are "fin" shaped, a variety of other shapes, such as projections, extensions, detents, and the like

Abbott Ex. 1003 - 153/1058

can be used. In preferred embodiments, the stabilizers substantially maintain the electrode support **280** within the fluid stream such that the electrode support **280** is substantially immobile, such that the flow of fluid about the electrode support **280** is substantially even (e.g., the same rate there around).

[0457] In some embodiments, the device is formed by injection molding, using techniques known in the art. In one exemplary embodiment, the sensors are placed in a mold, which is configured to hold the sensors in such an orientation that after the injection molding procedure, the sensors will be in the correct location and/or orientation for correct function of the device. After the sensors are placed in the mold, the mold is closed and injected with a material (e.g., molten plastic). During the injection molding process, the wall **260** of the device is thus formed about a portion of each sensor **240**, such that a sensing portion of each sensor (e.g., electroactive surface) will be disposed within the duct **212b/258** and another portion of each sensor (e.g., a portion configured for connection to sensor electronics) will be disposed at the exterior of the device. Similar manufacturing techniques are used for the manufacture of syringes and lancets, wherein the plastic portion of the device is formed about a portion of the needle.

[0458] In a medical setting, a variety of vascular access devices can be simultaneously made available for use in conjunction with a flow control device, as described elsewhere herein. As is understood by one skilled in the art, each vascular access device can require a unique flow profile, such that the flow control device infuses and draws back the correct amounts of fluid and/or sample, at the correct time and for the correct lengths of time, to enable optimal sensor operation. In some circumstances, a caretaker may select the wrong flow profile for an installed vascular access device; a medical error that might harm the patient. Accordingly, in some embodiments, the vascular access device is configured and arranged to provide identification information to flow control device, wherein the identification information is associated with the flow profile. For example, in some embodiments the identification information is provided by a mechanical structure (e.g., an engageable mechanical interlock wherein the vascular access device includes one of two portions of the mechanical interlock and the flow control device includes the second of the two portions of the mechanical interlock). In some embodiments, the identification information is provided by electronics of the vascular access device (e.g., a bar code (e.g., identified by a bar code

Abbott Ex. 1003 - 154/1058

scanner incorporated into the flow control device), an RFID chip configured for communication with the electronics of the vascular access device and the like). In some preferred embodiments, a flow profile associated with the vascular access device is initiated by the flow control device, after identification of the vascular access device *via* the identification module. In preferred embodiments, the system is configured to program the flow profile of the flow control device in response to automatic receipt of the identification information (e.g., transmission of the identification information without required user interaction). In this embodiment, because the user does not enter which flow profile to use with the vascular access device, user error is reduced, which in turn increases patient safety.

[0459] While not wishing to be bound by theory, a number of the systems and methods disclosed in the preferred embodiments (e.g., an analyte sensor to be disposed in communication with the host's blood), can be employed in transcutaneous (e.g., transdermal) or wholly implantable analyte sensor devices. For example, the sensor could be integrally formed on the *in vivo* portion of a subcutaneous device or a wholly implantable device. As another example, an enlarged surface area (e.g., bulbous end) can useful in the design of a transcutaneous analyte sensor.

Exemplary Sensor Configurations

[0460] Referring to **Figs. 3A** to **3C**, in some embodiments, the sensor can be configured similarly to the continuous analyte sensors disclosed in co-pending U.S. Patent Publication No. US-2007-0197889-A1 herein incorporated by reference in its entirety. The sensor includes a distal portion **342**, also referred to as the *in vivo* portion, adapted for insertion into the catheter as described above, and a proximal portion **340**, also referred to as an *ex vivo* portion, adapted to operably connect to the sensor electronics. Preferably, the sensor includes two or more electrodes: a working electrode **344** and at least one additional electrode, which can function as a counter electrode and/or reference electrode, hereinafter referred to as the reference electrode **346**. A membrane system is preferably deposited over the electrodes, such as described in more detail with reference to **Figs. 3A** to **3C**, below.

[0461] **Fig. 3B** is an expanded cutaway view of a distal portion of the sensor in one embodiment, showing working and reference electrodes. In preferred embodiments, the sensor is formed from a working electrode **344** (e.g., a wire) and a reference electrode **346** helically wound around the working electrode **344**. An insulator **345** is disposed between the working

Abbott Ex. 1003 - 155/1058

and reference electrodes to provide electrical insulation therebetween. Certain portions of the electrodes are exposed to enable electrochemical reaction thereon, for example, a window **343** can be formed in the insulator to expose a portion of the working electrode **344** for electrochemical reaction.

[0462] In preferred embodiments, each electrode is formed from a fine wire with a diameter of from about 0.001 inches or less to about 0.050 inches or more, for example, and is formed from, *e.g.*, a plated insulator, a plated wire, or bulk electrically conductive material. For example, in some embodiments, the wire used to form a working electrode is about 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, 0.040 or 0.045 inches in diameter. Although the illustrated electrode configuration and associated text describe one preferred method for forming a sensor, a variety of known sensor configurations can be employed with the analyte sensor system of the preferred embodiments, such as U.S. Patent No. 5,711,861, U.S. Patent No. 6,642,015, U.S. Patent No. 6,654,625, U.S. Patent 6,565,509, U.S. Patent No. 6,514,718, U.S. Patent No. 6,465,066, U.S. Patent No. 6,214,185, U.S. Patent No. 5,310,469, U.S. Patent No. 5,683,562, U.S. Patent No. 6,579,690, U.S. Patent No. 6,484,046, U.S. Patent No. 6,512,939, U.S. Patent No. 6,424,847, and U.S. Patent No. 6,424,847, for example. Each of the above patents is incorporated in its entirety herein by reference. The above patents are not inclusive of all applicable analyte sensors; in general, it should be understood that the disclosed embodiments are applicable to a variety of analyte sensor configurations. It is noted that much of the description of the preferred embodiments, for example the membrane system described below, can be implemented not only with *in vivo* sensors, but also with *in vitro* sensors, such as blood glucose meters (SMBG).

[0463] In some embodiments, the working electrode comprises a wire formed from a conductive material, such as platinum, platinum-iridium, palladium, graphite, gold, carbon, conductive polymer, alloys, and the like. Although the electrodes can by formed by a variety of manufacturing techniques (bulk metal processing, deposition of metal onto a substrate, and the like), it can be advantageous to form the electrodes from plated wire (*e.g.*, platinum on steel wire) or bulk metal (*e.g.*, platinum wire). It is believed that electrodes formed from bulk metal wire provide superior performance (*e.g.*, in contrast to deposited electrodes), including increased stability of assay, simplified manufacturability, resistance to contamination (*e.g.*,

Abbott Ex. 1003 - 156/1058

which can be introduced in deposition processes), and improved surface reaction (*e.g.*, due to purity of material) without peeling or delamination.

[0464] In some embodiments, the working electrode is formed of platinum-iridium or iridium wire. In general, platinum-iridium and iridium materials are generally stronger (e.g., more resilient and less likely to fail due to stress or strain fracture or fatigue). It is believed that platinum-iridium and/or iridium materials can facilitate a wire with a smaller diameter to further decrease the maximum diameter (size) of the sensor (e.g., *in vivo* portion). Advantageously, a smaller sensor diameter both reduces the risk of clot or thrombus formation (or other foreign body response) and allows the use of smaller catheters.

[0465] The electroactive window **343** of the working electrode **344** is configured to measure the concentration of an analyte. In an enzymatic electrochemical sensor for detecting glucose, for example, the working electrode measures the hydrogen peroxide produced by an enzyme catalyzed reaction of the analyte being detected and creates a measurable electronic current For example, in the detection of glucose wherein glucose oxidase produces hydrogen peroxide as a byproduct, hydrogen peroxide reacts with the surface of the working electrode producing two protons ($2H^+$), two electrons ($2e^-$) and one molecule of oxygen (O_2), which produces the electronic current being detected.

[0466] In preferred embodiments, the working electrode **344** is covered with an insulating material **345**, for example, a non-conductive polymer. Dip-coating, spray-coating, vapor-deposition, or other coating or deposition techniques can be used to deposit the insulating material on the working electrode. In one embodiment, the insulating material comprises parylene, which can be an advantageous polymer coating for its strength, lubricity, and electrical insulation properties. Generally, parylene is produced by vapor deposition and polymerization of para-xylylene (or its substituted derivatives). While not wishing to be bound by theory, it is believed that the lubricious (e.g., smooth) coating (e.g., parylene) on the sensors of some embodiments contributes to minimal trauma and extended sensor life. While parylene coatings are generally preferred in some embodiments, any suitable insulating material can be used, for example, fluorinated polymers, polyethyleneterephthalate, polyurethane, polyimide, other nonconducting polymers, and the like. Glass or ceramic materials can also be employed. Other materials suitable for use include surface energy modified coating systems such as are marketed under the trade names AMC18, AMC148, AMC141, and AMC321 by Advanced

Abbott Ex. 1003 - 157/1058

Materials Components Express of Bellafonte, PA. In some alternative embodiments, however, the working electrode may not require a coating of insulator.

[0467] The reference electrode **346**, which can function as a reference electrode alone, or as a dual reference and counter electrode, is formed from silver, silver/silver chloride, and the like. In some embodiments, the reference electrode **346** is juxtapositioned and/or twisted with or around the working electrode **344**; however other configurations are also possible (*e.g.*, coiled within the fluid connector/hub **18** or within a fluid coupler **20** or an intradermal or on-skin reference electrode). In the illustrated embodiments, the reference electrode **346** is helically wound around the working electrode **344**. The assembly of wires is then optionally coated or adhered together with an insulating material, similar to that described above, so as to provide an insulating attachment.

[0468] In some embodiments, a silver wire is formed onto the sensor as described above, and subsequently chloridized to form silver/silver chloride reference electrode. Advantageously, chloridizing the silver wire as described herein enables the manufacture of a reference electrode with optimal *in vivo* performance. Namely, by controlling the quantity and amount of chloridization of the silver to form silver/silver chloride, improved break-in time, stability of the reference electrode and extended life has been shown with some embodiments. Additionally, use of silver chloride as described above allows for relatively inexpensive and simple manufacture of the reference electrode.

[0469] In embodiments wherein an outer insulator is disposed, a portion of the coated assembly structure can be stripped or otherwise removed, for example, by hand, excimer lasing, chemical etching, laser ablation, grit-blasting (*e.g.*, with sodium bicarbonate or other suitable grit), and the like, to expose the electroactive surfaces. Alternatively, a portion of the electrode can be masked prior to depositing the insulator in order to maintain an exposed electroactive surface area. In one exemplary embodiment, grit blasting is implemented to expose the electroactive surfaces, preferably utilizing a grit material that is sufficiently hard to ablate the polymer material, while being sufficiently soft so as to minimize or avoid damage to the underlying metal electrode (*e.g.*, a platinum electrode). Although a variety of "grit" materials can be used (*e.g.*, sand, talc, walnut shell, ground plastic, sea salt, and the like), in some preferred embodiments, sodium bicarbonate is an advantageous grit-material because it is sufficiently hard to ablate, *e.g.*, a parylene coating, without damaging, *e.g.*, an underlying

Abbott Ex. 1003 - 158/1058

platinum conductor. One additional advantage of sodium bicarbonate blasting includes its polishing action on the metal as it strips the polymer layer, thereby eliminating a cleaning step that might otherwise be necessary.

[0470] In the embodiment illustrated in **Fig. 3B**, a radial window **343** is formed through the insulating material **345** to expose a circumferential electroactive surface of the working electrode. Additionally, sections of electroactive surface of the reference electrode are exposed. For example, the sections of electroactive surface can be masked during deposition of an outer insulating layer or etched after deposition of an outer insulating layer.

[0471] In some applications, cellular attack or migration of cells to the sensor can cause reduced sensitivity and/or function of the device, particularly after the first day of implantation. However, when the exposed electroactive surface is distributed circumferentially about the sensor (*e.g.*, as in a radial window), the available surface area for reaction can be sufficiently distributed so as to minimize the effect of local cellular invasion of the sensor on the sensor signal. Alternatively, a tangential exposed electroactive window can be formed, for example, by stripping only one side of the coated assembly structure. In other alternative embodiments, the window can be provided at the tip of the coated assembly structure such that the electroactive surfaces are exposed at the tip of the sensor. Other methods and configurations for exposing electroactive surfaces can also be employed.

[0472] In some embodiments, the working electrode has a diameter of from about 0.001 inches or less to about 0.010 inches or more, preferably from about 0.002 inches to about 0.008 inches, and more preferably from about 0.004 inches to about 0.005 inches. The length of the window can be from about 0.1 mm (about 0.004 inches) or less to about 2 mm (about 0.078 inches) or more, and preferably from about 0.25 mm (about 0.01 inches) to about 0.375 mm (about 0.015 inches). In such embodiments, the exposed surface area of the working electrode is preferably from about 0.000013 in^2 (0.0000839cm^2) or less to about 0.0025 in^2 (0.016129 cm^2) or more (assuming a diameter of from about 0.001 inches to about 0.010 inches and a length of from about 0.004 inches to about 0.078 inches). The preferred exposed surface area of the working electrode is selected to produce an analyte signal with a current in the picoAmp range, such as is described in more detail elsewhere herein. However, a current in the picoAmp range can be dependent upon a variety of factors, for example the electronic circuitry design (*e.g.*, sample rate, current draw, A/D converter bit resolution, etc.), the

Abbott Ex. 1003 - 159/1058

membrane system (*e.g.*, permeability of the analyte through the membrane system), and the exposed surface area of the working electrode. Accordingly, the exposed electroactive working electrode surface area can be selected to have a value greater than or less than the above-described ranges taking into consideration alterations in the membrane system and/or electronic circuitry. In preferred embodiments of a glucose sensor, it can be advantageous to minimize the surface area of the working electrode while maximizing the diffusivity of glucose in order to optimize the signal-to-noise ratio while maintaining sensor performance in both high and low glucose concentration ranges.

[0473] In some alternative embodiments, the exposed surface area of the working (and/or other) electrode can be increased by altering the cross-section of the electrode itself. For example, in some embodiments the cross-section of the working electrode can be defined by a cross, star, cloverleaf, ribbed, dimpled, ridged, irregular, or other non-circular configuration; thus, for any predetermined length of electrode, a specific increased surface area can be achieved (as compared to the area achieved by a circular cross-section). Increasing the surface area of the working electrode can be advantageous in providing an increased signal responsive to the analyte concentration, which in turn can be helpful in improving the signal-to-noise ratio, for example.

[0474] In some alternative embodiments, additional electrodes can be included within the assembly, for example, a three-electrode system (working, reference, and counter electrodes) and/or an additional working electrode (*e.g.*, an electrode which can be used to generate oxygen, which is configured as a baseline subtracting electrode, or which is configured for measuring additional analytes). U.S. Patent Publication No. US-2005-0161346-A1, U.S. Patent Publication No. US-2005-0143635-A1, and U.S. Patent Publication No. US-2007-0027385-A1 describe some systems and methods for implementing and using additional working, counter, and/or reference electrodes. In one implementation wherein the sensor comprises two working electrodes, the two working electrodes are juxtapositioned (*e.g.*, extend parallel to each other), around which the reference electrode is disposed (*e.g.*, helically wound). In some embodiments wherein two or more working electrodes are provided, the working electrodes can be formed in a double-, triple-, quad-, etc. helix configuration along the length of the sensor (for example, surrounding a reference electrode, insulated rod, or other support structure). The resulting electrode system can be configured with an appropriate membrane

Abbott Ex. 1003 - 160/1058

system, wherein the first working electrode is configured to measure a first signal including glucose and baseline (e.g., background noise) and the additional working electrode is configured to measure a baseline signal consisting of baseline only (*e.g.*, configured to be substantially similar to the first working electrode without an enzyme disposed thereon). In this way, the baseline signal can be subtracted from the first signal to produce a glucose-only signal that is substantially not subject to fluctuations in the baseline and/or interfering species on the signal.

[0475] Although the embodiments of **Figs. 3A** to **3C** illustrate one electrode configuration including one bulk metal wire helically wound around another bulk metal wire, other electrode configurations are also contemplated. In an alternative embodiment, the working electrode comprises a tube with a reference electrode disposed or coiled inside, including an insulator therebetween. Alternatively, the reference electrode comprises a tube with a working electrode disposed or coiled inside, including an insulator therebetween. In another alternative embodiment, a polymer (*e.g.*, insulating) rod is provided, wherein the electrodes are deposited (*e.g.*, electro-plated) thereon. In yet another alternative embodiment, a metallic (*e.g.*, steel) rod is provided, coated with an insulating material, onto which the working and reference electrodes are deposited. In yet another alternative embodiment, one or more working electrodes are helically wound around a reference electrode.

[0476] Preferably, the electrodes and membrane systems of the preferred embodiments are coaxially formed, namely, the electrodes and/or membrane system all share the same central axle. While not wishing to be bound by theory, it is believed that a coaxial design of the sensor enables a symmetrical design without a preferred bend radius. Namely, in contrast to prior art sensors comprising a substantially planar configuration that can suffer from regular bending about the plane of the sensor, the coaxial design of the preferred embodiments do not have a preferred bend radius and therefore are not subject to regular bending about a particular plane (which can cause fatigue failures and the like). However, non-coaxial sensors can be implemented with the sensor system of the preferred embodiments.

[0477] In addition to the above-described advantages, the coaxial sensor design of the preferred embodiments enables the diameter of the connecting end of the sensor (proximal portion) to be substantially the same as that of the sensing end (distal portion) such that the protective slotted sheath is able to insert the sensor into the catheter and subsequently slide

Abbott Ex. 1003 - 161/1058

back over the sensor and release the sensor from the protective slotted sheath, without complex multi-component designs.

[0478] In one such alternative embodiment, the two wires of the sensor are held apart and configured for insertion into the catheter in proximal but separate locations. The separation of the working and reference electrodes in such an embodiment can provide additional electrochemical stability with simplified manufacture and electrical connectivity. One skilled in the art will appreciate that a variety of electrode configurations can be implemented with the preferred embodiments.

[0479] In addition to the above-described configurations, the reference electrode can be separated from the working electrode, and coiled within a portion of the fluid connector, in some embodiments. In another embodiment, the reference electrode is coiled within the fluid connector and adjacent to its first side. In an alterative embodiment, the reference electrode is coiled within the fluid connector and adjacent to its second side. In such embodiments, the reference electrode is in contact with fluid, such as saline from a saline drip that is flowing into the host, or such as blood that is being withdrawn from the host. While not wishing to be bound by theory, this configuration is believed to be advantageous because the sensor is thinner, allowing the use of smaller catheters and/or a reduced likelihood to thrombus production.

[0480] In another embodiment, the reference electrode **346** can be disposed farther away from the electroactive portion of the working electrode **343** (e.g., closer to the fluid connector). In some embodiments, the reference electrode is located proximal to or within the fluid coupler, such as but not limited to, coiled about the catheter adjacent to the fluid coupler or coiled within the fluid coupler and in contact with fluid flowing through the fluid coupler, such as saline. These configurations can also minimize at least a portion of the sensor diameter and thereby allow the use of smaller catheters and reduce the risk of clots.

[0481] In addition to the embodiments described above, the sensor can be configured with additional working electrodes as described in U.S. Patent Publication No. US-2005-0143635-A1, U.S. Patent No. 7,081,195, and U.S. Patent Publication No. US-2007-0027385-A1, herein incorporated by reference in their entirety. For example, in one embodiment have an auxiliary working electrode, wherein the auxiliary working electrode comprises a wire formed from a conductive material, such as described with reference to the

Abbott Ex. 1003 - 162/1058

glucose-measuring working electrode above. Preferably, the reference electrode, which can function as a reference electrode alone, or as a dual reference and counter electrode, is formed from silver, Silver/Silver chloride, and the like.

[0482] In some embodiments, the electrodes are juxtapositioned and/or twisted with or around each other; however other configurations are also possible. In one example, the auxiliary working electrode and reference electrode can be helically wound around the glucose-measuring working electrode. Alternatively, the auxiliary working electrode and reference electrode can be formed as a double helix around a length of the glucose-measuring working electrode. The assembly of wires can then be optionally coated together with an insulating material, similar to that described above, in order to provide an insulating attachment. Some portion of the coated assembly structure is then stripped, for example using an excimer laser, chemical etching, and the like, to expose the necessary electroactive surfaces. In some alternative embodiments, additional electrodes can be included within the assembly, for example, a three-electrode system (including separate reference and counter electrodes) as is appreciated by one skilled in the art.

[0483] In some alternative embodiments, the sensor is configured as a dual-electrode system (e.g., **Figs. 2M-2O**, **2Q-2S**, and **3D-3I**) configured and arranged to detect two analyte and/or configured as plus-enzyme and minus-enzyme electrodes, as described herein. In one such dual-electrode system, a first electrode functions as a hydrogen peroxide sensor including a membrane system containing glucose-oxidase disposed thereon, which operates as described herein. A second electrode is a hydrogen peroxide sensor that is configured similar to the first electrode, but with a modified membrane system (without active enzyme, for example). This second electrode provides a signal composed mostly of the baseline signal, b.

[0484] In some dual-electrode systems, the baseline signal is (electronically or digitally) subtracted from the glucose signal to obtain a glucose signal substantially without baseline. Accordingly, calibration of the resultant difference signal can be performed by solving the equation $y=mx$ with a single paired measurement. Calibration of the inserted sensor in this alternative embodiment can be made less dependent on the values/range of the paired measurements, less sensitive to error in manual blood glucose measurements, and can facilitate the sensor's use as a primary source of glucose information for the user. U.S. Patent

Abbott Ex. 1003 - 163/1058

Publication No. US-2005-0143635-A1, U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, and U.S. Patent Publication No. US-2008-0083617-A1 each describe systems and methods for subtracting the baseline from a sensor signal, each of which is incorporated herein by reference in its entirety.

[0485] In some alternative dual-electrode system embodiments, the analyte sensor is configured to transmit signals obtained from each electrode separately (*e.g.*, without subtraction of the baseline signal). In this way, the receiver can process these signals to determine additional information about the sensor and/or analyte concentration. For example, by comparing the signals from the first and second electrodes, changes in baseline and/or sensitivity can be detected and/or measured and used to update calibration (*e.g.*, without the use of a reference analyte value). In one such example, by monitoring the corresponding first and second signals over time, an amount of signal contributed by baseline can be measured. In another such example, by comparing fluctuations in the correlating signals over time, changes in sensitivity can be detected and/or measured.

[0486] In some embodiments, the reference electrode can be disposed remotely from the working electrode. In one embodiment, the reference electrode remains within the fluid flow, but is disposed within the fluid coupler. For example, the reference electrode can be coiled within the fluid coupler such that it is contact with saline flowing into the host, but it is not in physical contact with the host's blood (except when blood is withdrawn from the catheter). In another embodiment, the reference electrode is removed from fluid flow, but still maintains bodily fluid contact. For example, the reference electrode can be wired to an adhesive patch that is adhered to the host, such that the reference electrode is in contact with the host's skin. In yet another embodiment, the reference electrode can be external from the system, such as but not limited to in contact with the exterior of the *ex vivo* portion of the system, in fluid or electrical contact with a connected saline drip or other medical device, or in bodily contact, such as is generally done with EKG electrical contacts. While not wishing to be bound by theory, it is believed to locating the reference electrode remotely from the working electrode permits manufacture of a smaller sensor footprint (e.g., diameter) that will have relatively less affect on the host's blood flow, such as less thrombosis, than a sensor having a relatively larger footprint (e.g., wherein both the working electrode and the reference electrode are adjacent to each other and within the blood path).

Abbott Ex. 1003 - 164/1058

[0487] In some embodiments of the sensor system, *in vivo* portion of the sensor (e.g., the tip **14a**) has an enlarged area (e.g., a bulbous, nail head-shaped, football-shaped, cone-shaped, cylindrical, etc. portion) as compared a substantial portion of the sensor (e.g., diameter of the *in vivo* portion of the sensor). The sensor tip can be made bulbous by any convenient systems and methods known in the art, such as but not limited to arc welding, crimping, smashing, welding, molding, heating, and plasma arc welding. While not wishing to be bound by theory, it is believed that an enlarged sensor tip (e.g., bulbous) will prevent vessel piercing as the sensor is pushed forward into the vessel.

[0488] The sensor of the preferred embodiments is designed with a minimally invasive architecture so as to minimize reactions or effects on the blood flow (or on the sensor in the blood flow). Accordingly, the sensor designs described herein, consider minimization of dimensions and arrangement of the electrodes and other components of the sensor system, particularly the *in vivo* portion of the sensor (or any portion of the sensor in fluid contact with the blood flow).

[0489] Accordingly, in some embodiments, a substantial portion of the *in vivo* portion of the sensor is designed with at least one dimension less than about 0.020, 0.015, 0.012, 0.010, 0.008, 0.006, 0.005, 0.004 inches. In some embodiments, a substantial portion of the sensor that is in fluid contact with the blood flow is designed with at least one dimension less than about 0.015, 0.012, 0.010, 0.008, 0.006, 0.005, 0.004, 0.003, 0.002, 0.001 inches. As one exemplary embodiment, a sensor such as described in more detail with reference to **Figs. 1A** to **1C** is formed from a 0.004 inch conductive wire (e.g., platinum) for a diameter of about 0.004 inches along a substantial portion of the sensor (e.g., *in vivo* portion or fluid contact portion). As another exemplary embodiment, a sensor such as described in more detail with reference to **Figs. 1A** to **1C** is formed from a 0.004 inch conductive wire and vapor deposited with an insulator material for a diameter of about 0.005 inches along a substantial portion of the sensor (e.g., *in vivo* portion or fluid contact portion), after which a desired electroactive surface area can be exposed. In the above two exemplary embodiments, the reference electrode can be located remote from the working electrode (e.g., formed from the conductive wire). While the devices and methods described herein are directed to use within the host's blood stream, one skilled in the art will recognize that the systems, configurations, methods and principles of operation described herein can be incorporated into other analyte sensing devices,

Abbott Ex. 1003 - 165/1058

such as but not limited to subcutaneous devices or wholly implantable devices such as described in U.S. Patent Publication No. US-2006-0016700-A1, which is incorporated herein by reference in its entirety.

[0490] **Fig. 3C** is a cross section of the sensor shown in **Fig. 3B**, taken at line **C – C**. Preferably, a membrane system (see **Fig. 3C**) is deposited over the electroactive surfaces of the sensor and includes a plurality of domains or layers, such as described in more detail below, with reference to **Figs. 3B** and **3C**. The membrane system can be deposited on the exposed electroactive surfaces using known thin film techniques (for example, spraying, electro-depositing, dipping, and the like). In one exemplary embodiment, each domain is deposited by dipping the sensor into a solution and drawing out the sensor at a speed that provides the appropriate domain thickness. In general, the membrane system can be disposed over (deposited on) the electroactive surfaces using methods appreciated by one skilled in the art.

[0491] In general, the membrane system includes a plurality of domains, for example, an electrode domain **347**, an interference domain **348**, an enzyme domain **349** (for example, including glucose oxidase), and a resistance domain **350**, as shown in **Fig. 3C**, and can include a high oxygen solubility domain, and/or a bioprotective domain (not shown), such as is described in more detail in U.S. Patent Publication No. US-2005-0245799-A1, and such as is described in more detail below. The membrane system can be deposited on the exposed electroactive surfaces using known thin film techniques (for example, vapor deposition, spraying, electro-depositing, dipping, and the like). In alternative embodiments, however, other vapor deposition processes (e.g., physical and/or chemical vapor deposition processes) can be useful for providing one or more of the insulating and/or membrane layers, including ultrasonic vapor deposition, electrostatic deposition, evaporative deposition, deposition by sputtering, pulsed laser deposition, high velocity oxygen fuel deposition, thermal evaporator deposition, electron beam evaporator deposition, deposition by reactive sputtering molecular beam epitaxy, atmospheric pressure chemical vapor deposition (CVD), atomic layer CVD, hot wire CVD, low-pressure CVD, microwave plasma-assisted CVD, plasma-enhanced CVD, rapid thermal CVD, remote plasma-enhanced CVD, and ultra-high vacuum CVD, for example. However, the membrane system can be disposed over (or deposited on) the electroactive surfaces using any known method, as will be appreciated by one skilled in the art.

Abbott Ex. 1003 - 166/1058

[0492] In some embodiments, one or more domains of the membrane systems are formed from materials such as described above in connection with the porous layer, such as silicone, polytetrafluoroethylene, polyethylene-co-tetrafluoroethylene, polyolefin, polyester, polycarbonate, biostable polytetrafluoroethylene, homopolymers, copolymers, terpolymers of polyurethanes, polypropylene (PP), polyvinylchloride (PVC), polyvinylidene fluoride (PVDF), polybutylene terephthalate (PBT), polymethylmethacrylate (PMMA), polyether ether ketone (PEEK), polyurethanes, cellulosic polymers, polysulfones and block copolymers thereof including, for example, di-block, tri-block, alternating, random and graft copolymers. U.S. Patent Publication No. US-2005-0245799-A1 describes biointerface and membrane system configurations and materials that may be applied to the preferred embodiments.

Electrode Domain

[0493] In selected embodiments, the membrane system comprises an electrode domain. The electrode domain **347** is provided to ensure that an electrochemical reaction occurs between the electroactive surfaces of the working electrode and the reference electrode, and thus the electrode domain **347** is preferably situated more proximal to the electroactive surfaces than the interference and/or enzyme domain. Preferably, the electrode domain includes a coating that maintains a layer of water at the electrochemically reactive surfaces of the sensor. In other words, the electrode domain is present to provide an environment between the surfaces of the working electrode and the reference electrode, which facilitates an electrochemical reaction between the electrodes. For example, a humectant in a binder material can be employed as an electrode domain; this allows for the full transport of ions in the aqueous environment. The electrode domain can also assist in stabilizing the operation of the sensor by accelerating electrode start-up and drifting problems caused by inadequate electrolyte. The material that forms the electrode domain can also provide an environment that protects against pH-mediated damage that can result from the formation of a large pH gradient due to the electrochemical activity of the electrodes.

[0494] In one embodiment, the electrode domain **347** includes a flexible, water-swellable, hydrogel film having a "dry film" thickness of from about 0.05 microns or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably still from about 3, 2.5, 2, or 1 microns, or less, to

Abbott Ex. 1003 - 167/1058

about 3.5, 4, 4.5, or 5 microns or more. "Dry film" thickness refers to the thickness of a cured film cast from a coating formulation by standard coating techniques.

[0495] In certain embodiments, the electrode domain **347** is formed of a curable mixture of a urethane polymer and a hydrophilic polymer. Particularly preferred coatings are formed of a polyurethane polymer having carboxylate or hydroxyl functional groups and non-ionic hydrophilic polyether segments, wherein the polyurethane polymer is crosslinked with a water-soluble carbodiimide (*e.g.*, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)) in the presence of polyvinylpyrrolidone and cured at a moderate temperature of about 50°C.

[0496] In some preferred embodiments, the electrode domain **347** is formed from a hydrophilic polymer (*e.g.*, a polyamide, a polylactone, a polyimide, a polylactam, a functionalized polyamide, a functionalized polylactone, a functionalized polyimide, a functionalized polylactam or a combination thereof) that renders the electrode domain substantially more hydrophilic than an overlying domain, (*e.g.*, interference domain, enzyme domain). In some embodiments, the electrode domain is formed substantially entirely and/or primarily from a hydrophilic polymer. In some embodiments, the electrode domain is formed substantially entirely from PVP. In some embodiments, the electrode domain is formed entirely from a hydrophilic polymer. Useful hydrophilic polymers include but are not limited to poly-N-vinylpyrrolidone (PVP), poly-N-vinyl-2-piperidone, poly-N-vinyl-2-caprolactam, poly-N-vinyl-3-methyl-2-caprolactam, poly-N-vinyl-3-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-piperidone, poly-N-vinyl-4-methyl-2-caprolactam, poly-N-vinyl-3-ethyl-2-pyrrolidone, poly-N-vinyl-4,5-dimethyl-2-pyrrolidone, polyvinylimidazole, poly-N,N-dimethylacrylamide, polyvinyl alcohol, polyacrylic acid, polyethylene oxide, poly-2-ethyl-oxazoline, copolymers thereof and mixtures thereof. A blend of two or more hydrophilic polymers is preferred in some embodiments. In some preferred embodiments, the hydrophilic polymer(s) is not crosslinked. In alternative embodiments, crosslinking is preferred, such as by adding a crosslinking agent, such as but not limited to EDC, or by irradiation at a wavelength sufficient to promote crosslinking between the hydrophilic polymer molecules, which is believed to create a more tortuous diffusion path through the domain.

[0497] An electrode domain formed from a hydrophilic polymer (*e.g.*, PVP) has been shown to substantially reduce break-in time of analyte sensors; for example, a glucose sensor utilizing a cellulosic-based interference domain such as described in more detail

Abbott Ex. 1003 - 168/1058

elsewhere herein. In some embodiments, a uni-component electrode domain formed from a single hydrophilic polymer (*e.g.*, PVP) has been shown to substantially reduce break-in time of a glucose sensor to less than about 2 hours, less than about 1 hour, less than about 20 minutes and/or substantially immediately, such as exemplified in Examples 9 through 11 and 13. Generally, sensor break-in is the amount of time required (after implantation) for the sensor signal to become substantially representative of the analyte concentration. Sensor break-in includes both membrane break-in and electrochemical break-in, which are described in more detail elsewhere herein. In some embodiments, break-in time is less than about 2 hours. In other embodiments, break-in time is less than about 1 hour. In still other embodiments, break-in time is less than about 30 minutes, less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or less. In a preferred embodiment, sensor break-in occurs substantially immediately. Advantageously, in embodiments wherein the break-in time is about 0 minutes (substantially immediately), the sensor can be inserted and begin providing substantially accurate analyte (*e.g.*, glucose) concentrations almost immediately post-insertion, for example, wherein membrane break-in does not limit start-up time.

[0498] While not wishing to be bound by theory, it is believed that providing an electrode domain that is substantially more hydrophilic than the next more distal membrane layer or domain (*e.g.*, the overlaying domain; the layer more distal to the electroactive surface than the electrode domain, such as an interference domain or an enzyme domain) reduces the break-in time of an implanted sensor, by increasing the rate at which the membrane system is hydrated by the surrounding host tissue. While not wishing to be bound by theory, it is believed that, in general, increasing the amount of hydrophilicity of the electrode domain relative to the overlaying layer (*e.g.*, the distal layer in contact with electrode domain, such as the interference domain, enzyme domain, etc.), increases the rate of water absorption, resulting in reduced sensor break-in time. The hydrophilicity of the electrode domain can be substantially increased by the proper selection of hydrophilic polymers, based on their hydrophilicity relative to each other and relative to the overlaying layer (*e.g.*, cellulosic-based interference domain), with preferred polymers being substantially more hydrophilic than the overlaying layer. In one exemplary embodiment, PVP forms the electrode domain, the interference domain is formed from a blend of cellulosic derivatives, such as but not limited to cellulose acetate butyrate and cellulose acetate; it is believed that since PVP is substantially more hydrophilic than the

Abbott Ex. 1003 - 169/1058

cellulosic- based interference domain, the PVP rapidly draws water into the membrane to the electrode domain, and enables the sensor to function with a desired sensitivity and accuracy and starting within a substantially reduced time period after implantation. Reductions in sensor break-in time reduce the amount of time a host must wait to obtain sensor readings, which is particularly advantageous not only in ambulatory applications, but particularly in hospital settings where time is critical.

[0499] While not wishing to be bound by theory, it is believed that when the water absorption of the overlying domain (*e.g.*, the domain overlying the electrode domain) is less than the water absorption of the electrode domain (*e.g.*, during membrane equilibration), then the difference in water absorption between the two domains will drive membrane equilibration and thus membrane break-in. Namely, increasing the difference in hydrophilicity (*e.g.*, between the two domains) results in an increase in the rate of water absorption, which, in turn, results in a decrease in membrane break-in time and/or sensor break-in time. As discussed elsewhere herein, the relative hydrophilicity of the electrode domain as compared to the overlying domain can be modulated by a selection of more hydrophilic materials for formation of the electrode domain (and/or more hydrophobic materials for the overlying domain(s)). For example, an electrode domain with hydrophilic polymer capable of absorbing larger amounts of water can be selected instead of a second hydrophilic polymer that is capable of absorbing less water than the first hydrophilic polymer. In some embodiments, the water content difference between the electrode domain and the overlying domain (*e.g.*, during or after membrane equilibration) is from about 1% or less to about 90% or more. In other embodiments, the water content difference between the electrode domain and the overlying domain is from about 10% or less to about 80% or more. In still other embodiments, the water content difference between the electrode domain and the overlying domain is from about 30% or less to about 60% or more. In preferred embodiments, the electrode domain absorbs 5 wt. % or less to 95 wt. % or more water, preferably 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt. % to about 55, 60, 65, 70, 75, 80, 85, 90 or 95 wt. % water than the adjacent (overlying) domain (*e.g.*, the domain that is more distal to the electroactive surface than the electrode domain).

[0500] In another example, the rate of water absorption by a polymer can be affected by other factors, such as but not limited to the polymer's molecular weight. For example, the rate of water absorption by PVP is dependent upon its molecular weight, which

Abbott Ex. 1003 - 170/1058

is typically from about 40 kDa or less to about 360 kDa or more; with a lower molecular weight PVP (*e.g.*, 40 kDa) absorbing water faster than a higher molecular weight PVP. Accordingly, modulating factors, such as molecular weight, that affect the rate of water absorption by a polymer, can promote the proper selection of materials for electrode domain fabrication. In one embodiment, a lower molecular weight PVP is selected, to reduce break-in time.

[0501] Preferably, the electrode domain is deposited by known thin film deposition techniques (*e.g.*, spray coating or dip-coating the electroactive surfaces of the sensor). In some embodiments, the electrode domain is formed by dip-coating the electroactive surfaces in an electrode domain solution (*e.g.*, 5, 10, 15, 20, 25 or 30% or more PVP in deionized water) and curing the domain for a time of from about 15 minutes to about 30 minutes at a temperature of from about 40°C to about 55°C (and can be accomplished under vacuum (*e.g.*, 20 to 30 mmHg)). In embodiments wherein dip-coating is used to deposit the electrode domain, a preferred insertion rate of from about 1 to about 3 inches per minute into the electrode domain solution, with a preferred dwell time of from about 0.5 to about 2 minutes in the electrode domain solution, and a preferred withdrawal rate of from about 0.25 to about 2 inches per minute from the electrode domain solution provide a functional coating. However, values outside of those set forth above can be acceptable or even desirable in certain embodiments, for example, depending upon solution viscosity and solution surface tension, as is appreciated by one skilled in the art. In one embodiment, the electroactive surfaces of the electrode system are dip-coated one time (one layer) and cured at 50°C under vacuum for 20 minutes. In another embodiment, the electroactive surfaces of the electrode system is dip-coated and cured at 50°C under vacuum for 20 minutes a first time, followed by dip coating and curing at 50°C under vacuum for 20 minutes a second time (two layers). In still other embodiments, the electroactive surfaces can be dip-coated three or more times (three or more layers). In other embodiments, the 1, 2, 3 or more layers of PVP are applied to the electroactive surfaces by spray coating or vapor deposition. In some embodiments, a crosslinking agent (*e.g.*, EDC) can be added to the electrode domain casting solution to promote crosslinking within the domain (*e.g.*, between electrode domain polymer components, latex, etc.). In some alternative embodiments however, no crosslinking agent is used and the electrode domain is not substantially crosslinked.

Abbott Ex. 1003 - 171/1058

[0502] In some embodiments, the deposited PVP electrode domain **347** has a "dry film" thickness of from about 0.05 microns or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably still from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns.

[0503] Although an independent electrode domain **347** is described herein, in some embodiments sufficient hydrophilicity can be provided in the interference domain and/or enzyme domain (the domain adjacent to the electroactive surfaces) so as to provide for the full transport of ions in the aqueous environment (*e.g.* without a distinct electrode domain). In these embodiments, an electrode domain is not necessary.

Interference Domain

[0504] Interferents are molecules or other species that are reduced or oxidized at the electrochemically reactive surfaces of the sensor, either directly or *via* an electron transfer agent, to produce a false positive analyte signal (*e.g.*, a non-analyte-related signal). This false positive signal causes the host's analyte concentration (*e.g.*, glucose concentration) to appear higher than the true analyte concentration. False-positive signal is a clinically significant problem in some conventional sensors. For example in a case of a dangerously hypoglycemic situation, wherein the host has ingested an interferent (*e.g.*, acetaminophen), the artificially high glucose signal can lead the host to believe that he is euglycemic (or, in some cases, hyperglycemic). As a result, the host can make inappropriate treatment decisions, such as taking no action, when the proper course of action is to begin eating. In another example, in the case of a euglycemic or hyperglycemic situation, wherein a host has consumed acetaminophen, an artificially high glucose signal caused by the acetaminophen can lead the host to believe that his or her glucose concentration is much higher than it truly is. Again, as a result of the artificially high glucose signal, the host can make inappropriate treatment decisions, such as giving himself too much insulin, which in turn can lead to a dangerous hypoglycemic episode.

[0505] In preferred embodiments, an interference domain **348** is provided that substantially restricts or blocks the flow of one or more interfering species therethrough; thereby substantially preventing artificial signal increases. Some known interfering species for a glucose sensor, as described in more detail herein, include acetaminophen, ascorbic acid,

Abbott Ex. 1003 - 172/1058

bilirubin, cholesterol, creatinine, dopamine, ephedrine, ibuprofen, L-dopa, methyl dopa, salicylate, tetracycline, tolazamide, tolbutamide, triglycerides, and uric acid. In general, the interference domain of the preferred embodiments is less permeable to one or more of the interfering species than to the measured species, *e.g.*, the product of an enzymatic reaction that is measured at the electroactive surface(s), such as but not limited to H_2O_2.

[0506] In one embodiment, the interference domain **348** is formed from one or more cellulosic derivatives. Cellulosic derivatives can include, but are not limited to, cellulose esters and cellulose ethers. In general, cellulosic derivatives include polymers such as cellulose acetate, cellulose acetate butyrate, 2-hydroxyethyl cellulose, cellulose acetate phthalate, cellulose acetate propionate, cellulose acetate trimellitate, and the like, as well as their copolymers and terpolymers with other cellulosic or non-cellulosic monomers. Cellulose is a polysaccharide polymer of β-D-glucose. While cellulosic derivatives are generally preferred, other polymeric polysaccharides having similar properties to cellulosic derivatives can also be employed in the preferred embodiments.

[0507] In one preferred embodiment, the interference domain **348** is formed from cellulose acetate butyrate. Cellulose acetate butyrate with a molecular weight of about 10,000 daltons to about 75,000 daltons, preferably from about 15,000, 20,000, or 25,000 daltons to about 50,000, 55,000, 60,000, 65,000, or 70,000 daltons, and more preferably about 20,000 daltons is employed. In certain embodiments, however, higher or lower molecular weights can be preferred. In some embodiments, a blend of two or more cellulose acetate butyrates having different molecular weights is preferred. While a "blend" as defined herein (a composition of two or more substances that are not substantially chemically combined with each other and are capable of being separated) is generally preferred, in certain embodiments a single polymer incorporating different constituents (*e.g.*, separate constituents as monomeric units and/or substituents on a single polymer chain) can be employed instead. Additionally, a casting solution or dispersion of cellulose acetate butyrate at a wt. % of from about 5% to about 25%, preferably from about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14% or 15% to about 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24% or 25%, and more preferably from about 5% to about 15% is preferred. Preferably, the casting solution includes a solvent or solvent system, for example an acetone:ethanol solvent system. Higher or lower concentrations can be preferred in certain embodiments. In alternative embodiments, a single solvent (*e.g.*,

Abbott Ex. 1003 - 173/1058

acetone) is used to form a symmetrical membrane domain. A single solvent is used in casting solutions for forming symmetric membrane layer(s). A plurality of layers of cellulose acetate butyrate can be advantageously combined to form the interference domain in some embodiments, for example, three layers can be employed. It can be desirable to employ a mixture of cellulose acetate butyrate components with different molecular weights in a single solution, or to deposit multiple layers of cellulose acetate butyrate from different solutions comprising cellulose acetate butyrate of different molecular weights, different concentrations, and/or different chemistries (*e.g.*, functional groups). It can also be desirable to include additional substances in the casting solutions or dispersions, *e.g.*, functionalizing agents, crosslinking agents, other polymeric substances, substances capable of modifying the hydrophilicity/hydrophobicity of the resulting layer, and the like.

[0508] In one alternative embodiment, the interference domain **348** is formed from cellulose acetate. Cellulose acetate with a molecular weight of about 30,000 daltons or less to about 100,000 daltons or more, preferably from about 35,000, 40,000, or 45,000 daltons to about 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000, 90,000, or 95,000 daltons, and more preferably about 50,000 daltons is preferred. In some embodiments, a blend of two or more cellulose acetates having different molecular weights is preferred. Additionally, a casting solution or dispersion of cellulose acetate at a weight percent of about 3% to about 10%, preferably from about 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, or 6.5% to about 7.5%, 8.0%, 8.5%, 9.0%, or 9.5%, and more preferably about 8% is preferred. In certain embodiments, however, higher or lower molecular weights and/or cellulose acetate weight percentages can be preferred. It can be desirable to employ a mixture of cellulose acetates with molecular weights in a single solution, or to deposit multiple layers of cellulose acetate from different solutions comprising cellulose acetates of different molecular weights, different concentrations, or different chemistries (*e.g.*, functional groups). It can also be desirable to include additional substances in the casting solutions or dispersions such as described in more detail above.

[0509] In addition to forming an interference domain from only cellulose acetate(s) or only cellulose acetate butyrate(s), the interference domain **348** can be formed from combinations or blends of cellulosic derivatives, such as but not limited to cellulose acetate and cellulose acetate butyrate, or combinations of layer(s) of cellulose acetate and layer(s) of

Abbott Ex. 1003 - 174/1058

cellulose acetate butyrate. In some embodiments, a blend of cellulosic derivatives (for formation of an interference domain) includes up to about 10 wt. % or more of cellulose acetate. For example, about 1, 2, 3, 4, 5, 6, 7, 8, 9 wt. % or more cellulose acetate is preferred, in some embodiments. In some embodiments, the cellulosic derivatives blend includes from about 90 wt. % or less to about 100 wt. % cellulose acetate butyrate. For example, in some embodiments, the blend includes about 91, 92, 93, 94, 95, 96, 97, 98 or 99 wt. % cellulose acetate butyrate. In some embodiments, the cellulosic derivative blend includes from about 1.5, 2.0, 2.5, 3.0 or 3.5 wt. % cellulose acetate to about 98.5, 98.0, 97.5, 97.0 or 96.5 wt. % cellulose acetate butyrate. In other embodiments, the blend includes from about 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5 or 8 wt. % cellulose acetate to about 96, 95.5, 95, 94.5, 94, 93.3, 93, 92.5 or 92 wt. % cellulose acetate butyrate. In still other embodiments, the blend includes from about 8.5, 9.0, 9.5, 10.0, 10.5 or 11.0 wt. % cellulose acetate to about 91.5, 91.0, 90.5, 90, 89.5 or 89 wt. % cellulose acetate butyrate.

[0510] In some embodiments, preferred blends of cellulose acetate and cellulose acetate butyrate contain from about 1.5 parts or less to about 60 parts or more cellulose acetate butyrate to one part of cellulose acetate. In some embodiments, a blend contains from about 2 parts to about 40 parts cellulose acetate butyrate to one part cellulose acetate. In other embodiments, about 4, 6, 8, 10, 12, 14, 16, 18 or 20 parts cellulose acetate butyrate to one part cellulose acetate is preferred for formation of the interference domain **348**. In still other embodiments, a blend having from 22, 24, 26, 28, 30, 32, 34, 36 or 38 parts cellulose acetate butyrate to one part cellulose acetate is preferred. As is discussed elsewhere herein, cellulose acetate butyrate is relatively more hydrophobic than cellulose acetate. Accordingly, the cellulose acetate/cellulose acetate butyrate blend contains substantially more hydrophobic than hydrophilic components.

[0511] Cellulose acetate butyrate is a cellulosic polymer having both acetyl and butyl groups, in addition to hydroxyl groups. Acetyl groups are more hydrophilic than butyl groups, and hydroxyl groups are more hydrophilic than both acetyl and butyl groups. Accordingly, the relative amounts of acetyl, butyl and hydroxyl groups can be used to modulate the hydrophilicity/hydrophobicity of the cellulose acetate butyrate of the cellulose acetate/cellulose acetate butyrate blend. A cellulose acetate butyrate can be selected based on the compound's relative amounts of acetate, butyrate and hydroxyl groups; and a cellulose

Abbott Ex. 1003 - 175/1058

acetate can be selected based on the compounds relative amounts of acetate and hydroxyl groups. For example, in some embodiments, a cellulose acetate butyrate having about 35 % or less acetyl groups, about 10 % to about 25 % butyl groups, and hydroxyl groups making up the remainder is preferred for formation of the interference domain **348**. In other embodiments a cellulose acetate butyrate having from about 25 % to about 34 % acetyl groups and from about 15 to about 20 % butyl groups is preferred. In still other embodiments, the preferred cellulose acetate butyrate contains from about 28 % to about 30 % acetyl groups and from about 16 to about 18 % butyl groups. In yet another embodiment, the cellulose acetate butyrate can have no acetate groups and from about 20 % to about 60 % butyrate groups. In yet another embodiment, the cellulose acetate butyrate has about 55 % butyrate groups and no acetate groups.

[0512] While an asymmetric interference domain can be used in some alternative embodiments, a symmetrical interference domain **348** (*e.g.*, of cellulosic-derivative blends, such as but not limited to blends of cellulose acetate components and cellulose acetate butyrate components) is preferred in some embodiments. Symmetrical membranes are uniform throughout their entire structure, without gradients of pore densities or sizes, or a skin on one side but not the other, for example. In various embodiments, a symmetrical interference domain **348** can be formed by the appropriate selection of a solvent (*e.g.*, no anti-solvent is used), for making the casting solution. Appropriate solvents include solvents belonging to the ketone family that are able to solvate the cellulose acetate and cellulose acetate butyrate. The solvents include but are not limited to acetone, methyl ethyl ketone, methyl n-propyl ketone, cyclohexanone, and diacetone alcohol. Other solvents, such as furans (*e.g.*, tetra-hydro-furan and 1,4-dioxane), may be preferred in some embodiments. In one exemplary embodiment, from about 7 wt. % to about 9 wt. % solids (*e.g.*, a blend of cellulosic derivatives, such as cellulose acetate and cellulose acetate butyrate) are blended with a single solvent (*e.g.*, acetone), to form the casting solution for a symmetrical interference domain. In another embodiment, from about 10 to about 15% solids are blended with acetone to form the casting solution. In yet another embodiment, from about 16 to about 18% solids are blended with acetone to form the casting solution. A relatively lower or greater weight percent of solids is preferred to form the casting solution, in some embodiments.

Abbott Ex. 1003 - 176/1058

[0513] The casting solution can be applied either directly to the electroactive surface(s) of the sensor or on top of an electrode domain layer (if included in the membrane system). The casting solution can be applied using any known thin film technique, as discussed elsewhere herein. Additionally, in various embodiments, a symmetrical interference domain **348** includes at least one layer; and in some embodiments, two, three or more layers are formed by the sequential application and curing of the casting solution.

[0514] The concentration of solids in the casting solution can be adjusted to deposit a sufficient amount of solids on the electrode in one layer (*e.g.*, in one dip or spray) to form a membrane layer with sufficient blocking ability, such that the equivalent glucose signal of an interferent (*e.g.*, compounds with an oxidation or reduction potential that overlaps with that of the measured species (*e.g.*, H_2O_2)), measured by the sensor, is about 60 mg/dL or less. For example, in some embodiments, the casting solution's percentage of solids is adjusted such that only a single layer (*e.g.*, dip one time) is required to deposit a sufficient amount of the cellulose acetate/cellulose acetate butyrate blend to form a functional symmetric interference domain that substantially blocks passage therethrough of at least one interferent, such as but not limited to acetaminophen, ascorbic acid, dopamine, ibuprofen, salicylic acid, tolbutamide, tetracycline, creatinine, uric acid, ephedrine, L-dopa, methyl dopa and tolazamide. In some embodiments, the amount of interference domain material deposited by as single dip is sufficient to reduce the equivalent glucose signal of the interferant (*e.g.*, measured by the sensor) to about 60 mg/dl or less. In preferred embodiments, the interferent's equivalent glucose signal response (measured by the sensor) is 50 mg/dl or less. In more preferred embodiments, the interferent produces an equivalent glucose signal response of 40 mg/dl or less. In still more preferred embodiments, the interferent produces an equivalent glucose signal response of less than about 30, 20 or 10 mg/dl. In one exemplary embodiment, the interference domain is configured to substantially block acetaminophen passage therethrough, wherein the equivalent glucose signal response of the acetaminophen is less than about 30 mg/dl.

[0515] In alternative embodiments, the interference domain **348** is configured to substantially block a therapeutic dose of acetaminophen. The term "therapeutic dose" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to the quantity of any substance required to effect the cure of a disease, to

Abbott Ex. 1003 - 177/1058

relieve pain, or that will correct the manifestations of a deficiency of a particular factor in the diet, such as the effective dose used with therapeutically applied compounds, such as drugs. For example, a therapeutic dose of acetaminophen can be an amount of acetaminophen required to relieve headache pain or reduce a fever. As a further example, 1,000 mg of acetaminophen taken orally, such as by swallowing two 500 mg tablets of acetaminophen, is the therapeutic dose frequently taken for headaches. In some embodiments, the interference membrane is configured to block a therapeutic dose of acetaminophen, wherein the equivalent glucose signal response of the acetaminophen is less than about 60 mg/dl. In a preferred embodiment, the interference membrane is configured to block a therapeutic dose of acetaminophen, wherein the equivalent glucose signal response of the acetaminophen is less than about 40 mg/dl. In a more preferred embodiment, the interference membrane is configured to block a therapeutic dose of acetaminophen, wherein the equivalent glucose signal response of the acetaminophen is less than about 30 mg/dl.

[0516] While not wishing to be bound by theory, it is believed that, with respect to symmetrical cellulosic-based membranes, there is an inversely proportional balance between interferent blocking and analyte sensitivity. Namely, changes to the interference domain configuration that increase interferent blocking can result in a corresponding decrease in sensor sensitivity. Sensor sensitivity is discussed in more detail elsewhere herein. It is believed that the balance between interferent blocking and sensor sensitivity is dependent upon the relative proportions of hydrophobic and hydrophilic components of the membrane layer (*e.g.*, the interference domain), with sensors having more hydrophobic interference domains having increased interferent blocking but reduces sensitivity; and sensors having more hydrophilic interference domains having reduced interferent blocking but increased sensitivity. It is believed that the hydrophobic and hydrophilic components of the interference domain can be balanced, to promote a desired level of interferent blocking while at the same time maintaining a desired level of analyte sensitivity. The interference domain hydrophobe-hydrophile balance can be manipulated and/or maintained by the proper selection and blending of the hydrophilic and hydrophobic interference domain components (*e.g.*, cellulosic derivatives having acetyl, butyryl, propionyl, methoxy, ethoxy, propoxy, hydroxyl, carboxymethyl, and/or carboxyethyl groups). For example, cellulose acetate is relatively more hydrophilic than cellulose acetate butyrate. In some embodiments, increasing the percentage of cellulose acetate (or reducing

Abbott Ex. 1003 - 178/1058

the percentage of cellulose acetate butyrate) can increase the hydrophilicity of the cellulose acetate/cellulose acetate butyrate blend, which promotes increased permeability to hydrophilic species, such as but not limited to glucose, H_2O_2 and some interferents (*e.g.*, acetaminophen). In another embodiment, the percentage of cellulose acetate butyrate is increased to increase blocking of interferants, but less permeability to some desired molecules, such as H_2O_2 and glucose, is also reduced.

[0517] One method, of manipulating the hydrophobe-hydrophile balance of the interference domain, is to select the appropriate percentages of acetyl groups (relatively more hydrophilic than butyl groups), butyl groups (relatively more hydrophobic than acetyl groups) and hydroxyl groups of the cellulose acetate butyrate used to form the interference domain **348**. For example, increasing the percentage of acetate groups on the cellulose acetate butyrate will make the cellulose acetate butyrate more hydrophilic. In another example, increasing the percentage of butyl groups on the cellulose acetate butyrate will make the cellulose acetate butyrate more hydrophobic. In yet another example, increasing the percentage of hydroxyl groups will increase the hydrophilicity of the cellulose acetate butyrate. Accordingly, the selection of a cellulose acetate butyrate that is more or less hydrophilic (or more or less hydrophobic) can modulate the over-all hydrophilicity of the cellulose acetate/cellulose acetate butyrate blend. In one exemplary embodiment, an interference domain can be configured to be relatively more hydrophobic (and therefore block interferants more strongly) by reducing the percentage of acetyl or hydroxyl groups or by increasing the percentage of butyl groups on the cellulose acetate butyrate used in the casting solution (while maintaining the relative ratio of cellulose acetate to cellulose acetate butyrate).

[0518] In some alternative embodiments, the interference domain **348** is formed of a blend of cellulosic derivatives, wherein the hydrophilic and hydrophobic components of the interference domain are balanced, such that the glucose sensitivity is from about 1 pA/mg/dL to about 100 pA/mg/dL, and at least one interferent is sufficiently blocked from passage through the interference domain such that the equivalent glucose signal response of the at least one interferent is less than about 60 mg/dL. In a preferred embodiment, the glucose sensitivity is from about 5 pA/mg/dL to about 25 pA/mg/dL. In a more preferred embodiments, the glucose sensitivity is from about 5 pA/mg/dL to about 25 pA/mg/dL and the equivalent glucose signal response of the at least one interferent is less than about 40 mg/dL. In a still more

Abbott Ex. 1003 - 179/1058

preferred embodiments, the glucose sensitivity is from about 5 pA/mg/dL to about 25 pA/mg/dL and the equivalent glucose signal response of the at least one interferent is less than about 30 mg/dL. In some embodiments, the balance between hydrophilic and hydrophobic components of the interference domain can be achieved by adjusting the amounts of hydrophilic and hydrophobic components, relative to each other, as well as adjusting the hydrophilic and hydrophobic groups (*e.g.*, acetyl, butyryl, propionyl, methoxy, ethoxy, propoxy, hydroxyl, carboxymethyl, and/or carboxyethyl groups) of the components themselves (*e.g.*, cellulosic derivatives, such as but not limited to cellulose acetate and cellulose acetate butyrate).

[0519] In some alternative embodiments, additional polymers, such as NAFION®, can be used in combination with cellulosic derivatives to provide equivalent and/or enhanced function of the interference domain **348**. As one example, a layer of a 5 wt. % NAFION® casting solution was applied over a previously applied (*e.g.*, and cured) layer of 8 wt. % cellulose acetate, *e.g.*, by dip coating at least one layer of cellulose acetate and subsequently dip coating at least one layer NAFION® onto a needle-type sensor such as described with reference to the preferred embodiments. Any number of coatings or layers formed in any order may be suitable for forming the interference domain of the preferred embodiments.

[0520] In some alternative embodiments, more than one cellulosic derivative can be used to form the interference domain **348** of the preferred embodiments. In general, the formation of the interference domain on a surface utilizes a solvent or solvent system, in order to solvate the cellulosic derivative(s) (or other polymer) prior to film formation thereon. In preferred embodiments, acetone and ethanol are used as solvents for cellulose acetate; however one skilled in the art appreciates the numerous solvents that are suitable for use with cellulosic derivatives (and other polymers). Additionally, one skilled in the art appreciates that the preferred relative amounts of solvent can be dependent upon the cellulosic derivative (or other polymer) used, its molecular weight, its method for deposition, its desired thickness, and the like. However, a percent solute of from about 1 wt. % to about 25 wt. % is preferably used to form the interference domain solution so as to yield an interference domain having the desired properties. The cellulosic derivative (or other polymer) used, its molecular weight, method for deposition, and desired thickness can be adjusted, depending upon one or more other of the parameters, and can be varied accordingly as is appreciated by one skilled in the art.

Abbott Ex. 1003 - 180/1058

[0521] In some alternative embodiments, other polymer types that can be utilized as a base material for the interference domain **348** including polyurethanes, polymers having pendant ionic groups, and polymers having controlled pore size, for example. In one such alternative embodiment, the interference domain includes a thin, hydrophobic membrane that is non-swellable and restricts diffusion of high molecular weight species. The interference domain **48** is permeable to relatively low molecular weight substances, such as hydrogen peroxide, but restricts the passage of higher molecular weight substances, including glucose and ascorbic acid. Other systems and methods for reducing or eliminating interference species that can be applied to the membrane system of the preferred embodiments are described in U.S. Patent No. 7,074,307, U.S. Patent Publication No. US-2005-0176136-A1, U.S. Patent No. 7,081,195, and U.S. Patent Publication No. US-2005-0143635-A1. In some alternative embodiments, a distinct interference domain is not included.

[0522] In some embodiments, the interference domain **348** is deposited either directly onto the electroactive surfaces of the sensor or onto the distal surface of the electrode domain, for a domain thickness of from about 0.05 micron or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably still from about 1, 1.5 or 2 microns to about 2.5 or 3 microns. Thicker membranes can also be desirable in certain embodiments, but thinner membranes are generally preferred because they have a lower impact on the rate of diffusion of hydrogen peroxide from the enzyme membrane to the electrodes

[0523] In general, the membrane systems of the preferred embodiments can be formed and/or deposited on the exposed electroactive surfaces (*e.g.*, one or more of the working and reference electrodes) using known thin film techniques (for example, casting, spray coating, drawing down, electro-depositing, dip coating, and the like), however casting or other known application techniques can also be utilized. Preferably, the interference domain **348** is deposited by spray or dip coating. In one exemplary embodiment of a needle-type (transcutaneous) sensor such as described herein, the interference domain is formed by dip coating the sensor into an interference domain solution using an insertion rate of from about 0.5 inch/min to about 60 inches/min, preferably 1 inch/min, a dwell time of from about 0 minute to about 2 minutes, preferably about 1 minute, and a withdrawal rate of from about 0.5

Abbott Ex. 1003 - 181/1058

inch/minute to about 60 inches/minute, preferably about 1 inch/minute, and curing (drying) the domain from about 1 minute to about 30 minutes, preferably from about 3 minutes to about 15 minutes (and can be accomplished at room temperature or under vacuum (*e.g.*, 20 to 30 mmHg)). In one exemplary embodiment including cellulose acetate butyrate interference domain, a 3-minute cure (*i.e.*, dry) time is preferred between each layer applied. In another exemplary embodiment employing a cellulose acetate interference domain, a 15 minute cure (*i.e.*, dry) time is preferred between each layer applied.

[0524] In some embodiments, the dip process can be repeated at least one time and up to 10 times or more. In other embodiments, only one dip is preferred. The preferred number of repeated dip processes depends upon the cellulosic derivative(s) used, their concentration, conditions during deposition (*e.g.*, dipping) and the desired thickness (*e.g.*, sufficient thickness to provide functional blocking of certain interferents), and the like. In some embodiments, 1 to 3 microns may be preferred for the interference domain thickness; however, values outside of these can be acceptable or even desirable in certain embodiments, for example, depending upon viscosity and surface tension, as is appreciated by one skilled in the art. In one exemplary embodiment, an interference domain is formed from three layers of cellulose acetate butyrate. In another exemplary embodiment, an interference domain is formed from 10 layers of cellulose acetate. In another embodiment, an interference domain is formed from 1 layer of a blend of cellulose acetate and cellulose acetate butyrate. In alternative embodiments, the interference domain can be formed using any known method and combination of cellulose acetate and cellulose acetate butyrate, as will be appreciated by one skilled in the art.

[0525] In some embodiments, the electroactive surface can be cleaned prior to application of the interference domain **348**. In some embodiments, the interference domain **348** of the preferred embodiments can be useful as a bioprotective or biocompatible domain, namely, a domain that interfaces with host tissue when implanted in an animal (*e.g.*, a human) due to its stability and biocompatibility.

Enzyme Domain

[0526] In preferred embodiments, the membrane system further includes an enzyme domain **349** disposed more distally from the electroactive surfaces than the interference domain **348**; however other configurations can be desirable. In the preferred embodiments, the enzyme domain provides an enzyme to catalyze the reaction of the analyte

Abbott Ex. 1003 - 182/1058

and its co-reactant, as described in more detail below. In the preferred embodiments of a glucose sensor, the enzyme domain includes glucose oxidase; however other oxidases, for example, galactose oxidase or uricase oxidase, can also be used.

[0527] For an enzyme-based electrochemical glucose sensor to perform well, the sensor's response is preferably limited by neither enzyme activity nor co-reactant concentration. Because enzymes, including glucose oxidase, are subject to deactivation as a function of time even in ambient conditions, this behavior is compensated for in forming the enzyme domain. Preferably, the enzyme domain is constructed of aqueous dispersions of colloidal polyurethane polymers including the enzyme. However, in alternative embodiments the enzyme domain is constructed from an oxygen enhancing material, for example, silicone, or fluorocarbon, in order to provide a supply of excess oxygen during transient ischemia. Preferably, the enzyme is immobilized within the domain. See, e.g., U.S. Patent Publication No. US-2005-0054909-A1.

[0528] In preferred embodiments, the enzyme domain is deposited onto the interference domain for a domain thickness of from about 0.05 micron or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably still from about 2, 2.5 or 3 microns to about 3.5, 4, 4.5, or 5 microns. However in some embodiments, the enzyme domain can be deposited directly onto the electroactive surfaces. Preferably, the enzyme domain is deposited by spray or dip coating. In one embodiment of needle-type (transcutaneous) sensor such as described herein, the enzyme domain is formed by dip coating the interference domain coated sensor into an enzyme domain solution and curing the domain for from about 15 to about 30 minutes at a temperature of from about 40°C to about 55°C (and can be accomplished under vacuum (*e.g.*, 20 to 30 mmHg)). In embodiments wherein dip coating is used to deposit the enzyme domain at room temperature, a preferred insertion rate of from about 0.25 inch per minute to about 3 inches per minute, with a preferred dwell time of from about 0.5 minutes to about 2 minutes, and a preferred withdrawal rate of from about 0.25 inch per minute to about 2 inches per minute provides a functional coating. However, values outside of those set forth above can be acceptable or even desirable in certain embodiments, for example, depending upon viscosity and surface tension, as is appreciated by one skilled in the art. In one embodiment, the enzyme

Abbott Ex. 1003 - 183/1058

domain is formed by dip coating two times (namely, forming two layers) in an enzyme domain solution and curing at 50°C under vacuum for 20 minutes. However, in some embodiments, the enzyme domain can be formed by dip coating and/or spray coating one or more layers at a predetermined concentration of the coating solution, insertion rate, dwell time, withdrawal rate, and/or desired thickness.

Resistance Domain

[0529] In preferred embodiments, the membrane system includes a resistance domain **350** disposed more distal from the electroactive surfaces than the enzyme domain. Although the following description is directed to a resistance domain for a glucose sensor, the resistance domain can be modified for other analytes and co-reactants as well.

[0530] There exists a molar excess of glucose relative to the amount of oxygen in blood; that is, for every free oxygen molecule in extracellular fluid, there are typically more than 100 glucose molecules present (see Updike *et al.*, Diabetes Care 5:207-21(1982)). However, an immobilized enzyme-based glucose sensor employing oxygen as co-reactant is preferably supplied with oxygen in non-rate-limiting excess in order for the sensor to respond linearly to changes in glucose concentration, while not responding to changes in oxygen concentration. Specifically, when a glucose-monitoring reaction is oxygen limited, linearity is not achieved above minimal concentrations of glucose. Without a semipermeable membrane situated over the enzyme domain to control the flux of glucose and oxygen, a linear response to glucose levels can be obtained only for glucose concentrations of up to about 40 mg/dL. However, in a clinical setting, a linear response to glucose levels is desirable up to at least about 400 mg/dL.

[0531] The resistance domain includes a semipermeable membrane that controls the flux of oxygen and glucose to the underlying enzyme domain, preferably rendering oxygen in a non-rate-limiting excess. As a result, the upper limit of linearity of glucose measurement is extended to a much higher value than that which is achieved without the resistance domain. In one embodiment, the resistance domain exhibits an oxygen to glucose permeability ratio of from about 50:1 or less to about 400:1 or more, preferably about 200:1. As a result, one-dimensional reactant diffusion is adequate to provide excess oxygen at all reasonable glucose and oxygen concentrations found in the subcutaneous matrix (See Rhodes *et al.*, Anal. Chem., 66:1520-1529 (1994)).

Abbott Ex. 1003 - 184/1058

[0532] In alternative embodiments, a lower ratio of oxygen-to-glucose can be sufficient to provide excess oxygen by using a high oxygen solubility domain (for example, a silicone or fluorocarbon-based material or domain) to enhance the supply/transport of oxygen to the enzyme domain. If more oxygen is supplied to the enzyme, then more glucose can also be supplied to the enzyme without creating an oxygen rate-limiting excess. In alternative embodiments, the resistance domain is formed from a silicone composition, such as is described in U.S. Patent Publication No. US-2005-0090607-A1.

[0533] In a preferred embodiment, the resistance domain includes a polyurethane membrane with both hydrophilic and hydrophobic regions to control the diffusion of glucose and oxygen to an analyte sensor, the membrane being fabricated easily and reproducibly from commercially available materials. A suitable hydrophobic polymer component is a polyurethane, or polyetherurethaneurea. Polyurethane is a polymer produced by the condensation reaction of a diisocyanate and a difunctional hydroxyl-containing material. A polyurethaneurea is a polymer produced by the condensation reaction of a diisocyanate and a difunctional amine-containing material. Preferred diisocyanates include aliphatic diisocyanates containing from about 4 to about 8 methylene units. Diisocyanates containing cycloaliphatic moieties can also be useful in the preparation of the polymer and copolymer components of the membranes of preferred embodiments. The material that forms the basis of the hydrophobic matrix of the resistance domain can be any of those known in the art as appropriate for use as membranes in sensor devices and as having sufficient permeability to allow relevant compounds to pass through it, for example, to allow an oxygen molecule to pass through the membrane from the sample under examination in order to reach the active enzyme or electrochemical electrodes. Examples of materials which can be used to make non-polyurethane type membranes include vinyl polymers, polyethers, polyesters, polyamides, inorganic polymers such as polysiloxanes and polycarbosiloxanes, natural polymers such as cellulosic and protein based materials, and mixtures or combinations thereof.

[0534] In a preferred embodiment, the hydrophilic polymer component is polyethylene oxide. For example, one useful hydrophobic-hydrophilic copolymer component is a polyurethane polymer that includes about 20% hydrophilic polyethylene oxide. The polyethylene oxide portions of the copolymer are thermodynamically driven to separate from the hydrophobic portions of the copolymer and the hydrophobic polymer component. The

Abbott Ex. 1003 - 185/1058

20% polyethylene oxide-based soft segment portion of the copolymer used to form the final blend affects the water pick-up and subsequent glucose permeability of the membrane.

[0535] In some embodiments, the resistance domain is formed from a silicone polymer modified to allow analyte (e.g., glucose) transport.

[0536] In some embodiments, the resistance domain is formed from a silicone polymer/hydrophobic-hydrophilic polymer blend. In one embodiment, The hydrophobic-hydrophilic polymer for use in the blend may be any suitable hydrophobic-hydrophilic polymer, including but not limited to components such as polyvinylpyrrolidone (PVP), polyhydroxyethyl methacrylate, polyvinylalcohol, polyacrylic acid, polyethers such as polyethylene glycol or polypropylene oxide, and copolymers thereof, including, for example, di-block, tri-block, alternating, random, comb, star, dendritic, and graft copolymers (block copolymers are discussed in U.S. Patent No. 4,803,243 and U.S. Patent No. 4,686,044, which are incorporated herein by reference). In one embodiment, the hydrophobic-hydrophilic polymer is a copolymer of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO). Suitable such polymers include, but are not limited to, PEO-PPO diblock copolymers, PPO-PEO-PPO triblock copolymers, PEO-PPO-PEO triblock copolymers, alternating block copolymers of PEO-PPO, random copolymers of ethylene oxide and propylene oxide, and blends thereof. In some embodiments, the copolymers may be optionally substituted with hydroxy substituents. Commercially available examples of PEO and PPO copolymers include the PLURONIC® brand of polymers available from BASF®. In one embodiment, PLURONIC® F-127 is used. Other PLURONIC® polymers include PPO-PEO-PPO triblock copolymers (e.g., PLURONIC® R products). Other suitable commercial polymers include, but are not limited to, SYNPERONICS® products available from UNIQEMA®. U.S. Patent Publication No. US-2007-0244379-A1 which is incorporated herein by reference in its entirety, describes systems and methods suitable for the resistance and/or other domains of the membrane system of the preferred embodiments.

[0537] In preferred embodiments, the resistance domain is deposited onto the enzyme domain to yield a domain thickness of from about 0.05 microns or less to about 20 microns or more, more preferably from about 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 1, 1.5, 2, 2.5, 3, or 3.5 microns to about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 19.5 microns, and more preferably still from about 2, 2.5 or 3 microns to about 3.5, 4,

Abbott Ex. 1003 - 186/1058

4.5, or 5 microns. Preferably, the resistance domain is deposited onto the enzyme domain by vapor deposition, spray coating, or dip coating. In one preferred embodiment, spray coating is the preferred deposition technique. The spraying process atomizes and mists the solution, and therefore most or all of the solvent is evaporated prior to the coating material settling on the underlying domain, thereby minimizing contact of the solvent with the enzyme.

[0538] In another preferred embodiment, physical vapor deposition (e.g., ultrasonic vapor deposition) is used for coating one or more of the membrane domain(s) onto the electrodes, wherein the vapor deposition apparatus and process include an ultrasonic nozzle that produces a mist of micro-droplets in a vacuum chamber. In these embodiments, the micro-droplets move turbulently within the vacuum chamber, isotropically impacting and adhering to the surface of the substrate. Advantageously, vapor deposition as described above can be implemented to provide high production throughput of membrane deposition processes (e.g., at least about 20 to about 200 or more electrodes per chamber), greater consistency of the membrane on each sensor, and increased uniformity of sensor performance, for example, as described below.

[0539] In some embodiments, depositing the resistance domain (for example, as described in the preferred embodiments above) includes formation of a membrane system that substantially blocks or resists ascorbate (a known electrochemical interferant in hydrogen peroxide-measuring glucose sensors). While not wishing to be bound by theory, it is believed that during the process of depositing the resistance domain as described in the preferred embodiments, a structural morphology is formed that is characterized in that ascorbate does not substantially permeate therethrough.

[0540] In a preferred embodiment, the resistance domain is deposited on the enzyme domain by spray coating a solution of from about 1 wt. % to about 5 wt. % polymer and from about 95 wt. % to about 99 wt. % solvent. In spraying a solution of resistance domain material, including a solvent, onto the enzyme domain, it is desirable to mitigate or substantially reduce any contact with enzyme of any solvent in the spray solution that can deactivate the underlying enzyme of the enzyme domain. Tetrahydrofuran (THF) is one solvent that minimally or negligibly affects the enzyme of the enzyme domain upon spraying. Other solvents can also be suitable for use, as is appreciated by one skilled in the art.

Abbott Ex. 1003 - 187/1058

[0541] Although a variety of spraying or deposition techniques can be used, spraying the resistance domain material and rotating the sensor at least one time by 180° can typically provide adequate coverage by the resistance domain. Spraying the resistance domain material and rotating the sensor at least two times by 120° provides even greater coverage (one layer of 360° coverage), thereby ensuring resistivity to glucose, such as is described in more detail above.

[0542] In preferred embodiments, the resistance domain is spray coated and subsequently cured for a time of from about 15 minutes to about 90 minutes at a temperature of from about 40°C to about 60°C (and can be accomplished under vacuum (*e.g.*, from 20 to 30 mmHg)). A cure time of up to about 90 minutes or more can be advantageous to ensure complete drying of the resistance domain.

[0543] In one embodiment, the resistance domain is formed by spray coating at least six layers (namely, rotating the sensor seventeen times by 120° for at least six layers of 360° coverage) and curing at 50°C under vacuum for 60 minutes. However, the resistance domain can be formed by dip coating or spray coating any layer or plurality of layers, depending upon the concentration of the solution, insertion rate, dwell time, withdrawal rate, and/or the desired thickness of the resulting film. Additionally, curing in a convention oven can also be employed.

[0544] In certain embodiments, a variable frequency microwave oven can be used to cure the membrane domains/layers. In general, microwave ovens directly excite the rotational mode of solvents. Consequently, microwave ovens cure coatings from the inside out rather than from the outside in as with conventional convection ovens. This direct rotational mode excitation is responsible for the typically observed "fast" curing within a microwave oven. In contrast to conventional microwave ovens, which rely upon a fixed frequency of emission that can cause arcing of dielectric (metallic) substrates if placed within a conventional microwave oven, Variable Frequency Microwave (VFM) ovens emit thousands of frequencies within 100 milliseconds, which substantially eliminates arcing of dielectric substrates. Consequently, the membrane domains/layers can be cured even after deposition on metallic electrodes as described herein. While not wishing to be bound by theory, it is believe that VFM curing can increase the rate and completeness of solvent evaporation from a liquid

Abbott Ex. 1003 - 188/1058

membrane solution applied to a sensor, as compared to the rate and completeness of solvent evaporation observed for curing in conventional convection ovens.

[0545] In certain embodiments, VFM is can be used together with convection oven curing to further accelerate cure time. In some sensor applications wherein the membrane is cured prior to application on the electrode (see, for example, U.S. Patent Publication No. US-2005-0245799-A1, which is incorporated herein by reference in its entirety), conventional microwave ovens (e.g., fixed frequency microwave ovens) can be used to cure the membrane layer.

Treatment of Interference Domain/Membrane System

[0546] Although the above-described methods generally include a curing step in formation of the membrane system, including the interference domain, the preferred embodiments further include an additional treatment step, which can be performed directly after the formation of the interference domain and/or some time after the formation of the entire membrane system (or anytime in between). In some embodiments, the additional treatment step is performed during (or in combination with) sterilization of the sensor.

[0547] In some embodiments, the membrane system (or interference domain) is treated by exposure to ionizing radiation, for example, electron beam radiation, UV radiation, X-ray radiation, gamma radiation, and the like. Alternatively, the membrane can be exposed to visible light when suitable photoinitiators are incorporated into the interference domain. While not wishing to be bound by theory, it is believed that exposing the interference domain to ionizing radiation substantially crosslinks the interference domain and thereby creates a tighter, less permeable network than an interference domain that has not been exposed to ionizing radiation.

[0548] In some embodiments, the membrane system (or interference domain) is crosslinked by forming free radicals, which may include the use of ionizing radiation, thermal initiators, chemical initiators, photoinitiators (e.g., UV and visible light), and the like. Any suitable initiator or any suitable initiator system can be employed, for example, α-hydroxyketone, α-aminoketone, ammonium persulfate (APS), redox systems such as APS/bisulfite, or potassium permanganate. Suitable thermal initiators include but are not limited to potassium persulfate, ammonium persulfate, sodium persulfate, and mixtures thereof.

Abbott Ex. 1003 - 189/1058

[0549] In embodiments wherein electron beam radiation is used to treat the membrane system (or interference domain), a preferred exposure time is from about 6k or 12kGy to about 25 or 50 kGy, more preferably about 25kGy. However, one skilled in the art appreciates that choice of molecular weight, composition of cellulosic derivative (or other polymer), and/or the thickness of the layer can affect the preferred exposure time of membrane to radiation. Preferably, the exposure is sufficient for substantially crosslinking the interference domain to form free radicals, but does not destroy or significantly break down the membrane or does not significantly damage the underlying electroactive surfaces.

[0550] In embodiments wherein UV radiation is employed to treat the membrane, UV rays from about 200 nm to about 400 nm are preferred; however values outside of this range can be employed in certain embodiments, dependent upon the cellulosic derivative and/or other polymer used.

[0551] In some embodiments, for example, wherein photoinitiators are employed to crosslink the interference domain, one or more additional domains can be provided adjacent to the interference domain for preventing delamination that may be caused by the crosslinking treatment. These additional domains can be "tie layers" (*i.e.*, film layers that enhance adhesion of the interference domain to other domains of the membrane system). In one exemplary embodiment, a membrane system is formed that includes the following domains: resistance domain, enzyme domain, electrode domain, and cellulosic-based interference domain, wherein the electrode domain is configured to ensure adhesion between the enzyme domain and the interference domain. In embodiments wherein photoinitiators are employed to crosslink the interference domain, UV radiation of greater than about 290 nm is preferred. Additionally, from about 0.01 to about 1 wt % photoinitiator is preferred weight-to-weight with a preselected cellulosic polymer (*e.g.,* cellulose acetate); however values outside of this range can be desirable dependent upon the cellulosic polymer selected.

[0552] In general, sterilization of the transcutaneous sensor can be completed after final assembly, utilizing methods such as electron beam radiation, gamma radiation, glutaraldehyde treatment, and the like. The sensor can be sterilized prior to or after packaging. In an alternative embodiment, one or more sensors can be sterilized using variable frequency microwave chamber(s), which can increase the speed and reduce the cost of the sterilization process. In another alternative embodiment, one or more sensors can be sterilized using

Abbott Ex. 1003 - 190/1058

ethylene oxide (EtO) gas sterilization, for example, by treating with 100% ethylene oxide, which can be used when the sensor electronics are not detachably connected to the sensor and/or when the sensor electronics must undergo a sterilization process. In one embodiment, one or more packaged sets of transcutaneous sensors (e.g., 1, 2, 3, 4, or 5 sensors or more) are sterilized simultaneously.

Therapeutic Agents

[0553] A variety of therapeutic (bioactive) agents can be used with the analyte sensor system of the preferred embodiments, such as the analyte sensor system of the embodiments shown in **Figs. 1A – 3C**. In some embodiments, the therapeutic agent is an anticoagulant. The term "anticoagulant" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substance the prevents coagulation (e.g., minimizes, reduces, or stops clotting of blood). In some embodiments, an anticoagulant is included in the analyte sensor system to prevent coagulation within or on the sensor (e.g., within or on the catheter or within or on the sensor). Suitable anticoagulants for incorporation into the sensor system include, but are not limited to, vitamin K antagonists (e.g., Acenocoumarol, Clorindione, Dicumarol (Dicoumarol), Diphenadione, Ethyl biscoumacetate, Phenprocoumon, Phenindione, Tioclomarol, or Warfarin), heparin group anticoagulants (e.g., Platelet aggregation inhibitors: Antithrombin III, Bemiparin, Dalteparin, Danaparoid, Enoxaparin, Heparin, Nadroparin, Parnaparin, Reviparin, Sulodexide, Tinzaparin), other platelet aggregation inhibitors (e.g., Abciximab, Acetylsalicylic acid (Aspirin), Aloxiprin, Beraprost, Ditazole, Carbasalate calcium, Cloricromen, Clopidogrel, Dipyridamole, Epoprostenol, Eptifibatide, Indobufen, Iloprost, Picotamide, Ticlopidine, Tirofiban, Treprostinil, Triflusal), enzymes (e.g., Alteplase, Ancrod, Anistreplase, Brinase, Drotrecogin alfa, Fibrinolysin, Protein C, Reteplase, Saruplase, Streptokinase, Tenecteplase, Urokinase), direct thrombin inhibitors (e.g., Argatroban, Bivalirudin, Desirudin, Lepirudin, Melagatran, Ximelagatran, other antithrombotics (e.g., Dabigatran, Defibrotide, Dermatan sulfate, Fondaparinux, Rivaroxaban) and the like.

[0554] In one embodiment, heparin is incorporated into the analyte sensor system. In a further embodiment, heparin is coated on the catheter (inner and/or outer diameter) and/or sensor, for example, by dipping or spraying. While not wishing to be bound by theory, it is

Abbott Ex. 1003 - 191/1058

believed that heparin coated on the catheter and/or sensor prevents aggregation and clotting of blood on the analyte sensor system, thereby preventing thromboembolization (e.g., prevention of blood flow by the thrombus or clot) and/or subsequent complications. In another embodiment, an antimicrobial is coated on the catheter (inner and/or outer diameter) and/or sensor.

[0555] In some embodiments, the therapeutic agent is an antimicrobial. The term "antimicrobial agent" as used in the preferred embodiments means antibiotics, antiseptics, disinfectants and synthetic moieties, and combinations thereof, that are soluble in organic solvents such as alcohols, ketones, ethers, aldehydes, acetonitrile, acetic acid, methylene chloride and chloroform.

[0556] Classes of antibiotics that can be used include tetracyclines (i.e. minocycline), rifamycins (i.e. rifampin), macrolides (i.e. erythromycin), penicillins (i.e. nafeillin), cephalosporins (i.e. cefazolin), other beta-lactam antibiotics (i.e. imipenem, aztreonam), aminoglycosides (i.e. gentamicin), chloramphenicol, sufonamides (i.e. sulfamethoxazole), glycopeptides (i.e. vancomycin), quinolones (i.e. ciprofloxacin), fusidic acid, trimethoprim, metronidazole, clindamycin, mupirocin, polyenes (i.e. amphotericin B), azoles (i.e. fluconazole) and beta-lactam inhibitors (i.e. sulbactam).

[0557] Examples of specific antibiotics that can be used include minocycline, rifampin, erythromycin, nafcillin, cefazolin, imipenem, aztreonam, gentamicin, sulfamethoxazole, vancomycin, ciprofloxacin, trimethoprim, metronidazole, clindamycin, teicoplanin, mupirocin, azithromycin, clarithromycin, ofloxacin, lomefloxacin, norfloxacin, nalidixic acid, sparfloxacin, pefloxacin, amifloxacin, enoxacin, fleroxacin, temafloxacin, tosufloxacin, clinafloxacin, sulbactam, clavulanic acid, amphotericin B, fluconazole, itraconazole, ketoconazole, and nystatin.

[0558] Examples of antiseptics and disinfectants are hexachlorophene, cationic bisiguanides (i.e. chlorhexidine, cyclohexidine) iodine and iodophores (i.e. povidoneiodine), para-chloro-meta-xylenol, triclosan, furan medical preparations (i.e. nitrofurantoin, nitrofurazone), methenamine, aldehydes (glutaraldehyde, formaldehyde) and alcohols. Other examples of antiseptics and disinfectants will readily suggest themselves to those of ordinary skill in the art.

Abbott Ex. 1003 - 192/1058

[0559] These antimicrobial agents can be used alone or in combination of two or more of them. The antimicrobial agents can be dispersed throughout the material of the sensor and/or catheter. The amount of each antimicrobial agent used to impregnate the medical device varies to some extent, but is at least of an effective concentration to inhibit the growth of bacterial and fungal organisms, such as staphylococci, gram-positive bacteria, gram-negative bacilli and Candida.

[0560] In some embodiments, the membrane system of the preferred embodiments preferably include a bioactive agent, which is incorporated into at least a portion of the membrane system, or which is incorporated into the device and adapted to diffuse through the membrane.

[0561] There are a variety of systems and methods by which the bioactive agent is incorporated into the membrane of the preferred embodiments. In some embodiments, the bioactive agent is incorporated at the time of manufacture of the membrane system. For example, the bioactive agent can be blended prior to curing the membrane system, or subsequent to membrane system manufacture, for example, by coating, imbibing, solvent-casting, or sorption of the bioactive agent into the membrane system. Although the bioactive agent is preferably incorporated into the membrane system, in some embodiments the bioactive agent can be administered concurrently with, prior to, or after insertion of the device intravascularly, for example, by oral administration, or locally, for example, by subcutaneous injection near the implantation site. A combination of bioactive agent incorporated in the membrane system and bioactive agent administration locally and/or systemically can be preferred in certain embodiments.

[0562] In general, a bioactive agent can be incorporated into the membrane system, and/or incorporated into the device and adapted to diffuse therefrom, in order to modify the tissue response of the host to the membrane. In some embodiments, the bioactive agent is incorporated only into a portion of the membrane system adjacent to the sensing region of the device, over the entire surface of the device except over the sensing region, or any combination thereof, which can be helpful in controlling different mechanisms and/or stages of thrombus formation. In some alternative embodiments however, the bioactive agent is incorporated into the device proximal to the membrane system, such that the bioactive agent diffuses through the membrane system to the host circulatory system.

Abbott Ex. 1003 - 193/1058

[0563] The bioactive agent can include a carrier matrix, wherein the matrix includes one or more of collagen, a particulate matrix, a resorbable or non-resorbable matrix, a controlled-release matrix, and/or a gel. In some embodiments, the carrier matrix includes a reservoir, wherein a bioactive agent is encapsulated within a microcapsule. The carrier matrix can include a system in which a bioactive agent is physically entrapped within a polymer network. In some embodiments, the bioactive agent is cross-linked with the membrane system, while in others the bioactive agent is sorbed into the membrane system, for example, by adsorption, absorption, or imbibing. The bioactive agent can be deposited in or on the membrane system, for example, by coating, filling, or solvent casting. In certain embodiments, ionic and nonionic surfactants, detergents, micelles, emulsifiers, demulsifiers, stabilizers, aqueous and oleaginous carriers, solvents, preservatives, antioxidants, or buffering agents are used to incorporate the bioactive agent into the membrane system. The bioactive agent can be incorporated into a polymer using techniques such as described above, and the polymer can be used to form the membrane system, coatings on the membrane system, portions of the membrane system, and/or any portion of the sensor system.

[0564] The membrane system can be manufactured using techniques known in the art. The bioactive agent can be sorbed into the membrane system, for example, by soaking the membrane system for a length of time (for example, from about an hour or less to about a week or more, preferably from about 4, 8, 12, 16, or 20 hours to about 1, 2, 3, 4, 5, or 7 days).

[0565] The bioactive agent can be blended into uncured polymer prior to forming the membrane system. The membrane system is then cured and the bioactive agent thereby cross-linked and/or encapsulated within the polymer that forms the membrane system.

[0566] In yet another embodiment, microspheres are used to encapsulate the bioactive agent. The microspheres can be formed of biodegradable polymers, most preferably synthetic polymers or natural polymers such as proteins and polysaccharides. As used herein, the term polymer is used to refer to both to synthetic polymers and proteins. U.S. Patent 6,281,015, which is incorporated herein by reference in its entirety, discloses some systems and methods that can be used in conjunction with the preferred embodiments. In general, bioactive agents can be incorporated in (1) the polymer matrix forming the microspheres, (2) microparticle(s) surrounded by the polymer which forms the microspheres, (3) a polymer core within a protein microsphere, (4) a polymer coating around a polymer microsphere, (5) mixed

Abbott Ex. 1003 - 194/1058

in with microspheres aggregated into a larger form, or (6) a combination thereof. Bioactive agents can be incorporated as particulates or by co-dissolving the factors with the polymer. Stabilizers can be incorporated by addition of the stabilizers to the factor solution prior to formation of the microspheres.

[0567] The bioactive agent can be incorporated into a hydrogel and coated or otherwise deposited in or on the membrane system. Some hydrogels suitable for use in the preferred embodiments include cross-linked, hydrophilic, three-dimensional polymer networks that are highly permeable to the bioactive agent and are triggered to release the bioactive agent based on a stimulus.

[0568] The bioactive agent can be incorporated into the membrane system by solvent casting, wherein a solution including dissolved bioactive agent is disposed on the surface of the membrane system, after which the solvent is removed to form a coating on the membrane surface.

[0569] The bioactive agent can be compounded into a plug of material, which is placed within the device, such as is described in U.S. Patent No. 4,506,680 and U.S. Patent No. 5,282,844, which are incorporated herein by reference in their entirety. In some embodiments, it is preferred to dispose the plug beneath a membrane system; in this way, the bioactive agent is controlled by diffusion through the membrane, which provides a mechanism for sustained-release of the bioactive agent in the host.

Release of Bioactive Agents

[0570] Numerous variables can affect the pharmacokinetics of bioactive agent release. The bioactive agents of the preferred embodiments can be optimized for short- and/or long-term release. In some embodiments, the bioactive agents of the preferred embodiments are designed to aid or overcome factors associated with short-term effects (e.g., acute inflammation and/or thrombosis) of sensor insertion. In some embodiments, the bioactive agents of the preferred embodiments are designed to aid or overcome factors associated with long-term effects, for example, chronic inflammation or build-up of fibrotic tissue and/or plaque material. In some embodiments, the bioactive agents of the preferred embodiments combine short- and long-term release to exploit the benefits of both.

[0571] As used herein, "controlled," "sustained," or "extended" release of the factors can be continuous or discontinuous, linear or non-linear. This can be accomplished

Abbott Ex. 1003 - 195/1058

using one or more types of polymer compositions, drug loadings, selections of excipients or degradation enhancers, or other modifications, administered alone, in combination or sequentially to produce the desired effect.

[0572] Short-term release of the bioactive agent in the preferred embodiments generally refers to release over a period of from about a few minutes or hours to about 2, 3, 4, 5, 6, or 7 days or more.

Loading of Bioactive Agents

[0573] The amount of loading of the bioactive agent into the membrane system can depend upon several factors. For example, the bioactive agent dosage and duration can vary with the intended use of the membrane system, for example, the intended length of use of the device and the like; differences among patients in the effective dose of bioactive agent; location and methods of loading the bioactive agent; and release rates associated with bioactive agents and optionally their carrier matrix. Therefore, one skilled in the art will appreciate the variability in the levels of loading the bioactive agent, for the reasons described above.

[0574] In some embodiments, wherein the bioactive agent is incorporated into the membrane system without a carrier matrix, the preferred level of loading of the bioactive agent into the membrane system can vary depending upon the nature of the bioactive agent. The level of loading of the bioactive agent is preferably sufficiently high such that a biological effect (e.g., thrombosis prevention) is observed. Above this threshold, bioactive agent can be loaded into the membrane system so as to imbibe up to 100% of the solid portions, cover all accessible surfaces of the membrane, and/or fill up to 100% of the accessible cavity space. Typically, the level of loading (based on the weight of bioactive agent(s), membrane system, and other substances present) is from about 1 ppm or less to about 1000 ppm or more, preferably from about 2, 3, 4, or 5 ppm up to about 10, 25, 50, 75, 100, 200, 300, 400, 500, 600, 700, 800, or 900 ppm. In certain embodiments, the level of loading can be 1 wt. % or less up to about 50 wt. % or more, preferably from about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 wt. % up to about 25, 30, 35, 40, or 45 wt. %.

[0575] When the bioactive agent is incorporated into the membrane system with a carrier matrix, such as a gel, the gel concentration can be optimized, for example, loaded with one or more test loadings of the bioactive agent. It is generally preferred that the gel contain from about 0.1 or less to about 50 wt. % or more of the bioactive agent(s), preferably from

Abbott Ex. 1003 - 196/1058

about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 wt. % to about 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 45 wt. % or more bioactive agent(s), more preferably from about 1, 2, or 3 wt. % to about 4 or 5 wt. % of the bioactive agent(s). Substances that are not bioactive can also be incorporated into the matrix.

[0576] Referring now to microencapsulate bioactive agents, the release of the agents from these polymeric systems generally occurs by two different mechanisms. The bioactive agent can be released by diffusion through aqueous filled channels generated in the dosage form by the dissolution of the agent or by voids created by the removal of the polymer solvent or a pore forming agent during the original micro-encapsulation. Alternatively, release can be enhanced due to the degradation of the encapsulating polymer. With time, the polymer erodes and generates increased porosity and microstructure within the device. This creates additional pathways for release of the bioactive agent.

[0577] In some embodiments, the sensor is designed to be bioinert, e.g., by the use of bioinert materials. Bioinert materials do not substantially cause any response from the host. As a result, cells can live adjacent to the material but do not form a bond with it. Bioinert materials include but are not limited to alumina, zirconia, titanium oxide or other bioinert materials generally used in the "catheter/catheterization" art. While not wishing to be bound by theory, it is believed that inclusion of a bioinert material in or on the sensor can reduce attachment of blood cells or proteins to the sensor, thrombosis or other host reactions to the sensor.

Dual-Electrode Analyte Sensors

[0578] In general, electrochemical analyte sensors provide at least one working electrode and at least one reference electrode, which are configured to generate a signal associated with a concentration of the analyte in the host, such as described herein, and as appreciated by one skilled in the art. The output signal is typically a raw data stream that is used to provide a useful value of the measured analyte concentration in a host to the patient or doctor, for example. However, the analyte sensors of the preferred embodiments may further measure at least one additional signal. For example, in some embodiments, the additional signal is associated with the baseline and/or sensitivity of the analyte sensor, thereby enabling monitoring of baseline and/or sensitivity changes that may occur in a continuous analyte sensor over time.

Abbott Ex. 1003 - 197/1058

[0579] In preferred embodiments, the analyte sensor comprises a first working electrode **E1** and a second working electrode **E2**, in addition to a reference electrode, which is referred to as a dual-electrode system herein. The first and second working electrodes may be in any useful conformation, as described in U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, U.S. Patent Publication No. US-2007-0027284-A1, U.S. Patent Publication No. US-2007-0032717-A1, U.S. Patent Publication No. US-2007-0093704-A1, and U.S. Patent Publication No. US-2008-0083617-A1, each of which is incorporated herein by reference in its entirety. In some preferred embodiments, the first and second working electrodes are twisted and/or bundled. For example, two wire working electrodes can be twisted together, such as in a helix conformation. The reference electrode can then be wrapped around the twisted pair of working electrodes. In some preferred embodiments, the first and second working electrodes include a coaxial configuration. A variety of dual-electrode system configurations are described with reference to **Figs. 7A1** through **11** of the references incorporated above. In some embodiments, the sensor is configured as a dual electrode sensor, such as described in U.S. Patent Publication No. US-2005-0143635-A1, U.S. Patent Publication No. US-2007-0027385-A1, U.S. Patent Publication No. US-2007-0213611-A1, and U.S. Patent Publication No. US-2008-0083617-A1, each of which is incorporated herein by reference in its entirety. However, a dual-electrode system can be provided in any planar or non-planar configuration, such as can be appreciated by one skilled in the art, and can be found in U.S. Patent No. 6,175,752, U.S. Patent No. 6,579,690, U.S. Patent No. 6,484,046, U.S. Patent No. 6,512,939, U.S. Patent No. 6,477,395, U.S. Patent No. 6,424,847, U.S. Patent No. 6,212,416, U.S. Patent No. 6,119,028, U.S. Patent No. 6,400,974, U.S. Patent No. 6,595,919, U.S. Patent No. 6,141,573, U.S. Patent No. 6,122,536; European Patent Publication No. EP 1153571, U.S. Patent No. 6,512,939, U.S. Patent No. 5,605,152, U.S. Patent No. 4,431,004, U.S. Patent No. 4,703,756, U.S. Patent No. 6,514,718, U.S. Patent No. 5,985,129, PCT Patent Publication No. WO04/021877, U.S. Patent No. 5,494,562, U.S. Patent No. 6,120,676, and U.S. Patent No. 6,542,765, each of which are incorporated in there entirety herein by reference in their entirety. In general, it is understood that the disclosed embodiments are applicable to a variety of continuous analyte measuring device configurations

Abbott Ex. 1003 - 198/1058

[0580] **Fig. 3D** illustrates a dual-electrode system in preferred embodiments. The dual-electrode sensor system includes a first working electrode **E1** and the second working electrode **E2**, both of which are disposed beneath a sensor membrane **M02**, such as but not limited to a membrane system similar to that described with reference to **Fig. 3C** and/or **Figs. 3F** through **3I**. The first working electrode **E1** is disposed beneath an active enzymatic portion **M04** of the sensor membrane **M02**, which includes an enzyme configured to detect the analyte or an analyte-related compound. Accordingly, the first working electrode **E1** is configured to generate a first signal composed of both signal related to the analyte and signal related to non-analyte electroactive compounds (e.g., physiological baseline, interferents, and non-constant noise) that have an oxidation/reduction potential that overlaps with the oxidation/reduction potential of the analyte. This oxidation/reduction potential may be referred to as a "first oxidation/reduction potential" herein. The second working electrode **E2** is disposed beneath an inactive-enzymatic or non-enzymatic portion **M06** of the sensor membrane **M02**. The non-enzymatic portion **M06** of the membrane includes either an inactivated form of the enzyme contained in the enzymatic portion **M04** of the membrane or no enzyme. In some embodiments, the non-enzymatic portion **M06** can include a non-specific protein, such as BSA, ovalbumin, milk protein, certain polypeptides, and the like. The non-enzymatic portion **M06** generates a second signal associated with noise of the analyte sensor. The noise of the sensor comprises signal contribution due to non-analyte electroactive species (e.g., interferents) that have an oxidation/reduction potential that substantially overlaps the first oxidation/reduction potential (e.g., that overlap with the oxidation/reduction potential of the analyte). In some embodiments of a dual-electrode analyte sensor configured for fluid communication with a host's circulatory system, the non-analyte related electroactive species comprises at least one species selected from the group consisting of interfering species, non-reaction-related hydrogen peroxide, and other electroactive species.

[0581] In one exemplary embodiment, the dual-electrode analyte sensor is a glucose sensor having a first working electrode **E1** configured to generate a first signal associated with both glucose and non-glucose related electroactive compounds that have a first oxidation/reduction potential. Non-glucose related electroactive compounds can be any compound, in the sensor's local environment that has an oxidation/reduction potential substantially overlapping with the oxidation/reduction potential of H_2O_2, for example. While

Abbott Ex. 1003 - 199/1058

not wishing to be bound by theory, it is believed that the glucose-measuring electrode can measure both the signal directly related to the reaction of glucose with GOx (produces H_2O_2 that is oxidized at the working electrode) and signals from unknown compounds that are in the blood surrounding the sensor. These unknown compounds can be constant or non-constant (e.g., intermittent or transient) in concentration and/or effect. In some circumstances, it is believed that some of these unknown compounds are related to the host's disease state. For example, it is known that blood chemistry changes dramatically during/after a heart attack (e.g., pH changes, changes in the concentration of various blood components/protein, and the like). Additionally, a variety of medicaments or infusion fluid components (e.g., acetaminophen, ascorbic acid, dopamine, ibuprofen, salicylic acid, tolbutamide, tetracycline, creatinine, uric acid, ephedrine, L-dopa, methyl dopa and tolazamide) that may be given to the host may have oxidation/reduction potentials that overlap with that of H_2O_2.

[0582] In this exemplary embodiment, the dual-electrode analyte sensor includes a second working electrode **E2** that is configured to generate a second signal associated with the non-glucose related electroactive compounds that have the same oxidation/reduction potential as the above-described first working electrode (e.g., *para supra*). In some embodiments, the non-glucose related electroactive species includes at least one of interfering species, non-reaction-related H_2O_2, and other electroactive species. For example, interfering species includes any compound that is not directly related to the electrochemical signal generated by the glucose-GOx reaction, such as but not limited to electroactive species in the local environment produces by other bodily processes (e.g., cellular metabolism, a disease process, and the like). Other electroactive species includes any compound that has an oxidation/reduction potential similar to or overlapping that of H_2O_2.

[0583] The non-analyte (e.g., non-glucose) signal produced by compounds other than the analyte (e.g., glucose) obscured the signal related to the analyte, contributes to sensor inaccuracy, and is considered background noise. As described in greater detail in the section entitled "Noise Reduction," background noise includes both constant and non-constant components and must be removed to accurately calculate the analyte concentration. While not wishing to be bound by theory, it is believed that the sensor of the preferred embodiments are designed (e.g., with symmetry, coaxial design and/or integral formation, and interference domain of the membrane described elsewhere herein) such that the first and second electrodes

Abbott Ex. 1003 - 200/1058

are influenced by substantially the same external/environmental factors, which enables substantially equivalent measurement of both the constant and non-constant species/noise. This advantageously allows the substantial elimination of noise on the sensor signal (using electronics described elsewhere herein) to substantially reduce or eliminate signal effects due to noise, including non-constant noise (e.g., unpredictable biological, biochemical species, medicaments, pH fluctuations, O_2 fluctuations, or the like) known to effect the accuracy of conventional continuous sensor signals. Preferably, the sensor includes electronics operably connected to the first and second working electrodes. The electronics are configured to provide the first and second signals that are used to generate glucose concentration data substantially without signal contribution due to non-glucose-related noise. Preferably, the electronics include at least a potentiostat that provides a bias to the electrodes. In some embodiments, sensor electronics are configured to measure the current (or voltage) to provide the first and second signals. The first and second signals are used to determine the glucose concentration substantially without signal contribution due to non-glucose-related noise such as by but not limited to subtraction of the second signal from the first signal or alternative data analysis techniques. In some embodiments, the sensor electronics include a transmitter that transmits the first and second signals to a receiver, where additional data analysis and/or calibration of glucose concentration can be processed. U.S. Patent Publication No. US-2005-0027463-A1, U.S. Patent Publication No. US-2005-0203360-A1 and U.S. Patent Publication No. US-2006-0036142-A1 describe systems and methods for processing sensor analyte data and are incorporated herein by reference in their entirety.

[0584] In preferred embodiments, the dual-electrode sensor is configured such that the first and second working electrodes **E1**, **E2** are equivalently influenced by *in vivo* environmental factors. For example, in one embodiment, the dual-electrode sensor is configured for fluid communication with the circulatory system of the host, such as by implantation in the host's vein or artery *via* a vascular access device (also referred to as a fluid communication device herein) such as a catheter and/or cannula. When the sensor is contacted with a sample of the host's circulatory system (e.g., blood), the first and second working electrodes **E1**, **E2** are configured such that they are equivalently influenced by a variety of environmental factors impinging upon the sensor, such as but not limited to non-analyte related electroactive species (e.g., interfering species, non-reaction-related H_2O_2, an other

Abbott Ex. 1003 - 201/1058

electroactive species). Because the first and second working electrodes are equivalently influenced by *in vivo* environmental factors, the signal component associated with the *in vivo* environmental factors (e.g., non-analyte related species with an oxidation/reduction potential that overlaps with that of the analyte) can be removed from the signal detected by the first working electrode (e.g., the first signal). This can give a substantially analyte-only signal. The effects of *in vivo* environmental factors upon the dual-electrode system are discussed in greater detail elsewhere herein with reference to **Figs. 3G-3I**.

[0585] In preferred embodiments, the dual-electrode sensor includes electronics (e.g., a processor module, processing memory) that are operably connected to the first and second working electrodes and are configured to provide the first and second signals to generate analyte concentration data substantially without signal contribution due to non-analyte-related noise. For example, the sensor electronics process and/or analyze the signals from the first and second working electrodes and calculate the portion of the first electrode signal that is due to analyte concentration only. The portion of the first electrode signal that is not due to the analyte concentration can be considered to be background, such as but not limited to noise. Accordingly, in one embodiment of a dual-electrode sensor system configured for fluid communication with a host's circulatory system (e.g., *via* a vascular access device) the system comprising electronics operably connected to the first and second working electrodes; the electronics are configured to process the first and second signals to generate analyte concentration data substantially without signal contribution due to noise.

[0586] As a non-limiting example, **Fig. 3E** illustrates one preferred embodiment, the dual-electrode analyte sensor. In this embodiment, the sensor comprises a first working electrode **E1** configured to detect the analyte and a second working electrode **E2**, wherein the first and second working electrodes are formed of two wire working electrodes twisted together to form a "twisted pair." The first working electrode **E1** is disposed beneath an enzymatic portion of the membrane (not shown) containing an analyte-detecting enzyme. For example, in a glucose-detecting dual-electrode analyte sensor, a glucose-detecting enzyme, such as GOX, is included in the enzymatic portion of the membrane. Accordingly, the first working electrode **E1** detects signal due to both the analyte and non-analyte-related species that have an oxidation/reduction potential that substantially overlaps with the oxidation/reduction potential of the analyte. The second working electrode **E2** is disposed beneath a portion of the

Abbott Ex. 1003 - 202/1058

membrane comprising either inactivated enzyme (e.g., inactivated by heat, chemical or UV treatment) or no enzyme. Accordingly, the second working electrode **E2** detects a signal associated with only the non-analyte electroactive species that have an oxidation/reduction potential that substantially overlaps with that of analyte. For example, in the glucose-detecting dual-electrode analyte sensor described above, the non-analyte (e.g., non-glucose) electroactive species have an oxidation/reduction potential that overlaps substantially with that of H_2O_2. A reference electrode **R**, such as a silver/silver chloride wire electrode, is wrapped around the twisted pair. The three electrodes **E1**, **E2** and **R** are connected to sensor electronics (not shown), such as described elsewhere herein. In preferred embodiments, the dual-electrode sensor is configured to provide an analyte-only signal (e.g., glucose-only signal) substantially without a signal component due to the non-analyte electroactive species (e.g., noise). For example, the dual-electrode sensor is operably connected to sensor electronics that process the first and second signals, such that a substantially analyte-only signal is provided (e.g., output to a user). In other exemplary embodiments, the dual-electrode sensor can be configured for detection of a variety of analytes other than glucose, such as but not limited to urea, creatinine, succinate, glutamine, oxygen, electrolytes, cholesterol, lipids, triglycerides, hormones, liver enzymes, and the like.

[0587] With reference to the analyte sensor embodiments disclosed herein, the surface area of the electroactive portion of the reference (and/or counter) electrode is at least six times the surface area of the working electrodes. In other embodiments, the reference (and/or counter) electrode surface is 1, 2, 3, 4, 5, 7, 8, 9 or 10 times the surface area of the working electrodes. In other embodiments, the reference (and/or counter) electrode surface area is 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 times the surface area of the working electrodes. For example, in a needle-type glucose sensor, similar to the embodiment shown in **Fig. 3E**, the surface area of the reference electrode (e.g., **R**) includes the exposed surface of the reference electrode, such as but not limited to the electrode surface facing away from the working electrodes **E1**, **E2**.

[0588] In various embodiments, the electrodes can be stacked or grouped similar to that of a leaf spring configuration, wherein layers of electrode and insulator (or individual insulated electrodes) are stacked in offset layers. The offset layers can be held together with bindings of non-conductive material, foil, or wire. As is appreciated by one skilled in the art,

Abbott Ex. 1003 - 203/1058

the strength, flexibility, and/or other material property of the leaf spring-configured or stacked sensor can be either modified (e.g., increased or decreased), by varying the amount of offset, the amount of binding, thickness of the layers, and/or materials selected and their thicknesses, for example. Alternative dual-electrode configurations include those illustrated in **Figs. 2G-2S**, as described herein.

[0589] In preferred embodiments, the analyte sensor substantially continuously measures the host's analyte concentration. In some embodiments, for example, the sensor can measure the analyte concentration every fraction of a second, about every fraction of a minute or every minute. In other exemplary embodiments, the sensor measures the analyte concentration about every 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes. In still other embodiments, the sensor measures the analyte concentration every fraction of an hour, such as but not limited to every 15, 30 or 45 minutes. Yet in other embodiments, the sensor measures the analyte concentration about every hour or longer. In some exemplary embodiments, the sensor measures the analyte concentration intermittently or periodically. In one preferred embodiment, the analyte sensor is a glucose sensor and measures the host's glucose concentration about every 4-6 minutes. In a further embodiment, the sensor measures the host's glucose concentration every 5 minutes.

[0590] As a non-limiting example, dual-electrode glucose sensor can be manufactured as follows. In one embodiment, the working electrodes are first coated with a layer of insulating material (e.g., non-conductive material or dielectric) to prevent direct contact between the working electrodes **E1**, **E2** and the reference electrode **R**. At this point, or at any point hereafter, the two working electrodes can be twisted and/or bundled to form a twisted pair. A portion of the insulator on an exterior surface of each working electrode is etched away, to expose the electrode's electroactive surface. In some embodiments, an enzyme solution (e.g., containing active GOx) is applied to the electroactive surfaces of both working electrodes, and dried. Thereafter, the enzyme applied to one of the electroactive surfaces is inactivated. As is known in the art, enzymes can be inactivated by a variety of means, such as by heat, treatment with inactivating (e.g., denaturing) solvents, proteolysis, laser irradiation or UV irradiation (e.g., at 254-320 nm). For example, the enzyme coating one of the electroactive surfaces can be inactivated by masking one of the electroactive surfaces (e.g., electrodes, **E1**, temporarily covered with a UV-blocking material); irradiating the sensor with UV light (e.g.,

Abbott Ex. 1003 - 204/1058

254-320 nm; a wavelength that inactivates the enzyme, such as by cross-linking amino acid residues) and removing the mask. Accordingly, the GOx on **E2** is inactivated by the UV treatment, but the **E1** GOx is still active due to the protective mask. In other embodiments, an enzyme solution containing active enzyme is applied to a first electroactive surface (e.g., **E1**) and an enzyme solution containing either inactivated enzyme or no enzyme is applied to the second electroactive surface (e.g., **E2**). Thus, the enzyme-coated first electroactive surface (e.g., **E1**) detects analyte-related signal and non-analyte-related signal; while the second electroactive surface (e.g., **E2**), which lacks active enzyme, detects non-analyte-related signal. As described herein, the sensor electronics can use the data collected from the two working electrodes to calculate the analyte-only signal.

[0591] In some circumstances, cross talk can interfere with analyte/noise detection. In general, cross talk occurs when signal (e.g., in the form of energy and/or a detectable species such as but not limited to H_2O_2) is transferred from one electrode (e.g., the first working electrode) to another (e.g., the second working electrode), and detected as a signal by the other electrode. To prevent cross talk, in preferred embodiments, the first and second working electrodes **E1**, **E2** are separated by diffusion barrier, such as an insulator, a non-conductive material, a reference electrode and/or the like.

[0592] **Fig. 3F** illustrates the use of a diffusion barrier to prevent cross talk in a dual-electrode glucose sensor, in one embodiment. The first and second working electrodes **E1**, **E2** are disposed beneath a membrane **348** and separated by a diffusion barrier ***D***. Within the membrane, glucose is metabolized by the GOx enzyme, which produces H_2O_2. The H_2O_2 produced by the enzymatic reaction can diffuse in any direction through the membrane **348**. A portion of the H_2O_2 diffuses to the surface of the first working electrode and is detected due to the transfer of two electrons to the electrode. Another portion of the H_2O_2 can diffuse out of the membrane. Since the diffusion barrier ***D*** is disposed between the working electrodes, the diffusion barrier substantially blocks diffusion of H_2O_2 to the second working electrode **E2**. If no diffusion barrier were present, the H_2O_2 would be able to diffuse to the second working electrode **E2** and cause a signal also referred to as cross talk. A variety of diffusion barriers can be employed to prevent cross talk. In some embodiments, the diffusion barrier ***D*** is a physical diffusion barrier, such as a structure between the working electrodes that blocks glucose and H_2O_2 from diffusing from the first working electrode **E1** to the second working

Abbott Ex. 1003 - 205/1058

electrode **E2**. In other embodiments, the diffusion barrier ***D*** is a spatial diffusion barrier, such as a distance between the working electrodes that blocks glucose and H_2O_2 from diffusing from the first working electrode **E1** to the second working electrode **E2**. In still other embodiments, the diffusion barrier ***D*** is a temporal diffusion barrier, such as a period of time between the activity of the working electrodes such that if glucose or H_2O_2 diffuses from the first working electrode **E1** to the second working electrode **E2**, the second working electrode **E2** will not substantially be influenced by the H_2O_2 from the first working electrode **E1.**

[0593] Accordingly, in some preferred embodiments, the dual-electrode sensor comprises an insulator, such as an electrical insulator, located between the first and second working electrodes, wherein the insulator comprises a physical diffusion barrier. The physical diffusion barrier is configured to structurally block a substantial amount of diffusion of at least one of an analyte (e.g., glucose) and a co-analyte (e.g., H_2O_2) between the first and second working electrodes. In some embodiments, the diffusion barrier comprises a structure that protrudes from a plane that intersects both the first and second working electrodes. In a further embodiment, the structure that protrudes comprises an electrical insulator and/or an electrode.

[0594] In some preferred embodiments, the dual-electrode sensor comprises an insulator located between the first and second working electrodes, wherein the insulator comprises a diffusion barrier configured to substantially block diffusion of at least one of an analyte and a co-analyte between the first and second working electrodes. In preferred embodiments, the diffusion barrier comprises a temporal diffusion barrier configured to block or avoid a substantial amount of diffusion or reaction of at least one of the analyte and the co-analyte between the first and second working electrodes.

[0595] In still other preferred embodiments, the dual-electrode sensor comprises a sensor membrane configured to substantially block diffusion of at least one of an analyte and a co-analyte between the first and second working electrodes by a discontinuity of the sensor membrane between the first and second working electrodes. A discontinuity of the sensor membrane is a type of physical diffusion barrier formed by a portion of the membrane between the two working electrodes, in some embodiments, wherein a discontinuity in the membrane structure blocks diffusion of H_2O_2 between the electrodes. Discontinuities of sensor membranes are discussed in greater detail with reference to **Fig. 3I**, in the section entitled "Sensor Configurations for Equivalent Measurement of Noise."

Abbott Ex. 1003 - 206/1058

[0596] In some embodiments, the dual-electrode sensor system is configured for fluid communication with a host's circulatory system, such as *via* a vascular access device. A variety of vascular access devices suitable for use with a dual-electrode analyte sensor are described elsewhere herein. In some embodiments, the vascular access device comprises a lumen and at least a portion of the sensor is disposed within the lumen; and in some embodiments, at least a portion of the sensor can extend into the vascular system. In some embodiments, the vascular access device comprises a hub and the continuous analyte sensor is disposed substantially within the hub. In some embodiments, the system includes a fluid coupler configured and arranged to mate with the vascular access device on a first end; wherein the sensor is disposed within a portion of the fluid coupler and/or at a surface of the fluid coupler. In some embodiments, the sensor is configured to reside substantially above a plane defined by the host's skin. In some embodiments, the sensor is disposed on a surface of the vascular access device. In some embodiments, the vascular access device is configured for insertion into at least one of an artery, a vein, a fistula, and an extracorporeal circulatory device configured to circulate at least a portion of the host's blood outside of the host's body. In some embodiments, the system includes a flow control device in fluid communication with the vascular access device. The flow control device is configured to meter a flow of a fluid (e.g., blood, saline, a reference solution) through the vascular access device. In some embodiments, the flow control device is further configured to control fluid contact with the continuous analyte sensor, as is described in the section entitled "Integrated Sensor System."

[0597] In preferred embodiments, the sensor electronics (e.g., electronic components) are operably connected to the first and second working electrodes. The electronics are configured to calculate at least one analyte sensor data point. For example, the electronics can include a potentiostat, A/D converter, RAM, ROM, transmitter, and the like. In some embodiments, the potentiostat converts the raw data (e.g., raw counts) collected from the sensor to a value familiar to the host and/or medical personnel. For example, the raw counts from a glucose sensor can be converted to milligrams of glucose per deciliter of glucose (e.g., mg/dl). In some embodiments, the electronics are operably connected to the first and second working electrodes and are configured to process the first and second signals to generate a glucose concentration substantially without signal contribution due to non-glucose noise artifacts. The sensor electronics determine the signals from glucose and non-glucose related

Abbott Ex. 1003 - 207/1058

signal with an overlapping measuring potential (e.g., from a first working electrode) and then non-glucose related signal with an overlapping measuring potential (e.g., from a second electrode). The sensor electronics then use these data to determine a substantially glucose-only concentration, such as but not limited to subtracting the second electrode's signal from the first electrode's signal, to give a signal (e.g., data) representative of substantially glucose-only concentration, for example. In general, the sensor electronics may perform additional operations, such as but not limited to data smoothing and noise analysis.

[0598] In preferred embodiments, the dual-electrode sensor includes electronics (e.g., a processor module, processing memory) that are operably connected to the first and second working electrodes and are configured to provide the first and second signals to generate an analyte concentration data substantially without signal contribution due to non-analyte-related noise. For example, the sensor electronics process and/or analyze the signals from the first and second working electrodes and calculate the portion of the first electrode signal that is due to analyte concentration only. The portion of the first electrode signal that is not due to the analyte concentration can be considered to be background, such as but not limited to noise. Accordingly, in one embodiment of a dual-electrode sensor system configured for fluid communication with a host's circulatory system (e.g., *via* a vascular access device) the system comprising electronics operably connected to the first and second working electrodes; the electronics are configured to process the first and second signals to generate analyte concentration data substantially without signal contribution due to noise.

[0599] In some embodiments, the dual-electrode analyte sensor includes a reference sensor/system, as described elsewhere therein, whereby reference data can be provided for calibration (e.g., internal to the system), without the use of an external (e.g., separate from the system) analyte-measuring device. In an exemplary embodiment, the dual-electrode sensor is a glucose sensor and external glucose data points (e.g., from a hand-held glucose meter or a YSI device) are not required for calibration of a dual-electrode glucose sensor system that includes a reference sensor. In some embodiments, the reference sensor is configured to be disposed within the same local environment as the dual-electrode analyte sensor, such that the reference sensor and the dual-electrode analyte sensor can be simultaneously exposed to a sample. In some embodiments, the reference sensor/system can be disposed remotely from the dual-electrode sensor. In these embodiments, the electronics

Abbott Ex. 1003 - 208/1058

module is configured to process the reference data with the first and second signals to generate analyte concentration data substantially without signal contribution due to noise. In some embodiments, the electronics module is configured to calibrate the dual-electrode analyte sensor data using the reference sensor data, as described elsewhere herein.

[0600] In some embodiments, the electronics module is configured to determine a scaling factor (k) as described in the section entitled "Calibration Systems and Methods." Briefly, a scaling factor defines a relationship between the enzymatic portion of the membrane and the non-enzymatic portion of the membrane. Accordingly, in some embodiments, the electronics module, also referred to as the processor module herein, is configured to and/or comprises programming to calibrate the analyte sensor data using the scaling factor, such that the calibrated sensor data does not include inaccuracies that can arise due to small differences between the plus- and minus-enzyme portions of the membrane at the first and second working electrodes, respectively.

[0601] In some embodiments, the system is configured to calibrate the continuous dual-electrode analyte sensor using a reference fluid (e.g., **602a**), as described in the section entitled "integrated sensor system." In some embodiments, the system is configured to calibrate the sensor using single-point calibration, in other embodiments, the system is configured to calibrate the sensor without a reference data point provided by an external analyte monitor (e.g., SMBG, YSI), as described elsewhere herein. In some embodiments, the system includes a reference sensor configured to generate a signal associated with a reference analyte in the sample (e.g., internal to the system), wherein the continuous analyte sensor is further configured to generate a third signal associated with the reference analyte, and wherein the system is configured to calibrate the continuous analyte sensor using the reference signal and the third signal. In some embodiments, the reference sensor comprises an optical sensing apparatus, such as but not limited to an optical O_2 sensor. In preferred embodiments, the continuous analyte sensor is a glucose sensor. In other embodiments, a substantial portion of the continuous analyte sensor has a diameter of less than about 0.008 inches, as is described elsewhere herein.

[0602] In some further embodiments, the continuous analyte sensor further comprises a bioinert material or a bioactive agent incorporated therein or thereon. Applicable bioactive agent include but are not limited to vitamin K antagonists, heparin group

Abbott Ex. 1003 - 209/1058

anticoagulants, platelet aggregation inhibitors, enzymes, direct thrombin inhibitors, Dabigatran, Defibrotide, Dermatan sulfate, Fondaparinux, and Rivaroxaban.

[0603] As a non-limiting example, in some preferred embodiments, a method for continuously detecting an analyte in the host *in vivo* using a dual-electrode analyte sensor is provided. In some embodiments, a vascular access device (e.g., a catheter) is inserted into the host's circulatory system, such as into a vein or artery. The sensor is contacted with a sample of the circulatory system, such as a sample of blood withdrawn into the catheter. A first signal is generated by the sensor, wherein the first signal is associated with associated with the analyte and non-analyte related electroactive compounds having a first oxidation/reduction potential in a sample of the circulatory system of the host. In preferred embodiments, the analyte sensor is configured to detect glucose. A second signal is also generated, wherein the second signal is associated with noise of the analyte sensor, wherein the noise comprises signal contribution due to non-analyte related electroactive species with an oxidation/reduction potential that substantially overlaps with the first oxidation/reduction potential in the sample. The first and second signals are processed to provide a processed signal substantially without a signal component associated with noise. In some embodiments, the first and second signals are processed to provide a scaling factor, which can then be used to calibrate the first signal. In some embodiments, a reference sensor is also contacted with the sample, and a third signal associated with a reference analyte generated. In some embodiments, the reference sensor is an optical detection apparatus, such as but not limited to an optical O_2 sensor. In this embodiment, the first and second signals can be calibrated using the third and/or reference signal. In some preferred embodiments, the processing step comprises evaluating steady-state information and transient information, wherein the first and second signals each comprise steady-state and transient information. In some further embodiments, the evaluating step includes evaluating at least one of sensitivity information and baseline information, wherein the steady-state information comprises the sensitivity and baseline information.

Optical Detection

[0604] In some embodiments, the continuous analyte sensor is configured to detect the analyte by optical means. In some embodiments, various types of Raman and/or fluorescent spectroscopic detection are used. For example, glucose can be detected *via* fiber optic visible fluorescence, using glucose dehydrogenase (GDH) and a modified flavin adenine

Abbott Ex. 1003 - 210/1058

dinucleotide (FAD) coenzyme system, Concanavalin A, or hexokinase. In some embodiments, a fluorescent molecule (e.g., a fluorophore) is attached to the co-enzyme or to a hydrogen peroxide end-product reactant, as in a colorimetric detection system. In an alternative embodiment, ferrocene is modified and used as a mediator in the reaction of GOX (or GHD) with glucose, wherein a pH-sensitive fluorophore is used to detect the reaction. In some embodiments, fiber optic probes are constructed by applying membrane systems configured for optical/fluorescent detection to an optical fiber. In some embodiments, multiple fiber optic probes are bundled, which enables a variety of integrative and/or subtractive signal correlations/corrections and to enhance error detection. Examples of optical detection can be found in U.S. Patent No. 7,289,836 and U.S. Patent No. 7,149,562, each of which is incorporated by reference herein in its entirety.

Sensor Signal Generation

[0605] In some embodiments, a continuous analyte detection system is provided, including a sensor configured and arranged for fluid contact with a host's circulatory system and a processor module. The sensor comprises both a continuous analyte sensor (e.g., either non-dual-electrode or dual-electrode) and a reference sensor. For example, in some embodiments the system includes a continuous analyte sensor including a working electrode and a reference electrode, and a reference sensor. In other embodiments, the system includes a dual-electrode analyte sensor, including first and second working electrodes and a reference electrode, and a reference sensor. The continuous analyte sensor is configured and arranged to generate a first signal associated with a test analyte and a second signal associated with a reference analyte. For example, in one embodiment, the test analyte is glucose and the reference analyte is oxygen; thus, the first signal is associated with glucose and the reference signal is associated with oxygen. The reference sensor is configured to generate a reference signal that is also associated with the reference analyte. In general, a "reference analyte" can be any analyte that can be measured by both the analyte sensor and the reference sensor, such those analytes listed under the definition of "analyte" in the section entitled "Definitions." In preferred embodiments, the reference analyte is one that is relatively stable within the host's body, such as but not limited to O_2, succinate, glutamine, and the like. In this embodiment, the processor module is configured to and/or comprises programming to process the second signal (e.g., related to the reference analyte) and the reference signal to calibrate the first signal

Abbott Ex. 1003 - 211/1058

(e.g., related to the analyte). In some embodiments, the processor module calibrates the second signal (e.g., the reference analyte signal detected by the analyte sensor) using the reference signal provided by the reference sensor, and then to calibrate the first signal (e.g., the analyte signal) using the second signal.

[0606] As a non-limiting example, in some embodiments, the system's continuous analyte sensor is a dual-electrode sensor that comprises both first and second working electrodes **E1**, **E2**. Accordingly, the first working electrode is disposed beneath an active enzymatic portion of a sensor membrane and generates a signal (e.g., the first signal) associated with both the analyte (e.g., glucose) and non-analyte related electroactive compounds (e.g., non-glucose compounds that have an oxidation/reduction potential that substantially overlaps with the oxidation/reduction potential of glucose). Additionally, the second working is disposed beneath an inactive-enzymatic or a non-enzymatic portion of the sensor membrane and generates a non-analyte-related signal associated with the non-analyte electroactive species. In this embodiment, the processor module configured to and/or comprises programming to process signals from the first and second working electrodes, and to thereby generate a first signal substantially without a non-analyte signal component.

[0607] The second signal (e.g., related to the reference analyte) can be generated by various means. For example, in some embodiments, the first working electrode of the dual-electrode analyte sensor is configured to generate both the first signal and the second signal. For example, in some embodiments, pulsed amperometric detection, including switching, cycling or pulsing the voltage of the electrode in an electrochemical system (e.g., between a positive voltage (e.g., +0.6 for detecting glucose) and a negative voltage (e.g., -0.6 for detecting oxygen)) can be employed to determine an oxygen measurement. For example, the first working electrode is configured to generate a signal associated with the analyte when a potential of +0.6mV is applied thereto. If the potential is switch to –0.6mV, then the first working electrode becomes an O_2 sensor and measures a signal associate with the amount of O_2 passing through the sensor's membrane system. U.S. Patent No. 4,680,268, which is incorporated by reference herein, described pulsed amperometric detection in greater detail. Additional oxygen sensors are described in U.S. Patent No. 6,512,939, which is incorporated herein by reference.

Abbott Ex. 1003 - 212/1058

[0608] As a non-limiting example, in one embodiment the dual-electrode analyte sensor is a glucose sensor configured for fluid communication with a host's circulatory system, wherein the sensor is configured to generate a first signal associated with glucose (at the first working electrode **E1**) at an applied potential of 0.6mV, and then to generate a second signal associated with O_2 (also at the first working electrode **E1**) at an applied potential of -0.6mV. Thus, in some embodiments, the potential applied to the first working electrode can be switched from +0.6mV to -0.6mV, such that the first working electrode switches from measuring the analyte-related signal (e.g., glucose) to measuring the second signal (e.g., associated with O_2).

[0609] In some alternative embodiments, the second working electrode **E2** (e.g., instead of the first working electrode **E1**) is configured to generate the second signal. As a non-limiting example, in another embodiment the dual-electrode analyte sensor is a glucose sensor configured for fluid communication with a host's circulatory system, wherein the sensor is configured to generate a first signal associated with glucose (at the first working electrode **E1**) at an applied potential of 0.6mV, to generate a non-analyte-related signal (at the second working electrode **E2**) at an applied potential of 0.6mV, and then to generate a second signal associated with O_2 (also at the second working electrode **E2**) at an applied potential of -0.6mV. Thus, in some embodiments, the potential applied to the second working electrode can be switched from 0.6mV to -0.6mV, such that the second working electrode switches from measuring the non-analyte-related signal to measuring the second signal (e.g., associated with O_2).

[0610] In still other embodiments, the second signal can be generated by a third working electrode disposed beneath the sensor's membrane. As a non-limiting example, in another embodiment the dual-electrode analyte sensor is a glucose sensor configured for fluid communication with a host's circulatory system, wherein the sensor is configured to generate a first signal associated with glucose (at the first working electrode **E1**) at an applied potential of 0.6mV, to generate a non-analyte-related signal (at the second working electrode **E2**) at an applied potential of 0.6mV, and then to generate the second signal associated with O_2 (at the third working electrode, e.g., **E3**, not shown) at an applied potential of -0.6mV. Thus, in some embodiments, switching the applied potential from 0.6mV to -0.6mV is not required.

Abbott Ex. 1003 - 213/1058

[0611] As described above, the system includes a reference sensor. In some embodiments, the reference sensor is an optical sensing apparatus, as described above. In other embodiments, the reference sensor is configured to detect the reference analyte by any means known in the art, such as but not limited to electrochemical, chemical, physical, immunochemical, calorimetric and/or radiometric means. Preferably, the reference sensor is disposed in the same local environment as the continuous analyte sensor, but not under the membrane system of the continuous analyte sensor. For example, the reference sensor can be disposed adjacent to the continuous analyte sensor, such that when the continuous analyte sensor is contacted with a sample the reference sensor is simultaneously contacted by the sample. As a non-limiting example, in some embodiments, a dual-electrode continuous analyte sensor and a reference sensor are disposed adjacently, such that they can be simultaneously exposed to a sample of the host's circulatory system.

[0612] As a non-limiting example, in some embodiments, a dual-electrode sensor includes a first working electrode configured to detect the analyte (including non-analyte-related noise) and a second working electrode is configured to detect the signal associated with non-analyte-related noise. In some embodiments, the first and second working electrodes are bundled and/or twisted, and the reference sensor is disposed adjacent to the first and second working electrodes. In some embodiments, either the first or the second working electrodes of the dual-electrode sensor is configured to detect a signal associated with the reference analyte (e.g., a second signal); while in other embodiments, the dual-electrode sensor includes a third working electrode configured to detect the reference analyte (e.g., the second signal).

[0613] As a non-limiting example, in one embodiment of a system comprising both a dual-electrode sensor and an optical reference sensor, the dual-electrode sensor is both a glucose sensor and an O_2 sensor, and the reference sensor is an optical O_2 sensor. Accordingly, as described elsewhere herein, the first working electrode of the dual-electrode sensor is configured to detect a signal associated with both glucose and non-glucose-related electroactive species (in a sample of the host's circulatory system), and the second working electrode is configured to detect the non-glucose related electroactive species. Either the first working electrode or the second working electrode is configured to detect O_2, such as *via* switching the applied potential from 0.6mV to -0.6MV, as described elsewhere herein. The reference sensor, which can be bundled with the dual-electrode sensor, is configured to

Abbott Ex. 1003 - 214/1058

optically detect a reference signal associated with the O_2 concentration of the sample. In some embodiments, instead of using the first or second working electrodes to detect O_2, the dual-electrode sensor includes a third electrode configured to detect O_2.

[0614] In preferred embodiments, the signal related to a reference analyte (e.g., O_2) can be used to calibrate the signals from a continuous analyte sensor, such as in the event of a drift in sensor sensitivity and/or baseline. Accordingly, the signals related to the reference analyte, from the continuous analyte and reference sensors, can be processed to determine a calibration factor. The calibration factor can then be used to calibrate the continuous analyte sensor data. As used herein, the term "calibration factor" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a mathematical function generated by processing the reference analyte-related signal of the continuous analyte sensor and the reference analyte-related signal of the reference sensor, which can be used to calibrate the continuous analyte sensor data initially and/or responsive to an occurrence of a drift in sensor sensitivity and/or baseline.

[0615] In some embodiments, a method for measuring an analyte in a host is provided. First, a continuous analyte detection system, which includes a continuous analyte sensor and a reference sensor, is provided. In preferred embodiments, the continuous analyte sensor is configured and arranged to generate a first signal associated with a test analyte (e.g., glucose) and a second signal associated with a reference analyte (e.g., O_2), and the reference sensor configured to generate a reference signal associated with the reference analyte (e.g., O_2).

[0616] Next, the detection system is exposed to a sample of a host's circulatory system *in vivo*. For example, the detection system can be fluidly coupled to a vascular access device implanted in a host's circulatory system, such that a sample of the host's blood can be drawn back an contacted with the detection system. Preferably, the continuous analyte sensor and the reference sensor are exposed to the sample simultaneously. Accordingly, measurements of the reference analyte can be made at the same time by the continuous analyte and reference sensors. In some embodiments, a fluid flow device configured for fluid communication with the circulatory system of the host and to meter a flow of a fluid therethrough is provided. In these embodiments, the fluid flow device comprises a vascular

Abbott Ex. 1003 - 215/1058

access device configured for insertion into either an artery or a vein of the host. Such fluid flow devices are described in detail in the sensor entitled "Integrated Sensor System." In preferred embodiments, the fluid flow device is coupled with the continuous analyte detection system, and a sample of the circulatory system of the host is withdrawn. In some preferred embodiments, the fluid flow device is further configured to meter the flow of a non-bodily fluid through the vascular access device. Non-bodily fluids include a variety of sterile infusion fluids, such as but are not limited to saline, reference solutions such as a glucose solution of defined concentration, nutritional supplements, IV medicaments, and the like.

[0617] When the sample contacts the system, signals are received from the continuous analyte sensor and the reference sensor. The signals received include a first signal (e.g., related to the test analyte, such as but not limited to glucose), a second signal (e.g., related to the reference analyte, such as but not limited to O_2) and a reference signal (e.g., related to the reference analyte). In some embodiments, the first signal is received from a first working electrode disposed under an enzymatic portion of a membrane system. For example, in the case of a glucose detection system, the first working electrode is disposed beneath a portion of the membrane system including active GOX and detects a first signal associated with the concentration of glucose in the sample. In some embodiments, the first working electrode also received the second signal, as described elsewhere herein. In other embodiments, the second signal is received from a second working electrode that is also disposed under the membrane system. In some embodiments, the second working electrode configured to also receive a non-analyte-related signal. For example, the second working electrode is disposed under a non-enzymatic portion of the membrane system, in some embodiments. In some other embodiments, the non-analyte-related signal is received from a third working electrode disposed under a non-enzymatic portion of the membrane system. In some embodiments, the reference sensor is configured to detect the reference analyte optically. For example, in some embodiments, the reference analyte is oxygen. Accordingly, the second signal and the reference signal received are associated with the concentration of oxygen in the sample.

[0618] After the signals have been received, a calibration factor is calculated, wherein the calibration factor is associated with a sensitivity and/or baseline of the continuous analyte sensor. For example, in some embodiments, the continuous analyte detection system is exposed to a bodily fluid (e.g., blood) and the calculating step includes comparing steady-

Abbott Ex. 1003 - 216/1058

state information of the first signal and steady-state information of the second signal. In some embodiments, the calibration factor can be calculated by examining the transient information of the first and second signals.

[0619] In some other embodiments, the continuous analyte detection system is configured to be exposed to a non-bodily fluid, such as saline or a reference fluid, such as to wash the previous blood sample off of the device. During the washing procedure, the non-bodily fluid can be held substantially stagnant (e.g., no flow or very little flow of the fluid past the sensor) for a period of time. During this period of time, the working electrodes of the continuous analyte sensor detect signals associated with non-analyte-related compounds diffusion to the first and second working electrodes. For example, in some embodiments, a saline solution containing a defined amount of glucose is used to wash the sensor. When the glucose-containing saline is held stagnant (e.g., after washing the previous sample off of the sensor), the GOX at the first working electrode metabolizes glucose diffusing through the membrane. As the glucose is metabolized, the reactant (e.g., H_2O_2) begins to accumulate and produce signals at both the first and second working electrodes. As a result, the signal increase on each of the first and second working electrodes (e.g., during the time period) can be compared to calculate the calibration factor. This method for calculating the calibration factor is discussed in greater detail elsewhere herein, with reference to **Figs. 3J** and **3K**.

[0620] After the calibration factor has been calculated, the signal(s) from the continuous analyte sensor are calibrated using the calibration factor. The process of calculating the calibration factor and then using the newly calculated calibration factor to calibrate the signals can be continuous, continual and/or intermittent; such that at time passes the calibration factor and calibration are updated. Thus, the system is configured to evaluate changes in membrane sensitivity and/or baseline, to adjust the calculation of analyte concentrations accordingly, whereby the host is provided with more accurate data for use in therapy decision-making.

Multi-sensor Apparatus

[0621] In some preferred embodiments, a multi-sensor apparatus configured for the detection of a plurality of analytes in a circulatory system of a host *in vivo* is provided. **Figs. 2G** through **2S** illustrate some exemplary embodiments of such a device. In prefered embodiments, the multi-sensor apparatus is a vascular access device (e.g., a catheter) or a

Abbott Ex. 1003 - 217/1058

connector configured for fluid communication with the circulatory system of the host. Preferably, the multi-sensor apparatus includes a lumen (e.g., a duct) sufficiently large to house the plurality of sensors, as described elsewhere herein. In an exemplary embodiment, the multi-sensor apparatus comprises a plurality of analyte sensors, wherein the plurality of analyte sensor are configured to detect at least one analyte and to contact a sample of the host's circulatory system. In one exemplary embodiment, the multi-sensor apparatus comprises a lumen, an external surface, and two orifices, wherein a first orifice is proximal relative to the host and the second orifice is distal. In some embodiments, such as in a catheter, the proximal orifice is referred to herein as the *in vivo* orifice and the distal orifice is referred to as the *ex vivo* orifice. Preferably, at least the distal orifice is configured to couple with a fluid flow device (or a component thereof), such as but not limited to a connector or coupler, a valve, IV tubing, a pump, and the like. For example, in an embodiment wherein the multi-sensor apparatus is a catheter, the distal orifice (e.g., the ex vivo orifice) is configured to couple to IV tubing, various types of IV connectors, and the like. In some embodiments, both the proximal and distal orifices are configured to couple with IV equipment. For example, in an embodiment wherein the multi-sensor apparatus is configured as a connector (e.g., a Leur lock) the proximal orifice is configured to couple with a vascular access device (e.g., a catheter/cannula), IV tubing, and/or other connectors, and the distal end is configured to couple with a fluid flow device (e.g., IV tubing, a pump, etc.). Preferably; a plurality of analyte sensors are disposed within the lumen of the multi-sensor apparatus. For example, 2, 3, 4, 5, 6, 7, or more sensors can be disposed within the lumen of the multi-sensor apparatus. In some embodiments, each of the plurality of analyte sensor is configured to detect a different analyte. In some embodiments, two or more of the plurality of analyte sensors are configured to detect the same analyte, thereby providing redundancy and/or fail-safes in analyte detection and/or sensor function.

[0622] **Fig. 2G** provides an exemplary embodiment of a multi-sensor apparatus, namely a catheter, including an *in vivo* portion configured for insertion into the host and an *ex vivo* portion **218** (e.g., a connector or hub) configured to remain outside the host's body after implantation/insertion of the *in vivo* portion into a host. The *in vivo* portion may also be referred to as the proximal portion/end of the catheter (e.g., with respect to the host) includes an *in vivo* orifice at or near the catheter's tip, for fluid communication with the host's

Abbott Ex. 1003 - 218/1058

circulatory system upon implantation into the host's vein or artery, or in an extracorporeal circulatory device. The *ex vivo* portion of the catheter may also be referred to as the proximal portion (e.g., with respect to the host). A plurality of analyte sensors **240** are disposed within the catheter's connector/hub, such as within the lumen/duct **254** and/or within a widened portion of the catheter's *in vivo* portion.

[0623] **Fig. 2H** provides another exemplary embodiment of a multi-sensor apparatus, namely a connector, such as a Leur lock, a Y-connector, a T-connector, an X-connector, or a valve configured for connecting IV equipment. The multi-sensor apparatus includes a proximal orifice (e.g., with respect to the host) configured to couple with a vascular access device (e.g., a catheter/cannula) or with various IV equipment, such as IV tubing or another connector, and a distal orifice (e.g., with respect to the host) configured to fluidly couple to other IV equipment, as described herein and is known to one skilled in the art. The analyte sensors **240** are disposed within the multi-sensor apparatus's lumen or duct **254**.

[0624] In various embodiments, the analyte sensors (of the multi-sensor apparatus) can be configured to detect an analyte using any means known in the art, such as but not limited to by enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or immunochemical techniques, or by a combination of these techniques. Further more, each sensor can use a different detection technique. For example, a first analyte sensor can detect a first analyte using a first technique, a second analyte sensor can detect a second analyte using a second technique, a third analyte sensor can detect a third analyte using a third technique, and so on. Additionally, in some embodiments, a detection technique can be used by more than one of the analyte sensors, wherein the technique is modified to detect a particular analyte of interest by each of the sensors. For example, a first sensor can be configured to detect glucose enzymatically, and a second sensor can be configured to detect cholesterol enzymatically. In some embodiments, one of the plurality of sensors is configured to detect an analyte optically, as described elsewhere herein. Additionally, in some embodiments, two or more of the sensors are configured to detect the same analyte, either by the same or different detection techniques.

[0625] **Figs. 2I** through **2L** are cross-sections of the multi-sensor apparatus of **Figs. 2G** and **2H** taken along line **2I – 2I**, looking towards the proximal ends (e.g., **212b/258**) of the devices. A plurality of analyte sensors **240** is located at the luminal surface of wall **260** (e.g.,

Abbott Ex. 1003 - 219/1058

the interior surface of the hub/connector). In some embodiments, one or more of the plurality of sensors is integrally formed with the multi-sensor apparatus. In some embodiments, the multi-sensor apparatus includes a plurality of sensor sites **262**, wherein each sensor site **262** is configured to receive a sensor. In some embodiments, at least one of the plurality of sensor sites **262** comprises a breakaway portion (or a plug) configured for insertion therethrough of a sensor, such that at least a portion of the sensor is disposed within the lumen. One or more of the breakaway portions can be removed, such a by punching them out, to form a channel through the wall **260**. In some embodiments, the multi-sensor apparatus is manufactured such that one or more of the sensor sites includes a channel (e.g., through the wall), such that a sensor can be inserted there through. The sensor(s) can be installed by insertion through the channel(s). An adhesive, press-fit, clip or other attachment means can be use to secure the sensor(s) in place. In some embodiments, a portion of a sensor **240** (e.g., the sensing portion) inserted through the wall **260** is disposed at the surface of the duct/lumen. In some embodiments, the portion of the sensor protrudes into the duct/lumen **254**. In some further embodiments, at least another portion of the sensor is disposed at the external surface of the connector/hub. In some embodiments, one or more sensors can be disposed (e.g., installed) within the duct/lumen by adhering the sensor at the surface of the duct/lumen. In some embodiments, one or more of the sensors is deposited at the surface of the duct/lumen using known analyte sensor deposition techniques. In some embodiments, conductive traces, leads or wires can be applied/installed, such that the sensor(s) can be connected to device electronics, as is understood by one skilled in the art. For example, the device shown in **Figs. 1A** and **1B** include a conductive lead **24**, for connecting the analyte sensor to electronics.

[0626] Referring again to **Fig. 2G**, in some embodiments, the multi-sensor apparatus is a vascular access device comprising an *in vivo* portion and an *ex vivo* portion. In some preferred embodiments, the plurality of analyte sensors are disposed only within the *ex vivo* portion of the device, and thus do not extend into the *in vivo* portion (e.g., catheter **212**). In this embodiment, the plurality of sensors does not extend beyond a plain defined by the host's skin. In some embodiments, the *in vivo* portion of the multi-sensor apparatus includes a widened portion, such as a portion adjacent to and/or near to the hub, and one or more of the plurality of sensors are disposed within the widened portion. In some embodiments, one or

Abbott Ex. 1003 - 220/1058

more of the analyte sensor can be configured to extend into the *in vivo* portion, and in some embodiments to extend into the host's circulatory system.

[0627] Referring again to **Fig. 2H**, in some embodiments, the multi-sensor apparatus is a connector configured to be disposed outside the host's body. Accordingly, the multi-sensor apparatus does not include an *in vivo* portion. In this embodiment, the multi-sensor apparatus is configured to fluidly couple to a vascular access device at its proximal end and to a flow control device at its distal end, such that the flow control device can meter the flow of a non-bodily fluid (e.g., saline, a glucose solution, etc.) through the device and into the host, as well as withdrawal of blood samples from the host (e.g., such that the sample(s) contact the analyte sensor(s)) and (optionally) reinfusion of the blood samples to the host. The multi-sensor apparatus of this embodiment includes a lumen and/or duct, in which the plurality of analyte sensors is disposed. In some embodiments, at least one of the plurality of analyte sensors is configured to extend into the lumen of a fluidly coupled catheter; and in some further embodiments to extend through the catheter and into the host's circulatory system.

[0628] In preferred embodiments, at least one of the plurality of sensors (of the multi-sensor apparatus) is configured to generate a signal associated with a concentration of an analyte in a sample of the host's circulatory system. More preferably, each of the analyte sensors generates a signal associated with a concentration of each sensor's respective analyte in the blood sample withdrawn from the host. In some embodiments, the sensors can be configured to generate signals associated with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more analytes and/or properties of the sample of the host's circulatory system. In some embodiments, two or more of the sensors are configured to detect the same analyte, such as to provide system redundancy and/or fail-safes. The analyte sensors can be configured to detect a wide variety of analytes, such as but not limited to glucose, oxygen, CO_2 (carbon dioxide, bicarbonate), pH, creatinine, urea (nitrogen), bilirubin, electrolytes (e.g., sodium, potassium, chloride, phosphorous, magnesium), albumin, total protein, liver enzymes (e.g., alkaline phosphatase, alanine amino transferase, aspartate amino transferase), antibodies against infective agents, fibrinogen, fibronectin, lipids, triglycerides, cholesterol-protein complexes and ratios thereof (e.g., LDL, HDL, chylomycrons), hormones (e.g., T3, T4, TSH, hGH, interleukins, etc.), medicaments, metabolites, and the like. A more extensive list of analytes can be found in the "Definitions" section. In some embodiments, at least one of the plurality of sensors is configured to generate

Abbott Ex. 1003 - 221/1058

a signal associated with a property of a sample of the host's circulatory system. Blood properties include but are not limited to pH, temperature, oxygen tension, hematocrit, viscosity, clotting, pressure, and the like.

[0629] The multi-sensor apparatus of the preferred embodiments can be manufactured using a variety of techniques known in the art. For example, in some embodiments, the analyte sensors are integrally formed with the multi-sensor apparatus. In some embodiments, at least one of the pluralities of sensors is deposited within the lumen of the multi-sensor apparatus, such as in the lumen/duct of the connector of the hub of the device illustrated in **Fig. 2G**, or in the lumen/duct of the device of **Fig. 2H**. In some embodiments, one or more of the analyte sensors is configured to extend out of the connector/hub. For example, in the exemplary embodiment illustrated in **Fig. 2G** one or more analyte sensors **240** can be configured to extend into and/or through the lumen **212a** of the catheter **212**. In another example, in the exemplary embodiment illustrated in **Fig. 2H** one or more analyte sensors **240** can be configured to extend out of the proximal end of the multi-sensor apparatus, such that the sensor(s) can be inserted into and/or through a vascular access device.

[0630] In some embodiments, the non-sensor portion of a multi-sensor apparatus is formed, and then the plurality of sensors are applied/installed. In some embodiments, at least one of the pluralities of sensors is deposited within the lumen, such as by screen printing. In some embodiments, at least one of the pluralities of sensors is applied to the interior surface of the lumen, such as *via* an adhesive.

[0631] Alternatively, the multi-sensor apparatus may be formed about the plurality of analyte sensors, such as by using injection molding. For example, a mold is prepared, including sites for the analyte sensors (e.g., these will be "sensor sites," as described elsewhere herein, when the manufacture process is complete). Prior to injection molding, the sensors (e.g., previously manufactured) are placed in the sites. The mold is closed and a material, such as but not limited to, e.g., molten plastic, is injected into the mold. The material fills all of the spaces within the mold, including flowing around portions of the analyte sensors, such that when the mold is cooled, the analyte sensors will be held in place by the wall of the multi-sensor apparatus. For example, one or more of the sensors pass through the wall of the multi-sensor apparatus. In another example, the sensor can be oriented such that when the injection molding process is completed, the analyte sensor is disposed on the surface of the lumen. In

Abbott Ex. 1003 - 222/1058

some embodiments, one or more of the analyte sensors can be installed in the multi-sensor apparatus during injection molding, followed by application of one or more additional sensors to the lumen of the device. Alternatively, the body of the multi-sensor apparatus, such as a fluid coupler, can be formed as mating injection-molded portions/pieces that mate together about sensors placed in sensor receiving sites (e.g., see **Figs. 2O-2P**). A detailed description of this manufacturing process can be found in the section entitled "Exemplary Sensor Configurations." In still other embodiments, the multi-sensor apparatuses can be formed as shown in **Figs. 2Q-2S**, as described elsewhere herein, by inserting whole sensors in place of individual electrodes, for example.

[0632] As a non-limiting example, a method for making a multi-sensor apparatus for the detection of a plurality of analytes in a circulatory system of a host *in vivo* is provided, in some embodiments. In some embodiments, a plurality of sensors is first provided. The sensors can be configured to detect one or more analytes using a variety of detection means known to one skilled in the art. Next, a multi-sensor apparatus is formed about the plurality of sensors. The multi-sensor apparatus formed includes a lumen, an external surface, and at least one orifice configured for coupling with a fluid flow device, as described herein.

[0633] As another non-limiting example, in some embodiments, a method for making a multi-sensor apparatus for the detection of a plurality of analytes in a circulatory of a host *in vivo* includes providing a multi-sensor apparatus comprising a lumen, an external surface, and at least one orifice configured for coupling with a fluid flow device a plurality of sensors; followed by forming a plurality of sensor within and/or on the multi-sensor apparatus.

[0634] As yet another non-limiting example, a method for detecting of a plurality of analytes in a circulatory of a host *in vivo*, using a multi-sensor apparatus of the preferred embodiments, is provided. Accordingly, a multi-sensor apparatus of the preferred embodiments is applied to the circulatory system of a host. As described elsewhere herein, the multi-sensor apparatus includes a lumen and a plurality of sensors, wherein the at least two sensor are disposed above a plane defined by the skin of the host when the multi-sensor apparatus is applied to the host's circulatory system. For example, in some embodiments, the multi-sensor apparatus is a catheter with sensors in the hub/connector, which is inserted/implanted into a host's artery/vein. After the catheter has been inserted/implanted into the host, at least two of the sensors remain disposed outside the host's body, as defined by the

Abbott Ex. 1003 - 223/1058

host's skin. As another example, in some embodiments, the multi-sensor apparatus is a connector with sensors within its lumen. In this embodiment, the multi-sensor apparatus must be fluidly coupled to a vascular access device, so that blood can be withdrawn from the host's artery/vein and then contact the sensors within the connector. Thus, at least two of the sensors within this embodiment of the multi-sensor apparatus remain disposed outside the host's body, as defined by the host's skin.

[0635] Next, a sample (e.g., blood) is withdrawn from the host's circulatory system. When the sample is withdrawn, it is then contacted with the plurality of sensors. Each of the sensors then generates a signal. As described elsewhere herein, each sensor is configured to detect an analyte. Accordingly, the signal generated by each sensor is associated with the analyte that sensor was configured to detect. The sensors can be configured to generate the signal using any method know in the art, such as but not limited to electrochemically generating the signal, optically generating the signal, radiochemically generating the signal, physically generating the signal, chemically generating the signal, immunochemically generating the signal, and/or enzymatically generating a signal, or combinations thereof.

[0636] In some embodiments, a withdrawn sample is reinfused into the host. For example, a flow control device can meter the flow of an infusion fluid into the host, and the infusion fluid pushes the withdrawn sample back into the host. In some embodiments, the device is configured to dispose of the withdrawn sample, such as by directing the sample to a waste container.

[0637] As described herein, in some embodiments, an infusion fluid is metered through the multi-sensor apparatus, and infused into the host. In some embodiments, the plurality of sensors is washed with the infusion fluid. For example, infusion of about 0.5, 1, 5, 10, 15 ml or more of infusion fluid into the host can effectively wash a previous blood sample off of the plurality of analyte sensor in some embodiments. A variety of infusion fluids can be used, including but not limited to saline, reference fluids, medicaments, parenteral nutrition fluids, hydration fluid and the like.

[0638] In preferred embodiments, the signal of at least one of the plurality of sensors can be calibrated. A variety of calibration methods can be used. In some embodiments, one or more of the analyte sensors can be calibrated using one or more reference data points provided by a device separate from the multi-sensor apparatus/system. For example, a hand-

Abbott Ex. 1003 - 224/1058

held glucose meter can be used to provide one or more data points for calibrating a glucose sensor disposed in the multi-sensor apparatus. In some embodiments, a substantially stable and/or constant analyte found in the host's blood can be used to calibrate one or more of the plurality of analyte sensors. In some embodiments, data from a recently disconnected multi-sensor apparatus can be used to calibrate one or more of the sensors of a newly installed/applied multi-sensor apparatus. In some embodiments, one of the pluralities of analyte sensors can be used to calibrate one or more of the other sensors. In some embodiments, one or more of the sensors can be calibrated by the manufacturer. Additional methods of calibration that can be used with the multi-sensor apparatus of the preferred embodiments are described elsewhere herein.

Noise

[0639] Generally, implantable sensors measure a signal (e.g., counts) related to an analyte of interest in a host. For example, an electrochemical sensor can measure glucose, creatinine, or urea in a host, such as an animal, especially a human. Generally, the signal is converted mathematically to a numeric value indicative of analyte status, such as analyte concentration. However, it is not unusual for a sensor to experience a certain level of noise. The term "noise" generally refers to a signal detected by the sensor that is substantially non-analyte related (e.g., non-glucose related). In other words, things other than the analyte concentration substantially cause noise. Noise is clinically important because it can reduce sensor performance, such as by making the analyte concentration appear higher or lower than the actual concentration. For example, if a host is hyperglycemic (e.g., blood sugar too high, greater than ~120 mg/dl) or euglycemic (e.g., ~80-120 mg/dl), noise can cause the host's blood sugar to appear higher than it truly is, which can lead to improper treatment decisions, such as to give the host an excessive insulin dose. An excessive insulin dose, in some circumstances, can lead to a dangerous hypoglycemic state (e.g., blood sugar too low, less than ~80 mg/dl). In the case of a hypoglycemic host, noise can cause the hosts blood sugar to appear euglycemic or even hyperglycemic, which can also lead to improper treatment decisions, such as not eating when necessary or taking insulin, for example. Accordingly, since noise can cause error and reduce sensor performance, noise reduction is desirable.

[0640] Noise is comprised of two components, constant noise and non-constant noise, and can be caused by a variety of factors, ranging from mechanical factors to biological

Abbott Ex. 1003 - 225/1058

factors. For example, it is known that macro- or micro-motion, ischemia, pH changes, temperature changes, pressure, stress, or even unknown mechanical, electrical, and/or biochemical sources can cause noise. In general, "constant noise" (sometimes referred to as constant background or baseline) is caused by factors that are relatively stable over time, including but not limited to electroactive species that arise from generally constant (e.g., daily) metabolic processes. In contrast, "non-constant noise" (sometimes referred to as non-constant background) is caused by transient events, such as during wound healing or in response to an illness, or due to ingestion (e.g., some drugs). In particular, noise can be caused by a variety of interfering species (constant or non-constant). Interfering species can be compounds, such as drugs that have been administered to the host, or products of various host metabolic processes. Exemplary interferents include but are not limited to a variety of drugs (e.g., acetaminophen), H_2O_2 from exterior sources, reactive metabolic species (e.g., reactive oxygen and nitrogen species, some hormones, etc.). In some circumstances, constant noise-causing factors can have an affect on the sensor signal similar to non-constant noise-causing factors, such as when the concentration of a constant noise-causing factor temporarily increases, such as due to temporary lack of lymph flow (see discussion of intermittent sedentary noise).

[0641] Noise can be difficult to remove from the sensor signal by calibration using standard calibration equations (e.g., because the background of the signal does not remain constant). Noise can significantly adversely affect the accuracy of the calibration of the analyte signal. Additionally noise, as described herein, can occur in the signal of conventional sensors with electrode configurations that are not particularly designed to measure noise substantially equally at both active and in-active electrodes (e.g., wherein the electrodes are spaced and/or non symmetrical, noise may not be equally measured and therefore not easily removed using conventional dual-electrode designs).

[0642] Noise can be recognized and/or analyzed in a variety of ways. In preferred embodiments, the sensor data stream is monitored, signal artifacts are detected and data processing is based at least in part on whether or not a signal artifact has been detected, such as described in U.S. Patent Publication No. US-2005-0043598-A1. Additional description can also be found in U.S. Patent Publication No. US-2007-0032706-A1, both herein incorporated by reference in their entirety.

Abbott Ex. 1003 - 226/1058

Reduction of Noise

[0643] Noise can be recognized and substantially reduced and/or eliminated by a variety of sensor configurations and/or methods, such as by using 1) sensor configurations that block and/or remove the interferent, or that specifically detect the noise and 2) mathematical algorithms that recognize and/or remove the signal noise component. The preferred embodiments provide devices and methods for reducing and/or eliminating noise, such as by blocking interferent passage to the sensor's electroactive surfaces, diluting and/or removing interferents around the sensor and mathematically determining and eliminating the noise signal component. Those knowledgeable in the art will recognize that the various sensor structures (e.g., multiple working electrodes, membrane interference domains, etc.), bioactive agents, algorithms and the like disclosed herein can be employed in a plurality of combinations, depending upon the desired effect and the noise reduction strategy selected. In preferred embodiments, the sensor comprises at least two working electrodes (one with and one without enzyme over its electroactive surface) and an interference domain configured to substantially block interferent passage therethrough, such that at least some interferent no longer has a substantial affect on sensor measurements (e.g., at either working electrode). The term "interference domain," as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to any mechanism of the membrane system configured to reduce any kind of noise or interferants, such as constant and/or non-constant noise. "Noise-reducing mechanisms" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to any sensor system component configuration that reduces and/or eliminates noise on the sensor signal. Such structural configurations include but are not limited to electrode configurations (e.g., two or more working electrodes), membrane configurations (e.g., interference domain), algorithmic configurations (e.g., signal processing to remove an identified noise component of the signal), and the like. In some embodiments, the interference domain is a component of the membrane system, such as shown in **Fig. 3C**. However, the interference domain can be disposed at any level (e.g., layer or domain) of the membrane system (e.g., more proximal or more distal to the electroactive surfaces than as shown in **Fig. 3C**). In some other

Abbott Ex. 1003 - 227/1058

embodiments, the interference domain is combined with an additional membrane domain, such as the resistance domain or the enzyme domain.

[0644] In another aspect, the sensor is configured to reduce noise, including non-constant non-analyte related noise with an overlapping measuring potential with the analyte. A variety of noise can occur when a sensor has been implanted in a host. Generally, implantable sensors measure a signal (e.g., counts) that generally comprises at least two components, the background signal (e.g., background noise) and the analyte signal. The background signal is composed substantially of signal contribution due to factors other than glucose (e.g., interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation/reduction potential that overlaps with the analyte or co-analyte). The analyte signal (e.g., glucose) is composed substantially of signal contribution due to the analyte. Consequently, because the signal includes these two components, a calibration is performed in order to determine the analyte (e.g., glucose) concentration by solving for the equation y=mx+b, where the value of b represents the background of the signal.

[0645] In some circumstances, the background is comprised of both constant (e.g., baseline) and non-constant (e.g., noise) factors. Generally, it is desirable to remove the background signal, to provide a more accurate analyte concentration to the host or health care professional.

[0646] The term "baseline" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substantially constant signal derived from certain electroactive compounds found in the human body that are relatively constant (e.g., baseline of the host's physiology, non-analyte related). Therefore, baseline does not significantly adversely affect the accuracy of the calibration of the analyte concentration (e.g., baseline can be relatively constantly eliminated using the equation $y=mx+b$).

[0647] In contrast, "noise" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and is not to be limited to a special or customized meaning), and refers without limitation to a substantially intermittent signal caused by relatively non-constant factors (e.g., the presence of intermittent noise-causing compounds that have an oxidation/reduction potential that substantially overlaps the

Abbott Ex. 1003 - 228/1058

oxidation/reduction potential of the analyte or co-analyte and arise due to the host's ingestion, metabolism, wound healing, and other mechanical, chemical and/or biochemical factors, also non-analyte related). Noise can be difficult to remove from the sensor signal by calibration using standard calibration equations (e.g., because the background of the signal does not remain constant). Noise can significantly adversely affect the accuracy of the calibration of the analyte signal. Additionally noise, as described herein, can occur in the signal of conventional sensors with electrode configurations that are not particularly designed to measure noise substantially equally at both active and in-active electrodes (e.g., wherein the electrodes are spaced and/or non symmetrical, noise may not be equally measured and therefore not easily removed using conventional dual-electrode designs).

[0648] There are a variety of ways noise can be recognized and/or analyzed. In preferred embodiments, the sensor data stream is monitored, signal artifacts are detected, and data processing is based at least in part on whether or not a signal artifact has been detected, such as described in U.S. Patent Publication No. US-2005-0043598-A1 and U.S. Patent Publication No. US-2007-0027370-A1, herein incorporated by reference in their entirety.

[0649] Accordingly, if a sensor is designed such that the signal contribution due to baseline and noise can be removed, then more accurate analyte concentration data can be provided to the host or a healthcare professional.

[0650] One embodiment provides an analyte sensor (e.g., glucose sensor) configured for insertion into a host for measuring an analyte (e.g., glucose) in the host. The sensor includes a first working electrode disposed beneath an active enzymatic portion of a membrane on the sensor; a second working electrode disposed beneath an inactive- or non-enzymatic portion of the membrane on the sensor; and electronics operably connected to the first and second working electrode and configured to process the first and second signals to generate an analyte (e.g., glucose) concentration substantially without signal contribution due to non-glucose related noise artifacts.

[0651] In one embodiment, the sensor is configured to substantially eliminate (e.g., subtract out) noise due to mechanical factors. Mechanical factors include macro-motion of the sensor, micro-motion of the sensor, pressure on the sensor, local tissue stress, and the like. Since both working electrodes are constructed substantially symmetrically and identically, and due to the sensor's small size, the working electrodes are substantially equally affected by

Abbott Ex. 1003 - 229/1058

mechanical factors impinging upon the sensor. For example, if a build-up of noise-causing compounds occurs (e.g., due to the host pressing upon and manipulating (e.g., fiddling with) the sensor, for example) both working electrodes will measure the resulting noise to substantially the same extend, while only one working electrode (the first working electrode, for example) will also measure signal due to the analyte concentration in the host's body. The sensor then calculates the analyte signal (e.g., glucose-only signal) by removing the noise that was measured by the second working electrode from the total signal that was measured by the first working electrode.

[0652] Non-analyte related noise can also be caused by biochemical and/or chemical factors (e.g., compounds with electroactive acidic, amine or sulfhydryl groups, urea, lactic acid, phosphates, citrates, peroxides, amino acids (e.g., L-arginine), amino acid precursors or break-down products, nitric oxide (NO), NO-donors, NO-precursors or other electroactive species or metabolites produced during cell metabolism and/or wound healing). As with noise due to mechanical factors, noise due to biochemical/chemical factors will impinge upon the two working electrodes of the preferred embodiments (e.g., with and without active GOx) about the same extent, because of the sensor's small size and symmetrical configuration. Accordingly, the sensor electronics can use these data to calculate the glucose-only signal, as described elsewhere herein.

[0653] In one exemplary embodiment, the analyte sensor is a glucose sensor that measures a first signal associated with both glucose and non-glucose related electroactive compounds having a first oxidation/reduction potential. For example, the oxidation/reduction potential of the non-glucose related electroactive compounds substantially overlaps with the oxidation/reduction potential of H_2O_2, which is produced according to the reaction of glucose with GOx and subsequently transfers electrons to the first working electrode (e.g., **E1**; **Fig. 3F**). The glucose sensor also measures a second signal, which is associated with background noise of the glucose sensor. The background noise is composed of signal contribution due to noise-causing compounds (e.g., interferents), non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation/reduction potential that substantially overlaps with the oxidation/reduction potential of H_2O_2 (the co-analyte). The first and second working electrodes integrally form at least a portion of the sensor, such as but not limited to the *in vivo* portion of the sensor, as discussed elsewhere herein. Furthermore, the sensor has a diffusion

Abbott Ex. 1003 - 230/1058

barrier that substantially blocks (e.g., attenuates) diffusion of glucose or H_2O_2 between the first and second working electrodes. In various embodiments, the sensor includes a diffusion barrier configured to be physical, spatial, and/or temporal.

[0654] **Fig. 3F** is a schematic illustrating one embodiment of a sensor (e.g., a portion of the *in vivo* portion of the sensor, such as but not limited to the sensor electroactive surfaces) having one or more components that act as a diffusion barrier (e.g., prevent diffusion of electroactive species from one electrode to another). The first working electrode **E1** is coated with an enzyme layer **348** comprising active enzyme. For example, in a glucose sensor, the first working electrode **E1** is coated with glucose oxidase enzyme (GOx). A second working electrode **E2** is separated from the first working electrode **E1** by a diffusion barrier ***D***, such as but not limited to a physical diffusion barrier (e.g., either a reference electrode or a layer of non-conductive material/insulator). The diffusion barrier can also be spatial or temporal, as discussed elsewhere herein.

[0655] Glucose and oxygen diffuse into the enzyme layer **348**, where they react with GOx, to produce gluconate and H_2O_2. At least a portion of the H_2O_2 diffuses to the first working electrode **E1**, where it is electrochemically oxidized to oxygen and transfers two electrons (e.g., $2e^-$) to the first working electrode **E1**, which results in a glucose signal that is recorded by the sensor electronics (not shown). The remaining H_2O_2 can diffuse to other locations in the enzyme layer or out of the enzyme layer (illustrated by the wavy arrows). Without a diffusion barrier ***D***, a portion of the H_2O_2 can diffuse to the second working electrode **E2**, which results in an aberrant signal that can be recorded by the sensor electronics as a non-glucose related signal (e.g., background).

[0656] Preferred embodiments provide for a substantial diffusion barrier ***D*** between the first and second working electrodes (**E1**, **E2**) such that the H_2O_2 cannot substantially diffuse from the first working electrode **E1** to the second working electrode **E2**. Accordingly, the possibility of an aberrant signal produced by H_2O_2 from the first working electrode **E1** (at the second working electrode **E2**) is reduced or avoided.

[0657] In some alternative embodiments, the sensor is provided with a spatial diffusion barrier between electrodes (e.g., the working electrodes). For example, a spatial diffusion barrier can be created by separating the first and second working electrodes by a distance that is too great for the H_2O_2 to substantially diffuse between the working electrodes.

Abbott Ex. 1003 - 231/1058

In some embodiments, the spatial diffusion barrier is about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, or 0.08 inches to about 0.09, 0.10, 0.11, or 0.120 inches. In other embodiments, the spatial diffusion barrier is about 0.020 inches to about 0.050 inches. Still in other embodiments, the spatial diffusion barrier is about 0.055 inches to about 0.095 inches. A reference electrode **R** (e.g., a silver or silver/silver chloride electrode) or a non-conductive material (e.g., a polymer structure or coating such as Parylene) can be configured to act as a spatial diffusion barrier.

[0658] In some preferred embodiment, the sensor is an indwelling sensor, such as configured for insertion into the host's circulatory system *via* a vein or an artery. In some exemplary embodiments, an indwelling sensor includes at least two working electrodes that are inserted into the host's blood stream through a catheter. The sensor includes at least a reference electrode that can be disposed either with the working electrodes or remotely from the working electrodes. The sensor includes a spatial, a physical, or a temporal diffusion barrier. A spatial diffusion barrier can be configured as described in U.S. Patent Publication No. US-2008-0083617-A1 which is incorporated by reference herein in its entirety.

[0659] In one exemplary embodiment of an indwelling analyte sensor, such as but not limited to an intravascular glucose sensor to be used from a few hours to ten days or longer. Namely, the sensor includes two working electrodes. A first working electrode detects the glucose-related signal (due to active GOx applied to the electroactive surface) as well as non-glucose related signal. The second working electrode detects only the non-glucose related signal (because no active GOx is applied to its electroactive surface). H_2O_2 is produced on the first working electrode (with active GOx). If the H_2O_2 diffuses to the second working electrode (the no GOx electrode) an aberrant signal will be detected at this electrode, resulting in reduced sensor activity. Accordingly, it is desirable to separate the electroactive surfaces with a diffusion barrier, such as but not limited to a spatial diffusion barrier. Indwelling sensors are described in more detail in copending U.S. Patent Publication No. US-2008-0119703-A1, herein incorporated in its entirety by reference.

[0660] To configure a spatial diffusion barrier between the working electrodes, the location of the active enzyme (e.g., GOx) is dependent upon the orientation of the sensor after insertion into the host's artery or vein. For example, in an embodiment configured for insertion in the host's blood flow (e.g., in an artery or vein), active GOx and the inactive GOX (or no

Abbott Ex. 1003 - 232/1058

GOx) would be applied to two working electrodes such that the active GOX would be downstream from the inactive GOX (e.g., relative to the direction of blood flow). Due to this configuration, H_2O_2 produced at plus-GOX electroactive surface would be carrier down stream (e.g., away from minus-GOX electroactive surface) and thus not affect the non-enzymatic working electrode.

[0661] In some embodiments, a physical diffusion barrier is provided by a physical structure, such as an electrode, insulator, and/or membrane. For example, in some embodiments, an insulator or reference electrode disposed between the working electrodes acts as a diffusion barrier. As another example, the diffusion barrier can be a bioprotective membrane (e.g., a membrane that substantially resists, attenuates or blocks the transport of a species (e.g., hydrogen peroxide), such as a polyurethane. As yet another example, the diffusion barrier can be a resistance domain, as described in more detail elsewhere herein; namely, a semipermeable membrane that controls the flux of oxygen and an analyte (e.g., glucose) to the underlying enzyme domain. Numerous other structures and membranes can function as a physical diffusion barrier as is appreciated by one skilled in the art.

[0662] In other embodiments, a temporal diffusion barrier is provided (e.g., between the working electrodes). By temporal diffusion barrier is meant a period of time that substantially prevents an electroactive species (e.g., H_2O_2) from diffusing from a first working electrode to a second working electrode. For example, in some embodiments, the differential measurement can be obtained by switching the bias potential of each electrode between the measurement potential and a non-measurement potential. The bias potentials can be held at each respective setting (e.g., high and low bias settings) for as short as milliseconds to as long as minutes or hours. Pulsed amperometric detection (PED) is one method for quickly switching voltages, such as described in Bisenberger, M.; Brauchle, C.; Hampp, N. A triple-step potential waveform at enzyme multisensors with thick-film gold electrodes for detection of glucose and sucrose. *Sensors and Actuators* 1995, *B*, 181-189, which is incorporated herein by reference in its entirety. In some embodiments, bias potential settings are held long enough to allow equilibration.

[0663] One preferred embodiment provides a glucose sensor configured for insertion into a host for measuring glucose in the host. The sensor includes first and second working electrodes and an insulator located between the first and second working electrodes.

Abbott Ex. 1003 - 233/1058

The first working electrode is disposed beneath an active enzymatic portion of a membrane on the sensor and the second working electrode is disposed beneath an inactive- or non-enzymatic portion of the membrane on the sensor. The sensor also includes a diffusion barrier configured to substantially block (e.g., attenuate, restrict, suppress) diffusion of glucose or hydrogen peroxide between the first and second working electrodes.

[0664] In a further embodiment, the glucose sensor includes a reference electrode configured integrally with the first and second working electrodes. In some embodiments, the reference electrode can be located remotely from the sensor, as described elsewhere herein. In some embodiments, the surface area of the reference electrode is at least six times the surface area of the working electrodes. In some embodiments, the sensor includes a counter electrode that is integral to the sensor or is located remote from the sensor, as described elsewhere herein.

[0665] In a further embodiment, the glucose sensor detects a first signal associated with glucose and non-glucose related electroactive compounds having a first oxidation/reduction potential (e.g., the oxidation/reduction potential of H_2O_2). In some embodiments, the glucose sensor also detects a second signal is associated with background noise of the glucose sensor comprising signal contribution due to interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation/reduction potential that substantially overlaps with the oxidation/reduction potential of hydrogen peroxide; the first and second working electrodes integrally form at least a portion of the sensor; and each of the first working electrode, the second working electrode and the non-conductive material/insulator are configured provide at least two functions such as but not limited to electrical conductance, insulation, structural support, and a diffusion barrier

[0666] In further embodiments, the glucose sensor includes electronics operably connected to the first and second working electrodes. The electronics are configured to calculate at least one analyte sensor data point using the first and second signals described above. In still another further embodiment, the electronics are operably connected to the first and second working electrode and are configured to process the first and second signals to generate a glucose concentration substantially without signal contribution due to non-glucose noise artifacts.

Abbott Ex. 1003 - 234/1058

Sensor Configurations for Equivalent Measurement of Noise Signals at the Two Working Electrodes

[0667] In dual-electrode biosensors (e.g., an analyte sensor having two working electrodes **E1**, **E2**), noise can be caused by a variety of sources, for example, located outside (e.g., by noise-causing species produced metabolically and/or consumed by the host) or within (e.g., crosstalk) the sensor. In some circumstances, biological and/or metabolic processes occurring in the host's body, such as in the locale of the implanted sensor, can cause noise. These metabolic processes, such as but not limited to wound healing, the body's response to illness and even daily cellular metabolic processes, can generate noise-causing metabolic species (e.g., compounds, substances) that impinge upon the sensor and cause noise on the signal. For example, some noise-causing species, the levels of which are relatively stable due to production during daily cellular metabolism, generally cause constant noise. In another example, some noise-causing species, the levels of which fluctuate due to production by intermittent metabolic process (e.g., wound healing or response to infection), generally cause non-constant noise. Noise-causing metabolic species include but are not limited to externally generated H_2O_2 (e.g., produced outside the sensor), compounds having electroactive acidic, amine or sulfhydryl groups, urea, lactic acid, phosphates, citrates, peroxides, amino acids (*e.g.*, L-arginine), amino acid precursors or break-down products, nitric oxide (NO), NO-donors, NO-precursors, reactive oxygen species or other electroactive species or metabolites produced during cell metabolism and/or wound healing, for example. Noise-causing species, such as drugs, vitamins and the like, can also be consumed by the host. These noise causing species include but are not limited to acetaminophen, ascorbic acid, dopamine, ephedrine, ibuprofen, L-dopa, methyldopa, salicylate, tetracycline, tolazamide, tolbutamide and triglycerides. Further discussion of noise and its sources can be found in U.S. Patent Publication No. US-2007-0027370-A1 and U.S. Patent Publication No. US-2007-0235331-A1, both of which are incorporated herein by reference in their entirety.

[0668] In dual-electrode sensors, noise can also be generated within the sensor, namely due to diffusion of a measured species (e.g., H_2O_2) from a first working electrode (e.g., the H_2O_2 is generated in an active enzymatic portion of the sensor membrane associated with the first working electrode) to a second working electrode and detection thereby (e.g., which is associated with a non-enzymatic portion of the sensor membrane). This type of noise is

Abbott Ex. 1003 - 235/1058

commonly referred to as "crosstalk." Crosstalk is undesirable as it causes sensor error, which can result in inaccurate reporting of sensor data. In conventional sensors, a common solution to the problem of crosstalk is to space the two working electrodes far enough apart that a measured species diffusing from one working electrode cannot reach the other working electrode; unfortunately, such spacing does not enable substantially equivalent measurement of noise-cause species, as discussed in more detail elsewhere herein. Unlike conventional sensors, the sensors of the preferred embodiments ensure accurate subtraction of noise signal by ensuring substantially equivalent measurement of the noise (e.g., noise component, constant and/or non-constant noise components) detected by the two working electrodes.

[0669] Depending upon the scale (e.g., point) of reference, noise has a dual nature. On a larger scale, with respect to the *in vivo* portion of the sensor and the surrounding tissue, noise occurs randomly (e.g., is scattered, intermittent, dispersed, unevenly distributed) in the local of an implanted sensor. Yet, on a smaller scale, such as that of a few cells (e.g., 100-300 microns), noise is a localized phenomenon because it creates hot spots of noise-causing species generation whose effects extend about a thousandths of an inch (e.g., localized nature, character). A "hot spot" of noise generation is referred to herein as a "point source." A point source (e.g., a localized hot spot for noise generation) can be a cell or a group of cells adjacent to the sensor membrane, or a noise-causing species (e.g., compound, substance, molecule) that diffused to the location of sensor implantation, such as by diffusion between cells (e.g., to the sensor). For example, in the circumstance of a single point source in contact with the sensor membrane's surface, noise is a local phenomenon, because the noise-causing species' ability to affect adjacent structures is limited by the maximum distance it can diffuse (e.g., through the membrane), which is generally very short (e.g., a few microns, such as between about 1-μm to about 500-μm). Due to the random yet localized nature of noise, the configuration of the electroactive surfaces (of the working electrodes) can substantially affect noise measurement. With respect to the configuration and arrangement (e.g., surface area) of the dual-electrode sensor's electroactive surfaces, the random yet localized nature of noise is discussed in greater detail below.

[0670] **Fig. 3G** is a two-dimensional schematic illustrating, on the scale of a sensor and the surrounding tissue (e.g., a generally larger scale), the random nature of noise relative to a dual-electrode sensor, in one exemplary embodiment. This figure is for illustrative

Abbott Ex. 1003 - 236/1058

purposes only, and should not be considered as a to-scale representation of a particular sensor configuration or of the events discussed herein. In the embodiment shown in **Fig. 3G**, the dual-electrode analyte sensor includes two electroactive surfaces **E1**, **E2** disposed beneath the sensor's membrane. While **Fig. 3G** illustrates only one dimension of the electroactive surfaces, in some embodiments, the electroactive surfaces (e.g., the surface area of each electroactive surface) can include both a length and a width. In some embodiments, the area can include additional dimensions, such as a circumference and/or a height. In some embodiments, the sensor can have a planar configuration. In some embodiments, the sensor can have a cylindrical, pyramidal, polygonal configuration. It should also be understood that the electroactive surfaces **E1**, **E2** are shown as boxes as a matter of illustrative convenience; however, electroactive surfaces can be thinner or thicker than illustrated in **Fig. 3G** or elsewhere herein. The membrane has a thickness ***D1*** and a surface **MS**. Depending upon the membrane configuration, fabrication methods and/or materials, ***D1*** can vary in size, from less than about 0.001, 0.002, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008, 0.009, or 0.010 inches to more than about 0.011, 0.012, 0.013, 0.014, 0.015, 0.015, 0.016, 0.017, 0.018, 0.019, 0.020, 0.025, 0.03, 0.035, or 0.050 inches. In some embodiments, a preferred membrane thickness is between about 0.001, 0.0012, 0.0014, 0.0016, or 0.0018 inches to about 0.002, 0.0022, 0.0024, 0.0026, 0.0028, or 0.003 inches. Noise-causing species (represented by squiggly arrows **N2**) can be generated by and/or at point sources **N1** (e.g., noise hot spots) unevenly distributed relative the *in vivo* portion of the sensor. For example, some of the point sources **N1** (shown in **Fig. 3G**) are concentrated at one end of electroactive surface **E1**, while some are distributed more evenly across electroactive surface **E2**. In some circumstances, the point source may be one or more cells (e.g., in contact with the membrane surface **MS**) that release the noise-causing species during wound healing or another metabolic process, such as when a sensor is implanted *in vivo*. In some circumstances, the implanted sensor can be located within the diffusion distance of one or more noise-causing species produced during a nearby metabolic process. In some circumstances, the noise-causing species (e.g., a compound consumed by the host) can be carried to the local of the sensor *via* the circulatory and/or lymph system and diffuse to the sensor (e.g., between cells).

[0671] Random and/or unequally distributed noise can be generated in a variety of circumstances. For example, a peroxide-generating immune cell could be located adjacent to

Abbott Ex. 1003 - 237/1058

one electroactive surface but not the other. In general, a noise-causing species must be generated and/or occur close enough to the sensor membrane such that it can diffuse to (and through) the membrane, to the electroactive surfaces, and affect the sensor signal. If the noise-causing species is generated farther away from the membrane than the diffusion distance of the noise-causing species, then the noise-causing species may be unable to reach the electroactive surfaces, and therefore may have little effect on sensor signal. For example, H_2O_2 (produced by metabolic process when the sensor is implanted in a host) must be generated sufficiently close to the membrane for it to diffuse to the membrane and affect sensor function. The maximum distance that the noise-causing species can diffuse (e.g., from the cell to the membrane, from one working electrode to another working electrode) and still substantially affect sensor function is referred to herein as a "diffusion distance."

[0672] The sensor electronics are configured to mathematically correct for noise on the sensor signal (e.g., such as by subtraction of the noise signal, applying a filter, averaging, or other calculations), such that a substantially analyte-only signal can be presented to the user. The inventors have discovered that successful mathematical correction of noise on the sensor signal can be substantially affected by the equivalence (e.g., similarity) of the noise signals detected by the two working electrodes. If the detected noise signals are substantially equivalent (e.g., similar amounts, amplitudes, levels, relatively equal), then the calculations will produce a more accurate resultant analyte signal. If, on the other hand, the detected noise signals are not substantially equal (e.g., have very different amplitudes and/or wave forms), then the calculations will have a greater degree of error. While not wishing to be bound by theory, it is believed that presentation of more accurate sensor data (e.g., to the host) will improve the host's management of his or her diabetes, which will prevent the immediate risks of hypoglycemia (e.g., loss of consciousness and death) and postpone and/or prevent long term diabetes complications (blindness, loss of limb, kidney dysfunction, and the like). Additionally, the increased accuracy afforded by the sensors of the preferred embodiment increases the feasibility of insulin dosing and/or an artificial pancreas system based on a continuous glucose sensor.

[0673] In order to compensate for the unevenly distributed nature of noise (e.g., the point sources are randomly and/or non-equally and/or non-equivalently distributed relative to the *in vivo* portion of the sensor) and thereby render the noise components equivalent, a

Abbott Ex. 1003 - 238/1058

continuous dual-electrode glucose sensor having sufficiently large electroactive surfaces, such that the noise components can be substantially equalized (e.g., made and/or become equivalent) by integration there across, is provided in one embodiment. The first working electrode includes a first electroactive surface (**E1**, **Fig. 3G**) disposed beneath an active enzymatic portion (e.g., plus-GOx) of the sensor's membrane, as described elsewhere herein. The first electroactive surface includes a first area (e.g., first electroactive surface area) configured to detect a first signal (e.g., including an analyte-related component and a noise component) having a first noise component related to a noise-causing species. The sensor also includes a second working electrode having a second electroactive surface (**E2**, **Fig. 3G**) disposed beneath an inactive-enzymatic or a non-enzymatic portion of the sensor membrane, as described elsewhere herein. For example, an inactive-enzymatic portion of the membrane can include inactivated GOx or no GOx. The second electroactive surface includes a second area (e.g., second electroactive surface area) configured to generate a second signal having a second noise component related to the noise-causing species. In preferred embodiments, the first and second areas are dimensioned (e.g., sized) to be sufficiently large such that the first and second noise components integrated there across, such that the first and second integrated noise signals (e.g., from the first and second electroactive surfaces, respectively) are substantially equivalent. In some embodiments, the first and second integrated noise signals (e.g., noise components) are within 20% of each other (e.g., plus or minus 10%). In some embodiments, the first and second electroactive surfaces are dimensioned to integrate noise caused by a plurality of local point sources that produce noise-causing species *in vivo*.

[0674] **Fig. 3H** is a two-dimensional schematic illustrating the localized character of noise species (represented by squiggly arrows **N2**) generated by a point source **N1**, when examined from a cellular scale, as discussed elsewhere herein. **Fig. 3H** depicts a cross-section of a sensor, in one embodiment, wherein the sensor includes two working electrodes having electroactive surfaces **E1** and **E2**, and a membrane having surface **MS** and thickness ***D1***. Distance ***D3*** separates the electroactive surfaces; the distance between their outer edges is denoted by ***D4***. Note that dimension ***D2***, described above, is not shown in this figure. The sensor of this exemplary embodiment can have a variety of configurations, such as but not limited to planar, cylindrical or polygonal. Accordingly, the dimensions of an electroactive surface's surface area (referred to as "area" herein) can include but are not limited to length,

Abbott Ex. 1003 - 239/1058

width, height, and/or circumference. For example, in some embodiments, the area of each electroactive surface is defined by a length and a width. In some embodiments, the area includes a length or width and a circumference. In some embodiments, the area includes length, width and height. Additionally, it is known to one skilled in the art that, in some circumstances, differences in signal amplitude and/or sensitivity (e.g., from the two working electrodes), due to differences in electrode sizes (or some differences in compositions of membranes) can be corrected (adjusted, compensated for, calibrated out) mathematically. For example, if a first electroactive surface is two times as large as the second electroactive surface, then the signal from the second electroactive surface can be multiplied by two, such that the sensitivities are substantially similar.

[0675] Referring now to **Fig. 3H**, in this exemplary circumstance the point source (e.g., noise hot spot) is an individual cell **N1** disposed adjacent to the membrane surface **MS** and generally above and/or over the sensor's electroactive surfaces **E1**, **E2**. The cell can produce noise-causing substances (e.g., **N2**) that can diffuse to and affect its local environment. In general, the ability of a noise-causing substance to affect the local environment is limited by the maximum distance the substance can diffuse (e.g., the substance's diffusion distance). In some circumstances, some of the noise-causing substances can diffuse through the sensor membrane and affect the sensor's electroactive surfaces. While not wishing to be bound by theory, the inventors have found that in order for the two electroactive surfaces to be substantially equivalently affected by the noise **N2** from a point source, such as a cell, the electroactive surfaces must be affected by substantially the same microenvironment. In various circumstances, the electroactive surfaces will be affected by substantially the same microenvironment, if the electroactive surfaces are configured and arranged such that the electroactive surfaces are sufficiently close together and/or their external edges are sufficiently close together.

[0676] **Fig. 3H** shows that the sensor's electroactive surfaces **E1**, **E2** are separated by a distance ***D3*** and their outer edges are spaced a distance ***D4*** (e.g., in at least one dimension), in one exemplary embodiment. In this example, a point source **N1** (e.g., a cell) of noise-causing species **1006** is adjacent to the membrane's surface **MS**. If the electroactive surfaces are configured and arranged such that ***D3*** is sufficiently small, then the noise-causing species diffusing from the point source can impinge equivalently on both of the electroactive surfaces.

Abbott Ex. 1003 - 240/1058

Additionally or alternatively, if ***D4*** is sufficiently small (e.g., the electroactive surfaces are sufficiently narrow in at least one dimension), then the noise-causing species diffusing from the point source can impinge equivalently on both of the electroactive surfaces. Accordingly, in preferred embodiments, the electroactive surfaces are spaced a distance (e.g., relative to each other, ***D3***) such that the electroactive surfaces (e.g., at least a portion of each electroactive surface) detect substantially equivalent noise from a point source. In some embodiments, the electroactive surfaces are sufficiently close together (e.g., such that the noise components measured are substantially equal) when the distance between the electroactive surfaces (***D3***) is between about 0.5-times to about 10-times (or more) the membrane thickness (***D1***). In some preferred embodiments, the electroactive surfaces are sufficiently close together when ***D3***is about 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-times the membrane thickness. In some embodiments, ***D3*** is between about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 microns or less to about 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 microns or more. In preferred embodiments, ***D3*** is between about 20 to about 40 microns. In some embodiments, ***D4*** is between about 25 microns or less to about 500 microns or more.

[0677] Depending upon the sensor's configuration, in some embodiments, ***D4*** can be the distance between the outer edges of the electroactive surfaces, or ***D4*** can be a distance equivalent to the maximum diameter of the bundles and/or twisted pair of working electrodes. For example, **Fig. 3H** illustrates a cross-section of a sensor (e.g., width and height), but doesn't illustrate any additional dimensions (e.g., length). The cross-section could be that of a planar sensor configuration, wherein the sensor also includes an additional dimension that has not been shown, such as but not limited to ***D2***. In some circumstances, the sensor can have a non-planar configuration. For example, in the embodiment shown in **Fig. 3I**, the working electrodes **E1**, **E2** are fabricated from two wires. Since the wires are cylindrical, the electroactive surfaces do not include outer edges. In this exemplary circumstance, ***D4*** is the total diameter of the bundled and/or twisted pair of working electrodes. In both types of sensor configurations (e.g., planar and non-planar), if ***D4*** is sufficiently small, then the two working electrodes can be equivalently affected by noise-causing species **N2** derived from a point source **N1**.

[0678] As described above, dual-electrode sensors can be affected by internally generated noise (e.g., generated by the sensor). The inventors have found that, in general,

Abbott Ex. 1003 - 241/1058

when ***D3*** is sized to be sufficiently small such that the electroactive surfaces are equivalently affect by noise from an adjacent point source, the electroactive surfaces are also close enough together that crosstalk (an internally generated noise) can occur. In general, crosstalk is detection of an analyte signal generated at the plus-GOx working electrode (wherein the electrode includes the membrane portion thereon) by the minus-GOx working electrode (including the No GOx membrane portion thereon). For example, when the measured species is H_2O_2, crosstalk occurs when the H_2O_2 diffuses from the plus-GOx enzyme domain to the No GOx working electrode and is detected (e.g., a signal is generated on the No GOx electrode). In general, crosstalk is undesirable as it causes sensor error. However, in order for the two working electrodes to measure equivalent noise signals from a point source **N1**, the electroactive surfaces must be spaced very close together. Accordingly, in preferred embodiments, this distance (***D3***) is less than a crosstalk diffusion distance of the measured species. In other words, ***D3*** is shorter than the diffusion distance of H_2O_2 (e.g., the maximum distance H_2O_2 can diffuse from a first electrode to a second and still cause a signal on the second electrode).

[0679] In conventional dual-electrode sensors, spacing the electroactive surfaces within the crosstalk diffusion distance of the measured species is generally undesirable due to increased sensor error. However, in preferred embodiments, the sensor includes a physical diffusion barrier configured to attenuate crosstalk by physically blocking (e.g., suppressing, blocking, restricting) some of the crosstalk from the active enzymatic portion of the sensor membrane to the second electroactive surface. More preferably, the physical diffusion barrier is configured and arranged to attenuate and/or physically block a substantial amount of the measurable species (e.g., H_2O_2) diffusing from the active enzymatic portion of the membrane to the second electroactive surface, such that there is substantially no signal associated with crosstalk measured at the second working electrode.

[0680] **Fig. 3I** is a schematic illustrating a perspective view of a cross-section of a dual-electrode sensor that includes a physical diffusion barrier **D**, in one exemplary embodiment. In this embodiment, wires form the working electrodes **E1**, **E2**. The working electrodes each include a membrane, including an electrode domain **347**, an enzyme domain **248** and a resistance domain **249**. For example, **E1** includes a first electrode domain, a first enzyme domain (Plus GOx) and a first resistance domain, and **E2** includes a second electrode

Abbott Ex. 1003 - 242/1058

domain, a second enzyme domain (No GOx) and a second resistance domain. In this particular exemplary embodiment, the electrodes are placed together and coated with an additional resistance domain **249A** (e.g., a third resistance domain). Depending upon the circumstances, the electrodes can be placed and/or held together using a variety of methods, such as bundling, twisting, wrapping, and the like, either alone or in combination. The distances shown are as follows; a thickness of the membrane ***D1***, at least one dimension of the electroactive surface ***D2***, a distance between the electroactive surfaces ***D3***, and a distance between the outer edges of the electroactive surfaces ***D4***. In the illustrated exemplary embodiment, the first and second electroactive surfaces extend about the circumferences of **E1** and **E2** (or portions thereof), respectively.

[0681] In preferred embodiments, the physical diffusion barrier **D** is disposed between the electroactive surfaces of working electrodes **E1** and **E2**. In some embodiments, the physical diffusion barrier is formed of one or more membrane materials, such as those used in formation of an interference domain and/or a resistance domain. Such materials include but are not limited to silicones, polyurethanes, cellulose derivatives (cellulose butyrates and cellulose acetates, and the like) and combinations thereof, as described elsewhere herein. In some embodiments, the physical diffusion barrier includes one or more membrane domains. For example, in the exemplary embodiment of **Fig. 3I**, the physical diffusion barrier is a discontinuous portion of the membrane (e.g., separate, distinct or discontinuous membrane structures) disposed between the first and second electroactive surfaces, and can include one or more membrane portion(s) within distance ***D3*** (e.g., interference and/or resistance domains). For example, in some embodiments, H_2O_2 diffusing from the Plus GOX working electrode to the No GOx working electrode must pass through two "sensor membranes" such as the first and second resistance domains disposed on **E1** and **E2** respectively, and optionally electrode, interference and/or enzyme domains disposed on **E2**. In some embodiments, the physical diffusion barrier includes first and second barrier layers formed independently on the first and second electrodes. In some embodiments the barrier layer is the resistance domain **349**. In still other embodiments, the physical diffusion barrier can be a continuous membrane (and/or membrane domain(s)) disposed between the electroactive surfaces. In some embodiments, the physical diffusion barrier attenuates (e.g., suppresses, blocks, prevents) diffusion of the H_2O_2 (e.g., crosstalk) by at least 2-fold. In preferred embodiments, crosstalk is attenuated at least 5-

Abbott Ex. 1003 - 243/1058

fold. In a more preferred embodiment, crosstalk is attenuated at least 10-fold. In some embodiments, the physical diffusion barrier attenuates crosstalk at least about 50%. In a further embodiment, the physical diffusion barrier is configured and arranged to physically block an amount of the measured species diffusing from the active enzymatic portion of the membrane to the second electroactive surface, such that there is substantially no signal associated with crosstalk measured at the second working electrode.

[0682] In some embodiments, a dual-electrode sensor having a physical barrier layer can be fabricated by initially preparing (e.g., fabricating, building) the first and second working electrodes **E1**, **E2** independently (e.g., separately from each other), followed by joining and/or grouping and/or bundling the working electrodes and optionally applying one or more additional membrane domains fabrication. In this exemplary embodiment, to the first working electrode **E1**, an optional electrode domain **347**, an enzyme domain **348** (e.g., plus-GOx), and at least one layer of the resistance domain material **349** (e.g., first resistance domain) are sequentially applied. Similarly, to the second working electrode **E2**, an optional electrode domain **347**, an enzyme domain **348** (e.g., no-GOx), and at least one layer of the resistance domain material **349** (e.g., second resistance domain) are sequentially applied. The working electrodes are then held together, such as but not limited to by bundling and/or twisting them together, wrapping a material around them, or by any other method known in the art. In this embodiment, the physical diffusion barrier **D** includes a discontinuous portion of a membrane (e.g., the initial layers of the resistance domain material applied independently to the two working electrodes) disposed between the first and second electroactive surfaces.

[0683] In an alternative exemplary sensor embodiment, the sensor includes working electrodes (including electroactive surfaces) disposed on a planar substrate and/or surface. The electroactive surfaces can be spaced a distance ***D3*** that is sufficiently close together that the electroactive surfaces are equivalently affected by an adjacent noise hot spot (e.g., point source). In this configuration, ***D3*** is also sufficiently small that crosstalk can occur between the Plus GOx working electrode (wherein the term "electrode" includes the membrane disposed thereon, for the purposes of this example) and the No GOx working electrode. However, in preferred embodiments, crosstalk is substantially attenuated by a physical diffusion barrier disposed between the working electrodes. Namely, the electrode domains (if present) and enzyme domains can be separately applied to the working electrodes and/or

Abbott Ex. 1003 - 244/1058

electroactive surfaces; followed by application of a continuous resistance domain applied thereon, such that a portion the resistance domain is deposited between the working electrodes. For example, a portion of resistance domain deposited on a planar substrate and between working electrodes can attenuate diffusion of the measured species (e.g., H_2O_2) from **E1** to **E2**, such that the noise measured on **E1** and **E2** is equivalent.

[0684] In the context of glucose sensors, one skilled in the art recognizes that equivalent noise signals can have different amplitudes, but equivalent signal patterns (e.g., rises, falls, trends and the like) such that a noise component can be subtracted out (as described elsewhere herein) while compensating for any difference in signal amplitude (e.g., sensitivity of the first and second working electrodes), as described elsewhere herein. In some circumstances, the membrane portions associated with the working electrodes (e.g., of a dual-electrode sensor) can possess different sensitivities (e.g., signal sensitivities), such that the amplitudes of the noise components measured by the working electrodes are not equivalent. In some circumstances, the areas of the electroactive surfaces may be different sizes, which can also result in non-equivalent signal amplitudes, differences in measured baselines and/or sensitivities between the first and second working electrodes. While such differences in signal baseline and/or sensitivity can be corrected mathematically (e.g., by mathematical filters), mathematical correction of noise, in general, is improved when the signal sensitivities of the first and second working electrodes are closer. Accordingly, in a preferred embodiment, an additional resistance domain **349A** (e.g., applied continuously over the discontinuous resistance domains **349** described elsewhere herein) is provided, such that the signal sensitivities are equivalent. In the exemplary embodiment shown in **Fig. 3I**, the signal sensitivities are substantially equalized on a sensor including the combination of discontinuous resistance domains (e.g., resistance domains **349**, applied independently to **E1** and **E2**) and a continuous resistance domain **349A** (e.g., applied over and/or adjacent to the discontinuous resistance domains). In other words, the noise signals detected on both **E1** and **E2** will have substantially the same amplitude (e.g., intensity, amount), as described with reference to **Example 7**, below. In a preferred embodiment, the sensitivities (of the working electrodes) are within 40% of each other (e.g., plus or minus 20%). In a preferred embodiment, the sensitivities (of the working electrodes) are within 20% of each other (e.g., plus or minus 10%).

Abbott Ex. 1003 - 245/1058

In a more preferred embodiment, the sensitivities (of the working electrodes) are within 10% of each other (e.g., plus or minus 5%).

[0685] In an alternative embodiment, the sensor electrodes can be disposed on a planar, cylindrical, pyramidal or otherwise shaped support. For example, the sensor's first and second working electrodes can be conductive traces deposited, such as by screen printing, sputtering or other thin film techniques known in the art, on a planar substrate. In this alternative embodiment, a physical diffusion barrier can be formed by layers of resistance domain material deposited separately (e.g., discontinuously) on each working electrode and/or between the electrodes, for example.

[0686] In the exemplary embodiments described above, diffusion of the H_2O_2 from the first working electrode **E1** to the electroactive surface of the second working electrode **E2** is first attenuated by the resistance domain **349** disposed over the first working electrode **E1** (an independently formed first barrier layer), and then again by the resistance domain **349** disposed over the second working electrode **E2** (an independently formed second barrier layer), such that only insubstantial amounts of H_2O_2 can reach the electroactive surface of the second working electrode. In preferred embodiments, the first and second resistance domains are configured and arranged to reduce diffusion of the measurable species (e.g., H_2O_2) from the first electroactive surface to the second electroactive surface by at least 2-fold. In more preferred embodiments, the physical diffusion barrier is configured and arranged to reduce diffusion of the measurable species by at least 10-fold. In some embodiments, the physical diffusion barrier is configured and arranged to reduce diffusion of the measurable species by at least 3-, 4-, 5-, 6-, 7-, 8-, or 9-fold. In some embodiments, the physical diffusion barrier is configured and arranged to reduce diffusion of the measurable species by at least 20-, 30-, 40- or 50- fold, or more. In some embodiments, the sensor's working electrodes **E1, E2** are by an insulator, which insulates the working electrodes from each other. In some embodiments, the insulator is at least a portion of the sensor membrane.

[0687] In some embodiments, a continuous glucose sensor configured for insertion into a host and detecting glucose in the host is provided. In general, the sensor includes first and second working electrodes, wherein each working electrode includes an electroactive surface (each including an area) disposed beneath a sensor membrane. The first electroactive surface (e.g., of the first working electrode) is disposed beneath an active enzymatic portion

Abbott Ex. 1003 - 246/1058

(plus-GOx) of the membrane while the second electroactive surface (of the second working electrode) is disposed beneath a non-enzymatic (no-GOx) portion of the membrane. The non-enzymatic portion of the membrane can include inactivated enzyme and/or no enzyme. Additionally, each working electrode is configured to generate a signal having a noise component related to a noise-causing species. In some circumstances, the noise-causing species is non-constant and related to a biological process. Preferably, the first and second areas are sufficiently large such that the noise components (e.g., first and second noise components detected by the first and second working electrodes) are substantially equivalent. In some embodiments, the first and second areas are each greater than the sum of the diameters of about 10 average human cells, in at least one dimension. In some embodiments, the first and second areas are each greater than about 500μm, in at least one dimension. Preferably, the first and second areas (e.g., of the electroactive surfaces) are configured and arranged such that the signals caused by a plurality of local point sources (that produce noise-causing species when implanted in a host) can be integrated along each area (e.g., each area independently from the other). In some further embodiments, the first and second areas are configured and arranged to integrate signals detected about a circumference of the sensor. Preferably, the first and second electroactive surfaces are spaced a distance that is less than a crosstalk diffusion distance of a measured species, such as H_2O_2 produced in the active enzymatic portion of the membrane. In some embodiments, the sensor includes a physical diffusion barrier configured and arranged to physically block some crosstalk from the active enzymatic portion of the membrane to the second electroactive surface. In some further embodiments, the physical diffusion barrier is configured and arranged to physically block a substantial amount of the measurable species diffusing from the active enzymatic portion of the membrane to the second electroactive surface (e.g., crosstalk), such that there is substantially no signal associated with crosstalk measured at the second working electrode. In some embodiments, the physical diffusion barrier is a discontinuous portion of the membrane disposed between the first and second electroactive surfaces. In some further embodiments, the physical diffusion barrier includes a first barrier layer formed on the first working electrode and a second barrier layer formed on the second working electrode, wherein the first and second barrier layers are independently formed (e.g., formed separately on the two electroactive surfaces). In some further embodiments, the physical diffusion barrier includes a first resistance domain formed

Abbott Ex. 1003 - 247/1058

on the first working electrode and a second resistance domain formed on the second working electrode, and wherein the first and second resistance domains are configured and arranged to reduce diffusion of the measurable species (e.g., crosstalk) from the active enzymatic portion of the sensor to the second electroactive surface by at least 2-fold. In a preferred embodiment, the physical diffusion barrier can reduce the diffusion of the measurable species (e.g., crosstalk) by at least 10-fold.

[0688] In some embodiments, the continuous glucose sensor includes first and second working electrodes, each working electrode including an electroactive surface (each including an area) disposed beneath a sensor membrane. As described elsewhere herein, the first electroactive surface is disposed beneath an active enzymatic portion of the membrane and the second electroactive surface is disposed beneath a non-enzymatic portion of the membrane. Preferably, the sensor includes a physical diffusion barrier, and the first and second electroactive surfaces are disposed sufficiently close together that the first and second noise components (detected by the first and second working electrodes) are substantially equivalent. In some embodiments, the distance between the first and second electroactive surfaces is less than about twice the thickness of the membrane. In some embodiments, the first and second electroactive surfaces are spaced a distance that is less than or equal to about a crosstalk diffusion distance of a measurable species, such as the H_2O_2 produced in the active enzymatic portion of the sensor membrane. In some embodiments, the physical diffusion barrier is configured and arranged to physically block some diffusion of the measurable species from the active enzymatic portion of the membrane to the second electroactive surface (e.g., crosstalk). In preferred embodiments, the physical diffusion barrier blocks a substantial amount of the measurable species, such that there is substantially no signal associated with crosstalk measured at the second working electrode. In some embodiments, the physical diffusion barrier is a discontinuous portion of the membrane disposed between the first and second electroactive surfaces. In some embodiments, the physical diffusion barrier is a first barrier layer formed on the first electrode and a second barrier layer formed on the second electrode, wherein the first and second barrier layers are independently formed. In some embodiments, the physical diffusion barrier includes a first resistance domain formed on the first electrode and a second resistance domain formed on the second electrode. Preferably, the first and second resistance domains reduce diffusion of the measurable species (e.g., crosstalk) by at

Abbott Ex. 1003 - 248/1058

least 2-fold. In more preferred embodiments, the diffusion of the measurable species is reduced by at least 10-fold. In some embodiments, the membrane is an insulator that insulates the first working electrode from the second working electrodes. In some further embodiments, the first and second areas are sufficiently large that the first and second noise components are substantially equivalent.

Sensor Electronics

[0689] The analyte sensor system has electronics, also referred to as a "computer system" that can include hardware, firmware, and/or software that enable measurement and processing of data associated with analyte levels in the host. In one exemplary embodiment, the electronics include a potentiostat, a power source for providing power to the sensor, and other components useful for signal processing. In another exemplary embodiment, the electronics include an RF module for transmitting data from sensor electronics to a receiver remote from the sensor. In another exemplary embodiment, the sensor electronics are wired to a receiver, which records the data and optionally transmits the data to a remote location, such as but not limited to a nurse's station, for tracking the host's progress and to alarm the staff is a hypoglycemic episode occurs. In another exemplary embodiment, the sensor electronics include a processor module configured to and/or comprises programming for processing sensor data, as described elsewhere herein. In some exemplary embodiments, the sensor electronics include a receiving module for receiving sensor signals, such as but not limited to from the working electrode(s), and/or externally provided reference data points. In some embodiments, the processor module can include the receiving module. The processor module and the receiving module can be located together and/or in any combination of sensor electronics local to and/or remote from the sensor.

[0690] Various components of the electronics of the sensor system can be disposed on or proximal to the analyte sensor, such as but not limited to disposed on the fluid coupler **20** of the system, such as the embodiment shown in **Fig. 1A**. In another embodiment, wherein the sensor is integrally formed on the catheter (e.g., see **Fig. 2A**) and the electronics are disposed on or proximal to the connector **218**. In some embodiments, only a portion of the electronics (e.g., the potentiostat) is disposed on the device (e.g., proximal to the sensor), while the remaining electronics are disposed remotely from the device, such as on a stand or by the

Abbott Ex. 1003 - 249/1058

bedside. In a further embodiment, a portion of the electronics can be disposed in a central location, such as a nurse's station.

[0691] In additional embodiments, some or all of the electronics can be in wired or wireless communication with the sensor and/or other portions of the electronics. For example, a potentiostat disposed on the device can be wired to the remaining electronics (e.g., a processor, a recorder, a transmitter, a receiver, etc.), which reside on the bedside. In another example, some portion of the electronics is wirelessly connected to another portion of the electronics, such as by infrared (IR) or RF. In one embodiment, a potentiostat resides on the fluid coupler and is connected to a receiver by RF; accordingly, a battery, RF transmitter, and/or other minimally necessary electronics are provided with the fluid coupler and the receiver includes an RF receiver.

[0692] Preferably, the potentiostat is operably connected to the electrode(s) (such as described above), which biases the sensor to enable measurement of a current signal indicative of the analyte concentration in the host (also referred to as the analog portion). In some embodiments, the potentiostat includes a resistor that translates the current into voltage. In some alternative embodiments, a current to frequency converter is provided that is configured to continuously integrate the measured current, for example, using a charge counting device.

[0693] In some embodiments, the electronics include an A/D converter that digitizes the analog signal into a digital signal, also referred to as "counts" for processing. Accordingly, the resulting raw data stream in counts, also referred to as raw sensor data, is directly related to the current measured by the potentiostat.

[0694] Typically, the electronics include a processor module that includes the central control unit that controls the processing of the sensor system. In some embodiments, the processor module includes a microprocessor, however a computer system other than a microprocessor can be used to process data as described herein, for example an ASIC can be used for some or all of the sensor's central processing. The processor typically provides semi-permanent storage of data, for example, storing data such as sensor identifier (ID) and programming to process data streams (for example, programming for data smoothing and/or replacement of signal artifacts such as is described in U.S. Patent Publication No. US-2005-0043598-A1). The processor additionally can be used for the system's cache memory, for

Abbott Ex. 1003 - 250/1058

example for temporarily storing recent sensor data. In some embodiments, the processor module comprises memory storage components such as ROM, RAM, dynamic-RAM, static-RAM, non-static RAM, EEPROM, rewritable ROMs, flash memory, and the like.

[0695] In some embodiments, the processor module comprises a digital filter (e.g., programming), for example, an infinite impulse response (IIR) or finite impulse response (FIR) filter, configured to smooth the raw data stream from the A/D converter. Generally, digital filters are programmed to filter data sampled at a predetermined time interval (also referred to as a sample rate). In some embodiments, wherein the potentiostat is configured to measure the analyte at discrete time intervals, these time intervals determine the sample rate of the digital filter. In some alternative embodiments, wherein the potentiostat is configured to continuously measure the analyte, for example, using a current-to-frequency converter as described above, the processor module can be programmed to request a digital value from the A/D converter at a predetermined time interval, also referred to as the acquisition time. In these alternative embodiments, the values obtained by the processor are advantageously averaged over the acquisition time due the continuity of the current measurement. Accordingly, the acquisition time determines the sample rate of the digital filter. In preferred embodiments, the processor module is configured with a programmable acquisition time, namely, the predetermined time interval for requesting the digital value from the A/D converter is programmable by a user within the digital circuitry of the processor module. An acquisition time of from about 2 seconds to about 512 seconds is preferred; however any acquisition time can be programmed into the processor module. A programmable acquisition time is advantageous in optimizing noise filtration, time lag, and processing/battery power.

[0696] In some embodiments, the processor module is configured to and/or comprises programming to build the data packet for transmission to an outside source, for example, an RF transmission to a receiver. Generally, the data packet comprises a plurality of bits that can include a preamble, a unique identifier identifying the electronics unit, the receiver, or both, (e.g., sensor ID code), data (e.g., raw data, filtered data, and/or an integrated value) and/or error detection or correction. Preferably, the data (transmission) packet has a length of from about 8 bits to about 128 bits, preferably about 48 bits; however, larger or smaller packets can be desirable in certain embodiments. The processor module can be configured to transmit any combination of raw and/or filtered data. In one exemplary

Abbott Ex. 1003 - 251/1058

embodiment, the transmission packet contains a fixed preamble, a unique ID of the electronics unit, a single five-minute average (e.g., integrated) sensor data value, and a cyclic redundancy code (CRC).

[0697] In some embodiments, the processor module further comprises a transmitter portion that determines the transmission interval of the sensor data to a receiver, and the like. In some embodiments, the transmitter portion, which determines the interval of transmission, is configured to be programmable. In one such embodiment, a coefficient can be chosen (*e.g.*, a number of from about 1 to about 100, or more), wherein the coefficient is multiplied by the acquisition time (or sampling rate), such as described above, to define the transmission interval of the data packet. Thus, in some embodiments, the transmission interval is programmable from about 2 seconds to about 850 minutes, more preferably from about 30 second to about 5 minutes; however, any transmission interval can be programmable or programmed into the processor module. However, a variety of alternative systems and methods for providing a programmable transmission interval can also be employed. By providing a programmable transmission interval, data transmission can be customized to meet a variety of design criteria (*e.g.*, reduced battery consumption, timeliness of reporting sensor values, etc.)

[0698] In some embodiments, the processor is further configured to and/or further comprises programming to perform the processing, such as storing data, analyzing data streams, calibrating analyte sensor data, estimating analyte values, comparing estimated analyte values with time corresponding measured analyte values, analyzing a variation of estimated analyte values, downloading data, and controlling the user interface by providing analyte values, prompts, messages, warnings, alarms, and the like. In such cases, the processor includes hardware and software that performs the processing described herein, for example flash memory provides permanent or semi-permanent storage of data, storing data such as sensor ID, receiver ID, and programming to process data streams (for example, programming for performing estimation and other algorithms described elsewhere herein) and random access memory (RAM) stores the system's cache memory and is helpful in data processing. Alternatively, some portion of the data processing (such as described with reference to the processor elsewhere herein) can be accomplished at another (e.g., remote) processor and can be configured to be in wired or wireless connection therewith.

Abbott Ex. 1003 - 252/1058

[0699] In some embodiments, an output module, which is integral with and/or operatively connected with the processor, includes programming for generating output based on the data stream received from the sensor system and it's processing incurred in the processor. In some embodiments, output is generated via a user interface.

[0700] In some embodiments, a user interface is provided integral with (e.g., on the patient inserted medical device), proximal to (e.g., a receiver near the medical device including bedside or on a stand), or remote from the sensor electronics (e.g., at a central station such as a nurse's station), wherein the user interface comprises a keyboard, speaker, vibrator, backlight, liquid crystal display (LCD) screen, and one or more buttons. The components that comprise the user interface include controls to allow interaction of the user with the sensor system. The keyboard can allow, for example, input of user information, such as mealtime, exercise, insulin administration, customized therapy recommendations, and reference analyte values. The speaker can produce, for example, audible signals or alerts for conditions such as present and/or estimated hyperglycemic or hypoglycemic conditions. The vibrator can provide, for example, tactile signals or alerts for reasons such as described with reference to the speaker, above. The backlight can be provided, for example, to aid a user in reading the LCD in low light conditions. The LCD can be provided, for example, to provide the user with visual data output, such as is described in U.S. Patent Publication No. US-2005-0203360-A1. In some embodiments, the LCD is a touch-activated screen, enabling each selection by a user, for example, from a menu on the screen. The buttons can provide for toggle, menu selection, option selection, mode selection, and reset, for example. In some alternative embodiments, a microphone can be provided to allow for voice-activated control.

[0701] In some embodiments, prompts or messages can be displayed on the user interface to convey information to the user, such as reference outlier values, requests for reference analyte values, therapy recommendations, deviation of the measured analyte values from the estimated analyte values, and the like. Additionally, prompts can be displayed to guide the user through calibration or trouble-shooting of the calibration.

[0702] Additionally, data output from the output module can provide wired or wireless, one- or two-way communication between the user interface and an external device. The external device can be any device that wherein interfaces or communicates with the user interface. In some embodiments, the external device is a computer, and the system is able to

Abbott Ex. 1003 - 253/1058

download historical data for retrospective analysis by the patient or physician, for example. In some embodiments, the external device is a modem or other telecommunications station, and the system is able to send alerts, warnings, emergency messages, and the like, via telecommunication lines to another party, such as a doctor or family member. In some embodiments, the external device is an insulin pen, and the system is able to communicate therapy recommendations, such as insulin amount and time to the insulin pen. In some embodiments, the external device is an insulin pump, and the system is able to communicate therapy recommendations, such as insulin amount and time to the insulin pump. The external device can include other technology or medical devices, for example pacemakers, implanted analyte sensor patches, other infusion devices, telemetry devices, and the like.

[0703] The user interface, including keyboard, buttons, a microphone (not shown), and optionally the external device, can be configured to allow input of data. Data input can be helpful in obtaining information about the patient (for example, meal time, insulin administration, and the like), receiving instructions from a physician (for example, customized therapy recommendations, targets, and the like), and downloading software updates, for example. Keyboard, buttons, touch-screen, and microphone are all examples of mechanisms by which a user can input data directly into the receiver. A server, personal computer, personal digital assistant, insulin pump, and insulin pen are examples of external devices that can provide useful information to the receiver. Other devices internal or external to the sensor that measure other aspects of a patient's body (for example, temperature sensor, accelerometer, heart rate monitor, oxygen monitor, and the like) can be used to provide input helpful in data processing. In one embodiment, the user interface can prompt the patient to select an activity most closely related to their present activity, such as medication taken, surgical procedures, and the like, which can be helpful in linking to an individual's physiological patterns, or other data processing. In another embodiment, a temperature sensor and/or heart rate monitor can provide information helpful in linking activity, metabolism, and glucose excursions of an individual. While a few examples of data input have been provided here, a variety of information can be input, which can be helpful in data processing.

Algorithms

[0704] In some embodiments, calibration of an analyte sensor can be required, which includes data processing that converts sensor data signal into an estimated analyte

Abbott Ex. 1003 - 254/1058

measurement that is meaningful to a user. In general, the sensor system has a computer system (e.g., within the electronics) that receives sensor data (*e.g.*, a data stream), including one or more time-spaced sensor data points, measured by the sensor. The sensor data point(s) can be smoothed (filtered) in certain embodiments using a filter, for example, a finite impulse response (FIR) or infinite impulse response (IIR) filter. During the initialization of the sensor, prior to initial calibration, the system can receive and store uncalibrated sensor data, however it can be configured to not display any data to the user until initial calibration and, optionally, stabilization of the sensor has been established. In some embodiments, the data stream can be evaluated to determine sensor break-in (equilibration of the sensor *in vitro* or *in vivo*).

[0705] In some embodiments, the system is configured to receive reference data from a reference analyte monitor, including one or more reference data points, also referred to as calibration information in some embodiments. The monitor can be of any suitable configuration. For example, in one embodiment, the reference analyte points can comprise results from a self-monitored blood analyte test (e.g., from a finger stick test, YSI, Beckman Glucose Analyzer, and the like), such as those described in U.S. Patent No. 6,045,567, U.S. Patent No. 6,156,051, U.S. Patent No. 6,197,040, U.S. Patent No. 6,284,125, U.S. Patent No. 6,413,410, and U.S. Patent No. 6,733,655. In one such embodiment, the user can administer a self-monitored blood analyte test to obtain an analyte value (e.g., point) using any suitable analyte sensor, and then enter the numeric analyte value into the computer system. In another such embodiment, a self-monitored blood analyte test comprises a wired or wireless connection to the computer system so that the user simply initiates a connection between the two devices, and the reference analyte data is passed or downloaded between the self-monitored blood analyte test and the system. In yet another such embodiment, the self-monitored analyte test is integral with the receiver so that the user simply provides a blood sample to the receiver, and the receiver runs the analyte test to determine a reference analyte value.

[0706] In some alternative embodiments, the reference data is based on sensor data from another substantially continuous analyte sensor such as described herein, or another type of suitable continuous analyte sensor. In an embodiment employing a series of two or more continuous sensors, the sensors can be employed so that they provide sensor data in discrete or overlapping periods. In such embodiments, the sensor data from one continuous sensor can

Abbott Ex. 1003 - 255/1058

be used to calibrate another continuous sensor, or be used to confirm the validity of a subsequently employed continuous sensor.

[0707] In some embodiments, the sensor system is coupled to a blood analysis device that periodically or intermittently collects a sample of the host's blood (e.g., through the sensor system) and measures the host's glucose concentration. In some embodiments, the blood analysis device collects a blood sample from the host about every 30 minutes, every hour, or every few hours (e.g., 2, 3, 4, 5, 6, 8, 9 or 10 hours or longer). In other embodiments, the blood analysis device can be activated manually (e.g., by a healthcare worker) to collect and analyze a blood sample from the host. The glucose concentration data generated by the blood analysis device can be used by the sensor system for calibration data. In some embodiments, the sensor system can electronically receive (either wired or wirelessly) these calibration data (from the blood analysis device). In other embodiments, these calibration data can be entered into the sensor system (e.g., sensor system electronics) by hand (e.g., manually entered by a healthcare worker).

[0708] In some embodiments, the sensor system is provided with one or more calibration solutions (e.g., glucose solutions). In some embodiments, the sensor is shipped in a calibration solution (e.g., soaked). The sensor is activated to calibrate itself (using the calibration solution in which it was shipped) before insertion into the host. In some embodiments, the sensor is shipped (e.g., soaked or dry) with one or more vials of calibration solution. The sensor can be soaked (e.g., sequentially) in the vial(s) of calibration solution; calibration data points collected and the sensor calibrated using those calibration points, before inserting the sensor into the host.

[0709] In one exemplary embodiment, the sensor is a glucose sensor, and it is shipped soaking in a sterile 50 mg/dl glucose solution with two accompanying calibration solutions (e.g., 100 mg/dl and 200 mg/dl sterile glucose solutions). Prior to insertion into the host, calibration data points are collected with the sensor in the 50 mg/dl, 100 mg/dl and 200 mg/dl glucose solutions respectively. The sensor system can be calibrated using the collected calibration data points (e.g., using regression as described in more detail elsewhere herein). In an alternative exemplary embodiment, the sensor is shipped dry (e.g., not soaking in a solution or buffer) with at least one calibration solution, for calibrating the sensor prior to insertion into the host. In some embodiments, a hand held glucose monitor (e.g., SMBG device described

Abbott Ex. 1003 - 256/1058

herein) can test the calibration solutions to generate calibration data points, which are transferred electronically or manually to the sensor system for calibration.

[0710] In some embodiments, a data matching module, also referred to as the processor module, is configured to and/or comprises programming to matches reference data (*e.g.*, one or more reference analyte data points) with substantially time corresponding sensor data (*e.g.*, one or more sensor data points) to provide one or more matched data pairs. One reference data point can be matched to one time corresponding sensor data point to form a matched data pair. Alternatively, a plurality of reference data points can be averaged (*e.g.*, equally or non-equally weighted average, mean-value, median, and the like) and matched to one time corresponding sensor data point to form a matched data pair, one reference data point can be matched to a plurality of time corresponding sensor data points averaged to form a matched data pair, or a plurality of reference data points can be averaged and matched to a plurality of time corresponding sensor data points averaged to form a matched data pair.

[0711] In some embodiments, a calibration set module, also referred to as the calibration module or processor module, is configured to and/or comprises programming to form an initial calibration set from a set of one or more matched data pairs, which are used to determine the relationship between the reference analyte data and the sensor analyte data. The matched data pairs, which make up the initial calibration set, can be selected according to predetermined criteria. The criteria for the initial calibration set can be the same as, or different from, the criteria for the updated calibration sets. In certain embodiments, the number (n) of data pair(s) selected for the initial calibration set is one. In other embodiments, n data pairs are selected for the initial calibration set wherein n is a function of the frequency of the received reference data points. In various embodiments, two data pairs make up the initial calibration set or six data pairs make up the initial calibration set. In an embodiment wherein a substantially continuous analyte sensor provides reference data, numerous data points are used to provide reference data from more than 6 data pairs (*e.g.*, dozens or even hundreds of data pairs). In one exemplary embodiment, a substantially continuous analyte sensor provides 288 reference data points per day (every five minutes for twenty-four hours), thereby providing an opportunity for a matched data pair 288 times per day, for example. While specific numbers of matched data pairs are referred to in the preferred embodiments, any suitable number of matched data pairs per a given time period can be employed.

Abbott Ex. 1003 - 257/1058

[0712] In some embodiments, a conversion function module, also referred to as the conversion module or processor module, is configured to and/or comprises programming to use the calibration set to create a conversion function. The conversion function substantially defines the relationship between the reference analyte data and the analyte sensor data.

[0713] A variety of known methods can be used with the preferred embodiments to create the conversion function from the calibration set. In one embodiment, wherein a plurality of matched data points form the calibration set, a linear least squares regression is used to calculate the conversion function; for example, this regression calculates a slope and an offset using the equation $y=mx+b$. A variety of regression or other conversion schemes can be implemented herein.

[0714] In some alternative embodiments, the sensor is a dual-electrode system. In one such dual-electrode system, a first electrode functions as a hydrogen peroxide sensor including a membrane system containing glucose-oxidase disposed thereon, which operates as described herein. A second electrode is a hydrogen peroxide sensor that is configured similar to the first electrode, but with a modified membrane system (with the enzyme domain removed, for example). This second electrode provides a signal composed mostly of the baseline signal, b.

[0715] In some dual-electrode systems, the baseline signal is (electronically or digitally) subtracted from the glucose signal to obtain a glucose signal substantially without baseline. Accordingly, calibration of the resultant difference signal can be performed by solving the equation $y = mx$ with a single paired measurement. Calibration of the implanted sensor in this alternative embodiment can be made less dependent on the values/range of the paired measurements, less sensitive to error in manual blood glucose measurements, and can facilitate the sensor's use as a primary source of glucose information for the user. U.S. Patent Publication No. US-2005-0143635-A1 describes systems and methods for subtracting the baseline from a sensor signal.

[0716] In some alternative dual-electrode system embodiments, the analyte sensor is configured to transmit signals obtained from each electrode separately (*e.g.*, without subtraction of the baseline signal). In this way, the receiver can process these signals to determine additional information about the sensor and/or analyte concentration. For example, by comparing the signals from the first and second electrodes, changes in baseline and/or

Abbott Ex. 1003 - 258/1058

sensitivity can be detected and/or measured and used to update calibration (*e.g.*, without the use of a reference analyte value). In one such example, by monitoring the corresponding first and second signals over time, an amount of signal contributed by baseline can be measured. In another such example, by comparing fluctuations in the correlating signals over time, changes in sensitivity can be detected and/or measured.

[0717] In some alternative embodiments, the processor module is configured to and/or comprises programming to use a regression equation $y=mx+b$ to calculate the conversion function; however, prior information can be provided for m and/or b, thereby enabling calibration to occur with fewer paired measurements. In one calibration technique, prior information (*e.g.*, obtained from *in vivo* or *in vitro* tests) determines a sensitivity of the sensor and/or the baseline signal of the sensor by analyzing sensor data from measurements taken by the sensor (*e.g.*, prior to inserting the sensor). For example, if there exists a predictive relationship between *in vitro* sensor parameters and *in vivo* parameters, then this information can be used by the calibration procedure. For example, if a predictive relationship exists between *in vitro* sensitivity and *in vivo* sensitivity, $m \approx f(m_{in\ vitro})$, then the predicted m can be used, along with a single matched pair, to solve for b ($b = y - mx$). If, in addition, b can be assumed = 0, for example with a dual-electrode configuration that enables subtraction of the baseline from the signal such as described above, then both m and b are known *a priori*, matched pairs are not needed for calibration, and the sensor can be completely calibrated *e.g.* without the need for reference analyte values (*e.g.* values obtained after implantation *in vivo*.)

[0718] In another alternative embodiment, prior information can be provided to guide or validate the baseline (b) and/or sensitivity (m) determined from the regression analysis. In this embodiment, boundaries can be set for the regression line that defines the conversion function such that working sensors are calibrated accurately and easily (with two points), and non-working sensors are prevented from being calibrated. If the boundaries are drawn too tightly, a working sensor may not enter into calibration. Likewise, if the boundaries are drawn too loosely, the scheme can result in inaccurate calibration or can permit non-working sensors to enter into calibration. For example, subsequent to performing regression, the resulting slope and/or baseline are tested to determine whether they fall within a predetermined acceptable threshold (boundaries). These predetermined acceptable boundaries can be obtained from *in vivo* or *in vitro* tests (*e.g.*, by a retrospective analysis of sensor

Abbott Ex. 1003 - 259/1058

sensitivities and/or baselines collected from a set of sensors/patients, assuming that the set is representative of future data).

[0719] In some alternative embodiments, the sensor system does not require initial and/or update calibration by the host; in these alternative embodiments, also referred to as "zero-point calibration" embodiments, use of the sensor system without requiring a reference analyte measurement for initial and/or update calibration is enabled. In general, the systems and methods of the preferred embodiments provide for stable and repeatable sensor manufacture, particularly when tightly controlled manufacturing processes are utilized. Namely, a batch of sensors of the preferred embodiments can be designed with substantially the same baseline (*b*) and/or sensitivity (*m*) (+/- 10%) when tested *in vitro*. Additionally, the sensor of the preferred embodiments can be designed for repeatable *m* and *b in vivo*. Thus, an initial calibration factor (conversion function) can be programmed into the sensor (sensor electronics and/or receiver electronics) that enables conversion of raw sensor data into calibrated sensor data solely using information obtained prior to implantation (namely, initial calibration does not require a reference analyte value). Additionally, to obviate the need for recalibration (update calibration) during the life of the sensor, the sensor is designed to minimize drift of the sensitivity and/or baseline over time *in vivo*. Accordingly, the preferred embodiments can be manufactured for zero point calibration.

[0720] In some embodiments, a sensor data transformation module, also referred to as the calibration module, conversion module, or processor module, is configured to and/or comprises programming to use the conversion function to transform sensor data into substantially real-time analyte value estimates, also referred to as calibrated data, or converted sensor data, as sensor data is continuously (or intermittently) received from the sensor. For example, the sensor data, which can be provided to the receiver in "counts," is translated in to estimate analyte value(s) in mg/dL. In other words, the offset value at any given point in time can be subtracted from the raw value (*e.g.*, in counts) and divided by the slope to obtain the estimate analyte value:

$$mg/dL = \frac{(rawvalue - offset)}{slope}$$

[0721] In some embodiments, an output module is configured to and/or comprises programming to provide output to the user *via* the user interface. The output is representative of the estimated analyte value, which is determined by converting the sensor data into a

Abbott Ex. 1003 - 260/1058

meaningful analyte value. User output can be in the form of a numeric estimated analyte value, an indication of directional trend of analyte concentration, and/or a graphical representation of the estimated analyte data over a period of time, for example. Other representations of the estimated analyte values are also possible, for example audio and tactile.

[0722] In some embodiments, annotations are provided on the graph; for example, bitmap images are displayed thereon, which represent events experienced by the host. For example, information about meals, medications, insulin, exercise, sensor insertion, sleep, and the like, can be obtained by the receiver (by user input or receipt of a transmission from another device) and displayed on the graphical representation of the host's glucose over time. It is believed that illustrating a host's life events matched with a host's glucose concentration over time can be helpful in educating the host to his or her metabolic response to the various events.

[0723] In yet another alternative embodiment, the sensor utilizes one or more additional electrodes to measure an additional analyte. Such measurements can provide a baseline or sensitivity value for use in calibrating the sensor. Furthermore, baseline and/or sensitivity values can be used to trigger events such as digital filtering of data or suspending display of data, all of which are described in more detail in U.S. Patent Publication No. US-2005-0143635-A1.

[0724] In one exemplary embodiment, the sensor can be calibrated by a calibration solution. For example, after the sensor system has been inserted into the host, a calibration solution can be injected so as to pass across the electroactive surface of the analyte-measuring electrode and the sensor calibrated thereby. For example, the saline drip can be changed to a known IV glucose or dextrose solution (e.g., D50 – a 50% dextrose solution, or D5W – a 5% dextrose solution). In one embodiment, a known volume of D5W is infused into the host at a known rate over a predetermined period of time (e.g., 5, 10, 15 or 20 minutes, or for shorter or longer periods). During and/or after the period of infusion, the sensor measures the signal at the analyte-measuring working electrode. The system, knowing the specifications of the infused calibration solution (also referred to as a calibration information in some embodiments), can calibrate the signal to obtain host's glucose concentration as is appreciated by one skilled in the art. In a further embodiment, two or more glucose or dextrose solutions can be infused, with a corresponding signal being measured during each infusion, to provide additional data for sensor calibration. Calibration can be performed after the sensor has first

Abbott Ex. 1003 - 261/1058

been inserted into the host, after a break-in time, at two or more different levels (high/low), regularly, intermittently, in response to sensor drift/shift, automatically or any other time when calibration is required. In some alternative embodiments, calibration can be determined during sensor break-in, such as described in more detail elsewhere herein.

[0725] In some circumstances, catheters are flushed with saline. For example, the analyte sensor system of the preferred embodiments can be flushed with saline prior to application of control solutions, after which a predetermined amount of glucose solution is flushed by the sensor, as described above, and the sensor is calibrated there from.

[0726] In still another embodiment, a blood sample can be withdrawn from an artery or vein, and used to calibrate the sensor, for example, by using a hand-held glucose meter, by an automatic extracorporeal glucose sensor such as but not limited to in conjunction with an automated bedside clinical chemistry device, or by sending the blood sample to the clinical laboratory for glucose analysis, after which the data is input (e.g., into the electronics associated with the sensor system).

[0727] In some embodiments, the sensor can be calibrated (and/or re-calibrated) during use (after initial calibration), for example, by withdrawing one or more blood samples (also referred to as calibration information in some embodiments), through the catheter (see Figs. 1 and 2) and used for calibration of the sensor, such as by measuring the glucose concentration of the blood sample with an additional system, such as but not limited to a hand-held glucose meter, optical methods or additional electrochemical methods. Blood samples can be withdrawn manually or automatically; additionally or alternatively, blood samples are withdrawn at regular intervals or at selected times, for example, using an extracorporeal blood analysis device as described herein.

[0728] In another embodiment of sensor calibration (and/or re-calibration) during use, a calibration solution (e.g., 40 mg/dL equivalent glucose, D540 or D5W) can be flushed through or by the sensor to enable calibration of the sensor (e.g., at one time, intermittently, or continuously), such as described in more detail above. In these embodiments, calibration solution can be flushed manually or automatically through the system; additionally or alternatively, calibration solution can be flushed at regular intervals or at selected times. In one exemplary embodiment, the system can be provided with a dual lumen, one for saline and another for the control solution. Additionally, the system is configured to automatically switch

Abbott Ex. 1003 - 262/1058

from the saline to control solution and perform the real-time system calibration, and then switch back to the saline solution.

Calibration Systems and Methods for Dual-Electrode Sensors

[0729] As described herein, continuous analyte sensors define a relationship between a sensor-generated signal and a reference measurement that is meaningful to a user (for example, blood glucose in mg/dL). This defined relationship must be monitored to ensure that the continuous analyte sensor maintains a substantially accurate calibration and thereby continually provides meaningful values to a user. Unfortunately, both sensitivity *m* and baseline *b* changes can occur during *in vivo* sensor use, which requires calibration updates (e.g., recalibration). Generally, any physical properties of the sensor or the fluid surrounding the sensor can influence diffusion or transport of molecules through the membrane, and thereby produce fluctuations in sensitivity and/or baseline, which in turn affect the sensor's calibration. These physical properties include, but are not limited to, blockage of sensor surface area due to cells and/or blood clotting at the membrane, biofouling, blood flow/sheer rate, blood pH, temperature, hematocrit, interfering drugs in the host's system, certain metabolic processes, disrupted host electrolyte balance due to disease and/or trauma, thickness and/or components of the sensor's membrane system, and the like.

[0730] In one aspect of the preferred embodiments, systems and methods are provided for measuring changes in sensitivity *m*, also referred to as changes in solute transport or membrane changes, of an analyte sensor implanted in a host over a time period. Preferably, the sensitivity value is a signal obtained by measuring a constant analyte other than the analyte being measured by the analyte sensor. For example, in a glucose sensor, a non-glucose constant analyte is measured, wherein the signal is measured beneath the membrane system on the glucose sensor. While not wishing to be bound by theory, it is believed that by monitoring the sensitivity *m* over a time period, a change associated with solute transport through the membrane system (e.g., diffusion there through) can be measured and used as an indication of a sensitivity change in the analyte measurement. In other words, a membrane monitor is provided, which is capable of monitoring changes in the membrane surrounding an implantable device, thereby enabling the measurement of sensitivity changes of an analyte sensor over time.

[0731] In some embodiments, the analyte sensor is provided with an auxiliary electrode (e.g., a second working electrode) configured as a transport-measuring electrode

Abbott Ex. 1003 - 263/1058

disposed beneath the membrane system. The transport-measuring electrode can be configured to measure any of a number of substantially constant analytes or factors, such that a change measured by the transport-measuring electrode can be used to indicate a change in solute (for example, glucose) transport through the membrane system. Some examples of substantially constant analytes or factors that can be measured include, but are not limited to, oxygen, carboxylic acids (such as urea), amino acids, hydrogen, pH, chloride, baseline, or the like. Thus, the transport-measuring electrode provides an independent measure of changes in solute transport to the membrane, and thus sensitivity changes over time.

[0732] In some embodiments, the transport-measuring electrode measures analytes similar to the analyte being measured by the analyte sensor. For example, in some embodiments of a glucose sensor, water soluble analytes are believed to better represent the changes in sensitivity to glucose over time than non-water soluble analytes (due to the water-solubility of glucose), however relevant information may be ascertained from a variety of molecules. Although some specific examples are described herein, one skilled in the art appreciates a variety of implementations of sensitivity values that can be used as to qualify or quantify solute transport through the membrane of the analyte sensor.

[0733] In one embodiment of a glucose sensor, the transport-measuring electrode is configured to measure urea, which is a water-soluble constant analyte that is known to react directly or indirectly at a hydrogen peroxide sensing electrode (similar to the working electrode of the glucose sensor example described in more detail above). In one exemplary implementation wherein urea is directly measured by the transport-measuring electrode, the glucose sensor comprises a membrane system as described in more detail above, however, does not include an active interference domain or active enzyme directly above the transport-measuring electrode, thereby allowing the urea to pass through the membrane system to the electroactive surface for measurement thereon. In one alternative exemplary implementation wherein urea is indirectly measured by the transport-measuring electrode, the glucose sensor comprises a membrane system as described in more detail above, and further includes an active uricase oxidase domain located directly above the transport-measuring electrode, thereby allowing the urea to react at the enzyme and produce hydrogen peroxide, which can be measured at the electroactive surface thereon.

Abbott Ex. 1003 - 264/1058

[0734] In some embodiments, the change in sensitivity *m* is measured by measuring a change in oxygen concentration and to indicate when recalibration of the system may be advantageous. In one alternative embodiment, oxygen is measured using pulsed amperometric detection on the glucose-measuring working electrode (eliminating the need for a separate auxiliary electrode), such as by switching the applied potential from +0.6mV to -0.6mV. In another embodiment, the auxiliary electrode is configured as an oxygen-measuring electrode. In some embodiments, a third electrode can be configured as an oxygen-measuring electrode. In another embodiment, an oxygen sensor (not shown) is added to the glucose sensor, as is appreciated by one skilled in the art, eliminating the need for an auxiliary electrode.

[0735] In some embodiments, sensitivity changes in an intravascular dual-electrode continuous analyte sensor can be provided *via* a reference sensor, such as an oxygen sensor, as described in the section entitled "Optical Detection." In some embodiments, auto-calibration (e.g., without a manual, external (to the system) reference value) is enabled by exposing the dual-electrode sensor and the reference sensor simultaneously to a reference/calibration solution, whereby reference data is provided for calibration of the sensor data. Advantageously, a dual-electrode continuous analyte sensor is configured to measure baseline *b*, and changes in sensitivity *m* are measured by exposure of the dual-electrode sensor to the reference/calibration solution. In some embodiments, the system is configured for "on demand" auto-calibration, such as *via* configuring the system such that a user can initiate (e.g., command) auto-calibration *via* a user interface (e.g., *via* selection from a menu, pressing a pre-programmed button and the like).

[0736] In some alternative embodiments, sensitivity changes can be used to update calibration. For example, the measured change in transport can be used to update the sensitivity *m* in the calibration equation. While not wishing to be bound by theory, it is believed that in some embodiments, the sensitivity *m* of the calibration of the glucose sensor is substantially proportional to the change in solute transport measured by the transport-measuring electrode.

[0737] It should be appreciated by one skilled in the art that in some embodiments, the implementation of sensitivity values of the preferred embodiments typically necessitate an addition to, or modification of, the existing electronics (for example, potentiostat configuration or settings) of the glucose sensor and/or receiver.

Abbott Ex. 1003 - 265/1058

[0738] In some embodiments, the signal from the oxygen measuring electrode may be digitally low-pass filtered (for example, with a passband of $0\text{-}10^{-5}$ Hz, dc-24 hour cycle lengths) to remove transient fluctuations in oxygen, due to local ischemia, postural effects, periods of apnea, or the like. Since oxygen delivery to tissues is held in tight homeostatic control, this filtered oxygen signal should oscillate about a relatively constant. In the interstitial fluid, it is thought that the levels are about equivalent with venous blood (40 mmHg). Once implanted, changes in the mean of the oxygen signal (for example, > 5%) may be indicative of change in transport through the membrane (change in sensor sensitivity and/or baseline due to changes in solute transport) and the need for system recalibration.

[0739] The oxygen signal may also be used in its unfiltered or a minimally filtered form to detect or predict oxygen deprivation-induced artifact in the glucose signal, and to control display of data to the user, or the method for smoothing, digital filtering, or otherwise replacement of glucose signal artifact. In some embodiments, the oxygen sensor may be implemented in conjunction with any signal artifact detection or prediction that may be performed on the counter electrode or working electrode voltage signals of the electrode system. U.S. Patent Publication No. US-2005-0043598-A1, which is incorporated by reference in its entirety herein, describes some methods of signal artifact detection and replacement that may be useful such as described herein.

[0740] Preferably, the transport-measuring electrode is located within the same local environment as the electrode system associated with the measurement of glucose, such that the transport properties at the transport-measuring electrode are substantially similar to the transport properties at the glucose-measuring electrode.

[0741] In a second aspect the preferred embodiments, systems and methods are provided for measuring baseline, namely non-glucose related electroactive compounds in the host. Preferably the auxiliary working electrode (e.g., second working electrode, non-enzymatic working electrode) is configured to measure the baseline of the analyte sensor over time. In some embodiments, the glucose-measuring working electrode (e.g., first working electrode) is a hydrogen peroxide sensor coupled to a membrane system containing an active enzyme located above the electrode. In some embodiments, the auxiliary working electrode (e.g., second working electrode) is another hydrogen peroxide sensor that is configured similar to the glucose-measuring working electrode however a portion of the membrane system above

Abbott Ex. 1003 - 266/1058

the base-measuring electrode does not have active enzyme therein, such as described in more detail with reference to **Fig. 3D**. The auxiliary working electrode provides a signal substantially comprising the baseline signal, *b*, which can be (for example, electronically or digitally) subtracted from the glucose signal obtained from the glucose-measuring working electrode to obtain the signal contribution due to glucose only according to the following equation:

$$\text{Signal}_{\text{glucose only}} = \text{Signal}_{\text{glucose-measuring working electrode}} - \text{Signal}_{\text{baseline-measuring working electrode}}$$

[0742] In some embodiments, electronic subtraction of the baseline signal from the glucose signal can be performed in the hardware of the sensor, for example using a differential amplifier. In some alternative embodiments, digital subtraction of the baseline signal from the glucose signal can be performed in the software or hardware of the sensor or an associated receiver, for example in the microprocessor.

[0743] One aspect the preferred embodiments provides for a simplified calibration technique, wherein the variability of the baseline has been eliminated (namely, subtracted). Namely, calibration of the resultant differential signal ($\text{Signal}_{\text{glucose only}}$) can be performed with a single matched data pair by solving the following equation:

$$y = mx$$

[0744] While not wishing to be bound by theory, it is believed that by calibrating using this simplified technique, the sensor is made less dependent on the range of values of the matched data pairs, which can be sensitive to human error in manual blood glucose measurements, for example. Additionally, by subtracting the baseline at the sensor (rather than solving for the baseline *b* as in conventional calibration schemes), accuracy of the sensor may increase by altering control of this variable (baseline *b*) from the user to the sensor. It is additionally believed that variability introduced by sensor calibration may be reduced.

[0745] In some embodiments, the glucose-measuring working electrode (e.g., first working electrode) is a hydrogen peroxide sensor coupled to a membrane system containing an active enzyme located above the electrode, such as described in more detail above; however the baseline signal is not subtracted from the glucose signal for calibration of the sensor. Rather, multiple matched data pairs are obtained in order to calibrate the sensor (for example using $y = mx + b$) in a conventional manner, and the auxiliary/second working electrode is used as an indicator of baseline shifts in the sensor signal. Namely, the auxiliary/second working

Abbott Ex. 1003 - 267/1058

electrode is monitored for changes above a certain threshold. When a significant change is detected, the system can trigger a request (for example, from the patient or caregiver) for a new reference glucose value (for example, SMBG), which can be used to recalibrate the sensor. By using the auxiliary/second working electrode signal as an indicator of baseline shifts, recalibration requiring user interaction (namely, new reference glucose values) can be minimized due to timeliness and appropriateness of the requests. In some embodiments, the sensor is re-calibrated responsive to a baseline shifts exceeding a preselected threshold value. In some embodiments, the sensor is calibrated repeatedly at a frequency responsive to the rate-of-change of the baseline.

[0746] In yet another alternative embodiment, the electrode system of the preferred embodiments is employed as described above, including determining the differential signal of glucose less baseline current in order to calibrate using the simplified equation ($y = mx$), and the auxiliary/second working electrode is further utilized as an indicator of baseline shifts in the sensor signal. While not wishing to be bound by theory, it is believed that shifts in baseline may also correlate and/or be related to changes in the sensitivity m of the glucose signal. Consequently, a shift in baseline may be indicative of a change in sensitivity m. Therefore, the auxiliary working electrode is monitored for changes above a certain threshold. When a significant change is detected, the system can trigger a request (for example, from the patient or caregiver) for a new reference glucose value (for example, SMBG), which can be used to recalibrate the sensor. By using the auxiliary (second) signal as an indicator of possible sensitivity changes, recalibration requiring user interaction (new reference glucose values) can be minimized due to timeliness and appropriateness of the requests.

[0747] In yet another alternative embodiment, wherein a dual-electrode analyte system is use, the baseline signal is (electronically or digitally) subtracted from the glucose + baseline signal to obtain a glucose signal substantially without baseline. Accordingly, calibration of the resultant difference signal can be performed by solving the equation $y = mx$ using a sensitivity value (m), which can be obtained from 1) the measured reference (calibrant) solution, b) by pairing a reference analyte signal with a reference analyte value (internal reference sensor example) and/or 3) with a sensitivity value obtained *a priori* (e.g., during sensor manufacture, such as but not limited to by testing in an isotonic solution). Accordingly, calibration of the implanted sensor in this embodiment can be less sensitive or insensitive to

Abbott Ex. 1003 - 268/1058

user error associated with providing external reference measurements, and can facilitate the sensor's use as a primary source of glucose information for the user. However, a single external reference value (e.g., from an external test device such as SMBG and/or YSI testing of a host blood sample) can be used to calibrate the sensor in some embodiments. U.S. Patent Publication No. US-2005-0143635-A1 describes systems and methods for subtracting the baseline from a sensor signal.

[0748] It is noted that, in some embodiments, infrequent new matching data pairs (e.g., auto-calibration, on demand calibration) may be useful over time to recalibrate the sensor because the sensitivity *m* of the sensor may change over time (for example, due to maturation of the membrane that may increase or decrease the glucose and/or oxygen availability to the sensor). However, the baseline shifts that have conventionally required numerous and/or regular blood glucose reference measurements for updating calibration (for example, due to interfering species, metabolism changes, or the like) can be consistently and accurately eliminated using the systems and methods of the preferred embodiments, allowing reduced interaction from the patient (for example, requesting less frequent reference glucose values such as daily or even as infrequently as monthly).

[0749] An additional advantage of the sensor of the preferred embodiments includes providing a method for eliminating signal effects of interfering species, which have conventionally been problematic in electrochemical glucose sensors. Namely, electrochemical sensors are subject to electrochemical reaction not only with the hydrogen peroxide (or other analyte to be measured), but additionally may react with other electroactive species that are not intentionally being measured (for example, interfering species), which cause a change in signal strength due to this interference. In other words, interfering species are compounds with an oxidation or reduction potential that overlap with the analyte being measured. Interfering species such as acetaminophen, ascorbate, and urate, are notorious in the art of glucose sensors for producing inaccurate signal strength when they are not properly controlled. Some glucose sensors utilize a membrane system that blocks at least some interfering species, such as ascorbate and urate. Unfortunately, it is difficult to find membranes that are satisfactory or reliable in use, especially *in vivo,* which effectively block all interferants and/or interfering species (for example, see U.S. Patent No. 4,776,944, U.S. Patent No. 5,356,786, U.S. Patent No. 5,593,852, U.S Patent No. 5,776,324, and U.S. Patent No. 6,356,776).

Abbott Ex. 1003 - 269/1058

[0750] The preferred embodiments are particularly advantageous in their inherent ability to eliminate the erroneous transient and non-transient signal effects normally caused by interfering species. For example, if an interferant such as acetaminophen is ingested by a host implanted with a conventional implantable electrochemical glucose sensor (namely, one without means for eliminating acetaminophen), a transient non-glucose related increase in signal output would occur. However, by utilizing the electrode system of the preferred embodiments, both working electrodes respond with substantially equivalent increased current generation due to oxidation of the acetaminophen, which would be eliminated by subtraction of the auxiliary electrode signal from the glucose-measuring electrode signal.

[0751] In summary, the system and methods of the preferred embodiments simplify the computation processes of calibration, decreases the susceptibility introduced by user error in calibration, and eliminates the effects of interfering species. Accordingly, the sensor requires less interaction by the patient (for example, less frequent calibration), increases patient convenience (for example, few reference glucose values), and improves accuracy (via simple and reliable calibration).

[0752] In another aspect of the preferred embodiments, the analyte sensor is configured to measure any combination of changes in baseline and/or in sensitivity, simultaneously and/or iteratively, using any of the above-described systems and methods. While not wishing to be bound by theory, the preferred embodiments provide for improved calibration of the sensor, increased patient convenience through less frequent patient interaction with the sensor, less dependence on the values/range of the paired measurements, less sensitivity to error normally found in manual reference glucose measurements, adaptation to the maturation of the membrane over time, elimination of erroneous signal due to non-constant analyte-related signal so interfering species, and/or self-diagnosis of the calibration for more intelligent recalibration of the sensor.

[0753] Preferably, a dual-electrode sensor's working electrodes **E1**, **E2** should function identically, with identical sensitivity and/or baseline measurements. However, in some circumstances, small differences in the portions of the membrane at the first and second working electrodes can result in slight differences in membrane sensitivities (m) and/or the baselines (b) signal associated with the working electrodes. While not wishing to be bound by theory, it is believed that such small differences can arise during manufacture, for example,

Abbott Ex. 1003 - 270/1058

when **E1** and **E2** have one or more separate manufacturing steps. Additionally, the compositions of the enzyme domains can be slightly different. For example, an **E1** enzyme domain can be somewhat more hydrophilic than an **E2** enzyme domain manufactured without any added enzyme. In some circumstances, certain characteristics of the blood samples (e.g., pH, certain medicaments in the host's circulatory system, temperature, pO_2) to which the sensor is exposed can, amplify the effects of these differences. In some circumstances, these small differences (between **E1** and **E2**) can contribute to sensor inaccuracies. In preferred embodiments, such sensor inaccuracies can be avoided by use of a scaling factor (k) that is calculated by evaluating the signal response at each of the working electrodes. In some embodiments, the scaling factor is measured *in vitro*, prior to sensor implantation.

[0754] In one preferred embodiment, a scaling factor (k) is calculated by evaluating the signal response after at point at which substantially all of the analyte present in a blood sample should have been used up. **Fig. 3J** is a graph that illustrates exemplary data collected upon exposure of a dual-electrode continuous analyte sensor to a blood sample. The Y-axis represents the signal generated and the X-axis represents time. The top graph is data generated by the plus-enzyme working electrode (e.g., first working electrode, **E1**). The bottom graph is time-corresponding data generated by the minus-enzyme working electrode (e.g., non-enzymatic, second working electrode, **E2**). In general, when the sensor is exposed to a blood sample, the **E1** signal will increase **1302** until substantially all of the available analyte is used up (e.g., at **t1**) by the enzyme at the plus-enzyme working electrode. In general, as with most enzymes, when all of the substrate (e.g., analyte) is used up, the signal should plateau (e.g., line **1306**). However, in spite of the lack of substrate (e.g., analyte) for the enzyme, the signal actually continues to increase a small amount, as is shown by line **1308**. While not wishing to be bound by theory, it is believed that the signal increase **1310** is due to signals caused by non-analyte-related electroactive species, which diffuse through the membrane more slowly than the analyte. This signal increase (line **1304**) is also observed on the non-enzymatic working electrode (e.g., **E2**). Accordingly, the signal response for E2, during the time period of t1 to t2, is the difference between lines **1305** and **1304**. The scaling factor (k, also referred to as the "buildup ratio") can be determined by evaluating the signal response at the two working electrodes (e.g., between $\mathbf{t_1}$ and $\mathbf{t_2}$) using the formula:

Abbott Ex. 1003 - 271/1058

$$k^{Sensor} = \frac{Signal\_response_{Enzyme}}{Signal\_response_{NoEnzyme}}$$

[0755] Accordingly, for the exemplary data shown in **Fig. 3J**, the scaling factor (*k*) is equal to the ratio of the plus-enzyme signal response **1310** to the minus-enzyme signal response **1312**. In a related embodiment, a scaling factor can be calculated by evaluating data generated at the early portion of the curve, soon after the switch from a wash/reference solution (e.g., saline, glucose, etc.) to blood, such as between about 2 second and about 2 minutes after the switch from blood to non-bodily fluid. The scaling factor can then be used to adjust the data (e.g., calibrate) for differences in membrane sensitivities, thereby providing increased sensor accuracy. In some embodiments, the dual-electrode sensor is a glucose sensor. However, dual-electrode sensors can be configured to detect other analytes as described elsewhere herein.

[0756] In some embodiments, the scaling factor can be determined by evaluating the signal responses of the first and second working electrodes **E1**, **E2** during exposure of the sensor to a non-bodily fluid (e.g., saline, reference/calibration solution, hydration fluid, wash fluid, nutritional fluid, medicament, etc.). As described elsewhere herein, an intravascularly implanted dual-electrode analyte sensor can be washed and/or calibrated between exposures to blood samples. To measure the signal response at the working electrodes, the non-bodily fluid can be held stagnant (e.g., substantially not moving) for a period of time (e.g., from **t1** to **t2**). Signal responses at the working electrodes, during the time period, can then be evaluated.

[0757] **Fig. 3K** is a graph that illustrates exemplary data received upon exposure of a dual-electrode sensor to a non-bodily fluid. The Y-axis represents signal generated at the working electrodes and the X-axis represents time. The top graph is data generated by the plus-enzyme working electrode (e.g., first working electrode, **E1**). The bottom graph is time-corresponding data generated by the minus-enzyme working electrode (e.g., non-enzymatic, second working electrode, **E2**). Starting at t=0, the flow of fluid over the dual-electrode continuous analyte sensor is stopped, such that the fluid is substantially stagnant (e.g., not moving). At the first working electrode **E1** (with enzyme), an increasing signal is generated, as is represented by line **1314**. An increasing signal is also generated at the second working electrode **E2** (no enzyme), as is illustrated by line **1316**. The **E1** signal response (**1318**) is the

Abbott Ex. 1003 - 272/1058

difference between lines **1315** and **1314** at **t2**. Similarly, the **E2** signal response (**1320**) is the difference between lines **1317** and **1316** at **t2**. While not wishing to be bound by theory, it is believed that the observed signal response is due to diffusion of non-analyte-related electroactive species through the plus and minus enzyme membrane portions, which are then detected at the working electrodes. The sensor scaling factor can be calculated using the equation described above.

[0758] In some embodiments, to improve sensor accuracy, a scaling factor can be calculated by comparing the signal response of a test sensor ($k^{TestSensor}$) to the signal response of a "perfect sensor" ($k^{PerfectSensor}$), using the following formula:

$$ScalingFactor = \frac{k^{TestSensor}}{k^{PerfectSensor}}$$

[0759] The signal response ($k^{PerfectSensor}$) for a perfect dual-electrode sensor (can be determined empirically by testing a plurality of sensors in the laboratory, such as by using methods known in the art.

[0760] As described in more detail elsewhere herein, useful information (e.g., sensitivity and/or scaling factor) can be extrapolated from periods in which the signal is transient, for example, during sensor break-in and/or during a period of signal artifact (e.g., noise). In some embodiments, the scaling factor is determined during electrochemical break-in of the sensor. Additionally or alternatively, the scaling factor is determined during a period of signal artifact, for example, wherein the flow of fluid across the sensor manipulated (e.g., disrupted) intentionally and/or accidentally (and detected). In one exemplary embodiment, the flow control device of the preferred embodiment is configured to jitter, reciprocate and/or dither in such a way so as to more effectively wash the sensor; in this exemplary embodiment, signal artifact is induced on the signal by the induced flow turbulence, which can be used to obtain useful information by transient analysis of the signal.

[0761] Due to the kinetics of the signal during these transient events, a noise amplitude can be determined for each of the first and second working electrodes of a dual electrode system, and the noise amplitude compared to obtain a scaling factor. In one embodiment, the scaling factor is determined by using a residual analysis, wherein filtered (e.g., smoothed) data is compared to raw data (e.g., in local and/or remote electronics) to obtain a signal residual. In one such embodiment, a signal residual is calculated as the difference

Abbott Ex. 1003 - 273/1058

between the filtered data and the raw data. For example, at one time point (or one time period that is represented by a single raw value and single filtered value), the filtered data can be measured at 50,000 counts and the raw data can be measured at 55,500 counts, which would result in a signal residual of 5,500 counts. In some embodiments, the residuals provide the noise amplitude information, which can be compared to obtain a scaling factor. However, in some embodiments, a stream of residuals (e.g., individual time points during a kinetic period of the signal) for each of the first and second working electrodes are averaged (e.g., using a moving average, or the like), and compared, to provide noise amplitude information for each of the first and second working electrodes, which can be used to define a scaling factor.

[0762] In some embodiments, the manufacturer determines a baseline (e.g., b_{offset}) and/or a scaling factor prior to sensor use in a host, such as but not limited to testing in one or more reference solutions, such as but not limited to an isotonic solution. The prospectively determined baseline (e.g., b_{offset}) and/or scaling factor can be included with the sensor provided to the user, such as by providing a calibration code that can be entered (e.g., manually) into the system electronics, that can be automatically detected by the system electronics upon sensor coupling thereto (e.g., via a detectable memory), and the like, similar to the manufacturer-provided calibration codes for glucose test strips.

[0763] As a non-limiting example, in preferred embodiments, a system for measuring an analyte, wherein differences in first and second working electrodes is accounted for, is provided. In this embodiment, the system includes a continuous analyte sensor, a vascular access device, a receiving module, and a processing module. The continuous analyte sensor is configured for exposure to a host's circulatory system *in vivo*, such as *via* fluidly coupling with a vascular access device in fluid contact with the host's circulatory system. The continuous analyte sensor includes first and second working electrodes **E1**, **E2**. The first working electrode **E1** is disposed beneath an enzymatic portion of a membrane system, wherein the enzymatic portion includes an enzyme for detecting the analyte. For example, if the analyte is glucose, the enzymatic portion includes GOX. If the analyte is cholesterol, the enzyme is a cholesterol-metabolizing enzyme. The second working electrode **E2** is disposed beneath a non-enzymatic portion of the membrane system, which includes either no enzyme or an inactive form of the enzyme. For example, the enzyme can be inactivated by a variety of methods, such as denaturing by heating, UV exposure, treatment with a protease or a

Abbott Ex. 1003 - 274/1058

denaturing chemical, and the like. In some embodiments, the enzyme layer of the membrane system over **E2** (e.g., the electroactive surface) includes another protein, such as BSA or ovalbumin, which is not involved in the metabolism of the analyte.

[0764] The system includes a receiving module configured to receive the signals from the working electrodes (e.g., a first signal from **E1** and a second signal from **E2**). As described elsewhere herein, the first signal is associated with both the analyte and non-analyte related electroactive compounds; the second signal is associated with non-analyte related electroactive compounds. The non-analyte related compounds have an oxidation/reduction potential that substantially overlaps with the analyte's oxidation/reduction potential. Accordingly, if the dual-electrode sensor is configured to detect glucose, **E1** detects a signal having components associated with glucose and non-glucose species that have oxidation/reduction potentials that substantially overlap with the oxidation and/or reduction potential of glucose (sometimes referred to herein as a first oxidation/reduction potential), and **E2** detects a signal related to the non-glucose species that have oxidation/reduction potentials that substantially overlap with the oxidation and/or reduction potential of glucose.

[0765] The system includes a processor module configured to and/or comprising programming that processes the first and second signals and to estimate a scaling factor. As described herein, the scaling factor defines a relationship between the first and second working electrodes (e.g., associated with the measured baseline of each first and second working electrodes). Preferably, the processor module processes the first and second signals using the scaling factor, to thereby obtain a signal (e.g., a glucose value) substantially without contribution due to non-analyte related electroactive compounds. For example, wherein the equation $b=kz$ defines the relationship (scaling factor (k)) between the baseline (b) of the first (enzymatic) working electrode and the baseline z of the second (non-enzymatic) working electrode. A calibration equation (y=mx+b) can be modified to include the scaling factor to calibrate the sensor (y-kz=mx).

[0766] In some preferred embodiments, the system includes a flow control device is configured to meter a flow of a fluid through the vascular access device. In some embodiments, the fluid is a bodily fluid and the flow control device is configured to withdraw a sample of bodily fluid (e.g., blood) from the host such that the sensor is contacted with the bodily fluid. In a further embodiment, the processor module is configured to and/or comprises

Abbott Ex. 1003 - 275/1058

programming that compares steady-state information of the first signal and steady-state information of the second signal. In some embodiments, the fluid is a non-bodily fluid and the flow control device is configured to hold the non-bodily fluid substantially stagnant during a time period, as described herein. In preferred embodiments, the processor module is configured to and/or comprises programming that compares a signal increase on each of the first and second working electrodes during the time period during which the non-bodily fluid is held stagnant, as described herein.

[0767] In preferred embodiments, a method for processing sensor data from a dual-electrode continuous analyte sensor, including estimating a scaling factor (k), is provided. The dual-electrode sensor, as described herein, is configured for *in vivo* exposure to a host's circulatory system. The dual-electrode continuous analyte sensor is applied to the host, such as *via* fluidly coupling the sensor to a fluid flow device. In some embodiments, the sensor is configured for insertion into a catheter or is a part of the catheter, as described above. In some embodiments, the sensor is part of a connecting device, such as a Leur lock, which is fluidly coupled to a catheter at a first end and to the rest of the fluid flow device (e.g., *via* IV tubing), such that blood samples can be withdrawn and contacted with the sensor. After the sensor has been applied to the host, signals from the working electrodes can be received, as described elsewhere herein. A scaling factor, which defines a relationship between a the first and second working electrodes, can be estimated from the received signals, and then the scaling factor can be used to process the signals and thereby to obtain a signal substantially without contribution due to non-analyte related electroactive compounds. In some embodiments, the scaling factor is determined while contacting the sensor with a bodily fluid (see above), such as by comparing steady-state information of the first signal and steady-state information of the second signal. In some embodiments, the scaling factor is determined while contacting the sensor with a substantially stagnant non-bodily fluid, such as by comparing a signal increase on each of the working electrodes during exposure to the substantially stagnant non-bodily fluid.

[0768] While not wishing to be bound by theory, it is believed that determination of a scaling factor as described herein provides a number of advantages. First, sample collection/testing is alternated with calibration and/or washing, sensor calibration is continuous and biofouling is substantially reduced. Since there is little biofouling, the sensor functions more rapidly (e.g., T_{90} is reached more rapidly). Since the sensor is continuously calibrated

Abbott Ex. 1003 - 276/1058

during use (e.g., such that background is removed) the user receives more accurate glucose information/values to be used in making therapeutic decisions. Thus, it is substantially easier and safer for the host to maintain tight control over his or her glucose levels, which can result in a better quality of life and reduced long-term diabetic complications.

[0769] In many circumstances, glucose sensors can be calibrated using data provided either by an analyte testing device separate from the continuous analyte sensor system. For example, points for a continuous glucose sensor, one or more reference data may be provided by testing a blood sample with a hand-held glucose meter or with an YSI glucose test device. However, in some preferred embodiments, a system, including a continuous analyte sensor (single working electrode or dual working electrode), is configured to provide one or more data points, with which the continuous analyte sensor can be calibrated, without the use of a separate (e.g., external to the system) device and/or testing of reference fluids.

[0770] Accordingly, in preferred embodiments, the continuous analyte detection system includes a continuous analyte sensor (e.g., described elsewhere herein) and a reference analyte sensor. The continuous analyte sensor is configured to detect a first signal associated with a test analyte and a second signal is associated with a reference analyte. The reference sensor is configured to generate a reference signal associated with the reference analyte. The test analyte can be any analyte that the sensor is configured to continuously monitor in the host. For example, in some preferred embodiments, the test analyte is glucose. The reference analyte is an analyte other than the test analyte, which is substantially stable within the host. For example, in general, the concentration of the reference analyte (e.g., in the host's circulatory system) does not fluctuate rapidly. In some preferred embodiments, the reference analyte is oxygen (O_2); however, a variety of other analytes can be used. The reference analyte selected is an analyte that can be measured by both the continuous analyte sensor and the reference sensor.

[0771] The continuous analyte sensor can be any type of continuous analyte sensor, including a continuous analyte sensor having a single working electrode or dual-working electrodes. In some embodiments, the continuous analyte sensor is a single working electrode continuous analyte sensor configured to detect glucose, and the first signal is associated with glucose. In this embodiment, the working electrode is configured to detect the second signal (associated with the reference analyte). For example, in some embodiments, the sensor is

Abbott Ex. 1003 - 277/1058

configured to generate a signal associated with glucose when a +0.6mV potential is applied to the sensor. In some circumstances, the sensor can detect another analyte, if a different potential is applied thereto. For example, if a –0.6mV potential is applied, the sensor can detect O_2. Accordingly, in some embodiment, the system is configured to detect both glucose and O_2 (e.g., first and second signals) at the working electrode of the continuous analyte sensor, by switching the potential applied to the sensor. In some embodiments, the continuous analyte sensor includes an auxiliary electrode, which can be configured to detect the reference analyte (second signal), as described herein with reference to "transport-measuring" electrodes.

[0772] In other embodiments, the continuous analyte sensor is a dual-working electrode continuous analyte sensor configured to detect glucose, and the first signal (detected by the working electrode disposed beneath an enzymatic portion of the membrane) is associated with glucose. In some embodiments, the system is configured to detect the second signal (associated with the reference analyte) using the dual-electrode sensor's first working electrode (**E1**, with enzyme) as described above. In other embodiments, the system is configured to detect the second signal (reference analyte) using the dual-electrode sensors second working electrode (**E2**, no enzyme), such as by applying a –0.6mV potential thereto. In this embodiment, the second signal associated with the reference analyte should not be confused with the signal detected by the second working electrode that is associated with non-analyte-related electroactive species that have an oxidation/reduction potential that substantially overlaps with the analyte's oxidation/reduction potential. For example, in some embodiments, the dual-electrode sensor is configured such that when a +0.6mV potential is applied to the second working electrode (**E2**, disposed beneath a non-enzymatic portion of the membrane) the signal generated is associated with the non-analyte-related electroactive species that have an oxidation/reduction potential that substantially overlaps with the analyte's oxidation/reduction potential; then, when a -0.6mV potential is applied to the second working electrode, the second working electrode detects the second signal (associated with the reference analyte).

[0773] In some embodiments, the continuous analyte sensor includes more than two working electrodes disposed beneath the membrane. In one exemplary embodiment, the sensor includes a first working electrode **E1** configured to generate a signal associated with the analyte (the first signal), a second working electrode **E2** configured to generate a second

Abbott Ex. 1003 - 278/1058

signal associated with the reference analyte, and a third working electrode **E3** configured to generate a signal associated with the non-analyte-related electroactive species that have an oxidation/reduction potential that substantially overlaps with the analyte's oxidation/reduction potential. In some embodiments, the sensor can include an additional working electrode (e.g., **E4**, $\mathbf{E_n}$) configured to detect another reference analyte and/or to generate signals associated with non-analyte-related species that have oxidation/reduction potentials that overlap with that of another analyte, the reference analyte, another reference analyte, and the like.

[0774] In preferred embodiments, the reference sensor is not disposed beneath the analyte sensor's membrane and is configured to detect the reference analyte using any means known in the art, such as but not limited to electrochemical, enzymatic, chemical, physical, immunochemical, radiometric, and the like. In some preferred embodiments, the reference sensor is an optical sensing apparatus configured to detect the reference analyte. For example, the reference sensor can be an optical O_2 sensing apparatus configured to use one of a variety of optical detection methods known in the art and a described herein in the section entitled "Optical Detection."

[0775] In preferred embodiments, the system is configured such that the continuous analyte sensor and the reference sensor are disposed in the same local environment and are therefore simultaneously exposed to (e.g., contacted by/with) the sample (e.g., blood). For example, in some embodiments, the system can be configured such that the continuous analyte sensor is a wire sensor configured to extend into a catheter, and the reference sensor comprises an optical fiber that is configured both to detect the reference analyte and to extend into a catheter such that the detecting portion of the reference sensor is adjacent to the sensing portion of the continuous analyte sensor. In another exemplary embodiment, the continuous analyte sensor and the reference sensor are disposed within a connector; such as described in the section entitled "Multi-sensor apparatus." In still another exemplary embodiment, the continuous analyte sensor and the reference sensor are integrally formed on a vascular access device, such as on the *in vivo* portion of a catheter. For example, an optical fiber can be incorporated into the *in vivo* portion of the catheter during manufacture (e.g., such as *via* injection molding techniques known in the art) or by attaching the optical fiber with an adhesive, and subsequent the deposition of the continuous analyte sensor electrodes to the exterior surface of the *in vivo* portion of the catheter, as described herein.

Abbott Ex. 1003 - 279/1058

[0776] In preferred embodiments, the system includes a processor module configured to and/or comprises programming that processes the second signal (associated with the reference analyte) and the reference signal to calibrate the first signal (associated with the analyte). For example, in some embodiments, the processor module uses the reference signal, which is generated by a sensor outside the membrane, to calibrate the second signal (generated under the membrane). Accordingly, shifts in baseline and/or sensitivity, which can arise over time during use of the sensor, are accounted for prior to calibration of the first signal (generated under the membrane). The processor configured to then calibrate the first signal (analyte signal) using the calibrated second signal, which generates a first signal substantially without a non-analyte signal component (and substantially unaffected by shifts in sensitivity (m) and/or baseline (b)).

[0777] As a non-limiting example, in one embodiment, the system includes a continuous glucose sensor configured to detect a first signal associated with glucose and a second signal associated with O_2. The system also includes an optical sensing apparatus configured to detect O_2. The system is configured such that the glucose sensor and the optical O_2 sensing apparatus can be exposed simultaneously to a sample. This method for calibration requires measurement of a second analyte that is already being monitored. For example, optical sensors are almost always used to measure O_2 in the host. In some embodiments, the glucose sensor's first working electrode generates both the analyte signal and the O_2 signal. In some embodiments, an electrode other than the first working electrode (e.g., a second or third working electrode) is configured to generate the O_2 signal. Then the optical O_2 sensor can be used to calibrate the O_2 electrode (of glucose sensor system). Assuming there is a known relationship between the sensitivities of an electrode configured to generate a glucose signal and an electrode configured to generate an O_2 signal, then the sensor's glucose electrode can be calibrated by the O_2 electrode.

[0778] While not wishing to be bound by theory, it is believed that an analyte detection system configured to calibrate the analyte signal using a second/reference analyte provides a plurality of advantages. Primarily, calibration of a system of the preferred embodiments does not require input (manually or automatically) of reference data points from a secondary detection system (e.g., separate from the analyte detection system), such as a hand-held glucose meter. Similarly, no special IV bag, mechanical components or dedicated IV

Abbott Ex. 1003 - 280/1058

lines are required. A wide variety of analytes can be detected by both electrochemical means and a secondary means, such as optical detection methods. All of these advantages conflate to provide highly accurate, "plug-and-play" style continuous analyte detection system that is usable in a wide variety of settings.

INTEGRATED SENSOR SYSTEM

System Overview

[0779] In the hospital environment, such as in Intensive Care Units, patients commonly have multiple access points to their circulatory systems, for drug and fluid infusion, and for each blood sample collection. In such settings, a variety of analytes in the host's blood are regularly monitored, by collection of a blood sample and sending the sample to an on-site laboratory for analysis. This system had serious drawbacks, such as giving slow, non-continuous analyte monitoring results and requiring a lot of hospital staff attention. For example, tight control of glucose levels is critical to patient outcome in a critical care medical setting, especially for diabetic hosts. Maintaining tight glucose control with current technology poses an undue burden to medical personnel, due to time constraints and the extensive patient contact required. Reducing medical staff workload is a key component of improving patient care in this setting. The preferred embodiments disclose systems and methods to automatically and continuously test host analytes at the bedside while reducing and/or minimizing staff-patient interactions. Additionally, the preferred embodiments decrease testing intervals and improve sensor accuracy and reliability.

[0780] **Figs. 6** and **7** illustrate one preferred embodiment of the integrated sensor system **600** (e.g., for use at the bedside), which couples to the analyte sensor **14** (e.g., a glucose sensor) and vascular access device **12** (e.g., a catheter placed in a peripheral vein or artery) described above (see **Figs. 1A-1E**), and which includes at least one fluid reservoir **602** (e.g., a bag of calibration or IV hydration solution), a flow control device **604** (e.g., to control delivery of an infusion fluid **602a** from the reservoir to the host *via* the catheter), a local analyzer **608** and a remote analyzer **610**. In some embodiments, the analyte sensor is configured to reside within the catheter lumen **12a** (see **Figs. 1A-1E**). In some embodiments, the sensor is disposed within the catheter such the sensor does not protrude from the catheter orifice **12b**. In other embodiments, the sensor is disposed within the catheter such that at least a portion of the sensor protrudes from the catheter orifice. In still other embodiments, the sensor is configured to

Abbott Ex. 1003 - 281/1058

move between protruding and non-protruding configurations. The analyte sensor and vascular access device used in the integrated sensor system **600** can be any types known in the art, such as but not limited to analyte sensors and vascular access devices described above, in the sections entitled "Applications/Uses" and "Exemplary Sensor Configurations." For convenience, the vascular access device **12** will be referred to as a catheter herein. However, one skilled in the art appreciates that other vascular access devices can be used in place of a catheter.

[0781] In some embodiments, at least one electronics module (not shown) is included in the local and/or remote analyzers **608**, **610** respectively, for controlling execution of various system functions, such as but not limited to system initiation, sensor calibration, movement of the flow control device **604** from one position to another, collecting and/or analyzing data, and the like. In preferred embodiments, the components and functions of the electronics module can be divided into two or more parts, such as between the local analyzer and remote analyzer, as is discussed in greater detail in the sections entitled "Local Analyzer" and "Remote Analyzer."

[0782] In some embodiments, the flow control device **604** includes one or more valves and is configured to control fluid delivery to the host and sample take-up (e.g., drawing blood back into the catheter until at least the sensor's electroactive surfaces are contacted by the blood). In some embodiments, the sensor **14** dwells within the lumen **12a** of the catheter **12**, as described elsewhere herein. In some embodiments, wherein an internal calibration is performed, an infusion fluid (e.g., calibration solution **602a**) flows over the indwelling sensor **14** and is infused into the host. Generally, analyte in the solution **602a** can be measured when the sensor electroactive surfaces are in contact with the solution **602a**. In some embodiments, the measurements of the solution **602a** can be used to calibrate the sensor **14**. After calibration, the system is configured such that a sample (e.g., blood or other bodily fluid) contacts the sensor's electroactive surfaces (e.g., by drawing blood back into the catheter). When the sample contacts the electroactive surfaces, the sample's analyte concentration can be detected by the sensor **14**. When a sample is drawn back, the sample can then be returned to the host. In some embodiments, the integrated sensor system **600** cycles between calibration (e.g., measurement of a reference calibration solution) and measurement (e.g., of a sample, such as blood, glucose concentration). In some embodiments, the system **600** continues operation in

Abbott Ex. 1003 - 282/1058

this cyclical manner, until the system **600** is either disconnected from the host or turned off for a period of time (e.g., during movement of the host from one location to another). For example, in one embodiment, the system **600** cycles between the calibration and measurement steps from about every 30 seconds or less to about every 2 hours or more. In another embodiment, the system **600** cycles between the calibration and measurement steps of from about every 2 minutes to about every 45 minutes. In still another embodiment, the system **600** cycles between the calibration and measurement steps from about every 1 minute to about every 10 minutes. In some embodiments, the user can adjust the time between steps. In some embodiments, the user can adjust the time between each step. In some embodiments, the system **600** can perform additional steps, such as but not limited to a flushing step, a keep vein open step (KVO), an extended infusion step, and the like. In some embodiments, the time is dependent upon sensors that detect a reference solution (e.g., calibration solution) and/or sample (e.g., blood) at the electroactive surfaces.

[0783] The integrated sensor system **600** of the preferred embodiments provides several advantages over prior art technology. Namely, in preferred embodiments, continuous analyte monitoring is enabled. When the analyte is glucose, continuous glucose monitoring enables tight glucose control, which can lead to reduced morbidity and mortality among diabetic hosts. Additionally, the medial staff is not unduly burdened by additional patient interaction requirements. Advantageously, there is no net sample (e.g., blood) loss for the host, which is a critical feature in some clinical settings. For example, in a neonatal intensive care unit, the host is extremely small and loss of even a few milliliters of blood can be life threatening. Furthermore, returning the body fluid sample to the host, instead of delivering to a waste container greatly reduces the accumulation of biohazardous waste that requires special disposal procedures. The integrated sensor system components, as well as their use in conjunction with an indwelling analyte sensor, are discussed in greater detail below.

Fluids

[0784] Referring to **Figs. 6** and **7**, in preferred embodiments, the integrated sensor system **600** includes at least one reservoir **602** that contains an infusion fluid **602a**, such as but not limited to reference (e.g., calibration), hydration and/or flushing solutions. For simplicity, the infusion fluid **602a** will be referred to herein as a solution **602a**. However, one skilled in

Abbott Ex. 1003 - 283/1058

the art recognizes that a wide variety of infusible fluids can be used in the embodiments discussed herein.

[0785] In some embodiments, the reservoir **602** includes a container such as but not limited to an IV bag. In other embodiments, the reservoir **602** can include two or more IV bags, or any other sterile infusion fluid container. In some embodiments, the reservoir **602** is a multi-compartment container, such as but not limited to a multi-compartment IV bag. If two or more solutions **602a** (e.g., calibration solutions, flush solutions, medication delivery solutions, etc.) are used, the solutions **602a** can be contained in two or more IV bags or in a multi-compartment IV bag, for example. In some embodiments, it is preferred to use a single solution **602a**. Use of a single solution **602a** for calibration, catheter flushing and the like simplifies the system **600** by reducing the complexity and/or number of system **600** components required for system **600** function. In some embodiments, two or more solutions **602a** are preferred, and can be provided by a multi-compartment IV bag or two or more separate reservoirs **602** (e.g., two or more bags, each containing a different solution **602a**). Advantageously, use of multiple solutions **602a** can increase system functionality **600** and can improve sensor accuracy.

[0786] Any infusion fluid (e.g., solution **602a**) known in the art can be used in conjunction with the present system **600**. In some embodiments, the solution **602a** is an analyte-containing solution that can be used as a reference or standard for sensor **14** calibration (generally referred to as a reference and/or calibration solution in the art). In some embodiments, a solution **602a** can be used as a flushing solution, to wash a sample off the sensor **14** and out of the catheter **12**. In some embodiments, two or more solutions **602a** (e.g., having different analyte concentrations) can used to provide two or more calibration measurements. In one exemplary embodiment, the analyte sensor **14** is a glucose sensor, and the solution **602a** contains dextrose or glucose at a concentration of from about 0 mg/dl to about 400 mg/dl. In preferred embodiments, the solution **602a** contains from about 75 mg/dl to about 200 mg/dl glucose. In more preferred embodiments, the solution **602a** contains from about 100 mg/dl to about 150 mg/dl glucose. In some embodiments, the solution **602a** is an isotonic saline solution. In some embodiments, the solution **602a** contains a sufficient concentration of an anticoagulant to substantially prevent blood clotting in and/or near the catheter **14**. In some embodiments, the solution **602a** contains a sufficient concentration of or

Abbott Ex. 1003 - 284/1058

antimicrobial to substantially prevent infection in and/or near the catheter. In one exemplary embodiment, the reservoir **602** is a 500 ml bag containing a sterile solution **602a** including 0.9% sodium chloride in water (e.g., normal saline), 2 IU/ml heparin and 100 mg/dl dextrose. In another exemplary embodiment, the reservoir **602** is a 500 ml bag containing heparinized saline.

[0787] In some embodiments, one, two or more solutions **602a** can be used in conjunction with the integrated sensor system **600**. For example, in some embodiments, two or more calibration solutions **602a** (e.g., solutions with different analyte concentrations) can be used. In one preferred embodiment, the analyte sensor **14** is a glucose sensor and the calibration solution **602a** includes a glucose concentration of from 0 mg/dl to about 300 mg/dl or more. In one exemplary embodiment, a single calibration solution **602a** (e.g., having a 100 mg/dl glucose concentration) can be used. In another exemplary embodiment, two calibration solutions **602a** (e.g., having 100 mg/dl and 0 mg/dl glucose concentrations) can be used. In other exemplary embodiments, three calibration (e.g., 0 mg/dl glucose, 75 mg/dl glucose and 300 mg/dl glucose) solutions **602a** can be used. In still other embodiments, more than three calibration solutions **602a** can be used. In addition to calibration solutions **602a**, non-calibration solutions **602a** can be used in conjunction with the integrated sensor system **600**, such as but not limited to intravenously administered drugs, insulin, enzymes, nutritional fluids, and the like.

[0788] In some circumstances, it is preferred to infuse two or more different solutions (e.g., provided in separate IV bags) to the host through the same IV tubing, while not mixing the solutions in the tubing. In some embodiments, the system is configured to infuse two or more separate solutions without mixing by inserting (e.g., injecting) a small oxygen bubble between the two different solutions as they are released from the IV bags (e.g., when switching from one solution to the other). In some embodiments, alternative gases or a small amount of glycerin is substituted for oxygen. The size of the bubble necessary to separate the two fluids depends in part on the inner diameter of the tubing. For example, a smaller bubble is required when smaller internal diameter tubing is used than when larger internal diameter tubing is used. In some embodiments, the bubble has a volume of from about 1, 3, 5-μl to about 6, 8, 10, 15, 20, 25 or 30-μl or greater. In some embodiments, the bubble is injected at the flow control device. In some embodiments, the system includes a bubble injector.

Abbott Ex. 1003 - 285/1058

[0789] The solution **602a** can be provided to the user in a variety of ways, depending upon local hospital protocol and/or physician preference. In some embodiments, the solution **602a** is supplied pre-mixed (e.g., an IV bag containing sodium chloride, dextrose and heparin), such that fluid reservoir **602** can be connected to an infusion set and infused into the host with minimal effort. In other embodiments, one or more of the solution components **602a** can be provided separately, such that the final solution **602a** is prepared at the host's bedside, at the nurse's station or in the hospital pharmacy, for example. In one exemplary embodiment, the solution **602a** can be provided to the medical staff as a kit including a bag of sterile solution (e.g., water) and injectable sodium chloride, dextrose and heparin aliquots of sufficient quantity to prepare the final solution **602a**. The solution **602a** can be mixed at the bedside or at a location remote from the host, and then applied to the host and to the integrated sensor system **600**. In some embodiments, the reservoir **602** is a 500 ml or 1000 ml bag containing a sterile solution of heparinized saline and 100 mg/dl, 150 mg/dl or 200 mg/dl glucose.

[0790] In various preferred embodiments, the solutions **602a** are administered with standard IV administration lines, such as those commonly used today, such as a sterile, single-use IV set, referred to herein as tubing **606**. In some embodiments, the tubing **606** can be provided with the solution(s) **602a**. While in other embodiments, the tubing **606** can be provided separately from the solution(s) **602a** or other system components. Additional system **600** components that can be provided with the solution(s) **602a** include but are not limited to a sensor **14**, a catheter **12**, tubing **606**, a local analyzer **608**, wires and/or cables for hard-wire connections between system components, and the like.

[0791] In some embodiments, multiple solutions **602a** can be infused through a multi-lumen catheter **12**, such as but not limited to a two-lumen or three-lumen catheter. In some embodiments, the sensor **14** is disposed in one of the catheter's lumens **12a**, through which one or more calibration solutions **602a** can be passed, while other fluids (e.g., hydration fluids, drugs, nutritional fluids) to be delivered to the patient are infused through the other catheter **12** lumens **12a** (e.g., second, third or more lumens).

[0792] In some embodiments, the reservoir **602** is held by a support **612**. The support **612** can take many forms, such as an elevated support. In some embodiments, the support **612** is an IV pole, such those commonly used in medical care facilities. In some

Abbott Ex. 1003 - 286/1058

embodiments, the reservoir **602** is suspended on the support **612**, and the height of the reservoir **602** can be adjusted (e.g., raised or lowered) to modulate solution **602a** discharge from the reservoir **602**.

[0793] In some embodiments, the reservoir **602** and solution **602a** can be provided with one or more system **600** components, such as in a kit. In one exemplary embodiment, a kit including the components to mix the solution **602a** can include an analyte sensor **14** and a standard infusion set (e.g., catheter **12**, cannula, IV tubing **606**, etc.). In other embodiments, a kit can include a premixed solution **602a**, with an analyte sensor **14**. In various embodiments, a kit can contain instructions for use, such as for mixing the solution **602a** and applying it to the integrated sensor system **600**. Advantageously, providing either a pre-mixed solution **602a** or solution components with one or more system **600** components (e.g., sensor **14**, catheter **12**, tubing **606**, local analyzer **608**) can increase efficiency of medical care and provide ease of use to the nursing staff.

Flow Regulators

[0794] Still referring to **Figs. 6** and **7**, in some embodiments, a flow regulator **602b** controls the solution **602a** flow rate from the reservoir **602** to the flow control device **604**, which is described below. A variety of flow regulators can be used with the preferred embodiments, including but not limited to pinch valves, such as rotating pinch valves and linear pinch valves, cams and the like. In one exemplary embodiment, the flow regulator **602b** is a pinch valve, supplied with the IV set and located on the tubing **606** adjacent to and below the drip chamber. In some embodiments, a flow regulator **602b** controls the flow rate from the reservoir **602** to a flow control device **604**, which is described in the section entitled "Flow Control Device." In some embodiments, a flow regulator is optional; and a flow control device **604** controls the flow rate (e.g., from the reservoir **602** to the catheter **14**, described elsewhere herein).

Flow Control Device

[0795] In preferred embodiments, the integrated sensor system **600** includes a flow control device **604**. In some embodiments, the flow control device **604** is configured to regulate the exposure of the sensor **14** to the solution **602a** and to host sample (e.g., blood or other bodily fluid). In some embodiments, the flow control device **604** can include a variety of flow regulating devices, such as but not limited to valves, cams, pumps, and the like. In one

Abbott Ex. 1003 - 287/1058

exemplary embodiment, the flow control device **604** includes a simple linear pinch valve. In another exemplary embodiment, the flow control device **604** includes two or more linear pinch valves. In another exemplary embodiment, the flow control device **604** includes one or more non-linear pinch valves. In another exemplary embodiment, the flow control device **604** includes a global valve. In still another exemplary embodiment, the flow control device **604** includes a gate valve, such as but not limited to a rising stem or non-rising-stem valve. In another exemplary embodiment, the flow control device **604** includes a butterfly valve or a ball valve. In still another exemplary embodiment, the flow control device **604** includes a pump, such as but not limited to volumetric infusion pumps, peristaltic pumps, piston pumps and syringe pumps. In still other exemplary embodiments, the flow control device **604** can be configured to vary the pressure at the reservoir **602**, such as but not limited to a pressure cuff around an IV bag and/or raising/lowering the reservoir adjust head pressure. In some embodiments, the flow control device **604** includes a gravity-fed valve. In still other embodiments, the flow control device **604** is configured to use flow dynamics at the catheter **12**, to regulate exposure to the sensor to solution or sample, as described elsewhere herein. Although some exemplary glucose sensors are described in detail herein, the system **600** can be configured to utilize a variety of analyte sensors including a variety of measurement technologies, such as enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, and the like.

[0796] Referring now to a preferred embodiment wherein the sensor is an enzyme-based sensor, it is known to those skilled in the art that the rate of an enzymatic reaction is temperature dependent. Depending upon the enzyme, temperature reductions generally slow enzymatic reaction rates; temperature increases generally increase reaction rates. Since the analyte sensors **14** described in the preferred embodiment herein depend upon an enzyme (e.g., GOX) to detect the analyte (e.g., glucose) temperature changes during sensor calibration can result in artifacts on the sensor signal. For example, if the solution **602a** temperature is reduced (relative to body temperature), the enzymatic reaction will proceed at a reduced rate (relative to the rate at body temperature), causing the solution's analyte concentration to appear artificially low, which can result in improper sensor calibration. In some circumstances, changes in the relative temperatures of the area of the host's body surrounding the sensor (e.g., the blood contacting the sensor and the flesh surrounding the implanted sensor) and of the

Abbott Ex. 1003 - 288/1058

solution **602a** can be caused by the host moving the implant site, covering (or uncovering) an implant site with a blanket, application of a heating pad or ice to the implant site, and the like. In some circumstances, a high flow rate can cause large temperature fluctuations when the sensor is alternately exposed to blood and solution **602a**. For example, if the flow rate is sufficiently slow, the infusion fluid **602a** can be sufficiently warmed by the body before it contacts the sensor; thus the calibration measurements taken will be made at a temperature substantially similar to the temperature with the test measurements are taken in blood. If the flow rate is too fast, the infusion fluid **602a** will not warm up sufficiently, and the temperature will be too cold when the calibration measurements are taken, which can lead to improper sensor calibration. An improperly calibrated sensor can aberrantly measure the analyte concentration in the sample (e.g., blood from the host). Aberrant readings of sample analyte concentration can lead to improper treatment decisions by the medical staff and/or the host. The effects of temperature on enzymatic reaction rates can be mathematically described using a temperature coefficient. Signal artifacts caused by temperature-related reductions in enzyme reaction rate are referred to herein as temperature coefficient artifacts.

[0797] Generally, the host tissue in which the catheter **12** has been implanted surrounds an *in vivo* portion of the catheter **12**. In preferred embodiments, the flow control device **604** is configured to pass the solution **602a** through the catheter **12** at a rate such that the solution's temperature substantially equilibrates with the temperature of the surrounding host tissue. In one exemplary embodiment, the flow control device **604** maintains a flow rate of from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more. In one exemplary embodiment, the flow rate is from about 0.5 μl/min or less to about 1.5 ml/min or more. In one preferred embodiment, the flow rate is from about 1 μl/min to about 1.0 ml/min. In one exemplary preferred embodiment, the flow rate is from about 0.01 ml/min to about 0.2 ml/min. In another exemplary preferred embodiment, the flow rate is from about 0.05 ml/min to about 0.1 ml/min. Advantageously, since the flow control device **604** infuses the solution **602a** at a rate sufficient to allow substantial temperature equilibration with the surrounding tissue, sensor **14** accuracy is improved and the integrated sensor system **600** has substantially no temperature coefficient artifacts.

Abbott Ex. 1003 - 289/1058

[0798] In some alternative embodiments, a faster flow rate that does not allow for temperature equilibration is preferred. In such circumstances, measurement inaccuracies due to temperature coefficient can be generally eliminated mathematically using b_{offset} and the calibration methods described in the section entitled "Systems and Methods for Processing Sensor Data."

[0799] In some embodiments, sample is taken up into the same catheter lumen **12a** through which the solution **602a** is infused into the host (described elsewhere herein). Thus, it is preferred that mixing of the sample and the solution **602a** is prevented. Similarly, it can be advantageous to detect when the sensor **14** is in contact with undiluted sample and/or undiluted solution. In some preferred embodiments of the integrated sensor system **600**, the flow control device **604** is configured to substantially prevent mixing of two or more fluids, such as but not limited to the solution **602a** and a host sample (e.g., blood). In preferred embodiments, mixing can be substantially prevented by a combination of factors, including specific gravity and flow rate. It is known that two solutions with different specific gravities tend not to mix, provided that the fluids are moved at a sufficiently slow rate (e.g., flow rate). Human whole blood has a specific gravity of about 1.05-1.06, while an infusion solution of 5% dextrose and 0.225% NaCl has a specific gravity of about 1.0189. Due to the difference in specific gravities, a blood sample and the solution **602a** tend to resist mixing within the tubing **606** when the flow rate is sufficiently slow. In preferred embodiments, the sample and the solution **602a** are moved within the catheter lumen **12a** at a rate such that substantially no mixing occurs therebetween. In some embodiments, the flow rate is from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more. In some embodiments, the flow rate is from about 0.01 ml/min to about 1.0 ml/min. In one exemplary embodiment, the flow rate is from about 0.02 ml/min to about 0.35 ml/min. In another exemplary embodiment, the flow rate is from about 0.02 ml/min to about 0.2 ml/min. In yet another exemplary embodiment, the flow rate is from about 0.085 ml/min to about 0.2 ml/min.

[0800] In preferred embodiments, the flow control device **604** can include a variety of fluid flow-regulating devices known in the art. In some embodiments, the flow control device **604** includes one or more valves, such as but not limited to linear and non-linear roller

Abbott Ex. 1003 - 290/1058

valves, linear and non-linear pinch valves, bi-directional valves (either linear or non-linear), peristaltic rollers, cams, combinations thereof, and the like. In some other embodiments, the flow control device **604** is configured to generate sufficient "head pressure" to overcome the host's blood pressure such that the solution **602a** is infused into the host at a controlled rate; this can include elevating the fluid reservoir **602** (e.g., gravity fed) and using a valve to control the fluid flow rate out of the reservoir **602** and into the host. In one exemplary embodiment, the fluid flows at a maximum rate (e.g., about 6.25 ml/hr, 0.1 ml/min) such that a maximum fluid volume of about 150 ml/day can be infused into the host, however ranges much higher and/or lower can be implemented with the preferred embodiments.

[0801] In one exemplary embodiment, the flow control device **604** is a rotating pinch valve that has first and second positions. The valve can move between the two positions, for example, backward and forward, and thereby move fluids in and out of the catheter, as described in the section entitled "Flow Control Device Function." Namely, solution **602a** can be moved from the reservoir **602**, over the electroactive surfaces of the sensor **14** and into the host; and sample can be drawn up from the host, to cover the electroactive surfaces of the sensor **14**, and then pushed back into the host, by movement of the valve between the first and second positions.

[0802] In one exemplary embodiment, the flow control device includes a rotating pinch valve as described with reference to **Figs. 8A** through **8C**. Although **Figs. 8A** to **8C** describe one implementation of a rotating pinch valve that can be implemented with the sensor system, some alternatives include rotating pinch valves with multiple pinch surfaces, for example around the circumference of the rotatable axle (**Figs. 8A-8C**, **804**), which enables the use of one valve for multiple infusion fluids (e.g., using multiple IV lines).

[0803] In some embodiments, the flow control device **604** includes one or more cams that regulate the flow rate. In one embodiment, the flow control device **604** includes a plurality of fixed orifices, which are opened and closed by the cams. As the cams are rotated, the flow increases and/or decreases in response. In one exemplary embodiment, the flow control device **604** includes three openings and three cams that mate with the openings (one cam per opening); fluid can flow through each opening at a given rate, X ml/min. Accordingly, when the cams close all three openings, flow is stopped. When one of the openings is opened, the fluid flows at X ml/min. If two openings are opened, fluid flows at $2X$ ml/min. Similarly,

Abbott Ex. 1003 - 291/1058

when the three openings are opened (e.g., by turning the cams such that they no longer close the openings), the fluid flows at 3*X* ml/min.

[0804] In another example, the flow control device **604** includes a plurality of cams and an equal plurality to tubes **606** passing through the cams, such that each cam can pinch closed the tube **606** that passes through it. In an exemplary embodiment, the cams are arranged such that they pinch and roll the tubing **606**, such that fluid is pushed into the host and sample taken up at pre-determined rates and times. For example, the flow control device **604** can include two cams, each having a tube **606** threaded therethrough. The cams are arranged such that each cam pinches and rolls the tubing **606** passing therethrough to push fluid into the host at one or more rates and to take up a blood sample.

[0805] In yet another example, the flow control device includes a rotating ball valve controlled by a motor, wherein the direction of the ball valve can be utilized to control a variety of functions, such as flow direction of the fluid.

[0806] As described in related herein, the sensor can be calibrated using more than one reference/calibration solution. For example, in some embodiments, the system is configured to calibrate using two reference solutions. In some embodiments, two solutions are used by metering the flow of one solution with the flow control device and intermittently stopping and intermittently manually injecting the second solution such that the solution contacts the sensor a sufficient period of time for calibration measurements to be taken. However, in preferred embodiments, the flow control device is configured to automate such "intermittent" calibrations (e.g., instead of manually injecting the calibration solution into the tubing) by actuating a secondary valve in a time-dependent manner, wherein the secondary valve in configured to meter the second calibration solution. The secondary valve can take on a variety of configurations, such as but not limited to a pinch valve, a ratchet valve, a cam, locking bearings or a ball valve (within the tubing).

[0807] As a non-limiting example, the secondary valve is a pinch valve that includes a ratcheting disk attached to the front of the flow control valve (e.g., *via* an axle), first and second arms, and includes a pin that can engage the tip of the second arm. In some preferred embodiments, the first and second arms are connected to each other by a joint, which includes a biasing means, such as a torsional spring, that pushes the second arm toward the ratcheting disk. The joint includes a stop pin, which limits the distance the second arm can

Abbott Ex. 1003 - 292/1058

move away from the ratcheting disk. The first arm includes a detent (e.g., a finger) that is pressed into the tubing (threaded through the flow control device) by another biasing means configured to push the first arm toward the ratcheting disk. Accordingly, in some embodiments, when the flow control device rotates in the first direction the ratcheting disk is not engaged, and the first arm pinches the tube closed. In other embodiments, when the flow control device rotates in the first direction, the disk rotates with the flow control device such that the tip of the second arm rides up and over the pin of the secondary valve. When the flow control device rotates in the second direction, it is configured to engage the ratcheting disk and has two positions. As the flow control device rotates to the first position, blood is taken up into the catheter. At this point, the flow control device is configured to reverse and rotate in the first direction. However, a portion of the time, the flow control device rotates to the second position. As the flow control device rotates to the second position, the ratcheting disk remains engaged and the disk rotates far enough that the pin (on the disk) engages the tip of the second arm. Accordingly, the second arm is pushed away from the flow control device. The continued movement of the second arm is prevented by the stop pin. Since the second arm must continue to move away from the flow control device /ratcheting disk, the first arm is engaged by the second arm, and the entire structure is pushed away from the flow control device. Accordingly, the pinch on the tubing (e.g., by the detent) is relieved and the fluid in the tubing can flow. After a desired amount of fluid has flowed through the tubing, the pinch of the tubing (by the detent) is reapplied, by moving the flow control device/ratcheting disk in the first direction.

[0808] As another non-limiting example, in some embodiments the flow control device includes a cam configured to control the pinching and un-pinching of the tubing. For example, a cam (e.g., weighted) is attached to the flow control device or another structure (e.g., a ratcheting disk) attached to the flow control device. The tubing is compressed (pinched) by a detent on an arm. The arm has a joint and is biased towards the flow control device via a biasing means. At desired time points, the flow control device is configured to move the cam to a second position (e.g., 180°), such that the arm is pushed upward (e.g., by the cam) and the pinch of the tubing is relieved. When the pinch of the tubing is relieved, the solution can flow through the tubing. The flow control device then returns the cam to its first position, so that the tubing is recompressed (pinched) and fluid flow is stopped.

Abbott Ex. 1003 - 293/1058

[0809] In some embodiments, an electronics module (not shown) is incorporated into the flow control device **604**, to provide local control over flow control device function; in these embodiments, the flow control device function can be transmitted to the local and/or remote analyzer for processing. In other embodiments, a remote analyzer **610** and/or electronics module, such as but not limited to a computer system, controls the flow control device **604**. System **600** components that regulate the flow control device **604** are discussed in greater detail elsewhere herein.

[0810] In a further embodiment, the flow control device **604** is a computer controlled rolling pinch valve that acts on the exterior of sterile tubing **606** in order to control the flow rate of a solution **602a** from an elevated fluid reservoir **602** into the host. In preferred embodiments, the flow control device **604** is configured to pinch and roll a small volume of tubing **606** such that a sample of host blood is drawn up into the catheter **12** (e.g., with a sensor **14** disposed therein) for analyte measurement, and to then push the sample back into the host with a solution (e.g., the calibration solution **602a**). In general, the flow control device **604** is configured to oscillate between drawing up a blood sample and allowing flow of the calibration solution **602a** at a predetermined rate. In some embodiments, the flow control device **604** includes at least one "hard stop" that ensures that the flow control device **604** does not move to a position that could endanger and/or injure the host, such as by draining the IV bag **602** of fluid **602a** or inappropriately (e.g., excessively) withdrawing blood, for example.

Tubing and Catheter

[0811] Referring again to **Figs. 6** and **7**, in preferred embodiments, the integrated sensor system **600** includes tubing **606** (e.g., sterile tubing configured for use in intravascular fluid infusion) and a catheter **12**, to deliver the solution **602a** from the reservoir **602** to the host. Generally, the tubing **606** and catheter **12** are sterile, single use devices generally used in medical fluid infusion, and may be referred to as an "infusion set." An infusion set may include additional components, such as but not limited to a cannula or needle for implanting the catheter, sterilization fluid (e.g., on a gauze pad) for cleaning and/or sterilizing the insertion site (e.g., the host's skin), tape, gauze, and the like. IV tubing is available in a variety of sizes and configurations, which find use in the preferred embodiments. For example, the tubing can be any size internal diameter, such as from about 0.5 mm to about 5 mm internal diameter. In

Abbott Ex. 1003 - 294/1058

various embodiments, the tubing can include a drip chamber and/or one or more access devices, such as but not limited to stopcocks, diaphragms and the like.

[0812] Catheters **12** are available in a variety of sizes and configurations. Catheters **12** for use in conjunction with an analyte sensor **14** are described in detail, elsewhere herein. Briefly, the catheter **12** can be any single- or multi-lumen catheter having a straight or divided tubing connector (e.g., straight-through, single shut off, double shut off, non-spill couplings, valves, T-connectors, Y-connectors, X-connectors, pinch clamps, Leur locks, back-flow valves, and the like). In some embodiment, the catheter is configured for insertion into the venous side of the host's circulatory system. In other embodiments, the catheter is configured for insertion into the arterial side of the host's circulatory system, into either a peripheral or a central artery. In some embodiments, the catheter **12** is configured with an integrally formed sensor **14**. In alternative embodiments, a non-integral sensor **14** is configured for insertion into the catheter **12** after catheter insertion. In some embodiments, the catheter **12** is a single lumen catheter that is configured for infusion of a fluid.

[0813] In another embodiment, the catheter includes at least two lumens (e.g., a dual-lumen catheter), wherein each lumen includes an orifice configured and arranged for fluid communication with the bodily fluid of the host. In some embodiments, the first lumen is configured for fluid infusion and the second lumen is configured for insertion of an analyte sensor. In preferred embodiments, the orifice of the second lumen is located more proximal to the second end of the catheter (e.g., the catheter hub) than the first lumen orifice, such that a bodily fluid drawn back into the second lumen is substantially undiluted by a fluid infused through the first lumen. Accordingly, a sample substantially undiluted by fluid being infused into the host can be drawn back for testing by the analyte sensor located in the second lumen. In this embodiment, the catheter is no longer a "dedicated line" that is dedicated to the analyte sensor. In some embodiments, the catheter includes three or more lumens. During insertion, a cannula or needle can be inserted into one of the catheter's lumens, such that the catheter is substantially supported during the insertion process. For example, in some embodiments, the sensor and dual-lumen catheter can be provided to the user with a cannula pre-inserted into the first lumen and the sensor pre-inserted into the second lumen. After insertion, the cannula is removed (the sensor remains in the second lumen) and IV tubing is connected to the catheter hub. In some embodiments, the catheter, such as but not limited to a dual lumen catheter, is

Abbott Ex. 1003 - 295/1058

formed from an extruded polymer containing an amount of Ag and/or AgCl such that the catheter itself functions as a reference electrode.

[0814] In some preferred embodiments, an indwelling sensor **14** is disposed within the catheter's lumen **12a**. In some embodiments, the catheter **12** and sensor **14** are provided to a user together. In other embodiments, the catheter **12** and sensor **14** are supplied separately. In an alternative embodiment, the catheter **12** is a multi-lumen catheter configured for infusion of two or more solutions. In preferred embodiments, a sensor **14** is disposed within one of the catheter's multiple lumens **12a**. For example, a calibration solution **602a** (e.g., 100 mg/dl glucose in saline) can be infused through the lumen **12a** in which the sensor **14** is disposed, while a hydration fluid (e.g., including a medication) can be infused through a second lumen. Advantageously, a dual lumen catheter **12** allows non-interrupted system use while other fluids are concurrently provided to the host.

[0815] In some embodiments, only the working electrode(s) of the sensor **14** are disposed within the catheter lumen **12a** and the reference electrode is disposed remotely from the working electrode(s). In other embodiments, the sensor **14** is configured to intermittently protrude from the catheter lumen **12a**.

[0816] Referring now to **Figs. 10A-10D**, in some embodiments, the flow control device and the IV tubing (e.g., the tubing set) are configured and arranged to releasably mate in a specific orientation. In some embodiments, the flow control device (e.g., the valve **604**) and the tubing (referred to herein as a "tubing assembly" **606a** or a tubing set) are configured and arranged for uni-directional tubing installation (e.g., the tubing can be installed in only one direction). For example, the tubing assembly shown in **Figs. 10A-10D** includes first and second connector ends **606c**, **606d** joined by a central portion of tubing **606b**. The central portion of tubing is sufficiently elastic that the tubing assembly can be stretched during installation into the valve. For example, the tubing assembly is held by the first and second ends **606c**, **606d** during insertion into grove **803** of the valve. After the tubing is installed in the groove, the first and second ends are released, allowing the central portion to relax into a less-stretched configuration. In some embodiments, the valve and/or tubing (e.g., the central portion) are configured and arranged such that the tubing is in a stretched state (e.g., elongated configuration) after installation. For example, the tubing can be slightly shorter than the distance from one end of the valve to the other (e.g., the longitudinal length of the groove). In

Abbott Ex. 1003 - 296/1058

some embodiments, the tension created by the remaining stretch in the central portion helps to hold the tubing assembly in place during valve operation. Advantageously, uni-directional tubing installation can enable alignment of tubing components with specific valve components, such that the aligned tubing and valve components can function together, such as described in the section entitled "Free Flow Mitigation."

[0817] In further embodiments, the valve and tubing (e.g., tubing assembly **606a**) are configured and arranged to form a mechanical interlock when mated. Advantageously, the mechanical interlock can reinforce and/or enable uni-directional tubing installation and/or help to maintain the installation of the tubing within the valve during valve operation. The mechanical interlock includes releasably engageable first and second portions; namely, the valve comprises the first portion **809** (described elsewhere herein) of the mechanical interlock and the tubing assembly comprises the second portion (e.g., the second end **606d** of the tubing assembly **606a**) of the mechanical interlock. For example, in **Figs. 10A** and **10B**, the bottom portion **606d** of the tubing assembly **606a** is configured as a male connector (e.g., including wings, fins, detents, fingers, etc.) configured to releasably mate with a female interconnection **809** on the valve. For example, in the embodiment illustrated in **Fig. 10A**, the bottom portion **606d** of the tubing assembly includes a male interconnection (e.g., a key) having a rectangular body and an optional female portion of a Leur connector (e.g., for releasably mating with the male Leur connector of IV tubing); the valve's interlocking female interconnection (e.g., a lock) includes a rectangular receptacle sized to receive the male interconnection, including a cylindrical indentation (e.g., a concave groove or well) sized and/or shaped to receive the optional Leur connector of the bottom portion. As another example, in the embodiment illustrated in **Fig. 10B**, the bottom portion **606d** of the tubing assembly includes fins having curved edges. Advantageously, the mechanical interlock, of the tubing assembly and the valve, prevents twisting (e.g., rotational movement) of the tubing assembly within the valve.

[0818] In some embodiments, the configuration of an interconnection (e.g., the male interconnection of the tubing assembly and/or the female interconnection of the valve) is associated with a specific flow profile. For example, a first interconnection configuration is associated with a first flow profile; a second interconnection configuration is associated with a second flow profile; and so on. In a further embodiment, the interconnection and/or flow profile is associated with a specific system configuration, such as for use in a specific

Abbott Ex. 1003 - 297/1058

circumstance. For example, the system can be configured for uses in pediatric and/or adult hosts. Each type of host has a set of requirements associated with the system configuration. For example, a pediatric host is much smaller than an adult host, and thus may require a smaller catheter/fluid coupler and analyte sensor and slower infusion relative to an adult host. In some embodiments, the system is configured to recognize an interconnection (e.g., the configuration) and to use (e.g., program, select) the flow profile associated with the recognized interconnection. In some embodiments, the interconnection is mechanical. In other embodiments, the interconnection includes an electronic component, such as but not limited to an RFID chip located in the tubing assembly (e.g., in the male interconnection of the mechanical interlock) that is detected by the flow control device.

[0819] As is described elsewhere herein, the valve is configured and arranged for at least two fluid flow positions, namely a gravity flow (also referred to as free flow) position and a controlled flow position. For example, in some embodiments, the valve is configured and arranged such that the tubing is substantially straight in the gravity flow position and the tubing is substantially non-linear in the controlled flow position. In general, the position of the valve, including its direction and rate of movement, is associated with (e.g., corresponds to) the flow position, which in turn is associated with (e.g., corresponds to) a flow rate. **Fig. 10C** illustrates the gravity flow valve position, which corresponds to a valve position in which the valve is substantially open (e.g., the tubing **606b** of the tubing assembly is not substantially pinched), such that the infusion fluid can flow freely through the valve. In some embodiments, the gravity flow position comprises a flow rate of at least about 600 ml/hr (e.g., 10-ml/min). In contrast, the controlled flow position (e.g., **Fig. 10D**) includes a pinch **808** in the tubing **606b** and movement of the pinch in the tubing (e.g., by the valve), such that the rate of fluid flow (e.g., including flow direction) is controlled by the valve. In some embodiments, the controlled flow position provides a flow rate of from about 0.001, 0.002, 0.003, 0.003, 0.004, 0.005, 0.006, 0.007, 0.008 or 0.009-ml/min or less to about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1-ml/min or more. In some embodiments, the controlled flow position provides a flow rate from about 0.006, 0.007, 0.008, 0.009, 0.01, or 0.02-ml/min to about 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09 or 0.1-ml/min. In some embodiments, the controlled flow position provides a flow rate from about 0.5-ml/hr to 4-ml/hr. Accordingly, in preferred embodiments, the valve is configured and arranged to

Abbott Ex. 1003 - 298/1058

preclude tubing installation when the valve is in a controlled flow position. Preferably, the tubing is installed when the valve is in a gravity flow position (e.g., **Fig. 10C**), wherein the valve is positioned such that the tubing can be installed in a substantially straight (e.g., linear, un-pinched) configuration.

[0820] In preferred embodiments, the vascular access device (e.g., the catheter and/or fluid coupler) and the tubing **606** (e.g., tubing assembly **606a**) are configured and arranged to substantially preclude twisting (e.g., rotational movement) between the vascular access device and the tubing when engaged (e.g., fluidly connected, in fluid communication with each other). Accordingly, in some embodiments, the interconnecting portions of the vascular access device and the tubing include a mechanical structure configured to prevent rotational movement of the connection past a predetermined point. For example, the interconnection of the vascular access device and the tubing includes a Leur lock, wherein the vascular access device includes the female portion of the Leur connection and the tubing includes the male portion of the Leur connection. In one embodiment, the female portion of the Leur connector includes a groove configured to mate with a detent on the male portion of the Leur connector, such that the male portion can be rotated within the female portion only until the detent enters the groove. In one embodiment, additional mechanisms for prevent twisting between the vascular access device and the tubing are contemplated in the preferred embodiments.

Free Flow Mitigation

[0821] As described herein, the valve includes a gravity flow valve position, which allows fluid to flow freely through the valve and into the host. In preferred embodiments, the system is configured to regulate the amount of fluid allowed to flow into the host, since unregulated flow (e.g., free flow) of IV solution into the host could be deleterious to the host's health. For example, if the IV solution contained a drug, such as insulin or heparin, infusion of too much IV solution could cause an unsafe drop in blood sugar or an unsafe decrease in the host's ability to form blood clots, respectively. However, in certain circumstances, such as a power failure, the system can be inadvertently stopped in the gravity flow valve position. Accordingly, to prevent unregulated flow (e.g., free flow) of fluid into the host, such as in the event of a power failure and/or related circumstances, in preferred embodiments, the system includes a free flow mitigation device biased in an occluded position. In some embodiments,

Abbott Ex. 1003 - 299/1058

the system is configured and arranged such that the free-flow mitigation device precludes flow through the tubing responsive to power removal and/or loss of power to the system and/or flow control device. In some embodiments, the free flow mitigation device **606e** is incorporated into the tubing assembly **606a**, such that flow through the tubing is blocked until the valve activates (e.g., opens) the free flow mitigation device. In one exemplary embodiment, the free flow mitigation device **606e** is a spring-clip occluder that closes (e.g., blocks, pinches, occludes) the tubing until it is activated. For example, in some embodiments, the valve includes an electronic solenoid **807** that is configured and arranged to activate the spring-clip occluder (e.g., causes the spring-clip occluder to open, such that fluid can flow through the tubing, biases the free flow mitigation device in an un-occluded position), when the tubing is installed in the valve. In preferred embodiments, the free flow mitigation device **606e** is located within the tubing **606a** such that the free flow mitigation device is aligned with the portion of the valve that activates it. For example with reference to **Fig. 10A**, the valve includes an electronic solenoid **807** located along grove **803**, such that (when the tubing assembly is installed) the spring-clip occluder **606e** is aligned with the electronic solenoid. In preferred embodiments, the electronic solenoid is configured and arranged such that free flow mitigation device returns to the occluded position (e.g., blocks free flow) responsive to power removal, such as during a power failure, during installation of the tubing into the valve (e.g., at the beginning of a sensor session), turning the system off (e.g., at the end of use and/or of a sensor session), and the like. Preferably, the system is configured and arranged for electronic control of the free flow mitigation device. For example, in preferred embodiments, the valve controls the flow of fluid into the host and drawback of samples for testing, according to a flow profile (described elsewhere herein). In preferred embodiments, the system is configured to electronically control the opening and closing of the free flow mitigation device (e.g., by energizing and de-energizing the solenoid) in response to the flow profile. For example, when the flow profile specifies infusion into the host or sample drawback, the system electronically activates the solenoid, which in turn biases the free flow mitigation device in the open position, so that the fluid can be infused, samples can be drawn back to the analyte sensor, samples can be returned to the host, the analyte sensor can be washed with infusion solution, drugs can be infused, and the like. Some free flow mitigation devices suitable for use with the present

Abbott Ex. 1003 - 300/1058

system can be found in U.S. Patent No. 5,810,323, U.S. Patent No. 6,142,979, and U.S. Patent No. 6,749,591, all of which are incorporated by reference herein in their entirety.

Sample-Contacting Sensor

[0822] In preferred embodiments, the integrated sensor system **600** is configured such that at least the sensor's electroactive surfaces can be exposed to a sample and the sample's analyte concentration can be detected. Contacting the sensor **14** with the sample can be accomplished in a variety of ways, depending upon sensor and/or catheter configuration. A wide variety of catheter **12** and/or sensor **14** configurations can be implemented in the preferred embodiments, to expose the sensor's electroactive surfaces to a biological sample. In one exemplary embodiment, the catheter **12** is disposed in the host's peripheral vascular system, such as in a peripheral vein or artery, and a blood sample is taken up into the catheter **12** such that the blood contacts the sensor's electroactive surfaces. In another exemplary embodiment, the catheter **12** can be disposed in the host's central vascular system or in an extracorporeal blood flow device, such as but not limited to an arterial-venous shunt, an extravascular blood-testing apparatus, a dialysis machine and the like, wherein blood samples can be taken up into the catheter **12** such that at least the sensor's electroactive surfaces are contacted by the drawn up blood sample.

[0823] In one exemplary embodiment, the sensor **14** is configured to reside within the catheter lumen **12a** (e.g., not protrude from the catheter tip); and the integrated sensor system **600** is configured to draw back a sample into the catheter lumen **12a** such that at least the sensor's electroactive surfaces are contacted by the sample. In some embodiments, the sensor **14** is a small-structured sensor having a width of less than about 1 mm. In one preferred embodiment, the sensor has a width of less than about 0.4 mm. In a more preferred embodiment, the sensor has a width of less than about 0.2 mm. In some embodiments, the catheter **12** has an internal diameter of from about 0.2 mm or less to about 2.0 mm or more, preferably from about 0.5 mm to about 1.0 mm. In some embodiments, the sensor **14** is configured such that its electroactive surfaces are at or adjacent to its tip, and the flow control device **604** is configured to take up sample into the catheter lumen **12a** until the sample covers at least the electroactive surfaces. In some embodiments, the electroactive surfaces are distal from the sensor's tip and sample is drawn farther back into the catheter lumen **12a** until the

Abbott Ex. 1003 - 301/1058

sample covers the electroactive surfaces. In some embodiments, the tip of the sensor is disposed about 3 cm, 2 cm, or 1 cm or less from a tip of the catheter.

[0824] In some embodiments, the sample taken up into the catheter's lumen **12a** covers only a portion of the sensor's *in vivo* portion. In other embodiments, the sample taken up into the catheter's lumen **12a** covers the entire *in vivo* portion of the sensor **14**. In some embodiments, a sample volume of from about 1 µl or less to about 2 ml or more is taken up into the catheter **12** and is sufficient to cover at least the electroactive surfaces of the sensor **14**. In some preferred embodiments, the sample volume is from about 10 µl to about 1 ml. In some preferred embodiments, the sample volume is from about 20 µl to about 500 µl. In other preferred embodiments, the sample volume is from about 25 µl to about 150 µl. In more preferred embodiments, the sample volume is from about 2 µl to about 15 µl.

[0825] In preferred embodiments, the sample taken up into the catheter's lumen **12a** remains within the *in vivo* portion of the catheter **12**. For example, in some embodiments, the sample is not drawn so far back into the catheter **12** that it enters the *ex vivo* portion of the catheter **12**, the tubing **606** or the reservoir **602**. In some embodiments, however, the sample can be drawn back as far as the catheter but not into the IV tubing. In some embodiments wherein the catheter **12** is implanted in a host, the blood sample never leaves the host's body (e.g., a plane defined by the host's skin). In some embodiments wherein the catheter **12** is implanted in an extracorporeal device, the sample does not substantially exit the extracorporeal device. In preferred embodiments, wherein blood is taken up into the catheter **12**, the blood is returned to the host (or extracorporeal device), which is described elsewhere herein. In preferred embodiments, the sample is blood taken up from the host's circulatory system and into the catheter **12** disposed within the circulatory system.

[0826] In another exemplary embodiment of the integrated sensor system, the sensor is configured to protrude from the catheter's orifice **12b**, at least intermittently. In preferred embodiments, the sensor is configured to protrude sufficiently far out of the catheter's lumen **12a** (e.g., into the circulatory system proper) that the sensor's electroactive surfaces are contacted by sample (e.g., blood). In a further embodiment, the sensor is configured to intermittently protrude from the catheter orifice **12b**, such as by moving back and forth, such that the electroactive surfaces are alternately disposed within the catheter **12** and outside of the catheter **12**. In one exemplary embodiment of a catheter is implanted in a

Abbott Ex. 1003 - 302/1058

host's vein, calibration solution **602a** is provided within the catheter **12** such that the sensor **14** is disposed within the catheter **12**, the sensor **14** is contacted by the calibration solution **602a** and calibration measurements can be obtained periodically, when the sensor **14** (e.g., electroactive surfaces) is moved outside of the catheter **12**, the sensor **14** is contacted by blood and blood analyte measurements can be obtained.

[0827] In some embodiments of the integrated sensor system **600**, the catheter **12** and sensor **14** are configured to take advantage of flow dynamics within the host's vascular system. By taking advantage of flow dynamics, the system can be simplified, such that the flow control device functions mainly to allow or block the flow of calibration solution.

[0828] **Fig. 9** is a cut-away illustration of one exemplary embodiment, in which a catheter **12** is implanted in a host's vessel **906**, such as but not limited to an artery or vein. The catheter **12** includes a sidewall **904** that can be configured to include one or more holes **902** (e.g., orifices or openings configured for fluid passage, such as from the exterior sidewall surface into the catheter lumen **12a**). The catheter **12** can be inserted into the host's vein (or artery, or an extracorporeal circulatory device) such that the catheter points either in the direction of blood flow (antegrade) or against the direction of blood flow (retrograde). The catheter is configured such that in an antegrade position, blood flows into the catheter lumen **12a** *via* the holes **902** and then out of the catheter orifice **12b**. In a retrograde position, blood enters the catheter lumen **12a** *via* the catheter orifice **12b** and flows out of the lumen through the holes **902**. In some embodiments, the sensor **14** can be disposed within the catheter lumen **12a** such that blood flowing between the holes **902** and the orifice **12b** contacts at least the sensor's electroactive surfaces. In some embodiments, the sensor **14** is configured to be substantially immobile within the lumen **12a**, while in other embodiments the sensor **14** is configured to be substantially moveable within the lumen **12a**, as described in more detail elsewhere herein.

[0829] Generally, the holes **902** can be placed in any location on the catheter's sidewall **904**. In some embodiments, the holes **902** can be located near or adjacent to the catheter orifice **12a**. In other embodiments, the holes **902** can be placed remotely from the catheter orifice **12a**. The size, shape and number of holes **902** can be selected to optimize the sample volume and flow rate through the catheter lumen **12a**. For example, in some embodiments, the holes **902** are round, ellipsoid, rectangular, triangular, star-shaped, X-

Abbott Ex. 1003 - 303/1058

shaped, slits, combinations thereof, variations there of, and the like. Similarly, in some embodiments, the catheter **12** can have from 1 to about 50 or more holes **902**. In other embodiments, the catheter can have from 2 to about 10 or more holes **902**.

[0830] In some alternative embodiments, the catheter includes at least one size wall orifice in place of an end tip orifice, which allows selective exposure of the sensor to the host's biological sample there through. A variety of alternative catheter configurations are contemplated in conjunction with the preferred embodiments.

[0831] In one exemplary embodiment of the integrated sensor system **600**, the flow control device **604** is configured to intermittently block the infusion of solution **602a** through the catheter **12**, which is configured with side holes **902** as described above. Additionally, the analyte sensor is disposed within the catheter lumen **12a** such that sample passing between the side holes **902** and the catheter orifice **12b** bathes the sensor's electroactive surfaces, during which time an analyte measurement can be obtained. When the flow control device **604** does not block infusion, the solution **602a** contacts the sensor's electroactive surfaces; and calibration measurements can be taken.

[0832] In some embodiments, a solution **602a** can be infused into the catheter **12** at a rate such that the flow of sample between the holes **902** and the orifice **12b** is substantially blocked and at least the electroactive surfaces are bathed in the solution **602a** (e.g., undiluted solution). In preferred embodiments, the sensor **14** can be calibrated while it is bathed in the undiluted solution **602a**.

[0833] In preferred embodiments, the sensor **14** is a small-structured sensor with at least one electrode, such as a working electrode, as described elsewhere herein. In some embodiments, the sensor **14** has two or more electrodes, such as but not limited to working, reference and counter electrodes. In some embodiments, the sensor **14** includes a reference electrode disposed remotely from the working electrode, as discussed elsewhere herein. In some embodiments, the sensor **14** includes two or more electrodes that are separated by an insulator, such as described in U.S. Patent Publication No. US-2007-0027385-A1, herein incorporated by reference in its entirety. In preferred embodiments, the electrode is a fine wire, such as but not limited to a wire formed from platinum, iridium, platinum-iridium, palladium, gold, silver, silver chloride, carbon, graphite, gold, conductive polymers, alloys and the like. In some exemplary embodiments, the sensor **14** includes one or more electrodes formed from

Abbott Ex. 1003 - 304/1058

a fine wire with a diameter of from about 0.001 or less to about 0.010 inches or more. Although the electrodes can by formed by a variety of manufacturing techniques (bulk metal processing, deposition of metal onto a substrate, and the like), it can be advantageous to form the electrodes from plated wire (*e.g.*, platinum on steel wire) or bulk metal (*e.g.*, platinum wire). It is believed that electrodes formed from bulk metal wire provide superior performance (*e.g.*, in contrast to deposited electrodes), including increased stability of assay, simplified manufacturability, resistance to contamination (*e.g.*, which can be introduced in deposition processes), and improved surface reaction (*e.g.*, due to purity of material) without peeling or delamination.

[0834] In some embodiments, one or more electrodes are disposed on a support, such as but not limited to a planar support of glass, polyimide, polyester and the like. In some exemplary embodiments, the electrodes include conductive inks and/or pastes including gold, platinum, palladium, chromium, copper, aluminum, pyrolitic carbon, composite material (e.g., metal-polymer blend), nickel, zinc, titanium, or an alloy, such as cobalt-nickel-chromium, or titanium-aluminum-vanadium, and are applied to the support using known techniques, such as but not limited to screen-printing and plating. Additional description can be found in U.S. Patent No. 7,153,265, U.S. Patent Publication No. US-2006-0293576-A1, U.S. Patent Publication No. US-2006-0253085-A1, U.S. Patent No. 7,003,340, and U.S. Patent No. 6,261,440, each of which is incorporated in its entirety by reference herein.

[0835] In some embodiments, an optional redundant sensor can be disposed within the catheter lumen, in addition to the sensor **14** described elsewhere herein. In one exemplary embodiment, a sensor **14** and a redundant sensor are disposed within the lumen of a sensor implanted in a host's peripheral vein, such that the electroactive surfaces of the sensor **14** are more proximal to the catheter orifice **12b** than the electroactive surfaces of the redundant sensor; wherein blood is taken up into the lumen **12a** such that the electroactive surfaces of both the sensor **14** and the redundant sensor are contact by the blood; such that analyte can be detected by both the sensor **14** and the redundant sensor and the redundant sensor measurements are used by the system **600** to confirm the sensor's **14** measurements. In a further embodiment, both the sensor **14** and the redundant sensor are intermittently concurrently contacted by the solution **602a** such that both the sensor **14** and the redundant sensor can take calibration measurements of the solution **602a**, wherein the calibration measurements of the redundant sensor are at least used to confirm the calibration

Abbott Ex. 1003 - 305/1058

measurements of the sensor **14**. In another embodiment, the calibration measurements from both the sensor **14** and the redundant sensor are used to calibrate the sensor **14**.

Local Analyzer

[0836] Referring to **Figs. 6** and **7**, in some embodiments, the integrated sensor system **600** includes a local analyzer **608** configured to operably connect to a remote analyzer **610**. In some embodiments, the local analyzer **608** is proximal to an analyte sensor **14** and the remote analyzer **610** is configured to operably connect to the local analyzer. However, alternative configurations are possible, such as the analyte sensor **14** can be operably connected to both the local and remote analyzers **608**, **610** respectively. The remote analyzer **610** of the preferred embodiments is discussed below. In various embodiments, one or more functions of the local analyzer **608** can be transferred to the remote analyzer, as is appreciated by one skilled in the art. Likewise, in some embodiments, one or more functions of the remote analyzer **610** can be incorporated into the local analyzer **608**. In further embodiments, functions of the local and/or remote analyzers **608**, **610** can be disposed in one, two, three or more physical bodies (e.g., separate housings), depending upon the integrated sensor system **600** configuration and/or component combinations. For example, in one embodiment, the local analyzer **608** includes a potentiostat, a power source (e.g., battery or connection to an electrical source), and data storage; and the local analyzer **608** is configured such that the potentiostat is disposed on the sensor's fluid coupler **20** and the remaining local analyzer **608** components are disposed elsewhere between the local analyzer **608** and the remote analyzer **610** (e.g., connected by wiring).

[0837] Operable connections between the local and remote analyzers **608**, **610** and the analyte sensor **14** can be accomplished by a hard wire (e.g., USB, serial), RF communication, IR communication, and the like. In some embodiments, operable connections include a connector known in the art, such as but not limited to mating plug and socket units, screw connectors, clips and the like. In some embodiments, the connectors are separable. In other embodiments, the connectors are inseparable. In some embodiments, the connectors include a lock, to prevent inadvertent disconnection. In some embodiments, the local analyzer can be isolated from the remote analyzer by an isolation transformer.

[0838] In some embodiments, the local analyzer **608** is operably connected to the sensor **14** (e.g., the sensor electrode(s)), such as by a wire connection. A detailed description

Abbott Ex. 1003 - 306/1058

of electronic components and configurations is described elsewhere herein, for example, in the section entitled "Sensor Electronics." In some embodiments, the local analyzer **608** is disposed on or adjacent to the sensor, such as on the sensor fluid coupler **20**. In one exemplary embodiment, the sensor's fluid coupler **20** includes a local analyzer housing that includes at least a potentiostat. In some embodiments, the housing can include a battery and electronics, such that the sensor **14** can be powered, and data can be collected and/or transmitted to additional system electronics (e.g., electronics units disposed remotely from the sensor, such as on the host's arm, on the host's bed and in the remote analyzer, and the like). In some embodiments, the local analyzer **608** includes a small housing that is connected to the sensor **14** *via* a short wire (e.g., from about 1 cm or less to about 10 cm or more) and is taped to the host's skin, such as adjacent to the catheter's insertion site on the host's arm or hand. In a further embodiment, the local analyzer **608** includes a connector, such as but not limited to a "plug" configured to mate with a "socket" wired to the sensor **14**, such that an electrical connection can be made between the local analyzer **608** and the sensor **14**. In another embodiment, the sensor **14** includes a cable having a plug configured to connection to the local analyzer **608** *via* a socket. In still another embodiment, both the sensor **14** and the local analyzer **608** include cables configured to mate with each other *via* a plug and socket mechanism. Advantageously, a detachable configuration allows catheter/sensor insertion without a cumbersome connection to the local analyzer **608** as well as re-use of the local analyzer **608**. In an alternative exemplary embodiment, the local analyzer **608** is permanently connected to the sensor **14** and cannot be disconnected therefrom; a single use, permanently connected configuration can simplify application to the host, can reduce the possibility of cross-contamination between hosts, does not require cleaning and/or sterilization between hosts, and can reduce operator error during application to the host.

[0839] In preferred embodiments, the local analyzer **608** includes at least the minimal electronic components and/or programming required to energize the sensor **14** and collect data therefrom, such as but not limited to a potentiostat. However, in some embodiments, the local analyzer **608** includes additional electronic components that can be programmed to analyze one or more components of the collected raw signal, or to store data, calibration information, a patient ID and the like. In one exemplary embodiment, the local analyzer **608** includes a potentiostat and a battery back up. The battery back up can maintain

Abbott Ex. 1003 - 307/1058

a potential on the sensor and store data (calibration and/or collected host data) for brief periods of time when the electronics can be disconnected, such as when the host is moved from one location to another. In one exemplary embodiment, the local analyzer **608** is disposed on or adjacent to the sensor **14** and is configured such that the host can be connected to a first remote analyzer **610** at one station, and then disconnected from the first remote analyzer **610**, moved to a new location and connected to a second remote analyzer **610** at the new location, and the local analyzer **608** retains sufficient data that the system **600** functions substantially without initialization or substantial delay upon connection to the new (second) remote analyzer **610**. In another example, the host can be disconnected from the first remote analyzer **610**, taken to another location for a procedure (e.g., for surgery, imaging, and the like) and then reconnected to the first remote analyzer **610** upon return to the original location without substantial loss of system **600** function upon reconnection.

[0840] In some embodiments, the local analyzer **608** includes two or more parts, such that only the potentiostat is disposed on or adjacent to the sensor **14** (e.g., sensor fluid coupler **20**) or the catheter (e.g., catheter connector **18**); other portions of the local analyzer **608** can be disposed remotely from the host, such as in a separate housing wired to the sensor and to the remote analyzer. In one exemplary embodiment, the two parts of the local analyzer **608** can be separated (e.g., unplugged) such that the host can be moved and the local analyzer **608** portion that is attached to the host goes with the host while the remaining portion stays with the remote analyzer **610**.

[0841] In still other embodiments, all sensor electronics components are disposed remotely from the host, such as in the remote analyzer **610**. For example, the sensor **14** can include an appropriate connector, plug and/or wiring to connect the sensor **14** to the remote analyzer **610**, which powers the sensor **14**, collects raw data from the sensor **14**, calibrates the sensor **14**, analyzes and presents the data, and the like. In one example, the sensor **14** includes a cable of sufficient length to permit plugging the sensor **14** into a remote analyzer **610** disposed at the host's bedside.

[0842] In still other embodiments, the local analyzer **608** can be incorporated into the remote analyzer **610**, such as housed in the same body as the remote analyzer **610**, for example. In one exemplary embodiment, both the local and remote analyzers **608, 610** are disposed in a housing attached to a support **612** (e.g., connected to an IV pole, placed on a

Abbott Ex. 1003 - 308/1058

bedside table, connected to the wall, clamped to the head of the host's bed) and connected to the analyte sensor *via* a wire or cable. In some embodiments, the cables/wires (e.g., for connecting the sensor to the local analyzer and/or the remote analyzer, and/or connecting the local analyzer to the remote analyzer) can be provided in the IV tubing set.

Remote analyzer

[0843] As discussed in the section entitled "Local Analyzer," the integrated sensor system **600** includes a remote analyzer **610**. In preferred embodiment, the remote analyzer **610** is configured to at least communicate with the local analyzer **608** and can be configured to control the flow control device **604** described in the sections entitled "Flow Control Device," and "Flow Control Device Function." Generally, the remote analyzer **610** is powered from a standard 120 VAC wall circuit or other suitable power source, for example. In some embodiments, the remote analyzer **610** is disposed at the host's bedside and can be configured to be disposed on a support **612**, such as but not limited to, mounted a mobile IV drip pole, attached to the wall, clamped to the host's bed, or sitting on a table or other nearby structure.

[0844] In preferred embodiments, the remote analyzer **610** includes a display, such as but not limited to a printout, an LED display, a monitor, a touch-screen monitor and the like. In some embodiments, the remote analyzer **610** includes both a hard copy display, such as a printer configured to print collected data, and a monitor. In some embodiments, the remote analyzer **610** is a programmable touch-screen panel PC configured to have different "screens" and "buttons" for control of system components (e.g., the sensor **14**, the flow control device **604**, etc.) and to display data, such as but not limited to host identification and condition, host food intake, medication schedules and dosage information, sensor identification, raw data, processed data, calibration information, and the like, such as in tables and/or graphs. In further preferred embodiments, the remote analyzer **610** is configured to be programmed, such that the operator can initiate system functions such as IV fluid line priming, starting and/or stopping the flow control device **604**, select among two or more solutions (e.g., between glucose concentrations), select the mode of data delivery (e.g., printer or on-screen), send data to a central location (e.g., the nurse's station or medical records), set alarms (e.g., for low and high glucose), and the like.

[0845] In some embodiments, the system **600** is configured to integrate with (e.g., be used in conjunction with) third party medical devices, such as but not limited to a pulse-

Abbott Ex. 1003 - 309/1058

oxygen meter, a blood pressure meter, a blood chemistry machine, and the like. In such embodiments, the local and/or remote analyzers **608**, **610** can be configured to communicate with the third party medical devices, such as but not limited to a patient monitor.

Flow Control Device Function

[0846] In some embodiments, the remote analyzer **610** controls the function of the flow control device **604**. In some embodiments, the flow control device includes electronics configured to control the flow control device. The flow control device **604** can be configured to perform a number of steps of operation, which are discussed below. Depending upon the system configuration and physician preferences, in some embodiments, one or more of the steps can be performed. In some embodiments, all of the steps are performed. In some embodiments, the steps of operation can be performed in the order in which they are presented herein. In other embodiments, the order of steps of operation can be varied (e.g., repeated, omitted, rearranged), depending upon various parameters, such as but not limited to the calibration solution **602a** selected, the particular infusion set selected, catheter **12** size, host condition, analyte of interest, type of sample and location of sample collection, integration with third party devices, additional infusion of fluids and the like.

[0847] **Figs. 8A** through **8C** are schematic illustrations of a flow control device in one exemplary embodiment, including its relative movement/positions and the consequential effect on the flow of fluids through the sensor/catheter inserted in a host. In general, steps performed by the flow control device **604**, include the steps of: contacting the sensor **14** with calibration solution **602a** (including sensor calibration) and contacting the sensor with a biological sample to be measured. In some embodiments, additional steps can be taken, such as but not limited to keep a vein open (KVO) step and a wash step. In the exemplary embodiment presented in **Figs 8A** though **8C**, the flow control device **604** is a roller valve configured to move between at least two positions, **810** and **812**, respectively. Movement of the flow control device **604** between positions **810** and **812** effectively concurrently moves the pinch point **808** (e.g., the point at which tubing **606** is pinched) between positions **810** and **812**. Additional flow control device positions are discussed below.

[0848] The top of **Figs. 8A** through **8C** are schematic drawings illustrating positions of the flow control device **604**. The bottom of **Figs. 8A** through **8C**, are a cut-away views of an implanted catheter **12,** including an indwelling sensor **14**, illustrating the

Abbott Ex. 1003 - 310/1058

corresponding activity at the implantation site, in response to movements of the flow control device **604**. For simplicity, for purposes of discussion only, it is assumed that the catheter **12** is implanted in a host's vein, that the sensor **12** does not protrude from the catheter's orifice **12b** and that the catheter **14** does not include side holes **902**. However, one skilled in the art appreciates that the catheter **14** could be implanted into any vessel of the host or into a variety of extracorporeal devices discussed elsewhere herein.

Step One: Contacting Sensor with Calibration Solution

[0849] In general, the system is configured to allow a calibration solution to contact the sensor using a flow control device such as a pump, valve or the like. In some embodiments, such as shown in **Figs. 8A** through **8C**, the flow control device **604** is a valve configured with a first structure **802** and a second structure **806**. For convenience, the first structure **802** is depicted as a roller connected to a rotatable axle **804**, however any flow control device such as described in the section entitled "Flow Control Device," can be configured to utilize the concepts and/or functions described herein. In general, when the flow control device is a valve, the valve is configured to allow no flow, gravity flow and/or metered flow through movement of the valve between one or more discreet positions.

[0850] In the embodiment shown in **Figs. 8A** through **8C**, the flow control device **604** is configured such that a tube **606** threaded between the first and second structures **802**, **806** (e.g., between the roller and the surface against which the roller presses) is compressed substantially closed. For convenience, the compressed location on the tubing is referred to herein as the "pinch point" **808**. In some embodiments, the flow control device **604** is configured such that the pinch point is moved along the tubing, either closer to or farther from the host. As the pinch point **808** is moved closer to the host, the tube **606** is progressively compressed, causing fluid (e.g., solution **602**) to be pushed into the host's vascular system (see the corresponding illustration of the sensor within the host's vessel at the bottom of **Fig. 8A**), at the catheter **12** implantation site. Conversely, as the pinch point **808** is moved away from the host, the portion of tubing **606** on the host side of the pinch point **808** progressively expands, causing sample (e.g., blood) to be drawn up into the catheter lumen **12a**. In an alternative embodiment, the flow control device **604** is configured such that the pinch point is substantially stationary and the first and second structures selectively compress the tubing at

Abbott Ex. 1003 - 311/1058

the pinch point (e.g., the tube **606** is either pinched fully closed or is fully open), which either stops or allows the flow of solution **602a**.

[0851] In the exemplary embodiment shown in **Fig. 8A** (bottom), the catheter **12** is implanted in the host's vein **906** (or artery), as described elsewhere herein. A sensor **14** is disposed with the catheter **12**. The catheter **12** is fluidly connected to a first end of tubing **606** that delivers the solution **602a** to the catheter **12**. The solution **602a** can move out of the catheter **12** and a sample of blood **814** can move in and out of the catheter **12**, *via* the catheter's orifice **12b**. In some alternative embodiments, the catheter **12** includes optional sidewall holes **902** (see Fig. 9, described elsewhere herein) and the solution **602a** and blood can move in and out of the catheter **12** *via* the sidewall holes **902** and the catheter orifice **12b**. In some alternative embodiments, the sensor is configured to move in and out of the catheter. In some embodiments, the catheter orifice **12b** is disposed in the sidewall **904** (e.g., near the catheter's tip) instead of at the tip. Tubing **606** is fluidly connected to the reservoir **602** on a second end (see **Figs. 6** and **7**).

[0852] Referring now to a calibration phase to be performed by the exemplary valve of **Fig. 8A**, in preferred embodiments, the flow control device **604** is configured to perform a step of contacting the sensor **14** with solution **602a**, wherein the flow control device **604** moves from position **810** to position **812** (e.g., forward, toward the host/catheter). When the flow control device **604** moves from position **810** to position **812**, the pinch point **808** is moved from position **810** to position **812**. As the pinch point **808** is moved from position **810** to position **812**, a first volume of the calibration solution **602a** is pushed through the tubing **606**, toward the catheter **12**.

[0853] Referring again to the bottom of **Fig. 8A**, a second volume of the solution **602a**, which is substantially equal to the first volume, is pushed into the host's vein **906**, in response to the first volume of solution **602a** moving toward the host. As the second volume of solution **602a** is pushed through the catheter **12** and into the host's vein the second volume contacts (e.g., bathes) the analyte sensor **14**, including the analyte sensor's electroactive surfaces. In some embodiments, the volume (e.g., the first and second volumes of fluid) moved is from about 3 μl or less to about 1 ml or more. In some preferred embodiments, the volume is from about 10 μl to about 500 μl, or more preferably from about 15 μl to about 50 μl. In general, the volume of fluid pushed through the catheter in a particular phase (e.g., calibration

Abbott Ex. 1003 - 312/1058

phase) is dependent upon the timing of the phase. For example, if a long phase, such as a 20 minute calibration phase (e.g., as compared to a shorter 5 minute phase) were selected, the volume of fluid pushed during the long phase would be 4X greater than the volume of fluid pushed during the shorter phase. Accordingly, one skilled in the art appreciates that the above described ranges of fluids infusion can be increased and/or decreased simply be increasing or decreasing the measurement phase and/or intervals (i.e., timing). In preferred embodiments, the fluid is moved at a flow rate that is sufficiently slow that the calibration solution's temperature substantially equilibrates with the temperature of the tissue surrounding the *in vivo* portion of the catheter and/or temperature of bodily fluid (e.g., blood), such that the temperature of the calibration solution and the temperature of the blood are substantially the same. In preferred embodiments, the flow rate is from about 0.95, 0.9, 0.85, 0.8, 0.75, 0.7, 0.65, 0.6, 0.55, 0.5, 0.45, 0.4, 0.35, 0.3, 0.25, 0.2, 0.15, 0.1, 0.05, 0.01, 0.001 µl/min or less to about 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10.0 ml/min or more. In one exemplary embodiment, the flow control device **604** maintains a flow rate from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1 or 0.05 µl/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more. In one exemplary embodiment, the flow rate is from about 1 µl/min to about 1.0 ml/min. In one exemplary embodiment, the flow rate is from about 0.01 ml/min to about 0.2 ml/min. In another exemplary embodiment, the flow rate is from about 0.05 ml/min to about 0.1 ml/min. In some embodiments, the flow rate is 0.0 ml/min.

[0854] In some embodiments, the system is configured such that the speed of the movement between the first and second discreet positions is regulated or metered to control the flow rate of the fluid through the catheter. In some embodiments, the system is configured such that the time of movement between the first and second discreet positions is from about 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 seconds or less to about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 seconds or more, preferably from about 0.5 to 10 seconds. In some embodiments, the system is configured such that an amount of pinch of the tubing regulates the flow rate of the fluid through the catheter. In some embodiments, the fluid flow is regulated through a combination of metering and/or pinching techniques, for example. Depending on the type of

Abbott Ex. 1003 - 313/1058

flow control device (e.g., valve), a variety of methods of metering and/or regulating the flow rate can be implemented as is appreciated by one skilled in the art.

[0855] Preferably, the sensor is configured to measure a signal associated with the solution (e.g., analyte concentration) during the movement of the flow control device from position **810** to position **812** and/or during contact of the sensor **14** with the solution **602a**. Electronics, such as an electronic module included in either the local or remote analyzer **608**, **610** controls signal measurement and processing, such as described in more detail elsewhere herein.

[0856] In general, a calibration measurement can be taken at any time during the flow control device **604** movement from position **810** to position **812**, and including a stationary (stagnant) time there after. In some embodiments, one or more calibration measurements are taken at the beginning of the flow control device **604** movement from position **810** to position **812**. In other embodiments, one or more calibration measurements are taken at some time in the middle of the flow control device **604** movement from position **810** to position **812**. In some embodiments, one or more calibration measurements are taken near the completion of the flow control device **604** movement from position **810** to position **812**. In some embodiments, one or more calibration measurements are taken after completion of the flow control device **604** movement from position **810** to position **812**. In still other embodiments, the flow control device is positioned such that fluid can flow followed by positioning the flow control device such that there is no fluid flow (e.g., 0 ml/min) during the calibration measurement. In preferred embodiments, one or more calibration measurements are taken when the temperature of the solution **602a** has substantially equilibrated with the temperature of the tissue surrounding the *in vivo* portion of the implanted catheter **12**. Processing of calibration measurements and sensor calibration are described elsewhere herein.

[0857] As a non-limiting example, in some embodiments, the sensor can be calibrated using one or more reference solutions. For example, if the analyte is glucose, a suitable reference (e.g., calibration solution) is saline containing 0, 25, 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300 mg/dl glucose or more. In some embodiments, two or more such reference solutions can be used to calibrate the sensor. In some embodiments, a baseline value of the sensor can be obtained by generating a signal when the sensor is exposed to a 0 mg/dl reference solution (e.g., 0 mg/dl analyte). In some embodiments, updated baseline values are

Abbott Ex. 1003 - 314/1058

continuously obtained by repeatedly exposing the sensor to the 0 mg/dl reference solution, such as every 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, or 60 or more minutes. In some embodiments, updated baseline values are continuously obtained by exposing the sensor to the 0 mg/dl reference solution for periods of time and continuously collecting baseline values. For example, the sensor can be exposed to the 0 mg/dl reference solution for 5, 10, 15, 20, 25, 30, 40, 50, or 60 minutes, or longer, while baseline signals are continuously generated. In this embodiment, sensitivity *m* calibration values can be obtained intermittently by exposing the sensor to an analyte-containing reference solution intermittently, such as but not limited to every 5, 10, 15, 20, 25, 30, 40, 50, or 60 minutes, or longer, such as at the conclusion of the exposure to the 0 mg/dl solution. In other embodiments, such calibrations measurements (e.g., to obtain a baseline value) are performed "intermittently," such as once every 24 hours.

[0858] In some embodiments, sensitivity *m* calibration values are obtained substantially continuously/continually, such as by exposure of the sensor to one or more analyte-containing reference solutions every 1, 2, 3, 4, 5, 10, 20, 30, 40, 60 or more minutes. In some embodiments, sensitivity *m* calibration values are obtained substantially continuously/continually by exposure of the sensor to one or more analyte-containing reference solutions for a period of time, such as but not limited to for 5, 10, 15, 20, 25, 30, 40, 50, or 60 minutes, or longer, while sensitivity signals are continuously generated. In one exemplary embodiment, continuous calibration measurements are performed by passing a 100-mg/dl glucose calibration solution across the sensor (e.g., to detect shifts in sensitivity *m*), and the intermittent calibration measurements are performed to determine baseline *b*, by passing a 0-mg/dl calibration solution across the sensor. While not wishing to be bound by theory, it is believed that in some circumstances, baseline drift is greater than sensitivity drift. Accordingly, in some embodiments, the system is configured to perform baseline calibration measurements (with 0-mg/dl glucose) automatically (e.g., every 5-minutes) and a sensitivity calibration measurement (with 100-mg/dl) intermittently (e.g., every hour).

Step Two: Sample Collection and Measurement

[0859] In general, the system is configured to allow a sample (e.g., blood) to contact the sensor using the flow control device. Referring now to the top of **Fig. 8B**, the flow control device **604** is configured to draw back (or take-in) a sample (e.g., blood) from the host. For example, to collect a sample, the flow control device **604** reverses and moves backward

Abbott Ex. 1003 - 315/1058

(e.g., away from the host/catheter), from position **812** to position **810**, thereby causing the pinch point **808** to move away from the host. As the pinch point is moved from position **812** to position **810,** the tube **606** (on the host side of the pinch point **808)** expands (e.g., the tube volume increases).

[0860] Referring now to the bottom of **Fig. 8B**, as the tube volume increases, a small, temporary vacuum is created, causing sample **814** (e.g., blood) to be taken up into the catheter lumen **12a**. In some embodiments, the flow control device **604** is configured to take up a sufficient volume of sample **814** such that at least the sensor's electroactive surfaces are contacted by the sample **814**. In some embodiments, a sample volume of from about 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9.0, 8.0, 7.0, 6.0, 5.0, 4.0, 3.0, 2.0, 1.0, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 μl or less to about 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, or 2 ml or more is taken up into the catheter **12** and is sufficient to cover at least the electroactive surfaces of the sensor **14**. In some embodiments, the sample volume is from about 10 μl to about 1 ml. In some embodiments, the sample volume is from about 20 μl to about 500 μl. In other embodiments, the sample volume is from about 25 μl to about 150 μl. In other embodiments, the sample volume is from about 2 μl to about 15 μl.

[0861] In some embodiments, the sample taken up into the catheter is taken up substantially no farther than the skin (or a plane defined by the skin of the patient). In some embodiments, the sample is taken up into the catheter substantially no farther than the catheter's inner lumen (e.g., substantially not into the IV tubing.)

[0862] In some embodiments, the rate of sample take-up is sufficiently slow that the temperature of the sample substantially equilibrates with the temperature of the surrounding tissue. Additionally, in some embodiments, the rate of sample take-up is sufficiently slow such that substantially no mixing of the sample **814** and solution **602a** occurs. In some embodiments, the flow rate is from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more. In one exemplary embodiment, the flow rate is from about 0.001 ml/min or less to about 2.0 ml/min or more. In preferred embodiments, the flow rate is from about 0.01 ml/min to about 1.0 ml/min. In one exemplary preferred embodiment, the flow rate is from about 0.02

Abbott Ex. 1003 - 316/1058

ml/min to about 0.35 ml/min. In another exemplary preferred embodiment, the flow rate is from about 0.0.02 ml/min to about 0.2 ml/min. In yet another exemplary preferred embodiment, the flow rate is from about 0.085 ml/min to about 0.2 ml/min.

[0863] As described above, in some embodiments, the system is configured such that the speed of the movement between the first and second discreet positions is regulated or metered to control the flow rate of the fluid through the catheter. In some embodiments, the system is configured such that the time of movement between the first and second discreet positions is from about 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 seconds to about 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 seconds, preferably from about 0.5 to 10 seconds. In some embodiments, the system is configured such that an amount of pinch of the tubing regulates the flow rate of the fluid through the catheter. In some embodiments, regulate the fluid flow through a combination of metering and/or pinching techniques, for example. Depending on the type of flow control device (e.g., valve), a variety of methods of metering and/or regulating the flow rate can be implemented as is appreciated by one skilled in the art.

[0864] Measurements of sample analyte concentration can be taken while the electroactive surfaces are in contact with the sample **814**. An electronics module included in the local and/or remote analyzer **608**, **610** controls sample analyte measurement, as described elsewhere herein. In some embodiments, one sample measurement is taken. In some embodiments, a plurality of sample measurements are taken, such as from about 2, 3, 4, 5, 6, 7, 8, 9, or 10 measurements to about 20, 25, 30, 35, 40, 45 or 50 or more measurements and/or at a sample rate of from about 1 measurement per second to about 1 measurement per minute. In some embodiments, the rate is from about 1 measurement per 2 seconds to about 1 measurement per 30 seconds. In preferred embodiments, sample measurements are taken substantially continuously, such as but not limited to substantially intermittently, as described elsewhere herein.

Optional Step: Flush

[0865] In some exemplary embodiments, the flow control device **604** is configured to perform one or more steps, in addition to steps one and two, described above. A flush step,

Abbott Ex. 1003 - 317/1058

during which the sensor **14** and/or catheter **12** are substantially washed and/or cleaned of host sample, is one such optional step.

[0866] Referring now to the top of **Fig. 8C**, the exemplary flow control device **604** performs a flush step by moving forward from position **810** (e.g., toward the host/catheter), past position **812** (e.g., around and over the top of structure **804**) and back to position **810**. For convenience, the movement illustrated by an arrow in the top of **Fig. 8C** is referred to herein as the "flush movement."

[0867] Referring now to the bottom of **Fig. 8C**, the flush movement pushes forward a volume of solution **602a** (e.g., a third volume) that pushes the collected blood sample **814** into the host. In some embodiments, the third volume of solution **602a** is substantially equal to the first and second volumes described above. In some embodiments, the flush movement is repeated at least one time. In some embodiments, the flush movement is repeated two, three or more times. With the exception of the first flush movement, which pushes the sample **814** back into the host, each repeat of the flush movement pushes a volume of solution **602a** into the host, for example. In some embodiments, the flush movement pushes the third volume of solution **602a** into the host at a rate of from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 ml/min or more. In some embodiments the flush movement pushes the third volume of solution into the host at a rate of from about 1.0 µl/min to about 1.0 ml/min. In alternative embodiments, the flow control device **604** is moved to a fully opened position (e.g., no pinch) and the flow regulator **602b** is set at a setting that allows more solution (e.g., an increased volume and/or at a faster rate) to infuse into the host than during the calibration phase (e.g., step one, above). In preferred embodiments, the flush movement washes enough blood off of the analyte sensor's electroactive surfaces that the sensor **14** can measure the solution **602a** substantially without any interference by any remaining blood. In some embodiments, the flush step is incorporated into step one, above.

[0868] Generally, the solution **602a** is flushed through the catheter **12**, to ensure that a sufficient amount of the sample has been removed from the sensor **14** and the catheter lumen **12a**, such that a calibration measurement can be taken. However, in some embodiments,

Abbott Ex. 1003 - 318/1058

sample is collected, measured and flushed out, followed by collection of the next sample, substantially without sensor calibration; the flush step can be executed between samples to ensure that the sample being analyzed is substantially uncontaminated by the previous sample. In some embodiments, a relatively extended flush is used, while in other embodiments the flush is just long enough to ensure no blood remains.

[0869] In some embodiments, the effectiveness of the flushing movement is dependent upon the solution **602a** composition (e.g., concentrations of sodium chloride, glucose/dextrose, anticoagulant, etc.). Accordingly, the amount of solution **602a** required to ensure that substantially no sample remains in the catheter **12** and/or on the sensor **14** can depend on the solution **602a** composition. For example, relatively more flush movements may be required to completely remove all of the sample when a non-heparinized solution is selected than when a heparinized solution is selected. In some embodiments, the effectiveness of the flushing movement is also dependent upon the flush flow rate. For example, a relatively faster flow rate can be more effective in removing sample from the sensor than a slower flow rate, while a slower flow rate can more effectively move a larger volume of fluid. Accordingly, in some embodiments, the number of flush movements selected is dependent upon the calibration solution and flow rate selected. In some embodiments, the flush step flow rate is from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 ml/min or more, and last for from about 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 seconds or less to about 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3 minutes or more. In one exemplary embodiment, about 0.33 ml of solution **602a** is flushed at a rate of about 1.0ml/min, which takes about 20 seconds.

[0870] In some embodiments, the flush step returns the sample **814** (e.g., blood) to the host, such that the host experiences substantially no net sample loss. Further more, the flush movement washes the sensor **14** and catheter lumen **12a** of a sufficient amount of sample, such that an accurate calibration measurement (e.g., of undiluted solution **602a**) can be taken during the next step of integrated sensor system **600** operations. In some embodiments, the number of sequential flush movements is sufficient to only wash substantially the sample from

Abbott Ex. 1003 - 319/1058

the sensor **14** and catheter lumen **12a**. In other embodiments, the number of sequential flush movements can be extended past the number of flush movements required to remove the sample from the sensor and catheter lumen, such as to provide additional fluid to the host, for example.

[0871] At the completion of the flush step, the flow control device **604** returns to step one, illustrated in **Fig. 8A**. In some embodiments, the steps illustrated in **Figs. 8A** through **8C** are repeated, until the system **600** is disconnected from the catheter/sensor, either temporarily (e.g., to move a host to an alternate location for a procedure) or permanently (e.g., at patient discharge or expiration of sensor life time). In some embodiments, additional optional steps can be performed.

Optional Step: Keep Vein Open (KVO)

[0872] Thrombosis and catheter occlusion are known problems encountered during use of an IV system, such as when the fluid flow is stopped for a period of time or flows at a too slow rate. For example, thrombi in, on and/or around the catheter **12**, such as at the catheter's orifice **12b** can cause an occlusion. Occlusion of the catheter can require insertion of a new catheter in another location. It is known that a slow flow of IV solution (e.g., saline or calibration fluid; with or without heparin) can prevent catheter occlusion due to thrombosis. This procedure is know as keep vein open (KVO).

[0873] In general, to infuse a fluid into a host, the infusion device must overcome the host's venous and/or arterial pressure. For example, during infusion of a hydration fluid, the IV bag is raised to a height such that the head pressure (from the IV bag) overcomes the venous pressure and the fluid flows into the host. If the head pressure is too low, some blood can flow out of the body and in to the tubing and/or bag. This sometimes occurs when the host stands up or raises his or her arm, which increases the venous pressure relative to the head pressure. This problem can be encountered with any fluid infusion device and can be overcome with a KVO procedure. KVO can maintain sufficient pressure to overcome the host's venous pressure and prevent "back flow" of blood into the tubing and/or reservoir.

[0874] In some embodiments, the flow control device **604** can be configured to perform a KVO step, wherein the fluid flow rate is reduced (but not completely stopped) relative to the calibration and/or wash flow rates. In preferred embodiments, the KVO flow rate is sufficient to prevent the catheter **12** from clotting off and is relatively lower than the

Abbott Ex. 1003 - 320/1058

flow rate used in step one (above). In preferred embodiments, the KVO flow rate is sufficient to overcome the host vessel pressure (e.g., venous pressure, arterial pressure) and is relatively lower than the flow rate used in step one (above). In some embodiments, the KVO flow rate is from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more. In some preferred embodiments, the KVO flow rate is from about 0.02 to about 0.2 ml/min. In some more preferred embodiments, the KVO flow rate is from about 0.05 ml/min to about 0.1 ml/min). In some embodiments, the KVO flow rate is less than about 60%, 50%, 40%, 30%, 20%, or 10% of the calibration and/or flush flow rate(s). In some embodiments, the KVO step is performed for from about 0.25 minutes or less to about 20 minutes or more. In preferred embodiments, the solution **602a** flows at a rate such that the temperature of the solution **602a** substantially equilibrates with the temperature of the tissue surrounding the *in vivo* portion of the catheter **12**. Advantageously, equilibrating the solution **602a** temperature with that of the surrounding tissue reduces the effect of temperature on sensor **14** calibration and/or sample measurement, thereby improving sensor accuracy and consistency. In some embodiments, the KVO step can be incorporated into one or more of the flow control device steps of operation described elsewhere herein, including steps one and two, and the flush step, above.

[0875] The KVO step can be executed in one or more ways. In some embodiments, the flow control device **604** can be configured to move to at least one addition position, wherein the tube **606** is partially pinched. For example, the flow control device **604** is configured to move to a position such that the pinch point **808** is partially closed/open. For example, in the embodiment shown in **Figs. 8A** through **8C**, the flow control device **604** can be moved forward somewhat past position **812**, such that the roller **802** causes the tube **606** to be partially pinched. In another example, the flow control device **604** can be moved backwards somewhat behind position **810**, such that the roller **802** again causes the tube **606** to be partially pinched. In preferred embodiment, the amount of pinch can be adjusted such that the desired KVO flow rate can be achieved. In some alternative embodiments, KVO is performed by moving the flow control device between positions **810** and **812** (e.g., see **Fig. 8A**) at a reduced speed, such that the flow rate is from about 0.1 μl/min or less to about 0.5 ml/min or more. In some embodiments, the system is configured such that the time of movement between the first and

Abbott Ex. 1003 - 321/1058

second discreet positions is from about 0.25 to 30 seconds, preferably from about 5 to 15 seconds. In some preferred embodiments, the tubing is pinched fully closed (e.g., between structures **802** and **806**) during the movement from position **810** and **812** (e.g., see **Fig. 8A**). In some preferred embodiments, after the flow control device reaches position **812**, the flow control device flips over the top and back to position **810** (e.g., see **Fig. 8C**) at a substantially rapid speed that the flow rate remains substantially unchanged. In an even further embodiment, during the KVO step the flow control device alternates between the slow and fast movements at least two times, such that the KVO step lasts a period of time.

[0876] In some circumstances, signal artifacts can occur due to the location a catheter is implanted and if the host has moved his or her arm (where the catheter is implanted/inserted) to certain positions (e.g., holding his or her arm up, vertically and/or hanging down). While not wishing to be bound by theory, it is believed that these signal artifacts can arise because femoral veins are relatively small (e.g., 1-2 mm diameter), and in some circumstances an inserted catheter can block the flow of at least some incoming blood, such that the incoming blood is "diverted" around the implantation site by flowing through adjacent alternative veins and/or capillaries. As a result, the blood in the vein containing the catheter can be diluted for a period of time (e.g., after flushing), which can lead to diluted analyte values, which appear as signal artifacts. As time passes, the dilution of the sample by the saline flush dissipates and undiluted blood samples are collected, which leads to termination of the signal artifact(s). The way the host holds his or her arm can affect the length of time required for the signal artifact to dissipate. For example, in some embodiments, if the host holds his or her arm at chest level, the vein is filled by blood at a first rate, and the sample dilution is dissipated within a first time period. If the host holds his or her arm down low, the blood flows through the vein at a second rate that is faster than the first rate, and the dilution is relieved sooner (e.g., within a second time period that is shorter than the first time period). Conversely, if the host raises his or her arm over his or her head, the blood flows into the vein at a third rate that is slower than the first rate; which results in the dilution dissipating within a third period of time that is longer than the first period of time.

[0877] In some embodiments, the signal artifacts resulting from blocking of the vein at the site of catheter implantation and subsequent sample dilution can be substantially eliminated (or reduced/shortened) by reducing the volume of 0 mg/dl solution used to wash

Abbott Ex. 1003 - 322/1058

away the 100-mg/dl calibration solution, depending upon the volume of the 100 mg/dl calibration solution used to calibrate the sensor. For example, in some embodiments a 0.5X, 1X, 2X, 3X, 4X, 5X, 6X, 7X, 8X, 9X, 10X (or greater) volume of the 0-mg/dl solution can be used to sufficiently wash out the volume 100 mg/dl calibration solution. In some embodiments, wherein a sufficiently small volume of 100 mg/dl solution is used during calibration, the flushing can be done at the KVO rate. In some embodiments, signal artifacts are prevented by using smaller volumes of calibration/wash fluids but switching more frequently between the fluids.

Maintaining Patency During A Sensor Session

[0878] In some embodiments, the analyte sensor is implanted in the host (e.g., *via* a vascular access device) for an extended period of time. For example, in some embodiments, a sensor session can last 3, 5, 7, 10, 21, 30 or more days. As used herein, the term "sensor session" is a broad term and refers without limitation to the period of time of sensor is applied to (e.g., implanted in) the host and is being used to obtain sensor values. For example, in some embodiments, a sensor session extends from the time of sensor (e.g., including implanting the vascular access device) implantation to when the sensor is removed. During this period of time, the vein's condition can deteriorate, such that vein and/or vascular access device is no longer patent (e.g., freely open, not occluded), and the system can no longer function optimally. While not wishing to be bound by theory, it is believed that patency can be substantially maintained during a sensor session by metering a reference/calibration solution through the vascular access device a sufficient amount of time (e.g., a percentage of the duration of the sensor session). As used herein, the phrase "a sufficient amount" is a broad term and refers without limitation to an amount that provides a desired function. For example, a sufficient amount can be a sufficient amount of time, a sufficient amount of fluid volume, and the like. In some embodiments, a sufficient amount can be expressed numerically, such as a percent (%), a volume, a weight, a period of time (e.g., minutes, hours, days, months), and the like. For example, in some embodiments, the flow control device is configured to meter a sufficient amount of a reference solution (e.g., through the vascular access device) such that the analyte sensor contacts the reference solution at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the time during a sensor session. It is generally preferred that the analyte sensor contacts the reference solution from about 50% to about 80%, 85%, 90% or 95% of the

Abbott Ex. 1003 - 323/1058

time during a sensor session In some embodiments, the sensor is located in or on the vascular access device and the flow control device meters the reference solution through the vascular access device for a sufficient amount of time (e.g., a portion of the sensor session), with a sufficient flow rate (e.g., from about 0.05 ml/min to about 0.5 ml/min, preferably about 0.1 ml/min) that the vascular access device remains patent during a sensor session. Advantageously, the flow rate is sufficient to maintain a patent vessel without infusing excess fluid. In a preferred embodiment, the vascular access device remains patent during a sensor session of at least about 1, 3, 5, 7, 10, 15, 20, 25, or 30 days, or longer. In one exemplary embodiment, the flow control device is configured to meter the reference solution through the vascular access device for at least about 50% of a sensor session, at a flow rate from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more, such that the vascular access device remains patent during a sensor session of at least about 5 days. In another exemplary embodiment, the flow control device is configured to meter the reference solution through the vascular access device for at least about 65% of a sensor session, at a flow rate from about 0.001 ml/min to about 2.0 ml/min, such that the vascular access device remains patent during a sensor session of between about 5 days and about 30 days. In still another exemplary embodiment, the flow control device is configured to meter the reference solution through the vascular access device for between about 50% and about 80% of a sensor session, at a flow rate from about 0.001 ml/min to about 2.0 ml/min, such that the vascular access device remains patent during a sensor session of at least about 30 days.

Preventing Sensor Biofouling During A Sensor Session

[0879] As discussed above, sensor sessions can last from about 3 days to 30 or more days. During this period of time, the sensor is repeatedly exposed to (contacted with) a bodily fluid (e.g., blood). In some circumstances, during sensor exposure to blood, some blood components/material, such as but not limited to proteins, lipids, carbohydrates and cells, can "stick" to the sensor, such that a layer of this material coats at least part of the sensor and the sensor can no longer function accurately. This process of blood components sticking to the sensor and disrupting the sensor's function is generally referred to as "biofouling." While not wishing to be bound by theory, it is believed that biofouling can be substantially reduced and/or

Abbott Ex. 1003 - 324/1058

eliminated by limiting the length of time the sensor is exposed to blood and/or by maintaining the sensor in a reference solution (or saline) a substantial portion of the sensor session, whereby sensor accuracy is maintained throughout the sensor session. Washing the sensor is described in detail in the section entitled "Maintaining Patency During A Sensor Session."

[0880] As a non-limiting example, in some embodiments, the flow control device is configured to meter the reference solution, such that the reference solution contacts the sensor a substantial amount of time such that biofouling does not occur for at least about 3 days of sensor use. For example, the sensor can be contacted with the reference solution about 50%, 60%, 70%, 80%, 90%, or 95% of the sensor session duration. In preferred embodiments, the system is configured such that biofouling does not occur for at least about 7, 10, 21, 30 or more days of sensor use.

[0881] In one exemplary embodiment, wherein the sensor is located in or on a vascular access device, the system includes a flow control device configured to meter a reference solution through the vascular access device for a sufficient amount of time and with a sufficient flow rate that substantially no biofouling of the sensor occurs during a sensor session of at least about 3 days. For example, in some embodiments, the flow control device meters the reference solution through the vascular access device for at least about 50% of a sensor session, at a flow rate from about 0.001 ml/min to about 2.0 ml/min, such that substantially no biofouling of the sensor occurs during a sensor session of at least about 5 days. In another exemplary embodiment, the flow control device meters the reference solution through the vascular access device for at least about 65% of a sensor session, at a flow rate from about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001 ml/min or less to about 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 or 2.0 ml/min or more, such that substantially no biofouling of the sensor occurs during a sensor session of between about 5 days and about 30 days. In still another exemplary embodiment, the flow control device meters the reference solution through the vascular access device for between about 50% and about 80% of a sensor session, at a flow rate from about 0.001 ml/min to about 2.0 ml/min, such that substantially no biofouling of the sensor occurs during a sensor session of at least about 30 days.

Abbott Ex. 1003 - 325/1058

Alternative Flow Control Device Configurations

[0882] As disclosed above, the flow control device **604** can be configured a variety of ways, which can require modifications to one or more of the steps of operation described above. For example, in some embodiments, the flow control device **604** can be configured to include a simple pinch valve, wherein the valve can be configured to open, close or partially open. In some embodiments, the flow control device **604** can be configured to include a non-linear rolling pinch valve, wherein the roller can move back and forth between opened, closed and partially opened positions, for example.

[0883] In some embodiments, the flow control device **604** can include one roller **802** (e.g., first structure) attached to an axle **804** and configured to press against a curved surface **806** (e.g., second structure), such that when the roller **802** is pressing against the curved surface **806** at or between positions **810** and **812**, the tubing **606** is pinched completely closed and the flow control device **604** moves the roller **802** forward (e.g., toward the host). In one exemplary embodiment, the flow control device **604** can be configured to perform step one (above, contacting the sensor **14** with solution **602a**) by moving the roller **802** forward (e.g., rotating from position **810** to **812**, see **Fig. 8A**), thereby causing solution **602a** to flow over the sensor **14**. In some embodiments, the flow control device **604** is configured to perform step two (contacting the sensor **14** with sample) by moving the roller **802** backwards (e.g., rotating from position **812** to **810**, see **Fig. 8B**), thereby causing blood **814** to enter the catheter **12** and contact the sensor **14**. Additionally, the flow control device **604** can be configured to perform a wash or KVO step by moving the roller **802** forward (from position **810**) past position **812** and around the axle **804** until position **810** is again reached a plurality of times sequentially (e.g., see **Fig. 8C**). In a further example, the flow control device **604** includes two, three or more rollers **802** arranged about axle **804,** such as by attachment to an oblong body attached to the axle. In some embodiments, the flow control device includes a plurality of rollers arranged about the axle, wherein the flow control device performs KVO by rotating the rollers about the axle a plurality of times, to substantially continuously push (e.g., for a period of time) the solution forward into the host.

[0884] In one alternative embodiment, back flow is substantially stopped, blocked and/or prevented by incorporation of a one-way, pressure-controlled valve into the system, such as at or adjacent to the catheter or sensor connector, whereby fluid can flow into the host

Abbott Ex. 1003 - 326/1058

only when fluid pressure (e.g., head pressure) is applied to the reservoir-side of the valve. In other words, fluid can only flow in the direction of the host (e.g., toward the host), not backwards towards the reservoir. In some embodiments, the valve is a two-way valve configured such that the pressure required to open the valve is greater than the venous pressure, such that back flow is substantially prevented.

[0885] The preferred embodiments provide several advantages over prior art devices. Advantageously, the movement of the solution **602a** and sample occur at a metered rate and are unaffected by changes in head pressure, such as but not limited to when the host elevates his or her arm or gets up to move around. Also, sample loss to the host is minimized, first by returning all collected samples to the host; and second by substantially preventing back-flow from the host (e.g., into the tubing or reservoir) with a "hard stop" (e.g., a point beyond which the flow control device cannot move fluid into or out of the host). For example, in one preferred embodiment, the flow control device can be configured to deliver no more than 25-ml of solution to the host per hour. In another exemplary embodiment, the flow control device can be configured to draw back no more than 100 μl of blood at any time. Advantageously, the flow rate of solution **602a** and sample **814** is carefully controlled, such that both the sample **814** and the solution **602a** remain substantially undiluted. Additionally, the solution **602a** warms to the host's local body temperature, such that the integrated sensor system **600** is substantially unaffected by temperature coefficient and sensor **14** accuracy is increased.

[0886] **Figs. 10A** through **10D** illustrate one exemplary embodiment of a flow control device **604** configured and arranged for use with a vascular access device (e.g., catheter and/or fluid coupler) and analyte sensor, such as those described elsewhere herein. The flow control device includes a groove **803** configured to receive the tubing assembly therein **606a**. In some embodiments, the groove **803** is configured and arranged to receive the tubing (of the tubing assembly) in a substantially straight configuration. The groove **803** intersects with a valve roller mechanism, which includes an oblong body comprising two rollers **802** (e.g., corresponding to the first structure **802**, which is attached to axle **804** of the embodiment shown in **Figs. 8A-8C**) and a compression surface **806** (e.g., corresponds to the second structure **806** of the embodiment shown in **Figs. 8A-8C**). The valve includes at least two valve positions, a gravity flow valve position and a controlled-flow valve position. **Fig. 10C** illustrates one embodiment of the gravity flow valve position, in which the rollers **802** are positioned such

Abbott Ex. 1003 - 327/1058

that they do not compress, pinch and/or occlude the tubing, such that fluid flowing from the IV bag can flow freely through the tubing **606b** in the valve. At gravity flow, the rate of fluid flow through tubing **606b** is from about 600-ml/hr (e.g., about 10 ml/min) to about 700-ml/hr (e.g., about 1.2 ml/min), depending upon the height of the IV bag **602**.

[0887] **Fig. 10D** illustrates one embodiment of the controlled-flow valve position, in which a roller **802** is positioned such that the tubing **606b** (of the tubing assembly) is pinched between the roller **802** and compression surface **806** (e.g., pinch point **808** exists), such that movement of fluid through the valve is controlled by the rotation of the oblong body (e.g., to which the roller is attached) on its axle. In the controlled flow position, the valve is configured and arranged to move fluid forward and/or backward at various rates, depending upon the speed and direction of oblong body rotation on the axle. Flow rates can be positive (e.g., infusing fluid) or negative (e.g., drawing back fluid/blood) and can range from about -10.0, -9.0, -8.0, -7.0, -6.0, -5.0, -4.0, -3.0, -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, -0.1, -0.05, -0.01, 0.0, 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 ml/hr to about 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0, 110.0, 130.0, 150.0, 175.0, 200.0, 225.0, 250.0, 275.0, 300.0, 350.0, 400.0, or 450.0 ml/hr or more. Useful flow rates and valve movement between the gravity flow and controlled-flow valve positions are described in greater detail elsewhere herein with reference to **Fig. 10E**.

[0888] The valve is configured to receive the tubing **606b** (e.g., of the tubing assembly **606a**), such as *via* groove **803** (e.g., tubing path or channel). One skilled in the art understands that while **Figs. 10A-10D** illustrate groove **803** running from the top of the valve to the bottom (e.g., on the face or front of the device), additional configurations are possible. Namely, the groove can be located in any direction or orientation along any surface of the device (e.g., top, bottom, sides), or the groove can be enclosed within the device, such as within a housing configured cover, supports and/or limit access to the valve, a portion of the tubing, and/or accessory devices. For example, in some embodiments, the valve is located within a housing, such that the valve and the tubing assembly are accessed *via* a door. The housing can include one or more orifices, such that the tubing can intersect (e.g., pass through) a wall of the housing and be installed into the valve within the housing. In some embodiments, the door includes a locking mechanism, such as but not limited to a mechanical key or electronics code key (e.g., electronically, such as such as to prevent tampering with the device).

Abbott Ex. 1003 - 328/1058

[0889] The valve is configured for uni-directional, releasable installation of the tubing assembly **606a** (also referred to herein as "tubing set"), such that the tubing assembly's elastic central portion **606b** (e.g., tubing) is received by the groove and the tubing's fluid connectors **606c, 606d** are disposed at opposite ends of the groove, in some embodiments. In some embodiments, the groove is sized to be somewhat longer than the central portion of the tubing assembly, such that the tubing (of the tubing assembly) must be stretched (e.g., by grasping the connectors and pulling in opposite directions) prior to and/or during installation into the channel/groove. After installation, the connector ends are released, such that the tubing relaxes. However, the tubing remains stretched (e.g., relative to its un-stretched state prior to installation) after installation. Maintaining the tubing in a stretched state can help maintain the tubing assembly within the valve without the tubing moving, twisting, kinking or falling out of the valve. The tubing assembly is configured for fluid communication with an IV bag (e.g., fluid reservoir **602**), such as *via* the first connector **606c**, and with the circulatory system of the host, such as *via* fluid connection of the second connector **606d** to a catheter implanted in the host.

[0890] In some embodiments, the valve is configured and arranged to receive the tubing assembly in only one orientation. For example, in some embodiments, the valve and the tubing assembly are configured and arranged to releasably interlock such that a portion of the valve mechanically interlocks with a portion of the tubing assembly. For example, in some embodiments, the valve includes the first portion of a mechanical interlock and the tubing assembly includes the second portion of the mechanical interlock. For example, in **Fig. 10A**, the valve includes a female interconnection **809** sized and shaped to releasably receive and engage the tubing assembly's second connector **606d** (which in this embodiment includes rectangular wings that project from a female Leur connector). As is appreciated by one skilled in the art, the system can be configured such that the mechanical interlock is located at either end of the groove **803** (e.g., such that connector **602** forms a portion of the mechanical interlock, instead of connector **606d**) or at some point in between. Advantageously, the mechanical interlock reinforces uni-directional installation of the tubing assembly, as well as helping to maintain the tubing within the valve in the correct configuration.

[0891] In some embodiments, the mechanical interlock is configured to engage a particular vascular access device (e.g., a specific type of catheter), wherein the mechanical

Abbott Ex. 1003 - 329/1058

interlock and/or the vascular access device are configured and arranged to provide additional structural and/or electronic identification information, to ensure and/or to promote the use of the correct vascular access device (e.g., catheter, fluid coupler) and/or to enable the correct selection of a flow profile associated with the vascular access device. For example, in one embodiment, the mechanical interlock is configured and arranged to identify (to the flow control device) the type of vascular access device and/or sensor being used (such as for identification of the flow profile that corresponds with the selected catheter). In some embodiments, the mechanical interlock provides identification information to the flow control device, wherein the identification information is associated with the vascular access device and a corresponding flow profile. In preferred embodiments, the identification information is provided automatically, such as by a mechanical structure of the vascular access device. In some embodiments, the identification information is provided by electronics associated with the vascular access device. For example, in one embodiment, the catheter includes the electronics that provide the identification information. In another embodiment, the fluid coupler includes the electronics that provide the identification information. In one exemplary embodiment, the system is configured to select a flow profile associated with a mechanical interlock (e.g., the identification information), when the mechanical interlock is engaged (e.g., the vascular access device is connected to the tubing assembly and/or the flow control device). Additional a mechanical interlock between the second end of the tubing assembly and the vascular access device is configured and arranged to prevent twisting of the connection between the tubing assembly and the vascular access device.

[0892] In some embodiments, uni-directional tubing installation is important for aligning functional portions of the valve with functional portions of the tubing assembly. For example the tubing assembly includes an elastic tubing portion configured to be manipulated by the valve (e.g., pinched, etc.). In another example, the valve can include one or more functional elements, such as but not limited to a bubble detector **805** (located along groove **803** and configured and arranged to detect bubbles in the tubing **606b**) and an electronic solenoid **807** (e.g., configured to align with the free flow mitigation device **606e** of the tubing and to open the free flow mitigation device, see "Free Flow Mitigation").

[0893] Referring now to **Figs. 10C-10D**, in some embodiments, the flow control device includes a flow profile comprising two valve positions, a gravity flow position and a

Abbott Ex. 1003 - 330/1058

controlled flow position. Flow profiles are described in detail with respect to **Fig. 10E**. In preferred embodiments, the valve is configured and arranged to move between the gravity flow and controlled flow valve positions, such that when the valve is in the gravity flow position, tubing received therein is in a substantially straight (e.g., linear) configuration and when the valve is in the controlled flow positions the tubing received therein is in a substantially non-linear configuration. As a non-limiting example, **Fig. 10C** illustrates a gravity flow position, in which the valve roller (e.g. the first structure **802**, a roller attached to an oblong rotating member or body configured to engage curved surface **806**) is oriented (e.g., positioned) such that there is no pinch point in the tubing (e.g., the tubing is not compressed between the first and second structures). In this embodiment, the tubing is in a substantially straight (e.g., un-bent, unpinched, and/or not occluded) configuration when the valve is in the gravity flow position. In the gravity flow position, IV fluid can flow freely through the vascular access device and into the host, simultaneously flushing and/or washing the analyte sensor. **Fig. 10D** illustrates the valve in a controlled flow position. In the controlled flow position, the rotating member **802** is rotated on its axle to an orientation such that the tubing **606b** is non-linear (e.g., curved, bent) and a pinch point **808** (e.g., between the rotating member **802** and the compression surface **806**) prevents fluid flow. The valve is configured to rotate the roller valve on an axle, such that the pinch point can be moved along the compression surface. Thus, the flow control device moves through a plurality of controlled flow positions. Movement of the valve is similar to the valve movements described with reference to **Figs. 8A-8C**. Accordingly, when the tubing is in a bent configuration, the pinch point **808** is pushed forward (e.g., along surface **806**) as the rotating member moves forward, and such that an amount of fluid is pushed forward (e.g., infusion fluid, calibrant, sample) through the tubing, as described with reference to **Fig. 8A**. Similarly, when the tubing is in a bent configuration, the pinch point **808** is pushed backwards (e.g., along surface **806**) as the rotating member moves in reverse, such that an amount of fluid is drawn back (e.g., infusion fluid, calibrant, sample) through the tubing, such that a sample is drawn back into the vascular access device and the analyte sensor is bathed in the sample.

[0894] **Fig. 10E** is a graph illustrating an exemplary flow profile, in one embodiment. In preferred embodiments, the flow control device (e.g., the valve) includes a flow profile that is configured and arranged to direct the movements of the flow control device

Abbott Ex. 1003 - 331/1058

(e.g., between the free flow and controlled flow valve positions, see **Figs. 10C-10D**), such that the analyte sensor is alternately bathed in samples and washed by the infusate (e.g., IV fluid, calibrant solution, a medicament solution, and the like). Referring to the exemplary flow profile depicted in **Fig. 10E**, time is shown on the X-axis and flow rate (e.g., the rate of fluid being moved through the valve) is shown on the Y-axis. Because this is a generic flow profile, for discussion purposes only, the Y-axis is relative and thus has no 0-ml/hr flow rate depicted. A specific flow profile can include a 0-ml/hr flow rate, as well as positive (e.g., valve moving forward) and negative (e.g., valve moving backwards) flow rates. The flow profile includes one or more phases (e.g., **phases X, Y** and **Z**); wherein each phase is configured to infuse an amount of fluid, to draw back an amount of sample and/or to hold an amount of fluid (e.g., infusion fluid and/or drawn-back sample) stagnant (e.g., substantially still). In general, a phase is associated with a function, such as but not limited to drawing back a sample (e.g., blood) such that the analyte sensor is bathed in the sample, returning the used sample to the host, washing the analyte sensor (e.g., with solution), calibrating the sensor, maintaining vessel patency, KVO, infusing a hydration fluid, infusing an amount of medicament (e.g., responsive to analyte sensor data and/or to a criterion and/or protocol), and the like. In general, a phase of the flow profile can include one or more flow rates, each of which can last various periods of time. A rate can be selected depending upon the function of the phase of the flow profile, the content of the infusion fluid, the size of the vascular access device (e.g., catheter size, sample size, etc.), a medication protocols, and the like.

[0895] As a non-limiting example, the flow profile depicted in **Fig. 10E** includes three phases (e.g., **X**, **Y**, and **Z**). **Phase X** includes two flow rates, **Rate A** and gravity flow (**GF**). **Phase Y** includes a second rate (**Rate B**), which is lower (e.g., slower) than **Rate A**. **Phase Z** contains a third rate (**Rate C**), which is lower than both **Rates A** and **B**. At **Rates A, B** and **C**, the valve is in a controlled flow valve position. When the valve is in a controlled flow position, it can be stationary (e.g., 0-ml/hr flow rate) or it can move through a plurality of positions in which the tubing is pinched between the roller **802** and the compression surface **806**. While not wishing to be bound by theory, one can consider an infinite number of controlled flow positions to exist, wherein the valve creates pinch point **808** by compressing the tubing between the roller **802** and compression surface **806**. Similarly, an infinite number of pinch points can exist along the compression surface, provided that the valve is in a

Abbott Ex. 1003 - 332/1058

controlled flow position. The valve is configured to move at a plurality of speeds, such that the valve can move the pinch point at a plurality of speeds (faster/slower), such that the desired (e.g., programmed and/or re-programmed) flow rates are achieved. For example, fluid can be infused at rates from about 0.0, 0.001, 0.01, 0.1, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0 ml/hr to about 20.0, 30.0, 40.0, 50.0, 60.0, 70.0, 80.0, 90.0, 100.0, 110.0, 130.0, 150.0, 175.0, 200.0, 225.0, 250.0, 275.0, 300.0, 350.0, 400.0, or 450.0 ml/hr or more. In another example, sample can be drawn back at rates from about -10.0, -9.0, -8.0, -7.0, -6.0, -5.0, -4.0, -3.0 ml/hr to about -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, -0.1, -0.05, -0.01 or -0.001 ml/hr or less. In some embodiments, when the valve is in the controlled flow position, the flow rate is from about 0.5-ml/hour to about 4.0-ml/hr. In some embodiments, a phase of the flow profile can include two, three, four or more rates. In some embodiments, a phase can include a period of gravity flow (e.g., **GF**), during which the valve is moved to the gravity flow position, which is discussed in greater detail below. In some embodiments, the one or more rates are optimized to achieve the function of the phase relative to a medical protocol. For example, during a wash phase, a slower flow rate can be used if the infusion solution contains heparin, as compared to the flow rate necessary to sufficiently clean the sensor of blood cells when a non-heparinized infusion solution is used. As another example, if the infusion solution contains a medicament, the flow rate of a wash phase can be selected to optimize sensor cleaning while still infusing the desired amount of medicament into the host. In still another example, a slower flow rate can be chosen to flush the sensor and return the sample to a neonatal host, due to the small lumen size of the catheters used in such tiny hosts, such that, for example, excessive amounts of fluid are not infused into the host. In yet another example, during a calibration phase, the calibrant can be slowly infused (e.g. prior to and/or during measurement of the calibration solution), such that the temperature of the calibration fluid equilibrates with the host's body temperature, as described elsewhere herein. In still another example, during a measurement phase, a sample can be drawn back at a rate selected to maintain the temperature of the sample, to prevent rupture of blood cells within the sample, and/or to optimize sensor function.

[0896] The flow profile can include periods of gravity flow (**GF**), during which the valve is in the gravity flow valve position and fluid **602a** can flow freely through the valve (e.g., through the tubing received by the valve). The rate of gravity flow is dependent upon

Abbott Ex. 1003 - 333/1058

the affect of gravity on the infusion fluid, and thus depends in part on the height of the bag **602**. For example, the bag can be located relatively higher or lower, with respect to the valve, the floor and/or the host. If the bag is higher, the flow rate will be relatively faster. If the bag is lower, the flow rate will be relatively slower. In some embodiments, gravity flow rates range from about 600, 630 or 650-ml/hour to about 670 or 700-ml/hour or more. In some embodiments, when the valve is in the gravity flow valve position, the flow rate is at least about 600-ml/hr. In some embodiments, the system is configured such that the analyte sensor is flushed (e.g., washed, cleaned, cleaned) by the solution when the valve is in the gravity flow valve position. For example, in some embodiments, gravity flow removes blood cells or other blood components from the sensor and/or the lumen of the vascular access device more efficiently that other (e.g., lower) flow rates.

[0897] In some embodiments, washing of the sensor is optimized by setting a ratio of gravity flow rate to controlled flow rate, such as *via* programming the flow profile to provide the flow rates. For example, in some embodiments, the ratio of gravity flow (e.g., a first flow rate) to controlled flow (e.g., a second flow rate) is at least about 10:1, wherein, the rate of gravity flow lasts 10-times greater than the controlled flow rate. In some embodiments, the ratio of the gravity flow rate to the controlled flow rate is at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or 9:1. In some embodiments, the ratio of the gravity flow rate to the controlled flow rate is from at least about 12:1, 15:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1 to at least about 125:1, 150:1, 175:1, 200:1, 250:1, 300:1, 350:1, 400:1, 450:1, or 500:1 or greater. In some embodiments, the ratio of the gravity flow rate to the controlled flow rate is optimized for sensor washing. For example, the ratio is optimized such that the washed sensor's measurement of the current sample is substantially unaffected by the presence of components of the previous blood sample. For example, in some embodiment, the optimal ratio of the gravity flow rate to the controlled flow rate, for sensor washing, is 10:1. In some embodiments, the optimal ratio (of gravity flow to controlled flow) for sensor washing is at least about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1 or 9:1. In some embodiments, the ratio of the gravity flow rate to the controlled flow rate is from at least about 12:1, 15:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1 to at least about 125:1, 150:1, 175:1, 200:1, 250:1, 300:1, 350:1, 400:1, 450:1, or 500:1 or greater. In some embodiments, a period of gravity flow is included in a phase of the flow profile, such as a wash or flush phase, or in a phase configured to infuse a

Abbott Ex. 1003 - 334/1058

programmed amount of infusion solution (e.g., for hydration, for nutrition and/or to deliver an amount of medicament). In some embodiments, the flow profile is configured to cycle between two or more flow rate ratios. In some embodiments, the ratio of flow rates is associated with the configuration of the system. For example, a system configuration for use in an adult host will have different flow profile requirements than a system configured for use in a pediatric host. In another example, a system configured access of the circulatory system *via* an artery will have different flow profile requirements than a system configured for access *via* a vein. In yet another example, a system having the sensor extend into a catheter's lumen may be have different flow profile requirements than a system having a sensor located in a fluid coupler.

[0898] Returning to **Fig. 10E**, the flow profile can be configured differently, depending upon the system configuration, the type of host, and the like. For example, the flow profile can include more or fewer phases. In another example, **Phase X** can include one or more additional flow rates, or it could consist of only **Rate A** or only **GF**. In another example, **Rate B** can be slower or faster than depicted, including even slower than **Rate C** or greater than **Rate A**. In another example, **Phase Y** can include additional periods of faster and/or slower rates and/or one or more periods of **GF**. **Rate C** can be even slower, or it could be faster. If **Rate C** is a negative rate, then sample is being drawn back and can be drawn back at slower (less negative) or faster (more negative) speeds. In another example, a phase can include two or more flow rates that are alternated intermittently and/or periodically throughout the phase. In yet another example, a phase can include a flow rate of about 0.0 ml/min, wherein the fluid and/or sample is held substantially stagnant for a period of time.

[0899] In some embodiments, at least a portion of a flow profile can be repeated. For example, two or more phases can be repeated for a period of time, such as but not limited to a period of time lasting from about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours to about 0.75, 1, 2, 3, 4 or more days. In some embodiments, the two or more phases of the flow profile are repeated until a criterion is met and/or exceeded (e.g., until a certain period of time has passed, until an amount of medicament is infused, until the host's blood analyte level falls within a preprogrammed range of concentrations, until a caretaker responds to an alarm by pressing a button on the user interface, and the like). In some embodiments, all of the phases of the flow profile are repeated, such as in a cyclical manner, such as until the end of the sensor session (e.g., when the sensor is removed from the host and/or the system is turned off). In some

Abbott Ex. 1003 - 335/1058

embodiments, the flow profile is configured to be paused and/or interrupted, such as during transfer of the host from his hospital room to another location for a procedure, for example.

[0900] In some embodiments, the flow profile is configured to be responsive to the analyte level measured/generated by the sensor. For example, the flow profile can be configured to use one or more optional phases, which can include one or more alternative flow rates, when the analyte measured meets/exceeds a criterion. For example, in some embodiments, the infusion solution includes a medicament. In some embodiments, the flow profile is configured to meter the flow of the medicament solution based at least in part on a measured analyte concentration. In one exemplary embodiment, the sensor includes a glucose sensor, the IV solution contains insulin, and the flow profile is configured to infuse an amount of the insulin solution in response to the host's glucose level. For example, the flow profile can be configured to infuse a low amount of insulin continuously (e.g., a basal amount) and when the host's blood glucose exceeds a programmed range, the flow profile can increase the rate of infusion for a period of time, such as until the host's glucose returns to the range (e.g., a bolus amount). In some embodiments, the amount of medicament (e.g., the insulin solution) to be infused is calculated by the processor module, responsive to the sensor data. In some embodiments, the processor module includes at least a portion of the flow profile. In some embodiments, the flow profile includes an optional phase, such as but not limited to an infusion phase, configured to infuse an amount of medicament. For example, in some embodiments, the processor module includes a medicament infusion phase configured to infuse an amount of insulin sufficient to return the host's blood glucose to a programmed range (e.g., between 80-120 mg/dl glucose). In some exemplary embodiments, the flow profile can be programmed (e.g., re-programmed), such as by the processor module (e.g., responsive to at least one criterion), such that a medicament infusion phase is added to the flow profile for one or more cycles. In some embodiments, the flow profile includes selectable sub-profiles, which can be automatically selected by the flow profile responsive to one or more criteria and/or selectable and/or programmable by a caretaker. In some embodiments, the flow profile includes a menu of selectable flow profiles (e.g., two or more), from which a user can select one to use when applying the system to a host (e.g., installation, set up). For example, in some embodiments, a user can select the flow profile to use from the menu, depending upon host physical properties, a drug to be infused, certain medical protocols, and the like.

Abbott Ex. 1003 - 336/1058

[0901] As described in the section entitled "Fluids," in some embodiments the infusion solution is a saline solution formulated for infusion into the host. In some embodiments, the infusion solution can contain an amount of the calibrant. For example, if the sensor is a glucose sensor, the infusion solution can contain an amount of glucose (e.g., 50, 75, 100, 125, 150, 175, or 200 mg/dl glucose or more) suitable for calibrating the glucose sensor. This type of solution may be referred to as a "calibration solution." In some embodiments, the medicament solution can include a calibrant. For example, if the sensor is a glucose sensor and the medicament is insulin, the insulin solution can also contain glucose. Alternatively or additionally, the calibration solution and the medicament solutions can be provided separately, such at in separate IV bags. Accordingly, in some embodiments, the system is configured to switch some one IV bag to the other (e.g., from the calibration solution (e.g., glucose) to the medicament solution (e.g., insulin) and *vice versa*) accordingly to the flow profile. In other embodiments, the system includes as mixing valve configured and arranged to mix the medicament solution and the calibrant solution, wherein a ratio of medicament solution to calibrant solution is based at least in part on a measured analyte concentration. For example, if the host's blood glucose exceeds the programmed range, then the flow profile can respond by directing mixing an amount of the insulin solution into the calibration solution being infused, wherein the amount of insulin is sufficient to return the host's glucose to the programmed range. In some embodiments, the flow control device is further configured and arranged for a piggyback connection with a medicament delivery device, such as a bedside or ambulatory infusion pump. In preferred embodiments, the piggyback connection includes at least one check valve. Check valves can be configured to provide a variety of functions. For example, in some embodiments, the check valve is configured to prevent backflow into the piggybacked medicament delivery device, such as flow of calibration solution into the medicament delivery device's medicament reservoir. In other embodiments, the check valve is configured to prevent inadvertent draining of the medicament reservoir into the host, such as when the system is shut off. Descriptions of some medicament infusion devices suitable to piggyback with the present system can be found in U.S. Patent No. U.S. Patent No. 4,685,903, U.S. Patent No. 4,898,578, U.S. Patent No. 4,925,444, U.S. Patent No. 5,158,437, U.S. Patent No. 5,219,279, U.S. Patent No. 5,207,642, U.S. Patent No. 5,248,300, U.S. Patent No. 5,321,392, U.S. Patent No. 5,496,273, U.S. Patent No. 5,522,798, U.S. Patent No. 5,482,446,

Abbott Ex. 1003 - 337/1058

U.S. Patent No. 5,547,470, U.S. Patent No. 5,551,850, U.S. Patent No. 5,630,710, U.S. Patent No. 5,681,285, U.S. Patent No. 5,685,844, U.S. Patent No. 5,745,378, U.S. Patent No. 6,231,320, U.S. Patent No. 6,231,560, U.S. Patent No. 6,269,340, U.S. Patent No. 6,544,229, U.S. Patent No. 6,648,821, U.S. Patent No. 6,817,990, U.S. Patent No. 6,692,457, U.S. Patent No. 6,985,870, U.S. Patent No. 7,018,361, U.S. Patent No. 7,109,878, U.S. Patent No. 7,204,823, U.S. Patent No. 7,402,153, U.S. Patent No. 7,417,729, U.S. Patent Publication No. US-2007-0060871-A1, U.S. Patent Publication No. US-2007-0112298-A1, U.S. Patent Publication No. US-2007-0213657-A1, U.S. Patent Publication No. US-2007-0299389-A1, U.S. Patent Publication No. US-2008-0033357-A1, U.S. Patent Publication No. US-2008-0097326-A1, U.S. Patent Publication No. US-2008-0103447-A1, U.S. Patent Publication No. US-2008-0154177-A1, U.S. Patent Publication No. US-2008-0147050-A1, U.S. Patent Publication No. US-2008-0161753-A1, and U.S. Patent Publication No. US-2008-0200897-A1, each of which is incorporated herein by reference in its entirety.

[0902] As described herein, in some embodiments, the flow control device includes an electronic solenoid **805** configured to operate a free flow mitigation device **606e** (e.g., a spring-clip occluder included in the tubing assembly **606a**). A free flow mitigation device is configured and arranged to prevent inadvertent free flow of IV solution into the host, such as during tubing installation and removal, or during power interruption to the system. The flow control device and tubing assembly are configured and arranged such that they are functionally engaged after the tubing is installed in the vascular access device. For example, in **Fig. 10A**, the free flow mitigation device **606e** and the electronic solenoid **805** are aligned such that the solenoid can bias (e.g., activate) the spring clip occluder in a non-occluded (e.g., un-pinched, opened) position, when the system is in operation. The spring clip occluder is configured and arranged to be engaged by an electronic solenoid **805** located in the flow control device. In preferred embodiments, the electronic solenoid **807** is configured and arranged such that free flow mitigation device returns to an occluded position when power is removed, such as when the system is turned off on in the event of a power outage. In preferred embodiments, the system configured and arranged to control the free flow mitigation device electronically, such as but not limited to by the flow profile. For example, in one embodiment, after system installation and/or initiation, the flow profile electronically controls the electronic solenoid to maintain the spring clip occluder in an opened position. In another embodiment, the flow

Abbott Ex. 1003 - 338/1058

profile directs the solenoid to activate (e.g., open, biased in the non-occluded position) the free flow mitigation device during solution infusion and/or sample drawback, and to deactivate (e.g., closed, bias in the occluded position) the free flow mitigation device if the system is paused and/or the system is switched off. In still another embodiment, the flow profile includes a phase with a 0-ml/hr (or 0-ml/min) flow rate, and the flow profile electronically directs the solenoid to deactivate the free flow mitigation device during this phase, and activation (e.g., reactivation) of the free flow mitigation device during the other phases of the flow profile. In some embodiments, the flow profile is configured to deactivate the free flow mitigation device (e.g., *via* the electronic solenoid) in response to a fail-safe, such as but not limited to in response to a fail-safe programmed to handle a fluidics problem or a sensor failure. Fail-safes are described in detail elsewhere herein.

[0903] In some embodiments, the system is configured to infuse an amount of medicament, responsive to the analyte sensor data. In one exemplary embodiment, the system includes a continuous glucose sensor and processor module including a flow profile (e.g., programming) configured for infusion of an amount of an insulin solution (e.g., such that a calculated amount of insulin is infused) in response to the host's glucose concentration. For example, processor module is configured to and/or includes programming that processes the continuous glucose sensor data, whereby the host's glucose level is determined in real time. In preferred embodiments, the processor module is configured to calculate the volume of insulin solution to be infused, such as if the host's blood glucose exceeds a predetermined threshold (e.g., the host is hyperglycemic; e.g., glucose above 120 mg/dl, 130 mg/dl, 140 mg/dl, 150 mg/dl, 160 mg/dl, 170 mg/dl or more), the processor calculates an amount of insulin to be delivered to the host (e.g., an amount of insulin solution sufficient to lower the host's glucose to or near the predetermined range). In preferred embodiments, the processor module re-programs the flow profile to deliver the amount of infusion solution required to deliver the calculated amount of insulin (e.g., a bolus amount), and the flow control device infuses the amount of solution responsive to the re-programming of the flow profile. For example, in some embodiments, the processor module is configured to insert (e.g., add) a medicament infusion phase into the flow profile. As the host's blood glucose level approaches and/or reaches the predetermined range, the processor module is configured to re-program the flow profile to reduce the amount of insulin-containing solution infused. For example, in some

Abbott Ex. 1003 - 339/1058

embodiments, the processor module is configured to re-program the flow profile to infuse a basal level of insulin, such as during washing of the sensor.

Pumpless Sample Withdrawal

[0904] In some circumstances, it is preferred to meter the flow of a fluid through a vascular access device (including withdrawal of at blood sample) without the use of a pump and/or a flow control device (e.g., described above). Accordingly, some embodiments provide a system for continuously measuring an analyte in an artery of a host *in vivo*, which does not require the use of the flow control device of the preferred embodiments or of a pump. Accordingly, in some preferred embodiments, the system includes an arterial infusion system and continuous analyte sensor coupled thereto. The arterial infusion system is configured and arranged to meter the flow of a fluid into and/or out of an artery of a host, and includes an arterial catheter, a pressure transducer, an infusion fluid, and a pressure system. The pressure system is configured to increase and/or reduce an amount of pressure applied to the infusion fluid, such that when the infusion system is applied to the host (e.g., the catheter is implanted in the host's artery), the pressure system can infuse the infusion fluid, withdraw a blood sample, and reinfuse a withdrawn sample into the host. In general, arteries are pressurized. Accordingly, blood will expelled from a puncture in the artery (e.g., an inserted/implanted catheter, a cut or breakage) unless pressure greater than the arterial pressure is applied thereto, such as via compression, a pressure cuff, a pressurized infusion system, and the like. An arterial pressure system can be configured to infuse fluid into the host by increasing the pressure applied to the infusion fluid, such as (but not limited to) by increasing the pressure applied with a blood pressure cuff, such that the applied pressure overcomes the arterial pressure. In preferred embodiments, the system is configured to withdraw a sample (e.g., contact the sensor with the blood sample) by reducing the applied pressure (in a controlled manner) until a sample of blood is pushed into the catheter (by the arterial pressure) and contacts the sensor. In some embodiments, the withdrawn sample is reinfused into the host, such as by increasing the applied pressure such that the arterial pressure is again overcome and infusion fluid flows into the host. In some embodiments, the withdrawn sample is diverted to waste disposal, such as *via* a valve. In some embodiments, the system is configured such that the sensing portion of the sensor are disposed within the host's body (e.g., within the artery) as described herein. However, in other embodiments, the sensor is disposed extracorporeally

Abbott Ex. 1003 - 340/1058

(e.g., above a plane defined by the host's skin) and the sample is withdrawn out of the host's body. In preferred embodiments, the system includes electronics configured to regulate the pressure system, such that infusion and sample withdrawal are controlled.

[0905] The analyte sensor can be configured to detect a variety of analytes, as described elsewhere herein. In some embodiments, the analyte sensor includes a single working electrode, which generates a first signal associated with the concentration of the analyte in the sample. In other embodiments, the analyte sensor is a dual-electrode continuous analyte sensor, as described elsewhere herein, and includes a first working electrode configured to generate the first signal (including an analyte-related signal component and a non-analyte-related signal component) and a second working electrode is configured to generate a second signal (including the non-analyte related signal component).

[0906] In some embodiments, a method for continuously measuring an analyte in an artery of a host *in vivo* is provided. In this embodiment, the method includes the steps of coupling a continuous analyte sensor with an arterial catheter system applied to a host, wherein the sensor is configured to generate an analyte-related signal associated with an analyte in a sample, and wherein the arterial catheter system includes an arterial catheter, a pressure transducer, an infusion fluid, and a pressure system configured to increase and/or reduce an amount of pressure applied to the infusion fluid; reducing the amount of pressure, such that a sample of arterial blood contacts the sensor; and generating the analyte-related signal with the sensor. In some embodiments, the coupling step includes coupling the sensor to the arterial catheter, such as by inserting the sensor into a lumen of the arterial catheter. In some embodiments, the method includes a step of reinfusing the sample into the host, such as by increasing the amount of pressure. In some embodiments, the arterial blood pressure of the host is monitored, using the pressure transducer. Arterial pressure monitors are known in the art. In preferred embodiments, the analyte-related signal is processed to provide an analyte value. In some embodiments, the signal is also calibrated.

[0907] In some embodiments, the generating step further includes generating a second signal with the sensor, wherein sensor includes a first working electrode configured to generate a first signal including an analyte-related signal component and a non-analyte-related signal component and the second working electrode is configured to generate the second signal including the non-analyte-related signal component. The first and second signals can be

Abbott Ex. 1003 - 341/1058

processed, to provide a processed signal substantially without a signal component due to the non-analyte-related signal component, and/or to provide a scaling factor. In some embodiments, the generating step further includes generating a reference signal associated with a reference analyte in the sample, wherein the sensor further includes a reference sensor configured to generate the reference signal.

Systems and Methods for Processing Sensor Data

[0908] In general, systems and methods for processing sensor data associated with the preferred embodiments and related sensor technologies include at least three steps: initialization, calibration, and measurement. Although some exemplary analyte sensors, such as glucose sensors, are described in detail herein, the systems and methods for processing sensor data can be implemented with a variety of analyte sensors utilizing a variety of measurement technologies including enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, and the like. Namely, analyte sensors using any known method, including invasive, minimally invasive, and non-invasive sensing techniques, configured to produce a data signal indicative of an analyte concentration in a host during exposure of the sensor to a biological sample, can be substituted for the exemplary analyte sensor described herein.

[0909] In some embodiments, the sensor system is initialized, wherein initialization includes application of the sensor and/or sensor system in or on the host. In some embodiments, the sensor system includes a computer system including programming configured for performing one or more of the following functions: turning the system on, requesting and/or receiving initial data (e.g., time, location, codes, etc), requesting and/or receiving patient data (e.g., age, conditions, medications, insulin dosing, etc), requesting and/or receiving calibration information (e.g., manufacturer calibration lot data, reference information such as solution(s) provided for calibration, etc.), requesting information related to the flow control device, and the like.

[0910] In some embodiments, the sensor system is configured with a predetermined initial break-in time. In other embodiments, the sensor system is configured to determine when break-in is complete (e.g., the sensor signal is substantially stabilized). In some embodiments, the sensor's sensitivity (e.g., sensor signal strength with respect to analyte concentration) and/or baseline is used to determine the stability of the sensor; for example,

Abbott Ex. 1003 - 342/1058

amplitude and/or variability of sensor sensitivity and/or baseline may be evaluated to determine the stability of the sensor signal. In alternative embodiments, detection of pH levels, oxygen, hypochlorite, interfering species (e.g., ascorbate, urea, and acetaminophen), correlation between sensor and reference values (e.g., R-value), and the like may be used to determine the stability of the sensor. In some embodiments, sensor stability is evaluated by determining if and/or when sensor break-in is complete. In some embodiments, the sensor is configured to calibrate during sensor break-in, thereby enabling measurement of the biological sample prior to completion of sensor break-in.

[0911] In one embodiment, systems and methods are configured to process calibrated sensor data during sensor break-in. In general, signals associated with a calibration and/or measurement phase of the sensor system can be measured during initial sensor break-in. Using a rate method for measuring an analyte (e.g., measuring the rate of change of a step change), a sensor signal can be calibrated with a correction factor to account for the rate of change of the break-in curve. In one exemplary embodiment, the bottom of sequential step responses (e.g., of calibration phases during sensor break-in) is fit to a line or curve (e.g., using linear or non-linear regression, such as least squares regression), to extrapolate the rate of change of the curve of the sensor break-in. Accordingly, the rate of change measured in a measurement phase is corrected to account for the rate of change of the sensor break-in curve, and the sensor signal calibrated. By calibrating during sensor break-in, sensor data can more quickly be provided (e.g., to the user interface) after sensor insertion.

[0912] In some embodiments, systems and methods are configured to determine an initial baseline value of the sensor. In general, baseline refers to a component of an analyte sensor signal that is not substantially related to the analyte concentration. In one example of a glucose sensor, the baseline is composed substantially of signal contribution due to factors other than glucose (for example, interfering species, non-reaction-related hydrogen peroxide, or other electroactive species with an oxidation/reduction potential that overlaps with hydrogen peroxide).

[0913] In preferred embodiments, the sensor system includes a computer system including programming configured to determine calibration information and calibrate a signal associated with a biological sample there from. In general, calibration of the signal includes initial calibration, update calibration and/or re-calibration of the sensor signal. Although some

Abbott Ex. 1003 - 343/1058

systems and methods for calibrating a sensor are described in more detail elsewhere herein, for example in the section entitled, "Sensor Electronics," additional and alternative methods for providing calibration information and calibrating the sensor's signal are provided in the following description and can be used in combination with and/or alternative to the methods described elsewhere herein.

[0914] The term "calibration information" generally refers to any information, such as data from an internal or external source, which provides at least a portion of the information necessary to calibrate a sensor. In some embodiments, calibration information includes steady state information, such as baseline information and/or sensitivity information obtained by processing reference data from an internal and/or external reference source, which is described in more detail elsewhere herein. In some embodiments, calibration information includes transient information, such as rate of change information and/or impulse response information obtained by processing a signal produced during exposure of the sensor to a step change (e.g., sudden or nearly sudden change) in analyte concentration, which is described in more detail elsewhere herein.

[0915] In some embodiments, steady state information includes reference data from an external source, such as an analyte sensor other than the sensor of the sensor system configured to continuously measure the biological sample, also referred to as external reference data or external reference value(s). In some embodiments, calibration information includes one, two, or more external reference values (e.g., from self-monitoring blood glucose meters (finger stick meters), YSI Glucose Analyzer, Beckman Glucose Analyzer, other continuous glucose sensors, and the like). In some embodiments, one or more external reference values are requested and/or required upon initial calibration. In some embodiments, external reference value(s) are requested and/or required for update calibration and/or re-calibration. In some embodiments, external reference values are utilized as calibration information for calibrating the sensor; additional or alternatively, external reference values can be used to confirm the accuracy of the sensor system and/or to detect drifts or shifts in the baseline and/or sensitivity of the sensor.

[0916] In one exemplary embodiment, at least one external reference value in combination with at least one internal reference value together provide calibration information useful for calibrating the sensor; for example, sensitivity of a sensor can be determined from

Abbott Ex. 1003 - 344/1058

an external reference value and baseline can be at least partially determined from an internal reference value (e.g., a data signal indicative of an analyte concentration in a reference solution during exposure of the sensor to the reference solution, which is described in more detail elsewhere herein).

[0917] In another exemplary embodiment, calibration information includes two or more external reference values that provide calibration information useful for calibrating the sensor; for example, at least two SMBG meter values can be used to draw a calibration line using linear regression, which is described in more detail elsewhere herein.

[0918] In yet another exemplary embodiment an external reference value is utilized to confirm calibration information otherwise determined (e.g., using internal reference values).

[0919] In some embodiments, steady state information includes reference data obtained from the analyte sensor to be calibrated, also referred to as internal reference data or internal reference values. In one exemplary embodiment, internal reference data includes a signal associated with exposure of the sensor to one or more reference solutions (e.g., calibration solutions), which is described in more detail elsewhere herein.

[0920] In some embodiments, the sensor system includes one or more reference solutions (e.g., calibration solutions in some embodiments), wherein the system is configured to expose the sensor to the one or more reference solution(s) to provide calibration information (e.g., an internal reference value), such as baseline and/or sensitivity information for the sensor. In one exemplary embodiment, a reference solution including a known analyte concentration is provided, wherein the system is configured to expose the sensor to the reference solution, and wherein the system is configured to produce a data signal indicative of an analyte concentration in the reference solution during exposure of the sensor to the reference solution, as described in more detail elsewhere herein. In some embodiments, two reference solutions with two different analyte concentrations are provided. For example, in order to generate reference values for detecting sensitivity drift of a glucose sensor, two saline solutions containing 100 and 200 mg/dl glucose respectively can be provided.

[0921] In general the system can be configured to obtain internal reference values at one or more time points, intermittently, and/or continuously. For example, in some embodiments, calibration for drift in baseline and/or sensitivity can be done at set time intervals, depending upon the severity of the drift. In some circumstances, it is preferred to

Abbott Ex. 1003 - 345/1058

calibrate very frequently (e.g., between about every 1 minute or less and about every 2, 3, 4, 5, 10, 15, 20 or 30 minutes or longer). In other circumstances, it is preferred to calibrate less frequently (e.g., about every 1, 2, 3, 5, 10, 15 or 24 hours or longer). For example, in some circumstances, baseline drift has a substantial effect on sensor accuracy, while sensitivity drift has little effect. Accordingly, a baseline calibration solution (e.g., 0-mg/dl glucose) can be used to calibrate the baseline about every 5 minutes. Thus, to calibrate for sensitivity drift, an analyte-containing calibration solution (e.g., 100-mg/dl glucose in saline) can be used to calibrate the sensor less frequently, such as about once every 1, 2, 3, 5, 10, 12, 24, 48 or more hours. In some embodiments, one or more external reference values, such as reference values obtained by testing a blood sample with SMBG or a YSI device, can be used to calibrate the system, in addition to the internally provided reference values (e.g., provided *via* the calibration solutions).

[0922] Although much of the description focuses on the use of a reference calibration solution to provide an internal reference value, other sensor technologies, such as optical sensing methods, are known to provide one or more internal reference standards (e.g., of known absorbance, reflectance, fluorescence, etc) to determine baseline and/or sensitivity information, as is appreciated by one skilled in the art; accordingly, the systems and methods described herein can be implemented with other types of internal reference values. Examples of analyte sensors configured for optical detection of the analyte and/or a reference analyte are described in detail in the section entitled "Optical Detection," above. In some embodiments, a "plateau" is reached when the sensor has been exposed to the sample of bodily fluid (e.g., blood) or a reference solution a sufficiently long period of time that the sensor's enzyme has used up (e.g., reacted with, detected) substantially all of the available analyte.

[0923] In some embodiments, the sensor system is configured to use a steady state measurement method, from which steady state information can be obtained. Steady state information can be obtained during exposure of the sensor to an analyte concentration when the signal has reached a "plateau" wherein the signal is representative of the analyte concentration; the term plateau does not limit the signal to a flat signal, rather the plateau represents a time point or time period during which the signal is substantially stable and a data point that represents the analyte concentration can be reliably obtained.

Abbott Ex. 1003 - 346/1058

[0924] **Fig. 11** is a graph that schematically illustrates a signal produced during exposure of the sensor to a step change in analyte concentration, in one exemplary embodiment. The x-axis represents time; the y-axis represents sensor signal (e.g., in counts). In general, a step change occurs when a sensor is sequentially exposed to first and second different analyte concentrations, wherein the signal (after the change from exposure of the sensor to the first analyte concentration to exposure of the sensor to the second analyte concentration) includes a measurable rate of change (transient information) that subsequently "plateaus" or substantially "plateaus" to a signal that substantially represents the analyte concentration to which the sensor is exposed (steady state information). As one example, a step change occurs when a sensor is exposed to a reference solution of a first analyte concentration and then subsequently exposed to a reference solution of a second, different, analyte concentration. As another example, a step change occurs when a sensor is exposed to a reference solution of a known analyte concentration and then subsequently exposed to a biological sample of unknown or uncalibrated analyte concentration.

[0925] Referring to **Fig. 11**, at a first time point **1002**, a sensor is exposed to a step change in analyte concentration, for example, from a zero concentration reference analyte solution to a biological sample of unknown or uncalibrated analyte concentration. During the initial signal response to the step change, a rate of change **1004** of the signal can be measured for a time period. In some embodiments, for example when the step change is between two known reference solutions, the rate of change information can provide transient information useful for calibrating the sensor, which is described in more detail elsewhere herein. However, if either of the first and/or second analyte concentrations of the step response is not known, the rate of change information, alone, cannot provide sufficient calibration information necessary to calibrate the sensor.

[0926] Point **1006** represents a point in time that the signal response shifts from transient information (e.g., rate of change) to steady state information (e.g., plateau), in some embodiments. Namely, the signal, beginning at point **1006**, substantially accurately represents the analyte concentration and can be used in steady state equations to determine an analyte concentration, in some embodiments. In one exemplary embodiment of steady state equations useful for calibrating the sensor system, the calibration information is obtained by solving for the equation $y=mx+b$, wherein: "y" represents the sensor data value (e.g., digitized in "counts")

Abbott Ex. 1003 - 347/1058

determined at a single point (or averaged value over a window of data where signal is indicative of analyte concentration, for example); "*b*" represents baseline (e.g., unrelated to the analyte); "*m*" represents sensitivity (e.g., for a glucose sensor, counts/mg/dL); and "*x*" is the concentration of the reference solution (e.g., known analyte concentration in a reference calibration solution (e.g., glucose in mg/dL)). In this exemplary embodiment, steady state information includes sensitivity and baseline.

[0927] In some embodiments, the sensor data value (*y*) can be obtained from a moving window that intelligently selects a plateau during exposure of the sensor to an analyte concentration. In some embodiments, the sensor system is configured to be exposed to two or more known reference calibration solutions from which steady state information (sensitivity and baseline) can be processed to calibrate the sensor system; namely, by providing two known analyte concentrations, the steady state equation described above can be utilized to solve for baseline and sensitivity of the sensor, which can be utilized to define a conversion function or calibration factor, such as described in more detail elsewhere herein.

[0928] Referring again to **Fig. 11**, point **1006** is a point that can be used as "*y*" in the steady state equation described above. In some embodiments, the point **1006** is easily determinable as it is the beginning of a signal plateau **1008** (represented by a dashed line); accordingly, the system includes programming to process the data signal to determine the signal plateau and/or a time point therein. In general, a step change produces a signal plateau in the signal response, which is indicative of a steady state response to the analyte concentration measurement. In some embodiments, the system includes programming configured determine the time period (window) during which the signal has reached a plateau and choose a single point or average point from that window.

[0929] In some situations, however, the point **1006** and/or plateau **1008** may not be easily determinable. For example, in some sensor systems, the diffusion of certain non-analyte species (e.g., baseline, background and/or interfering species), which may diffuse more slowly than the analyte (e.g., through a membrane system that covers the analyte sensor), do not reach a steady state during the same time period that the analyte reaches a steady state. In these situations, the signal may not "plateau" in a measurable manner because of the reaction of the lagging species through the membrane system, which generate additional signal over the actual analyte plateau **1008**. In other words, while the analyte concentration may have reached a

Abbott Ex. 1003 - 348/1058

plateau, the baseline has not. Dashed line **1010** represents the signal response to a step change in such a situation, for example, wherein the signal does not substantially "plateau" due to the lagging diffusion of certain non-analyte species, resulting in a non-measurable analyte plateau. In these situations, additional information is required in order to provide calibrated analyte sensor data. Systems and methods for providing additional information and/or to provide sufficient calibration information to calibrate an analyte sensor in such situations are described in more detail below, with reference to conjunctive measurements, for example.

[0930] In some embodiments, the sensor system is exposed to a reference solution with a known analyte concentration of about zero, and wherein the steady state information comprises baseline information about the sensor in the reference solution. For example, a glucose sensor system can be exposed to a 0 mg/dl glucose solution (e.g., an isotonic solution without any glucose concentration) and the signal associated with the zero glucose concentration in the reference solution provides calibration information (steady state) indicative of at least a portion of the baseline of the sensor.

[0931] It has been observed that, in some circumstances, the signal associated with the zero glucose concentration in a reference solution (such as saline) is not equivalent to the baseline signal when the sensor is exposed to a biological sample (e.g., blood) from which the sensor is configured to obtain its analyte concentration measurement; rather the baseline includes an additional amount of signal associated with the differences between the composition of the reference solution and the host's blood. This additional signal is referred to as "offset" (e.g., b_{offset}, see **Fig. 11**, **1016** and associated text). Offset is an indication of the level of noise present in the system, the presence of an interferent in the solution and/or in the blood, and/or the like. In some circumstances, additional information may be required in order to determine and/or confirm baseline of a biological sample (e.g., blood). In some embodiments, 1, 2, 3 or more external reference analyte values are obtained (e.g., *via* finger stick, a clinical analysis device (e.g., YSI) and the like) and entered into the system, such as for use in determining b_{offset}. For example, in some embodiments, the equitation $y = mx + (b + b_{offset})$ is used to calibrate the sensor, wherein m is determined when the sensor is exposed to calibration solution, b is determined from the dual-electrode and b_{offset} is an external reference value, such as but not limited to a finger-stick reference value (in counts). In some embodiments, error is substantially mitigated by evaluating two or more external reference

Abbott Ex. 1003 - 349/1058

analyte values for deviation therebetween, such as by averaging them, detecting outliers, and the like. In one embodiment, the external reference analyte value is compared to an estimated or calculated analyte value, such as to confirm the accuracy of a calculated b_{offset}. For example, in some embodiments, the difference between a finger-stick glucose value (e.g., in counts) and a calculated blood glucose value (e.g., in counts) is used as the b_{offset} in future calculations. In some embodiments, an offset threshold is set, based on *a priori* information (e.g., determined from numerous *in vitro* and/or *in vivo* experiments and/or the literature). For example, in some embodiments, the threshold is based on, at least in part, the maximum and/or minimum possible offsets for a given sensor configuration, a give type of host, and/or the like. In some embodiments, the calibration solution includes additional components provided to overcome baseline in blood, for example. In some embodiments, a factor is determined (e.g., from historical data) to determine an adjustment factor for a difference between baseline in the biological sample (e.g., blood) and baseline in the reference solution. In other embodiments, two calibration solutions are used to evaluate b_{offset}. In some embodiments, baselines of the working electrodes is determined prospectively, such as by testing in the reference solution by the manufacturer. In some embodiments, the difference in baseline of a biological sample (e.g., blood) and the baseline of the reference solution, also referred to as b_{offset} herein, is determined using other techniques, such as described in more detail below.

[0932] In general, the calibration information described above, including a known baseline and sensitivity, can be used to determine a conversion function or calibration factor applied to convert sensor data ("*y*") into blood glucose data ("*x*"), as described in more detail elsewhere herein.

[0933] In some embodiments, systems and methods are configured to obtain transient measurement information associated with exposure of the sensor to a reference solution of known analyte concentration and/or a biological fluid of unknown or uncalibrated analyte concentration. In some embodiments, the system is configured obtain transient information by exposing the sensor to a step change in analyte concentration and process the rate of change of the associated signal. In some embodiments, the system is configured to obtain transient information by exposing the sensor to a step change in analyte concentration and processing the impulse response of the associated signal.

Abbott Ex. 1003 - 350/1058

[0934] In one exemplary embodiment, the sensor is exposed to a first reference solution of a known analyte concentration and then to a second reference solution of a known analyte concentration to determine the rate of change of the signal response. In these embodiments, the equation ($\Delta y/\Delta t = r \cdot \Delta x$) can be used to obtain the transient information, wherein "Δx" is the difference between the two known solutions that are being measured (e.g., 0 mg/dL to 100 mg/dL in an exemplary glucose sensor), "Δy" is the measured difference between the sensor data (e.g., in counts) corresponding to the analyte concentration difference in known reference solutions (Δx), "Δt" is the time between the two "*y*" sensor measurements referenced with Δy, and "*r*" represents the rate of change calibration factor, or rate of change conversion function, that can be applied for that particular sensor to obtain calibrated blood glucose measurements from sensor rate of change data.

[0935] In some embodiments, transient information can be obtained from the rate of change of a signal produced during exposure of the sensor to a biological sample of unknown or uncalibrated analyte concentration. In some embodiments, transient information can be obtained from the step and/or impulse response of a signal produced during exposure of the sensor to a step change in analyte concentration.

[0936] In some embodiments, neither steady state information, nor transient calibration measurements are used in isolation in calibrating the sensor system, but rather steady state and transient information are combined to provide calibration information sufficient to calibrate sensor data such as described in more detail, below. For example, in some embodiments, wherein baseline is not completely known (e.g., b_{offset} must be determined), wherein a rate of change calibration factor is not easily determinable (e.g., when multiple known reference solutions cannot be pushed substantially immediately adjacent to each other to provide a rate of change indicative of the step or impulse response), wherein the a steady state measurement cannot be obtained (e.g., due to lagging species affecting the analyte signal plateau), and the like. In some embodiments, both steady state information and transient information are processed by the system to provide sensor calibration, confirmation, and/or diagnostics. In some embodiments, transient sensor information from unknown or uncalibrated blood glucose measurements can be processed to provide calibration information for the sensor system, such as described in more detail below.

Abbott Ex. 1003 - 351/1058

[0937] In some embodiments, once at least a portion of the calibration information is determined, the sensor system is configured to expose the sensor to a biological sample and measure a signal response thereto. In some embodiments, the sensor can be continuously exposed to the biological sample, wherein at least some external reference values are used as calibration information for calibrating the sensor system. In some embodiments, the sensor can be intermittently exposed to the biological sample, wherein at least some internal reference values are used as calibration information for calibrating the sensor system, also referred to as auto-calibration in some exemplary embodiments.

[0938] In some embodiments, the sensor system is calibrated solely using steady state information, such as described in more detail elsewhere herein. In one such embodiment, the sensor system is configured to be exposed to a biological sample and a value (y) determined from the signal plateau, which is used in combination with a conversion function (calibration factor) that uses steady state information (e.g., sensitivity and baseline) to obtain a calibrated analyte concentration (e.g., glucose concentration in mg/dL or mmol/L) equivalent to the measured sensor data value y.

[0939] In general, the sensor system of the preferred embodiments can be configured to utilize any combination the steady state information (e.g., from external and/or internal sources) described in more detail elsewhere herein. In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based on one, two, or more external reference values. In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based on one or more external reference values, which calibration can be confirmed using an internal reference value (e.g., zero analyte concentration reference solution). In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based on one external reference value in combination with one internal reference value to determine baseline and sensitivity information. In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based on internal reference values, also referred to as auto-calibration. In general, auto-calibration includes the use of one or more reference solution to calibrate the sensor system. In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based on prior information, which is described in more detail elsewhere herein. In some embodiments, the sensor system includes systems and

Abbott Ex. 1003 - 352/1058

methods configured to calibrate the sensor based on dual working electrodes, by substantially eliminating the baseline component of the steady state calibration equation (e.g., (y=mx)).

[0940] In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based solely on transient information (e.g., rate of change, decay, impulse response, etc) described in more detail elsewhere herein. In one exemplary embodiment, analyte concentration can be determined from the change in sensor data responsive to a step change (Δx), the time (Δt) elapsed between the sensor data measurements Δy, and the rate of change calibration factor/rate of change conversion function, such as described in more detail above.

[0941] In some embodiments, the sensor system includes systems and methods configured to calibrate the sensor based on conjunctive information, wherein the calibration information used to calibrate the sensor system includes both steady state information and transient information.

[0942] In one exemplary embodiment, the sensor system includes systems and methods configured to calibrate the sensor based on a rate of change (transient information) associated with a signal produced during exposure of the sensor to a step change between a reference solution of known analyte concentration (e.g., 0 mg/dl glucose) and a biological sample; in this exemplary embodiment, a reference value (steady state information) from an external analyte sensor (e.g., blood glucose meter) can be obtained for the analyte concentration in the biological sample, thereby providing sufficient information to solve for calibration using rate of change of the signal response to the step change there between. One advantage of using rate of change calibration methods includes its insensitivity to baseline and interfering species.

[0943] In one preferred embodiment, a system is provided for monitoring analyte concentration in a biological sample of a host, the system including: a substantially continuous analyte sensor configured to produce a data signal indicative of an analyte concentration in a host during exposure of the sensor to a biological sample; a reference solution including a known analyte concentration, wherein the system is configured to expose the sensor to the reference solution, and wherein the sensor is configured to produce a data signal indicative of an analyte concentration in the reference solution during exposure of the sensor to the reference solution; and a computer system including programming configured to determine calibration

Abbott Ex. 1003 - 353/1058

information and calibrate a signal associated with a biological sample there from, wherein the calibration information includes steady state information and transient information. In some embodiments, the calibration information is determined from a signal associated with exposure of the sensor to the reference solution and a signal associated with exposure of the sensor to a biological sample.

[0944] One situation wherein steady state information and transient information are useful together for calibrating a sensor system includes a situation where a baseline measurement obtained from an internal reference ($b_{reference}$) provides only a portion of the baseline information necessary for calibrating the sensor system. As one example, the baseline of blood is different from the baseline of saline (e.g., reference) and compounds or molecules that make up the baseline in blood can create artifacts (e.g., b_{offset}), which can make calibration using internally derived steady state information alone, difficult. Namely, plateau **1008** (**Fig. 11**) in the signal responsive to the step change in analyte concentration does not occur in blood, in some embodiments, due to slow diffusion of baseline-causing compounds/molecules to the sensor electroactive surface; instead, an artifact **1010** (**Fig. 11**) is observed in the signal. Accordingly, in some embodiments, baseline information useful for calibration of a sensor system includes both $b_{reference}$ and b_{offset}. A variety of systems and methods of determining b_{offset}, which can be useful in providing calibration information and/or diagnostics and fail-safes, has been discovered, as described in more detail elsewhere herein.

[0945] In some embodiments, b_{offset} can be determined from transient information derived from a signal associated with exposure of the sensor to a biological sample, wherein the biological sample is of unknown or uncalibrated analyte concentration.

[0946] In one preferred embodiment, a system for monitoring analyte concentration in a biological sample of a host is provided, the system including: a substantially continuous analyte sensor configured to produce a data signal indicative of an analyte concentration in a host during exposure of the sensor to a biological sample; a reference solution including a known analyte concentration, wherein the system is configured to expose the sensor to the reference solution, and wherein the system is configured to produce a data signal indicative of an analyte concentration in the reference solution during exposure of the sensor to the reference solution; and a computer system including programming configured to determine calibration information and calibrate a signal associated with a biological sample

Abbott Ex. 1003 - 354/1058

there from, wherein the calibration information is determined from a signal associated with exposure of the sensor to the reference solution and a signal associated with exposure of the sensor to a biological sample, wherein the biological sample is of unknown or uncalibrated analyte concentration.

[0947] In some embodiments, systems and methods are configured to process an impulse response of a signal associated with exposure of the sensor to a biological sample, wherein the biological sample is of unknown or uncalibrated analyte concentration, in order to determine an offset between a baseline measurement associated with a reference solution and a baseline measurement associated with a biological sample (e.g., b_{offset}).

[0948] **Fig. 12** is a graph that schematically illustrates a derivative of the step response shown in **Fig. 11**. **Fig. 12** can also be described, as the impulse response of the signal associated when a sensor is exposed to a step change to a biological sample of unknown or uncalibrated analyte concentration, in one exemplary embodiment. In this embodiment, the impulse response can be defined by a sum of two exponentials functions (e.g., $(ae^{-k1*t} - ae^{-k2*t})$, where k1 and k2 are time constants characteristic of the sensor), wherein the impulse response starts at 0 at t=0 and is expected to decay to 0 as t becomes large (as time passes). The impulse response reaches a peak, shown as point **1050** in **Fig. 12**, which represents the maximum rate of change of the associated signal (see **Fig. 11**, for example). Additionally, although it is expected that the signal will decay to 0 as t becomes large, **Fig. 12** illustrates a plateau **1052** above the y-axis; namely, wherein the plateau **1052** does not hit 0.

[0949] It has been discovered that the positive value **1054** of the plateau substantially represents the slope of the b_{offset} artifact **1010** (**Fig. 11**). Accordingly, when the slope is drawn from t=0 of the step response (see line **1012** of **Fig. 11**), the "y" value **1016** of that slope line at the end of the step response **1014**, represents b_{offset}. Accordingly, b_{offset} can then be added to the equation y=mx+b (where $b= b_{reference} + b_{offset}$) and a conversion function (calibration factor) can be determined to calibrate the sensor system (i.e., using both steady state information and transient information and including using the signal associated with exposure of the sensor to a biological sample of unknown or uncalibrated analyte concentration.)

[0950] In some alternative embodiments, systems and methods are configured to process an impulse response (such as shown in **Fig. 12**) associated with a step change (such as

Abbott Ex. 1003 - 355/1058

shown in **Fig. 11**) to determine a time point of a steady state measurement during which an analyte concentration can be obtained. As described above, in some circumstances, it can be difficult to determine a steady state time point (e.g., **1006** in **Fig. 11**) at which time point the signal accurately represents the analyte concentration. Accordingly, systems and methods configured to determine the time point (e.g., **1006** in **Fig. 11**) in the step response associated with exposure of the sensor to a biological sample of unknown or uncalibrated analyte concentration have been discovered, which time point accurately represents the analyte concentration in the biological sample. Because the impulse response can by defined by exponentials (discussed above), systems and methods can be configured to process the exponential equation(s) with variable parameters to determine a best-fit to the impulse response curve determined from exposure of the sensor to the biological sample. It has been discovered that this best fit of the impulse response provides sufficient information to determine the time point **1056** (**Fig. 10**) at which the decay curve should have decayed to the y-intercept; namely, the time point **1056** where the decay curve should have hit y=0 indicates the (steady state) time point in the step response (e.g., **1006** in **Fig. 11**) that accurately represents the analyte concentration without the b_{offset} artifact **1010**. Accordingly, (y=mx+b) can then be used to calibrate the sensor system, including the signal value "*y*" at the time indicated by the extrapolated impulse response curve (e.g., and using sensitivity and baseline information determined from one or more reference calibration solutions, such as described in more detail elsewhere herein.

[0951] In some other alternative embodiments, systems and methods are configured to compare steady state information and transient information for a plurality of time-spaced signals associated with biological samples of unknown or uncalibrated analyte concentration to determine an offset between a baseline measurement associated with a reference solution and a baseline measurement associated with the biological samples.

[0952] In some exemplary embodiments, b_{offset} is determined by plotting level (i.e., the point at which the step response plateaus or ends) vs. rate (i.e., maximum rate of change of the step response determined from the peak of the impulse response curve) for a plurality of step responses (e.g., time-spaced signals) and drawing a regression line of the plotted points, such as described in more detail with reference to **Fig. 13**.

Abbott Ex. 1003 - 356/1058

[0953] **Fig. 13** is a graph that illustrates level vs. rate for a plurality of time-spaced signals associated with exposure of the sensor to biological samples of unknown or uncalibrated analyte concentration. The y-axis represents maximum rate of change for each step response; the x-axis represents level (signal level (e.g., in counts) obtained at the plateau of the signal and/or the end of the step response.) Each point **1080** on the plot represents level vs. rate for each of the plurality of time-spaced signals. A regression line **1082** is drawn using known regression methods, as is appreciated by one skilled in the art. The point **1084** at which the line **1082** crosses the y-axis represents the signal associated with a reference (e.g., 100 mg/dL calibration solution) plus b_{offset}. Accordingly, b_{offset} can be determined by subtracting the signal associated with the reference from the point **1084** at which the line **1082** crosses the y-axis. Thus, b_{offset} determined from the plot as described above, can be included in the equation $y=mx+b$ (where $b= b_{reference} + b_{offset}$) and a conversion function (calibration factor) can be determined to calibrate the sensor system (i.e., using both steady state information and transient information and including using the signal associated with exposure of the sensor to a biological sample of unknown or uncalibrated analyte concentration.)

[0954] In some embodiments, b_{offset} is an adjustable parameter, wherein the sensor system includes systems and methods configured to determine b_{offset} with each measurement cycle (each time the sensor is exposed to the biological sample) and to adjust the calibration factor (conversion function), including b_{offset} with each measurement cycle, responsive to a change in b_{offset} above a predetermined threshold, and/or responsive to external information, for example.

[0955] In some embodiments, systems and methods are provided to detect a shift in the baseline and/or sensitivity of the signal based on a comparison of steady state information and transient information, such as described in more detail with reference to **Fig. 13**. In some embodiments, systems and methods are provided to correct for a shift in the baseline and/or sensitivity of the signal based on a comparison of steady state information and transient information. In some embodiments, systems and methods are provided to initiate a calibration responsive to detection of a shift in the baseline and/or sensitivity of the signal based on a comparison of steady state information and transient information.

[0956] Referring again to **Fig. 13**, regression line **1082** is shown for a selected plurality of time spaced signals. In some embodiments, multiple regression lines can be drawn

Abbott Ex. 1003 - 357/1058

for a plurality of different windows of time spaced signals (e.g., time-shifted windows). In these embodiments, a comparison of a regression line from a first window of time spaced signals as compared to a regression line drawn from a second window of time spaced signals can be used to diagnose a shift and/or drift in sensor sensitivity and/or baseline. For example, in **Fig. 13**, line **1082** represents a regression line drawn for a first window of data over a first period of time; dashed line **1086** represents a regression line drawn for a second window of data over a second period of time; and dashed line **1088** represents a regression line drawn for a third window of data over a third period of time. In this example, dashed line **1086** is shifted along the y-axis from the first line **1082**, indicating a drift or shift in the sensor's baseline from the first time period to the second time period; dashed line **1088** is shifted along the x-axis from the first line **1082**, indicating a drift or shift in the sensor's sensitivity from the first time period to the third time period. Accordingly, a shift in the regression line can be used to diagnose a shift or drift in the sensor's signal and can be used to trigger a corrective action, such as update calibration and/or re-calibration using any of the methods described herein. Additionally or alternatively, the shift in the line can be used to correct a shift or drift in the sensor's signal; for example, the amount of shift in the line can be used to update calibration accordingly (e.g., the change in y-value between two regression lines can be representative of a corresponding change in baseline between two time periods, and the calibration information updated accordingly). One skilled in the art appreciates that some combination of shift or drift of the baseline and sensitivity can occur in some situations, which can be similarly detected and/or corrected for.

Sensor Sensitivity Evaluation

[0957] In some circumstances, noise on the sensor signal can be mistaken as a drift in sensor sensitivity. It has been empirically determined, through evaluation of large *in vivo* and/or *in vitro* data sets, that sensor sensitivity generally follows an expected pattern of drift, over the period of sensor use. For example, in one exemplary sensor configuration, during the first hour or so, of sensor use (e.g., after start-up and/or re-start-up after a period of disuse), sensitivity tends to change rapidly; after this period, the sensitivity increase tends to level off and/or plateau. However other sensitivity profiles are possible based on sensor design. While each individual sensor's sensitivity profile can vary from that of other such sensors, depending upon factors such as sensor design, membrane chemistry, implantation site, and the like, it has

Abbott Ex. 1003 - 358/1058

been found that sensor profiles tend to follow an empirically determined pattern of drift within a range of about ±5%, ±10%, ±15%, ±20% or ±25%. Deviations from the expected pattern can be indicative of noise on the sensor, sensor failure, and/or the like, which can be dealt with as described elsewhere herein, such as the section entitled "Diagnostics and Fail-Safes."

[0958] **Fig. 14** is a flow chart illustrating sensor sensitivity evaluation, in some embodiments. In preferred embodiments, systems and methods are configured to process a plurality of sensitivity calculations, to determine if an apparent sensitivity drift falls within the expected profile.

[0959] At block **1400**, a method for evaluating a change in sensitivity of an analyte sensor over a predetermined time period is provided. In some embodiments, the predetermined time period is relatively short, such as but not limited to less than or equal to about 30 minutes, also referred to as short-term sensitivity evaluation. In some embodiments, relatively shorter periods of time, such as 25, 20, 15, 10, 5 minutes are preferred. For example, in one embodiment, the evaluated sensitivities are calculated about every 5 minutes. In other embodiments, the predetermined time period is longer. For example, in one embodiment, the time period is at least about 30 minutes, also referred to as long-term sensitivity evaluation. In other embodiments, the predetermined time period is at least about 60 minutes. For example, in some embodiments, the predetermined time period is about 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190 or 200 minutes, or longer.

[0960] At block **1402**, sensor data is received from an analyte sensor. For example, in some embodiments, the system includes an input module, also referred to as the processor module, configured to receive the sensor analyte data. The sensor data can include one or more sensor analyte values measured in a bodily fluid of a host (e.g., blood). In some embodiments, an individual measurement is used. In some embodiments, an average of a plurality of time-spaced points is used. In some embodiments, reference analyte values are also received by the input module. For example, *in vivo* reference analyte values can be generated when the sensor is contacted with a reference solution. In some embodiments, reference analyte values are intermittently received. For example, in some embodiments, the *in vivo* reference analyte values are generated when the sensor is intermittently in contact with the reference solution (e.g., calibrant), such as according to the flow profile (e.g., see **Fig. 10E**). For example, if the sensor is included in an integrated system, such as depicted in **Fig. 6** and as described with

Abbott Ex. 1003 - 359/1058

reference to **Figs. 10A-10E**, wherein the flow control device moves between the controlled flow and gravity flow valve positions, such as at flow rates and times specified by the flow profile, and the sensor generates sensor data when the sensor is contacted with blood and reference values when the sensor is in contact with the reference solution. Additionally or alternatively, in some embodiments, the reference analyte value(s) are obtained from an *in vitro* analyte monitor (e.g., external reference analyte values). For example, a self monitored blood glucose monitor can be used to obtain external reference glucose values (e.g., from a finger-stick blood sample), which can be entered into the system, as described elsewhere herein.

[0961] At block **1404**, analyte sensor sensitivity is calculated intermittently (e.g., periodically or non-periodically), based at least in part on the reference analyte data, such as described elsewhere herein. For example, in some embodiments, the processor module is configured to and/or includes programming that calculates sensor sensitivity using the formula $y = mx + b$, wherein m is the sensitivity value (e.g., estimated and/or measured). For example, in some embodiments, the intermittently received reference analyte values are used to intermittently calculate the sensitivity of the analyte sensor, such as but not limited to from about once every 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25 or 30-minutes to about once every 1, 1.5, 2, 2.5 or 3-hours or longer. In some embodiments, a plurality of sensitivities is calculated over a predetermined time period. For example, in some embodiments, the processor is configured to and/or includes programming that calculates 2, 3, 4, 5, 6, 7, 8, 9, 10 or more sensitivities over a pre-programmed time period of 10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 120-minutes or longer. In some embodiments, the sensitivities are calculated iteratively. For example, as the integrated system cycles through phases of blood and reference solution measurement according to the system's (e.g., the processor module's) flow profile (e.g., programming). In some embodiments, the sensitivity values are filtered, such that each calculated sensitivity value is a filtered value. For example, in some embodiments, the data (e.g., reference analyte values) are filtered prior to use in calculation of the sensor sensitivity m (e.g., *via* an IIR or FIR filter). In another example, in some embodiments, the data (within a window of data) are averaged (e.g., equally or non-equally weighted average, mean-value, median, or the like) prior to use in calculation of sensor

Abbott Ex. 1003 - 360/1058

sensitivity. In yet another example, in some embodiments, two or more calculated sensitivities are filtered, averaged, smoothed, and/or the like.

[0962] At block **1406**, a plurality of time-spaced sensitivity calculations are evaluated over a predetermined time period. For example, in some embodiments, the plurality of time-spaced sensor calculations are evaluated to determine whether or not the sensor's sensitivity did change (e.g., drift), and if so, did the change in calculated sensitivities follow the empirically determined pattern, was the observed change due to noise, and the like, as described below. In some embodiments, the processor is configured to calculate a change (e.g., drift) in sensor sensitivity using the formula $Drift = \frac{m_{t1} - m_{t2}}{m_{t1}}$ and/or the formula $Drift = \frac{m_{t1} - m_{t2}}{(m_{t1} + m_{t2})/2}$, wherein m_{t1} is the calculated sensitivity at time 1, and m_{t2} is the calculated sensitivity at time 2, for example. In preferred embodiments, this evaluation is performed iteratively on the plurality of time-spaced sensitivity calculations over the predetermined time period. In some embodiments, at least two sensitivity values are evaluated during the predetermined time period. For example, in some embodiments, the difference between two sensitivity calculations (e.g., the amount of change) is evaluated. In some embodiments, the at least two sensitivity values are averaged and/or filtered (e.g., smoothed to remove noise) before they are evaluated. Filtering the sensitivity calculations can provide a smoother trajectory (e.g., curve) for evaluation of sensitivity drift by eliminating outliers and/or random noise (e.g., non-specific noise). The sensitivity calculations can be filtered using a variety of methods (e.g., FIR, IIR, averaging) as described elsewhere herein. In other embodiments, all of the sensitivity calculations over the time period are evaluated. In further embodiments, all sensitivity calculations are evaluated at a plurality of time points during sensor use. For example, a sensor session can last from the time when the sensor is implanted and/or the flow control device is turned on to the time when the system is turned off and/or the sensor is removed. In another example, a sensor can be implanted for an extended period of time, such as three or more days, with intermittent periods of use (e.g., when the power is on and the system is functioning). For example, the system may be intermittently powered down, such as during certain medical procedures. The period of sensor use before the powering down is considered to be a sensor session, in some embodiments. Similarly, the period of sensor use

Abbott Ex. 1003 - 361/1058

after the restart (e.g., power-up, re-power-up) is considered to be a sensor session, in some embodiments.

[0963] In some embodiments, a change in sensitivity is evaluated by comparing it (the change in sensitivity) with one or more criteria. For example, in some embodiments, *a priori* sensitivity information is used (at least in part) to evaluate the change in sensitivity. In general, *a priori* information includes information, data and/or observations generated during many previous *in vitro* and/or *in vivo* experiments, as well as information, data, and/or observations gleaned from the scientific literature. In some embodiments, the *a priori* sensitivity information includes and/or provides an expected profile (e.g., an expected pattern and/or amount of sensitivity change/drift over time). For example, it has been observed that in some sensor designs, the sensor sensitivity tends to increase over time, wherein the increase tends to occur within an expected range. For example, it has been observed that sensor sensitivity tends to increase over time (e.g., no substantial decrease over time), wherein the increase tends to occur within an expected range, wherein the magnitude of the change is related to the length of time the sensor has been used and/or implanted and/or energized (e.g., turned on). Deviation from the expected profile can be indicative of a failure of a portion of the integrated system, a detrimental change in the host's condition, and/or the like, in some embodiments. In some embodiments, the system is configured to evaluate and/or consider a deviation from the expected profile in combination with additional information (e.g., interferents, noise, completion of break-in, etc.) to determine if a system failure has occurred.

[0964] In some embodiments, the *a priori* sensitivity information defines a range (e.g., within boundaries and/or guard bands) of acceptable change (increase and/or decrease) in sensitivity. For example, in some circumstances, sensitivity can change (e.g., drift) up to about ±5%, ±10%, ±15%, ±20%, ±25%, ±30%, ±40%, ±50%, ±60%, ±70%, ±80%, ±90%, ±100%, ±200% or more over a given time period (e.g., over a time period of about 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 minutes or longer). In some embodiments, an acceptable change in sensitivity is related to how long the sensor has been in use, implanted and/or energized.

[0965] In some embodiments, a change in sensitivity is evaluated using a "cone" of feasible sensitivity values of the sensor, such that aberrant sensitivity changes (e.g., artifacts) are detected whenever the sensitivity value (e.g., amount of sensitivity change, a calculated

Abbott Ex. 1003 - 362/1058

change in sensitivity over a time period) falls (e.g., occurs) outside of the cone of possibility. In one embodiment, the cone of possible sensitivity values is defined in terms of a range of allowable (or feasible) sensitivity change for a time point during a sensor session. The range of allowable sensitivity change can change over time during a sensor session, for example, by allowing a greater sensitivity change during an earlier time period of a sensor session than a later time period of a sensor session. In general, sensitivity information depends upon sensor design and can be obtained from analysis of data sets (e.g., *a priori* information). A known feasible range can be represented (e.g., drawn) on a graph as a "cone of possible sensitivity values" (e.g., a range of possible calculated sensitivity values, for the next time period, based at least in part on one or more previously calculated sensitivity value(s) and *a priori* information). In some embodiments, one or more criteria used to determine the cone of possible sensitivity values are defined by an expected profile. For example , the cone of possibility initiates at the calculated sensitivity value of a first time period (e.g., the point of the cone) and projects forward in time (e.g., becomes broader), such that the broadest portion of the cone (e.g., the "base" of the cone) is located at and/or is projected toward or past the second time period. At the second calculated sensitivity value graphed, another "cone of possibility" can be drawn for the next time period (e.g., a third time period), wherein this new cone of possibility is based on the expected profile, and so on.

[0966] Accordingly, in embodiments wherein sensitivity is evaluated in the short-term (e.g., over periods of 30-minutes or less), when the change in sensitivity meets the one or more criteria (e.g., falls within the boundaries of the expected profile, is within a cone of feasible change, and/or the like), the system is configured to use the most recent sensitivity calculation evaluated (e.g., for sensor calibration and the like). Similarly, the system is configured to not use a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity does not meet one or more criteria. In some circumstances, the change in sensitivity not meeting the one or more criteria can trigger a sensor failure, an alert, an alarm, a fail-safe, and the like, as described elsewhere herein.

[0967] In some embodiments, evaluation of sensor sensitivity is conducted using a dual-electrode continuous analyte sensor. As described elsewhere herein, a dual-electrode analyte sensor includes two working electrodes, which are configured to provide two signals. The first signal includes an analyte component and a baseline component. The second signal

Abbott Ex. 1003 - 363/1058

includes a baseline component without an analyte component. As described elsewhere herein, in some embodiments, sensitivity of a dual-electrode analyte sensor is calculated using the signal from either (or both) of the working electrodes. Accordingly, in some embodiments, the intermittent sensor sensitivity calculations are based at least in part on the first signal or based at least in part on the second signal. In a further embodiment, the second signal is subtracted from the first signal to obtain a subtracted signal, wherein the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on a subtracted signal, combined with signals measured by the sensor when exposed to reference solution and/or blood. In some embodiments, a difference in sensitivities of the plus-enzyme and no-enzyme working electrodes is evaluated. For example, with respect to a dual-electrode glucose sensor exposed to a calibration solution (e.g., a glucose-containing infusion solution) the sensitivity measured by the no-enzyme electrode can be used as the sensitivity value for the enzyme electrode and/or subtracted signal as described in more detail elsewhere herein..

[0968] In some embodiments, sensor sensitivity can be calculated using an external reference value generated from a blood sample (e.g., a split sample, finger-stick), wherein the external reference value is measured using another test device, at the bedside or in a clinical laboratory. For example, in the case of glucose sensors, external reference values can be generated by a finger-stick or testing a blood sample using an YSI device. Use of external reference values (e.g., baseline value obtained *via* finger-stick and/or YSI) in calculation of sensor sensitivity is preferred in some embodiments, such as but not limited to non-dual-electrode continuous analyte sensors.

[0969] In an exemplary embodiment, a method for evaluating a change in sensitivity of an analyte sensor over a predetermined time period is provided, wherein sensor data is received from an analyte sensor, wherein the sensor data includes one or more sensor analyte values measured in a biological sample of a host, a sensitivity of the analyte sensor is intermittently calculated based at least in part on reference analyte data, and a change in sensitivity is evaluated by evaluating a plurality of time-spaced sensitivity calculations over a predetermined time period. For example, the processor module is configured to and/or includes programming that evaluates the change in sensitivity of the analyte sensor over the predetermined time period. In some embodiments, the predetermined time period is less than

Abbott Ex. 1003 - 364/1058

or equal to about 30, 25, 20, 15, 10, or 5 minutes. In other embodiments, the predetermined time period is at least about 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 minutes.

[0970] In another exemplary embodiment, a system for evaluating a change in sensitivity of an analyte sensor over a predetermined time period is provided. In this embodiment, the system includes a computer system including an input module configured to receive sensor analyte data and reference analyte data, wherein the sensor data includes one or more sensor analyte values measured in a biological sample of a host and wherein the reference data includes one or more reference analyte values, and a processor module configured to (1) intermittently calculate a sensitivity of the analyte sensor based at least in part on the reference analyte data and to (2) evaluate a change in sensitivity by evaluating a plurality of time-spaced sensitivity calculations over a predetermined time period. In some embodiments, the predetermined time period is less than or equal to about 30, 25, 20, 15, 10, or 5 minutes. In other embodiments, the predetermined time period is at least about 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 minutes.

[0971] In some embodiments, wherein the predetermined time period is less than or equal to about 30 minutes, also referred to as short term sensitivity evaluation, evaluating a change in sensitivity includes evaluating at least two sensitivity measurements during the predetermined time period. For example, the processor module is configured to and/or includes programming that evaluates at least two sensitivity measurements during the predetermined time period, to evaluate the change in sensitivity. For example, in one embodiment, the at least two sensitivity measurements are separated by 30 minutes. In other embodiments, the at least two sensitivity measurements are separated by 25, 20, 15, 10, or 5 minutes. In some further embodiments, the processor module is configured to and/or includes programming that averages and/or filters the at least two sensitivity measurements prior to evaluating the at least two sensitivity measurements. In some circumstances, averaging and/or filtering the at least two sensitivity measurements can reduce the affect of outlier data points on the evaluation.

[0972] In some embodiments, wherein the predetermined time period is less than or equal to about 30 minutes, the processor module is configured to and/or includes programming that compares the change in sensitivity with one or more criteria. For example, the one or more criteria include but are not limited to an expected profile of sensitivity change

Abbott Ex. 1003 - 365/1058

for the time period and/or a cone of possibility (e.g., a range of allowable sensitivity change), such as described above. In some embodiments, the processor module is configured to and/or includes programming that uses a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity meets one or more criteria. In other embodiments, the processor module is configured to and/or includes programming that does not use a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity does not meet one or more criteria.

[0973] In some embodiments, wherein the predetermined time period is less than or equal to about 30 minutes, the step of intermittently calculating a sensitivity of the analyte sensor includes intermittently receiving a reference analyte value. For example, in some embodiments, the processor module (also referred to as a receiving module) is configured to and/or includes programming that intermittently receives the reference analyte value(s). In some circumstances, reference analyte values can be measured by the system. In some embodiments, the system is configured to periodically receive a measured analyte concentration from a reference analyte solution. For example, in some embodiments, the sensor is exposed to the reference analyte solution, such that the sensor measures the analyte concentration of the reference analyte solution. In other embodiments, the reference analyte values are measured outside of the system. For example, in some embodiments, a reference analyte value obtained from an *in vitro* analyte monitor is received by the system.

[0974] In some embodiments, wherein the predetermined time period is less than or equal to about 30 minutes, the step of evaluating a sensitivity is iteratively performed on the plurality of time-spaced sensitivity calculations over the predetermined time period. For example, in some embodiments, the processor module is configured to and/or includes programming that evaluates a sensitivity calculation every 5, 10, 15, 20, 25 or 30 minutes.

[0975] In some embodiments, wherein the predetermined time period is at least about 30 minutes, also referred to as long term sensitivity evaluation, the processor module is configured to and/or includes programming that iteratively performs the sensitivity evaluation on the plurality of time-spaced sensitivity calculations over the predetermined time period (e.g., at least about 30 minutes). In some embodiments, the step of evaluating a sensitivity includes evaluating all of the sensitivity calculations over a sensor session. For example, if the sensor session is 3-days, then all of the sensitivity calculations from the sensor session up to

Abbott Ex. 1003 - 366/1058

the time of sensitivity evaluation are evaluated. Similarly, if the sensor session lasts 4, 5, 6, or 7 days, then all of the sensitivity calculations over that period of days are evaluated. In some embodiments, the processor module is configured to evaluate a sensitivity based at least in part on *a priori* sensitivity information. For example, *a priori* sensitivity information can be obtained from previous sensor uses, such as numerous *in vitro* and/or *in vivo* experiments. In some embodiments, the *a priori* sensitivity information includes an expected profile. For example, during the first hour of sensor use, the expected profile may be a line having a slope and/or curvature within a first range; while during the second hour of use the expected profile may be a line having a slope and/or curvature within a second range. In some embodiments, the *a priori* sensitivity information defines a range of acceptable change in sensitivity, such as described with reference to a cone of possible acceptable and/or feasible sensitivity changes. For example, a range of acceptable change in sensitivity can include changes in sensitivity observed 80%, 85%, 90% or 95% of the time, in numerous previously conducted *in vitro* and/or *in vivo* experiments (e.g., uses), for a given time period of sensor use and/or implantation.

[0976] In some embodiments of evaluating a change in sensitivity of an analyte sensor over a predetermined time period, the analyte sensor includes two working electrodes configured to provide a first signal (e.g., from the plus-enzyme working electrode) including an analyte component and a baseline component and a second signal e.g., from the no-enzyme (e.g., non-enzymatic) working electrode) including a baseline component without an analyte component. In some further embodiments, the processor module is configured to and/or includes programming that intermittently calculates a sensitivity of the analyte sensor based at least in part on the first signal. In some further embodiments, the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on the second signal. In some further embodiments, the processor module is configured to and/or includes programming that subtracts the second signal from the first signal to obtain a subtracted signal, wherein the step of intermittently calculating a sensitivity of the analyte sensor is based at least in part on the subtracted signal.

[0977] In some embodiments of evaluating a change in sensitivity of an analyte sensor over a predetermined time period, the analyte sensor is intermittently exposed to a biological sample (e.g., blood) and to a reference solution (e.g., an infusion solution containing a defined amount of analyte), such as described elsewhere herein. In some further

Abbott Ex. 1003 - 367/1058

embodiments, the processor module is configured to and/or includes programming that intermittently calculates a sensitivity of the analyte sensor based at least in part on a signal obtained when the analyte sensor is exposed to a biological sample (e.g., when blood is drawn back by the flow control device, according to the flow profile). In some further embodiments, the processor module is configured to and/or includes programming that intermittently calculates a sensitivity of the analyte sensor based at least in part on a signal obtained when the analyte sensor is exposed to a reference solution (e.g., when the flow control device infuses the reference solution, according to the flow profile). In some further embodiments, the processor module is configured to and/or includes programming that intermittently calculates a sensitivity of the analyte sensor based at least in part on a signal obtained when the analyte sensor is exposed a biological sample and a signal obtained when the analyte sensor is exposed a reference solution. For example, in some embodiments, a subtracted signal, which is derived from the signals obtained when the analyte sensor is exposed to the biological sample and the reference solution, is used for calculation of sensor sensitivity.

Sensor Stability Evaluation

[0978] It is known that many continuous analyte sensors, such as but not limited to intravascular sensors, have an initial period of sensor use after which the sensor signal becomes more stable and substantially representative of the analyte concentration (*e.g.*, where the current output from the sensor is stable relative to the analyte level). This period of time is referred to as "break-in" or "run in." Sensor break-in is a two-part process, including electrochemical break-in of the electrodes (e.g., electroactive surfaces) and membrane break-in (e.g., equilibration with the local environment post implantation). In general, break-in is associated with an exponential signal decay related to break-in of the electroactive surfaces. It has been observed that in some sensor system configurations, in addition to the exponential signal decay, the non-enzyme working electrode signal response to blood exposure is unstable for at least the first few cycles of system operation (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more cycles), depending upon the flow profile and/or sensor configuration. In these circumstances, to effectively remove baseline, in a dual-electrode sensor, it is preferred that the error of the plus-enzyme and no-enzyme working electrodes be within about ±10% of each other. However, the additional instability observed on the no-enzyme working electrode, in these circumstances, tends to increase the difference between the errors (of the two working

Abbott Ex. 1003 - 368/1058

electrodes), which causes inaccuracies (e.g., errors) in signal processing (e.g., subtraction of the no-enzyme signal from the plus-enzyme signal). While not wishing to be bound by theory, it is believed that the non-enzyme electrode instability is caused, at least in part, by the affects of biological noise and/or interferents on some membrane systems. After break-in is complete, these problems with the no-enzyme signal response are generally no longer observed.

[0979] It has been observed that break-in is not a permanent phenomenon. For example, it has been observed that when an implanted (e.g., in use) sensor is turned off (e.g., de-energized), after a time, the signal tends to begin destabilizing. In some circumstances, sensor sensitivity (m) begins to deteriorate. For example, calculated sensitivity values (m) may no longer meet the criteria requirements of a sensitivity evaluation (e.g., fall within the cone of possibility). Further, the longer the sensor remains turned off, the less representative of the analyte concentration the signal can become. However, the sensor can break-in again, if it is re-energized (e.g., turned on again). The length of this next break-in period depends, at least in part, on how long the sensor was turned off. For example, if the sensor was turned off for only 10 to 20 minutes, the break-in period could be about 5-10 minutes. In another example, if the sensor was turned off for three hours, a full hour or longer may be necessary for the break-in process to be completed. Since it is preferred to use a stable analyte sensor when measuring a host's analyte levels, systems and methods for determining when the sensor (e.g., the signal) is stable are provided in some embodiments.

[0980] Accordingly, in preferred embodiments, the system is configured and arranged to evaluate sensor stability (e.g., determine when and/or if sensor break-in is complete). Advantageously, evaluation of sensor stability enables improved selection of sensitivity evaluation parameters, and thus improved sensor calibration. For example, in some embodiments, when the sensor is still breaking in, a wider set of sensitivity (e.g., drift) parameters are selected (e.g., to allow greater amounts of drift, such as ±30%, ±40%, ±50%, ±60%, ±70%, ±80%, ±90%, ±100%, ±200% or more sensitivity drift over a given time period (e.g., 30-min, 1-hr, 2-hrs)). Then, when the sensor signal has stabilized, a more narrow set of sensitivity parameters are selected (e.g., ±5%, ±10%, ±15%, ±20% sensitivity drift over about 5, 10 or 15 minutes). In yet another embodiment, when the sensor is still breaking in (e.g., unstable), the baseline can be determined by means other than subtraction of the no-enzyme signal from the plus-enzyme signal, such as but not limited to use of *a priori* information (e.g.,

Abbott Ex. 1003 - 369/1058

in vitro and/or *in vivo*) and/or external reference analyte values, as described elsewhere herein. In a further embodiment, the system is configured to prompt the user to enter an external reference value (e.g., a finger-stick) about, near, at and/or after completion of break-in. In some embodiments, the system is configured to intermittently (e.g., 1, 2, 3, 4, 5, 6, 7, or more times every 10, 20, 30, 40, 50 or 60-minute or more) evaluate sensor stability, and to request an external reference value if the sensor has not yet sufficiently stabilized (e.g., if break-in is not yet complete). An average break-in time can be empirically determined (e.g., *a priori* information). In some embodiments, the system is configured to wait a period of time associated with a predetermined break-in time, and to begin evaluating sensor stability after that time period has passed.

[0981] **Fig. 15** is a flow chart illustrating sensor stability evaluation, in one embodiment. At block **1500**, a method for determining a stability of an analyte sensor is provided, in one embodiment.

[0982] At block **1502**, sensor data is received from an analyte sensor, such as by a data receiving module (also referred to as the processor module) operably connected to the analyte sensor system and configured to receive the sensor data from the sensor. In preferred embodiments, the sensor is a dual-electrode sensor as described elsewhere herein. For example, the analyte sensor includes (1) a first working electrode (plus-enzyme electrode) configured to provide first sensor data (e.g., a first signal), which includes an analyte component and a baseline component, and (2) a second working electrode (no-enzyme electrode) configured to provide second sensor data (e.g., a second signal), which includes a baseline component without an analyte component. In some embodiments, the processor module is configured to and/or includes programming that uses first sensor data and/or second sensor data, when the dual-electrode sensor is exposed to a blood sample, to evaluate sensor stability. In some embodiments, the processor module is configured to and/or includes programming that uses the first sensor data and/or the second sensor data, when the dual-electrode sensor is exposed to an infusion solution, to evaluate sensor stability. In some embodiments, the processor module is configured to and/or includes programming that uses subtracted signals to evaluate sensor stability. In some embodiments, the processor module is configured to and/or includes programming that uses only the second sensor data, received when the sensor is exposed to blood and/or reference solution, in order to determine when

Abbott Ex. 1003 - 370/1058

membrane break-in (e.g., membrane stabilization between two working electrodes) is complete.

[0983] At block **1504**, a stability of the analyte sensor is determined, based at least in part on the second sensor data (e.g., data from the non-enzyme working electrode), such as *via* the processor module. In some embodiments, the processor module is configured to and/or includes programming that determines sensor stability by evaluating a change in an amplitude of a plurality of time spaced points (e.g., 2, 3, 4, 5, 10, 15, 20, 30, 40, 50 or 100 or more points) from the second sensor data, such as when the sensor is exposed to a sample and/or an infusion solution. The time space points are spaced by about 1, 3, 5, 10, 15, 20 or 30 minutes to about 1, 1.5 or 2-hours or more, in some embodiments. For example, in one embodiment, the processor module is configured to compare the peak amplitudes from a plurality of measurement phases, such as when the sensor is exposed to blood. In one exemplary embodiment, the processor is configured to and/or includes programming that compares the amplitude (e.g., peak) of a first measurement (e.g., blood) phase to the amplitude of a second measurement phase (e.g., the next measurement cycle). In another exemplary embodiment, the processor is configured to and/or includes programming that compares the amplitude of a first calibration (e.g., exposed to calibration or reference infusion solution) phase to the amplitude of a second calibration phase. In another exemplary embodiment, the processor is configured to compare a difference between the amplitudes of the calibration and measurements phases of a first cycle (e.g., of a flow profile) to a difference between the amplitudes of the calibration and measurement phases of a second cycle. In yet another exemplary embodiment, the processor is configured to use the subtracted amplitudes (e.g., the plus-enzyme signal minus the no-enzyme signal). In other embodiments, the processor module is configured to and/or includes programming that compares a first point to a second point, wherein the first point is measured when the analyte sensor is exposed to the biological sample and the second point is measured when the analyte sensor is exposed to the infusion solution (e.g., a calibration, wash and/or infusion phase). In other embodiments, the processor module is configured to and/or includes programming that utilizes transient information, such as described with reference to a step-change and **Fig. 11**, to evaluate the sensor's stability.

[0984] In some embodiments, the processor module is configured to and/or includes programming that evaluates sensor stability using rate of change (ROC) information,

Abbott Ex. 1003 - 371/1058

such as but not limited to a difference in ROCs between two measurement and/or calibration phases of the second (no-enzyme) signal. In some embodiments, the two measurement phases are consecutive (e.g., obtained during consecutive cycles of the flow profile). However, in other embodiments, the measurement phases are separated by one or more measurement and/or calibration phases (e.g., cycles of the flow profile) and/or spaced in time. For example, in some embodiments, the cycles (e.g., during which the two measurement phases or two calibration phases occur) are separated by 1, 2, 3, 4, 5, 6, 7 or more (intervening) cycles; or the cycles (or phases) are separated by 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110 or 120 minutes or longer. In some embodiments, the processor module is configured to wait a period of time, such as but not limited to a predetermined break-in time period (e.g., a period of time approximately the length of an average break-in time for a particular sensor configuration), prior to evaluating sensor stability. In a preferred embodiment, the processor module is configured to evaluate a plurality of ROCs, such as but not limited to a series of 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more ROCs. For example, in one embodiment, the processor module is configured evaluate a first ROC (e.g., calculated for first and second measurement phases) and a second ROC (e.g., calculate between second and third measurement phases), relative to a threshold, and so on. In some embodiments, the processor module is configured to evaluate a plurality of ROCs within a window (e.g., moving or non-moving) of calibration or measurement phases, relative to a threshold.

[0985] In one exemplary embodiment, the processor module is configured to and/or includes programming that evaluates sensor stability (e.g., membrane break-in) using a moving predetermined time period (e.g., a moving window) of ROCs calculated from the second signal (e.g., from the no-enzyme electrode). In some embodiments, the moving window encompasses 2, 3, 4, 5 or more calculated ROCs. In some embodiments, the processor module is configured to compare each calculated ROC and/or a difference between two ROCs to a threshold, and to assign the ROC a flag (e.g., +1, -1 or 0; categorized as pass/fail, etc.), based on the comparison. For example, during the first hour of sensor use, the expected ROC is about from ±30%, ±40% or ±50% per every 5, 10, 15 or 20 minutes to about ±60%, ±70%, ±80%, ±90%, ±100%, ±200% or more per every 5, 10, 15 or 20 minutes; whereas, during the second hour of sensor use, the expected ROC is from about ±5% or less every 5, 10, 15 or 20 minutes to about ±10%, ±15%, ±20% or ±25% more every 5, 10, 15 or 20 minutes.

Abbott Ex. 1003 - 372/1058

Accordingly, if the ROC exceeds the threshold, it is flagged as +1. If the ROC falls below the threshold, then it is flagged as -1. If, on the other hand, the ROC is within the threshold, then it is flagged as zero (0). In some embodiments, the processor module is configured to determine that the sensor is substantially stable (e.g., break-in is complete) when the sum of the flags is zero. For example, if the pre-determined time period (e.g., a window) encompasses five (5) ROCs, the sum of the 5 flags within the window should equal zero, for the sensor to be considered stable. Preferably, the window is a moving window. For example, in some embodiments, the processor is configured to slide the window forward one ROC with each new cycle. In alternative embodiments, the processor module is configured such that the sum of the flags within the moving window must equal zero at least two times before the sensor is determined to be substantially stable. In still other embodiments, the processor is configured to evaluate the flags, wherein the value of a plurality of sequential flags (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more flags) must equal zero before the sensor is declared to be substantially stable. In some embodiments, the threshold is associated with the expected profile. In some other embodiments, the processor module is configured to evaluate the first signal (e.g., the plus-enzyme signal) when a sensor (dual-electrode or non-dual electrode) is exposed to calibration solution, when determining sensor stability. However, in other embodiments, the system is configured to evaluate sensor stability using data received when the sensor is exposed to blood. For example, in some embodiments of a dual-electrode sensor, the processor module is configured to calculate the second signal ROCs for two or more measurement cycles when the sensor is exposed to blood.

[0986] In some embodiments, the sensor is considered to be stable when it reaches a predetermined level (e.g., threshold) of stability (e.g., the signal is stable and/or substantially representative of the analyte concentration). Preferably, the processor module is configured to and/or includes programming that determines a predetermined (e.g., programmed) level of stability has been reached, when an amplitude change of the second sensor data meets one or more criteria. For example, in some embodiments, the one or more criteria are designed (e.g., selected) to detect a predetermined threshold (e.g., range) of plateau of the second sensor data (see **Fig. 11** for examples of plateaus (e.g., **1008** and/or **1010**)). In some embodiments, the expected range of plateaus is based at least in part on *a priori* information. Accordingly, in some embodiments, the processor module is configured to determine that the sensor is stable

Abbott Ex. 1003 - 373/1058

when a plateau of measured second sensor data (e.g., the test data or waveform) is within the expected range, such as but not limited to within about ±5%, ±10%, ±15% or ±20% of the expected range. In addition to a moving window, sensor stability can be evaluated using other statistical techniques, such as but not limited to point-to-point comparisons, evaluating a measured profile relative to an expected profile using covariance, standard deviation, or *r*-value, and the like.

[0987] In preferred embodiments, the system is configured to and/or includes programming that provides an output, such as *via* an output module, also referred to as a processor module, in response to the determination of the sensor's level of stability relative to a predetermined threshold. For example, in some embodiments, the processor module is configured to and/or includes programming that displays (e.g., *via* the user interface) an analyte value, information associated with sensor stability and/or other information on a local and/or remote display of the user interface in response to a determination of a sensor's stability meeting a threshold (e.g., does the sensor stability meet the threshold or not). In one exemplary embodiment, the processor module is configured to and/or includes programming that displays a first message when the sensor meets the threshold of stability, and a second message when the sensor does not meet the threshold. In another exemplary embodiment, the processor module is configured to and/or includes programming that selects from a menu of messages, symbols, or other indications, responsive to the level of sensor stability determination. For example, in some embodiments, the output includes an indication of at least one of a numeric estimated analyte value, a directional trend of analyte concentration, and a graphical representation of a plurality of estimated analyte values. For example, the output can indicate a request for reference analyte data. For example, if the sensor is a glucose sensor, the system can request a finger-stick or YSI reference analyte value. In another example, the system can request an injection (e.g., into the tubing) of a defined amount of analyte, such that the system can take a reference measurement as the injected analyte contacts the sensor. In some circumstances, other instructions are provided to the caretaker, in response to the determination of the predetermined level of stability. For example, an alert and/or alarm is sounded, such as by visual and/or auditory components of the user interface.

[0988] As described above, the break-in process can occur at various times during sensor use, such as during and/or after start-up and after periods of disuse. Accordingly, in

Abbott Ex. 1003 - 374/1058

preferred embodiments, the processor module is configured to and/or includes programming that determines stability of the analyte sensor at system start-up and/or after exposure of the sensor to blood and/or a calibration, reference, or infusion solution. In some embodiments, the processor module is configured to and/or includes programming that determines (e.g., evaluates) stability of the analyte sensor after a predetermined time period. For example, it is known that, depending upon the sensor's configuration, break-in can take from about 10, 20, 30 or 40 minutes to about 60, 90, 120 or 180 minutes or longer. For a given type of sensor, the average break-in time (e.g., time period, length of time) can be determined mathematically using *a priori* information. Accordingly, in some embodiments, the system is configured to begin determining the sensor stability after a predetermined time period (e.g., about half, two-thirds, three-quarters or the entire average break-in period, for that sensor configuration, has passed). In one exemplary embodiment, an exemplary intravascular dual-electrode glucose sensor can take about 1-hour to break-in. In this embodiment, the system is configured to begin determining (e.g., evaluating) sensor stability at about 30, 40, 50 or 60-minutes or longer. In a similar embodiment, analyte sensor stability is determined after a system re-start, such as but not limited to in circumstances when the sensor has been turned off for a period of time. For example, the sensor may be turned off when moving the patient, and then re-started; thus, the sensor's stability is determined when the sensor system is re-started.

[0989] In one exemplary embodiment, the analyte sensor is a glucose sensor, such as but not limited to a substantially continuous glucose sensor described herein (see **Figs. 1A-1J**, **2G-3I** for exemplary sensor configurations). For example, in some embodiments, the sensor is a component of the integrated system depicted in **Fig. 6**, in some embodiments. Preferably, the system (e.g., the processor module is) configured to and/or includes programming that determines the glucose sensor's stability. For example, the system is configured to begin determining the glucose sensor's stability after about 30, 40, 50, 60 or 70 minutes of implantation. In some embodiments, the glucose sensor is a dual-electrode continuous glucose sensor, such as a sensor configured for implantation into a peripheral vein of the host, wherein the sensor's stability is determined using a plurality of time-spaced sensor data points received from the enzymatic working electrode and/or the non-enzymatic working electrode, such as but not limited to when the sensor is exposed to blood samples (e.g., during a measurement phase of the flow profile) and/or a calibration phase. Determining the glucose

Abbott Ex. 1003 - 375/1058

sensor's stability can include evaluating the sensor's stability relative to one or more predetermined criteria, such as but not limited to a profile range (e.g., within about ±5%, ±10%, ±15% or ±20% of an average profile) generally observed for that particular type of glucose sensor. In preferred embodiments, the glucose sensor system is configured to determine the sensor's stability iteratively and/or periodically. In a further embodiment, the glucose sensor system is configured to determine the sensor's stability after re-start, such as after a period of disuse, as described herein.

Diagnostics and Fail-Safes

[0990] In some embodiments, the system includes programming configured to diagnose a condition of at least one of the sensor and the host responsive to calibration information. In some embodiments, the system intermittently or continuously determines at least some calibration information (e.g., sensitivity information, b_{offset}, and the like), each time the sensor is exposed to a reference solution and/or a biological sample.

[0991] In one embodiment, systems and methods are configured to find a plateau and/or stable window of data in response to exposure of the sensor to at least one of a reference solution and a biological sample. In some embodiments, if the system cannot find the plateau and/or stable window of data, the system is configured to "fail-safe;" for example, in some circumstances, a lack of plateau and/or stable window of data may be indicative of dilution and/or mixture of the reference solution (e.g., calibration solution) with the biological sample (e.g., blood), and/or interruption/disruption of expected/desired fluid flow. Additionally, in some circumstances, a lack of plateau and/or stable window of data may be indicative of interfering species in the signal.

[0992] In general, the term "fail-safe" includes modifying the system (e.g., the processor module) processing and/or display of data in some manner responsive to a detected error, or unexpected condition, and thereby avoids reporting and/or processing of potentially inaccurate or clinically irrelevant analyte values.

[0993] In another embodiment, systems and methods are configured to process a signal responsive to exposure of the signal to a reference and/or biological sample to determine whether the signal is within a predetermined range; if the signal falls outside the range, the system is configured to fail-safe.

Abbott Ex. 1003 - 376/1058

[0994] In some embodiments, systems and methods are configured to determine calibration information including sensitivity information, wherein the system includes programming configured to diagnose an error responsive to a change in sensitivity above a predetermined amount. For example, in a sensor system as described in more detail with reference to the exemplary embodiment of **Figs. 8A** to **8C**, the system can be configured to determine a sensitivity value during each calibration phase; and wherein the system can be configured to fail-safe when the sensitivity of a calibration phase differs from the previously stored sensitivity by more than a predetermined threshold. In this exemplary embodiment, fail-safe can include not using the sensitivity information to update calibration, for example. While not wishing to be bound by theory, the predetermined threshold described above allows for drift in the sensitivity of the sensor, but prevents large fluctuations in the sensitivity values, which may be caused by noise and/or other errors in the system.

[0995] In some embodiments, systems (including programming) and methods are configured to diagnose error in the sensor system by ensuring the sensor signal (e.g., raw signal of the reference solution(s)) is within a predetermined range. In some embodiments, the sensor signal must be within a predetermined range of raw values (e.g., counts, current, etc). In some embodiments, one or more boundary lines can be set for a regression line drawn from the calibration phase. For example, subsequent to performing regression, the resulting slope and/or baseline are tested to determine whether they fall within a predetermined acceptable threshold (boundaries). These predetermined acceptable boundaries can be obtained from *in vivo* or *in vitro* tests (*e.g.*, by a retrospective analysis of sensor sensitivities and/or baselines collected from a set of sensors/patients, assuming that the set is representative of future data). U.S. Patent Publication No. US-2007-0197889-A1, which is incorporated herein by reference in its entirety, describes systems and methods for drawing boundaries lines. In some embodiments, different boundaries can be set for different reference solutions.

[0996] In some embodiments, systems and methods are configured for performing diagnostics of the sensor system (e.g., continuously or intermittently) during exposure of the sensor to a biological sample, also referred to as the measurement phase, for example, such as described in more detail above with reference to **Figs. 8A** to **8C**. In some embodiments, diagnostics includes determination and/or analysis of b_{offset}. In some embodiments, systems and methods are provided for comparing sequential b_{offset} values for sequential measurement

Abbott Ex. 1003 - 377/1058

phases. In some embodiments, the system includes programming configured to diagnose an error and fail-safe responsive to a change in the b_{offset} above a predetermined amount. In some embodiments, the system includes programming configured to re-calibrate the sensor responsive to changes in the b_{offset} above a predetermined amount. In some embodiments, the system includes programming configured to detect an interfering species responsive to a change in the b_{offset} above a predetermined amount.

[0997] In some embodiments, the system includes programming configured to diagnose a condition of the host's metabolic processes responsive to a change in b_{offset} above a predetermined amount. In some embodiments, the system includes programming configured to display or transmit a message associated with the host's condition responsive to diagnosing the condition. While not wishing to be bound by theory, it is believed that changes in b_{offset} can be the result of an increase (or decrease) in metabolic by-products (electroactive species), which may be a result of wounding, inflammation, or even more serious complications in the host; accordingly, changes in b_{offset} can be useful in diagnosing changes in the host's health condition.

[0998] In some embodiments, the system includes programming configured to detect sensor error, noise on the sensor signal, failure of the sensor, changes in baseline, and the like, responsive to a change in b_{offset} above a predetermined amount.

[0999] In some embodiments, the system includes programming configured to determine a time constant of the sensor. One method for calculating a time constant for a sensor includes determining an impulse response to a step change, wherein time at the peak of the impulse response represents a time constant for the sensor. While not wishing to be bound by theory, it is believed that the time constant determined from the peak of the impulse response should remain substantially the same throughout the life of the sensor. However, if a shift in the time constant (between step changes and their associated impulse response curves) above a predetermined range is detected, it can be indicative of an unexpected sensor condition or error, for example. Accordingly, by comparing time constants from a plurality of impulse response curves (derived from a plurality of step responses), programming can be configured to diagnose a sensor condition or error and initiate programming (e.g., fail-safe), accordingly.

[1000] Accordingly, the system can "fail-safe," including performing one or more of the following fail-safe responses: temporarily or permanently suspending (e.g.,

Abbott Ex. 1003 - 378/1058

discontinuing) display of analyte data, updating calibration or re-calibrating the sensor, requesting external reference values, using external reference value(s) as confirmation of a detected condition, using external reference value(s) to update calibration or re-calibrate the sensor, shutting the system down, processing the sensor data to compensate for the change in $b_{offset,}$ transmitting one or more messages to the user interface or other external source regarding the sensor condition, and the like.

[1001] In preferred embodiments, the sensor electronics include a fail-safe module that is configured to detect a system malfunction. The fail-safe module can be configured to detect a variety of system malfunctions. For example, the fail-safe module can be configured to detect electrical malfunctions, malfunctions of the system fluidics, malfunctions of the sensor, and/or the like. For example, the system electronics can be configured to test and/or track the functions of different system components, and to intelligently recognize aberrant changed in such functions as possible malfunctions.

[1002] In some embodiments, the fail-safe module is configured to detect electrical malfunctions, such as but not limited to short circuit and electrical malfunction associated with start-up and/or sensor break-in. For example, it is known that an I/R drop across an electrochemical sensor's working electrode(s) generally occurs during use. The I/R drop can be monitored for changes, which can be indicative of an electrical malfunction. Similarly, during use of an analyte sensor in an intravascular system, wherein the sensor is periodically/alternately exposed to at least one reference solution and a blood sample, the generated signal is expected to rise and fall in a regular fashion, for example a recognizable wave-form pattern including peaks and valleys. For example, when the enzyme sensor is exposed to blood, the rate of the step-response indicates the change in glucose from calibration solution to blood. The plateau of the response also indicates the glucose concentration (although the plateau generally indicates the absolute glucose concentration, not the change in glucose concentration). Accordingly, the fail-safe module can be configured to monitor the pattern of step-responses (e.g., over time) for substantial changes/deviations, which can be indicative of electrical malfunctions. For example, in some circumstances, the signal can "rail" or "zero," wherein the signal rapidly changes to a non-physiological analyte value and remains relatively stable at that non-physiological value for a period of time. In some circumstances, the rapid change in value occurs at a rate that is also not physiologically possible. In some

Abbott Ex. 1003 - 379/1058

circumstances, a comparison of the rate-response (e.g., transient/kinetic information) *versus* plateau response (e.g., steady state information) of each blood measurement can be used as an indicator of sensitivity drift. Similarly, in some embodiments, comparison of rate-response *versus* plateau response on a non-enzymatic electrode/sensor when expose to blood can provide information related to the sensor's response to non-glucose species in the sample, which can be used to determine if and/or when to fail-safe.

[1003] In some embodiments, the fail-safe module is configured to detect fluidics malfunctions, which can include a malfunction of any part of the system configured to contact and/or move a fluid. For example, the vascular access device (catheter) can become occluded, such as due to blood clotting or pressing the *in vivo* orifice (e.g., catheter tip) against a vessel wall such that fluid cannot move in an out of the vascular access device. In some circumstances, the tubing can become kinked, the host can move his or her arm such that the catheter becomes bent, bubbles may get into the system, and/or the flow control system can malfunction (e.g., not metering fluid flow into the host or not withdrawing blood samples as it was programmed to do), such that washing, calibration, sample collection and the like are not performed as programmed. For example, the sample can become diluted with calibration solution, there may be clotting on a portion of the sensor, and the like. In one exemplary embodiment, the fail-safe module is configured detect fluidics malfunctions by monitoring the pattern of signal increases/decreases generated on the working electrode(s), to detect periods of time during which the signal does not follow an expected waveform (e.g., using known waveform analysis methods and/or pattern recognition algorithms), such as when the signal hits upper and/or lower limits. For example, if the signal zeros for a period of time, the fluidics system may be unable to withdraw a blood sample due to kinking of the tubing or occlusion of the catheter. In another example, the signal on the working electrode(s) may stop going back down when the tested blood sample should be re-infused into the host and the sensor should be contacted with wash/reference solution, which is indicative of a malfunction of expelling the used sample, washing the sensor, and the like. For example, if the catheter becomes occluded by a blood clot, the flow control system will be unable to meter fluid through the catheter.

[1004] In some embodiments, the fail-safe module is also configured to detect malfunctions of the analyte sensor. For example, a sensor malfunction includes but is not

Abbott Ex. 1003 - 380/1058

limited to noise on the signal, drift of sensor sensitivity and/or baseline, a broken component of the sensor, blood clotting on a portion of the sensor, and cross-talk, as described in more detail elsewhere herein.

[1005] In preferred embodiments, the fail-safe module is further to evaluate a detected malfunction against a criterion. One or more criteria can be preprogrammed (including reprogrammed) into the system, such as be a host, a caretaker of the host, and/or the manufacturer. For example, in some embodiments, one or more criteria could be selected from a menu/list of criteria, or manually programmed into the system. Available criteria can be responsive to the different types of malfunctions can occur and/or a user-perceived level of severity and/or urgency.

[1006] After a system malfunction has been detected, the fail-safe module is configured to provide an alert, an alarm and /or an instruction, such as to the host and/or a caretaker of the host. For example, the system can be configured to provide an auditory alarm (e.g., beeps, busses, siren, pre-recorded voice message, etc.), a visual alert (e.g., blinking or flashing lights or display screen), a tactile alert (e.g., vibrating), transmitting alerts/instructions to a remote location, such as a nurse's station or a doctor's phone/PDA, and the like.

[1007] As a non-limiting example, a method is provided for detecting system malfunctions *via* the processing of the data of a continuous analyte sensor implanted in a host's circulatory system. As described elsewhere herein, the continuous analyte sensor is configured to generate a signal associated with an *in vivo* analyte concentration when the sensor is implanted in the host. Additionally, the sensor electronics includes a fail-safe module configured to detect a system malfunction. Accordingly, the method includes exposing the sensor to a sample from the host's circulatory system and detecting a malfunction of the system, such as but not limited to an electrical malfunction, a fluidics malfunction, and/or a sensor malfunction. In some embodiments, an equilibrium analysis and/or a kinetic analysis of received data/signal is performed. As described elsewhere herein, the data include steady state (e.g., sensitivity and/or baseline information) and/or transient state information, which can be evaluated/analyzed to provide alerts, alarms and/or instructions.

[1008] As described herein, the system (e.g., the processor module and/or fail-safe module) can be configured to analyze steady state and or transient state information generated during the step-up response of the sensor, such as during the switch from blood to reference

Abbott Ex. 1003 - 381/1058

solution and *vice versa*, also referred to as waveform analysis (for example, using pattern recognition algorithms, and the like). For example, by analyzing the step-up waveform of a dual-electrode sensors non-enzymatic working electrode, the quality of blood sample aspiration can be evaluated (e.g., fluidics). Similarly, by analyzing the step-down waveform of the sensor's non-enzymatic working electrode, the quality of washing can be evaluated (e.g., fluidics). As another example, analysis of direction of the step-up response of the plus-enzyme working electrode upon exposure to blood can used to evaluate calibration accuracy.

System Diagnostics

[1009] During operation of the integrated system, wherein the system includes a continuous analyte sensor implanted in the host's circulatory system and a flow control device (e.g., **Fig. 6-7**), system artifacts, such as but not limited to distortion of calibration and analyte measurement waveforms can occur unexpectedly, for a variety of reasons. For example, anything that affects IV tubing can cause a fluidics malfunction, such as the host leaning on the IV tubing, or a blood clot fouling the sensor or occluding the catheter and/or vessel. To some extent, sensor calibration and analyte concentration determination are dependent upon the quality of the calibration and measurement waveforms, respectively. For example, a good quality waveform can be an indicator that the sensor can be accurately calibrated with the data comprised in that waveform and/or in a substantially time-corresponding waveform. However, it has been observed that in some circumstances, a signal waveform will be of poor quality (e.g., not representative of the system's function), and the data contained in that waveform is likely to be unsuitable for subsequent calculations, processes, and the like. For example, a poor quality the waveform can be an indicator that analyte measurements may not be accurate. Such a circumstance could be detrimental to the host's health. In such circumstances, not using (e.g., "throwing out" or disregarding) the poor quality signal waveform and its associated data, for calculating an analyte concentration, maintains sensor accuracy and saves time. Accordingly, preferred embodiments provide systems and methods for performing system diagnostics on the analyte sensor system, for example, such that the quality of a waveform is evaluated prior to use of data comprised in the waveform for sensor calibration and/or determination of analyte calibration.

[1010] **Fig. 16** is a flow chart illustrating system diagnostics, in one embodiment. At block **1600**, a method for performing a diagnostic of an analyte sensor system is provided,

Abbott Ex. 1003 - 382/1058

wherein the method includes providing a sensor system, which includes an analyte sensor and a flow control device configured to intermittently expose the analyte sensor to a biological sample and to an infusion solution, wherein the analyte sensor includes (1) a first working electrode configured to provide a first signal (e.g., plus-enzyme working electrode) including an analyte component and a baseline component and (2) a second working electrode configured to provide a second signal (e.g., second sensor data) including a baseline component substantially without an analyte component (e.g., no-enzyme working electrode), and evaluating the sensor system based at least in part on the second signal. Suitable dual-electrode continuous analyte sensor systems, such as those including twisted or bundled working electrodes or with working electrodes located within the fluid coupler, are described in detail elsewhere herein, such as but not limited to the sections entitled "Dual-Electrode Analyte Sensors," "Multi-Sensor Apparatus," and "Sensor Configurations for Equivalent Measurement of Noise Signals at the Two Working Electrodes." However, other dual electrode analyte sensors can be used, such as but not limited to those described in U.S. Patent No. 6,175,752 and U.S. Patent Publication No. US-2008-0119703-A1, U.S. Patent Publication No. US-2008-0108942-A1, and U.S. Patent Publication No. US-2008-0200789-A1, each of which is incorporated herein by reference in its entirety.

[1011] In preferred embodiments, the processor module is configured to and/or includes programming that evaluates the second signal (e.g., the no-enzyme signal) for an expected shape and/or pattern when the sensor is exposed to a biological sample and/or to an infusion solution. For example, in some circumstances, this is done to determine if the system fluidics (e.g., draw-back and infusion) are functioning properly. In some embodiments, the system is configured such that the flow profile includes a measurement phase and an infusion phase. During the measurement phases, the flow control device is configured to draw-back a sample, such that the sample contacts the sensor. It has been observed that during a measurement phase, the second signal (e.g., no-enzyme working electrode) waveform tends to rise in a monotonic manner, if the draw-back was successful. It has also been observed (e.g., over numerous *in vitro* and *in vivo* experiments) that during infusion (e.g., re-infusion of the drawn-back sample, infusion of calibration, a calibration period/phase), the second signal waveform tends to fall (e.g., decline) in a monotonic manner, if the infusion was successful. Deviation from these observed patterns may indicate that the draw-back or infusion was not

Abbott Ex. 1003 - 383/1058

successful, and, therefore, data comprised in the waveform may be unsuitable for use in some calculations.

[1012] In one exemplary embodiment, the processor module is configured to and/or includes programming that evaluates the second signal to determine a success of drawing back a biological sample from a host's circulatory system to the sensor (e.g., to contact the sensor). For example, in some embodiments, the system is configured to use data contained in the measurement waveform to calculate the analyte concentration, if it (the system, processor module) determines that the draw-back was successful. On the other hand, the system is configured to disregard/not use data comprised in the measured waveform for subsequent calculations (e.g., analyte concentration, sensor calibration, etc.), if it is determined that the draw-back was unsuccessful. In a further embodiment, the system is configured to display an analyte value measured during the biological sample draw-back in response to determining that the draw-back of sample was successful. In another exemplary embodiment, the system is configured to evaluate the signal to determine if an infusion was successful. In some embodiments, a successful infusion includes at least one of re-infusing the biological sample into the host, washing the sensor (e.g., removing a sufficient amount of sample such that substantially accurate data can be obtained during the next sample draw-back without interference from components from the current sample draw-back) and infusing an amount of infusion solution. For example, in some embodiments, determining a successful infusion includes displaying an analyte value measured in a biological sample after the infusing the infusion solution in response to a determination of a successful infusion.

[1013] At block **1602**, the analyte sensor is intermittently exposed to a biological sample and to an infusion solution. For example, the flow profile can include analyte measurement and calibration phases, such that the flow control device intermittently draws back blood samples that contact the sensor and infuses at least one reference solution, as described elsewhere herein.

[1014] At block **1604**, the system receives a first signal (e.g., the signal from the first working (e.g., plus-enzyme, enzymatic) electrode) including analyte and baseline (e.g., non-analyte-related) components and a second signal (e.g., the signal from the second working electrode (e.g., the non-enzymatic, no-enzyme electrode) including a baseline component without an analyte component. As is understood in the art, the signal includes a waveform,

Abbott Ex. 1003 - 384/1058

which is referred to as the "signal waveform" and/or the "test waveform." For example, when the signal (e.g., in counts) is plotted against time, the graph looks like a wave. The waveform is associated with the intermittent (e.g., alternating, cyclical) exposure of the sensor to blood and infusion solution. The iterative (e.g., cyclical, periodic) intermittent exposure of the sensor to blood and infusion solution can generate a plurality of waveforms. If the signal waveform is generated during a calibration phase of the flow profile (e.g., during exposure of the sensor to a calibration solution), also referred to herein as a "calibration signal waveform," then at least a portion of the data generated can be used for calibrating the sensor. If the signal waveform is generated during a measurement phase (e.g., during exposure of the sensor to a sample of the host's blood), also referred to herein as a "measurement signal waveform," then at least a portion of the data generated can be used for determining the host's blood analyte concentration.

[1015] At block **1606**, the processor module is configured to and/or includes programming that evaluates the system, based at least in part on the second signal (e.g., the no-enzyme signal of the non-enzymatic (e.g., second) working electrode). Since the signal generated by the no-enzyme working electrode includes baseline but substantially no analyte signal component, the shape (e.g., pattern) of the signal waveform generated is associated with (e.g., diagnostic of) the quality of the system's function (e.g., how well the system is functioning). For example, fluidics and sensor function problems are reflected in the waveform as a deviation from an expected pattern, such as but not limited to an average waveform generally observed when a system is in use.

[1016] The signal waveform can be evaluated using a variety of methods. In some embodiments, the processor module is configured to and/or includes programming that evaluates the signal waveform (e.g., of the second signal) by evaluating the signal waveform for an expected shape and/or pattern when the sensor is exposed to a biological sample and/or to the infusion solution (e.g., a hydration, reference, and/or calibration solution). For example, it has been observed, through numerous *in vitro* and *in vivo* experiments, that the second signal waveform tends, in a characteristic way, to rise (e.g., increase) when the sensor is exposed to sample (e.g., blood) and to fall (e.g., decrease) when the sensor is exposed to an infusion solution. In some embodiments, the processor module evaluates the signal waveform by evaluating a similarity and/or correlation between the signal waveform and a waveform

Abbott Ex. 1003 - 385/1058

template. In a further embodiment, a second signal waveform is compared to this expected shape (e.g., pattern), such as by visual inspection or similar means. For example, the second signal waveform and the expected waveform pattern can be graphed together, and then observed and/or evaluated to determine if they have a similar shape, if they are close together, if they substantially overlap (e.g., overlap by about 80%, 85%, 90%, or 95%), and the like. In one exemplary embodiment, the system is configured to use at least some of the data from the second signal waveform in subsequent mathematical processes and/or calculations (e.g., sensor calibration, analyte concentration calculation) if the second signal waveform is substantially similar to the expected shape (e.g., pattern; the signal waveform is of sufficiently and/or substantially high quality). In a further embodiment, the system is configured to use at least some of the first signal waveform data (e.g., plus-enzyme electrode) for determining the analyte concentration, calculating sensor sensitivity, calibrating the sensor, and/or the like, when the second signal waveform is substantially similar to an expected shape (e.g., pattern) and/or meets one or more criteria (e.g., falls within a threshold). If the second signal waveform is not sufficiently and/or substantially similar to the expected shape (e.g., pattern) and/or does not meet the one or more criteria (e.g., it is of lower quality), then the system is configured to disregard (e.g., not use, throw out) the second signal waveform data for other purposes, such as subsequent calculations. In a further embodiment, the system is configured to disregard the first signal waveform data (e.g., plus-enzyme electrode) when the second signal waveform is not substantially similar to the expected shape (e.g., pattern) and/or exceeds the threshold.

[1017] In preferred embodiments, the processor module is configured to and/or includes programming that uses mathematical methods to evaluate a signal waveform. In some embodiments, one or more waveforms are evaluated using correlation waveform analysis (e.g., cross-correlation). Preferably, correlation waveform analysis quantifies a correlation and/or similarity of corresponding points (e.g., of a measured waveform vs. a waveform template) for a variance, which provides an indication or measurement associated with directional correlation of the points. Additionally or alternatively, waveform analysis can include systems and methods for quantifying overlap of the corresponding points, namely, an amplitude or amount of difference between the measured waveform vs. a waveform template. In some preferred embodiments, waveform analysis ensures normalization of data such that maximum and minimum amplitudes are equivalent for comparison purposes. In general, any of the

Abbott Ex. 1003 - 386/1058

waveform analysis described herein can be performed on actual waveforms (signal) or transforms of the waveform, as is appreciated by one skilled in the art.

[1018] In some embodiments, a level of quality of the signal waveform is evaluated (e.g., a level of reliability). In some further embodiments, the system is configured to perform one or more tasks, such as calibrating the sensor, displaying information, or the like, responsive to the level of quality of the signal waveform, such as described herein. In some embodiments, the level of reliability is classified as pass or fail, good *versus* bad, acceptable *versus* not acceptable. In some further embodiments, the system is configured to perform a task when the waveform is classified as pass, acceptable or the like, such as described herein. In some further embodiments, the system is configured to perform another task or do nothing when the waveform is not classified as pass, acceptable, or the like (e.g., the waveform is classified as failed, not acceptable, etc.).

[1019] In some embodiments, when the second signal waveform is compared to an expected shape (e.g., pattern), a similarity and/or correlation of the second signal waveform to a waveform template (e.g., seed template) is evaluated. In some embodiments, the waveform template is based at least in part on *a priori* information. For example, a waveform template (for a measurement or a calibration phase) is generated (e.g., created, calculated, provided, determined, and/or formed) by integrating a plurality of previously generated second signal waveforms. Preferably, a waveform template is generated from a plurality of second signal waveforms obtained during previous *in vitro* and/or *in vivo* experiments (e.g., system uses). While in some embodiments, about 2, 5, 10, 20, 30, 40 or 50 second signal waveforms to about 60, 70, 80, 90 or 100 second signal waveforms are integrated to generate (e.g., produce, form) the waveform template, in other embodiments, hundreds or thousands of second signal waveforms are integrated to generate a waveform template (e.g., seed template). In some embodiments, a waveform template is generated from previous sensor sessions from an individual host, such as to provide an adaptive waveform template.

[1020] In some embodiments, the waveform template contains information specific to the sensor system in use, in addition to *a priori* information. For example, in some embodiments, the waveform template is based at least in part on a second signal waveform measured by the system (e.g., the system in use). Preferably, the processor module is configured to and/or includes programming that updates the template waveform (e.g., with the

Abbott Ex. 1003 - 387/1058

second signal waveform) when a similarity and/or correlation between the (second) signal waveform and the waveform template meets one or more criteria (and/or fall within a threshold). For example, if the second signal waveform substantially correlates with (e.g., at least about 80%, 85%, 90% or 95%) the (current) waveform template, the signal waveform is used to update the waveform template, to generate an updated waveform template (e.g., newest, latest version of, most recently updated), also referred to herein as an "adaptive template." Conversely, if the second signal waveform does not meet the one or more criteria, the system is configured to not integrate the second signal waveform with the waveform template (e.g., the system can "throw out" the poor quality or bad waveform). In some embodiments, a similarity of the second signal waveform to the template is evaluated by plotting the second signal waveform (e.g., the waveform just measured) with the waveform template, wherein the processor module is configured to and/or includes programming that determines a correlation (or deviation) of the two waveforms in shape and/or amplitude. In other embodiments, the second signal waveform is mathematically correlated with the template waveform, to determine how they correlate (or deviate). While not wishing to be bound by theory, it is believed that an adaptive waveform template provides system diagnostics adapted for each host and use of the system. It should be noted herein that an initial waveform template is used when the sensor system is started up, with subsequent use of the adaptive template thereafter. Accordingly, in some embodiments, an adaptive template is substituted for a waveform template as soon as the adaptive template is generated.

[1021] In some embodiments, the processor module is configured to and/or includes programming that detects a level of interferent in the biological sample (e.g., such as described elsewhere herein). In some embodiments, the waveform template is updated when the level of interferent meets one or more criteria. For example, in some embodiments, the processor module is configured to update the waveform template when substantially no interferent (e.g., less than about 20%, 10%, 5%, 4%, 3%, 2% or 1% of the signal) is detected. In this embodiment, if interference is detected on the signal (e.g., above 1, 2, 3, 4, or 5% of the signal), then the signal waveform is not used to update the template. If, however, interference is not detected on the signal (or is less than or equal to about 5%, 4%, 3%, 2% or 1% of the signal), then the processor module updates the waveform template (or the adaptive template) with signal waveform. In some embodiments, a lower level of interferent on the signal, such

Abbott Ex. 1003 - 388/1058

as 15%, 10%, 5%, 4%, 3%, 2% or 1% or less of the signal is acceptable. Accordingly, if the level of interferent detected is less than or equal to the criteria (e.g., within the threshold) then the waveform template (or the adaptive template) is updated with the signal waveform. If the level of interferent does not meet the criteria (e.g., exceeds the threshold) then the waveform template (or adaptive template) is not updated.

[1022] In some embodiments, evaluating the sensor system includes detecting an interferent by evaluating an amplitude, a change in amplitude, the signal waveform and/or a change in the signal waveform (e.g., of the second signal) when the sensor is exposed to the biological sample. In some embodiments, interferent detection is further based at least in part on a calibrated analyte value. In one exemplary embodiment, the system is configured to look for a change in analyte concentration (e.g., amplitude) above a threshold (e.g., exceeding a criterion) in combination with evaluating a second signal waveform.

[1023] In preferred embodiments, the processor module is configured to and/or includes programming that controls a display of the sensor system based at least in part on a level of interferent detected. For example, in some embodiments, the processor module is configured to not display an analyte value measured in a biological sample in response to an amount (e.g., level) of interferent detected on the second signal based on one or more criteria. For example, when the detected interferent on the no-enzyme working electrode exceeds a predetermined threshold (e.g., an amount of the signal, such as but not limited to 5, 10, 15, 20, or 25% or more of the signal), the analyte value is not displayed. In an exemplary embodiment, what is displayed is responsive to the level of interferent detected. For example, if the level does not meet the criteria, then a first indication (e.g., message or value) is displayed; if the level meets the criteria, then a second indication is displayed; if the level exceeds the criteria, then a third indication is displayed. In another example, if the level of interferent detected meets a first criteria, then an indication or message associated with the first criteria is displayed; if the level of interferent detected meets a second criteria, then an indication or message associated with the second criteria is displayed; and the like.

[1024] In some embodiments, processor module is further configured to process the first signal and the second signal to obtain a subtracted signal, wherein the step of processing is based at least in part on the level of interferent on the sensor system. For example, in some circumstances, the signal is processed to remove offset of the baseline and/or

Abbott Ex. 1003 - 389/1058

compensate for a measured interferent (e.g., one or more interfering species) on the signal, and/or the like, such as described elsewhere herein.

[1025] In a further embodiment, the processor module is configured to fail-safe when the no-enzyme signal and the analyte concentration (or change in analyte concentration) do not meet one or more criteria.

[1026] As described above, the waveform of the non-enzyme working electrode (e.g., the second signal) has a characteristic pattern. In some embodiments, a characteristic pattern includes monotonicity or substantial monotonicity. The term "monotonicity" as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and are not to be limited to a special or customized meaning), and refers without limitation to a quality of a sequence or function, wherein it is either substantially increasing or substantially decreasing in value, such as but not limited to about 80%, 85%, 90%, 95% or more of the time. Thus, a measurement signal waveform generally smoothly rises, while a calibration signal waveform generally falls smoothly. Accordingly, in some embodiments, the step of evaluating the sensor system includes evaluating a monotonicity of the signal waveform (e.g., is the signal waveform monotonic or does is contain bump, jumps, blips, etc.). In some embodiments, the system is configured to evaluate the monotonicity of the signal waveform by performing cross-correlation of the signal waveform with a waveform template. If the signal waveform is not monotonic, is will not correlate well with the waveform template. In other embodiments, the monotonicity of the signal waveform is evaluated by performing a time-series analysis, or the like.

[1027] In some embodiments, the processor module is configured to and/or includes programming that evaluates a reliability of the system. For example, in some embodiments, the signal waveforms generated over a period of time (e.g., a window), such as 5, 10, 15, 20 or 30 minutes or longer, are evaluated, such as to ensure that the waveforms are substantially consistent over that period of time. In some embodiments, the window of waveforms to be evaluated is a moving window, encompassing the 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20 or 30 (or more) most recently generated second signal waveforms.

[1028] In some embodiments, evaluating the reliability of the system includes determining a level of reliability of the sensor system, such as by comparing an amplitude, a change in amplitude, a signal waveform and/or a change in a signal waveform of the second

Abbott Ex. 1003 - 390/1058

signal to one or more criteria. In some embodiments, the one or more criteria include an expected waveform shape and/or pattern. For example, if the second signal waveforms within a window are substantially monotonic, within a predetermined range of correlation, then the system is configured determine a level of reliability (e.g., reliable or "pass"). Conversely, if the second signal waveforms within a window are outside the predetermined range of monotonicity and/or correlation, the system is configured determine a reduced level of reliability (e.g., not reliable or "fail"). A level of 100% reliability of the sensor system can be defined using known methods, including time-series analysis, standard deviation, variance, covariance, and/or the like. Accordingly, in some embodiments, the level of reliability of the sensor system is 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% or more as compared to a 100% level as defined by the methods described above, for example. Depending upon the system configuration, various levels of reliability may be acceptable. For example, a low level of reliability may be acceptable for a first system configuration while only a high level of reliability may be acceptable for a second system configuration. Furthermore, in some embodiments, the system is configured to perform one or more functions or tasks, such as but not limited to calculating a value, displaying information, updating a template, and the like, depending upon the level of reliability, wherein the acceptability of the reliability is associated with the system configuration.

[1029] In other embodiments, evaluating the reliability of the system includes classifying a signal waveform, such as by comparing an amplitude, a change in amplitude, a signal waveform and/or a change in a signal waveform of the second signal to one or more criteria. For example, a signal waveform can be classified as "pass" or "fail," if it meets the one or more criteria. For example, in some embodiments, the system is configured to pass the signal waveform when it correlates with the template waveform by at least 50, 55, 56, 70, 75, 80, 85, 90 or 95%. The system can be configured to classify a signal waveform as "pass" or "fail" using other mathematical methods, described elsewhere herein. In some embodiments, the system is configured to use at least some of the data in the signal waveform (e.g., second signal) and/or data in a time-corresponding signal waveform (e.g., first signal) for subsequent mathematical processes, such as calibrating the sensor, calculating the analyte value and the like, when the signal waveform is classified (e.g., declared) as "pass," such as described herein.

Abbott Ex. 1003 - 391/1058

Conversely, in some embodiments, the system is configured to not use the data when the signal waveform is classified as "fail."

[1030] In some embodiments, the system is further configured to control a display of the sensor system based at least in part on the level of reliability of the sensor system (e.g., pass or fail). For example, if the system is determined to be reliable, then an analyte value is displayed to the user. If, on the other hand, the level of reliability does not meet one or more criteria, then the system is configured to respond in another way, such as not displaying an analyte value, sounding an alert or alarm, requesting input of information by the user, and the like. In a further embodiment, the system is configured to modify a subtraction of the second signal from the first signal (e.g., processing associated with the subtraction) based at least in part on the reliability of the sensor system.

[1031] In some embodiments, the system is configured to evaluate a portion of a second signal waveform, rather than the entire waveform. For example, it have been observed that, in some circumstances, an initial portion of a second signal waveform (e.g., the first eighth, fifth, third, quarter, half, two thirds, three quarters, etc.) may be somewhat unstable, while the portion of the second signal waveform from which data is used in subsequent calculations is substantially stabilized. While not wishing to be bound by theory, it is believed that the initial instability of the second signal waveform observed is caused by minute variations in the function of fluidics system (e.g., mechanical movement of the flow control device), membrane effects caused by switching from an infusion solution to blood (and/or back again, e.g., a step-change), fluid dynamics (e.g., turbulence) and the like that may not affect the reliability of the data. Accordingly, in some embodiments, the system is configured to disregard at least some of the initial portion of the second signal waveform, when performing system diagnostics, such as but not limited to evaluating the system (e.g., system fluidics, system reliability and/or the like).

[1032] In some embodiments, the processor module is configured to and/or includes programming that evaluates the sensor system based at least in part on the second signal by determining a success of a biological sample draw-back from a host's circulatory system to the sensor. A success can be determined and/or quantified by a level of reliability. For example, in some embodiments, the system is configured to determine that a drawback or infusion was successful if the reliability is at least 50%. Some embodiments may require a

Abbott Ex. 1003 - 392/1058

higher level of reliability to determine that the drawback or infusion was successful. For example, in some embodiments, the system is configured to determine that the drawback or infusion was successful when the reliability is at least 55, 60, 65, 70, 75, 80, 85, 90, or 95% or greater.

[1033] In some further embodiments, the system is configured to display an analyte value measured during the biological sample draw-back in response to a determination of a successful biological sample draw-back. For example, success of a draw-back (e.g., the level of reliability meets one or more criteria, or the draw-back is classified as pass) is an indication that the analyte sensor is sufficiently contacted by the sample such that an accurate measurement can be made. Thus, the displayed analyte value is not substantially affected by fluidics problems and can therefore be considered reliable. In some embodiments, the system is configured to not display the analyte value measured during the biological sample draw-back, when the draw-back is determined to be unsuccessful, such as when the reliability does not meet the one or more criteria and/or is classified as fail.

[1034] In some embodiments, the processor module is configured to and/or includes programming that evaluates the sensor system based at least in part on the second signal by determining a success of infusing the infusion solution such that a biological sample is washed from the sensor. As discussed elsewhere herein, the accuracy of sensor measurement can be affected by the presence of blood components, from the previously drawn back sample, on the sensor. For example, in some circumstances, red blood cells from a previous drawback might affect the current measurement and cause an inaccurate measurement to be made. In some embodiments, this problem can be prevented and/or avoided by sufficiently washing the sensor, such as by reinfusing a drawn-back blood sample and infusing one or more amounts of infusion solution at one or more rates, such as according to a flow profile. Thus, in some embodiments, the system is configured such that the sensor is washed of the biological sample when the success of the infusion meets one or more criteria. For example, in some embodiments, the level of success of infusion is determined and/or quantified by a level of reliability, such as described above. In other embodiments, the infusion is classified as successful (e.g., pass) or not successful (e.g., fail). In some embodiments, the system is configured to display an analyte value measured in a biological sample after the infusing the infusion solution in response to a determination of a successful infusion. Accordingly, if the

Abbott Ex. 1003 - 393/1058

infusion was successful, the system displays the analyte value; but if the infusion was not successful, the system does not display the analyte value.

[1035] As a non-limiting example, wherein the system is configured to use a 100 mg/dl glucose reference solution and the plus-enzyme working electrode is exposed to blood having a glucose concentration greater than 100 mg/dL, the signal response should step up. When the plus-GOX working electrode is exposed to blood having a glucose concentration less than 100 mg/dL, the signal response should step down. If the system calculated a glucose value less than 100 mg/dL (e.g. 70 mg/dL) when the plus-GOX working electrode stepped up, a calibration error is detected and the system can fail-safe. Similarly, if the system calculated a glucose value greater than 100 mg/dL (140 mg/dL) when the plus-GOX working electrode stepped down, an error is detected and the system can fail-safe.

Signal Amplitude and/or Noise Amplitude Analysis and Fail-Safes

[1036] In some embodiments, the system is configured to fail-safe when analysis of signal amplitude and/or noise amplitude (residual) of the sensor's working electrode(s) indicates that the integrity of the system's electrical connections are compromised, such as at the sensor or at one or more components of the system's electronics. For example, in the case of a dual-electrode sensor, an accuracy and/or reliability of the relationship of the plus-enzyme signal to the non-enzymatic signal is evaluated by comparing signal amplitudes in calibration solution (or in blood). For example, the non-enzymatic signal being greater than the plus-enzyme signal is indicative of a sensor malfunction, and the system can fail-safe.

[1037] In some embodiments, sensor diagnostics evaluates whether the calculated sensitivity falls within a predetermined limit and/or range, for example, 1-10 pA/mg/dL, as described in more detail elsewhere herein. In some embodiments, the sensor diagnostics evaluates a difference in signal (raw, filtered and/or calibrated) between the non-enzymatic working electrode and the enzymatic working electrode (e.g., in reference/calibration solution) to determine whether they fall within predetermined limits and/or ranges. As one example, a sensor/calibration diagnostic evaluates the baseline of the enzymatic and non-enzymatic electrodes to determine whether they fall within a predetermined limit/range.

[1038] In some embodiments, the system is configured to use *a priori* information to set tolerances for sensitivity and/or baseline drift. Preferably, the system is configured to discriminate between measured changes in sensitivity and/or baseline from signal artifacts,

Abbott Ex. 1003 - 394/1058

such as by using tolerance limits based on historical/empirical data. For example, in some embodiments, if the sensitivity and/or baseline drifts outside predetermined limits and the drift is not a transient artifact (e.g., it persists for a predetermined time period), an error can be detected in sensor function and/or calibration.

[1039] In yet another alternative embodiment of signal artifacts detection that utilizes examination or evaluation of the signal information content, filtered (e.g., smoothed) data is compared to raw data (e.g., in sensor electronics or in receiver electronics). In one such embodiment, a signal residual is calculated as the difference between the filtered data and the raw data. For example, at one time point (or one time period that is represented by a single raw value and single filtered value), the filtered data can be measured at 50,000 counts and the raw data can be measured at 55,500 counts, which would result in a signal residual of 5,500 counts. In some embodiments, a threshold can be set (e.g., 5000 counts) that represents a first level of noise (e.g., signal artifact) in the data signal, when the residual exceeds that level. Similarly, a second threshold can be set (e.g., 8,000 counts) that represents a second level of noise in the data signal. Additional thresholds and/or noise classifications can be defined as is appreciated by one skilled in the art. Consequently, signal filtering, processing, and/or displaying decisions can be executed based on these conditions (e.g., the predetermined levels of noise).

[1040] Although the above-described example illustrates one method for determining a level of noise, or signal artifact(s), based on a comparison of raw *vs.* filtered data for a time point (or single values representative of a time period), a variety of alternative methods are contemplated. In an alternative exemplary embodiment for determining noise, signal artifacts are evaluated for noise episodes lasting a certain period of time. For example, the processor (in the sensor or receiver) can be configured to look for a certain number of signal residuals above a predetermined threshold (representing noise time points or noisy time periods) for a predetermined period of time (e.g., a few minutes to a few hours or more).

[1041] In one exemplary embodiment, a processor is configured to determine a signal residual by subtracting the filtered signal from the raw signal for a predetermined time period. It is noted that the filtered signal can be filtered by any known smoothing algorithm such as described herein, for example a 3-point moving average-type filter. It is further noted that the raw signal can include an average value, e.g., wherein the value is integrated over a

Abbott Ex. 1003 - 395/1058

predetermined time period (such as 5-minutes). Furthermore, it is noted that the predetermined time period can be a time point or representative data for a time period (e.g., 5 minutes). In some embodiments, wherein a noise episode for a predetermined time period is being evaluated, a differential can be obtained by comparing a signal residual with a previous signal residual (e.g., a residual at time (t)=0 as compared to a residual at (t)-5 minutes.) Similar to the thresholds described above with regard to the signal residual, one or more thresholds can be set for the differentials, whereby one or more differentials above one of the predetermined differential thresholds defines a particular noise level. It has been shown in certain circumstances that a differential measurement as compared to a residual measurement as described herein, amplifies noise and therefore may be more sensitive to noise episodes, without increasing false positives due to fast, but physiological, rates of change. Accordingly, a noise episode, or noise episode level, can be defined by one or more points (e.g., residuals or differentials) above a predetermined threshold, and in some embodiments, for a predetermined period of time. Similarly, a noise level determination can be reduced or altered when a different (e.g., reduced) number of points above the predetermined threshold are calculated in a predetermined period of time.

[1042] In some embodiments, the amplitude of total signal, which can also be described as power of the total signal, analyte signal (with or without baseline (e.g., non-constant noise)), and/or non-constant noise, is periodically or continuously obtained using methods such as are described in more detail elsewhere herein (e.g., RMS method), wherein the amplitude is a measure of the strength of the signal component. In some embodiments, signal artifact events are detected by analysis of amplitudes of various signal components, such as the amplitude of the non-constant noise component as compared to the amplitude of the analyte signal (with or without baseline).

[1043] In some embodiments, a start of a signal artifact event is determined when the amplitude (power) of a signal artifact meets a first predetermined condition. In one embodiment, the first predetermined condition includes a residual amplitude of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20 or 25% of the total signal or analyte signal amplitude (with or without baseline). In another embodiment, the first predetermined condition includes a differential amplitude (amplitude of a differential) of at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20 or 25% of the total signal or analyte signal amplitude (with or without

Abbott Ex. 1003 - 396/1058

baseline). In some embodiments, the first predetermined condition includes a plurality of points (e.g., non-constant noise signal, residual, or differential) within a predetermined period (e.g., 5, 10, 30, or 60 minutes) above a predetermined threshold (e.g., an amplitude or a percentage amplitude), wherein the plurality of points includes 2, 3, 4, 5, 6, 7, 8 or more values.

[1044] In some embodiments, an end of a signal artifact event is determined when then the amplitude (power) of a signal artifact meets a second predetermined condition. In one embodiment, the second predetermined condition includes a residual amplitude of no more than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20 or 25% of the total signal or analyte signal amplitude (with or without baseline). In another embodiment, the second predetermined condition includes a differential amplitude of no more than about 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 18, 20 or 25% of the total signal or analyte signal amplitude (with or without baseline). In some embodiments, the second predetermined condition includes a plurality of points (e.g., non-constant noise signal, residual, or differential) within a predetermined period (e.g., 5, 10, 30, or 60 minutes) below a predetermined threshold (e.g., an amplitude or a percentage amplitude), wherein the plurality of points includes 2, 3, 4, 5, 6, 7, 8 or more values. Additional description can be found in US Patent Publication Nos. US-2005-0043598-A1, US-2007-0032706-A1, US-2007-0016381-A1, and US-2007-0033254-A1, each of which is incorporated by reference herein in its entirety.

Auto-Calibration

[1045] Some preferred embodiments are configured for auto-calibration of the sensor system, wherein "auto-calibration" includes the use of one or more internal references to calibrate the sensor system. In some embodiments, auto-calibration includes systems and methods configured to calibrate the sensor based solely on internal reference values. For example, the system can be configured to obtain internal reference values by exposing the sensor to one, two or more calibration/reference solution, as described elsewhere herein. As another example, the sensor can be configured with a reference sensor disposed adjacent to the continuous analyte sensor, wherein both the continuous analyte and reference sensors obtain internal reference values for a substantially constant reference analyte (e.g., O_2), which are then used to calibrate the continuous analyte sensor (see the sections entitled "Optical Detection" and "Calibration Systems and Methods of Calibrating Dual-Electrode Sensors"

Abbott Ex. 1003 - 397/1058

above). However, in some alternative embodiments of auto-calibration, one or more external reference values can be used to complement and/or confirm calibration of the sensor system.

[1046] In some preferred embodiments, the system is configured to intermittently expose the sensor to a biological sample; however configurations of the sensor system that allow continuous exposure of the sensor to the biological sample are contemplated. In some embodiments, the system is configured to intermittently or periodically expose the sensor to a reference, however configurations of the sensor system that allow one or more independent or non-regular reference measurements initiated by the sensor system and/or a user are contemplated. In the exemplary embodiment of a sensor system such as described with reference to **Figs. 8A** to **8C**, the system is configured to cycle between a measurement phase and calibration phase (with optional other phases interlaced therein (e.g., flush and KVO)).

[1047] In general, timing of auto-calibration can be driven by a variety of parameters: preset intervals (e.g., clock driven) and/or triggered by events (such as detection of a biological sample at a sensor). In some embodiments, one or more of the phases are purely clock driven, for example by a system configured to control the timing housed within a flow control device, remote analyzer, and/or other computer system. In some embodiments, one or more of the phases are driven by one or more events, including: exposure of the sensor to a biological sample (e.g., blood) exposure of sensor to a reference (e.g., calibration solution), completion of calibration measurement, completion of analyte measurement, stability of signal measurement, sensor for detecting a biological sample, and the like.

[1048] In one exemplary embodiment, calibration and measurement phases are driven by cleaning of sensor; namely, systems and methods are configured to detect when the sensor is in the biological sample and/or in the reference solution (e.g., calibration solution), wherein the system is configured to switch to appropriate phase responsive to detection of that sample/solution.

[1049] In another exemplary embodiment, an AC signal is placed on top of a DC signal (e.g., in an amperometric electrochemical analyte sensor), wherein systems and methods are configured to analyze an impedance response to the AC signal and detect a biological sample thereby.

[1050] In yet another exemplary embodiment, systems and methods are configured for analyzing the sensor's signal, wherein a change from a known reference solution (e.g., a

Abbott Ex. 1003 - 398/1058

known analyte concentration) can be detected on the signal, and the switch from the calibration phase to the measurement phase occur responsive thereto; similarly, the system can be configured to switch back to the calibration phase responsive to detection of the known signal value associated with the reference solution.

[1051] In yet another exemplary embodiment, systems and methods are configured to switch between phases responsive to one or more sensors configured to detect the biological sample and/or reference solution at a particular location.

[1052] In some embodiments, the sensor system is partially or fully controlled by a clock (e.g., predetermined time intervals), which timing can be confirmed by any of the events (e.g., triggers or sensors) described above.

[1053] In one exemplary embodiment, systems and methods are provided to enable auto-calibration of an integrated glucose sensor system with minimal user interaction. In this exemplary embodiment, the integrated sensor system is provided with the components described above, including a fluids bag, a flow control device, IV tubing, a flow control device, a remote analyzer, a local analyzer and a sensor/catheter, for example. At system start-up, a health care worker inserts the catheter and sensor into a host and injects a first reference solution (e.g., zero glucose saline solution) into the IV tubing, wherein the system is configured to allow a predetermined time period (e.g., 20 minutes) for the first reference solution to pass through the IV tubing and into the catheter. Subsequently, the health care worker couples the fluids bag to the IV tubing, wherein the fluids bag includes a second reference solution (e.g., 100 mg/dl glucose solution) configured to follow the first reference solution in the IV line. After injecting the first reference solution and coupling the second reference solution, the health care worker initiates the integrated sensor system (e.g., through the remote analyzer touch screen) after which the integrated sensor system automatically calibrates and functions for 24 hours without necessary user interface (for system calibration and/or initiation). In some embodiments, the sensor system is re-calibrated every 24 hours by injection of a new first reference solution (e.g., zero glucose saline solution).

[1054] In the above-described exemplary embodiment, the system is configured to calibrate the sensor with the first and second reference solution and using the methods described in the section entitled, "Systems and Methods for Processing Sensor Data." Additionally, the system is configured to automatically detect the difference in signal

Abbott Ex. 1003 - 399/1058

associated with the first and second reference solutions, for example, through steady state detection of a difference in signal level.

Methods of Integrated System Set-Up and Initial Use *In vivo*

[1055] Referring to **Fig. 6**, in one exemplary embodiment, the present system is configured and arranged for continuous analyte detection in the circulatory system of a host, such as a human, and for fluid infusion. As a non-limiting example, in some embodiments, the continuous analyte sensor is a glucose sensor at least partially disposed in a fluid coupler. In this embodiment, system **600** set-up and installation includes implanting a catheter into one of the host's peripheral veins, fluidly coupling the sensor (e.g., including fluid coupler) to the implanted catheter, fluidly coupling the IV tubing and infusion solution **602a** to the fluid coupler operatively connected to the sensor, to a controller and/or display (**604** and/or **610**), installation of the tubing into the flow control device **604**, and initializing the system (e.g., turning on the flow control device). In some circumstances, an operator (e.g., a nurse, doctor or other medical caretaker) prepares a calibration solution by injecting an amount of glucose into an IV bag of infusion solution, such as but not limited to a saline hydration solution, and mixing the contents of the bag. In other circumstances, a commercially prepared calibration solution is used. In some circumstances, a medicament, nutrient or other substance may be added to the infusion solution. The bag of prepared infusion solution **602a** is suspended on an IV stand **612**, such as a stand that also supports the flow control device **604**.

[1056] Referring to **Fig. 1F**, the operator implants a catheter **12** in one of the host's peripheral veins, such as a vein located in the host's forearm, using standard hospital protocol. Next, the operator grasps the fluid coupler **20,** inserts analyte sensor **14** into the catheter's lumen and fluidly couples the first end **20a** of the fluid coupler to the catheter's hub **18**. Note that the sensor is protected by the slotted sheath **26** during insertion. Advantageously, in some embodiments, the fluid coupler and the slotted sheath are configured and arranged such that the slotted sheath prevents blood from coming out of the fluid coupler's second end, until the slotted sheath is removed (e.g., just prior to connection of the second end **20b** to the IV tubing). In alternative embodiments, such as that shown in **Figs. 1F-1J**, the analyte sensor is located within the fluid coupler's lumen and the second end includes a cap configured and arranged to prevent blood coming out of the second end prior to connection of the IV tubing. In some embodiments, the operator (e.g., user) sets up the flow control device, then implants the

Abbott Ex. 1003 - 400/1058

catheter and sensor and then connects the tubing to the fluid coupler. In other embodiments, the catheter and sensor are implanted prior to set-up of the flow control device with subsequent connection of the IV tubing to the fluid coupler. Either sequence of events is acceptable, as well as a matter of personal preference and/or hospital protocol.

[1057] In preferred embodiments, the IV tubing **606** is configured and arranged for installation into a flow control device **604**. In some embodiments, the flow control device and tubing are configured and arranged such as is shown in **Figs. 10A-10D**. However, other flow control device and/or tubing configurations are used, in some embodiments. In some embodiment, the flow control device is configured to be moved (e.g., by hand or in response to pressing a button) to the gravity flow valve position (e.g., see **Fig. 10C**), if it is not already in that position, such that the **groove 803** is not blocked by the roller **802**. In preferred embodiments, the valve is configured to automatically move to the gravity flow valve position at shut-off and/or termination of a sensor session. In other embodiments, the system is configured such that the valve moves to the gravity flow position when the system is turned on.

[1058] In preferred embodiment, the operator fluidly couples the tubing assembly **606a** to the fluid reservoir and/or the fluid coupler. In some embodiments, additional lengths of IV tubing **606** are used to make these fluid connections, as is known in the art. To install the tubing assembly **606a**, the operator grasp by the connector ends **606c, 606d** and stretches the tubing therebetween. The operator orients the stretched tubing assembly such that its central portion **606b** aligns with the valve's channel **803** and the tubing's male interconnector (e.g., connector **606d**) aligns with the valve's female interconnector **809.** The operator then inserts the tubing assembly into the valve channel and releases the connectors, such that the tubing assembly's central portion relaxes to a less stretched (but still stretched and linear) configuration. The operator connects the tubing assembly (e.g., *via* an optional length of IV tubing) to the IV solution. Then, the operator removes the protective sheath from the sensor by pulling it out of the fluid coupler by its hub **28** and connects the tubing assembly to the fluid coupler's second end (e.g., *via* an optional length of IV tubing).

[1059] In preferred embodiments, the system is configured such that the operator initiates system start-up after installing the sensor, the tubing, and the like, such as described above. In some embodiments, system initiation and/or start-up include, but are not limited to,

Abbott Ex. 1003 - 401/1058

turning the system on, selecting a flow profile, entering system configuration information (e.g., type of sensor, type of catheter, type of infusion solution), entering user information (e.g., patient ID, patient type, patient target analyte levels, etc.). In some embodiments, the system is configured to be initiated when the user presses a button, flips a switch and/or selects (e.g., a start-up protocol) from a menu on the user interface. In some embodiments, the system is configured to automatically receive and/or recognize at least some of the start-up information, such as *via* a identification information, a code and/or key in the interconnection of the tubing assembly and the flow control device, *via* an RFID chip in the patient arm band, *via* optically scanning a bar code on the patient's chart/arm band and/or on the fluid coupler and/or catheter, and the like. In some embodiments, the flow control device system electronics are configured for operator selection of a flow profile from a menu of flow profiles (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more flow profiles). In preferred embodiments, the system is configured for selection of a flow profile (by the operator) at least during system start-up/initiation. However, in some further embodiments, the system electronics are configured for selection of another profile and/or modification (e.g., re-programming) of the flow profile during system use. For example, if during use of the system, infusion solution is changed from a first type to a second type (e.g., from saline to a glucose solution), the flow profile can be modified to accommodate that infusion solution change.

[1060] In some embodiments, the system is configured to begin intermittently infusing the calibration solution and drawing back samples of the host's blood (e.g., according to the flow profile), energizing the sensor and generating measurements of the calibration solution and blood, and the like, upon system initiation/start-up by the operator. For example, depending upon the flow profile specifications, the flow control device alternately infuses (e.g., at one or more rates) the calibration solution for about 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0 or more minutes, then draws back a blood sample, returns the sample to the host (e.g., reinfuse the sample), and then returns to infusing the calibration solution. Calibration measurements are taken during infusion phases of the flow profile. Blood analyte measurements are taken during draw-back phases of the flow profile (e.g., when the sensor is bathed in a blood sample). In some embodiments, the sensor is a dual-electrode glucose sensor, and the system is configured to collect signal(s) from both the plus-enzyme (e.g., plus GOX) and no-enzyme working electrodes.

Abbott Ex. 1003 - 402/1058

[1061] In some embodiments, the system is configured to follow a "break-in" procedure (also referred to as "run-in"). For example, in some embodiments, the system is configured to cycle between infusion and sample draw-back for about 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75 or 2-hours. In one embodiments, at about 1-hour, the processor module is configured to and/or includes programming that evaluates sensor stability (e.g., sensor break-in), such as by evaluating the rates of change of the no-enzyme waveform, the amplitude of the no-enzyme signal, and/or the like. In some embodiments, the system is configured to prompt the operator for input of a reference blood glucose value. For example, in one embodiment, the system is configured to wait about 1-hour to about 1.25-hours before prompting the operator for a reference analyte value. A reference analyte value can be obtained using any method known in the art. For example, in the case of a continuous glucose sensor, the operator can use a hand-held glucose meter to measure the host's blood glucose, and enter the measured value into the system *via* the user interface. In some embodiments, the processor module uses one or more entered reference values to calibrate the sensor using substantially time-corresponding sensor measurements. In some embodiments, the system is configured to utilize an entered reference value as a b_{offset}.

[1062] In some embodiments, the system is configured to display the host's blood glucose concentration in response to the processor module determining that break-in is complete and/or after sensor calibration. For example, if the processor module determines that the sensor signal has substantially stabilized, the system displays analyte values to the operator. If, on the other hand, the processor module determines that the sensor signal is not yet substantially stabilized, then the system does not display an analyte value to the operator. In some circumstances, the system is configured to prompt the operator to input additional reference analyte values. For example, in one embodiment, the system is configured to wait a period of time (e.g., 5, 10, 15, 20, 30, 40, 50 or 60 minutes) and then to request a reference analyte value. In a further embodiment, if the sensor signal has still not stabilized, then the system is configured to wait another period of time (e.g., 5, 10, 15, 20, 30, 40, 50 or 60 minutes) and then to request a reference analyte value. In another further embodiment, if the sensor signal has not substantially stabilized after a programmed period of time (e.g., 1.25, 1.5, 1.75, 2, 2.5, or 3-hours), then the system is configured to declare a sensor failure and to prompt the user to install a new sensor.

Abbott Ex. 1003 - 403/1058

[1063] In preferred embodiments, the flow control device is configured to infuse the calibrant and draw-back samples according to the flow profile selected by the operator. In preferred embodiments, the sensor is configured and arranged to generate sensor data, and the processor module is configured to and/or includes programming that processes the sensor data (e.g., as described elsewhere herein), such that the analyte concentration of the host's blood is measured in real-time and/or displayed on a user interface. In preferred embodiments, the processor module is configured to and/or includes programming that intermittently calibrates (e.g., re-calibrates) the sensor.

EXAMPLES

Example 1: Glucose Sensor System Trial in Dogs

[1064] Referring now to **Fig. 4**, glucose sensor systems of the embodiment shown in Fig. 1 were tested in dogs. The glucose sensors were built according to the preferred embodiments described herein. Namely, a first sensor (Test 1) was built by providing a platinum wire, vapor-depositing the platinum with Parylene to form an insulating coating, helically winding a silver wire around the insulated platinum wire (to form a "twisted pair"), masking sections of the electroactive surface of the silver wire, vapor-depositing Parylene on the twisted pair, chloridizing the silver electrode to form a silver chloride reference electrode, and removing a radial window on the insulated platinum wire to expose a circumferential electroactive working electrode surface area thereon, this assembly also referred to as a "parylene-coated twisted pair assembly."

[1065] An electrode domain was formed over the electroactive surface areas of the working and reference electrodes by dip coating the assembly in an electrode solution and drying. An enzyme domain was formed over the electrode domain by subsequently dip coating the assembly in an enzyme solution and drying. A resistance domain was formed over the enzyme domain by spraying the resistance domain solution on the sensor construct.

[1066] After the sensor was constructed, it was placed in the protective sheath and then threaded through and attached to the fluid coupler.

[1067] A second sensor (Test 2) was constructed in the same manner as the first, except that the silver wire was disposed within (e.g., coiled within) the fluid coupler. Accordingly, only the platinum working electrode (a single wire) was inserted into the catheter during the experiment.

Abbott Ex. 1003 - 404/1058

[1068] Prior to use, the sensors were sterilized using electron beam.

[1069] The forelimb of an anesthetized dog (2 years old, ~40 pounds) was cut down to the femoral artery and vein. An arterio-venous shunt was placed from the femoral artery to the femoral vein using 14 gauge catheters and 1/8-inch IV tubing. A pressurized arterial fluid line was connected to the sensor systems at all times. The test sensor systems (test 1 and test 2) included a 20 gauge x 1.25-inch catheter and took measurements every 30 seconds. The catheter was aseptically inserted into the shunt, followed by insertion of the sensor into the catheter. A transcutaneous glucose sensor (control) of the type disclosed in U.S. Patent Publication No. US-2006-0155180-A1 was built and placed in the dog's abdomen according to recommended procedures. The dog was challenged with continuous incremental IV infusion of a 10% dextrose solution ("glucose challenge") until the blood glucose concentration reached about 400 mg/dL.

[1070] **Fig. 4** shows the experimental results. The thick line represents data collected from the Test 1 sensor. The thin line represents data collected from the Test 2 sensor. Diamonds represent data collected from a hand-held blood glucose meter (SMBG) sampled from the dog's abdomen. Raw glucose test data (counts) are shown on the left-hand Y-axle, glucose concentrations for the "SMBG" controls are shown on the right-hand y-axle, and time is shown on the X-axle. Each time interval on the X-axle represents 29-minutes (e.g., 10:04 to 10:33 equals 29 minutes). Immediately upon insertion into a catheter, each test sensor began collecting data with substantially no sensor equilibration time (e.g., break-in time). Each test sensor responded to the glucose challenge substantially similarly to the control sensor. For example, each device shows the glucose signal increasing from about 3200 counts at 10:33 to about 6000-6700 counts at 11:31. Then, each device showed a rapid decrease in glucose signal, to about 4700 counts at 12:00. Additionally, the response of the test sensors and the control sensor were substantially similar (e.g., the majority of the test data was substantially equivalent to the SMBG data at each time point). From these experimental show that an indwelling glucose sensor system (as described herein) in contact with the circulatory system can provide substantially continuous glucose monitoring in a clinical setting.

Example 2: Glucose Sensor System Trial in Pigs

[1071] Referring now to **Fig. 5**, four glucose sensor systems of the embodiment shown in **Fig. 1** were tested in a pig (~104 lb), using the protocol described for Example 1,

Abbott Ex. 1003 - 405/1058

above. Glucose was continuously infused at increasing rates through a distally placed IV catheter until a readout of 300-400 mg/dl blood glucose was achieved (total 300 ml of a 10% dextrose IV solution). **Fig. 5** shows the experimental results. Lines indicated the data from the four sensors (Test 1 through Test 4). Diamonds represent control measurements made with a hand-held glucose meter (SMBG). Raw glucose test data (counts) are shown on the left-hand Y-axle, glucose concentrations for the "SMBG" controls are shown on the right-hand y-axle, and time is shown on the X-axle. Test results show that though the sensors varied in sensitivity, each test sensor responded to glucose challenge substantially similarly to the control sensor (SMBG). These experimental results show that an indwelling glucose sensor system (of the preferred embodiments) in contact with the circulatory system can substantially continuously track glucose in a clinical setting.

Example 3: Glucose Sensor System with Flow Control Device Trial in Pigs

[1072] Referring now to **Fig. 17**, a glucose sensor was built according to the preferred embodiments described herein. Namely, a test sensor was built by providing a platinum wire, vapor-depositing the platinum with Parylene to form an insulating coating, helically winding a silver wire around the insulated platinum wire (to form a "twisted pair"), masking sections of the electroactive surface of the silver wire, vapor-depositing Parylene on the twisted pair, chloridizing the silver electrode to form a silver chloride reference electrode, and removing a radial window on the insulated platinum wire to expose a circumferential electroactive working electrode surface area thereon, this assembly also referred to as a "parylene-coated twisted pair assembly."

[1073] An electrode domain was formed over the electroactive surface areas of the working and reference electrodes by dip coating the assembly in an electrode solution and drying. An interference domain was formed over the electrode domain by subsequently dip coating the assembly in an interference domain solution and drying. An enzyme domain was formed over the interference domain by subsequently dip coating the assembly in an enzyme solution and drying. A resistance domain was formed over the enzyme domain by spraying the resistance domain solution on the sensor construct.

[1074] The test sensor was then located within a 20 gauge catheter and inserted in the femoral vein of a non-diabetic pig. The catheter was connected to an integrated sensor system **600** of the preferred embodiments. The flow control device **604** (e.g., a roller valve as

Abbott Ex. 1003 - 406/1058

depicted in **Figs. 8A-8C**) was configured to move between steps one and two, as described in the section entitled "Flow Control Device Function," above. A 107-mg/dL glucose solution was used to calibrate the sensors (e.g., flows from the reservoir **602**, through the tubing **606**, to the catheter **12**). To mimic a diabetic's hyperglycemic state, a gradual infusion of 26% dextrose was given, until the pig's blood glucose was about 600 mg/dl. Then to mimic a hypoglycemic state, 10 U Humulin N was given, until the pig's blood glucose was about 50 mg/dl. Then, the pig's blood glucose was raised to about 100 mg/dl by a second 26% dextrose infusion.

[1075] **Fig. 17** is a graphical representation showing uncalibrated glucose sensor data and corresponding blood glucose values over time in a pig. Raw counts are represented on the left Y-axis. Glucose concentration is shown on the right Y-axis. Time is shown on the X-axis. Test measurements (e.g., measurements of blood glucose concentration obtained with the test sensor, raw counts) are shown as small, black dots. Control measurements (e.g., jugular vein blood samples analyzed on a Yellow Springs Instrument (YSI) glucose analyzer) are shown as diamonds.

[1076] During the experiment, the system was configured to alternate between calibration measurements (with the 107 mg/dl glucose solution) and blood glucose measurements, as described in the sections entitled "Step one: Contacting Sensor with Calibration Solution and Calibration" and "Step Two: Sample Collection and Measurement," respectively. Accordingly, as the experiment proceeded the test signal oscillated between calibration solution (107 mg/dl) and blood glucose measurements. The sensor (test) blood glucose measurement correlated tightly with the control blood glucose measurements. For example, as the pig's blood glucose concentration increased (due to infusion of glucose), so did the test measurements, reaching about 550 mg/dl at about 12:20. Similarly, as the pig's blood glucose concentration decreased (due to infusion of insulin), so did the test measurements, decreasing to about 50 mg/dl at about 14:45.

[1077] From these data, it was concluded that a glucose sensor system of the preferred embodiments (including a valve as described with reference to **Figs. 8A** to **8C**) accurately and sensitively measures intravenous glucose concentration over a wide dynamic range.

Abbott Ex. 1003 - 407/1058

Example 4: Glucose Sensor System with Flow Control Device Trial in Humans

[1078] Referring now to **Fig. 18**, a glucose sensor, constructed as described in Example 3, and an integrated sensor system (as described in Example 3) were tested in a volunteer, diabetic host. The flow control device was configured as shown in **Figs. 8A-8C**. The system was configured to alternate between a calibration phase and a blood glucose measurement phase, as described elsewhere herein. At sensor/catheter initialization, a 0 mg/dl glucose saline solution filled syringe was injected into the IV tubing and the fluids bag including 100 mg/dl glucose heparinized saline solution was subsequently coupled to the tubing. The system was then turned on (e.g., sensor initialized). The 0 mg/dl glucose saline solution passed over the sensor, after which the 100 mg/dl glucose heparinized saline solution subsequently passed over the sensor allowing for initial calibration information to be collected. The system, including a flow control device as described with reference to **Figs. 8A** to **8C**, then oscillated between exposure of the sensor to a blood sample and exposure of the sensor to the 100 mg/dl glucose heparinized saline solution. The sensor auto-calibrated by a combination of calibration information obtained from measurement of the 0 mg/dl-glucose and 100 mg/dl-glucose saline solutions and the step-change-response of the sensor to the blood sample, according to the methods described in the section entitled "Systems and methods for Processing Sensor Data." No external measurements (e.g., blood glucose measurements by YSI or finger stick) were used to calibrate the system in this example. During the experiment, the flow control device cycled between step one (measuring the 100 mg/dl-glucose solution) and step two (blood sample take up and measuring the blood glucose concentration), such that one cycle was completed every 5-minutes. The experiment was conducted for a period of about 2.5 days. The host followed her usual schedule of meals and insulin injections.

[1079] **Fig. 18** is a graphical representation showing calibrated venous blood glucose sensor measurements (test, black dots) and corresponding control blood glucose measurements (YSI, large circles) over time in the volunteer diabetic host. Glucose concentration is shown on the Y-axis and time on the X-axis. Test measurements tracked closely with control measurements, ranging from about 350 mg/dl, at about 10:00 and about 15:30, to about 50 mg/dl, at about 11:45. From these data, it has been concluded that 1) the sensor calibration methods of the preferred embodiments accurately calibrate the sensor and

Abbott Ex. 1003 - 408/1058

2) the glucose sensor system of the preferred embodiments accurately measures intravenous glucose concentration over a wide dynamic range, for two or more days, in humans.

Example 5: Detection of Crosstalk *In vitro*

[1080] In general, crosstalk in dual-electrode sensors can be examined by recording the signal detected at each working electrode while placing them in a series of analyte solutions. This example describes one exemplary *in vitro* test for crosstalk on a dual-electrode analyte sensor. A variety of dual-electrode analyte sensors can be tested for crosstalk, using this method.

[1081] First, the sensor to be tested is placed in a phosphate buffered saline (PBS) for several minutes, such as until a stable signal is detected from both working electrodes. Next, the sensor is challenged with glucose solutions and optionally with one or more known noise-causing substances. For example, sensor can be placed sequentially in a series of glucose solutions (e.g., 40-mg/dl, 200-mg/dl and 400-mg/dl glucose in PBS) and the signals from the two working electrodes graphed.

[1082] If there is no crosstalk between the working electrodes, then, as the sensor is placed in solutions of increasingly higher glucose concentration, the graphed signal of the Plus GOx electrode should show corresponding signal increases, while the No GOx electrode signal should exhibit little or no change in signal. However, when the sensor is placed in a solution of a known noise-causing species (e.g., acetaminophen, ibuprofen, vitamin C, urea, and the like), both working electrodes (Plus GOx and No GOx) should exhibit an increase in signal. In some circumstances, this increase in signal is a dramatic spike in signal.

[1083] If there is crosstalk, then the signals from both electrodes should increase as the sensor is moved to solutions of increased glucose concentration. Similarly, when the sensor is placed in a solution of a known noise-causing species, both working electrodes should exhibit an increase in signal.

Example 6: Effect of Electroactive Surface Size in Dual-Electrodes *In vivo*

[1084] The effect of size of the electroactive surfaces (of the working electrodes) on noise measurement was examined in non-diabetic human hosts. Sensors having electroactive surfaces of different sizes, and lacking GOx in the enzyme layer were constructed as follows. Clean, insulated Pt/Ir wires were separated into two groups. For **Group 1,** 0.029" of the insulation was removed from each wire (e.g., about its entire circumference), to expose

Abbott Ex. 1003 - 409/1058

electroactive surfaces. For **Group 2**, the same procedure was performed, except that two sequential 0.029" portions of the insulation were removed; effectively doubling the size of the **Group 2** electroactive surfaces relative to those of **Group 1**. After exposure of the electroactive surfaces, the two groups of wires were treated identically. On each wire, a portion of the sensor's membrane was fabricated by the sequential application (and curing thereof) of electrode domain, enzyme domain and resistance domain materials. The enzyme domain material contained no active GOx, so that the sensors would be able to detect only noise (no analyte). Next, pairs of wires (e.g., two **Group 1** wires or two **Group 2** wires) were aligned such that the electroactive surfaces were parallel to each other, and then twisted together. An Ag/AgCl ribbon was wrapped around a portion of the twisted wires (to form the reference electrode), and then additional resistance domain material was applied to the assembly. Each host consumed 1,000-mg of acetaminophen near the end of the trial, so that the affect of a known interferent could be examined.

[1085] **Fig. 19A** is a graph illustrating the *in vivo* experimental results from implantation of a **Group 1** sensor (one 0.029" electroactive surface area per electrode). The Y-axis represents raw counts and the X-axis represents time. The data collected from each electroactive surface is shown as a line (**E1, No GOx** and **E2, No GOx**). Please note that the data represents only the noise component of the signal. No analyte component was detected, due to the lack of GOx in the portions of the membrane adjacent to the electroactive surfaces. Referring now to **Fig. 19A**, the noise signal detected by each of the working electrodes (**E1**, **E2**) fluctuated widely throughout the implantation time. The amplitude of the noise component detected by **E2** was substantially greater than the noise component detected by **E1**. For example, referring to the data circled by oval **A**, the noise signal peaks detected by **E2** were substantially greater than those detected by **E1**. Additionally, the noise fluctuations between the two working electrodes were not always in the same direction. For example, referring to the data circled by oval **B**, the **E2** noise signal component increased while the **E1** noise signal component decreased. When the sensor was challenged with acetaminophen (drug consumption indicated by the arrow), both electrodes registered a substantial increase in noise signal, wherein the shapes of the curves were substantially similar. However, **E1** detected a substantially lower total amount of noise when compared with that detected by **E2**; this

Abbott Ex. 1003 - 410/1058

difference in signal amplitude (in response to a non-biologic interferent) indicates that the signals (e.g., on the two working electrodes) did not have substantially similar sensitivities.

[1086] **Fig. 19B** is a graph illustrating the *in vivo* experimental results from implantation of a **Group 2** sensor (two 0.029" electroactive surface areas per electrode). As described above, the **Group 2** electroactive surfaces are about two-times as large as those of the **Group 1** sensors. As before, the Y-axis represents raw counts and the X-axis represents time, and the data collected from each electroactive surface is shown as a line (**E1, No GOx** and **E2, No GOx**). As before, the data represents only the noise component of the signal. No analyte component was detected, due to the lack of GOx in the portions of the membrane adjacent to the electroactive surfaces. Referring now to **Fig. 19B**, the noise signal detected by each of the working electrodes (**E1**, **E2**). Throughout the course of the experiment (~20-hours), noise signals detected by **E1** and **E2** tracked very closely throughout the entire experiment. Namely, the noise signals detected by **E1** and **E2** were of substantially the same amplitude and followed substantially similar fluctuations, varying from about 7,000 counts (at 4:00 PM) to about 4500 counts (from about 6:30 AM to about 9:00 AM). Even when the **Group 2** sensor was challenged with acetaminophen (a known non-biological interferent that should cause a false signal on the sensor), the working electrodes recorded substantially equal signal amplitudes (~6,900 counts) and followed substantially similar wave forms having substantially equivalent amplitudes; these data indicate that the two working electrodes had substantially equal sensitivities.

[1087] From these data, the inventors concluded that the electroactive surfaces of a dual-electrode glucose sensor must be sufficiently large in order for the two electrodes to detect substantially equal noise signal components. For example, in this experiment, the electroactive surfaces of the **Group 1** working electrodes, which did not measure noise equivalently, were 0.029" (e.g., along the electrode's length); while electroactive surfaces of the **Group 2** working electrodes, which did measure noise substantially equivalently, were two times as large (e.g., 2x0.029"=0.058" along the electrode's length) as those of the **Group 1** working electrodes.

Example 7: Effect of Electroactive Surface Spacing in Dual-electrodes *In vivo*

[1088] The effect of the spacing of the electroactive surfaces (of the working electrodes) on noise measurement was examined in non-diabetic human hosts. Sensors having

Abbott Ex. 1003 - 411/1058

two different configurations were built and tested. Sensors of **Configuration 1** (**Config. 1**) included Plus GOx and No GOx working electrodes with non-aligned (e.g., miss-aligned, skewed) electroactive surfaces. In other words, the electroactive surfaces were spaced such that, in the completed sensor, one electroactive surface would be more proximal to the sensor's tip than then other. Sensors of **Configuration 2** (**Config. 2**) also included Plus GOx and No GOx working electrodes, except that the electroactive surfaces were closely aligned (e.g., parallel). In **Config. 2**, the membrane was the insulator between the two working electrodes, enabling the very close spacing (i.e., the thickness of the membrane determined the spacing between the two working electrodes, between about 0.001 inches to about 0.003 inches between the two working electrodes.)

[1089] **Config. 1** sensors were fabricated as follow. For each sensor, two clean, insulated Pt/Ir wires were wound together (and an Ag/AgCl ribbon twisted there around), followed by removal of a portion of the insulating material from each wire to create the electroactive surfaces. The electroactive surfaces were offset (e.g., not next to each other) relative to the sensor's tip. The twisted wire pairs were then dipped in enzyme domain solution (including GOx) just far enough such that only the electroactive surface closest to the tip of the sensor was coated with the enzyme domain material (e.g., **E1, Plus GOx**). The electroactive surface farthest from the sensor tip was not coated with the enzyme domain material (e.g., **E2, No GOx**). After curing, resistance domain material was applied to the twisted pairs of wires.

[1090] **Config. 2** sensors were fabricated as follow. Clean, insulated Pt/Ir wires were divided into two groups. Electrode and enzyme (Plus GOx) domain materials were sequentially applied to the **E1, Plus GOx** working electrode wires. Electrode and enzyme (No GOx) domain materials were sequentially applied to the **E2, No GOx** working electrode wires. Resistance domain material was applied to all wires individually (e.g., to form independent/discontinuous first and second resistance domains). After the resistance domain material was cured, one each of the **E1, Plus GOx** and **E2, No GOx** were placed together such that the wires' electroactive surfaces were aligned, and then twisted together to form a twisted pair. An Ag/AgCl ribbon was wrapped around each twisted pair (but not covering the electroactive surfaces), followed by application of a continuous resistance domain (e.g., a third resistance domain) over the sensor. The resulting sensors included a coaxial helix

Abbott Ex. 1003 - 412/1058

configuration similar to that shown in **Fig. 18** of U.S. Patent Publication No. US-2008-0083617-A1, incorporated herein by reference in its entirety.

[1091] **Fig. 20A** is a graph illustrating the *in vivo* experimental results from implantation of a **Config. 1** sensor (non-aligned electroactive surfaces). The Y-axis represents raw counts and the X-axis represents time. The **E1, Plus GOx** electrode detected both glucose and noise signal components while the **E2, No GOx** electrode detected only the noise signal component. Throughout most of the experiment's duration, the two working electrodes recorded signals having somewhat similar waveforms with the two lines being relatively flat with little fluctuation in amplitude (the volunteer was not diabetic, and thus would generally not have large fluctuations in glucose level). During the acetaminophen challenge, the **E1, Plus GOx** signal rapidly peaked at about 12,000 counts and then gradually declined, while the **E2, No GOx** signal peak was much lower in amplitude (~6,000 counts).

[1092] **Fig. 20B** is a graph illustrating the *in vivo* experimental results from implantation of a **Config. 2** sensor (aligned electroactive surfaces). The Y-axis represents raw counts and the X-axis represents time. In general, the **E1, Plus GOx** electrode detected both glucose and noise signal components while the **E2, No GOx** electrode detected only the noise signal component. Throughout most of the experiment's duration, the two electrodes recorded signals having substantially similar waveforms; though the **E1, Plus GOx** electrode signal was generally higher in amplitude than that of the **E2, No GOx** electrode. When the sensor was challenged with acetaminophen, the signals of both working electrodes rapidly peaked at about 11,000-12,000 counts (e.g., the amplitudes of the two peaks were substantially equivalent/similar) and then gradually declined.

[1093] From these data, the inventors concluded that the electroactive surfaces of a dual-electrode glucose sensor must be sufficiently close together in order for the two electrodes to detect substantially equivalent noise signal components. Additionally, the inventors concluded that for a dual-electrode sensor including the combination of a continuous resistance domain disposed over discontinuous resistance domains (e.g., applied independently to the two working electrodes) the detected signal amplitudes more closely correspond to each other. This improves mathematical noise correction by enabling better noise signal subtraction.

Abbott Ex. 1003 - 413/1058

Example 8: Use of Dual-Electrode Glucose Sensors in Intravenous Porcine Model

[1094] Six dual-electrode glucose sensor IV systems, including a dual-electrode glucose sensor (e.g., including a first working electrode **E1** (e.g., configured to generate signals associated with both glucose and non-glucose-related species having oxidation/reduction potentials that overlap with that of glucose) and a second working electrode **E2** (e.g., configured to generate signals associated with non-glucose-related species having oxidation/reduction potentials that overlap with that of glucose)) and a fluid control system (including a catheter inserted into a peripheral vein) were tested in a porcine model, as described elsewhere herein. A 100-mg/dl-glucose solution was used to calibrate and wash the dual-electrode sensor, according to procedures described elsewhere herein. To obtain an increase in serum glucose to hyperglycemic ranges, a 22.5% dextrose solution was gradually infused through the animal's left ear vein. The infusion was stopped once the blood glucose levels reached sufficiently high blood glucose values and a return to normal values was followed. Blood samples were collected in 5-minute intervals from the right jugular vein throughout the study. Plasma glucose values were determined on an YSI instrument. The study took about 4-hours.

[1095] **Fig. 21A** is a graph illustrating test results from an exemplary dual-electrode continuous glucose sensor coupled to a flow control system *via* a catheter inserted in the animal's femoral vein. The Y-axis represents glucose values (mg/dl) and the X-axis represents time. The small triangle represents glucose values provided by the dual-electrode glucose sensor system every 5 minutes, while the small diamond represents substantially time-corresponding control glucose values obtained from the YSI device.

[1096] **Fig. 21B** is a Clark Error Grid quantifying the clinical accuracy of the blood glucose estimates generated by the dual-electrode glucose sensor system as compared to a reference value (e.g., YSI). All values fall within area "**A**," which indicates that all values provided by the dual-electrode sensor are within 20% of the values provided by the YSI control test device. $R^2 = 0.9799$.

[1097] The dual-electrode glucose sensor tracked the animal's glucose values, from about 50-mg/dl to about 300-mg/dl over a period of about 4-hours. The signals generated by the first and second working electrodes were processed to provide the data shown in **Figs. 21A-21B**. The glucose values provided by the dual-electrode sensor tracked very closely with the

Abbott Ex. 1003 - 414/1058

control measurements provided by the YSI device. Additionally, all glucose values provided by the dual-electrode glucose sensor fell within the "**A**" portion of the Clark Error Grid. The sensor had an MARD of 7.5% and met the FDA's ISO standard for hand-held glucose monitors (±15-mg/dl or ±20%) by 100%.

[1098] From these data, the investigators concluded that continuous IV glucose tracking (*via* a peripheral vein) using a dual-electrode continuous glucose sensor, including first and second working electrodes configured as described herein, coupled with a catheter and a flow control system can provide consistently accurate glucose values *in vivo*.

Example 9

[1099] *In vivo* glucose data was generated using a dual-electrode glucose sensor implanted in a host's peripheral vein, as described elsewhere herein. A flow control system, such as that described with reference to **Figs. 7-8C,** was installed, including a reference glucose infusion solution (e.g., 100-mg/dl glucose). Upon initiation, the flow control device began drawing back blood samples to the glucose sensor, re-infusing the samples and infusing the reference solution, such as according to the programmed flow profile. Data were received from the plus-enzyme and no-enzyme working electrodes, such as described elsewhere herein. The signal waveforms of the non-enzyme working electrode data (e.g., second signal waveform) were evaluated to determine if the draw-back/infusion was successful**.** For exemplary purposes, one second signal waveform (from the no-enzyme working electrode) generated during a known successful infusion and one second signal waveform generated during a known unsuccessful infusion are presented.

[1100] **Fig. 22** is a graph of a second signal waveform (e.g., no-enzyme working electrode data) generated during a successful infusion of the reference solution into the host *versus* the adaptive calibration waveform template. Line **2202** is the adaptive calibration waveform template. Line **2204** represents the second signal waveform generated on the non-enzyme electrode during infusion of the reference solution into the host. The portion of the graph denoted by **2206** represents the data that could be used to calibrate the sensor, if the second signal waveform met at least one criterion. For example, in this experiment, the second signal waveform substantially overlapped with the adaptive waveform template. Additionally, the second signal waveform was substantially monotonic, like the adaptive waveform template. These facts indicated that the infusion was successful. The second signal waveform was

Abbott Ex. 1003 - 415/1058

integrated into the adaptive waveform template, to generate an updated adaptive waveform template. Additionally, a data value was displayed on the system's user interface.

[1101] **Fig. 23** is a graph of a second signal waveform generated during an unsuccessful infusion of the reference solution into the host *versus* the adaptive calibration waveform template. Line **2302** represents the adaptive calibration waveform template. Line **2304** represents the second signal waveform generated on the non-enzyme electrode during the unsuccessful infusion of the reference solution into the host. The portion of the graph denoted by **2306** represents the data that could have been used to calibrate the sensor, if the second signal waveform had met at least one criterion. Lines **2302** and **2304** substantially overlapped and had a negative slope, until about 70 sample points. At about 70 sample points, line **2304** exhibited a substantial peak. A second increase began at about 110 sample points and extended to 120 sample points, when the waveform ended. During this deviation (e.g., **2306**) the second signal waveform did not correlate with the adaptive template. Additionally, the second signal waveform was not monotonic. These data indicated that the infusion was not successful and the system was not reliable. The signal waveform was not integrated with the adaptive template. The signal data denoted by **2306** and corresponding generated first signal data were not used to calibrate the sensor.

Example 10

[1102] *In vivo* glucose data was generated using a dual-electrode glucose sensor implanted in a host's peripheral vein, as described elsewhere herein. A flow control system, such as that described with reference to **Figs. 7-8C** was installed, including a reference glucose infusion solution (e.g., 100-mg/dl glucose). Upon initiation, the flow control device began drawing back blood samples to the glucose sensor, re-infusing the samples and infusing the reference solution, such as according to the programmed flow profile.

[1103] **Fig. 24** is a graph of the signal generated from the plus-enzyme working electrode (black diamonds) and from the no-enzyme working electrode (black dots). Completion of sensor break-in is denoted by the dashed vertical line. The sensor was implanted in the host at about 2:00 P.M. Upon drawing-back a sample, the signal waveform increased. Upon re-infusion of the sample and infusion of the reference solution, the signal waveform decreased. Accordingly, with each cycle of sample draw-back and infusion, a signal peak and valley were generated. Upon sensor start-up, the sensor signal (e.g., baseline), on both working

Abbott Ex. 1003 - 416/1058

electrodes, started high (e.g., ~ 400-500 counts) and then drifted progressively downward over time (e.g., baseline drift). In this example, wherein the sensor system included a dual electrode sensor, and both electrochemical break-in (illustrated by the exponential decay during the first 30 minutes after sensor start-up) and membrane break-in (illustrated by a difference between the enzyme signal and non-enzyme signal during the first 30 minutes after sensor start-up) can be seen. After about the first 30 minutes, the sensor data, notably the second signal waveform (e.g., no-enzyme working electrode data), stabilized.

Example 11

[1104] *In vivo* glucose data was generated using a dual-electrode glucose sensor implanted in a host's peripheral vein, as described elsewhere herein. A flow control system, such as that described with reference to **Figs. 7-8C** were installed, including a reference glucose infusion solution (e.g., 100 mg/dL glucose). Upon initiation, the flow control device began drawing back blood samples to the glucose sensor, re-infusing the samples and infusing the reference solution, such as according to the programmed flow profile.

[1105] **Fig. 25** is a graph of calculated sensor sensitivities. The Y-axis represents sensor sensitivity (in pA/mg/dL). The X-axis represents time (e.g., of sensor implantation/use). Each point represents an individual sensitivity calculation determined using a subtracted signal from the dual-electrode sensor, wherein the sensitivity was determined when the sensor was exposed to the 100 mg/dL reference solution, as described in more detail elsewhere herein. Change in calculated sensor sensitivity was evaluated over short time periods (e.g., also referred to as short-term sensitivity evaluation; every 5-minutes) throughout sensor use, and over longer time periods (e.g., also referred to as long-term sensitivity evaluation) the total change in sensor sensitivity between the calculated sensor sensitivity at t=0 and at t = 1-hr, and between t = 1-hr and t = 2-hr). The change in sensitivity was calculated using the formula $(m_2-m_1)/m_1$. For the first hour of sensor use, when the sensor was breaking in and dramatic changes in sensitivity are observed, a change in sensitivity threshold was set at ±100% over the hour. For the second hour of sensor use, when changes in sensitivity begin to level off, the threshold was set at ±20%. For short time sensitivity evaluation, the threshold was set at a ±15% change in sensor sensitivity over 5-minutes. An example of 5 minute time period is shown at **2502**. The calculated sensitivity at point **2502a** was 2.2 pA/mg/dL and the calculated sensitivity at point **2502b** was also 2.2 pA/mg/dL, resulting in a sensitivity change of 0% in 5-minutes.

Abbott Ex. 1003 - 417/1058

Accordingly, the change in sensitivity between these two time points was well within the ±15% per 5-minutes threshold. An example of sensitivity drift during the first hour of sensor use is denoted by **2504**. At **2504a**, the sensitivity was 1.5 pA/mg/dL. At **2504b**, the sensitivity was about 2.2 pA/mg/dL, giving a 70% change in sensitivity over the first hour of sensor use. Accordingly, the increase in sensor sensitivity, during the first hour of sensor use, was within the ±100% threshold. Another example of sensitivity drift, during the second hour of sensor use, is denoted by **2506**. For the second hour of sensor use, the threshold was set at ±20% over the second hour. Again, at **2504b**, the sensitivity was about 2.2 pA/mg/dL. At point **2506a**, the sensitivity was 2.4 pA/mg/dL, giving a 20% drift in sensitivity, which met the ±20% threshold.

Example 12: Pain Monitoring by Continuous Intra-vascular Glucose Detection in the Neonatal Host

[1106] A newborn infant (the host) is transferred to the newborn intensive care unit (NICU) soon after birth. When the host arrives, a nurse inserts a 24-gauge catheter into one of the host's veins. The nurse inserts a continuous glucose sensor (e.g., see **Fig. 1F**) into the catheter and connects the fluid coupler to the catheter's hub. The sensor is configured such that it extends into the catheter's lumen such that the electroactive surface(s) are located adjacent to the catheter's orifice. Then the nurse sets up the fluid control device (e.g., see **Fig. 10A**) with an infusion solution, and connects the IV tubing to the fluid coupler. The nurse initiates the system and selects a flow profile optimized for a neonatal host. For example, the flow profile directs the drawback of minimum sample volumes (e.g., about 1, 2, 3, 4 or 5-μl), return of the sample to the host, and sensor washing using minimum volumes (e.g., about 10, 20, 30, 50 or 100-μl of solution). The system begins continuously monitoring the host's blood glucose level and to display the host's blood glucose level. After a period of time, the host's blood glucose begins to rise. The host's blood glucose exceeds a first programmed range (e.g., a euglycemic range) and the processor module provides an alarm to the nurse and/or to display at least one of an instruction to the nurse, the host's glucose level, and an indication of the host's level of comfort (e.g., pain, distress), wherein the level of the comfort is associated with the host's glucose concentration. For example, the nurse is alerted that the host is beginning to become distressed and may be feeling pain. The system is configured to instruct the nurse to check the host's vital signs and to provide appropriate care for the host's observed condition.

Abbott Ex. 1003 - 418/1058

The host's blood glucose continues to increase and exceeds a second programmed range (e.g., a hyperglycemic range). The system provides an alarm, which alerts the nurse to an increase in the host's distressed condition. Additionally, the system displays at least one of updated instructions to the nurse, the host's blood glucose level, and/or an indication of the host's pain level, wherein the pain level is associated with the host's blood glucose level. Upon checking on the host, the nurse observes that the host appears to be in pain, and follows instructions displayed on the display to administer pain medication. Alternatively, the system can be configured to automatically infuse basal and/or bolus amounts of pain medication based at least in part on the measured glucose concentration. As the pain medication becomes effective, the host's blood glucose begins to return to the first programmed range. The system displays at least one of the host's blood glucose level and/or an indication of the host's comfort (e.g., pain, distress) level, wherein the indication of the host's comfort level is associated with the host's glucose level.

[1107] Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Patent No. 4,994,167; U.S. Patent No. 4,757,022; U.S. Patent No. 6,001,067; U.S. Patent No. 6,741,877; U.S. Patent No. 6,702,857; U.S. Patent No. 6,558,321; U.S. Patent No. 6,931,327; U.S. Patent No. 6,862,465; U.S. Patent No. 7,074,307; U.S. Patent No. 7,081,195; U.S. Patent No. 7,108,778; U.S. Patent No. 7,110,803; U.S. Patent No. 7,192,450; U.S. Patent No. 7,226,978; U.S. Patent No. 7,310,544; U.S. Patent No. 7,364,592; U.S. Patent No. 7,366,556; and U.S. Patent No. 7,424,318.

[1108] Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Patent Publication No. US-2005-0143635-A1; U.S. Patent Publication No. US-2005-0181012-A1; U.S. Patent Publication No. US-2005-0177036-A1; U.S. Patent Publication No. US-2005-0124873-A1; U.S. Patent Publication No. US-2005-0115832-A1; U.S. Patent Publication No. US-2005-0245799-A1; U.S. Patent Publication No. US-2005-0245795-A1; U.S. Patent Publication No. US-2005-0242479-A1; U.S. Patent Publication No. US-2005-0182451-A1; U.S. Patent Publication No. US-2005-0056552-A1; U.S. Patent Publication No. US-2005-0192557-A1; U.S. Patent Publication No. US-2005-0154271-A1; U.S. Patent Publication No. US-2004-0199059-A1; U.S. Patent Publication No. US-2005-0054909-A1; U.S. Patent Publication No. US-2005-0051427-A1; U.S. Patent Publication No. US-2003-0032874-A1; U.S. Patent Publication No. US-2005-

Abbott Ex. 1003 - 419/1058

0103625-A1; U.S. Patent Publication No. US-2005-0203360-A1; U.S. Patent Publication No. US-2005-0090607-A1; U.S. Patent Publication No. US-2005-0187720-A1; U.S. Patent Publication No. US-2005-0161346-A1; U.S. Patent Publication No. US-2006-0015020-A1; U.S. Patent Publication No. US-2005-0043598-A1; U.S. Patent Publication No. US-2005-0033132-A1; U.S. Patent Publication No. US-2005-0031689-A1; U.S. Patent Publication No. US-2004-0186362-A1; U.S. Patent Publication No. US-2005-0027463-A1; U.S. Patent Publication No. US-2005-0027181-A1; U.S. Patent Publication No. US-2005-0027180-A1; U.S. Patent Publication No. US-2006-0020187-A1; U.S. Patent Publication No. US-2006-0036142-A1; U.S. Patent Publication No. US-2006-0020192-A1; U.S. Patent Publication No. US-2006-0036143-A1; U.S. Patent Publication No. US-2006-0036140-A1; U.S. Patent Publication No. US-2006-0019327-A1; U.S. Patent Publication No. US-2006-0020186-A1; U.S. Patent Publication No. US-2006-0036139-A1; U.S. Patent Publication No. US-2006-0020191-A1; U.S. Patent Publication No. US-2006-0020188-A1; U.S. Patent Publication No. US-2006-0036141-A1; U.S. Patent Publication No. US-2006-0020190-A1; U.S. Patent Publication No. US-2006-0036145-A1; U.S. Patent Publication No. US-2006-0036144-A1; U.S. Patent Publication No. US-2006-0016700-A1; U.S. Patent Publication No. US-2006-0142651-A1; U.S. Patent Publication No. US-2006-0086624-A1; U.S. Patent Publication No. US-2006-0068208-A1; U.S. Patent Publication No. US-2006-0040402-A1; U.S. Patent Publication No. US-2006-0036142-A1; U.S. Patent Publication No. US-2006-0036141-A1; U.S. Patent Publication No. US-2006-0036143-A1; U.S. Patent Publication No. US-2006-0036140-A1; U.S. Patent Publication No. US-2006-0036139-A1; U.S. Patent Publication No. US-2006-0142651-A1; U.S. Patent Publication No. US-2006-0036145-A1; U.S. Patent Publication No. US-2006-0036144-A1; U.S. Patent Publication No. US-2006-0200022-A1; U.S. Patent Publication No. US-2006-0198864-A1; U.S. Patent Publication No. US-2006-0200019-A1; U.S. Patent Publication No. US-2006-0189856-A1; U.S. Patent Publication No. US-2006-0200020-A1; U.S. Patent Publication No. US-2006-0200970-A1; U.S. Patent Publication No. US-2006-0183984-A1; U.S. Patent Publication No. US-2006-0183985-A1; U.S. Patent Publication No. US-2006-0195029-A1; U.S. Patent Publication No. US-2006-0229512-A1; U.S. Patent Publication No. US-2006-0222566-A1; U.S. Patent Publication No. US-2007-0032706-A1; U.S. Patent Publication No. US-2007-0016381-A1; U.S. Patent Publication No. US-2007-0027370-A1; U.S. Patent Publication No. US-2007-0027384-A1;

Abbott Ex. 1003 - 420/1058

U.S. Patent Publication No. US-2007-0032718-A1; U.S. Patent Publication No. US-2007-0059196-A1; U.S. Patent Publication No. US-2007-0066873-A1; U.S. Patent Publication No. US-2007-0197890-A1; U.S. Patent Publication No. US-2007-0173710-A1; U.S. Patent Publication No. US-2007-0163880-A1; U.S. Patent Publication No. US-2007-0203966-A1; U.S. Patent Publication No. US-2007-0213611-A1; U.S. Patent Publication No. US-2007-0232879-A1; U.S. Patent Publication No. US-2007-0235331-A1; U.S. Patent Publication No. US-2008-0021666-A1; U.S. Patent Publication No. US-2008-0033254-A1; U.S. Patent Publication No. US-2008-0045824-A1; U.S. Patent Publication No. US-2008-0071156-A1; U.S. Patent Publication No. US-2008-0086042-A1; U.S. Patent Publication No. US-2008-0086044-A1; U.S. Patent Publication No. US-2008-0086273-A1; U.S. Patent Publication No. US-2008-0083617-A1; U.S. Patent Publication No. US-2008-0119703-A1; U.S. Patent Publication No. US-2008-0119704-A1; U.S. Patent Publication No. US-2008-0119706-A1U.S. Patent Publication No. US-2008-0194936-A1; U.S. Patent Publication No. US-2008-0194937-A1; U.S. Patent Publication No. US-2008-0195967-A1; U.S. Patent Publication No. US-2008-0183061-A1; U.S. Patent Publication No. US-2008-0183399-A1; U.S. Patent Publication No. US-2008-0189051-A1; U.S. Patent Publication No. US-2008-0214918-A1; U.S. Patent Publication No. US-2008-0194938-A1; U.S. Patent Publication No. US-2008-0214915-A1; U.S. Patent Publication No. US-2008-0194935-A1; U.S. Patent Publication No. US-2008-0188731-A1; U.S. Patent Publication No. US-2008-0242961-A1; U.S. Patent Publication No. US-2008-0208025-A1; U.S. Patent Publication No. US-2008-0197024-A1; U.S. Patent Publication No. US-2008-0200788-A1; U.S. Patent Publication No. US-2008-0200789-A1; U.S. Patent Publication No. US-2008-0200791-A1; U.S. Patent Publication No. US-2008-0228054-A1; U.S. Patent Publication No. US-2008-0228051-A1; and U.S. Patent Publication No. US-2008-0262469-A1.

[1109] Methods and devices that are suitable for use in conjunction with aspects of the preferred embodiments are disclosed in U.S. Patent Application No. 09/447,227 filed November 22, 1999 and entitled "DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS"; U.S. Patent Application No. 11/654,135 filed January 17, 2007 and entitled "POROUS MEMBRANES FOR USE WITH IMPLANTABLE DEVICES"; U.S. Patent Application No. 11/654,140 filed January 17, 2007 and entitled "MEMBRANES FOR AN ANALYTE SENSOR"; U.S. Patent Application No. 11/691,426 filed March 26, 2007 and

Abbott Ex. 1003 - 421/1058

entitled "ANALYTE SENSOR"; U.S. Patent Application No. 12/103,594 filed April 15, 2008 and entitled "BIOINTERFACE WITH MACRO- AND MICRO-ARCHITECTURE"; U.S. Patent Application No. 12/113,724 filed May 1, 2008 and entitled "LOW OXYGEN IN VIVO ANALYTE SENSOR"; U.S. Patent Application No. 12/055,098 filed March 25, 2008 and entitled "ANALYTE SENSOR"; U.S. Patent Application No. 12/054,953 filed March 25, 2008 and entitled "ANALYTE SENSOR"; U.S. Patent Application No. 12/055,114 filed March 25, 2008 and entitled "ANALYTE SENSOR"; U.S. Patent Application No. 12/133,789 filed June 5, 2008 and entitled "INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/133,761 filed June 5, 2008 and entitled "INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/133,738 filed June 5, 2008 and entitled "INTEGRATED MEDICAMENT DELIVERY DEVICE FOR USE WITH CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/139,305 filed June 13, 2008 and entitled "ELECTRODE SYSTEMS FOR ELECTROCHEMICAL SENSORS"; U.S. Patent Application No. 12/175,391 filed July 17, 2008 and entitled "TRANSCUTANEOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/182,008 filed July 29, 2008 and entitled "INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/182,073 filed July 29, 2008 and entitled "INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/182,083 filed July 29, 2008 and entitled "INTEGRATED RECEIVER FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/195,191 filed August 20, 2008 and entitled "SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA"; U.S. Patent Application No. 12/195,773 filed August 21, 2008 and entitled "SYSTEM AND METHODS FOR PROCESSING ANALYTE SENSOR DATA"; U.S. Patent Application No. 12/247,137 filed October 7, 2008 and entitled "IMPLANTABLE ANALYTE SENSOR"; U.S. Patent Application No. 12/250,918 filed October 14, 2008 and entitled "ANALYTE SENSOR"; U.S. Patent Application No. 12/253,125 filed October 16, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/253,120 filed October 16, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/253,064 filed October 16, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE

Abbott Ex. 1003 - 422/1058

SENSOR"; U.S. Patent Application No. 12/252,996 filed October 16, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/252,967 filed October 16, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/252,952 filed October 16, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/260,017 filed October 28, 2008 and entitled "SENSOR HEAD FOR USE WITH IMPLANTABLE DEVICES"; U.S. Patent Application No. 12/258,320 filed October 24, 2008 and entitled "SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA"; U.S. Patent Application No. 12/263,993 filed November 3, 2008 and entitled "SIGNAL PROCESSING FOR CONTINUOUS ANALYTE SENSOR"; U.S. Patent Application No. 12/264,835 filed November 4, 2008 and entitled "IMPLANTABLE ANALYTE SENSOR"; U.S. Patent Application No. 12/258,235 filed October 24, 2008 and entitled "SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA"; U.S. Patent Application No. 12/258,345 filed October 24, 2008 and entitled "SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA"; U.S. Patent Application No. 12/258,325 filed October 24, 2008 and entitled "SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA"; U.S. Patent Application No. 12/258,318 filed October 24, 2008 and entitled "SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA"; U.S. Patent Application No. 12/258,335 filed October 24, 2008 and entitled "SYSTEMS AND METHODS FOR PROCESSING SENSOR DATA"; U.S. Patent Application No. 12/264,160 filed November 3, 2008 and entitled "DUAL ELECTRODE SYSTEM FOR A CONTINUOUS ANALYTE SENSOR."

[1110] All references cited herein, including but not limited to published and unpublished applications, patents, and literature references, are incorporated herein by reference in their entirety and are hereby made a part of this specification. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.

[1111] The term "comprising" as used herein is synonymous with "including," "containing," or "characterized by," and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

Abbott Ex. 1003 - 423/1058

[1112] All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.

[1113] The above description discloses several methods and materials of the present invention. This invention is susceptible to modifications in the methods and materials, as well as alterations in the fabrication methods and equipment. Such modifications will become apparent to those skilled in the art from a consideration of this disclosure or practice of the invention disclosed herein. Consequently, it is not intended that this invention be limited to the specific embodiments disclosed herein, but that it cover all modifications and alternatives coming within the true scope and spirit of the invention.

Abbott Ex. 1003 - 424/1058

WHAT IS CLAIMED IS:

1. A method for evaluating a change in a sensitivity of an implanted analyte sensor over a predetermined time period, comprising:

receiving sensor data from an analyte sensor implanted in a host, wherein the implanted sensor is configured to generate sensor data, wherein the sensor data comprises one or more sensor analyte values measured in a biological sample of a host;

intermittently calculating a sensitivity of the analyte sensor; and

evaluating, using an electronic device, a change in sensitivity by evaluating a plurality of time-spaced sensitivity calculations over a predetermined time period, wherein evaluating a change in sensitivity is based at least in part on using *a priori* sensitivity information throughout a sensor session, wherein the plurality of time spaced sensitivity calculations are not based on a blood-glucose measurement.

2. The method of Claim 1, wherein the predetermined time period is less than or equal to about 30 minutes.

3. The method of Claim 1, wherein the predetermined time period is less than or equal to about 20 minutes.

4. The method of Claim 1, wherein the predetermined time period is less than or equal to about 10 minutes.

5. The method of Claim 1, wherein evaluating a change in sensitivity comprises evaluating at least two sensitivity measurements during the predetermined time period.

6. The method of Claim 5, further comprising averaging and/or filtering the at least two sensitivity measurements prior to evaluating the at least two sensitivity measurements.

7. The method of Claim 1, wherein evaluating a change in sensitivity comprises comparing the change in sensitivity with one or more criteria.

8. The method of Claim 7, further comprising using a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity meets one or more criteria.

9. The method of Claim 7, further comprising not using a most recent sensitivity calculation evaluated to calibrate the analyte sensor when the change in sensitivity does not meet one or more criteria.

Abbott Ex. 1003 - 425/1058

10. The method of Claim 1, wherein evaluating a change in sensitivity is iteratively performed on the plurality of time-spaced sensitivity calculations over the predetermined time period.

11. The method of Claim 1, wherein the predetermined time period is at least about 30 minutes.

12. The method of Claim 1, wherein the predetermined time period is at least about 60 minutes.

13. The method of Claim 1, wherein the predetermined time period is at least about 120 minutes.

14. The method of Claim 1, wherein evaluating a change in sensitivity is iteratively performed on the plurality of time-spaced sensitivity calculations over the predetermined time period.

15. The method of Claim 1, wherein evaluating a change in sensitivity comprises evaluating all sensitivity calculations over a sensor session.

16. The method of Claim 1, wherein the *a priori* sensitivity information defines a range of acceptable change in sensitivity.

17. A method for evaluating a change in a sensitivity of an implanted analyte sensor over a predetermined time period, comprising:

receiving sensor data from an analyte sensor implanted in a host, wherein the implanted sensor is configured to generate sensor data, wherein the sensor data comprises one or more sensor analyte values measured in a biological sample of a host;

intermittently, using an electronic device, calculating a sensitivity of the analyte sensor;

measuring a change in sensitivity by evaluating a parameter indicative of a change in solute transport of a membrane of the analyte sensor; and

auto-calibrating the analyte sensor responsive to measurement of the change in sensitivity.

18. A method for evaluating a change in a sensitivity of an analyte sensor over a predetermined time period, the method comprising:

receiving sensor data from an analyte sensor, wherein the sensor data comprises one or more sensor analyte values measured in a biological sample of a host;

Abbott Ex. 1003 - 426/1058

intermittently calculating a sensitivity of the analyte;

filtering at least two sensitivity values, whereby filtered sensitivity values are obtained; and

evaluating, using an electronic device, a change in sensitivity by evaluating the filtered sensitivity values over a predetermined time period, wherein evaluating a change in sensitivity is based at least in part on using *a priori* sensitivity information throughout a sensor session.

Abbott Ex. 1003 - 427/1058

ANALYTE SENSOR

ABSTRACT OF THE DISCLOSURE

Systems and methods of use for continuous analyte measurement of a host's vascular system are provided. In some embodiments, a continuous glucose measurement system includes a vascular access device, a sensor and sensor electronics, the system being configured for insertion into communication with a host's circulatory system.

34091154

Abbott Ex. 1003 - 428/1058

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.
This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor 1 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Peter	C.	Simpson	

Residence Information (Select One) ● US Residency Non US Residency Active US Military Service

City	State/Province	Country of Residence
Cardiff	CA	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.
Address 2	6340 Sequence Drive
City	San Diego
State/Province	CA
Postal Code	92121
Country	US

Inventor 2 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Ying		Li	

Residence Information (Select One) ◉ US Residency Non US Residency Active US Military Service

City	State/Province	Country of Residence
San Diego	CA	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.
Address 2	6340 Sequence Drive
City	San Diego
State/Province	CA
Postal Code	92121
Country	US

Inventor 3 Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Apurv	Ullas	Kamath	

Residence Information (Select One) ◉ US Residency Non US Residency Active US Military Service

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

City	San Diego	State/Province	CA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

Inventor 4 — Remove

Legal Name

Prefix	Given Name	Middle Name	Family Name	Suffix
	Richard	C.	Yang	

Residence Information (Select One) ◉ US Residency ○ Non US Residency ○ Active US Military Service

City	Carlsbad	State/Province	CA	Country of Residence i	US

Mailing Address of Inventor:

Address 1	c/o DexCom, Inc.		
Address 2	6340 Sequence Drive		
City	San Diego	State/Province	CA
Postal Code	92121	Country i	US

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button. — Add

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ **An Address is being provided for the correspondence Information of this application.**

Customer Number	68851		
Email Address	efiling@knobbe.com	Add Email	Remove Email

Application Information:

Title of the Invention	ANALYTE SENSOR		
Attorney Docket Number	DEXCOM.167P1	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	56	Suggested Figure for Publication (if any)	

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	● Customer Number	US Patent Practitioner	◯ Limited Recognition (37 CFR 11.9)
Customer Number	68851		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation in part of	17/078609	2020-10-23

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

Prior Application Status	Pending		Remove
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
	Continuation in part of	17/082627	2020-10-28
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the **Add** button.			Add

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)[i] the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

			Remove
Application Number	Country[i]	Filing Date (YYYY-MM-DD)	Access Code[i] (if applicable)
Additional Foreign Priority Data may be generated within this form by selecting the **Add** button.			Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant 1 — Remove

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

● Assignee	Legal Representative under 35 U.S.C. 117	Joint Inventor
Person to whom the inventor is obligated to assign.	Person who shows sufficient proprietary interest	

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	DexCom, Inc.		
Mailing Address Information For Applicant:			
Address 1	6340 Sequence Drive		
Address 2			
City	San Diego	**State/Province**	CA
Country	US	Postal Code	92121
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button. Add

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

Assignee 1

Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.

Remove

If the Assignee or Non-Applicant Assignee is an Organization check here. ☐

Prefix	**Given Name**	Middle Name	**Family Name**	Suffix

Mailing Address Information For Assignee including Non-Applicant Assignee:

Address 1			
Address 2			
City		**State/Province**	
Country i		Postal Code	
Phone Number		Fax Number	
Email Address			

Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button. Add

Signature:

Remove

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). **However, if this Application Data Sheet is submitted with the INITIAL filing of the application and either box A or B is not checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).**

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a **juristic entity** (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Rose Thiessen/			Date (YYYY-MM-DD)	2020-12-23
First Name	Rose	Last Name	Thiessen	Registration Number	40202

Additional Signature may be generated within this form by selecting the Add button. Add

PTO/AIA/14 (02-18)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	DEXCOM.167P1
	Application Number	
Title of Invention	ANALYTE SENSOR	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1 The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.

2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.

3 A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.

4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).

5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent CooperationTreaty.

6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).

7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.

8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.

9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Abbott Ex. 1003 - 437/1058

Electronic Patent Application Fee Transmittal

Application Number:	
Filing Date:	
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Filer:	Rose M. Thiessen/Aly Quintong
Attorney Docket Number:	DEXCOM.167P1

Filed as Large Entity

Filing Fees for Track I Prioritized Examination - Nonprovisional Application under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
UTILITY APPLICATION FILING	1011	1	320	320
UTILITY SEARCH FEE	1111	1	700	700
UTILITY EXAMINATION FEE	1311	1	800	800
REQUEST FOR PRIORITIZED EXAMINATION	1817	1	4200	4200
Pages:				
UTILITY APPL SIZE FEE PER 50 SHEETS >100	1081	5	420	2100
Claims:				
Miscellaneous-Filing:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
PUBL. FEE- EARLY, VOLUNTARY, OR NORMAL	1504	1	0	0
PROCESSING FEE, EXCEPT PROV. APPLS.	1830	1	140	140

Petition:	
Patent-Appeals-and-Interference:	
Post-Allowance-and-Post-Issuance:	
Extension-of-Time:	
Miscellaneous:	
Total in USD ($)	**8260**

Electronic Acknowledgement Receipt

EFS ID:	41478756
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Rose M. Thiessen/Jennifer Neat
Filer Authorized By:	Rose M. Thiessen
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	23-DEC-2020
Filing Date:	
Time Stamp:	15:29:12
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$8260
RAM confirmation Number	E2020BMF30200491
Deposit Account	111410
Authorized User	Jennifer Neat

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.17 (Patent application and reexamination processing fees)

37 CFR 1.16 (National application filing, search, and examination fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	TrackOne Request	TRACK1.pdf	124441 c52a0e54d8cee916fd28f5e710df22db993300fe	no	2
Warnings:					
Information:					
2	Drawings-only black and white line drawings	drawings.pdf	1448046 bcd99f214ba7e6a49f4faecd664ff116ebf53c02	no	56
Warnings:					
Information:					
3		spec.pdf	1930112 a18e5c5cbca985a055786beda15ee8b636d88f0a	yes	370

Multipart Description/PDF files in .zip description

Document Description	Start	End
Specification	1	366
Claims	367	369
Abstract	370	370

Warnings:					
Information:					
4	Application Data Sheet	ADS.pdf	1256131 ce937cfed1e1179d3dfaf42f1bcc70ce1541ea70	no	9
Warnings:					
Information:					
5	Fee Worksheet (SB06)	fee-info.pdf	41838 56d0833fb4dd2f2103a6f8dd523b07424e904d6f	no	2

Warnings:	
Information:	
Total Files Size (in bytes):	4800568

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Unassigned
Art Unit	:	Unassigned
Conf. No.	:	2055

PRELIMINARY AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Prior to examination on the merits, Applicant submits the following:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.

Abbott Ex. 1003 - 443/1058

AMENDMENTS TO THE CLAIMS

1-18. (Cancelled)

19. (New) A method comprising:

calibrating sensor data.

20. (New) A transcutaneous analyte sensor system comprising:

a transcutaneous analyte sensor; and

sensor electronics operably connectable to the transcutaneous analyte sensor.

Abbott Ex. 1003 - 444/1058

REMARKS

Claim 1-18 are cancelled herein. Claims 19-20 are new, and do not constitute new matter. Prior to examination on the merits, Applicant requests entry of these amendments.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Any language or remarks referring to only a portion of a claim should not necessarily be understood to base patentability on solely that portion; rather, patentability rests on each claim taken as a whole.

Applicant respectfully submits that to the extent any disclaimers or statements were made previously during prosecution with respect to the scope of the claimed invention, such disclaimers and statements are hereby rescinded.

Applicant respectfully reserves the ability to traverse any of the rejections, assertions and submissions made in connection with the application, even if not discussed herein, including the right to challenge later whether any of the cited references is prior art. The absence of a reply to a specific rejection, issue, or comment does not signify agreement with or concession of that rejection, issue, or comment. In addition, because any arguments made may not be exhaustive, there may be other reasons that have not been expressed for patentability of any or all claims. When amendments are made to any claims, no acquiescence or estoppel is implied thereby; such amendments are made only to expedite prosecution of the present application and are without prejudice to the presentation or assertion, in the future, of claims directed to subject matter that is

Abbott Ex. 1003 - 445/1058

same as or similar to that previously presented. Nothing in this paper should be construed as an intent to concede, or actual concession of, any issue with regard to any claim, or to any cited art, except as specifically stated in this paper, and the amendment or cancellation of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment or cancellation.

Conclusion

Should the Examiner have any concerns that might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: December 30, 2020

By:/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34135097

Abbott Ex. 1003 - 446/1058

Electronic Acknowledgement Receipt

EFS ID:	41520694
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Ian W. Gillies/Aimee Kazan
Filer Authorized By:	Ian W. Gillies
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	30-DEC-2020
Filing Date:	
Time Stamp:	14:29:05
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		PA_DEXCOM_167P1.pdf	179132 424d6a357323f612418b2b8316160e9c1cb31b55	yes	4

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Preliminary Amendment	1	1
	Claims	2	2
	Applicant Arguments/Remarks Made in an Amendment	3	4
Warnings:			
Information:			
	Total Files Size (in bytes):	179132	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 1 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	001	US-RE31916	06-18-1985	OSWIN; Harry G. et al.	
	002	US-RE32361	02-24-1987	DUGGAN; Stephen R.	
	003	US-RE43039	12-20-2011	BRISTER; Mark et al.	
	004	US-RE43399	05-22-2012	SIMPSON; Peter C. et al.	
	005	US-52641	02-13-1866	GREGG; Brian A. et al.	
	006	US-62334	02-26-1867	BERNER; Bret et al.	
	007	US-65604	06-11-1867	HELLER; Adam et al.	
	008	US-1564641	12-08-1925	ST. JAMES; Robert T. et al.	
	009	US-2402306	06-18-1946	TURKEL; Henry	
	010	US-2719797	10-04-1955	ROSENBLATT; Edgar F. et al.	
	011	US-3210578	10-05-1965	SHERER; Glen H.	
	012	US-3219533	11-23-1965	MULLINS; John D.	
	013	US-3506032	04-14-1970	EVELEIGH; John William et al.	
	014	US-3539455	11-10-1970	CLARK, Jr.; Leland C.	
	015	US-3556950	01-19-1971	DAHMS; Harald	
	016	US-3581062	05-25-1971	ASTON; Keith	
	017	US-3610226	10-05-1971	ALBISSER; Anthony M.	
	018	US-3610230	10-05-1971	ANDERSEN; Harold Willids	
	019	US-3652475	03-28-1972	WADA; Tadashi et al.	
	020	US-3775182	11-27-1973	PATTON; Jimmie Donald et al.	
	021	US-3780727	12-25-1973	KING; Eugene	
	022	US-3791871	02-12-1974	ROWLEY; Leroy S.	
	023	US-3826244	07-30-1974	SALCMAN; Michael et al.	
	024	US-3837339	09-24-1974	AISENBERG; Sol et al.	
	025	US-3838033	09-24-1974	MINDT; W. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 2 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	026	US-3838682	10-01-1974	CLARK; Justin S. et al.	
	027	US-3874850	04-01-1975	SORENSEN; Soren Kai et al.	
	028	US-3898984	08-12-1975	MANDEL; Louis et al.	
	029	US-3910256	10-07-1975	CLARK; Justin S. et al.	
	030	US-3926760	12-16-1975	ALLEN; James S. et al.	
	031	US-3929971	12-30-1975	ROY; Della M.	
	032	US-3933593	01-20-1976	STERNBERG; James C.	
	033	US-3943918	03-16-1976	LEWIS; Ronald A.	
	034	US-3949388	04-06-1976	FULLER; Charles H.	
	035	US-3957613	05-18-1976	MACUR; Robert A.	
	036	US-3960497	06-01-1976	ACORD; William A.	
	037	US-3964974	06-22-1976	BANAUCH; Dieter et al.	
	038	US-3966580	06-29-1976	JANATA; Jiri A. et al.	
	039	US-3978856	09-07-1976	MICHEL; Walter A.	
	040	US-3979274	09-07-1976	NEWMAN; David P.	
	041	US-3982530	09-28-1976	STORCH; Egon	
	042	US-4008717	02-22-1977	KOWARSKI; Allen A.	
	043	US-4016866	04-12-1977	LAWTON; Richard W.	
	044	US-4024312	05-17-1977	KORPMAN; Ralf	
	045	US-4030640	06-21-1977	CITRIN; Paul S. et al.	
	046	US-4036749	07-19-1977	ANDERSON; Donald R.	
	047	US-4037563	07-26-1977	PFLUEGER; John M. et al.	
	048	US-4040908	08-09-1977	CLARK, Jr.; Leland C.	
	049	US-4052754	10-11-1977	HOMSY; Charles A.	
	050	US-4055175	10-25-1977	CLEMENS; Anton Hubert et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 3 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	051	US-4067322	01-10-1978	JOHNSON; Joseph H.	
	052	US-4073713	02-14-1978	NEWMAN; David P.	
	053	US-4076656	02-28-1978	WHITE; LeRoy A. et al.	
	054	US-4080292	03-21-1978	PRZYBYLOWICZ; Ryszard et al.	
	055	US-4109505	08-29-1978	CLARK; Justin S. et al.	
	056	US-4119406	10-10-1978	CLEMENS; Anton Hubert	
	057	US-4129128	12-12-1978	McFARLANE; Richard H.	
	058	US-4151845	05-01-1979	CLEMENS; Anton H.	
	059	US-4172770	10-30-1979	SEMERSKY; Frank E. et al.	
	060	US-4176659	12-04-1979	ROLFE; Peter	
	061	US-4197840	04-15-1980	BECK; Alexander et al.	
	062	US-4197852	04-15-1980	SCHINDLER; Johannes G. et al.	
	063	US-4206755	06-10-1980	KLEIN; Jean-Claude	
	064	US-4215703	08-05-1980	WILLSON; James K. V.	
	065	US-4240438	12-23-1980	UPDIKE; Stuart J. et al.	
	066	US-4240889	12-23-1980	YODA; Kentaro et al.	
	067	US-4245634	01-20-1981	ALBISSER; Anthony M. et al.	
	068	US-4253469	03-03-1981	ASLAN; Edward E.	
	069	US-4255500	03-10-1981	HOOKE; John W.	
	070	US-4259540	03-31-1981	SABIA; Raffaele A.	
	071	US-4265249	05-05-1981	SCHINDLER; Johannes G. et al.	
	072	US-4300572	11-17-1981	KNIGHTON; David R.	
	073	US-4327725	05-04-1982	CORTESE; Richard et al.	
	074	US-4344438	08-17-1982	SCHULTZ; Jerome S.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 4 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	075	US-4349728	09-14-1982	PHILLIPS; Robert B. et al.	
	076	US-4366040	12-28-1982	MARSONER; Hermann et al.	
	077	US-4369785	01-25-1983	REHKOPF; Paul G. et al.	
	078	US-4373527	06-27-1995	FISCHELL; Robert E.	
	079	US-4374013	02-15-1983	ENFORS; Sven-Olof	
	080	US-4378016	03-29-1983	LOEB; Marvin P.	
	081	US-4388166	06-14-1983	SUZUKI; Shuichi et al.	
	082	US-4392849	07-12-1983	PETRE; John H. et al.	
	083	US-4402694	09-06-1983	ASH; Stephen R. et al.	
	084	US-4403847	09-13-1983	CHRESTENSEN; Gene L.	
	085	US-4403984	09-13-1983	ASH; Stephen R. et al.	
	086	US-4407298	10-04-1983	LENTZ; David J. et al.	
	087	US-4415666	11-15-1983	D'ORAZIO; Paul A. et al.	
	088	US-4418148	11-29-1983	OBERHARDT; Bruce J.	
	089	US-4419535	12-06-1983	O'HARA; Robert J.	
	090	US-4420564	12-13-1983	TSUJI; Nobuhiko et al.	
	091	US-4425920	01-17-1984	BOURLAND; Joe D. et al.	
	092	US-4426621	01-17-1984	GALWEY; Ronald K. et al.	
	093	US-4431004	02-14-1984	BESSMAN; Samuel P. et al.	
	094	US-4431507	02-14-1984	NANKAI; Shiro et al.	
	095	US-4432366	02-21-1984	MARGULES; Gary S.	
	096	US-4436094	03-13-1984	CERAMI; Anthony	
	097	US-4441968	04-10-1984	EMMER; Ivan et al.	
	098	US-4442841	04-17-1984	UEHARA; Masaru et al.	
	099	US-4448188	05-15-1984	LOEB; Marvin P.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 5 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	100	US-4454295	06-12-1984	WITTMANN; Joseph W. et al.	
	101	US-4457339	07-03-1984	JUAN; Juan J. S. et al.	
	102	US-4462048	07-24-1984	ROSS; Michael D.	
	103	US-4478222	10-23-1984	KONING; Gerrit et al.	
	104	US-4478976	10-23-1984	GOERTZ; Hans-Helmut et al.	
	105	US-4484987	11-27-1984	GOUGH; David A.	
	106	US-4486290	12-04-1984	CAHALAN; Patrick T. et al.	
	107	US-4492575	01-08-1985	MABILLE; Pierre	
	108	US-4494950	01-22-1985	FISCHELL; Robert E.	
	109	US-4496454	01-29-1985	BERGER; Terry A.	
	110	US-4506680	03-26-1985	STOKES; Kenneth B.	
	111	US-4509531	04-09-1985	WARD; John W.	
	112	US-4519973	05-28-1985	CAHALAN; Patrick T. et al.	
	113	US-4526569	07-02-1985	BERNARDI; Luigi	
	114	US-4527240	07-02-1985	KVITASH; Vadim I.	
	115	US-4534355	08-13-1985	POTTER; William D.	
	116	US-4534825	08-13-1985	KONING; Gerrit et al.	
	117	US-4535786	08-20-1985	KATER; John A. R.	
	118	US-4538616	09-03-1985	ROGOFF; Robert	
	119	US-4545382	10-08-1985	HIGGINS; Irving J. et al.	
	120	US-4554927	11-26-1985	FUSSELL; Theodore J.	
	121	US-4561963	12-31-1985	OWEN; Jeffrey D. et al.	
	122	US-4565665	01-21-1986	FOGT; Eric J.	
	123	US-4565666	01-21-1986	CAHALAN; Patrick T. et al.	
	124	US-4568444	02-04-1986	NAKAMURA; Michihiro et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 6 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	125	US-4571292	02-18-1986	LIU; Chung-Chiun et al.	
	126	US-4573968	03-04-1986	PARKER; Kenneth B.	
	127	US-4577642	03-25-1986	STOKES; Kenneth B.	
	128	US-4578215	03-25-1986	BRADLEY; Robert F.	
	129	US-4583976	04-22-1986	FERGUSON; Keith T.	
	130	US-4592824	06-03-1986	SMITH; Rosemary L. et al.	
	131	US-4600495	07-15-1986	FOGT; Eric J.	
	132	US-4613328	09-23-1986	BOYD; Cecil	
	133	US-4614514	09-30-1986	CARR; Kenneth L. et al.	
	134	US-4619793	10-28-1986	LEE; Ping I.	
	135	US-4626104	12-02-1986	POINTON; Ronald H. et al.	
	136	US-4650547	03-17-1987	GOUGH; David A.	
	137	US-4655880	04-07-1987	LIU; Chung-Chiun	
	138	US-4663824	05-12-1987	KENMOCHI; Kazuei	
	139	US-4670007	06-02-1987	WHEELDON; Peter G. et al.	
	140	US-4671288	06-09-1987	GOUGH; David A.	
	141	US-4672970	06-16-1987	UCHIDA; Teruyoshi et al.	
	142	US-4680268	07-14-1987	CLARK, Jr.; Leland	
	143	US-4685463	08-11-1987	WILLIAMS; R. Bruce	
	144	US-4685903	08-11-1987	CABLE; Vaughn P. et al.	
	145	US-4685912	08-11-1987	JONES; J. Paul	
	146	US-4686044	08-11-1987	BEHNKE; Joachim et al.	
	147	US-4689309	08-25-1987	JONES; James E.	
	148	US-4694861	09-22-1987	GOODALE; David L. et al.	
	149	US-4703756	11-03-1987	GOUGH; David A. et al.	
	150	US-4705503	11-10-1987	DORMAN; Frank D. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 7 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	151	US-4711245	12-08-1987	HIGGINS; Irving J. et al.	
	152	US-4711251	12-08-1987	STOKES; Kenneth B.	
	153	US-4721677	01-26-1988	CLARK, Jr.; Leland C.	
	154	US-4731051	03-15-1988	FISCHELL; Robert E.	
	155	US-4731726	03-15-1988	ALLEN, III; Lyle M.	
	156	US-4736748	04-12-1988	NAKAMURA; Michihiro et al.	
	157	US-4747822	05-31-1988	PEABODY; Alan M.	
	158	US-4749985	06-07-1988	CORSBERG; Daniel R.	
	159	US-4750496	06-14-1988	REINHART; Richard et al.	
	160	US-4752935	06-21-1988	BECK; Rasmus	
	161	US-4753652	06-28-1988	LANGER; Robert et al.	
	162	US-4755168	07-05-1988	ROMANELLI; Pat et al.	
	163	US-4757022	07-12-1988	SHULTS; Mark C. et al.	
	164	US-4759366	07-26-1988	CALLAGHAN; Frank J.	
	165	US-4759828	07-26-1988	YOUNG; Chung C. et al.	
	166	US-4763648	08-16-1988	WYATT; Philip	
	167	US-4776944	10-11-1988	JANATA; Jiri et al.	
	168	US-4777953	10-18-1988	ASH; Stephen R. et al.	
	169	US-4779618	10-25-1988	MUND; Konrad et al.	
	170	US-4781798	11-01-1988	GOUGH; David A.	
	171	US-4783250	11-08-1988	PONS; B. Stanley et al.	
	172	US-4784157	11-15-1988	HALLS; Justin A. T. et al.	
	173	US-4786394	11-22-1988	ENZER; Steven et al.	
	174	US-4787398	11-29-1988	GARCIA; Fernando S. et al.	
	175	US-4789467	12-06-1988	LINDSAY; Edward R. et al.	
	176	US-4791932	12-20-1988	MARGULES; Gary S.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 8 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	177	US-4800495	01-24-1989	SMITH; Robert E.	
	178	US-4803243	02-07-1989	FUJIMOTO; Teruo et al.	
	179	US-4805624	02-21-1989	YAO; Shang J. et al.	
	180	US-4805625	02-21-1989	WYLER; Allen R.	
	181	US-4808089	02-28-1989	BUCHHOLTZ; Gerhard et al.	
	182	US-4808292	02-28-1989	KESSLER; Manfred et al.	
	183	US-4809704	03-07-1989	SOGAWA; Ichiro et al.	
	184	US-4810243	03-07-1989	HOWSON; David C.	
	185	US-4810470	03-07-1989	BURKHARDT; Alan E. et al.	
	186	US-4813423	03-21-1989	MIYASAKA; Katsuyuki et al.	
	187	US-4815471	03-28-1989	STOBIE; John J.	
	188	US-4820281	04-11-1989	LAWLER; Casimir E.	
	189	US-4822336	04-18-1989	DiTRAGLIA; John	
	190	US-4828544	05-09-1989	LANE; Rodney J. et al.	
	191	US-4830013	05-16-1989	MAXWELL; Thomas P.	
	192	US-4831070	05-16-1989	McINALLY; Linda J. et al.	
	193	US-4832005	05-23-1989	TAKAMIYA; Sanshiro et al.	
	194	US-4834101	05-30-1989	COLLISON; Michael E. et al.	
	195	US-4838281	06-13-1989	ROGERS; Wayne W. et al.	
	196	US-4841974	06-27-1989	GUMBRECHT; Walter et al.	
	197	US-4849458	07-18-1989	REED; Andrew M. et al.	
	198	US-4852573	08-01-1989	KENNEDY; Philip R.	
	199	US-4854322	08-08-1989	ASH; Stephen R. et al.	
	200	US-4858615	08-22-1989	MEINEMA; Ate. J.	
	201	US-4861454	08-29-1989	USHIZAWA; Norihiko et al.	
	202	US-4861830	08-29-1989	WARD, Jr.; Robert S.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 9 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	203	US-4863265	09-05-1989	FLOWER; Ronald J. et al.	
	204	US-4867741	09-19-1989	PORTNOY; Harold D.	
	205	US-4871351	10-03-1989	FEINGOLD; Vladimir	
	206	US-4871440	10-03-1989	NAGATA; Yasuhiro et al.	
	207	US-4874363	10-17-1989	ABELL; Walter L.	
	208	US-4883057	11-28-1989	BRODERICK; Patricia A.	
	209	US-4883467	11-28-1989	FRANETZKI; Manfred et al.	
	210	US-4889528	12-26-1989	NADAI; Tanekazu et al.	
	211	US-4889744	12-26-1989	QUAID; Joel	
	212	US-4890620	01-02-1990	GOUGH; David A.	
	213	US-4890621	01-02-1990	HAKKY; Said I.	
	214	US-4898578	02-06-1990	RUBALCABA, Jr.; Bernardino	
	215	US-4900305	02-13-1990	SMITH; Timothy J. N. et al.	
	216	US-4902294	02-20-1990	GOSSEREZ; Olivier	
	217	US-4907857	03-13-1990	GIULIANI; David et al.	
	218	US-4909786	03-20-1990	GIJSELHART; Paulus H. P. M. et al.	
	219	US-4919141	04-24-1990	ZIER; Horst D. et al.	
	220	US-4919649	04-24-1990	TIMOTHY; Earle J. et al.	
	221	US-4921477	05-01-1990	DAVIS; Rickey P.	
	222	US-4921480	05-01-1990	SEALFON; Andrew I.	
	223	US-4923819	05-08-1990	FERNANDEZ; Salvador M. et al.	
	224	US-4925268	05-15-1990	IYER; Lokanathan M. et al.	
	225	US-4925444	05-15-1990	ORKIN; Fredric I. et al.	
	226	US-4927407	05-22-1990	DORMAN; Frank	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 10 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	227	US-4927516	05-22-1990	YAMAGUCHI; Shuichiro et al.	
	228	US-4928694	05-29-1990	MAXWELL; Thomas P.	
	229	US-4934369	06-19-1990	MAXWELL; Thomas P.	
	230	US-4934375	06-19-1990	COLE; James E. et al.	
	231	US-4935345	06-19-1990	GUILBEAU; Eric J. et al.	
	232	US-4944299	07-31-1990	SILVIAN; Sergiu	
	233	US-4946439	08-07-1990	EGGERS; Philip N. et al.	
	234	US-4947845	08-14-1990	DAVIS; Mark W.	
	235	US-4951669	08-28-1990	MAXWELL; Thomas P. et al.	
	236	US-4953552	09-04-1990	DeMARZO; Arthur P.	
	237	US-4955861	09-11-1990	ENEGREN; Bradley J. et al.	
	238	US-4957483	09-18-1990	GONSER; Donald I. et al.	
	239	US-4958148	09-18-1990	OLSON; Jan B.	
	240	US-4963131	10-16-1990	WORTRICH; Theodore S.	
	241	US-4963595	10-16-1990	WARD; Robert S. et al.	
	242	US-4966579	10-30-1990	POLASCHEGG; Hans-Dietrich	
	243	US-4967940	11-06-1990	BLETTE; Russell E. et al.	
	244	US-4974592	12-04-1990	BRANCO; Flavio S. C.	
	245	US-4974929	12-04-1990	CURRY; Kenneth M.	
	246	US-4975175	12-04-1990	KARUBE; Isao et al.	
	247	US-4975636	12-04-1990	DESAUTELS; Patricia A.	
	248	US-4976687	12-11-1990	MARTIN; James	
	249	US-4979509	12-25-1990	HAKKY; Said I.	
	250	US-4984929	01-15-1991	ROCK; Erich et al.	
	251	US-4986271	01-22-1991	WILKINS; Ebtisam S.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 11 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	252	US-4986671	01-22-1991	SUN; Mei H. et al.	
	253	US-4988341	01-29-1991	COLUMBUS; Richard L. et al.	
	254	US-4988671	01-29-1991	JOHNSON; Robert E.	
	255	US-4988758	01-29-1991	FUKUDA; Takeshi et al.	
	256	US-4994026	02-19-1991	FECONDINI; Luciano	
	257	US-4994167	02-19-1991	SHULTS; Mark G. et al.	
	258	US-4995402	02-26-1991	SMITH; Roger E. et al.	
	259	US-4997627	03-05-1991	BERGKUIST; Carolyn et al.	
	260	US-5000180	03-19-1991	KUYPERS; Martinus H. et al.	
	261	US-5000419	03-19-1991	PALMER; Davey B. et al.	
	262	US-5002054	03-26-1991	ASH; Stephen R. et al.	
	263	US-5002055	03-26-1991	MERKI; Hans S. et al.	
	264	US-5002572	03-26-1991	PICHA; George J.	
	265	US-5006050	04-09-1991	COOKE; James E. et al.	
	266	US-5006111	04-09-1991	INOKUCHI; Kiyoshi et al.	
	267	US-5007929	04-16-1991	QUAID; Joel	
	268	US-5009251	04-23-1991	PIKE; Kelly A. et al.	
	269	US-5019974	05-28-1991	BECKERS; Andreas G. F.	
	270	US-5026348	06-25-1991	VENEGAS; Jose G.	
	271	US-5030199	07-09-1991	BARWICK; Carl B. et al.	
	272	US-5030333	07-09-1991	CLARK, Jr.; Leland	
	273	US-5034112	07-23-1991	MURASE; Isao et al.	
	274	US-5041092	08-20-1991	BARWICK; Carl	
	275	US-5045057	09-03-1991	VAN DRIESSCHE; Petrus J. D. M. et al.	
	276	US-5046496	09-10-1991	BETTS; Ronald E. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 12 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	277	US-5048525	09-17-1991	MAXWELL; Thomas P.	
	278	US-5050612	09-24-1991	MATSUMURA; Kenneth N.	
	279	US-5055171	10-08-1991	PECK; Robert L.	
	280	US-5055198	10-08-1991	SHETTIGAR; U. Ramakrishna	
	281	US-5059654	10-22-1991	HOU; Kenneth C. et al.	
	282	US-5067491	11-26-1991	TAYLOR, II; Maylon S. et al.	
	283	US-5068536	11-26-1991	ROSENTHAL; Robert D.	
	284	US-5077476	12-31-1991	ROSENTHAL; Robert D.	
	285	US-5082147	01-21-1992	JACOBS; Richard	
	286	US-5082550	01-21-1992	RISHPON; Judith et al.	
	287	US-5088981	02-18-1992	HOWSON; David C. et al.	
	288	US-5089112	02-18-1992	SKOTHEIM; Terje A. et al.	
	289	US-5089421	02-18-1992	DIEFFENBACH; Susan	
	290	US-5096669	03-17-1992	LAUKS; Imants R. et al.	
	291	US-5097834	03-24-1992	SKRABAL; Falko	
	292	US-5098377	03-24-1992	BORSANYI; Alexander et al.	
	293	US-5101814	04-07-1992	PALTI; Yoram	
	294	US-5106365	04-21-1992	HERNANDEZ; Luis	
	295	US-5108819	04-28-1992	HELLER; James W. et al.	
	296	US-5109850	05-05-1992	BLANCO; Ernesto E. et al.	
	297	US-5109860	05-05-1992	GELLY; Jean-Francois et al.	
	298	US-5112301	05-12-1992	FENTON, Jr.; Paul V. et al.	
	299	US-5112455	05-12-1992	COZZETTE; Stephen N. et al.	
	300	US-5113869	05-19-1992	NAPPHOLZ; Tibor A. et al.	
	301	US-5114859	05-19-1992	KAGENOW; Henrik	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 13 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	302	US-5116313	05-26-1992	McGREGOR; Gavin	
	303	US-5122925	06-16-1992	INPYN; Carl A.	
	304	US-5127405	07-07-1992	ALCALA; J. Ricardo et al.	
	305	US-5135004	08-04-1992	ADAMS; John M. et al.	
	306	US-5137028	08-11-1992	NISHIMURA; Kinji	
	307	US-5140985	08-25-1992	SCHROEDER; Jon M. et al.	
	308	US-5145565	09-08-1992	KATER; John et al.	
	309	US-5148812	09-22-1992	VERRIER; Richard L. et al.	
	310	US-5152746	10-06-1992	ATKINSON; Robert W. et al.	
	311	US-5156972	10-20-1992	ISSACHAR; David	
	312	US-5158437	10-27-1992	NATWICK; Vernon R. et al.	
	313	US-5160418	11-03-1992	MULLEN; William H.	
	314	US-5161532	11-10-1992	JOSEPH; Jose P.	
	315	US-5165406	11-24-1992	WONG; David K.	
	316	US-5165407	11-24-1992	WILSON; George S. et al.	
	317	US-5171689	12-15-1992	KAWAGURI; Mariko et al.	
	318	US-5174291	12-29-1992	SCHOONEN; Adelbert J. M. et al.	
	319	US-5176632	01-05-1993	BERNARDI; Luigi	
	320	US-5176658	01-05-1993	RANFORD; Alan B.	
	321	US-5178142	01-12-1993	HARJUNMAA; Hannu et al.	
	322	US-5178957	01-12-1993	KOLPE; Vasant V. et al.	
	323	US-5182004	01-26-1993	KOHNO; Takeshi	
	324	US-5188591	02-23-1993	DORSEY, III; James H.	
	325	US-5190041	03-02-1993	PALTI; Yoram	
	326	US-5195963	03-23-1993	YAFUSO; Masao et al.	
	327	US-5198771	03-30-1993	FIDLER; John C. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 14 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	328	US-5199428	04-06-1993	OBEL; Israel W. P. et al.	
	329	US-5202261	04-13-1993	MUSHO; Matthew K. et al.	
	330	US-5203326	04-20-1993	COLLINS; Kenneth A.	
	331	US-5204264	04-20-1993	KAMINER; Jon J.	
	332	US-5207642	05-04-1993	ORKIN; Fredric I. et al.	
	333	US-5208147	05-04-1993	KAGENOW; Henrik et al.	
	334	US-5210778	05-11-1993	MASSART; Desire J. L.	
	335	US-5216598	06-01-1993	BRANSTETTER; Ronald L. et al.	
	336	US-5219279	06-15-1993	NATWICK; Vernon R. et al.	
	337	US-5220917	06-22-1993	CAMMILLI; Leonardo et al.	
	338	US-5220920	06-22-1993	GHARIB; James	
	339	US-5224929	07-06-1993	REMISZEWSKI; Stanley H.	
	340	US-5225063	07-06-1993	GUMBRECHT; Walter et al.	
	341	US-5231988	08-03-1993	WERNICKE; Joachim F. et al.	
	342	US-5232434	08-03-1993	INAGAKI; Yoshitaka et al.	
	343	US-5235003	08-10-1993	WARD; Robert S. et al.	
	344	US-5237123	08-17-1993	MILLER; James M.	
	345	US-5243696	09-07-1993	CARR; Daniel J. et al.	
	346	US-5243982	09-14-1993	MOSTL; Anton et al.	
	347	US-5243983	09-14-1993	TARR; Randall V. et al.	
	348	US-5246867	09-21-1993	LAKOWICZ; Joseph R. et al.	
	349	US-5248300	09-28-1993	BRYANT; Peter L. et al.	
	350	US-5249576	10-05-1993	GOLDBERGER; Daniel S. et al.	
	351	US-5254102	10-19-1993	OGAWA; Genshiro	
	352	US-5262035	11-16-1993	GREGG; Brian A. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 15 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	353	US-5262305	11-16-1993	HELLER; Adam et al.	
	354	US-5264103	11-23-1993	YOSHIOKA; Toshihiko et al.	
	355	US-5264105	11-23-1993	GREGG; Brian A. et al.	
	356	US-5265594	11-30-1993	OLSSON; Sven-Gunnar et al.	
	357	US-5266179	11-30-1993	NANKAI; Shiro et al.	
	358	US-5269891	12-14-1993	COLIN; Fernand J. G.	
	359	US-5271736	12-21-1993	PICHA; George J.	
	360	US-5271815	12-21-1993	WONG; David K.	
	361	US-5275169	01-04-1994	AFROMOWITZ; Martin A. et al.	
	362	US-5279294	01-18-1994	ANDERSON; Paul J. et al.	
	363	US-5281319	01-25-1994	KANEKO; Hiroko et al.	
	364	US-5282844	02-01-1994	STOKES; Kenneth B. et al.	
	365	US-5282848	02-01-1994	SCHMITT; Peter J.	
	366	US-5284140	02-08-1994	ALLEN; Douglas J. et al.	
	367	US-5284570	02-08-1994	SAVAGE; Douglas R. et al.	
	368	US-5285513	02-08-1994	KAUFMAN; Stanley et al.	
	369	US-5285792	02-15-1994	SJOQUIST; Steven E. et al.	
	370	US-5287753	02-22-1994	ROUTH; Helen F. et al.	
	371	US-5293877	03-15-1994	O'HARA; Gary J. et al.	
	372	US-5298022	03-29-1994	BERNARDI; Luigi	
	373	US-5298144	03-29-1994	SPOKANE; Robert B.	
	374	US-5299571	04-05-1994	MASTROTOTARO; John J.	
	375	US-5302093	04-12-1994	OWENS; Dana J. et al.	
	376	US-5304468	04-19-1994	PHILLIPS; Roger et al.	
	377	US-5307263	04-26-1994	BROWN; Stephen J.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 16 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	378	US-5310469	05-10-1994	CUNNINGHAM; David D. et al.	
	379	US-5311908	05-17-1994	BARONE; David et al.	
	380	US-5312361	05-17-1994	ZADINI; Filiberto P. et al.	
	381	US-5313953	05-24-1994	YOMTOV; Barry M. et al.	
	382	US-5314471	05-24-1994	BRAUKER; James H. et al.	
	383	US-5315993	05-31-1994	ALCALA; J. Ricardo	
	384	US-5316008	05-31-1994	SUGA; Fusao et al.	
	385	US-5316452	05-31-1994	BOGEN; Steven A. et al.	
	386	US-5318511	06-07-1994	RIQUIER; Jean-Claude et al.	
	387	US-5320715	06-14-1994	BERG; Lloyd	
	388	US-5320725	06-14-1994	GREGG; Brian A. et al.	
	389	US-5321392	06-14-1994	SKAKOON; James G. et al.	
	390	US-5322063	06-21-1994	ALLEN; Douglas J. et al.	
	391	US-5324322	06-28-1994	GRILL, Jr.; Warren M. et al.	
	392	US-5324328	06-28-1994	LI; Hong et al.	
	393	US-5326356	07-05-1994	DELLA VALLE; Francesco et al.	
	394	US-5326449	07-05-1994	CUNNINGHAM; David D.	
	395	US-5328460	07-12-1994	LORD; Peter C. et al.	
	396	US-5330521	07-19-1994	COHEN; Donald M.	
	397	US-5330634	07-19-1994	WONG; David K. et al.	
	398	US-5331555	07-19-1994	HASHIMOTO; Katsuhiko et al.	
	399	US-5335658	08-09-1994	BEDINGHAM; William	
	400	US-5337747	08-16-1994	NEFTEL; Frederic	
	401	US-5340722	08-23-1994	WOLFBEIS; Otto S. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 17 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	402	US-5342409	08-30-1994	MULLETT; Keith R.	
	403	US-5342789	08-30-1994	CHICK; William L. et al.	
	404	US-5343869	09-06-1994	PROSS; Gerhard et al.	
	405	US-5345932	09-13-1994	YAFUSO; Masao et al.	
	406	US-5348788	09-20-1994	WHITE; Eugene W.	
	407	US-5352348	10-04-1994	YOUNG; Chung Chang et al.	
	408	US-5352349	10-04-1994	INAMOTO; Tomoyuki et al.	
	409	US-5352351	10-04-1994	WHITE; Bradley E. et al.	
	410	US-5354272	10-11-1994	SWENDSON; David L. et al.	
	411	US-5354449	10-11-1994	BAND; David M. et al.	
	412	US-5356217	10-18-1994	SHEFFIELD; Gary S.	
	413	US-5356375	10-18-1994	HIGLEY; Robert E.	
	414	US-5356378	10-18-1994	DOAN; David B.	
	415	US-5356786	10-18-1994	HELLER; Adam et al.	
	416	US-5360404	11-01-1994	NOVACEK; Laurel A. et al.	
	417	US-5365426	11-15-1994	SIEGEL; John H. et al.	
	418	US-5368224	11-29-1994	RICHARDSON; Charles A. et al.	
	419	US-5368562	11-29-1994	BLOMQUIST; Michael L. et al.	
	420	US-5372133	12-13-1994	HOGEN ESCH; Johannes H. L.	
	421	US-5372135	12-13-1994	MENDELSON; Yitzhak et al.	
	422	US-5372427	12-13-1994	PADOVANI; Francois A. et al.	
	423	US-5372709	12-13-1994	HOOD; Robert G.	
	424	US-5376070	12-27-1994	PURVIS; Richard E. et al.	
	425	US-5378229	01-03-1995	LAYER; James et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 18 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	426	US-5379238	01-03-1995	STARK; Edward W.	
	427	US-5380268	01-10-1995	WHEELER; Douglas E.	
	428	US-5380491	01-10-1995	CARVER, Jr.; Edward L. et al.	
	429	US-5380536	01-10-1995	HUBBELL; Jeffrey A. et al.	
	430	US-5380665	01-10-1995	CUSACK; Robert F. et al.	
	431	US-5384028	01-24-1995	ITO; Narushi	
	432	US-5384547	01-24-1995	LYNK, Jr.; Charles N. et al.	
	433	US-5390671	02-21-1995	LORD; Peter C. et al.	
	434	US-5391250	02-21-1995	CHENEY, II; Paul S. et al.	
	435	US-5397848	03-14-1995	YANG; Shin-Liang S. et al.	
	436	US-5398682	03-21-1995	LYNN; Lawrence A.	
	437	US-5400795	03-28-1995	MURPHY; Anthony J. et al.	
	438	US-5408999	04-25-1995	SINGH; Raghuvir et al.	
	439	US-5409666	04-25-1995	NAGEL; Colleen C. et al.	
	440	US-5411052	05-02-1995	MURRAY; Charles G.	
	441	US-5411551	05-02-1995	WINSTON; Thomas R. et al.	
	442	US-5411647	05-02-1995	JOHNSON; Kirk W. et al.	
	443	US-5411866	05-02-1995	LUONG; John H. T. et al.	
	444	US-5417206	05-23-1995	KANEYOSHI; Akio	
	445	US-5421328	06-06-1995	BEDINGHAM; William	
	446	US-5422829	06-06-1995	POLLOCK; Eugene J.	
	447	US-5423738	06-13-1995	ROBINSON; Thomas C. et al.	
	448	US-5423749	06-13-1995	MERTE; Kenneth E. et al.	
	449	US-5425375	06-20-1995	CHIN; Donald et al.	
	450	US-5425717	06-20-1995	MOHIUDDIN; Mahmood	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 19 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	451	US-5425749	06-20-1995	ADAMS; Theodore P.	
	452	US-5425868	06-20-1995	PEDERSEN; Knud G.	
	453	US-5428123	06-27-1995	WARD; Robert S. et al.	
	454	US-5429485	07-04-1995	DODGE; Larry H.	
	455	US-5429602	07-04-1995	HAUSER; Jean-Luc	
	456	US-5429735	07-04-1995	JOHNSON; Larry D. et al.	
	457	US-5431160	07-11-1995	WILKINS; Ebtisam S.	
	458	US-5431174	07-11-1995	KNUTE; Wallace L.	
	459	US-5431921	07-11-1995	THOMBRE; Avinash G.	
	460	US-5434412	07-18-1995	SODICKSON; Lester et al.	
	461	US-5437635	08-01-1995	FIELDS; Antony et al.	
	462	US-5438983	08-08-1995	FALCONE; Ronald	
	463	US-5445610	08-29-1995	EVERT; Carl F.	
	464	US-5448992	09-12-1995	KUPERSHMIDT; Vladimir	
	465	US-5453278	09-26-1995	CHAN; Eddie K. M. et al.	
	466	US-5462051	10-31-1995	OKA; Tohru et al.	
	467	US-5462064	10-31-1995	D'ANGELO; Joseph P. et al.	
	468	US-5462645	10-31-1995	ALBERY; John W. et al.	
	469	US-5466348	11-14-1995	HOLM-KENNEDY; James W.	
	470	US-5469846	11-28-1995	KHAN; Shahed U. M.	
	471	US-5472317	12-05-1995	FIELD; Jeffrey F. et al.	
	472	US-5474552	12-12-1995	PALTI; Yoram	
	473	US-5476094	12-19-1995	ALLEN; Douglas J. et al.	
	474	US-5476776	12-19-1995	WILKINS; Ebtisam S.	
	475	US-5482446	01-09-1996	WILLIAMSON; Mark E. et al.	
	476	US-5482473	01-09-1996	LORD; Peter C. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 20 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	477	US-5484404	01-16-1996	SCHULMAN; Joseph H. et al.	
	478	US-5486776	01-23-1996	CHIANG; David	
	479	US-5489414	02-06-1996	SCHREIBER; Joerg et al.	
	480	US-5491474	02-13-1996	SUNI; Jouko et al.	
	481	US-5494562	02-27-1996	MALEY; Thomas C. et al.	
	482	US-5496273	03-05-1996	PASTRONE; Giovanni et al.	
	483	US-5496453	03-05-1996	UENOYAMA; Harumi et al.	
	484	US-5497772	03-12-1996	SCHULMAN; Joseph H. et al.	
	485	US-5502396	03-26-1996	DESARZENS; Pierre et al.	
	486	US-5505828	04-09-1996	WONG; David K. et al.	
	487	US-5507288	07-08-1997	BOCKER; Dirk et al.	
	488	US-5508203	04-16-1996	FULLER; Milton E. et al.	
	489	US-5509410	04-23-1996	HILL; Hugh A. O. et al.	
	490	US-5509888	04-23-1996	MILLER; Paul L.	
	491	US-5512046	04-30-1996	PUSINELLI; Thomas et al.	
	492	US-5512246	04-30-1996	RUSSELL; Anthony P. et al.	
	493	US-5512248	04-30-1996	VAN; Jack F. J.	
	494	US-5513636	05-07-1996	PALTI; Yoram	
	495	US-5514253	05-07-1996	DAVIS; Graham et al.	
	496	US-5514718	05-07-1996	LEWIS; Richard T. et al.	
	497	US-5515851	05-14-1996	GOLDSTEIN; James A.	
	498	US-5517313	05-14-1996	COLVIN, Jr.; Arthur E.	
	499	US-5518601	05-21-1996	FOOS; Joseph S. et al.	
	500	US-5520191	05-28-1996	KARLSSON; Per et al.	
	501	US-5522798	06-04-1996	JOHNSON; Noel L. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 21 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	502	US-5529676	06-25-1996	MALEY; Thomas C. et al.	
	503	US-5531679	07-02-1996	SCHULMAN; Joseph H. et al.	
	504	US-5531878	07-02-1996	VADGAMA; Pankaj M. et al.	
	505	US-5540828	07-30-1996	YACYNYCH; Alexander	
	506	US-5543326	08-06-1996	HELLER; Adam et al.	
	507	US-5545220	08-13-1996	ANDREWS; Winston A. et al.	
	508	US-5547470	08-20-1996	JOHNSON; Noel L. et al.	
	509	US-5548569	08-20-1996	SHIMIZUME; Kazutoshi et al.	
	510	US-5549547	08-27-1996	COHEN; Herbert et al.	
	511	US-5549548	08-27-1996	LARSSON; Rolf	
	512	US-5549569	08-27-1996	LYNN; Lawrence A. et al.	
	513	US-5549651	08-27-1996	LYNN; Lawrence A.	
	514	US-5551850	09-03-1996	WILLIAMSON; Mark E. et al.	
	515	US-5552997	09-03-1996	MASSART; Desire J. L.	
	516	US-5553616	09-10-1996	HAM; Fredric M. et al.	
	517	US-5554339	09-10-1996	COZZETTE; Stephen N. et al.	
	518	US-5562614	10-08-1996	O'DONNELL; Joseph A.	
	519	US-5562615	10-08-1996	NASSIF; George A.	
	520	US-5564439	10-15-1996	PICHA; George J.	
	521	US-5568400	10-22-1996	STARK; Edward W. et al.	
	522	US-5568806	10-29-1996	CHENEY, II; Paul S. et al.	
	523	US-5569186	10-29-1996	LORD; Peter C. et al.	
	524	US-5569188	10-29-1996	MACKOOL; Richard J.	
	525	US-5569219	10-29-1996	HAKKI; A-Hamid et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 22 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	526	US-5571395	11-05-1996	PARK; Je Kyun et al.	
	527	US-5575930	11-19-1996	TIETJE-GIRAULT; Jordis et al.	
	528	US-5577499	11-26-1996	TEVES; Leonides Y.	
	529	US-5582184	12-10-1996	ERICKSON; Brian J. et al.	
	530	US-5582497	12-10-1996	NOGUCHI; Hirokazu	
	531	US-5582593	12-10-1996	HULTMAN; Barry W.	
	532	US-5582697	12-10-1996	IKEDA; Shin et al.	
	533	US-5584813	12-17-1996	LIVINGSTON; John H. et al.	
	534	US-5584876	12-17-1996	BRUCHMAN; William C. et al.	
	535	US-5586553	12-24-1996	HALILI; Edgardo C. et al.	
	536	US-5588560	12-31-1996	BENEDICT; Dale G. et al.	
	537	US-5589563	12-31-1996	WARD; Robert S. et al.	
	538	US-5590651	01-07-1997	SHAFFER; Thomas H. et al.	
	539	US-5593440	01-14-1997	BRAUKER; James H. et al.	
	540	US-5593852	01-14-1997	HELLER; Adam et al.	
	541	US-5601435	02-11-1997	QUY; Roger J.	
	542	US-5605152	02-25-1997	SLATE; John B. et al.	
	543	US-5606152	02-25-1997	HIGASHIURA; Atsushi et al.	
	544	US-5609572	03-11-1997	LANG; Volker	
	545	US-5609575	03-11-1997	LARSON; Stella D. et al.	
	546	US-5611900	03-18-1997	WORDEN; R. Mark et al.	
	547	US-5615671	04-01-1997	SCHOONEN; Adelbert J. M. et al.	
	548	US-5620579	04-15-1997	GENSHAW; Marvin A. et al.	
	549	US-5624409	04-29-1997	SEALE; Joseph B.	
	550	US-5624537	04-29-1997	TURNER; Robin F. B. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 23 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	551	US-5626563	05-06-1997	DODGE; Larry H. et al.	
	552	US-5628310	05-13-1997	RAO; Govind et al.	
	553	US-5628619	05-13-1997	WILSON; Larry	
	554	US-5628890	05-13-1997	CARTER; Nigel F. et al.	
	555	US-5630710	05-20-1997	TUNE; Joel et al.	
	556	US-5631170	05-20-1997	ATTRIDGE; John W.	
	557	US-5637083	06-10-1997	BERTRAND; William J. et al.	
	558	US-5640470	06-17-1997	IYER; Lokanathan M. et al.	
	559	US-5640954	06-24-1997	PFEIFFER; Ernst et al.	
	560	US-5643195	07-01-1997	DREVET; Jean-Baptiste et al.	
	561	US-5645077	07-08-1997	FOXLIN; Eric M.	
	562	US-5651767	07-29-1997	SCHULMAN; Joseph H. et al.	
	563	US-5653239	08-05-1997	POMPEI; Francesco et al.	
	564	US-5653756	08-05-1997	CLARKE; Robert A. et al.	
	565	US-5653863	08-05-1997	GENSHAW; Marvin A. et al.	
	566	US-5658250	08-19-1997	BLOMQUIST; Michael L. et al.	
	567	US-5660163	08-26-1997	SCHULMAN; Joseph H. et al.	
	568	US-5665061	09-09-1997	ANTWILER; Glen Delbert	
	569	US-5665065	09-09-1997	COLMAN; Fredric C. et al.	
	570	US-5665222	09-09-1997	HELLER; Adam et al.	
	571	US-5667504	09-16-1997	BAUMANN; Hans et al.	
	572	US-5676651	10-14-1997	LARSON, Jr.; Carl O. et al.	
	573	US-5676820	10-14-1997	WANG; Joseph et al.	
	574	US-5681285	10-28-1997	FORD; Alan D. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 24 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	575	US-5682884	11-04-1997	HILL; Hugh Allen Oliver et al.	
	576	US-5683562	11-04-1997	SCHAFFAR; Bernhard et al.	
	577	US-5685844	11-11-1997	MARTTILA; Constance M.	
	578	US-5686829	11-11-1997	GIRAULT; Hubert	
	579	US-5688239	11-18-1997	WALKER; Frank J.	
	580	US-5688244	11-18-1997	LANG; Volker	
	581	US-5695623	12-09-1997	MICHEL; Peter et al.	
	582	US-5697366	12-16-1997	KIMBALL; Victor E. et al.	
	583	US-5697899	12-16-1997	HILLMAN; Robert S. et al.	
	584	US-5704354	01-06-1998	PREIDEL; Walter et al.	
	585	US-5707502	01-13-1998	McCAFFREY; Robert et al.	
	586	US-5711001	01-20-1998	BUSSAN; Christopher F. et al.	
	587	US-5711861	01-27-1998	WARD; W. Kenneth et al.	
	588	US-5714931	02-03-1998	PETITE; Thomas D. et al.	
	589	US-5720295	02-24-1998	GREENHUT; Saul E. et al.	
	590	US-5730654	03-24-1998	BROWN; Stephen J.	
	591	US-5733259	03-31-1998	VALCKE; Christian P. et al.	
	592	US-5735273	04-07-1998	KURNIK; Ronald T. et al.	
	593	US-5735285	04-07-1998	ALBERT; David E. et al.	
	594	US-5738992	04-14-1998	COOK; Thomas A. et al.	
	595	US-5741211	04-21-1998	RENIRIE; Alexis C. M. et al.	
	596	US-5741634	04-21-1998	NOZOE; Yoshiteru et al.	
	597	US-5743262	04-28-1998	LEPPER, Jr.; James M. et al.	
	598	US-5745378	04-28-1998	BARKER; Craig S. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 25 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	599	US-5749832	05-12-1998	VADGAMA; Pankaj Madganlal et al.	
	600	US-5749907	05-12-1998	MANN; Brian M.	
	601	US-5755226	05-26-1998	CARIM; Hatim M. et al.	
	602	US-5755692	05-26-1998	MANICOM; Anthony William	
	603	US-5756632	05-26-1998	WARD; Robert S. et al.	
	604	US-5758643	06-02-1998	WONG; David K. et al.	
	605	US-5763760	06-09-1998	GUMBRECHT; Walter et al.	
	606	US-5766151	06-16-1998	VALLEY; Kirsten L. et al.	
	607	US-5771890	06-30-1998	TAMADA; Janet	
	608	US-5772586	06-30-1998	HEINONEN; Pekka et al.	
	609	US-5776324	07-07-1998	USALA; Anton-Lewis	
	610	US-5777060	07-07-1998	VAN ANTWERP; William Peter	
	611	US-5779665	07-14-1998	MASTROTOTARO; John J. et al.	
	612	US-5781455	07-14-1998	HYODO; Hiroshi	
	613	US-5782912	07-21-1998	BRAUKER; James H. et al.	
	614	US-5783054	07-21-1998	RAGUSE; Burkhard et al.	
	615	US-5785660	07-28-1998	VAN LAKE; Paul et al.	
	616	US-5787900	08-04-1998	BUTLER; Mark D. et al.	
	617	US-5791344	08-11-1998	SCHULMAN; Joseph H. et al.	
	618	US-5791880	08-11-1998	WILSON; Larry	
	619	US-5792065	08-11-1998	XUE; Qiuzhen et al.	
	620	US-5795774	08-18-1998	MATSUMOTO; Toru et al.	
	621	US-5798065	08-25-1998	PICHA; George J.	
	622	US-5800383	09-01-1998	CHANDLER; W. Jeffrey et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 26 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	623	US-5800420	09-01-1998	GROSS; Joseph et al.	
	624	US-5800529	09-01-1998	BRAUKER; James H. et al.	
	625	US-5804048	09-08-1998	WONG; David K. et al.	
	626	US-5806517	09-15-1998	GERHARDT; Greg Allen et al.	
	627	US-5807274	09-15-1998	HENNING; Timothy P. et al.	
	628	US-5807312	09-15-1998	DZWONKIEWICZ; Mark R.	
	629	US-5807375	09-15-1998	GROSS; Joseph et al.	
	630	US-5807406	09-15-1998	BRAUKER; James H. et al.	
	631	US-5810323	09-22-1998	WINTERER; Sean et al.	
	632	US-5810770	09-22-1998	CHIN; Sing Fatt et al.	
	633	US-5811487	09-22-1998	SCHULZ, Jr.; William James et al.	
	634	US-5814599	09-29-1998	MITRAGOTRI; Samir S. et al.	
	635	US-5820551	10-13-1998	HILL; Hugh Allen Oliver et al.	
	636	US-5820589	10-13-1998	TORGERSON; Nathan A. et al.	
	637	US-5822715	10-13-1998	WORTHINGTON; David R. L. et al.	
	638	US-5823802	10-20-1998	BARTLEY; Robert Michael	
	639	US-5833603	11-10-1998	KOVACS; Gregory T. A. et al.	
	640	US-5836887	11-17-1998	OKA; Tohru et al.	
	641	US-5836989	11-17-1998	SHELTON; Michael B.	
	642	US-5837454	11-17-1998	COZZETTE; Stephen N. et al.	
	643	US-5837728	11-17-1998	PURCELL; William P.	
	644	US-5840026	11-24-1998	HIRSCHMAN; Alan D. et al.	
	645	US-5851197	12-22-1998	MARANO; April A. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 27 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	646	US-5861019	01-19-1999	SUN; Weimin et al.	
	647	US-5863400	01-26-1999	DRUMMOND; Humphrey John Jardine et al.	
	648	US-5871514	02-16-1999	WIKLUND; Craig L. et al.	
	649	US-5873862	02-23-1999	LOPEZ; George A.	
	650	US-5879373	03-09-1999	ROPER; Josef et al.	
	651	US-5879828	03-09-1999	DEBE; Mark K. et al.	
	652	US-5882494	03-16-1999	VAN ANTWERP; William P.	
	653	US-5885844	03-23-1999	WEIR; Donald James et al.	
	654	US-5891047	04-06-1999	LANDER; Paul et al.	
	655	US-5891048	04-06-1999	NIGAM; Indra B. et al.	
	656	US-5897525	04-27-1999	DEY; Uwe et al.	
	657	US-5897578	04-27-1999	WIKLUND; Craig L. et al.	
	658	US-5899855	05-04-1999	BROWN; Stephen James	
	659	US-5904666	05-18-1999	DeDECKER; Paul G. et al.	
	660	US-5904708	05-18-1999	GOEDEKE; Steven D.	
	661	US-5910554	06-08-1999	KEMPE; Maria et al.	
	662	US-5911219	06-15-1999	AYLSWORTH; Alonzo C. et al.	
	663	US-5913998	06-22-1999	BUTLER; Mark D. et al.	
	664	US-5914026	06-22-1999	BRUNSMAN; Alan R. et al.	
	665	US-5917346	06-29-1999	GORD; John C.	
	666	US-5918603	07-06-1999	BROWN; Stephen J.	
	667	US-5921951	07-13-1999	MORRIS; Livingston B.	
	668	US-5925021	07-20-1999	CASTELLANO; Thomas P. et al.	
	669	US-5928130	07-27-1999	SCHMIDT; Bruno	
	670	US-5928155	07-27-1999	EGGERS; Philip E. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 28 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	671	US-5928182	07-27-1999	KRAUS; Robert G. et al.	
	672	US-5928189	07-27-1999	PHILLIPS; Robert E. et al.	
	673	US-5928195	07-27-1999	MALAMUD; Daniel et al.	
	674	US-5931814	08-03-1999	ALEX; Rainer et al.	
	675	US-5932175	08-03-1999	KNUTE; Wallace L. et al.	
	676	US-5933136	08-03-1999	BROWN; Stephen J.	
	677	US-5935224	08-10-1999	SVANCAREK; Mark K. et al.	
	678	US-5938636	08-17-1999	KRAMER; George C. et al.	
	679	US-5942979	08-24-1999	LUPPINO; Richard	
	680	US-5944661	08-31-1999	SWETTE; Larry L. et al.	
	681	US-5947911	09-07-1999	WONG; David K. et al.	
	682	US-5951521	09-14-1999	MASTROTOTARO; John J. et al.	
	683	US-5954643	09-21-1999	VANANTWERP; Nannette M. et al.	
	684	US-5954954	09-21-1999	HOUCK; Raymond K. et al.	
	685	US-5957854	09-28-1999	BESSON; Marcus et al.	
	686	US-5957903	09-28-1999	MIRZAEE; Daryush et al.	
	687	US-5960797	10-05-1999	KRAMER; George C. et al.	
	688	US-5961451	10-05-1999	REBER; William L. et al.	
	689	US-5964261	10-12-1999	NEUENFELDT; Steven et al.	
	690	US-5964993	10-12-1999	BLUBAUGH, Jr.; Elmo A. et al.	
	691	US-5965380	10-12-1999	HELLER; Adam et al.	
	692	US-5971922	10-26-1999	ARITA; Seizaburou et al.	
	693	US-5972199	10-26-1999	HELLER; Adam et al.	
	694	US-5976085	11-02-1999	KIMBALL; Victor E. et al.	
	695	US-5980728	11-09-1999	FARBER; Boris Y. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 29 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	696	US-5985129	11-16-1999	GOUGH; David A. et al.	
	697	US-5990422	11-23-1999	KOMORI; Susumu et al.	
	698	US-5995208	11-30-1999	SARGE; Jeffrey A. et al.	
	699	US-5995860	11-30-1999	SUN; Xiaoguang et al.	
	700	US-5999848	12-07-1999	GORD; John C. et al.	
	701	US-6001067	12-14-1999	SHULTS; Mark C. et al.	
	702	US-6001471	12-14-1999	BRIES; James L. et al.	
	703	US-6007775	12-28-1999	YAGER; Paul	
	704	US-6011984	01-04-2000	VAN ANTWERP; William Peter et al.	
	705	US-6013113	01-11-2000	MIKA; Mark L.	
	706	US-6014577	01-11-2000	HENNING; Timothy P. et al.	
	707	US-6016443	01-18-2000	EKWALL; Christer et al.	
	708	US-6016448	01-18-2000	BUSACKER; James W. et al.	
	709	US-6021350	02-01-2000	MATHSON; Goran	
	710	US-6023629	02-08-2000	TAMADA; Janet	
	711	US-6024699	02-15-2000	SURWIT; Richard S. et al.	
	712	US-6024720	02-15-2000	CHANDLER; W. Jeffrey et al.	
	713	US-6027445	02-22-2000	VON BAHR; Pontus	
	714	US-6027479	02-22-2000	ALEI; Philip E. et al.	
	715	US-6032059	02-29-2000	HENNING; Timothy P. et al.	
	716	US-6032667	03-07-2000	HEINONEN; Erkki	
	717	US-6036924	03-14-2000	SIMONS; Tad Decatur et al.	
	718	US-6038469	03-14-2000	KARLSSON; Per et al.	
	719	US-6045567	04-04-2000	TAYLOR; William C. et al.	
	720	US-6049727	04-11-2000	CROTHALL; Katherine D.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 30 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	721	US-6051389	04-18-2000	AHL; Thomas et al.	
	722	US-6059946	05-09-2000	YUKAWA; Keiko et al.	
	723	US-6063637	05-16-2000	ARNOLD; Frances H. et al.	
	724	US-6064900	05-16-2000	VADGAMA; Pankaj Madganlal et al.	
	725	US-6066088	05-23-2000	DAVIS; Phillip J.	
	726	US-6066448	05-23-2000	WOHLSTADTER; Jacob N. et al.	
	727	US-6071391	06-06-2000	GOTOH; Masao et al.	
	728	US-6073031	06-06-2000	HELSTAB; Edmond J. et al.	
	729	US-6074775	06-13-2000	GARTSTEIN; Vladimir et al.	
	730	US-6077299	06-20-2000	ADELBERG; Daniel A. et al.	
	731	US-6080583	06-27-2000	VON BAHR; Pontus	
	732	US-6081735	06-27-2000	DIAB; Mohamed K. et al.	
	733	US-6081736	06-27-2000	COLVIN; Michael S. et al.	
	734	US-6083523	07-04-2000	DIONNE; Keith E. et al.	
	735	US-6083710	07-04-2000	HELLER; Adam et al.	
	736	US-6088608	07-11-2000	SCHULMAN; Joseph H. et al.	
	737	US-6090087	07-18-2000	TSUKADA; Osamu et al.	
	738	US-6091975	07-18-2000	DADDONA; Peter E. et al.	
	739	US-6091976	07-18-2000	PFEIFFER; Margret et al.	
	740	US-6093156	07-25-2000	CUNNINGHAM; David D. et al.	
	741	US-6093172	07-25-2000	FUNDERBURK; Jeffery V. et al.	
	742	US-6099511	08-08-2000	DEVOS; Gilles J. et al.	
	743	US-6103033	08-15-2000	SAY; James et al.	
	744	US-6107083	08-22-2000	COLLINS; Thomas C. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 31 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	745	US-6108577	08-22-2000	BENSER; Michael Eric	
	746	US-6112116	08-29-2000	FISCHELL; Robert E. et al.	
	747	US-6115622	09-05-2000	MINOZ; Alain	
	748	US-6115628	09-05-2000	STADLER; Robert et al.	
	749	US-6115634	09-05-2000	DONDERS; Adrianus P. et al.	
	750	US-6117290	09-12-2000	SAY; James L. et al.	
	751	US-6119028	09-12-2000	SCHULMAN; Joseph H. et al.	
	752	US-6120676	09-19-2000	HELLER; Adam et al.	
	753	US-6121009	09-19-2000	HELLER; Adam et al.	
	754	US-6121611	09-19-2000	LINDSAY; Stuart M. et al.	
	755	US-6122351	09-19-2000	SCHLUETER, Jr.; Edward L. et al.	
	756	US-6122536	09-19-2000	SUN; Xiaoguong et al.	
	757	US-6123827	09-26-2000	WONG; David K. et al.	
	758	US-6127154	10-03-2000	MOSBACH; Klaus et al.	
	759	US-6128519	10-03-2000	SAY, I; James	
	760	US-6128526	10-03-2000	STADLER; Robert et al.	
	761	US-6134461	10-17-2000	SAY; James et al.	
	762	US-6135978	10-24-2000	HOUBEN; Richard P. M. et al.	
	763	US-6141573	10-31-2000	KURNIK; Ronald T. et al.	
	764	US-6142939	11-07-2000	EPPSTEIN; Jonathan A. et al.	
	765	US-6142979	11-07-2000	McNALLY; David J. et al.	
	766	US-6143164	11-07-2000	HELLER; Adam et al.	
	767	US-6144837	11-07-2000	QUY; Roger J.	
	768	US-6144869	11-07-2000	BERNER; Bret et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 32 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	769	US-6144871	11-07-2000	SAITO; Soichi et al.	
	770	US-6156051	12-05-2000	SCHRAGA; Steven	
	771	US-6159147	12-12-2000	LICHTER; Patrick A. et al.	
	772	US-6159186	12-12-2000	WICKHAM; Terrence et al.	
	773	US-6161095	12-12-2000	BROWN; Stephen J.	
	774	US-6162201	12-19-2000	COHEN; Kenneth L. et al.	
	775	US-6162611	12-19-2000	HELLER; Adam et al.	
	776	US-6164921	12-26-2000	MOUBAYED; Ahmad Maher et al.	
	777	US-6165154	12-26-2000	GRAY; Larry B. et al.	
	778	US-6165406	12-26-2000	JANG; Justin et al.	
	779	US-6167614	01-02-2001	TUTTLE; Mark E. et al.	
	780	US-6168568	01-02-2001	GAVRIELY; Noam	
	781	US-6169155	01-02-2001	ALVAREZ; Khristopher Edward et al.	
	782	US-6171276	01-09-2001	LIPPE; Barbara et al.	
	783	US-6175752	01-16-2001	SAY; James et al.	
	784	US-6175753	01-16-2001	MENKES; Alex et al.	
	785	US-6180416	01-30-2001	KURNIK; Ronald T. et al.	
	786	US-6183437	02-06-2001	WALKER; Frank J.	
	787	US-6187062	02-13-2001	OWEIS; Salah et al.	
	788	US-6189536	02-20-2001	MARTINEZ; Gonzalo et al.	
	789	US-6191860	02-20-2001	KLINGER; Leonid et al.	
	790	US-6197040	03-06-2001	LeVAUGHN; Richard Wayne et al.	
	791	US-6200265	03-13-2001	WALSH; Kevin K. et al.	
	792	US-6200772	03-13-2001	VADGAMA; Pankaj Maganlal et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 33 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	793	US-6201980	03-13-2001	DARROW; Christopher B. et al.	
	794	US-6201993	03-13-2001	KRUSE; John M. et al.	
	795	US-6206856	03-27-2001	MAHURKAR; Sakharam D.	
	796	US-6208894	03-27-2001	SCHULMAN; Joseph H. et al.	
	797	US-6212416	04-03-2001	WARD; W. Kenneth et al.	
	798	US-6212417	04-03-2001	IKEDA; Shin et al.	
	799	US-6212424	04-03-2001	ROBINSON; Mark Ries	
	800	US-6213739	04-10-2001	PHALLEN; Iver J. et al.	
	801	US-6214185	04-10-2001	OFFENBACHER; Helmut et al.	
	802	US-6219574	04-17-2001	CORMIER; Michel J. N. et al.	
	803	US-6223083	04-24-2001	ROSAR; George	
	804	US-6223283	04-24-2001	CHAIKEN; Craig L. et al.	
	805	US-6224562	05-01-2001	LURIE; Keith G. et al.	
	806	US-6230059	05-08-2001	DUFFIN; Edwin G.	
	807	US-6231320	05-15-2001	LAWLESS; Michael W. et al.	
	808	US-6231560	05-15-2001	BUI; Tuan et al.	
	809	US-6231879	05-15-2001	LI; Rebecca et al.	
	810	US-6233080	05-15-2001	BRENNER; Tomas et al.	
	811	US-6233486	05-15-2001	EKWALL; Christer et al.	
	812	US-6241863	06-05-2001	MONBOUQUETTE; Harold G.	
	813	US-6248067	06-19-2001	CAUSEY, III; James D. et al.	
	814	US-6248077	06-19-2001	ELSON; Edward E. et al.	
	815	US-6248093	06-19-2001	MOBERG; Sheldon	
	816	US-6249705	06-19-2001	SNELL; Jeffery D.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 34 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	817	US-6254586	07-03-2001	MANN; Alfred E. et al.	
	818	US-6256522	07-03-2001	SCHULTZ; Jerome S.	
	819	US-6256538	07-03-2001	EKWALL; Christer	
	820	US-6259937	07-10-2001	SCHULMAN; Joseph H. et al.	
	821	US-6261440	07-17-2001	HENNING; Timothy P. et al.	
	822	US-6263222	07-17-2001	DIAB; Mohamed K. et al.	
	823	US-6264606	07-24-2001	EKWALL; Christer et al.	
	824	US-6264825	07-24-2001	BLACKBURN; Gary et al.	
	825	US-6268161	07-31-2001	HAN; In Suk et al.	
	826	US-6269340	07-31-2001	FORD; Alan D. et al.	
	827	US-6270455	08-07-2001	BROWN; Stephen J.	
	828	US-6270478	08-07-2001	MERN.O SLASHED.E; Morton	
	829	US-6272364	08-07-2001	KURNIK; Ronald T.	
	830	US-6272379	08-07-2001	FISCHELL; Robert E. et al.	
	831	US-6272480	08-07-2001	TRESP; Volker et al.	
	832	US-6274285	08-14-2001	GRIES; Willi-Kurt et al.	
	833	US-6275717	08-14-2001	GROSS; Joseph et al.	
	834	US-6280408	08-28-2001	SIPIN; Anatole J.	
	835	US-6281015	08-28-2001	MOONEY; David J. et al.	
	836	US-6283761	09-04-2001	JOAO; Raymond Anthony	
	837	US-6284125	09-04-2001	HODGES; Alastair McIndoe et al.	
	838	US-6284478	09-04-2001	HELLER; Adam et al.	
	839	US-6293925	09-25-2001	SAFABASH; Jason H. et al.	
	840	US-6294281	09-25-2001	HELLER; Adam	
	841	US-6295506	09-25-2001	HEINONEN; Pekka et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 35 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	842	US-6298254	10-02-2001	TAMADA; Janet	
	843	US-6299578	10-09-2001	KURNIK; Ronald T. et al.	
	844	US-6299583	10-09-2001	EGGERS; Philip E. et al.	
	845	US-6299757	10-09-2001	FELDMAN; Benjamin J. et al.	
	846	US-6300002	10-09-2001	WEBB; Randle K. et al.	
	847	US-6302855	10-16-2001	LAV; Steffen et al.	
	848	US-6306104	10-23-2001	CUNNINGHAM; David D. et al.	
	849	US-6309351	10-30-2001	KURNIK; Ronald T. et al.	
	850	US-6309375	10-30-2001	GLINES; Robert C. et al.	
	851	US-6309884	10-30-2001	COOPER; Patrick J. et al.	
	852	US-6312388	11-06-2001	MARCOVECCHIO; Alan F. et al.	
	853	US-6325978	12-04-2001	LABUDA; Lawrence L. et al.	
	854	US-6325979	12-04-2001	HAHN; Dieter et al.	
	855	US-6326160	12-04-2001	DUNN; Timothy C. et al.	
	856	US-6329161	12-11-2001	HELLER; Adam et al.	
	857	US-6329929	12-11-2001	WEIJAND; Koen J. et al.	
	858	US-6330464	12-11-2001	COLVIN, Jr.; Arthur E. et al.	
	859	US-6338790	01-15-2002	FELDMAN; Benjamin J. et al.	
	860	US-6343225	01-29-2002	CLARK, Jr.; Leland C.	
	861	US-6348640	02-19-2002	NAVOT; Nir et al.	
	862	US-6356776	03-12-2002	BERNER; Bret et al.	
	863	US-6358225	03-19-2002	BUTTERFIELD; Robert D.	
	864	US-6359444	03-19-2002	GRIMES; Craig A.	
	865	US-6360888	03-26-2002	McIVOR; K. Collin et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 36 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	866	US-6361503	03-26-2002	STAROBIN; Joseph M. et al.	
	867	US-6365670	04-02-2002	FRY; Bryan E.	
	868	US-6366794	04-02-2002	MOUSSY; Francis et al.	
	869	US-6368141	04-09-2002	VANANTWERP; Nannette M. et al.	
	870	US-6368274	04-09-2002	VAN ANTWERP; William P. et al.	
	871	US-6370941	04-16-2002	NAKAMURA; Michihiro et al.	
	872	US-6372244	04-16-2002	ANTANAVICH; Richard D. et al.	
	873	US-6377828	04-23-2002	CHAIKEN; Joseph et al.	
	874	US-6377852	04-23-2002	BORNZIN; Gene A. et al.	
	875	US-6377894	04-23-2002	DEWEESE; Marshall D. et al.	
	876	US-6379301	04-30-2002	WORTHINGTON; David R. L. et al.	
	877	US-6381493	04-30-2002	STADLER; Robert et al.	
	878	US-6387048	05-14-2002	SCHULMAN; Joseph H. et al.	
	879	US-6387709	05-14-2002	MASON; Richard W. et al.	
	880	US-6391019	05-21-2002	ITO; Takashi	
	881	US-6400974	06-04-2002	LESHO; Jeffery C.	
	882	US-6402703	06-11-2002	KENSEY; Kenneth et al.	
	883	US-6403944	06-11-2002	MACKENZIE; Hugh Alexander et al.	
	884	US-6405066	06-11-2002	ESSENPREIS; Matthias et al.	
	885	US-6409674	06-25-2002	BROCKWAY; Brian P. et al.	
	886	US-6413393	07-02-2002	VAN ANTWERP; William P. et al.	
	887	US-6413396	07-02-2002	YANG; Haesik et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 37 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	888	US-6413410	07-02-2002	HODGES; Alastair McIndoe et al.	
	889	US-6416651	07-09-2002	MILLAR; Ord	
	890	US-6418332	07-09-2002	MASTROTOTARO; John J. et al.	
	891	US-6424847	07-23-2002	MASTROTOTARO; John J. et al.	
	892	US-6424861	07-23-2002	MEREDITH; Neil	
	893	US-6427088	07-30-2002	BOWMAN, IV; Sam W. et al.	
	894	US-6428123	08-06-2002	LUCHT; Wayne et al.	
	895	US-6430437	08-06-2002	MARRO; Dominic P.	
	896	US-6434430	08-13-2002	BORGERSEN; Svenn E. et al.	
	897	US-6440068	08-27-2002	BROWN; Michael Wayne et al.	
	898	US-6444115	09-03-2002	HODGES; Alastair et al.	
	899	US-6447448	09-10-2002	ISHIKAWA; Akira et al.	
	900	US-6447542	09-10-2002	WEADOCK; Kevin	
	901	US-6454710	09-24-2002	BALLERSTADT; Ralph et al.	
	902	US-6459917	10-01-2002	GOWDA; Ashok et al.	
	903	US-6461496	10-08-2002	FELDMAN; Benjamin J. et al.	
	904	US-6464849	10-15-2002	SAY; James L. et al.	
	905	US-6465066	10-15-2002	RULE; Mark et al.	
	906	US-6466810	10-15-2002	WARD; W. Kenneth et al.	
	907	US-6467480	10-22-2002	MEIER; Bernd Horst et al.	
	908	US-6471689	10-29-2002	JOSEPH, I; Jeffery et al.	
	909	US-6474360	11-05-2002	ITO; Takashi	
	910	US-6475372	11-05-2002	OHARA; Timothy J. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 38 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	911	US-6475750	11-05-2002	HAN; In Suk et al.	
	912	US-6477392	11-05-2002	HONIGS; David E. et al.	
	913	US-6477395	11-05-2002	SCHULMAN; Joseph H. et al.	
	914	US-6478736	11-12-2002	MAULT; James R.	
	915	US-6481440	11-19-2002	GIELEN; Frans L. H. et al.	
	916	US-6484045	11-19-2002	HOLKER; James D. et al.	
	917	US-6484046	11-19-2002	SAY; James et al.	
	918	US-6485449	11-26-2002	ITO; Takashi	
	919	US-6486661	11-26-2002	CHIA; Michael Ik-Ming et al.	
	920	US-6488652	12-03-2002	WEIJAND; Koen J. et al.	
	921	US-6494879	12-17-2002	LENNOX; Charles D. et al.	
	922	US-6498043	12-24-2002	SCHULMAN; Joseph H. et al.	
	923	US-6498941	12-24-2002	JACKSON; Gregg A.	
	924	US-6501976	12-31-2002	SOHRAB; Borzu	
	925	US-6501983	12-31-2002	NATARAJAN; Ananth et al.	
	926	US-6503381	01-07-2003	GOTOH; Masao et al.	
	927	US-6510329	01-21-2003	HECKEL; Donald W.	
	928	US-6512939	01-28-2003	COLVIN; Michael S. et al.	
	929	US-6514460	02-04-2003	FENDROCK; Charles	
	930	US-6514718	02-04-2003	HELLER; Adam et al.	
	931	US-6517508	02-11-2003	UTTERBERG; David S. et al.	
	932	US-6520326	02-18-2003	McIVOR; K. Collin et al.	
	933	US-6520477	02-18-2003	TRIMMER; William	
	934	US-6520937	02-18-2003	HART; Colin P. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 39 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	935	US-6520997	02-18-2003	PEKKARINEN; Michael O. et al.	
	936	US-6526298	02-25-2003	KHALIL; Omar S. et al.	
	937	US-6527729	03-04-2003	TURCOTT; Robert	
	938	US-6528318	03-04-2003	MIRAGLIOTTA; Joseph A. et al.	
	939	US-6536433	03-25-2003	CEWERS; Goran	
	940	US-6537318	03-25-2003	ITA; Essien Eyo-Okon et al.	
	941	US-6540891	04-01-2003	STEWART; Alan Andrew et al.	
	942	US-6541266	04-01-2003	MODZELEWSKI; Brent E. et al.	
	943	US-6542765	04-01-2003	GUY; Richard et al.	
	944	US-6543195	04-08-2003	RAHIMZADEH; Housh	
	945	US-6544212	04-08-2003	GALLEY; Paul J. et al.	
	946	US-6544229	04-08-2003	DANBY; Hal C. et al.	
	947	US-6545085	04-08-2003	KILGOUR; John A. et al.	
	948	US-6546268	04-08-2003	ISHIKAWA; Akira et al.	
	949	US-6546269	04-08-2003	KURNIK; Ronald T.	
	950	US-6547839	04-15-2003	ZHANG; Zhiwei et al.	
	951	US-6551494	04-22-2003	HELLER; Adam et al.	
	952	US-6551496	04-22-2003	MOLES; Donald R. et al.	
	953	US-6553241	04-22-2003	MANNHEIMER; Paul D. et al.	
	954	US-6553244	04-22-2003	LESHO; Matthew J. et al.	
	955	US-6554805	04-29-2003	HIEJIMA; Katsuhiro	
	956	US-6554822	04-29-2003	HOLSCHNEIDER; Daniel P. et al.	
	957	US-6558320	05-06-2003	CAUSEY, III; James D. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 40 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	958	US-6558321	05-06-2003	BURD; John F. et al.	
	959	US-6558347	05-06-2003	JHUBOO; Abdel Nasser et al.	
	960	US-6558351	05-06-2003	STEIL; Garry M. et al.	
	961	US-6561978	05-13-2003	CONN; Thomas E. et al.	
	962	US-6562001	05-13-2003	LEBEL; Ronald J. et al.	
	963	US-6564105	05-13-2003	STARKWEATHER; Timothy J. et al.	
	964	US-6565509	05-20-2003	SAY; James et al.	
	965	US-6565535	05-20-2003	ZAIAS; Nardo et al.	
	966	US-6565807	05-20-2003	PATTERSON; William R. et al.	
	967	US-6569309	05-27-2003	OTSUKA; Kiyoshi et al.	
	968	US-6569521	05-27-2003	SHERIDAN; Margaret M. et al.	
	969	US-6571128	05-27-2003	LEBEL; Ronald J. et al.	
	970	US-6572542	06-03-2003	HOUBEN; Richard et al.	
	971	US-6572545	06-03-2003	KNOBBE; Edward J. et al.	
	972	US-6572579	06-03-2003	RAGHAVAN; Raghu et al.	
	973	US-6574490	06-03-2003	ABBINK; Russell E. et al.	
	974	US-6575905	06-10-2003	KNOBBE; Edward J. et al.	
	975	US-6576101	06-10-2003	HELLER; Adam et al.	
	976	US-6577899	06-10-2003	LEBEL; Ronald J. et al.	
	977	US-6579257	06-17-2003	ELGAS; Roger J. et al.	
	978	US-6579498	06-17-2003	EGLISE; David	
	979	US-6579690	06-17-2003	BONNECAZE; Roger T. et al.	
	980	US-6584335	06-24-2003	HAAR; Hans-Peter et al.	
	981	US-6585644	07-01-2003	LEBEL; Ronald J. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 41 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	982	US-6585675	07-01-2003	O'MAHONY; John J. et al.	
	983	US-6585763	07-01-2003	KEILMAN; George W. et al.	
	984	US-6587705	07-01-2003	KIM; Lynn et al.	
	985	US-6589229	07-08-2003	CONNELLY; Robert I. et al.	
	986	US-6591125	07-08-2003	BUSE; John Bernard et al.	
	987	US-6592745	07-15-2003	FELDMAN; Benjamin J. et al.	
	988	US-6594514	07-15-2003	BERNER; Bret et al.	
	989	US-6595756	07-22-2003	GRAY; John et al.	
	990	US-6595919	07-22-2003	BERNER; Bret et al.	
	991	US-6600940	07-29-2003	FEIN; Michael E. et al.	
	992	US-6600997	07-29-2003	DEWEESE; Marshall D. et al.	
	993	US-6602221	08-05-2003	SARAVIA; Heber et al.	
	994	US-6605072	08-12-2003	STRUYS; Michel et al.	
	995	US-6605200	08-12-2003	MAO; Fei et al.	
	996	US-6605201	08-12-2003	MAO; Fei et al.	
	997	US-6607509	08-19-2003	BOBROFF; Randa M. et al.	
	998	US-6607658	08-19-2003	HELLER; Adam et al.	
	999	US-6609071	08-19-2003	SHAPIRO; Philip et al.	
	1000	US-6610012	08-26-2003	MAULT; James R.	
	1001	US-6612984	09-02-2003	KERR, II; Robert A.	
	1002	US-6613379	09-02-2003	WARD; W. Kenneth et al.	
	1003	US-6615061	09-02-2003	KHALIL; Omar S. et al.	
	1004	US-6615078	09-02-2003	BURSON; Kim K. et al.	
	1005	US-6616819	09-09-2003	LIAMOS; Charles T. et al.	
	1006	US-6618603	09-09-2003	VARALLI; Maurizio Claudio et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 42 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1007	US-6618934	09-16-2003	FELDMAN; Benjamin J. et al.	
	1008	US-6622045	09-16-2003	SNELL; Jeffery D. et al.	
	1009	US-6633772	10-14-2003	FORD; Russell et al.	
	1010	US-6635014	10-21-2003	STARKWEATHER; Timothy J. et al.	
	1011	US-6641533	11-04-2003	CAUSEY, III; James D. et al.	
	1012	US-6642015	11-04-2003	VACHON; David J. et al.	
	1013	US-6645181	11-11-2003	LAVI; Gilad et al.	
	1014	US-6648821	11-18-2003	LEBEL; Ronald J. et al.	
	1015	US-6650471	11-18-2003	DOI; Yasuhiro	
	1016	US-6653091	11-25-2003	DUNN; Timothy C. et al.	
	1017	US-6654625	11-25-2003	SAY; James L. et al.	
	1018	US-6656114	12-02-2003	POULSEN; Jens Ulrik et al.	
	1019	US-6656157	12-02-2003	DUCHON; Doug et al.	
	1020	US-6658396	12-02-2003	TANG; Sharon S. et al.	
	1021	US-6659948	12-09-2003	LEBEL; Ronald J. et al.	
	1022	US-6668196	12-23-2003	VILLEGAS; Daniel H. et al.	
	1023	US-6673022	01-06-2004	BOBO; Donald et al.	
	1024	US-6673596	01-06-2004	SAYLER; Gary S. et al.	
	1025	US-6675030	01-06-2004	CIURCZAK; Emil W. et al.	
	1026	US-6676816	01-13-2004	MAO; Fei et al.	
	1027	US-6679865	01-20-2004	SHEKALIM; Avraham	
	1028	US-6679872	01-20-2004	TUROVSKIY; Roman et al.	
	1029	US-6683535	01-27-2004	UTKE; Gene H.	
	1030	US-6684904	02-03-2004	ITO; Takashi	
	1031	US-6685668	02-03-2004	CHO; Steve T. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 43 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1032	US-6687522	02-03-2004	TAMADA; Janet	
	1033	US-6687546	02-03-2004	LEBEL; Ronald J. et al.	
	1034	US-6689056	02-10-2004	KILCOYNE; John T. et al.	
	1035	US-6689089	02-10-2004	TIEDTKE; Hans Jurgen et al.	
	1036	US-6689265	02-10-2004	HELLER; Adam et al.	
	1037	US-6689413	02-10-2004	LIU; Connie C. et al.	
	1038	US-6692457	02-17-2004	FLAHERTY; J. Christopher	
	1039	US-6694191	02-17-2004	STARKWEATHER; Timothy J. et al.	
	1040	US-6695860	02-24-2004	WARD; W. Kenneth et al.	
	1041	US-6698269	03-02-2004	BABER; Isaak et al.	
	1042	US-6699188	03-02-2004	WESSEL; Paul	
	1043	US-6699218	03-02-2004	FLAHERTY; J. Christopher et al.	
	1044	US-6702249	03-09-2004	ITO; Takashi	
	1045	US-6702857	03-09-2004	BRAUKER; James H. et al.	
	1046	US-6702972	03-09-2004	MARKLE; David Reed	
	1047	US-6711423	03-23-2004	COLVIN, Jr.; Arthur E.	
	1048	US-6711424	03-23-2004	FINE; Ilya et al.	
	1049	US-6712796	03-30-2004	FENTIS; Robert et al.	
	1050	US-6721582	04-13-2004	TREPAGNIER; Pierre et al.	
	1051	US-6721587	04-13-2004	GOUGH; David A.	
	1052	US-6723086	04-20-2004	BASSUK; William K. et al.	
	1053	US-6730200	05-04-2004	STEWART; Alan A. et al.	
	1054	US-6731976	05-04-2004	PENN; Richard D. et al.	
	1055	US-6731985	05-04-2004	POORE; John W. et al.	
	1056	US-6733446	05-11-2004	LEBEL; Ronald J. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 44 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1057	US-6733655	05-11-2004	DAVIES; Oliver W. H. et al.	
	1058	US-6736783	05-18-2004	BLAKE; Kevin R. et al.	
	1059	US-6736957	05-18-2004	FORROW; Nigel J. et al.	
	1060	US-6737158	05-18-2004	THOMPSON; Samuel A.	
	1061	US-6740075	05-25-2004	LEBEL; Ronald J. et al.	
	1062	US-6741877	05-25-2004	SHULTS; Mark C. et al.	
	1063	US-6742635	06-01-2004	HIRSHBERG; Jonathan	
	1064	US-6743635	06-01-2004	NEEL; Gary T. et al.	
	1065	US-6746582	06-08-2004	HELLER; Adam et al.	
	1066	US-6749587	06-15-2004	FLAHERTY; J. Christopher	
	1067	US-6749591	06-15-2004	McNALLY; David J. et al.	
	1068	US-6749740	06-15-2004	LIAMOS; Charles T. et al.	
	1069	US-6758810	07-06-2004	LEBEL; Ronald J. et al.	
	1070	US-6764581	07-20-2004	FORROW; Nigel J. et al.	
	1071	US-6770030	08-03-2004	SCHAUPP; Lukas et al.	
	1072	US-6770067	08-03-2004	LORENZEN; Eric et al.	
	1073	US-6773671	08-10-2004	LEWIS; Mark E. et al.	
	1074	US-6780297	08-24-2004	MATSUMOTO; Toru et al.	
	1075	US-6784274	08-31-2004	VAN ANTWERP; William Peter et al.	
	1076	US-6790178	09-14-2004	MAULT; James R. et al.	
	1077	US-6793632	09-21-2004	SOHRAB; Borzu	
	1078	US-6801041	10-05-2004	KARINKA; Shridhara Alva et al.	
	1079	US-6802957	10-12-2004	JUNG; Sung-Kw N. et al.	
	1080	US-6804002	10-12-2004	FINE; Ilya et al.	
	1081	US-6805693	10-19-2004	GRAY; John F. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 45 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1082	US-6809653	10-26-2004	MANN; Alfred E. et al.	
	1083	US-6810290	10-26-2004	LEBEL; Ronald J. et al.	
	1084	US-6811533	11-02-2004	LEBEL; Ronald J. et al.	
	1085	US-6811534	11-02-2004	BOWMAN, IV; Sam W. et al.	
	1086	US-6811548	11-02-2004	JEFFREY; Peter	
	1087	US-6813519	11-02-2004	LEBEL; Ronald J. et al.	
	1088	US-6817990	11-16-2004	YAP; Darren Y. K. et al.	
	1089	US-6846654	01-25-2005	BLACKBURN; Gary F. et al.	
	1090	US-6850790	02-01-2005	BERNER; Bret et al.	
	1091	US-6850859	02-01-2005	SCHUH; William C.	
	1092	US-6854317	02-15-2005	PORTER; Timothy L. et al.	
	1093	US-6858020	02-22-2005	RUSNAK; Christopher	
	1094	US-6862465	03-01-2005	SHULTS; Mark C. et al.	
	1095	US-6865407	03-08-2005	KIMBALL; Victor E. et al.	
	1096	US-6869413	03-22-2005	LANGLEY; Christopher Nigel et al.	
	1097	US-6873268	03-29-2005	LEBEL; Ronald J. et al.	
	1098	US-6881551	04-19-2005	HELLER; Adam et al.	
	1099	US-6882940	04-19-2005	POTTS; Russell O. et al.	
	1100	US-6887228	05-03-2005	McKAY; Douglas William	
	1101	US-6892085	05-10-2005	McIVOR; K. Collin et al.	
	1102	US-6893396	05-17-2005	SCHULZE; Arthur E. et al.	
	1103	US-6893545	05-17-2005	GOTOH; Masao et al.	
	1104	US-6893552	05-17-2005	WANG; Joseph et al.	
	1105	US-6895263	05-17-2005	SHIN; John J. et al.	
	1106	US-6895265	05-17-2005	SILVER; James H.	
	1107	US-6902544	06-07-2005	LUDIN; Lev et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 46 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1108	US-6912413	06-28-2005	RANTALA; Borje et al.	
	1109	US-6923763	08-02-2005	KOVATCHEV; Boris P. et al.	
	1110	US-6925393	08-02-2005	KALATZ; Brit et al.	
	1111	US-6926691	08-09-2005	MIETHKE; Christoph	
	1112	US-6931327	08-16-2005	GOODE, Jr.; Paul V. et al.	
	1113	US-6932584	08-23-2005	GRAY; John et al.	
	1114	US-6932892	08-23-2005	CHEN; Linlin et al.	
	1115	US-6932894	08-23-2005	MAO; Fei et al.	
	1116	US-6936006	08-30-2005	SABRA; Mads C.	
	1117	US-6942518	09-13-2005	LIAMOS; Charles T. et al.	
	1118	US-6945965	09-20-2005	WHITING; Howard Anthony	
	1119	US-6948492	09-27-2005	WERMELING; Daniel P. et al.	
	1120	US-6950708	09-27-2005	BOWMAN, IV; Sam W. et al.	
	1121	US-6952604	10-04-2005	DeNUZZIO; John D. et al.	
	1122	US-6954662	10-11-2005	FREGER; David et al.	
	1123	US-6958705	10-25-2005	LEBEL; Ronald J. et al.	
	1124	US-6960192	11-01-2005	FLAHERTY; J. Christopher et al.	
	1125	US-6965791	11-15-2005	HITCHCOCK; Robert W. et al.	
	1126	US-6966325	11-22-2005	ERICKSON; John	
	1127	US-6968294	11-22-2005	GUTTA; Srinivas et al.	
	1128	US-6971274	12-06-2005	OLIN; John George	
	1129	US-6972080	12-06-2005	TOMIOKA; Toshikazu et al.	
	1130	US-6974437	12-13-2005	LEBEL; Ronald J. et al.	
	1131	US-6975893	12-13-2005	SAY; James L. et al.	
	1132	US-6979315	12-27-2005	ROGERS; Charles et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 47 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1133	US-6985870	01-10-2006	MARTUCCI; James et al.	
	1134	US-6989891	01-24-2006	BRAIG; James R. et al.	
	1135	US-6990366	01-24-2006	SAY; James et al.	
	1136	US-6990422	01-24-2006	LALETIN; William H. et al.	
	1137	US-6996427	02-07-2006	ALI; Ammar Al et al.	
	1138	US-6997907	02-14-2006	SAFABASH; Jason H. et al.	
	1139	US-6997921	02-14-2006	GRAY; John F. et al.	
	1140	US-6998247	02-14-2006	MONFRE; Stephen L. et al.	
	1141	US-7003336	02-21-2006	HOLKER; James D. et al.	
	1142	US-7003340	02-21-2006	SAY; James et al.	
	1143	US-7003341	02-21-2006	SAY; James et al.	
	1144	US-7010345	03-07-2006	HILL; Michael R. S. et al.	
	1145	US-7011630	03-14-2006	DESAI; Shashi P. et al.	
	1146	US-7016713	03-21-2006	GARDNER; Craig M. et al.	
	1147	US-7016720	03-21-2006	KROLL; Mark W.	
	1148	US-7018361	03-28-2006	GILLESPIE, Jr.; John et al.	
	1149	US-7022072	04-04-2006	FOX; James Kelly et al.	
	1150	US-7022219	04-04-2006	MANSOURI; Sohrab et al.	
	1151	US-7024245	04-04-2006	LEBEL; Ronald J. et al.	
	1152	US-7025425	04-11-2006	KOVATCHEV; Boris P. et al.	
	1153	US-7025727	04-11-2006	BROCKWAY; Brian P. et al.	
	1154	US-7025743	04-11-2006	MANN; Alfred E. et al.	
	1155	US-7027848	04-11-2006	ROBINSON; Mark Ries et al.	
	1156	US-7029443	04-18-2006	KROLL; Mark W.	
	1157	US-7029444	04-18-2006	SHIN; John J. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 48 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1158	US-7041068	05-09-2006	FREEMAN; Dominique M. et al.	
	1159	US-7041209	05-09-2006	PIZZARIELLO; Andrea et al.	
	1160	US-7041468	05-09-2006	DRUCKER; Steven et al.	
	1161	US-7043287	05-09-2006	KHALIL; Omar S. et al.	
	1162	US-7048727	05-23-2006	MOSS; Gerald	
	1163	US-7052472	05-30-2006	MILLER; Mark Edward et al.	
	1164	US-7052483	05-30-2006	WOJCIK; Steven	
	1165	US-7056302	06-06-2006	DOUGLAS; Joel S.	
	1166	US-7060059	06-13-2006	KEITH; Steven et al.	
	1167	US-7061593	06-13-2006	BRAIG; James R. et al.	
	1168	US-7062385	06-13-2006	WHITE; Joel E. et al.	
	1169	US-7063086	06-20-2006	SHAHBAZPOUR; Mehdi et al.	
	1170	US-7066884	06-27-2006	CUSTER; Linda et al.	
	1171	US-7070577	07-04-2006	HALLER; Markus et al.	
	1172	US-7070580	07-04-2006	NIELSEN; Jens Egebjerg	
	1173	US-7074307	07-11-2006	SIMPSON; Peter C. et al.	
	1174	US-7074610	07-11-2006	COZZETTE; Stephen N. et al.	
	1175	US-7076300	07-11-2006	KROLL; Mark W. et al.	
	1176	US-7078582	07-18-2006	STEBBINGS; William L. et al.	
	1177	US-7081195	07-25-2006	SIMPSON; Peter et al.	
	1178	US-7092891	08-15-2006	MAUS; Christopher T. et al.	
	1179	US-7096064	08-22-2006	DENO; D. Curtis et al.	
	1180	US-7097775	08-29-2006	GREENBERG; Robert J. et al.	
	1181	US-7098803	08-29-2006	MANN; Alfred E. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 49 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1182	US-7100628	09-05-2006	IZENSON; Michael G. et al.	
	1183	US-7103412	09-05-2006	KROLL; Mark W.	
	1184	US-7108778	09-19-2006	SIMPSON; Peter C. et al.	
	1185	US-7109878	09-19-2006	MANN; Alfred E. et al.	
	1186	US-7110803	09-19-2006	SHULTS; Mark C. et al.	
	1187	US-7113821	09-26-2006	SUN; Ying et al.	
	1188	US-7115884	10-03-2006	WALT; David R. et al.	
	1189	US-7118667	10-10-2006	LEE; Jin Po	
	1190	US-7120483	10-10-2006	RUSSELL; Geoffrey A. et al.	
	1191	US-7123950	10-17-2006	MANNHEIMER; Paul D.	
	1192	US-7131967	11-07-2006	GRAY; John F. et al.	
	1193	US-7134999	11-14-2006	BRAUKER; James H. et al.	
	1194	US-7135342	11-14-2006	COLVIN, Jr.; Arthur E. et al.	
	1195	US-7136689	11-14-2006	SHULTS; Mark C. et al.	
	1196	US-7142911	11-28-2006	BOILEAU; Peter et al.	
	1197	US-7146202	12-05-2006	WARD; W. Kenneth et al.	
	1198	US-7149562	12-12-2006	WALKER; Steven C. et al.	
	1199	US-7150741	12-19-2006	ERICKSON; John et al.	
	1200	US-7153265	12-26-2006	VACHON; David J.	
	1201	US-7153458	12-26-2006	IDE; Akinori et al.	
	1202	US-7162290	01-09-2007	LEVIN; Paul D.	
	1203	US-7167818	01-23-2007	BROWN; Stephen J.	
	1204	US-7168597	01-30-2007	JONES; Anthony Patrick et al.	
	1205	US-7169289	01-30-2007	SCHULEIN; Jurgen et al.	
	1206	US-7171252	01-30-2007	SCARANTINO; Charles W. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 50 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1207	US-7171274	01-30-2007	STARKWEATHER; Timothy J. et al.	
	1208	US-7171312	01-30-2007	STEINTHAL; Gregory et al.	
	1209	US-7183102	02-27-2007	MONFRE; Stephen L. et al.	
	1210	US-7184810	02-27-2007	CADUFF; Andreas et al.	
	1211	US-7190988	03-13-2007	SAY; James et al.	
	1212	US-7192450	03-20-2007	BRAUKER; James H. et al.	
	1213	US-7198606	04-03-2007	BOECKER; Dirk et al.	
	1214	US-7204823	04-17-2007	ESTES; Mark C. et al.	
	1215	US-7207968	04-24-2007	HARCINSKE; John C.	
	1216	US-7207974	04-24-2007	SAFABASH; Jason H. et al.	
	1217	US-7211074	05-01-2007	SANSOUCY; Michael	
	1218	US-7211439	05-01-2007	VOSSMEYER; Tobias et al.	
	1219	US-7214190	05-08-2007	WILSON; Kitchener Clark	
	1220	US-7221970	05-22-2007	PARKER; Dawood	
	1221	US-7223253	05-29-2007	HOGENDIJK; Michael	
	1222	US-7225535	06-05-2007	FELDMAN; Benjamin J. et al.	
	1223	US-7226978	06-05-2007	TAPSAK; Mark A. et al.	
	1224	US-7228162	06-05-2007	WARD; W. Kenneth et al.	
	1225	US-7229288	06-12-2007	STUART; Steven et al.	
	1226	US-7238165	07-03-2007	VINCENT; Douglas et al.	
	1227	US-7244582	07-17-2007	NILSSON; Kurt et al.	
	1228	US-7247138	07-24-2007	REGHABI; Bahar et al.	
	1229	US-7247443	07-24-2007	SU; Wei-Wen	
	1230	US-7248912	07-24-2007	GOUGH; David A. et al.	
	1231	US-7253680	08-07-2007	LALETIN; William H.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 51 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1232	US-7254450	08-07-2007	CHRISTOPHERSON; Mark A. et al.	
	1233	US-7255690	08-14-2007	GRAY; John et al.	
	1234	US-7258673	08-21-2007	RACCHINI; Joel et al.	
	1235	US-7258681	08-21-2007	HOUDE; Eric	
	1236	US-7261690	08-28-2007	TELLER; Eric et al.	
	1237	US-7266400	09-04-2007	FINE; Ilya et al.	
	1238	US-7267665	09-11-2007	STEIL; Garry M. et al.	
	1239	US-7268562	09-11-2007	AISENBREY; Thomas	
	1240	US-7272436	09-18-2007	GILL; Jong et al.	
	1241	US-7273633	09-25-2007	RAYNOR; Jeffrey	
	1242	US-7276029	10-02-2007	GOODE, Jr.; Paul V. et al.	
	1243	US-7278983	10-09-2007	IRELAND; Jeffrey R. et al.	
	1244	US-7280879	10-09-2007	CHEN; Martin et al.	
	1245	US-7288085	10-30-2007	OLSEN; James M.	
	1246	US-7288368	10-30-2007	ZWEIG; Stephen Eliot	
	1247	US-7289204	10-30-2007	NIELSEN; Hans Ole et al.	
	1248	US-7289836	10-30-2007	COLVIN, Jr.; Arthur E.	
	1249	US-7291496	11-06-2007	HOLM-KENNEDY; James W.	
	1250	US-7295867	11-13-2007	BERNER; Bret et al.	
	1251	US-7297114	11-20-2007	GILL; Jong et al.	
	1252	US-7299082	11-20-2007	FELDMAN; Benjamin J. et al.	
	1253	US-7303875	12-04-2007	BOCK; Larry et al.	
	1254	US-7308292	12-11-2007	COLVIN; Arthur E. et al.	
	1255	US-7310544	12-18-2007	BRISTER; Mark et al.	
	1256	US-7311690	12-25-2007	BURNETT; Daniel R.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 52 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1257	US-7312040	12-25-2007	ROITMAN; Daniel B.	
	1258	US-7313425	12-25-2007	FINAROV; Alexander et al.	
	1259	US-7314452	01-01-2008	MADONIA; James R.	
	1260	US-7315752	01-01-2008	KRAEMER; Uwe et al.	
	1261	US-7315767	01-01-2008	CADUFF; Andreas et al.	
	1262	US-7316662	01-08-2008	DELNEVO; Annalisa et al.	
	1263	US-7317938	01-08-2008	LORENZ; Alexander D. et al.	
	1264	US-7317939	01-08-2008	FINE; Ilya et al.	
	1265	US-7318814	01-15-2008	LEVINE; Andy H. et al.	
	1266	US-7327273	02-05-2008	HUNG; Orlando R. et al.	
	1267	US-7329234	02-12-2008	SANSOUCY; Michael R.	
	1268	US-7334594	02-26-2008	LUDIN; Lev	
	1269	US-7335179	02-26-2008	BURNETT; Daniel Rogers	
	1270	US-7335195	02-26-2008	MEHIER; Henri	
	1271	US-7335294	02-26-2008	HELLER; Adam et al.	
	1272	US-7338464	03-04-2008	BLISCHAK; Brian et al.	
	1273	US-7338639	03-04-2008	BURKE; David W. et al.	
	1274	US-7344499	03-18-2008	PRAUSNITZ; Mark R. et al.	
	1275	US-7344626	03-18-2008	HARDING; Ian et al.	
	1276	US-7351321	04-01-2008	COHEN; Adam L.	
	1277	US-7354420	04-08-2008	STEIL; Garry M. et al.	
	1278	US-7359723	04-15-2008	JONES; Donald John	
	1279	US-7361155	04-22-2008	SAGE, Jr.; Burton H. et al.	
	1280	US-7364562	04-29-2008	BRAIG; James R. et al.	
	1281	US-7364592	04-29-2008	CARR-BRENDEL; Victoria et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 53 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1282	US-7365562	04-29-2008	JEON; Jin	
	1283	US-7366556	04-29-2008	BRISTER; Mark et al.	
	1284	US-7367942	05-06-2008	GRAGE; Henry et al.	
	1285	US-7372277	05-13-2008	DIAMOND; Steven et al.	
	1286	US-7379765	05-27-2008	PETISCE; James et al.	
	1287	US-7381184	06-03-2008	FUNDERBURK; Jeffery V. et al.	
	1288	US-7384532	06-10-2008	PARSONS, II; Dennis R. et al.	
	1289	US-7387811	06-17-2008	SELVAMANICKAM; Venkat	
	1290	US-7390667	06-24-2008	BURKE; David W. et al.	
	1291	US-7396353	07-08-2008	LORENZEN; Eric et al.	
	1292	US-7399277	07-15-2008	SAIDARA; Frank et al.	
	1293	US-7402153	07-22-2008	STEIL; Garry M. et al.	
	1294	US-7402349	07-22-2008	PEPIN; John Graeme	
	1295	US-7407811	08-05-2008	BURKE; David W. et al.	
	1296	US-7416802	08-26-2008	SAMMES; Nigel et al.	
	1297	US-7417164	08-26-2008	SURI; Jeff T.	
	1298	US-7417729	08-26-2008	GREENWALD; Roger J.	
	1299	US-7422727	09-09-2008	LEE; Chun-Hyuk et al.	
	1300	US-7424318	09-09-2008	BRISTER; Mark et al.	
	1301	US-7425877	09-16-2008	CASPER; Michael D. et al.	
	1302	US-7426408	09-16-2008	DeNUZZIO; John D. et al.	
	1303	US-7427338	09-23-2008	DORDI; Yezdi N. et al.	
	1304	US-7427560	09-23-2008	LIN; Mou-Shiung et al.	
	1305	US-7429552	09-30-2008	AFZALI-ARDAKANI; Ali et al.	
	1306	US-7433727	10-07-2008	WARD; W. Kenneth et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 54 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1307	US-7460898	12-02-2008	BRISTER; Mark et al.	
	1308	US-7467003	12-16-2008	BRISTER; Mark et al.	
	1309	US-7468125	12-23-2008	KRAFT; Ulrich et al.	
	1310	US-7471972	12-30-2008	RHODES; Rathbun et al.	
	1311	US-7474992	01-06-2009	ARIYUR; Kartik B.	
	1312	US-7488601	02-10-2009	BURKE; David W. et al.	
	1313	US-7494465	02-24-2009	BRISTER; Mark et al.	
	1314	US-7494816	02-24-2009	BURKE; David W. et al.	
	1315	US-7497827	03-03-2009	BRISTER; Mark et al.	
	1316	US-7499002	03-03-2009	BLASKO; Gabor et al.	
	1317	US-7501052	03-10-2009	IYENGAR; Sridhar G. et al.	
	1318	US-7502644	03-10-2009	GILL; Jong et al.	
	1319	US-7517439	04-14-2009	HARDING; Ian et al.	
	1320	US-7519408	04-14-2009	RASDAL; Andrew et al.	
	1321	US-7519478	04-14-2009	BARTKOWIAK; Miroslaw et al.	
	1322	US-7523004	04-21-2009	BARTKOWIAK; Miroslaw et al.	
	1323	US-7524287	04-28-2009	BHARMI; Rupinder	
	1324	US-7525298	04-28-2009	MORGAN; Wayne A. et al.	
	1325	US-7529574	05-05-2009	JANSEN; Lawrence B. et al.	
	1326	US-7547281	06-16-2009	HAYES; Andrew C. et al.	
	1327	US-7547382	06-16-2009	HARDING; Ian et al.	
	1328	US-7569030	08-04-2009	LEBEL; Ronald J. et al.	
	1329	US-7583990	09-01-2009	GOODE, Jr.; Paul V. et al.	
	1330	US-7591801	09-22-2009	BRAUKER; James H. et al.	
	1331	US-7599726	10-06-2009	GOODE, Jr.; Paul V. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 55 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1332	US-7604593	10-20-2009	PARRIS; Norman A. et al.	
	1333	US-7608042	10-27-2009	GOLDBERGER; Daniel et al.	
	1334	US-7613491	11-03-2009	BOOCK; Robert et al.	
	1335	US-7615007	11-10-2009	SHULTS; Mark et al.	
	1336	US-7618368	11-17-2009	BROWN; Stephen J.	
	1337	US-7618369	11-17-2009	HAYTER; Gary et al.	
	1338	US-7620438	11-17-2009	HE; Lei	
	1339	US-7624028	11-24-2009	BROWN; Stephen J.	
	1340	US-7630748	12-08-2009	BUDIMAN; Erwin S.	
	1341	US-7632228	12-15-2009	BRAUKER; James H. et al.	
	1342	US-7635594	12-22-2009	HOLMES; Elizabeth A. et al.	
	1343	US-7637868	12-29-2009	SAINT; Sean et al.	
	1344	US-7640032	12-29-2009	JONES; Donald John	
	1345	US-7640048	12-29-2009	DOBBLES; J. Michael et al.	
	1346	US-7645374	01-12-2010	DIAMOND; Steven et al.	
	1347	US-7647237	01-12-2010	MALAVE; Luis J. et al.	
	1348	US-7653425	01-26-2010	HAYTER; Gary et al.	
	1349	US-7654956	02-02-2010	BRISTER; Mark et al.	
	1350	US-7695434	04-13-2010	MALECHA; Michael	
	1351	US-7699775	04-20-2010	DESAI; Shashi P. et al.	
	1352	US-7699964	04-20-2010	FELDMAN; Benjamin et al.	
	1353	US-7711493	05-04-2010	BARTKOWIAK; Miroslaw et al.	
	1354	US-7713392	05-11-2010	HARDING; Ian et al.	
	1355	US-7715893	05-11-2010	KAMATH; Apurv Ullas et al.	
	1356	US-7731659	06-08-2010	MALECHA; Michael	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 56 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1357	US-7736310	06-15-2010	TAUB; Marc B.	
	1358	US-7749445	07-06-2010	MASTERS; Brett P.	
	1359	US-7751864	07-06-2010	BUCK, Jr.; Harvey B.	
	1360	US-7761126	07-20-2010	GARDNER; Craig M. et al.	
	1361	US-7761130	07-20-2010	SIMPSON; Peter C. et al.	
	1362	US-7766829	08-03-2010	SLOAN; Mark K. et al.	
	1363	US-7766830	08-03-2010	FOX; James Kelly et al.	
	1364	US-7771352	08-10-2010	SHULTS; Mark C. et al.	
	1365	US-7774038	08-10-2010	WANG; Lu et al.	
	1366	US-7774145	08-10-2010	BRAUKER; James H. et al.	
	1367	US-7775975	08-17-2010	BRISTER; Mark et al.	
	1368	US-7776559	08-17-2010	CHILDERS; Winthrop D. et al.	
	1369	US-7778679	08-17-2010	SCHULMAN; Joseph H. et al.	
	1370	US-7778680	08-17-2010	GOODE, Jr.; Paul V. et al.	
	1371	US-7826981	11-02-2010	GOODE, Jr.; Paul V. et al.	
	1372	US-7831287	11-09-2010	BRISTER; Mark et al.	
	1373	US-7838639	11-23-2010	TSCHOPP; Jurg et al.	
	1374	US-7856613	12-21-2010	WELING; Milind et al.	
	1375	US-7857760	12-28-2010	BRISTER; Mark et al.	
	1376	US-7866025	01-11-2011	JAMES; Frank O. et al.	
	1377	US-7866026	01-11-2011	WANG; Yi et al.	
	1378	US-7885697	02-08-2011	BRISTER; Mark et al.	
	1379	US-7885698	02-08-2011	FELDMAN; Benjamin J.	
	1380	US-7889069	02-15-2011	FIFOLT; Douglas A. et al.	
	1381	US-7894870	02-22-2011	LUCISANO; Joseph Y. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 57 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1382	US-7896809	03-01-2011	SIMPSON; Peter C. et al.	
	1383	US-7899511	03-01-2011	SHULTS; Mark C. et al.	
	1384	US-7901354	03-08-2011	SHULTS; Mark C. et al.	
	1385	US-7905833	03-15-2011	BRISTER; Mark et al.	
	1386	US-7914450	03-29-2011	GOODE, Jr.; Paul V. et al.	
	1387	US-7917186	03-29-2011	KAMATH; Apurv Ullas et al.	
	1388	US-7917186-C1	08-09-2011	KAMATH; Apurv Ullas et al.	
	1389	US-7920906	04-05-2011	GOODE, Jr.; Paul V. et al.	
	1390	US-7925321	04-12-2011	GOODE; Paul V. et al.	
	1391	US-7927274	04-19-2011	RASDAL; Andrew et al.	
	1392	US-7933639	04-26-2011	GOODE; Paul V. et al.	
	1393	US-7938797	05-10-2011	ESTES; Mark C.	
	1394	US-7943034	05-17-2011	DIAMOND; Steven et al.	
	1395	US-7946984	05-24-2011	BRISTER; Mark et al.	
	1396	US-7955261	06-07-2011	GOODE; Paul V. et al.	
	1397	US-7959569	06-14-2011	GOODE; Paul V. et al.	
	1398	US-7964089	06-21-2011	HARDING; Ian et al.	
	1399	US-7964146	06-21-2011	HARDING; Ian et al.	
	1400	US-7974672	07-05-2011	SHULTS; Mark C. et al.	
	1401	US-7979104	07-12-2011	KAMATH; Apurv U. et al.	
	1402	US-7985330	07-26-2011	WANG; Lu et al.	
	1403	US-7986986	07-26-2011	GOODE; Paul V. et al.	
	1404	US-7990828	08-02-2011	SU; I-Bing et al.	
	1405	US-7996158	08-09-2011	HAYTER; Gary et al.	
	1406	US-7998071	08-16-2011	GOODE, Jr.; Paul V. et al.	
	1407	US-8000763	08-16-2011	MAZZA; John C. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 58 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1408	US-8005524	08-23-2011	BRAUKER; James H. et al.	
	1409	US-8005525	08-23-2011	GOODE, Jr.; Paul V. et al.	
	1410	US-8010174	08-30-2011	GOODE, Jr.; Paul V. et al.	
	1411	US-8016997	09-13-2011	DIAMOND; Steven et al.	
	1412	US-8026104	09-27-2011	WU; Huan-Ping et al.	
	1413	US-8030942	10-04-2011	DIAMOND; Steven et al.	
	1414	US-8052601	11-08-2011	GOODE, Jr.; Paul V. et al.	
	1415	US-8060173	11-15-2011	GOODE, Jr.; Paul V. et al.	
	1416	US-8073519	12-06-2011	GOODE, Jr.; Paul V. et al.	
	1417	US-8073520	12-06-2011	KAMATH; Apurv U. et al.	
	1418	US-8103471	01-24-2012	HAYTER; Gary	
	1419	US-8109850	02-07-2012	AMMON; Urs et al.	
	1420	US-8112240	02-07-2012	FENNELL; Martin J.	
	1421	US-8114268	02-14-2012	WANG; Lu et al.	
	1422	US-8116837	02-14-2012	HUANG; Johnnie W.	
	1423	US-8123920	02-28-2012	IYENGAR; Sridhar G. et al.	
	1424	US-8128562	03-06-2012	GOODE, Jr.; Paul V. et al.	
	1425	US-8140312	03-20-2012	HAYTER; Gary et al.	
	1426	US-8149117	04-03-2012	FENNELL; Martin J. et al.	
	1427	US-8150488	04-03-2012	GOODE, Jr.; Paul V. et al.	
	1428	US-8160670	04-17-2012	OUYANG; Tianmei et al.	
	1429	US-8160671	04-17-2012	KAMATH; Apurv Ullas et al.	
	1430	US-8160834	04-17-2012	LIANG; Bradley Chi et al.	
	1431	US-8160900	04-17-2012	TAUB; Marc B. et al.	
	1432	US-8167801	05-01-2012	GOODE, Jr.; Paul V. et al.	
	1433	US-8170803	05-01-2012	KAMATH; Apurv Ullas et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 59 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1434	US-8195265	06-05-2012	GOODE, Jr.; Paul V. et al.	
	1435	US-8202491	06-19-2012	MASTERS; Brett et al.	
	1436	US-8211016	07-03-2012	BUDIMAN; Erwin S.	
	1437	US-8216137	07-10-2012	BUDIMAN; Erwin S.	
	1438	US-8216138	07-10-2012	McGARRAUGH; Geoffrey V.	
	1439	US-8219173	07-10-2012	BUDIMAN; Erwin Satrya et al.	
	1440	US-8224415	07-17-2012	BUDIMAN; Erwin Satrya	
	1441	US-8229536	07-24-2012	GOODE, Jr.; Paul V. et al.	
	1442	US-8233959	07-31-2012	KAMATH; Apurv et al.	
	1443	US-8239166	08-07-2012	HAYTER; Gary et al.	
	1444	US-8249683	08-21-2012	WANG; Lu et al.	
	1445	US-8255026	08-28-2012	AL-ALI; Ammar	
	1446	US-8257259	09-04-2012	BRAUKER; James H. et al.	
	1447	US-8260393	09-04-2012	KAMATH; Apurv Ullas et al.	
	1448	US-8260558	09-04-2012	HAYTER; Gary et al.	
	1449	US-8275438	09-25-2012	SIMPSON; Peter C. et al.	
	1450	US-8282549	10-09-2012	BRAUKER; James H. et al.	
	1451	US-8282550	10-09-2012	RASDAL; Andrew P. et al.	
	1452	US-8287453	10-16-2012	LI; Ying et al.	
	1453	US-8290559	10-16-2012	SHARIATI; Mohammad Ali et al.	
	1454	US-8290562	10-16-2012	GOODE, Jr.; Paul V. et al.	
	1455	US-8292810	10-23-2012	GOODE, Jr.; Paul V. et al.	
	1456	US-8298142	10-30-2012	SIMPSON; Peter C. et al.	
	1457	US-8332008	12-11-2012	GOODE; Paul V. et al.	
	1458	US-8346335	01-01-2013	HARPER; Wesley Scott et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 60 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1459	US-8346337	01-01-2013	HELLER; Adam et al.	
	1460	US-8346338	01-01-2013	GOODE, Jr.; Paul V. et al.	
	1461	US-8348923	01-08-2013	KANDERIAN, Jr.; Sami S. et al.	
	1462	US-8364230	01-29-2013	SIMPSON; Peter C. et al.	
	1463	US-8364231	01-29-2013	KAMATH; Apurv Ullas et al.	
	1464	US-8369919	02-05-2013	KAMATH; Apurv Ullas et al.	
	1465	US-8372351	02-12-2013	OW-WING; Kevin M.	
	1466	US-8374667	02-12-2013	BRAUKER; James H. et al.	
	1467	US-8376945	02-19-2013	HAYTER; Gary et al.	
	1468	US-8396528	03-12-2013	KAMATH; Apurv Ullas et al.	
	1469	US-8412301	04-02-2013	GOODE, Jr.; Paul V. et al.	
	1470	US-8417312	04-09-2013	KAMATH; Apurv Ullas et al.	
	1471	US-8423113	04-16-2013	SHARIATI; Mohammad Ali et al.	
	1472	US-8423114	04-16-2013	SIMPSON; Peter C. et al.	
	1473	US-8425416	04-23-2013	BRISTER; Mark et al.	
	1474	US-8425417	04-23-2013	LEACH; Jacob S. et al.	
	1475	US-8428678	04-23-2013	KAMATH; Apurv Ullas et al.	
	1476	US-8428679	04-23-2013	GOODE, Jr.; Paul V. et al.	
	1477	US-8435179	05-07-2013	GOODE, Jr.; Paul V. et al.	
	1478	US-8442610	05-14-2013	GOODE; Paul V. et al.	
	1479	US-8444560	05-21-2013	HAYTER; Gary et al.	
	1480	US-8447376	05-21-2013	SHARIATI; Mohammad Ali et al.	
	1481	US-8449464	05-28-2013	SIMPSON; Peter C. et al.	
	1482	US-8457703	06-04-2013	AL-ALI; Ammar	
	1483	US-8461985	06-11-2013	FENNELL; Martin J. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 61 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1484	US-8463350	06-11-2013	KAMATH; Apurv Ullas et al.	
	1485	US-8473022	06-25-2013	HAYTER; Gary et al.	
	1486	US-8475373	07-02-2013	BRISTER; Mark et al.	
	1487	US-8478377	07-02-2013	SHARIATI; Mohammad Ali et al.	
	1488	US-8478557	07-02-2013	HAYTER; Gary Alan et al.	
	1489	US-8484005	07-09-2013	HAYTER; Gary et al.	
	1490	US-8491474	07-23-2013	GOODE, Jr.; Paul V. et al.	
	1491	US-8509871	08-13-2013	RHODES; Rathbun K. et al.	
	1492	US-8515517	08-20-2013	HAYTER; Gary et al.	
	1493	US-8527025	09-03-2013	SHULTS; Mark C. et al.	
	1494	US-8532730	09-10-2013	BRISTER; Mark et al.	
	1495	US-8532935	09-10-2013	BUDIMAN; Erwin Satrya	
	1496	US-8543354	09-24-2013	LUO; Ying et al.	
	1497	US-8560037	10-15-2013	GOODE, Jr.; Paul V. et al.	
	1498	US-8560038	10-15-2013	HAYTER; Gary et al.	
	1499	US-8562528	10-22-2013	LEACH; Jacob S. et al.	
	1500	US-8571808	10-29-2013	HAYTER; Gary	
	1501	US-8583205	11-12-2013	BUDIMAN; Erwin Satrya et al.	
	1502	US-8593109	11-26-2013	HE; Lei	
	1503	US-8600681	12-03-2013	HAYTER; Gary et al.	
	1504	US-8612163	12-17-2013	HAYTER; Gary et al.	
	1505	US-8626257	01-07-2014	LI; Ying et al.	
	1506	US-8657745	02-25-2014	BRAUKER; James H. et al.	
	1507	US-8657746	02-25-2014	ROY; Anirban	
	1508	US-8663220	03-04-2014	WIENER; Eitan T. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 62 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1509	US-8665091	03-04-2014	FENNELL; Martin J. et al.	
	1510	US-8682615	03-25-2014	HAYTER; Gary et al.	
	1511	US-8718739	05-06-2014	HARPER; Wesley Scott et al.	
	1512	US-8718965	05-06-2014	HAYTER; Gary Alan et al.	
	1513	US-8744547	06-03-2014	BUDIMAN; Erwin Satrya et al.	
	1514	US-8774886	07-08-2014	BRISTER; Mark et al.	
	1515	US-8868151	10-21-2014	TELSON; Stanley A. et al.	
	1516	US-8868161	10-21-2014	THIERMAN; Jonathan	
	1517	US-8911367	12-16-2014	BRISTER; Mark et al.	
	1518	US-8933664	01-13-2015	HE; Lei	
	1519	US-8942778	01-27-2015	OCVIRK; Gregor et al.	
	1520	US-9060719	06-23-2015	HAYTER; Gary Alan et al.	
	1521	US-9113828	08-25-2015	BUDIMAN; Erwin S.	
	1522	US-9125548	09-08-2015	HAYTER; Gary	
	1523	US-9135402	09-15-2015	MENSINGER; Michael Robert et al.	
	1524	US-9149220	10-06-2015	BOHM; Sebastian et al.	
	1525	US-9161714	10-20-2015	MARTINI; Joerg et al.	
	1526	US-9247901	02-02-2016	KAMATH; Apurv et al.	
	1527	US-9314196	04-19-2016	PRYOR; Jack et al.	
	1528	US-9320462	04-26-2016	HARPER; Wesley Scott et al.	
	1529	US-9320468	04-26-2016	HAYTER; Gary Alan et al.	
	1530	US-9326709	05-03-2016	BUDIMAN; Erwin Satrya	
	1531	US-9332934	05-10-2016	HAYTER; Gary Alan et al.	
	1532	US-9339217	05-17-2016	HARPER; Wesley Scott et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 63 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1533	US-9357959	06-07-2016	HAYTER; Gary Alan et al.	
	1534	US-9380971	07-05-2016	HE; Lei	
	1535	US-9392969	07-19-2016	HAYTER; Gary et al.	
	1536	US-9398872	07-26-2016	HAYTER; Gary Alan et al.	
	1537	US-9408566	08-09-2016	HAYTER; Gary Alan et al.	
	1538	US-9451908	09-27-2016	KAMATH; Apurv Ullas et al.	
	1539	US-9483608	11-01-2016	HAYTER; Gary Alan et al.	
	1540	US-9498155	11-22-2016	BRAUKER; James H. et al.	
	1541	US-9558325	01-31-2017	HAYTER; Gary Alan et al.	
	1542	US-9629578	04-25-2017	HAYTER; Gary Alan et al.	
	1543	US-9662056	05-30-2017	BUDIMAN; Erwin Satrya et al.	
	1544	US-9675290	06-13-2017	BUDIMAN; Erwin Satrya et al.	
	1545	US-9730623	08-15-2017	HARPER; Wesley Scott et al.	
	1546	US-9737249	08-22-2017	HAYTER; Gary Alan et al.	
	1547	US-9743863	08-29-2017	HE; Lei	
	1548	US-9770211	09-26-2017	HAYTER; Gary Alan et al.	
	1549	US-9797880	10-24-2017	HAYTER; Gary Alan et al.	
	1550	US-9801571	10-31-2017	HAYTER; Gary Alan	
	1551	US-9801575	10-31-2017	BOHM; Sebastian et al.	
	1552	US-9801577	10-31-2017	BUDIMAN; Erwin Satrya et al.	
	1553	US-9804148	10-31-2017	HAYTER; Gary Alan et al.	
	1554	US-9804150	10-31-2017	HAYTER; Gary Alan et al.	
	1555	US-9808190	11-07-2017	BOHM; Sebastian et al.	
	1556	US-9814428	11-14-2017	BUDIMAN; Erwin S.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 64 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1557	US-9833181	12-05-2017	HAYTER; Gary Alan et al.	
	1558	US-9839383	12-12-2017	HAYTER; Gary Alan et al.	
	1559	US-9839395	12-12-2017	SHARIATI; Mohammad Ali et al.	
	1560	US-9848809	12-26-2017	BOHM; Sebastian et al.	
	1561	US-9936910	04-10-2018	HAYTER; Gary Alan et al.	
	1562	US-10002233	06-19-2018	HAYTER; Gary et al.	
	1563	US-10004442	06-26-2018	BOHM; Sebastian et al.	
	1564	US-10031002	07-24-2018	HAYTER; Gary Alan et al.	
	1565	US-10045720	08-14-2018	HAYTER; Gary Alan et al.	
	1566	US-10052055	08-21-2018	LI; Ying et al.	
	1567	US-10078380	09-18-2018	BUDIMAN; Erwin S.	
	1568	US-10082493	09-25-2018	HARPER; Wesley Scott et al.	
	1569	US-10089446	10-02-2018	BUDIMAN; Erwin Satrya	
	1570	US-10119956	11-06-2018	HAYTER; Gary Alan et al.	
	1571	US-10143409	12-04-2018	HAYTER; Gary Alan	
	1572	US-10188334	01-29-2019	BUDIMAN; Erwin Satrya et al.	
	1573	US-10188794	01-29-2019	HAYTER; Gary et al.	
	1574	US-10194868	02-05-2019	BUDIMAN; Erwin Satrya	
	1575	US-10261069	04-16-2019	HAYTER; Gary Alan et al.	
	1576	US-10278630	05-07-2019	HAYTER; Gary Alan et al.	
	1577	US-10327688	06-25-2019	BOHM; Sebastian et al.	
	1578	US-10335075	07-02-2019	VANSLYKE; Stephen J. et al.	
	1579	US-10349873	07-16-2019	KAMATH; Apurv Ullas et al.	
	1580	US-10448873	10-22-2019	BOHM; Sebastian et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 65 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1581	US-10561354	02-18-2020	BOHM; Sebastian et al.	
	1582	US-10610141	04-07-2020	BOHM; Sebastian et al.	
	1583	US-10624568	04-21-2020	BOHM; Sebastian et al.	
	1584	US-10682084	06-16-2020	BOHM; Sebastian et al.	
	1585	US-10722162	07-28-2020	BOHM; Sebastian et al.	
	1586	US-10835162	11-17-2020	BOHM; Sebastian et al.	
	1587	US-20010016682	08-23-2001	BERNER; Bret et al.	
	1588	US-20010021817	09-13-2001	BRUGGER; James M. et al.	
	1589	US-20010039053	11-08-2001	LISEO; John et al.	
	1590	US-20010041830	11-15-2001	VARALLI; Maurizio Claudio et al.	
	1591	US-20010041831	11-15-2001	STARKWEATHER; Timothy J. et al.	
	1592	US-20010051768	12-13-2001	SCHULMAN; Joseph H. et al.	
	1593	US-20020016534	02-07-2002	TREPAGNIER; Pierre et al.	
	1594	US-20020016535	02-07-2002	MARTIN; W. Blake et al.	
	1595	US-20020019022	02-14-2002	DUNN; Timothy C. et al.	
	1596	US-20020022883	02-21-2002	BURG; Karen J.L.	
	1597	US-20020023852	02-28-2002	MCIVOR; K. Collin et al.	
	1598	US-20020026110	02-28-2002	PARRIS; Norman A. et al.	
	1599	US-20020026111	02-28-2002	ACKERMAN; Neil	
	1600	US-20020027086	03-07-2002	SAFFELL; John R. et al.	
	1601	US-20020038101	03-28-2002	AVRAHAMI; Zohar et al.	
	1602	US-20020042090	04-11-2002	HELLER; Adam et al.	
	1603	US-20020042561	04-11-2002	SCHULMAN; Joseph H. et al.	
	1604	US-20020043471	04-18-2002	IKEDA; Shin et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 66 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1605	US-20020045808	04-18-2002	FORD; Russell et al.	
	1606	US-20020055673	05-09-2002	VAN ANTWERP; William P. et al.	
	1607	US-20020062132	05-23-2002	KRAMER; Kenneth S. et al.	
	1608	US-20020065453	05-30-2002	LESHO; Matthew J. et al.	
	1609	US-20020065454	05-30-2002	LEBEL; Ronald J. et al.	
	1610	US-20020068860	06-06-2002	CLARK, Jr.; Leland C.	
	1611	US-20020071776	06-13-2002	BANDIS; Steven et al.	
	1612	US-20020084196	07-04-2002	LIAMOS; Charles T. et al.	
	1613	US-20020099282	07-25-2002	KNOBBE; Edward J. et al.	
	1614	US-20020099997	07-25-2002	PIRET; Philippe	
	1615	US-20020103499	08-01-2002	PEREZ; Edward P. et al.	
	1616	US-20020106709	08-08-2002	POTTS; Russell O. et al.	
	1617	US-20020111547	08-15-2002	KNOBBE; Edward J. et al.	
	1618	US-20020115920	08-22-2002	RICH; Collin A. et al.	
	1619	US-20020119711	08-29-2002	VANANTWERP; Nannette M. et al.	
	1620	US-20020120186	08-29-2002	KEIMEL; John G.	
	1621	US-20020123048	09-05-2002	GAU, Jr.; Vincent Jen.	
	1622	US-20020128594	09-12-2002	DAS; Kusal K. et al.	
	1623	US-20020143266	10-03-2002	BOCK; Elizabeth Anne	
	1624	US-20020143372	10-03-2002	SNELL; Jeffery D. et al.	
	1625	US-20020151796	10-17-2002	KOULIK; Edouard	
	1626	US-20020155615	10-24-2002	NOVIKOV; Igor A. et al.	
	1627	US-20020156355	10-24-2002	GOUGH; David A.	
	1628	US-20020161288	10-31-2002	SHIN; John J. et al.	
	1629	US-20020169369	11-14-2002	WARD; W. Kenneth et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 67 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1630	US-20020169635	11-14-2002	SHILLINGBURG; Craig P.	
	1631	US-20020177763	11-28-2002	BURNS; David W. et al.	
	1632	US-20020177764	11-28-2002	SOHRAB; Borzu	
	1633	US-20020182241	12-05-2002	BORENSTEIN; Jeffrey T. et al.	
	1634	US-20020188185	12-12-2002	SOHRAB; Borzu	
	1635	US-20020193679	12-19-2002	MALAVE; Luis J. et al.	
	1636	US-20020193885	12-19-2002	LEGEAY; Gilbert et al.	
	1637	US-20020198513	12-26-2002	LEBEL; Ronald J. et al.	
	1638	US-20030003524	01-02-2003	TANIIKE; Yukio et al.	
	1639	US-20030004403	01-02-2003	DRINAN; Darrel et al.	
	1640	US-20030004432	01-02-2003	ASSENHEIMER; Michel	
	1641	US-20030004457	01-02-2003	ANDERSSON; Stig O.	
	1642	US-20030006669	01-09-2003	PEI; Qibing et al.	
	1643	US-20030023171	01-30-2003	SATO; Katsuhiko et al.	
	1644	US-20030023317	01-30-2003	BRAUKER; James H. et al.	
	1645	US-20030023461	01-30-2003	QUINTANILLA; Dan et al.	
	1646	US-20030028089	02-06-2003	GALLEY; Paul J. et al.	
	1647	US-20030032867	02-13-2003	CROTHALL; Katherine D. et al.	
	1648	US-20030032874	02-13-2003	RHODES; Rathbun et al.	
	1649	US-20030034305	02-20-2003	LUEHMANN; Douglas A. et al.	
	1650	US-20030036773	02-20-2003	WHITEHURST; Todd K. et al.	
	1651	US-20030042137	03-06-2003	MAO; Fei et al.	
	1652	US-20030050546	03-13-2003	DESAI; Shashi P. et al.	
	1653	US-20030054428	03-20-2003	MONFRE; Stephen L. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 68 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1654	US-20030060692	03-27-2003	L. RUCHTI; Timothy et al.	
	1655	US-20030065254	04-03-2003	SCHULMAN; Joseph H. et al.	
	1656	US-20030065308	04-03-2003	LEBEL; Ronald J. et al.	
	1657	US-20030070548	04-17-2003	CLAUSEN; Lydia	
	1658	US-20030076082	04-24-2003	MORGAN; Wayne A. et al.	
	1659	US-20030078481	04-24-2003	McIVOR; K. Collin et al.	
	1660	US-20030078560	04-24-2003	MILLER; Michael E. et al.	
	1661	US-20030097082	05-22-2003	PURDY; Phillip D. et al.	
	1662	US-20030100040	05-29-2003	BONNECAZE; Roger T. et al.	
	1663	US-20030100821	05-29-2003	HELLER; Adam et al.	
	1664	US-20030119201	06-26-2003	WOLFRAM; Evelyn et al.	
	1665	US-20030119208	06-26-2003	YOON; Hyun Chul et al.	
	1666	US-20030120152	06-26-2003	OMIYA; Jun	
	1667	US-20030125612	07-03-2003	FOX; James Kelly et al.	
	1668	US-20030125613	07-03-2003	ENEGREN; Bradley J. et al.	
	1669	US-20030130616	07-10-2003	STEIL; Garry M. et al.	
	1670	US-20030134347	07-17-2003	HELLER; Adam et al.	
	1671	US-20030138674	07-24-2003	ZEIKUS; Gregory J. et al.	
	1672	US-20030143746	07-31-2003	SAGE, Jr.; Burton H.	
	1673	US-20030153821	08-14-2003	BERNER; Bret et al.	
	1674	US-20030161288	08-28-2003	UNRUH; Lincoln J.	
	1675	US-20030168338	09-11-2003	GAO; Zhiqiang et al.	
	1676	US-20030175987	09-18-2003	VERDONK; Edward et al.	
	1677	US-20030176183	09-18-2003	DRUCKER; Steven et al.	
	1678	US-20030176933	09-18-2003	LEBEL; Ronald J. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 69 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1679	US-20030181794	09-25-2003	RINI; Christopher J. et al.	
	1680	US-20030187338	10-02-2003	SAY; James et al.	
	1681	US-20030188427	10-09-2003	SAY; James et al.	
	1682	US-20030191377	10-09-2003	ROBINSON; Mark Ries et al.	
	1683	US-20030199744	10-23-2003	BUSE; John Bernard et al.	
	1684	US-20030199790	10-23-2003	BOECKER; Dirk et al.	
	1685	US-20030203498	10-30-2003	NEEL; Gary T. et al.	
	1686	US-20030208113	11-06-2003	MAULT; James R. et al.	
	1687	US-20030211625	11-13-2003	COHAN; Bruce E. et al.	
	1688	US-20030212317	11-13-2003	KOVATCHEV; Boris P. et al.	
	1689	US-20030212346	11-13-2003	YUZHAKOV; Vadim V. et al.	
	1690	US-20030212347	11-13-2003	SOHRAB; Borzu	
	1691	US-20030212379	11-13-2003	BYLUND; Adam David et al.	
	1692	US-20030216630	11-20-2003	JERSEY-WILLUHN; Karen et al.	
	1693	US-20030217966	11-27-2003	TAPSAK; Mark A. et al.	
	1694	US-20030225437	12-04-2003	FERGUSON; Patrick J.	
	1695	US-20030228681	12-11-2003	RITTS; Rosalyn et al.	
	1696	US-20030235817	12-25-2003	BARTKOWIAK; Miroslaw et al.	
	1697	US-20040010186	01-15-2004	KIMBALL; Victor E. et al.	
	1698	US-20040010207	01-15-2004	FLAHERTY; J. Christopher et al.	
	1699	US-20040011671	01-22-2004	SHULTS; Mark C. et al.	
	1700	US-20040015063	01-22-2004	DeNUZZIO; John D. et al.	
	1701	US-20040015134	01-22-2004	LAVI; Gilad et al.	
	1702	US-20040023253	02-05-2004	KUNWAR; Sandeep et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 70 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1703	US-20040023317	02-05-2004	MOTAMEDI; Massoud et al.	
	1704	US-20040024327	02-05-2004	BRODNICK; Donald Eugene	
	1705	US-20040024553	02-05-2004	MONFRE; Stephen L. et al.	
	1706	US-20040030285	02-12-2004	LAVI; Gilad et al.	
	1707	US-20040030294	02-12-2004	MAHURKAR; Sakharam D.	
	1708	US-20040039298	02-26-2004	ABREU; Marcio Marc	
	1709	US-20040039406	02-26-2004	JESSEN; Jonh W.	
	1710	US-20040040840	03-04-2004	MAO; Fei et al.	
	1711	US-20040045879	03-11-2004	SHULTS; Mark C. et al.	
	1712	US-20040054263	03-18-2004	MOERMAN; Piet et al.	
	1713	US-20040054352	03-18-2004	ADAMS; H. Clark et al.	
	1714	US-20040064021	04-01-2004	PFEIFFER; Ulrich J.	
	1715	US-20040064068	04-01-2004	DeNUZZIO; John D. et al.	
	1716	US-20040068230	04-08-2004	ESTES; Mark C. et al.	
	1717	US-20040074785	04-22-2004	HOLKER; James D. et al.	
	1718	US-20040077962	04-22-2004	KROLL; Mark W.	
	1719	US-20040078065	04-22-2004	KROLL; Mark W.	
	1720	US-20040078219	04-22-2004	KAYLOR; Rosann et al.	
	1721	US-20040093167	05-13-2004	BRAIG; James R. et al.	
	1722	US-20040099529	05-27-2004	MAO; Fei et al.	
	1723	US-20040106857	06-03-2004	GOUGH; David A.	
	1724	US-20040106858	06-03-2004	SAY; James et al.	
	1725	US-20040106859	06-03-2004	SAY; James et al.	
	1726	US-20040108226	06-10-2004	POLYCHRONAKOS; Constantin et al.	
	1727	US-20040122353	06-24-2004	SHAHMIRIAN; Varaz et al.	
	1728	US-20040133131	07-08-2004	KUHN; David L. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 71 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1729	US-20040133164	07-08-2004	FUNDERBURK; Jeffery V. et al.	
	1730	US-20040135684	07-15-2004	STEINTHAL; Gregory et al.	
	1731	US-20040138588	07-15-2004	SAIKLEY; Charles R. et al.	
	1732	US-20040138716	07-15-2004	KON; Steve et al.	
	1733	US-20040142403	07-22-2004	HETZEL; Donald et al.	
	1734	US-20040143173	07-22-2004	REGHABI; Bahar et al.	
	1735	US-20040146909	07-29-2004	DUONG; Hau H. et al.	
	1736	US-20040147819	07-29-2004	CADUFF; Andreas et al.	
	1737	US-20040152187	08-05-2004	HAIGHT; LeVoy Golden et al.	
	1738	US-20040152622	08-05-2004	KEITH; Steven et al.	
	1739	US-20040158137	08-12-2004	EPPSTEIN; Jonathan A. et al.	
	1740	US-20040162678	08-19-2004	HETZEL; Donald et al.	
	1741	US-20040167801	08-26-2004	SAY; James et al.	
	1742	US-20040171921	09-02-2004	SAY; James et al.	
	1743	US-20040172307	09-02-2004	GRUBER; Martin A.	
	1744	US-20040173472	09-09-2004	JUNG; Sung-Kwon et al.	
	1745	US-20040176672	09-09-2004	SILVER; James H. et al.	
	1746	US-20040186362	09-23-2004	BRAUKER; James H. et al.	
	1747	US-20040186365	09-23-2004	JIN; Robert Y. et al.	
	1748	US-20040193025	09-30-2004	STEIL; Garry M. et al.	
	1749	US-20040193090	09-30-2004	LEBEL; Ronald J. et al.	
	1750	US-20040197846	10-07-2004	HOCKERSMITH; Linda et al.	
	1751	US-20040199059	10-07-2004	BRAUKER; James H. et al.	
	1752	US-20040204687	10-14-2004	MOGENSEN; Lasse Wesseltoft et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 72 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1753	US-20040208780	10-21-2004	FARIES, Jr.; Durward I. et al.	
	1754	US-20040219664	11-04-2004	HELLER; Adam et al.	
	1755	US-20040220517	11-04-2004	STARKWEATHER; Timothy J. et al.	
	1756	US-20040225338	11-11-2004	LEBEL; Ronald J. et al.	
	1757	US-20040236200	11-25-2004	SAY; James et al.	
	1758	US-20040236251	11-25-2004	ROE; Steven N. et al.	
	1759	US-20040242982	12-02-2004	SAKATA; Tetsuya et al.	
	1760	US-20040249253	12-09-2004	RACCHINI; Joel et al.	
	1761	US-20040249420	12-09-2004	OLSON; Walter H. et al.	
	1762	US-20040254433	12-16-2004	BANDIS; Steven D. et al.	
	1763	US-20040254434	12-16-2004	GOODNOW; Timothy T. et al.	
	1764	US-20040260478	12-23-2004	SCHWAMM; Lee H.	
	1765	US-20040263354	12-30-2004	MANN; Alfred E. et al.	
	1766	US-20040267300	12-30-2004	MACE; Chad Harold	
	1767	US-20050003470	01-06-2005	NELSON; Charles L. et al.	
	1768	US-20050004439	01-06-2005	SHIN; John J. et al.	
	1769	US-20050004494	01-06-2005	PEREZ; Edward P. et al.	
	1770	US-20050006122	01-13-2005	BURNETTE; David Ruffin	
	1771	US-20050010087	01-13-2005	BANET; Matthew et al.	
	1772	US-20050010265	01-13-2005	BARU FASSIO; Marcelo Daniel et al.	
	1773	US-20050010269	01-13-2005	LEBEL; Ronald J. et al.	
	1774	US-20050015020	01-20-2005	LeVAUGHN; Richard W. et al.	
	1775	US-20050016276	01-27-2005	GUAN; Shenheng et al.	
	1776	US-20050026689	02-03-2005	MARKS; Richard L.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 73 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1777	US-20050027177	02-03-2005	SHIN; John J. et al.	
	1778	US-20050027180	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1779	US-20050027181	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1780	US-20050027182	02-03-2005	SIDDIQUI; Uzair et al.	
	1781	US-20050027462	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1782	US-20050027463	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1783	US-20050031689	02-10-2005	SHULTS; Mark et al.	
	1784	US-20050033132	02-10-2005	SHULTS; Mark C. et al.	
	1785	US-20050038332	02-17-2005	SAIDARA; Frank et al.	
	1786	US-20050043598	02-24-2005	GOODE, Jr.; Paul V. et al.	
	1787	US-20050049179	03-03-2005	DAVIDSON; Paul C. et al.	
	1788	US-20050049473	03-03-2005	DESAI; Shashi P. et al.	
	1789	US-20050051427	03-10-2005	BRAUKER; James H. et al.	
	1790	US-20050051440	03-10-2005	SIMPSON; Peter C. et al.	
	1791	US-20050054905	03-10-2005	CORL; Paul D. et al.	
	1792	US-20050054909	03-10-2005	PETISCE; James et al.	
	1793	US-20050056551	03-17-2005	WHITE; Stephen Fredrick et al.	
	1794	US-20050056552	03-17-2005	SIMPSON; Peter C. et al.	
	1795	US-20050059871	03-17-2005	GOUGH; David A. et al.	
	1796	US-20050065464	03-24-2005	TALBOT; Cary D. et al.	
	1797	US-20050070774	03-31-2005	ADDISON; Paul Stanley et al.	
	1798	US-20050090607	04-28-2005	TAPSAK; Mark A. et al.	
	1799	US-20050096511	05-05-2005	FOX; James Kelly et al.	
	1800	US-20050096512	05-05-2005	FOX; James Kelly et al.	
	1801	US-20050096519	05-05-2005	DeNUZZIO; John D. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 74 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1802	US-20050101847	05-12-2005	ROUTT; Wilson et al.	
	1803	US-20050103625	05-19-2005	RHODES; Rathbun et al.	
	1804	US-20050112169	05-26-2005	BRAUKER; James H. et al.	
	1805	US-20050113653	05-26-2005	FOX; James Kelly et al.	
	1806	US-20050114068	05-26-2005	CHEY; S. Jay et al.	
	1807	US-20050115832	06-02-2005	SIMPSON; Peter C. et al.	
	1808	US-20050121322	06-09-2005	SAY; James et al.	
	1809	US-20050124873	06-09-2005	SHULTS; Mark C. et al.	
	1810	US-20050131305	06-16-2005	DANIELSON; Bo G. et al.	
	1811	US-20050131346	06-16-2005	DOUGLAS; Joel S.	
	1812	US-20050133368	06-23-2005	DAVIES; Oliver William Hardwicke et al.	
	1813	US-20050139489	06-30-2005	DAVIES; Oliver William Hardwicke et al.	
	1814	US-20050143635	06-30-2005	KAMATH; Apurv Ullas et al.	
	1815	US-20050143675	06-30-2005	NEEL; Gary T. et al.	
	1816	US-20050154271	07-14-2005	RASDAL; Andrew et al.	
	1817	US-20050161346	07-28-2005	SIMPSON; Peter et al.	
	1818	US-20050173245	08-11-2005	FELDMAN; Benjamin et al.	
	1819	US-20050176136	08-11-2005	BURD; John et al.	
	1820	US-20050177036	08-11-2005	SHULTS; Mark C. et al.	
	1821	US-20050177398	08-11-2005	WATANABE; Motokazu et al.	
	1822	US-20050181012	08-18-2005	SAINT; Sean et al.	
	1823	US-20050182306	08-18-2005	SLOAN; Mark K.	
	1824	US-20050182451	08-18-2005	GRIFFIN; Adam et al.	
	1825	US-20050183954	08-25-2005	HITCHCOCK; Robert W. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 75 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1826	US-20050187720	08-25-2005	GOODE, Jr.; Paul V. et al.	
	1827	US-20050192494	09-01-2005	GINSBERG; Barry H.	
	1828	US-20050192557	09-01-2005	BRAUKER; James H. et al.	
	1829	US-20050195930	09-08-2005	SPITAL; Glenn O. et al.	
	1830	US-20050196820	09-08-2005	ZWEIG; Stephen Eliot	
	1831	US-20050196821	09-08-2005	MONFRE; Stephen L. et al.	
	1832	US-20050197612	09-08-2005	LEVIN; Howard R. et al.	
	1833	US-20050199494	09-15-2005	SAY; James et al.	
	1834	US-20050203360	09-15-2005	BRAUKER; James H. et al.	
	1835	US-20050203364	09-15-2005	MONFRE; Stephen L. et al.	
	1836	US-20050211571	09-29-2005	SCHULEIN; Jurgen et al.	
	1837	US-20050214892	09-29-2005	KOVATCHEV; Boris P. et al.	
	1838	US-20050215871	09-29-2005	FELDMAN; Benjamin J. et al.	
	1839	US-20050215872	09-29-2005	BERNER; Bret et al.	
	1840	US-20050239154	10-27-2005	FELDMAN; Benjamin J. et al.	
	1841	US-20050239156	10-27-2005	DRUCKER; Steven et al.	
	1842	US-20050241957	11-03-2005	MAO; Fei et al.	
	1843	US-20050242479	11-03-2005	PETISCE; James R. et al.	
	1844	US-20050245795	11-03-2005	GOODE, Jr.; Paul V. et al.	
	1845	US-20050245799	11-03-2005	BRAUKER; James H. et al.	
	1846	US-20050245839	11-03-2005	STIVORIC; John et al.	
	1847	US-20050245904	11-03-2005	ESTES; Mark C. et al.	
	1848	US-20050258037	11-24-2005	HAJIZADEH; Kiamars et al.	
	1849	US-20050261563	11-24-2005	ZHOU; Peter et al.	
	1850	US-20050272989	12-08-2005	SHAH; Rajiv et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 76 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1851	US-20050277164	12-15-2005	DRUCKER; Steven et al.	
	1852	US-20050277912	12-15-2005	JOHN; Sasha	
	1853	US-20050287620	12-29-2005	HELLER; Adam et al.	
	1854	US-20050288596	12-29-2005	EIGLER; Neal L. et al.	
	1855	US-20050288725	12-29-2005	HETTRICK; Douglas A. et al.	
	1856	US-20060001538	01-05-2006	KRAFT; Ulrich et al.	
	1857	US-20060004270	01-05-2006	BEDARD; Michel et al.	
	1858	US-20060010098	01-12-2006	GOODNOW; Timothy T. et al.	
	1859	US-20060015020	01-19-2006	NEALE; Paul et al.	
	1860	US-20060015024	01-19-2006	BRISTER; Mark et al.	
	1861	US-20060016700	01-26-2006	BRISTER; Mark et al.	
	1862	US-20060017923	01-26-2006	RUCHTI; Timothy L. et al.	
	1863	US-20060019327	01-26-2006	BRISTER; Mark et al.	
	1864	US-20060020186	01-26-2006	BRISTER; Mark et al.	
	1865	US-20060020187	01-26-2006	BRISTER; Mark et al.	
	1866	US-20060020188	01-26-2006	KAMATH; Apurv Ullas et al.	
	1867	US-20060020189	01-26-2006	BRISTER; Mark et al.	
	1868	US-20060020190	01-26-2006	KAMATH; Apurv Ullas et al.	
	1869	US-20060020191	01-26-2006	BRISTER; Mark et al.	
	1870	US-20060020192	01-26-2006	BRISTER; Mark et al.	
	1871	US-20060025662	02-02-2006	BUSE; John Bernard et al.	
	1872	US-20060025663	02-02-2006	TALBOT; Cary D. et al.	
	1873	US-20060029177	02-09-2006	CRANFORD, Jr.; Hayden Clavie et al.	
	1874	US-20060031094	02-09-2006	COHEN; Gary et al.	
	1875	US-20060036139	02-16-2006	BRISTER; Mark et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 77 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1876	US-20060036140	02-16-2006	BRISTER; Mark et al.	
	1877	US-20060036141	02-16-2006	KAMATH; Apurv Ullas et al.	
	1878	US-20060036142	02-16-2006	BRISTER; Mark et al.	
	1879	US-20060036143	02-16-2006	BRISTER; Mark et al.	
	1880	US-20060036144	02-16-2006	BRISTER; Mark et al.	
	1881	US-20060036145	02-16-2006	BRISTER; Mark et al.	
	1882	US-20060040402	02-23-2006	BRAUKER; James H. et al.	
	1883	US-20060042353	03-02-2006	MARQUIS; Brent et al.	
	1884	US-20060047192	03-02-2006	HELLWIG; Robert et al.	
	1885	US-20060052745	03-09-2006	VAN ANTWERP; Nannette M. et al.	
	1886	US-20060068208	03-30-2006	TAPSAK; Mark A. et al.	
	1887	US-20060079809	04-13-2006	GOLDBERGER; Daniel et al.	
	1888	US-20060086624	04-27-2006	TAPSAK; Mark A. et al.	
	1889	US-20060091006	05-04-2006	WANG; Yi et al.	
	1890	US-20060094946	05-04-2006	KELLOGG; Scott C. et al.	
	1891	US-20060100588	05-11-2006	BRUNNBERG; Lennart et al.	
	1892	US-20060142651	06-29-2006	BRISTER; Mark et al.	
	1893	US-20060155180	07-13-2006	BRISTER; Mark et al.	
	1894	US-20060166629	07-27-2006	REGGIARDO; Christopher V.	
	1895	US-20060167365	07-27-2006	BHARMI; Rupinder	
	1896	US-20060167517	07-27-2006	GILL; Jong et al.	
	1897	US-20060167518	07-27-2006	GILL; Jong et al.	
	1898	US-20060167519	07-27-2006	GILL; Jong et al.	
	1899	US-20060173260	08-03-2006	GAONI; Yuval et al.	
	1900	US-20060173406	08-03-2006	HAYES; Andrew C. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 78 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1901	US-20060173444	08-03-2006	CHOY; David Y. et al.	
	1902	US-20060178617	08-10-2006	ADAMS; H. Clark et al.	
	1903	US-20060183984	08-17-2006	DOBBLES; J. Michael et al.	
	1904	US-20060183985	08-17-2006	BRISTER; Mark et al.	
	1905	US-20060189851	08-24-2006	TIVIG; Gerhard et al.	
	1906	US-20060189856	08-24-2006	PETISCE; James et al.	
	1907	US-20060189863	08-24-2006	PEYSER; Thomas et al.	
	1908	US-20060189925	08-24-2006	GABLE; Jennifer H. et al.	
	1909	US-20060193375	08-31-2006	LEE; U. Sang	
	1910	US-20060195029	08-31-2006	SHULTS; Mark C. et al.	
	1911	US-20060198864	09-07-2006	SHULTS; Mark et al.	
	1912	US-20060200009	09-07-2006	WEKELL; William et al.	
	1913	US-20060200019	09-07-2006	PETISCE; James et al.	
	1914	US-20060200020	09-07-2006	BRISTER; Mark et al.	
	1915	US-20060200022	09-07-2006	BRAUKER; James H. et al.	
	1916	US-20060200970	09-14-2006	BRISTER; Mark et al.	
	1917	US-20060222566	10-05-2006	BRAUKER; James H. et al.	
	1918	US-20060224109	10-05-2006	STEIL; Garry M. et al.	
	1919	US-20060224141	10-05-2006	RUSH; Benjamin M. et al.	
	1920	US-20060226985	10-12-2006	GOODNOW; Timothy T. et al.	
	1921	US-20060229512	10-12-2006	PETISCE; James R. et al.	
	1922	US-20060229531	10-12-2006	GOLDBERGER; Daniel et al.	
	1923	US-20060229533	10-12-2006	HOENES; Joachim et al.	
	1924	US-20060247508	11-02-2006	FENNELL; Martin J.	
	1925	US-20060247685	11-02-2006	BHARMI; Rupinder	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 79 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1926	US-20060247985	11-02-2006	LIAMOS; Charles T. et al.	
	1927	US-20060253012	11-09-2006	PETISCE; James R. et al.	
	1928	US-20060253085	11-09-2006	GEISMAR; Eric P. et al.	
	1929	US-20060257996	11-16-2006	SIMPSON; Peter C. et al.	
	1930	US-20060258761	11-16-2006	BOOCK; Robert et al.	
	1931	US-20060258929	11-16-2006	GOODE, Jr.; Paul V. et al.	
	1932	US-20060263839	11-23-2006	WARD; W. Kenneth et al.	
	1933	US-20060264785	11-23-2006	DRING; Barton et al.	
	1934	US-20060270922	11-30-2006	BRAUKER; James H. et al.	
	1935	US-20060270923	11-30-2006	BRAUKER; James H. et al.	
	1936	US-20060272652	12-07-2006	STOCKER; David N. et al.	
	1937	US-20060281985	12-14-2006	WARD; W. Kenneth et al.	
	1938	US-20060293576	12-28-2006	VAN ANTWERP; Nanette M. et al.	
	1939	US-20070016381	01-18-2007	KAMATH; Apurv et al.	
	1940	US-20070017805	01-25-2007	HODGES; Alastair et al.	
	1941	US-20070020641	01-25-2007	HEEGER; Alan J. et al.	
	1942	US-20070027284	02-01-2007	WEI; Kuang-Hwa et al.	
	1943	US-20070027370	02-01-2007	BRAUKER; James H. et al.	
	1944	US-20070027381	02-01-2007	STAFFORD; Gary Ashley	
	1945	US-20070027384	02-01-2007	BRISTER; Mark et al.	
	1946	US-20070027385	02-01-2007	BRISTER; Mark et al.	
	1947	US-20070032706	02-08-2007	KAMATH; Apurv et al.	
	1948	US-20070032717	02-08-2007	BRISTER; Mark et al.	
	1949	US-20070032718	02-08-2007	SHULTS; Mark C. et al.	
	1950	US-20070033074	02-08-2007	NITZAN; Tamir et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 80 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1951	US-20070033254	02-08-2007	AlHUSSEINI; Ibrahim Ameen et al.	
	1952	US-20070045902	03-01-2007	BRAUKER; James H. et al.	
	1953	US-20070049873	03-01-2007	HANSEN; Torben Strom et al.	
	1954	US-20070056858	03-15-2007	CHEN; Ting et al.	
	1955	US-20070059196	03-15-2007	BRISTER; Mark et al.	
	1956	US-20070060803	03-15-2007	LILJERYD; Lars Gustaf et al.	
	1957	US-20070060814	03-15-2007	STAFFORD; Gary Ashley	
	1958	US-20070060871	03-15-2007	ISTOC; Emilian et al.	
	1959	US-20070066873	03-22-2007	KAMATH; Apurv et al.	
	1960	US-20070068807	03-29-2007	FELDMAN; Benjamin J. et al.	
	1961	US-20070071681	03-29-2007	GADKAR; Kapil et al.	
	1962	US-20070073129	03-29-2007	SHAH; Rajiv et al.	
	1963	US-20070078320	04-05-2007	STAFFORD; Gary Ashley	
	1964	US-20070078321	04-05-2007	MAZZA; John C. et al.	
	1965	US-20070078322	04-05-2007	STAFFORD; Gary Ashley	
	1966	US-20070078323	04-05-2007	REGGIARDO; Christopher V. et al.	
	1967	US-20070085995	04-19-2007	PESACH; Benny et al.	
	1968	US-20070093704	04-26-2007	BRISTER; Mark et al.	
	1969	US-20070095661	05-03-2007	WANG; Yi et al.	
	1970	US-20070106135	05-10-2007	SLOAN; Mark K. et al.	
	1971	US-20070108048	05-17-2007	WANG; Yi et al.	
	1972	US-20070112298	05-17-2007	MUELLER, Jr.; John C. et al.	
	1973	US-20070116600	05-24-2007	KOCHAR; Manish Swarnaraj et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 81 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1974	US-20070118030	05-24-2007	BRUCE; Robert et al.	
	1975	US-20070118405	05-24-2007	CAMPBELL; Robert et al.	
	1976	US-20070124002	05-31-2007	ESTES; Mark C. et al.	
	1977	US-20070129619	06-07-2007	WARD; W. Kenneth et al.	
	1978	US-20070129621	06-07-2007	KELLOGG; Scott C. et al.	
	1979	US-20070135699	06-14-2007	WARD; W. Kenneth et al.	
	1980	US-20070142584	06-21-2007	SCHORZMAN; Derek et al.	
	1981	US-20070149875	06-28-2007	OUYANG; Tianmei et al.	
	1982	US-20070151869	07-05-2007	HELLER; Adam et al.	
	1983	US-20070156033	07-05-2007	CAUSEY, III; James D. et al.	
	1984	US-20070163880	07-19-2007	WOO; Kum Ming et al.	
	1985	US-20070168224	07-19-2007	LETZT; Alan M. et al.	
	1986	US-20070169533	07-26-2007	SHAH; Rajiv et al.	
	1987	US-20070170073	07-26-2007	WANG; Lu et al.	
	1988	US-20070173706	07-26-2007	NEINAST; Mark et al.	
	1989	US-20070173709	07-26-2007	PETISCE; James R. et al.	
	1990	US-20070173710	07-26-2007	PETISCE; James R. et al.	
	1991	US-20070173711	07-26-2007	SHAH; Rajiv et al.	
	1992	US-20070173712	07-26-2007	SHAH; Rajiv et al.	
	1993	US-20070173741	07-26-2007	DESHMUKH; Ajay et al.	
	1994	US-20070173761	07-26-2007	KANDERIAN, Jr.; Sami S. et al.	
	1995	US-20070179349	08-02-2007	HOYME; Kenneth P. et al.	
	1996	US-20070179352	08-02-2007	RANDLOV; Jette et al.	
	1997	US-20070179434	08-02-2007	WEINERT; Stefan et al.	
	1998	US-20070179436	08-02-2007	BRAIG; James R. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 82 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1999	US-20070191701	08-16-2007	FELDMAN; Benjamin J. et al.	
	2000	US-20070191716	08-16-2007	GOLDBERGER; Daniel et al.	
	2001	US-20070197889	08-23-2007	BRISTER; Mark et al.	
	2002	US-20070197890	08-23-2007	BOOCK; Robert et al.	
	2003	US-20070199818	08-30-2007	PETYT; Adrian et al.	
	2004	US-20070200254	08-30-2007	CURRY; Kenneth M.	
	2005	US-20070202562	08-30-2007	CURRY; Kenneth M.	
	2006	US-20070202672	08-30-2007	CURRY; Kenneth M.	
	2007	US-20070203407	08-30-2007	HOSS; Udo et al.	
	2008	US-20070203410	08-30-2007	SAY; James et al.	
	2009	US-20070203966	08-30-2007	BRAUKER; James H. et al.	
	2010	US-20070206193	09-06-2007	PESACH; Benny	
	2011	US-20070208244	09-06-2007	BRAUKER; James H. et al.	
	2012	US-20070208245	09-06-2007	BRAUKER; James H. et al.	
	2013	US-20070208246	09-06-2007	BRAUKER; James H. et al.	
	2014	US-20070213610	09-13-2007	SAY; James et al.	
	2015	US-20070213611	09-13-2007	SIMPSON; Peter C. et al.	
	2016	US-20070213657	09-13-2007	JENNEWINE; R. Curtis et al.	
	2017	US-20070218097	09-20-2007	HELLER; Adam et al.	
	2018	US-20070219441	09-20-2007	CARLIN; Patrick et al.	
	2019	US-20070224700	09-27-2007	MASTERS; Brett P.	
	2020	US-20070225675	09-27-2007	ROBINSON; Mark Ries et al.	
	2021	US-20070227911	10-04-2007	WANG; Yi et al.	
	2022	US-20070232877	10-04-2007	HE; Lei	
	2023	US-20070232878	10-04-2007	KOVATCHEV; Boris P. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 83 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2024	US-20070232879	10-04-2007	BRISTER; Mark et al.	
	2025	US-20070232880	10-04-2007	SIDDIQUI; Uzair et al.	
	2026	US-20070233013	10-04-2007	SCHOENBERG; Stephen J.	
	2027	US-20070235331	10-11-2007	SIMPSON; Peter C. et al.	
	2028	US-20070240497	10-18-2007	ROBINSON; Mark Ries et al.	
	2029	US-20070244379	10-18-2007	BOOCK; Robert et al.	
	2030	US-20070244381	10-18-2007	ROBINSON; Mark Ries et al.	
	2031	US-20070244382	10-18-2007	ROBINSON; Mark Ries et al.	
	2032	US-20070249916	10-25-2007	PESACH; Benny et al.	
	2033	US-20070249922	10-25-2007	PEYSER; Thomas A. et al.	
	2034	US-20070255321	11-01-2007	GERBER; Martin T. et al.	
	2035	US-20070259217	11-08-2007	LOGAN; Bruce	
	2036	US-20070299389	12-27-2007	HALBERT; Donald et al.	
	2037	US-20070299617	12-27-2007	WILLIS; John P.	
	2038	US-20080000779	01-03-2008	WANG; Lu et al.	
	2039	US-20080004515	01-03-2008	JENNEWINE; R. Curtis	
	2040	US-20080004601	01-03-2008	JENNEWINE; R. Curtis et al.	
	2041	US-20080009692	01-10-2008	STAFFORD; Gary Ashley	
	2042	US-20080012701	01-17-2008	KASS; Alex M. et al.	
	2043	US-20080017522	01-24-2008	HELLER; Adam et al.	
	2044	US-20080021666	01-24-2008	GOODE, Jr.; Paul V. et al.	
	2045	US-20080021972	01-24-2008	HUELSKAMP; Paul J. et al.	
	2046	US-20080029390	02-07-2008	ROCHE; Joelle et al.	
	2047	US-20080029391	02-07-2008	MAO; Fei et al.	
	2048	US-20080033254	02-07-2008	KAMATH; Apurv Ullas et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 84 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2049	US-20080033357	02-07-2008	MANN; Alfred E. et al.	
	2050	US-20080039702	02-14-2008	HAYTER; Gary et al.	
	2051	US-20080045824	02-21-2008	TAPSAK; Mark A. et al.	
	2052	US-20080058625	03-06-2008	McGARRAUGH; Geoffrey V. et al.	
	2053	US-20080064937	03-13-2008	McGARRAUGH; Geoffrey V. et al.	
	2054	US-20080066305	03-20-2008	WANG; Yi et al.	
	2055	US-20080071156	03-20-2008	BRISTER; Mark et al.	
	2056	US-20080071157	03-20-2008	McGARRAUGH; Geoffrey V. et al.	
	2057	US-20080071158	03-20-2008	McGARRAUGH; Geoffrey V. et al.	
	2058	US-20080072663	03-27-2008	KEENAN; Richard et al.	
	2059	US-20080081000	04-03-2008	MACLEOD; John et al.	
	2060	US-20080081977	04-03-2008	HAYTER; Gary et al.	
	2061	US-20080083617	04-10-2008	SIMPSON; Peter C. et al.	
	2062	US-20080086040	04-10-2008	HELLER; Adam et al.	
	2063	US-20080086041	04-10-2008	HELLER; Adam et al.	
	2064	US-20080086042	04-10-2008	BRISTER; Mark et al.	
	2065	US-20080086043	04-10-2008	HELLER; Adam et al.	
	2066	US-20080086044	04-10-2008	BRISTER; Mark et al.	
	2067	US-20080086273	04-10-2008	SHULTS; Mark et al.	
	2068	US-20080091094	04-17-2008	HELLER; Adam et al.	
	2069	US-20080091095	04-17-2008	HELLER; Adam et al.	
	2070	US-20080097197	04-24-2008	KALAFUT; John F. et al.	
	2071	US-20080097289	04-24-2008	STEIL; Garry M. et al.	
	2072	US-20080097326	04-24-2008	MOBERG; Sheldon B. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 85 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2073	US-20080102441	05-01-2008	CHEN; Ting et al.	
	2074	US-20080103447	05-01-2008	REGGIARDO; Christopher V. et al.	
	2075	US-20080108942	05-08-2008	BRISTER; Mark et al.	
	2076	US-20080114227	05-15-2008	HAAR; Hans-Peter et al.	
	2077	US-20080115599	05-22-2008	MASTERS; Brett et al.	
	2078	US-20080119703	05-22-2008	BRISTER; Mark et al.	
	2079	US-20080119704	05-22-2008	BRISTER; Mark et al.	
	2080	US-20080119706	05-22-2008	BRISTER; Mark et al.	
	2081	US-20080119708	05-22-2008	BUDIMAN; Erwin S.	
	2082	US-20080125751	05-29-2008	FJIELD; Todd et al.	
	2083	US-20080139910	06-12-2008	MASTROTOTARO; John J. et al.	
	2084	US-20080147050	06-19-2008	MANN; Alfred E. et al.	
	2085	US-20080148873	06-26-2008	WANG; Yi	
	2086	US-20080154101	06-26-2008	JAIN; Faquir et al.	
	2087	US-20080154177	06-26-2008	MOUBAYED; Ahmad-Maher et al.	
	2088	US-20080154513	06-26-2008	KOVATCHEV; Boris P. et al.	
	2089	US-20080156661	07-03-2008	COOPER; Kenneth W. et al.	
	2090	US-20080161664	07-03-2008	MASTROTOTARO; John J. et al.	
	2091	US-20080161666	07-03-2008	FELDMAN; Benjamin J. et al.	
	2092	US-20080161753	07-03-2008	GILLESPIE; John et al.	
	2093	US-20080167543	07-10-2008	SAY; James et al.	
	2094	US-20080168676	07-17-2008	MORRISON; Justin E. et al.	
	2095	US-20080172205	07-17-2008	BRETON; Marc D. et al.	
	2096	US-20080177149	07-24-2008	WEINERT; Stefan et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 86 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2097	US-20080177165	07-24-2008	BLOMQUIST; Michael et al.	
	2098	US-20080183060	07-31-2008	STEIL; Garry M. et al.	
	2099	US-20080183061	07-31-2008	GOODE; Paul V. et al.	
	2100	US-20080183399	07-31-2008	GOODE; Paul V. et al.	
	2101	US-20080187655	08-07-2008	MARKLE; David R. et al.	
	2102	US-20080188722	08-07-2008	MARKLE; David R. et al.	
	2103	US-20080188725	08-07-2008	MARKLE; David R. et al.	
	2104	US-20080188731	08-07-2008	BRISTER; Mark et al.	
	2105	US-20080188796	08-07-2008	STEIL; Garry M. et al.	
	2106	US-20080189051	08-07-2008	GOODE; Paul V. et al.	
	2107	US-20080193936	08-14-2008	SQUIRRELL; David James	
	2108	US-20080194837	08-14-2008	KIM; Yong-Chul et al.	
	2109	US-20080194934	08-14-2008	RAY; Pinaki et al.	
	2110	US-20080194935	08-14-2008	BRISTER; Mark et al.	
	2111	US-20080194936	08-14-2008	GOODE; Paul V. et al.	
	2112	US-20080194937	08-14-2008	GOODE; Paul V. et al.	
	2113	US-20080194938	08-14-2008	BRISTER; Mark et al.	
	2114	US-20080195232	08-14-2008	CARR-BRENDEL; Victoria et al.	
	2115	US-20080195967	08-14-2008	GOODE; Paul V. et al.	
	2116	US-20080197024	08-21-2008	SIMPSON; Peter C. et al.	
	2117	US-20080200788	08-21-2008	BRISTER; Mark et al.	
	2118	US-20080200789	08-21-2008	BRISTER; Mark et al.	
	2119	US-20080200791	08-21-2008	SIMPSON; Peter C. et al.	
	2120	US-20080200897	08-21-2008	HOSS; Udo et al.	
	2121	US-20080201325	08-21-2008	DONIGER; Kenneth J. et al.	
	2122	US-20080205481	08-28-2008	FARIES; Durward I. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 87 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2123	US-20080208025	08-28-2008	SHULTS; Mark C. et al.	
	2124	US-20080208113	08-28-2008	DAMIANO; Edward et al.	
	2125	US-20080214910	09-04-2008	BUCK; Harvey B.	
	2126	US-20080214915	09-04-2008	BRISTER; Mark et al.	
	2127	US-20080214918	09-04-2008	BRISTER; Mark et al.	
	2128	US-20080228051	09-18-2008	SHULTS; Mark C. et al.	
	2129	US-20080228054	09-18-2008	SHULTS; Mark C. et al.	
	2130	US-20080234943	09-25-2008	RAY; Pinaki et al.	
	2131	US-20080242961	10-02-2008	BRISTER; Mark et al.	
	2132	US-20080242963	10-02-2008	ESSENPREIS; Matthias et al.	
	2133	US-20080249385	10-09-2008	PHAN; Luong Ngoc	
	2134	US-20080255434	10-16-2008	HAYTER; Gary et al.	
	2135	US-20080255437	10-16-2008	HAYTER; Gary	
	2136	US-20080255438	10-16-2008	SAIDARA; Frank et al.	
	2137	US-20080255808	10-16-2008	HAYTER; Gary	
	2138	US-20080256048	10-16-2008	HAYTER; Gary	
	2139	US-20080262469	10-23-2008	BRISTER; Mark C. et al.	
	2140	US-20080267823	10-30-2008	WANG; Yi et al.	
	2141	US-20080269714	10-30-2008	MASTROTOTARO; John J. et al.	
	2142	US-20080275313	11-06-2008	BRISTER; Mark et al.	
	2143	US-20080278332	11-13-2008	FENNELL; Martin J. et al.	
	2144	US-20080287761	11-20-2008	HAYTER; Gary et al.	
	2145	US-20080287762	11-20-2008	HAYTER; Gary et al.	
	2146	US-20080287763	11-20-2008	HAYTER; Gary	
	2147	US-20080287764	11-20-2008	RASDAL; Andrew et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 88 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2148	US-20080287765	11-20-2008	RASDAL; Andrew et al.	
	2149	US-20080287766	11-20-2008	RASDAL; Andrew et al.	
	2150	US-20080288180	11-20-2008	HAYTER; Gary et al.	
	2151	US-20080288204	11-20-2008	HAYTER; Gary et al.	
	2152	US-20080296155	12-04-2008	SHULTS; Mark C. et al.	
	2153	US-20080300572	12-04-2008	RANKERS; Ulrich et al.	
	2154	US-20080305009	12-11-2008	GAMSEY; Soya et al.	
	2155	US-20080305506	12-11-2008	SURI; Jeff T.	
	2156	US-20080306368	12-11-2008	GOODE, Jr.; Paul V. et al.	
	2157	US-20080306433	12-11-2008	CESARONI; Anthony J.	
	2158	US-20080306434	12-11-2008	DOBBLES; John Michael et al.	
	2159	US-20080306435	12-11-2008	KAMATH; Apurv U. et al.	
	2160	US-20080306444	12-11-2008	BRISTER; Mark C. et al.	
	2161	US-20080306472	12-11-2008	PRYOR; Brian et al.	
	2162	US-20080312841	12-18-2008	HAYTER; Gary	
	2163	US-20080312842	12-18-2008	HAYTER; Gary et al.	
	2164	US-20080312844	12-18-2008	HAYTER; Gary et al.	
	2165	US-20080312845	12-18-2008	HAYTER; Gary et al.	
	2166	US-20080314395	12-25-2008	KOVATCHEV; Boris P. et al.	
	2167	US-20080319279	12-25-2008	RAMSAY; Erin B. et al.	
	2168	US-20080319295	12-25-2008	BERNSTEIN; Daniel et al.	
	2169	US-20080319296	12-25-2008	BERNSTEIN; Daniel et al.	
	2170	US-20090005665	01-01-2009	HAYTER; Gary et al.	
	2171	US-20090005666	01-01-2009	SHIN; John J. et al.	
	2172	US-20090006034	01-01-2009	HAYTER; Gary et al.	
	2173	US-20090006061	01-01-2009	THUKRAL; Ajay et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 89 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2174	US-20090012376	01-08-2009	AGUS; Michael	
	2175	US-20090012379	01-08-2009	GOODE, Jr.; Paul V. et al.	
	2176	US-20090018418	01-15-2009	MARKLE; David R. et al.	
	2177	US-20090018424	01-15-2009	KAMATH; Apurv Ullas et al.	
	2178	US-20090018425	01-15-2009	OUYANG; Tianmei et al.	
	2179	US-20090018426	01-15-2009	MARKLE; David R. et al.	
	2180	US-20090030293	01-29-2009	COOPER; Jonathan Mark et al.	
	2181	US-20090030294	01-29-2009	PETISCE; James R. et al.	
	2182	US-20090033482	02-05-2009	HAYTER; Gary et al.	
	2183	US-20090036747	02-05-2009	HAYTER; Gary et al.	
	2184	US-20090036758	02-05-2009	BRAUKER; James H. et al.	
	2185	US-20090036760	02-05-2009	HAYTER; Gary	
	2186	US-20090036763	02-05-2009	BRAUKER; James H. et al.	
	2187	US-20090043181	02-12-2009	BRAUKER; James H. et al.	
	2188	US-20090043182	02-12-2009	BRAUKER; James H. et al.	
	2189	US-20090043525	02-12-2009	BRAUKER; James H. et al.	
	2190	US-20090043541	02-12-2009	BRAUKER; James H. et al.	
	2191	US-20090043542	02-12-2009	BRAUKER; James H. et al.	
	2192	US-20090045055	02-19-2009	RHODES; Rathbun K. et al.	
	2193	US-20090048503	02-19-2009	DALAL; Yousufali H. et al.	
	2194	US-20090054745	02-26-2009	JENNEWINE; R. Curtis	
	2195	US-20090054748	02-26-2009	FELDMAN; Benjamin J.	
	2196	US-20090054749	02-26-2009	HE; Lei	
	2197	US-20090054753	02-26-2009	ROBINSON; Mark Ries et al.	
	2198	US-20090055149	02-26-2009	HAYTER; Gary et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 90 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2199	US-20090061528	03-05-2009	SURI; Jeff T.	
	2200	US-20090062633	03-05-2009	BRAUKER; James H. et al.	
	2201	US-20090062635	03-05-2009	BRAUKER; James H. et al.	
	2202	US-20090062645	03-05-2009	FEHRE; Jens et al.	
	2203	US-20090062767	03-05-2009	VAN ANTWERP; Nannette M. et al.	
	2204	US-20090063402	03-05-2009	HAYTER; Gary	
	2205	US-20090069649	03-12-2009	BUDIMAN; Erwin S.	
	2206	US-20090076356	03-19-2009	SIMPSON; Peter C. et al.	
	2207	US-20090076360	03-19-2009	BRISTER; Mark et al.	
	2208	US-20090076361	03-19-2009	KAMATH; Apurv Ullas et al.	
	2209	US-20090081803	03-26-2009	GAMSEY; Soya et al.	
	2210	US-20090082693	03-26-2009	STAFFORD; Gary Ashley	
	2211	US-20090085768	04-02-2009	PATEL; Himanshu et al.	
	2212	US-20090099434	04-16-2009	LIU; Zenghe et al.	
	2213	US-20090099436	04-16-2009	BRISTER; Mark et al.	
	2214	US-20090105570	04-23-2009	SLOAN; Mark K. et al.	
	2215	US-20090105636	04-23-2009	HAYTER; Gary et al.	
	2216	US-20090112478	04-30-2009	MUELLER, Jr.; John C. et al.	
	2217	US-20090112626	04-30-2009	TALBOT; Cary et al.	
	2218	US-20090118589	05-07-2009	UESHIMA; Hiromu et al.	
	2219	US-20090124877	05-14-2009	GOODE, Jr.; Paul V. et al.	
	2220	US-20090124878	05-14-2009	GOODE, Jr.; Paul V. et al.	
	2221	US-20090124879	05-14-2009	BRISTER; Mark et al.	
	2222	US-20090124964	05-14-2009	LEACH; Jacob S. et al.	
	2223	US-20090131768	05-21-2009	SIMPSON; Peter C. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 91 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2224	US-20090131769	05-21-2009	LEACH; Jacob S. et al.	
	2225	US-20090131776	05-21-2009	SIMPSON; Peter C. et al.	
	2226	US-20090131777	05-21-2009	SIMPSON; Peter C. et al.	
	2227	US-20090137886	05-28-2009	SHARIATI; Mohammad Ali et al.	
	2228	US-20090137887	05-28-2009	SHARIATI; Mohammad Ali et al.	
	2229	US-20090143659	06-04-2009	LI; Ying et al.	
	2230	US-20090143660	06-04-2009	BRISTER; Mark et al.	
	2231	US-20090143725	06-04-2009	PEYSER; Thomas A. et al.	
	2232	US-20090149728	06-11-2009	VAN ANTWERP; Nannette M. et al.	
	2233	US-20090156919	06-18-2009	BRISTER; Mark et al.	
	2234	US-20090156922	06-18-2009	GOLDBERGER; Daniel et al.	
	2235	US-20090156924	06-18-2009	SHARIATI; Mohammad Ali et al.	
	2236	US-20090163790	06-25-2009	BRISTER; Mark et al.	
	2237	US-20090163791	06-25-2009	BRISTER; Mark et al.	
	2238	US-20090163855	06-25-2009	SHIN; John et al.	
	2239	US-20090164190	06-25-2009	HAYTER; Gary	
	2240	US-20090164239	06-25-2009	HAYTER; Gary et al.	
	2241	US-20090164251	06-25-2009	HAYTER; Gary	
	2242	US-20090171178	07-02-2009	HE; Lei et al.	
	2243	US-20090177143	07-09-2009	MARKLE; William H. et al.	
	2244	US-20090178459	07-16-2009	LI; Ying et al.	
	2245	US-20090182217	07-16-2009	LI; Ying et al.	
	2246	US-20090182517	07-16-2009	GANDHI; Rajesh K. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 92 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2247	US-20090192366	07-30-2009	MENSINGER; Michael Robert et al.	
	2248	US-20090192380	07-30-2009	SHARIATI; Mohammad Ali et al.	
	2249	US-20090192722	07-30-2009	SHARIATI; Mohammad Ali et al.	
	2250	US-20090192724	07-30-2009	BRAUKER; James H. et al.	
	2251	US-20090192745	07-30-2009	KAMATH; Apurv Ullas et al.	
	2252	US-20090192751	07-30-2009	KAMATH; Apurv Ullas et al.	
	2253	US-20090198118	08-06-2009	HAYTER; Gary et al.	
	2254	US-20090203981	08-13-2009	BRAUKER; James H. et al.	
	2255	US-20090204340	08-13-2009	FELDMAN; Benjamin J. et al.	
	2256	US-20090204341	08-13-2009	BRAUKER; James H. et al.	
	2257	US-20090216103	08-27-2009	BRISTER; Mark et al.	
	2258	US-20090240120	09-24-2009	MENSINGER; Michael Robert et al.	
	2259	US-20090240128	09-24-2009	MENSINGER; Michael Robert et al.	
	2260	US-20090240193	09-24-2009	MENSINGER; Michael Robert et al.	
	2261	US-20090241028	09-24-2009	ISKEDJIAN; Michael	
	2262	US-20090242399	10-01-2009	KAMATH; Apurv Ullas et al.	
	2263	US-20090242425	10-01-2009	KAMATH; Apurv Ullas et al.	
	2264	US-20090247855	10-01-2009	BOOCK; Robert et al.	
	2265	US-20090247856	10-01-2009	BOOCK; Robert et al.	
	2266	US-20090247857	10-01-2009	HARPER; Wesley Scott et al.	
	2267	US-20090257911	10-15-2009	THOMAS; Christopher Allen et al.	
	2268	US-20090264719	10-22-2009	MARKLE; David R. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 93 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2269	US-20090281407	11-12-2009	BUDIMAN; Erwin S.	
	2270	US-20090287073	11-19-2009	BOOCK; Robert et al.	
	2271	US-20090287074	11-19-2009	SHULTS; Mark et al.	
	2272	US-20090294277	12-03-2009	THOMAS; Christopher Allen et al.	
	2273	US-20090299155	12-03-2009	YANG; Richard C. et al.	
	2274	US-20090299156	12-03-2009	SIMPSON; Peter C. et al.	
	2275	US-20090299162	12-03-2009	BRAUKER; James H. et al.	
	2276	US-20090299276	12-03-2009	BRAUKER; James H. et al.	
	2277	US-20100010324	01-14-2010	BRAUKER; James H. et al.	
	2278	US-20100010331	01-14-2010	BRAUKER; James H. et al.	
	2279	US-20100010332	01-14-2010	BRAUKER; James H. et al.	
	2280	US-20100016687	01-21-2010	BRAUKER; James H. et al.	
	2281	US-20100020309	01-28-2010	GOLDBERGER; Daniel et al.	
	2282	US-20100022855	01-28-2010	BRAUKER; James H. et al.	
	2283	US-20100023270	01-28-2010	HELLER; Adam et al.	
	2284	US-20100023291	01-28-2010	HAYTER; Gary et al.	
	2285	US-20100025238	02-04-2010	GOTTLIEB; Rebecca K. et al.	
	2286	US-20100030053	02-04-2010	GOODE, Jr.; Paul V. et al.	
	2287	US-20100030137	02-04-2010	HALL; W. Dale et al.	
	2288	US-20100030484	02-04-2010	BRAUKER; James H. et al.	
	2289	US-20100036215	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2290	US-20100036216	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2291	US-20100036222	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2292	US-20100036223	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2293	US-20100036224	02-11-2010	GOODE, Jr.; Paul V. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 94 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2294	US-20100036225	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2295	US-20100045231	02-25-2010	HE; Lei	
	2296	US-20100045465	02-25-2010	BRAUKER; James H. et al.	
	2297	US-20100049015	02-25-2010	MARTINI; Joerg et al.	
	2298	US-20100049021	02-25-2010	JINA; Arvind N. et al.	
	2299	US-20100057040	03-04-2010	HAYTER; Gary	
	2300	US-20100057041	03-04-2010	HAYTER; Gary	
	2301	US-20100057042	03-04-2010	HAYTER; Gary	
	2302	US-20100057044	03-04-2010	HAYTER; Gary	
	2303	US-20100057057	03-04-2010	HAYTER; Gary et al.	
	2304	US-20100063372	03-11-2010	POTTS; Russell O. et al.	
	2305	US-20100064764	03-18-2010	HAYTER; Gary et al.	
	2306	US-20100081906	04-01-2010	HAYTER; Gary et al.	
	2307	US-20100081908	04-01-2010	DOBBLES; J. Michael et al.	
	2308	US-20100081909	04-01-2010	BUDIMAN; Erwin Satrya et al.	
	2309	US-20100081910	04-01-2010	BRISTER; Mark et al.	
	2310	US-20100081953	04-01-2010	SYEDA-MAHMOOD; Tanveer F. et al.	
	2311	US-20100094111	04-15-2010	HELLER; Adam et al.	
	2312	US-20100121167	05-13-2010	McGARRAUGH; Geoffrey V.	
	2313	US-20100141656	06-10-2010	KRIEFTEWIRTH; Michael	
	2314	US-20100145174	06-10-2010	ALFERNESS; Clifton A. et al.	
	2315	US-20100152561	06-17-2010	GOODNOW; Timothy T. et al.	
	2316	US-20100160759	06-24-2010	CELENTANO; Michael J. et al.	
	2317	US-20100160761	06-24-2010	SAY; James et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 95 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2318	US-20100168538	07-01-2010	KEENAN; Desmond Barry et al.	
	2319	US-20100168546	07-01-2010	KAMATH; Apurv Ullas et al.	
	2320	US-20100169035	07-01-2010	LIANG; Bradley Chi et al.	
	2321	US-20100174167	07-08-2010	KAMATH; Apurv Ullas et al.	
	2322	US-20100174168	07-08-2010	GOODE, Jr.; Paul V. et al.	
	2323	US-20100174266	07-08-2010	ESTES; Mark C.	
	2324	US-20100179399	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2325	US-20100179402	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2326	US-20100179405	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2327	US-20100179406	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2328	US-20100179407	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2329	US-20100179408	07-15-2010	KAMATH; Apurv et al.	
	2330	US-20100179409	07-15-2010	KAMATH; Apurv Ullas et al.	
	2331	US-20100185065	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2332	US-20100185070	07-22-2010	BRISTER; Mark et al.	
	2333	US-20100185071	07-22-2010	SIMPSON; Peter C. et al.	
	2334	US-20100185072	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2335	US-20100185073	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2336	US-20100185074	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2337	US-20100191085	07-29-2010	BUDIMAN; Erwin Satrya	
	2338	US-20100191472	07-29-2010	DONIGER; Kenneth J. et al.	
	2339	US-20100198034	08-05-2010	THOMAS; Christopher Allen et al.	
	2340	US-20100198035	08-05-2010	KAMATH; Apurv Ullas et al.	
	2341	US-20100198142	08-05-2010	SLOAN; Mark K. et al.	
	2342	US-20100204557	08-12-2010	KIAIE; Namvar et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 96 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2343	US-20100213057	08-26-2010	FELDMAN; Benjamin et al.	
	2344	US-20100214104	08-26-2010	GOODE, Jr.; Paul V. et al.	
	2345	US-20100217106	08-26-2010	GOODE, Jr.; Paul V. et al.	
	2346	US-20100230285	09-16-2010	HOSS; Udo et al.	
	2347	US-20100234707	09-16-2010	GOODE, Jr.; Paul V. et al.	
	2348	US-20100234710	09-16-2010	BUDIMAN; Erwin Satrya et al.	
	2349	US-20100234796	09-16-2010	KAMATH; Apurv U. et al.	
	2350	US-20100235106	09-16-2010	KAMATH; Apurv U. et al.	
	2351	US-20100240975	09-23-2010	GOODE, Jr.; Paul V. et al.	
	2352	US-20100240976	09-23-2010	GOODE, Jr.; Paul V. et al.	
	2353	US-20100261987	10-14-2010	KAMATH; Apurv Ullas et al.	
	2354	US-20100265073	10-21-2010	HARPER; Wesley Scott	
	2355	US-20100274107	10-28-2010	BOOCK; Robert et al.	
	2356	US-20100274515	10-28-2010	HOSS; Udo et al.	
	2357	US-20100277342	11-04-2010	SICURELLO; Jeffrey Mario et al.	
	2358	US-20100280441	11-04-2010	WILINSKA; Malgorzata E. et al.	
	2359	US-20100280782	11-04-2010	HARPER; Wesley Scott	
	2360	US-20100286496	11-11-2010	SIMPSON; Peter C. et al.	
	2361	US-20100298684	11-25-2010	LEACH; Jacob S. et al.	
	2362	US-20100313105	12-09-2010	NEKOOMARAM; Saeed et al.	
	2363	US-20100317952	12-16-2010	BUDIMAN; Erwin S. et al.	
	2364	US-20100324392	12-23-2010	YEE; Phillip et al.	
	2365	US-20100326842	12-30-2010	MAZZA; John C. et al.	
	2366	US-20100331644	12-30-2010	NEALE; Paul V. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 97 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2367	US-20100331648	12-30-2010	KAMATH; Apurv Ullas et al.	
	2368	US-20100331655	12-30-2010	KAMATH; Apurv Ullas et al.	
	2369	US-20110021889	01-27-2011	HOSS; Udo et al.	
	2370	US-20110024043	02-03-2011	BOOCK; Robert et al.	
	2371	US-20110024307	02-03-2011	SIMPSON; Peter C. et al.	
	2372	US-20110027127	02-03-2011	SIMPSON; Peter C. et al.	
	2373	US-20110027453	02-03-2011	BOOCK; Robert et al.	
	2374	US-20110027458	02-03-2011	BOOCK; Robert et al.	
	2375	US-20110028815	02-03-2011	SIMPSON; Peter C. et al.	
	2376	US-20110028816	02-03-2011	SIMPSON; Peter C. et al.	
	2377	US-20110029247	02-03-2011	KALATHIL; Raghunath Mammulli	
	2378	US-20110029269	02-03-2011	HAYTER; Gary Alan et al.	
	2379	US-20110040163	02-17-2011	TELSON; Stanley A. et al.	
	2380	US-20110046467	02-24-2011	SIMPSON; Peter C. et al.	
	2381	US-20110060530	03-10-2011	FENNELL; Martin J.	
	2382	US-20110077490	03-31-2011	SIMPSON; Peter C. et al.	
	2383	US-20110077491	03-31-2011	SAY; James et al.	
	2384	US-20110077494	03-31-2011	DONIGER; Kenneth J. et al.	
	2385	US-20110081726	04-07-2011	BERMAN; Glenn Howard	
	2386	US-20110082484	04-07-2011	SARAVIA; Heber et al.	
	2387	US-20110105873	05-05-2011	FELDMAN; Benjamin Jay et al.	
	2388	US-20110106126	05-05-2011	LOVE; Michael et al.	
	2389	US-20110112696	05-12-2011	YODFAT; Ofer et al.	
	2390	US-20110118579	05-19-2011	GOODE, Jr.; Paul V. et al.	
	2391	US-20110124997	05-26-2011	GOODE, Jr.; Paul V. et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 98 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2392	US-20110125410	05-26-2011	GOODE, Jr.; Paul V. et al.	
	2393	US-20110130970	06-02-2011	GOODE, Jr.; Paul V. et al.	
	2394	US-20110137601	06-09-2011	GOODE, Jr.; Paul V. et al.	
	2395	US-20110148905	06-23-2011	SIMMONS; David A. et al.	
	2396	US-20110174638	07-21-2011	KATSUKI; Koji	
	2397	US-20110184268	07-28-2011	TAUB; Marc Barry	
	2398	US-20110190603	08-04-2011	STAFFORD; Gary A.	
	2399	US-20110191044	08-04-2011	STAFFORD; Gary A.	
	2400	US-20110193704	08-11-2011	HARPER; Wesley Scott et al.	
	2401	US-20110208027	08-25-2011	WAGNER; Robin et al.	
	2402	US-20110208155	08-25-2011	PALERM; Cesar C. et al.	
	2403	US-20110213225	09-01-2011	BERNSTEIN; Daniel Milfred et al.	
	2404	US-20110218414	09-08-2011	KAMATH; Apurv et al.	
	2405	US-20110224523	09-15-2011	BUDIMAN; Erwin Satrya	
	2406	US-20110230741	09-22-2011	LIANG; Bradley Chi et al.	
	2407	US-20110257495	10-20-2011	HOSS; Udo et al.	
	2408	US-20110257895	10-20-2011	BRAUKER; James H. et al.	
	2409	US-20110263958	10-27-2011	BRAUKER; James H. et al.	
	2410	US-20110270062	11-03-2011	GOODE, Jr.; Paul V. et al.	
	2411	US-20110288574	11-24-2011	CURRY; Samuel Mason et al.	
	2412	US-20110313317	12-22-2011	CALLICOAT; David N. et al.	
	2413	US-20110319729	12-29-2011	DONNAY; Manuel Luis et al.	
	2414	US-20110319734	12-29-2011	GOTTLIEB; Rebecca K. et al.	
	2415	US-20110319739	12-29-2011	KAMATH; Apurv Ullas et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 99 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2416	US-20110320130	12-29-2011	VALDES; Jorge et al.	
	2417	US-20110320167	12-29-2011	BUDIMAN; Erwin Satrya	
	2418	US-20120010642	01-12-2012	LEE; Daniel H. et al.	
	2419	US-20120078071	03-29-2012	BOHM; Sebastian et al.	
	2420	US-20120097554	04-26-2012	SHAH; Rajiv et al.	
	2421	US-20120108931	05-03-2012	TAUB; Marc Barry et al.	
	2422	US-20120108934	05-03-2012	VALDES; Jorge et al.	
	2423	US-20120123692	05-17-2012	HAYTER; Gary	
	2424	US-20120165626	06-28-2012	IRINA; Finkelshtein V. et al.	
	2425	US-20120165640	06-28-2012	GALLEY; Paul J. et al.	
	2426	US-20120173200	07-05-2012	BRETON; Marc D. et al.	
	2427	US-20120209099	08-16-2012	LJUHS; Michael Kjell et al.	
	2428	US-20120215462	08-23-2012	GOODE, Jr.; Paul V. et al.	
	2429	US-20120239304	09-20-2012	HAYTER; Gary et al.	
	2430	US-20120245447	09-27-2012	KARAN; Jai et al.	
	2431	US-20120265035	10-18-2012	BOHM; Sebastian et al.	
	2432	US-20120265036	10-18-2012	ESTES; Michael J. et al.	
	2433	US-20120277564	11-01-2012	BUDIMAN; Erwin Satrya et al.	
	2434	US-20120277565	11-01-2012	BUDIMAN; Erwin S.	
	2435	US-20120283542	11-08-2012	McGARRAUGH; Geoffrey V.	
	2436	US-20120283960	11-08-2012	BUDIMAN; Erwin Satrya	
	2437	US-20120291516	11-22-2012	HAYTER; Gary et al.	
	2438	US-20120330561	12-27-2012	HAYTER; Gary et al.	
	2439	US-20130006112	01-03-2013	VARDY; Terence	
	2440	US-20130035575	02-07-2013	MAYOU; Phil et al.	
	2441	US-20130060105	03-07-2013	SHAH; Rajiv et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 100 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2442	US-20130060112	03-07-2013	PRYOR; Jack et al.	
	2443	US-20130116527	05-09-2013	HARPER; Wesley Scott et al.	
	2444	US-20130137953	05-30-2013	HARPER; Wesley Scott et al.	
	2445	US-20130150690	06-13-2013	CURRY; Kenneth M.	
	2446	US-20130178727	07-11-2013	HAYTER; Gary Alan et al.	
	2447	US-20130184547	07-18-2013	TAUB; Marc Barry et al.	
	2448	US-20130199944	08-08-2013	PETISEE; James R.	
	2449	US-20130231541	09-05-2013	HAYTER; Gary Alan et al.	
	2450	US-20130245412	09-19-2013	RONG; Daiting et al.	
	2451	US-20130253846	09-26-2013	HAYTER; Gary Alan et al.	
	2452	US-20130281807	10-24-2013	HAYTER; Gary Alan et al.	
	2453	US-20130282322	10-24-2013	HAYTER; Gary Alan et al.	
	2454	US-20130282403	10-24-2013	HAYTER; Gary Alan et al.	
	2455	US-20130324823	12-05-2013	KOSKI; Salla et al.	
	2456	US-20130338454	12-19-2013	HAYTER; Gary Alan et al.	
	2457	US-20140005499	01-02-2014	CATT; Michael et al.	
	2458	US-20140005968	01-02-2014	BUDIMAN; Erwin Satrya	
	2459	US-20140018642	01-16-2014	HAYTER; Gary Alan	
	2460	US-20140041441	02-13-2014	HAYTER; Gary Alan et al.	
	2461	US-20140046155	02-13-2014	HAYTER; Gary Alan et al.	
	2462	US-20140046156	02-13-2014	HAYTER; Gary Alan et al.	
	2463	US-20140046157	02-13-2014	HAYTER; Gary Alan et al.	
	2464	US-20140046160	02-13-2014	TERASHIMA; Noriyoshi et al.	
	2465	US-20140046161	02-13-2014	HAYTER; Gary Alan et al.	
	2466	US-20140066736	03-06-2014	BUDIMAN; Erwin Satrya	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 101 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2467	US-20140088390	03-27-2014	HE; Lei	
	2468	US-20140088392	03-27-2014	BERNSTEIN; Daniel M. et al.	
	2469	US-20140088908	03-27-2014	HAYTER; Gary Alan et al.	
	2470	US-20140100796	04-10-2014	HAYTER; Gary Alan et al.	
	2471	US-20140114156	04-24-2014	BOHM; Sebastian et al.	
	2472	US-20140121480	05-01-2014	BUDIMAN; Erwin Satrya et al.	
	2473	US-20140121488	05-01-2014	BUDIMAN; Erwin Satrya	
	2474	US-20140207400	07-24-2014	HAYTER; Gary Alan et al.	
	2475	US-20140213869	07-31-2014	BRISTER; Mark et al.	
	2476	US-20140221966	08-07-2014	BUCKINGHAM; Bruce A. et al.	
	2477	US-20140236536	08-21-2014	HAYTER; Gary Alan et al.	
	2478	US-20140243638	08-28-2014	HARPER; Wesley Scott et al.	
	2479	US-20140257059	09-11-2014	BUDIMAN; Erwin Satrya et al.	
	2480	US-20150005601	01-01-2015	HOSS; Udo et al.	
	2481	US-20150006109	01-01-2015	FENNELL; Martin J. et al.	
	2482	US-20150094555	04-02-2015	HE; Lei	
	2483	US-20150216456	08-06-2015	BUDIMAN; Erwin Satrya	
	2484	US-20150241407	08-27-2015	OU; Junli et al.	
	2485	US-20150282742	10-08-2015	HAYTER; Gary Alan et al.	
	2486	US-20150366510	12-24-2015	BUDIMAN; Erwin S.	
	2487	US-20150374299	12-31-2015	HAYTER; Gary Alan	
	2488	US-20160022221	01-28-2016	OU; Junli et al.	
	2489	US-20160073941	03-17-2016	BOHM; Sebastian et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 102 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2490	US-20160151006	06-02-2016	HARPER; Wesley Scott et al.	
	2491	US-20160157758	06-09-2016	BOHM; Sebastian et al.	
	2492	US-20160198986	07-14-2016	BOHM; Sebastian et al.	
	2493	US-20160206233	07-21-2016	HAYTER; Gary Alan et al.	
	2494	US-20160220189	08-04-2016	HAYTER; Gary Alan et al.	
	2495	US-20160238589	08-18-2016	HARPER; Wesley Scott et al.	
	2496	US-20160245791	08-25-2016	HAYTER; Gary Alan et al.	
	2497	US-20160270705	09-22-2016	HE; Lei	
	2498	US-20160296697	10-13-2016	HAYTER; Gary et al.	
	2499	US-20160317069	11-03-2016	HAYTER; Gary Alan et al.	
	2500	US-20170003766	01-05-2017	BUDIMAN; Erwin S.	
	2501	US-20170027484	02-02-2017	HAYTER; Gary Alan et al.	
	2502	US-20170042456	02-16-2017	BUDIMAN; Erwin Satrya	
	2503	US-20170049369	02-23-2017	HAYTER; Gary Alan et al.	
	2504	US-20170124287	05-04-2017	HAYTER; Gary Alan et al.	
	2505	US-20170188909	07-06-2017	HAYTER; Gary Alan et al.	
	2506	US-20170224258	08-10-2017	HAYTER; Gary Alan et al.	
	2507	US-20170258379	09-14-2017	BUDIMAN; Erwin Satrya et al.	
	2508	US-20170265790	09-21-2017	BUDIMAN; Erwin Satrya et al.	
	2509	US-20170340250	11-30-2017	HAYTER; Gary Alan et al.	
	2510	US-20170347927	12-07-2017	HE; Lei	
	2511	US-20180000389	01-04-2018	HARPER; Wesley Scott et al.	
	2512	US-20180008174	01-11-2018	BOHM; Sebastian et al.	
	2513	US-20180008201	01-11-2018	HAYTER; Gary Alan et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 103 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2514	US-20180038844	02-08-2018	HAYTER; Gary Alan et al.	
	2515	US-20180042530	02-15-2018	BOHM; Sebastian et al.	
	2516	US-20180042531	02-15-2018	BUDIMAN; Erwin Satrya et al.	
	2517	US-20180042534	02-15-2018	HAYTER; Gary Alan	
	2518	US-20180045707	02-15-2018	HAYTER; Gary Alan et al.	
	2519	US-20180059093	03-01-2018	HAYTER; Gary Alan et al.	
	2520	US-20180064398	03-08-2018	BUDIMAN; Erwin Satrya	
	2521	US-20180085037	03-29-2018	HAYTER; Gary Alan et al.	
	2522	US-20180098721	04-12-2018	HAYTER; Gary Alan et al.	
	2523	US-20180271415	09-27-2018	BOHM; Sebastian et al.	
	2524	US-20180325437	11-15-2018	LI; Ying et al.	
	2525	US-20180328766	11-15-2018	HAYTER; Gary Alan et al.	
	2526	US-20180344220	12-06-2018	HAYTER; Gary Alan et al.	
	2527	US-20180364215	12-20-2018	HARPER; Wesley Scott et al.	
	2528	US-20190035488	01-31-2019	BUDIMAN; Erwin Satrya	
	2529	US-20190072538	03-07-2019	HAYTER; Gary Alan et al.	
	2530	US-20190083012	03-21-2019	HAYTER; Gary Alan et al.	
	2531	US-20190083015	03-21-2019	HAYTER; Gary Alan	
	2532	US-20190150802	05-23-2019	BUDIMAN; Erwin Satrya et al.	
	2533	US-20190151542	05-23-2019	HAYTER; Gary et al.	
	2534	US-20190159734	05-30-2019	BUDIMAN; Erwin Satrya	
	2535	US-20190187814	06-20-2019	BUDIMAN; Erwin S.	
	2536	US-20190192071	06-27-2019	TAUB; Marc Barry et al.	
	2537	US-20190254575	08-22-2019	HAYTER; Gary Alan et al.	
	2538	US-20190261902	08-29-2019	BOHM; Sebastian et al.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 104 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2539	US-20190282143	09-19-2019	KAMATH; Apurv Ullas et al.	
	2540	US-20190320948	10-24-2019	BOHM; Sebastian et al.	
	2541	US-20190320949	10-24-2019	BOHM; Sebastian et al.	
	2542	US-20190336051	11-07-2019	BOHM; Sebastian et al.	
	2543	US-20190350499	11-21-2019	BOHM; Sebastian et al.	
	2544	US-20190357817	11-28-2019	BOHM; Sebastian et al.	
	2545	US-20190357827	11-28-2019	LI; Ying et al.	
	2546	US-20190380627	12-19-2019	BOHM; Sebastian et al.	
	2547	US-20200022626	01-23-2020	BOHM; Sebastian et al.	
	2548	US-20200037934	02-06-2020	BOHM; Sebastian et al.	
	2549	US-20200037935	02-06-2020	BOHM; Sebastian et al.	
	2550	US-20200037936	02-06-2020	BOHM; Sebastian et al.	
	2551	US-20200037936	02-06-2020	BOHM; Sebastian et al.	
	2552	US-20200046272	02-13-2020	BRISTER; Mark et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	001	CA-2127172-C	07-14-1998	BAYER AG [US]		☐
	002	DE-2658734-A1	06-29-1978	DRAEGERWERK AG.		☒
	003	EP-0098592-A2	01-18-1984	FUJISAWA PHARMACEUTICAL CO [JP]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 105 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	004	EP-0107634-A2	05-02-1984	HELLGREN LARS GUSTAV INGE. et al.		☐
	005	EP-0127958-A2	12-12-1984	GENETICS INT INC [US]		☐
	006	EP-0284518-A2	09-28-1988	KARUBE ISAO [JP], et al.		☐
	007	EP-0286118-A2	10-12-1988	NOVA BIOMEDICAL CORP [US]		☐
	008	EP-0286118-B1	01-25-1995	NOVA BIOMEDICAL CORP [US]		☐
	009	EP-0288793-A2	11-02-1988	ABBOTT LAB [US]		☐
	010	EP-0320109-A1	06-14-1989	MEDISENSE INC [US]		☐
	011	EP-0323605-B1	01-26-1994	ABBOTT LAB [US]		☐
	012	EP-0352610-A2	01-31-1990	ABBOTT LAB [US]		☐
	013	EP-0352631-A2	01-31-1990	ABBOTT LAB [US]		☐
	014	EP-0353328-A1	02-07-1990	PPG HELLIGE BV [NL]		☐
	015	EP-0390390-A1	10-03-1990	ASS UNIVERSITIES INC [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 106 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	016	EP-0396788-A1	11-14-1990	DRAEGER NEDERLAND B V [NL]		☐
	017	EP-0406473-A1	01-09-1991	ABBOTT LAB [US]		☐
	018	EP-0424633-B1	01-17-1996	ABBOTT LAB [US]		☐
	019	EP-0440044-A1	08-07-1991	ABBOTT LAB [US]		☐
	020	EP-0441252-A2	08-14-1991	ABBOTT LAB [US]		☐
	021	EP-0441394-A2	08-14-1991	MINNESOTA MINING & MFG [US]		☐
	022	EP-0467078-A2	01-22-1992	ABBOTT LAB [US]		☐
	023	EP-0472411-A1	02-26-1992	TELECTRONICS NV [NL]		☐
	024	EP-0476980-A2	03-25-1992	FUJITSU LTD [JP]		☐
	025	EP-0534074-A1	03-31-1993	INST DIABETESTECHNOLOGIE GEMEI [DE]		☒
	026	EP-0563795-A1	10-06-1993	DAINIPPON PRINTING CO LTD [JP], et al.		☐
	027	EP-0647849-A2	04-12-1995	IGEN INC [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 107 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	028	EP-0690134-A1	01-03-1996	CIBA CORNING DIAGNOSTICS CORP [US]		☐
	029	EP-0776628-A2	06-04-1997	YOSHIDA AKITOSHI [JP]		☐
	030	EP-0817809-A1	01-14-1998	MINIMED INC [US]		☐
	031	EP-0838230-A2	04-29-1998	TERUMO CORP [JP]		☐
	032	EP-0867146-A1	09-30-1998	PACESETTER AB [SE]		☐
	033	EP-0880936-A2	12-02-1998	AKAI KOJI [JP]		☐
	034	EP-0885932-A2	12-23-1998	OSI SPECIALTIES INC [US]		☐
	035	EP-0939602-B1	09-22-2004	MEDTRONIC INC [US]		☐
	036	EP-0958495-B1	11-13-2002	THERASENSE INC [US]		☐
	037	EP-0995805-A1	04-26-2000	BEURET PIERRE [CH]		☒
	038	EP-1048264-A1	11-02-2000	MEDTRONIC INC [US]		☐
	039	EP-1077634-A1	02-28-2001	CYGNUS THERAPEUTIC SYSTEMS [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 108 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	040	EP-1078258-A1	02-28-2001	CYGNUS THERAPEUTIC SYSTEMS [US]		☐
	041	EP-1153571-A1	11-14-2001	MENARINI FARMA IND [IT]		☐
	042	EP-1236995-A1	09-04-2002	USF FILTRATION & SEPARATIONS [US]		☐
	043	EP-1266607-A2	12-18-2002	LIFESCAN INC [US]		☐
	044	EP-1419731-A1	05-19-2004	PACESETTER INC [US]		☐
	045	EP-1677668-B1	07-14-2010	NOVO NORDISK AS [DK]		☐
	046	EP-1785085-A1	05-16-2007	ROCHE DIAGNOSTICS GMBH [DE], et al.		☒
	047	EP-1850909-B1	04-07-2010	PACESETTER INC [US]		☐
	048	EP-2069772-B1	05-21-2014	DEXCOM INC [US]		☐
	049	EP-2223710-A1	09-01-2010	DEXCOM INC [US]		☐
	050	EP-2226086-A1	09-08-2010	DEXCOM INC [US]		☐
	051	FR-2656423-A1	06-28-1991	RHONE POULENC CHIMIE [FR]		☒

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 109 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	052	FR-2760962-A1	09-25-1998	KLEFSTAD SILLONVILLE FRANCIS [FR]		☒
	053	GB-1442303-A	07-14-1976	RADIOMETER AS.		☐
	054	GB-1556969-A	12-05-1979	DRAEGERWERK AG.		☐
	055	GB-2149918-A	06-19-1985	ANDERSON JOHN.		☐
	056	JP-2000060826-A	02-29-2000	OMRON TATEISI ELECTRONICS CO.		☒
	057	JP-2003108679-A	04-11-2003	TOSHIBA CORP.		☒
	058	JP-2003522558-A	07-29-2003	MINIMED INC.		☒
	059	JP-2007501028-A	01-25-2007	DEXCOM, INC.		☒
	060	JP-2008253482-A	10-23-2008	MATSUSHITA ELECTRIC IND CO LTD.		☒
	061	JP-H022913-A	01-08-1990	BRIDGESTONE CORP.		☒
	062	JP-H03293556-A	12-25-1991	KOKURITSU SHINTAI SHIYOUGAISHI.		☒
	063	JP-H11153575-A	06-08-1999	MITSUBISHI ELECTRIC CORP.		☒

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 110 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	064	JP-H11192886-A	07-21-1999	NISSAN MOTOR.		☒
	065	JP-S6283849-A	04-17-1987	YOSHINAKA REIJI., et al.		☒
	066	WO-0012720-A2	03-09-2000	ABBOTT LAB [US]		☐
	067	WO-0013002-A2	03-09-2000	ABBOTT LAB [US]		☐
	068	WO-0013003-A1	03-09-2000	SENSORS FOR MED & SCIENCE INC [US]		☐
	069	WO-0019887-A1	04-13-2000	MINIMED INC [US]		☐
	070	WO-0032098-A1	06-08-2000	HEALTH HERO NETWORK INC [US]		☐
	071	WO-0033065-A1	06-08-2000	LOCKHEED MARTIN ENERGY RES COR [US], et al.		☐
	072	WO-0049940-A2	08-31-2000	MINIMED INC [US]		☐
	073	WO-0049941-A1	08-31-2000	MINIMED INC [US]		☐
	074	WO-0059370-A1	10-12-2000	UNIV CAMBRIDGE TECH [GB], et al.		☐
	075	WO-0059373-A1	10-12-2000	SPECTRX INC [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 111 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	076	WO-0074753-A1	12-14-2000	MINIMED INC [US]		☐
	077	WO-0078210-A1	12-28-2000	MINIMED INC [US]		☐
	078	WO-0079258-A1	12-28-2000	ABBOTT LAB [US], et al.		☐
	079	WO-0112158-A1	02-22-2001	UNIV JEFFERSON [US], et al.		☐
	080	WO-0116579-A1	03-08-2001	CME TELEMETRIX INC [CA], et al.		☐
	081	WO-0120019-A2	03-22-2001	IMPLANTED BIOSYSTEMS INC [US]		☐
	082	WO-0120334-A1	03-22-2001	UNIV CALIFORNIA [US], et al.		☐
	083	WO-0134243-A1	05-17-2001	ST JUDE MEDICAL [SE], et al.		☐
	084	WO-0143660-A2	06-21-2001	BAXTER INT [US]		☐
	085	WO-0152727-A1	07-26-2001	MINIMED INC [US]		☐
	086	WO-0152935-A1	07-26-2001	MEDICAL RES GROUP INC [US]		☐
	087	WO-0154753-A2	08-02-2001	MEDICAL RES GROUP INC [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 112 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	088	WO-0158348-A2	08-16-2001	MINIMED INC [US]		☐
	089	WO-0168901-A2	09-20-2001	ROCHE DIAGNOSTICS GMBH [DE], et al.		☐
	090	WO-0169222-A2	09-20-2001	ROCHE DIAGNOSTICS GMBH [DE], et al.		☐
	091	WO-0188524-A1	11-22-2001	THERASENSE INC [US]		☐
	092	WO-0188534-A2	11-22-2001	CYGNUS THERAPEUTIC SYSTEMS [US]		☐
	093	WO-02053764-A2	07-11-2002	MEDTRONIC MINIMED INC [US]		☐
	094	WO-0205702-A2	01-24-2002	HEALTHETECH INC [US], et al.		☐
	095	WO-02082989-A1	10-24-2002	ABBOTT LAB [US]		☐
	096	WO-02089666-A2	11-14-2002	ISENSE CORP [US], et al.		☐
	097	WO-02100266-A1	12-19-2002	MATHEWS EDWARD HENRY [ZA], et al.		☐
	098	WO-0216905-A2	02-28-2002	EURO CELTIQUE SA [LU], et al.		☐
	099	WO-0224065-A1	03-28-2002	KNOBBE LIM & BUCKINGHAM [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 113 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	100	WO-0239086-A2	05-16-2002	NIPRO DIABETES SYSTEMS [US], et al.		☐
	101	WO-03000127-A2	01-03-2003	CYGNUS THERAPEUTIC SYSTEMS [US]		☐
	102	WO-03011131-A2	02-13-2003	DEXCOM INC [US], et al.		☐
	103	WO-03012422-A1	02-13-2003	NOVA BIOMEDICAL CORP [US]		☐
	104	WO-03016882-A1	02-27-2003	PURDUE RESEARCH FOUNDATION [US], et al.		☐
	105	WO-03032411-A2	04-17-2003	LIFESCAN INC [US], et al.		☐
	106	WO-03076893-A2	09-18-2003	SENSYS MEDICAL INC [US]		☐
	107	WO-03082091-A2	10-09-2003	INVERNESS MEDICAL LTD [GB], et al.		☐
	108	WO-03101862-A1	12-11-2003	DOW CORNING TORAY SILICONE [JP], et al.		☐
	109	WO-2004021877-A1	03-18-2004	PENDRAGON MEDICAL LTD [CH], et al.		☐
	110	WO-2004052190-A1	06-24-2004	KONINKL PHILIPS ELECTRONICS NV [NL], et al.		☐
	111	WO-2004060455-A1	07-22-2004	MEDTRONIC MINIMED INC [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 114 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	112	WO-2004069030-A2	08-19-2004	VERIMETRA INC [US], et al.		☐
	113	WO-2004110256-A2	12-23-2004	THERASENSE INC [US]		☐
	114	WO-2005010756-A2	02-03-2005	PHILIPS INTELLECTUAL PROPERTY [DE], et al.		☐
	115	WO-2005011489-A1	02-10-2005	DEXCOM INC [US], et al.		☐
	116	WO-2005012873-A2	02-10-2005	DEXCOM INC [US], et al.		☐
	117	WO-2005026689-A2	03-24-2005	I STAT CORP [US], et al.		☐
	118	WO-2005026689-A9	10-13-2005	I STAT CORP [US], et al.		☐
	119	WO-2005032400-A2	04-14-2005	NICAST LTD [IL], et al.		☐
	120	WO-2005045414-A1	05-19-2005	LIFESCAN SCOTLAND LTD [GB], et al.		☐
	121	WO-2005057168-A2	06-23-2005	DEXCOM INC [US], et al.		☐
	122	WO-2005057175-A2	06-23-2005	DEXCOM INC [US], et al.		☐
	123	WO-2005065542-A2	07-21-2005	MEDTRONIC MINIMED INC [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 115 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	124	WO-2005078424-A1	08-25-2005	THERASENSE INC [US], et al.		☐
	125	WO-2005122296-A2	12-22-2005	UNIV SURREY [GB], et al.		☐
	126	WO-2006008505-A1	01-26-2006	ALERTIS MEDICAL AS [NO], et al.		☐
	127	WO-2006017358-A1	02-16-2006	DEXCOM INC [US], et al.		☐
	128	WO-2006024671-A1	03-09-2006	NOVO NORDISK AS [DK], et al.		☐
	129	WO-2006039310-A2	04-13-2006	GLUCON INC [US], et al.		☐
	130	WO-2006050405-A1	05-11-2006	MEDTRONIC INC [US], et al.		☐
	131	WO-2006081336-A2	08-03-2006	PACESETTER INC [US]		☐
	132	WO-2006105146-A2	10-05-2006	ARKAL MEDICAL INC [US], et al.		☐
	133	WO-2006118713-A1	11-09-2006	MEDTRONIC INC [US], et al.		☐
	134	WO-2006127694-A2	11-30-2006	DEXCOM INC [US], et al.		☐
	135	WO-2006131288-A1	12-14-2006	ROCHE DIAGNOSTICS GMBH [DE], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 116 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	136	WO-2007002209-A2	01-04-2007	GLUCON INC [US], et al.		☐
	137	WO-2007002579-A2	01-04-2007	BIOVERIS CORP [US], et al.		☐
	138	WO-2007065285-A2	06-14-2007	HOFFMANN LA ROCHE [CH], et al.		☐
	139	WO-2007097754-A1	08-30-2007	DEXCOM INC [US], et al.		☐
	140	WO-2007114943-A2	10-11-2007	MEDTRONIC MINIMED INC [US], et al.		☐
	141	WO-2007127606-A1	11-08-2007	MEDTRONIC INC [US], et al.		☐
	142	WO-2007137286-A2	11-29-2007	GLUCON INC [US], et al.		☐
	143	WO-2007143225-A2	12-13-2007	ABBOTT DIABETES CARE INC [US], et al.		☐
	144	WO-2008001091-A1	01-03-2008	GLYSURE LTD [GB], et al.		☐
	145	WO-2008076868-A2	06-26-2008	ABBOTT LAB [US], et al.		☐
	146	WO-2008086541-A2	07-17-2008	MEDTRONIC MINIMED INC [US], et al.		☐
	147	WO-2010022387-A1	02-25-2010	EASTERN VIRGINIA MED SCHOOL [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 117 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	148	WO-2010078263-A2	07-08-2010	MEDTRONIC MINIMED INC [US], et al.		☐
	149	WO-2010099507-A1	09-02-2010	ABBOTT DIABETES CARE INC [US], et al.		☐
	150	WO-8706342-A1	10-22-1987	MARKWELL MEDICAL INST INC [US]		☐
	151	WO-8902720-A1	04-06-1989	GRONINGEN SCIENCE PARK [NL]		☐
	152	WO-9000738-A1	01-25-1990	MARKWELL MEDICAL INST INC [US]		☐
	153	WO-9010861-A1	09-20-1990	NOVO NORDISK AS [DK]		☐
	154	WO-9109302-A1	06-27-1991	UNIV CALIFORNIA [US]		☐
	155	WO-9116416-A1	10-31-1991	MARKWELL MEDICAL INST INC [US]		☐
	156	WO-9213271-A1	08-06-1992	MARKWELL MEDICAL INST INC [US]		☐
	157	WO-9305701-A1	04-01-1993	IMPERIAL COLLEGE [GB]		☐
	158	WO-9314693-A1	08-05-1993	UNIV MANCHESTER [GB]		☐
	159	WO-9323744-A1	11-25-1993	HELLER E & CO [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 118 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	160	WO-9325898-A1	12-23-1993	MEDISENSE INC [US], et al.		☐
	161	WO-9422367-A1	10-13-1994	PFIZER INC. [US], et al.		☐
	162	WO-9507109-A1	03-16-1995	OTTAWA HEART INST RESEARCH COR [CA]		☐
	163	WO-9614026-A1	05-17-1996	ELAN MED TECH [IE], et al.		☐
	164	WO-9625089-A1	08-22-1996	MINIMED INC [US]		☐
	165	WO-9630431-A1	10-03-1996	MINIMED INC [US]		☐
	166	WO-9635370-A1	11-14-1996	MASSACHUSETTS INST TECHNOLOGY [US]		☐
	167	WO-9701986-A1	01-23-1997	UNIV JEFFERSON [US], et al.		☐
	168	WO-9706727-A1	02-27-1997	CARDIAC CRC NOMINEES PTY LTD [AU], et al.		☐
	169	WO-9715227-A1	05-01-1997	MEDTRONIC INC [US]		☐
	170	WO-9728737-A1	08-14-1997	NOKIA MOBILE PHONES LTD [FI], et al.		☐
	171	WO-9738625-A1	10-23-1997	UNIV MASSACHUSETTS [US], et al.		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 119 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	172	WO-9743633-A1	11-20-1997	ENCELLE INC [US], et al.		☐
	173	WO-9819159-A1	05-07-1998	MERCURY DIAGNOSTICS INC [US], et al.		☐
	174	WO-9824358-A2	06-11-1998	ENACT HEALTH MANAGEMENT SYSTEM [US], et al.		☐
	175	WO-9835053-A2	08-13-1998	HELLER E & CO [US], et al.		☐
	176	WO-9838906-A1	09-11-1998	MARKWELL MEDICAL INST INC [US], et al.		☐
	177	WO-9842249-A1	10-01-1998	NELLCOR PURITAN BENNETT INC [US]		☐
	178	WO-9907878-A1	02-18-1999	UNIV MANCHESTER [GB], et al.		☐
	179	WO-9908485-A1	02-18-1999	STRIX LTD [GB], et al.		☐
	180	WO-9948419-A1	09-30-1999	EGLISE DAVID [GB]		☐
	181	WO-9956613-A1	11-11-1999	HELLER E & CO [US], et al.		☐
	182	WO-9958051-A1	11-18-1999	CYGNUS THERAPEUTIC SYSTEMS [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 120 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]–Number[4]–Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	183	WO-9958709-A1	11-18-1999	ABBOTT LAB [US], et al.		☐
	184	WO-9958973-A1	11-18-1999	CYGNUS THERAPEUTIC SYSTEMS [US]		☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 121 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	001	AALDERS, et al., "Development of a Wearable Glucose Sensor; Studies in Healthy Volunteers and in Diabetic Patients," The International Journal Of Artificial Organs, 1991, Vol. 14, No. 2, pp. 102-108.	☐
	002	ABE, et al., "Characterization of Glucose Microsensors for Intracellular Measurements," Analytical Chemistry, 1992, Vol. 64, No. 18, pp. 2160-2163.	☐
	003	ABEL, et al., "Biosensors For in Vivo Glucose Measurements: Can We Cross the Experimental Stage," Biosensors & Bioelectronics, 2002, Vol. 17, pp. 1059-1070.	☐
	004	ABEL, et al., "Experience With An Implantable Glucose Sensor as a Prerequisite of an Artificial Beta Cell," Biomed. Biochim. Actan, 1984, Vol. 43, No. 5, pp. 577-584.	☐
	005	ALCOCK S.J., et al., "Continuous Analyte Monitoring To Aid Clinical Practice," IEEE Engineering in Medicine & Biology, 1994, Vol. 13, pp. 319-325.	☐
	006	AMER M.M.B., "An Accurate Amperometric Glucose Sensor Based Glucometer with Eliminated Cross-Sensitivity," Journal of Medical Engineering & Technology, Vol. 26 (5), September/October 2002, pp. 208-213.	☐
	007	AMIN R., et al., "Hypoglycemia Prevalence in Prepubertal Children With Type 1 Diabetes on Standard Insulin Regimen: Use of Continuous Glucose Monitoring System," Diabetes Care, 2003, Vol. 26, No. 3, pp. 662-667.	☐
	008	ARMOUR J.C., et al., "Application of Chronic Intravascular Blood Glucose Sensor in Dogs," Diabetes, December 1990, Vol. 39, pp. 1519-1526.	☐
	009	ARNOLD M.A., et al., "Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors," Journal of Diabetes Science and Technology, Vol. 1 (4), July 2007, pp. 454-462.	☐
	010	ASSOLANT-VINET C.H., et al., "New Immobilized Enzyme Membranes for Tailor-Made Biosensors," Analytical Letters, 1986, Vol. 19(7&8), pp. 875-885.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 122 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	011	ATANASOV P., et al., "Biosensor for Continuous Glucose Monitoring," Biotechnology and Bioengineering, John Wiley & sons Inc, 1994, Vol. 43, pp. 262-266.	☐
	012	ATANASOV P., et al., "Implantation of a Refillable Glucose Monitoring-Telemetry Device," Biosensors and Bioelectronics, Vol. 12 (7), 1997, pp. 669-680.	☐
	013	AUSSEDAT B., et al., "A User-Friendly Method For Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycaemic Alarm," Elsevier Science Limited, Biosensors & Bioelectronic, 1997, Vol. 12, No. 11, pp. 1061-1071.	☐
	014	BAILEY T.S., et al., "Reduction in Hemoglobin A1C with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study," Diabetes Technology & Therapeutics, Vol. 9 (3), 2007, pp. 203-210.	☐
	015	BAKER D.A., et al., "Dynamic Concentration Challenges for Biosensor Characterization," Biosensors & Bioelectronics, Vol. 8, 1993, pp. 433-441.	☐
	016	BAKER D.A., et al., "Dynamic Delay and Maximal Dynamic Error in Continuous Biosensors," Analytical Chemistry, Vol. 68 (8), April 15, 1996, pp. 1292-1297.	☐
	017	BARD A.J., et al., "Electrochemical Methods," Fundamentals and Applications, John Wiley & Sons, New York, 1980, pp. 173-175.	☐
	018	BARDELETTI G., et al., "A Reliable L-Lactate Electrode with a New Membrane for Enzyme Immobilization for Amperometric Assay of Lactate," Analytica Chemica Acta, Vol. 187, 1986, pp. 47-54.	☐
	019	BEACH R.D., et al., "Subminiature Implantable Potentiostat and Modified Commercial Telemetry Device for Remote Glucose Monitoring," IEEE Transactions on Instrumentation and Measurement, Vol. 48 (6), December 1999, pp. 1239-1245.	☐
	020	BELLUCCI F., et al., "Electrochemical Behaviour of Graphite-Epoxy Composite Materials (GECM) in Aqueous Salt Solutions," Journal of Applied Electrochemistry, Vol. 16 (1), January 1986, pp. 15-22.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 123 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	021	BENNION N., et al., "Alternate Site Glucose Testing: a Crossover Design," Diabetes Technology & Therapeutics, Vol. 4 (1), 2002, pp. 25-33.	☐
	022	BERTRAND C., et al., "Multipurpose Electrode with Different Enzyme Systems Bound to Collagen Films," Analytica Chemica Acta, 1981, Vol. 126, pp. 23-34.	☐
	023	BESSMAN S.P., et al., "Progress toward a Glucose Sensor for the Artificial Pancreas," Proceedings of a Workshop on Ion-Selective Microelectrodes, June 4-5, 1973, Boston University, 1973, pp. 189-197.	☐
	024	BIERMANN E., et al., "How Would Patients Behave if they were Continually Informed of their Blood Glucose Levels? A Simulation Study Using a "Virtual" Patient," Diabetes Technology & Therapeutics, Vol. 10 (3), 2008, pp. 178-187.	☐
	025	BINDRA D.S., et al., "Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring," Analytical Chemistry, Vol. 63, September 1, 1991, pp. 1692-1696.	☐
	026	BINDRA D.S., et al., "Pulsed Amperometric Detection of Glucose in Biological Fluids at a Surface-Modified Gold Electrode," Analytical Chemistry, Vol. 61 (22), November 15, 1989, pp. 2566-2570.	☐
	027	BISENBERGER M., et al., "A Triple-Step Potential Waveform at Enzyme Multisensors with Thick-Film Gold Electrodes for Detection of Glucose and Sucrose," Sensors and Actuators B, Vol. 28, 1995, pp. 181-189.	☐
	028	BLAND J.M., et al., "A Note on the Use of the Intraclass Correlation Coefficient in the Evaluation of Agreement between Two Methods of Measurement," Computers in Biology and Medicine, Vol. 20 (5), 1990, pp. 337-340.	☐
	029	BLAND J.M., et al., "Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement," The Lancet, February 8, 1986, pp. 307-310.	☐
	030	BLANK T.B., et al., "Clinical Results From a Non-Invasive Blood Glucose Monitor," Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, Vol. 4624, 2002, pp. 1-10.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 124 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	031	BOBBIONI-HARSCH E., et al., "Lifespan of Subcutaneous Glucose Sensors and their Performances during Dynamic Glycaemia Changes in Rats," J. Biomed. Eng., Vol. 15, 1993, pp. 457-463.	☐
	032	BODE B.W., "Clinical Utility of the Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S35-S41.	☐
	033	BODE B.W., et al., "Continuous Glucose Monitoring Used to Adjust Diabetes Therapy Improves Glycosylated Hemoglobin: A Pilot Study," Diabetes Research and Clinical Practice, Vol. 46, 1999, pp. 183-190.	☐
	034	BOEDEKER PLASTICS INC, "Polyethylene Specifications," Polyethylene Data Sheet, Retrieved from http://www.boedeker.com/polye.sub.--p.htm on August 19, 2009, 4 pages.	☐
	035	BOLAND E., et al., "Limitations of Conventional Methods of Self-Monitoring of Blood Glucose," Diabetes Care, Vol. 24 (11), November 2001, pp. 1858-1862.	☐
	036	BOLINDER J., et al., "Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison with Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue during Ordinary Life Conditions," Diabetes Care, Vol. 20 (1), January 1997, pp. 64-70.	☐
	037	BOLINDER J., et al., "Microdialysis Measurement of the Absolute Glucose Concentration in Subcutaneous Adipose Tissue Allowing Glucose Monitoring in Diabetic Patients," Rapid Communication, Diabetologia, Vol. 35, 1992, pp. 1177-1180.	☐
	038	BOTT A.W., "A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry," Current Separations, Vol. 16 (1), 1997, pp. 23-26.	☐
	039	BOTT A.W., "Electrochemical Methods for the Determination of Glucose," Current Separations, Vol. 17 (1), 1998, pp. 25-31.	☐
	040	BOWMAN L., et al., "The Packaging of Implantable Integrated Sensors," IEEE Transactions in Biomedical Engineering, Vol. BME-33 (2), February 1986, pp. 248-255.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 125 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	041	BOYNE M.S., et al., "Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor," Diabetes, Vol. 52, November 2003, pp. 2790-2794.	☐
	042	BRAUKER J., et al., "Local Inflammatory Response Around Diffusion Chambers Containing Xenografts," Transplantation, Vol. 61 (12), June 27, 1996, pp. 1671-1677.	☐
	043	BRAUNWALD E., "Biomarkers in Heart Failure," Medical Progress, The New England Journal of Medicine, Vol. 358, May 15, 2008, pp. 2148-2159.	☐
	044	BREMER T., et al., "Is Blood Glucose Predictable from Previous Values? A Solicitation for Data," Perspectives in Diabetes, Vol. 48, March 1999, pp. 445-451.	☐
	045	BREMER T.M., et al., "Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies," Diabetes Technology & Therapeutics, Vol. 3 (3), 2001, pp. 409-418.	☐
	046	BROOKS S.L., et al., "Development of an On-line Glucose Sensor for Fermentation Monitoring," Biosensors, Vol. 3, 1987/1988, pp. 45-56.	☐
	047	BRUCKEL J., et al., "In Vivo Measurement of Subcutaneous Glucose Concentrations with an Enzymatic Glucose Sensor and a Wick Method," Klin Wochenschr, Vol. 67, 1989, pp. 491-495.	☐
	048	BRUNSTEIN E., et al., "Preparation and Validation of Implantable Electrodes for the Measurement of Oxygen and Glucose," Biomed Biochim. Acta, Vol. 48 (11/12), 1989, pp. 911-917.	☐
	049	CAI Q., et al., "A Wireless, Remote Query Glucose Biosensor Based on a pH-Sensitive Polymer," Analytical Chemistry, Vol. 76 (14), July 15, 2004, pp. 4038-4043.	☐
	050	CAMERON T., et al., "Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs," IEEE Transactions on Biomedical Engineering, Vol. 44 (9), September 1997, pp. 781-790.	☐
	051	CAMPANELLA L., et al., "Biosensor for Direct Determination of Glucose and Lactate in Undiluted Biological Fluids," Biosensors & Bioelectronics, Vol. 8, 1993, pp. 307-314.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 126 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	052	CANDAS B., et al., "An Adaptive Plasma Glucose Controller Based on a Nonlinear Insulin/Glucose Model," IEEE Transactions on Biomedical Engineering, Vol. 41 (2), February 1994, pp. 116-124.	☐
	053	CASS A.E.G., et al., "Ferrocene-Mediated Enzyme Electrodes for Amperometric Determination of Glucose," Analytical Chemistry, Vol. 56 (4), April 1984, pp. 667-671.	☐
	054	CASSIDY J.F., et al., "Novel Electrochemical Device for the Detection of Cholesterol or Glucose," Analyst, Vol. 118, April 1993, pp. 415-418.	☐
	055	CHASE H.P., et al., "Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes," Pediatrics, Vol. 107 (2), February 2001, pp. 222-226.	☐
	056	CHEN C.Y., et al., "A Biocompatible Needle-Type Glucose Sensor Based on Platinum-Electroplated Carbon Electrode," Appl. Biochem Biotechnol, September 1992, Vol. 36 (3), pp. 211-226.	☐
	057	CHEN T., et al., "Defining the Period of Recovery of the Glucose Concentration after its Local Perturbation by the Implantation of a Miniature Sensor," Clinical Chemistry and Laboratory Medicine, Vol. 40 (8), 2002, pp. 786-789.	☐
	058	CHEYNE E.H., et al., "Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers," Diabetes Technology & Therapeutics, Vol. 4 (5), 2002, pp. 607-613.	☐
	059	CHIA C.W., et al., "Glucose Sensors: Toward Closed Loop Insulin Delivery," Endocrinology and Metabolism Clinics of North America, Vol. 33, 2004, pp. 175-195.	☐
	060	CHOLEAU C., et al., "Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-point Calibration Method," Biosensors and Bioelectronics, Vol. 17 (8), 2002, pp. 647-654.	☐
	061	CHOLEAU C., et al., "Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1. Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current," Biosensors and Bioelectronics, Vol. 17, 2002, pp. 641-646.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 127 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	062	CIBA Specialty Chemicals, "Ciba® IRGACURE® 2959," Coating Effects Segment, Photoinitiator Product Description, Basel Switzerland, April 2, 1998, 3 pages.	☐
	063	CLAREMONT D.J., et al., "Potentially-Implantable, Ferrocene-Mediated Glucose Sensor," Journal of Biomedical Engineering, Vol. 8, July 1986, pp. 272-274.	☐
	064	CLAREMONT D.J., et al., "Subcutaneous Implantation of a Ferrocene-Mediated Glucose Sensor in Pigs," Diabetologia, Vol. 29, 1986, pp. 817-821.	☐
	065	CLARK L.C., et al., "Configurational Cyclic Voltammetry: Increasing the Specificity and Reliability of Implanted Electrodes," IEEE/Ninth Annual Conference of the Engineering in Medicine and Biology Society, 1987, pp. 0782-0783.	☐
	066	CLARK L.C., et al., "Long-Term Stability of Electroenzymatic Glucose Sensors Implanted in Mice," Vol. XXXIV, Transactions - American Society for Artificial Internal Organs, 1988, vol. 34, pp. 259-265.	☐
	067	CLARK L.C., et al., "One-Minute Electrochemical Enzymic Assay for Cholesterol in Biological Materials," Clinical Chemistry, Vol. 27 (12), 1981, pp. 1978-1982.	☐
	068	CLARKE W.L., et al., "Evaluating Clinical Accuracy of Systems for Self Monitoring of Blood Glucose," Technical Articles, Diabetes Care, Vol. 10 (5), September-October 1987, pp. 622-628.	☐
	069	COLANGELO V.J., et al., "Corrosion Rate Measurements in Vivo," Journal of Biomedical Materials Research, Vol. 1, 1967, pp. 405-414.	☐
	070	COLOWICK S.P., et al., "Methods in Enzymology," Vol. XLIV, Immobilized Enzymes, Edited by Mosbach K, New York Academic Press, 1976, 11 pages.	☐
	071	COULET P.R., et al., "Enzymes Immobilized on Collagen Membranes: A Tool for Fundamental Research and Enzyme Engineering," Journal of Chromatography, Vol. 215, 1981, pp. 65-72.	☐
	072	COULET P.R., "Polymeric Membranes and Coupled Enzymes in the Design of Biosensors," Journal of Membrane Science, 1992, Vol. 68, pp. 217-228.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 128 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	073	COX D.J., et al., "Accuracy of Perceiving Blood Glucose in IDDM," Diabetes Care, Vol. 8 (6), November-December 1985, pp. 529-536.	☐
	074	CSOREGI E., et al., "Amperometric Microbiosensors for Detection of Hydrogen Peroxide and Glucose Based on Peroxidase-Modified Carbon Fibers," Electroanalysis, Vol. 6, 1994, pp. 925-933.	☐
	075	CSOREGI E., et al., "Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on 'Wired' Glucose Oxidase," Analytical Chemistry, Vol. 67 (7), April 1, 1995, pp. 1240-1244.	☐
	076	CSOREGI E., et al., "Design, Characterization and One-Point in Vivo Calibration of a Subcutaneously Implanted Glucose Electrode," American Chemical Society, Analytical Chemistry, Vol. 66 (19), October 1, 1994, pp. 3131-3138.	☐
	077	CURRIE J.F., et al., "Novel Non-Intrusive Trans-Dermal Remote Wireless Micro-Fluidic Monitoring System Applied to Continuous Glucose and Lactate Assays for Casualty Care and Combat Readiness Assessment," RTO HFM Symposium, RTO-MP-HFM-109, August 16-18, 2004, pp. '24-1' - '24-18'.	☐
	078	DANIELSSON B., et al., "Enzyme Thermistors," Methods in Enzymology, Vol. 137, 1988, pp. 181-197.	☐
	079	D'ARRIGO G., et al., "Porous-Si Based Bio Reactors for Glucose Monitoring and Drugs Production," Proceedings of SPIE, 2003, Vol. 4982, pp. 178-184.	☐
	080	DASSAU E., et al., "In Silico Evaluation Platform for Artificial Pancreatic β- Cell Development - A Dynamic Simulator for Closed-Loop Control with Hardware-in-the-loop," Diabetes Technology & Therapeutics, Vol. 11 (3), 2009, pp. 1-8.	☐
	081	DAVIES M.L., et al., "Polymer Membranes in Clinical Sensor Applications," An overview of membrane function, Biomaterials, Vol. 13 (14), 1992, pp. 971-978.	☐
	082	DAVIS G., et al., "Bioelectrochemical Fuel Cell and Sensor Based on a Quinoprotein, Alcohol Dehydrogenase," Enzyme and Microbial Technology, Vol. 5 (5), September 1983, pp. 383-388.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 129 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	083	DEUTSCH T., et al., "Time Series Analysis and Control of Blood Glucose Levels in Diabetic Patients," Computer Methods and Programs in Biomedicine, Elsevier Scientific Publishers, Vol. 41, 1994, pp. 167-182.	☐
	084	DIXON B.M., et al., "Characterization in Vitro and in Vivo of the Oxygen Dependence of an Enzyme/Polymer Biosensor for Monitoring Brain Glucose," Journal of Neuroscience Methods, Vol. 119, 2002, pp. 135-142.	☐
	085	DuPont, "Dimension® AR Clinical Chemistry System," The Chemistry Analyzer that Makes the most of your Time, Money and Effort, Dade International, Chemistry Systems, Newark, 1998, 18 pages.	☐
	086	DURLIAT H., et al., "Spectrophotometric and Electrochemical Determinations of L(+)-Lactate in Blood by Use of Lactate Dehydrogenase from Yeast," Clinical Chemistry, Vol. 22 (11), 1976, pp. 1802-1805.	☐
	087	EDWARDS LIFESCIENCES, "Accuracy for You and Your Patients," Marketing materials, 2002, 4 pages.	☐
	088	EL DEGHEIDY M.M., et al., "Optimization of an Implantable Coated Wire Glucose Sensor," Journal of Biomedical Engineering, Vol. 8, April 1986, pp. 121-129.	☐
	089	ELCO Diagnostics Company, "Direct 30/30® Blood Glucose Sensor," Markwell Medical Catalog, 1990, 1 page.	☐
	090	EL-KHATIB F.H., et al., "Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Dual Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine," Journal of Diabetes Science and Technology, Diabetes Technology Society, Vol. 1 (2), 2007, pp. 181-192.	☐
	091	EL-SA'AD L., et al., "Moisture Absorption by Epoxy Resins: The Reverse Thermal Effect," Journal of Materials Science, Vol. 25, 1990, pp. 3577-3582.	☐
	092	EREN-ORUKLU M., et al., "Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models," Diabetes Technology & Therapeutics, Vol. 11 (4), 2009, pp. 243-253.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 130 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	093	ERNST H., et al., "Reliable Glucose Monitoring Through the Use of Microsystem Technology," Analytical Bioanalytical Chemistry, Vol. 373, 2002, pp. 758-761.	☐
	094	Examiner's First Report for Australian Patent Application No. 2007305002 dated June 01, 2012, 2 pages - Atty. Docket No. DEXCOM.088VAU.	☐
	095	Extended European Search Report for Application No. 12170103.1 dated November 06, 2012, 6 pages - Atty. Docket No. DEXCOM.016EPD3.	☐
	096	Extended European Search Report for Application No. 13275272.6, mailed March 3, 2014, 8 pages.	☐
	097	Extended European Search Report for Application No. 19185162.5 mailed August 13, 2019, 7 pages - Atty. Docket. No. DEXCOM.167VEPD1.	☐
	098	FABIETTI P.G., et al., "Clinical Validation of a New Control-Oriented Model of Insulin and Glucose Dynamics in Subjects with Type 1 Diabetes," Diabetes Technology & Therapeutics, Vol. 9 (4), 2007, pp. 327-338.	☐
	099	FAHY B.G., et al., "An Analysis: Hyperglycemic Intensive Care Patients Need Continuous Glucose Monitoring-Easier Said Than Done," Journal of Diabetes Science and Technology, Diabetes Technology Society, Vol. 2 (2), March 2008, pp. 201-204.	☐
	100	FARE T.L., et al., "Functional Characterization of a Conducting Polymer-Based Immunoassay System," Biosensors & Bioelectronics, Vol. 13 (3-4), 1998, pp. 459-470.	☐
	101	FELDMAN B., et al., "A Continuous Glucose Sensor Based on Wired EnzymeTM Technology-Results from a 3-Day Trial in Patients with Type 1 Diabetes," Diabetes Technology & Therapeutics, Vol. 5 (5), 2003, pp. 769-779.	☐
	102	FELDMAN B., et al., "Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change," Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004, 1 page.	☐
	103	File History of U.S. Patent Application No. 11/157,365, filed on June 21, 2005, 977 pages (see image file wrapper - Atty. Docket No. DEXCOM.061A1).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 131 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	104	File History of U.S. Patent Application No. 11/543,396, filed on October 4, 2006, 608 pages (see image file wrapper- Atty. Docket No. DEXCOM.088A).	☐
	105	File History of U.S. Patent Application No. 11/543,404, filed on October 4, 2006, 504 pages (see image file wrapper - Atty. Docket No. DEXCOM.096C8).	☐
	106	File History of U.S. Patent Application No. 11/543,490, filed on October 4, 2006, 639 pages (see image file wrapper - Atty. Docket No. DEXCOM.088A2).	☐
	107	File History of U.S. Patent Application No. 11/691,424, filed on March 26, 2007, 776 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP3).	☐
	108	File History of U.S. Patent Application No. 11/691,426, filed on March 26, 2007, 453 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP1).	☐
	109	File History of U.S. Patent Application No. 11/691,432, filed on March 26, 2007, 659 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP2).	☐
	110	File History of U.S. Patent Application No. 11/691,466, filed on March 26, 2007, 470 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP4).	☐
	111	File History of U.S. Patent Application No. 12/055,149, filed on March 25, 2008, 526 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CP1CP3).	☐
	112	File History of U.S. Patent Application No. 12/055,227, filed on March 25, 2008, 661 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CP1CP5).	☐
	113	File History of U.S. Patent Application No. 12/267,545, filed on November 7, 2008, 693 pages (see image file wrapper - Atty Docket No. DEXCOM.88CPP5P5).	☐
	114	File History of U.S. Patent Application No. 12/267,546, filed on November 7, 2008, 803 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CPP5P3).	☐
	115	File History of U.S. Patent Application No. 12/267,547, filed on November 7, 2008, 756 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CPP5P2).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 132 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	116	File History of U.S. Patent Application No. 15/616,916, filed on June 07, 2017, 169 pages (see image file wrapper).	☐
	117	File History of U.S. Patent Application No. 15/789,949, filed on October 20, 2017, 276 pages (see image file wrapper).	☐
	118	FISCHER U., et al., "Assessment of Subcutaneous Glucose Concentration: Validation of the Wick Technique as a Reference for Implanted Electrochemical Sensors in Normal and Diabetic Dogs," Diabetologia, Vol. 30, 1987, pp. 940-945.	☐
	119	FISCHER U., et al., "Hypoglycaemia-Warning by Means of Subcutaneous Electrochemical Glucose Sensors: An Animal Study," Horm. Metab. Res, Vol. 27, 1995, page 53. (Abstract Only).	☐
	120	FISCHER U., et al., "Oxygen Tension at the Subcutaneous Implantation Site of Glucose Sensors," Biomed. Biochim. Acta, Vol. 48 (11/12), 1989, pp. 965-971.	☐
	121	FREEDMAN D., et al., "Statistics," Second Edition, W.W. Norton & Company, New York & London, 1991, page 74 (3 pages).	☐
	122	FREIBERGER P., "Video Game Takes on Diabetes Superhero `Captain Novolin` Offers Treatment Tips," Fourth Edition, June 26, 1992, Business Section, 2 pages.	☐
	123	FROHNAUER M.K., et al., "Graphical Human Insulin Time-Activity Profiles Using Standardized Definitions," Diabetes Technology & Therapeutics, Vol. 3 (3), 2001, pp. 419-429.	☐
	124	FROST M.C., et al., "Implantable Chemical Sensors for Real-Time Clinical Monitoring: Progress and Challenges," Current Opinion in Chemical Biology, Analytical Techniques, Vol. 6, 2002, pp. 633-641.	☐
	125	GABBY R.A., et al., "Optical Coherence Tomography-Based Continuous Noninvasive Glucose Monitoring in Patients with Diabetes," Diabetes Technology & Therapeutics, Vol. 10, November 03, 2008, pp.188-193.	☐
	126	Gamry Instruments, "Basics of Electrochemical Impedance Spectroscopy," 2007, 30 pages.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 133 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	127	GANESAN N., et al., "Gold Layer-Based Dual Crosslinking Procedure of Glucose Oxidase with Ferrocene Monocarboxylic Acid Provides a Stable Biosensor," Analytical Biochemistry, Notes & Tips, Vol. 343, 2005, pp. 188-191.	☐
	128	GANESH A., et al., "Evaluation of the VIA® Blood Chemistry Monitor for Glucose in Healthy and Diabetic Volunteers," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 182-193.	☐
	129	GARG S.K., et al., "Correlation of Fingerstick Blood Glucose Measurements With GlucoWatch Biographer Glucose Results in Young Subjects With Type 1 Diabetes," Emerging Treatments and Technologies, Diabetes Care, Vol. 22 (10), October 1999, pp. 1708-1714.	☐
	130	GARG S.K., et al., "Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults With Type 1 Diabetes," Emerging Treatments and Technologies, Diabetes Care, Vol. 27 (3), 2004, pp. 734-738.	☐
	131	GEORGESCU B., et al., "Real-Time Multi-Model Tracking of Myocardium in Echocardiography Using Robust Information Fusion," Medical Image Computing and Computer-Assisted Intervention, Springer-Verlag Berlin Heidelberg, 2004, pp. 777-785.	☐
	132	GERRITSEN M., et al., "Performance of Subcutaneously Implanted Glucose Sensors for Continuous Monitoring," The Netherlands Journal of Medicine, Vol. 54, 1999, pp. 167-179.	☐
	133	GERRITSEN M., et al., "Problems Associated with Subcutaneously Implanted Glucose Sensors," Diabetes Care, Vol. 23 (2), February 2000, pp. 143-145.	☐
	134	GILLIGAN B.J., et al., "Evaluation of a Subcutaneous Glucose Sensor Out to 3 Months in a Dog Model" Diabetes Care, Vol. 17 (8), August 1994, pp. 882-887.	☐
	135	GILLIGAN B.J., et al., "Feasibility of Continuous Long-Term Glucose Monitoring from a Subcutaneous Glucose Sensor in Humans," Diabetes Technology & Therapeutics, Vol.6 (3), 2004, pp. 378-386.	☐
	136	GODSLAND I.F., et al., "Maximizing the Success Rate of Minimal Model Insulin Sensitivity Measurement in Humans: The Importance of Basal Glucose Levels," The Biochemical Society and the Medical Research Society, Clinical Science, Vol. 101, 2001, pp. 1-9.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 134 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	137	GOLDMAN J.M., et al., "Masimo Signal Extraction Pulse Oximetry," Journal of Clinical Monitoring and Computing, Vol. 16 (7), 2000, pp. 475-483.	☐
	138	GOUDA M.D., et al., "Thermal Inactivation of Glucose Oxidase," The Journal of Biological Chemistry, Vol. 278 (27), Issue of July 4, 2003, pp. 24324-24333.	☐
	139	GOUGH D.A., et al., "Frequency Characterization of Blood Glucose Dynamics," Annals of Biomedical Engineering, Vol. 31, 2003, pp. 91-97.	☐
	140	GOUGH D.A., et al., "Immobilized Glucose Oxidase in Implantable Glucose Sensor Technology," Diabetes Technology & Therapeutics, Vol. 2 (3), 2000, pp. 377-380.	☐
	141	GOUGH D.A., "The implantable Glucose Sensor: An Example of Bioengineering Design," Introduction to Bioengineering, 2001, Chapter 3, pp. 57-66.	☐
	142	GROSS, et al., "Diabetes Technology & Therapeutics," Letters to the Editor, Diabetes Technology & Therapeutics, Vol. 3 (1), 2001, pp. 129-131.	☐
	143	GROSS T.M., et al., "Efficacy and Reliability of the Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S19-S26.	☐
	144	GROSS T.M., et al., "Performance Evaluation Of The Minimed® Continuous Glucose Monitoring System During Patient Home Use," Diabetes Technology & Therapeutics, Vol. 2(1), 2000, pp. 49-56.	☐
	145	GUERCI B., et al., "Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs," Diabetes Care, Vol. 26, 2003, pp. 582-589.	☐
	146	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part 1. An Adsorption-controlled Mechanism," Electrochimica Acta, Vol. 43, Nos. 5/6, 1998, pp. 579-588.	☐
	147	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part II: Effect of potential," Electrochimica Acta, Vol. 43 (14-15), 1998, pp. 2015-2024.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 135 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	148	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part III: Effect of Temperature," Electrochimica Acta, Vol. 44, 1999, pp. 2455-2462.	☐
	149	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part IV: Phosphate Buffer Dependence," Electrochimica Acta, Vol. 44, 1999, pp. 4573-4582.	☐
	150	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part V: Inhibition by Chloride," Electrochimica Acta, Vol. 45, 2000, pp. 3573-3579.	☐
	151	HAMILTON, "Complete Guide to Selecting the Right Hamilton GASTIGHT, MICROLITER, and Specialty Syringe for your Application," Syringe Selection, http://www.hamiltoncompany.com 2006, 20 pages.	☐
	152	HARRISON, et al., "Characterization of Perfluorosulfonic Acid Polymer Coated Enzyme Electrodes and a Miniaturized Integrated Potentiostat for Glucose Analysis in Whole Blood," Analytical Chemistry, 1988, Vol. 60, pp. 2002-2007.	☐
	153	HASHIGUCHI Y., et al., "Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor with Microdialysis Sampling Method: Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients," Diabetes Care, Vol. 17, No. 5, May 1994, pp. 387-396.	☐
	154	HEISE T., et al., "Hypoglycemia warning signal and glucose sensors: Requirements and concepts," Diabetes Technology & Therapeutics, Vol. 5, No. 4, 2003, pp. 563-571.	☐
	155	HELLER A., "Electrical Connection of Enzyme Redox Centers to Electrodes," J. Phys. Chem., Vol. 96, 1992, pp. 3579-3587.	☐
	156	HELLER A., "Electrical Wiring of Redox Enzymes," Ace. Chem. Res., Vol. 23, 1990, pp. 128-134.	☐
	157	HELLER A., "Implanted Electrochemical Glucose Sensors for the Management of Diabetes," Annu. Rev., Biomed Eng., Vol. 1, 1999, pp. 153-175.	☐
	158	HELLER A., "Plugging Metal Connectors into Enzymes," Nature Biotechnology, Vol. 21, No. 6, June 2003, pp. 631-632.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 136 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	159	HICKS J.M., "In Situ Monitoring," Clinical Chemistry, Vol. 31 (12), 1985, pp. 1931-1935.	☐
	160	HITCHMAN M.L., "Measurement of Dissolved Oxygen," Edited by ELVING P.J et al., Chemical Analysis, New York, John Wiley & Sons, Vol. 49, Chapter 3, 1978, pp. 34-49 and 59-123.	☐
	161	HOEL P.G., "Elementary Statistics," Fourth Edition, John Wiley & Sons, Inc., 1976, pp. 113-114.	☐
	162	HOSS U., et al., "Continuous Glucose Monitoring in Subcutaneous Tissue Using Factory-Calibrated Sensors: A Pilot Study," Diabetes Technology & Therapeutics, 2010, Vol. 12 (8), pp. 591-597.	☐
	163	HOUGHTON MIFFLIN COMPANY, "American Heritage Dictionary," 4th Edition, 2000, pp. 82.	☐
	164	HOUGHTON MIFFLIN COMPANY, "Xenogenic, the American Heritage Stedman's Medical Dictionary," 2002, Answers.Com, retrieved from http://www.answers.com/topic/xenogenic, on November 07, 2006, 2 Pages.	☐
	165	HOVORKA R., et al., "Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes," Physiological Measurement, Vol. 25, July 2004, pp. 905-920.	☐
	166	HRAPOVIC S., et al., "Picoamperometric Detection of Glucose at Ultrasmall Platinum-Based Biosensors Preparation and Characterization," Anal. Chem, Vol. 75, 2003, pp. 3308-3315.	☐
	167	HU Y., et al., "A Needle-Type Enzyme-Based Lactate Sensor for In Vivo Monitoring," Analytica Chimica Acta, Vol. 281, 1993, pp. 503-511.	☐
	168	HUANG C., et al., "Electrochemical Generation of Oxygen. 1: The Effects of Anions and Cations on Hydrogen Chemisorption and Anodic Oxide Film Formation on Platinum Electrode. 2: The Effects of Anions and Cations on Oxygen Generation on Platinum Electrode," U.S. Department of Commence/NTIS, 1975, 126 pages.	☐
	169	HUANG Q., et al., "A 0.5mW Passive Telemetry IC for Biomedical Applications," Proceedings of the 23rd European Solid-State Circuits Conference (ESSCIRC '97), Southampton, UK, September 16-18, 1997, pp. 172-175.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 137 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	170	HUNTER I., et al., "Minimally Invasive Glucose Sensor and Insulin Delivery System," MIT Home Automation and Healthcare Consortium, March 31, 2000, Progress Report No. 25, 17 pages.	☐
	171	International Preliminary Report on Patentability for Application No. PCT/US2007/079220 mailed April 07, 2009, 11 pages - Atty. Docket No.DEXCOM.088VPC.	☐
	172	International Preliminary Report on Patentability for Application No. PCT/US2008/082905 mailed September 28, 2010, 13 pages - Atty. Docket No. DEXCOM.088HPC.	☐
	173	International Preliminary Report on Patentability for Application No. PCT/US2008/082870 mailed September 28, 2010, 6 pages - Atty. Docket No. DEXCOM.088BPC. .	☐
	174	International Search Report and Written Opinion for Application No. PCT/US2008/082870 mailed December 29, 2008, 6 pages - Atty. Docket. No. DEXCOM.088BPC.	☐
	175	International Search Report and Written Opinion for Application No. PCT/US2007/079220 mailed July 01, 2008, 16 pages - Atty. Docket No. DEXCOM.088VPC.	☐
	176	International Search Report and Written Opinion for Application No. PCT/US2008/082905 mailed March 16, 2009, 14 pages - Atty. Docket. No. DEXCOM.088HPC.	☐
	177	Invitation to Pay Additional Fees for Application No. PCT/US2007/079220, mailed April 25, 2008, 7 pages - Atty. Docket No. DEXCOM.088VPC.	☐
	178	ISERMANN R., et al., "Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes", Control Engineering Practice, Vol. 5 (5), 1997, pp. 709-719.	☐
	179	ISERMANN R., "Supervision, Fault-Detection and Fault-Diagnosis Methods - An Introduction," Control Engineering Practice, Vol. 5 (5), 1997, pp. 639-652.	☐
	180	ISHIKAWA M., et al., "Initial Evaluation of A 290-Mm Diameter Subcutaneous Glucose Sensor: Glucose Monitoring With A Biocompatible, Flexible-Wire, Enzyme-Based Amperometric Microsensor in Diabetic and Nondiabetic Humans," Journal of Diabetes and Its Complications, Vol. 12, 1998, pp. 295-301.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 138 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	181	JABLECKI M., et al., "Simulations of the Frequency Response of Implantable Glucose Sensors," Analytical Chemistry, Vol. 72, 2000, 1853-1859.	☐
	182	JAFFARI S.A., et al., "Recent Advances in Amperometric Glucose Biosensors for In Vivo Monitoring," Physiological Measurement, 1995, Vol. 16, pp. 1-15.	☐
	183	JAREMKO J., et al., "Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes," Diabetes Care, Vol. 21 (3), March 1998, pp. 444-450.	☐
	184	JENSEN M.B., et al., "Fast Wave Forms for Pulsed Electrochemical Detection of Glucose by Incorporation of Reductive Desorption of Oxidation Products, "Analytical Chemistry, Vol. 69 (9), May 1997, pp. 1776-1781.	☐
	185	JEONG R.A., et al., "In Vivo Calibration of the Subcutaneous Amperometric Glucose Sensors Using a Non-Enzyme Electrode," Biosensors and Bioelectronics, Elsevier, Vol. 19, 2003, pp. 313-319.	☐
	186	JEUTTER D.C., "A Transcutaneous Implanted Battery Recharging and Biotelemeter Power Switching System," IEEE Transactions on Biomedical Engineering, Vol. BME-29 (5), May 1982, pp. 314-321.	☐
	187	JEUTTER D.C., et al., "Design of a Radio-Linked Implantable Cochlear Prosthesis Using Surface Acoustic Wave Devices," IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, Vol. 40 (5), September 1993, pp. 469-477.	☐
	188	JOBST G., et al., "Thin-Film Microbiosensors for Glucose-Lactate Monitoring," Anal Chem, September 15, 1996, Vol. 68(18), pp. 3173-3179.	☐
	189	JOHNSON K.W., et al., "In Vivo Evaluation of an Electroenzymatic Glucose Sensor Implanted in Subcutaneous Tissue," Biosensors and Bioelectronics, 1992, Vol. 7, pp. 709-714.	☐
	190	JOHNSON K.W., "Reproducible Electrodeposition of Biomolecules for the Fabrication of Miniature Electroenzymatic Biosensors," Sensors and Actuators B, Vol. 5, 1991, pp. 85-89.	☐
	191	JOHNSON P.C., "Peripheral Circulation," John Wiley & Sons, 1978, page 198 (5 pages).	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 139 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	192	JOUNG G.B., et al., "An Energy Transmission System for an Artificial Heart Using Leakage Inductance Compensation of Transcutaneous Transformer," IEEE Transactions on Power Electronics, Vol. 13 (6), November 1998, pp. 1013-1022.	☐
	193	JOVANOVIC L.M.D., "The Role of Continuous Glucose Monitoring in Gestational Diabetes Mellitus," Diabetes Technology and Therapeutics, Vol. 2 (1), 2000, pp. S67-S71.	☐
	194	JUNGHEIM K., et al., "How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?," Diabetologia, 2002, Vol. 45, pp. A250-A276.	☐
	195	JUNGHEIM K., et al., "Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm," Diabetes Care, Vol. 24 (7), July 2001, pp. 1303-1304.	☐
	196	KACANIKLIC V., et al., "Amperometric Biosensors for Detection of L- and D-Amino Acids Based on Coimmoblized Peroxidase and L- and D-Amino Acid Oxidases in Carbon Paste Electrodes," Electroanalysis, Vol. 6, May-Jun 1994, pp. 381-390.	☐
	197	KAMATH A., et al., "Calibration of a Continuous Glucose Monitor: Effect of Glucose Rate of Change," Eighth Annual Diabetes Technology Meeting, November 13-15, 2008, pp. A88 (2 pages).	☐
	198	KANG S.K., et al., "In Vitro and Short-Term in Vivo Characteristics of a Kel-F Thin Film Modified Glucose Sensor," Analytical Sciences, Vol. 19, November 2003, pp. 1481-1486.	☐
	199	KAPLAN S.M., "Wiley Electrical and Electronics Engineering Dictionary," IEEE Press, John Wiley & Sons, Inc., 2004, pp. 141, 142, 548 & 549.	☐
	200	KARGOL M., et al., "Studies on the Structural Properties of Porous Membranes: Measurement of Linear Dimensions of Solutes," Biophysical Chemistry, 2001, Vol. 91, pp. 263-271.	☐
	201	KAUFMAN F.R., et al., "A Pilot Study of the Continuous Glucose Monitoring System," Diabetes Care, Vol. 24 (12), December 2001, pp. 2030-2034.	☐
	202	KAUFMAN F.R., "Role of the Continuous Glucose Monitoring System in Pediatric Patients," Diabetes Technology and Therapeutics, Vol. 2 (1), 2000, S49-S52.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 140 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	203	KAWAGOE J.L., et al., "Enzyme-Modified Organic Conducting Salt Microelectrode," Analytical Chemistry, Vol. 63, 1991, pp. 2961-2965.	☐
	204	KEEDY F.H., et al., "Determination of Urate in Undiluted Whole Blood by Enzyme Electrode," Biosensors and Bioelectronics, Vol. 6, 1991, pp. 491-499.	☐
	205	KERNER, et al., "A Potentially Implantable Enzyme Electrode for Amperometric Measurement of Glucose," Hormone and Metabolic Research Supplement, Vol. 20, 1988, pp. 8-13.	☐
	206	KERNER W., et al., "The Function of a Hydrogen Peroxide-Detecting Electroenzymatic Glucose Electrode is Markedly Impaired in Human Sub-Cutaneous Tissue and Plasma," Biosensors and Bioelectronics, Vol. 8, 1993, pp. 473-482.	☐
	207	KERNER W., "Implantable Glucose Sensors: Present Status and Future Developments," Experimental and Clinical Endocrinol Diabetes, Vol. 109 (2), 2001, pp. S341-S346.	☐
	208	KIECHLE F.L., "The Impact of Continuous Glucose Monitoring on Hospital Point-of-Care Testing Programs," Diabetes Technology and Therapeutics, Vol. 3 (4), 2001, pp.647-649.	☐
	209	KLONOFF D., et al., "Performance Metrics for Continuous Interstitial Glucose Monitoring; Approved Guideline," Clinical and Laboratory Standards Institute, POCT05-A, Vol. 28 (33), 2008, 72 pages.	☐
	210	KLUEH U., et al., "Use of Vascular Endothelial Cell Growth Factor Gene Transfer to Enhance Implantable Sensor Function in Vivo," Biosensor Function and VEGF-Gene Transfer, Vol. 67 (4), 2003, pp. 1072-1086.	☐
	211	KONDO T., et al., "A Miniature Glucose Sensor, Implantable in the Blood Stream," Diabetes Care, Vol. 5 (3), May-June 1982, 218-221.	☐
	212	KOSCHINSKY T., et al., "Sensors For Glucose Monitoring: Technical And Clinical Aspects," Diabetes Metabolism Research and Reviews, vol. 17, no. 2, 01 January 2001, pages 113-123.	☐
	213	KOSCHINSKY T., et al., "New Approach to Technical and Clinical Evaluation of Devices for Self-Monitoring of Blood Glucose," Diabetes Care, Vol. 11 (8), September 1988, pp. 619-629.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 141 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	214	KOST J., et al., "Glucose-Sensitive Membranes Containing Glucose Oxidase: Activity, Swelling, And Permeability Studies," Journal of Biomedical Materials Research, Vol. 19, 1985, pp. 1117-1133.	☐
	215	KOUDELKA M., et al., "In Vivo Response of Microfabricated Glucose Sensors to Glycemia Changes in Normal Rats," Biomed. Biochim. Acta, Vol. 48 (11/12), November - December 1989, pp. 953-956.	☐
	216	KOUDELKA M., et al., "In-Vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors," Biosensors and Bioelectronics, Vol. 6, 1991, pp. 31-36.	☐
	217	KOVATCHEV B.P., et al., "Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors: Continuous Glucose-Error Grid Analysis Illustrated by TheraSense Freestyle Navigator Data," Diabetes Care, Vol. 27 (8), August 2004, pp.1922-1928.	☐
	218	KOVATCHEV B.P., et al., "Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag," Diabetes Technology & Therapeutics, Vol. 11 (3), 2009, pp. 139-143.	☐
	219	KRAVER., et al., "A Mixed-Signal Sensor Interface Microinstrument," Sensors and Actuators A, Physical 2001, Vol. 91, pp. 266-277.	☐
	220	KROUWER J.S., "Setting Performance Goals and Evaluating Total Analytical Error for Diagnostic Assays," Clinical Chemistry, Vol. 48 (6), 2002, pp. 919-927.	☐
	221	KRUGER D., et al., "Psychological Motivation and Patient Education: A Role for Continuous Glucose Monitoring," Diabetes Technology and Therapeutics, Vol. 2 (1), 2000, pp. S93-S97.	☐
	222	KULYS J., et al., "Carbon-Paste Biosensors Array for Long-Term Glucose Measurement," Biosensors & Bioelectronics, Vol. 9, 1994, pp. 491-500.	☐
	223	KUNJAN K., et al., "Automated Blood Sampling and Glucose Sensing in Critical Care Settings," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 194-200.	☐
	224	KURNIK R.T., et al., "Application of the Mixtures of Experts Algorithm for Signal Processing in a Noninvasive Glucose Monitoring System," Sensors and Actuators B, Vol. 60, 1999, pp. 19-26.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 142 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	225	KURTZ T.W., et al., "Recommendations for Blood Pressure Measurement in Humans and Experimental Animals, Part 2: Blood Pressure Measurement In Experimental Animals: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research," Hypertension, February 2005, Vol. 45, pp. 299-310.	☐
	226	KUURE-KINSEY M., et al., "A Dual-Rate Kalman Filter for Continuous Glucose Monitoring," Conf Proc IEEE Eng Med Biol Soc., 2006, Vol. 1, pp. 63-66.	☐
	227	LACOURSE W.R., et al., "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry," Analytical Chemistry, Vol. 65, 1993, pp. 50-52.	☐
	228	LADD M.F.C., et al., "Structure Determination By X-Ray Crystallography," 3rd Edition, Plenum Press, 1994, Ch. 1, pp. xxi-xxiv and 1-58.	☐
	229	LEHMANN E.D., et al., "Retrospective Validation of a Physiological Model of Glucose-Insulin Interaction in Type 1 Diabetes Mellitus. Medical Engineering & Physics, Vol. 16, May 1994, pp. 193-202.	☐
	230	LEONHARDT A., et al., "The Potential Use of Silicon Compounds as Oxygen Carriers for Free and Immobilized Cells Containing L-Amino Acid Oxidase," Applied Microbiology and Biotechnology, Vol. 21, 1985, pp. 162-166.	☐
	231	LEWANDOWSKI J.J., et al., "Evaluation of a Miniature Blood Glucose Sensor," Transactions - American Society for Artificial Internal Organs, Vol. 34, 1988, pp. 255-258.	☐
	232	LEYPOLDT J.K., et al., "Model of a Two-Substrate Enzyme Electrode for Glucose," Analytical Chemistry, Vol. 56, 1984, pp. 2896-2904.	☐
	233	LINKE B., et al., "Amperometric Biosensor for In Vivo Glucose Sensing Based on Glucose Oxidase Immobilized In A Redox Hydrogel," Biosensors and Bioelectronics, Vol. 9, 1994, pp. 151-158.	☐
	234	LODWIG V., et al., "Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria," Diabetes Technology & Therapeutics, Vol. 5 (4), 2003, pp. 572-587.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 143 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	235	LOHN A., et al., "A Knowledge-Based System for Real-Time Validation of Calibrations and Measurements," Chemometrics and Intelligent Laboratory Systems, Vol. 46, 1999, pp. 57-66.	☐
	236	LORTZ J., et al., "What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology," In Smart Computing Learning Series, Wireless Computing, Vol. 8 (5), 2002, pp. 72-74.	☐
	237	LOWE C.R., "Biosensors," Trends in Biotechnology, Vol. 2 (3), 1984, pp. 59-65.	☐
	238	LUONG J.H.T., et al., "Solubilization of Multiwall Carbon Nanotubes by 3-Aminopropyltriethoxysilane towards the Fabrication of Electrochemical Biosensors with Promoted Electron Transfer," Electroanalysis, Vol. 16 (1-2), 2004, pp. 132-139.	☐
	239	LYANDRES O., et al. "Progress toward an In Vivo Surface-Enhanced Raman Spectroscopy Glucose Sensor," Diabetes Technology and Therapeutics, Vol. 10 (4), 2008, pp. 257-265.	☐
	240	LYNCH S.M., et al., "Estimation-Based Model Predictive Control of Blood Glucose in Type I Diabetics: A Simulation Study," Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference, 2001, pp. 79-80.	☐
	241	LYNN P.A., "Recursive Digital Filters for Biological Signals," Med. & Biol. Engineering, Vol. 9, 1971, pp. 37-43.	☐
	242	MAHER R.C., "A Method for Extrapolation of Missing Digital Audio Data," Preprints of Papers Presented at the AES Convention, New York, 1993, pp. 1-19.	☐
	243	MAHER R.C., "Audio Enhancement Using Nonlinear Time-Frequency Filtering," AES 26th International Conference, July 7-9, 2005, pp. 1-9.	☐
	244	MAIDAN R., et al., "Elimination of Electrooxidizable Interferent-Produced Currents in Amperometric Biosensors," Analytical Chemistry, Vol. 64, 1992, pp. 2889-2896.	☐
	245	MAKALE M.T., et al., "Tissue Window Chamber System for Validation of Implanted Oxygen Sensors," American Journal of Physiology-Heart and Circulatory Physiology, Vol. 284, February 21, 2003, pp. 1-27.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 144 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	246	MALIN S.F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy," Clinical Chemistry, Vol. 45 (9), 1999, pp. 1651-1658.	☐
	247	MANCY K.H., et al., "A Galvanic Cell Oxygen Analyzer," Journal of Electroanalytical Chemistry, Vol. 4, 1962, pp. 65-92.	☐
	248	MARAN A., et al., "Continuous Subcutaneous Glucose Monitoring in Diabetic Patients," A Multicenter Analysis, Diabetes Care, Vol. 25 (2), February 2002, pp. 347-352.	☐
	249	MARCH W.F., "Dealing with the Delay," Diabetes Technology & Therapeutics, Vol. 4 (1), 2002, pp. 49-50.	☐
	250	MARENA S., et al., "The Artificial Endocrine Pancreas in Clinical Practice and Research," Panminerva Medica, Vol. 35 (2), 1993, pp. 67-74.	☐
	251	MARTIN R.F., "General Deming Regression for Estimating Systematic Bias and its Confidence Interval in Method-Comparison Studies," Clinical Chemistry, Vol. 46 (1), 2000, pp. 100-104.	☐
	252	MASCINI M., et al., "Glucose Electrochemical Probe with Extended Linearity for Whole Blood," Journal Pharmaceutical and Biomedical Analysis, Vol. 7 (12), 1989, pp. 1507-1512.	☐
	253	MASTROTOTARO J.J., et al., "An Electroenzymatic Glucose Sensor Fabricated on a Flexible Substrate," Sensors and Actuators B, Vol. 5, 1991, pp. 139-144.	☐
	254	MASTROTOTARO J.J., et al., "Reproducibility of the Continuous Glucose Monitoring System Matches Previous Reports and the Intended Use of the Product," Diabetes Care, Vol. 26 (1), January 2003, pp. 256-257.	☐
	255	MASTROTOTARO J.J., "The MiniMed Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S13-S18.	☐
	256	MATSUKI H., "Energy Transfer System Utilizing Amorphous Wires For Implantable Medical Devices," IEEE Transactions on Magnetics, Vol. 31 (2), 1994, pp. 1276-1282.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 145 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	257	MATSUMOTO T., et al., "A long-Term Lifetime Amperometric Glucose Sensor with a Perfluorocarbon Polymer Coating," Biosensors & Bioelectronics, Vol. 16, 2001, pp. 271-276.	☐
	258	MATSUMOTO T., et al., "A Micro-Planar Amperometric Glucose Sensor Unsusceptible to Interference Species," Sensors and Actuators B, 49, 1998, pp. 68-72.	☐
	259	MATTHEWS D.R., et al., "An Amperometric Needle-Type Glucose Sensor Testing in Rats and Man," Diabetic Medicine, Vol. 5, 1988, pp. 248-252.	☐
	260	MAZZE R.S., et al., "Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis," Diabetes Technology & Therapeutics, Vol. 10 (3), 2008, pp. 149-159.	☐
	261	MAZZOLA F., et al., "Video Diabetes: A Teaching Tool for Children with Insulin-Dependent Diabetes," IEEE, Proceedings 7th Annual Symposium on Computer Applications in Medical Care, October 1983, 1 page Abstract.	☐
	262	McCARTNEY L.J., et al., "Near-Infrared Fluorescence Lifetime Assay for Serum Glucose Based on Allophycocyanin-Labeled Concanavalin A," Analytical Biochemistry, Vol. 292, 2001, pp. 216-221.	☐
	263	McGARRAUGH G., et al., "Glucose Measurements Using Blood Extracted From The Forearm And The Finger," TheraSense, Inc., 2001, pp. 1-8.	☐
	264	McGARRAUGH G., et al., "Physiological Influences on Off-Finger Glucose Testing", Diabetes Technology & Therapeutics, Vol. 3 (3), 2001, pp. 367-376.	☐
	265	McGRATH M.J., et al., "The Use of Differential Measurements with a Glucose Biosensor for Interference Compensation During Glucose Determinations by Flow Injection Analysis," Biosens Bioelectron, Vol. 10, 1995, pp. 937-943.	☐
	266	McKEAN B.D., et al., "A Telemetry Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors," IEEE Transactions on Biomedical Engineering, Vol. 35 (7), July 1988, pp. 526-532.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 146 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	267	MEMOLI A., et al., "A Comparison between Different Immobilised Glucoseoxidase-Based Electrodes," Journal of Pharmaceutical and Biomedical Analysis, Vol. 29, 2002, pp. 1045-1052.	☐
	268	MERRIAM WEBSTER Online Dictionary, Definition for "Aberrant," retrieved from https://www.merriam-webster.com/dictionary/aberrant August 19, 2008, 1 page.	☐
	269	MERRIAM-WEBSTER Online Dictionary, Definition of "Acceleration" retrieved from http://www.merriam-webster.com/dictionary/Acceleration January 11, 2010, 1 page.	☐
	270	MERRIAM-WEBSTER Online Dictionary, Definition of "Nominal" retrieved from http://www.merriam-webster.com/dictionary/nominal April 23, 2007, 1 page.	☐
	271	MERRIAM-WEBSTER Online Dictionary, Definition of "System". http://www.merriamwebster.com/dictionary/System January 11, 2010, 2 pages.	☐
	272	METZGER M., et al., "Reproducibility of Glucose Measurements using the Glucose Sensor," Diabetes Care, Vol. 25 (6), July 2002, pp. 1185-1191.	☐
	273	MEYERHOFF C., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose in Men by Combining Portable Glucosensor With Microdialysis," Diabetologia, Vol. 35 (11), 1992, pp. 1087-1092.	☐
	274	MILLER J.A., et al., "Development of an Autotuned Transcutaneous Energy Transfer System," ASAIO Journal, Vol. 39, 1993, pp. M706-M710.	☐
	275	MOATTI-SIRAT D., et al., "Evaluating In Vitro and In Vivo the Interference of Ascorbate and Acetaminophen on Glucose Detection by a Needle-Type Glucose Sensor," Biosensors and Bioelectronics, Vol. 7, 1992, pp. 345-352.	☐
	276	MOATTI-SIRAT D., et al., "Reduction of Acetaminophen Interference in Glucose Sensors by a Composite Nafion Membrane: Demonstration in Rats and Man," Diabetologia, Vol. 37 (6), June 1994, pp. 610-616.	☐
	277	MOATTI-SIRAT., et al., "Towards Continuous Glucose Monitoring: In Vivo Evaluation of a Miniaturized Glucose Sensor Implanted for Several Days in Rat Subcutaneous Tissue," Diabetologia, Vol. 35, 1992, pp. 224-230.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 147 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	278	MONSOD T.P., et al., "Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia And Hyperinsulinemia? ,"Diabetes Care, Vol. 25 (5), 2002, pp. 889-893.	☐
	279	MORBIDUCCI U., et al., "Improved Usability of the Minimal Model of Insulin Sensitivity Based on Automated Approach and Genetic Algorithms for Parameter Estimation," Clinical Science, Vol. 112 (4), 2006, 24 pages.	☐
	280	MORFF R.J., et al., "Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors," Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vol. 12 (2), 1990, pp. 0483-0484.	☐
	281	MOSBACH K., et al., "Determination of Heat Changes in the Proximity of Immobilized Enzymes with an Enzyme Thermistor and its Use for the Assay of Metabolites," Biochimica Biophysica Acta, Vol. 403, 1975, pp. 256-265.	☐
	282	MOTONAKA J., et al., "Determination of Cholesterol and Cholesterol Ester with Novel enzyme Microsensors," Anal. Chem., Vol. 65, 1993, pp. 3258-3261.	☐
	283	MOUGIAKAKOU S.G., et al., "A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients," Conf Proc IEEE Eng Med Biol Soc. 2005, Vol. 1, pp. 298-301.	☐
	284	MOUSSY F., et al., "A Miniaturized Nafion-Based Glucose Sensor: In Vitro and In Vivo Evaluation in Dogs," International Journals of Artificial Organs, Vol. 17 (2), 1994, pp. 88-94.	☐
	285	MOUSSY F., et al., "Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating," Analytical Chemistry, Vol. 65, August 1, 1993, pp. 2072-2077.	☐
	286	MOUSSY F., "Implantable Glucose Sensor: Progress and Problems," IEEE, November 2002, pp. 270-273.	☐
	287	MURPHY S.M., et al., "Polymer Membranes in Clinical Sensor Applications, II. The Design and Fabrication of Permselective Hydrogels for Electrochemical Devices," Biomaterials, 1992, Vol. 13 (14), pp. 979-990.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 148 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	288	MUSLU, "Trickling Filter Performance," Applied Biochemistry and Biotechnology, Vol. 37, 1992, pp. 211-224.	☐
	289	MYLER S., et al., "Ultra-Thin-Polysiloxane-Film-Composite Membranes for the Optimisation of Amperometric Oxidase Enzyme Electrodes," Biosensors & Bioelectronics, Vol. 17, 2002, pp. 35-43.	☐
	290	NEUBURGER G.G., et al., "Pulsed Amperometric Detection of Carbohydrates at Gold Electrodes with a Two-Step Potential Waveform," Anal. Chem., Vol. 59, 1987, pp. 150-154.	☐
	291	Nintendo Healthcare, Wired, December 1993, 1 page.	☐
	292	Notice of Allowance for U.S Application No. 14/066,650, mailed February 16, 2017, 7 pages.	☐
	293	Notice of Allowance for U.S Application No. 15/796,274, mailed July 20, 2018, 8 pages.	☐
	294	NOUJAIM S.E., et al., "Accuracy Requirements for a Hypoglycemia Detector: An Analytical Model to Evaluate the Effects of Bias, Precision and Rate of Glucose Change," Journal of Diabetes Science & Technology, Vol. 1 (5), September 2007, pp. 652-668.	☐
	295	NOVO NORDISK PHARMACEUTICALS Inc., "Diabetes Educational Video Game Recognized by Software Publishers Association," Press Release, March 14, 1994, 4 pages.	☐
	296	O'DONOGHUE M., et al., "Electrochemical Impedance Spectroscopy: Testing Coatings for Rapid Immersion Service," Materials Performance, September 2003, pp. 36-41.	☐
	297	Office Action for European Application No. 07840311.3, mailed August 18, 2011, 5 pages - Atty. Docket No. DEXCOM.088VEP.	☐
	298	Office Action for U.S Application No. 11/077,759, mailed July 10, 2008, 10 pages - Atty. Docket No. DEXCOM.050A.	☐
	299	Office Action for U.S Application No. 11/077,759, mailed March 31, 2008, 16 pages - Atty. Docket No. DEXCOM.050A.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 149 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	300	Office Action for U.S Application No. 11/077,759, mailed May 26, 2009, 8 pages - Atty. Docket No. DEXCOM.050A.	☐
	301	Office Action for U.S Application No. 11/360,819, mailed August 11, 2008, 10 pages - Atty. Docket No. DEXCOM.061CP4.	☐
	302	Office Action for U.S Application No. 11/360,819, mailed December 26, 2008, 12 pages - Atty. Docket No. DEXCOM.061CP4.	☐
	303	Office Action for U.S Application No. 11/691,424, mailed June 11, 2009, 21 pages - Atty. Docket No. DEXCOM.088CP3.	☐
	304	Office Action for U.S Application No. 11/691,424, mailed September 25, 2008, 15 pages - Atty. Docket No. DEXCOM.088CP3.	☐
	305	Office Action for U.S Application No. 11/691,432, mailed June 10, 2009, 17 pages - Atty. Docket No. DEXCOM.088CP2.	☐
	306	Office Action for U.S Application No. 11/691,432, mailed September 19, 2008, 11 pages - Atty. Docket No. DEXCOM.088CP2.	☐
	307	Office Action for U.S Application No. 11/691,466, mailed October 03, 2008, 15 pages - Atty. Docket No. DEXCOM.088CP4.	☐
	308	Office Action for U.S Application No. 12/055,098, mailed February 27, 2013, 14 pages - Atty. Docket No. DEXCOM.106A.	☐
	309	Office Action for U.S Application No. 12/055,098, mailed July 19, 2013, 12 pages - Atty. Docket No. DEXCOM.106A. .	☐
	310	Office Action for U.S Application No. 12/055,098, mailed March 25, 2011, 16 pages - Atty. Docket No. DEXCOM.106A.	☐
	311	Office Action for U.S Application No. 12/055,098, mailed October 05, 2010, 12 pages - Atty. Docket No. DEXCOM.106A.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 150 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	312	Office Action for U.S Application No. 12/267,542, mailed June 20, 2012, 8 pages - Atty. Docket No. DEXCOM.016CP2.	☐
	313	Office Action for U.S Application No. 12/267,542, mailed October 5, 2012, 8 pages - Atty. Docket No. DEXCOM.016CP2.	☐
	314	Office Action for U.S Application No. 14/066,650, mailed September 23, 2016, 6 pages.	☐
	315	Office Action for U.S Application No. 14/077,004, mailed July 26, 2016, 14 pages.	☐
	316	OHARA T.J., et al., "Glucose Electrodes Based On Cross-Linked [Os(bpy)2Cl](+/2+) Complexed Poly(1-Vinylimidazole) Films," Analytical Chemistry, Vol. 65, December 1993, pp. 3512-3517.	☐
	317	OHARA T.J., et al., ""Wired" Enzyme Electrodes for Amperometric Determination of Glucose or Lactate in the Presence of Interfering Substances," Anal Chem, Vol. 66, 1994, pp. 2451-2457.	☐
	318	OKUDA, et al., "Mutarotase Effect on Micro Determinations of D-Glucose and its Anomers with β D-Glucose Oxidase," Anal Biochem, Vol. 43 (1), 1971, pp. 312-315.	☐
	319	Oxford English Dictionary Online, Definition of "Impending," http://www.askoxford.com/results/?view=devdict&field-12668446_Impending&branch January 11, 2010, 1 page.	☐
	320	PALMISANO F., et al., "Simultaneous Monitoring of Glucose and Lactate by an Interference and Cross- Talk Free Dual Electrode Amperometric Biosensor Based on Electropolymerized Thin Films," Biosensors & Bioelectronics, Vol. 15, 2000, pp. 531-539.	☐
	321	PANTELEON A.E., et al., "The Role of the Independent Variable to Glucose Sensor Calibration," Diabetes Technology & Therapeutics, Vol. 5 (3), 2003, pp. 401-410.	☐
	322	PARK, et al., "Novel Instrumentation in Electrochemical Impedance Spectroscopy and a Full Description of an Electrochemical System," Pure Appl. Chem., 2006, Vol. 78 (5), pp. 1069-1080.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 151 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	323	PARKER R.S., et al., "A Model-Based Algorithm for Blood Glucose Control In Type I Diabetic Patients," IEEE Trans Biomed Engg (BME), Vol. 46(2), 1999, pp. 148-157.	☐
	324	PARKER R.S., et al., "Robust H∞ Glucose Control in Diabetes Using a Physiological Model," AIChE Journal, Vol. 46 (12), December 2000, pp. 2537-2549.	☐
	325	PATEL H., et al., "Amperometric Glucose Sensors Based on Ferrocene Containing Polymeric Electron Transfer Systems--A Preliminary Report," Biosensors & Bioelectronics, Vol. 18, 2003, pp. 1073-1076.	☐
	326	PEACOCK W.F., et al., "Cardiac Troponin and Outcome in Acute Heart Failure," N. Engl. J. Med., Vol. 358, 2008, pp. 2117-2126.	☐
	327	PEGUIN S., et al., "Pyruvate Oxidase and Oxaloacetate Decarboxylase Enzyme Electrodes--Simultaneous Determination of Transaminases with a Two-electrode-based Analyzer," Analytica Chimica Acta, Vol. 222, 1989, pp. 83-93.	☐
	328	PFEIFFER E.F., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose is Feasible by Combining Portable Glucosensor with Microdialysis," Horm. Metab. Res., Vol. 25, 1993, pp. 121-124.	☐
	329	PFEIFFER E.F., "The Glucose Sensor: The Missing Link in Diabetes Therapy," Horm Metab Res Suppl., Vol. 24, 1990, pp. 154-164.	☐
	330	PHILLIPS R.P., "A High Capacity Transcutaneous Energy Transmission System," ASIAO Journal, Vol. 41, 1995, pp. M259-M262.	☐
	331	PICHERT J.W., et al., "Issues for the Coming Age of Continuous Glucose Monitoring," Diabetes Educator, Vol. 26 (6), November-December 2000, pp. 969-980.	☐
	332	PICKUP J.C., et al., "Developing Glucose Sensors for In Vivo Use," Elsevier Science Publishers Ltd (UK), TIBTECH, Vol. 11, 1993, pp. 285-291.	☐
	333	PICKUP J.C., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensor Strategy," Biosensors, Vol. 3, (1987/1988), pp. 335-346.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 152 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	334	PICKUP J.C., et al., "In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer," Diabetologia, Vol. 32, 1989, pp. 213-217.	☐
	335	PICKUP J.C., et al., "Potentially-Implantable, Amperometric Glucose Sensors with Mediated Electron Transfer: Improving the Operating Stability," Biosensors, Vol. 4, 1989, pp. 109-119.	☐
	336	PICKUP J.C., et al., "Responses and Calibration of Amperometric Glucose Sensors Implanted in the Subcutaneous Tissue of Man," ACTA Diabetol, Vol. 30, 1993, pp. 143-148.	☐
	337	PINNER S.H., et al., "Cross-Linking of Cellulose Acetate by Ionizing Radiation," Nature, Vol. 184, October 24, 1959, pp. 1303-1304.	☐
	338	PISHKO M.V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels," Analytical Chemistry, Vol. 63 (20), 1991, pp. 2268-2272.	☐
	339	PITZER K.R., et al., "Detection of Hypoglycemia with the Glucowatch Biographer," Diabetes Care, Vol. 24 (5), 2001, pp. 881-885.	☐
	340	POIRIER J.Y., et al., "Clinical and Statistical Evaluation of Self-Monitoring Blood Glucose Meters," Diabetes Care, Vol. 21 (11), November 1998, pp. 1919-1924.	☐
	341	POITOUT V., et al., "A Glucose Monitoring System for on Line Estimation in Man of Blood Glucose Concentration Using a Miniaturized Glucose Sensor Implanted in the Subcutaneous Tissue and a Wearable Control Unit," Diabetologia, Vol. 36, 1993, pp. 658-663.	☐
	342	POITOUT V., et al., "Development of a Glucose Sensor for Glucose Monitoring in Man: The Disposable Implant Concept," Clinical Materials, Vol. 15, 1994, pp. 241-246.	☐
	343	POITOUT V., et al., "In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor," ASAIO Transactions, Vol. 37, 1991, pp. M298-M300.	☐
	344	POSTLETHWAITE T.A., et al., "Interdigitated Array Electrode as an Alternative to the Rotated Ring-Disk Electrode for Determination of the Reaction Products of Dioxygen Reduction," Analytical Chemistry, Vol. 68 (17), September 1996, pp. 2951-2958.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 153 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	345	PRABHU V.G., et al., "Electrochemical Studies of Hydrogen Peroxide at a Platinum Disc Electrode," Electrochimica Acta, Vol. 26 (6), 1981, pp. 725-729.	☐
	346	QUINN C.A.P., et al., "Biocompatible, Glucose-Permeable Hydrogel for In situ Coating of Implantable Biosensors," Biomaterials, Volume. 18 (24), 1997, pp. 1665-1670.	☐
	347	QUINN C.P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors," The American Physiological Society, Vol. 269, 1995, pp. E155-E161.	☐
	348	RABAH M.A., et al., "Electrochemical Wear of Graphite Anodes During Electrolysis of Brine," Carbon, Vol. 29 (2), 1991, pp. 165-171.	☐
	349	RAYA Systems Pioneers, "Raya Systems Pioneers Healthy Video Games," PlayRight, November 1993, pp. 14-15.	☐
	350	REACH G., "A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors," Biosensors, Vol. 2, 1986, pp. 211-220.	☐
	351	REACH G., et al., "Can Continuous Glucose Monitoring Be Used for the Treatment of Diabetes? ," Analytical Chemistry, Vol. 64 (6), March 15, 1992, pp. 381A-386A.	☐
	352	REACH G., "Which Threshold to Detect Hypoglycemia? Value of Receiver-Operator Curve Analysis to Find a Compromise Between Sensitivity and Specificity," Diabetes Care, Vol. 24 (5), May 2001, pp. 803-804.	☐
	353	REBRIN K., et al., "Automated Feedback Control of Subcutaneous Glucose Concentration in Diabetic Dogs," Diabetologia, Vol. 32, 1989, pp. 573-576.	☐
	354	REBRIN K., et al., "Subcutaneous Glucose Monitoring by Means of Electrochemical Sensors: Fiction or Reality?," Journal of Biomedical Engineering, Vol. 14, January 1992, pp. 33-40.	☐
	355	REBRIN K., et al., "Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring," The American Physiological Society, Vol. 277, 1999, pp. E561-E571.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 154 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	356	Response for European application No. 07843011.3, filed September 21, 2007, 11 pages - Atty. Docket No. DEXCOM.088VEP.	☐
	357	REUSH, "Organometallic Compounds," Chemical Reactivity, Virtual Textbook of Organic Chemistry, Retrieved from http://www.cem.msu.edu/-reuschlVirtualText/orgmetal.htm 2004, pp. 1-16.	☐
	358	RHODES R.K., et al., "Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis," Analytical Chemistry, Vol. 66 (9), May 1, 1994, pp. 1520-1529.	☐
	359	RIGLA M., et al., "Real-Time Continuous Glucose Monitoring Together with Telemedical Assistance Improves Glycemic Control and Glucose Stability in Pump-Treated Patients," Diabetes Technology & Therapeutics, Vol. 10 (3), 2008, pp. 194-199.	☐
	360	RINKEN T., et al., "Calibration of Glucose Biosensors By Using Pre-Steady State Kinetic Data," Biosensors & Bioelectronics, Vol. 13, 1998, pp. 801-807.	☐
	361	RIVERS E.P., et al., "Central Venous Oxygen Saturation Monitoring in the Critically Ill Patient," Current Opinion in Critical Care, 2001, Vol. 7, pp. 204-211.	☐
	362	ROE J.N., et al., "Bloodless Glucose Measurements," Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol. 15 (3), 1998, pp. 199-241.	☐
	363	SAKAKIDA M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations," Artif. Organs Today, Vol. 2 (2), 1992, pp. 145-158.	☐
	364	SAKAKIDA M., et al., "Ferrocene-Mediated Needle Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane," Sensors and Actuators B, Vol. 13-14, 1993, pp. 319-322.	☐
	365	SALARDI S., et al., "The Glucose Area Under the Profiles Obtained with Continuous Glucose Monitoring System Relationships with HbA1C in Pediatric Type 1 Diabetic Patients," Diabetes Care, Vol. 25 (10), October 2002, pp. 1840-1844.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 155 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	366	SALEHI C., et al., "A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors," Analytical Letters, Vol. 29 (13), 1996, pp. 2289-2308.	☐
	367	SAMUELS M.P., "The Effects of Flight and Altitude," Arch Dis Child, Vol. 89, 2004, pp. 448-455.	☐
	368	SAN DIEGO PLASTICS INC, "Polyethylene," Datasheet, Retrieved from http://www.sdplastics.com/polyeth.html on August 19, 2009, 7 pages.	☐
	369	SANSEN W., et al., "A Smart Sensor for the Voltammetric Measurement of Oxygen or Glucose Concentrations," Sensors and Actuators B1, 1990, pp. 298-302.	☐
	370	SANSEN W., et al., "Glucose Sensor with Telemetry System," In Implantable Sensors for Closed Loop Prosthetic Systems edited by KO W.H, Chapter 12, 1985, pp. 167-175.	☐
	371	SCHAFFAR B.P.H., "Thick Film Biosensors for Metabolites in Undiluted Whole Blood and Plasma Samples," Analytical Bioanalytical Chemistry, Dec 2001, Vol. 372, pp. 254-260.	☐
	372	SCHMIDT F.J., et al., "Calibration of a Wearable Glucose Sensor," The International Journal of Artificial Organs, Wichtig Publishing, IT, Vol. 15 (1), January 01, 1992, pp. 55-61.	☐
	373	SCHMIDT F.J., et al., "Glucose Concentration in Subcutaneous Extracellular Space," Diabetes Care, Vol. 16 (5), May 1993, pp. 695-700.	☐
	374	SCHMIDTKE D.W., et al., "Accuracy of the One-Point in Vivo Calibration of "Wired" Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration," Analytical Chemistry, Vol. 70 (10), May 15, 1998, pp. 2149-2155.	☐
	375	SCHMIDTKE D.W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin," Proceedings of the National Academy of Sciences, Vol. 95, January 1998, pp. 294-299.	☐
	376	SCHOEMAKER M., et al., "The SCGMI System: Subcutaneous Continuous Glucose Monitoring Based on Microdialysis Technique," Diabetes Technology & Therapeutics, Vol. 5 (4), 2003, pp. 599-608.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 156 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	377	SCHOONEN A.J.M., et al., "Development of a Potentially Wearable Glucose Sensor for Patients with Diabetes Mellitus: Design and In-vitro Evaluation," Biosensors & Bioelectronics, Vol. 5, 1990, pp. 37-46.	☐
	378	SCHULER, et al., "Modified Gas-Permeable Silicone Rubber Membranes for Covalent Immobilisation of Enzymes and their Use in Biosensor Development," Analyst, 1999, Vol. 124, pp. 1181-1184.	☐
	379	SERVICE F.J., et al., "Mean Amplitude of Glycemic Excursions, A Measure of Diabetic Instability," Diabetes, Vol. 19 (9), September 1970, pp. 644-655.	☐
	380	SERVICE F.J., et al., "Measurements of Glucose Control," Diabetes Care, Vol. 10 (2), March-April 1987, pp. 225-237.	☐
	381	SERVICE R.F., "Can Sensors Make a Home in the Body?," Science, Materials Science: Soft Surface, Volume. 297, August 9, 2002, pp. 962-963.	☐
	382	SHARKAWY A.A., et al., "Engineering the Tissue Which Encapsulates Subcutaneous Implants. I. Diffusion Properties," Journal of Biomedical Materials Research, Vol. 37, 1996, pp. 401-412.	☐
	383	SHAW G.W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients," Biosensors & Bioelectronics, Vol. 6, 1991, pp. 401-406.	☐
	384	SHICHIRI, et al., "In Vivo Characteristics of Needle-Type Glucose Sensor-Measurements of Subcutaneous Glucose Concentrations in Human Volunteers," Implantable Glucose Sensors-The State of the Art, Hormone and Metabolic Research Supplement Series, 1988, Vol. 20, pp. 17-20.	☐
	385	SHICHIRI M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas," Diabetologia, Vol. 24, 1983, pp. 179-184.	☐
	386	SHICHIRI M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor," Diabetes Nutrition & Metabolism, Vol. 2 (4), 1989, pp. 309-313.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 157 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	387	SHICHIRI M., et al., "Needle Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," In Implantable Sensors for Closed-Loop Prosthetic Systems edited by KO W.H, Chapter 15, 1985, pp. 197-210.	☐
	388	SHICHIRI M., et al., "Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals," Diabetes Care, Vol. 9 (3), May-June 1986, pp. 298-301.	☐
	389	SHICHIRI M., et al., "Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor," Preliminary Communication, Lancet, Vol. 2, November 20, 1982, pp. 1129-1131.	☐
	390	SHULTS M.C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors," IEEE Transactions on Biomedical Engineering, Vol. 41 (10), October 1994, pp. 937-942.	☐
	391	Sigma-Aldrich Corp. "Nafion® 117 Solution Product Description, Product No. 70160," retrieved from https//:http://www.sigmaaldrich.com/cgi-bin/hsrun/Suite7/Suite/HAHTpage/Suite.HsExternalProd on Apr. 7, 2005, 1 page.	☐
	392	SKYLER J.S., "The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S7-S12.	☐
	393	SLATER-MACLEAN L., et al., "Accuracy of Glycemic Measurements in the Critically Ill," Diabetes Technology and Therapeutics, Vol. 10 (3), 2008, pp. 169-177.	☐
	394	SMITH B., et al., "An Externally Powered, Multichannel, Implantable Stimulator-Telemeter for Control of Paralyzed Muscle," IEEE Transactions on Biomedical Engineering, Vol. 45 (4), April 1998, pp. 463-475.	☐
	395	SOKOL L., et al., "Immobilized-Enzyme Rate-Determination Method for Glucose Analysis," Clinical Chemistry, Vol. 26 (1), 1980, pp. 89-92.	☐
	396	SOKOLOV S., et al., "Metrological Opportunities of the Dynamic Mode of Operating an Enzyme Amperometric Biosensor," Medical Engineering & Physics, Vol. 17 (6), 1995, pp. 471-476.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 158 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	397	SPARACINO G., et al., "Continuous Glucose Monitoring Time Series and Hypo-Hyperglycemia Prevention: Requirements, Methods, Open Problems," Current Diabetes Reviews, Vol. 4 (3), 2008, pp. 181-192.	☐
	398	SPROULE B.A., et al., "Fuzzy Pharmacology: Theory and Applications," Trends in Pharmacological Sciences, Vol. 23 (9), September 2002, pp. 412-417.	☐
	399	SRIYUDTHSAK M., et al., "Enzyme-Epoxy Membrane Based Glucose Analyzing System and Medical Applications," Biosensors & Bioelectronics, Vol. 11 (8), 1996, pp. 735-742.	☐
	400	STEIL G.M., et al., "Closed-Loop Insulin Delivery--the Path of Physiological Glucose Control," Advanced Drug Delivery Reviews, Vol. 56, 2004, pp. 125-144.	☐
	401	STEIL G.M., et al., "Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor," Diabetes Technology & Therapeutics, Vol. 5 (1), 2003, pp. 27-31.	☐
	402	STERN M., et al., "Electrochemical Polarization: I. A Theoretical Analysis of the Shape of Polarization Curves," Journal of the Electrochemical Society, Vol. 104 (1), January 1957, pp. 56-63.	☐
	403	STERNBERG, et al., "Covalent Enzyme Coupling on Cellulose Acetate Membranes for Glucose Sensor Development," Anal Chem, December 1988, Vol. 60(24), pp. 2781-2786.	☐
	404	STERNBERG F., et al., "Does Fall in Tissue Glucose Precede Fall in Blood Glucose?," Diabetologia, Vol. 39, 1996, pp. 609-612.	☐
	405	STERNBERG R., et al., "Study and Development of Multilayer Needle-type Enzyme Based Glucose Microsensors," Biosensors, Vol. 4, 1988, pp. 27-40.	☐
	406	STREET J.O., et al., "A Note on Computing Robust Regression Estimates Via Iteratively Reweighted Least Squares," The American Statistician, Vol. 42 (2), May 1988, pp. 152-154.	☐
	407	SUMINO T., et al., "Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique," Proceedings of the 20th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vol. 20 (4), 1998, pp. 1775-1778.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 159 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	408	TAKATSU I., et al., "Solid State Biosensors Using Thin-Film Electrodes," Sensors and Actuators, 1987, Vol. 11, pp. 309-317.	☐
	409	TAKEGAMI S., et al., "Pervaporation of Ethanol/Water Mixtures Using Novel Hydrophobic Membranes Containing Polydimethylsiloxane," Journal of Membrane Science, Vol. 75, 1992, pp. 93-105.	☐
	410	TAMURA T., et al., "Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique and a Null Method-A Numerical Analysis," Frontiers of Medical & Biological Engineering, Vol. 10 (2), 2000, pp. 147-156.	☐
	411	TANENBERG R.J., et al., "Continuous Glucose Monitoring System: A New Approach to the Diagnosis of Diabetic Gastroparesis," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S73-S80.	☐
	412	TATSUMA T., et al., "Oxidase/Peroxidase Bilayer-Modified Electrodes as Sensors for Lactate, Pyruvate, Cholesterol and Uric Acid," Analytica Chimica Acta, Vol. 242, 1991, pp. 85-89.	☐
	413	The Diabetes Control and Complications Trial Research Group, "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus," The New England, Journal of Medicine, Vol. 329 (14), September 30, 1993, pp. 977-986.	☐
	414	THIJSSEN, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 1,Theory and Simulations, Analytica chimica Acta, 1984, Vol. 156, pp. 87-101.	☐
	415	THIJSSEN, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 3,Variance Reduction ,Analytica chimica Acta, 1985, Vol. 173, pp. 265-272.	☐
	416	THIJSSEN, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 4,Flow Injection Analysis, Analytica chimica Acta, 1985, Vol. 174, pp. 27-40.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 160 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	417	THIJSSEN P.C.,"A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 2,Optimal Designs, Analytica chimica Acta, Vol. 162, 1984, pp. 253-262.	☐
	418	THOME V., et al., "(Abstract) Can the Decrease in Subcutaneous Glucose Concentration Precede the Decrease in Blood Glucose Level? Proposition for a Push-Pull Kinetics Hypothesis," Horm. metab. Res., Vol. 27, 1995, page 53.	☐
	419	THOME-DURET V., et al., "Continuous Glucose Monitoring in the Free-Moving Rat," Metabolism, Vol. 47 (7), July 1998, pp. 799-803.	☐
	420	THOME-DURET V., et al., "Modification of the Sensitivity of Glucose Sensor Implanted into Subcutaneous Tissue," Diabetes & Metabolism, Vol. 22, 1996, pp. 174-178.	☐
	421	THOME-DURET V., et al., "Use of a Subcutaneous Glucose Sensor to Detect Decreases in Glucose Concentration Prior to Observation in Blood," Analytical Chemistry, Vol. 68 (21), November 1, 1996, pp. 3822-3826.	☐
	422	THOMPSON M., et al., "In Vivo Probes: Problems and Perspectives," Clinical Biochemistry, Vol. 19 (5), October 1986, pp. 255-261.	☐
	423	TIERNEY M.J., et al., "Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer," Diabetes Technology & Therapeutics, Vol. 2 (2), 2000, pp. 199-207.	☐
	424	TILBURY J.B., et al., "Receiver Operating Characteristic Analysis for Intelligent Medical Systems - A New Approach for Finding Confidence Intervals," IEEE Transactions on Biomedical Engineering, Vol. 47 (7), July 2000, pp. 952-963.	☐
	425	TORJMAN M.C., et al., "Glucose Monitoring in Acute Care: Technologies on the Horizon," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 178-181.	☐
	426	TRAJANOSKI Z., et al., "Neural Predictive Controller For Insulin Delivery Using The Subcutaneous Route," IEEE Transactions on Biomedical Engineering, Vol. 45(9), 1998, pp. 1122-1134.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 161 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	427	TRECROCI D., "A Glimpse into the Future-Continuous Monitoring of Glucose with a Microfiber," Diabetes Interview, July 2002, pp. 42-43.	☐
	428	TSE P.S.H., et al., "Time-Dependent Inactivation of Immobilized Glucose Oxidase and Catalase," Biotechnology & Bioengineering, Vol. 29, 1987, pp. 705-713.	☐
	429	TURNER A.P.F., "Amperometric Biosensor based on Mediator-Modified Electrodes," Methods in Enzymology, 1988, Vol. 137, pp. 90-103.	☐
	430	TURNER A.P.F., et al., "Carbon Monoxide: Acceptor Oxidoreductase from Pseudomonas Thermocarboxydovorans Strain C2 and its Use in a Carbon Monoxide Sensor," Analytica Chimica Acta, Vol. 163, 1984, pp. 161-174.	☐
	431	TURNER A.P.F., et al., "Diabetes Mellitus: Biosensors for Research and Management," Biosensors, Vol. 1, 1985, pp. 85-115.	☐
	432	UNGER J., et al., "Glucose Control in the Hospitalized Patient," Emergency Medicine, Vol. 36 (9), 2004, pp. 12-18. .	☐
	433	UPDIKE S.J., et al., "A Subcutaneous Glucose Sensor with Improved Longevity, Dynamic Range, and Stability of Calibration," Diabetes Care, Vol. 23 (2), February 2000, pp. 208-214.	☐
	434	UPDIKE S.J., et al., "Continuous Glucose Monitor Based on an Immobilized Enzyme Electrode Detector," Journal of Laboratory and Clinical Medicine, Vol. 93(4), 1979, pp. 518-527.	☐
	435	UPDIKE S.J., et al., "Enzymatic Glucose Sensor: Improved Long-Term Performance in Vitro and In Vivo," ASAIO Journal, Vol. 40 (2), April-June 1994, pp. 157-163.	☐
	436	UPDIKE S.J., et al., "Implanting the Glucose Enzyme Electrode: Problems, Progress, and Alternative Solutions," Diabetes Care, Vol. 5 (3), May-June 1982, pp. 207-212.	☐
	437	UPDIKE S.J., et al., "Laboratory Evaluation of New Reusable Blood Glucose Sensor," Diabetes Care, Vol. 11 (10), November-December 1988, pp.801-807.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 162 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	438	UPDIKE S.J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose Form Inside a Subcutaneous Foreign Body Capsule (FBC)," Edited by Fraser D M, Biosensors in the Body: Continuous in vivo Monitoring, John Wiley & Sons Ltd., New York, 1997, Chapter 4, pp. 117-137.	☐
	439	UPDIKE S.J., et al., "The Enzyme Electrode," Nature, Vol. 214, June 03, 1967, pp. 986-988.	☐
	440	US 5,234,749, 06/1995, Merte et al. (withdrawn).	☐
	441	US 7,530,950, 5/12/2009, Brister et al. (withdrawn).	☐
	442	U.S. File History of Provisional Application No. 61/155,889, filed 02/26/2009 (55 pages).	☒
	443	U.S. File History of Provisional Application No. 61/155,891, filed 02/26/2009 (51 pages).	☐
	444	U.S. File History of Provisional Application No. 61/155,893 filed 02/26/2009 (51 pages).	☒
	445	U.S. File History of Provisional Application No. 61/165,499 filed 03/31/2009 (64 pages).	☐
	446	U.S. File History of Provisional Application No. 61/238,461 filed 08/31/2009 (63 pages).	☐
	447	U.S. File History of Provisional Application No. 61/290,847 filed 08/31/2009 (74 pages).	☐
	448	Utah Medical Products Inc., "Deltran - Disposable Blood Pressure Transducers," Product Specifications, 2003-2006, 6 pages.	☐
	449	VADGAMA P., "Diffusion Limited Enzyme Electrodes," NATO ASI Series: Series C, Math and Phys. Sci, Vol. 226, 1988, pp. 359-377.	☐
	450	VADGAMA P., "Enzyme Electrodes as Practical Biosensors," Journal of Medical Engineering & Technology, Vol. 5 (6), November 1981, pp. 293-298.	☐
	451	VALDES T.I., et al., "In Vitro and In Vivo Degradation of Glucose Oxidase Enzyme used for an Implantable Glucose Biosensor," Diabetes Technology & Therapeutics, Vol. 2 (3), 2000, pp. 367-376.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 163 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	452	VAN DEN BERGHE, "Tight Blood Glucose Control with Insulin in "Real-Life" Intensive Care," Mayo Clinic Proceedings, Vol. 79 (8), August 2004, pp. 977-978.	☐
	453	VELHO G., et al., "In Vitro and In Vivo Stability of Electrode Potentials in Needle-Type Glucose Sensors," Influence of Needle Material, Diabetes, Vol. 38, February 1989, pp. 164-171.	☐
	454	VELHO G., et al., "Strategies for Calibrating a Subcutaneous Glucose Sensor," Biomed Biochim Acta, Vol. 48 (11/12), 1989, pp. 957-964.	☐
	455	VON WOEDTKE T., et al., "In Situ Calibration of Implanted Electrochemical Glucose Sensors," Biomed. Biochim. Acta 48 Vol.11/12, 1989, pp. 943-952.	☐
	456	WAGNER, et al., "Continuous Amperometric Monitoring of Glucose in a Brittle Diabetic Chimpanzee with a Miniature Subcutaneous Electrode," Proc. Natl. Acad. Sci. USA, Vol. 95, May 1998, pp. 6379-6382.	☐
	457	WANG J., "Electrochemical Glucose Biosensors," American Chemical Society, Chemical Reviews, Published on Web, December 23, 2007, pp. 1-12.	☐
	458	WANG J., et al., "Highly Selective Membrane-Free Mediator-Free Glucose Biosensor," Analytical Chemistry, Vol. 66 (21), November 01, 1994, pp. 3600-3603.	☐
	459	WANG X., et al., "Improved Ruggedness for Membrane-Based Amperometric Sensors using a Pulsed Amperometric Method," Analytical Chemistry, Vol. 69 (21), November 01, 1997, pp. 4482-4489.	☐
	460	WARD, et al., "A Wire-Based Dual-Analyte Sensor for Glucose and Lactate: In Vitro and In Vivo Evaluation," Diabetes Technology and Therapeutics, 2004, Vol. 6 (3), pp. 389-401.	☐
	461	WARD W.K., et al., "A New Amperometric Glucose Microsensor: In Vitro and Short-Term In Vivo Evaluation," Biosensors & Bioelectronics, Vol. 17, 2002, pp. 181-189.	☐
	462	WARD W.K., et al., "Assessment of Chronically Subcutaneous Glucose Sensors in Dogs: The Effect of Surrounding Fluid Masses," ASAIO Journal, 1999, Vol. 45 (6), pp. 555-561.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 164 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	463	WARD W.K., et al., "Rise in Background Current Over Time in a Subcutaneous Glucose Sensor in the Rabbit," Relevance to Calibration and Accuracy, Biosensors & Bioelectronics, Vol. 15, 2000, pp. 53-61.	☐
	464	WARD W.K., et al., "Understanding Spontaneous Output Fluctuations of an Amperometric Glucose Sensor: Effect of Inhalation Anesthesia and Use of a Nonenzyme Containing Electrode," ASAIO Journal, 2000, pp. 540-546.	☐
	465	WHIPPLE G., "Low Residual Noise Speech Enhancement Utilizing Time-Frequency Filtering," Proceedings of the International Conference on Acoustics, Speech, and Signal Processing, 1994, pp. I5-I8.	☐
	466	WIENTJES K.J.C., "Development of a Glucose Sensor for Diabetic Patients," (Ph.D. Thesis), 2000, 212 pages.	☐
	467	WIKIPEDIA., "Intravenous Therapy," http://en.wikipedia.org/wiki/Intravenous_therapy, August 15, 2006, 6 pages.	☐
	468	WILKINS E., et al., "Glucose Monitoring: State of the Art and Future Possibilities," Med. Eng. Phys., Vol. 18 (4), 1996, pp. 273-288.	☐
	469	WILKINS E., et al., "Integrated Implantable Device for Long-Term Glucose Monitoring," Biosensors & Bioelectronics, Vol. 10, 1995, pp. 485-494.	☐
	470	WILKINS E.S., et al., "The Coated Wire Electrode Glucose Sensor," Horm Metab Res Suppl., Vol. 20, 1988, pp. 50-55.	☐
	471	WILSON G.S., et al., "Enzyme-Based Biosensors for In Vivo Measurements," Chem. Rev., Vol. 100, 2000, pp. 2693-2704.	☐
	472	WILSON G.S., et al., "Progress Toward the Development of an Implantable Sensor for Glucose," Clinical Chemistry, Vol. 38 (9), 1992, pp. 1613-1617.	☐
	473	WOLFE P.J., et al., "Interpolation of Missing Data Values for Audio Signal Restoration Using a Gabor Regression Model," 2005 IEEE International Conference on Acoustics, Speech, and Signal Processing, Vol. 5, 2005, pp. 517-520.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 165 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	474	WOOD W D., et al., "Hermetic Sealing with Epoxy," Pave Technology-Mechanical Engineering, March 1990, 3 pages.	☐
	475	WOODWARD S.C., "How Fibroblasts and Giant Cells Encapsulate Implants: Considerations in Design of Glucose Sensors," Diabetes Care, Vol. 5 (3) May-June 1982, pp. 278-281.	☐
	476	WORSLEY G.J et al., "Measurement of Glucose in Blood with a Phenylboronic Acid Optical Sensor," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 213-220.	☐
	477	WRIGHT M., et al., "Bioelectrochemical Dehalogenations Via Direct Electrochemistry of Poly(ethylene oxide)-Modified Myoglobin," Electrochemistry Communications, Vol. 1, 1999, pp. 609-613.	☐
	478	WU H., et al., "In Situ Electrochemical Oxygen Generation with an Immunoisolation Device," Annals New York Academy of Sciences, Vol. 875, 1999, pp. 105-125.	☐
	479	YAMASAKI Y., et al., "Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor," Clinica Chimica Acta. 93, 1989, pp. 93-98.	☐
	480	YAMASAKI Y., "The Development of a Needle-Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," Medical Journal of Osaka University, Vol. 35 (1-2), September 1984, pp. 25-34.	☐
	481	YANG C., et al., "A Comparison of Physical Properties and Fuel Cell Performance of Nafion and Zirconium Phosphate/Nation Composite Membranes," Journal of Membrane Science, Vol. 237, 2004, pp. 145-161.	☐
	482	YANG Q., et al., "Development of Needle-Type Glucose Sensor with High Selectivity," Science and Actuators B, Vol. 46, 1998, pp. 249-256.	☐
	483	YANG S., et al., "A Glucose Biosensor Based On an Oxygen Electrode: In-Vitro Performances in a Model Buffer Solution and in Blood Plasma," Biomedical Instrumentation & Technology, Vol. 30 (1), 1996, pp. 55-61.	☐
	484	YANG S., et al., "Glucose Biosensors with Enzyme Entrapped in Polymer Coating," Biomedical Instrument and Technology, March/April 1995, Vol. 29 (2), pp. 125-133.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 166 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	485	YE L., et al., "High Current Density Wired' Quinoprotein Glucose Dehydrogenase Electrode," Analytical Chemistry, Vol. 65, 1993, pp. 238-241.	☐
	486	YOO, et al., "An Electrochemical Impedance Measurement Technique Employing Fourier Transform," Anal. Chem. 2000, Vol. 72, pp. 2035-2041.	☐
	487	ZAMZOW K.L., et al., "Development and Evaluation of a Wearable Blood Glucose Monitor," ASAIO Transactions, Vol. 36 (3), 1990, pp. M588-M591.	☐
	488	ZAVALKOFF S.R., et al., "Evaluation Of Conventional Blood Glucose Monitoring as An Indicator of Integrated Glucose Values Using a Continuous Subcutaneous Sensor," Diabetes Care, Vol. 25(9), 2002, pp. 1603-1606.	☐
	489	ZETHELIUS B., et al., "Use Of Multiple Biomarkers to Improve the Prediction of Death From Cardiovascular Causes," N. Engl. J. Med., Vol. 358, May 2008, pp. 2107-2116.	☐
	490	ZHANG, et al., "Elimination of the Acetaminophen Interference in an Implantable Glucose Sensor," Analytical Chemistry, 1994, Vol. 66 (7), pp. 1183-1188.	☐
	491	ZHANG Y., et al., "Electrochemical Oxidation Of H2O2 On Pt and Pt + Ir Electrodes in Physiological Buffer and its Applicability to H2O2- Based Biosensors," J. Electro Analytical Chemistry, Vol. 345, 1993, pp. 253-271.	☐
	492	ZHANG Y., et al., "In Vitro and In Vivo Evaluation of Oxygen Effects on a Glucose Oxidase Based Implantable Glucose Sensor," Analytica Chimica Acta, Vol. 281, 1993, pp. 513-520.	☐
	493	ZHU, et al., "Fabrication and Characterization of Glucose Sensors Based on a Microarray H2O2 Electrode," Biosensors & Bioelectronics, 1994, Vol. 9, pp. 295-300.	☐
	494	ZHU, et al., "Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian blue Layer," Sensors, 2002, Vol. 2, pp. 127-136.	☐
	495	ZIAIE, et al., "A Single-Channel Implantable Microstimulator for Functional Neuromuscular Stimulation," IEEE Transactions on Biomedical Engineering, 1997, Vol. 44(10), pp. 909-920.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 167 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ian W. Gillies/	Date (YYYY-MM-DD)	2021-01-04
Name/Print	Ian W. Gillies	Registration Number	62280

34140229:abt

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/132,664	**01/04/2021 07:05:10 PM ET**	**DEXCOM.167P1**

Title of Invention

ANALYTE SENSOR

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	-
CONFIRMATION #	2055	FILED BY	Alexa Terracin
PATENT CENTER #	60126670	FILING DATE	-
CUSTOMER #	68851	FIRST NAMED INVENTOR	Peter C. Simpson
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Ian Gillies

Documents

TOTAL DOCUMENTS: 3

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DEX167P1_20210104.pdf		168	-	2044 KB
DEX167P1_20210104-TRAN.LET.pdf	(1-1)	1	Transmittal Letter	18 KB
DEX167P1_20210104-IDS.pdf	(2-167)	166	Information Disclosure Statement (IDS) Form (SB08)	2019 KB
DEX167P1_20210104-TRAN.LET.pdf	(168-168)	1	Transmittal Letter	17 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)
DEX167P1_20210104.pdf	85961F3651B08925715FE9B2CDE684E31B2C25603DF9358AD4C80891A0754FA168AFEB2799A5F2917665B6BBA775FF40C6710337B35B486AC912EE71487AA893
DEX167P1_20210104-TRAN.LET.pdf	5C7278FCBB25D1A287CB3DBC58A5CD0E42A822F9E8F541945B7A14FF68FCBA94F2E619F83BF81390DAEAC1991F64F0DF1E54CD5E99CA107A66B4BEB3525364B2
DEX167P1_20210104-IDS.pdf	88BE44FBAC3279EA65027C26A4E76C4F901D7746BE6DDB138C568A2E2278D0D48F43485E5BD3F4D51BE1195B4CBF37011E73F467BF18921A90FA4E0FEE9834A1
DEX167P1_20210104-TRAN.LET.pdf	26C84A7C32B1369E0760281AE20E2B3FB1748A2CDBB4943BB8E1DD1F8ECE0E71DBB686B0F6557D50EDD6D13394254055CE1EC5F047EC6F8C176AA9F9E0037385

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

INFORMATION DISCLOSURE STATEMENT

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Unassigned
Art Unit	:	1778
Conf. No.	:	2055

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

References and Listing

Pursuant to 37 CFR 1.56, an Information Disclosure Statement listing references is provided herewith. Listed references are of record in U.S. patent application No. 17/078,609, filed October 23, 2020, which is relied upon for an earlier filing date under 35 USC 120. Copies of the references are not submitted pursuant to 37 CFR 1.98(d).

No Disclaimers

To the extent that anything in the Information Disclosure Statement or the listed references could be construed as a disclaimer of any subject matter supported by the present application, Applicant hereby rescinds and retracts such disclaimer.

Timing of Disclosure

This Information Disclosure Statement is being filed within three months of the filing date and no fee is required.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 4, 2021

By:/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34140309:abt

United States Patent and Trademark Office

Office of the Chief Financial Officer

Document Code:WFEE

User :C41739

Sale Accounting Date:01/15/2021

Sale Item Reference Number	Effective Date
17132664	12/23/2020

Document Number	Fee Code	Fee Code Description	Amount Paid	Payment Method
I20211EF18146052	1051	LATE FILING FEE FOR OATH OR DECLARATION	$160.00	Deposit Account

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/132,664	12/23/2020	1778	4080	DEXCOM.167P1	2	2

CONFIRMATION NO. 2055

FILING RECEIPT

68851
KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

OC000000122729192

Date Mailed: 01/21/2021

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Peter C. Simpson, Cardiff, CA;
Ying Li, San Diego, CA;
Apurv Ullas Kamath, San Diego, CA;
Richard C. Yang, Carlsbad, CA;

Applicant(s)

DexCom, Inc., San Diego, CA;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a CIP of 17/078,609 10/23/2020
and is a CIP of 17/082,627 10/28/2020

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Permission to Access Search Results: Yes

Abbott Ex. 1003 - 620/1058

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 01/15/2021

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/132,664**

Projected Publication Date: 04/28/2022

Non-Publication Request: No

Early Publication Request: No

Title

ANALYTE SENSOR

Preliminary Class

210

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific

Abbott Ex. 1003 - 621/1058

countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop

Abbott Ex. 1003 - 622/1058

technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Abbott Ex. 1003 - 623/1058

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/132,664

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY FEE($)
BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A			N/A	320
SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A	N/A			N/A	700
EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A			N/A	800
TOTAL CLAIMS (37 CFR 1.16(i))	2 minus 20 =	*			OR	x 100 =	0.00
INDEPENDENT CLAIMS (37 CFR 1.16(h))	2 minus 3 =	*				x 480 =	0.00
APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						2100
MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))							0.00
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL			TOTAL	3920

APPLICATION AS AMENDED - PART II

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT A	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

		(Column 1) CLAIMS REMAINING AFTER AMENDMENT		(Column 2) HIGHEST NUMBER PREVIOUSLY PAID FOR	(Column 3) PRESENT EXTRA	SMALL ENTITY RATE($)	SMALL ENTITY ADDITIONAL FEE($)	OR	OTHER THAN SMALL ENTITY RATE($)	OTHER THAN SMALL ENTITY ADDITIONAL FEE($)
AMENDMENT B	Total (37 CFR 1.16(i))	*	Minus	**	=	x =		OR	x =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=	x =		OR	x =	
	Application Size Fee (37 CFR 1.16(s))									
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							OR		
						TOTAL ADD'L FEE		OR	TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".
The "Highest Number Previously Paid For" (Total or Independent) is the highest found in the appropriate box in column 1.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1

CONFIRMATION NO. 2055

68851
KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

INFORMAL NOTICE

OC000000122729193

Date Mailed: 01/21/2021

INFORMATIONAL NOTICE TO APPLICANT

Applicant is notified that the above-identified application contains the deficiencies noted below. No period for reply is set forth in this notice for correction of these deficiencies. However, if a deficiency relates to the inventor's oath or declaration, the applicant must file an oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each actual inventor no later than the expiration of the time period set in the "Notice of Allowability" to avoid abandonment. See 37 CFR 1.53(f).

The item(s) indicated below are also required and should be submitted with any reply to this notice to avoid further processing delays.

- A properly executed inventor's oath or declaration has not been received for the following inventor(s):
  Peter C. Simpson
  Ying Li
  Apurv Ullas Kamath
  Richard C. Yang

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/hchin/

Abbott Ex. 1003 - 625/1058

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

68851 7590 02/04/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER	
ART UNIT	PAPER NUMBER
2684	

NOTIFICATION DATE	DELIVERY MODE
02/04/2021	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

efiling@knobbe.com
jayna.cartee@knobbe.com

Abbott Ex. 1003 - 626/1058

Decision Granting Request for Prioritized Examination (Track I)	**Application No.** 17/132,664	**Applicant(s)** Simpson et al.	
	Examiner CHERYL P GIBSON BAYLOR	**Art Unit** OPET	**AIA (FITF) Status** Yes

1. THE REQUEST FILED 23 December 2020 IS **GRANTED** .

The above-identified application has met the requirements for prioritized examination

A. ☑ for an original nonprovisional application (Track I).
B. ☐ for an application undergoing continued examination (RCE).

2. **The above-identified application will undergo prioritized examination**. The application will be accorded special status throughout its entire course of prosecution until one of the following occurs:

A. filing a **petition for extension of time** to extend the time period for filing a reply;

B. filing an **amendment to amend the application to contain more than four independent claims, more than thirty total claims** , or a multiple dependent claim;

C. filing a **request for continued examination** ;

D. filing a notice of appeal;

E. filing a request for suspension of action;

F. mailing of a notice of allowance;

G. mailing of a final Office action;

H. completion of examination as defined in 37 CFR 41.102; or

I. abandonment of the application.

Telephone inquiries with regard to this decision should be directed to CHERYL GIBSON BAYLOR at (571)272-3213. In his/her absence, calls may be directed to Petition Help Desk at (571) 272-3282.

/CHERYL GIBSON BAYLOR/ Paralegal Specialist, OPET	

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82A (07-13)
Approved for use through 03/31/2021. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	17/132664
Filing Date	December 23, 2020
First Named Inventor	Peter C. Simpson
Title	ANALYTE SENSOR
Art Unit	2684
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

SIGNATURE of Applicant or Patent Practitioner

Signature	/Ian W. Gillies/	Date (Optional)	
Name	Ian W. Gillies	Registration Number	62,280
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			

NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.

☑ *Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Doc Code: PA..
Document Description: Power of Attorney

PTO/AIA/82B (07-13)
Approved for use through 11/30/2014. OMB 0651-0051
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Application Number	Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

☑ I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above: 68851

OR

☐ I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter to:

☑ The address associated with the above-mentioned Customer Number

OR

☐ The address associated with Customer Number:

OR

Firm or Individual Name					
Address					
City		State		Zip	
Country					
Telephone		Email			

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

DexCom, Inc.

☐ Inventor or Joint Inventor (title not required below)

☐ Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)

☑ Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)

☐ Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Signature		Date (Optional)	8/28/17
Name	Kaare Larson		
Title	Assistant General Counsel, Intellectual Property		

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

☐ Total of forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt

EFS ID:	42027579
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Ian W. Gillies/Elizabeth Rutherford
Filer Authorized By:	Ian W. Gillies
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	25-FEB-2021
Filing Date:	23-DEC-2020
Time Stamp:	17:58:17
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	Hakim_DEXCOM_167P1.pdf	105741 2d6aee20a92f6b5e66ff1d704c74cac86dc111ef	no	1

Warnings:

Information:					
2	Power of Attorney	POA_Transmittal_DEXCOM_167P1.PDF	342954 cc02dfef4d3f3138aad2cdcb54aeec6da748e77e	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	448695	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

RESCISSION OF ANY PRIOR DISCLAIMERS AND REQUEST TO REVISIT ART

Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Unassigned
Art Unit	:	2684
Conf. No.	:	2055

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

The claims of the present application are different and possibly broader in scope than the claims pursued in the parent application(s). To the extent any prior amendments or characterizations of the scope of any claim or referenced art could be construed as a disclaimer of any subject matter supported by the present disclosure, Applicant hereby rescinds and retracts such disclaimer. Accordingly, the references previously considered in the parent application(s) may need to be re-visited.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

Knobbe, Martens, Olson & Bear, LLP

Dated: February 25, 2021

/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34477074

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1

CONFIRMATION NO. 2055

POA ACCEPTANCE LETTER

68851
KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

OC000000123726976

Date Mailed: 03/02/2021

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 02/25/2021.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

Questions about the contents of this notice and the requirements it sets forth should be directed to the Office of Data Management, Application Assistance Unit, at **(571) 272-4000** or **(571) 272-4200** or **1-888-786-0101**.

/ggasgedom/

Abbott Ex. 1003 - 633/1058

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

68851 7590 03/02/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER	
PREVIL, DANIEL	

ART UNIT	PAPER NUMBER
2684	

NOTIFICATION DATE	DELIVERY MODE
03/02/2021	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

efiling@knobbe.com
jayna.cartee@knobbe.com

Office Action Summary	Application No. 17/132,664	Applicant(s) Simpson et al.	
	Examiner DANIEL PREVIL	Art Unit 2684	AIA (FITF) Status Yes

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTHS FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☑ Responsive to communication(s) filed on 12/23/2020.

☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2a)☐ This action is **FINAL.** 2b) ☑ This action is non-final.

3)☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

4)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims*

5) ☑ Claim(s) 19-20 is/are pending in the application.

5a) Of the above claim(s) _____ is/are withdrawn from consideration.

6) ☐ Claim(s) _____ is/are allowed.

7) ☑ Claim(s) 19-20 is/are rejected.

8) ☐ Claim(s) _____ is/are objected to.

9) ☐ Claim(s) _____ are subject to restriction and/or election requirement

* If any claims have been determined allowable, you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see http://www.uspto.gov/patents/init_events/pph/index.jsp or send an inquiry to **PPHfeedback@uspto.gov.**

Application Papers

10)☐ The specification is objected to by the Examiner.

11)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

Certified copies:

a)☐ All b)☐ Some** c)☐ None of the:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

** See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☑ Notice of References Cited (PTO-892)

2) ☑ Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/SB/08b) Paper No(s)/Mail Date _____.

3) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date _____.

4) ☐ Other: _____.

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 *et seq.* for applications not subject to examination under the first inventor to file provisions of the AIA. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).

The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA/25, or PTO/AIA/26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.

Claims 19-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 2009/0178459. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims are arguably broader than 1 of U.S. Patent No. 2009/0178459 which encompasses the same metes, bounds, and limitations. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to eliminate the limitations of the narrower claims, since it has been held that omission of an element and its function and a combination where the remaining elements perform the same functions as before involves only routine skill in the art. See in re Karlson, 136 USPQ 184.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.

Claims 19-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Brister et al. (US 2009/0076360).

Regarding claim 19, Brister discloses a method (abstract) comprising: calibrating sensor data (page 31, [0355]).

Regarding claim 20, Brister discloses a transcutaneous analyte sensor system (abstract) comprising: a transcutaneous analyte sensor (page 25 [0296]); and sensor electronics operably connectable to the transcutaneous analyte sensor (page 25, [0296]).

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Schoonmaker et al. (US 2017/0112531) discloses transcutaneous.....methods.

Kamath et al. (US 2005/0143635) discloses calibration.....analyte sensor.

Shults et al. (US 2015/0374270) discloses low oxygen in vivo analyte sensor.

Brauker et al. (US 2007/0203966) discloses transcutaneous analyte sensor.

Kamath et al. (US 2007/0016381) discloses systems....sensor data.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL PREVIL whose telephone number is (571)272-2971. The examiner can normally be reached on Monday-Friday from 9:30 AM -6:00 PM.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Wang Quan-Zhen can be reached on 571 272 3114. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

DP

February 24, 2021

/DANIEL PREVIL/
Primary Examiner, Art Unit 2684

Notice of References Cited	Application/Control No. 17/132,664	Applicant(s)/Patent Under Reexamination Simpson et al.	
	Examiner DANIEL PREVIL	Art Unit 2684	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20090076360-A1	03-2009	Brister; Mark	G16Z99/00	600/365
*	B	US-20070016381-A1	01-2007	Kamath; Apurv	A61B5/14532	702/19
*	C	US-20070203966-A1	08-2007	Brauker; James H.	A61B5/0031	708/200
*	D	US-20150374270-A1	12-2015	Shults; Mark C.	A61B5/0002	600/347
*	E	US-20050143635-A1	06-2005	Kamath, Apurv Ullas	A61B5/14865	600/347
*	F	US-20170112531-A1	04-2017	Schoonmaker; Ryan Everett	A61B5/0004	1/1
*	G	US-20090178459-A1	07-2009	Li; Ying	A61B5/155	73/1.02
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	02/25/2021								
	1	-								
	2	-								
	3	-								
	4	-								
	5	-								
	6	-								
	7	-								
	8	-								
	9	-								
	10	-								
	11	-								
	12	-								
	13	-								
	14	-								
	15	-								
	16	-								
	17	-								
	18	-								
	19	✓								
	20	✓								

Abbott Ex. 1003 - 641/1058

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	**Art Unit**
	DANIEL PREVIL	2684

Abbott Ex. 1003 - 642/1058

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

CPC - Searched*		
Symbol	**Date**	**Examiner**
13 AND ((A61B5/14532 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/14503 OR A61B5/1495 OR A61B5/14865 OR A61B2560/0223 OR A61B5/14735 OR A61B5/1468 OR A61B5/1451 OR A61B5/6848 OR A61B5/0031 OR A61B5/0002 OR A61B5/0004 OR A61B5/6833 OR A61B5/14507 OR A61B5/6849 OR A61B5/150022 OR A61B5/1411 OR A61B5/145 OR A61B5/6801 OR A61B17/3468 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/68335 OR A61B5/14517 OR A61B2560/0276 OR A61B5/7257 OR A61B5/7267 OR A61B5/742 OR A61B2562/08 OR A61B5/7203 OR A61B2560/0214 OR A61B5/0022 OR A61B5/6832 OR A61B5/00 OR A61B5/150534 OR A61B5/746 OR A61B5/486 OR A61B2560/0209 OR A61B5/7445 OR A61B2560/0252 OR A61B2562/02 OR A61B5/002 OR A61B5/411 OR A61B5/418 OR A61B5/4839 OR A61B5/686 OR A61B5/6898 OR A61B5/7435 OR A61B5/7475 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0257 OR A61B2560/028 OR A61B2560/0295 OR A61B2560/0412 OR A61B2560/0443 OR A61B2562/0209 OR A61B2562/0219 OR A61B2562/028 OR A61B2562/043 OR A61B2562/125 OR A61B2562/164 OR A61B2562/227 OR A61B5/0024 OR A61B5/01 OR A61B5/14539 OR A61B5/14542 OR A61B5/681 OR A61B5/6846 OR A61B5/7221 OR A61B5/7225 OR A61B5/7235 OR A61B5/7239 OR A61B5/726 OR A61B5/7264 OR A61B5/7275 OR A61B5/7405 OR A61B5/743 OR A61B5/7455 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR Y02A50/30 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2005/14208 OR A61M2205/3553 OR A61M2205/50 OR A61M2230/201 OR A61M5/14248 OR G01N27/3274 OR G01N27/026 OR G01N33/49 OR G01N33/54366 OR G01N33/66 OR G01N27/3271 OR G01D18/00 OR H05K999/00 OR H05K999/99 OR H05K2201/053 OR H05K2201/10151 OR H05K2201/10401 OR H05K2201/10409 OR H05K3/325 OR H05K3/365 OR G16Z99/00 OR H04W76/14 OR H04W4/80 OR H04W12/06 OR H04W12/00 OR H04W48/10 OR H04W4/38 OR H04W52/0277 OR H04W76/10 OR H04W84/18 OR H04W84/22 OR H04W8/005 OR H04W12/068 OR H04W4/12 OR H04W4/20 OR H04W4/70 OR H04W52/0229 OR H04W88/02 OR G16H20/17 OR G16H40/40 OR G16H40/63 OR G16H10/60 OR G16H40/67 OR G16H10/65 OR G16H20/60 OR G16H50/20 OR G16H10/20 OR G16H10/40 OR G16H20/30 OR G16H20/70 OR G16H50/30 OR G16H80/00 OR H01L2924/00 OR H01L2924/07811 OR H01L2924/12042 OR H01L24/72 OR H04L63/101 OR H04L2209/88 OR H04L67/141 OR H04L67/34 OR Y02D30/70	02/25/2021	DP

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**
340	870.28, 522, 870.01, 539.12, 691.6, 539.1	02/25/2021	DP

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes		
Search Notes	**Date**	**Examiner**
Plus search, East search, Inventor search	02/25/2021	DP
CPC search	02/25/2021	DP

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**

Abbott Ex. 1003 - 644/1058

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	205	("0000002" | "0000059" | "0000791" | "0002508" | "0052641" | "0062334" | "0065604" | "0201800" | "10002233" | "10004442" | "10078380" | "10082493" | "10089446" | "10188334" | "10194868" | "10335075" | "10349873" | "10448873" | "10561354" | "10610141" | "10624568" | "10682084" | "20010016682" | "20010021817" | "20010039053" | "20010041830" | "20010041831" | "20010051768" | "20020016534" | "20020016535" | "20020019022" | "20020022883" | "20020023852" | "20020026110" | "20020026111" | "20020027086" | "20020038101" | "20020042090" | "20020042561" | "20020043471" | "20020045808" | "20020055673" | "20020062132" | "20020065453" | "20020065454" | "20020068860" | "20020071776" | "20020084196" | "20020099282" | "20020099997" | "20020103499" | "20020106709" | "20020111547" | "20020115920" | "20020119711" | "20020120186" | "20020123048" | "20020128594" | "20020143266" | "20020143372" | "20020151796" | "20020155615" | "20020156355" | "20020161288" | "20020169369" | "20020169635" | "20020177763" | "20020177764" | "20020182241" | "20020188185" | "20020193679" | "20020193885" | "20020198513" | "20030003524" | "20030004403" | "20030004432" | "20030004457" | "20030006669" | "20030023171" | "20030023317" | "20030023461" | "20030028089" | "20030032867" | "20030032874" | "20030034305" | "20030036773" | "20030042137" | "20030050546" | "20030054428" | "20030060692" | "20030065254" | "20030065308" | "20030076082" | "20030078481" | "20030078560" | "20030097082" | "20030100040" | "20030100821" | "20030119201" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20030119208" | "20030120152" |
"20030125612" | "20030125613" |
"20030130616" | "20030134347" |
"20030138674" | "20030143746" |
"20030153821" | "20030161288" |
"20030168338" | "20030175987" |
"20030176183" | "20030176933" |
"20030181794" | "20030187338" |
"20030188427" | "20030191377" |
"20030199744" | "20030199790" |
"20030203498" | "20030208113" |
"20030211625" | "20030212317" |
"20030212346" | "20030212347" |
"20030212379" | "20030216630" |
"20030217966" | "20030225437" |
"20030228681" | "20030235817" |
"20040010186" | "20040010207" |
"20040011671" | "20040015063" |
"20040015134" | "20040023253" |
"20040023317" | "20040024327" |
"20040024553" | "20040030285" |
"20040030294" | "20040039298" |
"20040039406" | "20040040840" |
"20040045879" | "20040054263" |
"20040054352" | "20040064021" |
"20040064068" | "20040068230" |
"20040074785" | "20040077962" |
"20040078065" | "20040078219" |
"20040093167" | "20040099529" |
"20040106857" | "20040106858" |
"20040106859" | "20040108226" |
"20040122353" | "20040133131" |
"20040133164" | "20040135684" |
"20040138588" | "20040138716" |
"20040142403" | "20040143173" |
"20040146909" | "20040147819" |
"20040152187" | "20040152622" |
"20040158137" | "20040162678" |
"20040167801" | "20040171921" |
"20040172307" | "20040173472" |
"20040176672" | "20040186362" |
"20040186365" | "20040193025" |
"20040193090" | "20040197846" |
"20040199059" | "20040204687" |
"20040208780" | "20040219664" |
"20040220517" | "20040225338" |
"20040236200" | "20040236251" |
"20040242982" | "20040249253" |
"20040249420" | "20040254433" |
"20040254434" | "20040260478" |
"20040263354" | "20040267300" |
"20050003470" | "20050004439" |
"20050004494" | "20050006122").PN.

L2	200	("20050010087" | "20050010265" | "20050010269" | "20050015020" | "20050016276" | "20050026689" | "20050027177" | "20050027180" | "20050027181" | "20050027182" | "20050027462" | "20050027463" | "20050031689" | "20050033132" | "20050038332" | "20050043598" | "20050049179" | "20050049473" | "20050051427" | "20050051440" | "20050054905" | "20050054909" | "20050056551" | "20050056552" | "20050059871" | "20050065464" | "20050070774" | "20050090607" | "20050096511" | "20050096512" | "20050096519" | "20050101847" | "20050103625" | "20050112169" | "20050113653" | "20050114068" | "20050115832" | "20050121322" | "20050124873" | "20050131305" | "20050131346" | "20050133368" | "20050139489" | "20050143635" | "20050143675" | "20050154271" | "20050161346" | "20050173245" | "20050176136" | "20050177036" | "20050177398" | "20050181012" | "20050182306" | "20050182451" | "20050183954" | "20050187720" | "20050192494" | "20050192557" | "20050195930" | "20050196820" | "20050196821" | "20050197612" | "20050199494" | "20050203360" | "20050203364" | "20050211571" | "20050214892" | "20050215871" | "20050215872" | "20050239154" | "20050239156" | "20050241957" | "20050242479" | "20050245795" | "20050245799" | "20050245839" | "20050245904" | "20050258037" | "20050261563" | "20050272989" | "20050277164" | "20050277912" | "20050287620" | "20050288596" | "20050288725" | "20060001538" | "20060004270" | "20060010098" | "20060015020" | "20060015024" | "20060016700" | "20060017923" | "20060019327" | "20060020186" | "20060020187" | "20060020188" | "20060020189" | "20060020190" | "20060020191" | "20060020192" | "20060025662" | "20060025663" | "20060029177" | "20060031094" | "20060036139" | "20060036140" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

		"20060036141" | "20060036142" | "20060036143" | "20060036144" | "20060036145" | "20060040402" | "20060042353" | "20060047192" | "20060052745" | "20060068208" | "20060079809" | "20060086624" | "20060091006" | "20060094946" | "20060100588" | "20060142651" | "20060155180" | "20060166629" | "20060167365" | "20060167517" | "20060167518" | "20060167519" | "20060173260" | "20060173406" | "20060173444" | "20060178617" | "20060183984" | "20060183985" | "20060189851" | "20060189856" | "20060189863" | "20060189925" | "20060193375" | "20060195029" | "20060198864" | "20060200009" | "20060200019" | "20060200020" | "20060200022" | "20060200970" | "20060222566" | "20060224109" | "20060224141" | "20060226985" | "20060229512" | "20060229531" | "20060229533" | "20060247508" | "20060247685" | "20060247985" | "20060253012" | "20060253085" | "20060257996" | "20060258761" | "20060258929" | "20060263839" | "20060264785" | "20060270922" | "20060270923" | "20060272652" | "20060281985" | "20060293576" | "20070016381" | "20070017805" | "20070020641" | "20070027284" | "20070027370" | "20070027381" | "20070027384" | "20070027385" | "20070032706" | "20070032717" | "20070032718" | "20070033074" | "20070033254" | "20070045902" | "20070049873" | "20070056858" | "20070059196" | "20070060803" | "20070060814" | "20070060871" | "20070066873" | "20070068807" | "20070071681" | "20070073129" | "20070078320" | "20070078321" | "20070078322" | "20070078323" | "20070085995" | "20070093704" | "20070095661" | "20070106135").PN.				
L3	200	("20070108048" | "20070112298" | "20070116600" | "20070118030" | "20070118405" | "20070124002" | "20070129619" | "20070129621" | "20070135699" | "20070142584" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20070149875" | "20070151869" |
"20070156033" | "20070163880" |
"20070168224" | "20070169533" |
"20070170073" | "20070173706" |
"20070173709" | "20070173710" |
"20070173711" | "20070173712" |
"20070173741" | "20070173761" |
"20070179349" | "20070179352" |
"20070179434" | "20070179436" |
"20070191701" | "20070191716" |
"20070197889" | "20070197890" |
"20070199818" | "20070200254" |
"20070202562" | "20070202672" |
"20070203407" | "20070203410" |
"20070203966" | "20070206193" |
"20070208244" | "20070208245" |
"20070208246" | "20070213610" |
"20070213611" | "20070213657" |
"20070218097" | "20070219441" |
"20070224700" | "20070225675" |
"20070227911" | "20070232877" |
"20070232878" | "20070232879" |
"20070232880" | "20070233013" |
"20070235331" | "20070240497" |
"20070244379" | "20070244381" |
"20070244382" | "20070249916" |
"20070249922" | "20070255321" |
"20070259217" | "20070299389" |
"20070299617" | "20080000779" |
"20080004515" | "20080004601" |
"20080009692" | "20080012701" |
"20080017522" | "20080021666" |
"20080021972" | "20080029390" |
"20080029391" | "20080033254" |
"20080033357" | "20080039702" |
"20080045824" | "20080058625" |
"20080064937" | "20080066305" |
"20080071156" | "20080071157" |
"20080071158" | "20080072663" |
"20080081000" | "20080081977" |
"20080083617" | "20080086040" |
"20080086041" | "20080086042" |
"20080086043" | "20080086044" |
"20080086273" | "20080091094" |
"20080091095" | "20080097197" |
"20080097289" | "20080097326" |
"20080102441" | "20080103447" |
"20080108942" | "20080114227" |
"20080115599" | "20080119703" |
"20080119704" | "20080119706" |
"20080119708" | "20080125751" |
"20080139910" | "20080147050" |
"20080148873" | "20080154101" |

		"20080154177" | "20080154513" | "20080156661" | "20080161664" | "20080161666" | "20080161753" | "20080167543" | "20080168676" | "20080172205" | "20080177149" | "20080177165" | "20080183060" | "20080183061" | "20080183399" | "20080187655" | "20080188722" | "20080188725" | "20080188731" | "20080188796" | "20080189051" | "20080193936" | "20080194837" | "20080194934" | "20080194935" | "20080194936" | "20080194937" | "20080194938" | "20080195232" | "20080195967" | "20080197024" | "20080200788" | "20080200789" | "20080200791" | "20080200897" | "20080201325" | "20080205481" | "20080208025" | "20080208113" | "20080214910" | "20080214915" | "20080214918" | "20080228051" | "20080228054" | "20080234943" | "20080242961" | "20080242963" | "20080249385" | "20080255434" | "20080255437" | "20080255438" | "20080255808" | "20080256048" | "20080262469" | "20080267823" | "20080269714" | "20080275313" | "20080278332" | "20080287761" | "20080287762" | "20080287763" | "20080287764" | "20080287765" | "20080287766" | "20080288180" | "20080288204" | "20080296155" | "20080300572" | "20080305009" | "20080305506" | "20080306368" | "20080306433" | "20080306434" | "20080306435" | "20080306444" | "20080306472" | "20080312841" | "20080312842" | "20080312844" | "20080312845" | "20080314395" | "20080319279" | "20080319295" | "20080319296" | "20090001923").PN.				
L4	200	("20090005665" | "20090005666" | "20090006034" | "20090006061" | "20090012376" | "20090012379" | "20090016379" | "20090018418" | "20090018424" | "20090018425" | "20090018426" | "20090030293" | "20090030294" | "20090033482" | "20090036747" | "20090036758" | "20090036760" | "20090036763" | "20090043181" | "20090043182" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20090043525" | "20090043541" |
"20090043542" | "20090045055" |
"20090048503" | "20090054745" |
"20090054748" | "20090054749" |
"20090054753" | "20090055149" |
"20090061528" | "20090062633" |
"20090062635" | "20090062645" |
"20090062767" | "20090063402" |
"20090069649" | "20090076356" |
"20090076360" | "20090076361" |
"20090081803" | "20090082693" |
"20090085768" | "20090099434" |
"20090099436" | "20090105570" |
"20090105636" | "20090112478" |
"20090112626" | "20090118589" |
"20090124877" | "20090124878" |
"20090124879" | "20090124964" |
"20090131768" | "20090131769" |
"20090131776" | "20090131777" |
"20090137886" | "20090137887" |
"20090143659" | "20090143660" |
"20090143725" | "20090149728" |
"20090156919" | "20090156922" |
"20090156924" | "20090163790" |
"20090163855" | "20090164190" |
"20090164239" | "20090164251" |
"20090171178" | "20090177143" |
"20090178459" | "20090182217" |
"20090182517" | "20090192366" |
"20090192722" | "20090192724" |
"20090192745" | "20090192751" |
"20090198118" | "20090203981" |
"20090204340" | "20090204341" |
"20090216103" | "20090240120" |
"20090240128" | "20090240193" |
"20090241028" | "20090242399" |
"20090242425" | "20090247855" |
"20090247856" | "20090247857" |
"20090257911" | "20090264719" |
"20090281407" | "20090287073" |
"20090287074" | "20090294277" |
"20090299155" | "20090299156" |
"20090299162" | "20090299276" |
"20100010324" | "20100010331" |
"20100010332" | "20100016687" |
"20100020309" | "20100022855" |
"20100023270" | "20100023291" |
"20100025238" | "20100030053" |
"20100030137" | "20100030484" |
"20100036215" | "20100036216" |
"20100036222" | "20100036223" |
"20100036224" | "20100036225" |
"20100045231" | "20100045465" |

		"20100049015" | "20100049021" | "20100057040" | "20100057041" | "20100057042" | "20100057044" | "20100057057" | "20100063372" | "20100064764" | "20100081906" | "20100081908" | "20100081909" | "20100081910" | "20100081953" | "20100094111" | "20100121167" | "20100141656" | "20100145174" | "20100152561" | "20100160759" | "20100160761" | "20100168538" | "20100168546" | "20100169035" | "20100174167" | "20100174168" | "20100174266" | "20100179399" | "20100179402" | "20100179405" | "20100179406" | "20100179407" | "20100179408" | "20100179409" | "20100185065" | "20100185070" | "20100185071" | "20100185072" | "20100185073" | "20100185074" | "20100191085" | "20100191472" | "20100198034" | "20100198035" | "20100198142" | "20100204557" | "20100213057" | "20100214104" | "20100217106" | "20100230285" | "20100234707" | "20100234710" | "20100234796" | "20100235106" | "20100240975" | "20100240976" | "20100261987" | "20100265073" | "20100274107" | "20100274515" | "20100277342" | "20100280441" | "20100280782" | "20100286496" | "20100298684" | "20100313105" | "20100317952" | "20100324392" | "20100326842" | "20100331644" | "20100331648" | "20100331655" | "20110021889" | "20110024043").PN.				
L5	208	("20110024307" | "20110027127" | "20110027453" | "20110027458" | "20110028815" | "20110028816" | "20110029247" | "20110029269" | "20110040163" | "20110046467" | "20110060530" | "20110077490" | "20110077491" | "20110077494" | "20110081726" | "20110082484" | "20110105873" | "20110106126" | "20110112696" | "20110118579" | "20110124997" | "20110125410" | "20110130970" | "20110137601" | "20110148905" | "20110174638" | "20110184268" | "20110190603" | "20110191044" | "20110193704" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20110208027" | "20110208155" |
"20110213225" | "20110218414" |
"20110224523" | "20110230741" |
"20110257495" | "20110257895" |
"20110263958" | "20110270062" |
"20110288574" | "20110313317" |
"20110319729" | "20110319734" |
"20110319739" | "20110320130" |
"20110320167" | "20120010642" |
"20120078071" | "20120097554" |
"20120108931" | "20120108934" |
"20120123692" | "20120165626" |
"20120165640" | "20120173200" |
"20120209099" | "20120215462" |
"20120239304" | "20120245447" |
"20120265035" | "20120265036" |
"20120277564" | "20120277565" |
"20120283542" | "20120283960" |
"20120291516" | "20120330561" |
"20130006112" | "20130035575" |
"20130060105" | "20130060112" |
"20130116527" | "20130137953" |
"20130150690" | "20130178727" |
"20130184547" | "20130199944" |
"20130231541" | "20130245412" |
"20130253846" | "20130281807" |
"20130282322" | "20130282403" |
"20130324823" | "20130338454" |
"20140005499" | "20140005968" |
"20140018642" | "20140041441" |
"20140046155" | "20140046156" |
"20140046157" | "20140046160" |
"20140046161" | "20140066736" |
"20140088390" | "20140088392" |
"20140088908" | "20140100796" |
"20140114156" | "20140121480" |
"20140121488" | "20140207400" |
"20140213869" | "20140221966" |
"20140236536" | "20140243638" |
"20140257059" | "20150005601" |
"20150006109" | "20150094555" |
"20150216456" | "20150241407" |
"20150282742" | "20150366510" |
"20150374299" | "20160022221" |
"20160073941" | "20160151006" |
"20160157758" | "20160198986" |
"20160206233" | "20160220189" |
"20160238589" | "20160245791" |
"20160270705" | "20160296697" |
"20160317069" | "20170003766" |
"20170027484" | "20170042456" |
"20170049369" | "20170124287" |
"20170188909" | "20170224258" |

		"20170258379" | "20170340250" | "20170347927" | "20180000004" | "20180000389" | "20180008174" | "20180008201" | "20180038844" | "20180042530" | "20180042531" | "20180059093" | "20180064398" | "20180085037" | "20180098721" | "20180271415" | "20180325437" | "20180328766" | "20180344220" | "20180364215" | "20190035488" | "20190072538" | "20190083012" | "20190083015" | "20190150802" | "20190151542" | "20190159734" | "20190187814" | "20190192071" | "20190254575" | "20190261902" | "20190282143" | "20190320948" | "20190320949" | "20190336051" | "20190350499" | "20190357817" | "20190357827" | "20190380627" | "20200022626" | "20200037934" | "20200037935" | "20200037936" | "20200046272" | "2402306" | "2719797" | "3210578" | "3219533" | "3506032" | "3539455" | "3556950" | "3581062" | "3610226" | "3610230" | "3652475" | "3775182" | "3780727" | "3791871" | "3826244" | "3837339" | "3838033" | "3838682" | "3874850" | "3898984" | "3910256" | "3926760" | "3929971" | "3933593" | "3943918" | "3949388" | "3957613" | "3960497" | "3964974").PN.				
L6	280	("3966580" | "3978856" | "3979274" | "3982530" | "4008717" | "4016866" | "4024312" | "4030640" | "4036749" | "4037563" | "4040908" | "4052754" | "4055175" | "4067322" | "4073713" | "4076656" | "4080292" | "4109505" | "4119406" | "4129128" | "4151845" | "4172770" | "4176659" | "4197840" | "4197852" | "4206755" | "4215703" | "4240438" | "4240889" | "4245634" | "4253469" | "4255500" | "4259540" | "4265249" | "4300572" | "4327725" | "4344438" | "4349728" | "4366040" | "4369785" | "4373527" | "4374013" | "4378016" | "4388166" | "4392849" | "4402694" | "4403847" | "4403984" | "4407298" | "4415666" | "4418148" | "4419535" | "4420564" | "4425920" | "4426621" | "4431004" | "4431507" | "4432366" | "4436094" | "4441968" | "4442841" | "4448188" | "4454295" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"4457339" | "4462048" | "4478222" |
"4478976" | "4484987" | "4486290" |
"4492575" | "4494950" | "4496454" |
"4506680" | "4509531" | "4519973" |
"4526569" | "4527240" | "4534355" |
"4534825" | "4535786" | "4538616" |
"4545382" | "4554927" | "4561963" |
"4565665" | "4565666" | "4568444" |
"4571292" | "4573968" | "4577642" |
"4578215" | "4583976" | "4592824" |
"4613328" | "4614514" | "4619793" |
"4626104" | "4650547" | "4655880" |
"4663824" | "4670007" | "4671288" |
"4672970" | "4680268" | "4685463" |
"4685903" | "4685912" | "4686044" |
"4689309" | "4694861" | "4703756" |
"4705503" | "4711245" | "4711251" |
"4721677" | "4731051" | "4731726" |
"4736748" | "4747822" | "4749985" |
"4750496" | "4752935" | "4753652" |
"4755168" | "4757022" | "4759366" |
"4759828" | "4763648" | "4776944" |
"4777953" | "4779618" | "4781798" |
"4783250" | "4784157" | "4786394" |
"4787398" | "4789467" | "4791932" |
"4800495" | "4803243" | "4805624" |
"4805625" | "4808089" | "4808292" |
"4809704" | "4810243" | "4810470" |
"4813423" | "4815471" | "4820281" |
"4822336" | "4828544" | "4830013" |
"4831070" | "4832005" | "4834101" |
"4838281" | "4841974" | "4849458" |
"4852573" | "4854322" | "4858615" |
"4861454" | "4861830" | "4863265" |
"4867741" | "4871351" | "4871440" |
"4874363" | "4883057" | "4883467" |
"4889528" | "4889744" | "4890620" |
"4890621" | "4898578" | "4900305" |
"4902294" | "4907857" | "4909786" |
"4919141" | "4919649" | "4921477" |
"4921480" | "4923819" | "4925268" |
"4925444" | "4927407" | "4927516" |
"4928694" | "4934369" | "4934375" |
"4935345" | "4944299" | "4946439" |
"4947845" | "4951669" | "4953552" |
"4955861" | "4957483" | "4958148" |
"4963131" | "4963595" | "4966579" |
"4967940" | "4974592" | "4974929" |
"4975175" | "4975636" | "4976687" |
"4979509" | "4984929" | "4986271" |
"4986671" | "4988341" | "4988671" |
"4988758" | "4994026" | "4994167" |
"4995402" | "4997627" | "5000180" |

		"5000419" | "5002054" | "5002055" | "5002572" | "5006050" | "5006111" | "5007929" | "5009251" | "5019974" | "5026348" | "5030199" | "5030333" | "5034112" | "5041092" | "5045057" | "5046496" | "5048525" | "5050612" | "5055171" | "5055198" | "5059654" | "5067491" | "5068536" | "5077476" | "5082147" | "5082550" | "5088981" | "5089112" | "5089421" | "5096669" | "5097834" | "5098377" | "5101814" | "5106365" | "5108819" | "5109850" | "5109860" | "5112301" | "5112455" | "5114859" | "5116313" | "5122925" | "5127405" | "5135004" | "5137028" | "5140985" | "5145565" | "5148812" | "5152746" | "5156972" | "5158437" | "5160418" | "5161532" | "5165406" | "5165407" | "5171689" | "5174291" | "5176632").PN.				
L7	280	("5176658" | "5178142" | "5178957" | "5182004" | "5188591" | "5190041" | "5195963" | "5198771" | "5199428" | "5202261" | "5203326" | "5204264" | "5207642" | "5208147" | "5210778" | "5216598" | "5219279" | "5220917" | "5220920" | "5224929" | "5225063" | "5231988" | "5232434" | "5235003" | "5237123" | "5243696" | "5243982" | "5243983" | "5246867" | "5248300" | "5249576" | "5254102" | "5262035" | "5262305" | "5264103" | "5264105" | "5265594" | "5266179" | "5269891" | "5271736" | "5271815" | "5275169" | "5279294" | "5281319" | "5282844" | "5282848" | "5284140" | "5284570" | "5285513" | "5285792" | "5287753" | "5293877" | "5298022" | "5298144" | "5299571" | "5302093" | "5304468" | "5307263" | "5310469" | "5311908" | "5312361" | "5313953" | "5314471" | "5315993" | "5316008" | "5316452" | "5318511" | "5320715" | "5320725" | "5321392" | "5322063" | "5324322" | "5324328" | "5326356" | "5326449" | "5328460" | "5330521" | "5330634" | "5331555" | "5335658" | "5337747" | "5340722" | "5342409" | "5342789" | "5343869" | "5345932" | "5348788" | "5352348" | "5352349" | "5352351" | "5354272" | "5354449" | "5356217" | "5356375" | "5356378" | "5356786" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"5360404" | "5365426" | "5368224" |
"5368562" | "5372133" | "5372135" |
"5372427" | "5372709" | "5376070" |
"5378229" | "5379238" | "5380268" |
"5380491" | "5380536" | "5380665" |
"5384028" | "5384547" | "5390671" |
"5391250" | "5397848" | "5398682" |
"5400795" | "5408999" | "5409666" |
"5411052" | "5411551" | "5411647" |
"5411866" | "5417206" | "5421328" |
"5422829" | "5423738" | "5423749" |
"5425375" | "5425717" | "5425749" |
"5425868" | "5428123" | "5429485" |
"5429602" | "5429735" | "5431160" |
"5431174" | "5431921" | "5434412" |
"5437635" | "5438983" | "5445610" |
"5448992" | "5453278" | "5462051" |
"5462064" | "5462645" | "5466348" |
"5469846" | "5472317" | "5474552" |
"5476094" | "5476776" | "5482446" |
"5482473" | "5484404" | "5486776" |
"5489414" | "5491474" | "5494562" |
"5496273" | "5496453" | "5497772" |
"5502396" | "5505828" | "5507288" |
"5508203" | "5509410" | "5509888" |
"5512046" | "5512246" | "5512248" |
"5513636" | "5514253" | "5514718" |
"5515851" | "5517313" | "5518601" |
"5520191" | "5522798" | "5529676" |
"5531679" | "5531878" | "5540828" |
"5543326" | "5545220" | "5547470" |
"5548569" | "5549547" | "5549548" |
"5549569" | "5549651" | "5551850" |
"5552997" | "5553616" | "5554339" |
"5562614" | "5562615" | "5564439" |
"5568400" | "5568806" | "5569186" |
"5569188" | "5569219" | "5571395" |
"5575930" | "5577499" | "5582184" |
"5582497" | "5582593" | "5582697" |
"5584813" | "5584876" | "5586553" |
"5588560" | "5589563" | "5590651" |
"5593440" | "5593852" | "5601435" |
"5605152" | "5606152" | "5609572" |
"5609575" | "5611900" | "5615671" |
"5620579" | "5624409" | "5624537" |
"5626563" | "5628310" | "5628619" |
"5628890" | "5630710" | "5631170" |
"5637083" | "5640470" | "5640954" |
"5643195" | "5645077" | "5651767" |
"5653239" | "5653756" | "5653863" |
"5658250" | "5660163" | "5665061" |
"5665065" | "5665222" | "5667504" |
"5676651" | "5676820" | "5681285" |

		"5682884" | "5683562" | "5685844" | "5686829" | "5688239" | "5688244" | "5695623" | "5697366" | "5697899" | "5704354" | "5707502" | "5711001" | "5711861" | "5714931" | "5720295" | "5730654" | "5733259" | "5735273" | "5735285" | "5738992" | "5741211" | "5741634" | "5743262" | "5745378" | "5749832").PN.				
L8	280	("5749907" | "5755226" | "5755692" | "5756632" | "5758643" | "5763760" | "5766151" | "5772586" | "5777060" | "5779665" | "5781455" | "5782912" | "5783054" | "5785660" | "5787900" | "5791344" | "5791880" | "5792065" | "5795774" | "5798065" | "5800383" | "5800420" | "5800529" | "5804048" | "5806517" | "5807274" | "5807312" | "5807375" | "5807406" | "5810323" | "5810770" | "5811487" | "5814599" | "5820551" | "5820589" | "5822715" | "5823802" | "5833603" | "5836887" | "5836989" | "5837454" | "5837728" | "5840026" | "5851197" | "5861019" | "5863400" | "5871514" | "5873862" | "5879373" | "5879828" | "5882494" | "5885844" | "5891047" | "5891048" | "5897525" | "5897578" | "5899855" | "5904666" | "5904708" | "5910554" | "5911219" | "5913998" | "5914026" | "5917346" | "5918603" | "5921951" | "5925021" | "5928130" | "5928155" | "5928182" | "5928189" | "5928195" | "5931814" | "5932175" | "5933136" | "5935224" | "5938636" | "5942979" | "5944661" | "5947911" | "5951521" | "5954643" | "5954954" | "5957854" | "5957903" | "5960797" | "5961451" | "5964261" | "5964993" | "5965380" | "5971922" | "5972199" | "5976085" | "5980728" | "5990422" | "5995208" | "5995860" | "5999848" | "6001067" | "6001471" | "6007775" | "6011984" | "6013113" | "6014577" | "6016443" | "6016448" | "6021350" | "6023629" | "6024699" | "6024720" | "6027445" | "6027479" | "6032059" | "6032667" | "6036924" | "6038469" | "6045567" | "6049727" | "6051389" | "6059946" | "6063637" | "6066088" | "6066448" | "6071391" | "6073031" | "6074775" | "6077299" | "6080583" | "6081735" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"6081736" | "6083523" | "6083710" |
"6088608" | "6090087" | "6091975" |
"6091976" | "6093156" | "6093172" |
"6099511" | "6103033" | "6107083" |
"6108577" | "6112116" | "6115622" |
"6115628" | "6115634" | "6117290" |
"6119028" | "6120676" | "6121009" |
"6121611" | "6122351" | "6122536" |
"6123827" | "6127154" | "6128519" |
"6128526" | "6134461" | "6135978" |
"6141573" | "6142939" | "6142979" |
"6143164" | "6144837" | "6144869" |
"6144871" | "6156051" | "6159147" |
"6159186" | "6161095" | "6162201" |
"6162611" | "6164921" | "6165154" |
"6165406" | "6167614" | "6168568" |
"6169155" | "6171276" | "6175752" |
"6175753" | "6180416" | "6183437" |
"6187062" | "6189536" | "6191860" |
"6197040" | "6200265" | "6200772" |
"6201980" | "6201993" | "6206856" |
"6208894" | "6212416" | "6212417" |
"6212424" | "6213739" | "6214185" |
"6219574" | "6223083" | "6223283" |
"6224562" | "6230059" | "6231320" |
"6231560" | "6231879" | "6233080" |
"6233486" | "6241863" | "6248067" |
"6248077" | "6248093" | "6249705" |
"6254586" | "6256522" | "6256538" |
"6259937" | "6261440" | "6263222" |
"6264606" | "6264825" | "6268161" |
"6269340" | "6270455" | "6270478" |
"6272364" | "6272379" | "6272480" |
"6274285" | "6275717" | "6280408" |
"6281015" | "6283761" | "6284125" |
"6284478" | "6293925" | "6294281" |
"6295506" | "6298254" | "6299578" |
"6299583" | "6299757" | "6300002" |
"6302855" | "6306104" | "6309351" |
"6309375" | "6309884" | "6312388" |
"6325978" | "6325979" | "6326160" |
"6329161" | "6329929" | "6330464" |
"6338790" | "6343225" | "6348640" |
"6356776" | "6358225" | "6359444" |
"6360888" | "6361503" | "6365670" |
"6366794" | "6368141" | "6368274" |
"6370941" | "6372244" | "6377828" |
"6377852" | "6377894" | "6379301" |
"6381493" | "6387048" | "6387709" |
"6391019" | "6400974" | "6402703" |
"6403944").PN.

L9	280	("6409674" | "6413393" | "6413396" | "6413410" | "6416651" | "6418332" | "6424847" | "6424861" | "6427088" | "6428123" | "6430437" | "6434430" | "6440068" | "6444115" | "6447448" | "6447542" | "6454710" | "6459917" | "6461496" | "6464849" | "6465066" | "6466810" | "6467480" | "6471689" | "6474360" | "6475372" | "6475750" | "6477392" | "6477395" | "6478736" | "6481440" | "6484045" | "6484046" | "6485449" | "6486661" | "6488652" | "6494879" | "6498043" | "6498941" | "6501976" | "6501983" | "6503381" | "6510329" | "6512939" | "6514460" | "6514718" | "6517508" | "6520326" | "6520477" | "6520937" | "6520997" | "6526298" | "6527729" | "6528318" | "6536433" | "6537318" | "6540891" | "6541266" | "6542765" | "6543195" | "6544212" | "6544229" | "6545085" | "6546268" | "6546269" | "6547839" | "6551494" | "6551496" | "6553241" | "6553244" | "6554805" | "6554822" | "6558320" | "6558321" | "6558347" | "6558351" | "6561978" | "6562001" | "6564105" | "6565509" | "6565535" | "6565807" | "6569309" | "6569521" | "6571128" | "6572542" | "6572545" | "6572579" | "6574490" | "6575905" | "6576101" | "6577899" | "6579257" | "6579498" | "6579690" | "6584335" | "6585644" | "6585675" | "6585763" | "6587705" | "6589229" | "6591125" | "6592745" | "6594514" | "6595756" | "6595919" | "6600940" | "6600997" | "6602221" | "6605072" | "6605200" | "6605201" | "6607509" | "6607658" | "6609071" | "6610012" | "6612984" | "6613379" | "6615061" | "6615078" | "6616819" | "6618603" | "6618934" | "6622045" | "6633772" | "6635014" | "6641533" | "6642015" | "6645181" | "6648821" | "6650471" | "6653091" | "6654625" | "6656114" | "6656157" | "6658396" | "6659948" | "6668196" | "6673022" | "6673596" | "6675030" | "6676816" | "6679865" | "6679872" | "6683535" | "6684904" | "6685668" | "6687522" | "6687546" | "6689056" | "6689089" | "6689265" | "6689413" | "6692457" | "6694191" | "6695860" | "6698269" | "6699188" | "6699218" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

		"6702249" | "6702857" | "6702972" | "6711423" | "6711424" | "6712796" | "6721582" | "6721587" | "6723086" | "6730200" | "6731976" | "6731985" | "6733446" | "6733655" | "6736783" | "6736957" | "6737158" | "6740075" | "6741877" | "6742635" | "6743635" | "6746582" | "6749587" | "6749591" | "6749740" | "6758810" | "6764581" | "6770030" | "6770067" | "6773671" | "6780297" | "6784274" | "6790178" | "6793632" | "6801041" | "6802957" | "6804002" | "6805693" | "6809653" | "6810290" | "6811533" | "6811534" | "6811548" | "6813519" | "6817990" | "6846654" | "6850790" | "6850859" | "6854317" | "6858020" | "6862465" | "6865407" | "6869413" | "6873268" | "6881551" | "6882940" | "6887228" | "6892085" | "6893396" | "6893545" | "6893552" | "6895263" | "6895265" | "6902544" | "6912413" | "6923763" | "6925393" | "6926691" | "6931327" | "6932584" | "6932892" | "6932894" | "6936006" | "6942518" | "6945965" | "6948492" | "6950708" | "6952604" | "6954662" | "6958705" | "6960192" | "6965791" | "6966325" | "6968294" | "6971274" | "6972080" | "6974437" | "6975893" | "6979315" | "6985870" | "6989891" | "6990366" | "6990422" | "6996427" | "6997907" | "6997921" | "6998247" | "7003336" | "7003340" | "7003341" | "7010345" | "7011630" | "7016713" | "7016720" | "7018361" | "7022072" | "7022219" | "7024245" | "7025425" | "7025727" | "7025743" | "7027848" | "7029443" | "7029444" | "7041068" | "7041209" | "7041468" | "7043287" | "7048727" | "7052472" | "7052483").PN.				
L10	280	("7056302" | "7060059" | "7061593" | "7062385" | "7063086" | "7066884" | "7070577" | "7070580" | "7074307" | "7074610" | "7076300" | "7078582" | "7081195" | "7092891" | "7096064" | "7097775" | "7098803" | "7100628" | "7110803" | "7115884" | "7120483" | "7123950" | "7131967" | "7135342" | "7149562" | "7150741" | "7153265" | "7153458" | "7167818" | "7169289" | "7171252" | "7171274" | "7183102" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"7190988" | "7192450" | "7204823" |
"7207968" | "7207974" | "7211074" |
"7211439" | "7214190" | "7221970" |
"7223253" | "7225535" | "7226978" |
"7228162" | "7229288" | "7238165" |
"7244582" | "7247138" | "7247443" |
"7248912" | "7253680" | "7254450" |
"7255690" | "7258673" | "7258681" |
"7261690" | "7266400" | "7267665" |
"7268562" | "7272436" | "7273633" |
"7276029" | "7278983" | "7280879" |
"7288085" | "7288368" | "7289204" |
"7289836" | "7291496" | "7295867" |
"7297114" | "7299082" | "7303875" |
"7308292" | "7310544" | "7311690" |
"7312040" | "7313425" | "7314452" |
"7315752" | "7315767" | "7316662" |
"7317938" | "7317939" | "7318814" |
"7327273" | "7329234" | "7334594" |
"7335179" | "7335195" | "7335294" |
"7338464" | "7338639" | "7344499" |
"7344626" | "7351321" | "7354420" |
"7359723" | "7361155" | "7364562" |
"7364592" | "7365562" | "7366556" |
"7367942" | "7372277" | "7379765" |
"7381184" | "7384532" | "7387811" |
"7390667" | "7396353" | "7399277" |
"7402153" | "7402349" | "7407811" |
"7416802" | "7417164" | "7417729" |
"7422727" | "7424318" | "7425877" |
"7426408" | "7427338" | "7427560" |
"7429552" | "7433727" | "7460898" |
"7467003" | "7468125" | "7471972" |
"7474992" | "7488601" | "7494465" |
"7494816" | "7497827" | "7499002" |
"7501052" | "7502644" | "7517439" |
"7519478" | "7523004" | "7524287" |
"7525298" | "7529574" | "7547281" |
"7547382" | "7569030" | "7583990" |
"7591801" | "7599726" | "7604593" |
"7608042" | "7613491" | "7615007" |
"7618368" | "7618369" | "7620438" |
"7624028" | "7630748" | "7632228" |
"7635594" | "7637868" | "7640032" |
"7640048" | "7645374" | "7647237" |
"7653425" | "7654956" | "7695434" |
"7699775" | "7699964" | "7711493" |
"7715893" | "7731659" | "7736310" |
"7749445" | "7751864" | "7761126" |
"7761130" | "7766829" | "7766830" |
"7771352" | "7774038" | "7774145" |
"7775975" | "7776559" | "7778679" |
"7778680" | "7826981" | "7831287" |

		"7838639" | "7856613" | "7857760" | "7866025" | "7866026" | "7885697" | "7885698" | "7889069" | "7894870" | "7896809" | "7899511" | "7901354" | "7905833" | "7914450" | "7920906" | "7925321" | "7927274" | "7933639" | "7938797" | "7943034" | "7946984" | "7955261" | "7959569" | "7964089" | "7964146" | "7974672" | "7979104" | "7985330" | "7986986" | "7990828" | "7996158" | "7998071" | "8000763" | "8005524" | "8005525" | "8010174" | "8016997" | "8026104" | "8030942" | "8052601" | "8060173" | "8073519" | "8073520" | "8103471" | "8109850" | "8112240" | "8114268" | "8116837" | "8123920" | "8128562" | "8140312" | "8149117" | "8150488" | "8160670" | "8160671" | "8160834" | "8160900" | "8167801" | "8170803" | "8195265" | "8202491" | "8211016" | "8216137" | "8216138" | "8219173" | "8224415" | "8229536" | "8233959" | "8239166" | "8249683" | "8255026" | "8257259" | "8260393" | "8260558" | "8275438" | "8282549" | "8282550" | "8287453" | "8290559" | "8290562" | "8292810" | "8298142" | "8332008" | "8346335" | "8346337" | "8346338" | "8348923" | "8364230").PN.				
L11	103	("8364231" | "8369919" | "8372351" | "8374667" | "8376945" | "8396528" | "8412301" | "8417312" | "8423113" | "8423114" | "8425416" | "8425417" | "8428678" | "8428679" | "8435179" | "8442610" | "8444560" | "8447376" | "8449464" | "8457703" | "8461985" | "8463350" | "8473022" | "8475373" | "8478377" | "8478557" | "8484005" | "8491474" | "8509871" | "8515517" | "8527025" | "8532730" | "8532935" | "8543354" | "8560037" | "8560038" | "8562528" | "8571808" | "8583205" | "8593109" | "8600681" | "8612163" | "8626257" | "8657745" | "8657746" | "8663220" | "8665091" | "8682615" | "8718739" | "8718965" | "8744547" | "8774886" | "8868151" | "8868161" | "8911367" | "8933664" | "8942778" | "9060719" | "9113828" | "9125548" | "9135402" | "9149220" | "9161714" | "9247901" | "9314196" | "9320462" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

		"9320468" | "9326709" | "9332934" | "9339217" | "9357959" | "9380971" | "9392969" | "9398872" | "9408566" | "9451908" | "9483608" | "9498155" | "9558325" | "9629578" | "9662056" | "9675290" | "9730623" | "9737249" | "9743863" | "9770211" | "9797880" | "9801571" | "9801575" | "9801577" | "9804148" | "9804150" | "9808190" | "9814428" | "9833181" | "9839383" | "9839395" | "9848809" | "9936910" | "RE31916" | "RE32361" | "RE43039" | "RE43399").PN.				
L12	561	calibrating near55 sensor near55 data and transcutaneous same analyte same sensor same sensor same electronics	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/25 13:13
L13	590	calibrating same sensor same data and transcutaneous same analyte same sensor same sensor same electronics	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/25 13:14

2/25/2021 1:14:47 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	576	sensor same electronics same (connect$3) same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:09
L2	417	l1 and calibrating near55 sensor near55 data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:10
L3	417	2 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/1495 OR A61B2560/0223 OR A61B5/14503 OR A61B5/1468 OR A61B5/14735 OR A61B5/0004 OR A61B5/6849 OR A61B5/6848 OR A61B5/6833 OR A61B5/0002 OR A61B5/0031 OR A61B5/1411 OR A61B5/150022 OR A61B5/14507 OR A61B5/1451 OR A61B17/3468 OR A61B2562/18 OR A61B5/68335 OR A61B5/145 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/6801 OR A61B5/742 OR A61B2562/08 OR A61B2562/12 OR A61B5/6832 OR A61B5/002 OR A61B2560/0214 OR A61B5/0022 OR A61B5/150534 OR A61B5/7203 OR A61B2560/063 OR A61B5/746 OR A61B5/411 OR A61B5/418 OR A61B2560/0276 OR A61B2560/028 OR A61B2560/0406 OR A61B2562/242 OR A61B5/14517 OR A61B5/486 OR A61B5/686 OR A61B5/688 OR A61B5/7264 OR A61B5/7445 OR A61B2560/04 OR A61B2560/0462 OR A61B2562/247 OR A61B5/0015 OR A61B5/076 OR A61B5/15142 OR A61B5/6846 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0412 OR A61B2560/0443	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:10

		OR A61B5/7207 OR A61B5/7221 OR A61B5/7275 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR Y02A50/30 OR A61M2005/1585 OR A61M5/14244 OR A61M5/1723 OR C08G18/12 OR C08G18/3234 OR C08G18/0828 OR C08G18/3857 OR C08G18/4018 OR C08G18/44 OR C08G18/4833 OR C08G18/755 OR C12Q1/006 OR C12Q1/002 OR G01N33/66 OR G01N27/3273 OR G01N27/3275 OR G01N33/54366).CPC.)				
L4	417	2 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/1495 OR A61B2560/0223 OR A61B5/14503 OR A61B5/1468 OR A61B5/14735 OR A61B5/0004 OR A61B5/6849 OR A61B5/6848 OR A61B5/6833 OR A61B5/0002 OR A61B5/0031 OR A61B5/1411 OR A61B5/150022 OR A61B5/14507 OR A61B5/1451 OR A61B17/3468 OR A61B2562/18 OR A61B5/68335 OR A61B5/145 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/6801 OR A61B5/742 OR A61B2562/08 OR A61B2562/12 OR A61B5/6832 OR A61B5/002 OR A61B2560/0214 OR A61B5/0022 OR A61B5/150534 OR A61B5/7203 OR A61B2560/063 OR A61B5/746 OR A61B5/411 OR A61B5/418 OR A61B2560/0276 OR A61B2560/028 OR A61B2560/0406 OR A61B2562/242 OR A61B5/14517 OR A61B5/486 OR A61B5/686 OR A61B5/688 OR A61B5/7264 OR A61B5/7445 OR A61B2560/04 OR A61B2560/0462 OR A61B2562/247 OR A61B5/0015 OR A61B5/076 OR A61B5/15142 OR A61B5/6846 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0412 OR A61B2560/0443 OR A61B5/7207 OR A61B5/7221 OR A61B5/7275 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR Y02A50/30 OR A61M2005/1585 OR A61M5/14244 OR A61M5/1723 OR C08G18/12 OR C08G18/3234 OR C08G18/0828 OR C08G18/3857 OR C08G18/4018 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:11

		C08G18/44 OR C08G18/4833 OR C08G18/755 OR C12Q1/006 OR C12Q1/002 OR G01N33/66 OR G01N27/3273 OR G01N27/3275 OR G01N33/54366 OR A61K31/045 OR A61K31/137 OR A61K31/46 OR A61K31/465 OR A61K31/485 OR A61K31/515 OR A61K31/56 OR A61K33/00 OR A61K36/185 OR A61K38/28 OR C08L39/06 OR C08L69/00 OR C08L75/04 OR C12N11/08 OR G16Z99/00 OR B33Y70/00 OR B33Y80/00 OR G16H10/60 OR G16H40/40 OR G16H40/63 OR G16H10/65 OR G16H20/17 OR G16H50/20 OR G16H15/00 OR G16H40/67 OR H04W12/06 OR H04W4/38 OR H04W4/80 OR H04W52/0277 OR H04W76/14 OR H04W12/02 OR H04W12/033 OR A61L2202/182 OR A61L2202/23 OR A61L2202/24 OR A61L2/12 OR A61L2/20 OR A61L2/206 OR G06F19/00 OR G06F16/90335 OR G06F16/9535 OR G06F21/6245 OR G06F3/1415).CPC.)				
L5	417	2 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/1495 OR A61B2560/0223 OR A61B5/14503 OR A61B5/1468 OR A61B5/14735 OR A61B5/0004 OR A61B5/6849 OR A61B5/6848 OR A61B5/6833 OR A61B5/0002 OR A61B5/0031 OR A61B5/1411 OR A61B5/150022 OR A61B5/14507 OR A61B5/1451 OR A61B17/3468 OR A61B2562/18 OR A61B5/68335 OR A61B5/145 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/6801 OR A61B5/742 OR A61B2562/08 OR A61B2562/12 OR A61B5/6832 OR A61B5/002 OR A61B2560/0214 OR A61B5/0022 OR A61B5/150534 OR A61B5/7203 OR A61B2560/063 OR A61B5/746 OR A61B5/411 OR A61B5/418 OR A61B2560/0276 OR A61B2560/028 OR A61B2560/0406 OR A61B2562/242 OR A61B5/14517 OR A61B5/486 OR A61B5/686 OR A61B5/688 OR A61B5/7264 OR A61B5/7445 OR A61B2560/04 OR A61B2560/0462 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:12

		A61B2562/247 OR A61B5/0015 OR A61B5/076 OR A61B5/15142 OR A61B5/6846 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0412 OR A61B2560/0443 OR A61B5/7207 OR A61B5/7221 OR A61B5/7275 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR Y02A50/30 OR A61M2005/1585 OR A61M5/14244 OR A61M5/1723 OR C08G18/12 OR C08G18/3234 OR C08G18/0828 OR C08G18/3857 OR C08G18/4018 OR C08G18/44 OR C08G18/4833 OR C08G18/755 OR C12Q1/006 OR C12Q1/002 OR G01N33/66 OR G01N27/3273 OR G01N27/3275 OR G01N33/54366 OR A61K31/045 OR A61K31/137 OR A61K31/46 OR A61K31/465 OR A61K31/485 OR A61K31/515 OR A61K31/56 OR A61K33/00 OR A61K36/185 OR A61K38/28 OR C08L39/06 OR C08L69/00 OR C08L75/04 OR C12N11/08 OR G16Z99/00 OR B33Y70/00 OR B33Y80/00 OR G16H10/60 OR G16H40/40 OR G16H40/63 OR G16H10/65 OR G16H20/17 OR G16H50/20 OR G16H15/00 OR G16H40/67 OR H04W12/06 OR H04W4/38 OR H04W4/80 OR H04W52/0277 OR H04W76/14 OR H04W12/02 OR H04W12/033 OR A61L2202/182 OR A61L2202/23 OR A61L2202/24 OR A61L2/12 OR A61L2/20 OR A61L2/206 OR G06F19/00 OR G06F16/90335 OR G06F16/9535 OR G06F21/6245 OR G06F3/1415 OR H04L2209/88 OR H04L63/101 OR Y02D30/70 OR Y10T29/49004 OR H04B1/03 OR G06Q2220/10 OR G06T11/001 OR G06T11/206 OR G09G2354/00 OR G09G2370/10 OR G09G2370/16 OR G09G5/377).CPC.)				

2/24/2021 9:12:55 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	576	sensor same electronics same (connect$3) same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:09
L2	417	l1 and calibrating near55 sensor near55 data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:10
L3	417	2 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/1495 OR A61B2560/0223 OR A61B5/14503 OR A61B5/1468 OR A61B5/14735 OR A61B5/0004 OR A61B5/6849 OR A61B5/6848 OR A61B5/6833 OR A61B5/0002 OR A61B5/0031 OR A61B5/1411 OR A61B5/150022 OR A61B5/14507 OR A61B5/1451 OR A61B17/3468 OR A61B2562/18 OR A61B5/68335 OR A61B5/145 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/6801 OR A61B5/742 OR A61B2562/08 OR A61B2562/12 OR A61B5/6832 OR A61B5/002 OR A61B2560/0214 OR A61B5/0022 OR A61B5/150534 OR A61B5/7203 OR A61B2560/063 OR A61B5/746 OR A61B5/411 OR A61B5/418 OR A61B2560/0276 OR A61B2560/028 OR A61B2560/0406 OR A61B2562/242 OR A61B5/14517 OR A61B5/486 OR A61B5/686 OR A61B5/688 OR A61B5/7264 OR A61B5/7445 OR A61B2560/04 OR A61B2560/0462 OR A61B2562/247 OR A61B5/0015 OR A61B5/076 OR A61B5/15142 OR A61B5/6846 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0412 OR A61B2560/0443 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:10

		A61B5/7207 OR A61B5/7221 OR A61B5/7275 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR Y02A50/30 OR A61M2005/1585 OR A61M5/14244 OR A61M5/1723 OR C08G18/12 OR C08G18/3234 OR C08G18/0828 OR C08G18/3857 OR C08G18/4018 OR C08G18/44 OR C08G18/4833 OR C08G18/755 OR C12Q1/006 OR C12Q1/002 OR G01N33/66 OR G01N27/3273 OR G01N27/3275 OR G01N33/54366).CPC.)				
L4	417	2 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/1495 OR A61B2560/0223 OR A61B5/14503 OR A61B5/1468 OR A61B5/14735 OR A61B5/0004 OR A61B5/6849 OR A61B5/6848 OR A61B5/6833 OR A61B5/0002 OR A61B5/0031 OR A61B5/1411 OR A61B5/150022 OR A61B5/14507 OR A61B5/1451 OR A61B17/3468 OR A61B2562/18 OR A61B5/68335 OR A61B5/145 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/6801 OR A61B5/742 OR A61B2562/08 OR A61B2562/12 OR A61B5/6832 OR A61B5/002 OR A61B2560/0214 OR A61B5/0022 OR A61B5/150534 OR A61B5/7203 OR A61B2560/063 OR A61B5/746 OR A61B5/411 OR A61B5/418 OR A61B2560/0276 OR A61B2560/028 OR A61B2560/0406 OR A61B2562/242 OR A61B5/14517 OR A61B5/486 OR A61B5/686 OR A61B5/688 OR A61B5/7264 OR A61B5/7445 OR A61B2560/04 OR A61B2560/0462 OR A61B2562/247 OR A61B5/0015 OR A61B5/076 OR A61B5/15142 OR A61B5/6846 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0412 OR A61B2560/0443 OR A61B5/7207 OR A61B5/7221 OR A61B5/7275 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR Y02A50/30 OR A61M2005/1585 OR A61M5/14244 OR A61M5/1723 OR C08G18/12 OR C08G18/3234 OR C08G18/0828 OR C08G18/3857 OR C08G18/4018 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:11

		C08G18/44 OR C08G18/4833 OR C08G18/755 OR C12Q1/006 OR C12Q1/002 OR G01N33/66 OR G01N27/3273 OR G01N27/3275 OR G01N33/54366 OR A61K31/045 OR A61K31/137 OR A61K31/46 OR A61K31/465 OR A61K31/485 OR A61K31/515 OR A61K31/56 OR A61K33/00 OR A61K36/185 OR A61K38/28 OR C08L39/06 OR C08L69/00 OR C08L75/04 OR C12N11/08 OR G16Z99/00 OR B33Y70/00 OR B33Y80/00 OR G16H10/60 OR G16H40/40 OR G16H40/63 OR G16H10/65 OR G16H20/17 OR G16H50/20 OR G16H15/00 OR G16H40/67 OR H04W12/06 OR H04W4/38 OR H04W4/80 OR H04W52/0277 OR H04W76/14 OR H04W12/02 OR H04W12/033 OR A61L2202/182 OR A61L2202/23 OR A61L2202/24 OR A61L2/12 OR A61L2/20 OR A61L2/206 OR G06F19/00 OR G06F16/90335 OR G06F16/9535 OR G06F21/6245 OR G06F3/1415).CPC.)				
L5	417	2 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/1495 OR A61B2560/0223 OR A61B5/14503 OR A61B5/1468 OR A61B5/14735 OR A61B5/0004 OR A61B5/6849 OR A61B5/6848 OR A61B5/6833 OR A61B5/0002 OR A61B5/0031 OR A61B5/1411 OR A61B5/150022 OR A61B5/14507 OR A61B5/1451 OR A61B17/3468 OR A61B2562/18 OR A61B5/68335 OR A61B5/145 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/6801 OR A61B5/742 OR A61B2562/08 OR A61B2562/12 OR A61B5/6832 OR A61B5/002 OR A61B2560/0214 OR A61B5/0022 OR A61B5/150534 OR A61B5/7203 OR A61B2560/063 OR A61B5/746 OR A61B5/411 OR A61B5/418 OR A61B2560/0276 OR A61B2560/028 OR A61B2560/0406 OR A61B2562/242 OR A61B5/14517 OR A61B5/486 OR A61B5/686 OR A61B5/688 OR A61B5/7264 OR A61B5/7445 OR A61B2560/04 OR A61B2560/0462 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 21:12

		A61B2562/247 OR A61B5/0015 OR A61B5/076 OR A61B5/15142 OR A61B5/6846 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0412 OR A61B2560/0443 OR A61B5/7207 OR A61B5/7221 OR A61B5/7275 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR Y02A50/30 OR A61M2005/1585 OR A61M5/14244 OR A61M5/1723 OR C08G18/12 OR C08G18/3234 OR C08G18/0828 OR C08G18/3857 OR C08G18/4018 OR C08G18/44 OR C08G18/4833 OR C08G18/755 OR C12Q1/006 OR C12Q1/002 OR G01N33/66 OR G01N27/3273 OR G01N27/3275 OR G01N33/54366 OR A61K31/045 OR A61K31/137 OR A61K31/46 OR A61K31/465 OR A61K31/485 OR A61K31/515 OR A61K31/56 OR A61K33/00 OR A61K36/185 OR A61K38/28 OR C08L39/06 OR C08L69/00 OR C08L75/04 OR C12N11/08 OR G16Z99/00 OR B33Y70/00 OR B33Y80/00 OR G16H10/60 OR G16H40/40 OR G16H40/63 OR G16H10/65 OR G16H20/17 OR G16H50/20 OR G16H15/00 OR G16H40/67 OR H04W12/06 OR H04W4/38 OR H04W4/80 OR H04W52/0277 OR H04W76/14 OR H04W12/02 OR H04W12/033 OR A61L2202/182 OR A61L2202/23 OR A61L2202/24 OR A61L2/12 OR A61L2/20 OR A61L2/206 OR G06F19/00 OR G06F16/90335 OR G06F16/9535 OR G06F21/6245 OR G06F3/1415 OR H04L2209/88 OR H04L63/101 OR Y02D30/70 OR Y10T29/49004 OR H04B1/03 OR G06Q2220/10 OR G06T11/001 OR G06T11/206 OR G09G2354/00 OR G09G2370/10 OR G09G2370/16 OR G09G5/377).CPC.)				
L6	12	(("20090143659") or ("20090178459") or ("20090131768") or ("20090131768") or ("20090131776") or ("20090137886")).PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/24 22:06

2/24/2021 10:15:17 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	205	("0000002" | "0000059" | "0000791" | "0002508" | "0052641" | "0062334" | "0065604" | "0201800" | "10002233" | "10004442" | "10078380" | "10082493" | "10089446" | "10188334" | "10194868" | "10335075" | "10349873" | "10448873" | "10561354" | "10610141" | "10624568" | "10682084" | "20010016682" | "20010021817" | "20010039053" | "20010041830" | "20010041831" | "20010051768" | "20020016534" | "20020016535" | "20020019022" | "20020022883" | "20020023852" | "20020026110" | "20020026111" | "20020027086" | "20020038101" | "20020042090" | "20020042561" | "20020043471" | "20020045808" | "20020055673" | "20020062132" | "20020065453" | "20020065454" | "20020068860" | "20020071776" | "20020084196" | "20020099282" | "20020099997" | "20020103499" | "20020106709" | "20020111547" | "20020115920" | "20020119711" | "20020120186" | "20020123048" | "20020128594" | "20020143266" | "20020143372" | "20020151796" | "20020155615" | "20020156355" | "20020161288" | "20020169369" | "20020169635" | "20020177763" | "20020177764" | "20020182241" | "20020188185" | "20020193679" | "20020193885" | "20020198513" | "20030003524" | "20030004403" | "20030004432" | "20030004457" | "20030006669" | "20030023171" | "20030023317" | "20030023461" | "20030028089" | "20030032867" | "20030032874" | "20030034305" | "20030036773" | "20030042137" | "20030050546" | "20030054428" | "20030060692" | "20030065254" | "20030065308" | "20030076082" | "20030078481" | "20030078560" | "20030097082" | "20030100040" | "20030100821" | "20030119201" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20030119208" | "20030120152" |
"20030125612" | "20030125613" |
"20030130616" | "20030134347" |
"20030138674" | "20030143746" |
"20030153821" | "20030161288" |
"20030168338" | "20030175987" |
"20030176183" | "20030176933" |
"20030181794" | "20030187338" |
"20030188427" | "20030191377" |
"20030199744" | "20030199790" |
"20030203498" | "20030208113" |
"20030211625" | "20030212317" |
"20030212346" | "20030212347" |
"20030212379" | "20030216630" |
"20030217966" | "20030225437" |
"20030228681" | "20030235817" |
"20040010186" | "20040010207" |
"20040011671" | "20040015063" |
"20040015134" | "20040023253" |
"20040023317" | "20040024327" |
"20040024553" | "20040030285" |
"20040030294" | "20040039298" |
"20040039406" | "20040040840" |
"20040045879" | "20040054263" |
"20040054352" | "20040064021" |
"20040064068" | "20040068230" |
"20040074785" | "20040077962" |
"20040078065" | "20040078219" |
"20040093167" | "20040099529" |
"20040106857" | "20040106858" |
"20040106859" | "20040108226" |
"20040122353" | "20040133131" |
"20040133164" | "20040135684" |
"20040138588" | "20040138716" |
"20040142403" | "20040143173" |
"20040146909" | "20040147819" |
"20040152187" | "20040152622" |
"20040158137" | "20040162678" |
"20040167801" | "20040171921" |
"20040172307" | "20040173472" |
"20040176672" | "20040186362" |
"20040186365" | "20040193025" |
"20040193090" | "20040197846" |
"20040199059" | "20040204687" |
"20040208780" | "20040219664" |
"20040220517" | "20040225338" |
"20040236200" | "20040236251" |
"20040242982" | "20040249253" |
"20040249420" | "20040254433" |
"20040254434" | "20040260478" |
"20040263354" | "20040267300" |
"20050003470" | "20050004439" |
"20050004494" | "20050006122").PN.

L2	200	("20050010087" | "20050010265" | "20050010269" | "20050015020" | "20050016276" | "20050026689" | "20050027177" | "20050027180" | "20050027181" | "20050027182" | "20050027462" | "20050027463" | "20050031689" | "20050033132" | "20050038332" | "20050043598" | "20050049179" | "20050049473" | "20050051427" | "20050051440" | "20050054905" | "20050054909" | "20050056551" | "20050056552" | "20050059871" | "20050065464" | "20050070774" | "20050090607" | "20050096511" | "20050096512" | "20050096519" | "20050101847" | "20050103625" | "20050112169" | "20050113653" | "20050114068" | "20050115832" | "20050121322" | "20050124873" | "20050131305" | "20050131346" | "20050133368" | "20050139489" | "20050143635" | "20050143675" | "20050154271" | "20050161346" | "20050173245" | "20050176136" | "20050177036" | "20050177398" | "20050181012" | "20050182306" | "20050182451" | "20050183954" | "20050187720" | "20050192494" | "20050192557" | "20050195930" | "20050196820" | "20050196821" | "20050197612" | "20050199494" | "20050203360" | "20050203364" | "20050211571" | "20050214892" | "20050215871" | "20050215872" | "20050239154" | "20050239156" | "20050241957" | "20050242479" | "20050245795" | "20050245799" | "20050245839" | "20050245904" | "20050258037" | "20050261563" | "20050272989" | "20050277164" | "20050277912" | "20050287620" | "20050288596" | "20050288725" | "20060001538" | "20060004270" | "20060010098" | "20060015020" | "20060015024" | "20060016700" | "20060017923" | "20060019327" | "20060020186" | "20060020187" | "20060020188" | "20060020189" | "20060020190" | "20060020191" | "20060020192" | "20060025662" | "20060025663" | "20060029177" | "20060031094" | "20060036139" | "20060036140" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"20060036141" | "20060036142" | "20060036143" | "20060036144" | "20060036145" | "20060040402" | "20060042353" | "20060047192" | "20060052745" | "20060068208" | "20060079809" | "20060086624" | "20060091006" | "20060094946" | "20060100588" | "20060142651" | "20060155180" | "20060166629" | "20060167365" | "20060167517" | "20060167518" | "20060167519" | "20060173260" | "20060173406" | "20060173444" | "20060178617" | "20060183984" | "20060183985" | "20060189851" | "20060189856" | "20060189863" | "20060189925" | "20060193375" | "20060195029" | "20060198864" | "20060200009" | "20060200019" | "20060200020" | "20060200022" | "20060200970" | "20060222566" | "20060224109" | "20060224141" | "20060226985" | "20060229512" | "20060229531" | "20060229533" | "20060247508" | "20060247685" | "20060247985" | "20060253012" | "20060253085" | "20060257996" | "20060258761" | "20060258929" | "20060263839" | "20060264785" | "20060270922" | "20060270923" | "20060272652" | "20060281985" | "20060293576" | "20070016381" | "20070017805" | "20070020641" | "20070027284" | "20070027370" | "20070027381" | "20070027384" | "20070027385" | "20070032706" | "20070032717" | "20070032718" | "20070033074" | "20070033254" | "20070045902" | "20070049873" | "20070056858" | "20070059196" | "20070060803" | "20070060814" | "20070060871" | "20070066873" | "20070068807" | "20070071681" | "20070073129" | "20070078320" | "20070078321" | "20070078322" | "20070078323" | "20070085995" | "20070093704" | "20070095661" | "20070106135").PN.				
L3	200	("20070108048" | "20070112298" | "20070116600" | "20070118030" | "20070118405" | "20070124002" | "20070129619" | "20070129621" | "20070135699" | "20070142584" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20070149875" | "20070151869" |
"20070156033" | "20070163880" |
"20070168224" | "20070169533" |
"20070170073" | "20070173706" |
"20070173709" | "20070173710" |
"20070173711" | "20070173712" |
"20070173741" | "20070173761" |
"20070179349" | "20070179352" |
"20070179434" | "20070179436" |
"20070191701" | "20070191716" |
"20070197889" | "20070197890" |
"20070199818" | "20070200254" |
"20070202562" | "20070202672" |
"20070203407" | "20070203410" |
"20070203966" | "20070206193" |
"20070208244" | "20070208245" |
"20070208246" | "20070213610" |
"20070213611" | "20070213657" |
"20070218097" | "20070219441" |
"20070224700" | "20070225675" |
"20070227911" | "20070232877" |
"20070232878" | "20070232879" |
"20070232880" | "20070233013" |
"20070235331" | "20070240497" |
"20070244379" | "20070244381" |
"20070244382" | "20070249916" |
"20070249922" | "20070255321" |
"20070259217" | "20070299389" |
"20070299617" | "20080000779" |
"20080004515" | "20080004601" |
"20080009692" | "20080012701" |
"20080017522" | "20080021666" |
"20080021972" | "20080029390" |
"20080029391" | "20080033254" |
"20080033357" | "20080039702" |
"20080045824" | "20080058625" |
"20080064937" | "20080066305" |
"20080071156" | "20080071157" |
"20080071158" | "20080072663" |
"20080081000" | "20080081977" |
"20080083617" | "20080086040" |
"20080086041" | "20080086042" |
"20080086043" | "20080086044" |
"20080086273" | "20080091094" |
"20080091095" | "20080097197" |
"20080097289" | "20080097326" |
"20080102441" | "20080103447" |
"20080108942" | "20080114227" |
"20080115599" | "20080119703" |
"20080119704" | "20080119706" |
"20080119708" | "20080125751" |
"20080139910" | "20080147050" |
"20080148873" | "20080154101" |

		"20080154177" | "20080154513" | "20080156661" | "20080161664" | "20080161666" | "20080161753" | "20080167543" | "20080168676" | "20080172205" | "20080177149" | "20080177165" | "20080183060" | "20080183061" | "20080183399" | "20080187655" | "20080188722" | "20080188725" | "20080188731" | "20080188796" | "20080189051" | "20080193936" | "20080194837" | "20080194934" | "20080194935" | "20080194936" | "20080194937" | "20080194938" | "20080195232" | "20080195967" | "20080197024" | "20080200788" | "20080200789" | "20080200791" | "20080200897" | "20080201325" | "20080205481" | "20080208025" | "20080208113" | "20080214910" | "20080214915" | "20080214918" | "20080228051" | "20080228054" | "20080234943" | "20080242961" | "20080242963" | "20080249385" | "20080255434" | "20080255437" | "20080255438" | "20080255808" | "20080256048" | "20080262469" | "20080267823" | "20080269714" | "20080275313" | "20080278332" | "20080287761" | "20080287762" | "20080287763" | "20080287764" | "20080287765" | "20080287766" | "20080288180" | "20080288204" | "20080296155" | "20080300572" | "20080305009" | "20080305506" | "20080306368" | "20080306433" | "20080306434" | "20080306435" | "20080306444" | "20080306472" | "20080312841" | "20080312842" | "20080312844" | "20080312845" | "20080314395" | "20080319279" | "20080319295" | "20080319296" | "20090001923").PN.				
L4	200	("20090005665" | "20090005666" | "20090006034" | "20090006061" | "20090012376" | "20090012379" | "20090016379" | "20090018418" | "20090018424" | "20090018425" | "20090018426" | "20090030293" | "20090030294" | "20090033482" | "20090036747" | "20090036758" | "20090036760" | "20090036763" | "20090043181" | "20090043182" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20090043525" | "20090043541" |
"20090043542" | "20090045055" |
"20090048503" | "20090054745" |
"20090054748" | "20090054749" |
"20090054753" | "20090055149" |
"20090061528" | "20090062633" |
"20090062635" | "20090062645" |
"20090062767" | "20090063402" |
"20090069649" | "20090076356" |
"20090076360" | "20090076361" |
"20090081803" | "20090082693" |
"20090085768" | "20090099434" |
"20090099436" | "20090105570" |
"20090105636" | "20090112478" |
"20090112626" | "20090118589" |
"20090124877" | "20090124878" |
"20090124879" | "20090124964" |
"20090131768" | "20090131769" |
"20090131776" | "20090131777" |
"20090137886" | "20090137887" |
"20090143659" | "20090143660" |
"20090143725" | "20090149728" |
"20090156919" | "20090156922" |
"20090156924" | "20090163790" |
"20090163855" | "20090164190" |
"20090164239" | "20090164251" |
"20090171178" | "20090177143" |
"20090178459" | "20090182217" |
"20090182517" | "20090192366" |
"20090192722" | "20090192724" |
"20090192745" | "20090192751" |
"20090198118" | "20090203981" |
"20090204340" | "20090204341" |
"20090216103" | "20090240120" |
"20090240128" | "20090240193" |
"20090241028" | "20090242399" |
"20090242425" | "20090247855" |
"20090247856" | "20090247857" |
"20090257911" | "20090264719" |
"20090281407" | "20090287073" |
"20090287074" | "20090294277" |
"20090299155" | "20090299156" |
"20090299162" | "20090299276" |
"20100010324" | "20100010331" |
"20100010332" | "20100016687" |
"20100020309" | "20100022855" |
"20100023270" | "20100023291" |
"20100025238" | "20100030053" |
"20100030137" | "20100030484" |
"20100036215" | "20100036216" |
"20100036222" | "20100036223" |
"20100036224" | "20100036225" |
"20100045231" | "20100045465" |

		"20100049015" | "20100049021" | "20100057040" | "20100057041" | "20100057042" | "20100057044" | "20100057057" | "20100063372" | "20100064764" | "20100081906" | "20100081908" | "20100081909" | "20100081910" | "20100081953" | "20100094111" | "20100121167" | "20100141656" | "20100145174" | "20100152561" | "20100160759" | "20100160761" | "20100168538" | "20100168546" | "20100169035" | "20100174167" | "20100174168" | "20100174266" | "20100179399" | "20100179402" | "20100179405" | "20100179406" | "20100179407" | "20100179408" | "20100179409" | "20100185065" | "20100185070" | "20100185071" | "20100185072" | "20100185073" | "20100185074" | "20100191085" | "20100191472" | "20100198034" | "20100198035" | "20100198142" | "20100204557" | "20100213057" | "20100214104" | "20100217106" | "20100230285" | "20100234707" | "20100234710" | "20100234796" | "20100235106" | "20100240975" | "20100240976" | "20100261987" | "20100265073" | "20100274107" | "20100274515" | "20100277342" | "20100280441" | "20100280782" | "20100286496" | "20100298684" | "20100313105" | "20100317952" | "20100324392" | "20100326842" | "20100331644" | "20100331648" | "20100331655" | "20110021889" | "20110024043").PN.				
L5	208	("20110024307" | "20110027127" | "20110027453" | "20110027458" | "20110028815" | "20110028816" | "20110029247" | "20110029269" | "20110040163" | "20110046467" | "20110060530" | "20110077490" | "20110077491" | "20110077494" | "20110081726" | "20110082484" | "20110105873" | "20110106126" | "20110112696" | "20110118579" | "20110124997" | "20110125410" | "20110130970" | "20110137601" | "20110148905" | "20110174638" | "20110184268" | "20110190603" | "20110191044" | "20110193704" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20110208027" | "20110208155" |
"20110213225" | "20110218414" |
"20110224523" | "20110230741" |
"20110257495" | "20110257895" |
"20110263958" | "20110270062" |
"20110288574" | "20110313317" |
"20110319729" | "20110319734" |
"20110319739" | "20110320130" |
"20110320167" | "20120010642" |
"20120078071" | "20120097554" |
"20120108931" | "20120108934" |
"20120123692" | "20120165626" |
"20120165640" | "20120173200" |
"20120209099" | "20120215462" |
"20120239304" | "20120245447" |
"20120265035" | "20120265036" |
"20120277564" | "20120277565" |
"20120283542" | "20120283960" |
"20120291516" | "20120330561" |
"20130006112" | "20130035575" |
"20130060105" | "20130060112" |
"20130116527" | "20130137953" |
"20130150690" | "20130178727" |
"20130184547" | "20130199944" |
"20130231541" | "20130245412" |
"20130253846" | "20130281807" |
"20130282322" | "20130282403" |
"20130324823" | "20130338454" |
"20140005499" | "20140005968" |
"20140018642" | "20140041441" |
"20140046155" | "20140046156" |
"20140046157" | "20140046160" |
"20140046161" | "20140066736" |
"20140088390" | "20140088392" |
"20140088908" | "20140100796" |
"20140114156" | "20140121480" |
"20140121488" | "20140207400" |
"20140213869" | "20140221966" |
"20140236536" | "20140243638" |
"20140257059" | "20150005601" |
"20150006109" | "20150094555" |
"20150216456" | "20150241407" |
"20150282742" | "20150366510" |
"20150374299" | "20160022221" |
"20160073941" | "20160151006" |
"20160157758" | "20160198986" |
"20160206233" | "20160220189" |
"20160238589" | "20160245791" |
"20160270705" | "20160296697" |
"20160317069" | "20170003766" |
"20170027484" | "20170042456" |
"20170049369" | "20170124287" |
"20170188909" | "20170224258" |

		"20170258379" | "20170340250" | "20170347927" | "20180000004" | "20180000389" | "20180008174" | "20180008201" | "20180038844" | "20180042530" | "20180042531" | "20180059093" | "20180064398" | "20180085037" | "20180098721" | "20180271415" | "20180325437" | "20180328766" | "20180344220" | "20180364215" | "20190035488" | "20190072538" | "20190083012" | "20190083015" | "20190150802" | "20190151542" | "20190159734" | "20190187814" | "20190192071" | "20190254575" | "20190261902" | "20190282143" | "20190320948" | "20190320949" | "20190336051" | "20190350499" | "20190357817" | "20190357827" | "20190380627" | "20200022626" | "20200037934" | "20200037935" | "20200037936" | "20200046272" | "2402306" | "2719797" | "3210578" | "3219533" | "3506032" | "3539455" | "3556950" | "3581062" | "3610226" | "3610230" | "3652475" | "3775182" | "3780727" | "3791871" | "3826244" | "3837339" | "3838033" | "3838682" | "3874850" | "3898984" | "3910256" | "3926760" | "3929971" | "3933593" | "3943918" | "3949388" | "3957613" | "3960497" | "3964974").PN.				
L6	280	("3966580" | "3978856" | "3979274" | "3982530" | "4008717" | "4016866" | "4024312" | "4030640" | "4036749" | "4037563" | "4040908" | "4052754" | "4055175" | "4067322" | "4073713" | "4076656" | "4080292" | "4109505" | "4119406" | "4129128" | "4151845" | "4172770" | "4176659" | "4197840" | "4197852" | "4206755" | "4215703" | "4240438" | "4240889" | "4245634" | "4253469" | "4255500" | "4259540" | "4265249" | "4300572" | "4327725" | "4344438" | "4349728" | "4366040" | "4369785" | "4373527" | "4374013" | "4378016" | "4388166" | "4392849" | "4402694" | "4403847" | "4403984" | "4407298" | "4415666" | "4418148" | "4419535" | "4420564" | "4425920" | "4426621" | "4431004" | "4431507" | "4432366" | "4436094" | "4441968" | "4442841" | "4448188" | "4454295" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"4457339" | "4462048" | "4478222" |
"4478976" | "4484987" | "4486290" |
"4492575" | "4494950" | "4496454" |
"4506680" | "4509531" | "4519973" |
"4526569" | "4527240" | "4534355" |
"4534825" | "4535786" | "4538616" |
"4545382" | "4554927" | "4561963" |
"4565665" | "4565666" | "4568444" |
"4571292" | "4573968" | "4577642" |
"4578215" | "4583976" | "4592824" |
"4613328" | "4614514" | "4619793" |
"4626104" | "4650547" | "4655880" |
"4663824" | "4670007" | "4671288" |
"4672970" | "4680268" | "4685463" |
"4685903" | "4685912" | "4686044" |
"4689309" | "4694861" | "4703756" |
"4705503" | "4711245" | "4711251" |
"4721677" | "4731051" | "4731726" |
"4736748" | "4747822" | "4749985" |
"4750496" | "4752935" | "4753652" |
"4755168" | "4757022" | "4759366" |
"4759828" | "4763648" | "4776944" |
"4777953" | "4779618" | "4781798" |
"4783250" | "4784157" | "4786394" |
"4787398" | "4789467" | "4791932" |
"4800495" | "4803243" | "4805624" |
"4805625" | "4808089" | "4808292" |
"4809704" | "4810243" | "4810470" |
"4813423" | "4815471" | "4820281" |
"4822336" | "4828544" | "4830013" |
"4831070" | "4832005" | "4834101" |
"4838281" | "4841974" | "4849458" |
"4852573" | "4854322" | "4858615" |
"4861454" | "4861830" | "4863265" |
"4867741" | "4871351" | "4871440" |
"4874363" | "4883057" | "4883467" |
"4889528" | "4889744" | "4890620" |
"4890621" | "4898578" | "4900305" |
"4902294" | "4907857" | "4909786" |
"4919141" | "4919649" | "4921477" |
"4921480" | "4923819" | "4925268" |
"4925444" | "4927407" | "4927516" |
"4928694" | "4934369" | "4934375" |
"4935345" | "4944299" | "4946439" |
"4947845" | "4951669" | "4953552" |
"4955861" | "4957483" | "4958148" |
"4963131" | "4963595" | "4966579" |
"4967940" | "4974592" | "4974929" |
"4975175" | "4975636" | "4976687" |
"4979509" | "4984929" | "4986271" |
"4986671" | "4988341" | "4988671" |
"4988758" | "4994026" | "4994167" |
"4995402" | "4997627" | "5000180" |

		"5000419" | "5002054" | "5002055" | "5002572" | "5006050" | "5006111" | "5007929" | "5009251" | "5019974" | "5026348" | "5030199" | "5030333" | "5034112" | "5041092" | "5045057" | "5046496" | "5048525" | "5050612" | "5055171" | "5055198" | "5059654" | "5067491" | "5068536" | "5077476" | "5082147" | "5082550" | "5088981" | "5089112" | "5089421" | "5096669" | "5097834" | "5098377" | "5101814" | "5106365" | "5108819" | "5109850" | "5109860" | "5112301" | "5112455" | "5114859" | "5116313" | "5122925" | "5127405" | "5135004" | "5137028" | "5140985" | "5145565" | "5148812" | "5152746" | "5156972" | "5158437" | "5160418" | "5161532" | "5165406" | "5165407" | "5171689" | "5174291" | "5176632").PN.				
L7	280	("5176658" | "5178142" | "5178957" | "5182004" | "5188591" | "5190041" | "5195963" | "5198771" | "5199428" | "5202261" | "5203326" | "5204264" | "5207642" | "5208147" | "5210778" | "5216598" | "5219279" | "5220917" | "5220920" | "5224929" | "5225063" | "5231988" | "5232434" | "5235003" | "5237123" | "5243696" | "5243982" | "5243983" | "5246867" | "5248300" | "5249576" | "5254102" | "5262035" | "5262305" | "5264103" | "5264105" | "5265594" | "5266179" | "5269891" | "5271736" | "5271815" | "5275169" | "5279294" | "5281319" | "5282844" | "5282848" | "5284140" | "5284570" | "5285513" | "5285792" | "5287753" | "5293877" | "5298022" | "5298144" | "5299571" | "5302093" | "5304468" | "5307263" | "5310469" | "5311908" | "5312361" | "5313953" | "5314471" | "5315993" | "5316008" | "5316452" | "5318511" | "5320715" | "5320725" | "5321392" | "5322063" | "5324322" | "5324328" | "5326356" | "5326449" | "5328460" | "5330521" | "5330634" | "5331555" | "5335658" | "5337747" | "5340722" | "5342409" | "5342789" | "5343869" | "5345932" | "5348788" | "5352348" | "5352349" | "5352351" | "5354272" | "5354449" | "5356217" | "5356375" | "5356378" | "5356786" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"5360404" | "5365426" | "5368224" |
"5368562" | "5372133" | "5372135" |
"5372427" | "5372709" | "5376070" |
"5378229" | "5379238" | "5380268" |
"5380491" | "5380536" | "5380665" |
"5384028" | "5384547" | "5390671" |
"5391250" | "5397848" | "5398682" |
"5400795" | "5408999" | "5409666" |
"5411052" | "5411551" | "5411647" |
"5411866" | "5417206" | "5421328" |
"5422829" | "5423738" | "5423749" |
"5425375" | "5425717" | "5425749" |
"5425868" | "5428123" | "5429485" |
"5429602" | "5429735" | "5431160" |
"5431174" | "5431921" | "5434412" |
"5437635" | "5438983" | "5445610" |
"5448992" | "5453278" | "5462051" |
"5462064" | "5462645" | "5466348" |
"5469846" | "5472317" | "5474552" |
"5476094" | "5476776" | "5482446" |
"5482473" | "5484404" | "5486776" |
"5489414" | "5491474" | "5494562" |
"5496273" | "5496453" | "5497772" |
"5502396" | "5505828" | "5507288" |
"5508203" | "5509410" | "5509888" |
"5512046" | "5512246" | "5512248" |
"5513636" | "5514253" | "5514718" |
"5515851" | "5517313" | "5518601" |
"5520191" | "5522798" | "5529676" |
"5531679" | "5531878" | "5540828" |
"5543326" | "5545220" | "5547470" |
"5548569" | "5549547" | "5549548" |
"5549569" | "5549651" | "5551850" |
"5552997" | "5553616" | "5554339" |
"5562614" | "5562615" | "5564439" |
"5568400" | "5568806" | "5569186" |
"5569188" | "5569219" | "5571395" |
"5575930" | "5577499" | "5582184" |
"5582497" | "5582593" | "5582697" |
"5584813" | "5584876" | "5586553" |
"5588560" | "5589563" | "5590651" |
"5593440" | "5593852" | "5601435" |
"5605152" | "5606152" | "5609572" |
"5609575" | "5611900" | "5615671" |
"5620579" | "5624409" | "5624537" |
"5626563" | "5628310" | "5628619" |
"5628890" | "5630710" | "5631170" |
"5637083" | "5640470" | "5640954" |
"5643195" | "5645077" | "5651767" |
"5653239" | "5653756" | "5653863" |
"5658250" | "5660163" | "5665061" |
"5665065" | "5665222" | "5667504" |
"5676651" | "5676820" | "5681285" |

		"5682884" | "5683562" | "5685844" | "5686829" | "5688239" | "5688244" | "5695623" | "5697366" | "5697899" | "5704354" | "5707502" | "5711001" | "5711861" | "5714931" | "5720295" | "5730654" | "5733259" | "5735273" | "5735285" | "5738992" | "5741211" | "5741634" | "5743262" | "5745378" | "5749832").PN.				
L8	280	("5749907" | "5755226" | "5755692" | "5756632" | "5758643" | "5763760" | "5766151" | "5772586" | "5777060" | "5779665" | "5781455" | "5782912" | "5783054" | "5785660" | "5787900" | "5791344" | "5791880" | "5792065" | "5795774" | "5798065" | "5800383" | "5800420" | "5800529" | "5804048" | "5806517" | "5807274" | "5807312" | "5807375" | "5807406" | "5810323" | "5810770" | "5811487" | "5814599" | "5820551" | "5820589" | "5822715" | "5823802" | "5833603" | "5836887" | "5836989" | "5837454" | "5837728" | "5840026" | "5851197" | "5861019" | "5863400" | "5871514" | "5873862" | "5879373" | "5879828" | "5882494" | "5885844" | "5891047" | "5891048" | "5897525" | "5897578" | "5899855" | "5904666" | "5904708" | "5910554" | "5911219" | "5913998" | "5914026" | "5917346" | "5918603" | "5921951" | "5925021" | "5928130" | "5928155" | "5928182" | "5928189" | "5928195" | "5931814" | "5932175" | "5933136" | "5935224" | "5938636" | "5942979" | "5944661" | "5947911" | "5951521" | "5954643" | "5954954" | "5957854" | "5957903" | "5960797" | "5961451" | "5964261" | "5964993" | "5965380" | "5971922" | "5972199" | "5976085" | "5980728" | "5990422" | "5995208" | "5995860" | "5999848" | "6001067" | "6001471" | "6007775" | "6011984" | "6013113" | "6014577" | "6016443" | "6016448" | "6021350" | "6023629" | "6024699" | "6024720" | "6027445" | "6027479" | "6032059" | "6032667" | "6036924" | "6038469" | "6045567" | "6049727" | "6051389" | "6059946" | "6063637" | "6066088" | "6066448" | "6071391" | "6073031" | "6074775" | "6077299" | "6080583" | "6081735" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"6081736" | "6083523" | "6083710" |
"6088608" | "6090087" | "6091975" |
"6091976" | "6093156" | "6093172" |
"6099511" | "6103033" | "6107083" |
"6108577" | "6112116" | "6115622" |
"6115628" | "6115634" | "6117290" |
"6119028" | "6120676" | "6121009" |
"6121611" | "6122351" | "6122536" |
"6123827" | "6127154" | "6128519" |
"6128526" | "6134461" | "6135978" |
"6141573" | "6142939" | "6142979" |
"6143164" | "6144837" | "6144869" |
"6144871" | "6156051" | "6159147" |
"6159186" | "6161095" | "6162201" |
"6162611" | "6164921" | "6165154" |
"6165406" | "6167614" | "6168568" |
"6169155" | "6171276" | "6175752" |
"6175753" | "6180416" | "6183437" |
"6187062" | "6189536" | "6191860" |
"6197040" | "6200265" | "6200772" |
"6201980" | "6201993" | "6206856" |
"6208894" | "6212416" | "6212417" |
"6212424" | "6213739" | "6214185" |
"6219574" | "6223083" | "6223283" |
"6224562" | "6230059" | "6231320" |
"6231560" | "6231879" | "6233080" |
"6233486" | "6241863" | "6248067" |
"6248077" | "6248093" | "6249705" |
"6254586" | "6256522" | "6256538" |
"6259937" | "6261440" | "6263222" |
"6264606" | "6264825" | "6268161" |
"6269340" | "6270455" | "6270478" |
"6272364" | "6272379" | "6272480" |
"6274285" | "6275717" | "6280408" |
"6281015" | "6283761" | "6284125" |
"6284478" | "6293925" | "6294281" |
"6295506" | "6298254" | "6299578" |
"6299583" | "6299757" | "6300002" |
"6302855" | "6306104" | "6309351" |
"6309375" | "6309884" | "6312388" |
"6325978" | "6325979" | "6326160" |
"6329161" | "6329929" | "6330464" |
"6338790" | "6343225" | "6348640" |
"6356776" | "6358225" | "6359444" |
"6360888" | "6361503" | "6365670" |
"6366794" | "6368141" | "6368274" |
"6370941" | "6372244" | "6377828" |
"6377852" | "6377894" | "6379301" |
"6381493" | "6387048" | "6387709" |
"6391019" | "6400974" | "6402703" |
"6403944").PN.

L9	280	("6409674" | "6413393" | "6413396" | "6413410" | "6416651" | "6418332" | "6424847" | "6424861" | "6427088" | "6428123" | "6430437" | "6434430" | "6440068" | "6444115" | "6447448" | "6447542" | "6454710" | "6459917" | "6461496" | "6464849" | "6465066" | "6466810" | "6467480" | "6471689" | "6474360" | "6475372" | "6475750" | "6477392" | "6477395" | "6478736" | "6481440" | "6484045" | "6484046" | "6485449" | "6486661" | "6488652" | "6494879" | "6498043" | "6498941" | "6501976" | "6501983" | "6503381" | "6510329" | "6512939" | "6514460" | "6514718" | "6517508" | "6520326" | "6520477" | "6520937" | "6520997" | "6526298" | "6527729" | "6528318" | "6536433" | "6537318" | "6540891" | "6541266" | "6542765" | "6543195" | "6544212" | "6544229" | "6545085" | "6546268" | "6546269" | "6547839" | "6551494" | "6551496" | "6553241" | "6553244" | "6554805" | "6554822" | "6558320" | "6558321" | "6558347" | "6558351" | "6561978" | "6562001" | "6564105" | "6565509" | "6565535" | "6565807" | "6569309" | "6569521" | "6571128" | "6572542" | "6572545" | "6572579" | "6574490" | "6575905" | "6576101" | "6577899" | "6579257" | "6579498" | "6579690" | "6584335" | "6585644" | "6585675" | "6585763" | "6587705" | "6589229" | "6591125" | "6592745" | "6594514" | "6595756" | "6595919" | "6600940" | "6600997" | "6602221" | "6605072" | "6605200" | "6605201" | "6607509" | "6607658" | "6609071" | "6610012" | "6612984" | "6613379" | "6615061" | "6615078" | "6616819" | "6618603" | "6618934" | "6622045" | "6633772" | "6635014" | "6641533" | "6642015" | "6645181" | "6648821" | "6650471" | "6653091" | "6654625" | "6656114" | "6656157" | "6658396" | "6659948" | "6668196" | "6673022" | "6673596" | "6675030" | "6676816" | "6679865" | "6679872" | "6683535" | "6684904" | "6685668" | "6687522" | "6687546" | "6689056" | "6689089" | "6689265" | "6689413" | "6692457" | "6694191" | "6695860" | "6698269" | "6699188" | "6699218" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"6702249" | "6702857" | "6702972" | "6711423" | "6711424" | "6712796" | "6721582" | "6721587" | "6723086" | "6730200" | "6731976" | "6731985" | "6733446" | "6733655" | "6736783" | "6736957" | "6737158" | "6740075" | "6741877" | "6742635" | "6743635" | "6746582" | "6749587" | "6749591" | "6749740" | "6758810" | "6764581" | "6770030" | "6770067" | "6773671" | "6780297" | "6784274" | "6790178" | "6793632" | "6801041" | "6802957" | "6804002" | "6805693" | "6809653" | "6810290" | "6811533" | "6811534" | "6811548" | "6813519" | "6817990" | "6846654" | "6850790" | "6850859" | "6854317" | "6858020" | "6862465" | "6865407" | "6869413" | "6873268" | "6881551" | "6882940" | "6887228" | "6892085" | "6893396" | "6893545" | "6893552" | "6895263" | "6895265" | "6902544" | "6912413" | "6923763" | "6925393" | "6926691" | "6931327" | "6932584" | "6932892" | "6932894" | "6936006" | "6942518" | "6945965" | "6948492" | "6950708" | "6952604" | "6954662" | "6958705" | "6960192" | "6965791" | "6966325" | "6968294" | "6971274" | "6972080" | "6974437" | "6975893" | "6979315" | "6985870" | "6989891" | "6990366" | "6990422" | "6996427" | "6997907" | "6997921" | "6998247" | "7003336" | "7003340" | "7003341" | "7010345" | "7011630" | "7016713" | "7016720" | "7018361" | "7022072" | "7022219" | "7024245" | "7025425" | "7025727" | "7025743" | "7027848" | "7029443" | "7029444" | "7041068" | "7041209" | "7041468" | "7043287" | "7048727" | "7052472" | "7052483").PN.				
L10	280	("7056302" | "7060059" | "7061593" | "7062385" | "7063086" | "7066884" | "7070577" | "7070580" | "7074307" | "7074610" | "7076300" | "7078582" | "7081195" | "7092891" | "7096064" | "7097775" | "7098803" | "7100628" | "7110803" | "7115884" | "7120483" | "7123950" | "7131967" | "7135342" | "7149562" | "7150741" | "7153265" | "7153458" | "7167818" | "7169289" | "7171252" | "7171274" | "7183102" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"7190988" | "7192450" | "7204823" |
"7207968" | "7207974" | "7211074" |
"7211439" | "7214190" | "7221970" |
"7223253" | "7225535" | "7226978" |
"7228162" | "7229288" | "7238165" |
"7244582" | "7247138" | "7247443" |
"7248912" | "7253680" | "7254450" |
"7255690" | "7258673" | "7258681" |
"7261690" | "7266400" | "7267665" |
"7268562" | "7272436" | "7273633" |
"7276029" | "7278983" | "7280879" |
"7288085" | "7288368" | "7289204" |
"7289836" | "7291496" | "7295867" |
"7297114" | "7299082" | "7303875" |
"7308292" | "7310544" | "7311690" |
"7312040" | "7313425" | "7314452" |
"7315752" | "7315767" | "7316662" |
"7317938" | "7317939" | "7318814" |
"7327273" | "7329234" | "7334594" |
"7335179" | "7335195" | "7335294" |
"7338464" | "7338639" | "7344499" |
"7344626" | "7351321" | "7354420" |
"7359723" | "7361155" | "7364562" |
"7364592" | "7365562" | "7366556" |
"7367942" | "7372277" | "7379765" |
"7381184" | "7384532" | "7387811" |
"7390667" | "7396353" | "7399277" |
"7402153" | "7402349" | "7407811" |
"7416802" | "7417164" | "7417729" |
"7422727" | "7424318" | "7425877" |
"7426408" | "7427338" | "7427560" |
"7429552" | "7433727" | "7460898" |
"7467003" | "7468125" | "7471972" |
"7474992" | "7488601" | "7494465" |
"7494816" | "7497827" | "7499002" |
"7501052" | "7502644" | "7517439" |
"7519478" | "7523004" | "7524287" |
"7525298" | "7529574" | "7547281" |
"7547382" | "7569030" | "7583990" |
"7591801" | "7599726" | "7604593" |
"7608042" | "7613491" | "7615007" |
"7618368" | "7618369" | "7620438" |
"7624028" | "7630748" | "7632228" |
"7635594" | "7637868" | "7640032" |
"7640048" | "7645374" | "7647237" |
"7653425" | "7654956" | "7695434" |
"7699775" | "7699964" | "7711493" |
"7715893" | "7731659" | "7736310" |
"7749445" | "7751864" | "7761126" |
"7761130" | "7766829" | "7766830" |
"7771352" | "7774038" | "7774145" |
"7775975" | "7776559" | "7778679" |
"7778680" | "7826981" | "7831287" |

		"7838639" | "7856613" | "7857760" | "7866025" | "7866026" | "7885697" | "7885698" | "7889069" | "7894870" | "7896809" | "7899511" | "7901354" | "7905833" | "7914450" | "7920906" | "7925321" | "7927274" | "7933639" | "7938797" | "7943034" | "7946984" | "7955261" | "7959569" | "7964089" | "7964146" | "7974672" | "7979104" | "7985330" | "7986986" | "7990828" | "7996158" | "7998071" | "8000763" | "8005524" | "8005525" | "8010174" | "8016997" | "8026104" | "8030942" | "8052601" | "8060173" | "8073519" | "8073520" | "8103471" | "8109850" | "8112240" | "8114268" | "8116837" | "8123920" | "8128562" | "8140312" | "8149117" | "8150488" | "8160670" | "8160671" | "8160834" | "8160900" | "8167801" | "8170803" | "8195265" | "8202491" | "8211016" | "8216137" | "8216138" | "8219173" | "8224415" | "8229536" | "8233959" | "8239166" | "8249683" | "8255026" | "8257259" | "8260393" | "8260558" | "8275438" | "8282549" | "8282550" | "8287453" | "8290559" | "8290562" | "8292810" | "8298142" | "8332008" | "8346335" | "8346337" | "8346338" | "8348923" | "8364230").PN.				
L11	103	("8364231" | "8369919" | "8372351" | "8374667" | "8376945" | "8396528" | "8412301" | "8417312" | "8423113" | "8423114" | "8425416" | "8425417" | "8428678" | "8428679" | "8435179" | "8442610" | "8444560" | "8447376" | "8449464" | "8457703" | "8461985" | "8463350" | "8473022" | "8475373" | "8478377" | "8478557" | "8484005" | "8491474" | "8509871" | "8515517" | "8527025" | "8532730" | "8532935" | "8543354" | "8560037" | "8560038" | "8562528" | "8571808" | "8583205" | "8593109" | "8600681" | "8612163" | "8626257" | "8657745" | "8657746" | "8663220" | "8665091" | "8682615" | "8718739" | "8718965" | "8744547" | "8774886" | "8868151" | "8868161" | "8911367" | "8933664" | "8942778" | "9060719" | "9113828" | "9125548" | "9135402" | "9149220" | "9161714" | "9247901" | "9314196" | "9320462" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"9320468" | "9326709" | "9332934" | "9339217" | "9357959" | "9380971" | "9392969" | "9398872" | "9408566" | "9451908" | "9483608" | "9498155" | "9558325" | "9629578" | "9662056" | "9675290" | "9730623" | "9737249" | "9743863" | "9770211" | "9797880" | "9801571" | "9801575" | "9801577" | "9804148" | "9804150" | "9808190" | "9814428" | "9833181" | "9839383" | "9839395" | "9848809" | "9936910" | "RE31916" | "RE32361" | "RE43039" | "RE43399").PN.				
L12	14	l1 and calibrating near55 sensor near55 data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:06
L13	31	l1 and calibrating same sensor same data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:06
L14	0	l13 and sensor same electronics same operably same connect$3 same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L15	0	l13 and sensor same electronics same connect$3 same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L16	6	l13 and sensor same electronics same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L17	711	sensor same electronics same (connect$3 or fasten$3 or coupl$3) same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:14

L18	576	sensor same electronics same (connect$3) same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:15
L19	41	sensor near5 electronics near5 (connect$3) near5 transcutaneous near5 analyte near5 sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:16
L20	417	l18 and calibrating near55 sensor near55 data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:20

2/24/2021 7:49:33 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	205	("0000002" | "0000059" | "0000791" | "0002508" | "0052641" | "0062334" | "0065604" | "0201800" | "10002233" | "10004442" | "10078380" | "10082493" | "10089446" | "10188334" | "10194868" | "10335075" | "10349873" | "10448873" | "10561354" | "10610141" | "10624568" | "10682084" | "20010016682" | "20010021817" | "20010039053" | "20010041830" | "20010041831" | "20010051768" | "20020016534" | "20020016535" | "20020019022" | "20020022883" | "20020023852" | "20020026110" | "20020026111" | "20020027086" | "20020038101" | "20020042090" | "20020042561" | "20020043471" | "20020045808" | "20020055673" | "20020062132" | "20020065453" | "20020065454" | "20020068860" | "20020071776" | "20020084196" | "20020099282" | "20020099997" | "20020103499" | "20020106709" | "20020111547" | "20020115920" | "20020119711" | "20020120186" | "20020123048" | "20020128594" | "20020143266" | "20020143372" | "20020151796" | "20020155615" | "20020156355" | "20020161288" | "20020169369" | "20020169635" | "20020177763" | "20020177764" | "20020182241" | "20020188185" | "20020193679" | "20020193885" | "20020198513" | "20030003524" | "20030004403" | "20030004432" | "20030004457" | "20030006669" | "20030023171" | "20030023317" | "20030023461" | "20030028089" | "20030032867" | "20030032874" | "20030034305" | "20030036773" | "20030042137" | "20030050546" | "20030054428" | "20030060692" | "20030065254" | "20030065308" | "20030076082" | "20030078481" | "20030078560" | "20030097082" | "20030100040" | "20030100821" | "20030119201" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20030119208" | "20030120152" |
"20030125612" | "20030125613" |
"20030130616" | "20030134347" |
"20030138674" | "20030143746" |
"20030153821" | "20030161288" |
"20030168338" | "20030175987" |
"20030176183" | "20030176933" |
"20030181794" | "20030187338" |
"20030188427" | "20030191377" |
"20030199744" | "20030199790" |
"20030203498" | "20030208113" |
"20030211625" | "20030212317" |
"20030212346" | "20030212347" |
"20030212379" | "20030216630" |
"20030217966" | "20030225437" |
"20030228681" | "20030235817" |
"20040010186" | "20040010207" |
"20040011671" | "20040015063" |
"20040015134" | "20040023253" |
"20040023317" | "20040024327" |
"20040024553" | "20040030285" |
"20040030294" | "20040039298" |
"20040039406" | "20040040840" |
"20040045879" | "20040054263" |
"20040054352" | "20040064021" |
"20040064068" | "20040068230" |
"20040074785" | "20040077962" |
"20040078065" | "20040078219" |
"20040093167" | "20040099529" |
"20040106857" | "20040106858" |
"20040106859" | "20040108226" |
"20040122353" | "20040133131" |
"20040133164" | "20040135684" |
"20040138588" | "20040138716" |
"20040142403" | "20040143173" |
"20040146909" | "20040147819" |
"20040152187" | "20040152622" |
"20040158137" | "20040162678" |
"20040167801" | "20040171921" |
"20040172307" | "20040173472" |
"20040176672" | "20040186362" |
"20040186365" | "20040193025" |
"20040193090" | "20040197846" |
"20040199059" | "20040204687" |
"20040208780" | "20040219664" |
"20040220517" | "20040225338" |
"20040236200" | "20040236251" |
"20040242982" | "20040249253" |
"20040249420" | "20040254433" |
"20040254434" | "20040260478" |
"20040263354" | "20040267300" |
"20050003470" | "20050004439" |
"20050004494" | "20050006122").PN.

L2	200	("20050010087" | "20050010265" | "20050010269" | "20050015020" | "20050016276" | "20050026689" | "20050027177" | "20050027180" | "20050027181" | "20050027182" | "20050027462" | "20050027463" | "20050031689" | "20050033132" | "20050038332" | "20050043598" | "20050049179" | "20050049473" | "20050051427" | "20050051440" | "20050054905" | "20050054909" | "20050056551" | "20050056552" | "20050059871" | "20050065464" | "20050070774" | "20050090607" | "20050096511" | "20050096512" | "20050096519" | "20050101847" | "20050103625" | "20050112169" | "20050113653" | "20050114068" | "20050115832" | "20050121322" | "20050124873" | "20050131305" | "20050131346" | "20050133368" | "20050139489" | "20050143635" | "20050143675" | "20050154271" | "20050161346" | "20050173245" | "20050176136" | "20050177036" | "20050177398" | "20050181012" | "20050182306" | "20050182451" | "20050183954" | "20050187720" | "20050192494" | "20050192557" | "20050195930" | "20050196820" | "20050196821" | "20050197612" | "20050199494" | "20050203360" | "20050203364" | "20050211571" | "20050214892" | "20050215871" | "20050215872" | "20050239154" | "20050239156" | "20050241957" | "20050242479" | "20050245795" | "20050245799" | "20050245839" | "20050245904" | "20050258037" | "20050261563" | "20050272989" | "20050277164" | "20050277912" | "20050287620" | "20050288596" | "20050288725" | "20060001538" | "20060004270" | "20060010098" | "20060015020" | "20060015024" | "20060016700" | "20060017923" | "20060019327" | "20060020186" | "20060020187" | "20060020188" | "20060020189" | "20060020190" | "20060020191" | "20060020192" | "20060025662" | "20060025663" | "20060029177" | "20060031094" | "20060036139" | "20060036140" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"20060036141" | "20060036142" | "20060036143" | "20060036144" | "20060036145" | "20060040402" | "20060042353" | "20060047192" | "20060052745" | "20060068208" | "20060079809" | "20060086624" | "20060091006" | "20060094946" | "20060100588" | "20060142651" | "20060155180" | "20060166629" | "20060167365" | "20060167517" | "20060167518" | "20060167519" | "20060173260" | "20060173406" | "20060173444" | "20060178617" | "20060183984" | "20060183985" | "20060189851" | "20060189856" | "20060189863" | "20060189925" | "20060193375" | "20060195029" | "20060198864" | "20060200009" | "20060200019" | "20060200020" | "20060200022" | "20060200970" | "20060222566" | "20060224109" | "20060224141" | "20060226985" | "20060229512" | "20060229531" | "20060229533" | "20060247508" | "20060247685" | "20060247985" | "20060253012" | "20060253085" | "20060257996" | "20060258761" | "20060258929" | "20060263839" | "20060264785" | "20060270922" | "20060270923" | "20060272652" | "20060281985" | "20060293576" | "20070016381" | "20070017805" | "20070020641" | "20070027284" | "20070027370" | "20070027381" | "20070027384" | "20070027385" | "20070032706" | "20070032717" | "20070032718" | "20070033074" | "20070033254" | "20070045902" | "20070049873" | "20070056858" | "20070059196" | "20070060803" | "20070060814" | "20070060871" | "20070066873" | "20070068807" | "20070071681" | "20070073129" | "20070078320" | "20070078321" | "20070078322" | "20070078323" | "20070085995" | "20070093704" | "20070095661" | "20070106135").PN.				
L3	200	("20070108048" | "20070112298" | "20070116600" | "20070118030" | "20070118405" | "20070124002" | "20070129619" | "20070129621" | "20070135699" | "20070142584" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20070149875" | "20070151869" |
"20070156033" | "20070163880" |
"20070168224" | "20070169533" |
"20070170073" | "20070173706" |
"20070173709" | "20070173710" |
"20070173711" | "20070173712" |
"20070173741" | "20070173761" |
"20070179349" | "20070179352" |
"20070179434" | "20070179436" |
"20070191701" | "20070191716" |
"20070197889" | "20070197890" |
"20070199818" | "20070200254" |
"20070202562" | "20070202672" |
"20070203407" | "20070203410" |
"20070203966" | "20070206193" |
"20070208244" | "20070208245" |
"20070208246" | "20070213610" |
"20070213611" | "20070213657" |
"20070218097" | "20070219441" |
"20070224700" | "20070225675" |
"20070227911" | "20070232877" |
"20070232878" | "20070232879" |
"20070232880" | "20070233013" |
"20070235331" | "20070240497" |
"20070244379" | "20070244381" |
"20070244382" | "20070249916" |
"20070249922" | "20070255321" |
"20070259217" | "20070299389" |
"20070299617" | "20080000779" |
"20080004515" | "20080004601" |
"20080009692" | "20080012701" |
"20080017522" | "20080021666" |
"20080021972" | "20080029390" |
"20080029391" | "20080033254" |
"20080033357" | "20080039702" |
"20080045824" | "20080058625" |
"20080064937" | "20080066305" |
"20080071156" | "20080071157" |
"20080071158" | "20080072663" |
"20080081000" | "20080081977" |
"20080083617" | "20080086040" |
"20080086041" | "20080086042" |
"20080086043" | "20080086044" |
"20080086273" | "20080091094" |
"20080091095" | "20080097197" |
"20080097289" | "20080097326" |
"20080102441" | "20080103447" |
"20080108942" | "20080114227" |
"20080115599" | "20080119703" |
"20080119704" | "20080119706" |
"20080119708" | "20080125751" |
"20080139910" | "20080147050" |
"20080148873" | "20080154101" |

		"20080154177" | "20080154513" | "20080156661" | "20080161664" | "20080161666" | "20080161753" | "20080167543" | "20080168676" | "20080172205" | "20080177149" | "20080177165" | "20080183060" | "20080183061" | "20080183399" | "20080187655" | "20080188722" | "20080188725" | "20080188731" | "20080188796" | "20080189051" | "20080193936" | "20080194837" | "20080194934" | "20080194935" | "20080194936" | "20080194937" | "20080194938" | "20080195232" | "20080195967" | "20080197024" | "20080200788" | "20080200789" | "20080200791" | "20080200897" | "20080201325" | "20080205481" | "20080208025" | "20080208113" | "20080214910" | "20080214915" | "20080214918" | "20080228051" | "20080228054" | "20080234943" | "20080242961" | "20080242963" | "20080249385" | "20080255434" | "20080255437" | "20080255438" | "20080255808" | "20080256048" | "20080262469" | "20080267823" | "20080269714" | "20080275313" | "20080278332" | "20080287761" | "20080287762" | "20080287763" | "20080287764" | "20080287765" | "20080287766" | "20080288180" | "20080288204" | "20080296155" | "20080300572" | "20080305009" | "20080305506" | "20080306368" | "20080306433" | "20080306434" | "20080306435" | "20080306444" | "20080306472" | "20080312841" | "20080312842" | "20080312844" | "20080312845" | "20080314395" | "20080319279" | "20080319295" | "20080319296" | "20090001923").PN.				
L4	200	("20090005665" | "20090005666" | "20090006034" | "20090006061" | "20090012376" | "20090012379" | "20090016379" | "20090018418" | "20090018424" | "20090018425" | "20090018426" | "20090030293" | "20090030294" | "20090033482" | "20090036747" | "20090036758" | "20090036760" | "20090036763" | "20090043181" | "20090043182" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20090043525" | "20090043541" |
"20090043542" | "20090045055" |
"20090048503" | "20090054745" |
"20090054748" | "20090054749" |
"20090054753" | "20090055149" |
"20090061528" | "20090062633" |
"20090062635" | "20090062645" |
"20090062767" | "20090063402" |
"20090069649" | "20090076356" |
"20090076360" | "20090076361" |
"20090081803" | "20090082693" |
"20090085768" | "20090099434" |
"20090099436" | "20090105570" |
"20090105636" | "20090112478" |
"20090112626" | "20090118589" |
"20090124877" | "20090124878" |
"20090124879" | "20090124964" |
"20090131768" | "20090131769" |
"20090131776" | "20090131777" |
"20090137886" | "20090137887" |
"20090143659" | "20090143660" |
"20090143725" | "20090149728" |
"20090156919" | "20090156922" |
"20090156924" | "20090163790" |
"20090163855" | "20090164190" |
"20090164239" | "20090164251" |
"20090171178" | "20090177143" |
"20090178459" | "20090182217" |
"20090182517" | "20090192366" |
"20090192722" | "20090192724" |
"20090192745" | "20090192751" |
"20090198118" | "20090203981" |
"20090204340" | "20090204341" |
"20090216103" | "20090240120" |
"20090240128" | "20090240193" |
"20090241028" | "20090242399" |
"20090242425" | "20090247855" |
"20090247856" | "20090247857" |
"20090257911" | "20090264719" |
"20090281407" | "20090287073" |
"20090287074" | "20090294277" |
"20090299155" | "20090299156" |
"20090299162" | "20090299276" |
"20100010324" | "20100010331" |
"20100010332" | "20100016687" |
"20100020309" | "20100022855" |
"20100023270" | "20100023291" |
"20100025238" | "20100030053" |
"20100030137" | "20100030484" |
"20100036215" | "20100036216" |
"20100036222" | "20100036223" |
"20100036224" | "20100036225" |
"20100045231" | "20100045465" |

		"20100049015" | "20100049021" | "20100057040" | "20100057041" | "20100057042" | "20100057044" | "20100057057" | "20100063372" | "20100064764" | "20100081906" | "20100081908" | "20100081909" | "20100081910" | "20100081953" | "20100094111" | "20100121167" | "20100141656" | "20100145174" | "20100152561" | "20100160759" | "20100160761" | "20100168538" | "20100168546" | "20100169035" | "20100174167" | "20100174168" | "20100174266" | "20100179399" | "20100179402" | "20100179405" | "20100179406" | "20100179407" | "20100179408" | "20100179409" | "20100185065" | "20100185070" | "20100185071" | "20100185072" | "20100185073" | "20100185074" | "20100191085" | "20100191472" | "20100198034" | "20100198035" | "20100198142" | "20100204557" | "20100213057" | "20100214104" | "20100217106" | "20100230285" | "20100234707" | "20100234710" | "20100234796" | "20100235106" | "20100240975" | "20100240976" | "20100261987" | "20100265073" | "20100274107" | "20100274515" | "20100277342" | "20100280441" | "20100280782" | "20100286496" | "20100298684" | "20100313105" | "20100317952" | "20100324392" | "20100326842" | "20100331644" | "20100331648" | "20100331655" | "20110021889" | "20110024043").PN.				
L5	208	("20110024307" | "20110027127" | "20110027453" | "20110027458" | "20110028815" | "20110028816" | "20110029247" | "20110029269" | "20110040163" | "20110046467" | "20110060530" | "20110077490" | "20110077491" | "20110077494" | "20110081726" | "20110082484" | "20110105873" | "20110106126" | "20110112696" | "20110118579" | "20110124997" | "20110125410" | "20110130970" | "20110137601" | "20110148905" | "20110174638" | "20110184268" | "20110190603" | "20110191044" | "20110193704" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20110208027" | "20110208155" |
"20110213225" | "20110218414" |
"20110224523" | "20110230741" |
"20110257495" | "20110257895" |
"20110263958" | "20110270062" |
"20110288574" | "20110313317" |
"20110319729" | "20110319734" |
"20110319739" | "20110320130" |
"20110320167" | "20120010642" |
"20120078071" | "20120097554" |
"20120108931" | "20120108934" |
"20120123692" | "20120165626" |
"20120165640" | "20120173200" |
"20120209099" | "20120215462" |
"20120239304" | "20120245447" |
"20120265035" | "20120265036" |
"20120277564" | "20120277565" |
"20120283542" | "20120283960" |
"20120291516" | "20120330561" |
"20130006112" | "20130035575" |
"20130060105" | "20130060112" |
"20130116527" | "20130137953" |
"20130150690" | "20130178727" |
"20130184547" | "20130199944" |
"20130231541" | "20130245412" |
"20130253846" | "20130281807" |
"20130282322" | "20130282403" |
"20130324823" | "20130338454" |
"20140005499" | "20140005968" |
"20140018642" | "20140041441" |
"20140046155" | "20140046156" |
"20140046157" | "20140046160" |
"20140046161" | "20140066736" |
"20140088390" | "20140088392" |
"20140088908" | "20140100796" |
"20140114156" | "20140121480" |
"20140121488" | "20140207400" |
"20140213869" | "20140221966" |
"20140236536" | "20140243638" |
"20140257059" | "20150005601" |
"20150006109" | "20150094555" |
"20150216456" | "20150241407" |
"20150282742" | "20150366510" |
"20150374299" | "20160022221" |
"20160073941" | "20160151006" |
"20160157758" | "20160198986" |
"20160206233" | "20160220189" |
"20160238589" | "20160245791" |
"20160270705" | "20160296697" |
"20160317069" | "20170003766" |
"20170027484" | "20170042456" |
"20170049369" | "20170124287" |
"20170188909" | "20170224258" |

		"20170258379" | "20170340250" | "20170347927" | "20180000004" | "20180000389" | "20180008174" | "20180008201" | "20180038844" | "20180042530" | "20180042531" | "20180059093" | "20180064398" | "20180085037" | "20180098721" | "20180271415" | "20180325437" | "20180328766" | "20180344220" | "20180364215" | "20190035488" | "20190072538" | "20190083012" | "20190083015" | "20190150802" | "20190151542" | "20190159734" | "20190187814" | "20190192071" | "20190254575" | "20190261902" | "20190282143" | "20190320948" | "20190320949" | "20190336051" | "20190350499" | "20190357817" | "20190357827" | "20190380627" | "20200022626" | "20200037934" | "20200037935" | "20200037936" | "20200046272" | "2402306" | "2719797" | "3210578" | "3219533" | "3506032" | "3539455" | "3556950" | "3581062" | "3610226" | "3610230" | "3652475" | "3775182" | "3780727" | "3791871" | "3826244" | "3837339" | "3838033" | "3838682" | "3874850" | "3898984" | "3910256" | "3926760" | "3929971" | "3933593" | "3943918" | "3949388" | "3957613" | "3960497" | "3964974").PN.				
L6	280	("3966580" | "3978856" | "3979274" | "3982530" | "4008717" | "4016866" | "4024312" | "4030640" | "4036749" | "4037563" | "4040908" | "4052754" | "4055175" | "4067322" | "4073713" | "4076656" | "4080292" | "4109505" | "4119406" | "4129128" | "4151845" | "4172770" | "4176659" | "4197840" | "4197852" | "4206755" | "4215703" | "4240438" | "4240889" | "4245634" | "4253469" | "4255500" | "4259540" | "4265249" | "4300572" | "4327725" | "4344438" | "4349728" | "4366040" | "4369785" | "4373527" | "4374013" | "4378016" | "4388166" | "4392849" | "4402694" | "4403847" | "4403984" | "4407298" | "4415666" | "4418148" | "4419535" | "4420564" | "4425920" | "4426621" | "4431004" | "4431507" | "4432366" | "4436094" | "4441968" | "4442841" | "4448188" | "4454295" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"4457339" | "4462048" | "4478222" |
"4478976" | "4484987" | "4486290" |
"4492575" | "4494950" | "4496454" |
"4506680" | "4509531" | "4519973" |
"4526569" | "4527240" | "4534355" |
"4534825" | "4535786" | "4538616" |
"4545382" | "4554927" | "4561963" |
"4565665" | "4565666" | "4568444" |
"4571292" | "4573968" | "4577642" |
"4578215" | "4583976" | "4592824" |
"4613328" | "4614514" | "4619793" |
"4626104" | "4650547" | "4655880" |
"4663824" | "4670007" | "4671288" |
"4672970" | "4680268" | "4685463" |
"4685903" | "4685912" | "4686044" |
"4689309" | "4694861" | "4703756" |
"4705503" | "4711245" | "4711251" |
"4721677" | "4731051" | "4731726" |
"4736748" | "4747822" | "4749985" |
"4750496" | "4752935" | "4753652" |
"4755168" | "4757022" | "4759366" |
"4759828" | "4763648" | "4776944" |
"4777953" | "4779618" | "4781798" |
"4783250" | "4784157" | "4786394" |
"4787398" | "4789467" | "4791932" |
"4800495" | "4803243" | "4805624" |
"4805625" | "4808089" | "4808292" |
"4809704" | "4810243" | "4810470" |
"4813423" | "4815471" | "4820281" |
"4822336" | "4828544" | "4830013" |
"4831070" | "4832005" | "4834101" |
"4838281" | "4841974" | "4849458" |
"4852573" | "4854322" | "4858615" |
"4861454" | "4861830" | "4863265" |
"4867741" | "4871351" | "4871440" |
"4874363" | "4883057" | "4883467" |
"4889528" | "4889744" | "4890620" |
"4890621" | "4898578" | "4900305" |
"4902294" | "4907857" | "4909786" |
"4919141" | "4919649" | "4921477" |
"4921480" | "4923819" | "4925268" |
"4925444" | "4927407" | "4927516" |
"4928694" | "4934369" | "4934375" |
"4935345" | "4944299" | "4946439" |
"4947845" | "4951669" | "4953552" |
"4955861" | "4957483" | "4958148" |
"4963131" | "4963595" | "4966579" |
"4967940" | "4974592" | "4974929" |
"4975175" | "4975636" | "4976687" |
"4979509" | "4984929" | "4986271" |
"4986671" | "4988341" | "4988671" |
"4988758" | "4994026" | "4994167" |
"4995402" | "4997627" | "5000180" |

		"5000419" | "5002054" | "5002055" | "5002572" | "5006050" | "5006111" | "5007929" | "5009251" | "5019974" | "5026348" | "5030199" | "5030333" | "5034112" | "5041092" | "5045057" | "5046496" | "5048525" | "5050612" | "5055171" | "5055198" | "5059654" | "5067491" | "5068536" | "5077476" | "5082147" | "5082550" | "5088981" | "5089112" | "5089421" | "5096669" | "5097834" | "5098377" | "5101814" | "5106365" | "5108819" | "5109850" | "5109860" | "5112301" | "5112455" | "5114859" | "5116313" | "5122925" | "5127405" | "5135004" | "5137028" | "5140985" | "5145565" | "5148812" | "5152746" | "5156972" | "5158437" | "5160418" | "5161532" | "5165406" | "5165407" | "5171689" | "5174291" | "5176632").PN.				
L7	280	("5176658" | "5178142" | "5178957" | "5182004" | "5188591" | "5190041" | "5195963" | "5198771" | "5199428" | "5202261" | "5203326" | "5204264" | "5207642" | "5208147" | "5210778" | "5216598" | "5219279" | "5220917" | "5220920" | "5224929" | "5225063" | "5231988" | "5232434" | "5235003" | "5237123" | "5243696" | "5243982" | "5243983" | "5246867" | "5248300" | "5249576" | "5254102" | "5262035" | "5262305" | "5264103" | "5264105" | "5265594" | "5266179" | "5269891" | "5271736" | "5271815" | "5275169" | "5279294" | "5281319" | "5282844" | "5282848" | "5284140" | "5284570" | "5285513" | "5285792" | "5287753" | "5293877" | "5298022" | "5298144" | "5299571" | "5302093" | "5304468" | "5307263" | "5310469" | "5311908" | "5312361" | "5313953" | "5314471" | "5315993" | "5316008" | "5316452" | "5318511" | "5320715" | "5320725" | "5321392" | "5322063" | "5324322" | "5324328" | "5326356" | "5326449" | "5328460" | "5330521" | "5330634" | "5331555" | "5335658" | "5337747" | "5340722" | "5342409" | "5342789" | "5343869" | "5345932" | "5348788" | "5352348" | "5352349" | "5352351" | "5354272" | "5354449" | "5356217" | "5356375" | "5356378" | "5356786" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"5360404" | "5365426" | "5368224" |
"5368562" | "5372133" | "5372135" |
"5372427" | "5372709" | "5376070" |
"5378229" | "5379238" | "5380268" |
"5380491" | "5380536" | "5380665" |
"5384028" | "5384547" | "5390671" |
"5391250" | "5397848" | "5398682" |
"5400795" | "5408999" | "5409666" |
"5411052" | "5411551" | "5411647" |
"5411866" | "5417206" | "5421328" |
"5422829" | "5423738" | "5423749" |
"5425375" | "5425717" | "5425749" |
"5425868" | "5428123" | "5429485" |
"5429602" | "5429735" | "5431160" |
"5431174" | "5431921" | "5434412" |
"5437635" | "5438983" | "5445610" |
"5448992" | "5453278" | "5462051" |
"5462064" | "5462645" | "5466348" |
"5469846" | "5472317" | "5474552" |
"5476094" | "5476776" | "5482446" |
"5482473" | "5484404" | "5486776" |
"5489414" | "5491474" | "5494562" |
"5496273" | "5496453" | "5497772" |
"5502396" | "5505828" | "5507288" |
"5508203" | "5509410" | "5509888" |
"5512046" | "5512246" | "5512248" |
"5513636" | "5514253" | "5514718" |
"5515851" | "5517313" | "5518601" |
"5520191" | "5522798" | "5529676" |
"5531679" | "5531878" | "5540828" |
"5543326" | "5545220" | "5547470" |
"5548569" | "5549547" | "5549548" |
"5549569" | "5549651" | "5551850" |
"5552997" | "5553616" | "5554339" |
"5562614" | "5562615" | "5564439" |
"5568400" | "5568806" | "5569186" |
"5569188" | "5569219" | "5571395" |
"5575930" | "5577499" | "5582184" |
"5582497" | "5582593" | "5582697" |
"5584813" | "5584876" | "5586553" |
"5588560" | "5589563" | "5590651" |
"5593440" | "5593852" | "5601435" |
"5605152" | "5606152" | "5609572" |
"5609575" | "5611900" | "5615671" |
"5620579" | "5624409" | "5624537" |
"5626563" | "5628310" | "5628619" |
"5628890" | "5630710" | "5631170" |
"5637083" | "5640470" | "5640954" |
"5643195" | "5645077" | "5651767" |
"5653239" | "5653756" | "5653863" |
"5658250" | "5660163" | "5665061" |
"5665065" | "5665222" | "5667504" |
"5676651" | "5676820" | "5681285" |

		"5682884" | "5683562" | "5685844" | "5686829" | "5688239" | "5688244" | "5695623" | "5697366" | "5697899" | "5704354" | "5707502" | "5711001" | "5711861" | "5714931" | "5720295" | "5730654" | "5733259" | "5735273" | "5735285" | "5738992" | "5741211" | "5741634" | "5743262" | "5745378" | "5749832").PN.				
L8	280	("5749907" | "5755226" | "5755692" | "5756632" | "5758643" | "5763760" | "5766151" | "5772586" | "5777060" | "5779665" | "5781455" | "5782912" | "5783054" | "5785660" | "5787900" | "5791344" | "5791880" | "5792065" | "5795774" | "5798065" | "5800383" | "5800420" | "5800529" | "5804048" | "5806517" | "5807274" | "5807312" | "5807375" | "5807406" | "5810323" | "5810770" | "5811487" | "5814599" | "5820551" | "5820589" | "5822715" | "5823802" | "5833603" | "5836887" | "5836989" | "5837454" | "5837728" | "5840026" | "5851197" | "5861019" | "5863400" | "5871514" | "5873862" | "5879373" | "5879828" | "5882494" | "5885844" | "5891047" | "5891048" | "5897525" | "5897578" | "5899855" | "5904666" | "5904708" | "5910554" | "5911219" | "5913998" | "5914026" | "5917346" | "5918603" | "5921951" | "5925021" | "5928130" | "5928155" | "5928182" | "5928189" | "5928195" | "5931814" | "5932175" | "5933136" | "5935224" | "5938636" | "5942979" | "5944661" | "5947911" | "5951521" | "5954643" | "5954954" | "5957854" | "5957903" | "5960797" | "5961451" | "5964261" | "5964993" | "5965380" | "5971922" | "5972199" | "5976085" | "5980728" | "5990422" | "5995208" | "5995860" | "5999848" | "6001067" | "6001471" | "6007775" | "6011984" | "6013113" | "6014577" | "6016443" | "6016448" | "6021350" | "6023629" | "6024699" | "6024720" | "6027445" | "6027479" | "6032059" | "6032667" | "6036924" | "6038469" | "6045567" | "6049727" | "6051389" | "6059946" | "6063637" | "6066088" | "6066448" | "6071391" | "6073031" | "6074775" | "6077299" | "6080583" | "6081735" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"6081736" | "6083523" | "6083710" |
"6088608" | "6090087" | "6091975" |
"6091976" | "6093156" | "6093172" |
"6099511" | "6103033" | "6107083" |
"6108577" | "6112116" | "6115622" |
"6115628" | "6115634" | "6117290" |
"6119028" | "6120676" | "6121009" |
"6121611" | "6122351" | "6122536" |
"6123827" | "6127154" | "6128519" |
"6128526" | "6134461" | "6135978" |
"6141573" | "6142939" | "6142979" |
"6143164" | "6144837" | "6144869" |
"6144871" | "6156051" | "6159147" |
"6159186" | "6161095" | "6162201" |
"6162611" | "6164921" | "6165154" |
"6165406" | "6167614" | "6168568" |
"6169155" | "6171276" | "6175752" |
"6175753" | "6180416" | "6183437" |
"6187062" | "6189536" | "6191860" |
"6197040" | "6200265" | "6200772" |
"6201980" | "6201993" | "6206856" |
"6208894" | "6212416" | "6212417" |
"6212424" | "6213739" | "6214185" |
"6219574" | "6223083" | "6223283" |
"6224562" | "6230059" | "6231320" |
"6231560" | "6231879" | "6233080" |
"6233486" | "6241863" | "6248067" |
"6248077" | "6248093" | "6249705" |
"6254586" | "6256522" | "6256538" |
"6259937" | "6261440" | "6263222" |
"6264606" | "6264825" | "6268161" |
"6269340" | "6270455" | "6270478" |
"6272364" | "6272379" | "6272480" |
"6274285" | "6275717" | "6280408" |
"6281015" | "6283761" | "6284125" |
"6284478" | "6293925" | "6294281" |
"6295506" | "6298254" | "6299578" |
"6299583" | "6299757" | "6300002" |
"6302855" | "6306104" | "6309351" |
"6309375" | "6309884" | "6312388" |
"6325978" | "6325979" | "6326160" |
"6329161" | "6329929" | "6330464" |
"6338790" | "6343225" | "6348640" |
"6356776" | "6358225" | "6359444" |
"6360888" | "6361503" | "6365670" |
"6366794" | "6368141" | "6368274" |
"6370941" | "6372244" | "6377828" |
"6377852" | "6377894" | "6379301" |
"6381493" | "6387048" | "6387709" |
"6391019" | "6400974" | "6402703" |
"6403944").PN.

L9	280	("6409674" | "6413393" | "6413396" | "6413410" | "6416651" | "6418332" | "6424847" | "6424861" | "6427088" | "6428123" | "6430437" | "6434430" | "6440068" | "6444115" | "6447448" | "6447542" | "6454710" | "6459917" | "6461496" | "6464849" | "6465066" | "6466810" | "6467480" | "6471689" | "6474360" | "6475372" | "6475750" | "6477392" | "6477395" | "6478736" | "6481440" | "6484045" | "6484046" | "6485449" | "6486661" | "6488652" | "6494879" | "6498043" | "6498941" | "6501976" | "6501983" | "6503381" | "6510329" | "6512939" | "6514460" | "6514718" | "6517508" | "6520326" | "6520477" | "6520937" | "6520997" | "6526298" | "6527729" | "6528318" | "6536433" | "6537318" | "6540891" | "6541266" | "6542765" | "6543195" | "6544212" | "6544229" | "6545085" | "6546268" | "6546269" | "6547839" | "6551494" | "6551496" | "6553241" | "6553244" | "6554805" | "6554822" | "6558320" | "6558321" | "6558347" | "6558351" | "6561978" | "6562001" | "6564105" | "6565509" | "6565535" | "6565807" | "6569309" | "6569521" | "6571128" | "6572542" | "6572545" | "6572579" | "6574490" | "6575905" | "6576101" | "6577899" | "6579257" | "6579498" | "6579690" | "6584335" | "6585644" | "6585675" | "6585763" | "6587705" | "6589229" | "6591125" | "6592745" | "6594514" | "6595756" | "6595919" | "6600940" | "6600997" | "6602221" | "6605072" | "6605200" | "6605201" | "6607509" | "6607658" | "6609071" | "6610012" | "6612984" | "6613379" | "6615061" | "6615078" | "6616819" | "6618603" | "6618934" | "6622045" | "6633772" | "6635014" | "6641533" | "6642015" | "6645181" | "6648821" | "6650471" | "6653091" | "6654625" | "6656114" | "6656157" | "6658396" | "6659948" | "6668196" | "6673022" | "6673596" | "6675030" | "6676816" | "6679865" | "6679872" | "6683535" | "6684904" | "6685668" | "6687522" | "6687546" | "6689056" | "6689089" | "6689265" | "6689413" | "6692457" | "6694191" | "6695860" | "6698269" | "6699188" | "6699218" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"6702249" | "6702857" | "6702972" | "6711423" | "6711424" | "6712796" | "6721582" | "6721587" | "6723086" | "6730200" | "6731976" | "6731985" | "6733446" | "6733655" | "6736783" | "6736957" | "6737158" | "6740075" | "6741877" | "6742635" | "6743635" | "6746582" | "6749587" | "6749591" | "6749740" | "6758810" | "6764581" | "6770030" | "6770067" | "6773671" | "6780297" | "6784274" | "6790178" | "6793632" | "6801041" | "6802957" | "6804002" | "6805693" | "6809653" | "6810290" | "6811533" | "6811534" | "6811548" | "6813519" | "6817990" | "6846654" | "6850790" | "6850859" | "6854317" | "6858020" | "6862465" | "6865407" | "6869413" | "6873268" | "6881551" | "6882940" | "6887228" | "6892085" | "6893396" | "6893545" | "6893552" | "6895263" | "6895265" | "6902544" | "6912413" | "6923763" | "6925393" | "6926691" | "6931327" | "6932584" | "6932892" | "6932894" | "6936006" | "6942518" | "6945965" | "6948492" | "6950708" | "6952604" | "6954662" | "6958705" | "6960192" | "6965791" | "6966325" | "6968294" | "6971274" | "6972080" | "6974437" | "6975893" | "6979315" | "6985870" | "6989891" | "6990366" | "6990422" | "6996427" | "6997907" | "6997921" | "6998247" | "7003336" | "7003340" | "7003341" | "7010345" | "7011630" | "7016713" | "7016720" | "7018361" | "7022072" | "7022219" | "7024245" | "7025425" | "7025727" | "7025743" | "7027848" | "7029443" | "7029444" | "7041068" | "7041209" | "7041468" | "7043287" | "7048727" | "7052472" | "7052483").PN.				
L10	280	("7056302" | "7060059" | "7061593" | "7062385" | "7063086" | "7066884" | "7070577" | "7070580" | "7074307" | "7074610" | "7076300" | "7078582" | "7081195" | "7092891" | "7096064" | "7097775" | "7098803" | "7100628" | "7110803" | "7115884" | "7120483" | "7123950" | "7131967" | "7135342" | "7149562" | "7150741" | "7153265" | "7153458" | "7167818" | "7169289" | "7171252" | "7171274" | "7183102" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"7190988" | "7192450" | "7204823" |
"7207968" | "7207974" | "7211074" |
"7211439" | "7214190" | "7221970" |
"7223253" | "7225535" | "7226978" |
"7228162" | "7229288" | "7238165" |
"7244582" | "7247138" | "7247443" |
"7248912" | "7253680" | "7254450" |
"7255690" | "7258673" | "7258681" |
"7261690" | "7266400" | "7267665" |
"7268562" | "7272436" | "7273633" |
"7276029" | "7278983" | "7280879" |
"7288085" | "7288368" | "7289204" |
"7289836" | "7291496" | "7295867" |
"7297114" | "7299082" | "7303875" |
"7308292" | "7310544" | "7311690" |
"7312040" | "7313425" | "7314452" |
"7315752" | "7315767" | "7316662" |
"7317938" | "7317939" | "7318814" |
"7327273" | "7329234" | "7334594" |
"7335179" | "7335195" | "7335294" |
"7338464" | "7338639" | "7344499" |
"7344626" | "7351321" | "7354420" |
"7359723" | "7361155" | "7364562" |
"7364592" | "7365562" | "7366556" |
"7367942" | "7372277" | "7379765" |
"7381184" | "7384532" | "7387811" |
"7390667" | "7396353" | "7399277" |
"7402153" | "7402349" | "7407811" |
"7416802" | "7417164" | "7417729" |
"7422727" | "7424318" | "7425877" |
"7426408" | "7427338" | "7427560" |
"7429552" | "7433727" | "7460898" |
"7467003" | "7468125" | "7471972" |
"7474992" | "7488601" | "7494465" |
"7494816" | "7497827" | "7499002" |
"7501052" | "7502644" | "7517439" |
"7519478" | "7523004" | "7524287" |
"7525298" | "7529574" | "7547281" |
"7547382" | "7569030" | "7583990" |
"7591801" | "7599726" | "7604593" |
"7608042" | "7613491" | "7615007" |
"7618368" | "7618369" | "7620438" |
"7624028" | "7630748" | "7632228" |
"7635594" | "7637868" | "7640032" |
"7640048" | "7645374" | "7647237" |
"7653425" | "7654956" | "7695434" |
"7699775" | "7699964" | "7711493" |
"7715893" | "7731659" | "7736310" |
"7749445" | "7751864" | "7761126" |
"7761130" | "7766829" | "7766830" |
"7771352" | "7774038" | "7774145" |
"7775975" | "7776559" | "7778679" |
"7778680" | "7826981" | "7831287" |

		"7838639" | "7856613" | "7857760" | "7866025" | "7866026" | "7885697" | "7885698" | "7889069" | "7894870" | "7896809" | "7899511" | "7901354" | "7905833" | "7914450" | "7920906" | "7925321" | "7927274" | "7933639" | "7938797" | "7943034" | "7946984" | "7955261" | "7959569" | "7964089" | "7964146" | "7974672" | "7979104" | "7985330" | "7986986" | "7990828" | "7996158" | "7998071" | "8000763" | "8005524" | "8005525" | "8010174" | "8016997" | "8026104" | "8030942" | "8052601" | "8060173" | "8073519" | "8073520" | "8103471" | "8109850" | "8112240" | "8114268" | "8116837" | "8123920" | "8128562" | "8140312" | "8149117" | "8150488" | "8160670" | "8160671" | "8160834" | "8160900" | "8167801" | "8170803" | "8195265" | "8202491" | "8211016" | "8216137" | "8216138" | "8219173" | "8224415" | "8229536" | "8233959" | "8239166" | "8249683" | "8255026" | "8257259" | "8260393" | "8260558" | "8275438" | "8282549" | "8282550" | "8287453" | "8290559" | "8290562" | "8292810" | "8298142" | "8332008" | "8346335" | "8346337" | "8346338" | "8348923" | "8364230").PN.				
L11	103	("8364231" | "8369919" | "8372351" | "8374667" | "8376945" | "8396528" | "8412301" | "8417312" | "8423113" | "8423114" | "8425416" | "8425417" | "8428678" | "8428679" | "8435179" | "8442610" | "8444560" | "8447376" | "8449464" | "8457703" | "8461985" | "8463350" | "8473022" | "8475373" | "8478377" | "8478557" | "8484005" | "8491474" | "8509871" | "8515517" | "8527025" | "8532730" | "8532935" | "8543354" | "8560037" | "8560038" | "8562528" | "8571808" | "8583205" | "8593109" | "8600681" | "8612163" | "8626257" | "8657745" | "8657746" | "8663220" | "8665091" | "8682615" | "8718739" | "8718965" | "8744547" | "8774886" | "8868151" | "8868161" | "8911367" | "8933664" | "8942778" | "9060719" | "9113828" | "9125548" | "9135402" | "9149220" | "9161714" | "9247901" | "9314196" | "9320462" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"9320468" | "9326709" | "9332934" | "9339217" | "9357959" | "9380971" | "9392969" | "9398872" | "9408566" | "9451908" | "9483608" | "9498155" | "9558325" | "9629578" | "9662056" | "9675290" | "9730623" | "9737249" | "9743863" | "9770211" | "9797880" | "9801571" | "9801575" | "9801577" | "9804148" | "9804150" | "9808190" | "9814428" | "9833181" | "9839383" | "9839395" | "9848809" | "9936910" | "RE31916" | "RE32361" | "RE43039" | "RE43399").PN.				
L12	14	l1 and calibrating near55 sensor near55 data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:06
L13	31	l1 and calibrating same sensor same data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:06
L14	0	l13 and sensor same electronics same operably same connect$3 same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L15	0	l13 and sensor same electronics same connect$3 same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L16	6	l13 and sensor same electronics same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08

2/24/2021 7:11:16 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	205	("0000002" | "0000059" | "0000791" | "0002508" | "0052641" | "0062334" | "0065604" | "0201800" | "10002233" | "10004442" | "10078380" | "10082493" | "10089446" | "10188334" | "10194868" | "10335075" | "10349873" | "10448873" | "10561354" | "10610141" | "10624568" | "10682084" | "20010016682" | "20010021817" | "20010039053" | "20010041830" | "20010041831" | "20010051768" | "20020016534" | "20020016535" | "20020019022" | "20020022883" | "20020023852" | "20020026110" | "20020026111" | "20020027086" | "20020038101" | "20020042090" | "20020042561" | "20020043471" | "20020045808" | "20020055673" | "20020062132" | "20020065453" | "20020065454" | "20020068860" | "20020071776" | "20020084196" | "20020099282" | "20020099997" | "20020103499" | "20020106709" | "20020111547" | "20020115920" | "20020119711" | "20020120186" | "20020123048" | "20020128594" | "20020143266" | "20020143372" | "20020151796" | "20020155615" | "20020156355" | "20020161288" | "20020169369" | "20020169635" | "20020177763" | "20020177764" | "20020182241" | "20020188185" | "20020193679" | "20020193885" | "20020198513" | "20030003524" | "20030004403" | "20030004432" | "20030004457" | "20030006669" | "20030023171" | "20030023317" | "20030023461" | "20030028089" | "20030032867" | "20030032874" | "20030034305" | "20030036773" | "20030042137" | "20030050546" | "20030054428" | "20030060692" | "20030065254" | "20030065308" | "20030076082" | "20030078481" | "20030078560" | "20030097082" | "20030100040" | "20030100821" | "20030119201" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20030119208" | "20030120152" |
"20030125612" | "20030125613" |
"20030130616" | "20030134347" |
"20030138674" | "20030143746" |
"20030153821" | "20030161288" |
"20030168338" | "20030175987" |
"20030176183" | "20030176933" |
"20030181794" | "20030187338" |
"20030188427" | "20030191377" |
"20030199744" | "20030199790" |
"20030203498" | "20030208113" |
"20030211625" | "20030212317" |
"20030212346" | "20030212347" |
"20030212379" | "20030216630" |
"20030217966" | "20030225437" |
"20030228681" | "20030235817" |
"20040010186" | "20040010207" |
"20040011671" | "20040015063" |
"20040015134" | "20040023253" |
"20040023317" | "20040024327" |
"20040024553" | "20040030285" |
"20040030294" | "20040039298" |
"20040039406" | "20040040840" |
"20040045879" | "20040054263" |
"20040054352" | "20040064021" |
"20040064068" | "20040068230" |
"20040074785" | "20040077962" |
"20040078065" | "20040078219" |
"20040093167" | "20040099529" |
"20040106857" | "20040106858" |
"20040106859" | "20040108226" |
"20040122353" | "20040133131" |
"20040133164" | "20040135684" |
"20040138588" | "20040138716" |
"20040142403" | "20040143173" |
"20040146909" | "20040147819" |
"20040152187" | "20040152622" |
"20040158137" | "20040162678" |
"20040167801" | "20040171921" |
"20040172307" | "20040173472" |
"20040176672" | "20040186362" |
"20040186365" | "20040193025" |
"20040193090" | "20040197846" |
"20040199059" | "20040204687" |
"20040208780" | "20040219664" |
"20040220517" | "20040225338" |
"20040236200" | "20040236251" |
"20040242982" | "20040249253" |
"20040249420" | "20040254433" |
"20040254434" | "20040260478" |
"20040263354" | "20040267300" |
"20050003470" | "20050004439" |
"20050004494" | "20050006122").PN.

L2	200	("20050010087" | "20050010265" | "20050010269" | "20050015020" | "20050016276" | "20050026689" | "20050027177" | "20050027180" | "20050027181" | "20050027182" | "20050027462" | "20050027463" | "20050031689" | "20050033132" | "20050038332" | "20050043598" | "20050049179" | "20050049473" | "20050051427" | "20050051440" | "20050054905" | "20050054909" | "20050056551" | "20050056552" | "20050059871" | "20050065464" | "20050070774" | "20050090607" | "20050096511" | "20050096512" | "20050096519" | "20050101847" | "20050103625" | "20050112169" | "20050113653" | "20050114068" | "20050115832" | "20050121322" | "20050124873" | "20050131305" | "20050131346" | "20050133368" | "20050139489" | "20050143635" | "20050143675" | "20050154271" | "20050161346" | "20050173245" | "20050176136" | "20050177036" | "20050177398" | "20050181012" | "20050182306" | "20050182451" | "20050183954" | "20050187720" | "20050192494" | "20050192557" | "20050195930" | "20050196820" | "20050196821" | "20050197612" | "20050199494" | "20050203360" | "20050203364" | "20050211571" | "20050214892" | "20050215871" | "20050215872" | "20050239154" | "20050239156" | "20050241957" | "20050242479" | "20050245795" | "20050245799" | "20050245839" | "20050245904" | "20050258037" | "20050261563" | "20050272989" | "20050277164" | "20050277912" | "20050287620" | "20050288596" | "20050288725" | "20060001538" | "20060004270" | "20060010098" | "20060015020" | "20060015024" | "20060016700" | "20060017923" | "20060019327" | "20060020186" | "20060020187" | "20060020188" | "20060020189" | "20060020190" | "20060020191" | "20060020192" | "20060025662" | "20060025663" | "20060029177" | "20060031094" | "20060036139" | "20060036140" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

		"20060036141" | "20060036142" | "20060036143" | "20060036144" | "20060036145" | "20060040402" | "20060042353" | "20060047192" | "20060052745" | "20060068208" | "20060079809" | "20060086624" | "20060091006" | "20060094946" | "20060100588" | "20060142651" | "20060155180" | "20060166629" | "20060167365" | "20060167517" | "20060167518" | "20060167519" | "20060173260" | "20060173406" | "20060173444" | "20060178617" | "20060183984" | "20060183985" | "20060189851" | "20060189856" | "20060189863" | "20060189925" | "20060193375" | "20060195029" | "20060198864" | "20060200009" | "20060200019" | "20060200020" | "20060200022" | "20060200970" | "20060222566" | "20060224109" | "20060224141" | "20060226985" | "20060229512" | "20060229531" | "20060229533" | "20060247508" | "20060247685" | "20060247985" | "20060253012" | "20060253085" | "20060257996" | "20060258761" | "20060258929" | "20060263839" | "20060264785" | "20060270922" | "20060270923" | "20060272652" | "20060281985" | "20060293576" | "20070016381" | "20070017805" | "20070020641" | "20070027284" | "20070027370" | "20070027381" | "20070027384" | "20070027385" | "20070032706" | "20070032717" | "20070032718" | "20070033074" | "20070033254" | "20070045902" | "20070049873" | "20070056858" | "20070059196" | "20070060803" | "20070060814" | "20070060871" | "20070066873" | "20070068807" | "20070071681" | "20070073129" | "20070078320" | "20070078321" | "20070078322" | "20070078323" | "20070085995" | "20070093704" | "20070095661" | "20070106135").PN.				
L3	200	("20070108048" | "20070112298" | "20070116600" | "20070118030" | "20070118405" | "20070124002" | "20070129619" | "20070129621" | "20070135699" | "20070142584" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20070149875" | "20070151869" |
"20070156033" | "20070163880" |
"20070168224" | "20070169533" |
"20070170073" | "20070173706" |
"20070173709" | "20070173710" |
"20070173711" | "20070173712" |
"20070173741" | "20070173761" |
"20070179349" | "20070179352" |
"20070179434" | "20070179436" |
"20070191701" | "20070191716" |
"20070197889" | "20070197890" |
"20070199818" | "20070200254" |
"20070202562" | "20070202672" |
"20070203407" | "20070203410" |
"20070203966" | "20070206193" |
"20070208244" | "20070208245" |
"20070208246" | "20070213610" |
"20070213611" | "20070213657" |
"20070218097" | "20070219441" |
"20070224700" | "20070225675" |
"20070227911" | "20070232877" |
"20070232878" | "20070232879" |
"20070232880" | "20070233013" |
"20070235331" | "20070240497" |
"20070244379" | "20070244381" |
"20070244382" | "20070249916" |
"20070249922" | "20070255321" |
"20070259217" | "20070299389" |
"20070299617" | "20080000779" |
"20080004515" | "20080004601" |
"20080009692" | "20080012701" |
"20080017522" | "20080021666" |
"20080021972" | "20080029390" |
"20080029391" | "20080033254" |
"20080033357" | "20080039702" |
"20080045824" | "20080058625" |
"20080064937" | "20080066305" |
"20080071156" | "20080071157" |
"20080071158" | "20080072663" |
"20080081000" | "20080081977" |
"20080083617" | "20080086040" |
"20080086041" | "20080086042" |
"20080086043" | "20080086044" |
"20080086273" | "20080091094" |
"20080091095" | "20080097197" |
"20080097289" | "20080097326" |
"20080102441" | "20080103447" |
"20080108942" | "20080114227" |
"20080115599" | "20080119703" |
"20080119704" | "20080119706" |
"20080119708" | "20080125751" |
"20080139910" | "20080147050" |
"20080148873" | "20080154101" |

		"20080154177" | "20080154513" | "20080156661" | "20080161664" | "20080161666" | "20080161753" | "20080167543" | "20080168676" | "20080172205" | "20080177149" | "20080177165" | "20080183060" | "20080183061" | "20080183399" | "20080187655" | "20080188722" | "20080188725" | "20080188731" | "20080188796" | "20080189051" | "20080193936" | "20080194837" | "20080194934" | "20080194935" | "20080194936" | "20080194937" | "20080194938" | "20080195232" | "20080195967" | "20080197024" | "20080200788" | "20080200789" | "20080200791" | "20080200897" | "20080201325" | "20080205481" | "20080208025" | "20080208113" | "20080214910" | "20080214915" | "20080214918" | "20080228051" | "20080228054" | "20080234943" | "20080242961" | "20080242963" | "20080249385" | "20080255434" | "20080255437" | "20080255438" | "20080255808" | "20080256048" | "20080262469" | "20080267823" | "20080269714" | "20080275313" | "20080278332" | "20080287761" | "20080287762" | "20080287763" | "20080287764" | "20080287765" | "20080287766" | "20080288180" | "20080288204" | "20080296155" | "20080300572" | "20080305009" | "20080305506" | "20080306368" | "20080306433" | "20080306434" | "20080306435" | "20080306444" | "20080306472" | "20080312841" | "20080312842" | "20080312844" | "20080312845" | "20080314395" | "20080319279" | "20080319295" | "20080319296" | "20090001923").PN.				
L4	200	("20090005665" | "20090005666" | "20090006034" | "20090006061" | "20090012376" | "20090012379" | "20090016379" | "20090018418" | "20090018424" | "20090018425" | "20090018426" | "20090030293" | "20090030294" | "20090033482" | "20090036747" | "20090036758" | "20090036760" | "20090036763" | "20090043181" | "20090043182" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20090043525" | "20090043541" |
"20090043542" | "20090045055" |
"20090048503" | "20090054745" |
"20090054748" | "20090054749" |
"20090054753" | "20090055149" |
"20090061528" | "20090062633" |
"20090062635" | "20090062645" |
"20090062767" | "20090063402" |
"20090069649" | "20090076356" |
"20090076360" | "20090076361" |
"20090081803" | "20090082693" |
"20090085768" | "20090099434" |
"20090099436" | "20090105570" |
"20090105636" | "20090112478" |
"20090112626" | "20090118589" |
"20090124877" | "20090124878" |
"20090124879" | "20090124964" |
"20090131768" | "20090131769" |
"20090131776" | "20090131777" |
"20090137886" | "20090137887" |
"20090143659" | "20090143660" |
"20090143725" | "20090149728" |
"20090156919" | "20090156922" |
"20090156924" | "20090163790" |
"20090163855" | "20090164190" |
"20090164239" | "20090164251" |
"20090171178" | "20090177143" |
"20090178459" | "20090182217" |
"20090182517" | "20090192366" |
"20090192722" | "20090192724" |
"20090192745" | "20090192751" |
"20090198118" | "20090203981" |
"20090204340" | "20090204341" |
"20090216103" | "20090240120" |
"20090240128" | "20090240193" |
"20090241028" | "20090242399" |
"20090242425" | "20090247855" |
"20090247856" | "20090247857" |
"20090257911" | "20090264719" |
"20090281407" | "20090287073" |
"20090287074" | "20090294277" |
"20090299155" | "20090299156" |
"20090299162" | "20090299276" |
"20100010324" | "20100010331" |
"20100010332" | "20100016687" |
"20100020309" | "20100022855" |
"20100023270" | "20100023291" |
"20100025238" | "20100030053" |
"20100030137" | "20100030484" |
"20100036215" | "20100036216" |
"20100036222" | "20100036223" |
"20100036224" | "20100036225" |
"20100045231" | "20100045465" |

		"20100049015" | "20100049021" | "20100057040" | "20100057041" | "20100057042" | "20100057044" | "20100057057" | "20100063372" | "20100064764" | "20100081906" | "20100081908" | "20100081909" | "20100081910" | "20100081953" | "20100094111" | "20100121167" | "20100141656" | "20100145174" | "20100152561" | "20100160759" | "20100160761" | "20100168538" | "20100168546" | "20100169035" | "20100174167" | "20100174168" | "20100174266" | "20100179399" | "20100179402" | "20100179405" | "20100179406" | "20100179407" | "20100179408" | "20100179409" | "20100185065" | "20100185070" | "20100185071" | "20100185072" | "20100185073" | "20100185074" | "20100191085" | "20100191472" | "20100198034" | "20100198035" | "20100198142" | "20100204557" | "20100213057" | "20100214104" | "20100217106" | "20100230285" | "20100234707" | "20100234710" | "20100234796" | "20100235106" | "20100240975" | "20100240976" | "20100261987" | "20100265073" | "20100274107" | "20100274515" | "20100277342" | "20100280441" | "20100280782" | "20100286496" | "20100298684" | "20100313105" | "20100317952" | "20100324392" | "20100326842" | "20100331644" | "20100331648" | "20100331655" | "20110021889" | "20110024043").PN.				
L5	208	("20110024307" | "20110027127" | "20110027453" | "20110027458" | "20110028815" | "20110028816" | "20110029247" | "20110029269" | "20110040163" | "20110046467" | "20110060530" | "20110077490" | "20110077491" | "20110077494" | "20110081726" | "20110082484" | "20110105873" | "20110106126" | "20110112696" | "20110118579" | "20110124997" | "20110125410" | "20110130970" | "20110137601" | "20110148905" | "20110174638" | "20110184268" | "20110190603" | "20110191044" | "20110193704" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"20110208027" | "20110208155" |
"20110213225" | "20110218414" |
"20110224523" | "20110230741" |
"20110257495" | "20110257895" |
"20110263958" | "20110270062" |
"20110288574" | "20110313317" |
"20110319729" | "20110319734" |
"20110319739" | "20110320130" |
"20110320167" | "20120010642" |
"20120078071" | "20120097554" |
"20120108931" | "20120108934" |
"20120123692" | "20120165626" |
"20120165640" | "20120173200" |
"20120209099" | "20120215462" |
"20120239304" | "20120245447" |
"20120265035" | "20120265036" |
"20120277564" | "20120277565" |
"20120283542" | "20120283960" |
"20120291516" | "20120330561" |
"20130006112" | "20130035575" |
"20130060105" | "20130060112" |
"20130116527" | "20130137953" |
"20130150690" | "20130178727" |
"20130184547" | "20130199944" |
"20130231541" | "20130245412" |
"20130253846" | "20130281807" |
"20130282322" | "20130282403" |
"20130324823" | "20130338454" |
"20140005499" | "20140005968" |
"20140018642" | "20140041441" |
"20140046155" | "20140046156" |
"20140046157" | "20140046160" |
"20140046161" | "20140066736" |
"20140088390" | "20140088392" |
"20140088908" | "20140100796" |
"20140114156" | "20140121480" |
"20140121488" | "20140207400" |
"20140213869" | "20140221966" |
"20140236536" | "20140243638" |
"20140257059" | "20150005601" |
"20150006109" | "20150094555" |
"20150216456" | "20150241407" |
"20150282742" | "20150366510" |
"20150374299" | "20160022221" |
"20160073941" | "20160151006" |
"20160157758" | "20160198986" |
"20160206233" | "20160220189" |
"20160238589" | "20160245791" |
"20160270705" | "20160296697" |
"20160317069" | "20170003766" |
"20170027484" | "20170042456" |
"20170049369" | "20170124287" |
"20170188909" | "20170224258" |

		"20170258379" | "20170340250" | "20170347927" | "20180000004" | "20180000389" | "20180008174" | "20180008201" | "20180038844" | "20180042530" | "20180042531" | "20180059093" | "20180064398" | "20180085037" | "20180098721" | "20180271415" | "20180325437" | "20180328766" | "20180344220" | "20180364215" | "20190035488" | "20190072538" | "20190083012" | "20190083015" | "20190150802" | "20190151542" | "20190159734" | "20190187814" | "20190192071" | "20190254575" | "20190261902" | "20190282143" | "20190320948" | "20190320949" | "20190336051" | "20190350499" | "20190357817" | "20190357827" | "20190380627" | "20200022626" | "20200037934" | "20200037935" | "20200037936" | "20200046272" | "2402306" | "2719797" | "3210578" | "3219533" | "3506032" | "3539455" | "3556950" | "3581062" | "3610226" | "3610230" | "3652475" | "3775182" | "3780727" | "3791871" | "3826244" | "3837339" | "3838033" | "3838682" | "3874850" | "3898984" | "3910256" | "3926760" | "3929971" | "3933593" | "3943918" | "3949388" | "3957613" | "3960497" | "3964974").PN.				
L6	280	("3966580" | "3978856" | "3979274" | "3982530" | "4008717" | "4016866" | "4024312" | "4030640" | "4036749" | "4037563" | "4040908" | "4052754" | "4055175" | "4067322" | "4073713" | "4076656" | "4080292" | "4109505" | "4119406" | "4129128" | "4151845" | "4172770" | "4176659" | "4197840" | "4197852" | "4206755" | "4215703" | "4240438" | "4240889" | "4245634" | "4253469" | "4255500" | "4259540" | "4265249" | "4300572" | "4327725" | "4344438" | "4349728" | "4366040" | "4369785" | "4373527" | "4374013" | "4378016" | "4388166" | "4392849" | "4402694" | "4403847" | "4403984" | "4407298" | "4415666" | "4418148" | "4419535" | "4420564" | "4425920" | "4426621" | "4431004" | "4431507" | "4432366" | "4436094" | "4441968" | "4442841" | "4448188" | "4454295" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"4457339" | "4462048" | "4478222" |
"4478976" | "4484987" | "4486290" |
"4492575" | "4494950" | "4496454" |
"4506680" | "4509531" | "4519973" |
"4526569" | "4527240" | "4534355" |
"4534825" | "4535786" | "4538616" |
"4545382" | "4554927" | "4561963" |
"4565665" | "4565666" | "4568444" |
"4571292" | "4573968" | "4577642" |
"4578215" | "4583976" | "4592824" |
"4613328" | "4614514" | "4619793" |
"4626104" | "4650547" | "4655880" |
"4663824" | "4670007" | "4671288" |
"4672970" | "4680268" | "4685463" |
"4685903" | "4685912" | "4686044" |
"4689309" | "4694861" | "4703756" |
"4705503" | "4711245" | "4711251" |
"4721677" | "4731051" | "4731726" |
"4736748" | "4747822" | "4749985" |
"4750496" | "4752935" | "4753652" |
"4755168" | "4757022" | "4759366" |
"4759828" | "4763648" | "4776944" |
"4777953" | "4779618" | "4781798" |
"4783250" | "4784157" | "4786394" |
"4787398" | "4789467" | "4791932" |
"4800495" | "4803243" | "4805624" |
"4805625" | "4808089" | "4808292" |
"4809704" | "4810243" | "4810470" |
"4813423" | "4815471" | "4820281" |
"4822336" | "4828544" | "4830013" |
"4831070" | "4832005" | "4834101" |
"4838281" | "4841974" | "4849458" |
"4852573" | "4854322" | "4858615" |
"4861454" | "4861830" | "4863265" |
"4867741" | "4871351" | "4871440" |
"4874363" | "4883057" | "4883467" |
"4889528" | "4889744" | "4890620" |
"4890621" | "4898578" | "4900305" |
"4902294" | "4907857" | "4909786" |
"4919141" | "4919649" | "4921477" |
"4921480" | "4923819" | "4925268" |
"4925444" | "4927407" | "4927516" |
"4928694" | "4934369" | "4934375" |
"4935345" | "4944299" | "4946439" |
"4947845" | "4951669" | "4953552" |
"4955861" | "4957483" | "4958148" |
"4963131" | "4963595" | "4966579" |
"4967940" | "4974592" | "4974929" |
"4975175" | "4975636" | "4976687" |
"4979509" | "4984929" | "4986271" |
"4986671" | "4988341" | "4988671" |
"4988758" | "4994026" | "4994167" |
"4995402" | "4997627" | "5000180" |

		"5000419" | "5002054" | "5002055" | "5002572" | "5006050" | "5006111" | "5007929" | "5009251" | "5019974" | "5026348" | "5030199" | "5030333" | "5034112" | "5041092" | "5045057" | "5046496" | "5048525" | "5050612" | "5055171" | "5055198" | "5059654" | "5067491" | "5068536" | "5077476" | "5082147" | "5082550" | "5088981" | "5089112" | "5089421" | "5096669" | "5097834" | "5098377" | "5101814" | "5106365" | "5108819" | "5109850" | "5109860" | "5112301" | "5112455" | "5114859" | "5116313" | "5122925" | "5127405" | "5135004" | "5137028" | "5140985" | "5145565" | "5148812" | "5152746" | "5156972" | "5158437" | "5160418" | "5161532" | "5165406" | "5165407" | "5171689" | "5174291" | "5176632").PN.				
L7	280	("5176658" | "5178142" | "5178957" | "5182004" | "5188591" | "5190041" | "5195963" | "5198771" | "5199428" | "5202261" | "5203326" | "5204264" | "5207642" | "5208147" | "5210778" | "5216598" | "5219279" | "5220917" | "5220920" | "5224929" | "5225063" | "5231988" | "5232434" | "5235003" | "5237123" | "5243696" | "5243982" | "5243983" | "5246867" | "5248300" | "5249576" | "5254102" | "5262035" | "5262305" | "5264103" | "5264105" | "5265594" | "5266179" | "5269891" | "5271736" | "5271815" | "5275169" | "5279294" | "5281319" | "5282844" | "5282848" | "5284140" | "5284570" | "5285513" | "5285792" | "5287753" | "5293877" | "5298022" | "5298144" | "5299571" | "5302093" | "5304468" | "5307263" | "5310469" | "5311908" | "5312361" | "5313953" | "5314471" | "5315993" | "5316008" | "5316452" | "5318511" | "5320715" | "5320725" | "5321392" | "5322063" | "5324322" | "5324328" | "5326356" | "5326449" | "5328460" | "5330521" | "5330634" | "5331555" | "5335658" | "5337747" | "5340722" | "5342409" | "5342789" | "5343869" | "5345932" | "5348788" | "5352348" | "5352349" | "5352351" | "5354272" | "5354449" | "5356217" | "5356375" | "5356378" | "5356786" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"5360404" | "5365426" | "5368224" |
"5368562" | "5372133" | "5372135" |
"5372427" | "5372709" | "5376070" |
"5378229" | "5379238" | "5380268" |
"5380491" | "5380536" | "5380665" |
"5384028" | "5384547" | "5390671" |
"5391250" | "5397848" | "5398682" |
"5400795" | "5408999" | "5409666" |
"5411052" | "5411551" | "5411647" |
"5411866" | "5417206" | "5421328" |
"5422829" | "5423738" | "5423749" |
"5425375" | "5425717" | "5425749" |
"5425868" | "5428123" | "5429485" |
"5429602" | "5429735" | "5431160" |
"5431174" | "5431921" | "5434412" |
"5437635" | "5438983" | "5445610" |
"5448992" | "5453278" | "5462051" |
"5462064" | "5462645" | "5466348" |
"5469846" | "5472317" | "5474552" |
"5476094" | "5476776" | "5482446" |
"5482473" | "5484404" | "5486776" |
"5489414" | "5491474" | "5494562" |
"5496273" | "5496453" | "5497772" |
"5502396" | "5505828" | "5507288" |
"5508203" | "5509410" | "5509888" |
"5512046" | "5512246" | "5512248" |
"5513636" | "5514253" | "5514718" |
"5515851" | "5517313" | "5518601" |
"5520191" | "5522798" | "5529676" |
"5531679" | "5531878" | "5540828" |
"5543326" | "5545220" | "5547470" |
"5548569" | "5549547" | "5549548" |
"5549569" | "5549651" | "5551850" |
"5552997" | "5553616" | "5554339" |
"5562614" | "5562615" | "5564439" |
"5568400" | "5568806" | "5569186" |
"5569188" | "5569219" | "5571395" |
"5575930" | "5577499" | "5582184" |
"5582497" | "5582593" | "5582697" |
"5584813" | "5584876" | "5586553" |
"5588560" | "5589563" | "5590651" |
"5593440" | "5593852" | "5601435" |
"5605152" | "5606152" | "5609572" |
"5609575" | "5611900" | "5615671" |
"5620579" | "5624409" | "5624537" |
"5626563" | "5628310" | "5628619" |
"5628890" | "5630710" | "5631170" |
"5637083" | "5640470" | "5640954" |
"5643195" | "5645077" | "5651767" |
"5653239" | "5653756" | "5653863" |
"5658250" | "5660163" | "5665061" |
"5665065" | "5665222" | "5667504" |
"5676651" | "5676820" | "5681285" |

		"5682884" | "5683562" | "5685844" | "5686829" | "5688239" | "5688244" | "5695623" | "5697366" | "5697899" | "5704354" | "5707502" | "5711001" | "5711861" | "5714931" | "5720295" | "5730654" | "5733259" | "5735273" | "5735285" | "5738992" | "5741211" | "5741634" | "5743262" | "5745378" | "5749832").PN.				
L8	280	("5749907" | "5755226" | "5755692" | "5756632" | "5758643" | "5763760" | "5766151" | "5772586" | "5777060" | "5779665" | "5781455" | "5782912" | "5783054" | "5785660" | "5787900" | "5791344" | "5791880" | "5792065" | "5795774" | "5798065" | "5800383" | "5800420" | "5800529" | "5804048" | "5806517" | "5807274" | "5807312" | "5807375" | "5807406" | "5810323" | "5810770" | "5811487" | "5814599" | "5820551" | "5820589" | "5822715" | "5823802" | "5833603" | "5836887" | "5836989" | "5837454" | "5837728" | "5840026" | "5851197" | "5861019" | "5863400" | "5871514" | "5873862" | "5879373" | "5879828" | "5882494" | "5885844" | "5891047" | "5891048" | "5897525" | "5897578" | "5899855" | "5904666" | "5904708" | "5910554" | "5911219" | "5913998" | "5914026" | "5917346" | "5918603" | "5921951" | "5925021" | "5928130" | "5928155" | "5928182" | "5928189" | "5928195" | "5931814" | "5932175" | "5933136" | "5935224" | "5938636" | "5942979" | "5944661" | "5947911" | "5951521" | "5954643" | "5954954" | "5957854" | "5957903" | "5960797" | "5961451" | "5964261" | "5964993" | "5965380" | "5971922" | "5972199" | "5976085" | "5980728" | "5990422" | "5995208" | "5995860" | "5999848" | "6001067" | "6001471" | "6007775" | "6011984" | "6013113" | "6014577" | "6016443" | "6016448" | "6021350" | "6023629" | "6024699" | "6024720" | "6027445" | "6027479" | "6032059" | "6032667" | "6036924" | "6038469" | "6045567" | "6049727" | "6051389" | "6059946" | "6063637" | "6066088" | "6066448" | "6071391" | "6073031" | "6074775" | "6077299" | "6080583" | "6081735" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"6081736" | "6083523" | "6083710" |
"6088608" | "6090087" | "6091975" |
"6091976" | "6093156" | "6093172" |
"6099511" | "6103033" | "6107083" |
"6108577" | "6112116" | "6115622" |
"6115628" | "6115634" | "6117290" |
"6119028" | "6120676" | "6121009" |
"6121611" | "6122351" | "6122536" |
"6123827" | "6127154" | "6128519" |
"6128526" | "6134461" | "6135978" |
"6141573" | "6142939" | "6142979" |
"6143164" | "6144837" | "6144869" |
"6144871" | "6156051" | "6159147" |
"6159186" | "6161095" | "6162201" |
"6162611" | "6164921" | "6165154" |
"6165406" | "6167614" | "6168568" |
"6169155" | "6171276" | "6175752" |
"6175753" | "6180416" | "6183437" |
"6187062" | "6189536" | "6191860" |
"6197040" | "6200265" | "6200772" |
"6201980" | "6201993" | "6206856" |
"6208894" | "6212416" | "6212417" |
"6212424" | "6213739" | "6214185" |
"6219574" | "6223083" | "6223283" |
"6224562" | "6230059" | "6231320" |
"6231560" | "6231879" | "6233080" |
"6233486" | "6241863" | "6248067" |
"6248077" | "6248093" | "6249705" |
"6254586" | "6256522" | "6256538" |
"6259937" | "6261440" | "6263222" |
"6264606" | "6264825" | "6268161" |
"6269340" | "6270455" | "6270478" |
"6272364" | "6272379" | "6272480" |
"6274285" | "6275717" | "6280408" |
"6281015" | "6283761" | "6284125" |
"6284478" | "6293925" | "6294281" |
"6295506" | "6298254" | "6299578" |
"6299583" | "6299757" | "6300002" |
"6302855" | "6306104" | "6309351" |
"6309375" | "6309884" | "6312388" |
"6325978" | "6325979" | "6326160" |
"6329161" | "6329929" | "6330464" |
"6338790" | "6343225" | "6348640" |
"6356776" | "6358225" | "6359444" |
"6360888" | "6361503" | "6365670" |
"6366794" | "6368141" | "6368274" |
"6370941" | "6372244" | "6377828" |
"6377852" | "6377894" | "6379301" |
"6381493" | "6387048" | "6387709" |
"6391019" | "6400974" | "6402703" |
"6403944").PN.

L9	280	("6409674" | "6413393" | "6413396" | "6413410" | "6416651" | "6418332" | "6424847" | "6424861" | "6427088" | "6428123" | "6430437" | "6434430" | "6440068" | "6444115" | "6447448" | "6447542" | "6454710" | "6459917" | "6461496" | "6464849" | "6465066" | "6466810" | "6467480" | "6471689" | "6474360" | "6475372" | "6475750" | "6477392" | "6477395" | "6478736" | "6481440" | "6484045" | "6484046" | "6485449" | "6486661" | "6488652" | "6494879" | "6498043" | "6498941" | "6501976" | "6501983" | "6503381" | "6510329" | "6512939" | "6514460" | "6514718" | "6517508" | "6520326" | "6520477" | "6520937" | "6520997" | "6526298" | "6527729" | "6528318" | "6536433" | "6537318" | "6540891" | "6541266" | "6542765" | "6543195" | "6544212" | "6544229" | "6545085" | "6546268" | "6546269" | "6547839" | "6551494" | "6551496" | "6553241" | "6553244" | "6554805" | "6554822" | "6558320" | "6558321" | "6558347" | "6558351" | "6561978" | "6562001" | "6564105" | "6565509" | "6565535" | "6565807" | "6569309" | "6569521" | "6571128" | "6572542" | "6572545" | "6572579" | "6574490" | "6575905" | "6576101" | "6577899" | "6579257" | "6579498" | "6579690" | "6584335" | "6585644" | "6585675" | "6585763" | "6587705" | "6589229" | "6591125" | "6592745" | "6594514" | "6595756" | "6595919" | "6600940" | "6600997" | "6602221" | "6605072" | "6605200" | "6605201" | "6607509" | "6607658" | "6609071" | "6610012" | "6612984" | "6613379" | "6615061" | "6615078" | "6616819" | "6618603" | "6618934" | "6622045" | "6633772" | "6635014" | "6641533" | "6642015" | "6645181" | "6648821" | "6650471" | "6653091" | "6654625" | "6656114" | "6656157" | "6658396" | "6659948" | "6668196" | "6673022" | "6673596" | "6675030" | "6676816" | "6679865" | "6679872" | "6683535" | "6684904" | "6685668" | "6687522" | "6687546" | "6689056" | "6689089" | "6689265" | "6689413" | "6692457" | "6694191" | "6695860" | "6698269" | "6699188" | "6699218" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

		"6702249" | "6702857" | "6702972" | "6711423" | "6711424" | "6712796" | "6721582" | "6721587" | "6723086" | "6730200" | "6731976" | "6731985" | "6733446" | "6733655" | "6736783" | "6736957" | "6737158" | "6740075" | "6741877" | "6742635" | "6743635" | "6746582" | "6749587" | "6749591" | "6749740" | "6758810" | "6764581" | "6770030" | "6770067" | "6773671" | "6780297" | "6784274" | "6790178" | "6793632" | "6801041" | "6802957" | "6804002" | "6805693" | "6809653" | "6810290" | "6811533" | "6811534" | "6811548" | "6813519" | "6817990" | "6846654" | "6850790" | "6850859" | "6854317" | "6858020" | "6862465" | "6865407" | "6869413" | "6873268" | "6881551" | "6882940" | "6887228" | "6892085" | "6893396" | "6893545" | "6893552" | "6895263" | "6895265" | "6902544" | "6912413" | "6923763" | "6925393" | "6926691" | "6931327" | "6932584" | "6932892" | "6932894" | "6936006" | "6942518" | "6945965" | "6948492" | "6950708" | "6952604" | "6954662" | "6958705" | "6960192" | "6965791" | "6966325" | "6968294" | "6971274" | "6972080" | "6974437" | "6975893" | "6979315" | "6985870" | "6989891" | "6990366" | "6990422" | "6996427" | "6997907" | "6997921" | "6998247" | "7003336" | "7003340" | "7003341" | "7010345" | "7011630" | "7016713" | "7016720" | "7018361" | "7022072" | "7022219" | "7024245" | "7025425" | "7025727" | "7025743" | "7027848" | "7029443" | "7029444" | "7041068" | "7041209" | "7041468" | "7043287" | "7048727" | "7052472" | "7052483").PN.				
L10	280	("7056302" | "7060059" | "7061593" | "7062385" | "7063086" | "7066884" | "7070577" | "7070580" | "7074307" | "7074610" | "7076300" | "7078582" | "7081195" | "7092891" | "7096064" | "7097775" | "7098803" | "7100628" | "7110803" | "7115884" | "7120483" | "7123950" | "7131967" | "7135342" | "7149562" | "7150741" | "7153265" | "7153458" | "7167818" | "7169289" | "7171252" | "7171274" | "7183102" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

"7190988" | "7192450" | "7204823" |
"7207968" | "7207974" | "7211074" |
"7211439" | "7214190" | "7221970" |
"7223253" | "7225535" | "7226978" |
"7228162" | "7229288" | "7238165" |
"7244582" | "7247138" | "7247443" |
"7248912" | "7253680" | "7254450" |
"7255690" | "7258673" | "7258681" |
"7261690" | "7266400" | "7267665" |
"7268562" | "7272436" | "7273633" |
"7276029" | "7278983" | "7280879" |
"7288085" | "7288368" | "7289204" |
"7289836" | "7291496" | "7295867" |
"7297114" | "7299082" | "7303875" |
"7308292" | "7310544" | "7311690" |
"7312040" | "7313425" | "7314452" |
"7315752" | "7315767" | "7316662" |
"7317938" | "7317939" | "7318814" |
"7327273" | "7329234" | "7334594" |
"7335179" | "7335195" | "7335294" |
"7338464" | "7338639" | "7344499" |
"7344626" | "7351321" | "7354420" |
"7359723" | "7361155" | "7364562" |
"7364592" | "7365562" | "7366556" |
"7367942" | "7372277" | "7379765" |
"7381184" | "7384532" | "7387811" |
"7390667" | "7396353" | "7399277" |
"7402153" | "7402349" | "7407811" |
"7416802" | "7417164" | "7417729" |
"7422727" | "7424318" | "7425877" |
"7426408" | "7427338" | "7427560" |
"7429552" | "7433727" | "7460898" |
"7467003" | "7468125" | "7471972" |
"7474992" | "7488601" | "7494465" |
"7494816" | "7497827" | "7499002" |
"7501052" | "7502644" | "7517439" |
"7519478" | "7523004" | "7524287" |
"7525298" | "7529574" | "7547281" |
"7547382" | "7569030" | "7583990" |
"7591801" | "7599726" | "7604593" |
"7608042" | "7613491" | "7615007" |
"7618368" | "7618369" | "7620438" |
"7624028" | "7630748" | "7632228" |
"7635594" | "7637868" | "7640032" |
"7640048" | "7645374" | "7647237" |
"7653425" | "7654956" | "7695434" |
"7699775" | "7699964" | "7711493" |
"7715893" | "7731659" | "7736310" |
"7749445" | "7751864" | "7761126" |
"7761130" | "7766829" | "7766830" |
"7771352" | "7774038" | "7774145" |
"7775975" | "7776559" | "7778679" |
"7778680" | "7826981" | "7831287" |

		"7838639" | "7856613" | "7857760" | "7866025" | "7866026" | "7885697" | "7885698" | "7889069" | "7894870" | "7896809" | "7899511" | "7901354" | "7905833" | "7914450" | "7920906" | "7925321" | "7927274" | "7933639" | "7938797" | "7943034" | "7946984" | "7955261" | "7959569" | "7964089" | "7964146" | "7974672" | "7979104" | "7985330" | "7986986" | "7990828" | "7996158" | "7998071" | "8000763" | "8005524" | "8005525" | "8010174" | "8016997" | "8026104" | "8030942" | "8052601" | "8060173" | "8073519" | "8073520" | "8103471" | "8109850" | "8112240" | "8114268" | "8116837" | "8123920" | "8128562" | "8140312" | "8149117" | "8150488" | "8160670" | "8160671" | "8160834" | "8160900" | "8167801" | "8170803" | "8195265" | "8202491" | "8211016" | "8216137" | "8216138" | "8219173" | "8224415" | "8229536" | "8233959" | "8239166" | "8249683" | "8255026" | "8257259" | "8260393" | "8260558" | "8275438" | "8282549" | "8282550" | "8287453" | "8290559" | "8290562" | "8292810" | "8298142" | "8332008" | "8346335" | "8346337" | "8346338" | "8348923" | "8364230").PN.				
L11	103	("8364231" | "8369919" | "8372351" | "8374667" | "8376945" | "8396528" | "8412301" | "8417312" | "8423113" | "8423114" | "8425416" | "8425417" | "8428678" | "8428679" | "8435179" | "8442610" | "8444560" | "8447376" | "8449464" | "8457703" | "8461985" | "8463350" | "8473022" | "8475373" | "8478377" | "8478557" | "8484005" | "8491474" | "8509871" | "8515517" | "8527025" | "8532730" | "8532935" | "8543354" | "8560037" | "8560038" | "8562528" | "8571808" | "8583205" | "8593109" | "8600681" | "8612163" | "8626257" | "8657745" | "8657746" | "8663220" | "8665091" | "8682615" | "8718739" | "8718965" | "8744547" | "8774886" | "8868151" | "8868161" | "8911367" | "8933664" | "8942778" | "9060719" | "9113828" | "9125548" | "9135402" | "9149220" | "9161714" | "9247901" | "9314196" | "9320462" |	US-PGPUB; USPAT	OR	OFF	2021/02/25 12:27

		"9320468" | "9326709" | "9332934" | "9339217" | "9357959" | "9380971" | "9392969" | "9398872" | "9408566" | "9451908" | "9483608" | "9498155" | "9558325" | "9629578" | "9662056" | "9675290" | "9730623" | "9737249" | "9743863" | "9770211" | "9797880" | "9801571" | "9801575" | "9801577" | "9804148" | "9804150" | "9808190" | "9814428" | "9833181" | "9839383" | "9839395" | "9848809" | "9936910" | "RE31916" | "RE32361" | "RE43039" | "RE43399").PN.				
L12	561	calibrating near55 sensor near55 data and transcutaneous same analyte same sensor same sensor same electronics	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/25 13:13
L13	590	calibrating same sensor same data and transcutaneous same analyte same sensor same sensor same electronics	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/25 13:14
L14	590	13 AND ((A61B5/14532 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/14503 OR A61B5/1495 OR A61B5/14865 OR A61B2560/0223 OR A61B5/14735 OR A61B5/1468 OR A61B5/1451 OR A61B5/6848 OR A61B5/0031 OR A61B5/0002 OR A61B5/0004 OR A61B5/6833 OR A61B5/14507 OR A61B5/6849 OR A61B5/150022 OR A61B5/1411 OR A61B5/145 OR A61B5/6801 OR A61B17/3468 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/68335 OR A61B5/14517 OR A61B2560/0276 OR A61B5/7257 OR A61B5/7267 OR A61B5/742 OR A61B2562/08 OR A61B5/7203 OR A61B2560/0214 OR A61B5/0022 OR A61B5/6832 OR A61B5/00 OR A61B5/150534 OR A61B5/746 OR A61B5/486 OR A61B2560/0209 OR A61B5/7445 OR A61B2560/0252 OR A61B2562/02 OR A61B5/002 OR A61B5/411 OR A61B5/418 OR A61B5/4839 OR A61B5/686 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/25 13:15

		A61B5/6898 OR A61B5/7435 OR A61B5/7475 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0257 OR A61B2560/028 OR A61B2560/0295 OR A61B2560/0412 OR A61B2560/0443 OR A61B2562/0209 OR A61B2562/0219 OR A61B2562/028 OR A61B2562/043 OR A61B2562/125 OR A61B2562/164 OR A61B2562/227 OR A61B5/0024 OR A61B5/01 OR A61B5/14539 OR A61B5/14542 OR A61B5/681 OR A61B5/6846 OR A61B5/7221 OR A61B5/7225 OR A61B5/7235 OR A61B5/7239 OR A61B5/726 OR A61B5/7264 OR A61B5/7275 OR A61B5/7405 OR A61B5/743 OR A61B5/7455 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR Y02A50/30 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2005/14208 OR A61M2205/3553 OR A61M2205/50 OR A61M2230/201 OR A61M5/14248 OR G01N27/3274 OR G01N27/026 OR G01N33/49 OR G01N33/54366 OR G01N33/66 OR G01N27/3271 OR G01D18/00 OR H05K999/00 OR H05K999/99 OR H05K2201/053 OR H05K2201/10151 OR H05K2201/10401 OR H05K2201/10409 OR H05K3/325 OR H05K3/365 OR G16Z99/00 OR H04W76/14 OR H04W4/80 OR H04W12/06 OR H04W12/00 OR H04W48/10 OR H04W4/38 OR H04W52/0277 OR H04W76/10 OR H04W84/18 OR H04W84/22 OR H04W8/005 OR H04W12/068 OR H04W4/12 OR H04W4/20 OR H04W4/70 OR H04W52/0229 OR H04W88/02 OR G16H20/17 OR G16H40/40 OR G16H40/63 OR G16H10/60 OR G16H40/67 OR G16H10/65 OR G16H20/60 OR G16H50/20 OR G16H10/20 OR G16H10/40 OR G16H20/30 OR G16H20/70 OR G16H50/30 OR G16H80/00).CPC.)				
L15	590	13 AND ((A61B5/14532 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/14503 OR A61B5/1495 OR A61B5/14865 OR A61B2560/0223 OR A61B5/14735 OR A61B5/1468 OR A61B5/1451 OR A61B5/6848 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2021/02/25 13:16

		A61B5/0031 OR A61B5/0002 OR A61B5/0004 OR A61B5/6833 OR A61B5/14507 OR A61B5/6849 OR A61B5/150022 OR A61B5/1411 OR A61B5/145 OR A61B5/6801 OR A61B17/3468 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/68335 OR A61B5/14517 OR A61B2560/0276 OR A61B5/7257 OR A61B5/7267 OR A61B5/742 OR A61B2562/08 OR A61B5/7203 OR A61B2560/0214 OR A61B5/0022 OR A61B5/6832 OR A61B5/00 OR A61B5/150534 OR A61B5/746 OR A61B5/486 OR A61B2560/0209 OR A61B5/7445 OR A61B2560/0252 OR A61B2562/02 OR A61B5/002 OR A61B5/411 OR A61B5/418 OR A61B5/4839 OR A61B5/686 OR A61B5/6898 OR A61B5/7435 OR A61B5/7475 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0257 OR A61B2560/028 OR A61B2560/0295 OR A61B2560/0412 OR A61B2560/0443 OR A61B2562/0209 OR A61B2562/0219 OR A61B2562/028 OR A61B2562/043 OR A61B2562/125 OR A61B2562/164 OR A61B2562/227 OR A61B5/0024 OR A61B5/01 OR A61B5/14539 OR A61B5/14542 OR A61B5/681 OR A61B5/6846 OR A61B5/7221 OR A61B5/7225 OR A61B5/7235 OR A61B5/7239 OR A61B5/726 OR A61B5/7264 OR A61B5/7275 OR A61B5/7405 OR A61B5/743 OR A61B5/7455 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR Y02A50/30 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2005/14208 OR A61M2205/3553 OR A61M2205/50 OR A61M2230/201 OR A61M5/14248 OR G01N27/3274 OR G01N27/026 OR G01N33/49 OR G01N33/54366 OR G01N33/66 OR G01N27/3271 OR G01D18/00 OR H05K999/00 OR H05K999/99 OR H05K2201/053 OR H05K2201/10151 OR H05K2201/10401 OR H05K2201/10409 OR H05K3/325 OR H05K3/365 OR G16Z99/00 OR H04W76/14 OR H04W4/80 OR H04W12/06 OR H04W12/00 OR H04W48/10 OR				

		H04W4/38 OR H04W52/0277 OR H04W76/10 OR H04W84/18 OR H04W84/22 OR H04W8/005 OR H04W12/068 OR H04W4/12 OR H04W4/20 OR H04W4/70 OR H04W52/0229 OR H04W88/02 OR G16H20/17 OR G16H40/40 OR G16H40/63 OR G16H10/60 OR G16H40/67 OR G16H10/65 OR G16H20/60 OR G16H50/20 OR G16H10/20 OR G16H10/40 OR G16H20/30 OR G16H20/70 OR G16H50/30 OR G16H80/00 OR H01L2924/00 OR H01L2924/07811 OR H01L2924/12042 OR H01L24/72 OR H04L63/101 OR H04L2209/88 OR H04L67/141 OR H04L67/34 OR Y02D30/70).CPC.)				

2/25/2021 1:16:37 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	205	("0000002" | "0000059" | "0000791" | "0002508" | "0052641" | "0062334" | "0065604" | "0201800" | "10002233" | "10004442" | "10078380" | "10082493" | "10089446" | "10188334" | "10194868" | "10335075" | "10349873" | "10448873" | "10561354" | "10610141" | "10624568" | "10682084" | "20010016682" | "20010021817" | "20010039053" | "20010041830" | "20010041831" | "20010051768" | "20020016534" | "20020016535" | "20020019022" | "20020022883" | "20020023852" | "20020026110" | "20020026111" | "20020027086" | "20020038101" | "20020042090" | "20020042561" | "20020043471" | "20020045808" | "20020055673" | "20020062132" | "20020065453" | "20020065454" | "20020068860" | "20020071776" | "20020084196" | "20020099282" | "20020099997" | "20020103499" | "20020106709" | "20020111547" | "20020115920" | "20020119711" | "20020120186" | "20020123048" | "20020128594" | "20020143266" | "20020143372" | "20020151796" | "20020155615" | "20020156355" | "20020161288" | "20020169369" | "20020169635" | "20020177763" | "20020177764" | "20020182241" | "20020188185" | "20020193679" | "20020193885" | "20020198513" | "20030003524" | "20030004403" | "20030004432" | "20030004457" | "20030006669" | "20030023171" | "20030023317" | "20030023461" | "20030028089" | "20030032867" | "20030032874" | "20030034305" | "20030036773" | "20030042137" | "20030050546" | "20030054428" | "20030060692" | "20030065254" | "20030065308" | "20030076082" | "20030078481" | "20030078560" | "20030097082" | "20030100040" | "20030100821" | "20030119201" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20030119208" | "20030120152" |
"20030125612" | "20030125613" |
"20030130616" | "20030134347" |
"20030138674" | "20030143746" |
"20030153821" | "20030161288" |
"20030168338" | "20030175987" |
"20030176183" | "20030176933" |
"20030181794" | "20030187338" |
"20030188427" | "20030191377" |
"20030199744" | "20030199790" |
"20030203498" | "20030208113" |
"20030211625" | "20030212317" |
"20030212346" | "20030212347" |
"20030212379" | "20030216630" |
"20030217966" | "20030225437" |
"20030228681" | "20030235817" |
"20040010186" | "20040010207" |
"20040011671" | "20040015063" |
"20040015134" | "20040023253" |
"20040023317" | "20040024327" |
"20040024553" | "20040030285" |
"20040030294" | "20040039298" |
"20040039406" | "20040040840" |
"20040045879" | "20040054263" |
"20040054352" | "20040064021" |
"20040064068" | "20040068230" |
"20040074785" | "20040077962" |
"20040078065" | "20040078219" |
"20040093167" | "20040099529" |
"20040106857" | "20040106858" |
"20040106859" | "20040108226" |
"20040122353" | "20040133131" |
"20040133164" | "20040135684" |
"20040138588" | "20040138716" |
"20040142403" | "20040143173" |
"20040146909" | "20040147819" |
"20040152187" | "20040152622" |
"20040158137" | "20040162678" |
"20040167801" | "20040171921" |
"20040172307" | "20040173472" |
"20040176672" | "20040186362" |
"20040186365" | "20040193025" |
"20040193090" | "20040197846" |
"20040199059" | "20040204687" |
"20040208780" | "20040219664" |
"20040220517" | "20040225338" |
"20040236200" | "20040236251" |
"20040242982" | "20040249253" |
"20040249420" | "20040254433" |
"20040254434" | "20040260478" |
"20040263354" | "20040267300" |
"20050003470" | "20050004439" |
"20050004494" | "20050006122").PN.

L2	200	("20050010087" | "20050010265" | "20050010269" | "20050015020" | "20050016276" | "20050026689" | "20050027177" | "20050027180" | "20050027181" | "20050027182" | "20050027462" | "20050027463" | "20050031689" | "20050033132" | "20050038332" | "20050043598" | "20050049179" | "20050049473" | "20050051427" | "20050051440" | "20050054905" | "20050054909" | "20050056551" | "20050056552" | "20050059871" | "20050065464" | "20050070774" | "20050090607" | "20050096511" | "20050096512" | "20050096519" | "20050101847" | "20050103625" | "20050112169" | "20050113653" | "20050114068" | "20050115832" | "20050121322" | "20050124873" | "20050131305" | "20050131346" | "20050133368" | "20050139489" | "20050143635" | "20050143675" | "20050154271" | "20050161346" | "20050173245" | "20050176136" | "20050177036" | "20050177398" | "20050181012" | "20050182306" | "20050182451" | "20050183954" | "20050187720" | "20050192494" | "20050192557" | "20050195930" | "20050196820" | "20050196821" | "20050197612" | "20050199494" | "20050203360" | "20050203364" | "20050211571" | "20050214892" | "20050215871" | "20050215872" | "20050239154" | "20050239156" | "20050241957" | "20050242479" | "20050245795" | "20050245799" | "20050245839" | "20050245904" | "20050258037" | "20050261563" | "20050272989" | "20050277164" | "20050277912" | "20050287620" | "20050288596" | "20050288725" | "20060001538" | "20060004270" | "20060010098" | "20060015020" | "20060015024" | "20060016700" | "20060017923" | "20060019327" | "20060020186" | "20060020187" | "20060020188" | "20060020189" | "20060020190" | "20060020191" | "20060020192" | "20060025662" | "20060025663" | "20060029177" | "20060031094" | "20060036139" | "20060036140" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"20060036141" | "20060036142" | "20060036143" | "20060036144" | "20060036145" | "20060040402" | "20060042353" | "20060047192" | "20060052745" | "20060068208" | "20060079809" | "20060086624" | "20060091006" | "20060094946" | "20060100588" | "20060142651" | "20060155180" | "20060166629" | "20060167365" | "20060167517" | "20060167518" | "20060167519" | "20060173260" | "20060173406" | "20060173444" | "20060178617" | "20060183984" | "20060183985" | "20060189851" | "20060189856" | "20060189863" | "20060189925" | "20060193375" | "20060195029" | "20060198864" | "20060200009" | "20060200019" | "20060200020" | "20060200022" | "20060200970" | "20060222566" | "20060224109" | "20060224141" | "20060226985" | "20060229512" | "20060229531" | "20060229533" | "20060247508" | "20060247685" | "20060247985" | "20060253012" | "20060253085" | "20060257996" | "20060258761" | "20060258929" | "20060263839" | "20060264785" | "20060270922" | "20060270923" | "20060272652" | "20060281985" | "20060293576" | "20070016381" | "20070017805" | "20070020641" | "20070027284" | "20070027370" | "20070027381" | "20070027384" | "20070027385" | "20070032706" | "20070032717" | "20070032718" | "20070033074" | "20070033254" | "20070045902" | "20070049873" | "20070056858" | "20070059196" | "20070060803" | "20070060814" | "20070060871" | "20070066873" | "20070068807" | "20070071681" | "20070073129" | "20070078320" | "20070078321" | "20070078322" | "20070078323" | "20070085995" | "20070093704" | "20070095661" | "20070106135").PN.				
L3	200	("20070108048" | "20070112298" | "20070116600" | "20070118030" | "20070118405" | "20070124002" | "20070129619" | "20070129621" | "20070135699" | "20070142584" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20070149875" | "20070151869" |
"20070156033" | "20070163880" |
"20070168224" | "20070169533" |
"20070170073" | "20070173706" |
"20070173709" | "20070173710" |
"20070173711" | "20070173712" |
"20070173741" | "20070173761" |
"20070179349" | "20070179352" |
"20070179434" | "20070179436" |
"20070191701" | "20070191716" |
"20070197889" | "20070197890" |
"20070199818" | "20070200254" |
"20070202562" | "20070202672" |
"20070203407" | "20070203410" |
"20070203966" | "20070206193" |
"20070208244" | "20070208245" |
"20070208246" | "20070213610" |
"20070213611" | "20070213657" |
"20070218097" | "20070219441" |
"20070224700" | "20070225675" |
"20070227911" | "20070232877" |
"20070232878" | "20070232879" |
"20070232880" | "20070233013" |
"20070235331" | "20070240497" |
"20070244379" | "20070244381" |
"20070244382" | "20070249916" |
"20070249922" | "20070255321" |
"20070259217" | "20070299389" |
"20070299617" | "20080000779" |
"20080004515" | "20080004601" |
"20080009692" | "20080012701" |
"20080017522" | "20080021666" |
"20080021972" | "20080029390" |
"20080029391" | "20080033254" |
"20080033357" | "20080039702" |
"20080045824" | "20080058625" |
"20080064937" | "20080066305" |
"20080071156" | "20080071157" |
"20080071158" | "20080072663" |
"20080081000" | "20080081977" |
"20080083617" | "20080086040" |
"20080086041" | "20080086042" |
"20080086043" | "20080086044" |
"20080086273" | "20080091094" |
"20080091095" | "20080097197" |
"20080097289" | "20080097326" |
"20080102441" | "20080103447" |
"20080108942" | "20080114227" |
"20080115599" | "20080119703" |
"20080119704" | "20080119706" |
"20080119708" | "20080125751" |
"20080139910" | "20080147050" |
"20080148873" | "20080154101" |

		"20080154177" | "20080154513" | "20080156661" | "20080161664" | "20080161666" | "20080161753" | "20080167543" | "20080168676" | "20080172205" | "20080177149" | "20080177165" | "20080183060" | "20080183061" | "20080183399" | "20080187655" | "20080188722" | "20080188725" | "20080188731" | "20080188796" | "20080189051" | "20080193936" | "20080194837" | "20080194934" | "20080194935" | "20080194936" | "20080194937" | "20080194938" | "20080195232" | "20080195967" | "20080197024" | "20080200788" | "20080200789" | "20080200791" | "20080200897" | "20080201325" | "20080205481" | "20080208025" | "20080208113" | "20080214910" | "20080214915" | "20080214918" | "20080228051" | "20080228054" | "20080234943" | "20080242961" | "20080242963" | "20080249385" | "20080255434" | "20080255437" | "20080255438" | "20080255808" | "20080256048" | "20080262469" | "20080267823" | "20080269714" | "20080275313" | "20080278332" | "20080287761" | "20080287762" | "20080287763" | "20080287764" | "20080287765" | "20080287766" | "20080288180" | "20080288204" | "20080296155" | "20080300572" | "20080305009" | "20080305506" | "20080306368" | "20080306433" | "20080306434" | "20080306435" | "20080306444" | "20080306472" | "20080312841" | "20080312842" | "20080312844" | "20080312845" | "20080314395" | "20080319279" | "20080319295" | "20080319296" | "20090001923").PN.				
L4	200	("20090005665" | "20090005666" | "20090006034" | "20090006061" | "20090012376" | "20090012379" | "20090016379" | "20090018418" | "20090018424" | "20090018425" | "20090018426" | "20090030293" | "20090030294" | "20090033482" | "20090036747" | "20090036758" | "20090036760" | "20090036763" | "20090043181" | "20090043182" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20090043525" | "20090043541" |
"20090043542" | "20090045055" |
"20090048503" | "20090054745" |
"20090054748" | "20090054749" |
"20090054753" | "20090055149" |
"20090061528" | "20090062633" |
"20090062635" | "20090062645" |
"20090062767" | "20090063402" |
"20090069649" | "20090076356" |
"20090076360" | "20090076361" |
"20090081803" | "20090082693" |
"20090085768" | "20090099434" |
"20090099436" | "20090105570" |
"20090105636" | "20090112478" |
"20090112626" | "20090118589" |
"20090124877" | "20090124878" |
"20090124879" | "20090124964" |
"20090131768" | "20090131769" |
"20090131776" | "20090131777" |
"20090137886" | "20090137887" |
"20090143659" | "20090143660" |
"20090143725" | "20090149728" |
"20090156919" | "20090156922" |
"20090156924" | "20090163790" |
"20090163855" | "20090164190" |
"20090164239" | "20090164251" |
"20090171178" | "20090177143" |
"20090178459" | "20090182217" |
"20090182517" | "20090192366" |
"20090192722" | "20090192724" |
"20090192745" | "20090192751" |
"20090198118" | "20090203981" |
"20090204340" | "20090204341" |
"20090216103" | "20090240120" |
"20090240128" | "20090240193" |
"20090241028" | "20090242399" |
"20090242425" | "20090247855" |
"20090247856" | "20090247857" |
"20090257911" | "20090264719" |
"20090281407" | "20090287073" |
"20090287074" | "20090294277" |
"20090299155" | "20090299156" |
"20090299162" | "20090299276" |
"20100010324" | "20100010331" |
"20100010332" | "20100016687" |
"20100020309" | "20100022855" |
"20100023270" | "20100023291" |
"20100025238" | "20100030053" |
"20100030137" | "20100030484" |
"20100036215" | "20100036216" |
"20100036222" | "20100036223" |
"20100036224" | "20100036225" |
"20100045231" | "20100045465" |

		"20100049015" | "20100049021" | "20100057040" | "20100057041" | "20100057042" | "20100057044" | "20100057057" | "20100063372" | "20100064764" | "20100081906" | "20100081908" | "20100081909" | "20100081910" | "20100081953" | "20100094111" | "20100121167" | "20100141656" | "20100145174" | "20100152561" | "20100160759" | "20100160761" | "20100168538" | "20100168546" | "20100169035" | "20100174167" | "20100174168" | "20100174266" | "20100179399" | "20100179402" | "20100179405" | "20100179406" | "20100179407" | "20100179408" | "20100179409" | "20100185065" | "20100185070" | "20100185071" | "20100185072" | "20100185073" | "20100185074" | "20100191085" | "20100191472" | "20100198034" | "20100198035" | "20100198142" | "20100204557" | "20100213057" | "20100214104" | "20100217106" | "20100230285" | "20100234707" | "20100234710" | "20100234796" | "20100235106" | "20100240975" | "20100240976" | "20100261987" | "20100265073" | "20100274107" | "20100274515" | "20100277342" | "20100280441" | "20100280782" | "20100286496" | "20100298684" | "20100313105" | "20100317952" | "20100324392" | "20100326842" | "20100331644" | "20100331648" | "20100331655" | "20110021889" | "20110024043").PN.				
L5	208	("20110024307" | "20110027127" | "20110027453" | "20110027458" | "20110028815" | "20110028816" | "20110029247" | "20110029269" | "20110040163" | "20110046467" | "20110060530" | "20110077490" | "20110077491" | "20110077494" | "20110081726" | "20110082484" | "20110105873" | "20110106126" | "20110112696" | "20110118579" | "20110124997" | "20110125410" | "20110130970" | "20110137601" | "20110148905" | "20110174638" | "20110184268" | "20110190603" | "20110191044" | "20110193704" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"20110208027" | "20110208155" |
"20110213225" | "20110218414" |
"20110224523" | "20110230741" |
"20110257495" | "20110257895" |
"20110263958" | "20110270062" |
"20110288574" | "20110313317" |
"20110319729" | "20110319734" |
"20110319739" | "20110320130" |
"20110320167" | "20120010642" |
"20120078071" | "20120097554" |
"20120108931" | "20120108934" |
"20120123692" | "20120165626" |
"20120165640" | "20120173200" |
"20120209099" | "20120215462" |
"20120239304" | "20120245447" |
"20120265035" | "20120265036" |
"20120277564" | "20120277565" |
"20120283542" | "20120283960" |
"20120291516" | "20120330561" |
"20130006112" | "20130035575" |
"20130060105" | "20130060112" |
"20130116527" | "20130137953" |
"20130150690" | "20130178727" |
"20130184547" | "20130199944" |
"20130231541" | "20130245412" |
"20130253846" | "20130281807" |
"20130282322" | "20130282403" |
"20130324823" | "20130338454" |
"20140005499" | "20140005968" |
"20140018642" | "20140041441" |
"20140046155" | "20140046156" |
"20140046157" | "20140046160" |
"20140046161" | "20140066736" |
"20140088390" | "20140088392" |
"20140088908" | "20140100796" |
"20140114156" | "20140121480" |
"20140121488" | "20140207400" |
"20140213869" | "20140221966" |
"20140236536" | "20140243638" |
"20140257059" | "20150005601" |
"20150006109" | "20150094555" |
"20150216456" | "20150241407" |
"20150282742" | "20150366510" |
"20150374299" | "20160022221" |
"20160073941" | "20160151006" |
"20160157758" | "20160198986" |
"20160206233" | "20160220189" |
"20160238589" | "20160245791" |
"20160270705" | "20160296697" |
"20160317069" | "20170003766" |
"20170027484" | "20170042456" |
"20170049369" | "20170124287" |
"20170188909" | "20170224258" |

		"20170258379" | "20170340250" | "20170347927" | "20180000004" | "20180000389" | "20180008174" | "20180008201" | "20180038844" | "20180042530" | "20180042531" | "20180059093" | "20180064398" | "20180085037" | "20180098721" | "20180271415" | "20180325437" | "20180328766" | "20180344220" | "20180364215" | "20190035488" | "20190072538" | "20190083012" | "20190083015" | "20190150802" | "20190151542" | "20190159734" | "20190187814" | "20190192071" | "20190254575" | "20190261902" | "20190282143" | "20190320948" | "20190320949" | "20190336051" | "20190350499" | "20190357817" | "20190357827" | "20190380627" | "20200022626" | "20200037934" | "20200037935" | "20200037936" | "20200046272" | "2402306" | "2719797" | "3210578" | "3219533" | "3506032" | "3539455" | "3556950" | "3581062" | "3610226" | "3610230" | "3652475" | "3775182" | "3780727" | "3791871" | "3826244" | "3837339" | "3838033" | "3838682" | "3874850" | "3898984" | "3910256" | "3926760" | "3929971" | "3933593" | "3943918" | "3949388" | "3957613" | "3960497" | "3964974").PN.				
L6	280	("3966580" | "3978856" | "3979274" | "3982530" | "4008717" | "4016866" | "4024312" | "4030640" | "4036749" | "4037563" | "4040908" | "4052754" | "4055175" | "4067322" | "4073713" | "4076656" | "4080292" | "4109505" | "4119406" | "4129128" | "4151845" | "4172770" | "4176659" | "4197840" | "4197852" | "4206755" | "4215703" | "4240438" | "4240889" | "4245634" | "4253469" | "4255500" | "4259540" | "4265249" | "4300572" | "4327725" | "4344438" | "4349728" | "4366040" | "4369785" | "4373527" | "4374013" | "4378016" | "4388166" | "4392849" | "4402694" | "4403847" | "4403984" | "4407298" | "4415666" | "4418148" | "4419535" | "4420564" | "4425920" | "4426621" | "4431004" | "4431507" | "4432366" | "4436094" | "4441968" | "4442841" | "4448188" | "4454295" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"4457339" | "4462048" | "4478222" |
"4478976" | "4484987" | "4486290" |
"4492575" | "4494950" | "4496454" |
"4506680" | "4509531" | "4519973" |
"4526569" | "4527240" | "4534355" |
"4534825" | "4535786" | "4538616" |
"4545382" | "4554927" | "4561963" |
"4565665" | "4565666" | "4568444" |
"4571292" | "4573968" | "4577642" |
"4578215" | "4583976" | "4592824" |
"4613328" | "4614514" | "4619793" |
"4626104" | "4650547" | "4655880" |
"4663824" | "4670007" | "4671288" |
"4672970" | "4680268" | "4685463" |
"4685903" | "4685912" | "4686044" |
"4689309" | "4694861" | "4703756" |
"4705503" | "4711245" | "4711251" |
"4721677" | "4731051" | "4731726" |
"4736748" | "4747822" | "4749985" |
"4750496" | "4752935" | "4753652" |
"4755168" | "4757022" | "4759366" |
"4759828" | "4763648" | "4776944" |
"4777953" | "4779618" | "4781798" |
"4783250" | "4784157" | "4786394" |
"4787398" | "4789467" | "4791932" |
"4800495" | "4803243" | "4805624" |
"4805625" | "4808089" | "4808292" |
"4809704" | "4810243" | "4810470" |
"4813423" | "4815471" | "4820281" |
"4822336" | "4828544" | "4830013" |
"4831070" | "4832005" | "4834101" |
"4838281" | "4841974" | "4849458" |
"4852573" | "4854322" | "4858615" |
"4861454" | "4861830" | "4863265" |
"4867741" | "4871351" | "4871440" |
"4874363" | "4883057" | "4883467" |
"4889528" | "4889744" | "4890620" |
"4890621" | "4898578" | "4900305" |
"4902294" | "4907857" | "4909786" |
"4919141" | "4919649" | "4921477" |
"4921480" | "4923819" | "4925268" |
"4925444" | "4927407" | "4927516" |
"4928694" | "4934369" | "4934375" |
"4935345" | "4944299" | "4946439" |
"4947845" | "4951669" | "4953552" |
"4955861" | "4957483" | "4958148" |
"4963131" | "4963595" | "4966579" |
"4967940" | "4974592" | "4974929" |
"4975175" | "4975636" | "4976687" |
"4979509" | "4984929" | "4986271" |
"4986671" | "4988341" | "4988671" |
"4988758" | "4994026" | "4994167" |
"4995402" | "4997627" | "5000180" |

		"5000419" | "5002054" | "5002055" | "5002572" | "5006050" | "5006111" | "5007929" | "5009251" | "5019974" | "5026348" | "5030199" | "5030333" | "5034112" | "5041092" | "5045057" | "5046496" | "5048525" | "5050612" | "5055171" | "5055198" | "5059654" | "5067491" | "5068536" | "5077476" | "5082147" | "5082550" | "5088981" | "5089112" | "5089421" | "5096669" | "5097834" | "5098377" | "5101814" | "5106365" | "5108819" | "5109850" | "5109860" | "5112301" | "5112455" | "5114859" | "5116313" | "5122925" | "5127405" | "5135004" | "5137028" | "5140985" | "5145565" | "5148812" | "5152746" | "5156972" | "5158437" | "5160418" | "5161532" | "5165406" | "5165407" | "5171689" | "5174291" | "5176632").PN.				
L7	280	("5176658" | "5178142" | "5178957" | "5182004" | "5188591" | "5190041" | "5195963" | "5198771" | "5199428" | "5202261" | "5203326" | "5204264" | "5207642" | "5208147" | "5210778" | "5216598" | "5219279" | "5220917" | "5220920" | "5224929" | "5225063" | "5231988" | "5232434" | "5235003" | "5237123" | "5243696" | "5243982" | "5243983" | "5246867" | "5248300" | "5249576" | "5254102" | "5262035" | "5262305" | "5264103" | "5264105" | "5265594" | "5266179" | "5269891" | "5271736" | "5271815" | "5275169" | "5279294" | "5281319" | "5282844" | "5282848" | "5284140" | "5284570" | "5285513" | "5285792" | "5287753" | "5293877" | "5298022" | "5298144" | "5299571" | "5302093" | "5304468" | "5307263" | "5310469" | "5311908" | "5312361" | "5313953" | "5314471" | "5315993" | "5316008" | "5316452" | "5318511" | "5320715" | "5320725" | "5321392" | "5322063" | "5324322" | "5324328" | "5326356" | "5326449" | "5328460" | "5330521" | "5330634" | "5331555" | "5335658" | "5337747" | "5340722" | "5342409" | "5342789" | "5343869" | "5345932" | "5348788" | "5352348" | "5352349" | "5352351" | "5354272" | "5354449" | "5356217" | "5356375" | "5356378" | "5356786" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"5360404" | "5365426" | "5368224" |
"5368562" | "5372133" | "5372135" |
"5372427" | "5372709" | "5376070" |
"5378229" | "5379238" | "5380268" |
"5380491" | "5380536" | "5380665" |
"5384028" | "5384547" | "5390671" |
"5391250" | "5397848" | "5398682" |
"5400795" | "5408999" | "5409666" |
"5411052" | "5411551" | "5411647" |
"5411866" | "5417206" | "5421328" |
"5422829" | "5423738" | "5423749" |
"5425375" | "5425717" | "5425749" |
"5425868" | "5428123" | "5429485" |
"5429602" | "5429735" | "5431160" |
"5431174" | "5431921" | "5434412" |
"5437635" | "5438983" | "5445610" |
"5448992" | "5453278" | "5462051" |
"5462064" | "5462645" | "5466348" |
"5469846" | "5472317" | "5474552" |
"5476094" | "5476776" | "5482446" |
"5482473" | "5484404" | "5486776" |
"5489414" | "5491474" | "5494562" |
"5496273" | "5496453" | "5497772" |
"5502396" | "5505828" | "5507288" |
"5508203" | "5509410" | "5509888" |
"5512046" | "5512246" | "5512248" |
"5513636" | "5514253" | "5514718" |
"5515851" | "5517313" | "5518601" |
"5520191" | "5522798" | "5529676" |
"5531679" | "5531878" | "5540828" |
"5543326" | "5545220" | "5547470" |
"5548569" | "5549547" | "5549548" |
"5549569" | "5549651" | "5551850" |
"5552997" | "5553616" | "5554339" |
"5562614" | "5562615" | "5564439" |
"5568400" | "5568806" | "5569186" |
"5569188" | "5569219" | "5571395" |
"5575930" | "5577499" | "5582184" |
"5582497" | "5582593" | "5582697" |
"5584813" | "5584876" | "5586553" |
"5588560" | "5589563" | "5590651" |
"5593440" | "5593852" | "5601435" |
"5605152" | "5606152" | "5609572" |
"5609575" | "5611900" | "5615671" |
"5620579" | "5624409" | "5624537" |
"5626563" | "5628310" | "5628619" |
"5628890" | "5630710" | "5631170" |
"5637083" | "5640470" | "5640954" |
"5643195" | "5645077" | "5651767" |
"5653239" | "5653756" | "5653863" |
"5658250" | "5660163" | "5665061" |
"5665065" | "5665222" | "5667504" |
"5676651" | "5676820" | "5681285" |

		"5682884" | "5683562" | "5685844" | "5686829" | "5688239" | "5688244" | "5695623" | "5697366" | "5697899" | "5704354" | "5707502" | "5711001" | "5711861" | "5714931" | "5720295" | "5730654" | "5733259" | "5735273" | "5735285" | "5738992" | "5741211" | "5741634" | "5743262" | "5745378" | "5749832").PN.				
L8	280	("5749907" | "5755226" | "5755692" | "5756632" | "5758643" | "5763760" | "5766151" | "5772586" | "5777060" | "5779665" | "5781455" | "5782912" | "5783054" | "5785660" | "5787900" | "5791344" | "5791880" | "5792065" | "5795774" | "5798065" | "5800383" | "5800420" | "5800529" | "5804048" | "5806517" | "5807274" | "5807312" | "5807375" | "5807406" | "5810323" | "5810770" | "5811487" | "5814599" | "5820551" | "5820589" | "5822715" | "5823802" | "5833603" | "5836887" | "5836989" | "5837454" | "5837728" | "5840026" | "5851197" | "5861019" | "5863400" | "5871514" | "5873862" | "5879373" | "5879828" | "5882494" | "5885844" | "5891047" | "5891048" | "5897525" | "5897578" | "5899855" | "5904666" | "5904708" | "5910554" | "5911219" | "5913998" | "5914026" | "5917346" | "5918603" | "5921951" | "5925021" | "5928130" | "5928155" | "5928182" | "5928189" | "5928195" | "5931814" | "5932175" | "5933136" | "5935224" | "5938636" | "5942979" | "5944661" | "5947911" | "5951521" | "5954643" | "5954954" | "5957854" | "5957903" | "5960797" | "5961451" | "5964261" | "5964993" | "5965380" | "5971922" | "5972199" | "5976085" | "5980728" | "5990422" | "5995208" | "5995860" | "5999848" | "6001067" | "6001471" | "6007775" | "6011984" | "6013113" | "6014577" | "6016443" | "6016448" | "6021350" | "6023629" | "6024699" | "6024720" | "6027445" | "6027479" | "6032059" | "6032667" | "6036924" | "6038469" | "6045567" | "6049727" | "6051389" | "6059946" | "6063637" | "6066088" | "6066448" | "6071391" | "6073031" | "6074775" | "6077299" | "6080583" | "6081735" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"6081736" | "6083523" | "6083710" |
"6088608" | "6090087" | "6091975" |
"6091976" | "6093156" | "6093172" |
"6099511" | "6103033" | "6107083" |
"6108577" | "6112116" | "6115622" |
"6115628" | "6115634" | "6117290" |
"6119028" | "6120676" | "6121009" |
"6121611" | "6122351" | "6122536" |
"6123827" | "6127154" | "6128519" |
"6128526" | "6134461" | "6135978" |
"6141573" | "6142939" | "6142979" |
"6143164" | "6144837" | "6144869" |
"6144871" | "6156051" | "6159147" |
"6159186" | "6161095" | "6162201" |
"6162611" | "6164921" | "6165154" |
"6165406" | "6167614" | "6168568" |
"6169155" | "6171276" | "6175752" |
"6175753" | "6180416" | "6183437" |
"6187062" | "6189536" | "6191860" |
"6197040" | "6200265" | "6200772" |
"6201980" | "6201993" | "6206856" |
"6208894" | "6212416" | "6212417" |
"6212424" | "6213739" | "6214185" |
"6219574" | "6223083" | "6223283" |
"6224562" | "6230059" | "6231320" |
"6231560" | "6231879" | "6233080" |
"6233486" | "6241863" | "6248067" |
"6248077" | "6248093" | "6249705" |
"6254586" | "6256522" | "6256538" |
"6259937" | "6261440" | "6263222" |
"6264606" | "6264825" | "6268161" |
"6269340" | "6270455" | "6270478" |
"6272364" | "6272379" | "6272480" |
"6274285" | "6275717" | "6280408" |
"6281015" | "6283761" | "6284125" |
"6284478" | "6293925" | "6294281" |
"6295506" | "6298254" | "6299578" |
"6299583" | "6299757" | "6300002" |
"6302855" | "6306104" | "6309351" |
"6309375" | "6309884" | "6312388" |
"6325978" | "6325979" | "6326160" |
"6329161" | "6329929" | "6330464" |
"6338790" | "6343225" | "6348640" |
"6356776" | "6358225" | "6359444" |
"6360888" | "6361503" | "6365670" |
"6366794" | "6368141" | "6368274" |
"6370941" | "6372244" | "6377828" |
"6377852" | "6377894" | "6379301" |
"6381493" | "6387048" | "6387709" |
"6391019" | "6400974" | "6402703" |
"6403944").PN.

L9	280	("6409674" | "6413393" | "6413396" | "6413410" | "6416651" | "6418332" | "6424847" | "6424861" | "6427088" | "6428123" | "6430437" | "6434430" | "6440068" | "6444115" | "6447448" | "6447542" | "6454710" | "6459917" | "6461496" | "6464849" | "6465066" | "6466810" | "6467480" | "6471689" | "6474360" | "6475372" | "6475750" | "6477392" | "6477395" | "6478736" | "6481440" | "6484045" | "6484046" | "6485449" | "6486661" | "6488652" | "6494879" | "6498043" | "6498941" | "6501976" | "6501983" | "6503381" | "6510329" | "6512939" | "6514460" | "6514718" | "6517508" | "6520326" | "6520477" | "6520937" | "6520997" | "6526298" | "6527729" | "6528318" | "6536433" | "6537318" | "6540891" | "6541266" | "6542765" | "6543195" | "6544212" | "6544229" | "6545085" | "6546268" | "6546269" | "6547839" | "6551494" | "6551496" | "6553241" | "6553244" | "6554805" | "6554822" | "6558320" | "6558321" | "6558347" | "6558351" | "6561978" | "6562001" | "6564105" | "6565509" | "6565535" | "6565807" | "6569309" | "6569521" | "6571128" | "6572542" | "6572545" | "6572579" | "6574490" | "6575905" | "6576101" | "6577899" | "6579257" | "6579498" | "6579690" | "6584335" | "6585644" | "6585675" | "6585763" | "6587705" | "6589229" | "6591125" | "6592745" | "6594514" | "6595756" | "6595919" | "6600940" | "6600997" | "6602221" | "6605072" | "6605200" | "6605201" | "6607509" | "6607658" | "6609071" | "6610012" | "6612984" | "6613379" | "6615061" | "6615078" | "6616819" | "6618603" | "6618934" | "6622045" | "6633772" | "6635014" | "6641533" | "6642015" | "6645181" | "6648821" | "6650471" | "6653091" | "6654625" | "6656114" | "6656157" | "6658396" | "6659948" | "6668196" | "6673022" | "6673596" | "6675030" | "6676816" | "6679865" | "6679872" | "6683535" | "6684904" | "6685668" | "6687522" | "6687546" | "6689056" | "6689089" | "6689265" | "6689413" | "6692457" | "6694191" | "6695860" | "6698269" | "6699188" | "6699218" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"6702249" | "6702857" | "6702972" | "6711423" | "6711424" | "6712796" | "6721582" | "6721587" | "6723086" | "6730200" | "6731976" | "6731985" | "6733446" | "6733655" | "6736783" | "6736957" | "6737158" | "6740075" | "6741877" | "6742635" | "6743635" | "6746582" | "6749587" | "6749591" | "6749740" | "6758810" | "6764581" | "6770030" | "6770067" | "6773671" | "6780297" | "6784274" | "6790178" | "6793632" | "6801041" | "6802957" | "6804002" | "6805693" | "6809653" | "6810290" | "6811533" | "6811534" | "6811548" | "6813519" | "6817990" | "6846654" | "6850790" | "6850859" | "6854317" | "6858020" | "6862465" | "6865407" | "6869413" | "6873268" | "6881551" | "6882940" | "6887228" | "6892085" | "6893396" | "6893545" | "6893552" | "6895263" | "6895265" | "6902544" | "6912413" | "6923763" | "6925393" | "6926691" | "6931327" | "6932584" | "6932892" | "6932894" | "6936006" | "6942518" | "6945965" | "6948492" | "6950708" | "6952604" | "6954662" | "6958705" | "6960192" | "6965791" | "6966325" | "6968294" | "6971274" | "6972080" | "6974437" | "6975893" | "6979315" | "6985870" | "6989891" | "6990366" | "6990422" | "6996427" | "6997907" | "6997921" | "6998247" | "7003336" | "7003340" | "7003341" | "7010345" | "7011630" | "7016713" | "7016720" | "7018361" | "7022072" | "7022219" | "7024245" | "7025425" | "7025727" | "7025743" | "7027848" | "7029443" | "7029444" | "7041068" | "7041209" | "7041468" | "7043287" | "7048727" | "7052472" | "7052483").PN.				
L10	280	("7056302" | "7060059" | "7061593" | "7062385" | "7063086" | "7066884" | "7070577" | "7070580" | "7074307" | "7074610" | "7076300" | "7078582" | "7081195" | "7092891" | "7096064" | "7097775" | "7098803" | "7100628" | "7110803" | "7115884" | "7120483" | "7123950" | "7131967" | "7135342" | "7149562" | "7150741" | "7153265" | "7153458" | "7167818" | "7169289" | "7171252" | "7171274" | "7183102" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

"7190988" | "7192450" | "7204823" |
"7207968" | "7207974" | "7211074" |
"7211439" | "7214190" | "7221970" |
"7223253" | "7225535" | "7226978" |
"7228162" | "7229288" | "7238165" |
"7244582" | "7247138" | "7247443" |
"7248912" | "7253680" | "7254450" |
"7255690" | "7258673" | "7258681" |
"7261690" | "7266400" | "7267665" |
"7268562" | "7272436" | "7273633" |
"7276029" | "7278983" | "7280879" |
"7288085" | "7288368" | "7289204" |
"7289836" | "7291496" | "7295867" |
"7297114" | "7299082" | "7303875" |
"7308292" | "7310544" | "7311690" |
"7312040" | "7313425" | "7314452" |
"7315752" | "7315767" | "7316662" |
"7317938" | "7317939" | "7318814" |
"7327273" | "7329234" | "7334594" |
"7335179" | "7335195" | "7335294" |
"7338464" | "7338639" | "7344499" |
"7344626" | "7351321" | "7354420" |
"7359723" | "7361155" | "7364562" |
"7364592" | "7365562" | "7366556" |
"7367942" | "7372277" | "7379765" |
"7381184" | "7384532" | "7387811" |
"7390667" | "7396353" | "7399277" |
"7402153" | "7402349" | "7407811" |
"7416802" | "7417164" | "7417729" |
"7422727" | "7424318" | "7425877" |
"7426408" | "7427338" | "7427560" |
"7429552" | "7433727" | "7460898" |
"7467003" | "7468125" | "7471972" |
"7474992" | "7488601" | "7494465" |
"7494816" | "7497827" | "7499002" |
"7501052" | "7502644" | "7517439" |
"7519478" | "7523004" | "7524287" |
"7525298" | "7529574" | "7547281" |
"7547382" | "7569030" | "7583990" |
"7591801" | "7599726" | "7604593" |
"7608042" | "7613491" | "7615007" |
"7618368" | "7618369" | "7620438" |
"7624028" | "7630748" | "7632228" |
"7635594" | "7637868" | "7640032" |
"7640048" | "7645374" | "7647237" |
"7653425" | "7654956" | "7695434" |
"7699775" | "7699964" | "7711493" |
"7715893" | "7731659" | "7736310" |
"7749445" | "7751864" | "7761126" |
"7761130" | "7766829" | "7766830" |
"7771352" | "7774038" | "7774145" |
"7775975" | "7776559" | "7778679" |
"7778680" | "7826981" | "7831287" |

		"7838639" | "7856613" | "7857760" | "7866025" | "7866026" | "7885697" | "7885698" | "7889069" | "7894870" | "7896809" | "7899511" | "7901354" | "7905833" | "7914450" | "7920906" | "7925321" | "7927274" | "7933639" | "7938797" | "7943034" | "7946984" | "7955261" | "7959569" | "7964089" | "7964146" | "7974672" | "7979104" | "7985330" | "7986986" | "7990828" | "7996158" | "7998071" | "8000763" | "8005524" | "8005525" | "8010174" | "8016997" | "8026104" | "8030942" | "8052601" | "8060173" | "8073519" | "8073520" | "8103471" | "8109850" | "8112240" | "8114268" | "8116837" | "8123920" | "8128562" | "8140312" | "8149117" | "8150488" | "8160670" | "8160671" | "8160834" | "8160900" | "8167801" | "8170803" | "8195265" | "8202491" | "8211016" | "8216137" | "8216138" | "8219173" | "8224415" | "8229536" | "8233959" | "8239166" | "8249683" | "8255026" | "8257259" | "8260393" | "8260558" | "8275438" | "8282549" | "8282550" | "8287453" | "8290559" | "8290562" | "8292810" | "8298142" | "8332008" | "8346335" | "8346337" | "8346338" | "8348923" | "8364230").PN.				
L11	103	("8364231" | "8369919" | "8372351" | "8374667" | "8376945" | "8396528" | "8412301" | "8417312" | "8423113" | "8423114" | "8425416" | "8425417" | "8428678" | "8428679" | "8435179" | "8442610" | "8444560" | "8447376" | "8449464" | "8457703" | "8461985" | "8463350" | "8473022" | "8475373" | "8478377" | "8478557" | "8484005" | "8491474" | "8509871" | "8515517" | "8527025" | "8532730" | "8532935" | "8543354" | "8560037" | "8560038" | "8562528" | "8571808" | "8583205" | "8593109" | "8600681" | "8612163" | "8626257" | "8657745" | "8657746" | "8663220" | "8665091" | "8682615" | "8718739" | "8718965" | "8744547" | "8774886" | "8868151" | "8868161" | "8911367" | "8933664" | "8942778" | "9060719" | "9113828" | "9125548" | "9135402" | "9149220" | "9161714" | "9247901" | "9314196" | "9320462" |	US-PGPUB; USPAT	OR	OFF	2021/02/24 19:02

		"9320468" | "9326709" | "9332934" | "9339217" | "9357959" | "9380971" | "9392969" | "9398872" | "9408566" | "9451908" | "9483608" | "9498155" | "9558325" | "9629578" | "9662056" | "9675290" | "9730623" | "9737249" | "9743863" | "9770211" | "9797880" | "9801571" | "9801575" | "9801577" | "9804148" | "9804150" | "9808190" | "9814428" | "9833181" | "9839383" | "9839395" | "9848809" | "9936910" | "RE31916" | "RE32361" | "RE43039" | "RE43399").PN.				
L12	14	l1 and calibrating near55 sensor near55 data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:06
L13	31	l1 and calibrating same sensor same data	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:06
L14	0	l13 and sensor same electronics same operably same connect$3 same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L15	0	l13 and sensor same electronics same connect$3 same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L16	6	l13 and sensor same electronics same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:08
L17	711	sensor same electronics same (connect$3 or fasten$3 or coupl$3) same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:14

L18	576	sensor same electronics same (connect$3) same transcutaneous same analyte same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:15
L19	41	sensor near5 electronics near5 (connect$3) near5 transcutaneous near5 analyte near5 sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/02/24 19:16

2/24/2021 7:17:06 PM

Bibliographic Data

Application No: 17/132,664

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☑ Met After Allowance

Verified and Acknowledged: /DANIEL PREVIL/ (Examiner's Signature) D.P (Initials)

Title: ANALYTE SENSOR

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
12/23/2020	073	2684	DEXCOM.167P1
RULE			

APPLICANTS

DexCom, Inc., San Diego, CA,

INVENTORS

Peter C. Simpson, Cardiff, CA, UNITED STATES

Ying Li, San Diego, CA, UNITED STATES

Apurv Ullas Kamath, San Diego, CA, UNITED STATES

Richard C. Yang, Carlsbad, CA, UNITED STATES

CONTINUING DATA

This application is a CIP of 17082627 10/28/2020

This application is a CIP of 17078609 10/23/2020

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

01/15/2021

STATE OR COUNTRY

UNITED STATES

ADDRESS

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614
UNITED STATES

FILING FEE RECEIVED

$8,260

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 1 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned Daniel Previl
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.P/	001	US-RE31916	06-18-1985	OSWIN; Harry G. et al.	
/D.P/	002	US-RE32361	02-24-1987	DUGGAN; Stephen R.	
	003	US-RE43039	12-20-2011	BRISTER; Mark et al.	
	004	US-RE43399	05-22-2012	SIMPSON; Peter C. et al.	
	005	US-52641	02-13-1866	GREGG; Brian A. et al.	
	006	US-62334	02-26-1867	BERNER; Bret et al.	
	007	US-65604	06-11-1867	HELLER; Adam et al.	
	008	US-1564641	12-08-1925	ST. JAMES; Robert T. et al.	
	009	US-2402306	06-18-1946	TURKEL; Henry	
	010	US-2719797	10-04-1955	ROSENBLATT; Edgar F. et al.	
	011	US-3210578	10-05-1965	SHERER; Glen H.	
	012	US-3219533	11-23-1965	MULLINS; John D.	
	013	US-3506032	04-14-1970	EVELEIGH; John William et al.	
	014	US-3539455	11-10-1970	CLARK, Jr.; Leland C.	
	015	US-3556950	01-19-1971	DAHMS; Harald	
	016	US-3581062	05-25-1971	ASTON; Keith	
	017	US-3610226	10-05-1971	ALBISSER; Anthony M.	
	018	US-3610230	10-05-1971	ANDERSEN; Harold Willids	
	019	US-3652475	03-28-1972	WADA; Tadashi et al.	
	020	US-3775182	11-27-1973	PATTON; Jimmie Donald et al.	
	021	US-3780727	12-25-1973	KING; Eugene	
	022	US-3791871	02-12-1974	ROWLEY; Leroy S.	
	023	US-3826244	07-30-1974	SALCMAN; Michael et al.	
	024	US-3837339	09-24-1974	AISENBERG; Sol et al.	
	025	US-3838033	09-24-1974	MINDT; W. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 2 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	026	US-3838682	10-01-1974	CLARK; Justin S. et al.	
	027	US-3874850	04-01-1975	SORENSEN; Soren Kai et al.	
	028	US-3898984	08-12-1975	MANDEL; Louis et al.	
	029	US-3910256	10-07-1975	CLARK; Justin S. et al.	
	030	US-3926760	12-16-1975	ALLEN; James S. et al.	
	031	US-3929971	12-30-1975	ROY; Della M.	
	032	US-3933593	01-20-1976	STERNBERG; James C.	
	033	US-3943918	03-16-1976	LEWIS; Ronald A.	
	034	US-3949388	04-06-1976	FULLER; Charles H.	
	035	US-3957613	05-18-1976	MACUR; Robert A.	
	036	US-3960497	06-01-1976	ACORD; William A.	
	037	US-3964974	06-22-1976	BANAUCH; Dieter et al.	
	038	US-3966580	06-29-1976	JANATA; Jiri A. et al.	
	039	US-3978856	09-07-1976	MICHEL; Walter A.	
	040	US-3979274	09-07-1976	NEWMAN; David P.	
	041	US-3982530	09-28-1976	STORCH; Egon	
	042	US-4008717	02-22-1977	KOWARSKI; Allen A.	
	043	US-4016866	04-12-1977	LAWTON; Richard W.	
	044	US-4024312	05-17-1977	KORPMAN; Ralf	
	045	US-4030640	06-21-1977	CITRIN; Paul S. et al.	
	046	US-4036749	07-19-1977	ANDERSON; Donald R.	
	047	US-4037563	07-26-1977	PFLUEGER; John M. et al.	
	048	US-4040908	08-09-1977	CLARK, Jr.; Leland C.	
	049	US-4052754	10-11-1977	HOMSY; Charles A.	
	050	US-4055175	10-25-1977	CLEMENS; Anton Hubert et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 3 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	051	US-4067322	01-10-1978	JOHNSON; Joseph H.	
	052	US-4073713	02-14-1978	NEWMAN; David P.	
	053	US-4076656	02-28-1978	WHITE; LeRoy A. et al.	
	054	US-4080292	03-21-1978	PRZYBYLOWICZ; Ryszard et al.	
	055	US-4109505	08-29-1978	CLARK; Justin S. et al.	
	056	US-4119406	10-10-1978	CLEMENS; Anton Hubert	
	057	US-4129128	12-12-1978	McFARLANE; Richard H.	
	058	US-4151845	05-01-1979	CLEMENS; Anton H.	
	059	US-4172770	10-30-1979	SEMERSKY; Frank E. et al.	
	060	US-4176659	12-04-1979	ROLFE; Peter	
	061	US-4197840	04-15-1980	BECK; Alexander et al.	
	062	US-4197852	04-15-1980	SCHINDLER; Johannes G. et al.	
	063	US-4206755	06-10-1980	KLEIN; Jean-Claude	
	064	US-4215703	08-05-1980	WILLSON; James K. V.	
	065	US-4240438	12-23-1980	UPDIKE; Stuart J. et al.	
	066	US-4240889	12-23-1980	YODA; Kentaro et al.	
	067	US-4245634	01-20-1981	ALBISSER; Anthony M. et al.	
	068	US-4253469	03-03-1981	ASLAN; Edward E.	
	069	US-4255500	03-10-1981	HOOKE; John W.	
	070	US-4259540	03-31-1981	SABIA; Raffaele A.	
	071	US-4265249	05-05-1981	SCHINDLER; Johannes G. et al.	
	072	US-4300572	11-17-1981	KNIGHTON; David R.	
	073	US-4327725	05-04-1982	CORTESE; Richard et al.	
	074	US-4344438	08-17-1982	SCHULTZ; Jerome S.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 4 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	075	US-4349728	09-14-1982	PHILLIPS; Robert B. et al.	
	076	US-4366040	12-28-1982	MARSONER; Hermann et al.	
	077	US-4369785	01-25-1983	REHKOPF; Paul G. et al.	
	078	US-4373527	06-27-1995	FISCHELL; Robert E.	
	079	US-4374013	02-15-1983	ENFORS; Sven-Olof	
	080	US-4378016	03-29-1983	LOEB; Marvin P.	
	081	US-4388166	06-14-1983	SUZUKI; Shuichi et al.	
	082	US-4392849	07-12-1983	PETRE; John H. et al.	
	083	US-4402694	09-06-1983	ASH; Stephen R. et al.	
	084	US-4403847	09-13-1983	CHRESTENSEN; Gene L.	
	085	US-4403984	09-13-1983	ASH; Stephen R. et al.	
	086	US-4407298	10-04-1983	LENTZ; David J. et al.	
	087	US-4415666	11-15-1983	D'ORAZIO; Paul A. et al.	
	088	US-4418148	11-29-1983	OBERHARDT; Bruce J.	
	089	US-4419535	12-06-1983	O'HARA; Robert J.	
	090	US-4420564	12-13-1983	TSUJI; Nobuhiko et al.	
	091	US-4425920	01-17-1984	BOURLAND; Joe D. et al.	
	092	US-4426621	01-17-1984	GALWEY; Ronald K. et al.	
	093	US-4431004	02-14-1984	BESSMAN; Samuel P. et al.	
	094	US-4431507	02-14-1984	NANKAI; Shiro et al.	
	095	US-4432366	02-21-1984	MARGULES; Gary S.	
	096	US-4436094	03-13-1984	CERAMI; Anthony	
	097	US-4441968	04-10-1984	EMMER; Ivan et al.	
	098	US-4442841	04-17-1984	UEHARA; Masaru et al.	
	099	US-4448188	05-15-1984	LOEB; Marvin P.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 5 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	100	US-4454295	06-12-1984	WITTMANN; Joseph W. et al.	
	101	US-4457339	07-03-1984	JUAN; Juan J. S. et al.	
	102	US-4462048	07-24-1984	ROSS; Michael D.	
	103	US-4478222	10-23-1984	KONING; Gerrit et al.	
	104	US-4478976	10-23-1984	GOERTZ; Hans-Helmut et al.	
	105	US-4484987	11-27-1984	GOUGH; David A.	
	106	US-4486290	12-04-1984	CAHALAN; Patrick T. et al.	
	107	US-4492575	01-08-1985	MABILLE; Pierre	
	108	US-4494950	01-22-1985	FISCHELL; Robert E.	
	109	US-4496454	01-29-1985	BERGER; Terry A.	
	110	US-4506680	03-26-1985	STOKES; Kenneth B.	
	111	US-4509531	04-09-1985	WARD; John W.	
	112	US-4519973	05-28-1985	CAHALAN; Patrick T. et al.	
	113	US-4526569	07-02-1985	BERNARDI; Luigi	
	114	US-4527240	07-02-1985	KVITASH; Vadim I.	
	115	US-4534355	08-13-1985	POTTER; William D.	
	116	US-4534825	08-13-1985	KONING; Gerrit et al.	
	117	US-4535786	08-20-1985	KATER; John A. R.	
	118	US-4538616	09-03-1985	ROGOFF; Robert	
	119	US-4545382	10-08-1985	HIGGINS; Irving J. et al.	
	120	US-4554927	11-26-1985	FUSSELL; Theodore J.	
	121	US-4561963	12-31-1985	OWEN; Jeffrey D. et al.	
	122	US-4565665	01-21-1986	FOGT; Eric J.	
	123	US-4565666	01-21-1986	CAHALAN; Patrick T. et al.	
	124	US-4568444	02-04-1986	NAKAMURA; Michihiro et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 6 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	125	US-4571292	02-18-1986	LIU; Chung-Chiun et al.	
	126	US-4573968	03-04-1986	PARKER; Kenneth B.	
	127	US-4577642	03-25-1986	STOKES; Kenneth B.	
	128	US-4578215	03-25-1986	BRADLEY; Robert F.	
	129	US-4583976	04-22-1986	FERGUSON; Keith T.	
	130	US-4592824	06-03-1986	SMITH; Rosemary L. et al.	
	131	US-4600495	07-15-1986	FOGT; Eric J.	
	132	US-4613328	09-23-1986	BOYD; Cecil	
	133	US-4614514	09-30-1986	CARR; Kenneth L. et al.	
	134	US-4619793	10-28-1986	LEE; Ping I.	
	135	US-4626104	12-02-1986	POINTON; Ronald H. et al.	
	136	US-4650547	03-17-1987	GOUGH; David A.	
	137	US-4655880	04-07-1987	LIU; Chung-Chiun	
	138	US-4663824	05-12-1987	KENMOCHI; Kazuei	
	139	US-4670007	06-02-1987	WHEELDON; Peter G. et al.	
	140	US-4671288	06-09-1987	GOUGH; David A.	
	141	US-4672970	06-16-1987	UCHIDA; Teruyoshi et al.	
	142	US-4680268	07-14-1987	CLARK, Jr.; Leland	
	143	US-4685463	08-11-1987	WILLIAMS; R. Bruce	
	144	US-4685903	08-11-1987	CABLE; Vaughn P. et al.	
	145	US-4685912	08-11-1987	JONES; J. Paul	
	146	US-4686044	08-11-1987	BEHNKE; Joachim et al.	
	147	US-4689309	08-25-1987	JONES; James E.	
	148	US-4694861	09-22-1987	GOODALE; David L. et al.	
	149	US-4703756	11-03-1987	GOUGH; David A. et al.	
	150	US-4705503	11-10-1987	DORMAN; Frank D. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 7 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	151	US-4711245	12-08-1987	HIGGINS; Irving J. et al.	
	152	US-4711251	12-08-1987	STOKES; Kenneth B.	
	153	US-4721677	01-26-1988	CLARK, Jr.; Leland C.	
	154	US-4731051	03-15-1988	FISCHELL; Robert E.	
	155	US-4731726	03-15-1988	ALLEN, III; Lyle M.	
	156	US-4736748	04-12-1988	NAKAMURA; Michihiro et al.	
	157	US-4747822	05-31-1988	PEABODY; Alan M.	
	158	US-4749985	06-07-1988	CORSBERG; Daniel R.	
	159	US-4750496	06-14-1988	REINHART; Richard et al.	
	160	US-4752935	06-21-1988	BECK; Rasmus	
	161	US-4753652	06-28-1988	LANGER; Robert et al.	
	162	US-4755168	07-05-1988	ROMANELLI; Pat et al.	
	163	US-4757022	07-12-1988	SHULTS; Mark C. et al.	
	164	US-4759366	07-26-1988	CALLAGHAN; Frank J.	
	165	US-4759828	07-26-1988	YOUNG; Chung C. et al.	
	166	US-4763648	08-16-1988	WYATT; Philip	
	167	US-4776944	10-11-1988	JANATA; Jiri et al.	
	168	US-4777953	10-18-1988	ASH; Stephen R. et al.	
	169	US-4779618	10-25-1988	MUND; Konrad et al.	
	170	US-4781798	11-01-1988	GOUGH; David A.	
	171	US-4783250	11-08-1988	PONS; B. Stanley et al.	
	172	US-4784157	11-15-1988	HALLS; Justin A. T. et al.	
	173	US-4786394	11-22-1988	ENZER; Steven et al.	
	174	US-4787398	11-29-1988	GARCIA; Fernando S. et al.	
	175	US-4789467	12-06-1988	LINDSAY; Edward R. et al.	
	176	US-4791932	12-20-1988	MARGULES; Gary S.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 8 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	177	US-4800495	01-24-1989	SMITH; Robert E.	
	178	US-4803243	02-07-1989	FUJIMOTO; Teruo et al.	
	179	US-4805624	02-21-1989	YAO; Shang J. et al.	
	180	US-4805625	02-21-1989	WYLER; Allen R.	
	181	US-4808089	02-28-1989	BUCHHOLTZ; Gerhard et al.	
	182	US-4808292	02-28-1989	KESSLER; Manfred et al.	
	183	US-4809704	03-07-1989	SOGAWA; Ichiro et al.	
	184	US-4810243	03-07-1989	HOWSON; David C.	
	185	US-4810470	03-07-1989	BURKHARDT; Alan E. et al.	
	186	US-4813423	03-21-1989	MIYASAKA; Katsuyuki et al.	
	187	US-4815471	03-28-1989	STOBIE; John J.	
	188	US-4820281	04-11-1989	LAWLER; Casimir E.	
	189	US-4822336	04-18-1989	DiTRAGLIA; John	
	190	US-4828544	05-09-1989	LANE; Rodney J. et al.	
	191	US-4830013	05-16-1989	MAXWELL; Thomas P.	
	192	US-4831070	05-16-1989	McINALLY; Linda J. et al.	
	193	US-4832005	05-23-1989	TAKAMIYA; Sanshiro et al.	
	194	US-4834101	05-30-1989	COLLISON; Michael E. et al.	
	195	US-4838281	06-13-1989	ROGERS; Wayne W. et al.	
	196	US-4841974	06-27-1989	GUMBRECHT; Walter et al.	
	197	US-4849458	07-18-1989	REED; Andrew M. et al.	
	198	US-4852573	08-01-1989	KENNEDY; Philip R.	
	199	US-4854322	08-08-1989	ASH; Stephen R. et al.	
	200	US-4858615	08-22-1989	MEINEMA; Ate. J.	
	201	US-4861454	08-29-1989	USHIZAWA; Norihiko et al.	
	202	US-4861830	08-29-1989	WARD, Jr.; Robert S.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 9 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	203	US-4863265	09-05-1989	FLOWER; Ronald J. et al.	
	204	US-4867741	09-19-1989	PORTNOY; Harold D.	
	205	US-4871351	10-03-1989	FEINGOLD; Vladimir	
	206	US-4871440	10-03-1989	NAGATA; Yasuhiro et al.	
	207	US-4874363	10-17-1989	ABELL; Walter L.	
	208	US-4883057	11-28-1989	BRODERICK; Patricia A.	
	209	US-4883467	11-28-1989	FRANETZKI; Manfred et al.	
	210	US-4889528	12-26-1989	NADAI; Tanekazu et al.	
	211	US-4889744	12-26-1989	QUAID; Joel	
	212	US-4890620	01-02-1990	GOUGH; David A.	
	213	US-4890621	01-02-1990	HAKKY; Said I.	
	214	US-4898578	02-06-1990	RUBALCABA, Jr.; Bernardino	
	215	US-4900305	02-13-1990	SMITH; Timothy J. N. et al.	
	216	US-4902294	02-20-1990	GOSSEREZ; Olivier	
	217	US-4907857	03-13-1990	GIULIANI; David et al.	
	218	US-4909786	03-20-1990	GIJSELHART; Paulus H. P. M. et al.	
	219	US-4919141	04-24-1990	ZIER; Horst D. et al.	
	220	US-4919649	04-24-1990	TIMOTHY; Earle J. et al.	
	221	US-4921477	05-01-1990	DAVIS; Rickey P.	
	222	US-4921480	05-01-1990	SEALFON; Andrew I.	
	223	US-4923819	05-08-1990	FERNANDEZ; Salvador M. et al.	
	224	US-4925268	05-15-1990	IYER; Lokanathan M. et al.	
	225	US-4925444	05-15-1990	ORKIN; Fredric I. et al.	
	226	US-4927407	05-22-1990	DORMAN; Frank	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 10 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	227	US-4927516	05-22-1990	YAMAGUCHI; Shuichiro et al.	
	228	US-4928694	05-29-1990	MAXWELL; Thomas P.	
	229	US-4934369	06-19-1990	MAXWELL; Thomas P.	
	230	US-4934375	06-19-1990	COLE; James E. et al.	
	231	US-4935345	06-19-1990	GUILBEAU; Eric J. et al.	
	232	US-4944299	07-31-1990	SILVIAN; Sergiu	
	233	US-4946439	08-07-1990	EGGERS; Philip N. et al.	
	234	US-4947845	08-14-1990	DAVIS; Mark W.	
	235	US-4951669	08-28-1990	MAXWELL; Thomas P. et al.	
	236	US-4953552	09-04-1990	DeMARZO; Arthur P.	
	237	US-4955861	09-11-1990	ENEGREN; Bradley J. et al.	
	238	US-4957483	09-18-1990	GONSER; Donald I. et al.	
	239	US-4958148	09-18-1990	OLSON; Jan B.	
	240	US-4963131	10-16-1990	WORTRICH; Theodore S.	
	241	US-4963595	10-16-1990	WARD; Robert S. et al.	
	242	US-4966579	10-30-1990	POLASCHEGG; Hans-Dietrich	
	243	US-4967940	11-06-1990	BLETTE; Russell E. et al.	
	244	US-4974592	12-04-1990	BRANCO; Flavio S. C.	
	245	US-4974929	12-04-1990	CURRY; Kenneth M.	
	246	US-4975175	12-04-1990	KARUBE; Isao et al.	
	247	US-4975636	12-04-1990	DESAUTELS; Patricia A.	
	248	US-4976687	12-11-1990	MARTIN; James	
	249	US-4979509	12-25-1990	HAKKY; Said I.	
	250	US-4984929	01-15-1991	ROCK; Erich et al.	
	251	US-4986271	01-22-1991	WILKINS; Ebtisam S.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 11 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	252	US-4986671	01-22-1991	SUN; Mei H. et al.	
	253	US-4988341	01-29-1991	COLUMBUS; Richard L. et al.	
	254	US-4988671	01-29-1991	JOHNSON; Robert E.	
	255	US-4988758	01-29-1991	FUKUDA; Takeshi et al.	
	256	US-4994026	02-19-1991	FECONDINI; Luciano	
	257	US-4994167	02-19-1991	SHULTS; Mark G. et al.	
	258	US-4995402	02-26-1991	SMITH; Roger E. et al.	
	259	US-4997627	03-05-1991	BERGKUIST; Carolyn et al.	
	260	US-5000180	03-19-1991	KUYPERS; Martinus H. et al.	
	261	US-5000419	03-19-1991	PALMER; Davey B. et al.	
	262	US-5002054	03-26-1991	ASH; Stephen R. et al.	
	263	US-5002055	03-26-1991	MERKI; Hans S. et al.	
	264	US-5002572	03-26-1991	PICHA; George J.	
	265	US-5006050	04-09-1991	COOKE; James E. et al.	
	266	US-5006111	04-09-1991	INOKUCHI; Kiyoshi et al.	
	267	US-5007929	04-16-1991	QUAID; Joel	
	268	US-5009251	04-23-1991	PIKE; Kelly A. et al.	
	269	US-5019974	05-28-1991	BECKERS; Andreas G. F.	
	270	US-5026348	06-25-1991	VENEGAS; Jose G.	
	271	US-5030199	07-09-1991	BARWICK; Carl B. et al.	
	272	US-5030333	07-09-1991	CLARK, Jr.; Leland	
	273	US-5034112	07-23-1991	MURASE; Isao et al.	
	274	US-5041092	08-20-1991	BARWICK; Carl	
	275	US-5045057	09-03-1991	VAN DRIESSCHE; Petrus J. D. M. et al.	
	276	US-5046496	09-10-1991	BETTS; Ronald E. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 12 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	277	US-5048525	09-17-1991	MAXWELL; Thomas P.	
	278	US-5050612	09-24-1991	MATSUMURA; Kenneth N.	
	279	US-5055171	10-08-1991	PECK; Robert L.	
	280	US-5055198	10-08-1991	SHETTIGAR; U. Ramakrishna	
	281	US-5059654	10-22-1991	HOU; Kenneth C. et al.	
	282	US-5067491	11-26-1991	TAYLOR, II; Maylon S. et al.	
	283	US-5068536	11-26-1991	ROSENTHAL; Robert D.	
	284	US-5077476	12-31-1991	ROSENTHAL; Robert D.	
	285	US-5082147	01-21-1992	JACOBS; Richard	
	286	US-5082550	01-21-1992	RISHPON; Judith et al.	
	287	US-5088981	02-18-1992	HOWSON; David C. et al.	
	288	US-5089112	02-18-1992	SKOTHEIM; Terje A. et al.	
	289	US-5089421	02-18-1992	DIEFFENBACH; Susan	
	290	US-5096669	03-17-1992	LAUKS; Imants R. et al.	
	291	US-5097834	03-24-1992	SKRABAL; Falko	
	292	US-5098377	03-24-1992	BORSANYI; Alexander et al.	
	293	US-5101814	04-07-1992	PALTI; Yoram	
	294	US-5106365	04-21-1992	HERNANDEZ; Luis	
	295	US-5108819	04-28-1992	HELLER; James W. et al.	
	296	US-5109850	05-05-1992	BLANCO; Ernesto E. et al.	
	297	US-5109860	05-05-1992	GELLY; Jean-Francois et al.	
	298	US-5112301	05-12-1992	FENTON, Jr.; Paul V. et al.	
	299	US-5112455	05-12-1992	COZZETTE; Stephen N. et al.	
	300	US-5113869	05-19-1992	NAPPHOLZ; Tibor A. et al.	
	301	US-5114859	05-19-1992	KAGENOW; Henrik	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 13 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	302	US-5116313	05-26-1992	McGREGOR; Gavin	
	303	US-5122925	06-16-1992	INPYN; Carl A.	
	304	US-5127405	07-07-1992	ALCALA; J. Ricardo et al.	
	305	US-5135004	08-04-1992	ADAMS; John M. et al.	
	306	US-5137028	08-11-1992	NISHIMURA; Kinji	
	307	US-5140985	08-25-1992	SCHROEDER; Jon M. et al.	
	308	US-5145565	09-08-1992	KATER; John et al.	
	309	US-5148812	09-22-1992	VERRIER; Richard L. et al.	
	310	US-5152746	10-06-1992	ATKINSON; Robert W. et al.	
	311	US-5156972	10-20-1992	ISSACHAR; David	
	312	US-5158437	10-27-1992	NATWICK; Vernon R. et al.	
	313	US-5160418	11-03-1992	MULLEN; William H.	
	314	US-5161532	11-10-1992	JOSEPH; Jose P.	
	315	US-5165406	11-24-1992	WONG; David K.	
	316	US-5165407	11-24-1992	WILSON; George S. et al.	
	317	US-5171689	12-15-1992	KAWAGURI; Mariko et al.	
	318	US-5174291	12-29-1992	SCHOONEN; Adelbert J. M. et al.	
	319	US-5176632	01-05-1993	BERNARDI; Luigi	
	320	US-5176658	01-05-1993	RANFORD; Alan B.	
	321	US-5178142	01-12-1993	HARJUNMAA; Hannu et al.	
	322	US-5178957	01-12-1993	KOLPE; Vasant V. et al.	
	323	US-5182004	01-26-1993	KOHNO; Takeshi	
	324	US-5188591	02-23-1993	DORSEY, III; James H.	
	325	US-5190041	03-02-1993	PALTI; Yoram	
	326	US-5195963	03-23-1993	YAFUSO; Masao et al.	
	327	US-5198771	03-30-1993	FIDLER; John C. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 14 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	328	US-5199428	04-06-1993	OBEL; Israel W. P. et al.	
	329	US-5202261	04-13-1993	MUSHO; Matthew K. et al.	
	330	US-5203326	04-20-1993	COLLINS; Kenneth A.	
	331	US-5204264	04-20-1993	KAMINER; Jon J.	
	332	US-5207642	05-04-1993	ORKIN; Fredric I. et al.	
	333	US-5208147	05-04-1993	KAGENOW; Henrik et al.	
	334	US-5210778	05-11-1993	MASSART; Desire J. L.	
	335	US-5216598	06-01-1993	BRANSTETTER; Ronald L. et al.	
	336	US-5219279	06-15-1993	NATWICK; Vernon R. et al.	
	337	US-5220917	06-22-1993	CAMMILLI; Leonardo et al.	
	338	US-5220920	06-22-1993	GHARIB; James	
	339	US-5224929	07-06-1993	REMISZEWSKI; Stanley H.	
	340	US-5225063	07-06-1993	GUMBRECHT; Walter et al.	
	341	US-5231988	08-03-1993	WERNICKE; Joachim F. et al.	
	342	US-5232434	08-03-1993	INAGAKI; Yoshitaka et al.	
	343	US-5235003	08-10-1993	WARD; Robert S. et al.	
	344	US-5237123	08-17-1993	MILLER; James M.	
	345	US-5243696	09-07-1993	CARR; Daniel J. et al.	
	346	US-5243982	09-14-1993	MOSTL; Anton et al.	
	347	US-5243983	09-14-1993	TARR; Randall V. et al.	
	348	US-5246867	09-21-1993	LAKOWICZ; Joseph R. et al.	
	349	US-5248300	09-28-1993	BRYANT; Peter L. et al.	
	350	US-5249576	10-05-1993	GOLDBERGER; Daniel S. et al.	
	351	US-5254102	10-19-1993	OGAWA; Genshiro	
	352	US-5262035	11-16-1993	GREGG; Brian A. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 15 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	353	US-5262305	11-16-1993	HELLER; Adam et al.	
	354	US-5264103	11-23-1993	YOSHIOKA; Toshihiko et al.	
	355	US-5264105	11-23-1993	GREGG; Brian A. et al.	
	356	US-5265594	11-30-1993	OLSSON; Sven-Gunnar et al.	
	357	US-5266179	11-30-1993	NANKAI; Shiro et al.	
	358	US-5269891	12-14-1993	COLIN; Fernand J. G.	
	359	US-5271736	12-21-1993	PICHA; George J.	
	360	US-5271815	12-21-1993	WONG; David K.	
	361	US-5275169	01-04-1994	AFROMOWITZ; Martin A. et al.	
	362	US-5279294	01-18-1994	ANDERSON; Paul J. et al.	
	363	US-5281319	01-25-1994	KANEKO; Hiroko et al.	
	364	US-5282844	02-01-1994	STOKES; Kenneth B. et al.	
	365	US-5282848	02-01-1994	SCHMITT; Peter J.	
	366	US-5284140	02-08-1994	ALLEN; Douglas J. et al.	
	367	US-5284570	02-08-1994	SAVAGE; Douglas R. et al.	
	368	US-5285513	02-08-1994	KAUFMAN; Stanley et al.	
	369	US-5285792	02-15-1994	SJOQUIST; Steven E. et al.	
	370	US-5287753	02-22-1994	ROUTH; Helen F. et al.	
	371	US-5293877	03-15-1994	O'HARA; Gary J. et al.	
	372	US-5298022	03-29-1994	BERNARDI; Luigi	
	373	US-5298144	03-29-1994	SPOKANE; Robert B.	
	374	US-5299571	04-05-1994	MASTROTOTARO; John J.	
	375	US-5302093	04-12-1994	OWENS; Dana J. et al.	
	376	US-5304468	04-19-1994	PHILLIPS; Roger et al.	
	377	US-5307263	04-26-1994	BROWN; Stephen J.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 16 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	378	US-5310469	05-10-1994	CUNNINGHAM; David D. et al.	
	379	US-5311908	05-17-1994	BARONE; David et al.	
	380	US-5312361	05-17-1994	ZADINI; Filiberto P. et al.	
	381	US-5313953	05-24-1994	YOMTOV; Barry M. et al.	
	382	US-5314471	05-24-1994	BRAUKER; James H. et al.	
	383	US-5315993	05-31-1994	ALCALA; J. Ricardo	
	384	US-5316008	05-31-1994	SUGA; Fusao et al.	
	385	US-5316452	05-31-1994	BOGEN; Steven A. et al.	
	386	US-5318511	06-07-1994	RIQUIER; Jean-Claude et al.	
	387	US-5320715	06-14-1994	BERG; Lloyd	
	388	US-5320725	06-14-1994	GREGG; Brian A. et al.	
	389	US-5321392	06-14-1994	SKAKOON; James G. et al.	
	390	US-5322063	06-21-1994	ALLEN; Douglas J. et al.	
	391	US-5324322	06-28-1994	GRILL, Jr.; Warren M. et al.	
	392	US-5324328	06-28-1994	LI; Hong et al.	
	393	US-5326356	07-05-1994	DELLA VALLE; Francesco et al.	
	394	US-5326449	07-05-1994	CUNNINGHAM; David D.	
	395	US-5328460	07-12-1994	LORD; Peter C. et al.	
	396	US-5330521	07-19-1994	COHEN; Donald M.	
	397	US-5330634	07-19-1994	WONG; David K. et al.	
	398	US-5331555	07-19-1994	HASHIMOTO; Katsuhiko et al.	
	399	US-5335658	08-09-1994	BEDINGHAM; William	
	400	US-5337747	08-16-1994	NEFTEL; Frederic	
	401	US-5340722	08-23-1994	WOLFBEIS; Otto S. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 17 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	402	US-5342409	08-30-1994	MULLETT; Keith R.	
	403	US-5342789	08-30-1994	CHICK; William L. et al.	
	404	US-5343869	09-06-1994	PROSS; Gerhard et al.	
	405	US-5345932	09-13-1994	YAFUSO; Masao et al.	
	406	US-5348788	09-20-1994	WHITE; Eugene W.	
	407	US-5352348	10-04-1994	YOUNG; Chung Chang et al.	
	408	US-5352349	10-04-1994	INAMOTO; Tomoyuki et al.	
	409	US-5352351	10-04-1994	WHITE; Bradley E. et al.	
	410	US-5354272	10-11-1994	SWENDSON; David L. et al.	
	411	US-5354449	10-11-1994	BAND; David M. et al.	
	412	US-5356217	10-18-1994	SHEFFIELD; Gary S.	
	413	US-5356375	10-18-1994	HIGLEY; Robert E.	
	414	US-5356378	10-18-1994	DOAN; David B.	
	415	US-5356786	10-18-1994	HELLER; Adam et al.	
	416	US-5360404	11-01-1994	NOVACEK; Laurel A. et al.	
	417	US-5365426	11-15-1994	SIEGEL; John H. et al.	
	418	US-5368224	11-29-1994	RICHARDSON; Charles A. et al.	
	419	US-5368562	11-29-1994	BLOMQUIST; Michael L. et al.	
	420	US-5372133	12-13-1994	HOGEN ESCH; Johannes H. L.	
	421	US-5372135	12-13-1994	MENDELSON; Yitzhak et al.	
	422	US-5372427	12-13-1994	PADOVANI; Francois A. et al.	
	423	US-5372709	12-13-1994	HOOD; Robert G.	
	424	US-5376070	12-27-1994	PURVIS; Richard E. et al.	
	425	US-5378229	01-03-1995	LAYER; James et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 18 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	426	US-5379238	01-03-1995	STARK; Edward W.	
	427	US-5380268	01-10-1995	WHEELER; Douglas E.	
	428	US-5380491	01-10-1995	CARVER, Jr.; Edward L. et al.	
	429	US-5380536	01-10-1995	HUBBELL; Jeffrey A. et al.	
	430	US-5380665	01-10-1995	CUSACK; Robert F. et al.	
	431	US-5384028	01-24-1995	ITO; Narushi	
	432	US-5384547	01-24-1995	LYNK, Jr.; Charles N. et al.	
	433	US-5390671	02-21-1995	LORD; Peter C. et al.	
	434	US-5391250	02-21-1995	CHENEY, II; Paul S. et al.	
	435	US-5397848	03-14-1995	YANG; Shin-Liang S. et al.	
	436	US-5398682	03-21-1995	LYNN; Lawrence A.	
	437	US-5400795	03-28-1995	MURPHY; Anthony J. et al.	
	438	US-5408999	04-25-1995	SINGH; Raghuvir et al.	
	439	US-5409666	04-25-1995	NAGEL; Colleen C. et al.	
	440	US-5411052	05-02-1995	MURRAY; Charles G.	
	441	US-5411551	05-02-1995	WINSTON; Thomas R. et al.	
	442	US-5411647	05-02-1995	JOHNSON; Kirk W. et al.	
	443	US-5411866	05-02-1995	LUONG; John H. T. et al.	
	444	US-5417206	05-23-1995	KANEYOSHI; Akio	
	445	US-5421328	06-06-1995	BEDINGHAM; William	
	446	US-5422829	06-06-1995	POLLOCK; Eugene J.	
	447	US-5423738	06-13-1995	ROBINSON; Thomas C. et al.	
	448	US-5423749	06-13-1995	MERTE; Kenneth E. et al.	
	449	US-5425375	06-20-1995	CHIN; Donald et al.	
	450	US-5425717	06-20-1995	MOHIUDDIN; Mahmood	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 19 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	451	US-5425749	06-20-1995	ADAMS; Theodore P.	
	452	US-5425868	06-20-1995	PEDERSEN; Knud G.	
	453	US-5428123	06-27-1995	WARD; Robert S. et al.	
	454	US-5429485	07-04-1995	DODGE; Larry H.	
	455	US-5429602	07-04-1995	HAUSER; Jean-Luc	
	456	US-5429735	07-04-1995	JOHNSON; Larry D. et al.	
	457	US-5431160	07-11-1995	WILKINS; Ebtisam S.	
	458	US-5431174	07-11-1995	KNUTE; Wallace L.	
	459	US-5431921	07-11-1995	THOMBRE; Avinash G.	
	460	US-5434412	07-18-1995	SODICKSON; Lester et al.	
	461	US-5437635	08-01-1995	FIELDS; Antony et al.	
	462	US-5438983	08-08-1995	FALCONE; Ronald	
	463	US-5445610	08-29-1995	EVERT; Carl F.	
	464	US-5448992	09-12-1995	KUPERSHMIDT; Vladimir	
	465	US-5453278	09-26-1995	CHAN; Eddie K. M. et al.	
	466	US-5462051	10-31-1995	OKA; Tohru et al.	
	467	US-5462064	10-31-1995	D'ANGELO; Joseph P. et al.	
	468	US-5462645	10-31-1995	ALBERY; John W. et al.	
	469	US-5466348	11-14-1995	HOLM-KENNEDY; James W.	
	470	US-5469846	11-28-1995	KHAN; Shahed U. M.	
	471	US-5472317	12-05-1995	FIELD; Jeffrey F. et al.	
	472	US-5474552	12-12-1995	PALTI; Yoram	
	473	US-5476094	12-19-1995	ALLEN; Douglas J. et al.	
	474	US-5476776	12-19-1995	WILKINS; Ebtisam S.	
	475	US-5482446	01-09-1996	WILLIAMSON; Mark E. et al.	
	476	US-5482473	01-09-1996	LORD; Peter C. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 20 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	477	US-5484404	01-16-1996	SCHULMAN; Joseph H. et al.	
	478	US-5486776	01-23-1996	CHIANG; David	
	479	US-5489414	02-06-1996	SCHREIBER; Joerg et al.	
	480	US-5491474	02-13-1996	SUNI; Jouko et al.	
	481	US-5494562	02-27-1996	MALEY; Thomas C. et al.	
	482	US-5496273	03-05-1996	PASTRONE; Giovanni et al.	
	483	US-5496453	03-05-1996	UENOYAMA; Harumi et al.	
	484	US-5497772	03-12-1996	SCHULMAN; Joseph H. et al.	
	485	US-5502396	03-26-1996	DESARZENS; Pierre et al.	
	486	US-5505828	04-09-1996	WONG; David K. et al.	
	487	US-5507288	07-08-1997	BOCKER; Dirk et al.	
	488	US-5508203	04-16-1996	FULLER; Milton E. et al.	
	489	US-5509410	04-23-1996	HILL; Hugh A. O. et al.	
	490	US-5509888	04-23-1996	MILLER; Paul L.	
	491	US-5512046	04-30-1996	PUSINELLI; Thomas et al.	
	492	US-5512246	04-30-1996	RUSSELL; Anthony P. et al.	
	493	US-5512248	04-30-1996	VAN; Jack F. J.	
	494	US-5513636	05-07-1996	PALTI; Yoram	
	495	US-5514253	05-07-1996	DAVIS; Graham et al.	
	496	US-5514718	05-07-1996	LEWIS; Richard T. et al.	
	497	US-5515851	05-14-1996	GOLDSTEIN; James A.	
	498	US-5517313	05-14-1996	COLVIN, Jr.; Arthur E.	
	499	US-5518601	05-21-1996	FOOS; Joseph S. et al.	
	500	US-5520191	05-28-1996	KARLSSON; Per et al.	
	501	US-5522798	06-04-1996	JOHNSON; Noel L. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 21 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	502	US-5529676	06-25-1996	MALEY; Thomas C. et al.	
	503	US-5531679	07-02-1996	SCHULMAN; Joseph H. et al.	
	504	US-5531878	07-02-1996	VADGAMA; Pankaj M. et al.	
	505	US-5540828	07-30-1996	YACYNYCH; Alexander	
	506	US-5543326	08-06-1996	HELLER; Adam et al.	
	507	US-5545220	08-13-1996	ANDREWS; Winston A. et al.	
	508	US-5547470	08-20-1996	JOHNSON; Noel L. et al.	
	509	US-5548569	08-20-1996	SHIMIZUME; Kazutoshi et al.	
	510	US-5549547	08-27-1996	COHEN; Herbert et al.	
	511	US-5549548	08-27-1996	LARSSON; Rolf	
	512	US-5549569	08-27-1996	LYNN; Lawrence A. et al.	
	513	US-5549651	08-27-1996	LYNN; Lawrence A.	
	514	US-5551850	09-03-1996	WILLIAMSON; Mark E. et al.	
	515	US-5552997	09-03-1996	MASSART; Desire J. L.	
	516	US-5553616	09-10-1996	HAM; Fredric M. et al.	
	517	US-5554339	09-10-1996	COZZETTE; Stephen N. et al.	
	518	US-5562614	10-08-1996	O'DONNELL; Joseph A.	
	519	US-5562615	10-08-1996	NASSIF; George A.	
	520	US-5564439	10-15-1996	PICHA; George J.	
	521	US-5568400	10-22-1996	STARK; Edward W. et al.	
	522	US-5568806	10-29-1996	CHENEY, II; Paul S. et al.	
	523	US-5569186	10-29-1996	LORD; Peter C. et al.	
	524	US-5569188	10-29-1996	MACKOOL; Richard J.	
	525	US-5569219	10-29-1996	HAKKI; A-Hamid et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 22 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	526	US-5571395	11-05-1996	PARK; Je Kyun et al.	
	527	US-5575930	11-19-1996	TIETJE-GIRAULT; Jordis et al.	
	528	US-5577499	11-26-1996	TEVES; Leonides Y.	
	529	US-5582184	12-10-1996	ERICKSON; Brian J. et al.	
	530	US-5582497	12-10-1996	NOGUCHI; Hirokazu	
	531	US-5582593	12-10-1996	HULTMAN; Barry W.	
	532	US-5582697	12-10-1996	IKEDA; Shin et al.	
	533	US-5584813	12-17-1996	LIVINGSTON; John H. et al.	
	534	US-5584876	12-17-1996	BRUCHMAN; William C. et al.	
	535	US-5586553	12-24-1996	HALILI; Edgardo C. et al.	
	536	US-5588560	12-31-1996	BENEDICT; Dale G. et al.	
	537	US-5589563	12-31-1996	WARD; Robert S. et al.	
	538	US-5590651	01-07-1997	SHAFFER; Thomas H. et al.	
	539	US-5593440	01-14-1997	BRAUKER; James H. et al.	
	540	US-5593852	01-14-1997	HELLER; Adam et al.	
	541	US-5601435	02-11-1997	QUY; Roger J.	
	542	US-5605152	02-25-1997	SLATE; John B. et al.	
	543	US-5606152	02-25-1997	HIGASHIURA; Atsushi et al.	
	544	US-5609572	03-11-1997	LANG; Volker	
	545	US-5609575	03-11-1997	LARSON; Stella D. et al.	
	546	US-5611900	03-18-1997	WORDEN; R. Mark et al.	
	547	US-5615671	04-01-1997	SCHOONEN; Adelbert J. M. et al.	
	548	US-5620579	04-15-1997	GENSHAW; Marvin A. et al.	
	549	US-5624409	04-29-1997	SEALE; Joseph B.	
	550	US-5624537	04-29-1997	TURNER; Robin F. B. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 23 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	551	US-5626563	05-06-1997	DODGE; Larry H. et al.	
	552	US-5628310	05-13-1997	RAO; Govind et al.	
	553	US-5628619	05-13-1997	WILSON; Larry	
	554	US-5628890	05-13-1997	CARTER; Nigel F. et al.	
	555	US-5630710	05-20-1997	TUNE; Joel et al.	
	556	US-5631170	05-20-1997	ATTRIDGE; John W.	
	557	US-5637083	06-10-1997	BERTRAND; William J. et al.	
	558	US-5640470	06-17-1997	IYER; Lokanathan M. et al.	
	559	US-5640954	06-24-1997	PFEIFFER; Ernst et al.	
	560	US-5643195	07-01-1997	DREVET; Jean-Baptiste et al.	
	561	US-5645077	07-08-1997	FOXLIN; Eric M.	
	562	US-5651767	07-29-1997	SCHULMAN; Joseph H. et al.	
	563	US-5653239	08-05-1997	POMPEI; Francesco et al.	
	564	US-5653756	08-05-1997	CLARKE; Robert A. et al.	
	565	US-5653863	08-05-1997	GENSHAW; Marvin A. et al.	
	566	US-5658250	08-19-1997	BLOMQUIST; Michael L. et al.	
	567	US-5660163	08-26-1997	SCHULMAN; Joseph H. et al.	
	568	US-5665061	09-09-1997	ANTWILER; Glen Delbert	
	569	US-5665065	09-09-1997	COLMAN; Fredric C. et al.	
	570	US-5665222	09-09-1997	HELLER; Adam et al.	
	571	US-5667504	09-16-1997	BAUMANN; Hans et al.	
	572	US-5676651	10-14-1997	LARSON, Jr.; Carl O. et al.	
	573	US-5676820	10-14-1997	WANG; Joseph et al.	
	574	US-5681285	10-28-1997	FORD; Alan D. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 24 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	575	US-5682884	11-04-1997	HILL; Hugh Allen Oliver et al.	
	576	US-5683562	11-04-1997	SCHAFFAR; Bernhard et al.	
	577	US-5685844	11-11-1997	MARTTILA; Constance M.	
	578	US-5686829	11-11-1997	GIRAULT; Hubert	
	579	US-5688239	11-18-1997	WALKER; Frank J.	
	580	US-5688244	11-18-1997	LANG; Volker	
	581	US-5695623	12-09-1997	MICHEL; Peter et al.	
	582	US-5697366	12-16-1997	KIMBALL; Victor E. et al.	
	583	US-5697899	12-16-1997	HILLMAN; Robert S. et al.	
	584	US-5704354	01-06-1998	PREIDEL; Walter et al.	
	585	US-5707502	01-13-1998	McCAFFREY; Robert et al.	
	586	US-5711001	01-20-1998	BUSSAN; Christopher F. et al.	
	587	US-5711861	01-27-1998	WARD; W. Kenneth et al.	
	588	US-5714931	02-03-1998	PETITE; Thomas D. et al.	
	589	US-5720295	02-24-1998	GREENHUT; Saul E. et al.	
	590	US-5730654	03-24-1998	BROWN; Stephen J.	
	591	US-5733259	03-31-1998	VALCKE; Christian P. et al.	
	592	US-5735273	04-07-1998	KURNIK; Ronald T. et al.	
	593	US-5735285	04-07-1998	ALBERT; David E. et al.	
	594	US-5738992	04-14-1998	COOK; Thomas A. et al.	
	595	US-5741211	04-21-1998	RENIRIE; Alexis C. M. et al.	
	596	US-5741634	04-21-1998	NOZOE; Yoshiteru et al.	
	597	US-5743262	04-28-1998	LEPPER, Jr.; James M. et al.	
	598	US-5745378	04-28-1998	BARKER; Craig S. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 25 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	599	US-5749832	05-12-1998	VADGAMA; Pankaj Madganlal et al.	
	600	US-5749907	05-12-1998	MANN; Brian M.	
	601	US-5755226	05-26-1998	CARIM; Hatim M. et al.	
	602	US-5755692	05-26-1998	MANICOM; Anthony William	
	603	US-5756632	05-26-1998	WARD; Robert S. et al.	
	604	US-5758643	06-02-1998	WONG; David K. et al.	
	605	US-5763760	06-09-1998	GUMBRECHT; Walter et al.	
	606	US-5766151	06-16-1998	VALLEY; Kirsten L. et al.	
	607	US-5771890	06-30-1998	TAMADA; Janet	
	608	US-5772586	06-30-1998	HEINONEN; Pekka et al.	
	609	US-5776324	07-07-1998	USALA; Anton-Lewis	
	610	US-5777060	07-07-1998	VAN ANTWERP; William Peter	
	611	US-5779665	07-14-1998	MASTROTOTARO; John J. et al.	
	612	US-5781455	07-14-1998	HYODO; Hiroshi	
	613	US-5782912	07-21-1998	BRAUKER; James H. et al.	
	614	US-5783054	07-21-1998	RAGUSE; Burkhard et al.	
	615	US-5785660	07-28-1998	VAN LAKE; Paul et al.	
	616	US-5787900	08-04-1998	BUTLER; Mark D. et al.	
	617	US-5791344	08-11-1998	SCHULMAN; Joseph H. et al.	
	618	US-5791880	08-11-1998	WILSON; Larry	
	619	US-5792065	08-11-1998	XUE; Qiuzhen et al.	
	620	US-5795774	08-18-1998	MATSUMOTO; Toru et al.	
	621	US-5798065	08-25-1998	PICHA; George J.	
	622	US-5800383	09-01-1998	CHANDLER; W. Jeffrey et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 26 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	623	US-5800420	09-01-1998	GROSS; Joseph et al.	
	624	US-5800529	09-01-1998	BRAUKER; James H. et al.	
	625	US-5804048	09-08-1998	WONG; David K. et al.	
	626	US-5806517	09-15-1998	GERHARDT; Greg Allen et al.	
	627	US-5807274	09-15-1998	HENNING; Timothy P. et al.	
	628	US-5807312	09-15-1998	DZWONKIEWICZ; Mark R.	
	629	US-5807375	09-15-1998	GROSS; Joseph et al.	
	630	US-5807406	09-15-1998	BRAUKER; James H. et al.	
	631	US-5810323	09-22-1998	WINTERER; Sean et al.	
	632	US-5810770	09-22-1998	CHIN; Sing Fatt et al.	
	633	US-5811487	09-22-1998	SCHULZ, Jr.; William James et al.	
	634	US-5814599	09-29-1998	MITRAGOTRI; Samir S. et al.	
	635	US-5820551	10-13-1998	HILL; Hugh Allen Oliver et al.	
	636	US-5820589	10-13-1998	TORGERSON; Nathan A. et al.	
	637	US-5822715	10-13-1998	WORTHINGTON; David R. L. et al.	
	638	US-5823802	10-20-1998	BARTLEY; Robert Michael	
	639	US-5833603	11-10-1998	KOVACS; Gregory T. A. et al.	
	640	US-5836887	11-17-1998	OKA; Tohru et al.	
	641	US-5836989	11-17-1998	SHELTON; Michael B.	
	642	US-5837454	11-17-1998	COZZETTE; Stephen N. et al.	
	643	US-5837728	11-17-1998	PURCELL; William P.	
	644	US-5840026	11-24-1998	HIRSCHMAN; Alan D. et al.	
	645	US-5851197	12-22-1998	MARANO; April A. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 27 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	646	US-5861019	01-19-1999	SUN; Weimin et al.	
	647	US-5863400	01-26-1999	DRUMMOND; Humphrey John Jardine et al.	
	648	US-5871514	02-16-1999	WIKLUND; Craig L. et al.	
	649	US-5873862	02-23-1999	LOPEZ; George A.	
	650	US-5879373	03-09-1999	ROPER; Josef et al.	
	651	US-5879828	03-09-1999	DEBE; Mark K. et al.	
	652	US-5882494	03-16-1999	VAN ANTWERP; William P.	
	653	US-5885844	03-23-1999	WEIR; Donald James et al.	
	654	US-5891047	04-06-1999	LANDER; Paul et al.	
	655	US-5891048	04-06-1999	NIGAM; Indra B. et al.	
	656	US-5897525	04-27-1999	DEY; Uwe et al.	
	657	US-5897578	04-27-1999	WIKLUND; Craig L. et al.	
	658	US-5899855	05-04-1999	BROWN; Stephen James	
	659	US-5904666	05-18-1999	DeDECKER; Paul G. et al.	
	660	US-5904708	05-18-1999	GOEDEKE; Steven D.	
	661	US-5910554	06-08-1999	KEMPE; Maria et al.	
	662	US-5911219	06-15-1999	AYLSWORTH; Alonzo C. et al.	
	663	US-5913998	06-22-1999	BUTLER; Mark D. et al.	
	664	US-5914026	06-22-1999	BRUNSMAN; Alan R. et al.	
	665	US-5917346	06-29-1999	GORD; John C.	
	666	US-5918603	07-06-1999	BROWN; Stephen J.	
	667	US-5921951	07-13-1999	MORRIS; Livingston B.	
	668	US-5925021	07-20-1999	CASTELLANO; Thomas P. et al.	
	669	US-5928130	07-27-1999	SCHMIDT; Bruno	
	670	US-5928155	07-27-1999	EGGERS; Philip E. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 28 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	671	US-5928182	07-27-1999	KRAUS; Robert G. et al.	
	672	US-5928189	07-27-1999	PHILLIPS; Robert E. et al.	
	673	US-5928195	07-27-1999	MALAMUD; Daniel et al.	
	674	US-5931814	08-03-1999	ALEX; Rainer et al.	
	675	US-5932175	08-03-1999	KNUTE; Wallace L. et al.	
	676	US-5933136	08-03-1999	BROWN; Stephen J.	
	677	US-5935224	08-10-1999	SVANCAREK; Mark K. et al.	
	678	US-5938636	08-17-1999	KRAMER; George C. et al.	
	679	US-5942979	08-24-1999	LUPPINO; Richard	
	680	US-5944661	08-31-1999	SWETTE; Larry L. et al.	
	681	US-5947911	09-07-1999	WONG; David K. et al.	
	682	US-5951521	09-14-1999	MASTROTOTARO; John J. et al.	
	683	US-5954643	09-21-1999	VANANTWERP; Nannette M. et al.	
	684	US-5954954	09-21-1999	HOUCK; Raymond K. et al.	
	685	US-5957854	09-28-1999	BESSON; Marcus et al.	
	686	US-5957903	09-28-1999	MIRZAEE; Daryush et al.	
	687	US-5960797	10-05-1999	KRAMER; George C. et al.	
	688	US-5961451	10-05-1999	REBER; William L. et al.	
	689	US-5964261	10-12-1999	NEUENFELDT; Steven et al.	
	690	US-5964993	10-12-1999	BLUBAUGH, Jr.; Elmo A. et al.	
	691	US-5965380	10-12-1999	HELLER; Adam et al.	
	692	US-5971922	10-26-1999	ARITA; Seizaburou et al.	
	693	US-5972199	10-26-1999	HELLER; Adam et al.	
	694	US-5976085	11-02-1999	KIMBALL; Victor E. et al.	
	695	US-5980728	11-09-1999	FARBER; Boris Y. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 29 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	696	US-5985129	11-16-1999	GOUGH; David A. et al.	
	697	US-5990422	11-23-1999	KOMORI; Susumu et al.	
	698	US-5995208	11-30-1999	SARGE; Jeffrey A. et al.	
	699	US-5995860	11-30-1999	SUN; Xiaoguang et al.	
	700	US-5999848	12-07-1999	GORD; John C. et al.	
	701	US-6001067	12-14-1999	SHULTS; Mark C. et al.	
	702	US-6001471	12-14-1999	BRIES; James L. et al.	
	703	US-6007775	12-28-1999	YAGER; Paul	
	704	US-6011984	01-04-2000	VAN ANTWERP; William Peter et al.	
	705	US-6013113	01-11-2000	MIKA; Mark L.	
	706	US-6014577	01-11-2000	HENNING; Timothy P. et al.	
	707	US-6016443	01-18-2000	EKWALL; Christer et al.	
	708	US-6016448	01-18-2000	BUSACKER; James W. et al.	
	709	US-6021350	02-01-2000	MATHSON; Goran	
	710	US-6023629	02-08-2000	TAMADA; Janet	
	711	US-6024699	02-15-2000	SURWIT; Richard S. et al.	
	712	US-6024720	02-15-2000	CHANDLER; W. Jeffrey et al.	
	713	US-6027445	02-22-2000	VON BAHR; Pontus	
	714	US-6027479	02-22-2000	ALEI; Philip E. et al.	
	715	US-6032059	02-29-2000	HENNING; Timothy P. et al.	
	716	US-6032667	03-07-2000	HEINONEN; Erkki	
	717	US-6036924	03-14-2000	SIMONS; Tad Decatur et al.	
	718	US-6038469	03-14-2000	KARLSSON; Per et al.	
	719	US-6045567	04-04-2000	TAYLOR; William C. et al.	
	720	US-6049727	04-11-2000	CROTHALL; Katherine D.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 30 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	721	US-6051389	04-18-2000	AHL; Thomas et al.	
	722	US-6059946	05-09-2000	YUKAWA; Keiko et al.	
	723	US-6063637	05-16-2000	ARNOLD; Frances H. et al.	
	724	US-6064900	05-16-2000	VADGAMA; Pankaj Madganlal et al.	
	725	US-6066088	05-23-2000	DAVIS; Phillip J.	
	726	US-6066448	05-23-2000	WOHLSTADTER; Jacob N. et al.	
	727	US-6071391	06-06-2000	GOTOH; Masao et al.	
	728	US-6073031	06-06-2000	HELSTAB; Edmond J. et al.	
	729	US-6074775	06-13-2000	GARTSTEIN; Vladimir et al.	
	730	US-6077299	06-20-2000	ADELBERG; Daniel A. et al.	
	731	US-6080583	06-27-2000	VON BAHR; Pontus	
	732	US-6081735	06-27-2000	DIAB; Mohamed K. et al.	
	733	US-6081736	06-27-2000	COLVIN; Michael S. et al.	
	734	US-6083523	07-04-2000	DIONNE; Keith E. et al.	
	735	US-6083710	07-04-2000	HELLER; Adam et al.	
	736	US-6088608	07-11-2000	SCHULMAN; Joseph H. et al.	
	737	US-6090087	07-18-2000	TSUKADA; Osamu et al.	
	738	US-6091975	07-18-2000	DADDONA; Peter E. et al.	
	739	US-6091976	07-18-2000	PFEIFFER; Margret et al.	
	740	US-6093156	07-25-2000	CUNNINGHAM; David D. et al.	
	741	US-6093172	07-25-2000	FUNDERBURK; Jeffery V. et al.	
	742	US-6099511	08-08-2000	DEVOS; Gilles J. et al.	
	743	US-6103033	08-15-2000	SAY; James et al.	
	744	US-6107083	08-22-2000	COLLINS; Thomas C. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 31 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	745	US-6108577	08-22-2000	BENSER; Michael Eric	
	746	US-6112116	08-29-2000	FISCHELL; Robert E. et al.	
	747	US-6115622	09-05-2000	MINOZ; Alain	
	748	US-6115628	09-05-2000	STADLER; Robert et al.	
	749	US-6115634	09-05-2000	DONDERS; Adrianus P. et al.	
	750	US-6117290	09-12-2000	SAY; James L. et al.	
	751	US-6119028	09-12-2000	SCHULMAN; Joseph H. et al.	
	752	US-6120676	09-19-2000	HELLER; Adam et al.	
	753	US-6121009	09-19-2000	HELLER; Adam et al.	
	754	US-6121611	09-19-2000	LINDSAY; Stuart M. et al.	
	755	US-6122351	09-19-2000	SCHLUETER, Jr.; Edward L. et al.	
	756	US-6122536	09-19-2000	SUN; Xiaoguong et al.	
	757	US-6123827	09-26-2000	WONG; David K. et al.	
	758	US-6127154	10-03-2000	MOSBACH; Klaus et al.	
	759	US-6128519	10-03-2000	SAY, I; James	
	760	US-6128526	10-03-2000	STADLER; Robert et al.	
	761	US-6134461	10-17-2000	SAY; James et al.	
	762	US-6135978	10-24-2000	HOUBEN; Richard P. M. et al.	
	763	US-6141573	10-31-2000	KURNIK; Ronald T. et al.	
	764	US-6142939	11-07-2000	EPPSTEIN; Jonathan A. et al.	
	765	US-6142979	11-07-2000	McNALLY; David J. et al.	
	766	US-6143164	11-07-2000	HELLER; Adam et al.	
	767	US-6144837	11-07-2000	QUY; Roger J.	
	768	US-6144869	11-07-2000	BERNER; Bret et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 32 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	769	US-6144871	11-07-2000	SAITO; Soichi et al.	
	770	US-6156051	12-05-2000	SCHRAGA; Steven	
	771	US-6159147	12-12-2000	LICHTER; Patrick A. et al.	
	772	US-6159186	12-12-2000	WICKHAM; Terrence et al.	
	773	US-6161095	12-12-2000	BROWN; Stephen J.	
	774	US-6162201	12-19-2000	COHEN; Kenneth L. et al.	
	775	US-6162611	12-19-2000	HELLER; Adam et al.	
	776	US-6164921	12-26-2000	MOUBAYED; Ahmad Maher et al.	
	777	US-6165154	12-26-2000	GRAY; Larry B. et al.	
	778	US-6165406	12-26-2000	JANG; Justin et al.	
	779	US-6167614	01-02-2001	TUTTLE; Mark E. et al.	
	780	US-6168568	01-02-2001	GAVRIELY; Noam	
	781	US-6169155	01-02-2001	ALVAREZ; Khristopher Edward et al.	
	782	US-6171276	01-09-2001	LIPPE; Barbara et al.	
	783	US-6175752	01-16-2001	SAY; James et al.	
	784	US-6175753	01-16-2001	MENKES; Alex et al.	
	785	US-6180416	01-30-2001	KURNIK; Ronald T. et al.	
	786	US-6183437	02-06-2001	WALKER; Frank J.	
	787	US-6187062	02-13-2001	OWEIS; Salah et al.	
	788	US-6189536	02-20-2001	MARTINEZ; Gonzalo et al.	
	789	US-6191860	02-20-2001	KLINGER; Leonid et al.	
	790	US-6197040	03-06-2001	LeVAUGHN; Richard Wayne et al.	
	791	US-6200265	03-13-2001	WALSH; Kevin K. et al.	
	792	US-6200772	03-13-2001	VADGAMA; Pankaj Maganlal et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 33 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	793	US-6201980	03-13-2001	DARROW; Christopher B. et al.	
	794	US-6201993	03-13-2001	KRUSE; John M. et al.	
	795	US-6206856	03-27-2001	MAHURKAR; Sakharam D.	
	796	US-6208894	03-27-2001	SCHULMAN; Joseph H. et al.	
	797	US-6212416	04-03-2001	WARD; W. Kenneth et al.	
	798	US-6212417	04-03-2001	IKEDA; Shin et al.	
	799	US-6212424	04-03-2001	ROBINSON; Mark Ries	
	800	US-6213739	04-10-2001	PHALLEN; Iver J. et al.	
	801	US-6214185	04-10-2001	OFFENBACHER; Helmut et al.	
	802	US-6219574	04-17-2001	CORMIER; Michel J. N. et al.	
	803	US-6223083	04-24-2001	ROSAR; George	
	804	US-6223283	04-24-2001	CHAIKEN; Craig L. et al.	
	805	US-6224562	05-01-2001	LURIE; Keith G. et al.	
	806	US-6230059	05-08-2001	DUFFIN; Edwin G.	
	807	US-6231320	05-15-2001	LAWLESS; Michael W. et al.	
	808	US-6231560	05-15-2001	BUI; Tuan et al.	
	809	US-6231879	05-15-2001	LI; Rebecca et al.	
	810	US-6233080	05-15-2001	BRENNER; Tomas et al.	
	811	US-6233486	05-15-2001	EKWALL; Christer et al.	
	812	US-6241863	06-05-2001	MONBOUQUETTE; Harold G.	
	813	US-6248067	06-19-2001	CAUSEY, III; James D. et al.	
	814	US-6248077	06-19-2001	ELSON; Edward E. et al.	
	815	US-6248093	06-19-2001	MOBERG; Sheldon	
	816	US-6249705	06-19-2001	SNELL; Jeffery D.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 34 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	817	US-6254586	07-03-2001	MANN; Alfred E. et al.	
	818	US-6256522	07-03-2001	SCHULTZ; Jerome S.	
	819	US-6256538	07-03-2001	EKWALL; Christer	
	820	US-6259937	07-10-2001	SCHULMAN; Joseph H. et al.	
	821	US-6261440	07-17-2001	HENNING; Timothy P. et al.	
	822	US-6263222	07-17-2001	DIAB; Mohamed K. et al.	
	823	US-6264606	07-24-2001	EKWALL; Christer et al.	
	824	US-6264825	07-24-2001	BLACKBURN; Gary et al.	
	825	US-6268161	07-31-2001	HAN; In Suk et al.	
	826	US-6269340	07-31-2001	FORD; Alan D. et al.	
	827	US-6270455	08-07-2001	BROWN; Stephen J.	
	828	US-6270478	08-07-2001	MERN.O SLASHED.E; Morton	
	829	US-6272364	08-07-2001	KURNIK; Ronald T.	
	830	US-6272379	08-07-2001	FISCHELL; Robert E. et al.	
	831	US-6272480	08-07-2001	TRESP; Volker et al.	
	832	US-6274285	08-14-2001	GRIES; Willi-Kurt et al.	
	833	US-6275717	08-14-2001	GROSS; Joseph et al.	
	834	US-6280408	08-28-2001	SIPIN; Anatole J.	
	835	US-6281015	08-28-2001	MOONEY; David J. et al.	
	836	US-6283761	09-04-2001	JOAO; Raymond Anthony	
	837	US-6284125	09-04-2001	HODGES; Alastair McIndoe et al.	
	838	US-6284478	09-04-2001	HELLER; Adam et al.	
	839	US-6293925	09-25-2001	SAFABASH; Jason H. et al.	
	840	US-6294281	09-25-2001	HELLER; Adam	
	841	US-6295506	09-25-2001	HEINONEN; Pekka et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 35 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	842	US-6298254	10-02-2001	TAMADA; Janet	
	843	US-6299578	10-09-2001	KURNIK; Ronald T. et al.	
	844	US-6299583	10-09-2001	EGGERS; Philip E. et al.	
	845	US-6299757	10-09-2001	FELDMAN; Benjamin J. et al.	
	846	US-6300002	10-09-2001	WEBB; Randle K. et al.	
	847	US-6302855	10-16-2001	LAV; Steffen et al.	
	848	US-6306104	10-23-2001	CUNNINGHAM; David D. et al.	
	849	US-6309351	10-30-2001	KURNIK; Ronald T. et al.	
	850	US-6309375	10-30-2001	GLINES; Robert C. et al.	
	851	US-6309884	10-30-2001	COOPER; Patrick J. et al.	
	852	US-6312388	11-06-2001	MARCOVECCHIO; Alan F. et al.	
	853	US-6325978	12-04-2001	LABUDA; Lawrence L. et al.	
	854	US-6325979	12-04-2001	HAHN; Dieter et al.	
	855	US-6326160	12-04-2001	DUNN; Timothy C. et al.	
	856	US-6329161	12-11-2001	HELLER; Adam et al.	
	857	US-6329929	12-11-2001	WEIJAND; Koen J. et al.	
	858	US-6330464	12-11-2001	COLVIN, Jr.; Arthur E. et al.	
	859	US-6338790	01-15-2002	FELDMAN; Benjamin J. et al.	
	860	US-6343225	01-29-2002	CLARK, Jr.; Leland C.	
	861	US-6348640	02-19-2002	NAVOT; Nir et al.	
	862	US-6356776	03-12-2002	BERNER; Bret et al.	
	863	US-6358225	03-19-2002	BUTTERFIELD; Robert D.	
	864	US-6359444	03-19-2002	GRIMES; Craig A.	
	865	US-6360888	03-26-2002	McIVOR; K. Collin et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 36 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	866	US-6361503	03-26-2002	STAROBIN; Joseph M. et al.	
	867	US-6365670	04-02-2002	FRY; Bryan E.	
	868	US-6366794	04-02-2002	MOUSSY; Francis et al.	
	869	US-6368141	04-09-2002	VANANTWERP; Nannette M. et al.	
	870	US-6368274	04-09-2002	VAN ANTWERP; William P. et al.	
	871	US-6370941	04-16-2002	NAKAMURA; Michihiro et al.	
	872	US-6372244	04-16-2002	ANTANAVICH; Richard D. et al.	
	873	US-6377828	04-23-2002	CHAIKEN; Joseph et al.	
	874	US-6377852	04-23-2002	BORNZIN; Gene A. et al.	
	875	US-6377894	04-23-2002	DEWEESE; Marshall D. et al.	
	876	US-6379301	04-30-2002	WORTHINGTON; David R. L. et al.	
	877	US-6381493	04-30-2002	STADLER; Robert et al.	
	878	US-6387048	05-14-2002	SCHULMAN; Joseph H. et al.	
	879	US-6387709	05-14-2002	MASON; Richard W. et al.	
	880	US-6391019	05-21-2002	ITO; Takashi	
	881	US-6400974	06-04-2002	LESHO; Jeffery C.	
	882	US-6402703	06-11-2002	KENSEY; Kenneth et al.	
	883	US-6403944	06-11-2002	MACKENZIE; Hugh Alexander et al.	
	884	US-6405066	06-11-2002	ESSENPREIS; Matthias et al.	
	885	US-6409674	06-25-2002	BROCKWAY; Brian P. et al.	
	886	US-6413393	07-02-2002	VAN ANTWERP; William P. et al.	
	887	US-6413396	07-02-2002	YANG; Haesik et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 37 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	888	US-6413410	07-02-2002	HODGES; Alastair McIndoe et al.	
	889	US-6416651	07-09-2002	MILLAR; Ord	
	890	US-6418332	07-09-2002	MASTROTOTARO; John J. et al.	
	891	US-6424847	07-23-2002	MASTROTOTARO; John J. et al.	
	892	US-6424861	07-23-2002	MEREDITH; Neil	
	893	US-6427088	07-30-2002	BOWMAN, IV; Sam W. et al.	
	894	US-6428123	08-06-2002	LUCHT; Wayne et al.	
	895	US-6430437	08-06-2002	MARRO; Dominic P.	
	896	US-6434430	08-13-2002	BORGERSEN; Svenn E. et al.	
	897	US-6440068	08-27-2002	BROWN; Michael Wayne et al.	
	898	US-6444115	09-03-2002	HODGES; Alastair et al.	
	899	US-6447448	09-10-2002	ISHIKAWA; Akira et al.	
	900	US-6447542	09-10-2002	WEADOCK; Kevin	
	901	US-6454710	09-24-2002	BALLERSTADT; Ralph et al.	
	902	US-6459917	10-01-2002	GOWDA; Ashok et al.	
	903	US-6461496	10-08-2002	FELDMAN; Benjamin J. et al.	
	904	US-6464849	10-15-2002	SAY; James L. et al.	
	905	US-6465066	10-15-2002	RULE; Mark et al.	
	906	US-6466810	10-15-2002	WARD; W. Kenneth et al.	
	907	US-6467480	10-22-2002	MEIER; Bernd Horst et al.	
	908	US-6471689	10-29-2002	JOSEPH, I; Jeffery et al.	
	909	US-6474360	11-05-2002	ITO; Takashi	
	910	US-6475372	11-05-2002	OHARA; Timothy J. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 38 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	911	US-6475750	11-05-2002	HAN; In Suk et al.	
	912	US-6477392	11-05-2002	HONIGS; David E. et al.	
	913	US-6477395	11-05-2002	SCHULMAN; Joseph H. et al.	
	914	US-6478736	11-12-2002	MAULT; James R.	
	915	US-6481440	11-19-2002	GIELEN; Frans L. H. et al.	
	916	US-6484045	11-19-2002	HOLKER; James D. et al.	
	917	US-6484046	11-19-2002	SAY; James et al.	
	918	US-6485449	11-26-2002	ITO; Takashi	
	919	US-6486661	11-26-2002	CHIA; Michael Ik-Ming et al.	
	920	US-6488652	12-03-2002	WEIJAND; Koen J. et al.	
	921	US-6494879	12-17-2002	LENNOX; Charles D. et al.	
	922	US-6498043	12-24-2002	SCHULMAN; Joseph H. et al.	
	923	US-6498941	12-24-2002	JACKSON; Gregg A.	
	924	US-6501976	12-31-2002	SOHRAB; Borzu	
	925	US-6501983	12-31-2002	NATARAJAN; Ananth et al.	
	926	US-6503381	01-07-2003	GOTOH; Masao et al.	
	927	US-6510329	01-21-2003	HECKEL; Donald W.	
	928	US-6512939	01-28-2003	COLVIN; Michael S. et al.	
	929	US-6514460	02-04-2003	FENDROCK; Charles	
	930	US-6514718	02-04-2003	HELLER; Adam et al.	
	931	US-6517508	02-11-2003	UTTERBERG; David S. et al.	
	932	US-6520326	02-18-2003	McIVOR; K. Collin et al.	
	933	US-6520477	02-18-2003	TRIMMER; William	
	934	US-6520937	02-18-2003	HART; Colin P. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 39 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	935	US-6520997	02-18-2003	PEKKARINEN; Michael O. et al.	
	936	US-6526298	02-25-2003	KHALIL; Omar S. et al.	
	937	US-6527729	03-04-2003	TURCOTT; Robert	
	938	US-6528318	03-04-2003	MIRAGLIOTTA; Joseph A. et al.	
	939	US-6536433	03-25-2003	CEWERS; Goran	
	940	US-6537318	03-25-2003	ITA; Essien Eyo-Okon et al.	
	941	US-6540891	04-01-2003	STEWART; Alan Andrew et al.	
	942	US-6541266	04-01-2003	MODZELEWSKI; Brent E. et al.	
	943	US-6542765	04-01-2003	GUY; Richard et al.	
	944	US-6543195	04-08-2003	RAHIMZADEH; Housh	
	945	US-6544212	04-08-2003	GALLEY; Paul J. et al.	
	946	US-6544229	04-08-2003	DANBY; Hal C. et al.	
	947	US-6545085	04-08-2003	KILGOUR; John A. et al.	
	948	US-6546268	04-08-2003	ISHIKAWA; Akira et al.	
	949	US-6546269	04-08-2003	KURNIK; Ronald T.	
	950	US-6547839	04-15-2003	ZHANG; Zhiwei et al.	
	951	US-6551494	04-22-2003	HELLER; Adam et al.	
	952	US-6551496	04-22-2003	MOLES; Donald R. et al.	
	953	US-6553241	04-22-2003	MANNHEIMER; Paul D. et al.	
	954	US-6553244	04-22-2003	LESHO; Matthew J. et al.	
	955	US-6554805	04-29-2003	HIEJIMA; Katsuhiro	
	956	US-6554822	04-29-2003	HOLSCHNEIDER; Daniel P. et al.	
	957	US-6558320	05-06-2003	CAUSEY, III; James D. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 40 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	958	US-6558321	05-06-2003	BURD; John F. et al.	
	959	US-6558347	05-06-2003	JHUBOO; Abdel Nasser et al.	
	960	US-6558351	05-06-2003	STEIL; Garry M. et al.	
	961	US-6561978	05-13-2003	CONN; Thomas E. et al.	
	962	US-6562001	05-13-2003	LEBEL; Ronald J. et al.	
	963	US-6564105	05-13-2003	STARKWEATHER; Timothy J. et al.	
	964	US-6565509	05-20-2003	SAY; James et al.	
	965	US-6565535	05-20-2003	ZAIAS; Nardo et al.	
	966	US-6565807	05-20-2003	PATTERSON; William R. et al.	
	967	US-6569309	05-27-2003	OTSUKA; Kiyoshi et al.	
	968	US-6569521	05-27-2003	SHERIDAN; Margaret M. et al.	
	969	US-6571128	05-27-2003	LEBEL; Ronald J. et al.	
	970	US-6572542	06-03-2003	HOUBEN; Richard et al.	
	971	US-6572545	06-03-2003	KNOBBE; Edward J. et al.	
	972	US-6572579	06-03-2003	RAGHAVAN; Raghu et al.	
	973	US-6574490	06-03-2003	ABBINK; Russell E. et al.	
	974	US-6575905	06-10-2003	KNOBBE; Edward J. et al.	
	975	US-6576101	06-10-2003	HELLER; Adam et al.	
	976	US-6577899	06-10-2003	LEBEL; Ronald J. et al.	
	977	US-6579257	06-17-2003	ELGAS; Roger J. et al.	
	978	US-6579498	06-17-2003	EGLISE; David	
	979	US-6579690	06-17-2003	BONNECAZE; Roger T. et al.	
	980	US-6584335	06-24-2003	HAAR; Hans-Peter et al.	
	981	US-6585644	07-01-2003	LEBEL; Ronald J. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 41 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	982	US-6585675	07-01-2003	O'MAHONY; John J. et al.	
	983	US-6585763	07-01-2003	KEILMAN; George W. et al.	
	984	US-6587705	07-01-2003	KIM; Lynn et al.	
	985	US-6589229	07-08-2003	CONNELLY; Robert I. et al.	
	986	US-6591125	07-08-2003	BUSE; John Bernard et al.	
	987	US-6592745	07-15-2003	FELDMAN; Benjamin J. et al.	
	988	US-6594514	07-15-2003	BERNER; Bret et al.	
	989	US-6595756	07-22-2003	GRAY; John et al.	
	990	US-6595919	07-22-2003	BERNER; Bret et al.	
	991	US-6600940	07-29-2003	FEIN; Michael E. et al.	
	992	US-6600997	07-29-2003	DEWEESE; Marshall D. et al.	
	993	US-6602221	08-05-2003	SARAVIA; Heber et al.	
	994	US-6605072	08-12-2003	STRUYS; Michel et al.	
	995	US-6605200	08-12-2003	MAO; Fei et al.	
	996	US-6605201	08-12-2003	MAO; Fei et al.	
	997	US-6607509	08-19-2003	BOBROFF; Randa M. et al.	
	998	US-6607658	08-19-2003	HELLER; Adam et al.	
	999	US-6609071	08-19-2003	SHAPIRO; Philip et al.	
	1000	US-6610012	08-26-2003	MAULT; James R.	
	1001	US-6612984	09-02-2003	KERR, II; Robert A.	
	1002	US-6613379	09-02-2003	WARD; W. Kenneth et al.	
	1003	US-6615061	09-02-2003	KHALIL; Omar S. et al.	
	1004	US-6615078	09-02-2003	BURSON; Kim K. et al.	
	1005	US-6616819	09-09-2003	LIAMOS; Charles T. et al.	
	1006	US-6618603	09-09-2003	VARALLI; Maurizio Claudio et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 42 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1007	US-6618934	09-16-2003	FELDMAN; Benjamin J. et al.	
	1008	US-6622045	09-16-2003	SNELL; Jeffery D. et al.	
	1009	US-6633772	10-14-2003	FORD; Russell et al.	
	1010	US-6635014	10-21-2003	STARKWEATHER; Timothy J. et al.	
	1011	US-6641533	11-04-2003	CAUSEY, III; James D. et al.	
	1012	US-6642015	11-04-2003	VACHON; David J. et al.	
	1013	US-6645181	11-11-2003	LAVI; Gilad et al.	
	1014	US-6648821	11-18-2003	LEBEL; Ronald J. et al.	
	1015	US-6650471	11-18-2003	DOI; Yasuhiro	
	1016	US-6653091	11-25-2003	DUNN; Timothy C. et al.	
	1017	US-6654625	11-25-2003	SAY; James L. et al.	
	1018	US-6656114	12-02-2003	POULSEN; Jens Ulrik et al.	
	1019	US-6656157	12-02-2003	DUCHON; Doug et al.	
	1020	US-6658396	12-02-2003	TANG; Sharon S. et al.	
	1021	US-6659948	12-09-2003	LEBEL; Ronald J. et al.	
	1022	US-6668196	12-23-2003	VILLEGAS; Daniel H. et al.	
	1023	US-6673022	01-06-2004	BOBO; Donald et al.	
	1024	US-6673596	01-06-2004	SAYLER; Gary S. et al.	
	1025	US-6675030	01-06-2004	CIURCZAK; Emil W. et al.	
	1026	US-6676816	01-13-2004	MAO; Fei et al.	
	1027	US-6679865	01-20-2004	SHEKALIM; Avraham	
	1028	US-6679872	01-20-2004	TUROVSKIY; Roman et al.	
	1029	US-6683535	01-27-2004	UTKE; Gene H.	
	1030	US-6684904	02-03-2004	ITO; Takashi	
	1031	US-6685668	02-03-2004	CHO; Steve T. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 43 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1032	US-6687522	02-03-2004	TAMADA; Janet	
	1033	US-6687546	02-03-2004	LEBEL; Ronald J. et al.	
	1034	US-6689056	02-10-2004	KILCOYNE; John T. et al.	
	1035	US-6689089	02-10-2004	TIEDTKE; Hans Jurgen et al.	
	1036	US-6689265	02-10-2004	HELLER; Adam et al.	
	1037	US-6689413	02-10-2004	LIU; Connie C. et al.	
	1038	US-6692457	02-17-2004	FLAHERTY; J. Christopher	
	1039	US-6694191	02-17-2004	STARKWEATHER; Timothy J. et al.	
	1040	US-6695860	02-24-2004	WARD; W. Kenneth et al.	
	1041	US-6698269	03-02-2004	BABER; Isaak et al.	
	1042	US-6699188	03-02-2004	WESSEL; Paul	
	1043	US-6699218	03-02-2004	FLAHERTY; J. Christopher et al.	
	1044	US-6702249	03-09-2004	ITO; Takashi	
	1045	US-6702857	03-09-2004	BRAUKER; James H. et al.	
	1046	US-6702972	03-09-2004	MARKLE; David Reed	
	1047	US-6711423	03-23-2004	COLVIN, Jr.; Arthur E.	
	1048	US-6711424	03-23-2004	FINE; Ilya et al.	
	1049	US-6712796	03-30-2004	FENTIS; Robert et al.	
	1050	US-6721582	04-13-2004	TREPAGNIER; Pierre et al.	
	1051	US-6721587	04-13-2004	GOUGH; David A.	
	1052	US-6723086	04-20-2004	BASSUK; William K. et al.	
	1053	US-6730200	05-04-2004	STEWART; Alan A. et al.	
	1054	US-6731976	05-04-2004	PENN; Richard D. et al.	
	1055	US-6731985	05-04-2004	POORE; John W. et al.	
	1056	US-6733446	05-11-2004	LEBEL; Ronald J. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 44 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1057	US-6733655	05-11-2004	DAVIES; Oliver W. H. et al.	
	1058	US-6736783	05-18-2004	BLAKE; Kevin R. et al.	
	1059	US-6736957	05-18-2004	FORROW; Nigel J. et al.	
	1060	US-6737158	05-18-2004	THOMPSON; Samuel A.	
	1061	US-6740075	05-25-2004	LEBEL; Ronald J. et al.	
	1062	US-6741877	05-25-2004	SHULTS; Mark C. et al.	
	1063	US-6742635	06-01-2004	HIRSHBERG; Jonathan	
	1064	US-6743635	06-01-2004	NEEL; Gary T. et al.	
	1065	US-6746582	06-08-2004	HELLER; Adam et al.	
	1066	US-6749587	06-15-2004	FLAHERTY; J. Christopher	
	1067	US-6749591	06-15-2004	McNALLY; David J. et al.	
	1068	US-6749740	06-15-2004	LIAMOS; Charles T. et al.	
	1069	US-6758810	07-06-2004	LEBEL; Ronald J. et al.	
	1070	US-6764581	07-20-2004	FORROW; Nigel J. et al.	
	1071	US-6770030	08-03-2004	SCHAUPP; Lukas et al.	
	1072	US-6770067	08-03-2004	LORENZEN; Eric et al.	
	1073	US-6773671	08-10-2004	LEWIS; Mark E. et al.	
	1074	US-6780297	08-24-2004	MATSUMOTO; Toru et al.	
	1075	US-6784274	08-31-2004	VAN ANTWERP; William Peter et al.	
	1076	US-6790178	09-14-2004	MAULT; James R. et al.	
	1077	US-6793632	09-21-2004	SOHRAB; Borzu	
	1078	US-6801041	10-05-2004	KARINKA; Shridhara Alva et al.	
	1079	US-6802957	10-12-2004	JUNG; Sung-Kw N. et al.	
	1080	US-6804002	10-12-2004	FINE; Ilya et al.	
	1081	US-6805693	10-19-2004	GRAY; John F. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 45 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1082	US-6809653	10-26-2004	MANN; Alfred E. et al.	
	1083	US-6810290	10-26-2004	LEBEL; Ronald J. et al.	
	1084	US-6811533	11-02-2004	LEBEL; Ronald J. et al.	
	1085	US-6811534	11-02-2004	BOWMAN, IV; Sam W. et al.	
	1086	US-6811548	11-02-2004	JEFFREY; Peter	
	1087	US-6813519	11-02-2004	LEBEL; Ronald J. et al.	
	1088	US-6817990	11-16-2004	YAP; Darren Y. K. et al.	
	1089	US-6846654	01-25-2005	BLACKBURN; Gary F. et al.	
	1090	US-6850790	02-01-2005	BERNER; Bret et al.	
	1091	US-6850859	02-01-2005	SCHUH; William C.	
	1092	US-6854317	02-15-2005	PORTER; Timothy L. et al.	
	1093	US-6858020	02-22-2005	RUSNAK; Christopher	
	1094	US-6862465	03-01-2005	SHULTS; Mark C. et al.	
	1095	US-6865407	03-08-2005	KIMBALL; Victor E. et al.	
	1096	US-6869413	03-22-2005	LANGLEY; Christopher Nigel et al.	
	1097	US-6873268	03-29-2005	LEBEL; Ronald J. et al.	
	1098	US-6881551	04-19-2005	HELLER; Adam et al.	
	1099	US-6882940	04-19-2005	POTTS; Russell O. et al.	
	1100	US-6887228	05-03-2005	McKAY; Douglas William	
	1101	US-6892085	05-10-2005	McIVOR; K. Collin et al.	
	1102	US-6893396	05-17-2005	SCHULZE; Arthur E. et al.	
	1103	US-6893545	05-17-2005	GOTOH; Masao et al.	
	1104	US-6893552	05-17-2005	WANG; Joseph et al.	
	1105	US-6895263	05-17-2005	SHIN; John J. et al.	
	1106	US-6895265	05-17-2005	SILVER; James H.	
	1107	US-6902544	06-07-2005	LUDIN; Lev et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 46 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1108	US-6912413	06-28-2005	RANTALA; Borje et al.	
	1109	US-6923763	08-02-2005	KOVATCHEV; Boris P. et al.	
	1110	US-6925393	08-02-2005	KALATZ; Brit et al.	
	1111	US-6926691	08-09-2005	MIETHKE; Christoph	
	1112	US-6931327	08-16-2005	GOODE, Jr.; Paul V. et al.	
	1113	US-6932584	08-23-2005	GRAY; John et al.	
	1114	US-6932892	08-23-2005	CHEN; Linlin et al.	
	1115	US-6932894	08-23-2005	MAO; Fei et al.	
	1116	US-6936006	08-30-2005	SABRA; Mads C.	
	1117	US-6942518	09-13-2005	LIAMOS; Charles T. et al.	
	1118	US-6945965	09-20-2005	WHITING; Howard Anthony	
	1119	US-6948492	09-27-2005	WERMELING; Daniel P. et al.	
	1120	US-6950708	09-27-2005	BOWMAN, IV; Sam W. et al.	
	1121	US-6952604	10-04-2005	DeNUZZIO; John D. et al.	
	1122	US-6954662	10-11-2005	FREGER; David et al.	
	1123	US-6958705	10-25-2005	LEBEL; Ronald J. et al.	
	1124	US-6960192	11-01-2005	FLAHERTY; J. Christopher et al.	
	1125	US-6965791	11-15-2005	HITCHCOCK; Robert W. et al.	
	1126	US-6966325	11-22-2005	ERICKSON; John	
	1127	US-6968294	11-22-2005	GUTTA; Srinivas et al.	
	1128	US-6971274	12-06-2005	OLIN; John George	
	1129	US-6972080	12-06-2005	TOMIOKA; Toshikazu et al.	
	1130	US-6974437	12-13-2005	LEBEL; Ronald J. et al.	
	1131	US-6975893	12-13-2005	SAY; James L. et al.	
	1132	US-6979315	12-27-2005	ROGERS; Charles et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 47 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1133	US-6985870	01-10-2006	MARTUCCI; James et al.	
	1134	US-6989891	01-24-2006	BRAIG; James R. et al.	
	1135	US-6990366	01-24-2006	SAY; James et al.	
	1136	US-6990422	01-24-2006	LALETIN; William H. et al.	
	1137	US-6996427	02-07-2006	ALI; Ammar Al et al.	
	1138	US-6997907	02-14-2006	SAFABASH; Jason H. et al.	
	1139	US-6997921	02-14-2006	GRAY; John F. et al.	
	1140	US-6998247	02-14-2006	MONFRE; Stephen L. et al.	
	1141	US-7003336	02-21-2006	HOLKER; James D. et al.	
	1142	US-7003340	02-21-2006	SAY; James et al.	
	1143	US-7003341	02-21-2006	SAY; James et al.	
	1144	US-7010345	03-07-2006	HILL; Michael R. S. et al.	
	1145	US-7011630	03-14-2006	DESAI; Shashi P. et al.	
	1146	US-7016713	03-21-2006	GARDNER; Craig M. et al.	
	1147	US-7016720	03-21-2006	KROLL; Mark W.	
	1148	US-7018361	03-28-2006	GILLESPIE, Jr.; John et al.	
	1149	US-7022072	04-04-2006	FOX; James Kelly et al.	
	1150	US-7022219	04-04-2006	MANSOURI; Sohrab et al.	
	1151	US-7024245	04-04-2006	LEBEL; Ronald J. et al.	
	1152	US-7025425	04-11-2006	KOVATCHEV; Boris P. et al.	
	1153	US-7025727	04-11-2006	BROCKWAY; Brian P. et al.	
	1154	US-7025743	04-11-2006	MANN; Alfred E. et al.	
	1155	US-7027848	04-11-2006	ROBINSON; Mark Ries et al.	
	1156	US-7029443	04-18-2006	KROLL; Mark W.	
	1157	US-7029444	04-18-2006	SHIN; John J. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 48 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1158	US-7041068	05-09-2006	FREEMAN; Dominique M. et al.	
	1159	US-7041209	05-09-2006	PIZZARIELLO; Andrea et al.	
	1160	US-7041468	05-09-2006	DRUCKER; Steven et al.	
	1161	US-7043287	05-09-2006	KHALIL; Omar S. et al.	
	1162	US-7048727	05-23-2006	MOSS; Gerald	
	1163	US-7052472	05-30-2006	MILLER; Mark Edward et al.	
	1164	US-7052483	05-30-2006	WOJCIK; Steven	
	1165	US-7056302	06-06-2006	DOUGLAS; Joel S.	
	1166	US-7060059	06-13-2006	KEITH; Steven et al.	
	1167	US-7061593	06-13-2006	BRAIG; James R. et al.	
	1168	US-7062385	06-13-2006	WHITE; Joel E. et al.	
	1169	US-7063086	06-20-2006	SHAHBAZPOUR; Mehdi et al.	
	1170	US-7066884	06-27-2006	CUSTER; Linda et al.	
	1171	US-7070577	07-04-2006	HALLER; Markus et al.	
	1172	US-7070580	07-04-2006	NIELSEN; Jens Egebjerg	
	1173	US-7074307	07-11-2006	SIMPSON; Peter C. et al.	
	1174	US-7074610	07-11-2006	COZZETTE; Stephen N. et al.	
	1175	US-7076300	07-11-2006	KROLL; Mark W. et al.	
	1176	US-7078582	07-18-2006	STEBBINGS; William L. et al.	
	1177	US-7081195	07-25-2006	SIMPSON; Peter et al.	
	1178	US-7092891	08-15-2006	MAUS; Christopher T. et al.	
	1179	US-7096064	08-22-2006	DENO; D. Curtis et al.	
	1180	US-7097775	08-29-2006	GREENBERG; Robert J. et al.	
	1181	US-7098803	08-29-2006	MANN; Alfred E. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 49 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1182	US-7100628	09-05-2006	IZENSON; Michael G. et al.	
	1183	US-7103412	09-05-2006	KROLL; Mark W.	
	1184	US-7108778	09-19-2006	SIMPSON; Peter C. et al.	
	1185	US-7109878	09-19-2006	MANN; Alfred E. et al.	
	1186	US-7110803	09-19-2006	SHULTS; Mark C. et al.	
	1187	US-7113821	09-26-2006	SUN; Ying et al.	
	1188	US-7115884	10-03-2006	WALT; David R. et al.	
	1189	US-7118667	10-10-2006	LEE; Jin Po	
	1190	US-7120483	10-10-2006	RUSSELL; Geoffrey A. et al.	
	1191	US-7123950	10-17-2006	MANNHEIMER; Paul D.	
	1192	US-7131967	11-07-2006	GRAY; John F. et al.	
	1193	US-7134999	11-14-2006	BRAUKER; James H. et al.	
	1194	US-7135342	11-14-2006	COLVIN, Jr.; Arthur E. et al.	
	1195	US-7136689	11-14-2006	SHULTS; Mark C. et al.	
	1196	US-7142911	11-28-2006	BOILEAU; Peter et al.	
	1197	US-7146202	12-05-2006	WARD; W. Kenneth et al.	
	1198	US-7149562	12-12-2006	WALKER; Steven C. et al.	
	1199	US-7150741	12-19-2006	ERICKSON; John et al.	
	1200	US-7153265	12-26-2006	VACHON; David J.	
	1201	US-7153458	12-26-2006	IDE; Akinori et al.	
	1202	US-7162290	01-09-2007	LEVIN; Paul D.	
	1203	US-7167818	01-23-2007	BROWN; Stephen J.	
	1204	US-7168597	01-30-2007	JONES; Anthony Patrick et al.	
	1205	US-7169289	01-30-2007	SCHULEIN; Jurgen et al.	
	1206	US-7171252	01-30-2007	SCARANTINO; Charles W. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 50 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1207	US-7171274	01-30-2007	STARKWEATHER; Timothy J. et al.	
	1208	US-7171312	01-30-2007	STEINTHAL; Gregory et al.	
	1209	US-7183102	02-27-2007	MONFRE; Stephen L. et al.	
	1210	US-7184810	02-27-2007	CADUFF; Andreas et al.	
	1211	US-7190988	03-13-2007	SAY; James et al.	
	1212	US-7192450	03-20-2007	BRAUKER; James H. et al.	
	1213	US-7198606	04-03-2007	BOECKER; Dirk et al.	
	1214	US-7204823	04-17-2007	ESTES; Mark C. et al.	
	1215	US-7207968	04-24-2007	HARCINSKE; John C.	
	1216	US-7207974	04-24-2007	SAFABASH; Jason H. et al.	
	1217	US-7211074	05-01-2007	SANSOUCY; Michael	
	1218	US-7211439	05-01-2007	VOSSMEYER; Tobias et al.	
	1219	US-7214190	05-08-2007	WILSON; Kitchener Clark	
	1220	US-7221970	05-22-2007	PARKER; Dawood	
	1221	US-7223253	05-29-2007	HOGENDIJK; Michael	
	1222	US-7225535	06-05-2007	FELDMAN; Benjamin J. et al.	
	1223	US-7226978	06-05-2007	TAPSAK; Mark A. et al.	
	1224	US-7228162	06-05-2007	WARD; W. Kenneth et al.	
	1225	US-7229288	06-12-2007	STUART; Steven et al.	
	1226	US-7238165	07-03-2007	VINCENT; Douglas et al.	
	1227	US-7244582	07-17-2007	NILSSON; Kurt et al.	
	1228	US-7247138	07-24-2007	REGHABI; Bahar et al.	
	1229	US-7247443	07-24-2007	SU; Wei-Wen	
	1230	US-7248912	07-24-2007	GOUGH; David A. et al.	
	1231	US-7253680	08-07-2007	LALETIN; William H.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 51 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1232	US-7254450	08-07-2007	CHRISTOPHERSON; Mark A. et al.	
	1233	US-7255690	08-14-2007	GRAY; John et al.	
	1234	US-7258673	08-21-2007	RACCHINI; Joel et al.	
	1235	US-7258681	08-21-2007	HOUDE; Eric	
	1236	US-7261690	08-28-2007	TELLER; Eric et al.	
	1237	US-7266400	09-04-2007	FINE; Ilya et al.	
	1238	US-7267665	09-11-2007	STEIL; Garry M. et al.	
	1239	US-7268562	09-11-2007	AISENBREY; Thomas	
	1240	US-7272436	09-18-2007	GILL; Jong et al.	
	1241	US-7273633	09-25-2007	RAYNOR; Jeffrey	
	1242	US-7276029	10-02-2007	GOODE, Jr.; Paul V. et al.	
	1243	US-7278983	10-09-2007	IRELAND; Jeffrey R. et al.	
	1244	US-7280879	10-09-2007	CHEN; Martin et al.	
	1245	US-7288085	10-30-2007	OLSEN; James M.	
	1246	US-7288368	10-30-2007	ZWEIG; Stephen Eliot	
	1247	US-7289204	10-30-2007	NIELSEN; Hans Ole et al.	
	1248	US-7289836	10-30-2007	COLVIN, Jr.; Arthur E.	
	1249	US-7291496	11-06-2007	HOLM-KENNEDY; James W.	
	1250	US-7295867	11-13-2007	BERNER; Bret et al.	
	1251	US-7297114	11-20-2007	GILL; Jong et al.	
	1252	US-7299082	11-20-2007	FELDMAN; Benjamin J. et al.	
	1253	US-7303875	12-04-2007	BOCK; Larry et al.	
	1254	US-7308292	12-11-2007	COLVIN; Arthur E. et al.	
	1255	US-7310544	12-18-2007	BRISTER; Mark et al.	
	1256	US-7311690	12-25-2007	BURNETT; Daniel R.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 52 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1257	US-7312040	12-25-2007	ROITMAN; Daniel B.	
	1258	US-7313425	12-25-2007	FINAROV; Alexander et al.	
	1259	US-7314452	01-01-2008	MADONIA; James R.	
	1260	US-7315752	01-01-2008	KRAEMER; Uwe et al.	
	1261	US-7315767	01-01-2008	CADUFF; Andreas et al.	
	1262	US-7316662	01-08-2008	DELNEVO; Annalisa et al.	
	1263	US-7317938	01-08-2008	LORENZ; Alexander D. et al.	
	1264	US-7317939	01-08-2008	FINE; Ilya et al.	
	1265	US-7318814	01-15-2008	LEVINE; Andy H. et al.	
	1266	US-7327273	02-05-2008	HUNG; Orlando R. et al.	
	1267	US-7329234	02-12-2008	SANSOUCY; Michael R.	
	1268	US-7334594	02-26-2008	LUDIN; Lev	
	1269	US-7335179	02-26-2008	BURNETT; Daniel Rogers	
	1270	US-7335195	02-26-2008	MEHIER; Henri	
	1271	US-7335294	02-26-2008	HELLER; Adam et al.	
	1272	US-7338464	03-04-2008	BLISCHAK; Brian et al.	
	1273	US-7338639	03-04-2008	BURKE; David W. et al.	
	1274	US-7344499	03-18-2008	PRAUSNITZ; Mark R. et al.	
	1275	US-7344626	03-18-2008	HARDING; Ian et al.	
	1276	US-7351321	04-01-2008	COHEN; Adam L.	
	1277	US-7354420	04-08-2008	STEIL; Garry M. et al.	
	1278	US-7359723	04-15-2008	JONES; Donald John	
	1279	US-7361155	04-22-2008	SAGE, Jr.; Burton H. et al.	
	1280	US-7364562	04-29-2008	BRAIG; James R. et al.	
	1281	US-7364592	04-29-2008	CARR-BRENDEL; Victoria et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 53 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1282	US-7365562	04-29-2008	JEON; Jin	
	1283	US-7366556	04-29-2008	BRISTER; Mark et al.	
	1284	US-7367942	05-06-2008	GRAGE; Henry et al.	
	1285	US-7372277	05-13-2008	DIAMOND; Steven et al.	
	1286	US-7379765	05-27-2008	PETISCE; James et al.	
	1287	US-7381184	06-03-2008	FUNDERBURK; Jeffery V. et al.	
	1288	US-7384532	06-10-2008	PARSONS, II; Dennis R. et al.	
	1289	US-7387811	06-17-2008	SELVAMANICKAM; Venkat	
	1290	US-7390667	06-24-2008	BURKE; David W. et al.	
	1291	US-7396353	07-08-2008	LORENZEN; Eric et al.	
	1292	US-7399277	07-15-2008	SAIDARA; Frank et al.	
	1293	US-7402153	07-22-2008	STEIL; Garry M. et al.	
	1294	US-7402349	07-22-2008	PEPIN; John Graeme	
	1295	US-7407811	08-05-2008	BURKE; David W. et al.	
	1296	US-7416802	08-26-2008	SAMMES; Nigel et al.	
	1297	US-7417164	08-26-2008	SURI; Jeff T.	
	1298	US-7417729	08-26-2008	GREENWALD; Roger J.	
	1299	US-7422727	09-09-2008	LEE; Chun-Hyuk et al.	
	1300	US-7424318	09-09-2008	BRISTER; Mark et al.	
	1301	US-7425877	09-16-2008	CASPER; Michael D. et al.	
	1302	US-7426408	09-16-2008	DeNUZZIO; John D. et al.	
	1303	US-7427338	09-23-2008	DORDI; Yezdi N. et al.	
	1304	US-7427560	09-23-2008	LIN; Mou-Shiung et al.	
	1305	US-7429552	09-30-2008	AFZALI-ARDAKANI; Ali et al.	
	1306	US-7433727	10-07-2008	WARD; W. Kenneth et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 54 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1307	US-7460898	12-02-2008	BRISTER; Mark et al.	
	1308	US-7467003	12-16-2008	BRISTER; Mark et al.	
	1309	US-7468125	12-23-2008	KRAFT; Ulrich et al.	
	1310	US-7471972	12-30-2008	RHODES; Rathbun et al.	
	1311	US-7474992	01-06-2009	ARIYUR; Kartik B.	
	1312	US-7488601	02-10-2009	BURKE; David W. et al.	
	1313	US-7494465	02-24-2009	BRISTER; Mark et al.	
	1314	US-7494816	02-24-2009	BURKE; David W. et al.	
	1315	US-7497827	03-03-2009	BRISTER; Mark et al.	
	1316	US-7499002	03-03-2009	BLASKO; Gabor et al.	
	1317	US-7501052	03-10-2009	IYENGAR; Sridhar G. et al.	
	1318	US-7502644	03-10-2009	GILL; Jong et al.	
	1319	US-7517439	04-14-2009	HARDING; Ian et al.	
	1320	US-7519408	04-14-2009	RASDAL; Andrew et al.	
	1321	US-7519478	04-14-2009	BARTKOWIAK; Miroslaw et al.	
	1322	US-7523004	04-21-2009	BARTKOWIAK; Miroslaw et al.	
	1323	US-7524287	04-28-2009	BHARMI; Rupinder	
	1324	US-7525298	04-28-2009	MORGAN; Wayne A. et al.	
	1325	US-7529574	05-05-2009	JANSEN; Lawrence B. et al.	
	1326	US-7547281	06-16-2009	HAYES; Andrew C. et al.	
	1327	US-7547382	06-16-2009	HARDING; Ian et al.	
	1328	US-7569030	08-04-2009	LEBEL; Ronald J. et al.	
	1329	US-7583990	09-01-2009	GOODE, Jr.; Paul V. et al.	
	1330	US-7591801	09-22-2009	BRAUKER; James H. et al.	
	1331	US-7599726	10-06-2009	GOODE, Jr.; Paul V. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 55 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1332	US-7604593	10-20-2009	PARRIS; Norman A. et al.	
	1333	US-7608042	10-27-2009	GOLDBERGER; Daniel et al.	
	1334	US-7613491	11-03-2009	BOOCK; Robert et al.	
	1335	US-7615007	11-10-2009	SHULTS; Mark et al.	
	1336	US-7618368	11-17-2009	BROWN; Stephen J.	
	1337	US-7618369	11-17-2009	HAYTER; Gary et al.	
	1338	US-7620438	11-17-2009	HE; Lei	
	1339	US-7624028	11-24-2009	BROWN; Stephen J.	
	1340	US-7630748	12-08-2009	BUDIMAN; Erwin S.	
	1341	US-7632228	12-15-2009	BRAUKER; James H. et al.	
	1342	US-7635594	12-22-2009	HOLMES; Elizabeth A. et al.	
	1343	US-7637868	12-29-2009	SAINT; Sean et al.	
	1344	US-7640032	12-29-2009	JONES; Donald John	
	1345	US-7640048	12-29-2009	DOBBLES; J. Michael et al.	
	1346	US-7645374	01-12-2010	DIAMOND; Steven et al.	
	1347	US-7647237	01-12-2010	MALAVE; Luis J. et al.	
	1348	US-7653425	01-26-2010	HAYTER; Gary et al.	
	1349	US-7654956	02-02-2010	BRISTER; Mark et al.	
	1350	US-7695434	04-13-2010	MALECHA; Michael	
	1351	US-7699775	04-20-2010	DESAI; Shashi P. et al.	
	1352	US-7699964	04-20-2010	FELDMAN; Benjamin et al.	
	1353	US-7711493	05-04-2010	BARTKOWIAK; Miroslaw et al.	
	1354	US-7713392	05-11-2010	HARDING; Ian et al.	
	1355	US-7715893	05-11-2010	KAMATH; Apurv Ullas et al.	
	1356	US-7731659	06-08-2010	MALECHA; Michael	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 56 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1357	US-7736310	06-15-2010	TAUB; Marc B.	
	1358	US-7749445	07-06-2010	MASTERS; Brett P.	
	1359	US-7751864	07-06-2010	BUCK, Jr.; Harvey B.	
	1360	US-7761126	07-20-2010	GARDNER; Craig M. et al.	
	1361	US-7761130	07-20-2010	SIMPSON; Peter C. et al.	
	1362	US-7766829	08-03-2010	SLOAN; Mark K. et al.	
	1363	US-7766830	08-03-2010	FOX; James Kelly et al.	
	1364	US-7771352	08-10-2010	SHULTS; Mark C. et al.	
	1365	US-7774038	08-10-2010	WANG; Lu et al.	
	1366	US-7774145	08-10-2010	BRAUKER; James H. et al.	
	1367	US-7775975	08-17-2010	BRISTER; Mark et al.	
	1368	US-7776559	08-17-2010	CHILDERS; Winthrop D. et al.	
	1369	US-7778679	08-17-2010	SCHULMAN; Joseph H. et al.	
	1370	US-7778680	08-17-2010	GOODE, Jr.; Paul V. et al.	
	1371	US-7826981	11-02-2010	GOODE, Jr.; Paul V. et al.	
	1372	US-7831287	11-09-2010	BRISTER; Mark et al.	
	1373	US-7838639	11-23-2010	TSCHOPP; Jurg et al.	
	1374	US-7856613	12-21-2010	WELING; Milind et al.	
	1375	US-7857760	12-28-2010	BRISTER; Mark et al.	
	1376	US-7866025	01-11-2011	JAMES; Frank O. et al.	
	1377	US-7866026	01-11-2011	WANG; Yi et al.	
	1378	US-7885697	02-08-2011	BRISTER; Mark et al.	
	1379	US-7885698	02-08-2011	FELDMAN; Benjamin J.	
	1380	US-7889069	02-15-2011	FIFOLT; Douglas A. et al.	
	1381	US-7894870	02-22-2011	LUCISANO; Joseph Y. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 57 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1382	US-7896809	03-01-2011	SIMPSON; Peter C. et al.	
	1383	US-7899511	03-01-2011	SHULTS; Mark C. et al.	
	1384	US-7901354	03-08-2011	SHULTS; Mark C. et al.	
	1385	US-7905833	03-15-2011	BRISTER; Mark et al.	
	1386	US-7914450	03-29-2011	GOODE, Jr.; Paul V. et al.	
	1387	US-7917186	03-29-2011	KAMATH; Apurv Ullas et al.	
	1388	US-7917186-C1	08-09-2011	KAMATH; Apurv Ullas et al.	
	1389	US-7920906	04-05-2011	GOODE, Jr.; Paul V. et al.	
	1390	US-7925321	04-12-2011	GOODE; Paul V. et al.	
	1391	US-7927274	04-19-2011	RASDAL; Andrew et al.	
	1392	US-7933639	04-26-2011	GOODE; Paul V. et al.	
	1393	US-7938797	05-10-2011	ESTES; Mark C.	
	1394	US-7943034	05-17-2011	DIAMOND; Steven et al.	
	1395	US-7946984	05-24-2011	BRISTER; Mark et al.	
	1396	US-7955261	06-07-2011	GOODE; Paul V. et al.	
	1397	US-7959569	06-14-2011	GOODE; Paul V. et al.	
	1398	US-7964089	06-21-2011	HARDING; Ian et al.	
	1399	US-7964146	06-21-2011	HARDING; Ian et al.	
	1400	US-7974672	07-05-2011	SHULTS; Mark C. et al.	
	1401	US-7979104	07-12-2011	KAMATH; Apurv U. et al.	
	1402	US-7985330	07-26-2011	WANG; Lu et al.	
	1403	US-7986986	07-26-2011	GOODE; Paul V. et al.	
	1404	US-7990828	08-02-2011	SU; I-Bing et al.	
	1405	US-7996158	08-09-2011	HAYTER; Gary et al.	
	1406	US-7998071	08-16-2011	GOODE, Jr.; Paul V. et al.	
	1407	US-8000763	08-16-2011	MAZZA; John C. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 58 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1408	US-8005524	08-23-2011	BRAUKER; James H. et al.	
	1409	US-8005525	08-23-2011	GOODE, Jr.; Paul V. et al.	
	1410	US-8010174	08-30-2011	GOODE, Jr.; Paul V. et al.	
	1411	US-8016997	09-13-2011	DIAMOND; Steven et al.	
	1412	US-8026104	09-27-2011	WU; Huan-Ping et al.	
	1413	US-8030942	10-04-2011	DIAMOND; Steven et al.	
	1414	US-8052601	11-08-2011	GOODE, Jr.; Paul V. et al.	
	1415	US-8060173	11-15-2011	GOODE, Jr.; Paul V. et al.	
	1416	US-8073519	12-06-2011	GOODE, Jr.; Paul V. et al.	
	1417	US-8073520	12-06-2011	KAMATH; Apurv U. et al.	
	1418	US-8103471	01-24-2012	HAYTER; Gary	
	1419	US-8109850	02-07-2012	AMMON; Urs et al.	
	1420	US-8112240	02-07-2012	FENNELL; Martin J.	
	1421	US-8114268	02-14-2012	WANG; Lu et al.	
	1422	US-8116837	02-14-2012	HUANG; Johnnie W.	
	1423	US-8123920	02-28-2012	IYENGAR; Sridhar G. et al.	
	1424	US-8128562	03-06-2012	GOODE, Jr.; Paul V. et al.	
	1425	US-8140312	03-20-2012	HAYTER; Gary et al.	
	1426	US-8149117	04-03-2012	FENNELL; Martin J. et al.	
	1427	US-8150488	04-03-2012	GOODE, Jr.; Paul V. et al.	
	1428	US-8160670	04-17-2012	OUYANG; Tianmei et al.	
	1429	US-8160671	04-17-2012	KAMATH; Apurv Ullas et al.	
	1430	US-8160834	04-17-2012	LIANG; Bradley Chi et al.	
	1431	US-8160900	04-17-2012	TAUB; Marc B. et al.	
	1432	US-8167801	05-01-2012	GOODE, Jr.; Paul V. et al.	
	1433	US-8170803	05-01-2012	KAMATH; Apurv Ullas et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 59 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1434	US-8195265	06-05-2012	GOODE, Jr.; Paul V. et al.	
	1435	US-8202491	06-19-2012	MASTERS; Brett et al.	
	1436	US-8211016	07-03-2012	BUDIMAN; Erwin S.	
	1437	US-8216137	07-10-2012	BUDIMAN; Erwin S.	
	1438	US-8216138	07-10-2012	McGARRAUGH; Geoffrey V.	
	1439	US-8219173	07-10-2012	BUDIMAN; Erwin Satrya et al.	
	1440	US-8224415	07-17-2012	BUDIMAN; Erwin Satrya	
	1441	US-8229536	07-24-2012	GOODE, Jr.; Paul V. et al.	
	1442	US-8233959	07-31-2012	KAMATH; Apurv et al.	
	1443	US-8239166	08-07-2012	HAYTER; Gary et al.	
	1444	US-8249683	08-21-2012	WANG; Lu et al.	
	1445	US-8255026	08-28-2012	AL-ALI; Ammar	
	1446	US-8257259	09-04-2012	BRAUKER; James H. et al.	
	1447	US-8260393	09-04-2012	KAMATH; Apurv Ullas et al.	
	1448	US-8260558	09-04-2012	HAYTER; Gary et al.	
	1449	US-8275438	09-25-2012	SIMPSON; Peter C. et al.	
	1450	US-8282549	10-09-2012	BRAUKER; James H. et al.	
	1451	US-8282550	10-09-2012	RASDAL; Andrew P. et al.	
	1452	US-8287453	10-16-2012	LI; Ying et al.	
	1453	US-8290559	10-16-2012	SHARIATI; Mohammad Ali et al.	
	1454	US-8290562	10-16-2012	GOODE, Jr.; Paul V. et al.	
	1455	US-8292810	10-23-2012	GOODE, Jr.; Paul V. et al.	
	1456	US-8298142	10-30-2012	SIMPSON; Peter C. et al.	
	1457	US-8332008	12-11-2012	GOODE; Paul V. et al.	
	1458	US-8346335	01-01-2013	HARPER; Wesley Scott et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 60 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1459	US-8346337	01-01-2013	HELLER; Adam et al.	
	1460	US-8346338	01-01-2013	GOODE, Jr.; Paul V. et al.	
	1461	US-8348923	01-08-2013	KANDERIAN, Jr.; Sami S. et al.	
	1462	US-8364230	01-29-2013	SIMPSON; Peter C. et al.	
	1463	US-8364231	01-29-2013	KAMATH; Apurv Ullas et al.	
	1464	US-8369919	02-05-2013	KAMATH; Apurv Ullas et al.	
	1465	US-8372351	02-12-2013	OW-WING; Kevin M.	
	1466	US-8374667	02-12-2013	BRAUKER; James H. et al.	
	1467	US-8376945	02-19-2013	HAYTER; Gary et al.	
	1468	US-8396528	03-12-2013	KAMATH; Apurv Ullas et al.	
	1469	US-8412301	04-02-2013	GOODE, Jr.; Paul V. et al.	
	1470	US-8417312	04-09-2013	KAMATH; Apurv Ullas et al.	
	1471	US-8423113	04-16-2013	SHARIATI; Mohammad Ali et al.	
	1472	US-8423114	04-16-2013	SIMPSON; Peter C. et al.	
	1473	US-8425416	04-23-2013	BRISTER; Mark et al.	
	1474	US-8425417	04-23-2013	LEACH; Jacob S. et al.	
	1475	US-8428678	04-23-2013	KAMATH; Apurv Ullas et al.	
	1476	US-8428679	04-23-2013	GOODE, Jr.; Paul V. et al.	
	1477	US-8435179	05-07-2013	GOODE, Jr.; Paul V. et al.	
	1478	US-8442610	05-14-2013	GOODE; Paul V. et al.	
	1479	US-8444560	05-21-2013	HAYTER; Gary et al.	
	1480	US-8447376	05-21-2013	SHARIATI; Mohammad Ali et al.	
	1481	US-8449464	05-28-2013	SIMPSON; Peter C. et al.	
	1482	US-8457703	06-04-2013	AL-ALI; Ammar	
	1483	US-8461985	06-11-2013	FENNELL; Martin J. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 61 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1484	US-8463350	06-11-2013	KAMATH; Apurv Ullas et al.	
	1485	US-8473022	06-25-2013	HAYTER; Gary et al.	
	1486	US-8475373	07-02-2013	BRISTER; Mark et al.	
	1487	US-8478377	07-02-2013	SHARIATI; Mohammad Ali et al.	
	1488	US-8478557	07-02-2013	HAYTER; Gary Alan et al.	
	1489	US-8484005	07-09-2013	HAYTER; Gary et al.	
	1490	US-8491474	07-23-2013	GOODE, Jr.; Paul V. et al.	
	1491	US-8509871	08-13-2013	RHODES; Rathbun K. et al.	
	1492	US-8515517	08-20-2013	HAYTER; Gary et al.	
	1493	US-8527025	09-03-2013	SHULTS; Mark C. et al.	
	1494	US-8532730	09-10-2013	BRISTER; Mark et al.	
	1495	US-8532935	09-10-2013	BUDIMAN; Erwin Satrya	
	1496	US-8543354	09-24-2013	LUO; Ying et al.	
	1497	US-8560037	10-15-2013	GOODE, Jr.; Paul V. et al.	
	1498	US-8560038	10-15-2013	HAYTER; Gary et al.	
	1499	US-8562528	10-22-2013	LEACH; Jacob S. et al.	
	1500	US-8571808	10-29-2013	HAYTER; Gary	
	1501	US-8583205	11-12-2013	BUDIMAN; Erwin Satrya et al.	
	1502	US-8593109	11-26-2013	HE; Lei	
	1503	US-8600681	12-03-2013	HAYTER; Gary et al.	
	1504	US-8612163	12-17-2013	HAYTER; Gary et al.	
	1505	US-8626257	01-07-2014	LI; Ying et al.	
	1506	US-8657745	02-25-2014	BRAUKER; James H. et al.	
	1507	US-8657746	02-25-2014	ROY; Anirban	
	1508	US-8663220	03-04-2014	WIENER; Eitan T. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 62 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1509	US-8665091	03-04-2014	FENNELL; Martin J. et al.	
	1510	US-8682615	03-25-2014	HAYTER; Gary et al.	
	1511	US-8718739	05-06-2014	HARPER; Wesley Scott et al.	
	1512	US-8718965	05-06-2014	HAYTER; Gary Alan et al.	
	1513	US-8744547	06-03-2014	BUDIMAN; Erwin Satrya et al.	
	1514	US-8774886	07-08-2014	BRISTER; Mark et al.	
	1515	US-8868151	10-21-2014	TELSON; Stanley A. et al.	
	1516	US-8868161	10-21-2014	THIERMAN; Jonathan	
	1517	US-8911367	12-16-2014	BRISTER; Mark et al.	
	1518	US-8933664	01-13-2015	HE; Lei	
	1519	US-8942778	01-27-2015	OCVIRK; Gregor et al.	
	1520	US-9060719	06-23-2015	HAYTER; Gary Alan et al.	
	1521	US-9113828	08-25-2015	BUDIMAN; Erwin S.	
	1522	US-9125548	09-08-2015	HAYTER; Gary	
	1523	US-9135402	09-15-2015	MENSINGER; Michael Robert et al.	
	1524	US-9149220	10-06-2015	BOHM; Sebastian et al.	
	1525	US-9161714	10-20-2015	MARTINI; Joerg et al.	
	1526	US-9247901	02-02-2016	KAMATH; Apurv et al.	
	1527	US-9314196	04-19-2016	PRYOR; Jack et al.	
	1528	US-9320462	04-26-2016	HARPER; Wesley Scott et al.	
	1529	US-9320468	04-26-2016	HAYTER; Gary Alan et al.	
	1530	US-9326709	05-03-2016	BUDIMAN; Erwin Satrya	
	1531	US-9332934	05-10-2016	HAYTER; Gary Alan et al.	
	1532	US-9339217	05-17-2016	HARPER; Wesley Scott et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 63 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1533	US-9357959	06-07-2016	HAYTER; Gary Alan et al.	
	1534	US-9380971	07-05-2016	HE; Lei	
	1535	US-9392969	07-19-2016	HAYTER; Gary et al.	
	1536	US-9398872	07-26-2016	HAYTER; Gary Alan et al.	
	1537	US-9408566	08-09-2016	HAYTER; Gary Alan et al.	
	1538	US-9451908	09-27-2016	KAMATH; Apurv Ullas et al.	
	1539	US-9483608	11-01-2016	HAYTER; Gary Alan et al.	
	1540	US-9498155	11-22-2016	BRAUKER; James H. et al.	
	1541	US-9558325	01-31-2017	HAYTER; Gary Alan et al.	
	1542	US-9629578	04-25-2017	HAYTER; Gary Alan et al.	
	1543	US-9662056	05-30-2017	BUDIMAN; Erwin Satrya et al.	
	1544	US-9675290	06-13-2017	BUDIMAN; Erwin Satrya et al.	
	1545	US-9730623	08-15-2017	HARPER; Wesley Scott et al.	
	1546	US-9737249	08-22-2017	HAYTER; Gary Alan et al.	
	1547	US-9743863	08-29-2017	HE; Lei	
	1548	US-9770211	09-26-2017	HAYTER; Gary Alan et al.	
	1549	US-9797880	10-24-2017	HAYTER; Gary Alan et al.	
	1550	US-9801571	10-31-2017	HAYTER; Gary Alan	
	1551	US-9801575	10-31-2017	BOHM; Sebastian et al.	
	1552	US-9801577	10-31-2017	BUDIMAN; Erwin Satrya et al.	
	1553	US-9804148	10-31-2017	HAYTER; Gary Alan et al.	
	1554	US-9804150	10-31-2017	HAYTER; Gary Alan et al.	
	1555	US-9808190	11-07-2017	BOHM; Sebastian et al.	
	1556	US-9814428	11-14-2017	BUDIMAN; Erwin S.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 64 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1557	US-9833181	12-05-2017	HAYTER; Gary Alan et al.	
	1558	US-9839383	12-12-2017	HAYTER; Gary Alan et al.	
	1559	US-9839395	12-12-2017	SHARIATI; Mohammad Ali et al.	
	1560	US-9848809	12-26-2017	BOHM; Sebastian et al.	
	1561	US-9936910	04-10-2018	HAYTER; Gary Alan et al.	
	1562	US-10002233	06-19-2018	HAYTER; Gary et al.	
	1563	US-10004442	06-26-2018	BOHM; Sebastian et al.	
	1564	US-10031002	07-24-2018	HAYTER; Gary Alan et al.	
	1565	US-10045720	08-14-2018	HAYTER; Gary Alan et al.	
	1566	US-10052055	08-21-2018	LI; Ying et al.	
	1567	US-10078380	09-18-2018	BUDIMAN; Erwin S.	
	1568	US-10082493	09-25-2018	HARPER; Wesley Scott et al.	
	1569	US-10089446	10-02-2018	BUDIMAN; Erwin Satrya	
	1570	US-10119956	11-06-2018	HAYTER; Gary Alan et al.	
	1571	US-10143409	12-04-2018	HAYTER; Gary Alan	
	1572	US-10188334	01-29-2019	BUDIMAN; Erwin Satrya et al.	
	1573	US-10188794	01-29-2019	HAYTER; Gary et al.	
	1574	US-10194868	02-05-2019	BUDIMAN; Erwin Satrya	
	1575	US-10261069	04-16-2019	HAYTER; Gary Alan et al.	
	1576	US-10278630	05-07-2019	HAYTER; Gary Alan et al.	
	1577	US-10327688	06-25-2019	BOHM; Sebastian et al.	
	1578	US-10335075	07-02-2019	VANSLYKE; Stephen J. et al.	
	1579	US-10349873	07-16-2019	KAMATH; Apurv Ullas et al.	
	1580	US-10448873	10-22-2019	BOHM; Sebastian et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 65 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1581	US-10561354	02-18-2020	BOHM; Sebastian et al.	
	1582	US-10610141	04-07-2020	BOHM; Sebastian et al.	
	1583	US-10624568	04-21-2020	BOHM; Sebastian et al.	
	1584	US-10682084	06-16-2020	BOHM; Sebastian et al.	
	1585	US-10722162	07-28-2020	BOHM; Sebastian et al.	
	1586	US-10835162	11-17-2020	BOHM; Sebastian et al.	
	1587	US-20010016682	08-23-2001	BERNER; Bret et al.	
	1588	US-20010021817	09-13-2001	BRUGGER; James M. et al.	
	1589	US-20010039053	11-08-2001	LISEO; John et al.	
	1590	US-20010041830	11-15-2001	VARALLI; Maurizio Claudio et al.	
	1591	US-20010041831	11-15-2001	STARKWEATHER; Timothy J. et al.	
	1592	US-20010051768	12-13-2001	SCHULMAN; Joseph H. et al.	
	1593	US-20020016534	02-07-2002	TREPAGNIER; Pierre et al.	
	1594	US-20020016535	02-07-2002	MARTIN; W. Blake et al.	
	1595	US-20020019022	02-14-2002	DUNN; Timothy C. et al.	
	1596	US-20020022883	02-21-2002	BURG; Karen J.L.	
	1597	US-20020023852	02-28-2002	MCIVOR; K. Collin et al.	
	1598	US-20020026110	02-28-2002	PARRIS; Norman A. et al.	
	1599	US-20020026111	02-28-2002	ACKERMAN; Neil	
	1600	US-20020027086	03-07-2002	SAFFELL; John R. et al.	
	1601	US-20020038101	03-28-2002	AVRAHAMI; Zohar et al.	
	1602	US-20020042090	04-11-2002	HELLER; Adam et al.	
	1603	US-20020042561	04-11-2002	SCHULMAN; Joseph H. et al.	
	1604	US-20020043471	04-18-2002	IKEDA; Shin et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 66 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1605	US-20020045808	04-18-2002	FORD; Russell et al.	
	1606	US-20020055673	05-09-2002	VAN ANTWERP; William P. et al.	
	1607	US-20020062132	05-23-2002	KRAMER; Kenneth S. et al.	
	1608	US-20020065453	05-30-2002	LESHO; Matthew J. et al.	
	1609	US-20020065454	05-30-2002	LEBEL; Ronald J. et al.	
	1610	US-20020068860	06-06-2002	CLARK, Jr.; Leland C.	
	1611	US-20020071776	06-13-2002	BANDIS; Steven et al.	
	1612	US-20020084196	07-04-2002	LIAMOS; Charles T. et al.	
	1613	US-20020099282	07-25-2002	KNOBBE; Edward J. et al.	
	1614	US-20020099997	07-25-2002	PIRET; Philippe	
	1615	US-20020103499	08-01-2002	PEREZ; Edward P. et al.	
	1616	US-20020106709	08-08-2002	POTTS; Russell O. et al.	
	1617	US-20020111547	08-15-2002	KNOBBE; Edward J. et al.	
	1618	US-20020115920	08-22-2002	RICH; Collin A. et al.	
	1619	US-20020119711	08-29-2002	VANANTWERP; Nannette M. et al.	
	1620	US-20020120186	08-29-2002	KEIMEL; John G.	
	1621	US-20020123048	09-05-2002	GAU, Jr.; Vincent Jen.	
	1622	US-20020128594	09-12-2002	DAS; Kusal K. et al.	
	1623	US-20020143266	10-03-2002	BOCK; Elizabeth Anne	
	1624	US-20020143372	10-03-2002	SNELL; Jeffery D. et al.	
	1625	US-20020151796	10-17-2002	KOULIK; Edouard	
	1626	US-20020155615	10-24-2002	NOVIKOV; Igor A. et al.	
	1627	US-20020156355	10-24-2002	GOUGH; David A.	
	1628	US-20020161288	10-31-2002	SHIN; John J. et al.	
	1629	US-20020169369	11-14-2002	WARD; W. Kenneth et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 67 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1630	US-20020169635	11-14-2002	SHILLINGBURG; Craig P.	
	1631	US-20020177763	11-28-2002	BURNS; David W. et al.	
	1632	US-20020177764	11-28-2002	SOHRAB; Borzu	
	1633	US-20020182241	12-05-2002	BORENSTEIN; Jeffrey T. et al.	
	1634	US-20020188185	12-12-2002	SOHRAB; Borzu	
	1635	US-20020193679	12-19-2002	MALAVE; Luis J. et al.	
	1636	US-20020193885	12-19-2002	LEGEAY; Gilbert et al.	
	1637	US-20020198513	12-26-2002	LEBEL; Ronald J. et al.	
	1638	US-20030003524	01-02-2003	TANIIKE; Yukio et al.	
	1639	US-20030004403	01-02-2003	DRINAN; Darrel et al.	
	1640	US-20030004432	01-02-2003	ASSENHEIMER; Michel	
	1641	US-20030004457	01-02-2003	ANDERSSON; Stig O.	
	1642	US-20030006669	01-09-2003	PEI; Qibing et al.	
	1643	US-20030023171	01-30-2003	SATO; Katsuhiko et al.	
	1644	US-20030023317	01-30-2003	BRAUKER; James H. et al.	
	1645	US-20030023461	01-30-2003	QUINTANILLA; Dan et al.	
	1646	US-20030028089	02-06-2003	GALLEY; Paul J. et al.	
	1647	US-20030032867	02-13-2003	CROTHALL; Katherine D. et al.	
	1648	US-20030032874	02-13-2003	RHODES; Rathbun et al.	
	1649	US-20030034305	02-20-2003	LUEHMANN; Douglas A. et al.	
	1650	US-20030036773	02-20-2003	WHITEHURST; Todd K. et al.	
	1651	US-20030042137	03-06-2003	MAO; Fei et al.	
	1652	US-20030050546	03-13-2003	DESAI; Shashi P. et al.	
	1653	US-20030054428	03-20-2003	MONFRE; Stephen L. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 68 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1654	US-20030060692	03-27-2003	L. RUCHTI; Timothy et al.	
	1655	US-20030065254	04-03-2003	SCHULMAN; Joseph H. et al.	
	1656	US-20030065308	04-03-2003	LEBEL; Ronald J. et al.	
	1657	US-20030070548	04-17-2003	CLAUSEN; Lydia	
	1658	US-20030076082	04-24-2003	MORGAN; Wayne A. et al.	
	1659	US-20030078481	04-24-2003	McIVOR; K. Collin et al.	
	1660	US-20030078560	04-24-2003	MILLER; Michael E. et al.	
	1661	US-20030097082	05-22-2003	PURDY; Phillip D. et al.	
	1662	US-20030100040	05-29-2003	BONNECAZE; Roger T. et al.	
	1663	US-20030100821	05-29-2003	HELLER; Adam et al.	
	1664	US-20030119201	06-26-2003	WOLFRAM; Evelyn et al.	
	1665	US-20030119208	06-26-2003	YOON; Hyun Chul et al.	
	1666	US-20030120152	06-26-2003	OMIYA; Jun	
	1667	US-20030125612	07-03-2003	FOX; James Kelly et al.	
	1668	US-20030125613	07-03-2003	ENEGREN; Bradley J. et al.	
	1669	US-20030130616	07-10-2003	STEIL; Garry M. et al.	
	1670	US-20030134347	07-17-2003	HELLER; Adam et al.	
	1671	US-20030138674	07-24-2003	ZEIKUS; Gregory J. et al.	
	1672	US-20030143746	07-31-2003	SAGE, Jr.; Burton H.	
	1673	US-20030153821	08-14-2003	BERNER; Bret et al.	
	1674	US-20030161288	08-28-2003	UNRUH; Lincoln J.	
	1675	US-20030168338	09-11-2003	GAO; Zhiqiang et al.	
	1676	US-20030175987	09-18-2003	VERDONK; Edward et al.	
	1677	US-20030176183	09-18-2003	DRUCKER; Steven et al.	
	1678	US-20030176933	09-18-2003	LEBEL; Ronald J. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 69 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1679	US-20030181794	09-25-2003	RINI; Christopher J. et al.	
	1680	US-20030187338	10-02-2003	SAY; James et al.	
	1681	US-20030188427	10-09-2003	SAY; James et al.	
	1682	US-20030191377	10-09-2003	ROBINSON; Mark Ries et al.	
	1683	US-20030199744	10-23-2003	BUSE; John Bernard et al.	
	1684	US-20030199790	10-23-2003	BOECKER; Dirk et al.	
	1685	US-20030203498	10-30-2003	NEEL; Gary T. et al.	
	1686	US-20030208113	11-06-2003	MAULT; James R. et al.	
	1687	US-20030211625	11-13-2003	COHAN; Bruce E. et al.	
	1688	US-20030212317	11-13-2003	KOVATCHEV; Boris P. et al.	
	1689	US-20030212346	11-13-2003	YUZHAKOV; Vadim V. et al.	
	1690	US-20030212347	11-13-2003	SOHRAB; Borzu	
	1691	US-20030212379	11-13-2003	BYLUND; Adam David et al.	
	1692	US-20030216630	11-20-2003	JERSEY-WILLUHN; Karen et al.	
	1693	US-20030217966	11-27-2003	TAPSAK; Mark A. et al.	
	1694	US-20030225437	12-04-2003	FERGUSON; Patrick J.	
	1695	US-20030228681	12-11-2003	RITTS; Rosalyn et al.	
	1696	US-20030235817	12-25-2003	BARTKOWIAK; Miroslaw et al.	
	1697	US-20040010186	01-15-2004	KIMBALL; Victor E. et al.	
	1698	US-20040010207	01-15-2004	FLAHERTY; J. Christopher et al.	
	1699	US-20040011671	01-22-2004	SHULTS; Mark C. et al.	
	1700	US-20040015063	01-22-2004	DeNUZZIO; John D. et al.	
	1701	US-20040015134	01-22-2004	LAVI; Gilad et al.	
	1702	US-20040023253	02-05-2004	KUNWAR; Sandeep et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 70 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1703	US-20040023317	02-05-2004	MOTAMEDI; Massoud et al.	
	1704	US-20040024327	02-05-2004	BRODNICK; Donald Eugene	
	1705	US-20040024553	02-05-2004	MONFRE; Stephen L. et al.	
	1706	US-20040030285	02-12-2004	LAVI; Gilad et al.	
	1707	US-20040030294	02-12-2004	MAHURKAR; Sakharam D.	
	1708	US-20040039298	02-26-2004	ABREU; Marcio Marc	
	1709	US-20040039406	02-26-2004	JESSEN; Jonh W.	
	1710	US-20040040840	03-04-2004	MAO; Fei et al.	
	1711	US-20040045879	03-11-2004	SHULTS; Mark C. et al.	
	1712	US-20040054263	03-18-2004	MOERMAN; Piet et al.	
	1713	US-20040054352	03-18-2004	ADAMS; H. Clark et al.	
	1714	US-20040064021	04-01-2004	PFEIFFER; Ulrich J.	
	1715	US-20040064068	04-01-2004	DeNUZZIO; John D. et al.	
	1716	US-20040068230	04-08-2004	ESTES; Mark C. et al.	
	1717	US-20040074785	04-22-2004	HOLKER; James D. et al.	
	1718	US-20040077962	04-22-2004	KROLL; Mark W.	
	1719	US-20040078065	04-22-2004	KROLL; Mark W.	
	1720	US-20040078219	04-22-2004	KAYLOR; Rosann et al.	
	1721	US-20040093167	05-13-2004	BRAIG; James R. et al.	
	1722	US-20040099529	05-27-2004	MAO; Fei et al.	
	1723	US-20040106857	06-03-2004	GOUGH; David A.	
	1724	US-20040106858	06-03-2004	SAY; James et al.	
	1725	US-20040106859	06-03-2004	SAY; James et al.	
	1726	US-20040108226	06-10-2004	POLYCHRONAKOS; Constantin et al.	
	1727	US-20040122353	06-24-2004	SHAHMIRIAN; Varaz et al.	
	1728	US-20040133131	07-08-2004	KUHN; David L. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 71 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1729	US-20040133164	07-08-2004	FUNDERBURK; Jeffery V. et al.	
	1730	US-20040135684	07-15-2004	STEINTHAL; Gregory et al.	
	1731	US-20040138588	07-15-2004	SAIKLEY; Charles R. et al.	
	1732	US-20040138716	07-15-2004	KON; Steve et al.	
	1733	US-20040142403	07-22-2004	HETZEL; Donald et al.	
	1734	US-20040143173	07-22-2004	REGHABI; Bahar et al.	
	1735	US-20040146909	07-29-2004	DUONG; Hau H. et al.	
	1736	US-20040147819	07-29-2004	CADUFF; Andreas et al.	
	1737	US-20040152187	08-05-2004	HAIGHT; LeVoy Golden et al.	
	1738	US-20040152622	08-05-2004	KEITH; Steven et al.	
	1739	US-20040158137	08-12-2004	EPPSTEIN; Jonathan A. et al.	
	1740	US-20040162678	08-19-2004	HETZEL; Donald et al.	
	1741	US-20040167801	08-26-2004	SAY; James et al.	
	1742	US-20040171921	09-02-2004	SAY; James et al.	
	1743	US-20040172307	09-02-2004	GRUBER; Martin A.	
	1744	US-20040173472	09-09-2004	JUNG; Sung-Kwon et al.	
	1745	US-20040176672	09-09-2004	SILVER; James H. et al.	
	1746	US-20040186362	09-23-2004	BRAUKER; James H. et al.	
	1747	US-20040186365	09-23-2004	JIN; Robert Y. et al.	
	1748	US-20040193025	09-30-2004	STEIL; Garry M. et al.	
	1749	US-20040193090	09-30-2004	LEBEL; Ronald J. et al.	
	1750	US-20040197846	10-07-2004	HOCKERSMITH; Linda et al.	
	1751	US-20040199059	10-07-2004	BRAUKER; James H. et al.	
	1752	US-20040204687	10-14-2004	MOGENSEN; Lasse Wesseltoft et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 72 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1753	US-20040208780	10-21-2004	FARIES, Jr.; Durward I. et al.	
	1754	US-20040219664	11-04-2004	HELLER; Adam et al.	
	1755	US-20040220517	11-04-2004	STARKWEATHER; Timothy J. et al.	
	1756	US-20040225338	11-11-2004	LEBEL; Ronald J. et al.	
	1757	US-20040236200	11-25-2004	SAY; James et al.	
	1758	US-20040236251	11-25-2004	ROE; Steven N. et al.	
	1759	US-20040242982	12-02-2004	SAKATA; Tetsuya et al.	
	1760	US-20040249253	12-09-2004	RACCHINI; Joel et al.	
	1761	US-20040249420	12-09-2004	OLSON; Walter H. et al.	
	1762	US-20040254433	12-16-2004	BANDIS; Steven D. et al.	
	1763	US-20040254434	12-16-2004	GOODNOW; Timothy T. et al.	
	1764	US-20040260478	12-23-2004	SCHWAMM; Lee H.	
	1765	US-20040263354	12-30-2004	MANN; Alfred E. et al.	
	1766	US-20040267300	12-30-2004	MACE; Chad Harold	
	1767	US-20050003470	01-06-2005	NELSON; Charles L. et al.	
	1768	US-20050004439	01-06-2005	SHIN; John J. et al.	
	1769	US-20050004494	01-06-2005	PEREZ; Edward P. et al.	
	1770	US-20050006122	01-13-2005	BURNETTE; David Ruffin	
	1771	US-20050010087	01-13-2005	BANET; Matthew et al.	
	1772	US-20050010265	01-13-2005	BARU FASSIO; Marcelo Daniel et al.	
	1773	US-20050010269	01-13-2005	LEBEL; Ronald J. et al.	
	1774	US-20050015020	01-20-2005	LeVAUGHN; Richard W. et al.	
	1775	US-20050016276	01-27-2005	GUAN; Shenheng et al.	
	1776	US-20050026689	02-03-2005	MARKS; Richard L.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 73 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1777	US-20050027177	02-03-2005	SHIN; John J. et al.	
	1778	US-20050027180	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1779	US-20050027181	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1780	US-20050027182	02-03-2005	SIDDIQUI; Uzair et al.	
	1781	US-20050027462	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1782	US-20050027463	02-03-2005	GOODE, Jr.; Paul V. et al.	
	1783	US-20050031689	02-10-2005	SHULTS; Mark et al.	
	1784	US-20050033132	02-10-2005	SHULTS; Mark C. et al.	
	1785	US-20050038332	02-17-2005	SAIDARA; Frank et al.	
	1786	US-20050043598	02-24-2005	GOODE, Jr.; Paul V. et al.	
	1787	US-20050049179	03-03-2005	DAVIDSON; Paul C. et al.	
	1788	US-20050049473	03-03-2005	DESAI; Shashi P. et al.	
	1789	US-20050051427	03-10-2005	BRAUKER; James H. et al.	
	1790	US-20050051440	03-10-2005	SIMPSON; Peter C. et al.	
	1791	US-20050054905	03-10-2005	CORL; Paul D. et al.	
	1792	US-20050054909	03-10-2005	PETISCE; James et al.	
	1793	US-20050056551	03-17-2005	WHITE; Stephen Fredrick et al.	
	1794	US-20050056552	03-17-2005	SIMPSON; Peter C. et al.	
	1795	US-20050059871	03-17-2005	GOUGH; David A. et al.	
	1796	US-20050065464	03-24-2005	TALBOT; Cary D. et al.	
	1797	US-20050070774	03-31-2005	ADDISON; Paul Stanley et al.	
	1798	US-20050090607	04-28-2005	TAPSAK; Mark A. et al.	
	1799	US-20050096511	05-05-2005	FOX; James Kelly et al.	
	1800	US-20050096512	05-05-2005	FOX; James Kelly et al.	
	1801	US-20050096519	05-05-2005	DeNUZZIO; John D. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 74 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1802	US-20050101847	05-12-2005	ROUTT; Wilson et al.	
	1803	US-20050103625	05-19-2005	RHODES; Rathbun et al.	
	1804	US-20050112169	05-26-2005	BRAUKER; James H. et al.	
	1805	US-20050113653	05-26-2005	FOX; James Kelly et al.	
	1806	US-20050114068	05-26-2005	CHEY; S. Jay et al.	
	1807	US-20050115832	06-02-2005	SIMPSON; Peter C. et al.	
	1808	US-20050121322	06-09-2005	SAY; James et al.	
	1809	US-20050124873	06-09-2005	SHULTS; Mark C. et al.	
	1810	US-20050131305	06-16-2005	DANIELSON; Bo G. et al.	
	1811	US-20050131346	06-16-2005	DOUGLAS; Joel S.	
	1812	US-20050133368	06-23-2005	DAVIES; Oliver William Hardwicke et al.	
	1813	US-20050139489	06-30-2005	DAVIES; Oliver William Hardwicke et al.	
	1814	US-20050143635	06-30-2005	KAMATH; Apurv Ullas et al.	
	1815	US-20050143675	06-30-2005	NEEL; Gary T. et al.	
	1816	US-20050154271	07-14-2005	RASDAL; Andrew et al.	
	1817	US-20050161346	07-28-2005	SIMPSON; Peter et al.	
	1818	US-20050173245	08-11-2005	FELDMAN; Benjamin et al.	
	1819	US-20050176136	08-11-2005	BURD; John et al.	
	1820	US-20050177036	08-11-2005	SHULTS; Mark C. et al.	
	1821	US-20050177398	08-11-2005	WATANABE; Motokazu et al.	
	1822	US-20050181012	08-18-2005	SAINT; Sean et al.	
	1823	US-20050182306	08-18-2005	SLOAN; Mark K.	
	1824	US-20050182451	08-18-2005	GRIFFIN; Adam et al.	
	1825	US-20050183954	08-25-2005	HITCHCOCK; Robert W. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 75 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1826	US-20050187720	08-25-2005	GOODE, Jr.; Paul V. et al.	
	1827	US-20050192494	09-01-2005	GINSBERG; Barry H.	
	1828	US-20050192557	09-01-2005	BRAUKER; James H. et al.	
	1829	US-20050195930	09-08-2005	SPITAL; Glenn O. et al.	
	1830	US-20050196820	09-08-2005	ZWEIG; Stephen Eliot	
	1831	US-20050196821	09-08-2005	MONFRE; Stephen L. et al.	
	1832	US-20050197612	09-08-2005	LEVIN; Howard R. et al.	
	1833	US-20050199494	09-15-2005	SAY; James et al.	
	1834	US-20050203360	09-15-2005	BRAUKER; James H. et al.	
	1835	US-20050203364	09-15-2005	MONFRE; Stephen L. et al.	
	1836	US-20050211571	09-29-2005	SCHULEIN; Jurgen et al.	
	1837	US-20050214892	09-29-2005	KOVATCHEV; Boris P. et al.	
	1838	US-20050215871	09-29-2005	FELDMAN; Benjamin J. et al.	
	1839	US-20050215872	09-29-2005	BERNER; Bret et al.	
	1840	US-20050239154	10-27-2005	FELDMAN; Benjamin J. et al.	
	1841	US-20050239156	10-27-2005	DRUCKER; Steven et al.	
	1842	US-20050241957	11-03-2005	MAO; Fei et al.	
	1843	US-20050242479	11-03-2005	PETISCE; James R. et al.	
	1844	US-20050245795	11-03-2005	GOODE, Jr.; Paul V. et al.	
	1845	US-20050245799	11-03-2005	BRAUKER; James H. et al.	
	1846	US-20050245839	11-03-2005	STIVORIC; John et al.	
	1847	US-20050245904	11-03-2005	ESTES; Mark C. et al.	
	1848	US-20050258037	11-24-2005	HAJIZADEH; Kiamars et al.	
	1849	US-20050261563	11-24-2005	ZHOU; Peter et al.	
	1850	US-20050272989	12-08-2005	SHAH; Rajiv et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 76 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1851	US-20050277164	12-15-2005	DRUCKER; Steven et al.	
	1852	US-20050277912	12-15-2005	JOHN; Sasha	
	1853	US-20050287620	12-29-2005	HELLER; Adam et al.	
	1854	US-20050288596	12-29-2005	EIGLER; Neal L. et al.	
	1855	US-20050288725	12-29-2005	HETTRICK; Douglas A. et al.	
	1856	US-20060001538	01-05-2006	KRAFT; Ulrich et al.	
	1857	US-20060004270	01-05-2006	BEDARD; Michel et al.	
	1858	US-20060010098	01-12-2006	GOODNOW; Timothy T. et al.	
	1859	US-20060015020	01-19-2006	NEALE; Paul et al.	
	1860	US-20060015024	01-19-2006	BRISTER; Mark et al.	
	1861	US-20060016700	01-26-2006	BRISTER; Mark et al.	
	1862	US-20060017923	01-26-2006	RUCHTI; Timothy L. et al.	
	1863	US-20060019327	01-26-2006	BRISTER; Mark et al.	
	1864	US-20060020186	01-26-2006	BRISTER; Mark et al.	
	1865	US-20060020187	01-26-2006	BRISTER; Mark et al.	
	1866	US-20060020188	01-26-2006	KAMATH; Apurv Ullas et al.	
	1867	US-20060020189	01-26-2006	BRISTER; Mark et al.	
	1868	US-20060020190	01-26-2006	KAMATH; Apurv Ullas et al.	
	1869	US-20060020191	01-26-2006	BRISTER; Mark et al.	
	1870	US-20060020192	01-26-2006	BRISTER; Mark et al.	
	1871	US-20060025662	02-02-2006	BUSE; John Bernard et al.	
	1872	US-20060025663	02-02-2006	TALBOT; Cary D. et al.	
	1873	US-20060029177	02-09-2006	CRANFORD, Jr.; Hayden Clavie et al.	
	1874	US-20060031094	02-09-2006	COHEN; Gary et al.	
	1875	US-20060036139	02-16-2006	BRISTER; Mark et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 77 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1876	US-20060036140	02-16-2006	BRISTER; Mark et al.	
	1877	US-20060036141	02-16-2006	KAMATH; Apurv Ullas et al.	
	1878	US-20060036142	02-16-2006	BRISTER; Mark et al.	
	1879	US-20060036143	02-16-2006	BRISTER; Mark et al.	
	1880	US-20060036144	02-16-2006	BRISTER; Mark et al.	
	1881	US-20060036145	02-16-2006	BRISTER; Mark et al.	
	1882	US-20060040402	02-23-2006	BRAUKER; James H. et al.	
	1883	US-20060042353	03-02-2006	MARQUIS; Brent et al.	
	1884	US-20060047192	03-02-2006	HELLWIG; Robert et al.	
	1885	US-20060052745	03-09-2006	VAN ANTWERP; Nannette M. et al.	
	1886	US-20060068208	03-30-2006	TAPSAK; Mark A. et al.	
	1887	US-20060079809	04-13-2006	GOLDBERGER; Daniel et al.	
	1888	US-20060086624	04-27-2006	TAPSAK; Mark A. et al.	
	1889	US-20060091006	05-04-2006	WANG; Yi et al.	
	1890	US-20060094946	05-04-2006	KELLOGG; Scott C. et al.	
	1891	US-20060100588	05-11-2006	BRUNNBERG; Lennart et al.	
	1892	US-20060142651	06-29-2006	BRISTER; Mark et al.	
	1893	US-20060155180	07-13-2006	BRISTER; Mark et al.	
	1894	US-20060166629	07-27-2006	REGGIARDO; Christopher V.	
	1895	US-20060167365	07-27-2006	BHARMI; Rupinder	
	1896	US-20060167517	07-27-2006	GILL; Jong et al.	
	1897	US-20060167518	07-27-2006	GILL; Jong et al.	
	1898	US-20060167519	07-27-2006	GILL; Jong et al.	
	1899	US-20060173260	08-03-2006	GAONI; Yuval et al.	
	1900	US-20060173406	08-03-2006	HAYES; Andrew C. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 78 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1901	US-20060173444	08-03-2006	CHOY; David Y. et al.	
	1902	US-20060178617	08-10-2006	ADAMS; H. Clark et al.	
	1903	US-20060183984	08-17-2006	DOBBLES; J. Michael et al.	
	1904	US-20060183985	08-17-2006	BRISTER; Mark et al.	
	1905	US-20060189851	08-24-2006	TIVIG; Gerhard et al.	
	1906	US-20060189856	08-24-2006	PETISCE; James et al.	
	1907	US-20060189863	08-24-2006	PEYSER; Thomas et al.	
	1908	US-20060189925	08-24-2006	GABLE; Jennifer H. et al.	
	1909	US-20060193375	08-31-2006	LEE; U. Sang	
	1910	US-20060195029	08-31-2006	SHULTS; Mark C. et al.	
	1911	US-20060198864	09-07-2006	SHULTS; Mark et al.	
	1912	US-20060200009	09-07-2006	WEKELL; William et al.	
	1913	US-20060200019	09-07-2006	PETISCE; James et al.	
	1914	US-20060200020	09-07-2006	BRISTER; Mark et al.	
	1915	US-20060200022	09-07-2006	BRAUKER; James H. et al.	
	1916	US-20060200970	09-14-2006	BRISTER; Mark et al.	
	1917	US-20060222566	10-05-2006	BRAUKER; James H. et al.	
	1918	US-20060224109	10-05-2006	STEIL; Garry M. et al.	
	1919	US-20060224141	10-05-2006	RUSH; Benjamin M. et al.	
	1920	US-20060226985	10-12-2006	GOODNOW; Timothy T. et al.	
	1921	US-20060229512	10-12-2006	PETISCE; James R. et al.	
	1922	US-20060229531	10-12-2006	GOLDBERGER; Daniel et al.	
	1923	US-20060229533	10-12-2006	HOENES; Joachim et al.	
	1924	US-20060247508	11-02-2006	FENNELL; Martin J.	
	1925	US-20060247685	11-02-2006	BHARMI; Rupinder	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 79 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1926	US-20060247985	11-02-2006	LIAMOS; Charles T. et al.	
	1927	US-20060253012	11-09-2006	PETISCE; James R. et al.	
	1928	US-20060253085	11-09-2006	GEISMAR; Eric P. et al.	
	1929	US-20060257996	11-16-2006	SIMPSON; Peter C. et al.	
	1930	US-20060258761	11-16-2006	BOOCK; Robert et al.	
	1931	US-20060258929	11-16-2006	GOODE, Jr.; Paul V. et al.	
	1932	US-20060263839	11-23-2006	WARD; W. Kenneth et al.	
	1933	US-20060264785	11-23-2006	DRING; Barton et al.	
	1934	US-20060270922	11-30-2006	BRAUKER; James H. et al.	
	1935	US-20060270923	11-30-2006	BRAUKER; James H. et al.	
	1936	US-20060272652	12-07-2006	STOCKER; David N. et al.	
	1937	US-20060281985	12-14-2006	WARD; W. Kenneth et al.	
	1938	US-20060293576	12-28-2006	VAN ANTWERP; Nanette M. et al.	
	1939	US-20070016381	01-18-2007	KAMATH; Apurv et al.	
	1940	US-20070017805	01-25-2007	HODGES; Alastair et al.	
	1941	US-20070020641	01-25-2007	HEEGER; Alan J. et al.	
	1942	US-20070027284	02-01-2007	WEI; Kuang-Hwa et al.	
	1943	US-20070027370	02-01-2007	BRAUKER; James H. et al.	
	1944	US-20070027381	02-01-2007	STAFFORD; Gary Ashley	
	1945	US-20070027384	02-01-2007	BRISTER; Mark et al.	
	1946	US-20070027385	02-01-2007	BRISTER; Mark et al.	
	1947	US-20070032706	02-08-2007	KAMATH; Apurv et al.	
	1948	US-20070032717	02-08-2007	BRISTER; Mark et al.	
	1949	US-20070032718	02-08-2007	SHULTS; Mark C. et al.	
	1950	US-20070033074	02-08-2007	NITZAN; Tamir et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 80 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1951	US-20070033254	02-08-2007	AlHUSSEINI; Ibrahim Ameen et al.	
	1952	US-20070045902	03-01-2007	BRAUKER; James H. et al.	
	1953	US-20070049873	03-01-2007	HANSEN; Torben Strom et al.	
	1954	US-20070056858	03-15-2007	CHEN; Ting et al.	
	1955	US-20070059196	03-15-2007	BRISTER; Mark et al.	
	1956	US-20070060803	03-15-2007	LILJERYD; Lars Gustaf et al.	
	1957	US-20070060814	03-15-2007	STAFFORD; Gary Ashley	
	1958	US-20070060871	03-15-2007	ISTOC; Emilian et al.	
	1959	US-20070066873	03-22-2007	KAMATH; Apurv et al.	
	1960	US-20070068807	03-29-2007	FELDMAN; Benjamin J. et al.	
	1961	US-20070071681	03-29-2007	GADKAR; Kapil et al.	
	1962	US-20070073129	03-29-2007	SHAH; Rajiv et al.	
	1963	US-20070078320	04-05-2007	STAFFORD; Gary Ashley	
	1964	US-20070078321	04-05-2007	MAZZA; John C. et al.	
	1965	US-20070078322	04-05-2007	STAFFORD; Gary Ashley	
	1966	US-20070078323	04-05-2007	REGGIARDO; Christopher V. et al.	
	1967	US-20070085995	04-19-2007	PESACH; Benny et al.	
	1968	US-20070093704	04-26-2007	BRISTER; Mark et al.	
	1969	US-20070095661	05-03-2007	WANG; Yi et al.	
	1970	US-20070106135	05-10-2007	SLOAN; Mark K. et al.	
	1971	US-20070108048	05-17-2007	WANG; Yi et al.	
	1972	US-20070112298	05-17-2007	MUELLER, Jr.; John C. et al.	
	1973	US-20070116600	05-24-2007	KOCHAR; Manish Swarnaraj et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 81 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1974	US-20070118030	05-24-2007	BRUCE; Robert et al.	
	1975	US-20070118405	05-24-2007	CAMPBELL; Robert et al.	
	1976	US-20070124002	05-31-2007	ESTES; Mark C. et al.	
	1977	US-20070129619	06-07-2007	WARD; W. Kenneth et al.	
	1978	US-20070129621	06-07-2007	KELLOGG; Scott C. et al.	
	1979	US-20070135699	06-14-2007	WARD; W. Kenneth et al.	
	1980	US-20070142584	06-21-2007	SCHORZMAN; Derek et al.	
	1981	US-20070149875	06-28-2007	OUYANG; Tianmei et al.	
	1982	US-20070151869	07-05-2007	HELLER; Adam et al.	
	1983	US-20070156033	07-05-2007	CAUSEY, III; James D. et al.	
	1984	US-20070163880	07-19-2007	WOO; Kum Ming et al.	
	1985	US-20070168224	07-19-2007	LETZT; Alan M. et al.	
	1986	US-20070169533	07-26-2007	SHAH; Rajiv et al.	
	1987	US-20070170073	07-26-2007	WANG; Lu et al.	
	1988	US-20070173706	07-26-2007	NEINAST; Mark et al.	
	1989	US-20070173709	07-26-2007	PETISCE; James R. et al.	
	1990	US-20070173710	07-26-2007	PETISCE; James R. et al.	
	1991	US-20070173711	07-26-2007	SHAH; Rajiv et al.	
	1992	US-20070173712	07-26-2007	SHAH; Rajiv et al.	
	1993	US-20070173741	07-26-2007	DESHMUKH; Ajay et al.	
	1994	US-20070173761	07-26-2007	KANDERIAN, Jr.; Sami S. et al.	
	1995	US-20070179349	08-02-2007	HOYME; Kenneth P. et al.	
	1996	US-20070179352	08-02-2007	RANDLOV; Jette et al.	
	1997	US-20070179434	08-02-2007	WEINERT; Stefan et al.	
	1998	US-20070179436	08-02-2007	BRAIG; James R. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 82 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1999	US-20070191701	08-16-2007	FELDMAN; Benjamin J. et al.	
	2000	US-20070191716	08-16-2007	GOLDBERGER; Daniel et al.	
	2001	US-20070197889	08-23-2007	BRISTER; Mark et al.	
	2002	US-20070197890	08-23-2007	BOOCK; Robert et al.	
	2003	US-20070199818	08-30-2007	PETYT; Adrian et al.	
	2004	US-20070200254	08-30-2007	CURRY; Kenneth M.	
	2005	US-20070202562	08-30-2007	CURRY; Kenneth M.	
	2006	US-20070202672	08-30-2007	CURRY; Kenneth M.	
	2007	US-20070203407	08-30-2007	HOSS; Udo et al.	
	2008	US-20070203410	08-30-2007	SAY; James et al.	
	2009	US-20070203966	08-30-2007	BRAUKER; James H. et al.	
	2010	US-20070206193	09-06-2007	PESACH; Benny	
	2011	US-20070208244	09-06-2007	BRAUKER; James H. et al.	
	2012	US-20070208245	09-06-2007	BRAUKER; James H. et al.	
	2013	US-20070208246	09-06-2007	BRAUKER; James H. et al.	
	2014	US-20070213610	09-13-2007	SAY; James et al.	
	2015	US-20070213611	09-13-2007	SIMPSON; Peter C. et al.	
	2016	US-20070213657	09-13-2007	JENNEWINE; R. Curtis et al.	
	2017	US-20070218097	09-20-2007	HELLER; Adam et al.	
	2018	US-20070219441	09-20-2007	CARLIN; Patrick et al.	
	2019	US-20070224700	09-27-2007	MASTERS; Brett P.	
	2020	US-20070225675	09-27-2007	ROBINSON; Mark Ries et al.	
	2021	US-20070227911	10-04-2007	WANG; Yi et al.	
	2022	US-20070232877	10-04-2007	HE; Lei	
	2023	US-20070232878	10-04-2007	KOVATCHEV; Boris P. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 83 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2024	US-20070232879	10-04-2007	BRISTER; Mark et al.	
	2025	US-20070232880	10-04-2007	SIDDIQUI; Uzair et al.	
	2026	US-20070233013	10-04-2007	SCHOENBERG; Stephen J.	
	2027	US-20070235331	10-11-2007	SIMPSON; Peter C. et al.	
	2028	US-20070240497	10-18-2007	ROBINSON; Mark Ries et al.	
	2029	US-20070244379	10-18-2007	BOOCK; Robert et al.	
	2030	US-20070244381	10-18-2007	ROBINSON; Mark Ries et al.	
	2031	US-20070244382	10-18-2007	ROBINSON; Mark Ries et al.	
	2032	US-20070249916	10-25-2007	PESACH; Benny et al.	
	2033	US-20070249922	10-25-2007	PEYSER; Thomas A. et al.	
	2034	US-20070255321	11-01-2007	GERBER; Martin T. et al.	
	2035	US-20070259217	11-08-2007	LOGAN; Bruce	
	2036	US-20070299389	12-27-2007	HALBERT; Donald et al.	
	2037	US-20070299617	12-27-2007	WILLIS; John P.	
	2038	US-20080000779	01-03-2008	WANG; Lu et al.	
	2039	US-20080004515	01-03-2008	JENNEWINE; R. Curtis	
	2040	US-20080004601	01-03-2008	JENNEWINE; R. Curtis et al.	
	2041	US-20080009692	01-10-2008	STAFFORD; Gary Ashley	
	2042	US-20080012701	01-17-2008	KASS; Alex M. et al.	
	2043	US-20080017522	01-24-2008	HELLER; Adam et al.	
	2044	US-20080021666	01-24-2008	GOODE, Jr.; Paul V. et al.	
	2045	US-20080021972	01-24-2008	HUELSKAMP; Paul J. et al.	
	2046	US-20080029390	02-07-2008	ROCHE; Joelle et al.	
	2047	US-20080029391	02-07-2008	MAO; Fei et al.	
	2048	US-20080033254	02-07-2008	KAMATH; Apurv Ullas et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 84 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2049	US-20080033357	02-07-2008	MANN; Alfred E. et al.	
	2050	US-20080039702	02-14-2008	HAYTER; Gary et al.	
	2051	US-20080045824	02-21-2008	TAPSAK; Mark A. et al.	
	2052	US-20080058625	03-06-2008	McGARRAUGH; Geoffrey V. et al.	
	2053	US-20080064937	03-13-2008	McGARRAUGH; Geoffrey V. et al.	
	2054	US-20080066305	03-20-2008	WANG; Yi et al.	
	2055	US-20080071156	03-20-2008	BRISTER; Mark et al.	
	2056	US-20080071157	03-20-2008	McGARRAUGH; Geoffrey V. et al.	
	2057	US-20080071158	03-20-2008	McGARRAUGH; Geoffrey V. et al.	
	2058	US-20080072663	03-27-2008	KEENAN; Richard et al.	
	2059	US-20080081000	04-03-2008	MACLEOD; John et al.	
	2060	US-20080081977	04-03-2008	HAYTER; Gary et al.	
	2061	US-20080083617	04-10-2008	SIMPSON; Peter C. et al.	
	2062	US-20080086040	04-10-2008	HELLER; Adam et al.	
	2063	US-20080086041	04-10-2008	HELLER; Adam et al.	
	2064	US-20080086042	04-10-2008	BRISTER; Mark et al.	
	2065	US-20080086043	04-10-2008	HELLER; Adam et al.	
	2066	US-20080086044	04-10-2008	BRISTER; Mark et al.	
	2067	US-20080086273	04-10-2008	SHULTS; Mark et al.	
	2068	US-20080091094	04-17-2008	HELLER; Adam et al.	
	2069	US-20080091095	04-17-2008	HELLER; Adam et al.	
	2070	US-20080097197	04-24-2008	KALAFUT; John F. et al.	
	2071	US-20080097289	04-24-2008	STEIL; Garry M. et al.	
	2072	US-20080097326	04-24-2008	MOBERG; Sheldon B. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 85 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2073	US-20080102441	05-01-2008	CHEN; Ting et al.	
	2074	US-20080103447	05-01-2008	REGGIARDO; Christopher V. et al.	
	2075	US-20080108942	05-08-2008	BRISTER; Mark et al.	
	2076	US-20080114227	05-15-2008	HAAR; Hans-Peter et al.	
	2077	US-20080115599	05-22-2008	MASTERS; Brett et al.	
	2078	US-20080119703	05-22-2008	BRISTER; Mark et al.	
	2079	US-20080119704	05-22-2008	BRISTER; Mark et al.	
	2080	US-20080119706	05-22-2008	BRISTER; Mark et al.	
	2081	US-20080119708	05-22-2008	BUDIMAN; Erwin S.	
	2082	US-20080125751	05-29-2008	FJIELD; Todd et al.	
	2083	US-20080139910	06-12-2008	MASTROTOTARO; John J. et al.	
	2084	US-20080147050	06-19-2008	MANN; Alfred E. et al.	
	2085	US-20080148873	06-26-2008	WANG; Yi	
	2086	US-20080154101	06-26-2008	JAIN; Faquir et al.	
	2087	US-20080154177	06-26-2008	MOUBAYED; Ahmad-Maher et al.	
	2088	US-20080154513	06-26-2008	KOVATCHEV; Boris P. et al.	
	2089	US-20080156661	07-03-2008	COOPER; Kenneth W. et al.	
	2090	US-20080161664	07-03-2008	MASTROTOTARO; John J. et al.	
	2091	US-20080161666	07-03-2008	FELDMAN; Benjamin J. et al.	
	2092	US-20080161753	07-03-2008	GILLESPIE; John et al.	
	2093	US-20080167543	07-10-2008	SAY; James et al.	
	2094	US-20080168676	07-17-2008	MORRISON; Justin E. et al.	
	2095	US-20080172205	07-17-2008	BRETON; Marc D. et al.	
	2096	US-20080177149	07-24-2008	WEINERT; Stefan et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 86 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2097	US-20080177165	07-24-2008	BLOMQUIST; Michael et al.	
	2098	US-20080183060	07-31-2008	STEIL; Garry M. et al.	
	2099	US-20080183061	07-31-2008	GOODE; Paul V. et al.	
	2100	US-20080183399	07-31-2008	GOODE; Paul V. et al.	
	2101	US-20080187655	08-07-2008	MARKLE; David R. et al.	
	2102	US-20080188722	08-07-2008	MARKLE; David R. et al.	
	2103	US-20080188725	08-07-2008	MARKLE; David R. et al.	
	2104	US-20080188731	08-07-2008	BRISTER; Mark et al.	
	2105	US-20080188796	08-07-2008	STEIL; Garry M. et al.	
	2106	US-20080189051	08-07-2008	GOODE; Paul V. et al.	
	2107	US-20080193936	08-14-2008	SQUIRRELL; David James	
	2108	US-20080194837	08-14-2008	KIM; Yong-Chul et al.	
	2109	US-20080194934	08-14-2008	RAY; Pinaki et al.	
	2110	US-20080194935	08-14-2008	BRISTER; Mark et al.	
	2111	US-20080194936	08-14-2008	GOODE; Paul V. et al.	
	2112	US-20080194937	08-14-2008	GOODE; Paul V. et al.	
	2113	US-20080194938	08-14-2008	BRISTER; Mark et al.	
	2114	US-20080195232	08-14-2008	CARR-BRENDEL; Victoria et al.	
	2115	US-20080195967	08-14-2008	GOODE; Paul V. et al.	
	2116	US-20080197024	08-21-2008	SIMPSON; Peter C. et al.	
	2117	US-20080200788	08-21-2008	BRISTER; Mark et al.	
	2118	US-20080200789	08-21-2008	BRISTER; Mark et al.	
	2119	US-20080200791	08-21-2008	SIMPSON; Peter C. et al.	
	2120	US-20080200897	08-21-2008	HOSS; Udo et al.	
	2121	US-20080201325	08-21-2008	DONIGER; Kenneth J. et al.	
	2122	US-20080205481	08-28-2008	FARIES; Durward I. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 87 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2123	US-20080208025	08-28-2008	SHULTS; Mark C. et al.	
	2124	US-20080208113	08-28-2008	DAMIANO; Edward et al.	
	2125	US-20080214910	09-04-2008	BUCK; Harvey B.	
	2126	US-20080214915	09-04-2008	BRISTER; Mark et al.	
	2127	US-20080214918	09-04-2008	BRISTER; Mark et al.	
	2128	US-20080228051	09-18-2008	SHULTS; Mark C. et al.	
	2129	US-20080228054	09-18-2008	SHULTS; Mark C. et al.	
	2130	US-20080234943	09-25-2008	RAY; Pinaki et al.	
	2131	US-20080242961	10-02-2008	BRISTER; Mark et al.	
	2132	US-20080242963	10-02-2008	ESSENPREIS; Matthias et al.	
	2133	US-20080249385	10-09-2008	PHAN; Luong Ngoc	
	2134	US-20080255434	10-16-2008	HAYTER; Gary et al.	
	2135	US-20080255437	10-16-2008	HAYTER; Gary	
	2136	US-20080255438	10-16-2008	SAIDARA; Frank et al.	
	2137	US-20080255808	10-16-2008	HAYTER; Gary	
	2138	US-20080256048	10-16-2008	HAYTER; Gary	
	2139	US-20080262469	10-23-2008	BRISTER; Mark C. et al.	
	2140	US-20080267823	10-30-2008	WANG; Yi et al.	
	2141	US-20080269714	10-30-2008	MASTROTOTARO; John J. et al.	
	2142	US-20080275313	11-06-2008	BRISTER; Mark et al.	
	2143	US-20080278332	11-13-2008	FENNELL; Martin J. et al.	
	2144	US-20080287761	11-20-2008	HAYTER; Gary et al.	
	2145	US-20080287762	11-20-2008	HAYTER; Gary et al.	
	2146	US-20080287763	11-20-2008	HAYTER; Gary	
	2147	US-20080287764	11-20-2008	RASDAL; Andrew et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 88 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2148	US-20080287765	11-20-2008	RASDAL; Andrew et al.	
	2149	US-20080287766	11-20-2008	RASDAL; Andrew et al.	
	2150	US-20080288180	11-20-2008	HAYTER; Gary et al.	
	2151	US-20080288204	11-20-2008	HAYTER; Gary et al.	
	2152	US-20080296155	12-04-2008	SHULTS; Mark C. et al.	
	2153	US-20080300572	12-04-2008	RANKERS; Ulrich et al.	
	2154	US-20080305009	12-11-2008	GAMSEY; Soya et al.	
	2155	US-20080305506	12-11-2008	SURI; Jeff T.	
	2156	US-20080306368	12-11-2008	GOODE, Jr.; Paul V. et al.	
	2157	US-20080306433	12-11-2008	CESARONI; Anthony J.	
	2158	US-20080306434	12-11-2008	DOBBLES; John Michael et al.	
	2159	US-20080306435	12-11-2008	KAMATH; Apurv U. et al.	
	2160	US-20080306444	12-11-2008	BRISTER; Mark C. et al.	
	2161	US-20080306472	12-11-2008	PRYOR; Brian et al.	
	2162	US-20080312841	12-18-2008	HAYTER; Gary	
	2163	US-20080312842	12-18-2008	HAYTER; Gary et al.	
	2164	US-20080312844	12-18-2008	HAYTER; Gary et al.	
	2165	US-20080312845	12-18-2008	HAYTER; Gary et al.	
	2166	US-20080314395	12-25-2008	KOVATCHEV; Boris P. et al.	
	2167	US-20080319279	12-25-2008	RAMSAY; Erin B. et al.	
	2168	US-20080319295	12-25-2008	BERNSTEIN; Daniel et al.	
	2169	US-20080319296	12-25-2008	BERNSTEIN; Daniel et al.	
	2170	US-20090005665	01-01-2009	HAYTER; Gary et al.	
	2171	US-20090005666	01-01-2009	SHIN; John J. et al.	
	2172	US-20090006034	01-01-2009	HAYTER; Gary et al.	
	2173	US-20090006061	01-01-2009	THUKRAL; Ajay et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 89 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2174	US-20090012376	01-08-2009	AGUS; Michael	
	2175	US-20090012379	01-08-2009	GOODE, Jr.; Paul V. et al.	
	2176	US-20090018418	01-15-2009	MARKLE; David R. et al.	
	2177	US-20090018424	01-15-2009	KAMATH; Apurv Ullas et al.	
	2178	US-20090018425	01-15-2009	OUYANG; Tianmei et al.	
	2179	US-20090018426	01-15-2009	MARKLE; David R. et al.	
	2180	US-20090030293	01-29-2009	COOPER; Jonathan Mark et al.	
	2181	US-20090030294	01-29-2009	PETISCE; James R. et al.	
	2182	US-20090033482	02-05-2009	HAYTER; Gary et al.	
	2183	US-20090036747	02-05-2009	HAYTER; Gary et al.	
	2184	US-20090036758	02-05-2009	BRAUKER; James H. et al.	
	2185	US-20090036760	02-05-2009	HAYTER; Gary	
	2186	US-20090036763	02-05-2009	BRAUKER; James H. et al.	
	2187	US-20090043181	02-12-2009	BRAUKER; James H. et al.	
	2188	US-20090043182	02-12-2009	BRAUKER; James H. et al.	
	2189	US-20090043525	02-12-2009	BRAUKER; James H. et al.	
	2190	US-20090043541	02-12-2009	BRAUKER; James H. et al.	
	2191	US-20090043542	02-12-2009	BRAUKER; James H. et al.	
	2192	US-20090045055	02-19-2009	RHODES; Rathbun K. et al.	
	2193	US-20090048503	02-19-2009	DALAL; Yousufali H. et al.	
	2194	US-20090054745	02-26-2009	JENNEWINE; R. Curtis	
	2195	US-20090054748	02-26-2009	FELDMAN; Benjamin J.	
	2196	US-20090054749	02-26-2009	HE; Lei	
	2197	US-20090054753	02-26-2009	ROBINSON; Mark Ries et al.	
	2198	US-20090055149	02-26-2009	HAYTER; Gary et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 90 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2199	US-20090061528	03-05-2009	SURI; Jeff T.	
	2200	US-20090062633	03-05-2009	BRAUKER; James H. et al.	
	2201	US-20090062635	03-05-2009	BRAUKER; James H. et al.	
	2202	US-20090062645	03-05-2009	FEHRE; Jens et al.	
	2203	US-20090062767	03-05-2009	VAN ANTWERP; Nannette M. et al.	
	2204	US-20090063402	03-05-2009	HAYTER; Gary	
	2205	US-20090069649	03-12-2009	BUDIMAN; Erwin S.	
	2206	US-20090076356	03-19-2009	SIMPSON; Peter C. et al.	
	2207	US-20090076360	03-19-2009	BRISTER; Mark et al.	
	2208	US-20090076361	03-19-2009	KAMATH; Apurv Ullas et al.	
	2209	US-20090081803	03-26-2009	GAMSEY; Soya et al.	
	2210	US-20090082693	03-26-2009	STAFFORD; Gary Ashley	
	2211	US-20090085768	04-02-2009	PATEL; Himanshu et al.	
	2212	US-20090099434	04-16-2009	LIU; Zenghe et al.	
	2213	US-20090099436	04-16-2009	BRISTER; Mark et al.	
	2214	US-20090105570	04-23-2009	SLOAN; Mark K. et al.	
	2215	US-20090105636	04-23-2009	HAYTER; Gary et al.	
	2216	US-20090112478	04-30-2009	MUELLER, Jr.; John C. et al.	
	2217	US-20090112626	04-30-2009	TALBOT; Cary et al.	
	2218	US-20090118589	05-07-2009	UESHIMA; Hiromu et al.	
	2219	US-20090124877	05-14-2009	GOODE, Jr.; Paul V. et al.	
	2220	US-20090124878	05-14-2009	GOODE, Jr.; Paul V. et al.	
	2221	US-20090124879	05-14-2009	BRISTER; Mark et al.	
	2222	US-20090124964	05-14-2009	LEACH; Jacob S. et al.	
	2223	US-20090131768	05-21-2009	SIMPSON; Peter C. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 91 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2224	US-20090131769	05-21-2009	LEACH; Jacob S. et al.	
	2225	US-20090131776	05-21-2009	SIMPSON; Peter C. et al.	
	2226	US-20090131777	05-21-2009	SIMPSON; Peter C. et al.	
	2227	US-20090137886	05-28-2009	SHARIATI; Mohammad Ali et al.	
	2228	US-20090137887	05-28-2009	SHARIATI; Mohammad Ali et al.	
	2229	US-20090143659	06-04-2009	LI; Ying et al.	
	2230	US-20090143660	06-04-2009	BRISTER; Mark et al.	
	2231	US-20090143725	06-04-2009	PEYSER; Thomas A. et al.	
	2232	US-20090149728	06-11-2009	VAN ANTWERP; Nannette M. et al.	
	2233	US-20090156919	06-18-2009	BRISTER; Mark et al.	
	2234	US-20090156922	06-18-2009	GOLDBERGER; Daniel et al.	
	2235	US-20090156924	06-18-2009	SHARIATI; Mohammad Ali et al.	
	2236	US-20090163790	06-25-2009	BRISTER; Mark et al.	
	2237	US-20090163791	06-25-2009	BRISTER; Mark et al.	
	2238	US-20090163855	06-25-2009	SHIN; John et al.	
	2239	US-20090164190	06-25-2009	HAYTER; Gary	
	2240	US-20090164239	06-25-2009	HAYTER; Gary et al.	
	2241	US-20090164251	06-25-2009	HAYTER; Gary	
	2242	US-20090171178	07-02-2009	HE; Lei et al.	
	2243	US-20090177143	07-09-2009	MARKLE; William H. et al.	
	2244	US-20090178459	07-16-2009	LI; Ying et al.	
	2245	US-20090182217	07-16-2009	LI; Ying et al.	
	2246	US-20090182517	07-16-2009	GANDHI; Rajesh K. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 92 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2247	US-20090192366	07-30-2009	MENSINGER; Michael Robert et al.	
	2248	US-20090192380	07-30-2009	SHARIATI; Mohammad Ali et al.	
	2249	US-20090192722	07-30-2009	SHARIATI; Mohammad Ali et al.	
	2250	US-20090192724	07-30-2009	BRAUKER; James H. et al.	
	2251	US-20090192745	07-30-2009	KAMATH; Apurv Ullas et al.	
	2252	US-20090192751	07-30-2009	KAMATH; Apurv Ullas et al.	
	2253	US-20090198118	08-06-2009	HAYTER; Gary et al.	
	2254	US-20090203981	08-13-2009	BRAUKER; James H. et al.	
	2255	US-20090204340	08-13-2009	FELDMAN; Benjamin J. et al.	
	2256	US-20090204341	08-13-2009	BRAUKER; James H. et al.	
	2257	US-20090216103	08-27-2009	BRISTER; Mark et al.	
	2258	US-20090240120	09-24-2009	MENSINGER; Michael Robert et al.	
	2259	US-20090240128	09-24-2009	MENSINGER; Michael Robert et al.	
	2260	US-20090240193	09-24-2009	MENSINGER; Michael Robert et al.	
	2261	US-20090241028	09-24-2009	ISKEDJIAN; Michael	
	2262	US-20090242399	10-01-2009	KAMATH; Apurv Ullas et al.	
	2263	US-20090242425	10-01-2009	KAMATH; Apurv Ullas et al.	
	2264	US-20090247855	10-01-2009	BOOCK; Robert et al.	
	2265	US-20090247856	10-01-2009	BOOCK; Robert et al.	
	2266	US-20090247857	10-01-2009	HARPER; Wesley Scott et al.	
	2267	US-20090257911	10-15-2009	THOMAS; Christopher Allen et al.	
	2268	US-20090264719	10-22-2009	MARKLE; David R. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 93 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2269	US-20090281407	11-12-2009	BUDIMAN; Erwin S.	
	2270	US-20090287073	11-19-2009	BOOCK; Robert et al.	
	2271	US-20090287074	11-19-2009	SHULTS; Mark et al.	
	2272	US-20090294277	12-03-2009	THOMAS; Christopher Allen et al.	
	2273	US-20090299155	12-03-2009	YANG; Richard C. et al.	
	2274	US-20090299156	12-03-2009	SIMPSON; Peter C. et al.	
	2275	US-20090299162	12-03-2009	BRAUKER; James H. et al.	
	2276	US-20090299276	12-03-2009	BRAUKER; James H. et al.	
	2277	US-20100010324	01-14-2010	BRAUKER; James H. et al.	
	2278	US-20100010331	01-14-2010	BRAUKER; James H. et al.	
	2279	US-20100010332	01-14-2010	BRAUKER; James H. et al.	
	2280	US-20100016687	01-21-2010	BRAUKER; James H. et al.	
	2281	US-20100020309	01-28-2010	GOLDBERGER; Daniel et al.	
	2282	US-20100022855	01-28-2010	BRAUKER; James H. et al.	
	2283	US-20100023270	01-28-2010	HELLER; Adam et al.	
	2284	US-20100023291	01-28-2010	HAYTER; Gary et al.	
	2285	US-20100025238	02-04-2010	GOTTLIEB; Rebecca K. et al.	
	2286	US-20100030053	02-04-2010	GOODE, Jr.; Paul V. et al.	
	2287	US-20100030137	02-04-2010	HALL; W. Dale et al.	
	2288	US-20100030484	02-04-2010	BRAUKER; James H. et al.	
	2289	US-20100036215	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2290	US-20100036216	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2291	US-20100036222	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2292	US-20100036223	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2293	US-20100036224	02-11-2010	GOODE, Jr.; Paul V. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 94 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2294	US-20100036225	02-11-2010	GOODE, Jr.; Paul V. et al.	
	2295	US-20100045231	02-25-2010	HE; Lei	
	2296	US-20100045465	02-25-2010	BRAUKER; James H. et al.	
	2297	US-20100049015	02-25-2010	MARTINI; Joerg et al.	
	2298	US-20100049021	02-25-2010	JINA; Arvind N. et al.	
	2299	US-20100057040	03-04-2010	HAYTER; Gary	
	2300	US-20100057041	03-04-2010	HAYTER; Gary	
	2301	US-20100057042	03-04-2010	HAYTER; Gary	
	2302	US-20100057044	03-04-2010	HAYTER; Gary	
	2303	US-20100057057	03-04-2010	HAYTER; Gary et al.	
	2304	US-20100063372	03-11-2010	POTTS; Russell O. et al.	
	2305	US-20100064764	03-18-2010	HAYTER; Gary et al.	
	2306	US-20100081906	04-01-2010	HAYTER; Gary et al.	
	2307	US-20100081908	04-01-2010	DOBBLES; J. Michael et al.	
	2308	US-20100081909	04-01-2010	BUDIMAN; Erwin Satrya et al.	
	2309	US-20100081910	04-01-2010	BRISTER; Mark et al.	
	2310	US-20100081953	04-01-2010	SYEDA-MAHMOOD; Tanveer F. et al.	
	2311	US-20100094111	04-15-2010	HELLER; Adam et al.	
	2312	US-20100121167	05-13-2010	McGARRAUGH; Geoffrey V.	
	2313	US-20100141656	06-10-2010	KRIEFTEWIRTH; Michael	
	2314	US-20100145174	06-10-2010	ALFERNESS; Clifton A. et al.	
	2315	US-20100152561	06-17-2010	GOODNOW; Timothy T. et al.	
	2316	US-20100160759	06-24-2010	CELENTANO; Michael J. et al.	
	2317	US-20100160761	06-24-2010	SAY; James et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 95 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2318	US-20100168538	07-01-2010	KEENAN; Desmond Barry et al.	
	2319	US-20100168546	07-01-2010	KAMATH; Apurv Ullas et al.	
	2320	US-20100169035	07-01-2010	LIANG; Bradley Chi et al.	
	2321	US-20100174167	07-08-2010	KAMATH; Apurv Ullas et al.	
	2322	US-20100174168	07-08-2010	GOODE, Jr.; Paul V. et al.	
	2323	US-20100174266	07-08-2010	ESTES; Mark C.	
	2324	US-20100179399	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2325	US-20100179402	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2326	US-20100179405	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2327	US-20100179406	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2328	US-20100179407	07-15-2010	GOODE, Jr.; Paul V. et al.	
	2329	US-20100179408	07-15-2010	KAMATH; Apurv et al.	
	2330	US-20100179409	07-15-2010	KAMATH; Apurv Ullas et al.	
	2331	US-20100185065	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2332	US-20100185070	07-22-2010	BRISTER; Mark et al.	
	2333	US-20100185071	07-22-2010	SIMPSON; Peter C. et al.	
	2334	US-20100185072	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2335	US-20100185073	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2336	US-20100185074	07-22-2010	GOODE, Jr.; Paul V. et al.	
	2337	US-20100191085	07-29-2010	BUDIMAN; Erwin Satrya	
	2338	US-20100191472	07-29-2010	DONIGER; Kenneth J. et al.	
	2339	US-20100198034	08-05-2010	THOMAS; Christopher Allen et al.	
	2340	US-20100198035	08-05-2010	KAMATH; Apurv Ullas et al.	
	2341	US-20100198142	08-05-2010	SLOAN; Mark K. et al.	
	2342	US-20100204557	08-12-2010	KIAIE; Namvar et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 96 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2343	US-20100213057	08-26-2010	FELDMAN; Benjamin et al.	
	2344	US-20100214104	08-26-2010	GOODE, Jr.; Paul V. et al.	
	2345	US-20100217106	08-26-2010	GOODE, Jr.; Paul V. et al.	
	2346	US-20100230285	09-16-2010	HOSS; Udo et al.	
	2347	US-20100234707	09-16-2010	GOODE, Jr.; Paul V. et al.	
	2348	US-20100234710	09-16-2010	BUDIMAN; Erwin Satrya et al.	
	2349	US-20100234796	09-16-2010	KAMATH; Apurv U. et al.	
	2350	US-20100235106	09-16-2010	KAMATH; Apurv U. et al.	
	2351	US-20100240975	09-23-2010	GOODE, Jr.; Paul V. et al.	
	2352	US-20100240976	09-23-2010	GOODE, Jr.; Paul V. et al.	
	2353	US-20100261987	10-14-2010	KAMATH; Apurv Ullas et al.	
	2354	US-20100265073	10-21-2010	HARPER; Wesley Scott	
	2355	US-20100274107	10-28-2010	BOOCK; Robert et al.	
	2356	US-20100274515	10-28-2010	HOSS; Udo et al.	
	2357	US-20100277342	11-04-2010	SICURELLO; Jeffrey Mario et al.	
	2358	US-20100280441	11-04-2010	WILINSKA; Malgorzata E. et al.	
	2359	US-20100280782	11-04-2010	HARPER; Wesley Scott	
	2360	US-20100286496	11-11-2010	SIMPSON; Peter C. et al.	
	2361	US-20100298684	11-25-2010	LEACH; Jacob S. et al.	
	2362	US-20100313105	12-09-2010	NEKOOMARAM; Saeed et al.	
	2363	US-20100317952	12-16-2010	BUDIMAN; Erwin S. et al.	
	2364	US-20100324392	12-23-2010	YEE; Phillip et al.	
	2365	US-20100326842	12-30-2010	MAZZA; John C. et al.	
	2366	US-20100331644	12-30-2010	NEALE; Paul V. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 97 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2367	US-20100331648	12-30-2010	KAMATH; Apurv Ullas et al.	
	2368	US-20100331655	12-30-2010	KAMATH; Apurv Ullas et al.	
	2369	US-20110021889	01-27-2011	HOSS; Udo et al.	
	2370	US-20110024043	02-03-2011	BOOCK; Robert et al.	
	2371	US-20110024307	02-03-2011	SIMPSON; Peter C. et al.	
	2372	US-20110027127	02-03-2011	SIMPSON; Peter C. et al.	
	2373	US-20110027453	02-03-2011	BOOCK; Robert et al.	
	2374	US-20110027458	02-03-2011	BOOCK; Robert et al.	
	2375	US-20110028815	02-03-2011	SIMPSON; Peter C. et al.	
	2376	US-20110028816	02-03-2011	SIMPSON; Peter C. et al.	
	2377	US-20110029247	02-03-2011	KALATHIL; Raghunath Mammulli	
	2378	US-20110029269	02-03-2011	HAYTER; Gary Alan et al.	
	2379	US-20110040163	02-17-2011	TELSON; Stanley A. et al.	
	2380	US-20110046467	02-24-2011	SIMPSON; Peter C. et al.	
	2381	US-20110060530	03-10-2011	FENNELL; Martin J.	
	2382	US-20110077490	03-31-2011	SIMPSON; Peter C. et al.	
	2383	US-20110077491	03-31-2011	SAY; James et al.	
	2384	US-20110077494	03-31-2011	DONIGER; Kenneth J. et al.	
	2385	US-20110081726	04-07-2011	BERMAN; Glenn Howard	
	2386	US-20110082484	04-07-2011	SARAVIA; Heber et al.	
	2387	US-20110105873	05-05-2011	FELDMAN; Benjamin Jay et al.	
	2388	US-20110106126	05-05-2011	LOVE; Michael et al.	
	2389	US-20110112696	05-12-2011	YODFAT; Ofer et al.	
	2390	US-20110118579	05-19-2011	GOODE, Jr.; Paul V. et al.	
	2391	US-20110124997	05-26-2011	GOODE, Jr.; Paul V. et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 98 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2392	US-20110125410	05-26-2011	GOODE, Jr.; Paul V. et al.	
	2393	US-20110130970	06-02-2011	GOODE, Jr.; Paul V. et al.	
	2394	US-20110137601	06-09-2011	GOODE, Jr.; Paul V. et al.	
	2395	US-20110148905	06-23-2011	SIMMONS; David A. et al.	
	2396	US-20110174638	07-21-2011	KATSUKI; Koji	
	2397	US-20110184268	07-28-2011	TAUB; Marc Barry	
	2398	US-20110190603	08-04-2011	STAFFORD; Gary A.	
	2399	US-20110191044	08-04-2011	STAFFORD; Gary A.	
	2400	US-20110193704	08-11-2011	HARPER; Wesley Scott et al.	
	2401	US-20110208027	08-25-2011	WAGNER; Robin et al.	
	2402	US-20110208155	08-25-2011	PALERM; Cesar C. et al.	
	2403	US-20110213225	09-01-2011	BERNSTEIN; Daniel Milfred et al.	
	2404	US-20110218414	09-08-2011	KAMATH; Apurv et al.	
	2405	US-20110224523	09-15-2011	BUDIMAN; Erwin Satrya	
	2406	US-20110230741	09-22-2011	LIANG; Bradley Chi et al.	
	2407	US-20110257495	10-20-2011	HOSS; Udo et al.	
	2408	US-20110257895	10-20-2011	BRAUKER; James H. et al.	
	2409	US-20110263958	10-27-2011	BRAUKER; James H. et al.	
	2410	US-20110270062	11-03-2011	GOODE, Jr.; Paul V. et al.	
	2411	US-20110288574	11-24-2011	CURRY; Samuel Mason et al.	
	2412	US-20110313317	12-22-2011	CALLICOAT; David N. et al.	
	2413	US-20110319729	12-29-2011	DONNAY; Manuel Luis et al.	
	2414	US-20110319734	12-29-2011	GOTTLIEB; Rebecca K. et al.	
	2415	US-20110319739	12-29-2011	KAMATH; Apurv Ullas et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 99 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2416	US-20110320130	12-29-2011	VALDES; Jorge et al.	
	2417	US-20110320167	12-29-2011	BUDIMAN; Erwin Satrya	
	2418	US-20120010642	01-12-2012	LEE; Daniel H. et al.	
	2419	US-20120078071	03-29-2012	BOHM; Sebastian et al.	
	2420	US-20120097554	04-26-2012	SHAH; Rajiv et al.	
	2421	US-20120108931	05-03-2012	TAUB; Marc Barry et al.	
	2422	US-20120108934	05-03-2012	VALDES; Jorge et al.	
	2423	US-20120123692	05-17-2012	HAYTER; Gary	
	2424	US-20120165626	06-28-2012	IRINA; Finkelshtein V. et al.	
	2425	US-20120165640	06-28-2012	GALLEY; Paul J. et al.	
	2426	US-20120173200	07-05-2012	BRETON; Marc D. et al.	
	2427	US-20120209099	08-16-2012	LJUHS; Michael Kjell et al.	
	2428	US-20120215462	08-23-2012	GOODE, Jr.; Paul V. et al.	
	2429	US-20120239304	09-20-2012	HAYTER; Gary et al.	
	2430	US-20120245447	09-27-2012	KARAN; Jai et al.	
	2431	US-20120265035	10-18-2012	BOHM; Sebastian et al.	
	2432	US-20120265036	10-18-2012	ESTES; Michael J. et al.	
	2433	US-20120277564	11-01-2012	BUDIMAN; Erwin Satrya et al.	
	2434	US-20120277565	11-01-2012	BUDIMAN; Erwin S.	
	2435	US-20120283542	11-08-2012	McGARRAUGH; Geoffrey V.	
	2436	US-20120283960	11-08-2012	BUDIMAN; Erwin Satrya	
	2437	US-20120291516	11-22-2012	HAYTER; Gary et al.	
	2438	US-20120330561	12-27-2012	HAYTER; Gary et al.	
	2439	US-20130006112	01-03-2013	VARDY; Terence	
	2440	US-20130035575	02-07-2013	MAYOU; Phil et al.	
	2441	US-20130060105	03-07-2013	SHAH; Rajiv et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 100 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2442	US-20130060112	03-07-2013	PRYOR; Jack et al.	
	2443	US-20130116527	05-09-2013	HARPER; Wesley Scott et al.	
	2444	US-20130137953	05-30-2013	HARPER; Wesley Scott et al.	
	2445	US-20130150690	06-13-2013	CURRY; Kenneth M.	
	2446	US-20130178727	07-11-2013	HAYTER; Gary Alan et al.	
	2447	US-20130184547	07-18-2013	TAUB; Marc Barry et al.	
	2448	US-20130199944	08-08-2013	PETISEE; James R.	
	2449	US-20130231541	09-05-2013	HAYTER; Gary Alan et al.	
	2450	US-20130245412	09-19-2013	RONG; Daiting et al.	
	2451	US-20130253846	09-26-2013	HAYTER; Gary Alan et al.	
	2452	US-20130281807	10-24-2013	HAYTER; Gary Alan et al.	
	2453	US-20130282322	10-24-2013	HAYTER; Gary Alan et al.	
	2454	US-20130282403	10-24-2013	HAYTER; Gary Alan et al.	
	2455	US-20130324823	12-05-2013	KOSKI; Salla et al.	
	2456	US-20130338454	12-19-2013	HAYTER; Gary Alan et al.	
	2457	US-20140005499	01-02-2014	CATT; Michael et al.	
	2458	US-20140005968	01-02-2014	BUDIMAN; Erwin Satrya	
	2459	US-20140018642	01-16-2014	HAYTER; Gary Alan	
	2460	US-20140041441	02-13-2014	HAYTER; Gary Alan et al.	
	2461	US-20140046155	02-13-2014	HAYTER; Gary Alan et al.	
	2462	US-20140046156	02-13-2014	HAYTER; Gary Alan et al.	
	2463	US-20140046157	02-13-2014	HAYTER; Gary Alan et al.	
	2464	US-20140046160	02-13-2014	TERASHIMA; Noriyoshi et al.	
	2465	US-20140046161	02-13-2014	HAYTER; Gary Alan et al.	
	2466	US-20140066736	03-06-2014	BUDIMAN; Erwin Satrya	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 101 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2467	US-20140088390	03-27-2014	HE; Lei	
	2468	US-20140088392	03-27-2014	BERNSTEIN; Daniel M. et al.	
	2469	US-20140088908	03-27-2014	HAYTER; Gary Alan et al.	
	2470	US-20140100796	04-10-2014	HAYTER; Gary Alan et al.	
	2471	US-20140114156	04-24-2014	BOHM; Sebastian et al.	
	2472	US-20140121480	05-01-2014	BUDIMAN; Erwin Satrya et al.	
	2473	US-20140121488	05-01-2014	BUDIMAN; Erwin Satrya	
	2474	US-20140207400	07-24-2014	HAYTER; Gary Alan et al.	
	2475	US-20140213869	07-31-2014	BRISTER; Mark et al.	
	2476	US-20140221966	08-07-2014	BUCKINGHAM; Bruce A. et al.	
	2477	US-20140236536	08-21-2014	HAYTER; Gary Alan et al.	
	2478	US-20140243638	08-28-2014	HARPER; Wesley Scott et al.	
	2479	US-20140257059	09-11-2014	BUDIMAN; Erwin Satrya et al.	
	2480	US-20150005601	01-01-2015	HOSS; Udo et al.	
	2481	US-20150006109	01-01-2015	FENNELL; Martin J. et al.	
	2482	US-20150094555	04-02-2015	HE; Lei	
	2483	US-20150216456	08-06-2015	BUDIMAN; Erwin Satrya	
	2484	US-20150241407	08-27-2015	OU; Junli et al.	
	2485	US-20150282742	10-08-2015	HAYTER; Gary Alan et al.	
	2486	US-20150366510	12-24-2015	BUDIMAN; Erwin S.	
	2487	US-20150374299	12-31-2015	HAYTER; Gary Alan	
	2488	US-20160022221	01-28-2016	OU; Junli et al.	
	2489	US-20160073941	03-17-2016	BOHM; Sebastian et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 102 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2490	US-20160151006	06-02-2016	HARPER; Wesley Scott et al.	
	2491	US-20160157758	06-09-2016	BOHM; Sebastian et al.	
	2492	US-20160198986	07-14-2016	BOHM; Sebastian et al.	
	2493	US-20160206233	07-21-2016	HAYTER; Gary Alan et al.	
	2494	US-20160220189	08-04-2016	HAYTER; Gary Alan et al.	
	2495	US-20160238589	08-18-2016	HARPER; Wesley Scott et al.	
	2496	US-20160245791	08-25-2016	HAYTER; Gary Alan et al.	
	2497	US-20160270705	09-22-2016	HE; Lei	
	2498	US-20160296697	10-13-2016	HAYTER; Gary et al.	
	2499	US-20160317069	11-03-2016	HAYTER; Gary Alan et al.	
	2500	US-20170003766	01-05-2017	BUDIMAN; Erwin S.	
	2501	US-20170027484	02-02-2017	HAYTER; Gary Alan et al.	
	2502	US-20170042456	02-16-2017	BUDIMAN; Erwin Satrya	
	2503	US-20170049369	02-23-2017	HAYTER; Gary Alan et al.	
	2504	US-20170124287	05-04-2017	HAYTER; Gary Alan et al.	
	2505	US-20170188909	07-06-2017	HAYTER; Gary Alan et al.	
	2506	US-20170224258	08-10-2017	HAYTER; Gary Alan et al.	
	2507	US-20170258379	09-14-2017	BUDIMAN; Erwin Satrya et al.	
	2508	US-20170265790	09-21-2017	BUDIMAN; Erwin Satrya et al.	
	2509	US-20170340250	11-30-2017	HAYTER; Gary Alan et al.	
	2510	US-20170347927	12-07-2017	HE; Lei	
	2511	US-20180000389	01-04-2018	HARPER; Wesley Scott et al.	
	2512	US-20180008174	01-11-2018	BOHM; Sebastian et al.	
	2513	US-20180008201	01-11-2018	HAYTER; Gary Alan et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 103 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2514	US-20180038844	02-08-2018	HAYTER; Gary Alan et al.	
	2515	US-20180042530	02-15-2018	BOHM; Sebastian et al.	
	2516	US-20180042531	02-15-2018	BUDIMAN; Erwin Satrya et al.	
	2517	US-20180042534	02-15-2018	HAYTER; Gary Alan	
	2518	US-20180045707	02-15-2018	HAYTER; Gary Alan et al.	
	2519	US-20180059093	03-01-2018	HAYTER; Gary Alan et al.	
	2520	US-20180064398	03-08-2018	BUDIMAN; Erwin Satrya	
	2521	US-20180085037	03-29-2018	HAYTER; Gary Alan et al.	
	2522	US-20180098721	04-12-2018	HAYTER; Gary Alan et al.	
	2523	US-20180271415	09-27-2018	BOHM; Sebastian et al.	
	2524	US-20180325437	11-15-2018	LI; Ying et al.	
	2525	US-20180328766	11-15-2018	HAYTER; Gary Alan et al.	
	2526	US-20180344220	12-06-2018	HAYTER; Gary Alan et al.	
	2527	US-20180364215	12-20-2018	HARPER; Wesley Scott et al.	
	2528	US-20190035488	01-31-2019	BUDIMAN; Erwin Satrya	
	2529	US-20190072538	03-07-2019	HAYTER; Gary Alan et al.	
	2530	US-20190083012	03-21-2019	HAYTER; Gary Alan et al.	
	2531	US-20190083015	03-21-2019	HAYTER; Gary Alan	
	2532	US-20190150802	05-23-2019	BUDIMAN; Erwin Satrya et al.	
	2533	US-20190151542	05-23-2019	HAYTER; Gary et al.	
	2534	US-20190159734	05-30-2019	BUDIMAN; Erwin Satrya	
	2535	US-20190187814	06-20-2019	BUDIMAN; Erwin S.	
	2536	US-20190192071	06-27-2019	TAUB; Marc Barry et al.	
	2537	US-20190254575	08-22-2019	HAYTER; Gary Alan et al.	
	2538	US-20190261902	08-29-2019	BOHM; Sebastian et al.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 104 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2539	US-20190282143	09-19-2019	KAMATH; Apurv Ullas et al.	
	2540	US-20190320948	10-24-2019	BOHM; Sebastian et al.	
	2541	US-20190320949	10-24-2019	BOHM; Sebastian et al.	
	2542	US-20190336051	11-07-2019	BOHM; Sebastian et al.	
	2543	US-20190350499	11-21-2019	BOHM; Sebastian et al.	
	2544	US-20190357817	11-28-2019	BOHM; Sebastian et al.	
	2545	US-20190357827	11-28-2019	LI; Ying et al.	
	2546	US-20190380627	12-19-2019	BOHM; Sebastian et al.	
	2547	US-20200022626	01-23-2020	BOHM; Sebastian et al.	
	2548	US-20200037934	02-06-2020	BOHM; Sebastian et al.	
	2549	US-20200037935	02-06-2020	BOHM; Sebastian et al.	
	2550	US-20200037936	02-06-2020	BOHM; Sebastian et al.	
	2551	US-20200037936	02-06-2020	BOHM; Sebastian et al.	
	2552	US-20200046272	02-13-2020	BRISTER; Mark et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	001	CA-2127172-C	07-14-1998	BAYER AG [US]		☐
	002	DE-2658734-A1	06-29-1978	DRAEGERWERK AG.		☒
	003	EP-0098592-A2	01-18-1984	FUJISAWA PHARMACEUTICAL CO [JP]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 105 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	004	EP-0107634-A2	05-02-1984	HELLGREN LARS GUSTAV INGE. et al.		☐
	005	EP-0127958-A2	12-12-1984	GENETICS INT INC [US]		☐
	006	EP-0284518-A2	09-28-1988	KARUBE ISAO [JP], et al.		☐
	007	EP-0286118-A2	10-12-1988	NOVA BIOMEDICAL CORP [US]		☐
	008	EP-0286118-B1	01-25-1995	NOVA BIOMEDICAL CORP [US]		☐
	009	EP-0288793-A2	11-02-1988	ABBOTT LAB [US]		☐
	010	EP-0320109-A1	06-14-1989	MEDISENSE INC [US]		☐
	011	EP-0323605-B1	01-26-1994	ABBOTT LAB [US]		☐
	012	EP-0352610-A2	01-31-1990	ABBOTT LAB [US]		☐
	013	EP-0352631-A2	01-31-1990	ABBOTT LAB [US]		☐
	014	EP-0353328-A1	02-07-1990	PPG HELLIGE BV [NL]		☐
	015	EP-0390390-A1	10-03-1990	ASS UNIVERSITIES INC [US], et al.		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 106 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	016	EP-0396788-A1	11-14-1990	DRAEGER NEDERLAND B V [NL]		☐
	017	EP-0406473-A1	01-09-1991	ABBOTT LAB [US]		☐
	018	EP-0424633-B1	01-17-1996	ABBOTT LAB [US]		☐
	019	EP-0440044-A1	08-07-1991	ABBOTT LAB [US]		☐
	020	EP-0441252-A2	08-14-1991	ABBOTT LAB [US]		☐
	021	EP-0441394-A2	08-14-1991	MINNESOTA MINING & MFG [US]		☐
	022	EP-0467078-A2	01-22-1992	ABBOTT LAB [US]		☐
	023	EP-0472411-A1	02-26-1992	TELECTRONICS NV [NL]		☐
	024	EP-0476980-A2	03-25-1992	FUJITSU LTD [JP]		☐
	025	EP-0534074-A1	03-31-1993	INST DIABETESTECHNOLOGIE GEMEI [DE]		☒
	026	EP-0563795-A1	10-06-1993	DAINIPPON PRINTING CO LTD [JP], et al.		☐
	027	EP-0647849-A2	04-12-1995	IGEN INC [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 107 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	028	EP-0690134-A1	01-03-1996	CIBA CORNING DIAGNOSTICS CORP [US]		☐
	029	EP-0776628-A2	06-04-1997	YOSHIDA AKITOSHI [JP]		☐
	030	EP-0817809-A1	01-14-1998	MINIMED INC [US]		☐
	031	EP-0838230-A2	04-29-1998	TERUMO CORP [JP]		☐
	032	EP-0867146-A1	09-30-1998	PACESETTER AB [SE]		☐
	033	EP-0880936-A2	12-02-1998	AKAI KOJI [JP]		☐
	034	EP-0885932-A2	12-23-1998	OSI SPECIALTIES INC [US]		☐
	035	EP-0939602-B1	09-22-2004	MEDTRONIC INC [US]		☐
	036	EP-0958495-B1	11-13-2002	THERASENSE INC [US]		☐
	037	EP-0995805-A1	04-26-2000	BEURET PIERRE [CH]		☒
	038	EP-1048264-A1	11-02-2000	MEDTRONIC INC [US]		☐
	039	EP-1077634-A1	02-28-2001	CYGNUS THERAPEUTIC SYSTEMS [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 108 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	040	EP-1078258-A1	02-28-2001	CYGNUS THERAPEUTIC SYSTEMS [US]		☐
	041	EP-1153571-A1	11-14-2001	MENARINI FARMA IND [IT]		☐
	042	EP-1236995-A1	09-04-2002	USF FILTRATION & SEPARATIONS [US]		☐
	043	EP-1266607-A2	12-18-2002	LIFESCAN INC [US]		☐
	044	EP-1419731-A1	05-19-2004	PACESETTER INC [US]		☐
	045	EP-1677668-B1	07-14-2010	NOVO NORDISK AS [DK]		☐
	046	EP-1785085-A1	05-16-2007	ROCHE DIAGNOSTICS GMBH [DE], et al.		☒
	047	EP-1850909-B1	04-07-2010	PACESETTER INC [US]		☐
	048	EP-2069772-B1	05-21-2014	DEXCOM INC [US]		☐
	049	EP-2223710-A1	09-01-2010	DEXCOM INC [US]		☐
	050	EP-2226086-A1	09-08-2010	DEXCOM INC [US]		☐
	051	FR-2656423-A1	06-28-1991	RHONE POULENC CHIMIE [FR]		☒

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 109 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	052	FR-2760962-A1	09-25-1998	KLEFSTAD SILLONVILLE FRANCIS [FR]		☒
	053	GB-1442303-A	07-14-1976	RADIOMETER AS.		☐
	054	GB-1556969-A	12-05-1979	DRAEGERWERK AG.		☐
	055	GB-2149918-A	06-19-1985	ANDERSON JOHN.		☐
	056	JP-2000060826-A	02-29-2000	OMRON TATEISI ELECTRONICS CO.		☒
	057	JP-2003108679-A	04-11-2003	TOSHIBA CORP.		☒
	058	JP-2003522558-A	07-29-2003	MINIMED INC.		☒
	059	JP-2007501028-A	01-25-2007	DEXCOM, INC.		☒
	060	JP-2008253482-A	10-23-2008	MATSUSHITA ELECTRIC IND CO LTD.		☒
	061	JP-H022913-A	01-08-1990	BRIDGESTONE CORP.		☒
	062	JP-H03293556-A	12-25-1991	KOKURITSU SHINTAI SHIYOUGAISHI.		☒
	063	JP-H11153575-A	06-08-1999	MITSUBISHI ELECTRIC CORP.		☒

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 110 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	064	JP-H11192886-A	07-21-1999	NISSAN MOTOR.		☒
	065	JP-S6283849-A	04-17-1987	YOSHINAKA REIJI., et al.		☒
	066	WO-0012720-A2	03-09-2000	ABBOTT LAB [US]		☐
	067	WO-0013002-A2	03-09-2000	ABBOTT LAB [US]		☐
	068	WO-0013003-A1	03-09-2000	SENSORS FOR MED & SCIENCE INC [US]		☐
	069	WO-0019887-A1	04-13-2000	MINIMED INC [US]		☐
	070	WO-0032098-A1	06-08-2000	HEALTH HERO NETWORK INC [US]		☐
	071	WO-0033065-A1	06-08-2000	LOCKHEED MARTIN ENERGY RES COR [US], et al.		☐
	072	WO-0049940-A2	08-31-2000	MINIMED INC [US]		☐
	073	WO-0049941-A1	08-31-2000	MINIMED INC [US]		☐
	074	WO-0059370-A1	10-12-2000	UNIV CAMBRIDGE TECH [GB], et al.		☐
	075	WO-0059373-A1	10-12-2000	SPECTRX INC [US], et al.		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 111 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	076	WO-0074753-A1	12-14-2000	MINIMED INC [US]		☐
	077	WO-0078210-A1	12-28-2000	MINIMED INC [US]		☐
	078	WO-0079258-A1	12-28-2000	ABBOTT LAB [US], et al.		☐
	079	WO-0112158-A1	02-22-2001	UNIV JEFFERSON [US], et al.		☐
	080	WO-0116579-A1	03-08-2001	CME TELEMETRIX INC [CA], et al.		☐
	081	WO-0120019-A2	03-22-2001	IMPLANTED BIOSYSTEMS INC [US]		☐
	082	WO-0120334-A1	03-22-2001	UNIV CALIFORNIA [US], et al.		☐
	083	WO-0134243-A1	05-17-2001	ST JUDE MEDICAL [SE], et al.		☐
	084	WO-0143660-A2	06-21-2001	BAXTER INT [US]		☐
	085	WO-0152727-A1	07-26-2001	MINIMED INC [US]		☐
	086	WO-0152935-A1	07-26-2001	MEDICAL RES GROUP INC [US]		☐
	087	WO-0154753-A2	08-02-2001	MEDICAL RES GROUP INC [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 112 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	088	WO-0158348-A2	08-16-2001	MINIMED INC [US]		☐
	089	WO-0168901-A2	09-20-2001	ROCHE DIAGNOSTICS GMBH [DE], et al.		☐
	090	WO-0169222-A2	09-20-2001	ROCHE DIAGNOSTICS GMBH [DE], et al.		☐
	091	WO-0188524-A1	11-22-2001	THERASENSE INC [US]		☐
	092	WO-0188534-A2	11-22-2001	CYGNUS THERAPEUTIC SYSTEMS [US]		☐
	093	WO-02053764-A2	07-11-2002	MEDTRONIC MINIMED INC [US]		☐
	094	WO-0205702-A2	01-24-2002	HEALTHETECH INC [US], et al.		☐
	095	WO-02082989-A1	10-24-2002	ABBOTT LAB [US]		☐
	096	WO-02089666-A2	11-14-2002	ISENSE CORP [US], et al.		☐
	097	WO-02100266-A1	12-19-2002	MATHEWS EDWARD HENRY [ZA], et al.		☐
	098	WO-0216905-A2	02-28-2002	EURO CELTIQUE SA [LU], et al.		☐
	099	WO-0224065-A1	03-28-2002	KNOBBE LIM & BUCKINGHAM [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 113 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	100	WO-0239086-A2	05-16-2002	NIPRO DIABETES SYSTEMS [US], et al.		☐
	101	WO-03000127-A2	01-03-2003	CYGNUS THERAPEUTIC SYSTEMS [US]		☐
	102	WO-03011131-A2	02-13-2003	DEXCOM INC [US], et al.		☐
	103	WO-03012422-A1	02-13-2003	NOVA BIOMEDICAL CORP [US]		☐
	104	WO-03016882-A1	02-27-2003	PURDUE RESEARCH FOUNDATION [US], et al.		☐
	105	WO-03032411-A2	04-17-2003	LIFESCAN INC [US], et al.		☐
	106	WO-03076893-A2	09-18-2003	SENSYS MEDICAL INC [US]		☐
	107	WO-03082091-A2	10-09-2003	INVERNESS MEDICAL LTD [GB], et al.		☐
	108	WO-03101862-A1	12-11-2003	DOW CORNING TORAY SILICONE [JP], et al.		☐
	109	WO-2004021877-A1	03-18-2004	PENDRAGON MEDICAL LTD [CH], et al.		☐
	110	WO-2004052190-A1	06-24-2004	KONINKL PHILIPS ELECTRONICS NV [NL], et al.		☐
	111	WO-2004060455-A1	07-22-2004	MEDTRONIC MINIMED INC [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 114 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	112	WO-2004069030-A2	08-19-2004	VERIMETRA INC [US], et al.		☐
	113	WO-2004110256-A2	12-23-2004	THERASENSE INC [US]		☐
	114	WO-2005010756-A2	02-03-2005	PHILIPS INTELLECTUAL PROPERTY [DE], et al.		☐
	115	WO-2005011489-A1	02-10-2005	DEXCOM INC [US], et al.		☐
	116	WO-2005012873-A2	02-10-2005	DEXCOM INC [US], et al.		☐
	117	WO-2005026689-A2	03-24-2005	I STAT CORP [US], et al.		☐
	118	WO-2005026689-A9	10-13-2005	I STAT CORP [US], et al.		☐
	119	WO-2005032400-A2	04-14-2005	NICAST LTD [IL], et al.		☐
	120	WO-2005045414-A1	05-19-2005	LIFESCAN SCOTLAND LTD [GB], et al.		☐
	121	WO-2005057168-A2	06-23-2005	DEXCOM INC [US], et al.		☐
	122	WO-2005057175-A2	06-23-2005	DEXCOM INC [US], et al.		☐
	123	WO-2005065542-A2	07-21-2005	MEDTRONIC MINIMED INC [US], et al.		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 115 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	124	WO-2005078424-A1	08-25-2005	THERASENSE INC [US], et al.		☐
	125	WO-2005122296-A2	12-22-2005	UNIV SURREY [GB], et al.		☐
	126	WO-2006008505-A1	01-26-2006	ALERTIS MEDICAL AS [NO], et al.		☐
	127	WO-2006017358-A1	02-16-2006	DEXCOM INC [US], et al.		☐
	128	WO-2006024671-A1	03-09-2006	NOVO NORDISK AS [DK], et al.		☐
	129	WO-2006039310-A2	04-13-2006	GLUCON INC [US], et al.		☐
	130	WO-2006050405-A1	05-11-2006	MEDTRONIC INC [US], et al.		☐
	131	WO-2006081336-A2	08-03-2006	PACESETTER INC [US]		☐
	132	WO-2006105146-A2	10-05-2006	ARKAL MEDICAL INC [US], et al.		☐
	133	WO-2006118713-A1	11-09-2006	MEDTRONIC INC [US], et al.		☐
	134	WO-2006127694-A2	11-30-2006	DEXCOM INC [US], et al.		☐
	135	WO-2006131288-A1	12-14-2006	ROCHE DIAGNOSTICS GMBH [DE], et al.		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 116 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	136	WO-2007002209-A2	01-04-2007	GLUCON INC [US], et al.		☐
	137	WO-2007002579-A2	01-04-2007	BIOVERIS CORP [US], et al.		☐
	138	WO-2007065285-A2	06-14-2007	HOFFMANN LA ROCHE [CH], et al.		☐
	139	WO-2007097754-A1	08-30-2007	DEXCOM INC [US], et al.		☐
	140	WO-2007114943-A2	10-11-2007	MEDTRONIC MINIMED INC [US], et al.		☐
	141	WO-2007127606-A1	11-08-2007	MEDTRONIC INC [US], et al.		☐
	142	WO-2007137286-A2	11-29-2007	GLUCON INC [US], et al.		☐
	143	WO-2007143225-A2	12-13-2007	ABBOTT DIABETES CARE INC [US], et al.		☐
	144	WO-2008001091-A1	01-03-2008	GLYSURE LTD [GB], et al.		☐
	145	WO-2008076868-A2	06-26-2008	ABBOTT LAB [US], et al.		☐
	146	WO-2008086541-A2	07-17-2008	MEDTRONIC MINIMED INC [US], et al.		☐
	147	WO-2010022387-A1	02-25-2010	EASTERN VIRGINIA MED SCHOOL [US], et al.		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 117 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	148	WO-2010078263-A2	07-08-2010	MEDTRONIC MINIMED INC [US], et al.		☐
	149	WO-2010099507-A1	09-02-2010	ABBOTT DIABETES CARE INC [US], et al.		☐
	150	WO-8706342-A1	10-22-1987	MARKWELL MEDICAL INST INC [US]		☐
	151	WO-8902720-A1	04-06-1989	GRONINGEN SCIENCE PARK [NL]		☐
	152	WO-9000738-A1	01-25-1990	MARKWELL MEDICAL INST INC [US]		☐
	153	WO-9010861-A1	09-20-1990	NOVO NORDISK AS [DK]		☐
	154	WO-9109302-A1	06-27-1991	UNIV CALIFORNIA [US]		☐
	155	WO-9116416-A1	10-31-1991	MARKWELL MEDICAL INST INC [US]		☐
	156	WO-9213271-A1	08-06-1992	MARKWELL MEDICAL INST INC [US]		☐
	157	WO-9305701-A1	04-01-1993	IMPERIAL COLLEGE [GB]		☐
	158	WO-9314693-A1	08-05-1993	UNIV MANCHESTER [GB]		☐
	159	WO-9323744-A1	11-25-1993	HELLER E & CO [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 118 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	160	WO-9325898-A1	12-23-1993	MEDISENSE INC [US], et al.		☐
	161	WO-9422367-A1	10-13-1994	PFIZER INC. [US], et al.		☐
	162	WO-9507109-A1	03-16-1995	OTTAWA HEART INST RESEARCH COR [CA]		☐
	163	WO-9614026-A1	05-17-1996	ELAN MED TECH [IE], et al.		☐
	164	WO-9625089-A1	08-22-1996	MINIMED INC [US]		☐
	165	WO-9630431-A1	10-03-1996	MINIMED INC [US]		☐
	166	WO-9635370-A1	11-14-1996	MASSACHUSETTS INST TECHNOLOGY [US]		☐
	167	WO-9701986-A1	01-23-1997	UNIV JEFFERSON [US], et al.		☐
	168	WO-9706727-A1	02-27-1997	CARDIAC CRC NOMINEES PTY LTD [AU], et al.		☐
	169	WO-9715227-A1	05-01-1997	MEDTRONIC INC [US]		☐
	170	WO-9728737-A1	08-14-1997	NOKIA MOBILE PHONES LTD [FI], et al.		☐
	171	WO-9738625-A1	10-23-1997	UNIV MASSACHUSETTS [US], et al.		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 119 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	172	WO-9743633-A1	11-20-1997	ENCELLE INC [US], et al.		☐
	173	WO-9819159-A1	05-07-1998	MERCURY DIAGNOSTICS INC [US], et al.		☐
	174	WO-9824358-A2	06-11-1998	ENACT HEALTH MANAGEMENT SYSTEM [US], et al.		☐
	175	WO-9835053-A2	08-13-1998	HELLER E & CO [US], et al.		☐
	176	WO-9838906-A1	09-11-1998	MARKWELL MEDICAL INST INC [US], et al.		☐
	177	WO-9842249-A1	10-01-1998	NELLCOR PURITAN BENNETT INC [US]		☐
	178	WO-9907878-A1	02-18-1999	UNIV MANCHESTER [GB], et al.		☐
	179	WO-9908485-A1	02-18-1999	STRIX LTD [GB], et al.		☐
	180	WO-9948419-A1	09-30-1999	EGLISE DAVID [GB]		☐
	181	WO-9956613-A1	11-11-1999	HELLER E & CO [US], et al.		☐
	182	WO-9958051-A1	11-18-1999	CYGNUS THERAPEUTIC SYSTEMS [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 120 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	183	WO-9958709-A1	11-18-1999	ABBOTT LAB [US], et al.		☐
	184	WO-9958973-A1	11-18-1999	CYGNUS THERAPEUTIC SYSTEMS [US]		☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 121 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	001	AALDERS, et al., "Development of a Wearable Glucose Sensor; Studies in Healthy Volunteers and in Diabetic Patients," The International Journal Of Artificial Organs, 1991, Vol. 14, No. 2, pp. 102-108.	☐
	002	ABE, et al., "Characterization of Glucose Microsensors for Intracellular Measurements," Analytical Chemistry, 1992, Vol. 64, No. 18, pp. 2160-2163.	☐
	003	ABEL, et al., "Biosensors For in Vivo Glucose Measurements: Can We Cross the Experimental Stage," Biosensors & Bioelectronics, 2002, Vol. 17, pp. 1059-1070.	☐
	004	ABEL, et al., "Experience With An Implantable Glucose Sensor as a Prerequisite of an Artificial Beta Cell," Biomed. Biochim. Actan, 1984, Vol. 43, No. 5, pp. 577-584.	☐
	005	ALCOCK S.J., et al., "Continuous Analyte Monitoring To Aid Clinical Practice," IEEE Engineering in Medicine & Biology, 1994, Vol. 13, pp. 319-325.	☐
	006	AMER M.M.B., "An Accurate Amperometric Glucose Sensor Based Glucometer with Eliminated Cross-Sensitivity," Journal of Medical Engineering & Technology, Vol. 26 (5), September/October 2002, pp. 208-213.	☐
	007	AMIN R., et al., "Hypoglycemia Prevalence in Prepubertal Children With Type 1 Diabetes on Standard Insulin Regimen: Use of Continuous Glucose Monitoring System," Diabetes Care, 2003, Vol. 26, No. 3, pp. 662-667.	☐
	008	ARMOUR J.C., et al., "Application of Chronic Intravascular Blood Glucose Sensor in Dogs," Diabetes, December 1990, Vol. 39, pp. 1519-1526.	☐
	009	ARNOLD M.A., et al., "Selectivity Assessment of Noninvasive Glucose Measurements Based on Analysis of Multivariate Calibration Vectors," Journal of Diabetes Science and Technology, Vol. 1 (4), July 2007, pp. 454-462.	☐
	010	ASSOLANT-VINET C.H., et al., "New Immobilized Enzyme Membranes for Tailor-Made Biosensors," Analytical Letters, 1986, Vol. 19(7&8), pp. 875-885.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 122 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	011	ATANASOV P., et al., "Biosensor for Continuous Glucose Monitoring," Biotechnology and Bioengineering, John Wiley & sons Inc, 1994, Vol. 43, pp. 262-266.	☐
	012	ATANASOV P., et al., "Implantation of a Refillable Glucose Monitoring-Telemetry Device," Biosensors and Bioelectronics, Vol. 12 (7), 1997, pp. 669-680.	☐
	013	AUSSEDAT B., et al., "A User-Friendly Method For Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycaemic Alarm," Elsevier Science Limited, Biosensors & Bioelectronic, 1997, Vol. 12, No. 11, pp. 1061-1071.	☐
	014	BAILEY T.S., et al., "Reduction in Hemoglobin A1C with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study," Diabetes Technology & Therapeutics, Vol. 9 (3), 2007, pp. 203-210.	☐
	015	BAKER D.A., et al., "Dynamic Concentration Challenges for Biosensor Characterization," Biosensors & Bioelectronics, Vol. 8, 1993, pp. 433-441.	☐
	016	BAKER D.A., et al., "Dynamic Delay and Maximal Dynamic Error in Continuous Biosensors," Analytical Chemistry, Vol. 68 (8), April 15, 1996, pp. 1292-1297.	☐
	017	BARD A.J., et al., "Electrochemical Methods," Fundamentals and Applications, John Wiley & Sons, New York, 1980, pp. 173-175.	☐
	018	BARDELETTI G., et al., "A Reliable L-Lactate Electrode with a New Membrane for Enzyme Immobilization for Amperometric Assay of Lactate," Analytica Chemica Acta, Vol. 187, 1986, pp. 47-54.	☐
	019	BEACH R.D., et al., "Subminiature Implantable Potentiostat and Modified Commercial Telemetry Device for Remote Glucose Monitoring," IEEE Transactions on Instrumentation and Measurement, Vol. 48 (6), December 1999, pp. 1239-1245.	☐
	020	BELLUCCI F., et al., "Electrochemical Behaviour of Graphite-Epoxy Composite Materials (GECM) in Aqueous Salt Solutions," Journal of Applied Electrochemistry, Vol. 16 (1), January 1986, pp. 15-22.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 123 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	021	BENNION N., et al., "Alternate Site Glucose Testing: a Crossover Design," Diabetes Technology & Therapeutics, Vol. 4 (1), 2002, pp. 25-33.	☐
	022	BERTRAND C., et al., "Multipurpose Electrode with Different Enzyme Systems Bound to Collagen Films," Analytica Chemica Acta, 1981, Vol. 126, pp. 23-34.	☐
	023	BESSMAN S.P., et al., "Progress toward a Glucose Sensor for the Artificial Pancreas," Proceedings of a Workshop on Ion-Selective Microelectrodes, June 4-5, 1973, Boston University, 1973, pp. 189-197.	☐
	024	BIERMANN E., et al., "How Would Patients Behave if they were Continually Informed of their Blood Glucose Levels? A Simulation Study Using a "Virtual" Patient," Diabetes Technology & Therapeutics, Vol. 10 (3), 2008, pp. 178-187.	☐
	025	BINDRA D.S., et al., "Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring," Analytical Chemistry, Vol. 63, September 1, 1991, pp. 1692-1696.	☐
	026	BINDRA D.S., et al., "Pulsed Amperometric Detection of Glucose in Biological Fluids at a Surface-Modified Gold Electrode," Analytical Chemistry, Vol. 61 (22), November 15, 1989, pp. 2566-2570.	☐
	027	BISENBERGER M., et al., "A Triple-Step Potential Waveform at Enzyme Multisensors with Thick-Film Gold Electrodes for Detection of Glucose and Sucrose," Sensors and Actuators B, Vol. 28, 1995, pp. 181-189.	☐
	028	BLAND J.M., et al., "A Note on the Use of the Intraclass Correlation Coefficient in the Evaluation of Agreement between Two Methods of Measurement," Computers in Biology and Medicine, Vol. 20 (5), 1990, pp. 337-340.	☐
	029	BLAND J.M., et al., "Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement," The Lancet, February 8, 1986, pp. 307-310.	☐
	030	BLANK T.B., et al., "Clinical Results From a Non-Invasive Blood Glucose Monitor," Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, Vol. 4624, 2002, pp. 1-10.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 124 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	031	BOBBIONI-HARSCH E., et al., "Lifespan of Subcutaneous Glucose Sensors and their Performances during Dynamic Glycaemia Changes in Rats," J. Biomed. Eng., Vol. 15, 1993, pp. 457-463.	☐
	032	BODE B.W., "Clinical Utility of the Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S35-S41.	☐
	033	BODE B.W., et al., "Continuous Glucose Monitoring Used to Adjust Diabetes Therapy Improves Glycosylated Hemoglobin: A Pilot Study," Diabetes Research and Clinical Practice, Vol. 46, 1999, pp. 183-190.	☐
	034	BOEDEKER PLASTICS INC, "Polyethylene Specifications," Polyethylene Data Sheet, Retrieved from http://www.boedeker.com/polye.sub.--p.htm on August 19, 2009, 4 pages.	☐
	035	BOLAND E., et al., "Limitations of Conventional Methods of Self-Monitoring of Blood Glucose," Diabetes Care, Vol. 24 (11), November 2001, pp. 1858-1862.	☐
	036	BOLINDER J., et al., "Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison with Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue during Ordinary Life Conditions," Diabetes Care, Vol. 20 (1), January 1997, pp. 64-70.	☐
	037	BOLINDER J., et al., "Microdialysis Measurement of the Absolute Glucose Concentration in Subcutaneous Adipose Tissue Allowing Glucose Monitoring in Diabetic Patients," Rapid Communication, Diabetologia, Vol. 35, 1992, pp. 1177-1180.	☐
	038	BOTT A.W., "A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry," Current Separations, Vol. 16 (1), 1997, pp. 23-26.	☐
	039	BOTT A.W., "Electrochemical Methods for the Determination of Glucose," Current Separations, Vol. 17 (1), 1998, pp. 25-31.	☐
	040	BOWMAN L., et al., "The Packaging of Implantable Integrated Sensors," IEEE Transactions in Biomedical Engineering, Vol. BME-33 (2), February 1986, pp. 248-255.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 125 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	041	BOYNE M.S., et al., "Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor," Diabetes, Vol. 52, November 2003, pp. 2790-2794.	☐
	042	BRAUKER J., et al., "Local Inflammatory Response Around Diffusion Chambers Containing Xenografts," Transplantation, Vol. 61 (12), June 27, 1996, pp. 1671-1677.	☐
	043	BRAUNWALD E., "Biomarkers in Heart Failure," Medical Progress, The New England Journal of Medicine, Vol. 358, May 15, 2008, pp. 2148-2159.	☐
	044	BREMER T., et al., "Is Blood Glucose Predictable from Previous Values? A Solicitation for Data," Perspectives in Diabetes, Vol. 48, March 1999, pp. 445-451.	☐
	045	BREMER T.M., et al., "Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies," Diabetes Technology & Therapeutics, Vol. 3 (3), 2001, pp. 409-418.	☐
	046	BROOKS S.L., et al., "Development of an On-line Glucose Sensor for Fermentation Monitoring," Biosensors, Vol. 3, 1987/1988, pp. 45-56.	☐
	047	BRUCKEL J., et al., "In Vivo Measurement of Subcutaneous Glucose Concentrations with an Enzymatic Glucose Sensor and a Wick Method," Klin Wochenschr, Vol. 67, 1989, pp. 491-495.	☐
	048	BRUNSTEIN E., et al., "Preparation and Validation of Implantable Electrodes for the Measurement of Oxygen and Glucose," Biomed Biochim. Acta, Vol. 48 (11/12), 1989, pp. 911-917.	☐
	049	CAI Q., et al., "A Wireless, Remote Query Glucose Biosensor Based on a pH-Sensitive Polymer," Analytical Chemistry, Vol. 76 (14), July 15, 2004, pp. 4038-4043.	☐
	050	CAMERON T., et al., "Micromodular Implants to Provide Electrical Stimulation of Paralyzed Muscles and Limbs," IEEE Transactions on Biomedical Engineering, Vol. 44 (9), September 1997, pp. 781-790.	☐
	051	CAMPANELLA L., et al., "Biosensor for Direct Determination of Glucose and Lactate in Undiluted Biological Fluids," Biosensors & Bioelectronics, Vol. 8, 1993, pp. 307-314.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 126 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	052	CANDAS B., et al., "An Adaptive Plasma Glucose Controller Based on a Nonlinear Insulin/Glucose Model," IEEE Transactions on Biomedical Engineering, Vol. 41 (2), February 1994, pp. 116-124.	☐
	053	CASS A.E.G., et al., "Ferrocene-Mediated Enzyme Electrodes for Amperometric Determination of Glucose," Analytical Chemistry, Vol. 56 (4), April 1984, pp. 667-671.	☐
	054	CASSIDY J.F., et al., "Novel Electrochemical Device for the Detection of Cholesterol or Glucose," Analyst, Vol. 118, April 1993, pp. 415-418.	☐
	055	CHASE H.P., et al., "Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes," Pediatrics, Vol. 107 (2), February 2001, pp. 222-226.	☐
	056	CHEN C.Y., et al., "A Biocompatible Needle-Type Glucose Sensor Based on Platinum-Electroplated Carbon Electrode," Appl. Biochem Biotechnol, September 1992, Vol. 36 (3), pp. 211-226.	☐
	057	CHEN T., et al., "Defining the Period of Recovery of the Glucose Concentration after its Local Perturbation by the Implantation of a Miniature Sensor," Clinical Chemistry and Laboratory Medicine, Vol. 40 (8), 2002, pp. 786-789.	☐
	058	CHEYNE E.H., et al., "Performance of a Continuous Glucose Monitoring System During Controlled Hypoglycaemia in Healthy Volunteers," Diabetes Technology & Therapeutics, Vol. 4 (5), 2002, pp. 607-613.	☐
	059	CHIA C.W., et al., "Glucose Sensors: Toward Closed Loop Insulin Delivery," Endocrinology and Metabolism Clinics of North America, Vol. 33, 2004, pp. 175-195.	☐
	060	CHOLEAU C., et al., "Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2. Superiority of the One-point Calibration Method," Biosensors and Bioelectronics, Vol. 17 (8), 2002, pp. 647-654.	☐
	061	CHOLEAU C., et al., "Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1. Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current," Biosensors and Bioelectronics, Vol. 17, 2002, pp. 641-646.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P./

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 127 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	062	CIBA Specialty Chemicals, "Ciba® IRGACURE® 2959," Coating Effects Segment, Photoinitiator Product Description, Basel Switzerland, April 2, 1998, 3 pages.	☐
	063	CLAREMONT D.J., et al., "Potentially-Implantable, Ferrocene-Mediated Glucose Sensor," Journal of Biomedical Engineering, Vol. 8, July 1986, pp. 272-274.	☐
	064	CLAREMONT D.J., et al., "Subcutaneous Implantation of a Ferrocene-Mediated Glucose Sensor in Pigs," Diabetologia, Vol. 29, 1986, pp. 817-821.	☐
	065	CLARK L.C., et al., "Configurational Cyclic Voltammetry: Increasing the Specificity and Reliability of Implanted Electrodes," IEEE/Ninth Annual Conference of the Engineering in Medicine and Biology Society, 1987, pp. 0782-0783.	☐
	066	CLARK L.C., et al., "Long-Term Stability of Electroenzymatic Glucose Sensors Implanted in Mice," Vol. XXXIV, Transactions - American Society for Artificial Internal Organs, 1988, vol. 34, pp. 259-265.	☐
	067	CLARK L.C., et al., "One-Minute Electrochemical Enzymic Assay for Cholesterol in Biological Materials," Clinical Chemistry, Vol. 27 (12), 1981, pp. 1978-1982.	☐
	068	CLARKE W.L., et al., "Evaluating Clinical Accuracy of Systems for Self Monitoring of Blood Glucose," Technical Articles, Diabetes Care, Vol. 10 (5), September-October 1987, pp. 622-628.	☐
	069	COLANGELO V.J., et al., "Corrosion Rate Measurements in Vivo," Journal of Biomedical Materials Research, Vol. 1, 1967, pp. 405-414.	☐
	070	COLOWICK S.P., et al., "Methods in Enzymology," Vol. XLIV, Immobilized Enzymes, Edited by Mosbach K, New York Academic Press, 1976, 11 pages.	☐
	071	COULET P.R., et al., "Enzymes Immobilized on Collagen Membranes: A Tool for Fundamental Research and Enzyme Engineering," Journal of Chromatography, Vol. 215, 1981, pp. 65-72.	☐
	072	COULET P.R., "Polymeric Membranes and Coupled Enzymes in the Design of Biosensors," Journal of Membrane Science, 1992, Vol. 68, pp. 217-228.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 128 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	073	COX D.J., et al., "Accuracy of Perceiving Blood Glucose in IDDM," Diabetes Care, Vol. 8 (6), November-December 1985, pp. 529-536.	☐
	074	CSOREGI E., et al., "Amperometric Microbiosensors for Detection of Hydrogen Peroxide and Glucose Based on Peroxidase-Modified Carbon Fibers," Electroanalysis, Vol. 6, 1994, pp. 925-933.	☐
	075	CSOREGI E., et al., "Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on 'Wired' Glucose Oxidase," Analytical Chemistry, Vol. 67 (7), April 1, 1995, pp. 1240-1244.	☐
	076	CSOREGI E., et al., "Design, Characterization and One-Point in Vivo Calibration of a Subcutaneously Implanted Glucose Electrode," American Chemical Society, Analytical Chemistry, Vol. 66 (19), October 1, 1994, pp. 3131-3138.	☐
	077	CURRIE J.F., et al., "Novel Non-Intrusive Trans-Dermal Remote Wireless Micro-Fluidic Monitoring System Applied to Continuous Glucose and Lactate Assays for Casualty Care and Combat Readiness Assessment," RTO HFM Symposium, RTO-MP-HFM-109, August 16-18, 2004, pp. '24-1' - '24-18'.	☐
	078	DANIELSSON B., et al., "Enzyme Thermistors," Methods in Enzymology, Vol. 137, 1988, pp. 181-197.	☐
	079	D'ARRIGO G., et al., "Porous-Si Based Bio Reactors for Glucose Monitoring and Drugs Production," Proceedings of SPIE, 2003, Vol. 4982, pp. 178-184.	☐
	080	DASSAU E., et al., "In Silico Evaluation Platform for Artificial Pancreatic β- Cell Development - A Dynamic Simulator for Closed-Loop Control with Hardware-in-the-loop," Diabetes Technology & Therapeutics, Vol. 11 (3), 2009, pp. 1-8.	☐
	081	DAVIES M.L., et al., "Polymer Membranes in Clinical Sensor Applications," An overview of membrane function, Biomaterials, Vol. 13 (14), 1992, pp. 971-978.	☐
	082	DAVIS G., et al., "Bioelectrochemical Fuel Cell and Sensor Based on a Quinoprotein, Alcohol Dehydrogenase," Enzyme and Microbial Technology, Vol. 5 (5), September 1983, pp. 383-388.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 129 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	083	DEUTSCH T., et al., "Time Series Analysis and Control of Blood Glucose Levels in Diabetic Patients," Computer Methods and Programs in Biomedicine, Elsevier Scientific Publishers, Vol. 41, 1994, pp. 167-182.	☐
	084	DIXON B.M., et al., "Characterization in Vitro and in Vivo of the Oxygen Dependence of an Enzyme/Polymer Biosensor for Monitoring Brain Glucose," Journal of Neuroscience Methods, Vol. 119, 2002, pp. 135-142.	☐
	085	DuPont, "Dimension® AR Clinical Chemistry System," The Chemistry Analyzer that Makes the most of your Time, Money and Effort, Dade International, Chemistry Systems, Newark, 1998, 18 pages.	☐
	086	DURLIAT H., et al., "Spectrophotometric and Electrochemical Determinations of L(+)-Lactate in Blood by Use of Lactate Dehydrogenase from Yeast," Clinical Chemistry, Vol. 22 (11), 1976, pp. 1802-1805.	☐
	087	EDWARDS LIFESCIENCES, "Accuracy for You and Your Patients," Marketing materials, 2002, 4 pages.	☐
	088	EL DEGHEIDY M.M., et al., "Optimization of an Implantable Coated Wire Glucose Sensor," Journal of Biomedical Engineering, Vol. 8, April 1986, pp. 121-129.	☐
	089	ELCO Diagnostics Company, "Direct 30/30® Blood Glucose Sensor," Markwell Medical Catalog, 1990, 1 page.	☐
	090	EL-KHATIB F.H., et al., "Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Dual Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine," Journal of Diabetes Science and Technology, Diabetes Technology Society, Vol. 1 (2), 2007, pp. 181-192.	☐
	091	EL-SA'AD L., et al., "Moisture Absorption by Epoxy Resins: The Reverse Thermal Effect," Journal of Materials Science, Vol. 25, 1990, pp. 3577-3582.	☐
	092	EREN-ORUKLU M., et al., "Estimation of Future Glucose Concentrations with Subject-Specific Recursive Linear Models," Diabetes Technology & Therapeutics, Vol. 11 (4), 2009, pp. 243-253.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 130 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	093	ERNST H., et al., "Reliable Glucose Monitoring Through the Use of Microsystem Technology," Analytical Bioanalytical Chemistry, Vol. 373, 2002, pp. 758-761.	☐
	094	Examiner's First Report for Australian Patent Application No. 2007305002 dated June 01, 2012, 2 pages - Atty. Docket No. DEXCOM.088VAU.	☐
	095	Extended European Search Report for Application No. 12170103.1 dated November 06, 2012, 6 pages - Atty. Docket No. DEXCOM.016EPD3.	☐
	096	Extended European Search Report for Application No. 13275272.6, mailed March 3, 2014, 8 pages.	☐
	097	Extended European Search Report for Application No. 19185162.5 mailed August 13, 2019, 7 pages - Atty. Docket. No. DEXCOM.167VEPD1.	☐
	098	FABIETTI P.G., et al., "Clinical Validation of a New Control-Oriented Model of Insulin and Glucose Dynamics in Subjects with Type 1 Diabetes," Diabetes Technology & Therapeutics, Vol. 9 (4), 2007, pp. 327-338.	☐
	099	FAHY B.G., et al., "An Analysis: Hyperglycemic Intensive Care Patients Need Continuous Glucose Monitoring-Easier Said Than Done," Journal of Diabetes Science and Technology, Diabetes Technology Society, Vol. 2 (2), March 2008, pp. 201-204.	☐
	100	FARE T.L., et al., "Functional Characterization of a Conducting Polymer-Based Immunoassay System," Biosensors & Bioelectronics, Vol. 13 (3-4), 1998, pp. 459-470.	☐
	101	FELDMAN B., et al., "A Continuous Glucose Sensor Based on Wired EnzymeTM Technology-Results from a 3-Day Trial in Patients with Type 1 Diabetes," Diabetes Technology & Therapeutics, Vol. 5 (5), 2003, pp. 769-779.	☐
	102	FELDMAN B., et al., "Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change," Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet, 2004, 1 page.	☐
	103	File History of U.S. Patent Application No. 11/157,365, filed on June 21, 2005, 977 pages (see image file wrapper - Atty. Docket No. DEXCOM.061A1).	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 131 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	104	File History of U.S. Patent Application No. 11/543,396, filed on October 4, 2006, 608 pages (see image file wrapper- Atty. Docket No. DEXCOM.088A).	☐
	105	File History of U.S. Patent Application No. 11/543,404, filed on October 4, 2006, 504 pages (see image file wrapper - Atty. Docket No. DEXCOM.096C8).	☐
	106	File History of U.S. Patent Application No. 11/543,490, filed on October 4, 2006, 639 pages (see image file wrapper - Atty. Docket No. DEXCOM.088A2).	☐
	107	File History of U.S. Patent Application No. 11/691,424, filed on March 26, 2007, 776 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP3).	☐
	108	File History of U.S. Patent Application No. 11/691,426, filed on March 26, 2007, 453 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP1).	☐
	109	File History of U.S. Patent Application No. 11/691,432, filed on March 26, 2007, 659 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP2).	☐
	110	File History of U.S. Patent Application No. 11/691,466, filed on March 26, 2007, 470 pages (see image file wrapper - Atty. Docket No. DEXCOM.088CP4).	☐
	111	File History of U.S. Patent Application No. 12/055,149, filed on March 25, 2008, 526 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CP1CP3).	☐
	112	File History of U.S. Patent Application No. 12/055,227, filed on March 25, 2008, 661 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CP1CP5).	☐
	113	File History of U.S. Patent Application No. 12/267,545, filed on November 7, 2008, 693 pages (see image file wrapper - Atty Docket No. DEXCOM.88CPP5P5).	☐
	114	File History of U.S. Patent Application No. 12/267,546, filed on November 7, 2008, 803 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CPP5P3).	☐
	115	File History of U.S. Patent Application No. 12/267,547, filed on November 7, 2008, 756 pages (see image file wrapper - Atty. Docket No. DEXCOM.88CPP5P2).	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 132 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	116	File History of U.S. Patent Application No. 15/616,916, filed on June 07, 2017, 169 pages (see image file wrapper).	☐
	117	File History of U.S. Patent Application No. 15/789,949, filed on October 20, 2017, 276 pages (see image file wrapper).	☐
	118	FISCHER U., et al., "Assessment of Subcutaneous Glucose Concentration: Validation of the Wick Technique as a Reference for Implanted Electrochemical Sensors in Normal and Diabetic Dogs," Diabetologia, Vol. 30, 1987, pp. 940-945.	☐
	119	FISCHER U., et al., "Hypoglycaemia-Warning by Means of Subcutaneous Electrochemical Glucose Sensors: An Animal Study," Horm. Metab. Res, Vol. 27, 1995, page 53. (Abstract Only).	☐
	120	FISCHER U., et al., "Oxygen Tension at the Subcutaneous Implantation Site of Glucose Sensors," Biomed. Biochim. Acta, Vol. 48 (11/12), 1989, pp. 965-971.	☐
	121	FREEDMAN D., et al., "Statistics," Second Edition, W.W. Norton & Company, New York & London, 1991, page 74 (3 pages).	☐
	122	FREIBERGER P., "Video Game Takes on Diabetes Superhero `Captain Novolin` Offers Treatment Tips," Fourth Edition, June 26, 1992, Business Section, 2 pages.	☐
	123	FROHNAUER M.K., et al., "Graphical Human Insulin Time-Activity Profiles Using Standardized Definitions," Diabetes Technology & Therapeutics, Vol. 3 (3), 2001, pp. 419-429.	☐
	124	FROST M.C., et al., "Implantable Chemical Sensors for Real-Time Clinical Monitoring: Progress and Challenges," Current Opinion in Chemical Biology, Analytical Techniques, Vol. 6, 2002, pp. 633-641.	☐
	125	GABBY R.A., et al., "Optical Coherence Tomography-Based Continuous Noninvasive Glucose Monitoring in Patients with Diabetes," Diabetes Technology & Therapeutics, Vol. 10, November 03, 2008, pp.188-193.	☐
	126	Gamry Instruments, "Basics of Electrochemical Impedance Spectroscopy," 2007, 30 pages.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 133 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	127	GANESAN N., et al., "Gold Layer-Based Dual Crosslinking Procedure of Glucose Oxidase with Ferrocene Monocarboxylic Acid Provides a Stable Biosensor," Analytical Biochemistry, Notes & Tips, Vol. 343, 2005, pp. 188-191.	☐
	128	GANESH A., et al., "Evaluation of the VIA® Blood Chemistry Monitor for Glucose in Healthy and Diabetic Volunteers," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 182-193.	☐
	129	GARG S.K., et al., "Correlation of Fingerstick Blood Glucose Measurements With GlucoWatch Biographer Glucose Results in Young Subjects With Type 1 Diabetes," Emerging Treatments and Technologies, Diabetes Care, Vol. 22 (10), October 1999, pp. 1708-1714.	☐
	130	GARG S.K., et al., "Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults With Type 1 Diabetes," Emerging Treatments and Technologies, Diabetes Care, Vol. 27 (3), 2004, pp. 734-738.	☐
	131	GEORGESCU B., et al., "Real-Time Multi-Model Tracking of Myocardium in Echocardiography Using Robust Information Fusion," Medical Image Computing and Computer-Assisted Intervention, Springer-Verlag Berlin Heidelberg, 2004, pp. 777-785.	☐
	132	GERRITSEN M., et al., "Performance of Subcutaneously Implanted Glucose Sensors for Continuous Monitoring," The Netherlands Journal of Medicine, Vol. 54, 1999, pp. 167-179.	☐
	133	GERRITSEN M., et al., "Problems Associated with Subcutaneously Implanted Glucose Sensors," Diabetes Care, Vol. 23 (2), February 2000, pp. 143-145.	☐
	134	GILLIGAN B.J., et al., "Evaluation of a Subcutaneous Glucose Sensor Out to 3 Months in a Dog Model" Diabetes Care, Vol. 17 (8), August 1994, pp. 882-887.	☐
	135	GILLIGAN B.J., et al., "Feasibility of Continuous Long-Term Glucose Monitoring from a Subcutaneous Glucose Sensor in Humans," Diabetes Technology & Therapeutics, Vol.6 (3), 2004, pp. 378-386.	☐
	136	GODSLAND I.F., et al., "Maximizing the Success Rate of Minimal Model Insulin Sensitivity Measurement in Humans: The Importance of Basal Glucose Levels," The Biochemical Society and the Medical Research Society, Clinical Science, Vol. 101, 2001, pp. 1-9.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 134 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	137	GOLDMAN J.M., et al., "Masimo Signal Extraction Pulse Oximetry," Journal of Clinical Monitoring and Computing, Vol. 16 (7), 2000, pp. 475-483.	☐
	138	GOUDA M.D., et al., "Thermal Inactivation of Glucose Oxidase," The Journal of Biological Chemistry, Vol. 278 (27), Issue of July 4, 2003, pp. 24324-24333.	☐
	139	GOUGH D.A., et al., "Frequency Characterization of Blood Glucose Dynamics," Annals of Biomedical Engineering, Vol. 31, 2003, pp. 91-97.	☐
	140	GOUGH D.A., et al., "Immobilized Glucose Oxidase in Implantable Glucose Sensor Technology," Diabetes Technology & Therapeutics, Vol. 2 (3), 2000, pp. 377-380.	☐
	141	GOUGH D.A., "The implantable Glucose Sensor: An Example of Bioengineering Design," Introduction to Bioengineering, 2001, Chapter 3, pp. 57-66.	☐
	142	GROSS, et al., "Diabetes Technology & Therapeutics," Letters to the Editor, Diabetes Technology & Therapeutics, Vol. 3 (1), 2001, pp. 129-131.	☐
	143	GROSS T.M., et al., "Efficacy and Reliability of the Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S19-S26.	☐
	144	GROSS T.M., et al., "Performance Evaluation Of The Minimed® Continuous Glucose Monitoring System During Patient Home Use," Diabetes Technology & Therapeutics, Vol. 2(1), 2000, pp. 49-56.	☐
	145	GUERCI B., et al., "Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs," Diabetes Care, Vol. 26, 2003, pp. 582-589.	☐
	146	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part 1. An Adsorption-controlled Mechanism," Electrochimica Acta, Vol. 43, Nos. 5/6, 1998, pp. 579-588.	☐
	147	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part II: Effect of potential," Electrochimica Acta, Vol. 43 (14-15), 1998, pp. 2015-2024.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 135 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	148	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part III: Effect of Temperature," Electrochimica Acta, Vol. 44, 1999, pp. 2455-2462.	☐
	149	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part IV: Phosphate Buffer Dependence," Electrochimica Acta, Vol. 44, 1999, pp. 4573-4582.	☐
	150	HALL S.B., et al., "Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes. Part V: Inhibition by Chloride," Electrochimica Acta, Vol. 45, 2000, pp. 3573-3579.	☐
	151	HAMILTON, "Complete Guide to Selecting the Right Hamilton GASTIGHT, MICROLITER, and Specialty Syringe for your Application," Syringe Selection, http://www.hamiltoncompany.com 2006, 20 pages.	☐
	152	HARRISON, et al., "Characterization of Perfluorosulfonic Acid Polymer Coated Enzyme Electrodes and a Miniaturized Integrated Potentiostat for Glucose Analysis in Whole Blood," Analytical Chemistry, 1988, Vol. 60, pp. 2002-2007.	☐
	153	HASHIGUCHI Y., et al., "Development of a Miniaturized Glucose Monitoring System by Combining a Needle-Type Glucose Sensor with Microdialysis Sampling Method: Long-term subcutaneous tissue glucose monitoring in ambulatory diabetic patients," Diabetes Care, Vol. 17, No. 5, May 1994, pp. 387-396.	☐
	154	HEISE T., et al., "Hypoglycemia warning signal and glucose sensors: Requirements and concepts," Diabetes Technology & Therapeutics, Vol. 5, No. 4, 2003, pp. 563-571.	☐
	155	HELLER A., "Electrical Connection of Enzyme Redox Centers to Electrodes," J. Phys. Chem., Vol. 96, 1992, pp. 3579-3587.	☐
	156	HELLER A., "Electrical Wiring of Redox Enzymes," Ace. Chem. Res., Vol. 23, 1990, pp. 128-134.	☐
	157	HELLER A., "Implanted Electrochemical Glucose Sensors for the Management of Diabetes," Annu. Rev., Biomed Eng., Vol. 1, 1999, pp. 153-175.	☐
	158	HELLER A., "Plugging Metal Connectors into Enzymes," Nature Biotechnology, Vol. 21, No. 6, June 2003, pp. 631-632.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 136 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	159	HICKS J.M., "In Situ Monitoring," Clinical Chemistry, Vol. 31 (12), 1985, pp. 1931-1935.	☐
	160	HITCHMAN M.L., "Measurement of Dissolved Oxygen," Edited by ELVING P.J et al., Chemical Analysis, New York, John Wiley & Sons, Vol. 49, Chapter 3, 1978, pp. 34-49 and 59-123.	☐
	161	HOEL P.G., "Elementary Statistics," Fourth Edition, John Wiley & Sons, Inc., 1976, pp. 113-114.	☐
	162	HOSS U., et al., "Continuous Glucose Monitoring in Subcutaneous Tissue Using Factory-Calibrated Sensors: A Pilot Study," Diabetes Technology & Therapeutics, 2010, Vol. 12 (8), pp. 591-597.	☐
	163	HOUGHTON MIFFLIN COMPANY, "American Heritage Dictionary," 4th Edition, 2000, pp. 82.	☐
	164	HOUGHTON MIFFLIN COMPANY, "Xenogenic, the American Heritage Stedman's Medical Dictionary," 2002, Answers.Com, retrieved from http://www.answers.com/topic/xenogenic, on November 07, 2006, 2 Pages.	☐
	165	HOVORKA R., et al., "Nonlinear Model Predictive Control of Glucose Concentration in Subjects with Type 1 Diabetes," Physiological Measurement, Vol. 25, July 2004, pp. 905-920.	☐
	166	HRAPOVIC S., et al., "Picoamperometric Detection of Glucose at Ultrasmall Platinum-Based Biosensors Preparation and Characterization," Anal. Chem, Vol. 75, 2003, pp. 3308-3315.	☐
	167	HU Y., et al., "A Needle-Type Enzyme-Based Lactate Sensor for In Vivo Monitoring," Analytica Chimica Acta, Vol. 281, 1993, pp. 503-511.	☐
	168	HUANG C., et al., "Electrochemical Generation of Oxygen. 1: The Effects of Anions and Cations on Hydrogen Chemisorption and Anodic Oxide Film Formation on Platinum Electrode. 2: The Effects of Anions and Cations on Oxygen Generation on Platinum Electrode," U.S. Department of Commence/NTIS, 1975, 126 pages.	☐
	169	HUANG Q., et al., "A 0.5mW Passive Telemetry IC for Biomedical Applications," Proceedings of the 23rd European Solid-State Circuits Conference (ESSCIRC '97), Southampton, UK, September 16-18, 1997, pp. 172-175.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 137 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	170	HUNTER I., et al., "Minimally Invasive Glucose Sensor and Insulin Delivery System," MIT Home Automation and Healthcare Consortium, March 31, 2000, Progress Report No. 25, 17 pages.	☐
	171	International Preliminary Report on Patentability for Application No. PCT/US2007/079220 mailed April 07, 2009, 11 pages - Atty. Docket No.DEXCOM.088VPC.	☐
	172	International Preliminary Report on Patentability for Application No. PCT/US2008/082905 mailed September 28, 2010, 13 pages - Atty. Docket No. DEXCOM.088HPC.	☐
	173	International Preliminary Report on Patentability for Application No. PCT/US2008/082870 mailed September 28, 2010, 6 pages - Atty. Docket No. DEXCOM.088BPC. .	☐
	174	International Search Report and Written Opinion for Application No. PCT/US2008/082870 mailed December 29, 2008, 6 pages - Atty. Docket. No. DEXCOM.088BPC.	☐
	175	International Search Report and Written Opinion for Application No. PCT/US2007/079220 mailed July 01, 2008, 16 pages - Atty. Docket No. DEXCOM.088VPC.	☐
	176	International Search Report and Written Opinion for Application No. PCT/US2008/082905 mailed March 16, 2009, 14 pages - Atty. Docket. No. DEXCOM.088HPC.	☐
	177	Invitation to Pay Additional Fees for Application No. PCT/US2007/079220, mailed April 25, 2008, 7 pages - Atty. Docket No. DEXCOM.088VPC.	☐
	178	ISERMANN R., et al., "Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes", Control Engineering Practice, Vol. 5 (5), 1997, pp. 709-719.	☐
	179	ISERMANN R., "Supervision, Fault-Detection and Fault-Diagnosis Methods - An Introduction," Control Engineering Practice, Vol. 5 (5), 1997, pp. 639-652.	☐
	180	ISHIKAWA M., et al., "Initial Evaluation of A 290-Mm Diameter Subcutaneous Glucose Sensor: Glucose Monitoring With A Biocompatible, Flexible-Wire, Enzyme-Based Amperometric Microsensor in Diabetic and Nondiabetic Humans," Journal of Diabetes and Its Complications, Vol. 12, 1998, pp. 295-301.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 138 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	181	JABLECKI M., et al., "Simulations of the Frequency Response of Implantable Glucose Sensors," Analytical Chemistry, Vol. 72, 2000, 1853-1859.	☐
	182	JAFFARI S.A., et al., "Recent Advances in Amperometric Glucose Biosensors for In Vivo Monitoring," Physiological Measurement, 1995, Vol. 16, pp. 1-15.	☐
	183	JAREMKO J., et al., "Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes," Diabetes Care, Vol. 21 (3), March 1998, pp. 444-450.	☐
	184	JENSEN M.B., et al., "Fast Wave Forms for Pulsed Electrochemical Detection of Glucose by Incorporation of Reductive Desorption of Oxidation Products, "Analytical Chemistry, Vol. 69 (9), May 1997, pp. 1776-1781.	☐
	185	JEONG R.A., et al., "In Vivo Calibration of the Subcutaneous Amperometric Glucose Sensors Using a Non-Enzyme Electrode," Biosensors and Bioelectronics, Elsevier, Vol. 19, 2003, pp. 313-319.	☐
	186	JEUTTER D.C., "A Transcutaneous Implanted Battery Recharging and Biotelemeter Power Switching System," IEEE Transactions on Biomedical Engineering, Vol. BME-29 (5), May 1982, pp. 314-321.	☐
	187	JEUTTER D.C., et al., "Design of a Radio-Linked Implantable Cochlear Prosthesis Using Surface Acoustic Wave Devices," IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, Vol. 40 (5), September 1993, pp. 469-477.	☐
	188	JOBST G., et al., "Thin-Film Microbiosensors for Glucose-Lactate Monitoring," Anal Chem, September 15, 1996, Vol. 68(18), pp. 3173-3179.	☐
	189	JOHNSON K.W., et al., "In Vivo Evaluation of an Electroenzymatic Glucose Sensor Implanted in Subcutaneous Tissue," Biosensors and Bioelectronics, 1992, Vol. 7, pp. 709-714.	☐
	190	JOHNSON K.W., "Reproducible Electrodeposition of Biomolecules for the Fabrication of Miniature Electroenzymatic Biosensors," Sensors and Actuators B, Vol. 5, 1991, pp. 85-89.	☐
	191	JOHNSON P.C., "Peripheral Circulation," John Wiley & Sons, 1978, page 198 (5 pages).	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 139 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	192	JOUNG G.B., et al., "An Energy Transmission System for an Artificial Heart Using Leakage Inductance Compensation of Transcutaneous Transformer," IEEE Transactions on Power Electronics, Vol. 13 (6), November 1998, pp. 1013-1022.	☐
	193	JOVANOVIC L.M.D., "The Role of Continuous Glucose Monitoring in Gestational Diabetes Mellitus," Diabetes Technology and Therapeutics, Vol. 2 (1), 2000, pp. S67-S71.	☐
	194	JUNGHEIM K., et al., "How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?," Diabetologia, 2002, Vol. 45, pp. A250-A276.	☐
	195	JUNGHEIM K., et al., "Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm," Diabetes Care, Vol. 24 (7), July 2001, pp. 1303-1304.	☐
	196	KACANIKLIC V., et al., "Amperometric Biosensors for Detection of L- and D-Amino Acids Based on Coimmoblized Peroxidase and L- and D-Amino Acid Oxidases in Carbon Paste Electrodes," Electroanalysis, Vol. 6, May-Jun 1994, pp. 381-390.	☐
	197	KAMATH A., et al., "Calibration of a Continuous Glucose Monitor: Effect of Glucose Rate of Change," Eighth Annual Diabetes Technology Meeting, November 13-15, 2008, pp. A88 (2 pages).	☐
	198	KANG S.K., et al., "In Vitro and Short-Term in Vivo Characteristics of a Kel-F Thin Film Modified Glucose Sensor," Analytical Sciences, Vol. 19, November 2003, pp. 1481-1486.	☐
	199	KAPLAN S.M., "Wiley Electrical and Electronics Engineering Dictionary," IEEE Press, John Wiley & Sons, Inc., 2004, pp. 141, 142, 548 & 549.	☐
	200	KARGOL M., et al., "Studies on the Structural Properties of Porous Membranes: Measurement of Linear Dimensions of Solutes," Biophysical Chemistry, 2001, Vol. 91, pp. 263-271.	☐
	201	KAUFMAN F.R., et al., "A Pilot Study of the Continuous Glucose Monitoring System," Diabetes Care, Vol. 24 (12), December 2001, pp. 2030-2034.	☐
	202	KAUFMAN F.R., "Role of the Continuous Glucose Monitoring System in Pediatric Patients," Diabetes Technology and Therapeutics, Vol. 2 (1), 2000, S49-S52.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 140 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	203	KAWAGOE J.L., et al., "Enzyme-Modified Organic Conducting Salt Microelectrode," Analytical Chemistry, Vol. 63, 1991, pp. 2961-2965.	☐
	204	KEEDY F.H., et al., "Determination of Urate in Undiluted Whole Blood by Enzyme Electrode," Biosensors and Bioelectronics, Vol. 6, 1991, pp. 491-499.	☐
	205	KERNER, et al., "A Potentially Implantable Enzyme Electrode for Amperometric Measurement of Glucose," Hormone and Metabolic Research Supplement, Vol. 20, 1988, pp. 8-13.	☐
	206	KERNER W., et al., "The Function of a Hydrogen Peroxide-Detecting Electroenzymatic Glucose Electrode is Markedly Impaired in Human Sub-Cutaneous Tissue and Plasma," Biosensors and Bioelectronics, Vol. 8, 1993, pp. 473-482.	☐
	207	KERNER W., "Implantable Glucose Sensors: Present Status and Future Developments," Experimental and Clinical Endocrinol Diabetes, Vol. 109 (2), 2001, pp. S341-S346.	☐
	208	KIECHLE F.L., "The Impact of Continuous Glucose Monitoring on Hospital Point-of-Care Testing Programs," Diabetes Technology and Therapeutics, Vol. 3 (4), 2001, pp.647-649.	☐
	209	KLONOFF D., et al., "Performance Metrics for Continuous Interstitial Glucose Monitoring; Approved Guideline," Clinical and Laboratory Standards Institute, POCT05-A, Vol. 28 (33), 2008, 72 pages.	☐
	210	KLUEH U., et al., "Use of Vascular Endothelial Cell Growth Factor Gene Transfer to Enhance Implantable Sensor Function in Vivo," Biosensor Function and VEGF-Gene Transfer, Vol. 67 (4), 2003, pp. 1072-1086.	☐
	211	KONDO T., et al., "A Miniature Glucose Sensor, Implantable in the Blood Stream," Diabetes Care, Vol. 5 (3), May-June 1982, 218-221.	☐
	212	KOSCHINSKY T., et al., "Sensors For Glucose Monitoring: Technical And Clinical Aspects," Diabetes Metabolism Research and Reviews, vol. 17, no. 2, 01 January 2001, pages 113-123.	☐
	213	KOSCHINSKY T., et al., "New Approach to Technical and Clinical Evaluation of Devices for Self-Monitoring of Blood Glucose," Diabetes Care, Vol. 11 (8), September 1988, pp. 619-629.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 141 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	214	KOST J., et al., "Glucose-Sensitive Membranes Containing Glucose Oxidase: Activity, Swelling, And Permeability Studies," Journal of Biomedical Materials Research, Vol. 19, 1985, pp. 1117-1133.	☐
	215	KOUDELKA M., et al., "In Vivo Response of Microfabricated Glucose Sensors to Glycemia Changes in Normal Rats," Biomed. Biochim. Acta, Vol. 48 (11/12), November - December 1989, pp. 953-956.	☐
	216	KOUDELKA M., et al., "In-Vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors," Biosensors and Bioelectronics, Vol. 6, 1991, pp. 31-36.	☐
	217	KOVATCHEV B.P., et al., "Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors: Continuous Glucose-Error Grid Analysis Illustrated by TheraSense Freestyle Navigator Data," Diabetes Care, Vol. 27 (8), August 2004, pp.1922-1928.	☐
	218	KOVATCHEV B.P., et al., "Graphical and Numerical Evaluation of Continuous Glucose Sensing Time Lag," Diabetes Technology & Therapeutics, Vol. 11 (3), 2009, pp. 139-143.	☐
	219	KRAVER., et al., "A Mixed-Signal Sensor Interface Microinstrument," Sensors and Actuators A, Physical 2001, Vol. 91, pp. 266-277.	☐
	220	KROUWER J.S., "Setting Performance Goals and Evaluating Total Analytical Error for Diagnostic Assays," Clinical Chemistry, Vol. 48 (6), 2002, pp. 919-927.	☐
	221	KRUGER D., et al., "Psychological Motivation and Patient Education: A Role for Continuous Glucose Monitoring," Diabetes Technology and Therapeutics, Vol. 2 (1), 2000, pp. S93-S97.	☐
	222	KULYS J., et al., "Carbon-Paste Biosensors Array for Long-Term Glucose Measurement," Biosensors & Bioelectronics, Vol. 9, 1994, pp. 491-500.	☐
	223	KUNJAN K., et al., "Automated Blood Sampling and Glucose Sensing in Critical Care Settings," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 194-200.	☐
	224	KURNIK R.T., et al., "Application of the Mixtures of Experts Algorithm for Signal Processing in a Noninvasive Glucose Monitoring System," Sensors and Actuators B, Vol. 60, 1999, pp. 19-26.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 142 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	225	KURTZ T.W., et al., "Recommendations for Blood Pressure Measurement in Humans and Experimental Animals, Part 2: Blood Pressure Measurement In Experimental Animals: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research," Hypertension, February 2005, Vol. 45, pp. 299-310.	☐
	226	KUURE-KINSEY M., et al., "A Dual-Rate Kalman Filter for Continuous Glucose Monitoring," Conf Proc IEEE Eng Med Biol Soc., 2006, Vol. 1, pp. 63-66.	☐
	227	LACOURSE W.R., et al., "Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry," Analytical Chemistry, Vol. 65, 1993, pp. 50-52.	☐
	228	LADD M.F.C., et al., "Structure Determination By X-Ray Crystallography," 3rd Edition, Plenum Press, 1994, Ch. 1, pp. xxi-xxiv and 1-58.	☐
	229	LEHMANN E.D., et al., "Retrospective Validation of a Physiological Model of Glucose-Insulin Interaction in Type 1 Diabetes Mellitus. Medical Engineering & Physics, Vol. 16, May 1994, pp. 193-202.	☐
	230	LEONHARDT A., et al., "The Potential Use of Silicon Compounds as Oxygen Carriers for Free and Immobilized Cells Containing L-Amino Acid Oxidase," Applied Microbiology and Biotechnology, Vol. 21, 1985, pp. 162-166.	☐
	231	LEWANDOWSKI J.J., et al., "Evaluation of a Miniature Blood Glucose Sensor," Transactions - American Society for Artificial Internal Organs, Vol. 34, 1988, pp. 255-258.	☐
	232	LEYPOLDT J.K., et al., "Model of a Two-Substrate Enzyme Electrode for Glucose," Analytical Chemistry, Vol. 56, 1984, pp. 2896-2904.	☐
	233	LINKE B., et al., "Amperometric Biosensor for In Vivo Glucose Sensing Based on Glucose Oxidase Immobilized In A Redox Hydrogel," Biosensors and Bioelectronics, Vol. 9, 1994, pp. 151-158.	☐
	234	LODWIG V., et al., "Continuous Glucose Monitoring with Glucose Sensors: Calibration and Assessment Criteria," Diabetes Technology & Therapeutics, Vol. 5 (4), 2003, pp. 572-587.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 143 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	235	LOHN A., et al., "A Knowledge-Based System for Real-Time Validation of Calibrations and Measurements," Chemometrics and Intelligent Laboratory Systems, Vol. 46, 1999, pp. 57-66.	☐
	236	LORTZ J., et al., "What is Bluetooth? We Explain the Newest Short-Range Connectivity Technology," In Smart Computing Learning Series, Wireless Computing, Vol. 8 (5), 2002, pp. 72-74.	☐
	237	LOWE C.R., "Biosensors," Trends in Biotechnology, Vol. 2 (3), 1984, pp. 59-65.	☐
	238	LUONG J.H.T., et al., "Solubilization of Multiwall Carbon Nanotubes by 3-Aminopropyltriethoxysilane towards the Fabrication of Electrochemical Biosensors with Promoted Electron Transfer," Electroanalysis, Vol. 16 (1-2), 2004, pp. 132-139.	☐
	239	LYANDRES O., et al. "Progress toward an In Vivo Surface-Enhanced Raman Spectroscopy Glucose Sensor," Diabetes Technology and Therapeutics, Vol. 10 (4), 2008, pp. 257-265.	☐
	240	LYNCH S.M., et al., "Estimation-Based Model Predictive Control of Blood Glucose in Type I Diabetics: A Simulation Study," Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference, 2001, pp. 79-80.	☐
	241	LYNN P.A., "Recursive Digital Filters for Biological Signals," Med. & Biol. Engineering, Vol. 9, 1971, pp. 37-43.	☐
	242	MAHER R.C., "A Method for Extrapolation of Missing Digital Audio Data," Preprints of Papers Presented at the AES Convention, New York, 1993, pp. 1-19.	☐
	243	MAHER R.C., "Audio Enhancement Using Nonlinear Time-Frequency Filtering," AES 26th International Conference, July 7-9, 2005, pp. 1-9.	☐
	244	MAIDAN R., et al., "Elimination of Electrooxidizable Interferent-Produced Currents in Amperometric Biosensors," Analytical Chemistry, Vol. 64, 1992, pp. 2889-2896.	☐
	245	MAKALE M.T., et al., "Tissue Window Chamber System for Validation of Implanted Oxygen Sensors," American Journal of Physiology-Heart and Circulatory Physiology, Vol. 284, February 21, 2003, pp. 1-27.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 144 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	246	MALIN S.F., et al., "Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectroscopy," Clinical Chemistry, Vol. 45 (9), 1999, pp. 1651-1658.	☐
	247	MANCY K.H., et al., "A Galvanic Cell Oxygen Analyzer," Journal of Electroanalytical Chemistry, Vol. 4, 1962, pp. 65-92.	☐
	248	MARAN A., et al., "Continuous Subcutaneous Glucose Monitoring in Diabetic Patients," A Multicenter Analysis, Diabetes Care, Vol. 25 (2), February 2002, pp. 347-352.	☐
	249	MARCH W.F., "Dealing with the Delay," Diabetes Technology & Therapeutics, Vol. 4 (1), 2002, pp. 49-50.	☐
	250	MARENA S., et al., "The Artificial Endocrine Pancreas in Clinical Practice and Research," Panminerva Medica, Vol. 35 (2), 1993, pp. 67-74.	☐
	251	MARTIN R.F., "General Deming Regression for Estimating Systematic Bias and its Confidence Interval in Method-Comparison Studies," Clinical Chemistry, Vol. 46 (1), 2000, pp. 100-104.	☐
	252	MASCINI M., et al., "Glucose Electrochemical Probe with Extended Linearity for Whole Blood," Journal Pharmaceutical and Biomedical Analysis, Vol. 7 (12), 1989, pp. 1507-1512.	☐
	253	MASTROTOTARO J.J., et al., "An Electroenzymatic Glucose Sensor Fabricated on a Flexible Substrate," Sensors and Actuators B, Vol. 5, 1991, pp. 139-144.	☐
	254	MASTROTOTARO J.J., et al., "Reproducibility of the Continuous Glucose Monitoring System Matches Previous Reports and the Intended Use of the Product," Diabetes Care, Vol. 26 (1), January 2003, pp. 256-257.	☐
	255	MASTROTOTARO J.J., "The MiniMed Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S13-S18.	☐
	256	MATSUKI H., "Energy Transfer System Utilizing Amorphous Wires For Implantable Medical Devices," IEEE Transactions on Magnetics, Vol. 31 (2), 1994, pp. 1276-1282.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 145 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	257	MATSUMOTO T., et al., "A long-Term Lifetime Amperometric Glucose Sensor with a Perfluorocarbon Polymer Coating," Biosensors & Bioelectronics, Vol. 16, 2001, pp. 271-276.	☐
	258	MATSUMOTO T., et al., "A Micro-Planar Amperometric Glucose Sensor Unsusceptible to Interference Species," Sensors and Actuators B, 49, 1998, pp. 68-72.	☐
	259	MATTHEWS D.R., et al., "An Amperometric Needle-Type Glucose Sensor Testing in Rats and Man," Diabetic Medicine, Vol. 5, 1988, pp. 248-252.	☐
	260	MAZZE R.S., et al., "Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis," Diabetes Technology & Therapeutics, Vol. 10 (3), 2008, pp. 149-159.	☐
	261	MAZZOLA F., et al., "Video Diabetes: A Teaching Tool for Children with Insulin-Dependent Diabetes," IEEE, Proceedings 7th Annual Symposium on Computer Applications in Medical Care, October 1983, 1 page Abstract.	☐
	262	McCARTNEY L.J., et al., "Near-Infrared Fluorescence Lifetime Assay for Serum Glucose Based on Allophycocyanin-Labeled Concanavalin A," Analytical Biochemistry, Vol. 292, 2001, pp. 216-221.	☐
	263	McGARRAUGH G., et al., "Glucose Measurements Using Blood Extracted From The Forearm And The Finger," TheraSense, Inc., 2001, pp. 1-8.	☐
	264	McGARRAUGH G., et al., "Physiological Influences on Off-Finger Glucose Testing", Diabetes Technology & Therapeutics, Vol. 3 (3), 2001, pp. 367-376.	☐
	265	McGRATH M.J., et al., "The Use of Differential Measurements with a Glucose Biosensor for Interference Compensation During Glucose Determinations by Flow Injection Analysis," Biosens Bioelectron, Vol. 10, 1995, pp. 937-943.	☐
	266	McKEAN B.D., et al., "A Telemetry Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors," IEEE Transactions on Biomedical Engineering, Vol. 35 (7), July 1988, pp. 526-532.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 146 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	267	MEMOLI A., et al., "A Comparison between Different Immobilised Glucoseoxidase-Based Electrodes," Journal of Pharmaceutical and Biomedical Analysis, Vol. 29, 2002, pp. 1045-1052.	☐
	268	MERRIAM WEBSTER Online Dictionary, Definition for "Aberrant," retrieved from https://www.merriam-webster.com/dictionary/aberrant August 19, 2008, 1 page.	☐
	269	MERRIAM-WEBSTER Online Dictionary, Definition of "Acceleration" retrieved from http://www.merriam-webster.com/dictionary/Acceleration January 11, 2010, 1 page.	☐
	270	MERRIAM-WEBSTER Online Dictionary, Definition of "Nominal" retrieved from http://www.merriam-webster.com/dictionary/nominal April 23, 2007, 1 page.	☐
	271	MERRIAM-WEBSTER Online Dictionary, Definition of "System". http://www.merriamwebster.com/dictionary/System January 11, 2010, 2 pages.	☐
	272	METZGER M., et al., "Reproducibility of Glucose Measurements using the Glucose Sensor," Diabetes Care, Vol. 25 (6), July 2002, pp. 1185-1191.	☐
	273	MEYERHOFF C., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose in Men by Combining Portable Glucosensor With Microdialysis," Diabetologia, Vol. 35 (11), 1992, pp. 1087-1092.	☐
	274	MILLER J.A., et al., "Development of an Autotuned Transcutaneous Energy Transfer System," ASAIO Journal, Vol. 39, 1993, pp. M706-M710.	☐
	275	MOATTI-SIRAT D., et al., "Evaluating In Vitro and In Vivo the Interference of Ascorbate and Acetaminophen on Glucose Detection by a Needle-Type Glucose Sensor," Biosensors and Bioelectronics, Vol. 7, 1992, pp. 345-352.	☐
	276	MOATTI-SIRAT D., et al., "Reduction of Acetaminophen Interference in Glucose Sensors by a Composite Nafion Membrane: Demonstration in Rats and Man," Diabetologia, Vol. 37 (6), June 1994, pp. 610-616.	☐
	277	MOATTI-SIRAT., et al., "Towards Continuous Glucose Monitoring: In Vivo Evaluation of a Miniaturized Glucose Sensor Implanted for Several Days in Rat Subcutaneous Tissue," Diabetologia, Vol. 35, 1992, pp. 224-230.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 147 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	278	MONSOD T.P., et al., "Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia And Hyperinsulinemia? ,"Diabetes Care, Vol. 25 (5), 2002, pp. 889-893.	☐
	279	MORBIDUCCI U., et al., "Improved Usability of the Minimal Model of Insulin Sensitivity Based on Automated Approach and Genetic Algorithms for Parameter Estimation," Clinical Science, Vol. 112 (4), 2006, 24 pages.	☐
	280	MORFF R.J., et al., "Microfabrication of Reproducible, Economical, Electroenzymatic Glucose Sensors," Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vol. 12 (2), 1990, pp. 0483-0484.	☐
	281	MOSBACH K., et al., "Determination of Heat Changes in the Proximity of Immobilized Enzymes with an Enzyme Thermistor and its Use for the Assay of Metabolites," Biochimica Biophysica Acta, Vol. 403, 1975, pp. 256-265.	☐
	282	MOTONAKA J., et al., "Determination of Cholesterol and Cholesterol Ester with Novel enzyme Microsensors," Anal. Chem., Vol. 65, 1993, pp. 3258-3261.	☐
	283	MOUGIAKAKOU S.G., et al., "A Real Time Simulation Model of Glucose-Insulin Metabolism for Type 1 Diabetes Patients," Conf Proc IEEE Eng Med Biol Soc. 2005, Vol. 1, pp. 298-301.	☐
	284	MOUSSY F., et al., "A Miniaturized Nafion-Based Glucose Sensor: In Vitro and In Vivo Evaluation in Dogs," International Journals of Artificial Organs, Vol. 17 (2), 1994, pp. 88-94.	☐
	285	MOUSSY F., et al., "Performance of Subcutaneously Implanted Needle-Type Glucose Sensors Employing a Novel Trilayer Coating," Analytical Chemistry, Vol. 65, August 1, 1993, pp. 2072-2077.	☐
	286	MOUSSY F., "Implantable Glucose Sensor: Progress and Problems," IEEE, November 2002, pp. 270-273.	☐
	287	MURPHY S.M., et al., "Polymer Membranes in Clinical Sensor Applications, II. The Design and Fabrication of Permselective Hydrogels for Electrochemical Devices," Biomaterials, 1992, Vol. 13 (14), pp. 979-990.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 148 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	288	MUSLU, "Trickling Filter Performance," Applied Biochemistry and Biotechnology, Vol. 37, 1992, pp. 211-224.	☐
	289	MYLER S., et al., "Ultra-Thin-Polysiloxane-Film-Composite Membranes for the Optimisation of Amperometric Oxidase Enzyme Electrodes," Biosensors & Bioelectronics, Vol. 17, 2002, pp. 35-43.	☐
	290	NEUBURGER G.G., et al., "Pulsed Amperometric Detection of Carbohydrates at Gold Electrodes with a Two-Step Potential Waveform," Anal. Chem., Vol. 59, 1987, pp. 150-154.	☐
	291	Nintendo Healthcare, Wired, December 1993, 1 page.	☐
	292	Notice of Allowance for U.S Application No. 14/066,650, mailed February 16, 2017, 7 pages.	☐
	293	Notice of Allowance for U.S Application No. 15/796,274, mailed July 20, 2018, 8 pages.	☐
	294	NOUJAIM S.E., et al., "Accuracy Requirements for a Hypoglycemia Detector: An Analytical Model to Evaluate the Effects of Bias, Precision and Rate of Glucose Change," Journal of Diabetes Science & Technology, Vol. 1 (5), September 2007, pp. 652-668.	☐
	295	NOVO NORDISK PHARMACEUTICALS Inc., "Diabetes Educational Video Game Recognized by Software Publishers Association," Press Release, March 14, 1994, 4 pages.	☐
	296	O'DONOGHUE M., et al., "Electrochemical Impedance Spectroscopy: Testing Coatings for Rapid Immersion Service," Materials Performance, September 2003, pp. 36-41.	☐
	297	Office Action for European Application No. 07840311.3, mailed August 18, 2011, 5 pages - Atty. Docket No. DEXCOM.088VEP.	☐
	298	Office Action for U.S Application No. 11/077,759, mailed July 10, 2008, 10 pages - Atty. Docket No. DEXCOM.050A.	☐
	299	Office Action for U.S Application No. 11/077,759, mailed March 31, 2008, 16 pages - Atty. Docket No. DEXCOM.050A.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 149 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	300	Office Action for U.S Application No. 11/077,759, mailed May 26, 2009, 8 pages - Atty. Docket No. DEXCOM.050A.	☐
	301	Office Action for U.S Application No. 11/360,819, mailed August 11, 2008, 10 pages - Atty. Docket No. DEXCOM.061CP4.	☐
	302	Office Action for U.S Application No. 11/360,819, mailed December 26, 2008, 12 pages - Atty. Docket No. DEXCOM.061CP4.	☐
	303	Office Action for U.S Application No. 11/691,424, mailed June 11, 2009, 21 pages - Atty. Docket No. DEXCOM.088CP3.	☐
	304	Office Action for U.S Application No. 11/691,424, mailed September 25, 2008, 15 pages - Atty. Docket No. DEXCOM.088CP3.	☐
	305	Office Action for U.S Application No. 11/691,432, mailed June 10, 2009, 17 pages - Atty. Docket No. DEXCOM.088CP2.	☐
	306	Office Action for U.S Application No. 11/691,432, mailed September 19, 2008, 11 pages - Atty. Docket No. DEXCOM.088CP2.	☐
	307	Office Action for U.S Application No. 11/691,466, mailed October 03, 2008, 15 pages - Atty. Docket No. DEXCOM.088CP4.	☐
	308	Office Action for U.S Application No. 12/055,098, mailed February 27, 2013, 14 pages - Atty. Docket No. DEXCOM.106A.	☐
	309	Office Action for U.S Application No. 12/055,098, mailed July 19, 2013, 12 pages - Atty. Docket No. DEXCOM.106A. .	☐
	310	Office Action for U.S Application No. 12/055,098, mailed March 25, 2011, 16 pages - Atty. Docket No. DEXCOM.106A.	☐
	311	Office Action for U.S Application No. 12/055,098, mailed October 05, 2010, 12 pages - Atty. Docket No. DEXCOM.106A.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 150 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	312	Office Action for U.S Application No. 12/267,542, mailed June 20, 2012, 8 pages - Atty. Docket No. DEXCOM.016CP2.	☐
	313	Office Action for U.S Application No. 12/267,542, mailed October 5, 2012, 8 pages - Atty. Docket No. DEXCOM.016CP2.	☐
	314	Office Action for U.S Application No. 14/066,650, mailed September 23, 2016, 6 pages.	☐
	315	Office Action for U.S Application No. 14/077,004, mailed July 26, 2016, 14 pages.	☐
	316	OHARA T.J., et al., "Glucose Electrodes Based On Cross-Linked [Os(bpy)2Cl](+/2+) Complexed Poly(1-Vinylimidazole) Films," Analytical Chemistry, Vol. 65, December 1993, pp. 3512-3517.	☐
	317	OHARA T.J., et al., ""Wired" Enzyme Electrodes for Amperometric Determination of Glucose or Lactate in the Presence of Interfering Substances," Anal Chem, Vol. 66, 1994, pp. 2451-2457.	☐
	318	OKUDA, et al., "Mutarotase Effect on Micro Determinations of D-Glucose and its Anomers with β D-Glucose Oxidase," Anal Biochem, Vol. 43 (1), 1971, pp. 312-315.	☐
	319	Oxford English Dictionary Online, Definition of "Impending," http://www.askoxford.com/results/?view=devdict&field-12668446_Impending&branch January 11, 2010, 1 page.	☐
	320	PALMISANO F., et al., "Simultaneous Monitoring of Glucose and Lactate by an Interference and Cross- Talk Free Dual Electrode Amperometric Biosensor Based on Electropolymerized Thin Films," Biosensors & Bioelectronics, Vol. 15, 2000, pp. 531-539.	☐
	321	PANTELEON A.E., et al., "The Role of the Independent Variable to Glucose Sensor Calibration," Diabetes Technology & Therapeutics, Vol. 5 (3), 2003, pp. 401-410.	☐
	322	PARK, et al., "Novel Instrumentation in Electrochemical Impedance Spectroscopy and a Full Description of an Electrochemical System," Pure Appl. Chem., 2006, Vol. 78 (5), pp. 1069-1080.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 151 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	323	PARKER R.S., et al., "A Model-Based Algorithm for Blood Glucose Control In Type I Diabetic Patients," IEEE Trans Biomed Engg (BME), Vol. 46(2), 1999, pp. 148-157.	☐
	324	PARKER R.S., et al., "Robust H∞ Glucose Control in Diabetes Using a Physiological Model," AIChE Journal, Vol. 46 (12), December 2000, pp. 2537-2549.	☐
	325	PATEL H., et al., "Amperometric Glucose Sensors Based on Ferrocene Containing Polymeric Electron Transfer Systems--A Preliminary Report," Biosensors & Bioelectronics, Vol. 18, 2003, pp. 1073-1076.	☐
	326	PEACOCK W.F., et al., "Cardiac Troponin and Outcome in Acute Heart Failure," N. Engl. J. Med., Vol. 358, 2008, pp. 2117-2126.	☐
	327	PEGUIN S., et al., "Pyruvate Oxidase and Oxaloacetate Decarboxylase Enzyme Electrodes--Simultaneous Determination of Transaminases with a Two-electrode-based Analyzer," Analytica Chimica Acta, Vol. 222, 1989, pp. 83-93.	☐
	328	PFEIFFER E.F., et al., "On Line Continuous Monitoring of Subcutaneous Tissue Glucose is Feasible by Combining Portable Glucosensor with Microdialysis," Horm. Metab. Res., Vol. 25, 1993, pp. 121-124.	☐
	329	PFEIFFER E.F., "The Glucose Sensor: The Missing Link in Diabetes Therapy," Horm Metab Res Suppl., Vol. 24, 1990, pp. 154-164.	☐
	330	PHILLIPS R.P., "A High Capacity Transcutaneous Energy Transmission System," ASIAO Journal, Vol. 41, 1995, pp. M259-M262.	☐
	331	PICHERT J.W., et al., "Issues for the Coming Age of Continuous Glucose Monitoring," Diabetes Educator, Vol. 26 (6), November-December 2000, pp. 969-980.	☐
	332	PICKUP J.C., et al., "Developing Glucose Sensors for In Vivo Use," Elsevier Science Publishers Ltd (UK), TIBTECH, Vol. 11, 1993, pp. 285-291.	☐
	333	PICKUP J.C., et al., "Implantable Glucose Sensors: Choosing the Appropriate Sensor Strategy," Biosensors, Vol. 3, (1987/1988), pp. 335-346.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 152 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	334	PICKUP J.C., et al., "In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer," Diabetologia, Vol. 32, 1989, pp. 213-217.	☐
	335	PICKUP J.C., et al., "Potentially-Implantable, Amperometric Glucose Sensors with Mediated Electron Transfer: Improving the Operating Stability," Biosensors, Vol. 4, 1989, pp. 109-119.	☐
	336	PICKUP J.C., et al., "Responses and Calibration of Amperometric Glucose Sensors Implanted in the Subcutaneous Tissue of Man," ACTA Diabetol, Vol. 30, 1993, pp. 143-148.	☐
	337	PINNER S.H., et al., "Cross-Linking of Cellulose Acetate by Ionizing Radiation," Nature, Vol. 184, October 24, 1959, pp. 1303-1304.	☐
	338	PISHKO M.V., et al., "Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels," Analytical Chemistry, Vol. 63 (20), 1991, pp. 2268-2272.	☐
	339	PITZER K.R., et al., "Detection of Hypoglycemia with the Glucowatch Biographer," Diabetes Care, Vol. 24 (5), 2001, pp. 881-885.	☐
	340	POIRIER J.Y., et al., "Clinical and Statistical Evaluation of Self-Monitoring Blood Glucose Meters," Diabetes Care, Vol. 21 (11), November 1998, pp. 1919-1924.	☐
	341	POITOUT V., et al., "A Glucose Monitoring System for on Line Estimation in Man of Blood Glucose Concentration Using a Miniaturized Glucose Sensor Implanted in the Subcutaneous Tissue and a Wearable Control Unit," Diabetologia, Vol. 36, 1993, pp. 658-663.	☐
	342	POITOUT V., et al., "Development of a Glucose Sensor for Glucose Monitoring in Man: The Disposable Implant Concept," Clinical Materials, Vol. 15, 1994, pp. 241-246.	☐
	343	POITOUT V., et al., "In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor," ASAIO Transactions, Vol. 37, 1991, pp. M298-M300.	☐
	344	POSTLETHWAITE T.A., et al., "Interdigitated Array Electrode as an Alternative to the Rotated Ring-Disk Electrode for Determination of the Reaction Products of Dioxygen Reduction," Analytical Chemistry, Vol. 68 (17), September 1996, pp. 2951-2958.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 153 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	345	PRABHU V.G., et al., "Electrochemical Studies of Hydrogen Peroxide at a Platinum Disc Electrode," Electrochimica Acta, Vol. 26 (6), 1981, pp. 725-729.	☐
	346	QUINN C.A.P., et al., "Biocompatible, Glucose-Permeable Hydrogel for In situ Coating of Implantable Biosensors," Biomaterials, Volume. 18 (24), 1997, pp. 1665-1670.	☐
	347	QUINN C.P., et al., "Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors," The American Physiological Society, Vol. 269, 1995, pp. E155-E161.	☐
	348	RABAH M.A., et al., "Electrochemical Wear of Graphite Anodes During Electrolysis of Brine," Carbon, Vol. 29 (2), 1991, pp. 165-171.	☐
	349	RAYA Systems Pioneers, "Raya Systems Pioneers Healthy Video Games," PlayRight, November 1993, pp. 14-15.	☐
	350	REACH G., "A Method for Evaluating in vivo the Functional Characteristics of Glucose Sensors," Biosensors, Vol. 2, 1986, pp. 211-220.	☐
	351	REACH G., et al., "Can Continuous Glucose Monitoring Be Used for the Treatment of Diabetes? ," Analytical Chemistry, Vol. 64 (6), March 15, 1992, pp. 381A-386A.	☐
	352	REACH G., "Which Threshold to Detect Hypoglycemia? Value of Receiver-Operator Curve Analysis to Find a Compromise Between Sensitivity and Specificity," Diabetes Care, Vol. 24 (5), May 2001, pp. 803-804.	☐
	353	REBRIN K., et al., "Automated Feedback Control of Subcutaneous Glucose Concentration in Diabetic Dogs," Diabetologia, Vol. 32, 1989, pp. 573-576.	☐
	354	REBRIN K., et al., "Subcutaneous Glucose Monitoring by Means of Electrochemical Sensors: Fiction or Reality?," Journal of Biomedical Engineering, Vol. 14, January 1992, pp. 33-40.	☐
	355	REBRIN K., et al., "Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring," The American Physiological Society, Vol. 277, 1999, pp. E561-E571.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 154 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	356	Response for European application No. 07843011.3, filed September 21, 2007, 11 pages - Atty. Docket No. DEXCOM.088VEP.	☐
	357	REUSH, "Organometallic Compounds," Chemical Reactivity, Virtual Textbook of Organic Chemistry, Retrieved from http://www.cem.msu.edu/-reuschlVirtualText/orgmetal.htm 2004, pp. 1-16.	☐
	358	RHODES R.K., et al., "Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis," Analytical Chemistry, Vol. 66 (9), May 1, 1994, pp. 1520-1529.	☐
	359	RIGLA M., et al., "Real-Time Continuous Glucose Monitoring Together with Telemedical Assistance Improves Glycemic Control and Glucose Stability in Pump-Treated Patients," Diabetes Technology & Therapeutics, Vol. 10 (3), 2008, pp. 194-199.	☐
	360	RINKEN T., et al., "Calibration of Glucose Biosensors By Using Pre-Steady State Kinetic Data," Biosensors & Bioelectronics, Vol. 13, 1998, pp. 801-807.	☐
	361	RIVERS E.P., et al., "Central Venous Oxygen Saturation Monitoring in the Critically Ill Patient," Current Opinion in Critical Care, 2001, Vol. 7, pp. 204-211.	☐
	362	ROE J.N., et al., "Bloodless Glucose Measurements," Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol. 15 (3), 1998, pp. 199-241.	☐
	363	SAKAKIDA M., et al., "Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations," Artif. Organs Today, Vol. 2 (2), 1992, pp. 145-158.	☐
	364	SAKAKIDA M., et al., "Ferrocene-Mediated Needle Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane," Sensors and Actuators B, Vol. 13-14, 1993, pp. 319-322.	☐
	365	SALARDI S., et al., "The Glucose Area Under the Profiles Obtained with Continuous Glucose Monitoring System Relationships with HbA1C in Pediatric Type 1 Diabetic Patients," Diabetes Care, Vol. 25 (10), October 2002, pp. 1840-1844.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 155 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	366	SALEHI C., et al., "A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors," Analytical Letters, Vol. 29 (13), 1996, pp. 2289-2308.	☐
	367	SAMUELS M.P., "The Effects of Flight and Altitude," Arch Dis Child, Vol. 89, 2004, pp. 448-455.	☐
	368	SAN DIEGO PLASTICS INC, "Polyethylene," Datasheet, Retrieved from http://www.sdplastics.com/polyeth.html on August 19, 2009, 7 pages.	☐
	369	SANSEN W., et al., "A Smart Sensor for the Voltammetric Measurement of Oxygen or Glucose Concentrations," Sensors and Actuators B1, 1990, pp. 298-302.	☐
	370	SANSEN W., et al., "Glucose Sensor with Telemetry System," In Implantable Sensors for Closed Loop Prosthetic Systems edited by KO W.H, Chapter 12, 1985, pp. 167-175.	☐
	371	SCHAFFAR B.P.H., "Thick Film Biosensors for Metabolites in Undiluted Whole Blood and Plasma Samples," Analytical Bioanalytical Chemistry, Dec 2001, Vol. 372, pp. 254-260.	☐
	372	SCHMIDT F.J., et al., "Calibration of a Wearable Glucose Sensor," The International Journal of Artificial Organs, Wichtig Publishing, IT, Vol. 15 (1), January 01, 1992, pp. 55-61.	☐
	373	SCHMIDT F.J., et al., "Glucose Concentration in Subcutaneous Extracellular Space," Diabetes Care, Vol. 16 (5), May 1993, pp. 695-700.	☐
	374	SCHMIDTKE D.W., et al., "Accuracy of the One-Point in Vivo Calibration of "Wired" Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration," Analytical Chemistry, Vol. 70 (10), May 15, 1998, pp. 2149-2155.	☐
	375	SCHMIDTKE D.W., et al., "Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin," Proceedings of the National Academy of Sciences, Vol. 95, January 1998, pp. 294-299.	☐
	376	SCHOEMAKER M., et al., "The SCGMI System: Subcutaneous Continuous Glucose Monitoring Based on Microdialysis Technique," Diabetes Technology & Therapeutics, Vol. 5 (4), 2003, pp. 599-608.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 156 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	377	SCHOONEN A.J.M., et al., "Development of a Potentially Wearable Glucose Sensor for Patients with Diabetes Mellitus: Design and In-vitro Evaluation," Biosensors & Bioelectronics, Vol. 5, 1990, pp. 37-46.	☐
	378	SCHULER, et al., "Modified Gas-Permeable Silicone Rubber Membranes for Covalent Immobilisation of Enzymes and their Use in Biosensor Development," Analyst, 1999, Vol. 124, pp. 1181-1184.	☐
	379	SERVICE F.J., et al., "Mean Amplitude of Glycemic Excursions, A Measure of Diabetic Instability," Diabetes, Vol. 19 (9), September 1970, pp. 644-655.	☐
	380	SERVICE F.J., et al., "Measurements of Glucose Control," Diabetes Care, Vol. 10 (2), March-April 1987, pp. 225-237.	☐
	381	SERVICE R.F., "Can Sensors Make a Home in the Body?," Science, Materials Science: Soft Surface, Volume. 297, August 9, 2002, pp. 962-963.	☐
	382	SHARKAWY A.A., et al., "Engineering the Tissue Which Encapsulates Subcutaneous Implants. I. Diffusion Properties," Journal of Biomedical Materials Research, Vol. 37, 1996, pp. 401-412.	☐
	383	SHAW G.W., et al., "In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients," Biosensors & Bioelectronics, Vol. 6, 1991, pp. 401-406.	☐
	384	SHICHIRI, et al., "In Vivo Characteristics of Needle-Type Glucose Sensor-Measurements of Subcutaneous Glucose Concentrations in Human Volunteers," Implantable Glucose Sensors-The State of the Art, Hormone and Metabolic Research Supplement Series, 1988, Vol. 20, pp. 17-20.	☐
	385	SHICHIRI M., et al., "Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas," Diabetologia, Vol. 24, 1983, pp. 179-184.	☐
	386	SHICHIRI M., et al., "Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor," Diabetes Nutrition & Metabolism, Vol. 2 (4), 1989, pp. 309-313.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 157 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	387	SHICHIRI M., et al., "Needle Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," In Implantable Sensors for Closed-Loop Prosthetic Systems edited by KO W.H, Chapter 15, 1985, pp. 197-210.	☐
	388	SHICHIRI M., et al., "Telemetry Glucose Monitoring Device with Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals," Diabetes Care, Vol. 9 (3), May-June 1986, pp. 298-301.	☐
	389	SHICHIRI M., et al., "Wearable Artificial Endocrine Pancreas with Needle-Type Glucose Sensor," Preliminary Communication, Lancet, Vol. 2, November 20, 1982, pp. 1129-1131.	☐
	390	SHULTS M.C., et al., "A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors," IEEE Transactions on Biomedical Engineering, Vol. 41 (10), October 1994, pp. 937-942.	☐
	391	Sigma-Aldrich Corp. "Nafion® 117 Solution Product Description, Product No. 70160," retrieved from https//:http://www.sigmaaldrich.com/cgi-bin/hsrun/Suite7/Suite/HAHTpage/Suite.HsExternalProd on Apr. 7, 2005, 1 page.	☐
	392	SKYLER J.S., "The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S7-S12.	☐
	393	SLATER-MACLEAN L., et al., "Accuracy of Glycemic Measurements in the Critically Ill," Diabetes Technology and Therapeutics, Vol. 10 (3), 2008, pp. 169-177.	☐
	394	SMITH B., et al., "An Externally Powered, Multichannel, Implantable Stimulator-Telemeter for Control of Paralyzed Muscle," IEEE Transactions on Biomedical Engineering, Vol. 45 (4), April 1998, pp. 463-475.	☐
	395	SOKOL L., et al., "Immobilized-Enzyme Rate-Determination Method for Glucose Analysis," Clinical Chemistry, Vol. 26 (1), 1980, pp. 89-92.	☐
	396	SOKOLOV S., et al., "Metrological Opportunities of the Dynamic Mode of Operating an Enzyme Amperometric Biosensor," Medical Engineering & Physics, Vol. 17 (6), 1995, pp. 471-476.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 158 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	397	SPARACINO G., et al., "Continuous Glucose Monitoring Time Series and Hypo-Hyperglycemia Prevention: Requirements, Methods, Open Problems," Current Diabetes Reviews, Vol. 4 (3), 2008, pp. 181-192.	☐
	398	SPROULE B.A., et al., "Fuzzy Pharmacology: Theory and Applications," Trends in Pharmacological Sciences, Vol. 23 (9), September 2002, pp. 412-417.	☐
	399	SRIYUDTHSAK M., et al., "Enzyme-Epoxy Membrane Based Glucose Analyzing System and Medical Applications," Biosensors & Bioelectronics, Vol. 11 (8), 1996, pp. 735-742.	☐
	400	STEIL G.M., et al., "Closed-Loop Insulin Delivery--the Path of Physiological Glucose Control," Advanced Drug Delivery Reviews, Vol. 56, 2004, pp. 125-144.	☐
	401	STEIL G.M., et al., "Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor," Diabetes Technology & Therapeutics, Vol. 5 (1), 2003, pp. 27-31.	☐
	402	STERN M., et al., "Electrochemical Polarization: I. A Theoretical Analysis of the Shape of Polarization Curves," Journal of the Electrochemical Society, Vol. 104 (1), January 1957, pp. 56-63.	☐
	403	STERNBERG, et al., "Covalent Enzyme Coupling on Cellulose Acetate Membranes for Glucose Sensor Development," Anal Chem, December 1988, Vol. 60(24), pp. 2781-2786.	☐
	404	STERNBERG F., et al., "Does Fall in Tissue Glucose Precede Fall in Blood Glucose?," Diabetologia, Vol. 39, 1996, pp. 609-612.	☐
	405	STERNBERG R., et al., "Study and Development of Multilayer Needle-type Enzyme Based Glucose Microsensors," Biosensors, Vol. 4, 1988, pp. 27-40.	☐
	406	STREET J.O., et al., "A Note on Computing Robust Regression Estimates Via Iteratively Reweighted Least Squares," The American Statistician, Vol. 42 (2), May 1988, pp. 152-154.	☐
	407	SUMINO T., et al., "Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique," Proceedings of the 20th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Vol. 20 (4), 1998, pp. 1775-1778.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 159 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	408	TAKATSU I., et al., "Solid State Biosensors Using Thin-Film Electrodes," Sensors and Actuators, 1987, Vol. 11, pp. 309-317.	☐
	409	TAKEGAMI S., et al., "Pervaporation of Ethanol/Water Mixtures Using Novel Hydrophobic Membranes Containing Polydimethylsiloxane," Journal of Membrane Science, Vol. 75, 1992, pp. 93-105.	☐
	410	TAMURA T., et al., "Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique and a Null Method-A Numerical Analysis," Frontiers of Medical & Biological Engineering, Vol. 10 (2), 2000, pp. 147-156.	☐
	411	TANENBERG R.J., et al., "Continuous Glucose Monitoring System: A New Approach to the Diagnosis of Diabetic Gastroparesis," Diabetes Technology & Therapeutics, Vol. 2, Supplement 1, 2000, pp. S73-S80.	☐
	412	TATSUMA T., et al., "Oxidase/Peroxidase Bilayer-Modified Electrodes as Sensors for Lactate, Pyruvate, Cholesterol and Uric Acid," Analytica Chimica Acta, Vol. 242, 1991, pp. 85-89.	☐
	413	The Diabetes Control and Complications Trial Research Group, "The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus," The New England, Journal of Medicine, Vol. 329 (14), September 30, 1993, pp. 977-986.	☐
	414	THIJSSEN, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 1,Theory and Simulations, Analytica chimica Acta, 1984, Vol. 156, pp. 87-101.	☐
	415	THIJSSEN, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 3,Variance Reduction ,Analytica chimica Acta, 1985, Vol. 173, pp. 265-272.	☐
	416	THIJSSEN, et al., "A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 4,Flow Injection Analysis, Analytica chimica Acta, 1985, Vol. 174, pp. 27-40.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 160 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	417	THIJSSEN P.C.,"A Kalman Filter for Calibration, Evaluation of Unknown Samples and Quality Control in Drifting Systems," Part 2,Optimal Designs, Analytica chimica Acta, Vol. 162, 1984, pp. 253-262.	☐
	418	THOME V., et al., "(Abstract) Can the Decrease in Subcutaneous Glucose Concentration Precede the Decrease in Blood Glucose Level? Proposition for a Push-Pull Kinetics Hypothesis," Horm. metab. Res., Vol. 27, 1995, page 53.	☐
	419	THOME-DURET V., et al., "Continuous Glucose Monitoring in the Free-Moving Rat," Metabolism, Vol. 47 (7), July 1998, pp. 799-803.	☐
	420	THOME-DURET V., et al., "Modification of the Sensitivity of Glucose Sensor Implanted into Subcutaneous Tissue," Diabetes & Metabolism, Vol. 22, 1996, pp. 174-178.	☐
	421	THOME-DURET V., et al., "Use of a Subcutaneous Glucose Sensor to Detect Decreases in Glucose Concentration Prior to Observation in Blood," Analytical Chemistry, Vol. 68 (21), November 1, 1996, pp. 3822-3826.	☐
	422	THOMPSON M., et al., "In Vivo Probes: Problems and Perspectives," Clinical Biochemistry, Vol. 19 (5), October 1986, pp. 255-261.	☐
	423	TIERNEY M.J., et al., "Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer," Diabetes Technology & Therapeutics, Vol. 2 (2), 2000, pp. 199-207.	☐
	424	TILBURY J.B., et al., "Receiver Operating Characteristic Analysis for Intelligent Medical Systems - A New Approach for Finding Confidence Intervals," IEEE Transactions on Biomedical Engineering, Vol. 47 (7), July 2000, pp. 952-963.	☐
	425	TORJMAN M.C., et al., "Glucose Monitoring in Acute Care: Technologies on the Horizon," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 178-181.	☐
	426	TRAJANOSKI Z., et al., "Neural Predictive Controller For Insulin Delivery Using The Subcutaneous Route," IEEE Transactions on Biomedical Engineering, Vol. 45(9), 1998, pp. 1122-1134.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 161 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	427	TRECROCI D., "A Glimpse into the Future-Continuous Monitoring of Glucose with a Microfiber," Diabetes Interview, July 2002, pp. 42-43.	☐
	428	TSE P.S.H., et al., "Time-Dependent Inactivation of Immobilized Glucose Oxidase and Catalase," Biotechnology & Bioengineering, Vol. 29, 1987, pp. 705-713.	☐
	429	TURNER A.P.F., "Amperometric Biosensor based on Mediator-Modified Electrodes," Methods in Enzymology, 1988, Vol. 137, pp. 90-103.	☐
	430	TURNER A.P.F., et al., "Carbon Monoxide: Acceptor Oxidoreductase from Pseudomonas Thermocarboxydovorans Strain C2 and its Use in a Carbon Monoxide Sensor," Analytica Chimica Acta, Vol. 163, 1984, pp. 161-174.	☐
	431	TURNER A.P.F., et al., "Diabetes Mellitus: Biosensors for Research and Management," Biosensors, Vol. 1, 1985, pp. 85-115.	☐
	432	UNGER J., et al., "Glucose Control in the Hospitalized Patient," Emergency Medicine, Vol. 36 (9), 2004, pp. 12-18. .	☐
	433	UPDIKE S.J., et al., "A Subcutaneous Glucose Sensor with Improved Longevity, Dynamic Range, and Stability of Calibration," Diabetes Care, Vol. 23 (2), February 2000, pp. 208-214.	☐
	434	UPDIKE S.J., et al., "Continuous Glucose Monitor Based on an Immobilized Enzyme Electrode Detector," Journal of Laboratory and Clinical Medicine, Vol. 93(4), 1979, pp. 518-527.	☐
	435	UPDIKE S.J., et al., "Enzymatic Glucose Sensor: Improved Long-Term Performance in Vitro and In Vivo," ASAIO Journal, Vol. 40 (2), April-June 1994, pp. 157-163.	☐
	436	UPDIKE S.J., et al., "Implanting the Glucose Enzyme Electrode: Problems, Progress, and Alternative Solutions," Diabetes Care, Vol. 5 (3), May-June 1982, pp. 207-212.	☐
	437	UPDIKE S.J., et al., "Laboratory Evaluation of New Reusable Blood Glucose Sensor," Diabetes Care, Vol. 11 (10), November-December 1988, pp.801-807.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 162 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	438	UPDIKE S.J., et al., "Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose Form Inside a Subcutaneous Foreign Body Capsule (FBC)," Edited by Fraser D M, Biosensors in the Body: Continuous in vivo Monitoring, John Wiley & Sons Ltd., New York, 1997, Chapter 4, pp. 117-137.	☐
	439	UPDIKE S.J., et al., "The Enzyme Electrode," Nature, Vol. 214, June 03, 1967, pp. 986-988.	☐
	440	US 5,234,749, 06/1995, Merte et al. (withdrawn).	☐
	441	US 7,530,950, 5/12/2009, Brister et al. (withdrawn).	☐
	442	U.S. File History of Provisional Application No. 61/155,889, filed 02/26/2009 (55 pages).	☒
	443	U.S. File History of Provisional Application No. 61/155,891, filed 02/26/2009 (51 pages).	☐
	444	U.S. File History of Provisional Application No. 61/155,893 filed 02/26/2009 (51 pages).	☒
	445	U.S. File History of Provisional Application No. 61/165,499 filed 03/31/2009 (64 pages).	☐
	446	U.S. File History of Provisional Application No. 61/238,461 filed 08/31/2009 (63 pages).	☐
	447	U.S. File History of Provisional Application No. 61/290,847 filed 08/31/2009 (74 pages).	☐
	448	Utah Medical Products Inc., "Deltran - Disposable Blood Pressure Transducers," Product Specifications, 2003-2006, 6 pages.	☐
	449	VADGAMA P., "Diffusion Limited Enzyme Electrodes," NATO ASI Series: Series C, Math and Phys. Sci, Vol. 226, 1988, pp. 359-377.	☐
	450	VADGAMA P., "Enzyme Electrodes as Practical Biosensors," Journal of Medical Engineering & Technology, Vol. 5 (6), November 1981, pp. 293-298.	☐
	451	VALDES T.I., et al., "In Vitro and In Vivo Degradation of Glucose Oxidase Enzyme used for an Implantable Glucose Biosensor," Diabetes Technology & Therapeutics, Vol. 2 (3), 2000, pp. 367-376.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 163 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	452	VAN DEN BERGHE, "Tight Blood Glucose Control with Insulin in "Real-Life" Intensive Care," Mayo Clinic Proceedings, Vol. 79 (8), August 2004, pp. 977-978.	☐
	453	VELHO G., et al., "In Vitro and In Vivo Stability of Electrode Potentials in Needle-Type Glucose Sensors," Influence of Needle Material, Diabetes, Vol. 38, February 1989, pp. 164-171.	☐
	454	VELHO G., et al., "Strategies for Calibrating a Subcutaneous Glucose Sensor," Biomed Biochim Acta, Vol. 48 (11/12), 1989, pp. 957-964.	☐
	455	VON WOEDTKE T., et al., "In Situ Calibration of Implanted Electrochemical Glucose Sensors," Biomed. Biochim. Acta 48 Vol.11/12, 1989, pp. 943-952.	☐
	456	WAGNER, et al., "Continuous Amperometric Monitoring of Glucose in a Brittle Diabetic Chimpanzee with a Miniature Subcutaneous Electrode," Proc. Natl. Acad. Sci. USA, Vol. 95, May 1998, pp. 6379-6382.	☐
	457	WANG J., "Electrochemical Glucose Biosensors," American Chemical Society, Chemical Reviews, Published on Web, December 23, 2007, pp. 1-12.	☐
	458	WANG J., et al., "Highly Selective Membrane-Free Mediator-Free Glucose Biosensor," Analytical Chemistry, Vol. 66 (21), November 01, 1994, pp. 3600-3603.	☐
	459	WANG X., et al., "Improved Ruggedness for Membrane-Based Amperometric Sensors using a Pulsed Amperometric Method," Analytical Chemistry, Vol. 69 (21), November 01, 1997, pp. 4482-4489.	☐
	460	WARD, et al., "A Wire-Based Dual-Analyte Sensor for Glucose and Lactate: In Vitro and In Vivo Evaluation," Diabetes Technology and Therapeutics, 2004, Vol. 6 (3), pp. 389-401.	☐
	461	WARD W.K., et al., "A New Amperometric Glucose Microsensor: In Vitro and Short-Term In Vivo Evaluation," Biosensors & Bioelectronics, Vol. 17, 2002, pp. 181-189.	☐
	462	WARD W.K., et al., "Assessment of Chronically Subcutaneous Glucose Sensors in Dogs: The Effect of Surrounding Fluid Masses," ASAIO Journal, 1999, Vol. 45 (6), pp. 555-561.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 164 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	463	WARD W.K., et al., "Rise in Background Current Over Time in a Subcutaneous Glucose Sensor in the Rabbit," Relevance to Calibration and Accuracy, Biosensors & Bioelectronics, Vol. 15, 2000, pp. 53-61.	☐
	464	WARD W.K., et al., "Understanding Spontaneous Output Fluctuations of an Amperometric Glucose Sensor: Effect of Inhalation Anesthesia and Use of a Nonenzyme Containing Electrode," ASAIO Journal, 2000, pp. 540-546.	☐
	465	WHIPPLE G., "Low Residual Noise Speech Enhancement Utilizing Time-Frequency Filtering," Proceedings of the International Conference on Acoustics, Speech, and Signal Processing, 1994, pp. I5-I8.	☐
	466	WIENTJES K.J.C., "Development of a Glucose Sensor for Diabetic Patients," (Ph.D. Thesis), 2000, 212 pages.	☐
	467	WIKIPEDIA., "Intravenous Therapy," http://en.wikipedia.org/wiki/Intravenous_therapy, August 15, 2006, 6 pages.	☐
	468	WILKINS E., et al., "Glucose Monitoring: State of the Art and Future Possibilities," Med. Eng. Phys., Vol. 18 (4), 1996, pp. 273-288.	☐
	469	WILKINS E., et al., "Integrated Implantable Device for Long-Term Glucose Monitoring," Biosensors & Bioelectronics, Vol. 10, 1995, pp. 485-494.	☐
	470	WILKINS E.S., et al., "The Coated Wire Electrode Glucose Sensor," Horm Metab Res Suppl., Vol. 20, 1988, pp. 50-55.	☐
	471	WILSON G.S., et al., "Enzyme-Based Biosensors for In Vivo Measurements," Chem. Rev., Vol. 100, 2000, pp. 2693-2704.	☐
	472	WILSON G.S., et al., "Progress Toward the Development of an Implantable Sensor for Glucose," Clinical Chemistry, Vol. 38 (9), 1992, pp. 1613-1617.	☐
	473	WOLFE P.J., et al., "Interpolation of Missing Data Values for Audio Signal Restoration Using a Gabor Regression Model," 2005 IEEE International Conference on Acoustics, Speech, and Signal Processing, Vol. 5, 2005, pp. 517-520.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 165 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	474	WOOD W D., et al., "Hermetic Sealing with Epoxy," Pave Technology-Mechanical Engineering, March 1990, 3 pages.	☐
	475	WOODWARD S.C., "How Fibroblasts and Giant Cells Encapsulate Implants: Considerations in Design of Glucose Sensors," Diabetes Care, Vol. 5 (3) May-June 1982, pp. 278-281.	☐
	476	WORSLEY G.J et al., "Measurement of Glucose in Blood with a Phenylboronic Acid Optical Sensor," Journal of Diabetes Science and Technology, Vol. 2 (2), March 2008, pp. 213-220.	☐
	477	WRIGHT M., et al., "Bioelectrochemical Dehalogenations Via Direct Electrochemistry of Poly(ethylene oxide)-Modified Myoglobin," Electrochemistry Communications, Vol. 1, 1999, pp. 609-613.	☐
	478	WU H., et al., "In Situ Electrochemical Oxygen Generation with an Immunoisolation Device," Annals New York Academy of Sciences, Vol. 875, 1999, pp. 105-125.	☐
	479	YAMASAKI Y., et al., "Direct Measurement of Whole Blood Glucose by a Needle-Type Sensor," Clinica Chimica Acta. 93, 1989, pp. 93-98.	☐
	480	YAMASAKI Y., "The Development of a Needle-Type Glucose Sensor for Wearable Artificial Endocrine Pancreas," Medical Journal of Osaka University, Vol. 35 (1-2), September 1984, pp. 25-34.	☐
	481	YANG C., et al., "A Comparison of Physical Properties and Fuel Cell Performance of Nafion and Zirconium Phosphate/Nation Composite Membranes," Journal of Membrane Science, Vol. 237, 2004, pp. 145-161.	☐
	482	YANG Q., et al., "Development of Needle-Type Glucose Sensor with High Selectivity," Science and Actuators B, Vol. 46, 1998, pp. 249-256.	☐
	483	YANG S., et al., "A Glucose Biosensor Based On an Oxygen Electrode: In-Vitro Performances in a Model Buffer Solution and in Blood Plasma," Biomedical Instrumentation & Technology, Vol. 30 (1), 1996, pp. 55-61.	☐
	484	YANG S., et al., "Glucose Biosensors with Enzyme Entrapped in Polymer Coating," Biomedical Instrument and Technology, March/April 1995, Vol. 29 (2), pp. 125-133.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 166 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
	485	YE L., et al., "High Current Density Wired' Quinoprotein Glucose Dehydrogenase Electrode," Analytical Chemistry, Vol. 65, 1993, pp. 238-241.	☐
	486	YOO, et al., "An Electrochemical Impedance Measurement Technique Employing Fourier Transform," Anal. Chem. 2000, Vol. 72, pp. 2035-2041.	☐
	487	ZAMZOW K.L., et al., "Development and Evaluation of a Wearable Blood Glucose Monitor," ASAIO Transactions, Vol. 36 (3), 1990, pp. M588-M591.	☐
	488	ZAVALKOFF S.R., et al., "Evaluation Of Conventional Blood Glucose Monitoring as An Indicator of Integrated Glucose Values Using a Continuous Subcutaneous Sensor," Diabetes Care, Vol. 25(9), 2002, pp. 1603-1606.	☐
	489	ZETHELIUS B., et al., "Use Of Multiple Biomarkers to Improve the Prediction of Death From Cardiovascular Causes," N. Engl. J. Med., Vol. 358, May 2008, pp. 2107-2116.	☐
	490	ZHANG, et al., "Elimination of the Acetaminophen Interference in an Implantable Glucose Sensor," Analytical Chemistry, 1994, Vol. 66 (7), pp. 1183-1188.	☐
	491	ZHANG Y., et al., "Electrochemical Oxidation Of H2O2 On Pt and Pt + Ir Electrodes in Physiological Buffer and its Applicability to H2O2- Based Biosensors," J. Electro Analytical Chemistry, Vol. 345, 1993, pp. 253-271.	☐
	492	ZHANG Y., et al., "In Vitro and In Vivo Evaluation of Oxygen Effects on a Glucose Oxidase Based Implantable Glucose Sensor," Analytica Chimica Acta, Vol. 281, 1993, pp. 513-520.	☐
	493	ZHU, et al., "Fabrication and Characterization of Glucose Sensors Based on a Microarray H2O2 Electrode," Biosensors & Bioelectronics, 1994, Vol. 9, pp. 295-300.	☐
/D.P/	494	ZHU, et al., "Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian blue Layer," Sensors, 2002, Vol. 2, pp. 127-136.	☐
/D.P/	495	ZIAIE, et al., "A Single-Channel Implantable Microstimulator for Functional Neuromuscular Stimulation," IEEE Transactions on Biomedical Engineering, 1997, Vol. 44(10), pp. 909-920.	☐

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

PTO/SB/06 (09-11)
Approved for use through 1/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PATENT APPLICATION FEE DETERMINATION RECORD Substitute for Form PTO-875	Application or Docket Number 17/132,664	Filing Date 12/23/2020	☐ To be Mailed

ENTITY: ☑ LARGE ☐ SMALL ☐ MICRO

APPLICATION AS FILED - PART I

FOR	(Column 1) NUMBER FILED	(Column 2) NUMBER EXTRA		RATE ($)	FEE ($)
☐ BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A		N/A	
☐ SEARCH FEE (37 CFR 1.16(k), (i), or (m))	N/A	N/A		N/A	
☐ EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A		N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*		x $100 =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*		x $480 =	
☐ APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is $310 ($155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).				
☐ MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))					
* If the difference in column 1 is less than zero, enter "0" in column 2.				TOTAL	

APPLICATION AS AMENDED - PART II

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT	03/15/2021	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	* 46	Minus	** 20	= 26		x $100 =	2600
	Independent (37 CFR 1.16(h))	* 5	Minus	*** 3	= 2		x $480 =	960
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	3560

		(Column 1)		(Column 2)	(Column 3)			
AMENDMENT		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA		RATE ($)	ADDITIONAL FEE ($)
	Total (37 CFR 1.16(i))	*	Minus	**	=		x $0 =	
	Independent (37 CFR 1.16(h))	*	Minus	***	=		x $0 =	
	☐ Application Size Fee (37 CFR 1.16(s))							
	☐ FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))							
							TOTAL ADD'L FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.	SLIE
** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".	/APRIL L. WALKER/
*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".	
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.	

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

RESPONSE TO NON-FINAL OFFICE ACTION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

In response to the Office Action dated March 2, 2021 Applicant respectfully requests that the Examiner enter the following amendments and consider the following remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 10 of this paper.

Abbott Ex. 1003 - 926/1058

AMENDMENTS TO THE CLAIMS

Please cancel claim 19 without prejudice.

Please amend claim 20 and add claims 21-65 as follows.

1-18. (Canceled)

19. (Canceled)

20. (Currently Amended) A ~~transcutaneous analyte sensor~~ system for monitoring a glucose concentration, the system comprising:

a transcutaneous ~~analyte~~ glucose sensor comprising:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted into the body of the host, wherein the *in vivo* portion comprises:

an electrode; and

a membrane disposed over at least a portion of the electrode, wherein the membrane comprises at least one enzyme;

wherein the transcutaneous glucose sensor is configured to generate a signal, wherein the magnitude of the signal depends upon a glucose concentration existing at the *in vivo* portion of the transcutaneous glucose sensor inserted into the body of the host; and

~~sensor~~ electronics configured to operably ~~connectable~~ connect to the transcutaneous ~~analyte~~ glucose sensor, wherein the electronics comprises a memory, wherein the memory stores information associated with a profile, wherein the profile is based at least in part on *a priori* information related to expected sensitivity changes associated with a length of time the *in vivo* portion of the transcutaneous glucose sensor has been inserted into the body of the host.

21. (New) The system of claim 20, wherein the electronics is configured to determine a glucose concentration value based at least in part on the information associated with the profile.

Abbott Ex. 1003 - 927/1058

22. (New) The system of claim 21 wherein the electronics is configured to determine the glucose concentration value solely using information obtained prior to insertion of the *in vivo* portion of the transcutaneous glucose sensor into the body of the host.

23. (New) The system of claim 21, wherein the electronics is configured to use a conversion function to determine the glucose concentration value.

24. (New) The system of claim 23, wherein the conversion function is based at least in part on a predictive relationship between *in vitro* sensitivity and *in vivo* sensitivity.

25. (New) The system of claim 21 wherein the electronics is configured to use a calibration factor to determine the glucose concentration value.

26. (New) The system of claim 21, further comprising a temperature sensor for providing a temperature measurement, wherein the glucose concentration value is derived at least in part from the temperature measurement from the temperature sensor.

27. (New) The system of claim 20, wherein the profile accounts for a break-in of the transcutaneous glucose sensor after the *in vivo* portion of the transcutaneous glucose sensor has been inserted into the body of the host.

28. (New) The system of claim 20, wherein the electronics comprises sensor electronics.

29. (New) The system of claim 20, wherein the electronics comprises receiver electronics.

30. (New) The system of claim 20, wherein the electronics comprises sensor electronics and receiver electronics.

31. (New) The system of claim 20, wherein the expected sensitivity changes are associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

Abbott Ex. 1003 - 928/1058

32. (New) A method of monitoring a glucose concentration, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted within the body of the host, wherein the *in vivo* portion comprises:

an electrode; and

a membrane disposed over at least a portion of the electrode, wherein the membrane comprises at least one enzyme;

generating sensor data at least in part from a signal received from the *in vivo* portion of the transcutaneous glucose sensor; and

calibrating the sensor data based at least in part on *a priori* information, wherein the *a priori* information comprises a profile associated with a drift in a sensitivity of the *in vivo* portion of the transcutaneous glucose sensor over time.

33. (New) The method of claim 32, wherein the *a priori* information is based at least in part on expected sensitivity changes associated with a length of time the transcutaneous glucose sensor has been inserted within the body of the host.

34. (New) The method of claim 32, wherein the calibrating comprises applying a conversion function based at least in part on a predictive relationship between *in vitro* sensitivity and *in vivo* sensitivity.

35. (New) The method of claim 32, wherein the calibrating comprises applying a calibration factor based at least in part on a predictive relationship between *in vitro* sensitivity and *in vivo* sensitivity.

36. (New) The method of claim of claim 32, wherein the calibrating is performed without a need for a reference analyte value obtained after insertion of *in vivo* portion of the transcutaneous glucose sensor into the body of the host.

37. (New) The method of claim 32, wherein the membrane comprises a plurality of different membrane layers.

Abbott Ex. 1003 - 929/1058

38. (New) The method of claim 32, wherein the drift in the sensitivity is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

39. (New) The method of claim 32 wherein the profile accounts for break-in of the transcutaneous glucose sensor.

40. (New) A method for monitoring a glucose concentration, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted within the body of the host;

generating sensor data derived at least in part from the transcutaneous glucose sensor;

determining a glucose concentration value based at least in part on the sensor data and information associated with a drift profile, wherein the drift profile is associated with a shift over time in measurement characteristic of the transcutaneous glucose sensor to the glucose concentration within the body of the host resulting from the *in vivo* portion of the transcutaneous glucose sensor being within the body of the host for a period of time; and

displaying the glucose concentration value.

41. (New) The method of claim 40 wherein the *in vivo* portion of the transcutaneous glucose sensor comprises a substantially planar configuration.

42. (New) The method of claim 40 wherein the drift profile accounts for a break-in of the transcutaneous glucose sensor after the *in vivo* portion of the transcutaneous glucose sensor has been inserted into the body of the host.

43. (New) The method of claim 40 wherein the drift profile accounts for a change in sensitivity over time of the *in vivo* portion of the transcutaneous glucose sensor to the glucose concentration within the body of the host.

Abbott Ex. 1003 - 930/1058

44. (New) The method of claim 40 wherein the drift profile accounts for a change in baseline over time associated with the *in vivo* portion of the transcutaneous glucose sensor.

45. (New) The method of claim 40 wherein the drift profile accounts for a change in baseline over time associated with the *in vivo* portion of the transcutaneous glucose sensor and a change in sensitivity over time of the *in vivo* portion of the transcutaneous glucose sensor to the glucose concentration within the body of the host.

46. (New) The method of claim 40 wherein the shift over time is an elapsed time measured from the beginning of the sensor session.

47. (New) The method of claim 40 wherein the shift over time is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

48. (New) The method of claim 47 wherein the one or more physical properties of the environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host is associated with at least one of: trauma, wound healing, blockage of a surface of the transcutaneous glucose sensor, inflammation, blood clotting, or biofouling.

49. (New) The method of claim 40 wherein the shift over time is associated at least in part with a physical property of the transcutaneous glucose sensor, wherein the physical property corresponds to a membrane of the *in vivo* portion of the transcutaneous glucose sensor.

50. (New) The method of claim 40 wherein the shift over time is an elapsed time measured from the insertion of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

51. (New) A sensor system comprising:

a transcutaneous glucose sensor comprising:

an *ex vivo* portion configured to remain outside of a body of a host; and

Abbott Ex. 1003 - 931/1058

an *in vivo* portion configured to be implanted within the body of the host, wherein the *in vivo* portion comprises:

an electrode; and

a membrane disposed over at least a portion of the electrode, wherein the membrane comprises at least one enzyme;

wherein the transcutaneous glucose sensor generates a signal associated with a glucose concentration within the body of the host; and

electronics configured to receive the signal from the transcutaneous glucose sensor, wherein the electronics comprises a memory, wherein the memory stores information associated with an expected change over time in a relationship between the signal and the glucose concentration within the body of the host, wherein the electronics are configured to generate a glucose concentration value based at least in part on the signal and the information associated with the expected change over time in the relationship.

52. (New) The sensor system of claim 51 wherein the change over time in the relationship is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

53. (New) The sensor system of claim 52, wherein the one or more physical properties of the environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host include trauma, wound healing, blockage of a surface of the transcutaneous glucose sensor, inflammation, blood clotting, or biofouling.

54. (New) The sensor system of claim 51 wherein the change over time in the relationship is associated with the implantation of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

55. (New) The sensor system of claim 51 wherein the change over time in the relationship is over an elapsed time measured from a beginning of a sensor session after implantation of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

Abbott Ex. 1003 - 932/1058

56. (New) The sensor system of claim 51 wherein the change over time in the relationship is over an elapsed time measured from the implantation of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

57. (New) The sensor system of claim 51 wherein the change over time in the relationship is associated at least in part with a physical property of the transcutaneous glucose sensor, wherein the physical property of the transcutaneous glucose sensor corresponds to membrane of the *in vivo* portion of the transcutaneous glucose sensor.

58. (New) A method for monitoring a glucose concentration, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted within the body of the host;

wherein the transcutaneous glucose sensor is configured to generate a signal;

calibrating the transcutaneous glucose sensor by applying *a priori* information, wherein the *a priori* information comprises an expected relationship between the signal and a glucose concentration existing within the body of the host, wherein the relationship changes as a function of time;

generating a glucose concentration value based at least in part on the calibrating; and

displaying the glucose concentration value.

59. (New) The method of claim 58 wherein the time the relationship changes is an elapsed time measured from the beginning of the sensor session.

60. (New) The method of claim 58 wherein the relationship changes as a function of time is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

61. (New) The method of claim 60 wherein the one or more physical properties of the environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the

Abbott Ex. 1003 - 933/1058

body of the host include trauma, wound healing, blockage of a surface of the transcutaneous glucose sensor, inflammation, blood clotting, or biofouling.

62. (New) The method of claim 58 wherein the relationship changes as a function of time is associated at least in part with a physical property of the transcutaneous glucose sensor, wherein the physical property of the transcutaneous glucose sensor corresponds to a membrane of the *in vivo* portion of the transcutaneous glucose sensor.

63. (New) The system of claim 20 wherein the profile has a first slope associated with a first time and a second slope associated with a second time, wherein the first time is different from the second time, wherein the first slope is different from the second slope.

64. (New) The method of claim 32 wherein the profile has a first slope associated with a first time and a second slope associated with a second time, wherein the first time is different from the second time, wherein the first slope is different from the second slope.

65. (New) The method of claim 40 wherein the drift profile has a first slope associated with a first time and a second slope associated with a second time, wherein the first time is different from the second time, wherein the first slope is different from the second slope.

Abbott Ex. 1003 - 934/1058

REMARKS

This is intended as a full and complete response to the Non-Final Office Action dated March 2, 2021. Claim 19 has been cancelled without prejudice or disclaimer of the subject matter. Claim 20 has been amended. Claims 21-65 have been added. No new matter is believed to have been introduced by the amendments.

Nonstatutory Double Patenting Rejection

Claims 19-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent Application Publication No. 2009/0178459. Applicant respectfully traverses the rejection. However, in order to expedite the prosecution of this application and without agreeing with the merits of the grounds of the rejection, Applicant has cancelled claim 19 and significantly amended claim 20 to include additional technical features compared to the rejected claims. Applicant has also added new claims 21-65 that include additional technical features compared to the rejected claims. Thus, the nonstatutory double patenting rejection may not be appropriate in view of the substantial amendment and new claims. Applicant will address any nonstatutory double patenting rejection, if necessary, after the remaining rejection is overcome.

Claim Rejection under 35 USC § 102

Claims 19 and 20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 2009/0076360 (hereafter "*Brister*"). Applicant respectfully traverses the rejection. However, in order to expedite the prosecution of the application and without agreeing with the merits of the grounds of the rejection, as discussed above, Applicant has cancelled claim 19, and significantly amended claim 20. Applicant believes that *Brister* fails to teach all of the features recited in amended claim 20. Withdrawal of the rejection is respectfully requested.

New Claims 21-65

New dependent claims 21-31 depend from base claim 20, and further define additional technical features. Because at least claim 20 is allowable, new claims 21-31 are patentable over the cited reference for at least the same reasons and for their additional features.

Each of new independent claims 32, 40, 51 and 58 includes additional technical features compared to the rejected claims. Applicant believes that the cited reference fails to teach all of

Abbott Ex. 1003 - 935/1058

the features recited in each of new independent claims 32, 40, 51 and 58, and thus they are patentable over the cited reference. New claims 33-39, 41-50, 52-57 and 59-65 depend from base claim 32, 40, 51 or 58, and further define additional technical features. In view of the patentability of their base claims, and in further view of their additional technical features, Applicant respectfully submits that the new dependent claims are patentable over the cited reference. Furthermore, new claims 21-65 are clear and definite and recite patent eligible subject matter. Moreover, as discussed above, Applicant believes that the nonstatutory double patenting rejection may not be appropriate to the new claims.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Any language or remarks referring to only a portion of a claim should not necessarily be understood to base patentability on solely that portion; rather, patentability rests on each claim taken as a whole.

Applicant respectfully submits that to the extent any disclaimers or statements were made previously during prosecution with respect to the scope of the claimed invention, such disclaimers and statements are hereby rescinded.

Applicant respectfully reserves the ability to traverse any of the rejections, assertions and submissions made in connection with the application, even if not discussed herein, including the right to challenge later whether any of the cited references is prior art. The absence of a reply to a specific rejection, issue, or comment does not signify agreement with or concession of that rejection, issue, or comment. In addition, because any arguments made may not be exhaustive,

Abbott Ex. 1003 - 936/1058

there may be other reasons that have not been expressed for patentability of any or all claims. When amendments are made to any claims, no acquiescence or estoppel is implied thereby; such amendments are made only to expedite prosecution of the present application and are without prejudice to the presentation or assertion, in the future, of claims directed to subject matter that is same as or similar to that previously presented. Nothing in this paper should be construed as an intent to concede, or actual concession of, any issue with regard to any claim, or to any cited art, except as specifically stated in this paper, and the amendment or cancellation of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment or cancellation.

Conclusion

Should the Examiner have any concerns that might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 15, 2021

By: /Heungsoo Choi/
Heungsoo Choi
Registration No. 69,282
Registered Practitioner
(858) 707-4157

34605211

Abbott Ex. 1003 - 937/1058

Electronic Patent Application Fee Transmittal

Application Number:	17132664
Filing Date:	23-Dec-2020
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Filer:	Heungsoo Choi/Tristan Rust
Attorney Docket Number:	DEXCOM.167P1

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
CLAIMS IN EXCESS OF 20	1202	26	100	2600
INDEPENDENT CLAIMS IN EXCESS OF 3	1201	2	480	960
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Post-Allowance-and-Post-Issuance:				
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**3560**

Electronic Acknowledgement Receipt

EFS ID:	42186228
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Heungsoo Choi/Jim Nyenhuis
Filer Authorized By:	Heungsoo Choi
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	15-MAR-2021
Filing Date:	23-DEC-2020
Time Stamp:	20:18:58
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$3560
RAM confirmation Number	E20213EK19172503
Deposit Account	111410
Authorized User	Jim Nyenhuis

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.17 (Patent application and reexamination processing fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		OAR_DEXCOM-167P1.pdf	141200 858c5af4e4aa9d25939d459506c42a742e48e43d	yes	12

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Amendment/Req. Reconsideration-After Non-Final Reject	1	1
	Claims	2	9
	Applicant Arguments/Remarks Made in an Amendment	10	12

Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	31797 10b2afe843b0470a5a95762be35376dc644ab3da	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	172997		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Doc Code: DIST.E.FILE Document Description: Electronic Terminal Disclaimer - Filed	PTO/SB/25 PTO/SB/26 U.S. Patent and Trademark Office Department of Commerce

Electronic Petition Request	**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING "REFERENCE" APPLICATION AND TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT**
Application Number	17132664
Filing Date	23-Dec-2020
First Named Inventor	Peter Simpson
Attorney Docket Number	DEXCOM.167P1
Title of Invention	ANALYTE SENSOR

☒ Filing of terminal disclaimer does not obviate requirement for response under 37 CFR 1.111 to outstanding Office Action

☒ This electronic Terminal Disclaimer is not being used for a Joint Research Agreement.

Owner	Percent Interest
DexCom, Inc.	100 %

The owner(s) of percent interest listed above in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number(s)

17132646 filed on 12/23/2020

17082627 filed on 10/28/2020

as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application," in the event that any such patent granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

The owner(s) with percent interest listed above in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of prior patent number(s)

10327688

10682084

10561354

10835162

9801575

9149220

10004442

as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:
- expires for failure to pay a maintenance fee;
- is held unenforceable;
- is found invalid by a court of competent jurisdiction;
- is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321;
- has all claims canceled by a reexamination certificate;
- is reissued; or
- is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

◉ Terminal disclaimer fee under 37 CFR 1.20(d) is included with Electronic Terminal Disclaimer request.

○ I certify, in accordance with 37 CFR 1.4(d)(4), that the terminal disclaimer fee under 37 CFR 1.20(d) required for this terminal disclaimer has already been paid in the above-identified application.

Applicants claims the following fee status:

○ Small Entity

○ Micro Entity

◉ Regular Undiscounted

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

THIS PORTION MUST BE COMPLETED BY THE SIGNATORY OR SIGNATORIES

I certify, in accordance with 37 CFR 1.4(d)(4) that I am:

- (●) An attorney or agent registered to practice before the Patent and Trademark Office who is of record in this application

  Registration Number 62280

- ( ) A sole inventor
- ( ) A joint inventor; I certify that I am authorized to sign this submission on behalf of all of the inventors as evidenced by the power of attorney in the application
- ( ) A joint inventor; all of whom are signing this request

Signature	/Ian Gillies/
Name	Ian W. Gillies

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).
Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

Electronic Patent Application Fee Transmittal

Application Number:	17132664
Filing Date:	23-Dec-2020
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Filer:	Ian W. Gillies/Jennifer Neat
Attorney Docket Number:	DEXCOM.167P1

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
STATUTORY OR TERMINAL DISCLAIMER	1814	1	170	170
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**170**

Doc Code: DISQ.E.FILE
Document Description: Electronic Terminal Disclaimer – Approved

Application No.: 17132664

Filing Date: 23-Dec-2020

Applicant/Patent under Reexamination: Simpson

Electronic Terminal Disclaimer filed on March 16, 2021

☒ APPROVED

This patent is subject to a terminal disclaimer

☐ DISAPPROVED

Approved/Disapproved by: Electronic Terminal Disclaimer automatically approved by EFS-Web

U.S. Patent and Trademark Office

Electronic Acknowledgement Receipt

EFS ID:	42199619
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Ian W. Gillies/Jennifer Neat
Filer Authorized By:	Ian W. Gillies
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	16-MAR-2021
Filing Date:	23-DEC-2020
Time Stamp:	20:53:48
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$170
RAM confirmation Number	E20213FK53421695
Deposit Account	111410
Authorized User	Jennifer Neat

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.17 (Patent application and reexamination processing fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Terminal Disclaimer-Filed (Electronic)	eTerminal-Disclaimer.pdf	39162 f6fb362bf191791f18deb1b174531907db2face2	no	3
Warnings:					
Information:					
2	Fee Worksheet (SB06)	fee-info.pdf	30331 2d9cb234a621cd56878fa7c579029999923a5504	no	2
Warnings:					
Information:					
		Total Files Size (in bytes):	69493		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

SUPPLEMENTAL AMENDMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Applicant respectfully requests entry of the following:

Amendments to the Specification begin on page 2 of this paper.

Summary of Interview begins on page 3 of this paper.

Remarks/Arguments begin on page 4 of this paper.

Abbott Ex. 1003 - 951/1058

AMENDMENTS TO THE SPECIFICATION

Please amend paragraph [0001] of the specification as follows:

[0001] Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. ~~This application is a continuation in part of U.S. Application No. 17/078,609, filed October 23, 2020, and is a continuation in part of U.S. Application No. 17/082,627, filed October 28, 2020.~~ This application is a continuation of U.S. Application No. 16/526,910, filed July 30, 2019, which is a continuation of U.S. Application No. 16/036,808, filed July 16, 2018, which is a continuation of U.S. Application No. 14/072,659, filed November 5, 2013, now U.S. Patent No. 10052055, issued August 21, 2018, which is a continuation of U.S. Application No. 12/267,525, filed November 7, 2008, now U.S. Patent No. 8626257, issued January 7, 2014. The disclosures of each of the abovementioned applications is hereby expressly incorporated by reference in its entirety and is hereby expressly made a portion of this application.

Abbott Ex. 1003 - 952/1058

SUMMARY OF INTERVIEW

Attendees, Date and Type of Interview

The interview was conducted via phone on March 16, 2021 and attended by Examiner Daniel Previl and by Applicant's Representatives Paul Lee and Erik Squier.

Exhibits and/or Demonstrations

None.

Identification of Claims Discussed

Pending Claims.

Principal Arguments and Other Matters / Results of Interview

Applicant's Representatives and Examiner Previl discussed the claim amendments filed on March 15, 2021. Examiner Previl agreed that the claim amendments filed on March 15, 2021 were patentable in light of the prior art.

Applicant's Representatives and Examiner Previl further discussed potential double patenting with respect to certain Dexcom patents and applications and the possibility of filing terminal disclaimers to address these potential double patenting issues.

Applicant's Representatives also discussed changing the priority claim on the Application.

Abbott Ex. 1003 - 953/1058

REMARKS

The specification has been amended for consistency with the updated priority claim in the Corrective Application Data Sheet Filed herewith.

Terminal Disclaimer

As discussed in the Interview, a terminal disclaimer is filed herewith to obviate any prophetic double patenting rejection with respect to the following U.S. Patent(s) or Patent Application(s):

- US 17/082,627
- US 17/132,646
- US 10,327,688
- US 10,682,084
- US 10,561,354
- US 10,835,162
- US 9,801,575
- US 9,149,220
- US 10,004,442

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Abbott Ex. 1003 - 954/1058

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 16, 2021

By:/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(949) 760-0404

34615446

Abbott Ex. 1003 - 955/1058

REQUEST FOR UPDATED OR CORRECTED FILING RECEIPT

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Applicant hereby requests the Office issue an Updated Filing Receipt to correct information identified on the Corrected Application Data Sheet filed herewith.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 16, 2021

By:/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34615591

Electronic Acknowledgement Receipt

EFS ID:	42199938
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Ian W. Gillies/Jennifer Neat
Filer Authorized By:	Ian W. Gillies
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	16-MAR-2021
Filing Date:	23-DEC-2020
Time Stamp:	21:15:10
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Application Data Sheet	167P1_CORRADS.pdf	40971 db10484356d8d5865112f301fdaa26a29df24ec7	no	2

Warnings:

Information:					
This is not an USPTO supplied ADS fillable form					
2		67P1_SUPPAMEND.pdf	34957 a69b0a2072439d629f077cff9a1451c008257c3a	yes	5

	Multipart Description/PDF files in .zip description		
	Document Description	**Start**	**End**
	Supplemental Response or Supplemental Amendment	1	1
	Specification	2	2
	Applicant summary of interview with examiner	3	3
	Applicant Arguments/Remarks Made in an Amendment	4	5

Warnings:					
Information:					
3	Request for Corrected Filing Receipt	167P1_REQCORRFR.pdf	15437 2a7bf21f59a2da124c14c1a175ba50fe1b3a2499	no	1
Warnings:					
Information:					
		Total Files Size (in bytes):	91365		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

APPLICATION DATA SHEET

Application Information

Application Number:	17/132664
Filing Date:	December 23, 2020
Application Type:	Regular
Subject Matter:	Utility
Title:	ANALYTE SENSOR
Attorney Docket Number:	DEXCOM.167P1

Correspondence Information

Correspondence Customer Number:	68851
Phone Number:	(949) 760-0404
Fax Number:	(949) 760-9502
E-Mail Address:	efiling@knobbe.com

Representative Information

Representative Customer Number: 68851

Domestic Priority Information

Application:	Continuity Type:	Parent Application:	Parent Filing Date:
~~This Application~~	~~Continuation-in-part of~~	~~17/078,609~~	~~2020-10-23~~
~~This Application~~	~~Continuation-in-part of~~	~~17/082,627~~	~~2020-10-28~~
This Application	Continuation of	16/526,910	2019-07-30
16/526,910	Continuation of	16/036,808	2018-07-16
16/036,808	Continuation of	14/072,659	2013-11-05
14/072,659	Continuation of	12/267,525	2008-11-07

Dated: March 16, 2021

By:/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
Customer No. 68851
(858) 707-4000

34615655

Abbott Ex. 1003 - 960/1058

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1

CONFIRMATION NO. 2055

NEW OR REVISED PPD NOTICE

68851
KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

OC000000124200615

NOTICE OF NEW OR REVISED PROJECTED PUBLICATION DATE

The above-identified application has a new or revised projected publication date. The current projected publication date for this application is 06/24/2021. If this is a new projected publication date (there was no previous projected publication date), the application has been cleared by Licensing & Review or a secrecy order has been rescinded and the application is now in the publication queue.

If this is a revised projected publication date (one that is different from a previously communicated projected publication date), the publication date has been revised due to processing delays in the USPTO or the abandonment and subsequent revival of an application. The application is anticipated to be published on a date that is more than six weeks different from the originally-projected publication date.

More detailed publication information is available through the private side of Patent Application Information Retrieval (PAIR) System. The direct link to access PAIR is currently http://pair.uspto.gov. Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Questions relating to this Notice should be directed to the Office of Data Management, Application Assistance Unit at (571) 272-4000, or (571) 272-4200, or 1-888-786-0101.

Abbott Ex. 1003 - 961/1058

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	TOT CLAIMS	IND CLAIMS
17/132,664	12/23/2020	2684	7640	DEXCOM.167P1	2	2

CONFIRMATION NO. 2055

CORRECTED FILING RECEIPT

68851
KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

OC000000124183989

Date Mailed: 03/19/2021

Receipt is acknowledged of this non-provisional utility patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF FIRST INVENTOR, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection.

Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a corrected Filing Receipt, including a properly marked-up ADS showing the changes with strike-through for deletions and underlining for additions. If you received a "Notice to File Missing Parts" or other Notice requiring a response for this application, please submit any request for correction to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections provided that the request is grantable.

Inventor(s)

Peter C. Simpson, Cardiff, CA;
Ying Li, San Diego, CA;
Apurv Ullas Kamath, San Diego, CA;
Richard C. Yang, Carlsbad, CA;

Applicant(s)

DexCom, Inc., San Diego, CA;

Power of Attorney: The patent practitioners associated with Customer Number 68851

Domestic Priority data as claimed by applicant

This application is a CON of 16/526,910 07/30/2019
which is a CON of 16/036,808 07/16/2018 ABN
which is a CON of 14/072,659 11/05/2013 PAT 10052055
which is a CON of 12/267,525 11/07/2008 PAT 8626257

Foreign Applications for which priority is claimed (You may be eligible to benefit from the **Patent Prosecution Highway** program at the USPTO. Please see http://www.uspto.gov for more information.) - None.
Foreign application information must be provided in an Application Data Sheet in order to constitute a claim to foreign priority. See 37 CFR 1.55 and 1.76.

Permission to Access Application via Priority Document Exchange: Yes

Abbott Ex. 1003 - 962/1058

Permission to Access Search Results: Yes

Applicant may provide or rescind an authorization for access using Form PTO/SB/39 or Form PTO/SB/69 as appropriate.

If Required, Foreign Filing License Granted: 01/15/2021
The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 17/132,664**
Projected Publication Date: 06/24/2021
Non-Publication Request: No
Early Publication Request: No
Title

ANALYTE SENSOR

Preliminary Class

073

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications: No

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific

Abbott Ex. 1003 - 963/1058

countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4258).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign AssetsControl, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

SelectUSA

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The U.S. offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to promote and facilitate business investment. SelectUSA provides information assistance to the international investor community; serves as an ombudsman for existing and potential investors; advocates on behalf of U.S. cities, states, and regions competing for global investment; and counsels U.S. economic development organizations on investment attraction best practices. To learn more about why the United States is the best country in the world to develop

Abbott Ex. 1003 - 964/1058

technology, manufacture products, deliver services, and grow your business, visit http://www.SelectUSA.gov or call +1-202-482-6800.

Abbott Ex. 1003 - 965/1058

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

68851 7590 03/19/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER	
PREVIL, DANIEL	

ART UNIT	PAPER NUMBER
2684	

NOTIFICATION DATE	DELIVERY MODE
03/19/2021	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

efiling@knobbe.com
jayna.cartee@knobbe.com

Applicant-Initiated Interview Summary	**Application No.** 17/132,664	**Applicant(s)** Simpson et al.		
	Examiner DANIEL PREVIL	**Art Unit** 2684	**AIA (First Inventor to File) Status** Yes	**Page** 1 of 1

All Participants (applicant, applicants representative, PTO personnel)	**Title**	**Type**
DANIEL PREVIL	Primary Examiner	Telephonic
Erickson Squier	Attorney	
Paul Lee	Attorney	

Date of Interview: 16 March 2021

Issues Discussed:

Proposed Amendment(s)

In light of the discussion, the applicant proposed amendment may appear to overcome the prior art of record. The examiner will conduct a thorough search when a formal response is filed.

/DANIEL PREVIL/ Primary Examiner, Art Unit 2684	

Applicant is reminded that a complete written statement as to the substance of the interview must be made of record in the application file. It is the applicants responsibility to provide the written statement, unless the interview was initiated by the Examiner and the Examiner has indicated that a written summary will be provided. See MPEP 713.04
Please further see:
MPEP 713.04
Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews, paragraph (b)
37 CFR § 1.2 Business to be transacted in writing

Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

Bibliographic Data

Application No: 17/132,664

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☑ Met After Allowance

Verified and Acknowledged: /DANIEL PREVIL/ (Examiner's Signature) D.P (Initials)

Title: ANALYTE SENSOR

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
12/23/2020	073	2684	DEXCOM.167P1
RULE			

APPLICANTS

DexCom, Inc., San Diego, CA,

INVENTORS

Peter C. Simpson, Cardiff, CA, UNITED STATES

Ying Li, San Diego, CA, UNITED STATES

Apurv Ullas Kamath, San Diego, CA, UNITED STATES

Richard C. Yang, Carlsbad, CA, UNITED STATES

CONTINUING DATA

This application is a CIP of 17082627 10/28/2020

This application is a CIP of 17078609 10/23/2020ABN

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

01/15/2021

STATE OR COUNTRY

UNITED STATES

ADDRESS

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614
UNITED STATES

FILING FEE RECEIVED

$8,260

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

AMENDMENT UNDER 37 CFR 1.312

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Further to the Notice of Allowance dated March 26, 2021, Applicant respectfully requests entry of the following amendments under 37 C.F.R. § 1.312. Applicant's request is filed after the mailing of a Notice of Allowance and before payment of the Issue Fee, and therefore this request pursuant to 37 C.F.R. § 1.312 is timely filed.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.

Abbott Ex. 1003 - 969/1058

AMENDMENTS TO THE CLAIMS

1-18. (Canceled)

19. (Canceled)

20. (Previously Presented) A system for monitoring a glucose concentration, the system comprising:

a transcutaneous glucose sensor comprising:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted into the body of the host, wherein the *in vivo* portion comprises:

an electrode; and

a membrane disposed over at least a portion of the electrode, wherein the membrane comprises at least one enzyme;

wherein the transcutaneous glucose sensor is configured to generate a signal, wherein the magnitude of the signal depends upon a glucose concentration existing at the *in vivo* portion of the transcutaneous glucose sensor inserted into the body of the host; and

electronics configured to operably connect to the transcutaneous glucose sensor, wherein the electronics comprises a memory, wherein the memory stores information associated with a profile, wherein the profile is based at least in part on *a priori* information related to expected sensitivity changes associated with a length of time the *in vivo* portion of the transcutaneous glucose sensor has been inserted into the body of the host.

21. (Previously Presented) The system of claim 20, wherein the electronics is configured to determine a glucose concentration value based at least in part on the information associated with the profile.

Abbott Ex. 1003 - 970/1058

22. (Previously Presented) The system of claim 21 wherein the electronics is configured to determine the glucose concentration value solely using information obtained prior to insertion of the *in vivo* portion of the transcutaneous glucose sensor into the body of the host.

23. (Previously Presented) The system of claim 21, wherein the electronics is configured to use a conversion function to determine the glucose concentration value.

24. (Previously Presented) The system of claim 23, wherein the conversion function is based at least in part on a predictive relationship between *in vitro* sensitivity and *in vivo* sensitivity.

25. (Previously Presented) The system of claim 21 wherein the electronics is configured to use a calibration factor to determine the glucose concentration value.

26. (Previously Presented) The system of claim 21, further comprising a temperature sensor for providing a temperature measurement, wherein the glucose concentration value is derived at least in part from the temperature measurement from the temperature sensor.

27. (Previously Presented) The system of claim 20, wherein the profile accounts for a break-in of the transcutaneous glucose sensor after the *in vivo* portion of the transcutaneous glucose sensor has been inserted into the body of the host.

28. (Previously Presented) The system of claim 20, wherein the electronics comprises sensor electronics.

29. (Previously Presented) The system of claim 20, wherein the electronics comprises receiver electronics.

30. (Previously Presented) The system of claim 20, wherein the electronics comprises sensor electronics and receiver electronics.

Abbott Ex. 1003 - 971/1058

31. (Previously Presented) The system of claim 20, wherein the expected sensitivity changes are associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

32. (Previously Presented) A method of monitoring a glucose concentration, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted within the body of the host, wherein the *in vivo* portion comprises:

an electrode; and

a membrane disposed over at least a portion of the electrode, wherein the membrane comprises at least one enzyme;

generating sensor data at least in part from a signal received from the *in vivo* portion of the transcutaneous glucose sensor; and

calibrating the sensor data based at least in part on *a priori* information, wherein the *a priori* information comprises a profile associated with a drift in a sensitivity of the *in vivo* portion of the transcutaneous glucose sensor over time.

33. (Previously Presented) The method of claim 32, wherein the *a priori* information is based at least in part on expected sensitivity changes associated with a length of time the transcutaneous glucose sensor has been inserted within the body of the host.

34. (Previously Presented) The method of claim 32, wherein the calibrating comprises applying a conversion function based at least in part on a predictive relationship between *in vitro* sensitivity and *in vivo* sensitivity.

35. (Previously Presented) The method of claim 32, wherein the calibrating comprises applying a calibration factor based at least in part on a predictive relationship between *in vitro* sensitivity and *in vivo* sensitivity.

Abbott Ex. 1003 - 972/1058

36. (Previously Presented) The method of claim of claim 32, wherein the calibrating is performed without a need for a reference analyte value obtained after insertion of *in vivo* portion of the transcutaneous glucose sensor into the body of the host.

37. (Previously Presented) The method of claim 32, wherein the membrane comprises a plurality of different membrane layers.

38. (Previously Presented) The method of claim 32, wherein the drift in the sensitivity is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

39. (Previously Presented) The method of claim 32 wherein the profile accounts for break-in of the transcutaneous glucose sensor.

40. (Previously Presented) A method for monitoring a glucose concentration, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted within the body of the host;

generating sensor data derived at least in part from the transcutaneous glucose sensor;

determining a glucose concentration value based at least in part on the sensor data and information associated with a drift profile, wherein the drift profile is associated with a shift over time in measurement characteristic of the transcutaneous glucose sensor to the glucose concentration within the body of the host resulting from the *in vivo* portion of the transcutaneous glucose sensor being within the body of the host for a period of time; and

displaying the glucose concentration value.

41. (Previously Presented) The method of claim 40 wherein the *in vivo* portion of the transcutaneous glucose sensor comprises a substantially planar configuration.

Abbott Ex. 1003 - 973/1058

42. (Previously Presented) The method of claim 40 wherein the drift profile accounts for a break-in of the transcutaneous glucose sensor after the *in vivo* portion of the transcutaneous glucose sensor has been inserted into the body of the host.

43. (Previously Presented) The method of claim 40 wherein the drift profile accounts for a change in sensitivity over time of the *in vivo* portion of the transcutaneous glucose sensor to the glucose concentration within the body of the host.

44. (Previously Presented) The method of claim 40 wherein the drift profile accounts for a change in baseline over time associated with the *in vivo* portion of the transcutaneous glucose sensor.

45. (Previously Presented) The method of claim 40 wherein the drift profile accounts for a change in baseline over time associated with the *in vivo* portion of the transcutaneous glucose sensor and a change in sensitivity over time of the *in vivo* portion of the transcutaneous glucose sensor to the glucose concentration within the body of the host.

46. (Previously Presented) The method of claim 40 wherein the shift over time is an elapsed time measured from the beginning of the sensor session.

47. (Previously Presented) The method of claim 40 wherein the shift over time is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

48. (Previously Presented) The method of claim 47 wherein the one or more physical properties of the environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host is associated with at least one of: trauma, wound healing, blockage of a surface of the transcutaneous glucose sensor, inflammation, blood clotting, or biofouling.

Abbott Ex. 1003 - 974/1058

49. (Previously Presented) The method of claim 40 wherein the shift over time is associated at least in part with a physical property of the transcutaneous glucose sensor, wherein the physical property corresponds to a membrane of the *in vivo* portion of the transcutaneous glucose sensor.

50. (Previously Presented) The method of claim 40 wherein the shift over time is an elapsed time measured from the insertion of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

51. (Currently Amended) A sensor system comprising:

a transcutaneous glucose sensor comprising:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be implanted within the body of the host, wherein the *in vivo* portion comprises:

an electrode; and

a membrane disposed over at least a portion of the electrode, wherein the membrane comprises at least one enzyme;

wherein the transcutaneous glucose sensor generates a signal associated with a glucose concentration within the body of the host; and

electronics configured to receive the signal from the transcutaneous glucose sensor, wherein the electronics comprises a memory, wherein the memory stores information associated with an expected change over time in a relationship between the signal and the glucose concentration within the body of the host, wherein the electronics is ~~electronics are~~ configured to generate a glucose concentration value based at least in part on the signal and the information associated with the expected change over time in the relationship.

52. (Previously Presented) The sensor system of claim 51 wherein the change over time in the relationship is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

Abbott Ex. 1003 - 975/1058

53. (Previously Presented) The sensor system of claim 52, wherein the one or more physical properties of the environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host include trauma, wound healing, blockage of a surface of the transcutaneous glucose sensor, inflammation, blood clotting, or biofouling.

54. (Previously Presented) The sensor system of claim 51 wherein the change over time in the relationship is associated with the implantation of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

55. (Previously Presented) The sensor system of claim 51 wherein the change over time in the relationship is over an elapsed time measured from a beginning of a sensor session after implantation of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

56. (Previously Presented) The sensor system of claim 51 wherein the change over time in the relationship is over an elapsed time measured from the implantation of the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

57. (Previously Presented) The sensor system of claim 51 wherein the change over time in the relationship is associated at least in part with a physical property of the transcutaneous glucose sensor, wherein the physical property of the transcutaneous glucose sensor corresponds to membrane of the *in vivo* portion of the transcutaneous glucose sensor.

58. (Previously Presented) A method for monitoring a glucose concentration, the method comprising:

beginning a sensor session associated with use of a transcutaneous glucose sensor, wherein the transcutaneous glucose sensor comprises:

an *ex vivo* portion configured to remain outside of a body of a host; and

an *in vivo* portion configured to be inserted within the body of the host;

wherein the transcutaneous glucose sensor is configured to generate a signal;

Abbott Ex. 1003 - 976/1058

calibrating the transcutaneous glucose sensor by applying *a priori* information, wherein the *a priori* information comprises an expected relationship between the signal and a glucose concentration existing within the body of the host, wherein the relationship changes as a function of time;

generating a glucose concentration value based at least in part on the calibrating; and

displaying the glucose concentration value.

59. (Previously Presented) The method of claim 58 wherein the time the relationship changes is an elapsed time measured from the beginning of the sensor session.

60. (Previously Presented) The method of claim 58 wherein the relationship changes as a function of time is associated at least in part with a change in one or more physical properties of an environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host.

61. (Previously Presented) The method of claim 60 wherein the one or more physical properties of the environment surrounding the *in vivo* portion of the transcutaneous glucose sensor within the body of the host include trauma, wound healing, blockage of a surface of the transcutaneous glucose sensor, inflammation, blood clotting, or biofouling.

62. (Previously Presented) The method of claim 58 wherein the relationship changes as a function of time is associated at least in part with a physical property of the transcutaneous glucose sensor, wherein the physical property of the transcutaneous glucose sensor corresponds to a membrane of the *in vivo* portion of the transcutaneous glucose sensor.

63. (Previously Presented) The system of claim 20 wherein the profile has a first slope associated with a first time and a second slope associated with a second time, wherein the first time is different from the second time, wherein the first slope is different from the second slope.

Abbott Ex. 1003 - 977/1058

64. (Previously Presented) The method of claim 32 wherein the profile has a first slope associated with a first time and a second slope associated with a second time, wherein the first time is different from the second time, wherein the first slope is different from the second slope.

65. (Previously Presented) The method of claim 40 wherein the drift profile has a first slope associated with a first time and a second slope associated with a second time, wherein the first time is different from the second time, wherein the first slope is different from the second slope.

Abbott Ex. 1003 - 978/1058

REMARKS

Amendments to the Claims

Please amend Claim 51 as shown above. These amendments are provided merely for clarity, consistence of terms, to correct typographical errors, and/or for proper antecedent basis. These amendments do not require further search or consideration, and are supported in the original application as filed and thus do not constitute new matter.

Additional Remarks Regarding Independent Claim 20

Applicant notes that allowed Claim 20 was inadvertently omitted in the Notice of Allowability, which indicates that Claims 21-65 were allowed. Applicant respectfully requests correction prior to issuance.

Cancellation and/or amendment of certain claims in this response or any other response is not to be construed as a dedication to the public of any of the subject matter of the claims as previously presented, and Applicants reserve the ability to pursue the amended claims as filed, the canceled claims or similar claims in one or more continuing applications, e.g., continuation, divisional, or continuation-in-part applications.

No Disclaimers or Disavowals

Although the present communication may include alterations to the application or claims, or characterizations of claim scope or referenced art, Applicant is not conceding in this application that previously pending claims are not patentable over the cited references. Rather, any alterations or characterizations are being made to facilitate expeditious prosecution of this application. Applicant reserves the right to pursue at a later date any previously pending or other broader or narrower claims that capture any subject matter supported by the present disclosure, including subject matter found to be specifically disclaimed herein or by any prior prosecution. Accordingly, reviewers of this or any parent, child or related prosecution history shall not reasonably infer that Applicant has made any disclaimers or disavowals of any subject matter supported by the present application.

Abbott Ex. 1003 - 979/1058

Any remarks in support of patentability of one claim should not be imputed to any other claim, even if similar terminology is used. Any language or remarks referring to only a portion of a claim should not necessarily be understood to base patentability on solely that portion; rather, patentability rests on each claim taken as a whole.

Applicant respectfully submits that to the extent any disclaimers or statements were made previously during prosecution with respect to the scope of the claimed invention, such disclaimers and statements are hereby rescinded.

Applicant respectfully reserves the ability to traverse any of the rejections, assertions and submissions made in connection with the application, even if not discussed herein, including the right to challenge later whether any of the cited references is prior art. The absence of a reply to a specific rejection, issue, or comment does not signify agreement with or concession of that rejection, issue, or comment. In addition, because any arguments made may not be exhaustive, there may be other reasons that have not been expressed for patentability of any or all claims. When amendments are made to any claims, no acquiescence or estoppel is implied thereby; such amendments are made only to expedite prosecution of the present application and are without prejudice to the presentation or assertion, in the future, of claims directed to subject matter that is same as or similar to that previously presented. Nothing in this paper should be construed as an intent to concede, or actual concession of, any issue with regard to any claim, or to any cited art, except as specifically stated in this paper, and the amendment or cancellation of any claim does not necessarily signify concession of unpatentability of the claim prior to its amendment or cancellation.

Conclusion

Should the Examiner have any concerns that might prevent the prompt allowance of the application, the Examiner is respectfully invited to contact the undersigned at the telephone number below.

Abbott Ex. 1003 - 980/1058

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 26, 2021

By:/Ian W. Gillies/_____
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34683006

Abbott Ex. 1003 - 981/1058

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

68851 7590 03/26/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

TITLE OF INVENTION: ANALYTE SENSOR

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	06/28/2021

EXAMINER	ART UNIT	CLASS-SUBCLASS
PREVIL, DANIEL	2684	073-001020

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 Knobbe Martens
2 Olson & Bear, LLP
3

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE: DexCom, Inc.

(B) RESIDENCE: (CITY and STATE OR COUNTRY): San Diego, CA

Please check the appropriate assignee category or categories (will not be printed on the patent) : ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. Fees submitted: ☒ Issue Fee ☐ Publication Fee (if required) ☐ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

☒ Electronic Payment via EFS-Web ☐ Enclosed check ☐ Non-electronic payment by credit card (Attach form PTO-2038)

☒ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. 11-1410

5. **Change in Entity Status** (from status indicated above)

☐ Applicant certifying micro entity status. See 37 CFR 1.29

☐ Applicant asserting small entity status. See 37 CFR 1.27

☐ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature /Ian W. Gillies/ Date March 26, 2021

Typed or printed name Ian W. Gillies Registration No. 62280

Abbott Ex. 1003 - 982/1058

RESPONSE TO INFORMATIONAL NOTICE

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The above-captioned application was filed without a Declaration and/or Substitute Statement. Enclosed in compliance with 37 CFR 1.53(f) and in response to the Informational Notice to Applicant dated January 21, 2021 are the following;

(X) Declarations of:

Peter C. Simpson, Ying Li, Apurv Ullas Kamath, and Richard C. Yang

The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment, to Account No. 11-1410.

/Ian W. Gillies/
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34683196

Electronic Patent Application Fee Transmittal

Application Number:	17132664
Filing Date:	23-Dec-2020
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Filer:	Ian W. Gillies/Edgar Compton
Attorney Docket Number:	DEXCOM.167P1

Filed as Large Entity

Filing Fees for Utility under 35 USC 111(a)

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Basic Filing:				
Pages:				
Claims:				
Miscellaneous-Filing:				
Petition:				
Patent-Appeals-and-Interference:				
Post-Allowance-and-Post-Issuance:				
UTILITY APPL ISSUE FEE	1501	1	1200	1200

Description	Fee Code	Quantity	Amount	Sub-Total in USD($)
Extension-of-Time:				
Miscellaneous:				
			Total in USD ($)	**1200**

Electronic Acknowledgement Receipt

EFS ID:	42299630
Application Number:	17132664
International Application Number:	
Confirmation Number:	2055
Title of Invention:	ANALYTE SENSOR
First Named Inventor/Applicant Name:	Peter C. Simpson
Customer Number:	68851
Filer:	Ian W. Gillies/Melanie Terrazas
Filer Authorized By:	Ian W. Gillies
Attorney Docket Number:	DEXCOM.167P1
Receipt Date:	26-MAR-2021
Filing Date:	23-DEC-2020
Time Stamp:	20:15:33
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	$1200
RAM confirmation Number	E20213PK15554760
Deposit Account	111410
Authorized User	Melanie Terrazas

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.17 (Patent application and reexamination processing fees)

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	167P1_COMMENTS.pdf	19042 34509d12cf497cb17cce18533eb08c0a0afae641	no	2
Warnings:					
Information:					
2	Oath or Declaration filed	167P1_DECS.pdf	451069 f6506c0e804d75debd1107c63bd4bfa6b8d32386	no	4
Warnings:					
Information:					
3		167P1_312AMEND.pdf	61448 e1cea0f9a6a5cd62d60d43cfc09c5cffd1fe26e2	yes	13

Multipart Description/PDF files in .zip description

Document Description	Start	End
Amendment after Notice of Allowance (Rule 312)	1	1
Claims	2	10
Applicant Arguments/Remarks Made in an Amendment	11	13

Warnings:					
Information:					
4	Issue Fee Payment (PTO-85B)	167P1_ISSUEFEE.pdf	192651 85f0d7c7c55ba2973913f951170c9609f08b1204	no	1
Warnings:					
Information:					
5	Miscellaneous Incoming Letter	167P1_RESP.pdf	17533 24a17d56808925376730b3ac26638494c36cbe72	no	1

Warnings:					
Information:					
6	Fee Worksheet (SB06)	fee-info.pdf	30177 35435ded552e21013eea32193719f373d29fe754	no	2
Warnings:					
Information:					
			Total Files Size (in bytes):	771920	

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

COMMENTS ON STATEMENT OF REASONS FOR ALLOWANCE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

It is recognized that in accordance with M.P.E.P. § 1302.14, the Examiner's reasons for allowance need not set forth all of the details as to why the claims are allowed. In the above-referenced application, it is not conceded that the Examiner's stated reasons for allowance are the only reasons for which the claims are allowable. The Examiner's reasons for allowance indicate that particular claim elements are not disclosed or suggested by the prior art of record, yet the claims may be patentable for other reasons as well, including the inventive combination of all of the recited claim elements. It is not conceded that the specific limitations identified by the Examiner are necessary to distinguish the art of record or to satisfy the requirements of 35 U.S.C. § 112. Moreover, the Examiner does not assert, and it would not be conceded, that the Examiner's reasons have any bearing on the patentability of claims in any other applications directed to the disclosed subject matter.

Abbott Ex. 1003 - 989/1058

In addition, each dependent claim stands on its own and may be allowable on its own merits. In particular, each dependent claim may be allowable on the basis of a combination of some of the features recited in the dependent claim and its base claim(s), which combination of features may not include all of the limitations identified in the Examiner's reasons for allowance.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 26, 2021

By:/Ian W. Gillies/
Ian W. Gillies
Registration No. 62,280
Registered Practitioner
(858) 707-4000

34680030

Abbott Ex. 1003 - 990/1058

PTO/AIA/01 (06-12)
Approved for use through 11/30/2020. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	ANALYTE SENSOR

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 17/132664

filed on December 23, 2020.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Peter C. Simpson Date (Optional): 3/26/21

Signature: /Peter C. Simpson/

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (08-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	ANALYTE SENSOR

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/072659

filed on November 5, 2013.

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Ying Li Date (Optional): 11/13/13

Signature: _____

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	ANALYTE SENSOR

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/072659

filed on November 5, 2013

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Apurv Ullas Kamath Date (Optional): November 26, 2013

Signature: [signature]

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/AIA/01 (06-12)
Approved for use through 01/31/2014. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	ANALYTE SENSOR

As the below named inventor, I hereby declare that:

This declaration is directed to:

☐ The attached application, or

☒ United States application or PCT international application number 14/072659

filed on November 5, 2013

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.


I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

LEGAL NAME OF INVENTOR

Inventor: Richard C. Yang Date (Optional): 12/30/13

Signature: 

Note: An application data sheet (PTO/SB/14 or equivalent), including naming the entire inventive entity, must accompany this form or must have been previously filed. Use an additional PTO/AIA/01 form for each additional inventor.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

68851 7590 03/26/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER
PREVIL, DANIEL

ART UNIT	PAPER NUMBER
2684	

DATE MAILED: 03/26/2021

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

TITLE OF INVENTION: ANALYTE SENSOR

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	06/28/2021

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Maintenance fees are due in utility patents issuing on applications filed on or after Dec. 12, 1980. It is patentee's responsibility to ensure timely payment of maintenance fees when due. More information is available at www.uspto.gov/PatentMaintenanceFees.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), by mail or fax, or via EFS-Web.

By mail, send to: Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

By fax, send to: (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

68851 7590 03/26/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being transmitted to the USPTO via EFS-Web or by facsimile to (571) 273-2885, on the date below.

(Typed or printed name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

TITLE OF INVENTION: ANALYTE SENSOR

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	$1200	$0.00	$0.00	$1200	06/28/2021

EXAMINER	ART UNIT	CLASS-SUBCLASS
PREVIL, DANIEL	2684	073-001020

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

❑ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.

❑ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-09 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list
(1) The names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 _____
2 _____
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document must have been previously recorded, or filed for recordation, as set forth in 37 CFR 3.11 and 37 CFR 3.81(a). Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent) : ❑ Individual ❑ Corporation or other private group entity ❑ Government

4a. Fees submitted: ❑ Issue Fee ❑ Publication Fee (if required) ❑ Advance Order - # of Copies _____

4b. Method of Payment: *(Please first reapply any previously paid fee shown above)*

❑ Electronic Payment via EFS-Web ❑ Enclosed check ❑ Non-electronic payment by credit card (Attach form PTO-2038)

❑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment to Deposit Account No. _____

5. **Change in Entity Status** (from status indicated above)

❑ Applicant certifying micro entity status. See 37 CFR 1.29

❑ Applicant asserting small entity status. See 37 CFR 1.27

❑ Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.
NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature _____ Date _____

Typed or printed name _____ Registration No. _____

Abbott Ex. 1003 - 996/1058

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

68851 7590 03/26/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER	
PREVIL, DANIEL	
ART UNIT	**PAPER NUMBER**
2684	

DATE MAILED: 03/26/2021

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

Abbott Ex. 1003 - 997/1058

Notice Requiring Inventor's Oath or Declaration	Application No. 17/132,664	Applicant(s) Peter C. Simpson	
	Examiner PREVIL, DANIEL	Art Unit 2684	

This notice is an attachment to the Notice of Allowability (PTOL-37), or the Notice of Allowability For A Design Application (PTOL-37D).

An inventor's oath or declaration in compliance with 37 CFR 1.63 or 1.64 executed by or with respect to each inventor has not yet been submitted.

An oath or declaration in compliance with 37 CFR 1.63, or a substitute statement in compliance with 37 CFR 1.64, executed by or with respect to each inventor (for any inventor for which a compliant oath, declaration, or substitute statement has not yet been submitted) MUST be filed no later than the date on which the issue fee is paid. See 35 U.S.C. 115(f). Failure to timely comply will result in ABANDONMENT of this application.

A properly executed inventor's oath to declaration has not been received for the following inventor(s):

If applicant previously filed one or more oaths, declarations, or substitute statements, applicant may have received an informational notice regarding deficiencies therein.

The following deficiencies are noted:

INFORMAL ACTION PROBLEMS

- A properly executed inventor's oath or declaration has not been received for the following inventor(s): **Peter C. Simpson**, **Ying Li**, **Apurv Ullas Kamath**, and **Richard C. Yang**.
  Applicant may submit the inventor's oath or declaration at any time before the Notice of Allowance and Fee(s) Due, PTOL-85, is mailed.

Questions relating to this Notice should be directed to the Application Assistance Unit at 571-272-4200.

OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

Abbott Ex. 1003 - 999/1058

Notice of Allowability	Application No. 17/132,664	Applicant(s) Simpson et al.	
	Examiner DANIEL PREVIL	Art Unit 2684	AIA (FITF) Status No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☑ This communication is responsive to 3/15/2021.
   ☐ A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on _____.

2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.

3. ☑ The allowed claim(s) is/are 21-65 . As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see **http://www.uspto.gov/patents/init_events/pph/index.jsp** or send an inquiry to **PPHfeedback@uspto.gov.**

4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

   Certified copies:

   a) ☐ All b) ☐ Some *c) ☐ None of the:

   1. ☐ Certified copies of the priority documents have been received.
   2. ☐ Certified copies of the priority documents have been received in Application No. _____ .
   3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

   * Certified copies not received: _____ .

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
   ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____ .

   Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☑ Notice of References Cited (PTO-892)
2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date _____.
3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material _____.
4. ☐ Interview Summary (PTO-413), Paper No./Mail Date. _____.
5. ☐ Examiner's Amendment/Comment
6. ☑ Examiner's Statement of Reasons for Allowance
7. ☐ Other _____.

/DANIEL PREVIL/
Primary Examiner, Art Unit 2684

DETAILED ACTION

Notice of Pre-AIA or AIA Status

The present application is being examined under the pre-AIA first to invent provisions.

Allowable Subject Matter

The following is an examiner's statement of reasons for allowance: In combination with all the limitations in the claims, the prior arts fail to teach or make obvious: wherein the transcutaneous glucose sensor is configured to generate a signal, wherein the magnitude of the signal depends upon a glucose concentration existing at the in vivo portion of the transcutaneous glucose sensor inserted into the body of the host: and electronics configured to operably connect to the transcutaneous glucose sensor, wherein the electronics comprises a memory, wherein the memory stores information associated with a profile, wherein the profile is based at least in part on a priori information related to expected sensitivity changes associated with a length of time the in vivo portion of the transcutaneous glucose sensor has been inserted into the body of the host.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL PREVIL whose telephone number is (571)272-2971. The examiner can normally be reached on Monday-Friday from 9:30 AM -6:00 PM.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Wang Quan-Zhen can be reached on 571 272 3114. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

DP

March 23, 2021

/DANIEL PREVIL/
Primary Examiner, Art Unit 2684

Notice of References Cited	Application/Control No. 17/132,664	Applicant(s)/Patent Under Reexamination Simpson et al.	
	Examiner DANIEL PREVIL	Art Unit 2684	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	CPC Classification	US Classification
*	A	US-20090076360-A1	03-2009	Brister; Mark	G16Z99/00	600/365
*	B	US-20170112531-A1	04-2017	Schoonmaker; Ryan Everett	A61B5/0004	1/1
*	C	US-20150374270-A1	12-2015	Shults; Mark C.	A61B5/0002	600/347
	D					
	E					
	F					
	G					
	H					
	I					
	J					
	K					
	L					
	M					

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	CPC Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	**Art Unit**
	DANIEL PREVIL	2684

CPC						
Symbol					**Type**	**Version**
A61B	/	5	/	1495	F	2013-01-01
A61M	/	5	/	1723	I	2013-01-01
A61B	/	5	/	6866	I	2013-01-01
A61B	/	5	/	14546	I	2013-01-01

CPC Combination Sets							
Symbol					**Type**	**Set**	**Ranking**	**Version**
	/		/					

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	46	
/DANIEL PREVIL/ Primary Examiner, Art Unit 2684	23 March 2021	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	1A

U.S. Patent and Trademark Office — Part of Paper No.: 20210323

Abbott Ex. 1003 - 1004/1058

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	**Art Unit**
	DANIEL PREVIL	2684

INTERNATIONAL CLASSIFICATION				
CLAIMED				
G08C	/	23	/	00

NON-CLAIMED				
	/		/	

US ORIGINAL CLASSIFICATION	
CLASS	**SUBCLASS**
340	870.28

CROSS REFERENCES(S)						
CLASS	**SUBCLASS (ONE SUBCLASS PER BLOCK)**					
340	539.1	522				

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	46	
/DANIEL PREVIL/ Primary Examiner, Art Unit 2684	23 March 2021	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	1A

U.S. Patent and Trademark Office — Part of Paper No.: 20210323

Abbott Ex. 1003 - 1005/1058

Issue Classification	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	**Art Unit**
	DANIEL PREVIL	2684

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIMS

Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1		10		19	9	28	19	37	29	46	39	55	22	64
	2		11	1	20	10	29	20	38	30	47	40	56	34	65
	3		12	2	21	11	30	21	39	31	48	41	57		
	4		13	3	22	12	31	23	40	32	49	42	58		
	5		14	4	23	14	32	24	41	33	50	43	59		
	6		15	5	24	15	33	25	42	35	51	44	60		
	7		16	6	25	16	34	26	43	36	52	45	61		
	8		17	7	26	17	35	27	44	37	53	46	62		
	9		18	8	27	18	36	28	45	38	54	13	63		

NONE		**Total Claims Allowed:**	
(Assistant Examiner)	(Date)	46	
/DANIEL PREVIL/ Primary Examiner, Art Unit 2684	23 March 2021	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	1A

U.S. Patent and Trademark Office

Part of Paper No.: 20210323

Abbott Ex. 1003 - 1006/1058

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

✓	Rejected	-	Cancelled	N	Non-Elected	A	Appeal
=	Allowed	÷	Restricted	I	Interference	O	Objected

CLAIMS

☐ Claims renumbered in the same order as presented by applicant ☐ CPA ☐ T.D. ☐ R.1.47

CLAIM		DATE								
Final	Original	02/25/2021	03/23/2021							
	1	-	-							
	2	-	-							
	3	-	-							
	4	-	-							
	5	-	-							
	6	-	-							
	7	-	-							
	8	-	-							
	9	-	-							
	10	-	-							
	11	-	-							
	12	-	-							
	13	-	-							
	14	-	-							
	15	-	-							
	16	-	-							
	17	-	-							
	18	-	-							
	19	✓	-							
1	20	✓	=							
2	21		=							
3	22		=							
4	23		=							
5	24		=							
6	25		=							
7	26		=							
8	27		=							
9	28		=							
10	29		=							
11	30		=							
12	31		=							
14	32		=							
15	33		=							
16	34		=							
17	35		=							
18	36		=							
19	37		=							
20	38		=							
21	39		=							
23	40		=							
24	41		=							
25	42		=							

Index of Claims	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	**Art Unit**
	DANIEL PREVIL	2684

CLAIM		DATE								
Final	Original	02/25/2021	03/23/2021							
26	43		=							
27	44		=							
28	45		=							
29	46		=							
30	47		=							
31	48		=							
32	49		=							
33	50		=							
35	51		=							
36	52		=							
37	53		=							
38	54		=							
39	55		=							
40	56		=							
41	57		=							
42	58		=							
43	59		=							
44	60		=							
45	61		=							
46	62		=							
13	63		=							
22	64		=							
34	65		=							

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

Abbott Ex. 1003 - 1009/1058

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

CPC - Searched*		
Symbol	**Date**	**Examiner**
13 AND ((A61B5/14532 OR A61B5/14546 OR A61B5/1473 OR A61B5/1486 OR A61B5/14503 OR A61B5/1495 OR A61B5/14865 OR A61B2560/0223 OR A61B5/14735 OR A61B5/1468 OR A61B5/1451 OR A61B5/6848 OR A61B5/0031 OR A61B5/0002 OR A61B5/0004 OR A61B5/6833 OR A61B5/14507 OR A61B5/6849 OR A61B5/150022 OR A61B5/1411 OR A61B5/145 OR A61B5/6801 OR A61B17/3468 OR A61B5/72 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/05 OR A61B5/14 OR A61B5/14514 OR A61B5/68335 OR A61B5/14517 OR A61B2560/0276 OR A61B5/7257 OR A61B5/7267 OR A61B5/742 OR A61B2562/08 OR A61B5/7203 OR A61B2560/0214 OR A61B5/0022 OR A61B5/6832 OR A61B5/00 OR A61B5/150534 OR A61B5/746 OR A61B5/486 OR A61B2560/0209 OR A61B5/7445 OR A61B2560/0252 OR A61B2562/02 OR A61B5/002 OR A61B5/411 OR A61B5/418 OR A61B5/4839 OR A61B5/686 OR A61B5/6898 OR A61B5/7435 OR A61B5/7475 OR A61B2017/0023 OR A61B2017/00407 OR A61B2017/00862 OR A61B2560/0257 OR A61B2560/028 OR A61B2560/0295 OR A61B2560/0412 OR A61B2560/0443 OR A61B2562/0209 OR A61B2562/0219 OR A61B2562/028 OR A61B2562/043 OR A61B2562/125 OR A61B2562/164 OR A61B2562/227 OR A61B5/0024 OR A61B5/01 OR A61B5/14539 OR A61B5/14542 OR A61B5/681 OR A61B5/6846 OR A61B5/7221 OR A61B5/7225 OR A61B5/7235 OR A61B5/7239 OR A61B5/726 OR A61B5/7264 OR A61B5/7275 OR A61B5/7405 OR A61B5/743 OR A61B5/7455 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR Y02A50/30 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2005/14208 OR A61M2205/3553 OR A61M2205/50 OR A61M2230/201 OR A61M5/14248 OR G01N27/3274 OR G01N27/026 OR G01N33/49 OR G01N33/54366 OR G01N33/66 OR G01N27/3271 OR G01D18/00 OR H05K999/00 OR H05K999/99 OR H05K2201/053 OR H05K2201/10151 OR H05K2201/10401 OR H05K2201/10409 OR H05K3/325 OR H05K3/365 OR G16Z99/00 OR H04W76/14 OR H04W4/80 OR H04W12/06 OR H04W12/00 OR H04W48/10 OR H04W4/38 OR H04W52/0277 OR H04W76/10 OR H04W84/18 OR H04W84/22 OR H04W8/005 OR H04W12/068 OR H04W4/12 OR H04W4/20 OR H04W4/70 OR H04W52/0229 OR H04W88/02 OR G16H20/17 OR G16H40/40 OR G16H40/63 OR G16H10/60 OR G16H40/67 OR G16H10/65 OR G16H20/60 OR G16H50/20 OR G16H10/20 OR G16H10/40 OR G16H20/30 OR G16H20/70 OR G16H50/30 OR G16H80/00 OR H01L2924/00 OR H01L2924/07811 OR H01L2924/12042 OR H01L24/72 OR H04L63/101 OR H04L2209/88 OR H04L67/141 OR H04L67/34 OR Y02D30/70	02/25/2021	DP

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

CPC Combination Sets - Searched*		
Symbol	**Date**	**Examiner**
A61B5/14532 OR A61B5/14865 OR A61B5/1495 OR A61B5/14546 OR A61B2560/0223 OR A61B5/6849 OR A61B5/6848 OR A61B5/1473 OR A61B5/6833 OR A61B5/145 OR A61B5/1486 OR A61B5/1468 OR A61B5/0004 OR A61B5/1411 OR A61B5/72 OR A61B5/14735 OR A61B5/14542 OR A61B17/3468 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/0002 OR A61B5/05 OR A61B5/14 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/150022 OR A61B5/6801 OR A61B5/68335 OR A61B5/412 OR A61B5/0031 OR A61B5/14539 OR A61B5/742 OR A61B2560/04 OR A61B2562/085 OR A61B5/4839 OR A61B5/7275 OR A61B5/743 OR A61B2560/0276 OR A61B2560/028 OR A61B5/1451 OR A61B5/14517 OR A61B5/6832 OR A61B5/7264 OR A61B5/6852 OR A61B5/002 OR A61B5/14535 OR A61B5/15142 OR A61B5/7203 OR A61B5/7207 OR A61B5/746 OR A61B5/1455 OR A61B5/14551 OR A61B5/1459 OR A61B5/15003 OR A61B5/150992 OR A61B5/155 OR A61B5/157 OR A61B5/4094 OR A61B5/7235 OR A61B5/686 OR A61B5/7221 OR A61B6/586 OR A61B2562/02 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2230/201 OR A61M5/14 OR A61M5/16804 OR A61M2005/14296 OR A61M25/007 OR A61M25/00 OR G16H40/40 OR G16H20/17 OR G16H10/40 OR G16H40/63 OR G16H50/00 OR C12Q1/001 OR C12Q1/006 OR C12Q1/002 OR C12Q1/003 OR A61L2/12 OR A61L2/206 OR Y10T29/49004 OR G06F19/00	03/23/2021	DP

US Classification - Searched*			
Class	**Subclass**	**Date**	**Examiner**
340	870.28, 522, 870.01, 539.12, 691.6, 539.1	02/25/2021	DP

* See search history printout included with this form or the SEARCH NOTES box below to determine the scope of the search.

Search Notes	Application/Control No.	Applicant(s)/Patent Under Reexamination
	17/132,664	Simpson et al.
	Examiner	Art Unit
	DANIEL PREVIL	2684

Search Notes		
Search Notes	**Date**	**Examiner**
Plus search, East search, Inventor search	02/25/2021	DP
CPC search	02/25/2021	DP
search updated above on	03/23/2021	DP

Interference Search			
US Class/CPC Symbol	**US Subclass/CPC Group**	**Date**	**Examiner**
340	870.28, 539.1, 522	03/23/2021	DP

Abbott Ex. 1003 - 1012/1058

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05
L7	12	drift near55 profile near55 shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:07

L8	170	drift same profile same shift same over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:08
L9	0	l1 and l8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L10	3,315	display$3 same glucose same concentration same value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L11	0	l8 and l10	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:14
L12	0	l8 and transcutaneous same glucose same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:15
L13	0	l8 and transcutaneous same glucose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L14	0	l8 and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L15	2,655	monitor$3 near55 glucose near55 concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36

L16	3,553	monitor$3 same glucose same concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36
L17	454	l16 and ex near55 vivo near55 remain$3 near55 outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:38
L18	445	l17 and display$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:39
L19	429	l18 and in near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:40
L20	393	l18 and in near55 vivo near55 insert$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:41
L21	393	l20 and period near55 time	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:42
L22	0	l21 and drift near55 profile same shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L23	0	l21 and drift near55 profile same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43

L24	140	l21 and drift same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L25	140	l24 and sensor near55 data near55 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:44

3/23/2021 4:45:35 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05
L7	12	drift near55 profile near55 shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:07

L8	170	drift same profile same shift same over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:08
L9	0	l1 and l8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L10	3,315	display$3 same glucose same concentration same value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L11	0	l8 and l10	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:14
L12	0	l8 and transcutaneous same glucose same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:15
L13	0	l8 and transcutaneous same glucose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L14	0	l8 and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L15	2,655	monitor$3 near55 glucose near55 concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36

L16	3,553	monitor$3 same glucose same concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36
L17	454	l16 and ex near55 vivo near55 remain$3 near55 outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:38
L18	445	l17 and display$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:39
L19	429	l18 and in near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:40
L20	393	l18 and in near55 vivo near55 insert$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:41
L21	393	l20 and period near55 time	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:42
L22	0	l21 and drift near55 profile same shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L23	0	l21 and drift near55 profile same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43

L24	140	l21 and drift same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L25	140	l24 and sensor near55 data near55 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:44
L26	140	25 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/1495 OR A61B5/14546 OR A61B2560/0223 OR A61B5/6849 OR A61B5/6848 OR A61B5/1473 OR A61B5/6833 OR A61B5/145 OR A61B5/1486 OR A61B5/1468 OR A61B5/0004 OR A61B5/1411 OR A61B5/72 OR A61B5/14735 OR A61B5/14542 OR A61B17/3468 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/0002 OR A61B5/05 OR A61B5/14 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/150022 OR A61B5/6801 OR A61B5/68335 OR A61B5/412 OR A61B5/0031 OR A61B5/14539 OR A61B5/742 OR A61B2560/04 OR A61B2562/085 OR A61B5/4839 OR A61B5/7275 OR A61B5/743 OR A61B2560/0276 OR A61B2560/028 OR A61B5/1451 OR A61B5/14517 OR A61B5/6832 OR A61B5/7264 OR A61B5/6852 OR A61B5/002 OR A61B5/14535 OR A61B5/15142 OR A61B5/7203 OR A61B5/7207 OR A61B5/746 OR A61B5/1455 OR A61B5/14551 OR A61B5/1459 OR A61B5/15003 OR A61B5/150992 OR A61B5/155 OR A61B5/157 OR A61B5/4094 OR A61B5/7235 OR A61B5/686 OR A61B5/7221 OR A61B6/586 OR A61B2562/02 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2230/201 OR A61M5/14 OR A61M5/16804 OR A61M2005/14296 OR A61M25/007 OR A61M25/00).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:53

L27	140	25 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/1495 OR A61B5/14546 OR A61B2560/0223 OR A61B5/6849 OR A61B5/6848 OR A61B5/1473 OR A61B5/6833 OR A61B5/145 OR A61B5/1486 OR A61B5/1468 OR A61B5/0004 OR A61B5/1411 OR A61B5/72 OR A61B5/14735 OR A61B5/14542 OR A61B17/3468 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/0002 OR A61B5/05 OR A61B5/14 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/150022 OR A61B5/6801 OR A61B5/68335 OR A61B5/412 OR A61B5/0031 OR A61B5/14539 OR A61B5/742 OR A61B2560/04 OR A61B2562/085 OR A61B5/4839 OR A61B5/7275 OR A61B5/743 OR A61B2560/0276 OR A61B2560/028 OR A61B5/1451 OR A61B5/14517 OR A61B5/6832 OR A61B5/7264 OR A61B5/6852 OR A61B5/002 OR A61B5/14535 OR A61B5/15142 OR A61B5/7203 OR A61B5/7207 OR A61B5/746 OR A61B5/1455 OR A61B5/14551 OR A61B5/1459 OR A61B5/15003 OR A61B5/150992 OR A61B5/155 OR A61B5/157 OR A61B5/4094 OR A61B5/7235 OR A61B5/686 OR A61B5/7221 OR A61B6/586 OR A61B2562/02 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2230/201 OR A61M5/14 OR A61M5/16804 OR A61M2005/14296 OR A61M25/007 OR A61M25/00 OR G16H40/40 OR G16H20/17 OR G16H10/40 OR G16H40/63 OR G16H50/00 OR C12Q1/001 OR C12Q1/006 OR C12Q1/002 OR C12Q1/003 OR A61L2/12 OR A61L2/206 OR Y10T29/49004 OR G06F19/00).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:54

3/23/2021 4:54:57 PM

Bibliographic Data

Application No: 17/132,664

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☑ Met After Allowance

Verified and Acknowledged: /DANIEL PREVIL/ (Examiner's Signature) | D.P (Initials)

Title: ANALYTE SENSOR

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
12/23/2020	073	2684	DEXCOM.167P1
RULE			

APPLICANTS

DexCom, Inc., San Diego, CA,

INVENTORS

Peter C. Simpson, Cardiff, CA, UNITED STATES

Ying Li, San Diego, CA, UNITED STATES

Apurv Ullas Kamath, San Diego, CA, UNITED STATES

Richard C. Yang, Carlsbad, CA, UNITED STATES

CONTINUING DATA

This application is a CON of 16526910 07/30/2019

16526910 is a CON of 16036808 07/16/2018ABN

16036808 is a CON of 14072659 11/05/2013 PAT 10052055

14072659 is a CON of 12267525 11/07/2008 PAT 8626257

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

01/15/2021

STATE OR COUNTRY

UNITED STATES

ADDRESS

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614
UNITED STATES

FILING FEE RECEIVED

$8,260

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05
L7	12	drift near55 profile near55 shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:07

L8	170	drift same profile same shift same over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:08
L9	0	l1 and l8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L10	3,315	display$3 same glucose same concentration same value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L11	0	l8 and l10	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:14
L12	0	l8 and transcutaneous same glucose same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:15
L13	0	l8 and transcutaneous same glucose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L14	0	l8 and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L15	2,655	monitor$3 near55 glucose near55 concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36

L16	3,553	monitor$3 same glucose same concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36
L17	454	l16 and ex near55 vivo near55 remain$3 near55 outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:38
L18	445	l17 and display$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:39
L19	429	l18 and in near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:40
L20	393	l18 and in near55 vivo near55 insert$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:41
L21	393	l20 and period near55 time	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:42
L22	0	l21 and drift near55 profile same shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L23	0	l21 and drift near55 profile same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43

L24	140	l21 and drift same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L25	140	l24 and sensor near55 data near55 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:44

3/23/2021 4:53:22 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05
L7	12	drift near55 profile near55 shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:07

L8	170	drift same profile same shift same over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:08
L9	0	l1 and l8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L10	3,315	display$3 same glucose same concentration same value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L11	0	l8 and l10	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:14
L12	0	l8 and transcutaneous same glucose same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:15
L13	0	l8 and transcutaneous same glucose	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L14	0	l8 and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:17
L15	2,655	monitor$3 near55 glucose near55 concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36

L16	3,553	monitor$3 same glucose same concentration and transcutaneous	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:36
L17	454	l16 and ex near55 vivo near55 remain$3 near55 outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:38
L18	445	l17 and display$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:39
L19	429	l18 and in near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:40
L20	393	l18 and in near55 vivo near55 insert$3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:41
L21	393	l20 and period near55 time	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:42
L22	0	l21 and drift near55 profile same shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L23	0	l21 and drift near55 profile same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43

L24	140	l21 and drift same shift	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:43
L25	140	l24 and sensor near55 data near55 information	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:44
L26	140	25 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/1495 OR A61B5/14546 OR A61B2560/0223 OR A61B5/6849 OR A61B5/6848 OR A61B5/1473 OR A61B5/6833 OR A61B5/145 OR A61B5/1486 OR A61B5/1468 OR A61B5/0004 OR A61B5/1411 OR A61B5/72 OR A61B5/14735 OR A61B5/14542 OR A61B17/3468 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/0002 OR A61B5/05 OR A61B5/14 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/150022 OR A61B5/6801 OR A61B5/68335 OR A61B5/412 OR A61B5/0031 OR A61B5/14539 OR A61B5/742 OR A61B2560/04 OR A61B2562/085 OR A61B5/4839 OR A61B5/7275 OR A61B5/743 OR A61B2560/0276 OR A61B2560/028 OR A61B5/1451 OR A61B5/14517 OR A61B5/6832 OR A61B5/7264 OR A61B5/6852 OR A61B5/002 OR A61B5/14535 OR A61B5/15142 OR A61B5/7203 OR A61B5/7207 OR A61B5/746 OR A61B5/1455 OR A61B5/14551 OR A61B5/1459 OR A61B5/15003 OR A61B5/150992 OR A61B5/155 OR A61B5/157 OR A61B5/4094 OR A61B5/7235 OR A61B5/686 OR A61B5/7221 OR A61B6/586 OR A61B2562/02 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2230/201 OR A61M5/14 OR A61M5/16804 OR A61M2005/14296 OR A61M25/007 OR A61M25/00).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:53

L27	140	25 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/1495 OR A61B5/14546 OR A61B2560/0223 OR A61B5/6849 OR A61B5/6848 OR A61B5/1473 OR A61B5/6833 OR A61B5/145 OR A61B5/1486 OR A61B5/1468 OR A61B5/0004 OR A61B5/1411 OR A61B5/72 OR A61B5/14735 OR A61B5/14542 OR A61B17/3468 OR A61B2017/3492 OR A61B2560/045 OR A61B2562/18 OR A61B5/0002 OR A61B5/05 OR A61B5/14 OR A61B5/14503 OR A61B5/14507 OR A61B5/14514 OR A61B5/150022 OR A61B5/6801 OR A61B5/68335 OR A61B5/412 OR A61B5/0031 OR A61B5/14539 OR A61B5/742 OR A61B2560/04 OR A61B2562/085 OR A61B5/4839 OR A61B5/7275 OR A61B5/743 OR A61B2560/0276 OR A61B2560/028 OR A61B5/1451 OR A61B5/14517 OR A61B5/6832 OR A61B5/7264 OR A61B5/6852 OR A61B5/002 OR A61B5/14535 OR A61B5/15142 OR A61B5/7203 OR A61B5/7207 OR A61B5/746 OR A61B5/1455 OR A61B5/14551 OR A61B5/1459 OR A61B5/15003 OR A61B5/150992 OR A61B5/155 OR A61B5/157 OR A61B5/4094 OR A61B5/7235 OR A61B5/686 OR A61B5/7221 OR A61B6/586 OR A61B2562/02 OR Y02A90/10 OR Y02A90/26 OR Y02A90/22 OR A61M5/1723 OR A61M2005/1585 OR A61M5/14244 OR A61M2230/201 OR A61M5/14 OR A61M5/16804 OR A61M2005/14296 OR A61M25/007 OR A61M25/00 OR G16H40/40 OR G16H20/17 OR G16H10/40 OR G16H40/63 OR G16H50/00 OR C12Q1/001 OR C12Q1/006 OR C12Q1/002 OR C12Q1/003 OR A61L2/12 OR A61L2/206 OR Y10T29/49004 OR G06F19/00).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:54

3/23/2021 4:56:32 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05
L7	12	drift near55 profile near55 shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:07

L8	170	drift same profile same shift same over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:08
L9	0	l1 and l8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L10	3,315	display$3 same glucose same concentration same value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:13
L11	0	l8 and l10	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:14
L12	0	l8 and transcutaneous same glucose same sensor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:15

3/23/2021 4:17:20 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56

3/23/2021 4:02:45 PM

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05
L7	12	drift near55 profile near55 shift near55 over	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:07

EAST Search History

EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1,030	display$3 near55 glucose near55 concentration near55 value	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:53
L2	162	l1 and ex near55 vivo	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:54
L3	24	l1 and ex same vivo same remain$3 same outside same body same host	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 15:56
L4	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:04
L5	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO;	OR	ON	2021/03/23 16:04

		A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49).CPC.)	DERWENT; IBM_TDB			
L6	24	3 AND ((A61B5/14532 OR A61B5/14865 OR A61B5/6848 OR A61B5/7257 OR A61B5/726 OR A61B5/01 OR A61B5/145 OR A61B5/14539 OR A61B5/7203 OR A61B2560/0252 OR A61B5/742 OR A61B5/14542 OR A61B5/7225 OR A61B5/7239 OR A61B5/1495 OR A61B5/743 OR A61B5/725 OR A61B5/7475 OR A61B5/14546 OR A61B2560/0223 OR A61B5/0002 OR A61B5/6833 OR A61B5/1473 OR A61B5/1486 OR A61B5/6849 OR A61B2560/0214 OR A61B2560/0276 OR A61B2560/04 OR A61B2562/08 OR A61B2562/085 OR A61B5/0022 OR A61B5/0031 OR A61B5/1411 OR A61B5/14503 OR A61B5/14507 OR A61B5/1451 OR A61B5/14517 OR A61B5/150022 OR A61B5/150534 OR A61B5/4839 OR A61B5/6832 OR A61B5/7267 OR Y02A90/10 OR Y02A90/22 OR Y02A90/26 OR G01D18/00 OR G01N27/026 OR G01N27/3274 OR G01N33/49 OR G16Z99/00 OR H05K999/00 OR H05K999/99).CPC.)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2021/03/23 16:05

3/23/2021 4:05:32 PM

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1	2055

68851 7590 04/29/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

EXAMINER	
PREVIL, DANIEL	

ART UNIT	PAPER NUMBER
2684	

NOTIFICATION DATE	DELIVERY MODE
04/29/2021	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

efiling@knobbe.com
jayna.cartee@knobbe.com

Abbott Ex. 1003 - 1046/1058

Response to Rule 312 Communication	Application No.	Applicant(s)	
	17/132,664	Simpson et al.	
	Examiner	Art Unit	AIA (FITF) Status
	DANIEL PREVIL	2684	No

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☑ The amendment filed on 26 March 2021 under 37 CFR 1.312 has been considered, and has been:

a) ☑ entered.

b) ☐ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

/DANIEL PREVIL/
Primary Examiner, Art Unit 2684

Bibliographic Data

Application No: 17/132,664

Foreign Priority claimed: ○ Yes ◉ No

35 USC 119 (a-d) conditions met: ☐ Yes ☑ No ☑ Met After Allowance

Verified and Acknowledged: /DANIEL PREVIL/ (Examiner's Signature) | D.P (Initials)

Title: ANALYTE SENSOR

FILING or 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
12/23/2020	073	2684	DEXCOM.167P1
RULE			

APPLICANTS

DexCom, Inc., San Diego, CA,

INVENTORS

Peter C. Simpson, Cardiff, CA, UNITED STATES

Ying Li, San Diego, CA, UNITED STATES

Apurv Ullas Kamath, San Diego, CA, UNITED STATES

Richard C. Yang, Carlsbad, CA, UNITED STATES

CONTINUING DATA

This application is a CON of 16526910 07/30/2019

16526910 is a CON of 16036808 07/16/2018ABN

16036808 is a CON of 14072659 11/05/2013 PAT 10052055

14072659 is a CON of 12267525 11/07/2008 PAT 8626257

FOREIGN APPLICATIONS

IF REQUIRED, FOREIGN LICENSE GRANTED**

01/15/2021

STATE OR COUNTRY

UNITED STATES

ADDRESS

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614
UNITED STATES

FILING FEE RECEIVED

$8,260

First Inventor	:	Peter C. Simpson
App. No.	:	17/132664
Filed	:	December 23, 2020
For	:	ANALYTE SENSOR
Examiner	:	Previl, Daniel
Art Unit	:	2684
Conf. No.	:	2055

AMENDMENT UNDER 37 CFR 1.312

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Commissioner:

Further to the Notice of Allowance dated March 26, 2021, Applicant respectfully requests entry of the following amendments under 37 C.F.R. § 1.312. Applicant's request is filed after the mailing of a Notice of Allowance and before payment of the Issue Fee, and therefore this request pursuant to 37 C.F.R. § 1.312 is timely filed.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 11 of this paper.

OK to enter
4/23/2021
DP

Abbott Ex. 1003 - 1050/1058

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 4 | of | 167

Complete if Known	
Application Number	17/132664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	1778
Examiner Name	Unassigned
Attorney Docket Number	DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	075	US-4349728	09-14-1982	PHILLIPS; Robert B. et al.	
	076	US-4366040	12-28-1982	MARSONER; Hermann et al.	
	077	US-4369785	01-25-1983	REHKOPF; Paul G. et al.	
Change(s) applied to document, /M.H.E./ 4/6/2021	078	US-4373527	~~08-27-1995~~	FISCHELL; Robert E.	02/1983
	079	US-4374013	02-15-1983	ENFORS; Sven-Olof	
	080	US-4378016	03-29-1983	LOEB; Marvin P.	
	081	US-4388166	06-14-1983	SUZUKI; Shuichi et al.	
	082	US-4392849	07-12-1983	PETRE; John H. et al.	
	083	US-4402694	09-06-1983	ASH; Stephen R. et al.	
	084	US-4403847	09-13-1983	CHRESTENSEN; Gene L.	
	085	US-4403984	09-13-1983	ASH; Stephen R. et al.	
	086	US-4407298	10-04-1983	LENTZ; David J. et al.	
	087	US-4415666	11-15-1983	D'ORAZIO; Paul A. et al.	
	088	US-4418148	11-29-1983	OBERHARDT; Bruce J.	
	089	US-4419535	12-06-1983	O'HARA; Robert J.	
	090	US-4420564	12-13-1983	TSUJI; Nobuhiko et al.	
	091	US-4425920	01-17-1984	BOURLAND; Joe D. et al.	
	092	US-4426621	01-17-1984	GALWEY; Ronald K. et al.	
	093	US-4431004	02-14-1984	BESSMAN; Samuel P. et al.	
	094	US-4431507	02-14-1984	NANKAI; Shiro et al.	
	095	US-4432366	02-21-1984	MARGULES; Gary S.	
	096	US-4436094	03-13-1984	CERAMI; Anthony	
	097	US-4441968	04-10-1984	EMMER; Ivan et al.	
	098	US-4442841	04-17-1984	UEHARA; Masaru et al.	
	099	US-4448188	05-15-1984	LOEB; Marvin P.	

Examiner Signature	/DANIEL PREVIL/	Date Considered	02/24/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.P/

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
17/132,664	06/01/2021	11020031	DEXCOM.167P1	2055

68851 7590 05/12/2021

KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site http://pair.uspto.gov for additional applicants):

DexCom, Inc., San Diego, CA;
Peter C. Simpson, Cardiff, CA;
Ying Li, San Diego, CA;
Apurv Ullas Kamath, San Diego, CA;
Richard C. Yang, Carlsbad, CA;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit SelectUSA.gov.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 1 | of | 3

Complete if Known	
Application Number	17/132,664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	2684
Examiner Name	PREVIL, Daniel
Attorney Docket Number	0167-US11CIP / DEXCOM.167P1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	001	US-10682984	06-16-2020	DOI; Yuta	
	002	US-20130267809	10-10-2013	BRISTER; Mark C. et al.	
	003	US-20200037874	02-06-2020	SIMPSON; Peter C. et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
		None				

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 2 | of | 3

Complete if Known	
Application Number	17/132,664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	2684
Examiner Name	PREVIL, Daniel
Attorney Docket Number	0167-US11CIP / DEXCOM.167P1

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author(in CAPITAL LETTERS),title of the article(when appropriate), title of the item (book,magazine,journal,serial,symposium,catalog,etc.),date,page(s),volume-issue number(s),publisher, city and/or country where published.	T[2]
		None	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet | 3 | of | 3

Complete if Known	
Application Number	17/132,664
Filing Date	12-23-2020
First Named Inventor	SIMPSON; Peter C.
Art Unit	2684
Examiner Name	PREVIL, Daniel
Attorney Docket Number	0167-US11CIP / DEXCOM.167P1

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ A certification statement is not submitted herewith. Please place these references in the file in accordance with 37 CFR 1.97(i).

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Ian W. Gillies/	Date (YYYY-MM-DD)	2021-05-19
Name/Print	Ian W. Gillies	Registration Number	62280

34940505:abt

UNITED STATES
PATENT AND TRADEMARK OFFICE

P.O. Box 1450
Alexandria, VA 22313 - 1450
www.uspto.gov

ELECTRONIC ACKNOWLEDGEMENT RECEIPT

APPLICATION #	RECEIPT DATE / TIME	ATTORNEY DOCKET #
17/132,664	**05/19/2021 12:21:45 PM ET**	**DEXCOM.167P1**

Title of Invention

ANALYTE SENSOR

Application Information

APPLICATION TYPE	Utility - Nonprovisional Application under 35 USC 111(a)	PATENT #	11020031
CONFIRMATION #	2055	FILED BY	Alexa Terracin
PATENT CENTER #	60197657	FILING DATE	12/23/2020
CUSTOMER #	68851	FIRST NAMED INVENTOR	Peter C. Simpson
CORRESPONDENCE ADDRESS	-	AUTHORIZED BY	Ian Gillies

Documents

TOTAL DOCUMENTS: 2

DOCUMENT		PAGES	DESCRIPTION	SIZE (KB)
DEX167P1_20210519.pdf		3	-	37 KB
DEX167P1_20210519-IDS.pdf	(1-2)	2	Information Disclosure Statement (IDS) Form (SB08)	28 KB
DEX167P1_20210519-TRAN.LET.pdf	(3-3)	1	Transmittal Letter	16 KB

Digest

DOCUMENT	MESSAGE DIGEST(SHA-512)

DEX167P1_20210519.pdf	49F59DDFAD4D5B701C89BD95358210802F2B0CBEC70CBE34 C45D586C1378A7AD4C1E0DF1EF7C4FA3E3532AD44259A3864 560C8C5EED655821F2546384B15BD06
DEX167P1_20210519-IDS.pdf	9CF0BB1BBF97F31C2DE298EBA741123DC1795723AEFED5FA B453D8C367DA7751B2722530BFD0679B05421A77AFB93D071 ABC6825D218A52F83A521611E7C61AE
DEX167P1_20210519- TRAN.LET.pdf	5089E57E4EE19B748E2B271AC8657C626800E72B75680F3208 AAC35BDE36595469A60B60FD2AF12C6F5A05587901EDB06FC 369F6EC688781132B650ED062080F

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371(C) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
17/132,664	12/23/2020	Peter C. Simpson	DEXCOM.167P1

CONFIRMATION NO. 2055

68851
KNOBBE, MARTENS, OLSON & BEAR, LLP
DEXCOM, INC.
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

PUBLICATION NOTICE

OC000000126519756

Title:ANALYTE SENSOR

Publication No.US-2021-0186383-A1
Publication Date:06/24/2021

NOTICE OF PUBLICATION OF APPLICATION

The above-identified application will be electronically published as a patent application publication pursuant to 37 CFR 1.211, et seq. The patent application publication number and publication date are set forth above.

The publication may be accessed through the USPTO's publically available Searchable Databases via the Internet at www.uspto.gov. The direct link to access the publication is currently http://www.uspto.gov/patft/.

The publication process established by the Office does not provide for mailing a copy of the publication to applicant. A copy of the publication may be obtained from the Office upon payment of the appropriate fee set forth in 37 CFR 1.19(a)(1). Orders for copies of patent application publications are handled by the USPTO's Public Records Division. The Public Records Division can be reached by telephone at (571) 272-3150 or (800) 972-6382, by facsimile at (571) 273-3250, by mail addressed to the United States Patent and Trademark Office, Public Records Division, Alexandria, VA 22313-1450 or via the Internet.

In addition, information on the status of the application, including the mailing date of Office actions and the dates of receipt of correspondence filed in the Office, may also be accessed via the Internet through the Patent Electronic Business Center at www.uspto.gov using the public side of the Patent Application Information and Retrieval (PAIR) system. The direct link to access this status information is currently https://portal.uspto.gov/pair/PublicPair. Prior to publication, such status information is confidential and may only be obtained by applicant using the private side of PAIR.

Further assistance in electronically accessing the publication, or about PAIR, is available by calling the Patent Electronic Business Center at 1-866-217-9197.

Office of Data Managment, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

Abbott Ex. 1003 - 1058/1058